PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Schneiderman, LJ; Gilmer, T; Teetzel, HD; Dugan, DO; Blustein, J; Cranford, R; Briggs, KB; Komatsu, GI; Goodman-Crews, P; Cohn, F; Young, EWD				Schneiderman, LJ; Gilmer, T; Teetzel, HD; Dugan, DO; Blustein, J; Cranford, R; Briggs, KB; Komatsu, GI; Goodman-Crews, P; Cohn, F; Young, EWD			Effect of ethics consultations on nonbeneficial life-sustaining treatments in the intensive care setting - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERVICE	Context Ethics consultations increasingly are being used to resolve conflicts about life-sustaining interventions, but few studies have reported their outcomes. Objective To investigate whether ethics consultations in the intensive care setting reduce the use of life-sustaining treatments delivered to patients who ultimately did not survive to hospital discharge, as well as the reactions to the consultations of physicians, nurses, and patients/surrogates. Design Prospective, multicenter, randomized controlled trial from November 2000 to December 2002. Setting Adult intensive care units (ICUs) of 7 US hospitals representing a spectrum of institutional characteristics. Patients Five hundred fifty-one patients in whom value-related treatment conflicts arose during the course of treatment. Interventions Patients were randomly assigned either to an intervention (ethics consultation offered) (n=278) or to usual care (n=273). Main Outcome Measures The primary outcomes were ICU days and life-sustaining treatments in those patients who did not survive to hospital discharge. We examined the same measures in those who did survive to discharge and also compared the overall mortality rates of the intervention and usual care groups. We also interviewed physicians and nurses and patients/surrogates about their views of the ethics consultation. Results The intervention and usual-care groups showed no difference in mortality. However, ethics consultations were associated with reductions in hospital (-2.95 days, P=.01) and ICU (-1.44 days, P=.03) days and life-sustaining treatments (-1.7 days with ventilation, P=.03) in those patients who ultimately did not survive to discharge. The majority (87%) of physicians, nurses, and patients/surrogates agreed that ethics consultations in the ICU were helpful in addressing treatment conflicts. Conclusion Ethics consultations were useful in resolving conflicts that may have inappropriately prolonged nonbeneficial or unwanted treatments in the ICU.	Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Swedish Covenant Hosp, Eth Dept, Chicago, IL USA; Montefiore Med Ctr, Dept Epidemiol & Social Med, New York, NY USA; Hennepin Cty Med Ctr, Dept Neurol, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Social Serv Dept, Minneapolis, MN 55415 USA; Mary Hosp, Little co, Neonatol & Bioeth Intens Care Unit, Torrance, CA USA; Kaiser Permanente San Diego, Bioeth Consultant Qual Resource Management, San Diego, CA USA; Univ Calif Irvine, Coll Med, Dept Med, Irvine, CA 92717 USA; Stanford Univ, Sch Med, Ctr Biomed Eth, Stanford, CA 94305 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Montefiore Medical Center; Hennepin County Medical Center; Hennepin County Medical Center; Kaiser Permanente; University of California System; University of California Irvine; Stanford University	Schneiderman, LJ (corresponding author), Univ Calif San Diego, Dept Family & Prevent Med, 9500 Gilman Dr,MC 0622, La Jolla, CA 92093 USA.				AHRQ HHS [1 R01 HS10251] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010251] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM SOC BIOETH HUM, 1998, COR COMP HLTH CAR ET; Berger VW, 2000, STAT MED, V19, P1319, DOI 10.1002/(SICI)1097-0258(20000530)19:10<1319::AID-SIM490>3.0.CO;2-0; Dowdy MD, 1998, CRIT CARE MED, V26, P252, DOI 10.1097/00003246-199802000-00020; ESSERMAN L, 1995, JAMA-J AM MED ASSOC, V274, P1544, DOI 10.1001/jama.274.19.1544; Fletcher JC, 1996, J CLIN ETHIC, V7, P122; LAPUMA J, 1988, JAMA-J AM MED ASSOC, V260, P808, DOI 10.1001/jama.260.6.808; LAPUMA J, 1992, AM J MED, V92, P346, DOI 10.1016/0002-9343(92)90262-A; McClung JA, 1996, AM J MED, V100, P456, DOI 10.1016/S0002-9343(97)89523-X; Orr RD, 1996, AM J MED, V101, P135, DOI 10.1016/S0002-9343(96)80067-2; ORR RD, 1994, J CLIN ETHIC, V5, P323; Schneiderman LJ, 2000, CRIT CARE MED, V28, P3920, DOI 10.1097/00003246-200012000-00033; Wenger N. S., 1996, JGIM, V11, P120; Yen B M, 1999, J Perinatol, V19, P373, DOI 10.1038/sj.jp.7200188	13	435	445	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1166	1172		10.1001/jama.290.9.1166	http://dx.doi.org/10.1001/jama.290.9.1166			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717LK	12952998				2023-01-03	WOS:000185090400011
J	Chene, G; Sterne, JA; May, M; Costagliola, D; Ledergerber, B; Phillips, AN; Dabis, F; Lundgren, J; Monforte, AD; de Wolf, F; Hogg, R; Reiss, P; Justice, A; Leport, C; Staszewski, S; Gill, J; Fatkenheuer, G; Egger, ME				Chene, G; Sterne, JA; May, M; Costagliola, D; Ledergerber, B; Phillips, AN; Dabis, F; Lundgren, J; Monforte, AD; de Wolf, F; Hogg, R; Reiss, P; Justice, A; Leport, C; Staszewski, S; Gill, J; Fatkenheuer, G; Egger, ME		ART Cohort Collaboration	Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies	LANCET			English	Article							HEPATITIS-C VIRUS; VIROLOGICAL TREATMENT FAILURE; PROTEASE INHIBITOR THERAPY; CD4 CELL COUNT; CLINICAL PROGRESSION; VIRAL LOAD; HIV; COHORT; COINFECTION; COMBINATION	Background We examined whether the initial virological and immunological response to highly active antiretroviral treatment (HAART) is prognostic in patients with HIV-1 who start HAART. Methods We analysed 13 cohort studies from Europe and North America including 9323 adult treatment-naive patients who were starting HAART with a combination of at least three drugs. We modelled clinical progression from month 6 after starting HAART, taking into account CD4 count and HIV-1 RNA measured at baseline and 6 months. Findings During 13 408 years of follow-up 152 patients died and 874 developed AIDS or died. Compared with patients who had a 6-month CD4 count of fewer than 25 cells/muL, adjusted hazard ratios for AIDS or death were 0.55 (95%CI 0.32-0.96) for 25-49 cells/muL, 0.62 (0.40-0.96) for 50-99 cells/muL, 0.42 (0.28-0.64) for 100-199 cells/muL, 0.25 (0.16-0.38) for 200-349 cells/muL, and 0.18 (0.11-0.29) for 350 or more cells/muL at 6 months. Compared with patients who had a 6-month HIV-1 RNA of 100 000 copies/mL or greater, adjusted hazard ratios for AIDS or death were 0.59 (0.41-0.86) for 10 000-99 999 copies/mL, 0.42 (0.29-0.61) for 500-9999 copies/mL, and 0.29 (0.21-0.39) for 6-month HIV-1 RNA of 500 copies/mL or fewer. Baseline CD4 and HIV-1 RNA were not associated with progression after controlling for 6-month concentrations. The probability of progression at 3 years ranged from 2.4% in the patients in the lowest-risk stratum to 83% in patients in the highest-risk stratum. Interpretation At 6 months after starting HAART, the current CD4 cell count and viral load, but not values at baseline, are strongly associated with subsequent disease progression. Our findings should inform guidelines on when to modify HAART.	Univ Victor Segalen Bordeaux 2, Inst Sante Publ Epidemiol & Dev, F-33076 Bordeaux, France; Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland	UDICE-French Research Universities; Universite de Bordeaux; University of Bern	Chene, G (corresponding author), Univ Victor Segalen Bordeaux 2, Inst Sante Publ Epidemiol & Dev, 146 rue Leo Saignat, F-33076 Bordeaux, France.	genevieve.chene@isped.u-bordeaux2.fr	VALLET, Yannick/F-9979-2011; Phillips, Andrew N/B-4427-2008; Ledergerber, Bruno/B-5656-2009; Hogg, Robert S/B-2783-2012; Costagliola, Dominique/H-5849-2011; chene, genevieve/H-8665-2014; DABIS, FRANCOIS/S-9298-2019; Sterne, Jonathan/Z-3106-2019; Dodsley, Maria/G-7083-2016; Lundgren, Jens/AAE-6876-2019; Gill, Michael John/G-7083-2016	Phillips, Andrew N/0000-0003-2384-4807; Ledergerber, Bruno/0000-0002-6881-4401; Hogg, Robert S/0000-0003-3463-5488; Costagliola, Dominique/0000-0003-0765-0869; chene, genevieve/0000-0002-8368-6460; DABIS, FRANCOIS/0000-0002-1614-8857; Sterne, Jonathan/0000-0001-8496-6053; Dodsley, Maria/0000-0001-7587-558X; Egger, Matthias/0000-0001-7462-5132; Gill, Michael John/0000-0002-8546-8790	Medical Research Council [G0100221] Funding Source: researchfish; MRC [G0100221] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Becker SL, 2001, J ACQ IMMUN DEF SYND, V26, P72, DOI 10.1097/00126334-200101010-00011; Binquet C, 2001, AM J EPIDEMIOL, V153, P386, DOI 10.1093/aje/153.4.386; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; DARMINIO MA, 1999, AIDS, V13, P1669; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Grabar S, 2000, AIDS, V14, P141, DOI 10.1097/00002030-200001280-00009; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Kitchen CM, 2001, CLIN INFECT DIS, V33, P466, DOI 10.1086/321900; Le Moing V, 2002, J INFECT DIS, V185, P471, DOI 10.1086/338929; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lewden C, 2002, J INFECT DIS, V186, P710, DOI 10.1086/342047; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Lundgren JD, 2002, J INFECT DIS, V185, P178, DOI 10.1086/338267; Mocroft A, 1999, AIDS, V13, P1255, DOI 10.1097/00002030-199907090-00016; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Mocroft A, 2000, AIDS, V14, P1545, DOI 10.1097/00002030-200007280-00010; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; Rancinan C, 2002, AIDS, V16, P1357, DOI 10.1097/00002030-200207050-00007; Rhone SA, 1998, AIDS, V12, P619, DOI 10.1097/00002030-199806000-00011; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; Staszewski S, 1999, AIDS, V13, P951, DOI 10.1097/00002030-199905280-00011; Tedaldi EM, 2003, CLIN INFECT DIS, V36, P363, DOI 10.1086/345953; Wit FWNM, 1999, J INFECT DIS, V179, P790, DOI 10.1086/314675	35	206	210	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	2003	362	9385					679	686						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957089				2023-01-03	WOS:000185034800007
J	Rayment, R; Birchall, J; Yarranton, H; Hewertson, J; Allen, D; Murphy, MF; Roberts, DJ				Rayment, R; Birchall, J; Yarranton, H; Hewertson, J; Allen, D; Murphy, MF; Roberts, DJ			Neonatal alloimmune thrombocytopenia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MANAGEMENT		John Radcliffe Hosp, Natl Blood Serv, Oxford OX3 9DU, England; Southmead Gen Hosp, Natl Blood Serv, Bristol BS10 5ND, Avon, England; Norfolk & Norwich Univ Hosp NHS Trust, Dept Haematol, Norwich NR4 7UY, Norfolk, England; Northampton Gen Hosp, Northampton NN1 5BD, England	University of Oxford; Southmead Hospital; Norfolk & Norwich University Hospitals NHS Foundation Trust	Roberts, DJ (corresponding author), John Radcliffe Hosp, Natl Blood Serv, Oxford OX3 9DU, England.	david.roberts@ndcls.ox.ac.uk						Blanchette VS, 2000, BEST PRACT RES CL HA, V13, P365, DOI 10.1053/beha.2000.0083; BURROWS RF, 1993, NEW ENGL J MED, V329, P1463, DOI 10.1056/NEJM199311113292005; KAPLAN C, 1991, COLLOQ INSE, V206, P267; KIEFEL V, 1987, BLOOD, V70, P1722; MARZUSCH K, 1993, ACTA OBSTET GYN SCAN, V72, P583, DOI 10.3109/00016349309058169; Moulinier J, 1953, P 6 C EUR SOC HAEM, P817; MUELLERECKHARDT C, 1989, LANCET, V1, P363; Murphy MF, 1999, BRIT J HAEMATOL, V105, P123, DOI 10.1111/j.1365-2141.1999.01276.x; Ouwehand WH, 2000, ARCH DIS CHILD-FETAL, V82, pF173, DOI 10.1136/fn.82.3.F173; PROULX C, 1994, BRIT J HAEMATOL, V87, P813, DOI 10.1111/j.1365-2141.1994.tb06742.x; VALENTIN N, 1990, HUM IMMUNOL, V27, P73, DOI 10.1016/0198-8859(90)90104-W; VONDEMBORNE AEGK, 1978, BRIT J HAEMATOL, V39, P195; Williamson LM, 1998, BLOOD, V92, P2280, DOI 10.1182/blood.V92.7.2280.2280_2280_2287; ZALNERAITIS EL, 1979, J PEDIATR-US, V95, P611, DOI 10.1016/S0022-3476(79)80781-7	14	8	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 9	2003	327	7410					331	332		10.1136/bmj.327.7410.331	http://dx.doi.org/10.1136/bmj.327.7410.331			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	710JE	12907491	Green Published			2023-01-03	WOS:000184676400026
J	Schultz, CH; Koenig, KL; Lewis, RJ				Schultz, CH; Koenig, KL; Lewis, RJ			Implications of hospital evacuation after the Northridge, California, earthquake	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND: On January 17, 1994, an earthquake with a moment magnitude (total energy release) of 6.7 occurred in Northridge, California, leading to the evacuation of patients from several hospitals. We examined the reasons for and methods of evacuation and the emergency-management strategies used. The experience in California may have implications for hospital strategies for responding to any major disaster, including an act of terrorism. METHODS: From September 1995 to September 1996, we surveyed all acute care hospitals in Los Angeles County that reported having evacuated patients after the Northridge earthquake. Physicians, nurses, hospital administrators, and staff on duty at the hospitals during the evacuation responded to a 58-item structured questionnaire. RESULTS: Eight of 91 acute care hospitals (9 percent) were evacuated. Six hospitals evacuated patients within 24 hours (the immediate-evacuation group), four completely and two partially. All six cited nonstructural damage such as water damage and loss of electrical power as a major reason for evacuation. Five hospitals evacuated the most seriously ill patients first, and one hospital evacuated the healthiest patients first. All hospitals used available equipment to transport patients (blankets, backboards, and gurneys) rather than specialized devices. No deaths resulted from evacuation. One hospital evacuated patients after 3 days and another after 14 days because of structural damage, even though initial inspections had shown no damage (the delayed-evacuation group). Both hospitals required demolition. Some hospitals identified destinations for their evacuated patients independently, whereas others sought the assistance of the Los Angeles County Emergency Operations Center; the two strategies were equally effective. CONCLUSIONS: After even a moderate earthquake, hospitals are at risk for both immediate nonstructural damage that may force them to evacuate patients and the delayed discovery of structural damage resulting in permanent closure. Evacuation of large numbers of inpatients from multiple hospitals can be accomplished quickly and safely with the use of available resources and personnel.	Univ Calif Irvine, Irvine Med Ctr, Emergency Dept, Orange, CA 92668 USA; Univ Calif Irvine, Coll Med, Irvine, CA 92717 USA; George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; Dept Vet Affairs, Vet Hlth Adm, Hlth Sci & Emergency Management Strateg Healthcar, Washington, DC USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; George Washington University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Schultz, CH (corresponding author), Univ Calif Irvine, Irvine Med Ctr, Emergency Dept, Rte 128,101 City Dr, Orange, CA 92668 USA.	schultzc@uci.edu						ARNOLD C, 1983, HOSP SAN FERNANDO EA; BLASER M J, 1985, Journal of Emergency Medicine, V3, P387, DOI 10.1016/0736-4679(85)90323-3; Chavez C W, 1996, J Emerg Med, V14, P445, DOI 10.1016/0736-4679(96)00083-2; De Lorenzo R A, 1996, Prehosp Disaster Med, V11, P270; FISHER HL, 1986, MIL MED, V151, P154, DOI 10.1093/milmed/151.3.154; Gretenkort Peter, 2002, Prehosp Disaster Med, V17, P42; JONES L, 1994, SCIENCE, V266, P389, DOI 10.1126/science.266.5184.398; KOBAYASHI H, 1996, JPN J DISASTER MED, V1, P73; *OFF STAT HLTH PLA, 2001, SUMM HOSP SEISM PERF; Schultz CH, 1996, NEW ENGL J MED, V334, P438, DOI 10.1056/NEJM199602153340706; Tanaka H, 1998, J Emerg Med, V16, P439, DOI 10.1016/S0736-4679(98)00014-6; TSUBOI S, 1996, JPN J DISASTER MED, V1, P36; Ukai T, 1997, RENAL FAILURE, V19, P633, DOI 10.3109/08860229709109029; *US ARM SOLD BIOL, 2002, MASS CAS CAR STRAT B	14	105	105	1	26	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1349	1355		10.1056/NEJMsa021807	http://dx.doi.org/10.1056/NEJMsa021807			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672863				2023-01-03	WOS:000181949100007
J	Kozower, BD; Christofidou-Solomidou, M; Sweitzer, TD; Muro, S; Buerk, DG; Solomides, CC; Albelda, SM; Patterson, GA; Muzykantov, VR				Kozower, BD; Christofidou-Solomidou, M; Sweitzer, TD; Muro, S; Buerk, DG; Solomides, CC; Albelda, SM; Patterson, GA; Muzykantov, VR			Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury	NATURE BIOTECHNOLOGY			English	Article							CELL-ADHESION MOLECULE-1; IN-VIVO; REPERFUSION INJURY; GLUCOSE-OXIDASE; NEUTROPHIL RECRUITMENT; SUPEROXIDE-DISMUTASE; VASCULAR ENDOTHELIUM; DELIVERY; ISCHEMIA; STRATEGY	Vascular immunotargeting may facilitate the rapid and specific delivery of therapeutic agents to endothelial cells. We investigated whether targeting of an antioxidant enzyme, catalase, to the pulmonary endothelium alleviates oxidative stress in an in vivo model of lung transplantation. Intravenously injected enzymes, conjugated with an antibody to platelet-endothelial cell adhesion molecule-1, accumulate in the pulmonary vasculature and retain their activity during prolonged cold storage and transplantation. Immunotargeting of catalase to donor rats augments the antioxidant capacity of the pulmonary endothelium, reduces oxidative stress, ameliorates ischemia-reperfusion injury, prolongs the acceptable cold ischemia period of lung grafts, and improves the function of transplanted lung grafts. These findings validate the therapeutic potential of vascular immunotargeting as a drug delivery strategy to reduce endothelial injury. Potential applications of this strategy include improving the outcome of clinical lung transplantation and treating a wide variety of endothelial disorders.	Univ Penn, Sch Med, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Temple Univ Hosp & Med Sch, Dept Pathol, Philadelphia, PA 19140 USA; Washington Univ, Sch Med, Div Cardiothorac Surg, St Louis, MO 63110 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Washington University (WUSTL)	Muzykantov, VR (corresponding author), Univ Penn, Sch Med, Inst Environm Med, Philadelphia, PA 19104 USA.	muzykant@mail.med.upenn.edu	Buerk, Donald G/F-6888-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041281, P50HL060290] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL41281, HL 60290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; Atochina EN, 1997, AM J RESP CRIT CARE, V156, P1114, DOI 10.1164/ajrccm.156.4.96-12116; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; BUERK DG, 1993, BIOSENSORS THEORY AP, P39; Chabot F, 1998, EUR RESPIR J, V11, P745; Christie JD, 1998, CHEST, V114, P51, DOI 10.1378/chest.114.1.51; Christofidou-Solomidou M, 2000, AM J PHYSIOL-LUNG C, V278, pL794, DOI 10.1152/ajplung.2000.278.4.L794; Christofidou-Solomidou M, 2002, AM J PATHOL, V160, P1155, DOI 10.1016/S0002-9440(10)64935-8; CORVO M, 1999, BIOCHIM BIOPHYS ACTA, P1; Danilov SM, 2001, AM J PHYSIOL-LUNG C, V280, pL1335, DOI 10.1152/ajplung.2001.280.6.L1335; DAVIES MG, 1993, ANN SURG, V218, P593, DOI 10.1097/00000658-199321850-00003; DUO L, 2000, NAT BIOTECHNOL, V18, P33; ECKENHOFF RG, 1992, J APPL PHYSIOL, V72, P1454, DOI 10.1152/jappl.1992.72.4.1454; Eppinger MJ, 1997, AM J PATHOL, V150, P1773; FREEMAN BA, 1982, LAB INVEST, V47, P412; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; Gow AJ, 1999, AM J PHYSIOL-LUNG C, V277, pL271, DOI 10.1152/ajplung.1999.277.2.L271; Hiratsuka M, 1998, J HEART LUNG TRANSPL, V17, P1238; Kelly RF, 2000, J LAB CLIN MED, V136, P427, DOI 10.1067/mlc.2000.110906; King RC, 2000, ANN THORAC SURG, V69, P1681, DOI 10.1016/S0003-4975(00)01425-9; Kozower BD, 2002, AM J TRANSPLANT, V2, P837, DOI 10.1034/j.1600-6143.2002.20905.x; Langer R, 1998, NATURE, V392, P5; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Li S, 2000, AM J PHYSIOL-LUNG C, V278, pL504, DOI 10.1152/ajplung.2000.278.3.L504; MARUYAMA K, 1990, P NATL ACAD SCI USA, V87, P5744, DOI 10.1073/pnas.87.15.5744; McIntosh DP, 2002, P NATL ACAD SCI USA, V99, P1996, DOI 10.1073/pnas.251662398; Meyers BF, 1999, ANN SURG, V230, P362, DOI 10.1097/00000658-199909000-00009; MIZUTA T, 1989, J THORAC CARDIOV SUR, V97, P578; Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379; Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213; Muzykantov VR, 2001, J CONTROL RELEASE, V71, P1, DOI 10.1016/S0168-3659(01)00215-2; Muzykantov VR, 1998, PATHOPHYSIOLOGY, V5, P15; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Novick RJ, 1996, ANN THORAC SURG, V62, P302, DOI 10.1016/0003-4975(96)00333-5; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Reynolds PN, 2001, NAT BIOTECHNOL, V19, P838, DOI 10.1038/nbt0901-838; Scherpereel A, 2002, J PHARMACOL EXP THER, V300, P777, DOI 10.1124/jpet.300.3.777; Scherpereel A, 2001, FASEB J, V15, P416, DOI 10.1096/fj.00-0022com; SIFLINGERBIRNBOIM A, 1993, J CELL PHYSIOL, V155, P234, DOI 10.1002/jcp.1041550203; Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795; TURRENS JF, 1984, J CLIN INVEST, V73, P87, DOI 10.1172/JCI111210; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Wiewrodt R, 2002, BLOOD, V99, P912, DOI 10.1182/blood.V99.3.912; Williams A, 1999, FREE RADICAL RES, V30, P383, DOI 10.1080/10715769900300421; Yabe Y, 1999, J PHARMACOL EXP THER, V289, P1176	46	116	124	2	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2003	21	4					392	398		10.1038/nbt806	http://dx.doi.org/10.1038/nbt806			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	664VH	12652312				2023-01-03	WOS:000182082400020
J	Shiraki, T; Sakai, N; Kanaya, E; Jingami, H				Shiraki, T; Sakai, N; Kanaya, E; Jingami, H			Activation of orphan nuclear constitutive androstane receptor requires subnuclear targeting by peroxisome proliferator-activated receptor gamma coactivator-1 alpha - Possible link between xenobiotic response and nutritional state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; TRANSCRIPTIONAL COACTIVATOR; HEPATIC GLUCONEOGENESIS; HORMONE-RECEPTOR; SPLICING FACTOR; SR PROTEINS; CYP2B GENE; PGC-1; CAR; ALPHA	In contrast to the classical nuclear receptors, the constitutive androstane receptor (CAR) is transcriptionally active in the absence of ligand. In the course of searching for the mediator of CAR activation, we found that ligand-independent activation of CAR was achieved in cooperation with the peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha). PGC-1beta, a PGC-1alpha homologue, also activated CAR to less of an extent than PGC-1alpha. Coexpression of the ligand-binding domain of a heterodimerization partner, retinoid X receptor alpha, enhanced the PGC-1alpha-mediated activation of CAR, although it had a weak effect on the basal activity of CAR in the absence of PGC-1alpha. Both the N-terminal region, with the LXXLL motif, and the C-terminal region, with a serine/arginine-rich domain (RS domain), in PGC-1alpha were required for full activation of CAR. Pull-down experiments using recombinant proteins revealed that CAR directly interacted with both the LXXLL motif and the RS domain. Furthermore, we demonstrated that the RS domain of PGC-1alpha was required for CAR localization at nuclear speckles. These results indicate that PGC-1alpha mediates the ligand-independent activation of CAR by means of subnuclear targeting through the RS domain of PGC-1alpha.	Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan		Jingami, H (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.							Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Clayton GM, 2001, P NATL ACAD SCI USA, V98, P1549, DOI 10.1073/pnas.041611298; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Dussault I, 2002, MOL CELL BIOL, V22, P5270, DOI 10.1128/MCB.22.15.5270-5280.2002; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Glass CK, 2000, GENE DEV, V14, P121; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502	35	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11344	11350		10.1074/jbc.M212859200	http://dx.doi.org/10.1074/jbc.M212859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551939	Green Submitted, hybrid			2023-01-03	WOS:000181855400062
J	Lokkegaard, E; Pedersen, AT; Heitmann, BL; Jovanovic, Z; Keiding, N; Hundrup, YA; Obel, EB; Ottesen, B				Lokkegaard, E; Pedersen, AT; Heitmann, BL; Jovanovic, Z; Keiding, N; Hundrup, YA; Obel, EB; Ottesen, B			Relation between hormone replacement therapy and ischaemic heart disease in women: prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; PLASMA-LIPIDS; RISK FACTOR; PREVENTION; NONUSERS; COHORT; NIDDM	Objective To investigate the risk of ischaemic heart disease and myocardial infarction among women using hormone replacement therapy, especially the potential modifying effect of cardiovascular risk factors. Design Prospective observational study. Setting Denmark. Participants 19 898 nurses aged 45 and over completing a questionnaire on lifestyle and use of hormone replacement therapy in 1993. Main outcome measures All cases of death and incident cases of ischaemic heart disease and myocardial infarction until the end of 1998. Results Current users of hormone replacement therapy smoked more, consumed more alcohol, had lower self rated health, but were slimmer and had a lower prevalence of diabetes than never users. In current users compared with never users, hormone replacement therapy had no protective effect on ischaemic heart disease (hazard ratio 1.2, 0.9 to 1.7) or myocardial infarction (1.0, 0.6 to 1.7), whereas current users with diabetes had an increased risk of death (3.2, 1.4 to 7.5), ischaemic heart disease (4.2, 1.4 to 12.5), and myocardial infarction (9.2, 2.0 to 41.4) compared with never users with diabetes. Conclusion Hormone replacement therapy showed no protective effect on ischaemic heart disease, but there was a significantly increased risk of death from all causes and ischaemic heart disease among women with diabetes.	Hvidovre Univ Hosp, Dept Obstet & Gynaecol, DK-2650 Hvidovre, Denmark; Univ Copenhagen, Rigshosp, Juliane Marie Ctr, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Panum Inst, Dept Biostat, DK-2100 Copenhagen, Denmark; Natl Inst Publ Hlth, Danish Nurse Study, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Inst Prevent Med, Res Unit Dietary Studies, DK-1399 Copenhagen, Denmark	University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen	Lokkegaard, E (corresponding author), Hvidovre Univ Hosp, Dept Obstet & Gynaecol, Kettegard Alle 30, DK-2650 Hvidovre, Denmark.	loekkegaard@dadlnet.dk	Andersen, Zorana Jovanovic/P-4983-2014	Andersen, Zorana Jovanovic/0000-0003-4138-9828; Lokkegaard, Ellen/0000-0003-4149-5663; Heitmann, Berit Lilienthal/0000-0002-6809-4504				Andersson B, 1997, J CLIN ENDOCR METAB, V82, P638, DOI 10.1210/jc.82.2.638; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; Brussaard HE, 1997, DIABETOLOGIA, V40, P843, DOI 10.1007/s001250050758; Cornu C, 2000, MATURITAS, V37, P95, DOI 10.1016/S0378-5122(00)00164-X; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; Friday KE, 2001, J CLIN ENDOCR METAB, V86, P48, DOI 10.1210/jc.86.1.48; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY J, 2002, JAMA-J AM MED ASSOC, V288, P49; Grodstein F, 1999, EPIDEMIOLOGY, V10, P476, DOI 10.1097/00001648-199909000-00003; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Gu K, 1999, JAMA-J AM MED ASSOC, V281, P1291, DOI 10.1001/jama.281.14.1291; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hundrup YA, 2000, ACTA OBSTET GYN SCAN, V79, P194, DOI 10.1080/j.1600-0412.2000.079003194.x; Hundrup YA, 2002, SCAND J PUBLIC HEALT, V30, P47, DOI 10.1080/140349401753481583; Koh KK, 2001, J AM COLL CARDIOL, V38, P1409, DOI 10.1016/S0735-1097(01)01566-2; Manwaring P, 2000, MATURITAS, V34, P239, DOI 10.1016/S0378-5122(99)00112-7; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Rodstrom K, 1999, BMJ-BRIT MED J, V319, P890, DOI 10.1136/bmj.319.7214.890; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Troisi RJ, 2000, OBSTET GYNECOL, V96, P665, DOI 10.1097/00006250-200011000-00005	25	32	33	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	2003	326	7386					426	428A		10.1136/bmj.326.7386.426	http://dx.doi.org/10.1136/bmj.326.7386.426			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	651KA	12595383	Green Published, Bronze			2023-01-03	WOS:000181318000020
J	Groner, JI				Groner, JI			Lethal injection: a stain on the face of medicine	BRITISH MEDICAL JOURNAL			English	Article									Childrens Hosp, Dept Surg, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Groner, JI (corresponding author), Childrens Hosp, Dept Surg, 700 Childrens Dr, Columbus, OH 43205 USA.		Groner, Jonathan/E-3156-2011	Groner, Jonathan/0000-0002-0998-593X				*AM COLL PHYS HUM, 1994, BREACH TRUST PHYS PA; *AM MED ASS, 2000, COD MED ETH CURR OP, P15; ANDERSON K, 1982, TIME            1220, P28; Christen A G, 2000, J Hist Dent, V48, P117; COLBURN D, 1990, WASHINGTON POST 1211, pZ14; COOK R, 2002, ATLANTA J CONST 0125, pC3; Emanuel LL, 2001, ANN INTERN MED, V135, P922, DOI 10.7326/0003-4819-135-10-200111200-00013; Farber NJ, 2001, ANN INTERN MED, V135, P884, DOI 10.7326/0003-4819-135-10-200111200-00008; Gallagher H.G., 1995, TRUST BETRAYED PATIE; *GEORG DEP CORR, 2000, ADM EX PROC LETH INJ; HOBSON S, 2002, AUGUSTA CHRNICL 0125; Lifton Robert Jay, 2000, WHO OWNS DEATH CAPIT; PRICE J, 1991, WASHINGTON TIME 0103, pA4; SHULL RK, 1996, INDIANAPOLIS NE 0813, pA9; TROMBLEY S, 1992, EXECUTION PROTOCOL I; WEINER DB, 1972, J AMER MED ASSOC, V220, P85, DOI 10.1001/jama.220.1.85	16	18	18	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					1026	1028		10.1136/bmj.325.7371.1026	http://dx.doi.org/10.1136/bmj.325.7371.1026			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411367	Green Published			2023-01-03	WOS:000179415600029
J	Piantadosi, CA				Piantadosi, CA			Perspective - Carbon monoxide poisoning	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Duke Univ, Med Ctr, Durham, NC 27710 USA	Duke University	Piantadosi, CA (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.								0	75	79	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1054	1055		10.1056/NEJMp020104	http://dx.doi.org/10.1056/NEJMp020104			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362005				2023-01-03	WOS:000178332900001
J	Jost, S; Bernard, MC; Kaiser, L; Yerly, S; Hirschel, B; Samri, A; Autran, B; Goh, LE; Perrin, L				Jost, S; Bernard, MC; Kaiser, L; Yerly, S; Hirschel, B; Samri, A; Autran, B; Goh, LE; Perrin, L			A patient with HIV-1 superinfection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SEROCONVERSION; PROGRESSION; COINFECTION; INFECTIONS; RESISTANCE; AIDS		Univ Geneva, Div Infect Dis, CH-1211 Geneva 4, Switzerland; Hop La Pitie Salpetriere, Lab Immunol Cellulaire, Paris, France; GlaxoSmithKline, Clin Dev Med Affairs, Greenford, Middx, England	University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; GlaxoSmithKline	Perrin, L (corresponding author), Univ Hosp Geneva, Virol Lab, CH-1211 Geneva 14, Switzerland.			Kaiser, Laurent/0000-0002-0857-2252				ANGEL JB, 2000, 7 C RETR OPP INF SAN, P235; [Anonymous], PHYLIP PHYLOGENY INF; Farzadegan H, 1996, J ACQ IMMUN DEF SYND, V13, P448, DOI 10.1097/00042560-199612150-00008; Goh L E, 2001, HIV Clin Trials, V2, P438; Kampinga GA, 1997, VIROLOGY, V227, P63, DOI 10.1006/viro.1996.8318; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997; *LOS AL NAT LAB, 2002, HIV SEQ DAT BAS CIRC; Malim MH, 2001, CELL, V104, P469, DOI 10.1016/S0092-8674(01)00234-3; Samri A, 2000, J VIROL, V74, P9306, DOI 10.1128/JVI.74.19.9306-9312.2000; Shibata R, 1996, J VIROL, V70, P4361, DOI 10.1128/JVI.70.7.4361-4369.1996; StahlHennig C, 1996, J GEN VIROL, V77, P2969, DOI 10.1099/0022-1317-77-12-2969; Stephens EB, 1997, VIROLOGY, V234, P328, DOI 10.1006/viro.1997.8662; Yerly S, 2001, AIDS, V15, P2287, DOI 10.1097/00002030-200111230-00010; Yerly S, 2001, J INFECT DIS, V184, P369, DOI 10.1086/322036; ZHU TF, 1995, J VIROL, V69, P1324, DOI 10.1128/JVI.69.2.1324-1327.1995; 1999, CLIN INVESTIGATORS B	17	186	190	0	13	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	2002	347	10					731	736		10.1056/NEJMoa020263	http://dx.doi.org/10.1056/NEJMoa020263			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	589NH	12213944				2023-01-03	WOS:000177765800005
J	Courtney, SE; Durand, DJ; Asselin, JM; Hudak, ML; Aschner, JL; Shoemaker, CT				Courtney, SE; Durand, DJ; Asselin, JM; Hudak, ML; Aschner, JL; Shoemaker, CT		Neonatal Ventilation Study Grp	High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERMITTENT MANDATORY VENTILATION; RESPIRATORY-DISTRESS-SYNDROME; EXOGENOUS SURFACTANT THERAPY; HYALINE-MEMBRANE DISEASE; PRETERM INFANTS; INTRAVENTRICULAR HEMORRHAGE; LUNG INJURY; TRIGGERED VENTILATION; VOLUME OPTIMIZATION; CONTROLLED-TRIAL	Background The efficacy and safety of early high-frequency oscillatory ventilation as compared with conventional synchronized intermittent mandatory ventilation for the treatment of infants with very low birth weight have not been established. Methods We conducted a randomized, multicenter clinical trial to determine whether infants treated with early high-frequency oscillatory ventilation were more likely than infants treated with synchronized intermittent mandatory ventilation to be alive without requiring supplemental oxygen at 36 weeks of postmenstrual age. Eligible infants weighed 601 to 1200 g at birth, were less than four hours of age, had received one dose of surfactant, and required ventilation with a mean airway pressure of at least 6 cm of water and a fraction of inspired oxygen of at least 0.25. Infants were stratified according to birth weight and exposure to prenatal corticosteroids and then randomly assigned to high-frequency oscillatory ventilation or synchronized intermittent mandatory ventilation. Ventilation was managed according to protocols designed to optimize lung inflation and blood gas values. Results Five hundred infants were enrolled in the study. Infants randomly assigned to high-frequency oscillatory ventilation were successfully extubated earlier than infants assigned to synchronized intermittent mandatory ventilation (P < 0.001). Of infants assigned to high-frequency oscillatory ventilation, 56 percent were alive without a need for supplemental oxygen at 36 weeks of postmenstrual age, as compared with 47 percent of those receiving synchronized intermittent mandatory ventilation (P = 0.046). There was no difference between the groups in the risk of intracranial hemorrhage, cystic periventricular leukomalacia, or other complications. Conclusions There was a small but significant benefit of high-frequency oscillatory ventilation in terms of the pulmonary outcome for very-low-birth-weight infants without an increase in the occurrence of other complications of premature birth.	Cooper Univ Hosp, Div Neonatol, Camden, NJ 08103 USA; Childrens Hosp & Res Ctr, Div Neonatol, Oakland, CA USA; Childrens Hosp & Res Ctr, Neonatal Pediat Res Grp, Oakland, CA USA; Univ Florida, Div Neonatol, Jacksonville, FL USA; Wolfson Childrens Hosp, Div Neonatol, Jacksonville, FL USA; Wake Forest Univ, Div Neonatol, Sch Med, Winston Salem, NC 27109 USA; Meritcare Childrens Hosp, Fargo, ND USA	Cooper University Hospital; State University System of Florida; University of Florida; Wake Forest University	Courtney, SE (corresponding author), Long Isl Jewish Med Ctr, Schneider Childrens Hosp, Div Neonatol, 270-05 76th Ave, New Hyde Pk, NY 11040 USA.	scourtney@lij.edu		Durand, David/0000-0003-1181-0941				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; AMITAY M, 1993, CRIT CARE MED, V21, P118, DOI 10.1097/00003246-199301000-00022; BERNSTEIN G, 1994, AM J RESP CRIT CARE, V150, P1444, DOI 10.1164/ajrccm.150.5.7952573; Bernstein G, 1996, J PEDIATR-US, V128, P453, DOI 10.1016/S0022-3476(96)70354-2; Bhuta T, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.5.e6; BOYNTON BR, 1991, J APPL PHYSIOL, V70, P701, DOI 10.1152/jappl.1991.70.2.701; BRYAN AC, 1986, AM REV RESPIR DIS, V133, P928; BRYAN AC, 1991, PEDIATRICS, V87, P565; Cannon ML, 2000, AM J RESP CRIT CARE, V162, P2109, DOI 10.1164/ajrccm.162.6.9906112; CHAN V, 1993, EUR J PEDIATR, V152, P51, DOI 10.1007/BF02072516; Claris O, 1996, BIOL NEONATE, V70, P29; Clark RH, 2000, PEDIATRICS, V105, P112, DOI 10.1542/peds.105.1.112; CLARK RH, 1992, PEDIATRICS, V89, P5; Clark RH, 1996, PEDIATRICS, V98, P1058; CLEARY JP, 1995, J PEDIATR-US, V126, P407, DOI 10.1016/S0022-3476(95)70460-4; DELEMOS RA, 1987, PEDIATR RES, V21, P594, DOI 10.1203/00006450-198706000-00018; DELEMOS RA, 1989, ACTA ANAESTH SCAND, V33, P102, DOI 10.1111/j.1399-6576.1989.tb03013.x; Durand D J, 2001, J Perinatol, V21, P221, DOI 10.1038/sj.jp.7210527; DURAND DJ, 1993, J PEDIATR-US, V122, P609; Froese AB, 1997, CRIT CARE MED, V25, P906, DOI 10.1097/00003246-199706000-00004; FROESE AB, 1989, ACTA ANAESTH SCAND, V33, P126, DOI 10.1111/j.1399-6576.1989.tb03018.x; FROESE AB, 1993, AM REV RESPIR DIS, V148, P569, DOI 10.1164/ajrccm/148.3.569; Gerstmann DR, 1996, PEDIATRICS, V98, P1044; GERSTMANN DR, 1990, PEDIATR RES, V28, P367, DOI 10.1203/00006450-199010000-00013; GOETZ MC, 1995, AM J PERINAT, V12, P325, DOI 10.1055/s-2007-994486; GREENOUGH A, 1991, J PERINAT MED, V19, P471, DOI 10.1515/jpme.1991.19.6.471; HAMILTON PP, 1983, J APPL PHYSIOL, V55, P131, DOI 10.1152/jappl.1983.55.1.131; HERSHENSON MB, 1995, CRIT CARE MED, V23, P1443, DOI 10.1097/00003246-199508000-00022; HIFI Study Group, 1989, N Engl J Med, V320, P88; HORBAR JD, 2000, VERMONT OXFORD NETWO; Ito Y, 1998, AM J RESP CRIT CARE, V157, P149, DOI 10.1164/ajrccm.157.1.9701073; JACKSON JC, 1994, AM J RESP CRIT CARE, V150, P534, DOI 10.1164/ajrccm.150.2.8049842; Kalenga M, 1998, J APPL PHYSIOL, V84, P1174, DOI 10.1152/jappl.1998.84.4.1174; Keszler M, 1997, PEDIATRICS, V100, P593, DOI 10.1542/peds.100.4.593; KESZLER M, 1991, J PEDIATR-US, V119, P85, DOI 10.1016/S0022-3476(05)81046-7; KINSELLA JP, 1991, PEDIATR RES, V29, P160, DOI 10.1203/00006450-199102000-00012; MCCULLOCH PR, 1988, AM REV RESPIR DIS, V137, P1185, DOI 10.1164/ajrccm/137.5.1185; MENT LR, 1994, PEDIATRICS, V93, P543; MEREDITH KS, 1989, J APPL PHYSIOL, V66, P2150, DOI 10.1152/jappl.1989.66.5.2150; Moriette G, 2001, PEDIATRICS, V107, P363, DOI 10.1542/peds.107.2.363; OGAWA Y, 1993, EARLY HUM DEV, V32, P1, DOI 10.1016/0378-3782(93)90088-C; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PARDOU A, 1993, INTENS CARE MED, V19, P406, DOI 10.1007/BF01724881; PATEL CA, 1995, ARCH PEDIAT ADOL MED, V149, P317, DOI 10.1001/archpedi.1995.02170150097019; Perlman JM, 1996, PEDIATRICS, V97, P822; Pierrat V, 2001, ARCH DIS CHILD-FETAL, V84, pF151, DOI 10.1136/fn.84.3.F151; Pillow JJ, 1999, J APPL PHYSIOL, V87, P407, DOI 10.1152/jappl.1999.87.1.407; Plavka R, 1999, INTENS CARE MED, V25, P68, DOI 10.1007/s001340050789; Rimensberger PC, 2000, PEDIATRICS, V105, P1202, DOI 10.1542/peds.105.6.1202; ROJAS MA, 1995, J PEDIATR-US, V126, P605, DOI 10.1016/S0022-3476(95)70362-4; Simma B, 1996, PEDIATR PULM, V22, P263, DOI 10.1002/(SICI)1099-0496(199610)22:4<263::AID-PPUL6>3.0.CO;2-N; Stevenson DK, 1998, AM J OBSTET GYNECOL, V179, P1632, DOI 10.1016/S0002-9378(98)70037-7; Suzuki H, 1992, Acta Paediatr Jpn, V34, P494; Synnes AR, 2001, J PEDIATR-US, V138, P525, DOI 10.1067/mpd.2001.111822; Thome U, 1999, J PEDIATR-US, V135, P39, DOI 10.1016/S0022-3476(99)70325-2; TRUOG WE, 1984, AM REV RESPIR DIS, V130, P76; Wada K, 1997, J APPL PHYSIOL, V83, P1054, DOI 10.1152/jappl.1997.83.4.1054; Yoder BA, 2000, AM J RESP CRIT CARE, V162, P1867, DOI 10.1164/ajrccm.162.5.9912145; Zubrow A B, 1995, J Perinatol, V15, P470	59	214	248	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	2002	347	9					643	652		10.1056/NEJMoa012750	http://dx.doi.org/10.1056/NEJMoa012750			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	587ZT	12200551	Bronze			2023-01-03	WOS:000177675500003
J	Nelson, HD				Nelson, HD			Assessing benefits and harms of hormone replacement therapy - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HEART; METAANALYSIS; DISEASE; CANCER; WOMEN; RISK	An estimated one third of postmenopausal women in the United States use hormone replacement therapy (HRT) to treat symptoms of menopause and prevent chronic conditions. In the context of this widespread use, evidence has been growing about the potential harms of HRT, particularly regarding long-term use. Physicians and patients are often confused about how to use results of studies in individual cases. This article applies the current state of evidence for the benefits and harms of HRT to management decisions in 4 clinical situations. Patient preferences, as well as evidence, are important for these decisions. Benefits and harms need to be readdressed periodically to apply newly published evidence and to reassess emerging risks, comorbidities, and needs of individuals.	Oregon Hlth Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Evidence Based Practice Ctr, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Med Serv, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Nelson, HD (corresponding author), Oregon Hlth Sci Univ, Div Med Informat & Outcomes Res, Mail Code BICC 504,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							Cauley JA, 2001, J CLIN ENDOCR METAB, V86, P5700, DOI 10.1210/jc.86.12.5700; CRANNEY A, 2000, NAT I HLTH CONS DEV; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Grady D, 2002, JAMA-J AM MED ASSOC, V287, P2130, DOI 10.1001/jama.287.16.2130; Grady D, 2001, OBSTET GYNECOL, V97, P116, DOI 10.1016/S0029-7844(00)01115-7; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUMPHREY LL, IN PRESS ANN INTERN; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; National Cancer Institute, BREAST CANC RISK ASS; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; NELSON HD, IN PRESS ARCH INTERN; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004	21	21	23	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	2002	288	7					882	884		10.1001/jama.288.7.882	http://dx.doi.org/10.1001/jama.288.7.882			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	585FC	12186606	Bronze			2023-01-03	WOS:000177513100031
J	Dabis, F				Dabis, F			Children and HIV in Africa: what is next?	LANCET			English	Editorial Material									Univ Victor Segalen, INSERM, U593, Inst Sante Publ Epidemiol & Dev, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Dabis, F (corresponding author), Univ Victor Segalen, INSERM, U593, Inst Sante Publ Epidemiol & Dev, F-33076 Bordeaux, France.		DABIS, FRANCOIS/S-9298-2019	DABIS, FRANCOIS/0000-0002-1614-8857				ASSIIMWEOKIROR G, 1997, AIDS, V11, P1757; *COL U MAILM SCH P, MTCT PLUS EXP HIV AI; Dabis F, 2002, LANCET, V359, P2097, DOI 10.1016/S0140-6736(02)08909-2; DABIS F, 2003, ANTIVIR THER S, V8, pS236; Foster G, 2002, NEW ENGL J MED, V346, P1907, DOI 10.1056/NEJMsb020718; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; NEWELL ML, 2003, 13 INT C AIDS SEX TR; OTIENO P, 2003, 13 INT C AIDS SEX TR; Rouet F, 2003, PEDIATRICS, V112, pE289, DOI 10.1542/peds.112.4.e289; *UNAIDS, 2002, HIV AIDS EP SURV UPD; *WHO, 2003, GLOB AIDS TREATM STR	11	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1597	1598		10.1016/S0140-6736(03)14839-8	http://dx.doi.org/10.1016/S0140-6736(03)14839-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630437				2023-01-03	WOS:000186637400005
J	Lang, AE				Lang, AE			Subthalamic stimulation for Parkinson's disease - Living better electrically?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Toronto, Toronto, ON, Canada	University of Toronto	Lang, AE (corresponding author), Univ Toronto, Toronto, ON, Canada.		Lang, Anthony/ABF-8114-2021	Lang, Anthony/0000-0003-1229-3667				Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4	3	10	10	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1888	1891		10.1056/NEJMp038160	http://dx.doi.org/10.1056/NEJMp038160			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614163				2023-01-03	WOS:000186502400002
J	Bruera, E; Kim, HN				Bruera, E; Kim, HN			Cancer pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORPHINE; SYSTEM; TRIAL		Univ Texas, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil med, Unit 008, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bruera, E (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil med, Unit 008, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Bennett, Sally/B-3367-2010; Bruera, Eduardo/AAA-1550-2022	Bennett, Sally/0000-0002-4353-5027; 				BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; Bruera E, 1996, J PAIN SYMPTOM MANAG, V11, P147, DOI 10.1016/0885-3924(95)00161-1; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Bruera E, 1989, J Pain Symptom Manage, V4, P3, DOI 10.1016/0885-3924(89)90057-2; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Bruera E, 1999, SUPPORT CARE CANCER, V7, P321, DOI 10.1007/s005200050269; BRUERA E, IN PRES J CLIN ONCOL; BRUERA E, 2003, CLIN PAIN MANAGEMENT, P63; BRUERA E, IN PRESS J PAIN SYMP; Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; Centeno C, 2003, HDB ADV CANC CARE, P27; CHERNEY IN, 2002, PRINCIPLE PRACTICE P, P3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Foley KM, 2000, HOSP PRACT, V35, P101, DOI 10.3810/hp.2000.04.193; Hassenbusch SJ, 2003, CANCER PAIN: ASSESSMENT AND MANAGEMENT, P261, DOI 10.1017/CBO9780511550096.016; Mancini I, 2002, GASTROINTESTINAL SYM, P193; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P338, DOI 10.1016/S0885-3924(01)00250-0; PEREIRA J, 1998, TOPICS PALLIATIVE CA, V3, P79; RAWLINS MC, 1998, PALLIATIVE MED, P355; Ripamonti C, 2003, CANCER PAIN: ASSESSMENT AND MANAGEMENT, P124, DOI 10.1017/CBO9780511550096.009; Ripamonti C, 1998, TUMORI J, V84, P289, DOI 10.1177/030089169808400302; Ross JR, 2003, BMJ-BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; STRASSER F, 2003, IN PRESS CANC PAIN; WHO, 1996, WORLD HLTH REP 1996; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; GUIDELINES USING EDM	27	124	133	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2476	2479		10.1001/jama.290.18.2476	http://dx.doi.org/10.1001/jama.290.18.2476			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742LH	14612485				2023-01-03	WOS:000186518300035
J	Bruynseels, P; Jorens, PG; Demey, HE; Goossens, H; Pattyn, SR; Elseviers, MM; Weyler, J; Bossaert, LL; Mentens, Y; Ieven, M				Bruynseels, P; Jorens, PG; Demey, HE; Goossens, H; Pattyn, SR; Elseviers, MM; Weyler, J; Bossaert, LL; Mentens, Y; Ieven, M			Herpes simplex virus in the respiratory tract of critical care patients: a prospective study	LANCET			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; DISTRESS SYNDROME; SURGICAL PATIENTS; INFECTION; PATHOGENESIS; MECHANISMS	Background Herpes simplex virus (HSV) is occasionally detected in the lower respiratory tract of patients in intensive care, but its clinical importance in such situations remains unclear. We did a prospective cohort study to define the prevalence, origin, risk factors, and clinical relevance of HSV in the respiratory tract of patients undergoing critical care. Methods We tested 764 patients admitted to intensive care for the presence of HSV in the respiratory tract, and assessed statistical relations between this virus and clinical variables. Findings HSV was detected by oropharyngeal swab in the upper respiratory tract of 169 (22%) of 764 patients, within 10 days of admission for 150 (89%) of these individuals. The virus was isolated in 58 (16%) of 361 patients whose lower respiratory tract was sampled. The presence of HSV in the throat was a risk factor for development of HSV infections in the lower respiratory tract (p<0-001). HSV was isolated most frequently in patients with severe disease. HSV in the throat was associated with acute respiratory distress syndrome (p<0-001) and with increased length of stay in intensive care (P<0-001). Interpretation Our data suggest that HSV reactivation or infection of the upper respiratory tract is frequent among patients in intensive care, and is a risk factor for development of lower respiratory tract infection with this virus, possibly by means of aspiration.	Univ Antwerp Hosp, Dept Microbiol, B-2650 Antwerp, Belgium; Univ Antwerp Hosp, Dept Intens Care Med, B-2650 Antwerp, Belgium; Univ Antwerp Hosp, Dept Resp Med, B-2650 Antwerp, Belgium; Univ Antwerp, Dept Epidemiol & Community Med, B-2020 Antwerp, Belgium	University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp	Bruynseels, P (corresponding author), Univ Antwerp Hosp, Dept Microbiol, Wilrijkstr 10, B-2650 Antwerp, Belgium.		Weyler, Joost JJ/O-8594-2016	Weyler, Joost JJ/0000-0001-7271-5492; Elseviers, Monique/0000-0001-9415-6900				AURELIAN L, 2000, CLIN VIROLOGY MANUAL; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BEYERS RJ, 1996, EUR RESPIR J, V9, P2313; Cook CH, 1998, AM J SURG, V176, P357, DOI 10.1016/S0002-9610(98)00205-0; ESTES RJ, 1995, INTENS CARE MED, V21, P365, DOI 10.1007/BF01705418; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Hart GD, 2001, REV MED VIROL, V11, P73, DOI 10.1002/rmv.309; JORENS PG, 1997, YB INTENSIVE CARE EM, P83; Kingreen D, 1997, BONE MARROW TRANSPL, V20, P989, DOI 10.1038/sj.bmt.1700995; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Koerner RJ, 1997, J HOSP INFECT, V35, P83, DOI 10.1016/S0195-6701(97)90096-7; LEVEN M, 1996, J INFECT DIS, V173, P1445; Livingston BM, 2000, CRIT CARE MED, V28, P389, DOI 10.1097/00003246-200002000-00017; MCINTOSH K, 1990, FIELDS VIROLOGY; MCMILLAN JA, 1993, PEDIATR INFECT DIS J, V12, P280, DOI 10.1097/00006454-199304000-00004; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P781, DOI 10.1056/NEJM197310112891505; PORTEOUS C, 1984, CRIT CARE MED, V12, P626, DOI 10.1097/00003246-198408000-00003; RAMSEY PG, 1982, ANN INTERN MED, V97, P813, DOI 10.7326/0003-4819-97-6-813; TUXEN DV, 1982, AM REV RESPIR DIS, V126, P416; TUXEN DV, 1987, AM REV RESPIR DIS, V136, P402, DOI 10.1164/ajrccm/136.2.402; Ursi D, 1998, MOL CELL PROBE, V12, P235, DOI 10.1006/mcpr.1998.0180; WARREN KG, 1978, NEW ENGL J MED, V298, P1068, DOI 10.1056/NEJM197805112981907; Whitley RJ, 2001, LANCET, V357, P1513, DOI 10.1016/S0140-6736(00)04638-9	23	116	116	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1536	1541		10.1016/S0140-6736(03)14740-X	http://dx.doi.org/10.1016/S0140-6736(03)14740-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615108				2023-01-03	WOS:000186464500009
J	Elwyn, G; Edwards, A; Britten, N				Elwyn, G; Edwards, A; Britten, N			"Doing prescribing": how doctors can be more effective	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHARED DECISION-MAKING; GENERAL-PRACTICE; CARE; PRESCRIPTIONS; CONSULTATIONS; MANAGEMENT		Univ Wales Swansea, Swansea Clin Sch, Primary Care Grp, Swansea SA2 8PP, W Glam, Wales; Peninsula Med Sch, Inst Clin Educ, Exeter, Devon, England	Swansea University; University of Exeter	Elwyn, G (corresponding author), Univ Wales Swansea, Swansea Clin Sch, Primary Care Grp, Swansea SA2 8PP, W Glam, Wales.	g.elwyn@swansea.ac.uk	Elwyn, G./L-4292-2015; Elwyn, Glyn/B-4798-2009	Elwyn, Glyn/0000-0002-0917-6286				ASHCROFT A, 2001, EVIDENCE BASED PATIE; Barry CA, 2000, BRIT MED J, V320, P1246, DOI 10.1136/bmj.320.7244.1246; BEKKER H, 2003, ENCY HUMAN GENOME ET; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; Britten Nicky, 2002, Health Expect, V5, P256, DOI 10.1046/j.1369-6513.2002.00187.x; Campion P, 2002, BRIT MED J, V325, P691, DOI 10.1136/bmj.325.7366.691; Carter S, 2003, QUESTION CHOICE COMP; Coulter A, 2002, AUTONOMOUS PATIENT; Cox K, 2002, SYSTEMATIC REV COMMU; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; Drew P, 2001, Health Expect, V4, P58, DOI 10.1046/j.1369-6513.2001.00125.x; Elwyn G, 1999, BRIT J GEN PRACT, V49, P477; Elwyn G, 2000, BRIT J GEN PRACT, V50, P892; Elwyn G, 2003, QUAL SAF HEALTH CARE, V12, P93, DOI 10.1136/qhc.12.2.93; Gafaranga J, 2003, FAM PRACT, V20, P242, DOI 10.1093/fampra/cmg303; Haynes R B, 2002, Cochrane Database Syst Rev, pCD000011; JENKINS L, 2002, RESOURCE PACK REV MO; Marinker M, 1997, BRIT MED J, V314, P747, DOI 10.1136/bmj.314.7082.747; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; Stevenson FA, 2003, SOC SCI MED, V57, P513, DOI 10.1016/S0277-9536(02)00377-5; Stevenson FA, 2000, SOC SCI MED, V50, P829, DOI 10.1016/S0277-9536(99)00376-7; Weinstein Neil D., 1999, Journal of the National Cancer Institute Monographs, P15	25	73	74	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	2003	327	7419					864	867		10.1136/bmj.327.7419.864	http://dx.doi.org/10.1136/bmj.327.7419.864			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551110	Green Published			2023-01-03	WOS:000185921200032
J	Khodorova, A; Navarro, B; Jouaville, LS; Murphy, E; Rice, FL; Mazurkiewicz, JE; Long-Woodward, D; Stoffel, M; Strichartz, GR; Yukhananov, R; Davar, G				Khodorova, A; Navarro, B; Jouaville, LS; Murphy, E; Rice, FL; Mazurkiewicz, JE; Long-Woodward, D; Stoffel, M; Strichartz, GR; Yukhananov, R; Davar, G			Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury	NATURE MEDICINE			English	Article							PAIN-LIKE BEHAVIOR; SELECTIVE ANTAGONIST; LOCAL INJECTION; RAT; IDENTIFICATION; INVOLVEMENT; MECHANISMS; CHANNEL; POTENT; OPIATE	Endothelin-1 (ET-1) is a newly described pain mediator that is involved in the pathogenesis of pain states ranging from trauma to cancer. ET-1 is synthesized by keratinocytes in normal skin and is locally released after cutaneous injury. While it is able to trigger pain through its actions on endothelin-A (ETA) receptors of local nociceptors, it can coincidentally produce analgesia through endothelin-B (ETB) receptors. Here we map a new endogenous analgesic circuit, in which ETB receptor activation induces the release of beta-endorphin from keratinocytes and the activation of G-protein-coupled inwardly rectifying potassium channels (GIRKs, also named Kir-3) linked to opioid receptors on nociceptors. These results indicate the existence of an intrinsic feedback mechanism to control peripheral pain in skin, and establish keratinocytes as an ETB receptor-operated opioid pool.	Brigham & Womens Hosp, Mol Neurobiol Pain Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Cardiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Sensory Neurophysiol Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Harvard Skin Dis Res Ctr, Boston, MA 02115 USA; Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA; Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Pain Res Ctr, Neurogenom Lab, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Albany Medical College; Rockefeller University; Harvard University; Brigham & Women's Hospital	Davar, G (corresponding author), Brigham & Womens Hosp, Mol Neurobiol Pain Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	gdavar@zeus.bwh.harvard.edu						Ahn Gun Young, 1998, Journal of Dermatology (Tokyo), V25, P78; AKIL H, 1976, SCIENCE, V191, P961, DOI 10.1126/science.1251210; AKIL H, 1972, CR ACAD SCI D NAT, V274, P3603; Blanchet C, 2002, P NATL ACAD SCI USA, V99, P4674, DOI 10.1073/pnas.072075399; BLEDNOV YA, 2003, P NATL ACAD SCI USA, V100, P77; Broadbear JH, 2000, J PHARMACOL EXP THER, V294, P933; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carducci MA, 2002, J CLIN ONCOL, V20, P2171, DOI 10.1200/JCO.2002.08.028; Davar G, 1998, NEUROREPORT, V9, P2279, DOI 10.1097/00001756-199807130-00025; De-Melo JD, 1998, PAIN, V77, P261, DOI 10.1016/S0304-3959(98)00098-0; Fareed MU, 2000, J PAIN, V1, P46, DOI 10.1016/S1526-5900(00)90087-7; FERREIRA SH, 1989, J CARDIOVASC PHARM, V13, pS220, DOI 10.1097/00005344-198900135-00065; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.neuro.14.1.219; Gokin AP, 2001, J NEUROSCI, V21, P5358, DOI 10.1523/JNEUROSCI.21-14-05358.2001; Gutstein HB, 1998, NEUROREPORT, V9, P1777, DOI 10.1097/00001756-199806010-00019; HARGREAVES KM, 1990, AM J PHYSIOL, V258, pE235, DOI 10.1152/ajpendo.1990.258.2.E235; Harris JA, 1996, J PHYSIOL-PARIS, V90, P15, DOI 10.1016/0928-4257(96)87165-8; HICKEY KA, 1985, AM J PHYSIOL, V248, pC550, DOI 10.1152/ajpcell.1985.248.5.C550; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; Ikeda K, 2000, NEUROSCI RES, V38, P113, DOI 10.1016/S0168-0102(00)00144-9; Jarvis MF, 2000, EUR J PHARMACOL, V388, P29, DOI 10.1016/S0014-2999(99)00865-1; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Khodorova A, 2002, J NEUROSCI, V22, P7788; Luscher TF, 2000, CIRCULATION, V102, P2434, DOI 10.1161/01.CIR.102.19.2434; Machelska H, 1998, NAT MED, V4, P1425, DOI 10.1038/4017; Mark MD, 2000, EUR J BIOCHEM, V267, P5830, DOI 10.1046/j.1432-1327.2000.01670.x; MCQUAY H, 1998, EVIDENCE BASED RESOU, P23; Mitrovic I, 2003, P NATL ACAD SCI USA, V100, P271, DOI 10.1073/pnas.0136822100; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Piovezan AP, 2000, BRIT J PHARMACOL, V129, P961, DOI 10.1038/sj.bjp.0703154; Pomonis JD, 2001, J NEUROSCI, V21, P999, DOI 10.1523/JNEUROSCI.21-03-00999.2001; Rogalski SL, 1999, J NEUROCHEM, V72, P1409, DOI 10.1046/j.1471-4159.1999.721409.x; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Signorini S, 1997, P NATL ACAD SCI USA, V94, P923, DOI 10.1073/pnas.94.3.923; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; STEIN C, 1993, ANESTH ANALG, V76, P182; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Torrecilla M, 2002, J NEUROSCI, V22, P4328, DOI 10.1523/JNEUROSCI.22-11-04328.2002; Wacnik PW, 2001, J NEUROSCI, V21, P9355, DOI 10.1523/JNEUROSCI.21-23-09355.2001; Wettstein JG, 1996, PHARMACOL BIOCHEM BE, V53, P411, DOI 10.1016/0091-3057(95)02043-8; Wintzen M, 1996, J INVEST DERMATOL, V106, P673, DOI 10.1111/1523-1747.ep12345496; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zanello SB, 1999, ANN NY ACAD SCI, V885, P85; Zhou QL, 2001, NEUROREPORT, V12, P3853, DOI 10.1097/00001756-200112040-00050; Zhou ZR, 2002, J NEUROSCI, V22, P6325; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	49	185	188	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2003	9	8					1055	1061		10.1038/nm885	http://dx.doi.org/10.1038/nm885			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12847519				2023-01-03	WOS:000184484900030
J	Murciano, JC; Medinilla, S; Eslin, D; Atochina, E; Cines, DB; Muzykantov, VR				Murciano, JC; Medinilla, S; Eslin, D; Atochina, E; Cines, DB; Muzykantov, VR			Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes	NATURE BIOTECHNOLOGY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; RED-BLOOD-CELLS; MONOCLONAL-ANTIBODIES; THROMBOLYTIC THERAPY; MEDIATED DELIVERY; IN-VITRO; T-PA; LYSIS; ATTACHMENT; BIOTIN	A fibrinolytic agent consisting of a tissue-type plasminogen activator (tPA) coupled to the surface of red blood cells (RBCs) can dissolve nascent clots from within the clot, in a Trojan horse-like strategy, while having minimal effects on preexisting hemostatic clots or extravascular tissue. After intravenous injection, the fibrinolytic activity of RBC-tPA persisted in the bloodstream at least tenfold longer than did that of free tPA. In a model of venous thrombosis induced by intravenously injected fibrin microemboli aggregating in pulmonary vasculature, soluble tPA lysed pulmonary clots lodged before but not after tPA injection, whereas the converse was true for RBC-tPA. Free tPA failed to lyse occlusive carotid thrombosis whether injected before or after vascular trauma, whereas RBC-tPA circulating before, but not injected after, thrombus formation restored blood flow. This RBC-based drug delivery strategy alters the fibrinolytic profile of tPA, permitting prophylactic fibrinolysis.	Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Pediat Hematol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Muzykantov, VR (corresponding author), Univ Penn, Inst Environm Med, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	muzykant@mail.med.upenn.edu	Murciano, Juan Carlos/AAG-6253-2021; Atochina-Vasserman, Elena/AAN-2286-2020	Murciano, Juan Carlos/0000-0002-4894-046X; Atochina-Vasserman, Elena N/0000-0001-7950-7004	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066442, R01HL060169] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66442, HL-60169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578; Anand S, 1996, CIRCULATION, V94, P763, DOI 10.1161/01.CIR.94.4.763; Bax BE, 2000, BRIT J HAEMATOL, V109, P549, DOI 10.1046/j.1365-2141.2000.02059.x; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; BENEDICT CR, 1995, CIRCULATION, V92, P3032, DOI 10.1161/01.CIR.92.10.3032; BEUTLER E, 1977, P NATL ACAD SCI USA, V74, P4620, DOI 10.1073/pnas.74.10.4620; Blackall DP, 2001, BLOOD, V97, P551, DOI 10.1182/blood.V97.2.551; Brown WR, 2000, STROKE, V31, P707, DOI 10.1161/01.STR.31.3.707; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CAVILL I, 1988, BRIT J HAEMATOL, V70, P491, DOI 10.1111/j.1365-2141.1988.tb02522.x; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; Collen D, 1996, CIRCULATION, V93, P857, DOI 10.1161/01.CIR.93.5.857; CORNACOFF JB, 1983, J CLIN INVEST, V71, P236, DOI 10.1172/JCI110764; Deklunder G, 1998, STROKE, V29, P1821, DOI 10.1161/01.STR.29.9.1821; Farrehi PM, 1998, CIRCULATION, V97, P1002; Figueroa BE, 1998, STROKE, V29, P1202, DOI 10.1161/01.STR.29.6.1202; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; Gurwitz JH, 1998, ANN INTERN MED, V129, P597, DOI 10.7326/0003-4819-129-8-199810150-00002; HEEREMANS JLM, 1995, THROMB HAEMOSTASIS, V73, P488; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; HOLVOET P, 1993, CIRCULATION, V87, P1007, DOI 10.1161/01.CIR.87.3.1007; IHLER GM, 1973, P NATL ACAD SCI USA, V70, P2663, DOI 10.1073/pnas.70.9.2663; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; KALOFONOS HP, 1990, J NUCL MED, V31, P1791; Krishnamurti C, 1996, BLOOD, V87, P14; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Langer R, 1998, NATURE, V392, P5; MAGNANI M, 1992, P NATL ACAD SCI USA, V89, P6477, DOI 10.1073/pnas.89.14.6477; MAGNANI M, 1992, BIOTECHNOL APPL BIOC, V16, P188; Magnani M, 2002, GENE THER, V9, P749, DOI 10.1038/sj.gt.3301758; Murciano JC, 2002, AM J PHYSIOL-LUNG C, V282, pL529, DOI 10.1152/ajplung.00112.2001; MUZYKANTOV VR, 1994, ANAL BIOCHEM, V223, P142, DOI 10.1006/abio.1994.1559; MUZYKANTOV VR, 1991, BLOOD, V78, P2611; Muzykantov VR, 1996, ANAL BIOCHEM, V241, P109, DOI 10.1006/abio.1996.0384; Muzykantov VR, 1996, J PHARMACOL EXP THER, V279, P1026; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; PAGANELLI G, 1992, EUR J NUCL MED, V19, P322; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; Rogove AD, 1999, J CELL SCI, V112, P4007; Rossi L, 2001, BIOTECHNOL APPL BIOC, V33, P85, DOI 10.1042/BA20000087; Runge MS, 1996, CIRCULATION, V94, P1412, DOI 10.1161/01.CIR.94.6.1412; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; Scott MD, 1997, P NATL ACAD SCI USA, V94, P7566, DOI 10.1073/pnas.94.14.7566; SMIRNOV VN, 1986, P NATL ACAD SCI USA, V83, P6603, DOI 10.1073/pnas.83.17.6603; TAYLOR RP, 1991, P NATL ACAD SCI USA, V88, P3305, DOI 10.1073/pnas.88.8.3305; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; ZALTZMAN AB, 1995, BIOCHEM J, V307, P651, DOI 10.1042/bj3070651	50	143	152	3	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2003	21	8					891	896		10.1038/nbt846	http://dx.doi.org/10.1038/nbt846			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	706ZH	12845330				2023-01-03	WOS:000184484600031
J	Teng, M; Wolf, M; Lowrie, E; Ofsthun, N; Lazarus, JM; Thadhani, R				Teng, M; Wolf, M; Lowrie, E; Ofsthun, N; Lazarus, JM; Thadhani, R			Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SECONDARY HYPERPARATHYROIDISM; ARTERY CALCIFICATION; PARATHYROID-HORMONE; DIALYSIS PATIENTS; MORTALITY RISK; ADYNAMIC BONE; YOUNG-ADULTS; CORONARY; ASSOCIATION; DISEASE	BACKGROUND: Elevated calcium and phosphorus levels after therapy with injectable vitamin D for secondary hyperparathyroidism may accelerate vascular disease and hasten death in patients undergoing long-term hemodialysis. Paricalcitol, a new vitamin D analogue, appears to lessen the elevations in serum calcium and phosphorus levels, as compared with calcitriol, the standard form of injectable vitamin D. METHODS: We conducted a historical cohort study to compare the 36-month survival rate among patients undergoing long-term hemodialysis who started to receive treatment with paricalcitol (29,021 patients) or calcitriol (38,378 patients) between 1999 and 2001. Crude and adjusted survival rates were calculated and stratified analyses were performed. A subgroup of 16,483 patients who switched regimens was also evaluated. RESULTS: The mortality rate among patients receiving paricalcitol was 3417 per 19,031 person-years (0.180 per person-year), as compared with 6805 per 30,471 person-years (0.223 per person-year) among those receiving calcitriol (P<0.001). The difference in survival was significant at 12 months and increased with time (P<0.001). In the adjusted analysis, the mortality rate was 16 percent lower (95 percent confidence interval, 10 to 21 percent) among paricalcitol-treated patients than among calcitriol-treated patients. A significant survival benefit was evident in 28 of 42 strata examined, and in no stratum was calcitriol favored. At 12 months, calcium and phosphorus levels had increased by 6.7 and 11.9 percent, respectively, in the paricalcitol group, as compared with 8.2 and 13.9 percent, respectively, in the calcitriol group (P<0.001). The two-year survival rate among patients who switched from calcitriol to paricalcitol was 73 percent, as compared with 64 percent among those who switched from paricalcitol to calcitriol (P=0.04). CONCLUSIONS: Patients who receive paricalcitol while undergoing long-term hemodialysis appear to have a significant survival advantage over those who receive calcitriol. A prospective, randomized study is critical to confirm these findings.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Renal Unit, Boston, MA 02114 USA; Fresenius Med Care N Amer, Lexington, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Thadhani, R (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Renal Unit, Bullfinch 127,55 Fruit St, Boston, MA 02114 USA.	thadhani.r@mgh.harvard.edu						ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; Atsumi K, 1999, AM J KIDNEY DIS, V33, P287, DOI 10.1016/S0272-6386(99)70302-1; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; Brown AJ, 2000, J AM SOC NEPHROL, V11, P2088, DOI 10.1681/ASN.V11112088; Brown AJ, 2001, AM J KIDNEY DIS, V38, pS3, DOI 10.1053/ajkd.2001.28111; Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523-1755.2002.00434.x; Coco M, 2000, AM J KIDNEY DIS, V36, P1115, DOI 10.1053/ajkd.2000.19812; Collins AJ, 2000, SEMIN NEPHROL, V20, P345; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Couttenye MM, 1996, NEPHROL DIAL TRANSPL, V11, P1065; Davies MR, 2001, KIDNEY INT, V60, P472, DOI 10.1046/j.1523-1755.2001.060002472.x; Finch JL, 1999, J AM SOC NEPHROL, V10, P980; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380; Gupta A, 2000, J AM SOC NEPHROL, V11, P330, DOI 10.1681/ASN.V112330; Ifudu O, 1998, NEW ENGL J MED, V339, P1054, DOI 10.1056/NEJM199810083391507; Kuizon BD, 1998, KIDNEY INT, V53, P205, DOI 10.1046/j.1523-1755.1998.00724.x; Liu YY, 1997, J BIOL CHEM, V272, P3336, DOI 10.1074/jbc.272.6.3336; Llach F, 1998, AM J KIDNEY DIS, V32, pS3; Llach F, 2001, AM J KIDNEY DIS, V38, pS45, DOI 10.1053/ajkd.2001.28114; LOWRIE EG, 1981, NEW ENGL J MED, V305, P1176, DOI 10.1056/NEJM198111123052003; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Lowrie EG, 2001, KIDNEY INT, V60, P1917, DOI 10.1046/j.1523-1755.2001.00029.x; MALLICK NP, 1968, LANCET, V2, P1316; Martin KJ, 1998, AM J KIDNEY DIS, V32, pS61, DOI 10.1053/ajkd.1998.v32.pm9808145; Martin KJ, 2001, AM J KIDNEY DIS, V38, pS34, DOI 10.1053/ajkd.2001.28109; MILLINER DS, 1990, KIDNEY INT, V38, P931, DOI 10.1038/ki.1990.293; Moe SM, 2002, KIDNEY INT, V61, P638, DOI 10.1046/j.1523-1755.2002.00170.x; *NAT I DIAB DIG KI, 2000, REN DAT SYST USRDS 2; Oh J, 2002, CIRCULATION, V106, P100, DOI 10.1161/01.CIR.0000020222.63035.C0; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; QUNIBI WY, 2002, KIDNEY INT S, V82, P73; Ritz E, 1999, KIDNEY INT, V56, pS94, DOI 10.1046/j.1523-1755.1999.07314.x; SJODEN G, 1985, P SOC EXP BIOL MED, V178, P432; Sprague SM, 2001, AM J KIDNEY DIS, V38, pS51, DOI 10.1053/ajkd.2001.28110; VINCENTI F, 1981, JAMA-J AM MED ASSOC, V245, P930, DOI 10.1001/jama.245.9.930; World Health Organization, 1980, INT CLASSIFICATION D; Zager RA, 1999, AM J PATHOL, V154, P1899, DOI 10.1016/S0002-9440(10)65448-X	41	775	815	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 31	2003	349	5					446	456		10.1056/NEJMoa022536	http://dx.doi.org/10.1056/NEJMoa022536			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	706FV	12890843				2023-01-03	WOS:000184443700006
J	Diehl, V; Franklin, J; Pfreundschuh, M; Lathan, B; Paulus, U; Hasenclever, D; Tesch, H; Herrmann, R; Dorken, B; Muller-Hermelink, H; Duhmke, E; Loeffler, M				Diehl, V; Franklin, J; Pfreundschuh, M; Lathan, B; Paulus, U; Hasenclever, D; Tesch, H; Herrmann, R; Dorken, B; Muller-Hermelink, H; Duhmke, E; Loeffler, M		German Hodgkin's Lymphoma Study Gr	Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOMA STUDY-GROUP; ADJUVANT RADIOTHERAPY; PROGNOSTIC SCORE; MOPP; REGIMEN; TRIAL; LEUKEMIA; MALIGNANCIES; ESCALATION; TOXICITY	Background: Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy. Methods: From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or stage IIIB or IV were randomly assigned to receive eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP-ABVD); bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP); or increased-dose BEACOPP, each followed by local radiotherapy when indicated. Enrollment in the COPP-ABVD group was stopped in 1996 owing to inferior results. Results: For the final analysis, 1195 of 1201 patients could be evaluated: 260 in the COPP-ABVD group, 469 in the BEACOPP group, and 466 in the increased-dose BEACOPP group; the median follow-up was 72, 54, and 51 months, respectively. The rate of freedom from treatment failure at five years was 69 percent in the COPP-ABVD group, 76 percent in the BEACOPP group, and 87 percent in the increased-dose BEACOPP group (P=0.04 for the comparison of the COPP-ABVD group with the BEACOPP group and P<0.001 for the comparison of the increased-dose BEACOPP group with the COPP-ABVD group and with the BEACOPP group), and the five-year rates of overall survival were 83 percent, 88 percent, and 91 percent, respectively (P=0.16 for the comparison of the COPP-ABVD group with the BEACOPP group, P=0.06 for the comparison of the BEACOPP group with the increased-dose BEACOPP group, and P=0.002 for the comparison of the COPP-ABVD group with the increased-dose BEACOPP group). Rates of early progression were significantly lower with increased-dose BEACOPP than with COPP-ABVD or standard BEACOPP. Conclusions: Increased-dose BEACOPP resulted in better tumor control and overall survival than did COPP-ABVD. .	Univ Cologne, Innere Med Klin 1, Dept Internal Med 1, D-50924 Cologne, Germany; Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany; Canton Hosp, Basel, Switzerland; Charite Hosp, Berlin, Germany; Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany; Univ Munich, Dept Radiotherapy, Munich, Germany	University of Cologne; Leipzig University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; University of Munich	Diehl, V (corresponding author), Univ Cologne, Innere Med Klin 1, Dept Internal Med 1, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	v.diehl@uni-koeln.de		Franklin, Jeremy/0000-0003-1536-0925				[Anonymous], 1992, DESIGN ANAL SEQUENTI; Bonfante V, 1997, J CLIN ONCOL, V15, P528, DOI 10.1200/JCO.1997.15.2.528; Brusamolino E, 2000, HAEMATOLOGICA, V85, P1032; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; Carde P, 2000, Hematol J, V1, P282, DOI 10.1038/sj.thj.6200037; Connors, 1997, J CLIN ONCOL, V15, P2762, DOI 10.1200/JCO.1997.15.7.2762; Connors JM, 1997, J CLIN ONCOL, V15, P1638, DOI 10.1200/JCO.1997.15.4.1638; CULLEN MH, 1994, J CLIN ONCOL, V12, P779, DOI 10.1200/JCO.1994.12.4.779; Diehl V, 1998, J CLIN ONCOL, V16, P3810, DOI 10.1200/JCO.1998.16.12.3810; Diehl V, 1997, ANN ONCOL, V8, P143, DOI 10.1023/A:1008294312741; Diehl V, 2001, LEUK LYMPHOMA S2, V42, P16; DUGGAN D, 1997, P AN M AM SOC CLIN, V16, pA12; Engel C, 2000, ANN ONCOL, V11, P1105, DOI 10.1023/A:1008301225839; Franklin J, 2002, ANN ONCOL, V13, P98, DOI 10.1093/annonc/13.S1.98; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; HANCOCK BW, 1992, J CLIN ONCOL, V10, P1252, DOI 10.1200/JCO.1992.10.8.1252; Hasenclever D, 1996, ANN ONCOL, V7, P95; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; HESS CF, 1994, EUR J CANCER, V30A, P1441, DOI 10.1016/0959-8049(94)00284-C; Horning SJ, 2002, J CLIN ONCOL, V20, P630, DOI 10.1200/JCO.20.3.630; Josting A, 2002, J CLIN ONCOL, V20, P221, DOI 10.1200/JCO.20.1.221; KHALIFA E, 1992, HUM REPROD, V7, P105, DOI 10.1093/oxfordjournals.humrep.a137539; KREUSER ED, 1992, ANN ONCOL, V3, pS105, DOI 10.1093/annonc/3.suppl_4.S105; Loeffler M, 1998, ANN ONCOL, V9, P73, DOI 10.1023/A:1008413113949; Loeffler M, 1998, J CLIN ONCOL, V16, P818, DOI 10.1200/JCO.1998.16.3.818; LONGO DL, 1991, J CLIN ONCOL, V9, P1409, DOI 10.1200/JCO.1991.9.8.1409; Micallef INM, 2000, J CLIN ONCOL, V18, P947, DOI 10.1200/JCO.2000.18.5.947; Radford JA, 2002, J CLIN ONCOL, V20, P2988, DOI 10.1200/JCO.2002.11.107; Raemaekers J, 1997, ANN ONCOL, V8, P111, DOI 10.1023/A:1008286824606; Tesch H, 1998, BLOOD, V92, P4560, DOI 10.1182/blood.V92.12.4560.424k07_4560_4567; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P1063, DOI 10.1200/JCO.1994.12.5.1063; VANRIJSWIJK REN, 1989, J CLIN ONCOL, V7, P1776, DOI 10.1200/JCO.1989.7.12.1776; Walshe R, 2001, LEUK LYMPHOMA S2, V42, P106	34	599	630	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2386	2395		10.1056/NEJMoa022473	http://dx.doi.org/10.1056/NEJMoa022473			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802024	Green Accepted, Bronze			2023-01-03	WOS:000183428900004
J	Vetter, N				Vetter, N			Inappropriately delayed discharge from hospital: What do we know?	BRITISH MEDICAL JOURNAL			English	Article							APPROPRIATENESS EVALUATION PROTOCOL; CARE; HOME; BEDS		Univ Wales Coll Med, Dept Epidemiol & Stat, Cardiff CF14 4XL, S Glam, Wales; Univ Wales Coll Med, Dept Publ Hlth, Cardiff CF14 4XL, S Glam, Wales	Cardiff University; Cardiff University	Vetter, N (corresponding author), Univ Wales Coll Med, Dept Epidemiol & Stat, Heath Pk, Cardiff CF14 4XL, S Glam, Wales.							ANDERSON P, 1988, BRIT MED J, V297, P910, DOI 10.1136/bmj.297.6653.910; Chopard P, 1998, INT J EPIDEMIOL, V27, P513, DOI 10.1093/ije/27.3.513; Coast J, 1996, INT J QUAL HEALTH C, V8, P31, DOI 10.1093/intqhc/8.1.31; Epstein J, 2001, SOC WORK HEALTH CARE, V32, P43, DOI 10.1300/J010v32n04_03; FALCONE D, 1991, HEALTH SERV RES, V26, P339; GERTMAN PM, 1981, MED CARE, V19, P855, DOI 10.1097/00005650-198108000-00005; Hermans E, 1996, SCAND J CARING SCI, V10, P81, DOI 10.1111/j.1471-6712.1996.tb00316.x; HIRSCH CH, 1990, J AM GERIATR SOC, V38, P1296, DOI 10.1111/j.1532-5415.1990.tb03451.x; Hyde CJ, 2000, AGE AGEING, V29, P271, DOI 10.1093/ageing/29.3.271; LEWIS H, 1988, NEW ZEAL MED J, V101, P575; McDonagh MS, 2000, HEALTH POLICY, V53, P157, DOI 10.1016/S0168-8510(00)00092-0; Minichiello T M, 2001, Eff Clin Pract, V4, P250; Patterson CJ, 1999, CLIN REHABIL, V13, P101, DOI 10.1191/026921599677096598; STRUMWASSER I, 1990, MED CARE, V28, P95, DOI 10.1097/00005650-199002000-00001; STYRBORN K, 1993, SCAND J SOC MED, V21, P272, DOI 10.1177/140349489302100407	15	33	34	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 26	2003	326	7395					927	928		10.1136/bmj.326.7395.927	http://dx.doi.org/10.1136/bmj.326.7395.927			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	673WQ	12714477	Green Published			2023-01-03	WOS:000182603600024
J	Juurlink, DN; Mamdani, M; Kopp, A; Laupacis, A; Redelmeier, DA				Juurlink, DN; Mamdani, M; Kopp, A; Laupacis, A; Redelmeier, DA			Drug-drug interactions among elderly patients hospitalized for drug toxicity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual North American Congress of Clinical Toxicology	SEP 24-29, 2002	PALM SPRINGS, CA				CONVERTING ENZYME-INHIBITORS; DIGOXIN TOXICITY; P-GLYCOPROTEIN; CISAPRIDE; CLARITHROMYCIN; HYPERKALEMIA; ASSOCIATION; EVENTS; CYP2C9; SULFAMETHOXAZOLE	Context Drug-drug interactions are a preventable cause of morbidity and mortality, yet their consequences in the community are not well characterized. Objective To determine whether elderly patients admitted to hospital with specific drug toxicities were likely to have been,prescribed an interacting drug in the week prior to admission. Design Three population-based, nested case-control studies. Setting Ontario, Canada, from January 1, 1994, to December 31, 2000. Patients All Ontario residents aged 66 years or older treated with glyburide, digoxin, or an angiotensin-converting enzyme (ACE) inhibitor. Case patients were those admitted to hospital for drug-related toxicity. Prescription records of cases were compared with those of controls (matched on age, sex, use of the same medication, and presence or absence of renal disease) for receipt of interacting medications (co-trimoxazole with glyburide, clarithromycin with digoxin, and potassium-sparing diuretics with ACE inhibitors). Main Outcome Measure Odds ratio for association between hospital admission for drug toxicity (hypoglycemia, digoxin toxicity, or hyperkalemia, respectively) and use of an interacting medication in the preceding-week, adjusted for diagnoses, receipt of other medications, the number of prescription drugs, and the number of hospital admissions in the year preceding the index date. Results During the 7-year study period, 909 elderly patients receiving glyburide were admitted with a diagnosis of hypoglycemia. In the primary analysis, those patients admitted for hypoglycemia were more than 6 times as likely to have been treated with co-trimoxazole in the previous week (adjusted odds ratio, 6.6; 95% confidence interval, 4.5-9.7). Patients admitted with digoxin toxicity (n=1051) were about 12 times more likely to have been treated with clarithromycin (adjusted odds ratio, 11.7; 95% confidence interval, 7.5-18.2) in the previous week, and patients treated with ACE inhibitors admitted with a diagnosis of hyperkalemia (n=523) were about 20 times more likely to have been treated with a potassium-sparing diuretic (adjusted odds ratio, 20.3; 95% confidence interval, 13.4-30.7) in the previous week. No increased risk of drug toxicity was found for drugs with similar indications but no known interactions (amoxicillin, cefuroxime, and indapamide, respectively). Conclusions Many hospital admissions of elderly patients for drug toxicity occur after administration of a drug known to cause drug-drug interactions. Many of these interactions could have been avoided.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Clin Epidemiol & Healthcare Res Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Pharm, Toronto, ON M4N 3M5, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Juurlink, DN (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, G Wing 106,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	david.juurlink@ices.on.ca						Ahuja TS, 2000, AM J NEPHROL, V20, P268, DOI 10.1159/000013599; Alvarez-Requejo A, 1998, EUR J CLIN PHARMACOL, V54, P483, DOI 10.1007/s002280050498; Atkin PA, 1999, DRUG AGING, V14, P141, DOI 10.2165/00002512-199914020-00005; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; BRIAN WR, 2000, METABOLIC DRUG INTER, P529; Brown BA, 1997, CLIN INFECT DIS, V24, P92, DOI 10.1093/clinids/24.1.92; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; CHRISTENSEN LK, 1969, ACTA DIABETOLOGICA S, V1, P116; Crighton EJ, 2001, BMC HEALTH SERV RES, V1, DOI 10.1186/1472-6963-1-7; Del Fiol G, 2000, J AM MED INFORM ASSN, P171; DUSSUSKE LM, 1999, CLIN THER, V21, P281; Efron B., 1993, INTRO BOOTSTRAP; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Glassman PA, 2002, MED CARE, V40, P1161, DOI 10.1097/00005650-200212000-00004; Gooderham MJ, 1999, ANN PHARMACOTHER, V33, P796, DOI 10.1345/aph.18330; Guerriero SE, 1997, PHARMACOTHERAPY, V17, P1035; Guzey C, 2002, DRUG SAFETY, V25, P553; Halkin H, 2001, CLIN PHARMACOL THER, V69, P260, DOI 10.1067/mcp.2001.114228; Hansten P D, 2001, J Am Pharm Assoc (Wash), V41, P161; Hazlet T K, 2001, J Am Pharm Assoc (Wash), V41, P200; Heeley E, 2001, LANCET, V358, P1872, DOI 10.1016/S0140-6736(01)06898-2; Jha AK, 2001, PHARMACOEPIDEM DR S, V10, P113, DOI 10.1002/pds.568; JOHNSON JF, 1990, DICP ANN PHARMAC, V24, P250, DOI 10.1177/106002809002400307; Jones JK, 2001, JAMA-J AM MED ASSOC, V286, P1607, DOI 10.1001/jama.286.13.1607; KIFOR I, 1991, ENDOCRINOLOGY, V129, P823, DOI 10.1210/endo-129-2-823; Kirchheiner J, 2002, CLIN PHARMACOL THER, V71, P286, DOI 10.1067/mcp.2002.122476; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; Koren G, 1998, VET HUM TOXICOL, V40, P45; Langdorf MI, 2000, ACAD EMERG MED, V7, P1321, DOI 10.1111/j.1553-2712.2000.tb00483.x; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lehmann DF, 2000, J CLIN PHARMACOL, V40, P939, DOI 10.1177/00912700022009675; Mamdani MM, 2000, CAN MED ASSOC J, V162, P1421; Mamdani MM, 2000, AM J MED, V108, P418, DOI 10.1016/S0002-9343(99)00452-0; Michalets EL, 2000, CLIN PHARMACOKINET, V39, P49, DOI 10.2165/00003088-200039010-00004; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; Moride Y, 1997, BRIT J CLIN PHARMACO, V43, P177, DOI 10.1046/j.1365-2125.1997.05417.x; Niemi M, 2002, CLIN PHARMACOL THER, V72, P326, DOI 10.1067/mcp.2002.127495; Peterson J F, 2001, J Am Pharm Assoc (Wash), V41, P159; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Potasman I, 1980, Harefuah, V98, P78; *PRACT MAN INF COR, 2003, INT CLASS DIS; Ray JG, 2001, ARCH INTERN MED, V161, P1405, DOI 10.1001/archinte.161.11.1405; Reardon LC, 1998, ARCH INTERN MED, V158, P26, DOI 10.1001/archinte.158.1.26; Roberts RL, 2002, NEW ZEAL MED J, V115, P137; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Roden DM, 2002, NAT REV DRUG DISCOV, V1, P37, DOI 10.1038/nrd705; Rosholm JU, 1998, DAN MED BULL, V45, P210; Schepkens H, 2001, AM J MED, V110, P438, DOI 10.1016/S0002-9343(01)00642-8; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Seymour RM, 1998, DRUG AGING, V12, P485, DOI 10.2165/00002512-199812060-00006; Shaoul R, 2002, PEDIATRICS, V109, P1118, DOI 10.1542/peds.109.6.1118; Shapiro LE, 1999, CAN MED ASSOC J, V161, P1266; Statistics Canada, 2010, POP AG GROUP; Tamblyn RM, 1996, CAN MED ASSOC J, V154, P1177; Wakasugi H, 1998, CLIN PHARMACOL THER, V64, P123, DOI 10.1016/S0009-9236(98)90030-3; Weideman RA, 1999, AM J HEALTH-SYST PH, V56, P1524, DOI 10.1093/ajhp/56.15.1524; Wen X, 2002, DRUG METAB DISPOS, V30, P631, DOI 10.1124/dmd.30.6.631; Wynn Richard L., 1993, General Dentistry, V41, P27; Wysowski DK, 1996, NEW ENGL J MED, V335, P290, DOI 10.1056/NEJM199607253350416; Wysowski DK, 2001, AM J GASTROENTEROL, V96, P1698, DOI 10.1016/S0002-9270(01)02490-X; ZECHNICH AD, 1994, WESTERN J MED, V160, P321	65	493	512	1	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1652	1658		10.1001/jama.289.13.1652	http://dx.doi.org/10.1001/jama.289.13.1652			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	662JX	12672733	Green Published			2023-01-03	WOS:000181944500028
J	Collard, HR; Saint, S; Matthay, MA				Collard, HR; Saint, S; Matthay, MA			Prevention of ventilator-associated pneumonia: An evidence-based systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; STRESS-ULCER PROPHYLAXIS; SELECTIVE DIGESTIVE DECONTAMINATION; RESPIRATORY-TRACT INFECTIONS; RANDOMIZED CONTROLLED-TRIALS; NOSOCOMIAL PNEUMONIA; MECHANICAL VENTILATION; CIRCUIT CHANGES; SUBGLOTTIC SECRETIONS	Background: Ventilator-associated pneumonia is a common cause of morbidity in critically ill patients. Interventions beneficial to the prevention of ventilator-associated pneumonia would therefore have a significant impact on the care of these patients. Purpose: To perform a literature review and synthesis of methods for prevention of ventilator-associated pneumonia. Data Sources: MEDLINE (1966-2001), the Cochrane Library, and bibliographies of retrieved articles. Study Selection: Studies were required to be prospective and controlled in design and to evaluate clinically important or surrogate outcomes. Surrogate outcomes were required to have a direct link to clinically important outcomes supported by the literature. Data Extraction: Data on patients, definitions, study design, and outcomes were abstracted and graded by using preestablished criteria. Data Synthesis: The preventive practices with the strongest supportive evidence were semi-recumbent positioning, sucralfate instead of H-2-antagonists for stress ulcer prophylaxis, and selective digestive tract decontamination. Aspiration of subglottic secretions and oscillating beds may be useful in select populations. There is no evidence to support specific methods of enteral feeding or increased frequency of ventilator circuitry changes. Conclusions: After evaluation of potential benefits and risks, the authors recommend considering several specific interventions to reduce the incidence of ventilator-associated pneumonia: semi-recumbent positioning in all eligible patients, sucralfate rather than H-2-antagonists in patients at low to moderate risk for gastrointestinal tract bleeding, and aspiration of subglottic secretions and oscillating beds in select patient populations. Selective digestive tract decontamination is not recommended because. routine use may increase antimicrobial resistance.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI USA; Univ Michigan, Ann Arbor, MI 48109 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of California System; University of California San Francisco	Collard, HR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,Campus Box C272, Denver, CO 80262 USA.	hal.collard@uchsc.edu	Saint, Sanjay/AAF-5126-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051856] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL51856] Funding Source: Medline; PHS HHS [290-97-0013] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AERDTS SJA, 1993, BRIT MED J, V307, P525; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; BARTLETT JG, 1995, CRIT CARE MED, V23, P613, DOI 10.1097/00003246-199504000-00002; BASSIN AS, 1995, CLIN CHEST MED, V16, P195; BenMenachem T, 1996, CRIT CARE MED, V24, P338, DOI 10.1097/00003246-199602000-00026; Bonten MJM, 1996, AM J RESP CRIT CARE, V154, P394, DOI 10.1164/ajrccm.154.2.8756812; CHOI SC, 1992, J CRIT CARE, V7, P57, DOI 10.1016/0883-9441(92)90008-U; COLLARD HR, 2001, AHRQ PUBLICATION; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; COOK DJ, 1995, SCAND J GASTROENTERO, V30, P48, DOI 10.3109/00365529509090271; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; Craven D E, 1996, Semin Respir Infect, V11, P32; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; Davis K, 2000, CRIT CARE MED, V28, P1412, DOI 10.1097/00003246-200005000-00026; DONOWITZ LG, 1986, INFECT CONT HOSP EP, V7, P23, DOI 10.1017/S0195941700063748; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; DREYFUSS D, 1991, AM REV RESPIR DIS, V143, P738, DOI 10.1164/ajrccm/143.4_Pt_1.738; Ebner W, 2000, EUR J CLIN MICROBIOL, V19, P243, DOI 10.1007/s100960050470; Erstad BL, 1997, CRIT CARE MED, V25, P1678, DOI 10.1097/00003246-199710000-00017; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; Garcia MS, 1998, AM J RESP CRIT CARE, V158, P908, DOI 10.1164/ajrccm.158.3.9712079; George DL, 1998, AM J RESP CRIT CARE, V158, P1839, DOI 10.1164/ajrccm.158.6.9610069; Heyland DK, 1999, CRIT CARE MED, V27, P2399, DOI 10.1097/00003246-199911000-00013; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; Heyland DK, 1999, AM J RESP CRIT CARE, V159, P1249, DOI 10.1164/ajrccm.159.4.9807050; HURLEY JC, 1995, ANTIMICROB AGENTS CH, V39, P941, DOI 10.1128/AAC.39.4.941; Ibrahim EH, 2001, CHEST, V120, P555, DOI 10.1378/chest.120.2.555; Joiner G A, 1996, Am J Med Qual, V11, P100, DOI 10.1177/0885713X9601100208; Kearns PJ, 2000, CRIT CARE MED, V28, P1742, DOI 10.1097/00003246-200006000-00007; KELLEGHAN SI, 1993, AM J INFECT CONTROL, V21, P322, DOI 10.1016/0196-6553(93)90390-P; Kimura A, 1998, J TRAUMA, V45, P383, DOI 10.1097/00005373-199808000-00032; Kirton OC, 1997, CHEST, V112, P1055, DOI 10.1378/chest.112.4.1055; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; Kollef MH, 1999, CHEST, V116, P1339, DOI 10.1378/chest.116.5.1339; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kollef MH, 1999, NEW ENGL J MED, V340, P627, DOI 10.1056/NEJM199902253400807; KOLLEF MH, 1995, ANN INTERN MED, V123, P168, DOI 10.7326/0003-4819-123-3-199508010-00002; Livingston D H, 2000, Am J Surg, V179, p12S; LODE H, 1992, Intensive Care Medicine, V18, pS24, DOI 10.1007/BF01752973; Long MN, 1996, INFECT CONT HOSP EP, V17, P14; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; Manangan LP, 2000, AM J INFECT CONTROL, V28, P222, DOI 10.1067/mic.2000.106278; MERMEL L, 1994, 4 ANN M SOC HOSP EP; Messori A, 2000, BMJ-BRIT MED J, V321, P1103, DOI 10.1136/bmj.321.7269.1103; Nathens AB, 1999, ARCH SURG-CHICAGO, V134, P170, DOI 10.1001/archsurg.134.2.170; OROZCOLEVI M, 1995, AM J RESP CRIT CARE, V152, P1387, DOI 10.1164/ajrccm.152.4.7551400; Pittet D, 2001, AM J RESP CRIT CARE, V164, P338, DOI 10.1164/ajrccm.164.3.2105072b; Quinio B, 1996, CHEST, V109, P765, DOI 10.1378/chest.109.3.765; Saint S, 1998, AM J MED, V105, P515, DOI 10.1016/S0002-9343(98)00322-2; Silvestri L, 2000, J HOSP INFECT, V45, P185, DOI 10.1053/jhin.2000.0737; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Stamm AM, 1998, AM J INFECT CONTROL, V26, P71, DOI 10.1016/S0196-6553(98)70064-1; Stoutenbeek C P, 1997, Semin Respir Infect, V12, P294; SUMMER WR, 1989, J CRIT CARE, V4, P45, DOI 10.1016/0883-9441(89)90091-9; THOMPSON R, 1994, MED CLIN N AM, V78, P1185, DOI 10.1016/S0025-7125(16)30126-2; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TRAVER GA, 1995, J CRIT CARE, V10, P97, DOI 10.1016/0883-9441(95)90000-4; TRYBA M, 1991, CRIT CARE MED, V19, P942, DOI 10.1097/00003246-199107000-00020; TRYBA M, 1991, J CLIN GASTROENTEROL, V13, pS44; TRYBA M, 1995, SCAND J GASTROENTERO, V30, P53, DOI 10.3109/00365529509090272; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; van Nieuwenhoven CA, 2001, JAMA-J AM MED ASSOC, V286, P335, DOI 10.1001/jama.286.3.335; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; VANSAENE HKF, 1991, J HOSP INFECT, V18, P261, DOI 10.1016/0195-6701(91)90184-A; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014; Yavagal DR, 2000, CRIT CARE MED, V28, P1408, DOI 10.1097/00003246-200005000-00025	68	176	214	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					494	501		10.7326/0003-4819-138-6-200303180-00015	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00015			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639084				2023-01-03	WOS:000181562400008
J	Smith, O				Smith, O			Weathering the big chill	SCIENCE			English	Editorial Material																		Hoffmeister KM, 2003, CELL, V112, P87, DOI 10.1016/S0092-8674(02)01253-9; HOFFMEISTER KM, 2002, BLOOD, V100	2	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 24	2003	299	5606					530	530		10.1126/science.299.5606.530	http://dx.doi.org/10.1126/science.299.5606.530			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	638EZ	12543964				2023-01-03	WOS:000180559800037
J	Kanaya, AM; Herrington, D; Vittinghoff, E; Lin, F; Grady, D; Bittner, V; Cauley, JA; Barrett-Connor, E				Kanaya, AM; Herrington, D; Vittinghoff, E; Lin, F; Grady, D; Bittner, V; Cauley, JA; Barrett-Connor, E			Glycemic effects of postmenopausal hormone therapy: The heart and estrogen/progestin replacement study - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVASCULAR RISK-FACTORS; DEPENDENT DIABETES-MELLITUS; TRANSDERMAL ESTROGEN REPLACEMENT; IMPAIRED FASTING GLUCOSE; INSULIN SENSITIVITY; CARBOHYDRATE-METABOLISM; GROWTH-HORMONE; PLASMA-LIPIDS; MEDROXYPROGESTERONE ACETATE; WOMEN	Background: Randomized trials of postmenopausal hormone therapy have found differing effects on fasting glucose levels. No trial has evaluated the effect of hormone therapy on diabetes incidence. Objective: To evaluate the effect of hormone therapy on fasting glucose level and incident diabetes. Design: Randomized, double-blind, placebo-controlled trial. Setting: 20 U.S. clinical centers. Participants: 2763 postmenopausal women with coronary heart disease who were followed for 4.1 years. At baseline, 734 women had diabetes, 218 women had impaired fasting glucose, and 1811 women were normoglycemic; the 2029 women without diabetes were followed for incident diabetes. Intervention: 0.625 mg of conjugated estrogen plus 2.5 ring of medroxyprogesterone acetate daily, or placebo. Measurements: Fasting glucose level was measured at baseline, at year 1, and at the end of the trial. incident diabetes was defined by self-report of diabetes or disease complication, fasting glucose level of 6.9 mmol/L or greater (greater than or equal to 126 mg/dL), or initiation of therapy with diabetes medication. Results: Fasting glucose levels increased significantly among women assigned to placebo but did not change among women receiving hormone therapy. The incidence of diabetes was 6.2% in the hormone therapy group and 9.5% in the placebo group (relative hazard, 0.65 [95% Cl, 0.48 to 0.89]; P = 0.006). The number needed to treat for benefit to prevent one case of diabetes was 30 (Cl, 18 to 103). Changes in weight and waist circumference did not mediate this effect. Conclusions: in women with coronary disease, hormone therapy reduced the incidence of diabetes by 35%. This observation provides important insights into the metabolic effects of postmenopausal hormones but is insufficient to recommend the use of hormones for secondary prevention of heart disease.	Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC 27157 USA; Univ Alabama Birmingham, Birmingham, AL 35294 USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA	University of California System; University of California San Francisco; University of California System; University of California San Diego; Wake Forest University; Wake Forest Baptist Medical Center; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kanaya, AM (corresponding author), Univ Calif San Francisco, Div Gen Internal Med, 1701 Divisadero St,Suite 536, San Francisco, CA 94143 USA.	alkak@itsa.ucsf.edu	Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Bittner, Vera/0000-0001-9456-850X	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [D15PE050109] Funding Source: NIH RePORTER; BHP HRSA HHS [1D08PE50109-01] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); BHP HRSA HHS		AJABOR LN, 1972, AM J OBSTET GYNECOL, V113, P383, DOI 10.1016/0002-9378(72)90689-8; Andersson B, 1997, J CLIN ENDOCR METAB, V82, P638, DOI 10.1210/jc.82.2.638; Ashley CD, 2000, SPORTS MED, V29, P221, DOI 10.2165/00007256-200029040-00001; Balkau B, 1999, DIABETES CARE, V22, P1667; BARRETTCONNOR E, 1990, ARTERIOSCLEROSIS, V10, P531, DOI 10.1161/01.ATV.10.4.531; BENGTSSON C, 1984, BMJ-BRIT MED J, V289, P1495, DOI 10.1136/bmj.289.6457.1495; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BLUNT BA, 1991, DIABETES CARE, V14, P989, DOI 10.2337/diacare.14.11.989; Brussaard HE, 1997, ARTERIOSCL THROM VAS, V17, P324, DOI 10.1161/01.ATV.17.2.324; CAGNACCI A, 1992, J CLIN ENDOCR METAB, V74, P1396, DOI 10.1210/jc.74.6.1396; Colacurci N, 1998, PANMINERVA MED, V40, P18; Darko DA, 2001, DIABETES RES CLIN PR, V54, P157, DOI 10.1016/S0168-8227(01)00297-2; Davidson MH, 2000, ARCH INTERN MED, V160, P3315, DOI 10.1001/archinte.160.21.3315; de Valk-de Roo GW, 1999, ARTERIOSCL THROM VAS, V19, P2993, DOI 10.1161/01.ATV.19.12.2993; Espeland MA, 1998, DIABETES CARE, V21, P1589, DOI 10.2337/diacare.21.10.1589; Ferrara A, 2001, DIABETES CARE, V24, P1144, DOI 10.2337/diacare.24.7.1144; Friday KE, 2001, J CLIN ENDOCR METAB, V86, P48, DOI 10.1210/jc.86.1.48; Friend KE, 1996, J CLIN ENDOCR METAB, V81, P2250, DOI 10.1210/jc.81.6.2250; Gabal LL, 1997, AM J PUBLIC HEALTH, V87, P443, DOI 10.2105/AJPH.87.3.443; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P537, DOI 10.1016/0002-9378(79)90289-8; Hemminki E, 2000, LANCET, V355, P566, DOI 10.1016/S0140-6736(99)03432-7; HERITAGE AS, 1980, SCIENCE, V207, P1377, DOI 10.1126/science.7355296; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KAHN CR, 1978, ENDOCRINOLOGY, V103, P1054; Karjalainen A, 2001, CLIN ENDOCRINOL, V54, P165, DOI 10.1046/j.1365-2265.2001.01208.x; Kimmerle R, 1999, MENOPAUSE, V6, P36; KUMAGAI S, 1993, ACTA PHYSIOL SCAND, V149, P91, DOI 10.1111/j.1748-1716.1993.tb09596.x; LARSSONCOHN U, 1977, ACTA ENDOCRINOL-COP, V86, P583, DOI 10.1530/acta.0.0860583; LINDHEIM SR, 1994, FERTIL STERIL, V62, P1176; Lobo RA, 2001, FERTIL STERIL, V76, P13, DOI 10.1016/S0015-0282(01)01829-5; LOBO RA, 1994, OBSTET GYNECOL, V84, P987; Manning PJ, 2001, ARCH INTERN MED, V161, P1772, DOI 10.1001/archinte.161.14.1772; Manson J E, 1992, Ann Epidemiol, V2, P665; MATUTE ML, 1973, ENDOCRINOLOGY, V92, P762, DOI 10.1210/endo-92-3-762; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; OSULLIVAN AJ, 1995, J CLIN ENDOCR METAB, V80, P1783, DOI 10.1210/jc.80.6.1783; Perera M, 2001, J CLIN ENDOCR METAB, V86, P1140, DOI 10.1210/jc.86.3.1140; Porte D, 1999, ANN NY ACAD SCI, V892, P73, DOI 10.1111/j.1749-6632.1999.tb07786.x; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Samaras K, 1999, DIABETES CARE, V22, P1401, DOI 10.2337/diacare.22.9.1401; Sargeant LA, 2000, DIABETES-METAB RES, V16, P20, DOI 10.1002/(SICI)1520-7560(200001/02)16:1<20::AID-DMRR76>3.3.CO;2-1; Seed M, 2000, FAM PRACT, V17, P497, DOI 10.1093/fampra/17.6.497; Shaw JA, 1999, DIABETES CARE, V22, P399, DOI 10.2337/diacare.22.3.399; SPELLACY WN, 1972, AM J OBSTET GYNECOL, V114, P378, DOI 10.1016/0002-9378(72)90615-1; STEVENSON JC, 1995, BRIT J CLIN PRACT, V49, P87; STOLK RP, 1993, EUR J EPIDEMIOL, V9, P134, DOI 10.1007/BF00158782; Troisi RJ, 2000, OBSTET GYNECOL, V96, P665, DOI 10.1097/00006250-200011000-00005; Vaccaro O, 1999, DIABETES CARE, V22, P1490, DOI 10.2337/diacare.22.9.1490; Vehkavaara S, 2000, J CLIN ENDOCR METAB, V85, P4663, DOI 10.1210/jc.85.12.4663; Zhang Y, 2002, DIABETES CARE, V25, P500, DOI 10.2337/diacare.25.3.500; 2002, DIABETES CARE S1, V25, pS21	57	430	446	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 7	2003	138	1					1	9		10.7326/0003-4819-138-1-200301070-00005	http://dx.doi.org/10.7326/0003-4819-138-1-200301070-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645TV	12513038				2023-01-03	WOS:000180996200001
J	Collins, S; Sadler, K				Collins, S; Sadler, K			Outpatient care for severely malnourished children in emergency relief programmes: a retrospective cohort study	LANCET			English	Article							SEVERE MALNUTRITION; MORTALITY	Background In emergency nutritional relief programmes, therapeutic feeding centres are the accepted intervention for the treatment of severely malnourished people. These centres often cannot treat all the people requiring care. Consequently, coverage of therapeutic feeding centre programmes can be low, reducing their effectiveness. We aimed to assess the effectiveness of outpatient treatment for severe malnutrition in an emergency relief programme. Methods We did a retrospective cohort study in an outpatient therapeutic feeding programme in Ethiopia from September, 2000, to January, 2001. We assessed clinical records for 170 children aged 6-120 months. The children had either marasmus, kwashiorkor, or marasmic kwashiorkor. Outcomes were mortality, default from programme, discharge from programme, rate of weight gain, and length of stay in programme. Findings 144 (85%) patients recovered, seven (4%) died, 11 (6%) were transferred, and eight (5%) defaulted. Median time to discharge was 42 days (IQR 28-56), days to death 14 (7-26), and days to default 14 (7-28). Median rate of weight gain was 3.16 g kg(-1) day(-1) (1.86-5.60). In patients who recovered, median rates of weight gain were 4.80 g kg(-1) day(-1) (2.95-8.07) for marasmic patients, 4.03 g kg(-1) day(-1) (2.68-4.29) for marasmic kwashiorkor patients, and 2.70 g kg(-1) day(-1) (0.00-4.76) for kwashiorkor patients. Interpretation Outpatient treatment exceeded internationally accepted minimum standards for recovery, default, and mortality rates. Time spent in the programme and rates of weight gain did not meet these standards. Outpatient care could provide a complementary treatment strategy to therapeutic feeding centres. Further research should compare the effectiveness of outpatient and centre-based treatment of severe malnutrition in emergency nutritional interventions.	Valid Int, London, England; Inst Child Hlth, Ctr Int Child Hlth, London, England; Concern Worldwide, Dublin, Ireland	University of London; University College London	Collins, S (corresponding author), 37 Squires Court,Binfield Rd, London SW4 6TD, England.							Ashworth A, 1997, HEALTH POLICY PLANN, V12, P115, DOI 10.1093/heapol/12.2.115; BEATON GH, 1982, AM J CLIN NUTR, V35, P864, DOI 10.1093/ajcn/35.4.864; BOELAERT M, 1995, NUTR GUIDELINES; Briend A, 1999, LANCET, V353, P1767, DOI 10.1016/S0140-6736(99)01078-8; Collins S, 1998, AM J CLIN NUTR, V68, P193, DOI 10.1093/ajcn/68.1.193; Collins S, 2001, LANCET, V358, P498, DOI 10.1016/S0140-6736(01)05630-6; de Waal A., 1989, FAMINE KILLS DARFUR; DEGOYET CV, 2000, MANAGEMENT NUTR EMER; GOLDEN MHN, 1993, LANCET, V342, P360, DOI 10.1016/0140-6736(93)91491-4; Gomez Federico, 1956, J Trop Pediatr (Lond), V2, P77; Khanum S, 1998, AM J CLIN NUTR, V67, P940, DOI 10.1093/ajcn/67.5.940; KHANUM S, 1994, LANCET, V344, P1728; *NAT CTR HLTH STAT, 1979, NCHS GROWTH CURV CHI; Prudhon C, 1997, EUR J CLIN NUTR, V51, P771, DOI 10.1038/sj.ejcn.1600483; *SPHER PROJ, 2000, PROJ TEAM SPHER PROJ; WATERLOW JC, 1993, PROTEIN ENERGY MALNU; *WHO UN HIGH COMM, 2000, MAN NUTR MAJ EM; *WORLD FOOD PROGR, 2000, FOOD NUTR HDB; World Health Organization, 1998, MAN SEV MALN MAN PHY	19	91	92	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 7	2002	360	9348					1824	1830		10.1016/S0140-6736(02)11770-3	http://dx.doi.org/10.1016/S0140-6736(02)11770-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623MB	12480359				2023-01-03	WOS:000179706100009
J	Gibbs, S; Harvey, I; Sterling, J; Stark, R				Gibbs, S; Harvey, I; Sterling, J; Stark, R			Local treatments for cutaneous warts: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							COMMON VIRAL WARTS; 5-AMINOLEVULINIC ACID; PHOTODYNAMIC THERAPY; ALPHA-2 INTERFERON; SALICYLIC-ACID; CRYOTHERAPY; BLEOMYCIN; TRIAL; REGRESSION; VULGARIS	Objective To assess the evidence for the efficacy of local treatments for cutaneous warts. Methods Systematic review of randomised controlled trials. Main outcomes measures Total clearance of warts and adverse effects such as irritation, pain, and blistering. Study selection Randomised controlled trials of any local treatment for uncomplicated cutaneous warts. All published and unpublished material was considered, with no restriction on date or language. Results 50 included trials provided generally weak evidence because of poor methods and reporting. The best evidence was for topical treatments containing salicylic acid. Data pooled from six placebo controlled trials showed a cure rate of 75% (144 of 19 1) in cases compared with 48% (89 of 185) in controls (odds ratio 3.91,95% confidence interval 2.40 to 6.36). Some evidence for the efficacy of contact immunotherapy was provided by two small trials comparing dinitrochlorobenzene with placebo. Evidence for the efficacy of cryotherapy was limited. No consistent evidence was found for the efficacy of intralesional bleomycin, and only limited evidence was found for the efficacy of topical fluorouracil, intralesional interferons, photodynamic therapy, and pulsed dye laser. Conclusions Reviewed trials of local treatments for cutaneous warts were highly variable in methods and quality, and there was a paucity of evidence from randomised, placebo controlled trials on which to base the rational use of the treatments. There is good evidence that topical treatments containing salicylic acid have a therapeutic effect and some evidence for the efficacy of dinitrochlorobenzene. Less evidence was found for the efficacy of all the other treatments reviewed, including cryotherapy.	Ipswich Hosp NHS Trust, Dept Dermatol, Ipswich IP4 5PD, Suffolk, England; Univ E Anglia, Sch Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Addenbrookes NHS Trust, Dept Dermatol, Cambridge CB2 2QQ, England; Norfolk Hlth Author, Dept Serv Dev Finance & Informat, Norwich, Norfolk, England	Ipswich Hospital NHS Trust; Ipswich Hospital; University of East Anglia; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital	Gibbs, S (corresponding author), Ipswich Hosp NHS Trust, Dept Dermatol, Ipswich IP4 5PD, Suffolk, England.	sgibbs@fish.co.uk						ABOUAUDA H, 1987, CURR THER RES CLIN E, V41, P552; Artese O, 1994, DERMATOL CLIN, V14, P55; Auken G, 1975, Ugeskr Laeger, V137, P3036; BART BJ, 1989, J AM ACAD DERMATOL, V20, P74, DOI 10.1016/S0190-9622(89)70010-4; BERMAN B, 1986, J INFECT DIS, V154, P328, DOI 10.1093/infdis/154.2.328; BERTHJONES J, 1992, BRIT J DERMATOL, V127, P262, DOI 10.1111/j.1365-2133.1992.tb00125.x; BERTHJONES J, 1994, BRIT J DERMATOL, V131, P883, DOI 10.1111/j.1365-2133.1994.tb08594.x; BOURKE JF, 1995, BRIT J DERMATOL, V132, P433, DOI 10.1111/j.1365-2133.1995.tb08678.x; BUNNEY MH, 1976, BRIT J DERMATOL, V94, P667, DOI 10.1111/j.1365-2133.1976.tb05167.x; BUNNEY MH, 1973, BRIT J DERMATOL, V89, P96, DOI 10.1111/j.1365-2133.1973.tb01926.x; BUNNEY MH, 1971, PRACTITIONER, V207, P197; BUNNEY MH, 1984, BRIT J DERMATOL, V111, P197, DOI 10.1111/j.1365-2133.1984.tb04044.x; Caballero Martinez F, 1996, Aten Primaria, V18, P211; Clarke M, 2000, COCHRANE REV HDB 4 1; Connolly M, 2001, BRIT J DERMATOL, V145, P554, DOI 10.1046/j.1365-2133.2001.04449.x; ERKENS AMJ, 1992, J DERMATOLOGICAL TRE, V3, P193; Felt BT, 1998, AM J CLIN HYPN, V41, P130, DOI 10.1080/00029157.1998.10404199; FLINDTHANSEN H, 1984, ACTA DERM-VENEREOL, V64, P177; GIBBS S, 2001, COCHRANE LIB; GIBSON JR, 1984, DERMATOLOGICA, V168, P178, DOI 10.1159/000249695; Hansen J G, 1986, Ugeskr Laeger, V148, P173; HAYES ME, 1986, J AM ACAD DERMATOL, V15, P1002, DOI 10.1016/S0190-9622(86)70264-8; HURSTHOUSE MW, 1975, BRIT J DERMATOL, V92, P93; Larsen PO, 1996, J DERMATOL TREAT, V7, P29, DOI 10.3109/09546639609086866; LEE S W, 1990, Annals of Dermatology, V2, P77; Marroquin E. A., 1997, Fitoterapia, V68, P160; MUNKVAD M, 1983, DERMATOLOGICA, V167, P86, DOI 10.1159/000249753; NIIMURA M, 1990, J INVEST DERMATOL, V95, pS149, DOI 10.1111/1523-1747.ep12875129; Parton AM, 1994, BR J POD MED, V131, P883; PAZIN GJ, 1982, J INTERFERON RES, V2, P235, DOI 10.1089/jir.1982.2.235; Perez AR, 1992, DERMATOL VENEZ, V30, P176; Robson KJ, 2000, J AM ACAD DERMATOL, V43, P275, DOI 10.1067/mjd.2000.106365; Rosado-Cancino MA, 1989, DERMATOL REV MEX, V33, P245; Rossi E, 1981, DERMATOL REV MEX, V25, P158; SCHMIDT H, 1981, Zeitschrift fuer Hautkrankheiten, V56, P41; SONNEX TS, 1988, BRIT J DERMATOL, V119, P38; SPANOS NP, 1990, PSYCHOSOM MED, V52, P109, DOI 10.1097/00006842-199001000-00009; STAHL D, 1979, CLIN EXP DERMATOL, V4, P81, DOI 10.1111/j.1365-2230.1979.tb01594.x; STEELE K, 1988, BRIT J DERMATOL, V118, P537, DOI 10.1111/j.1365-2133.1988.tb02464.x; STEELE K, 1988, J ROY COLL GEN PRACT, V38, P256; Stender IM, 1999, CLIN EXP DERMATOL, V24, P154, DOI 10.1046/j.1365-2230.1999.00441.x; Stender IM, 2000, LANCET, V355, P963, DOI 10.1016/S0140-6736(00)90013-8; Sterling JC, 1998, ROOK TXB DERMATOLOGY; VANCE JC, 1986, ARCH DERMATOL, V122, P272, DOI 10.1001/archderm.122.3.272; Varnavides CK, 1997, J DERMATOL TREAT, V8, P169, DOI 10.3109/09546639709160513; VEIEN NK, 1977, ACTA DERM-VENEREOL, V57, P445; Veien NK, 1991, J DERMATOL TREAT, V2, P59, DOI DOI 10.3109/09546639109086776; Wilson J. T., 1983, Nutrition and Health, V2, P191; WILSON P, 1983, SCOT MED J, V28, P191	50	120	128	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 31	2002	325	7362					461	464		10.1136/bmj.325.7362.461	http://dx.doi.org/10.1136/bmj.325.7362.461			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592EZ	12202325	Green Published, Bronze			2023-01-03	WOS:000177924900016
J	Batta, K; Goodyear, HM; Moss, C; Williams, HC; Hiller, L; Waters, R				Batta, K; Goodyear, HM; Moss, C; Williams, HC; Hiller, L; Waters, R			Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis	LANCET			English	Article							CUTANEOUS HEMANGIOMAS; CAPILLARY HEMANGIOMAS; MANAGEMENT; INFANCY; THERAPY; CARE	Introduction The role of pulsed dye lasers (PDL) in the treatment of childhood haemangiomas is controversial. Our aim was to compare treatment with PDL with a wait-and-see policy. Methods We did a prospective, randomised controlled trial in which we enrolled 121 infants aged 1-14 weeks with early haemangiomas. We assigned infants to PDL treatment (n=60) or observation (n=61), and followed them up to age I year. The main outcome measures assessed were proportion of lesions completely clear or with minimum residual signs, adverse reactions, including pigmentary disturbance and skin atrophy, complications such as ulceration and infection, proportion of children whose parents considered the haemangioma a problem, characteristics of the haemangioma, and an independent assessment of the haemangioma problem by a panel of five parents. Analysis was by intention to treat. Findings All infants completed the study. The number of children whose lesions showed complete clearance or minimum residual signs at 1 year was not significantly different in the PDL treated and observation groups (25, 42%, vs 27, 44%; p=0.92). However, PDL treated infants were more likely to have skin atrophy (17, 28%, vs 5, 8%; p=0.008) and hypopigmentation (27, 45%, vs 9, 15%; p=0.001). The frequency of complications was similar between groups. The only objective measure of resolution that improved with PDL treatment was haemangioma redness. The number of children whose parents considered the haemangioma to be a problem at 1 year did not differ much between groups (11 of 60, 18%, vs 9 of 61, 15%; p=0.78). The independent parent panel validated this result. Interpretation PDL treatment in uncomplicated haemangiomas is no better than a wait-and-see policy.	Birmingham Childrens Hosp NHS Trust, Dept Dermatol, Birmingham B4 6NL, W Midlands, England; Birmingham Childrens Hosp NHS Trust, Dept Plast Surg, Birmingham B4 6NL, W Midlands, England; Birmingham Heartlands Hosp, Dept Paediat, Birmingham B9 5ST, W Midlands, England; Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England; Univ Birmingham, Inst Canc Studies, Canc Res UK Trials Unit, Birmingham, W Midlands, England	Heart of England NHS Foundation Trust; University of Birmingham; University of Nottingham; University of Birmingham	Batta, K (corresponding author), Birmingham Childrens Hosp NHS Trust, Dept Dermatol, Birmingham B4 6NL, W Midlands, England.	kapilabatta@yahoo.co.uk		williams, hywel/0000-0002-5646-3093				Achauer BM, 1997, PLAST RECONSTR SURG, V99, P1301, DOI 10.1097/00006534-199704001-00014; ASHINOFF R, 1991, ARCH DERMATOL, V127, P202, DOI 10.1001/archderm.127.2.202; Barlow RJ, 1996, BRIT J DERMATOL, V134, P700, DOI 10.1111/j.1365-2133.1996.tb06974.x; Bennett ML, 2001, ARCH DERMATOL, V137, P1208; BOWERS RE, 1960, ARCH DERMATOL, V82, P667, DOI 10.1001/archderm.1960.01580050009002; Drolet BA, 1999, NEW ENGL J MED, V341, P173, DOI 10.1056/NEJM199907153410307; ENJOLRAS O, 1990, PEDIATRICS, V85, P491; FINN MC, 1983, J PEDIATR SURG, V18, P894; Frieden IJ, 1997, J AM ACAD DERMATOL, V37, P631, DOI 10.1016/S0190-9622(97)70183-X; Frieden IJ, 1997, PEDIATR DERMATOL, V14, P57; GARDEN JM, 1992, J PEDIATR-US, V120, P555, DOI 10.1016/S0022-3476(05)82481-3; GOLDMAN MP, 1993, J PEDIATR-US, V122, P71, DOI 10.1016/S0022-3476(05)83489-4; HIDANO A, 1972, BRIT J DERMATOL, V87, P138, DOI 10.1111/j.1365-2133.1972.tb16188.x; Hohenleutner S, 2001, LASER SURG MED, V28, P273, DOI 10.1002/lsm.1050; HOLMDAHL K, 1955, Acta Paediatr, V44, P370, DOI 10.1111/j.1651-2227.1955.tb04151.x; JACOBS ALVIN H., 1957, CALIFORNIA MED, V86, P8; Kim HJ, 2001, J AM ACAD DERMATOL, V44, P962, DOI 10.1067/mjd.2001.112382; Lacour M, 1996, ARCH DIS CHILD, V74, P161, DOI 10.1136/adc.74.2.161; LANDTHALER M, 1995, BRIT J DERMATOL, V133, P275, DOI 10.1111/j.1365-2133.1995.tb02629.x; Maier H, 1996, LANCET, V347, P131, DOI 10.1016/S0140-6736(96)90263-9; MICHEL S, 1998, HAUZART, V29, P192; Poetke M, 2000, ARCH DERMATOL, V136, P628, DOI 10.1001/archderm.136.5.628; Ricci RM, 1998, LASER SURG MED, V22, P10, DOI 10.1002/(SICI)1096-9101(1998)22:1<10::AID-LSM5>3.0.CO;2-#; SCHEEPERS JH, 1995, PLAST RECONSTR SURG, V95, P305, DOI 10.1097/00006534-199502000-00010; Scherer K, 2001, BRIT J DERMATOL, V145, P79, DOI 10.1046/j.1365-2133.2001.04285.x; Tanner JL, 1998, PEDIATRICS, V101, P446, DOI 10.1542/peds.101.3.446; WANER M, 1992, LARYNGOSCOPE, V102, P1123, DOI 10.1288/00005537-199210000-00007; WANER M, 1994, J DERMATOL SURG ONC, V20, P43, DOI 10.1111/j.1524-4725.1994.tb03748.x	28	133	138	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 17	2002	360	9332					521	527		10.1016/S0140-6736(02)09741-6	http://dx.doi.org/10.1016/S0140-6736(02)09741-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	585EZ	12241656				2023-01-03	WOS:000177512800010
J	Ivic, L; Sands, TTJ; Fishkin, N; Nakanishi, K; Kriegstein, AR; Stromgaard, K				Ivic, L; Sands, TTJ; Fishkin, N; Nakanishi, K; Kriegstein, AR; Stromgaard, K			Terpene trilactones from Ginkgo biloba are antagonists of cortical glycine and GABA(A) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY NEOCORTICAL DEVELOPMENT; GLUTAMIC-ACID DECARBOXYLASE; RADIAL GLIAL-CELLS; SECO-PREZIZAANE; SESQUITERPENE; PICROTOXININ; HIPPOCAMPUS; CHANNELS; LEAVES; SLICES	Glycine and gamma-aminobutyric acid, type A (GABA(A)) receptors are members of the ligand-gated ion channel superfamily that mediate inhibitory synaptic transmission in the adult central nervous system. During development, the activation of these receptors leads to membrane depolarization. Ligands for the two receptors have important implications both in disease therapy and as pharmacological tools. Terpene trilactones (ginkgolides and bilobalide) are unique constituents of Ginkgo biloba extracts that have various effects on the central nervous system. We have investigated the relative potency of these compounds on glycine and GABA(A) receptors. We find that most of the ginkgolides are selective and potent antagonists of the glycine receptor. Bilobalide, the single major component in G. biloba extracts, also reduces glycine-induced currents, although to a lesser extent. Both ginkgolides and bilobalide inhibit GABA(A) receptors, with bilobalide demonstrating a more potent effect. Additionally, we provide evidence that open channels are required for glycine receptor inhibition by ginkgolides. Finally, we employ molecular modeling to elucidate the similarities and differences in the structure of the terpene trilactones to account for the pharmacological properties of these compounds and demonstrate a striking similarity between ginkgolides and picrotoxinin, a GABA(A) and recombinant glycine alpha-homomeric receptor antagonist.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University	Kriegstein, AR (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.		Stromgaard, Kristian/E-3380-2010	Stromgaard, Kristian/0000-0003-2206-4737	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS038658] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 38658] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS PR, 1983, AUST J CHEM, V36, P2219, DOI 10.1071/CH9832219; Betz H, 1999, ANN NY ACAD SCI, V868, P667, DOI 10.1111/j.1749-6632.1999.tb11343.x; BETZ H, 2001, HDB EXPT PHARM, P150; DeFeudis F. V., 2000, Current Drug Targets, V1, P25, DOI 10.2174/1389450003349380; DeFeudis F.V., 1998, GINKGO BILOBA EXTRAC; DUPONT L, 1986, ACTA CRYSTALLOGR C, V42, P1759, DOI 10.1107/S0108270186090662; Flint AC, 1998, NEURON, V20, P43, DOI 10.1016/S0896-6273(00)80433-X; Granger AS, 2001, AGE AGEING, V30, P523, DOI 10.1093/ageing/30.6.523; HARIHARAN PC, 1974, MOL PHYS, V27, P209, DOI 10.1080/00268977400100171; Huang SH, 2003, EUR J PHARMACOL, V464, P1, DOI 10.1016/S0014-2999(03)01344-X; Jones FA, 2002, AMINO ACIDS, V22, P369, DOI 10.1007/s007260200021; KLUNK WE, 1983, MOL PHARMACOL, V23, P511; Kondratskaya EL, 2002, NEUROCHEM INT, V40, P647, DOI 10.1016/S0197-0186(01)00109-7; Kuriyama T, 2002, BIOORGAN MED CHEM, V10, P1873, DOI 10.1016/S0968-0896(02)00011-1; Leite JF, 2001, MOL CELL NEUROSCI, V17, P777, DOI 10.1006/mcne.2001.0984; Lichtblau D, 2002, J NAT PROD, V65, P1501, DOI 10.1021/np0201974; LoTurco JJ, 1995, NEURON, V15, P1287, DOI 10.1016/0896-6273(95)90008-X; Malatesta P, 2000, DEVELOPMENT, V127, P5253; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Mori M, 2002, J PHYSIOL-LONDON, V539, P191, DOI 10.1113/jphysiol.2001.013147; NAKANISHI K, 1971, J AM CHEM SOC, V93, P3544, DOI 10.1021/ja00743a051; NAKANISHI KOJI, 1967, PURE APPL CHEM, V14, P89, DOI 10.1351/pac196714010089; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Owens DF, 1999, J NEUROPHYSIOL, V82, P570, DOI 10.1152/jn.1999.82.2.570; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; Sasaki K, 1999, EUR J PHARMACOL, V367, P165, DOI 10.1016/S0014-2999(98)00968-6; Sasaki K, 2000, LIFE SCI, V67, P709, DOI 10.1016/S0024-3205(00)00657-3; Sasaki K, 1999, COMP BIOCHEM PHYS C, V124, P315, DOI 10.1016/S0742-8413(99)00082-1; Schmidt TJ, 1999, BIOORGAN MED CHEM, V7, P2857, DOI 10.1016/S0968-0896(99)00240-0; Solomon PR, 2002, JAMA-J AM MED ASSOC, V288, P835, DOI 10.1001/jama.288.7.835; vanBeek TA, 1997, J NAT PROD, V60, P735, DOI 10.1021/np970060r; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	33	93	97	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49279	49285		10.1074/jbc.M304034200	http://dx.doi.org/10.1074/jbc.M304034200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504293	hybrid			2023-01-03	WOS:000186829000094
J	Schulz, R; Mendelsohn, AB; Haley, WE; Mahoney, D; Allen, RS; Zhang, S; Thompson, L; Belle, SH				Schulz, R; Mendelsohn, AB; Haley, WE; Mahoney, D; Allen, RS; Zhang, S; Thompson, L; Belle, SH		REACH Investigators	End-of-life care and the effects of bereavement on family caregivers of persons with dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; PREVALENCE	Background: Although family caregiving has been intensively studied in the past decade, little attention has been paid to the impact of end-of-life care on caregivers who are family members of persons with dementia or to the caregivers' responses to the death of the patient. Methods: Using standardized assessment instruments and structured questions, we assessed the type and intensity of care provided by 217 family caregivers to persons with dementia during the year before the patient's death and assessed the caregivers' responses to the death. Results: Half the caregivers reported spending at least 46 hours per week assisting patients with activities of daily living and instrumental activities of daily living. More than half the caregivers reported that they felt they were ``on duty'' 24 hours a day, that the patient had frequent pain, and that they had had to end or reduce employment owing to the demands of caregiving. Caregivers exhibited high levels of depressive symptoms while providing care to the relative with dementia, but they showed remarkable resilience after the death. Within three months of the death, caregivers had clinically significant declines in the level of depressive symptoms, and within one year the levels of symptoms were substantially lower than levels reported while they were acting as caregivers. Seventy-two percent of caregivers reported that the death was a relief to them, and more than 90 percent reported belief that it was a relief to the patient. Conclusions: End-of-life care for patients with dementia was extremely demanding of family caregivers. Intervention and support services were needed most before the patient's death. When death was preceded by a protracted and stressful period of caregiving, caregivers reported considerable relief at the death itself.	Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Inst Aging, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA; Univ S Florida, Dept Gerontol, Tampa, FL USA; Hebrew Rehabil Ctr Aged, Boston, MA 02131 USA; Univ Alabama, Dept Psychol, Tuscaloosa, AL 35487 USA; Stanford Univ, Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA 94305 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of South Florida; University of Alabama System; University of Alabama Tuscaloosa; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Schulz, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 121 Univ Pl,6th Fl, Pittsburgh, PA 15260 USA.	schulz@pitt.edu	Haley, William E/B-6133-2017	Haley, William E/0000-0003-0780-3482; Mahoney, Diane/0000-0002-6415-475X; Allen, Rebecca Sue/0000-0002-2563-4996; Mendelsohn, Aaron/0000-0002-0560-1177	NIA NIH HHS [AG 13305] Funding Source: Medline; NINR NIH HHS [NR 13269] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG013255, U01AG013305] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Brown H., 1999, APPL MIXED MODELS ME; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Grant I, 2002, PSYCHOSOM MED, V64, P477, DOI 10.1097/00006842-200205000-00012; Harrell Frank E., 2001, REGRESSION MODELING; Hurley AC, 2002, JAMA-J AM MED ASSOC, V288, P2324, DOI 10.1001/jama.288.18.2324; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Langa KM, 2001, J GEN INTERN MED, V16, P770, DOI 10.1111/j.1525-1497.2001.10123.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; *OFF ASS SECR PLAN, 1998, INF CAR COMP ACT; Ory MG, 1999, GERONTOLOGIST, V39, P177, DOI 10.1093/geront/39.2.177; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Schulz R, 2001, JAMA-J AM MED ASSOC, V285, P3123, DOI 10.1001/jama.285.24.3123; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622; Wisniewski SR, 2003, PSYCHOL AGING, V18, P375, DOI 10.1037/0882-7974.18.3.375	19	338	342	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1936	1942		10.1056/NEJMsa035373	http://dx.doi.org/10.1056/NEJMsa035373			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742EA	14614169				2023-01-03	WOS:000186502400010
J	Maio, M; Coral, S; Fratta, E; Altomonte, M; Sigalotti, L				Maio, M; Coral, S; Fratta, E; Altomonte, M; Sigalotti, L			Epigenetic targets for immune intervention in human malignancies	ONCOGENE			English	Review						DNA methylation; histone acetylation; cancer; immunotherapy; HLA antigens; tumor antigens	CANCER-TESTIS ANTIGENS; CLASS-I ANTIGENS; 5-AZA-2'-DEOXYCYTIDINE DECITABINE TREATMENT; CYTOLYTIC T-LYMPHOCYTES; SQUAMOUS-CELL CARCINOMA; HUMAN GENE MAGE-1; DNA METHYLATION; MYELODYSPLASTIC SYNDROME; MELANOMA-CELLS; HETEROGENEOUS EXPRESSION	Emerging evidences suggest that epigenetic events associated with tumor development and progression, such as deregulated methylation of CpG dinucleotides and aberrant histone acetylation, may impair the immunogenic potential of cancer cells. In fact, DNA hypermethylation and/or histone deacetylation contribute to the absent or downregulated expression of different components of the 'tumor recognition complex' (i.e., HLA class I antigens, cancer/testis antigens and accessory/costimulatory molecules) in solid and hemopoietic human malignancies. However, pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation can modify these epigenetic phenomena, restoring the defective expression of selected components of the 'tumor recognition complex' in cancer cells. These antigenic modi. cations positively modulate the immunogenicity and the immune recognition of cancer cells, making epigenetic drugs attractive agents to design new combined chemoimmunotherapeutic strategies for the treatment of cancer patients.	IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, I-33081 Aviano, Italy	IRCCS Aviano (CRO)	Maio, M (corresponding author), IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, Via Pedemontana Occle 12, I-33081 Aviano, Italy.	mmaio@cro.it	Fratta, Elisabetta/J-8707-2016; Sigalotti, Luca/A-5893-2013; altomonte, maresa/G-7734-2011; Sigalotti, Luca/AAC-2926-2020; Coral, Sandra/AAB-9552-2022	Fratta, Elisabetta/0000-0002-7472-8841; Sigalotti, Luca/0000-0003-3362-5026; Sigalotti, Luca/0000-0002-1436-2358; Maio, Michele/0000-0002-0323-6321; Altomonte, Maresa/0000-0001-8021-1921; coral, sandra/0000-0002-1308-3082				ALTOMONTE M, 1993, CANCER RES, V53, P3343; Arnold JM, 2001, BRIT J CANCER, V85, P1351, DOI 10.1054/bjoc.2001.2075; Boussiotis VA, 1996, IMMUNOL REV, V153, P5, DOI 10.1111/j.1600-065X.1996.tb00918.x; BRASSEUR F, 1992, INT J CANCER, V52, P839, DOI 10.1002/ijc.2910520528; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chambost H, 2001, LEUKEMIA, V15, P1769, DOI 10.1038/sj.leu.2402278; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Coral S, 1999, J IMMUNOTHER, V22, P16, DOI 10.1097/00002371-199901000-00003; Coral S, 2002, CLIN CANCER RES, V8, P2690; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DESMET C, 1995, IMMUNOGENETICS, V42, P282, DOI 10.1007/BF00176446; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; dos Santos NR, 2000, CANCER RES, V60, P1654; EURA M, 1995, INT J CANCER, V64, P304, DOI 10.1002/ijc.2910640504; Fonsatti E, 2003, INT J CANCER, V105, P430, DOI 10.1002/ijc.11077; Fujie T, 1997, ANN ONCOL, V8, P369, DOI 10.1023/A:1008255630202; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Jager E, 2000, P NATL ACAD SCI USA, V97, P4760, DOI 10.1073/pnas.97.9.4760; Jungbluth AA, 2000, BRIT J CANCER, V83, P493, DOI 10.1054/bjoc.2000.1291; Jungbluth AA, 2001, INT J CANCER, V92, P856, DOI 10.1002/ijc.1282; Kienstra MA, 2003, HEAD NECK-J SCI SPEC, V25, P457, DOI 10.1002/hed.10223; Kim JJ, 1999, J CLIN INVEST, V103, P869, DOI 10.1172/JCI6024; Li J, 1996, CLIN CANCER RES, V2, P1619; Luo Guorong, 2002, Cancer Immun, V2, P11; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Maio M, 2003, J CLIN ENDOCR METAB, V88, P748, DOI 10.1210/jc.2002-020830; Mashino K, 2001, BRIT J CANCER, V85, P713, DOI 10.1054/bjoc.2001.1974; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Mori M, 1996, ANN SURG, V224, P183, DOI 10.1097/00000658-199608000-00011; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Nie Y, 2001, CARCINOGENESIS, V22, P1615, DOI 10.1093/carcin/22.10.1615; Quillien V, 1997, ANTICANCER RES, V17, P387; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Sandor V, 2002, CLIN CANCER RES, V8, P718; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Scanlan MJ, 2000, CANCER LETT, V150, P155, DOI 10.1016/S0304-3835(99)00385-7; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Seliger B, 2002, SEMIN CANCER BIOL, V12, P3, DOI 10.1006/scbi.2001.0404; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Sigalotti L, 2003, BLOOD, V101, P4644, DOI 10.1182/blood-2002-11-3458; Sigalotti L, 2002, BRIT J CANCER, V86, P979, DOI 10.1038/sj.bjc.6600174; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Soling A, 1999, ANTICANCER RES, V19, P2205; Traversari C, 1999, MINERVA BIOTECNOL, V11, P243; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; WEBER J, 1994, CANCER RES, V54, P1766; Weiser TS, 2001, ANN THORAC SURG, V71, P295, DOI 10.1016/S0003-4975(00)02421-8; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Worm J, 2002, J ORAL PATHOL MED, V31, P443, DOI 10.1034/j.1600-0714.2002.00034.x; Zendman AJW, 2003, J CELL PHYSIOL, V194, P272, DOI 10.1002/jcp.10215; Zuckerman LA, 1998, J IMMUNOL, V160, P3259	54	55	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6484	6488		10.1038/sj.onc.1206956	http://dx.doi.org/10.1038/sj.onc.1206956			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528272				2023-01-03	WOS:000185700700004
J	Blackledge, HM; Newton, J; Squire, IB				Blackledge, HM; Newton, J; Squire, IB			Prognosis for South Asian and white patients newly admitted to hospital with heart failure in the United Kingdom: historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							LEFT-VENTRICULAR DYSFUNCTION; CORONARY-ARTERY DISEASE; RACIAL-DIFFERENCES; RISK-FACTORS; POPULATION; MORTALITY; ENGLAND; SINGAPORE; SURVIVAL; CHINESE	Objectives To compare patterns of admission to hospital and prognosis in white and South Asian patients newly admitted with heart failure, and to evaluate the effect of personal characteristics and comorbidity on outcome. Design Historical cohort study. Setting UK district health authority (population 960 000). Participants 5789 consecutive patients newly admitted with heart failure. Main outcome measures Population admission rates, incidence rates for first admission with heart failure, survival, and readmission rates. Results When compared with the white population, South Asian patients had significantly higher age adjusted admission rates (rate ratio 3.8 for men and 5.2 for women) and hospital incidence rates (2.2 and 2.9). Among 5789 incident cases of heart failure, South Asian patients were younger and more often male than white patients (70 (SD 0.6) upsilon 78 (SD 0.1) years and 56.5% (190/336) upsilon 49.3% (2494/5057)). South Asian patients were also more likely to have previous myocardial infarction (10.1% (n = 34) upsilon 5.5% (n = 278)) or concomitant myocardial infarction (18.8% (n = 63) upsilon 10.7% (n = 539)) or diabetes (45.8% (n = 154) upsilon 16.2% (n = 817), all P < 0.001). A trend was shown to longer unadjusted survival for both sexes among South Asian patients. After adjustment for covariables, South Asian patients had a significantly lower risk of death (hazard ratio 0.82, 95% confidence interval 0.68 to 0.99) and a similar probability of death or readmission (0.96, 0.81 to 1.09) compared with white patients. Conclusions Population admission rates for heart failure are higher among South Asian patients than white patients in Leicestershire. At first admission South Asian patients were younger and more often had concomitant diabetes or acute ischaemic heart disease than white patients. Despite major differences in personal characteristics and risk factors between white and South Asian patients, outcome was similar, if not better, in South Asian patients.	Univ Leicester, Leicester Royal Infirm, Dept Med & Therapeut, Leicester, Leics, England; Leicestershire Area Hlth Author, Dept Publ Hlth Med, Leicester, Leics, England	University of Leicester	Squire, IB (corresponding author), Univ Leicester, Leicester Royal Infirm, Dept Med & Therapeut, Leicester, Leics, England.							ALEXANDER M, 1995, JAMA-J AM MED ASSOC, V274, P1037, DOI 10.1001/jama.274.13.1037; Alexander M, 1999, AM HEART J, V137, P919, DOI 10.1016/S0002-8703(99)70417-5; Armitage P, 1998, STAT METHODS MED RES; BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; Balarajan R, 1996, HLTH TRENDS, V28, P45; Collet D., 1994, MODELLING SURVIVAL D; Davies MK, 2001, LANCET, V358, P439, DOI 10.1016/S0140-6736(01)05620-3; Dries DL, 1999, NEW ENGL J MED, V340, P609, DOI 10.1056/NEJM199902253400804; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Goldsmith I, 1999, EUR HEART J, V20, P1094, DOI 10.1053/euhj.1998.1450; Heiat A, 2002, ARCH INTERN MED, V162, P1682, DOI 10.1001/archinte.162.15.1682; HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P24, DOI 10.1136/jech.44.1.24; Iribarren C, 2001, CIRCULATION, V103, P2668; Jong P, 2002, ARCH INTERN MED, V162, P1689, DOI 10.1001/archinte.162.15.1689; Lee J, 2001, INT J EPIDEMIOL, V30, P983, DOI 10.1093/ije/30.5.983; Lip GYH, 1997, INT J CLIN PRACT, V51, P223; LOWRY PJ, 1984, BRIT HEART J, V52, P610, DOI 10.1136/hrt.52.6.610; LOWY AGJ, 1991, J PUBLIC HEALTH MED, V13, P276; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; MCKEIGUE PM, 1985, LANCET, V2, P1086; MUHKTAR HT, 1995, BRIT HEART J, V73, P122; Sheifer SE, 2000, AM HEART J, V139, P848, DOI 10.1016/S0002-8703(00)90017-6; Stewart S, 2001, EUR HEART J, V22, P209, DOI 10.1053/euhj.2000.2291; Taira DA, 2001, CELL MOL BIOL, V47, P1209; Wild S, 1997, BRIT MED J, V314, P705, DOI 10.1136/bmj.314.7082.705	26	64	65	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					526	530		10.1136/bmj.327.7414.526	http://dx.doi.org/10.1136/bmj.327.7414.526			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958110	Green Published, Bronze			2023-01-03	WOS:000185283700015
J	McWilliams, JM; Zaslavsky, AM; Meara, E; Ayanian, JZ				McWilliams, JM; Zaslavsky, AM; Meara, E; Ayanian, JZ			Impact of Medicare coverage on basic clinical services for previously uninsured adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-INSURANCE COVERAGE; RIGHT HEART CATHETERIZATION; SUPPLEMENTAL INSURANCE; PREVENTIVE-SERVICES; ELDERLY PATIENTS; MAMMOGRAPHY; CARE; CANCER; TERMINATION; PREDICTORS	Context Uninsured adults receive less appropriate care and have more adverse health consequences than insured adults. Longitudinal studies would help to more clearly define the effects of health insurance on health care and health. Objective To assess the differential effects of gaining Medicare coverage on use of basic clinical services and medications by previously insured and uninsured adults. Design and Setting Household survey data from the nationally representative Health and Retirement Study were used to analyze differences in receipt of basic clinical services by adults in 1996 and 2000, before and after becoming eligible for Medicare at age 65 years. Participants A total of 2203 adults aged 60 to 64 years in 1996 who were classified as continuously uninsured (n=167), intermittently uninsured (n=216), or continuously insured (n=1820) in 1994 and 1996, prior to Medicare eligibility. Main Outcome Measures Individuals' reports of receiving cholesterol testing, mammography (in women), prostate examination (in men), and treatment of arthritis and hypertension in the prior 2 years. Results The difference in cholesterol testing between continuously insured and continuously uninsured adults was significantly reduced after Medicare eligibility (35.4% vs 17.7%; change of -17.7% [95% Cl, -29.3 % to -6.2%]; P=.003), and the reduction was substantially greater among those with hypertension or diabetes than among other adults (29.2% vs 7.7%; difference of 21.5% [95% Cl, 0.2% to 42.9%1; P=.048). Differences in use were similarly reduced after Medicare eligibility for mammography in women (30.3% vs 15.0%; change of -15.3% [95% Cl, -29.9% to -0.7%1; P=.04) and prostate examination in men (45.2% vs 20.0%; change of -25.2% [95% Cl, -45.4% to -5.1 %]; P=.01). Continuously uninsured adults with arthritis reported significantly greater increases in arthritis-related medical visits and limitations of activity than continuously insured adults after Medicare eligibility, but not greater increases in arthritis treatments. Among adults with hypertension, differences in use of antihypertensive medications between continuously uninsured and insured adults were essentially unchanged after Medicare coverage. Conclusions Previously uninsured adults substantially increased their use of covered basic clinical services but not medications after gaining Medicare coverage. An affordable option through which near-elderly uninsured adults could purchase Medicare coverage might have similar effects.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Boston, MA 02115 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; National Bureau of Economic Research	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	ayanian@hcp.med.harvard.edu		Meara, Ellen/0000-0003-0211-1970				Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; Ayanian JZ, 2002, NEW ENGL J MED, V347, P1678, DOI 10.1056/NEJMsa020080; AYANIAN JZ, IN PRESS AM J PUBLIC; Baker DW, 2001, NEW ENGL J MED, V345, P1106, DOI 10.1056/NEJMsa002887; BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; BOWLIN SJ, 1993, J CLIN EPIDEMIOL, V46, P561, DOI 10.1016/0895-4356(93)90129-O; BRENNAN N, 2000, NEW FEDERALISM NAT B; Brown ME, 1998, MED CARE RES REV, V55, P177, DOI 10.1177/107755879805500203; Chulis G S, 1993, Health Care Financ Rev, V14, P163; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; *COMM FUND COMM EL, 1993, UNF AG IMPR WELL BEI; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Cummings DM, 2000, ARCH FAM MED, V9, P870, DOI 10.1001/archfami.9.9.870; Davis K, 1997, HEALTH SERV RES, V31, P641; Decker S., 2002, 8761 NAT BUR EC RES; DEGNAN D, 1992, AM J PUBLIC HEALTH, V82, P1386, DOI 10.2105/AJPH.82.10.1386; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; Feinberg E, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e29; FIHN SD, 1988, J GEN INTERN MED, V3, P356, DOI 10.1007/BF02595794; Harris R, 2002, ANN INTERN MED, V137, P917, DOI 10.7326/0003-4819-137-11-200212030-00014; Heeringa S.G., 1995, TECHNICAL DESCRIPTIO; Huttin C, 2000, CLIN DRUG INVEST, V20, P181, DOI 10.2165/00044011-200020030-00006; Institute of Medicine, 2002, CAR COV TOO LITTL TO; Institute of Medicine, 2001, COV MATT INS HLTH CA; Johnson RW, 1997, HEALTH CARE FINANC R, V18, P123; JOHNSON RW, 2002, MED BUY IN NEAR ELDE; Kasper JD, 2000, MED CARE RES REV, V57, P298, DOI 10.1177/107755870005700302; Kinsella K., 2001, AGEING WORLD, DOI [10.1037/e407472005-001, DOI 10.1037/E407472005-001]; LANDRUM MB, 2001, HLTH SERV OUTCOMES R, V2, P221, DOI DOI 10.1023/A:1020367111374; Lemon S, 2001, AM J PUBLIC HEALTH, V91, P1264, DOI 10.2105/AJPH.91.8.1264; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MEYER BD, 1995, J BUS ECON STAT, V13, P151, DOI 10.2307/1392369; Pearlman DN, 1996, AM J PREV MED, V12, P327, DOI 10.1016/S0749-3797(18)30287-3; Petersen LA, 2000, NEW ENGL J MED, V343, P1934, DOI 10.1056/NEJM200012283432606; Polanczyk CA, 2001, JAMA-J AM MED ASSOC, V286, P309, DOI 10.1001/jama.286.3.309; Powell-Griner E, 1999, AM J PUBLIC HEALTH, V89, P882, DOI 10.2105/AJPH.89.6.882; RHOADES J, 2000, AHRQ PUBLICATION, V23; RHOADES J, 2001, AHRQ PUBLICATION; Roetzheim RG, 1999, J NATL CANCER I, V91, P1409, DOI 10.1093/jnci/91.16.1409; Sarndal C.-E., 1991, MODEL ASSISTED SURVE; Schoen C, 2000, HEALTH SERV RES, V35, P187; SCHOEN C, 2000, COUNTING MED PERSPEC; Shea DG, 2001, HEALTH AFFAIR, V20, P219, DOI 10.1377/hlthaff.20.1.219; SHEILS J, 2001, MED BUY IN OPTIONS E; Sudano JJ, 2003, AM J PUBLIC HEALTH, V93, P130, DOI 10.2105/AJPH.93.1.130; Sundararajan V, 2002, ANN INTERN MED, V136, P349, DOI 10.7326/0003-4819-136-5-200203050-00007; United States Preventive Services Task Force, 1996, GUID CLIN PREV SERV; *US GEN ACC OFF, 2001, GAO01374 US GEN ACC	50	148	148	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2003	290	6					757	764		10.1001/jama.290.6.757	http://dx.doi.org/10.1001/jama.290.6.757			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	709VU	12915428				2023-01-03	WOS:000184647700026
J	Mak, YYW; Elwyn, G; Finlay, IG				Mak, YYW; Elwyn, G; Finlay, IG			Patients' voices are needed in debates on euthanasia	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN-ASSISTED SUICIDE; TERMINALLY ILL; DESIRE; PEOPLE; DEATH		Bradbury Hospice, Shatin, Hong Kong, Peoples R China; Univ Coll Swansea, Swansea Clin Sch, Primary Care Res Grp, Swansea SA2 8PP, W Glam, Wales; Univ Wales Coll Med, Sch Med, Cardiff CF14 7XL, S Glam, Wales	Swansea University; Cardiff University	Mak, YYW (corresponding author), Bradbury Hospice, A Kung Kok Shan Rd, Shatin, Hong Kong, Peoples R China.		Elwyn, G./L-4292-2015; Elwyn, Glyn/B-4798-2009	Elwyn, Glyn/0000-0002-0917-6286				Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Bolton G., 2001, REFLECTIVE PRACTICE; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; EMANUEL F, 1996, LANCET, V347, P1805; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; *HOUS LORDS SEL CO, 2003, REP MED ETH; Hurwitz B, 2002, BMJ-BRIT MED J, V325, P667, DOI 10.1136/bmj.325.7366.667; JOHANSEN S, IN PRESS PALLIAT MED; Lavery JV, 2001, LANCET, V358, P362, DOI 10.1016/S0140-6736(01)05555-6; Mak Y, 2003, PALLIATIVE MED, V17, P395, DOI 10.1191/0269216303pm775oa; Malterud K, 2001, LANCET, V358, P397, DOI 10.1016/S0140-6736(01)05548-9; MISHARA B, 1999, OMEGA, V39, pR2; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; ROY D, 1998, OXFORD TXB PALLIATIV, P120; SEALE C, 1994, SOC SCI MED, V39, P647, DOI 10.1016/0277-9536(94)90021-3; Sullivan M, 1997, J PALLIAT CARE, V13, P18, DOI 10.1177/082585979701300304; WOODRUFF R, 1999, EUTHANASIA PHYSICIAN	19	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 26	2003	327	7408					213	215		10.1136/bmj.327.7408.213	http://dx.doi.org/10.1136/bmj.327.7408.213			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	706DL	12881268	Green Published			2023-01-03	WOS:000184437300024
J	Letvin, NL; Walker, BD				Letvin, NL; Walker, BD			Immunopathogenesis and immunotherapy in AIDS virus infections	NATURE MEDICINE			English	Review							CYTOTOXIC T-LYMPHOCYTES; NEUTRALIZING ANTIBODY-RESPONSES; CELLULAR IMMUNE-RESPONSES; AMINO-ACID CHANGE; SIMIAN IMMUNODEFICIENCY; HIV-1 INFECTION; ANTIRETROVIRAL THERAPY; MONOCLONAL-ANTIBODIES; RHESUS-MONKEYS; TREATMENT INTERRUPTIONS	The heterogeneity of HIV and the different human leukocyte antigen (HLA) backgrounds of infected individuals have posed challenges to understanding the pathogenesis of HIV infection. But continuing advances in our knowledge of the role of immune responses in controlling HIV viremia should help to define goals for immune-based therapies and vaccine strategies against AIDS.	Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA; Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div AIDS, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Walker, BD (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA.	bwalker@partners.org						Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Altfeld M, 2002, J CLIN INVEST, V109, P837, DOI 10.1172/JCI0214789; Altfeld M, 2001, J EXP MED, V193, P169, DOI 10.1084/jem.193.2.169; ALTFELD M, IN PRESS J VIROL; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405; Brodie SJ, 1999, NAT MED, V5, P34, DOI 10.1038/4716; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; CDC, 1981, MMWR MORB MORTAL WKL, V30, P305; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; CHEN ZW, 1995, J EXP MED, V182, P21, DOI 10.1084/jem.182.1.21; Chen ZW, 2000, J VIROL, V74, P7442, DOI 10.1128/JVI.74.16.7442-7450.2000; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Dalod M, 1999, J CLIN INVEST, V104, P1431, DOI 10.1172/JCI7162; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Garcia F, 2001, AIDS, V15, pF29, DOI 10.1097/00002030-200106150-00002; Goulder PJR, 2001, J EXP MED, V193, P181, DOI 10.1084/jem.193.2.181; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; Hay CM, 1999, J VIROL, V73, P5509, DOI 10.1128/JVI.73.7.5509-5519.1999; Jacobson JM, 1998, MT SINAI J MED, V65, P22; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Kaslow RA, 2001, J VIROL, V75, P8681, DOI 10.1128/JVI.75.18.8681-8689.2001; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; Kuroda MJ, 1999, J IMMUNOL, V162, P5127; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; Lieberman J, 2001, BLOOD, V98, P1667, DOI 10.1182/blood.V98.6.1667; LISZIEWICZ J, 2003, NEW ENGL J MED, V340, P1683; Lu W, 2003, NAT MED, V9, P27, DOI 10.1038/nm806; Luzuriaga K, 2000, J VIROL, V74, P6984, DOI 10.1128/JVI.74.15.6984-6991.2000; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; Markowitz M, 2002, J INFECT DIS, V186, P634, DOI 10.1086/342559; Mascola JR, 1997, J VIROL, V71, P7198, DOI 10.1128/JVI.71.10.7198-7206.1997; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; MATLOUBIAN M, 1990, J EXP MED, V172, P1043, DOI 10.1084/jem.172.4.1043; MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993; McKay PF, 2003, J VIROL, V77, P4695, DOI 10.1128/JVI.77.8.4695-4702.2003; McNeil AC, 2001, P NATL ACAD SCI USA, V98, P13878, DOI 10.1073/pnas.251539598; MEYERHANS A, 1991, EUR J IMMUNOL, V21, P2637, DOI 10.1002/eji.1830211051; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Montefiori DC, 1996, J INFECT DIS, V173, P60, DOI 10.1093/infdis/173.1.60; Moog C, 1997, J VIROL, V71, P3734, DOI 10.1128/JVI.71.5.3734-3741.1997; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Ogg GS, 1999, J VIROL, V73, P797, DOI 10.1128/JVI.73.1.797-800.1999; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Oxenius A, 2002, P NATL ACAD SCI USA, V99, P13747, DOI 10.1073/pnas.202372199; Pal R, 2002, J VIROL, V76, P292, DOI 10.1128/JVI.76.1.292-302.2002; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; ROBBINS G, IN PRESS AIDS; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Schmitz JE, 2003, J VIROL, V77, P2165, DOI 10.1128/JVI.77.3.2165-2173.2003; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Seth A, 2000, J VIROL, V74, P2502, DOI 10.1128/JVI.74.6.2502-2509.2000; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; Trachtenberg E, 2003, NAT MED, V9, P928, DOI 10.1038/nm893; Trimble LA, 2000, J VIROL, V74, P7320, DOI 10.1128/JVI.74.16.7320-7330.2000; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997; Yang OO, 2002, J VIROL, V76, P1626, DOI 10.1128/JVI.76.4.1626-1631.2002; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993; Yusim K, 2002, J VIROL, V76, P8757, DOI 10.1128/JVI.76.17.8757-8768.2002; Zhang D, 2003, BLOOD, V101, P226, DOI 10.1182/blood-2002-03-0791; Zhang LQ, 2002, SCIENCE, V298, P995, DOI 10.1126/science.1076185	106	184	200	0	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					861	866		10.1038/nm0703-861	http://dx.doi.org/10.1038/nm0703-861			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835706	Bronze			2023-01-03	WOS:000183979300025
J	Hays, J; Ockene, JK; Brunner, RL; Kotchen, JM; Manson, JE; Patterson, RE; Aragaki, AK; Shumaker, SA; Brzyski, RG; LaCroix, AZ; Granek, IA; Valanis, BG				Hays, J; Ockene, JK; Brunner, RL; Kotchen, JM; Manson, JE; Patterson, RE; Aragaki, AK; Shumaker, SA; Brzyski, RG; LaCroix, AZ; Granek, IA; Valanis, BG		Women's Hlth Initiative Investigat	Effects of estrogen plus progestin on health-related quality of life	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; SURVEY SF-36; SYMPTOMS; DIFFERENCE	BACKGROUND: The Women's Health Initiative (WHI) and other clinical trials indicate that significant health risks are associated with combination hormone use. Less is known about the effect of hormone therapy on health-related quality of life. METHODS: The WHI randomly assigned 16,608 postmenopausal women 50 to 79 years of age (mean, 63) with an intact uterus at base line to estrogen plus progestin (0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate, in 8506 women) or placebo (in 8102 women). Quality-of-life measures were collected at base line and at one year in all women and at three years in a subgroup of 1511 women. RESULTS: Randomization to estrogen plus progestin resulted in no significant effects on general health, vitality, mental health, depressive symptoms, or sexual satisfaction. The use of estrogen plus progestin was associated with a statistically significant but small and not clinically meaningful benefit in terms of sleep disturbance, physical functioning, and bodily pain after one year (the mean benefit in terms of sleep disturbance was 0.4 point on a 20-point scale, in terms of physical functioning 0.8 point on a 100-point scale, and in terms of pain 1.9 points on a 100-point scale). At three years, there were no significant benefits in terms of any quality-of-life outcomes. Among women 50 to 54 years of age with moderate-to-severe vasomotor symptoms at base line, estrogen and progestin improved vasomotor symptoms and resulted in a small benefit in terms of sleep disturbance but no benefit in terms of the other quality-of-life outcomes. CONCLUSIONS: In this trial in postmenopausal women, estrogen plus progestin did not have a clinically meaningful effect on health-related quality of life.	Baylor Coll Med, Dept Med, Ctr Womens Hlth, Houston, TX 77025 USA; Univ Massachusetts, Sch Med, Div Prevent & Behav Med, Worcester, MA USA; Univ Nevada, Sch Med, Womens Hlth Ctr, Reno, NV 89557 USA; Med Coll Wisconsin, Div Epidemiol, Milwaukee, WI 53226 USA; Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Univ Texas, Hlth Sci Ctr, Dept Obstet & Gynecol, San Antonio, TX 78284 USA; SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA; Kaiser Permanente Ctr Hlth Res, Epidemiol & Dis Prevent Program, Portland, OR USA	Baylor College of Medicine; University of Massachusetts System; University of Massachusetts Worcester; Nevada System of Higher Education (NSHE); University of Nevada Reno; Medical College of Wisconsin; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Fred Hutchinson Cancer Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Health San Antonio; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Kaiser Permanente	Hays, J (corresponding author), Baylor Coll Med, Dept Med, Ctr Womens Hlth, 6535 Fannin St,MS A701, Houston, TX 77025 USA.	jhays@bcm.tmc.edu		Hays-Grudo, Jennifer/0000-0002-8107-1243				*ACOG, 2002, QUEST ANS HORM THER; Alder EM, 2002, HORMONE REPLACEMENT THERAPY AND QUALITY OF LIFE, P11; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Barnabei VM, 2002, OBSTET GYNECOL, V100, P1209, DOI 10.1016/S0029-7844(02)02369-4; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; BURNAM MA, 1988, MED CARE, V26, P775, DOI 10.1097/00005650-198808000-00004; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; Cohen J., 2013, STAT POWER ANAL BEHA; *FDA, 2003, FDA APPR NEW LAB EST; Girdler SS, 1999, J WOMEN HEALTH GEN-B, V8, P637, DOI 10.1089/jwh.1.1999.8.637; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 2002, JAMA-J AM MED ASSOC, V288, P1064; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; Hays RD, 2000, PHARMACOECONOMICS, V18, P419, DOI 10.2165/00019053-200018050-00001; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; LEVINE DW, IN PRESS PSYCHOL ASS; Matthews KA, 1997, AM PSYCHOL, V52, P101, DOI 10.1037/0003-066X.52.2.101; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rodstrom K, 2002, MENOPAUSE, V9, P156; Rosenthal R., 1994, HDB RES SYNTHESIS, P231; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; ROTHERT M, 1994, EXP GERONTOL, V29, P463, DOI 10.1016/0531-5565(94)90026-4; Sarrel PM, 2000, J WOMEN HEALTH GEN-B, V9, pS25, DOI 10.1089/152460900318830; Sarrel PM, 2001, J WOMEN HEALTH GEN-B, V10, P91; *SAS I, STAT AN SYST VERS 8; Shah M G, 2001, Am J Clin Dermatol, V2, P143; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; van Walraven C, 1999, J CLIN EPIDEMIOL, V52, P717, DOI 10.1016/S0895-4356(99)00050-5; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Zethraeus N, 1997, BRIT J OBSTET GYNAEC, V104, P1191, DOI 10.1111/j.1471-0528.1997.tb10945.x; Zweifel JE, 1997, PSYCHONEUROENDOCRINO, V22, P655	38	489	512	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1839	1854		10.1056/NEJMoa030311	http://dx.doi.org/10.1056/NEJMoa030311			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675FY	12642637	Green Published			2023-01-03	WOS:000182684100003
J	Marmottant, P; Hilgenfeldt, S				Marmottant, P; Hilgenfeldt, S			Controlled vesicle deformation and lysis by single oscillating bubbles	NATURE			English	Article							SONOLUMINESCENCE; CAVITATION; ULTRASOUND; SONOPORATION; BOUNDARY; DYNAMICS; FLOW	The ability of collapsing (cavitating) bubbles to focus and concentrate energy, forces and stresses is at the root of phenomena such as cavitation damage, sonochemistry or sonoluminescence(1,2). In a biomedical context, ultrasound-driven microbubbles have been used to enhance contrast in ultrasonic images(3). The observation of bubble-enhanced sonoporation(4-6)-acoustically induced rupture of membranes-has also opened up intriguing possibilities for the therapeutic application of sonoporation as an alternative to cell-wall permeation techniques such as electroporation(7) and particle guns(8). However, these pioneering experiments have not been able to pinpoint the mechanism by which the violently collapsing bubble opens pores or larger holes in membranes. Here we present an experiment in which gentle (linear) bubble oscillations are sufficient to achieve rupture of lipid membranes. In this regime, the bubble dynamics and the ensuing sonoporation can be accurately controlled. The use of microbubbles as focusing agents makes acoustics on the micrometre scale (microacoustics) a viable tool, with possible applications in cell manipulation and cell-wall permeation as well as in microfluidic devices.	Univ Twente, Fac Appl Phys, NL-7500 AE Enschede, Netherlands	University of Twente	Marmottant, P (corresponding author), Univ Twente, Fac Appl Phys, POB 217, NL-7500 AE Enschede, Netherlands.		Hilgenfeldt, Sascha/B-7356-2009; Marmottant, Philippe/D-6808-2012; Hilgenfeldt, Sascha/A-4593-2014	Hilgenfeldt, Sascha/0000-0002-6799-2118				BLAKE JR, 1974, J ENG MATH, V8, P23, DOI 10.1007/BF02353701; Boal D., 2002, MECH CELL; Brujan EA, 2001, J FLUID MECH, V433, P251, DOI 10.1017/S0022112000003347; Chang D.C., 1992, GUIDE ELECTROPORATIO; CHANG DC, 1993, ADV ECHO IMAGING USI; DAVIDSON BJ, 1971, J SOUND VIB, V15, P217, DOI 10.1016/0022-460X(71)90536-0; DIMITROV DS, 1987, PROG COLLOID POLYM S, V73, P48; ELDER SA, 1959, J ACOUST SOC AM, V31, P54, DOI 10.1121/1.1907611; Greenleaf WJ, 1998, ULTRASOUND MED BIOL, V24, P587, DOI 10.1016/S0301-5629(98)00003-9; Hilgenfeldt S, 2000, J ACOUST SOC AM, V107, P3530, DOI 10.1121/1.429438; Hilgenfeldt S, 1999, NATURE, V398, P402, DOI 10.1038/18842; Leighton T.G., 1994, ACOUSTIC BUBBLE, DOI 10.1121/1.410082; LIGHTHILL J, 1978, J SOUND VIB, V61, P391, DOI 10.1016/0022-460X(78)90388-7; Longuet-Higgins MS, 1998, P ROY SOC A-MATH PHY, V454, P725, DOI 10.1098/rspa.1998.0183; MILLER DL, 1988, J ACOUST SOC AM, V84, P1378, DOI 10.1121/1.396636; MILLER DL, 1979, SCIENCE, V205, P505, DOI 10.1126/science.451616; Miller DL, 2000, ULTRASOUND MED BIOL, V26, P661, DOI 10.1016/S0301-5629(99)00170-2; PLESSET MS, 1977, ANNU REV FLUID MECH, V9, P145, DOI 10.1146/annurev.fl.09.010177.001045; Popinet S, 1999, INT J NUMER METH FL, V30, P775, DOI 10.1002/(SICI)1097-0363(19990730)30:6<775::AID-FLD864>3.0.CO;2-#; Pozrikidis C., 1992, BOUNDARY INTEGRAL SI; Prosperetti A, 1997, J ACOUST SOC AM, V101, P2003, DOI 10.1121/1.418133; Rawicz W, 2000, BIOPHYS J, V79, P328, DOI 10.1016/S0006-3495(00)76295-3; RILEY N, 1966, Q J MECH APPL MATH, V19, P461, DOI 10.1093/qjmam/19.4.461; ROONEY JA, 1970, SCIENCE, V169, P869, DOI 10.1126/science.169.3948.869; Seifert U, 1999, EUR PHYS J B, V8, P405, DOI 10.1007/s100510050706; SEKI M, 1991, PLANT MOL BIOL, V17, P259, DOI 10.1007/BF00039501; SUSLICK KS, 1990, SCIENCE, V247, P1439, DOI 10.1126/science.247.4949.1439; Tachibana K, 1999, LANCET, V353, P1409, DOI 10.1016/S0140-6736(99)01244-1; Wang ZQ, 1999, PHYS REV E, V59, P1777, DOI 10.1103/PhysRevE.59.1777; Ward M, 2000, ULTRASOUND MED BIOL, V26, P1169, DOI 10.1016/S0301-5629(00)00260-X	30	627	646	11	281	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					153	156		10.1038/nature01613	http://dx.doi.org/10.1038/nature01613			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736680	Bronze			2023-01-03	WOS:000182699600041
J	Palmer, LI				Palmer, LI			The legal and political future of physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OREGON		Univ Louisville, Louisville, KY 40292 USA	University of Louisville	Palmer, LI (corresponding author), Univ Louisville, Louisville, KY 40292 USA.							ASHCROFT J, 2001, COMMUNCIATION   1106; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Steinbrook R, 2002, NEW ENGL J MED, V346, P460, DOI 10.1056/NEJM200202073460624; 2001, FED REG         1109, V66, P56607	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2283	2283		10.1001/jama.289.17.2283	http://dx.doi.org/10.1001/jama.289.17.2283			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675ET	12734144	Green Published, Bronze			2023-01-03	WOS:000182680700035
J	Maughan, TS; James, RD; Kerr, DJ; Ledermann, JA; Seymour, MT; Topham, C; McArdle, C; Cain, D; Stephens, RJ				Maughan, TS; James, RD; Kerr, DJ; Ledermann, JA; Seymour, MT; Topham, C; McArdle, C; Cain, D; Stephens, RJ		Med Res Council Colorectal Canc Gr	Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial	LANCET			English	Article							ADVANCED BREAST-CANCER; CELL LUNG-CANCER; METASTATIC CARCINOMA; FAVORABLE-PROGNOSIS; HODGKINS-DISEASE; LEUCOVORIN; CYCLES; 5-FLUOROURACIL; CISPLATIN; DURATION	Background Policies of UK clinicians regarding the duration of chemotherapy for patients with advanced colorectal cancer are not consistent. We aimed to compare effectiveness of continuous and intermittent chemotherapy in such patients. Methods Patients who responded or had stable disease after receiving 12 weeks of the regimens described by de Gramont and Lokich, or raltitrexed chemotherapy, were randomised to either intermittent (a break in chemotherapy, re-starting on the same drug on progression), or continuous chemotherapy until progression. Findings 354 patients (178 intermittent, 176 continuous) were enrolled from 42 UK centres. At randomisation, 41% of participants had part or complete response; 59% were stable. Only 66 (37%) patients allocated to intermittent treatment restarted as planned, after a median of 130 days. Median time on treatment after restarting was 84 days. Patients in the continuous group remained on treatment for a median of a further 92 days. Similar proportions of patients in both groups received second-line therapy. Patients on intermittent chemotherapy had significantly fewer toxic effects and serious adverse events than those in the continuous group. There was no clear evidence of a difference in overall survival (hazard ratio 0.87 favouring intermittent, 95% CI 0.69-1.09, p=0.23). Interpretation Our findings provided no clear evidence of a benefit in continuing therapy indefinitely until disease progression. They showed that it is safe to stop chemotherapy after 12 weeks and re-start the same treatment on progression in patients with chemosensitive advanced colorectal cancer.	Velindre Hosp, Dept Oncol, Cardiff, S Glam, Wales; Maidstone Hlth Author, Kent Canc Ctr, Maidstone, Kent, England; Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England; UCL Hosp, Dept Oncol, London, England; Cookridge Hosp, Canc Res UK Clin Ctr, Leeds LS16 6QB, W Yorkshire, England; Royal Surrey Cty Hosp, St Lukes Canc Ctr, Guildford, Surrey, England; Royal Infirm, Univ Dept Surg, Glasgow G31 2ER, Lanark, Scotland; MRC, Clin Trials Unit, Canc Div, London, England	Velindre Hospital; Radcliffe Infirmary; University College London Hospitals NHS Foundation Trust; University of London; University College London; Cancer Research UK; Cookridge Hospital; University of Leeds; Royal Surrey County Hospital; Royal Infirmary of Edinburgh; University of Glasgow; Medical Research Council Clinical Trials Unit	Stephens, RJ (corresponding author), MRC, Clin Trials Unit, Div Canc, 222 Euston Rd, London NW1 2DA, England.	rs@ctu.mrc.ac.uk	Maughan, Timothy/D-5032-2011	Seymour, Matthew/0000-0002-2441-9629				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; ABE O, 1992, LANCET, V339, P71; Bastit P, 2000, J CLIN ONCOL, V18, P3115, DOI 10.1200/JCO.2000.18.17.3115; Beith JM, 1996, EUR J CANCER, V32A, P438, DOI 10.1016/0959-8049(95)00608-7; BERTELSEN K, 1993, GYNECOL ONCOL, V49, P30, DOI 10.1006/gyno.1993.1081; BUCCHERI GF, 1989, CANCER, V63, P428, DOI 10.1002/1097-0142(19890201)63:3<428::AID-CNCR2820630305>3.0.CO;2-V; Childhood A, 1996, LANCET, V347, P1783, DOI DOI 10.1016/S0140-6736(96)91615-3; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; Cunningham D, 1996, ANN ONCOL, V7, P961, DOI 10.1093/oxfordjournals.annonc.a010800; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; EINHORN LH, 1989, J CLIN ONCOL, V7, P387, DOI 10.1200/JCO.1989.7.3.387; EJLERTSEN B, 1993, EUR J CANCER, V29A, P527, DOI 10.1016/S0959-8049(05)80145-5; Elonen E, 1998, LEUKEMIA, V12, P1041, DOI 10.1038/sj.leu.2401068; FISHER RI, 1979, ANN INTERN MED, V90, P761, DOI 10.7326/0003-4819-90-5-761; Giacchetti S, 1999, ANN ONCOL, V10, P663, DOI 10.1023/A:1008347829017; Gregory RK, 1997, EUR J CANCER, V33, P2194, DOI 10.1016/S0959-8049(97)00396-1; HAKES TB, 1992, GYNECOL ONCOL, V45, P284, DOI 10.1016/0090-8258(92)90305-3; HARRIS AL, 1990, LANCET, V335, P186, DOI 10.1016/0140-6736(90)90277-C; Ito K, 2000, ANTICANCER RES, V20, P4681; LOKICH JJ, 1991, CANCER, V67, P14, DOI 10.1002/1097-0142(19910101)67:1<14::AID-CNCR2820670104>3.0.CO;2-M; Maughan TS, 2002, LANCET, V359, P1555, DOI 10.1016/S0140-6736(02)08514-8; MUSS HB, 1991, NEW ENGL J MED, V325, P1342, DOI 10.1056/NEJM199111073251904; OCONNELL MJ, 1996, P AN M AM SOC CLIN, V15, P209; PACCAGNELLA A, 1983, EUR J CANCER CLIN ON, V19, P1345, DOI 10.1016/0277-5379(93)90002-M; Pavlovsky S, 1997, J CLIN ONCOL, V15, P2652, DOI 10.1200/JCO.1997.15.7.2652; Seymour M T, 1997, Clin Oncol (R Coll Radiol), V9, P248, DOI 10.1016/S0936-6555(97)80010-6; Seymour MT, 1996, J CLIN ONCOL, V14, P2280, DOI 10.1200/JCO.1996.14.8.2280; SMALLEY RV, 1976, CANCER RES, V36, P3911; SPIRO SG, 1990, THORAX, V45, P1, DOI 10.1136/thx.45.1.1; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	156	161	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	2003	361	9356					457	464		10.1016/S0140-6736(03)12461-0	http://dx.doi.org/10.1016/S0140-6736(03)12461-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644CP	12583944				2023-01-03	WOS:000180900600009
J	Choudhry, NK; Choudhry, S; Singer, PA				Choudhry, NK; Choudhry, S; Singer, PA			CPR for patients labeled DNR: The role of the limited aggressive therapy order	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HOSPITAL CARDIAC-ARREST; NOT-RESUSCITATE ORDERS; CARDIOPULMONARY-RESUSCITATION; OPERATING-ROOM; ADVERSE EVENTS; SURVIVAL; SURGERY; ANESTHESIA; PREFERENCES; COMMUNITY	Patients who sustain a cardiac arrest have a less than 20% chance of surviving to hospital discharge. Patients may request do-not-resuscitate (DNR) orders if they believe that their chances for a meaningful recovery after cardiopulmonary arrest are low. However, in some identifiable circumstances, cardiopulmonary resuscitation (CPR) has a higher chance of success and lower likelihood of neurologic impairment. The probability of survival from a cardiac arrest influences patients' wishes regarding resuscitation; thus, when CPR has a higher likelihood of success, patients' expressed preferences for treatment as contained within a DNR order may not accurately reflect their intended goals. Patients should be offered the option of consenting to CPR for "higher-success" situations, including a witnessed cardiopulmonary arrest in which the initial cardiac rhythm is ventricular tachycardia or fibrillation, cardiac arrest in the operating room, and cardiac arrest resulting from a readily identifiable iatrogenic cause. This new level of resuscitation could be called a "limited aggressive therapy" order.	Univ Toronto, Toronto, ON M5G 1L4, Canada; Harvard Univ, Cambridge, MA 02138 USA	University of Toronto; Harvard University	Singer, PA (corresponding author), Univ Toronto, 88 Coll St, Toronto, ON M5G 1L4, Canada.			Choudhry, Sujit/0000-0002-6543-6644				BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BERNAT JL, 1993, SURG NEUROL, V40, P7, DOI 10.1016/0090-3019(93)90161-S; BEURET P, 1993, RESUSCITATION, V25, P171, DOI 10.1016/0300-9572(93)90093-6; BIALECKI L, 1995, CHEST, V108, P1009, DOI 10.1378/chest.108.4.1009; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BURNS R, 1989, ARCH INTERN MED, V149, P1318, DOI 10.1001/archinte.149.6.1318; Casarett D, 1997, NEW ENGL J MED, V336, P1908, DOI 10.1056/NEJM199706263362611; Cobbe SM, 1996, BRIT MED J, V312, P1633, DOI 10.1136/bmj.312.7047.1633; COHEN CB, 1991, NEW ENGL J MED, V325, P1879, DOI 10.1056/NEJM199112263252611; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; de Vos R, 1999, ARCH INTERN MED, V159, P845, DOI 10.1001/archinte.159.8.845; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; GASCHO JA, 1979, CIRCULATION, V60, P231, DOI 10.1161/01.CIR.60.2.231; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; MARGOLIS JO, 1995, ANESTH ANALG, V80, P806, DOI 10.1097/00000539-199504000-00027; MILES SH, 1982, ANN INTERN MED, V96, P660, DOI 10.7326/0003-4819-96-5-660; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; OLSSON GL, 1988, ACTA ANAESTH SCAND, V32, P653, DOI 10.1111/j.1399-6576.1988.tb02804.x; OTOOLE EE, 1994, ARCH INTERN MED, V154, P425, DOI 10.1001/archinte.154.4.425; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; Plaisance P, 1999, NEW ENGL J MED, V341, P569, DOI 10.1056/NEJM199908193410804; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SINGER PA, 1995, J AM SOC NEPHROL, V6, P1410; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TRESCH DD, 1989, AM J MED, V86, P145, DOI 10.1016/0002-9343(89)90259-3; TRESCH DD, 1990, AM J CARDIOL, V65, P453, DOI 10.1016/0002-9149(90)90809-F; Truog RD, 1999, ANESTHESIOLOGY, V90, P289, DOI 10.1097/00000542-199901000-00034; TRUOG RD, 1991, ANESTHESIOLOGY, V74, P606, DOI 10.1097/00000542-199103000-00030; van Walraven C, 1999, ARCH INTERN MED, V159, P129, DOI 10.1001/archinte.159.2.129; WALKER RM, 1991, JAMA-J AM MED ASSOC, V266, P2407, DOI 10.1001/jama.266.17.2407; Wenger NS, 1997, J CLIN ETHIC, V8, P250; YOUNGNER SJ, 1991, JAMA-J AM MED ASSOC, V266, P2433, DOI 10.1001/jama.266.17.2433; 1999, AM J KIDNEY DIS, V33, P980; 1983, DECIDING FORGO LIFE	40	21	21	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 7	2003	138	1					65	68		10.7326/0003-4819-138-1-200301070-00014	http://dx.doi.org/10.7326/0003-4819-138-1-200301070-00014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645TV	12513047				2023-01-03	WOS:000180996200009
J	Chiu, SS; Lau, YL; Chan, KH; Wong, WHS; Peiris, JSM				Chiu, SS; Lau, YL; Chan, KH; Wong, WHS; Peiris, JSM			Influenza-related hospitalizations among children in Hong Kong	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISEASE; COST-EFFECTIVENESS; VIRUS INFECTION; YOUNG-CHILDREN; INFANTS; IMPACT; EPIDEMICS; DIAGNOSIS; VACCINE; ILLNESS	Background: It has been difficult to define the burden of influenza in children because of confounding by the cocirculation of respiratory syncytial virus (RSV). In Hong Kong, China, the influenza and RSV infection seasons sometimes do not overlap, thus providing an opportunity to estimate the rate of influenza-related hospitalization in a defined population, free from the effects of RSV. Methods: In a retrospective, population-based study, we estimated the influenza-associated excess rate of hospitalization among children 15 years old or younger in the Hong Kong Special Administrative Region from 1997 to 1999. Data from a single hospital with intensive use of virologic analyses for diagnosis were obtained to define and adjust for underestimation of the model. Results: Peaks of influenza and RSV infection activity were well separated in 1998 and 1999 but overlapped in 1997. The adjusted rates of excess hospitalization for acute respiratory disease that were attributable to influenza were 278.5 and 288.2 per 10,000 children less than 1 year of age in 1998 and 1999, respectively; 218.4 and 209.3 per 10,000 children 1 to less than 2 years of age; 125.6 and 77.3 per 10,000 children 2 to less than 5 years of age; 57.3 and 20.9 per 10,000 children 5 to less than 10 years of age; and 16.4 and 8.1 per 10,000 children 10 to 15 years of age. Conclusions: In the subtropics, influenza is an important cause of hospitalization among children, with rates exceeding those reported for temperate regions.	Univ Hong Kong, Dept Pediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Peiris, JSM (corresponding author), Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg, Pokfulam, Hong Kong, Peoples R China.	malik@hkucc.hku.hk	Wong, Wilfred/Q-8751-2019; Chan, Kwok Hung/ABD-5399-2021; Lau, Yu Lung/C-4322-2009; Chiu, Susan Shui Seng/C-4247-2009	Lau, Yu Lung/0000-0002-4780-0289; Chiu, Susan Shui Seng/0000-0002-3908-1974; Wong, Hing Sang Wilfred/0000-0001-8396-2368				ADAMS PF, 1995, VITAL HLTH STAT, V10; [Anonymous], 2002, Wkly Epidemiol Rec, V77, P191; [Anonymous], 2001, MMWR-MORBID MORTAL W, V50, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1204; Chiu SS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e63; Cohen GM, 2000, PEDIATRICS, V106, P973, DOI 10.1542/peds.106.5.973; Drinka P, 1999, J AM GERIATR SOC, V47, P1363; Edwards KM, 2001, PEDIATRICS, V108, P1004, DOI 10.1542/peds.108.4.1004; Fitzner K. A., 1999, Hong Kong Medical Journal, V5, P87; Fitzner KA, 2001, HEALTH POLICY, V56, P215, DOI 10.1016/S0168-8510(00)00140-8; Glezen WP, 1999, JAMA-J AM MED ASSOC, V281, P944, DOI 10.1001/jama.281.10.944; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; Glezen WP, 1997, PEDIATR INFECT DIS J, V16, P1065, DOI 10.1097/00006454-199711000-00012; *GOV HONG KONG SPE, INFL SURV; *HONG KONG GOV, 1993, HONG KONG COR REP; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; KIM HW, 1979, AM J EPIDEMIOL, V109, P464, DOI 10.1093/oxfordjournals.aje.a112704; McIntosh K, 2000, NEW ENGL J MED, V342, P275, DOI 10.1056/NEJM200001273420409; Monto Arnold S., 1997, Journal of Infectious Diseases, V176, pS32, DOI 10.1086/514172; MULLOOLY JP, 1982, AM J PUBLIC HEALTH, V72, P1008, DOI 10.2105/AJPH.72.9.1008; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Neuzil KM, 2000, J PEDIATR-US, V137, P856, DOI 10.1067/mpd.2000.110445; Neuzil KM, 2001, INFECT DIS CLIN N AM, V15, P123, DOI 10.1016/S0891-5520(05)70271-3; Poland GA, 1999, PEDIATRICS, V103, P1280, DOI 10.1542/peds.103.6.1280; SHORTRIDGE KF, 1995, LANCET, V346, P1210, DOI 10.1016/S0140-6736(95)92906-1; SHORTRIDGE KF, 1982, LANCET, V2, P812; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; SUGAYA N, 1992, J INFECT DIS, V165, P373, DOI 10.1093/infdis/165.2.373; Szucs TD, 1999, PHARMACOECONOMICS, V16, P27, DOI 10.2165/00019053-199916001-00004; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; 2000, N ENGL J MED, V342, P1752	32	225	241	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	2002	347	26					2097	2103		10.1056/NEJMoa020546	http://dx.doi.org/10.1056/NEJMoa020546			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	629FZ	12501221	Green Published, Bronze			2023-01-03	WOS:000180040900002
J	Waters, DD; Alderman, EL; Hsia, J; Howard, BV; Cobb, FR; Rogers, WJ; Ouyang, P; Thompson, P; Tardif, JC; Higginson, L; Bittner, V; Steffes, M; Gordon, DJ; Proschan, M; Younes, N; Verter, JI				Waters, DD; Alderman, EL; Hsia, J; Howard, BV; Cobb, FR; Rogers, WJ; Ouyang, P; Thompson, P; Tardif, JC; Higginson, L; Bittner, V; Steffes, M; Gordon, DJ; Proschan, M; Younes, N; Verter, JI			Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN-REPLACEMENT; HEART-DISEASE; ARTERY DISEASE; CARDIOVASCULAR-DISEASE; E CONSUMPTION; PROGRESSION; RISK; PREVENTION; SIMVASTATIN; PROGESTIN	Context Hormone replacement therapy (HRT) and antioxidant vitamins are widely used for secondary prevention in postmenopausal women with coronary disease, but no clinical trials have demonstrated benefit to support their use. Objective To determine whether HRT or antioxidant vitamin supplements, alone or in combination, influence the progression of coronary artery disease in postmenopausal women, as measured by serial quantitative coronary angiography. Design, Setting, and Patients The Women's Angiographic Vitamin and Estrogen (WAVE) Trial, a randomized, double-blind trial of 423 postmenopausal women with at least one 15% to 75% coronary stenosis at baseline coronary angiography. The trial was conducted from July 1997 to January 2002 in 7 clinical centers in the United States and Canada. Interventions Patients were randomly assigned in a 2 x 2 factorial design to receive either 0.625 mg/d of conjugated equine estrogen (plus 2.5 mg/d of medroxyprogesterone acetate for women who had not had a hysterectomy), or matching placebo, and 400 IU of vitamin E twice daily plus 500 mg of vitamin C twice daily, or placebo. Main Outcome Measure Annualized mean (SD) change in minimum lumen diameter (MLD) from baseline to concluding angiogram of all qualifying coronary lesions averaged for each patient. Patients with intercurrent death or myocardial infarction (MI) were imputed the worst rank of angiographic outcome. Results The mean (SD) interval between angiograms was 2.8 (0.9) years. Coronary progression, measured in mean (SD) change, worsened with HRT by 0.047 (015) mm/y and by 0.024 (0.15) mm/y with HRT placebo (P=.17); and for antioxidant vitamins by 0.044 (0.15) mm/y and with vitamin placebo by 0.028 (0.15) mm/y (P=32). When patients with intercurrent death or MI were included, the primary outcome showed an increased risk for women in the active HRT group (P=.045), and suggested an increased risk in the active vitamin group (P=.09). Fourteen patients died in the HRT group and 8 in the HRT placebo group (hazard ratio [HR], 1.8; 95% confidence interval [CI], 0.75-4.3), and 16 in the vitamin group and 6 in the vitamin placebo group (HR, 2.8; 95% CI, 1.1-7.2). Death, nonfatal MI, or stroke occurred in 26 HRT patients vs 15 HRT controls (HR, 1.9; 95% CI, 0.97-3.6) and in 26 vitamin patients and 18 vitamin controls (HR, 1.5; 95% CI, 0.80-2.9). There was no interaction between the 2 treatment interventions. Conclusion In postmenopausal women with coronary disease, neither HRT nor antioxidant vitamin supplements provide cardiovascular benefit. Instead, a potential for harm was suggested with each treatment.	San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Stanford Univ, Div Cardiovasc Med, Stanford, CA 94305 USA; George Washington Univ, Dept Med, Washington, DC USA; George Washington Univ, Dept Stat, Washington, DC 20052 USA; Medstar Res Inst, Dept Cardiol, Washington, DC USA; Duke Univ, Duke Ctr Living, Durham, NC USA; Univ Alabama, Div Cardiol, Birmingham, AL USA; Johns Hopkins Bayview Med Ctr, Div Cardiol, Baltimore, MD USA; Hartford Hosp, Div Cardiol, Hartford, CT 06115 USA; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; Univ Ottawa, Inst Heart, Ottawa, ON, Canada; Univ Minnesota, Cent Biochem Lab, Minneapolis, MN USA; NHLBI, NIH, Bethesda, MD 20892 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Stanford University; George Washington University; George Washington University; Duke University; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins Medicine; Hartford Hospital; Universite de Montreal; University of Ottawa; University of Ottawa Heart Institute; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Waters, DD (corresponding author), San Francisco Gen Hosp, Div Cardiol, Room 5G1,1001 Potrero Ave, San Francisco, CA 94110 USA.		Dubé, Marie-Pierre/B-9364-2008	Dubé, Marie-Pierre/0000-0001-8442-4393; Bittner, Vera/0000-0001-9456-850X	NCRR NIH HHS [M01 RR02715] Funding Source: Medline; NHLBI NIH HHS [N01-HV-68165, N01-HV-68170] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV068165, N01HV068170] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S14RR002715] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Azen SP, 1996, CIRCULATION, V93, P34, DOI 10.1161/01.CIR.93.1.34; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; Cheung MC, 2001, ARTERIOSCL THROM VAS, V21, P1320, DOI 10.1161/hq0801.095151; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; CONOVER WJ, 1971, PRACTICAL NONPARAMET, P318; DAGENAIS DR, 2000, CURR CARDIOL REP, V2, P293; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GAZIANO JM, 1992, ANN NY ACAD SCI, V669, P249; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; HODIS HN, 1995, JAMA-J AM MED ASSOC, V273, P1849, DOI 10.1001/jama.273.23.1849; HSIA J, IN PRESS CONTROL CLI; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; LEUNG WH, 1991, CATHETER CARDIO DIAG, V24, P121, DOI 10.1002/ccd.1810240211; Lynch S M, 1996, Subcell Biochem, V25, P331; Manson JE, 2001, NEW ENGL J MED, V345, P34, DOI 10.1056/NEJM200107053450106; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Newton KM, 1997, AM J EPIDEMIOL, V145, P269; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; Sullivan JM, 1997, AM J CARDIOL, V79, P847, DOI 10.1016/S0002-9149(97)00001-5; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; Waters DD, 2002, J AM COLL CARDIOL, V39, P238, DOI 10.1016/S0735-1097(01)01735-1; Yusuf S, 2000, NEW ENGL J MED, V342, P145	34	417	432	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2002	288	19					2432	2440		10.1001/jama.288.19.2432	http://dx.doi.org/10.1001/jama.288.19.2432			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FB	12435256	Bronze			2023-01-03	WOS:000179292300026
J	Pronovost, PJ; Angus, DC; Dorman, T; Robinson, KA; Dremsizov, TT; Young, TL				Pronovost, PJ; Angus, DC; Dorman, T; Robinson, KA; Dremsizov, TT; Young, TL			Physician staffing patterns and clinical outcomes in critically ill patients - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-of-Critical-Care-Medicine	FEB 12-22, 2000	ORLANDO, FL	Soc Crit Care Med			INTENSIVE-CARE-UNIT; MIX-ADJUSTED MORTALITY; ORGANIZATIONAL-CHANGE; RESOURCE UTILIZATION; PEDIATRIC RISK; CAVE UNIT; IMPACT; QUALITY; COST; METAANALYSIS	Context Intensive care unit (ICU) physician staffing varies widely, and its association with patient outcomes remains unclear. Objective To evaluate the association between ICU physician staffing and patient outcomes. Data Sources We searched MEDLINE (January 1, 1965, through September 30, 2001) for the following medical subject heading (MeSH) terms: intensive care units, ICU, health resources/utilization, hospitalization, medical staff hospital organization and administration, personnel staffing and scheduling, length of stay, and LOS. We also used the following text words: staffing, intensivist, critical, care, and specialist. To identify observational studies, we added the MeSH terms case-control study and retrospective study. Although we searched for non-English-language citations, we reviewed only English-language articles. We also searched EMBASE, HealthStar (Health Services, Technology, Administration, and Research), and HSRPROJ (Health Services Research Projects in Progress) via Internet Grateful Med and The Cochrane Library and hand searched abstract proceedings from intensive care national scientific meetings (January 1, 1994, through December 31, 2001). Study Selection We selected randomized and observational controlled trials of critically ill adults or children. Studies examined ICU attending physician staffing strategies and the outcomes of hospital and ICU mortality and length of stay (LOS). Studies were selected and critiqued by 2 reviewers. We reviewed 2590 abstracts and identified 26 relevant observational studies (of which 1 included 2 comparisons), resulting in 27 comparisons of alternative staffing strategies. Twenty studies focused on a single ICU. Data Synthesis We grouped ICU physician staffing into low-intensity (no intensivist or elective intensivist consultation) or high-intensity (mandatory intensivist consultation or closed ICU [all care directed by intensivist]) groups. High-intensity staffing was associated with lower hospital mortality in 16 of 17 studies (94%) and with a pooled estimate of the relative risk for hospital mortality of 0.71 (95% confidence interval [CI], 0.62-0.82). High-intensity staffing was associated with a lower ICU mortality in 14 of 15 studies (93%) and with a pooled estimate of the relative risk for ICU mortality of 0.61 (95 % CI, 0.50-0.75). High-intensity staffing reduced hospital LOS in 10 of 13 studies and reduced ICU LOS in 14 of 18 studies without case-mix adjustment. Conclusions High-intensity staffing was associated with reduced hospital LOS in 2 of 4 studies and ICU LOS in both studies that adjusted for case mix. No study found increased LOS with high-intensity staffing after case-mix adjustment.	Univ Pittsburgh, Dept Crit Care Med, CRISMA Lab, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA; Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA; Johns Hopkins Univ, Dept Surg, Baltimore, MD USA; Johns Hopkins Univ, Dept Med, Baltimore, MD USA; Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Angus, DC (corresponding author), Univ Pittsburgh, Dept Crit Care Med, CRISMA Lab, 604 Scaife Hall,200 Lothrop St, Pittsburgh, PA 15213 USA.	angusdc@ccm.upmc.edu	Angus, Derek C/E-9671-2012	dorman, todd/0000-0002-8616-8677				Al-Asadi L, 1996, AM J RESP CRIT CARE, V153, pA360; Audit Commission, 1999, CRIT SUCC PLAC EFF E; Baldock G, 2001, INTENS CARE MED, V27, P865, DOI 10.1007/s001340100938; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Berlin J, 1996, AHCPR9720; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BIRKMEYER JD, 2002, LEAPFROG SAFETY STAN; Blunt MC, 2000, LANCET, V356, P735, DOI 10.1016/S0140-6736(00)02634-9; Brilli RJ, 2001, CRIT CARE MED, V29, P2007, DOI 10.1097/00003246-200110000-00026; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BROWN JJ, 1989, CHEST, V96, P127, DOI 10.1378/chest.96.1.127; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; Cole L, 2000, AM J RESP CRIT CARE, V162, P191, DOI 10.1164/ajrccm.162.1.9907016; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Cowen J, 1999, CRIT CARE MED, V27, pA35, DOI 10.1097/00003246-199901001-00029; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DiCosmo BF, 1999, CHEST, V116, pS238; Dimick JB, 2001, CRIT CARE MED, V29, P753, DOI 10.1097/00003246-200104000-00012; Dimick JB, 2000, CRIT CARE MED, V28, pA77; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; EAGLE KA, 1991, MED CARE, V29, P1237, DOI 10.1097/00005650-199112000-00006; Ferdinande P, 1997, INTENS CARE MED, V23, P226, DOI 10.1007/s001340050321; Ghorra S, 1999, ANN SURG, V229, P163, DOI 10.1097/00000658-199902000-00001; Goh AYT, 2001, LANCET, V357, P445, DOI 10.1016/S0140-6736(00)04014-9; GROEGER JS, 1992, CRIT CARE MED, V20, P846, DOI 10.1097/00003246-199206000-00024; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; JACOBS MC, 1998, CHEST, V114, pS276; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kuo H, 2000, CRIT CARE SHOCK, V3, P57; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; Lima C, 1995, CRIT CARE MED, V23, pA238; Manthous CA, 1997, MAYO CLIN PROC, V72, P391, DOI 10.4065/72.5.391; Marini CP NI, 1995, CRIT CARE MED, V23, pA235; Mark D H, 1997, Fam Med, V29, P132; Milstein A, 2000, Eff Clin Pract, V3, P313; Mirski MA, 2001, J NEUROSURG ANESTH, V13, P83, DOI 10.1097/00008506-200104000-00004; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; MOHER D, 2002, DOES LANGUAGE PUBLIC; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; Park CA, 2001, AM SURGEON, V67, P665; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Pollack MM, 1997, CRIT CARE MED, V25, P1637, DOI 10.1097/00003246-199710000-00011; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Pronovost P J, 2001, Eff Clin Pract, V4, P199; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; REICH HS, 1998, CRIT CARE MED, V25, pA44; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150; Rosenfeld BA, 2000, CRIT CARE MED, V28, P3925, DOI 10.1097/00003246-200012000-00034; SCHMITZ R, 1999, FUTURE WORKFORCE NEE; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tai D. Y. H., 1998, Annals Academy of Medicine Singapore, V27, P309; TEASDALE G, 1974, LANCET, V2, P81; Teres D, 1983, Inquiry, V20, P282; Topeli A, 2000, AM J RESP CRIT CARE, V161, pA397; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vincent JL, 2000, LANCET, V356, P695, DOI 10.1016/S0140-6736(00)02622-2; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; YEH TS, 1984, PEDIATR RES, V18, P445, DOI 10.1203/00006450-198405000-00011	68	1010	1041	1	68	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2151	2162		10.1001/jama.288.17.2151	http://dx.doi.org/10.1001/jama.288.17.2151			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	611ZJ	12413375	Bronze			2023-01-03	WOS:000179048100026
J	Clark, HW				Clark, HW			Office-based practice and opioid-use disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Subst Abuse & Mental Hlth Serv Adm, Ctr Subst Abuse Treatment, US Dept HHS, Rockville, MD USA		Clark, HW (corresponding author), Subst Abuse & Mental Hlth Serv Adm, Ctr Subst Abuse Treatment, US Dept HHS, Rockville, MD USA.							Gibson AE, 2003, MED J AUSTRALIA, V179, P38, DOI 10.5694/j.1326-5377.2003.tb05417.x; Gueye PN, 2002, ADDICTION, V97, P1295, DOI 10.1046/j.1360-0443.2002.00189.x; *SUBST AB MENT HLT, 2003, NHSDA REP NONM US PR; *SUBST AB MENT HLT, 2002, DAWN SER D, V21	4	19	19	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					928	930		10.1056/NEJMp038126	http://dx.doi.org/10.1056/NEJMp038126			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717HJ	12954740				2023-01-03	WOS:000185081400003
J	Ross, L; Johansen, C; Dalton, SO; Mellemkjae, L; Thomassen, LH; Mortensen, PB; Olsen, JH				Ross, L; Johansen, C; Dalton, SO; Mellemkjae, L; Thomassen, LH; Mortensen, PB; Olsen, JH			Psychiatric hospitalizations among survivors of cancer in childhood or adolescence	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VOLUME CHANGES; SCHIZOPHRENIA; DISORDER; REGISTER; CONSEQUENCES; RADIATION; DENMARK	BACKGROUND We investigated whether children and adolescents who survive cancer are at increased risk for psychiatric hospitalization. METHODS In a nationwide, population-based, retrospective cohort study, 3710 persons who survived at least three years after a diagnosis of cancer in childhood or adolescence in the period from 1943 to 1990, and who were alive on January 1, 1970, or were born after that date, were identified in the Danish Cancer Registry. This population was followed up for psychiatric hospitalization from January 1, 1970, through 1993 by linkage with the Danish national Psychiatric Central Register. The number of expected cases was based on the national rates of hospitalization for psychiatric disease. RESULTS Among the 3710 survivors of cancer in childhood or adolescence, there was a total of 88 psychiatric hospitalizations. The risk of hospitalization for any psychiatric disease was higher among the survivors than in the general population, but the excess risk was restricted to survivors of brain tumor (the standardized hospitalization ratio [SHR], corresponding to the ratio of observed to expected cases of hospitalization for psychiatric disease, was 1.8; 95 percent confidence interval, 1.5 to 2.2). An increased risk of psychoses of somatic, cerebral causes (SHR, 7.7; 95 percent confidence interval, 4.1 to 13.2), psychiatric disorders in somatic disease (SHR, 5.1; 95 percent confidence interval, 2.5 to 9.1), and schizophrenia and related disorders (SHR, 2.4; 95 percent confidence interval, 1.2 to 4.4) was observed among survivors of brain tumor. There was no evidence of a significantly increased risk of major depression. CONCLUSIONS The risk of hospitalization for a psychiatric disorder is not increased among survivors of cancer in childhood or adolescence, except among survivors of brain tumor.	Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen, Denmark; Aarhus Univ, Natl Ctr Register Based Res, Aarhus, Denmark	Danish Cancer Society; Aarhus University	Johansen, C (corresponding author), Danish Canc Soc, Inst Canc Epidemiol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	christof@cancer.dk	Mortensen, Preben B/D-2358-2015; Johansen, Christoffer/AAG-7916-2020	Mortensen, Preben B/0000-0002-5230-9865; Johansen, Christoffer/0000-0002-4384-206X; Olsen, Jorgen Helge/0000-0001-9633-5662; Ross, Lone/0000-0002-4406-604X; Dalton, Susanne Oksbjerg/0000-0002-5485-2730				Arvidson J, 1999, PSYCHO-ONCOLOGY, V8, P123; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BROWN PD, 1995, ACTA PAEDIATR, V84, P316, DOI 10.1111/j.1651-2227.1995.tb13636.x; COUSENS P, 1988, J CHILD PSYCHOL PSYC, V29, P839, DOI 10.1111/j.1469-7610.1988.tb00757.x; *DAN NAT BOARD HLT, 2003, CANC INC DENM 1998; *DAN NAT BOARD HLT, 1976, KLASS SYGD; Eiser C, 1998, J CHILD PSYCHOL PSYC, V39, P621, DOI 10.1111/1469-7610.00362; Garwicz S, 2000, INT J CANCER, V88, P672, DOI 10.1002/1097-0215(20001115)88:4<672::AID-IJC24>3.0.CO;2-N; GLAUSER TA, 1991, CHILD NERV SYST, V7, P2, DOI 10.1007/BF00263824; Gray R. E., 1992, PSYCHO-ONCOLOGY, V1, P235, DOI [10.1002/pon.2960010406, DOI 10.1002/PON.2960010406]; GREENBERG HS, 1989, J PEDIATR-US, V114, P488, DOI 10.1016/S0022-3476(89)80581-5; Hulshoff HE, 2002, AM J PSYCHIAT, V159, P244, DOI 10.1176/appi.ajp.159.2.244; *I PSYCH DEM, 1994, ANN REP 1993; Kessing LV, 1998, EUR PSYCHIAT, V13, P392, DOI 10.1016/S0924-9338(99)80685-3; Kokkonen J, 1997, PEDIATR HEMAT ONCOL, V14, P223, DOI 10.3109/08880019709009492; LESKO LM, 1990, PROG CLIN BIOL RES, V352, P423; Lieberman JA, 1999, BIOL PSYCHIAT, V46, P729, DOI 10.1016/S0006-3223(99)00147-X; LOFFLER W, 1994, ACTA PSYCHIAT SCAND, V90, P196, DOI 10.1111/j.1600-0447.1994.tb01577.x; Loganovsky KN, 2000, SCHIZOPHRENIA BULL, V26, P751, DOI 10.1093/oxfordjournals.schbul.a033492; Mathalon DH, 2001, ARCH GEN PSYCHIAT, V58, P148, DOI 10.1001/archpsyc.58.2.148; McGlashan TH, 2000, ARCH GEN PSYCHIAT, V57, P637, DOI 10.1001/archpsyc.57.7.637; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; MUNKJORGENSEN P, 1992, BRIT J PSYCHIAT, V161, P489, DOI 10.1192/bjp.161.4.489; Percy C., 1990, INT CLASSIFICATION D; ROMAN DD, 1995, INT J RADIAT ONCOL, V31, P983, DOI 10.1016/0360-3016(94)00550-8; Rothman K, 1979, NIH PUBL; SCHMALE AH, 1983, PSYCHOSOM MED, V45, P163, DOI 10.1097/00006842-198305000-00008; Storm HH, 1997, DAN MED BULL, V44, P535; TETA MJ, 1986, J CHRON DIS, V39, P751, DOI 10.1016/0021-9681(86)90158-X; Woods BT, 1998, AM J PSYCHIAT, V155, P1661, DOI 10.1176/ajp.155.12.1661	30	50	51	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2003	349	7					650	657		10.1056/NEJMoa022672	http://dx.doi.org/10.1056/NEJMoa022672			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	711FL	12917301				2023-01-03	WOS:000184728900005
J	Kaushik, JK; Bhat, R				Kaushik, JK; Bhat, R			Why is trehalose an exceptional protein stabilizer? An analysis of the thermal stability of proteins in the presence of the compatible osmolyte trehalose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AQUEOUS POLYOL SOLUTIONS; SACCHAROMYCES-CEREVISIAE; PREFERENTIAL HYDRATION; MOLECULAR-BIOLOGY; HIGH-TEMPERATURES; ENZYME STRUCTURE; SURFACE-TENSION; HEAT-CAPACITIES; RIBONUCLEASE-A; AMINO-ACIDS	Trehalose, a naturally occurring osmolyte, is known to be an exceptional stabilizer of proteins and helps retain the activity of enzymes in solution as well as in the freeze-dried state. To understand the mechanism of action of trehalose in detail, we have conducted a thorough investigation of its effect on the thermal stability in aqueous solutions of five well characterized proteins differing in their various physico-chemical properties. Among them, RNase A has been used as a model enzyme to investigate the effect of trehalose on the retention of enzymatic activity upon incubation at high temperatures. 2 M trehalose was observed to raise the transition temperature, T-m of RNase A by as much as 18degreesC and Gibbs free energy by 4.8 kcal mol(-1) at pH 2.5. There is a decrease in the heat capacity of protein denaturation (DeltaC(p)) in trehalose solutions for all the studied proteins. An increase in the DeltaG and a decrease in the DeltaC(p) values for all the proteins points toward a general mechanism of stabilization due to the elevation and broadening of the stability curve (DeltaG versus T). A direct correlation of the surface tension of trehalose solutions and the thermal stability of various proteins has been observed. Wyman linkage analysis indicates that at 1.5 M concentration 4-7 molecules of trehalose are excluded from the vicinity of protein molecules upon denaturation. We further show that an increase in the stability of proteins in the presence of trehalose depends upon the length of the polypeptide chain. The pH dependence data suggest that even though the charge status of a protein contributes significantly, trehalose can be expected to work as a universal stabilizer of protein conformation due to its exceptional effect on the structure and properties of solvent water compared with other sugars and polyols.	Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi	Bhat, R (corresponding author), Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India.	rajivbhat@hotmail.com		Kaushik, Jai/0000-0002-8872-0066				ARAKAWA T, 1982, BIOCHEMISTRY-US, V21, P6536, DOI 10.1021/bi00268a033; BACK JF, 1979, BIOCHEMISTRY-US, V18, P5191, DOI 10.1021/bi00590a025; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Baskakov IV, 1999, PROTEIN SCI, V8, P1314, DOI 10.1110/ps.8.6.1314; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; Carninci P, 1998, P NATL ACAD SCI USA, V95, P520, DOI 10.1073/pnas.95.2.520; CARPENTER JF, 1993, ARCH BIOCHEM BIOPHYS, V303, P456, DOI 10.1006/abbi.1993.1309; CARPENTER JF, 1989, BIOCHEMISTRY-US, V28, P3916, DOI 10.1021/bi00435a044; Celinski SA, 2002, PROTEIN SCI, V11, P2048, DOI 10.1110/ps.0211702; Chalikian TV, 1997, J MOL BIOL, V274, P237, DOI 10.1006/jmbi.1997.1394; COLACO C, 1992, BIO-TECHNOL, V10, P1007, DOI 10.1038/nbt0992-1007; Consalvi V, 2000, PROTEIN ENG, V13, P501, DOI 10.1093/protein/13.7.501; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; Devi YS, 1998, PROGR BIOTECHNOL, V15, P263; DIPAOLA G, 1977, CAN J CHEM, V55, P3825, DOI 10.1139/v77-540; DYSON HJ, 1982, J BIOL CHEM, V257, P2267; Funahashi J, 2001, PROTEIN ENG, V14, P127, DOI 10.1093/protein/14.2.127; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P1643, DOI 10.1093/oxfordjournals.jbchem.a133639; GEKKO K, 1982, J BIOCHEM-TOKYO, V91, P1197, DOI 10.1093/oxfordjournals.jbchem.a133803; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P51, DOI 10.1093/oxfordjournals.jbchem.a133469; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P1633, DOI 10.1093/oxfordjournals.jbchem.a133638; Goldberg ME, 1996, FOLD DES, V1, P21, DOI 10.1016/S1359-0278(96)00008-9; GRIKO YV, 1994, J MOL BIOL, V243, P93, DOI 10.1006/jmbi.1994.1632; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; JASRA RV, 1984, J CHEM THERMODYN, V16, P583, DOI 10.1016/0021-9614(84)90010-7; Kaushik JK, 1999, PROTEIN SCI, V8, P222; Kaushik JK, 1998, J PHYS CHEM B, V102, P7058, DOI 10.1021/jp981119l; Kaushik JK, 2002, J MOL BIOL, V316, P991, DOI 10.1006/jmbi.2001.5355; KITA Y, 1994, BIOCHEMISTRY-US, V33, P15178, DOI 10.1021/bi00254a029; Konno T, 1997, BBA-PROTEIN STRUCT M, V1342, P73, DOI 10.1016/S0167-4838(97)00092-7; Kreilgaard L, 1998, ARCH BIOCHEM BIOPHYS, V360, P121, DOI 10.1006/abbi.1998.0948; Kuhn LA, 1995, PROTEINS, V23, P536, DOI 10.1002/prot.340230408; LEE JC, 1981, J BIOL CHEM, V256, P7193; Lin TY, 1996, PROTEIN SCI, V5, P372; Liu YF, 1996, BIOCHEMISTRY-US, V35, P3059, DOI 10.1021/bi952198j; LIU YF, 1995, BIOCHEMISTRY-US, V34, P12884, DOI 10.1021/bi00039a051; MAEDA Y, 1995, PROTEIN ENG, V8, P201, DOI 10.1093/protein/8.2.201; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nwaka S, 1998, PROG NUCLEIC ACID RE, V58, P197; PACE CN, 1989, BIOCHEMISTRY-US, V28, P2520, DOI 10.1021/bi00432a026; Qu YX, 1998, P NATL ACAD SCI USA, V95, P9268, DOI 10.1073/pnas.95.16.9268; Sampedro JG, 1998, CRYOBIOLOGY, V37, P131, DOI 10.1006/cryo.1998.2109; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P5278, DOI 10.1021/bi00138a006; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Sola-Penna M, 1998, ARCH BIOCHEM BIOPHYS, V360, P10, DOI 10.1006/abbi.1998.0906; SolaPenna M, 1997, EUR J BIOCHEM, V248, P24, DOI 10.1111/j.1432-1033.1997.00024.x; SOMERO GN, 1986, AM J PHYSIOL, V251, pR197, DOI 10.1152/ajpregu.1986.251.2.R197; Sun WQ, 1998, BBA-GEN SUBJECTS, V1425, P235, DOI 10.1016/S0304-4165(98)00076-2; TAYLOR LS, 1995, BBA-PROTEIN STRUCT M, V1253, P39, DOI 10.1016/0167-4838(95)00142-H; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; Ueda T, 2001, J BIOCHEM-TOKYO, V130, P491, DOI 10.1093/oxfordjournals.jbchem.a003011; WANG A, 1995, BIOCHEMISTRY-US, V34, P15096, DOI 10.1021/bi00046a016; Weatherly GT, 2001, PROTEIN SCI, V10, P12, DOI 10.1110/ps.29301; Xie GF, 1997, BIOPHYS CHEM, V64, P25, DOI 10.1016/S0301-4622(96)02222-3; Xie GF, 1997, PROTEIN SCI, V6, P211; ZALE SE, 1986, BIOCHEMISTRY-US, V25, P5432, DOI 10.1021/bi00367a014	59	449	498	1	99	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26458	26465		10.1074/jbc.M300815200	http://dx.doi.org/10.1074/jbc.M300815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12702728	hybrid			2023-01-03	WOS:000184155700023
J	Rapp, SR; Espeland, MA; Shumaker, SA; Henderson, VW; Brunner, RL; Manson, JE; Gass, MLS; Stefanick, ML; Lane, DS; Hays, J; Johnson, KC; Coker, LH; Dailey, M; Bowen, D				Rapp, SR; Espeland, MA; Shumaker, SA; Henderson, VW; Brunner, RL; Manson, JE; Gass, MLS; Stefanick, ML; Lane, DS; Hays, J; Johnson, KC; Coker, LH; Dailey, M; Bowen, D		WHIMS Investigators	Effect of estrogen plus progestin on global cognitive function in postmenopausal women - The Women's Health Initiative Memory Study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE-REPLACEMENT THERAPY; MENTAL-STATE-EXAMINATION; CEREBRAL BLOOD-FLOW; OLDER WOMEN; ELDERLY WOMEN; DEMENTIA; PREVALENCE; IMPAIRMENT; COMMUNITY; 3MS	Context Observational studies have suggested that postmenopausal hormone treatment may improve cognitive function, but data from randomized clinical trials have been sparse and inconclusive. The Women's Health Initiative Memory Study (WHIMS) is an ancillary study of the Women's Health Initiative (WHI) hormone therapy trials. On July 8, 2002, the estrogen plus progestin therapy in the WHI trial was discontinued because of certain increased health risks for women. Objective To determine whether estrogen plus progestin therapy protects global cognitive function in older postmenopausal women. Design, Setting, and Participants A randomized, double-blind, placebo-controlled clinical trial, WHIMS is an ancillary study of geographically diverse, community-dwelling women aged 65 years or older from 39 of 40 clinical centers within the WHI estrogen plus progestin trial that started in June 1995. Of 4894 eligible postmenopausal women aged 65 years or older and free of probable dementia at baseline, 4532 (92.6%) were enrolled in the estrogen plus progestin component of WHIMS. A total of 4381 participants (96.7%) provided at least 1 valid cognitive function score between June 1995 and July 8, 2002. Interventions Participants received either 1 daily tablet containing 0.625 mg of conjugated equine estrogen with 2.5 mg of medroxyprogesterone acetate (n=2145) or matching placebo (n=2236). Main Outcome Measure Global cognitive function measured annually with the Modified Mini-Mental State Examination. Results The Modified Mini-Mental State Examination mean total scores in both groups increased slightly over time (mean follow-up of 4.2 years). Women in the estrogen plus progestin group had smaller average increases in total scores compared with women receiving placebo (P=.03), but these differences were not clinically important. Removing women by censoring them after adjudicated dementia, mild cognitive impairment, or stroke, and nonadherence to study protocol, did not alter the findings. Prior hormone therapy use and duration of prior use did not affect the interpretation of the results, nor did timing of prior hormone therapy initiation with respect to the final menstrual period. More women in the estrogen plus progestin group had a substantial and clinically important decline (greater than or equal to2 SDs) in Modified Mini-Mental State Examination total score (6.7%) compared with the placebo group (4.8%) (P=.008). Conclusions Among postmenopausal women aged 65 years or older, estrogen plus progestin did not improve cognitive function when compared with placebo. While most women receiving estrogen plus progestin did not experience clinically relevant adverse effects on cognition compared with placebo, a small increased risk of clinically meaningful cognitive decline occurred in the estrogen plus progestin group.	Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; Univ Nevada, Dept Family & Community Med, Reno, NV 89557 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA USA; Univ Cincinnati, Dept Obstet & Gynecol, Cincinnati, OH USA; Stanford Univ, Stanford Ctr Res Dis Prevent, Stanford, CA 94305 USA; SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Tennessee, Dept Prevent Med, Memphis, TN USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Arkansas System; University of Arkansas Medical Sciences; Nevada System of Higher Education (NSHE); University of Nevada Reno; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University System of Ohio; University of Cincinnati; Stanford University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Baylor College of Medicine; University of Tennessee System; University of Tennessee Health Science Center; Fred Hutchinson Cancer Center	Rapp, SR (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Med, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.		Henderson, V/AAW-4744-2021	Hays-Grudo, Jennifer/0000-0002-8107-1243; Bowen, Deborah/0000-0002-5177-8520				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; BARKER A, 1995, BRIT J PSYCHIAT, V167, P642, DOI 10.1192/bjp.167.5.642; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Bethea CL, 2002, FRONT NEUROENDOCRIN, V23, P41, DOI 10.1006/frne.2001.0225; Binder EF, 2001, MATURITAS, V38, P137, DOI 10.1016/S0378-5122(00)00214-0; Bland RC, 2001, CAN J PSYCHIAT, V46, P506, DOI 10.1177/070674370104600604; Bravo G, 1997, NEUROEPIDEMIOLOGY, V16, P141; Brinton RD, 2000, NEUROBIOL AGING, V21, P475, DOI 10.1016/S0197-4580(00)00109-3; Carlson MC, 2001, NEUROLOGY, V57, P2210, DOI 10.1212/WNL.57.12.2210; CORIA F, 1993, J NEUROL NEUROSUR PS, V56, P973, DOI 10.1136/jnnp.56.9.973; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; Foy MR, 2000, CURR DIR PSYCHOL SCI, V9, P148, DOI 10.1111/1467-8721.00081; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; HAYS J, 2003, N ENGL J MED; Henderson VW, 2003, NEUROLOGY, V60, P1369, DOI 10.1212/01.WNL.0000059413.75888.BE; HENDERSON VW, 2000, HORMONE THERAPY BRAI; Hogervorst E, 2000, NEUROSCIENCE, V101, P485, DOI 10.1016/S0306-4522(00)00410-3; Hogervorst E, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003122; HOLST J, 1989, MATURITAS, V11, P13, DOI 10.1016/0378-5122(89)90116-3; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; Kuller LH, 2003, NEUROEPIDEMIOLOGY, V22, P13, DOI 10.1159/000067109; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Larrabee G J, 1994, Int Psychogeriatr, V6, P95, DOI 10.1017/S1041610294001663; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Littell R.C., 1996, SAS SYSTEMS MIXED MO; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Maki PM, 2001, AM J PSYCHIAT, V158, P227, DOI 10.1176/appi.ajp.158.2.227; Maki PM, 2000, NEUROBIOL AGING, V21, P373, DOI 10.1016/S0197-4580(00)00123-8; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; McCaffrey RJ, 1995, NEUROPSYCHOL REV, V5, P203, DOI 10.1007/BF02214762; McDowell I, 1997, J CLIN EPIDEMIOL, V50, P377, DOI 10.1016/S0895-4356(97)00060-7; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Murray DM, 1998, STAT MED, V17, P1581, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1581::AID-SIM864>3.0.CO;2-N; NADLER JD, 1995, J GERIATR PSYCH NEUR, V8, P177, DOI 10.1177/089198879500800307; Osterlund MK, 2000, J NEUROCHEM, V75, P1390, DOI 10.1046/j.1471-4159.2000.0751390.x; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Polo-Kantola P, 1998, OBSTET GYNECOL, V91, P459, DOI 10.1016/S0029-7844(97)00700-X; Resnick SM, 1998, HORM BEHAV, V34, P171, DOI 10.1006/hbeh.1998.1476; Resnick SM, 1997, NEUROLOGY, V49, P1491, DOI 10.1212/WNL.49.6.1491; Rice MM, 2000, ARCH INTERN MED, V160, P1641, DOI 10.1001/archinte.160.11.1641; Rosendaal FR, 2002, ARTERIOSCL THROM VAS, V22, P201, DOI 10.1161/hq0202.102318; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SCHAIE KW, 1994, AM PSYCHOL, V49, P304, DOI 10.1037/0003-066X.49.4.304; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TENG EL, 1990, PSYCHOGERIATRICS BIO, P189; Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48; TORANALLERAND CD, 1991, PSYCHONEUROENDOCRINO, V16, P7, DOI 10.1016/0306-4530(91)90068-5; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Yaffe K, 2001, NEW ENGL J MED, V344, P1207, DOI 10.1056/NEJM200104193441604	58	686	710	1	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2663	2672		10.1001/jama.289.20.2663	http://dx.doi.org/10.1001/jama.289.20.2663			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	682DG	12771113				2023-01-03	WOS:000183075600025
J	Ng, J; O'Grady, G; Pettit, T; Frith, R				Ng, J; O'Grady, G; Pettit, T; Frith, R			Nitrous oxide use in first-year students at Auckland University	LANCET			English	Article								In a recent Lancet Case report, a patient presented with subacute combined degeneration of the spinal cord after recreational use of nitrous oxide (N2O). There is very little information about use of this substance as a recreational drug. In a questionnaire-based study, we surveyed 1782 students in their first year at the University of Auckland, New Zealand. 1360 (76%) questionnaires were completed and consistent. 780 (57%) students were aware of recreational use of N2O, 158 (12%) used the substance recreationally, and 39 (3%) inhaled It at least monthly. Users were most likely to be white and to be men. Our results show a high frequency of recreational N2O use in first-year students at Auckland University. Although this study does not accurately reflect use of this substance in the wider community, the high prevalence suggests that presentations of subacute myelopathy in an otherwise fit young person should prompt an enquiry about use of N2O.	Auckland Hosp, Dept Neurol, Auckland 1001, New Zealand	Auckland City Hospital	Frith, R (corresponding author), Auckland Hosp, Dept Neurol, Auckland 1001, New Zealand.							DEACON R, 1978, LANCET, V2, P1023, DOI 10.1016/S0140-6736(78)92341-3; Ng J, 2002, LANCET, V360, P384, DOI 10.1016/S0140-6736(02)09611-3; *STAT NZ, 1998, GUID COLL COMM INF, P7	3	42	44	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1349	1350		10.1016/S0140-6736(03)13045-0	http://dx.doi.org/10.1016/S0140-6736(03)13045-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711474				2023-01-03	WOS:000182346100016
J	Rabbitts, TH; Stocks, MR				Rabbitts, TH; Stocks, MR			Chromosomal translocation products engender new intracellular therapeutic technologies	NATURE MEDICINE			English	Editorial Material							EMBRYONIC LETHALITY; MYELOID-LEUKEMIA; EXPRESSION; SELECTION; CANCER; RECOMBINATION; TRANSDUCTION; PROTEINS; DELIVERY; GENES	Chromosomal translocations occur in leukemias, lymphomas, sarcomas and some epithelial tumors and some generate unique fusion proteins. These translocation products may provide tumor-specific targets for the development of new therapeutic strategies tailored to a malignant cell.	MRC, Mol Biol Lab, Cambridge, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Cambridge, England.		Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Druker B, 2001, SEMIN HEMATOL, V38, P9, DOI 10.1016/S0037-1963(01)90112-X; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Geyer CR, 2000, METHOD ENZYMOL, V328, P171, DOI 10.1016/S0076-6879(00)28398-5; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Kuwabara T, 1998, MOL CELL, V2, P617, DOI 10.1016/S1097-2765(00)80160-4; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; Pinilla-Ibarz J, 2000, BLOOD REV, V14, P111, DOI 10.1054/blre.2000.0127; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; STOCKS MR, 2002, EMBO REPORTS, V11, P59; TANAKA T, IN PRESS EMBO J; Tse E, 2000, P NATL ACAD SCI USA, V97, P12266, DOI 10.1073/pnas.97.22.12266; Ullu E, 2002, PHILOS T ROY SOC B, V357, P65, DOI 10.1098/rstb.2001.0952; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	23	39	42	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2003	9	4					383	386		10.1038/nm0403-383	http://dx.doi.org/10.1038/nm0403-383			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	663CD	12669051				2023-01-03	WOS:000181987400017
J	Gurwitz, JH; Field, TS; Harrold, LR; Rothschild, J; Debellis, K; Seger, AC; Cadoret, C; Garber, L; Kelleher, M; Bates, DW				Gurwitz, JH; Field, TS; Harrold, LR; Rothschild, J; Debellis, K; Seger, AC; Cadoret, C; Garber, L; Kelleher, M; Bates, DW			Incidence and preventability of adverse drug events among older persons in the ambulatory setting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICATION ERRORS; ELDERLY PATIENTS; UNITED-STATES; MEDICINE; QUALITY; PRESCRIPTION; POPULATION; DEATHS; SAFETY; COSTS	Context Adverse drug events, especially those that may be preventable, are among the most serious concerns about medication use in older persons cared for in the ambulatory clinical setting. Objective To assess the incidence and preventability of adverse drug events among older persons in the ambulatory clinical setting. Design, Setting, and Patients Cohort study of all Medicare enrollees (30 397 person-years of observation) cared for by a multispecialty group practice during a 12-month study period (July 1, 1999, through June 30, 2000), in which possible drug-related incidents occurring in the ambulatory clinical setting were detected using multiple methods, including reports from health care providers; review of hospital discharge summaries; review of emergency department notes; computer-generated signals; automated free-text review of electronic clinic notes; and review of administrative incident reports concerning medication errors. Main Outcome Measures Number of adverse drug events, severity of the events (classified as significant, serious, life-threatening, or fatal), and whether the events were preventable. Results There were 1523 identified adverse drug events, of which 27.6% (421) were considered preventable. The overall rate of adverse drug events was 50.1 per 1000 person-years, with a rate of 13.8 preventable adverse drug events per 1000 person-years. Of the adverse drug events, 578 (38.0%) were categorized as serious, life-threatening, or fatal; 244 (42.2%) of these more severe events were deemed preventable compared with 177 (18.7%) of the 945 significant adverse drug events. Errors associated with preventable adverse drug events occurred most often at the stages of prescribing (n = 246, 58.4%) and monitoring (n = 256, 60.8%), and errors involving patient adherence (n = 89, 21.1%) also were common. Cardiovascular medications (24.5%), followed by diuretics (22.1%), nonopioid analgesics (15.4%), hypoglytemics (10.9%), and anticoagulants (10.2%) were the most common medication categories associated with preventable adverse drug events. Electrolyte/renal (26.6%), gastrointestinal tract (21.1%), hemorrhagic (15.9%), metabolic/endocrine (13.8%), and neuropsychiatric (8.6%) events were the most common types of preventable adverse drug events. Conclusions Adverse drug events are common and often preventable among older persons in the ambulatory Clinical setting. More serious adverse drug events are more likely to be preventable. Prevention strategies should target the prescribing and monitoring stages of. pharmaceutical care. Interventions focused on improving patient adherence with prescribed regimens and monitoring of prescribed medications also may be beneficial.	Meyers Primary Care Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Worcester, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Partners Healthcare Syst, Boston, MA USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Brigham & Women's Hospital; Partners Healthcare System	Gurwitz, JH (corresponding author), Meyers Primary Care Inst, 630 Plantat St, Worcester, MA 01605 USA.	jgurwitz@meyersprimary.org		Cadoret, Cynthia/0000-0001-6713-2823	NATIONAL INSTITUTE ON AGING [R01AG015979] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Applegate WB, 2002, JAMA-J AM MED ASSOC, V288, P495, DOI 10.1001/jama.288.4.495; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Chertow GM, 2001, JAMA-J AM MED ASSOC, V286, P2839, DOI 10.1001/jama.286.22.2839; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; *CTR MED MED SERV, MED MAN CAR CONTR PL; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; Gandhi TK, 2000, J GEN INTERN MED, V15, P149, DOI 10.1046/j.1525-1497.2000.04199.x; Gurwitz JH, 2000, AM J MED, V109, P87, DOI 10.1016/S0002-9343(00)00451-4; Gurwitz JH, 2002, ARCH INTERN MED, V162, P1670, DOI 10.1001/archinte.162.15.1670; Hanlon JT, 2000, PHARMACOTHERAPY, V20, P575, DOI 10.1592/phco.20.6.575.35163; Hanlon JT, 2002, J AM GERIATR SOC, V50, P26, DOI 10.1046/j.1532-5415.2002.50004.x; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; Honigman B, 2001, INT J MED INFORM, V61, P21, DOI 10.1016/S1386-5056(00)00131-3; Honigman B, 2001, J AM MED INFORM ASSN, V8, P254, DOI 10.1136/jamia.2001.0080254; KATZ JN, 1992, ARTHRITIS RHEUM-US, V35, P1257, DOI 10.1002/art.1780351103; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kaushal R, 2001, JAMA-J AM MED ASSOC, V285, P2114, DOI 10.1001/jama.285.16.2114; Kaushal R, 2001, ARCH PEDIAT ADOL MED, V155, P1002, DOI 10.1001/archpedi.155.9.1002; Knight EL, 2001, ANN INTERN MED, V135, P703, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00009; Kohn LT, 2000, ERR IS HUMAN BUILDIN; KOZAK LJ, 2002, ADV DATA VITAL HLTH, V13; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; *LEAPFR GROUP, 2002, PAT SAF SURV RES SUM; Linder JA, 2001, JAMA-J AM MED ASSOC, V286, P1181, DOI 10.1001/jama.286.10.1181; Matchar DB, 2002, AM J MED, V113, P42, DOI 10.1016/S0002-9343(02)01131-2; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; *NAT CTR HLTH STAT, POP AG SEX RAC NAT S; Pitkala KH, 2002, ARCH INTERN MED, V162, P1707, DOI 10.1001/archinte.162.15.1707; Rosner B., 2010, FUNDAMENTALS BIOSTAT; Sackett D.L., 1991, CLIN EPIDEMIOLOGY BA, V2nd; SHOJANIA K, 2001, AHRQ PUBLICATION; Sox H C Jr, 2000, Eff Clin Pract, V3, P277; Thomas EJ, 2002, ANN INTERN MED, V136, P812, DOI 10.7326/0003-4819-136-11-200206040-00009; WALTON RT, 2001, COCHRANE DB SYST REV, V1; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; Zhan Chunliu, 2001, JAMA (Journal of the American Medical Association), V286, P2823	45	1081	1116	1	61	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	2003	289	9					1107	1116		10.1001/jama.289.9.1107	http://dx.doi.org/10.1001/jama.289.9.1107			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650XM	12622580	Bronze			2023-01-03	WOS:000181289400026
J	Kauer, JA				Kauer, JA			Addictive drugs and stress trigger a common change at VTA Synapses	NEURON			English	Editorial Material							AMPHETAMINE; SENSITIZATION; EXPOSURE		Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University	Kauer, JA (corresponding author), Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.			Kauer, Julie/0000-0002-3362-1642				Everitt BJ, 2002, J NEUROSCI, V22, P3312; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Jones S, 2000, J NEUROSCI, V20, P5575, DOI 10.1523/JNEUROSCI.20-15-05575.2000; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Marinelli M, 2002, EUR J NEUROSCI, V16, P387, DOI 10.1046/j.1460-9568.2002.02089.x; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Pacchioni AM, 2002, ANN NY ACAD SCI, V965, P233; Piazza PV, 1998, TRENDS PHARMACOL SCI, V19, P67, DOI 10.1016/S0165-6147(97)01115-2; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7; Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2; Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077; VEZINA P, 1993, BRAIN RES, V605, P332, DOI 10.1016/0006-8993(93)91761-G; Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7	14	20	23	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	FEB 20	2003	37	4					549	550		10.1016/S0896-6273(03)00087-4	http://dx.doi.org/10.1016/S0896-6273(03)00087-4			2	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	648EH	12597851	Bronze			2023-01-03	WOS:000181136500002
J	Rymer, J; Wilson, R; Ballard, K				Rymer, J; Wilson, R; Ballard, K			Making decisions about hormone replacement therapy	BRITISH MEDICAL JOURNAL			English	Review							CORONARY HEART-DISEASE; POSTMENOPAUSAL WOMEN; ENDOMETRIAL CANCER; VENOUS THROMBOEMBOLISM; ESTROGEN REPLACEMENT; RISK; METAANALYSIS; POPULATION; PREVENTION; MENOPAUSE		Guys & St Thomas Hosp Trust, Guys Kings & St Thomass Sch Med, London SE1 7EH, England; Queens Univ, Dept Family Med, Kingston, ON, Canada; Univ London Kings Coll, Guys Kings & St Thomass Sch Med, Dept Gen & Primary Care, London SE11 6SP, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Queens University - Canada; University of London; King's College London	Rymer, J (corresponding author), St Thomas Hosp, Dept Obstet & Gynaecol, London SE1 7EH, England.							ABRAHAM S, 1995, MATURITAS, V21, P91, DOI 10.1016/0378-5122(94)00881-7; Avis NE, 2001, SOC SCI MED, V52, P345, DOI 10.1016/S0277-9536(00)00147-7; Ballard K, 2002, BRIT J GEN PRACT, V52, P835; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; Cooper C, 1996, OSTEOPOROSIS NEW PER, P1; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; ERIKSEN PS, 1992, EUR J OBSTET GYN R B, V44, P137, DOI 10.1016/0028-2243(92)90059-8; Fletcher SW, 2002, JAMA-J AM MED ASSOC, V288, P366, DOI 10.1001/jama.288.3.366; Gold EB, 2000, AM J EPIDEMIOL, V152, P463, DOI 10.1093/aje/152.5.463; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Griffiths F, 1999, SOC SCI MED, V49, P469, DOI 10.1016/S0277-9536(99)00141-0; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hunter MS, 1997, SOC SCI MED, V45, P1541, DOI 10.1016/S0277-9536(97)00091-9; Hunter MS, 1999, MATURITAS, V33, P37, DOI 10.1016/S0378-5122(99)00041-9; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Kuh D, 2000, BRIT J OBSTET GYNAEC, V107, P731, DOI 10.1111/j.1471-0528.2000.tb13333.x; Kuh DL, 1997, BRIT J OBSTET GYNAEC, V104, P923, DOI 10.1111/j.1471-0528.1997.tb14352.x; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Lock M, 1994, ENCOUNTERS AGEING MY; Porter M, 1996, BRIT J OBSTET GYNAEC, V103, P1025, DOI 10.1111/j.1471-0528.1996.tb09555.x; Raudaskoski T, 2002, BJOG-INT J OBSTET GY, V109, P136, DOI 10.1016/S1470-0328(02)01167-9; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; RYMER J, 2002, BRIT MED J, V321, P1516; Sturdee DW, 2000, BRIT J OBSTET GYNAEC, V107, P1392, DOI 10.1111/j.1471-0528.2000.tb11654.x; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131; Wells M, 2002, BMJ-BRIT MED J, V325, P239, DOI 10.1136/bmj.325.7358.239; ZETHRACUS N, 1999, BRIT J OBSTET GYNAEC, V104, P1191	34	62	63	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 8	2003	326	7384					322	326		10.1136/bmj.326.7384.322	http://dx.doi.org/10.1136/bmj.326.7384.322			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645UD	12574048	Green Published			2023-01-03	WOS:000180997000022
J	Weinshilboum, R				Weinshilboum, R			Genomic medicine - Inheritance and drug response.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CATECHOL-O-METHYLTRANSFERASE; S-MEPHENYTOIN METABOLISM; THIOPURINE METHYLTRANSFERASE; GENETIC-POLYMORPHISM; DIHYDROPYRIMIDINE DEHYDROGENASE; CYTOCHROME-P450 CYP2C9; FAMILIAL PYRIMIDINEMIA; CLINICAL CONSEQUENCES; DOSE REQUIREMENT; HUMAN-SERUM		Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Mol Pharmacol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Expt Therapeut & Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Weinshilboum, R (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Mol Pharmacol & Expt Therapeut, 200 1st St SW, Rochester, MN 55905 USA.	weinshilboum.richard@mayo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061388, R01GM028157, R01GM035720] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM28157, UO1 GM61388, R01 GM35720] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441; BALIAN JD, 1995, CLIN PHARMACOL THER, V57, P662, DOI 10.1016/0009-9236(95)90229-5; BERTILSSON, 1994, CLIN PHARMACOL THER, V55, P648; BERTILSSON L, 1992, CLIN PHARMACOL THER, V51, P388, DOI 10.1038/clpt.1992.38; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; Brandolese R, 2001, CLIN PHARMACOL THER, V70, P391, DOI 10.1067/mcp.2001.118868; Collie-Duguid ESR, 1999, PHARMACOGENETICS, V9, P37, DOI 10.1097/00008571-199902000-00006; Dalen P, 1998, CLIN PHARMACOL THER, V63, P444, DOI 10.1016/S0009-9236(98)90040-6; DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419; DIASIO RB, 1988, J CLIN INVEST, V81, P47, DOI 10.1172/JCI113308; DRAYER DE, 1977, CLIN PHARMACOL THER, V22, P251; DUFOUR AP, 1964, SCIENCE, V145, P391, DOI 10.1126/science.145.3630.391; EICHELBAUM M, 1979, EUR J CLIN PHARMACOL, V16, P183, DOI 10.1007/BF00562059; EVANS DAP, 1960, BRIT MED J, V2, P485, DOI 10.1136/bmj.2.5197.485; EVANS DAP, 1993, GENETIC FACTORS DRUG; EVANS DAP, 1992, INT ENCY PHARM THERA, V43, P95; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Furuta T, 1998, ANN INTERN MED, V129, P1027, DOI 10.7326/0003-4819-129-12-199812150-00006; GONZALEZ F J, 1988, Genomics, V2, P174, DOI 10.1016/0888-7543(88)90100-0; Hall D, 1999, PHARMACOGENETICS, V9, P591, DOI 10.1097/01213011-199910000-00006; Ingelman-Sundberg M, 2001, PHARMACOGENETICS, V11, P553, DOI 10.1097/00008571-200110000-00002; Iyer L, 1999, CLIN PHARMACOL THER, V65, P576, DOI 10.1016/S0009-9236(99)70078-0; Iyer L., 2002, Pharmacogenomics Journal, V2, P43, DOI 10.1038/sj.tpj.6500072; JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825; KALOW W, 1957, J PHARMACOL EXP THER, V120, P203; KALOW W, 1959, ANN HUM GENET, V23, P239, DOI 10.1111/j.1469-1809.1959.tb01467.x; KALOW W, 1990, LIFE SCI, V47, P1385, DOI 10.1016/0024-3205(90)90517-U; Kalow Werner, 1963, PHARMACOGENETICS HER; KIMURA S, 1989, AM J HUM GENET, V45, P889; KROEMER HK, 1995, LIFE SCI, V56, P2285, DOI 10.1016/0024-3205(95)00223-S; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Lampe JW, 1999, PHARMACOGENETICS, V9, P341, DOI 10.1097/00008571-199906000-00009; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LENNARD L, 1992, EUR J CLIN PHARMACOL, V43, P329, DOI 10.1007/BF02220605; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LENNARD L, 1989, CLIN PHARMACOL THER, V46, P149, DOI 10.1038/clpt.1989.119; LIN HJ, 1993, AM J HUM GENET, V52, P827; Lockridge O., 1992, PHARMACOGENETICS DRU, P15; Loebstein R, 2001, CLIN PHARMACOL THER, V70, P159, DOI 10.1067/mcp.2001.117444; MAHGOUB A, 1977, LANCET, V2, P584, DOI 10.1016/S0140-6736(77)91430-1; MCGUIRE MC, 1989, P NATL ACAD SCI USA, V86, P953, DOI 10.1073/pnas.86.3.953; McLeod HL, 1998, PHARMACOGENETICS, V8, P455, DOI 10.1097/00008571-199812000-00001; MORTIMER O, 1990, CLIN PHARMACOL THER, V47, P27, DOI 10.1038/clpt.1990.4; NAKAMURA K, 1985, CLIN PHARMACOL THER, V38, P402, DOI 10.1038/clpt.1985.194; Raida M, 2001, CLIN CANCER RES, V7, P2832; REIDENBERG MM, 1975, CLIN PHARMACOL THER, V17, P722; REILLY DK, 1980, CLIN PHARMACOL THER, V28, P278, DOI 10.1038/clpt.1980.161; REMY CN, 1963, J BIOL CHEM, V238, P1078; Ross EM, 2001, GOODMAN GILMANS PHAR, P31; Sindrup SH, 1995, PHARMACOGENETICS, V5, P335, DOI 10.1097/00008571-199512000-00001; Stubbins MJ, 1996, PHARMACOGENETICS, V6, P429, DOI 10.1097/00008571-199610000-00007; Szumlanski C, 1996, DNA CELL BIOL, V15, P17, DOI 10.1089/dna.1996.15.17; Tai HL, 1996, AM J HUM GENET, V58, P694; Tai HL, 1997, P NATL ACAD SCI USA, V94, P6444, DOI 10.1073/pnas.94.12.6444; Tanigawara Y, 1999, CLIN PHARMACOL THER, V66, P528, DOI 10.1016/S0009-9236(99)70017-2; TIMBRELL JA, 1980, CLIN PHARMACOL THER, V28, P350, DOI 10.1038/clpt.1980.173; TUCHMAN M, 1985, NEW ENGL J MED, V313, P245, DOI 10.1056/NEJM198507253130407; Tybring G, 1997, CLIN PHARMACOL THER, V62, P129, DOI 10.1016/S0009-9236(97)90060-6; van der Weide J, 2001, PHARMACOGENETICS, V11, P287, DOI 10.1097/00008571-200106000-00002; Venter JC, 2001, SCIENCE, V292, P1838; WEBER WW, 1997, PHARMACOGENETICS; WEINSHILBOUM RM, 1977, AM J HUM GENET, V29, P125; Weinshilboum RM, 1999, ANNU REV PHARMACOL, V39, P19, DOI 10.1146/annurev.pharmtox.39.1.19; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WILKINSON GR, 2001, GOODMAN GILMANS PHAR, P3; WOODSON LC, 1983, BIOCHEM PHARMACOL, V32, P819, DOI 10.1016/0006-2952(83)90582-8	68	672	727	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 6	2003	348	6					529	537		10.1056/NEJMra020021	http://dx.doi.org/10.1056/NEJMra020021			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642JY	12571261	Bronze			2023-01-03	WOS:000180801400007
J	Thorne, C; Fiore, S; Rudin, C				Thorne, C; Fiore, S; Rudin, C			Antiretroviral therapy during pregnancy and the risk of an adverse outcome	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Inst Child Hlth, London WC1N 1EH, England; Univ Childrens Hosp, CH-4008 Basel, Switzerland	University of London; University College London	Thorne, C (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.		Thorne, Claire/C-5943-2008; SHCS, MoCHIV/G-4081-2011	Thorne, Claire/0000-0003-0389-1956; Mofenson, Lynne/0000-0002-2818-9808				Aebi C, 2000, AIDS, V14, P2913, DOI 10.1097/00002030-200012220-00013; Martinez-Valverde I, 2000, ARCH LATINOAM NUTR, V50, P5; Newell ML, 2002, AIDS, V16, pS1; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159	4	10	10	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	2003	348	5					471	471						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639RU	12556551				2023-01-03	WOS:000180643800022
J	Murchie, P; Campbell, NC; Ritchie, LD; Simpson, JA; Thain, J				Murchie, P; Campbell, NC; Ritchie, LD; Simpson, JA; Thain, J			Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care	BRITISH MEDICAL JOURNAL			English	Article							HIGH CARDIOVASCULAR RISK; GENERAL-PRACTICE; HEALTH PROMOTION	Objectives To evaluate the effects of nurse led clinics in primary care on secondary prevention, total mortality, and coronary event rates after four years. Design Follow up of a randomised controlled trial by postal questionnaires and review of case notes and national datasets. Setting Stratified, random sample of 19 general practices in north east Scotland. Participants 1343 patients (673 intervention and 670 control) under 80 years with a working diagnosis of coronary heart disease but without terminal illness or dementia and not housebound. Intervention Nurse led secondary prevention clinics promoted medical and lifestyle components of secondary prevention and offered regular follow up for one year. Main outcome measures Components of secondary prevention (aspirin, blood pressure management, lipid management; healthy diet, exercise, non-smoking), total mortality, and coronary events (non-fatal myocardial infarctions and coronary deaths). Results Mean follow up was at 4.7 years. Significant improvements were shown in the intervention group in all components of secondary prevention except smoking at one year, and these were sustained after four years except for exercise. The control group, most of whom attended clinics after the initial year, caught up before final follow up, and differences between groups were no longer significant. At 4.7 years, 100 patients in the intervention group and 128 in the control group had died: cumulative death rates were 14.5% and 18.9%, respectively (P=0.038). 100 coronary events occurred in the intervention group and 125 in the control group: cumulative event rates were 14.2% and 18.2%, respectively (P=0.052). Adjusting for age, sex, general practice, and baseline secondary prevention, proportional hazard ratios, were 0.75 for all deaths (95% confidence intervals 0.58 to 0.98; P=0.036) and 0.76 for coronary events (0.58 to 1.00; P=0.049) Conclusions Nurse led secondary prevention improved medical and lifestyle components of secondary prevention and this seemed to lead to significantly fewer total deaths and probably fewer coronary events. Secondary prevention clinics should be started sooner rather than later.	Univ Aberdeen, Dept Gen Practice & Primary Care, Foresterhill Hlth Ctr, Aberdeen AB25 2AY, Scotland; Westburn Ctr, Aberdeen AB25 2XG, Scotland	University of Aberdeen; University of Aberdeen	Murchie, P (corresponding author), Univ Aberdeen, Dept Gen Practice & Primary Care, Foresterhill Hlth Ctr, Aberdeen AB25 2AY, Scotland.		Simpson, Julie A/P-7299-2014	Murchie, Peter/0000-0001-9968-5991; Simpson, Julie/0000-0002-2660-2013				Bain N S, 1997, Health Bull (Edinb), V55, P94; Berkman LF, 1983, HLTH WAYS LIVING ALA; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; Campbell NC, 1998, HEART, V80, P447, DOI 10.1136/hrt.80.5.447; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1434, DOI 10.1136/bmj.316.7142.1434; CAMPBELL NC, 2001, THESIS U CAMBRIDGE; CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/bmj.309.6960.993; Cupples ME, 1999, BMJ-BRIT MED J, V319, P687, DOI 10.1136/bmj.319.7211.687; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; Kotseva K, 2001, EUR HEART J, V22, P554, DOI 10.1053/euhj.2001.2610; McAlister FA, 2001, BRIT MED J, V323, P957, DOI 10.1136/bmj.323.7319.957; MILLS JK, 1999, ACP J CLUB       MAY; Moher M, 2001, BMJ-BRIT MED J, V322, P1338, DOI 10.1136/bmj.322.7298.1338; ROE L, 1994, FAM PRACT, V11, P375, DOI 10.1093/fampra/11.4.375; *SCOTT INT GUID NE, 2001, SIGN GUID NUMB 51 MA; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; van der Weijden T, 1998, BMJ-BRIT MED J, V316, P1400, DOI 10.1136/bmj.316.7142.1400; WOODEND AK, 1999, EVIDENCE BASED NURS, V2, P21	19	166	167	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 11	2003	326	7380					84	+		10.1136/bmj.326.7380.84	http://dx.doi.org/10.1136/bmj.326.7380.84			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	635YC	12521974	Green Published, Bronze			2023-01-03	WOS:000180426900018
J	Rabkin, M; El-Sadr, W; Katzenstein, DA; Mukherjee, J; Masur, H; Mugyenyi, P; Munderi, P; Darbyshire, J				Rabkin, M; El-Sadr, W; Katzenstein, DA; Mukherjee, J; Masur, H; Mugyenyi, P; Munderi, P; Darbyshire, J			Antiretroviral treatment in resource-poor settings: clinical research priorities	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION; CD4 CELL COUNT; VIRAL LOAD; DISEASE PROGRESSION; CONTROLLED TRIAL; THERAPY; ADHERENCE; INDINAVIR; AIDS		Columbia Univ, Dept Med, New York, NY 10027 USA; Columbia Univ, Harlem Hosp, Mailman Sch Publ Hlth, New York, NY USA; Columbia Univ, Harlem Hosp, Div Infect Dis, New York, NY USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA; NIH, Dept Crit Care Med, Bethesda, MD 20892 USA; Joint Clin Res Ctr, Kampala, Uganda; WHO, Dept Essential Drugs & Med, CH-1211 Geneva, Switzerland; Med Res Ctr, Clin Trials Unit, London, England	Columbia University; Columbia University; Columbia University; Stanford University; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; Joint Clinic Research Center - United Arab Emirates; World Health Organization; Medical Research Council Clinical Trials Unit	Rabkin, M (corresponding author), Columbia Univ, Dept Med, New York, NY 10027 USA.			katzenstein, david/0000-0002-8593-4560				Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; BEDELL R, 2001, 1 IAS C HIV PATH TRE; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; CHAPMAN K, 2001, UNAIDS0193E; Deeks SG, 2002, AIDS, V16, P201, DOI 10.1097/00002030-200201250-00009; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; DIDER JM, 2001, J ACQ IMMUN DEF SYND, V26, P193; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrington M, 2000, LANCET, V355, P2147, DOI 10.1016/S0140-6736(00)02388-6; Henry K, 2000, ANN INTERN MED, V132, P306, DOI 10.7326/0003-4819-132-4-200002150-00009; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Janossy G, 2000, BRIT J HAEMATOL, V111, P1198, DOI 10.1046/j.1365-2141.2000.02433.x; KITYO C, 2002, 14 INT AIDS C BARC; LAURENT C, 2002, 9 C RETR OPP INF SEA; Ledergerber B, 2000, J INFECT DIS, V181, P1280, DOI 10.1086/315366; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; Post FA, 1996, QJM-MON J ASSOC PHYS, V89, P505; SCHECHTER M, 1994, J ACQ IMMUN DEF SYND, V7, P163; Sterling TR, 2001, AIDS, V15, P2251, DOI 10.1097/00002030-200111230-00006; *US DEP HHS HJ KAI, 2002, GUID US ANT AG HIV 1; *WHO, 2002, SCAL ANT THER RES LI; Zwerner RK, 1997, J ACQ IMMUN DEF SYND, V14, P31, DOI 10.1097/00042560-199701010-00006	26	38	39	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1503	1505		10.1016/S0140-6736(02)11478-4	http://dx.doi.org/10.1016/S0140-6736(02)11478-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433534				2023-01-03	WOS:000179186000031
J	Dixon, J				Dixon, J			Uses of error - Pattern recognition	LANCET			English	Editorial Material									Coach House, London NW3 2UT, England		Dixon, J (corresponding author), Coach House, London NW3 2UT, England.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1418	1418		10.1016/S0140-6736(02)11396-1	http://dx.doi.org/10.1016/S0140-6736(02)11396-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12424007				2023-01-03	WOS:000179081600033
J	Grol, R; Grimshaw, J				Grol, R; Grimshaw, J			From best evidence to best practice: effective implementation of change in patients' care	LANCET			English	Review							CONTINUING MEDICAL-EDUCATION; CLINICAL-PRACTICE GUIDELINES; DECISION-SUPPORT-SYSTEMS; HEALTH-CARE; HAND HYGIENE; PHYSICIAN PERFORMANCE; BUILDING BRIDGES; GENERAL-PRACTICE; INTERVENTIONS; QUALITY	Major difficulties arise when introducing evidence and clinical guidelines into routine daily practice. Data show that many patients do not receive appropriate care, or receive unnecessary or harmful care. Many approaches claim to offer solutions to this problem; which ones are as yet the most effective and efficient is unclear. We aim to provide an overview of present knowledge about initiatives to changing medical practice. Substantial evidence suggests that to change behaviour is possible, but this change generally requires comprehensive approaches at different levels (doctor, team practice, hospital, wider environment), tailored to specific settings and target groups. Plans for change should be based on characteristics of the evidence or guideline itself and barriers and facilitators to change. In general, evidence shows that none of the approaches for transferring evidence to practice is superior to all changes in all situations.	Univ Nijmegen & Univ Maastricht, Ctr Qual Care Res WOK, NL-6500 HB Nijmegen, Netherlands; Ottawa Hlth Res Inst, Clin Epidemiol Programme, Ottawa, ON, Canada	Maastricht University; Radboud University Nijmegen; University of Ottawa; Ottawa Hospital Research Institute	Grol, R (corresponding author), Univ Nijmegen & Univ Maastricht, Ctr Qual Care Res WOK, POB 9101,WOK 229, NL-6500 HB Nijmegen, Netherlands.	R.Grol@WOK.umcn.nl	Grimshaw, Jeremy/D-8726-2013; Grol, Richard/C-8523-2013	Grimshaw, Jeremy/0000-0001-8015-8243				Aiello AE, 2002, LANCET INFECT DIS, V2, P103, DOI 10.1016/S1473-3099(02)00184-6; Anderson GM, 1996, CAN MED ASSOC J, V154, P1013; AUSTIN SM, 1994, J AM MED INFORM ASSN, P121; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; Balas EA, 1996, J GEN INTERN MED, V11, P584, DOI 10.1007/BF02599025; Beaudry JS, 1989, J CONTIN EDUC HEALTH, V9, P285, DOI DOI 10.1002/CHP.4750090414; Beilby JJ, 1997, MED J AUSTRALIA, V167, P89, DOI 10.5694/j.1326-5377.1997.tb138787.x; BENEY J, 2000, COCHRANE LIB; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; BERTRAM DA, 1977, HEALTH EDUC QUART, V5, P330, DOI 10.1177/109019817700500404; Bodenheimer T, 1999, NEW ENGL J MED, V340, P488, DOI 10.1056/NEJM199902113400621; BOWER P, 2000, COCHRANE LIB; BUNTINX F, 1993, FAM PRACT, V10, P219, DOI 10.1093/fampra/10.2.219; BURGERS J, 2002, INT J TECHN ASS HLTH, V18, P955; Burgers JS, 2003, BRIT J GEN PRACT, V53, P15; BUSHMAN B., 1994, HDB RES SYNTHESIS; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Chaix-Couturier C, 2000, INT J QUAL HEALTH C, V12, P133, DOI 10.1093/intqhc/12.2.133; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Cluzeau F, 2003, QUAL SAF HEALTH CARE, V12, P18; *COCHR COLL, 2002, COCHR CONTR TRIAL RE; COHEN PA, 1992, EVAL HEALTH PROF, V15, P259, DOI 10.1177/016327879201500301; Cookson B, 1999, BRIT MED J, V318, P686; *CTR REV DISS, 1999, EFF HLTH CAR, P5; CURRELL R, 2000, COCHRANE LIB; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Davis DA, 1997, CAN MED ASSOC J, V157, P408; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DEMAESENEER JM, IN PRESS LANCET; Ferlie EB, 2001, MILBANK Q, V79, P281, DOI 10.1111/1468-0009.00206; Foy R, 2002, J CLIN EPIDEMIOL, V55, P717, DOI 10.1016/S0895-4356(02)00403-1; FREEMANTLE N, 1998, COCHRANE LIB; Garside P, 1998, QUAL HEALTH CARE, V7, pS8; Gill PS, 1999, PHARM WORLD SCI, V21, P158, DOI 10.1023/A:1008719129305; GIUFFRIDA A, 1999, COCHRANE LIB; Gosden T, 1997, HEALTH POLICY, V40, P103, DOI 10.1016/S0168-8510(96)00888-3; GOSDEN T, 2000, COCHRANE LIB; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; GRILLI R, 2000, COCHRANE LIB; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; Grimshaw Jeremy M, 2002, J Contin Educ Health Prof, V22, P237, DOI 10.1002/chp.1340220408; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Grol R, 2001, MED CARE, V39, pII46; Grol R, 2001, JAMA-J AM MED ASSOC, V286, P2578, DOI 10.1001/jama.286.20.2578; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Grol R., 2001, IMPLEMENTATION EFFEC; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; Guyatt GH, 2000, BRIT MED J, V320, P954, DOI 10.1136/bmj.320.7240.954; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS14; Haines A, 2001, EVIDENCE BASED PRACT, V2nd; HARVEY EL, 1999, COCHRANE LIB; Hearn J, 1998, PALLIATIVE MED, V12, P317, DOI 10.1191/026921698676226729; Hugonnet S, 2000, CLIN MICROBIOL INFEC, V6, P350; Hulscher MEJL, 1999, AM J PUBLIC HEALTH, V89, P737, DOI 10.2105/AJPH.89.5.737; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; JARVIS WR, 1994, LANCET, V344, P1311, DOI 10.1016/S0140-6736(94)90687-4; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kidd M, 2001, EVIDENCE BASED PRACT; Lancaster T, 1998, COCHRANE LIB; LANIER DC, IN PRESS LANCET; Larson EL, 1997, AM J INFECT CONTROL, V25, P3, DOI 10.1016/S0196-6553(97)90046-8; LOMAS J, 1988, American Journal of Preventive Medicine, V4, P77; MANDELBLATT J, 1995, J FAM PRACTICE, V40, P162; MUGFORD M, 1998, BMJ-BRIT MED J, V303, P398; Naikoba S, 2001, J HOSP INFECT, V47, P173, DOI 10.1053/jhin.2000.0882; O'Boyle CA, 2001, AM J INFECT CONTROL, V29, P352, DOI 10.1067/mic.2001.18405; OXMAN A, 2001, EVIDENCE BASED PRACT; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PIPPALLA RS, 1995, J CLIN PHARM THER, V20, P189, DOI 10.1111/j.1365-2710.1995.tb00648.x; Pittet D, 2000, INFECT CONT HOSP EP, V21, P381, DOI 10.1086/501777; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; PRATT RJ, 2001, J HOSP INFECT, V47, P82; RUBENSTEIN L Z, 1991, Journal of the American Geriatrics Society, V39, p8S; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Shaneyfelt TM, 2001, JAMA-J AM MED ASSOC, V286, P2600, DOI 10.1001/jama.286.20.2600; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; Shortell SM, 1998, MILBANK Q, V76, P593, DOI 10.1111/1468-0009.00107; Silagy C, 1994, Qual Health Care, V3, P193, DOI 10.1136/qshc.3.4.193; Snell JL, 1996, PREV MED, V25, P702, DOI 10.1006/pmed.1996.0109; Solberg L I, 2000, Jt Comm J Qual Improv, V26, P171; Solomon DH, 1998, JAMA-J AM MED ASSOC, V280, P2020, DOI 10.1001/jama.280.23.2020; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; Stone SP, 2001, J ROY SOC MED, V94, P278, DOI 10.1177/014107680109400606; Sulch D, 2000, AGE AGEING, V29, P349, DOI 10.1093/ageing/29.4.349; SULLIVAN F, 1995, BMJ-BRIT MED J, V311, P848, DOI 10.1136/bmj.311.7009.848; Teare L, 2001, BRIT MED J, V323, P411, DOI 10.1136/bmj.323.7310.411; Thomas LH, 1998, QUAL HEALTH CARE, V7, P183, DOI 10.1136/qshc.7.4.183; THOMSON MA, 1997, COCHRANE LIB 1; THOMSON MA, 1997, COCHRANE LIB 2; van Weel C, 2003, Ned Tijdschr Geneeskd, V147, P229; VANDERWEIJDEN T, 2000, INTERVENTIONS AIMED; Waddell D L, 1991, J Contin Educ Nurs, V22, P113; Walton R, 1999, BRIT MED J, V318, P984, DOI 10.1136/bmj.318.7189.984; Wensing M, 1998, BRIT J GEN PRACT, V48, P991; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; WORRALL G, 1997, CMAJ, V155, P1705; ZWARENSTEIN M, 1997, COCHRANE LIB	101	2888	2910	3	253	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1225	1230		10.1016/S0140-6736(03)14546-1	http://dx.doi.org/10.1016/S0140-6736(03)14546-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CW	14568747				2023-01-03	WOS:000185924100026
J	Mair, W; Goymer, P; Pletcher, SD; Partridge, L				Mair, W; Goymer, P; Pletcher, SD; Partridge, L			Demography of dietary restriction and death in Drosophila	SCIENCE			English	Article							AGE-SPECIFIC MORTALITY; LIFE-SPAN; CALORIE RESTRICTION; OXIDATIVE STRESS; MELANOGASTER; LONGEVITY; MICE; RECEPTOR	Dietary restriction (DR) increases life-span in organisms from yeast to mammals, presumably by slowing the accumulation of aging-related damage. Here we show that in Drosophila, DR extends life-span entirely by reducing the short-term risk of death. Two days after the application of DR at any age for the first time, previously fully fed flies are no more likely to die than flies of the same age that have been subjected to long-term DR. DR of mammals may also reduce short-term risk of death, and hence DR instigated at any age could generate a full reversal of mortality.	UCL, Dept Biol, London WC1E 6BT, England; Univ London Imperial Coll Sci Technol & Med, Ctr Populat Biol, NERC, Ascot SL5 7PY, Berks, England	University of London; University College London; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Partridge, L (corresponding author), UCL, Dept Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.	l.partridge@ucl.ac.uk	Partridge, Linda/E-7342-2015; Partridge, Linda/A-5501-2010	Partridge, Linda/0000-0001-9615-0094; Goymer, Patrick/0000-0002-2789-9373; Mair, William/0000-0002-0661-1342	Biotechnology and Biological Sciences Research Council [SF19106] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Carey J. R., 2003, LONGEVITY BIOL DEMOG, DOI [10.1515/9780691224084, DOI 10.1515/9780691224084]; Carey JR, 1998, SCIENCE, V281, P996, DOI 10.1126/science.281.5379.996; Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; Good TP, 2001, J INSECT PHYSIOL, V47, P1467, DOI 10.1016/S0022-1910(01)00138-X; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Kealy RD, 2002, J AM VET MED ASSOC, V220, P1315, DOI 10.2460/javma.2002.220.1315; Kenyon C, 1996, CELL, V84, P501, DOI 10.1016/S0092-8674(00)81024-7; Lee E, 2013, STAT METHODS SURVIVA; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; MIQUEL J, 1976, MECH AGEING DEV, V5, P347, DOI 10.1016/0047-6374(76)90034-8; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; PARTRIDGE L, 1985, J INSECT PHYSIOL, V31, P393, DOI 10.1016/0022-1910(85)90084-8; Pearl R., 1928, RATE LIVING; Pletcher SD, 2000, J GERONTOL A-BIOL, V55, pB381, DOI 10.1093/gerona/55.8.B381; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; Richardson A., 1992, POTENTIAL NUTR MODUL, P177; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854	21	374	389	4	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1731	1733		10.1126/science.1086016	http://dx.doi.org/10.1126/science.1086016			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500985				2023-01-03	WOS:000185387700047
J	Markowitz, AJ; Rabow, MW				Markowitz, AJ; Rabow, MW			Practical considerations in dialysis withdrawal - "To have that option is a blessing"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Cohen LM, 2003, JAMA-J AM MED ASSOC, V289, P2113, DOI 10.1001/jama.289.16.2113	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2003	290	6					815	815		10.1001/jama.290.6.815	http://dx.doi.org/10.1001/jama.290.6.815			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709VU	12915435				2023-01-03	WOS:000184647700033
J	Marquet, RL; Bartelds, A; Visser, GJ; Spreeuwenberg, P; Peters, L				Marquet, RL; Bartelds, A; Visser, GJ; Spreeuwenberg, P; Peters, L			Twenty five years of requests for euthanasia and physician assisted suicide in Dutch general practice: trend analysis	BRITISH MEDICAL JOURNAL			English	Article									Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands	Netherlands Institute for Health Services Research	Marquet, RL (corresponding author), Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands.							de Wit MAS, 2001, EMERG INFECT DIS, V7, P82, DOI 10.3201/eid0701.010113; Hughes J, 2000, J Appl Philos, V17, P213, DOI 10.1111/1468-5930.00155; Lavery JV, 2001, LANCET, V358, P362, DOI 10.1016/S0140-6736(01)05555-6; ONWUTEAKAPHILIP.BD, 1990, LANCET; Thynne Kelisiana, 2002, J Law Med, V10, P232	5	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 26	2003	327	7408					201	202		10.1136/bmj.327.7408.201	http://dx.doi.org/10.1136/bmj.327.7408.201			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	706DL	12881262	Bronze, Green Published			2023-01-03	WOS:000184437300018
J	Saunders, Y; Ross, JR; Riley, J				Saunders, Y; Ross, JR; Riley, J			Planning for a good death: responding to unexpected events	BRITISH MEDICAL JOURNAL			English	Article							CRITICALLY ILL; PHYSICIANS; CARE; FUTILITY; PATIENT; CANCER		Royal Marsden Hosp, Dept Palliat Med, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Saunders, Y (corresponding author), Royal Marsden Hosp, Dept Palliat Med, London SW3 6JJ, England.							BARRY PW, 1994, ARCH DIS CHILD, V71, P8, DOI 10.1136/adc.71.1.8; BRODY H, 1994, J AM GERIATR SOC, V42, P875, DOI 10.1111/j.1532-5415.1994.tb06562.x; Choudhry NK, 2003, ANN INTERN MED, V138, P65, DOI 10.7326/0003-4819-138-1-200301070-00014; FABERLANGENDOEN K, 1991, ARCH INTERN MED, V151, P235, DOI 10.1001/archinte.151.2.235; Finlay I, 1996, BRIT J HOSP MED, V56, P264; Flabouris A, 1999, ANAESTH INTENS CARE, V27, P385, DOI 10.1177/0310057X9902700410; HAVILL JH, 1995, NEW ZEAL MED J, V108, P378; Iserson KV, 1996, ANN EMERG MED, V28, P51, DOI 10.1016/S0196-0644(96)70139-7; JASTREMSKI MS, 1993, CRIT CARE MED, V21, P931; SCHNEIDERMAN LJ, 1994, J AM GERIATR SOC, V42, P883, DOI 10.1111/j.1532-5415.1994.tb06564.x; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Smith R, 2000, BMJ-BRIT MED J, V320, P129, DOI 10.1136/bmj.320.7228.129; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; VEATCH RM, 1994, J AM GERIATR SOC, V42, P871, DOI 10.1111/j.1532-5415.1994.tb06561.x	14	20	21	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 26	2003	327	7408					204	206		10.1136/bmj.327.7408.204	http://dx.doi.org/10.1136/bmj.327.7408.204			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	706DL	12881264	Green Published			2023-01-03	WOS:000184437300020
J	Stadler, WM; Lerner, SP				Stadler, WM; Lerner, SP			Perloperative chemotherapy in locally advanced bladder cancer	LANCET			English	Editorial Material							PHASE-III; METHOTREXATE; VINBLASTINE; DOXORUBICIN; CARCINOMA; CISPLATIN; P53		Univ Chicago, Dept Med, Sect Hematol Oncol & Urol, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Sect Hematol Oncol & Urol, Chicago, IL 60637 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA	University of Chicago; University of Chicago; Baylor College of Medicine	Stadler, WM (corresponding author), Univ Chicago, Dept Med, Sect Hematol Oncol & Urol, 5841 S Maryland Ave, Chicago, IL 60637 USA.							Bajorin DF, 1999, J CLIN ONCOL, V17, P3173, DOI 10.1200/JCO.1999.17.10.3173; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Cote RJ, 1999, CANCER J, V5, P2; DENNEY E, 2002, LUNG CANC TRIAL RESU; Lerner SP, 2000, COMPREHENSIVE TXB GE, P425; Saxman SB, 1997, J CLIN ONCOL, V15, P2564, DOI 10.1200/JCO.1997.15.7.2564; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068	8	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1922	1923		10.1016/S0140-6736(03)13598-2	http://dx.doi.org/10.1016/S0140-6736(03)13598-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801730				2023-01-03	WOS:000183359700002
J	Dazard, JE; Gal, H; Amariglio, N; Rechavi, G; Domany, E; Givol, D				Dazard, JE; Gal, H; Amariglio, N; Rechavi, G; Domany, E; Givol, D			Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer	ONCOGENE			English	Article						microarray; clustering; epidermis; apoptosis; chemokines	B-INDUCED APOPTOSIS; HISTONE H2AX; P53; EXPRESSION; INDUCTION; REPAIR; P63; SUPPRESSION; ONSET; CARCINOGENESIS	To gain insight into the transformation of epidermal cells into squamous carcinoma cells (SCC), we compared the response to ultraviolet B radiation (UVB) of normal human epidermal keratinocytes (NHEK) versus their transformed counterpart, SCC, using biological and molecular profiling. DNA microarray analyses (Affymetrix(R), similar to12 000 genes) indicated that the major group of upregulated genes in keratinocytes fall into three categories: (i) antiapoptotic and cell survival factors, including chemokines of the CXC/CC subfamilies (e.g. IL-8, GRO-1, -2, -3, SCYA20), growth factors (e.g. HB-EGF, CTGF, INSL-4), and proinflammatory mediators (e.g. COX-2, S100A9), (ii) DNA repair-related genes (e.g. GADD45, ERCC, BTG-1, Histones), and (iii) ECM proteases (MMP-1, -10). The major downregulated genes are DeltaNp63 and PUMILIO, two potential markers for the maintenance of keratinocyte stem cells. NHEK were found to be more resistant than SCC to UVB-induced apoptosis and this resistance was mainly because of the protection from cell death by secreted survival factors, since it can be transferred from NHEK to SCC cultures by the conditioned medium. Whereas the response of keratinocytes to UVB involved regulation of key checkpoint genes (p53, MDM2, p21(Cip1), DeltaNp63), as well as antiapoptotic and DNA repair-related genes - no or little regulation of these genes was observed in SCC. The effect of UVB on NHEK and SCC resulted in upregulation of 251 and 127 genes, respectively, and downregulation of 322 genes in NHEK and 117 genes in SCC. To further analyse these changes, we used a novel unsupervised coupled two-way clustering method that allowed the identification of groups of genes that clearly partitioned keratinocytes from SCC, including a group of genes whose constitutive expression levels were similar before UVB. This allowed the identification of discriminating genes not otherwise revealed by simple static comparison in the absence of UVB irradiation. The implication of the changes in gene profile in keratinocytes for epithelial cancer is discussed.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		DOMANY, EYTAN/K-1560-2012					Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; Brinkmann U, 1996, BIOCHEMISTRY-US, V35, P6891, DOI 10.1021/bi952829+; Brune Bernhard, 2002, J Environ Pathol Toxicol Oncol, V21, P103; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chazal M, 2002, ONCOGENE, V21, P2652, DOI 10.1038/sj.onc.1205349; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; Decraene D, 2002, J BIOL CHEM, V277, P32587, DOI 10.1074/jbc.M111106200; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Garssen J, 2001, CRIT REV IMMUNOL, V21, P359; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; Gloster HM, 1996, DERMATOL SURG, V22, P217, DOI 10.1111/j.1524-4725.1996.tb00312.x; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greinert R, 2000, PHOTOCHEM PHOTOBIOL, V72, P701, DOI 10.1562/0031-8655(2000)072<0701:TDDOCD>2.0.CO;2; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hanson KM, 2002, PHOTOCHEM PHOTOBIOL, V76, P57, DOI 10.1562/0031-8655(2002)076<0057:OAQOUI>2.0.CO;2; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Liefer KM, 2000, CANCER RES, V60, P4016; Lotem J, 1999, P NATL ACAD SCI USA, V96, P12016, DOI 10.1073/pnas.96.21.12016; Loukinova E, 2001, INT J CANCER, V94, P637, DOI 10.1002/ijc.1514; Martini EMD, 2002, GENETICS, V160, P1375; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Notterman DA, 2001, CANCER RES, V61, P3124; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; Selgrade MK, 2001, PHOTOCHEM PHOTOBIOL, V74, P88, DOI 10.1562/0031-8655(2001)074<0088:DRFUII>2.0.CO;2; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Singh RK, 1999, MELANOMA RES, V9, P383, DOI 10.1097/00008390-199908000-00007; Soehnge Holly, 1997, Frontiers in Bioscience, V2, pD538; Soufir N, 1999, ONCOGENE, V18, P5477, DOI 10.1038/sj.onc.1202915; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Xing PX, 2001, FRONT BIOSCI-LANDMRK, V6, pD1284, DOI 10.2741/Xing; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhao RB, 2000, GENE DEV, V14, P981; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	56	75	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2993	3006		10.1038/sj.onc.1206537	http://dx.doi.org/10.1038/sj.onc.1206537			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771951				2023-01-03	WOS:000182824800015
J	Ray, WA; Daugherty, JR; Meador, KG				Ray, WA; Daugherty, JR; Meador, KG			Effect of a mental health "carve-out'' program on the continuity of antipsychotic therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MANAGED CARE; SCHIZOPHRENIA; MEDICAID; SERVICES; PHARMACOEPIDEMIOLOGY; CONTRACTS; DATABASES; OUTCOMES; POLICY; AGENTS	BACKGROUND: On July 1, 1996, as a cost-containment strategy, Tennessee's expanded Medicaid program, TennCare, rapidly shifted the provision of mental health services to a fully capitated, specialty ``carve-out'' program, TennCare Partners. We studied the effect of this transition on the continuity of antipsychotic therapy among patients with severe mental illness who had previously adhered to treatment. METHODS: Study patients were 21 to 64 years of age, were enrolled throughout the study period, and had adhered to antipsychotic therapy during a 6-month base-line period that preceded the 12 months of study follow-up. The study population included 4507 patients whose follow-up began on the day the change was implemented (the post-transition cohort) and 3644 patients whose follow-up began one year earlier (the pretransition cohort). We compared the two cohorts in terms of the loss of continuity of antipsychotic therapy (missed treatment for more than 60 days during follow-up) and the mean number of days of antipsychotic therapy during follow-up. RESULTS: As compared with the pretransition cohort, the post-transition cohort had increased odds of loss of continuity (a multivariate odds ratio of 1.18 [95 percent confidence interval, 1.07 to 1.30], P=0.001) and a shorter mean duration of antipsychotic therapy (a mean reduction of 4.2 days [95 percent confidence interval, 1.7 to 6.7], P=0.001) during follow-up. This difference was most pronounced among high-risk patients (those requiring the administration of extended-release [depot] injections of antipsychotic medications or who had been hospitalized for psychosis) at base line, for whom continuity was most important (odds ratio for loss of continuity, 1.79 [95 percent confidence interval, 1.45 to 2.22]; P<0.001; mean reduction in the number of days of antipsychotic therapy, 14.4 days [95 percent confidence interval, 9.4 to 19.4]; P<0.001). These patients had decreased use of antipsychotic drugs immediately after the transition; the lower level persisted throughout the 12 months of follow-up. CONCLUSIONS: These findings underscore the need to ensure that shifts to widely used carve-out programs, which are designed primarily to contain costs, do not adversely affect clinical outcomes.	Nashville Vet Affairs Med Ctr, Dept Prevent Med, Div Pharmacoepidemiol, Nashville, TN USA; Nashville Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; Durham Vet Affairs Med Ctr, Durham, NC USA	Geriatric Research Education & Clinical Center; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Ray, WA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Prevent Med, Med Ctr N,A-1124, Nashville, TN 37232 USA.	cindy.naron@mcmail.vanderbilt.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060075] Funding Source: NIH RePORTER; AHRQ HHS [HS1-0384] Funding Source: Medline; NIMH NIH HHS [MH60075] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AM MED ASS, 1995, DRUG EV ANN 1995; Bloom Joan R., 1998, J Ment Health Policy Econ, V1, P3, DOI 10.1002/(SICI)1099-176X(199803)1:1<3::AID-MHP4>3.0.CO;2-Q; BRUNELLO N, 1995, NEUROPSYCHOPHARMACOL, V13, P177, DOI 10.1038/sj.npp.1380287; Catalano R, 2000, AM J PUBLIC HEALTH, V90, P1861, DOI 10.2105/AJPH.90.12.1861; Chang CF, 1998, JAMA-J AM MED ASSOC, V279, P864, DOI 10.1001/jama.279.11.864; Csernansky JG, 2002, NEW ENGL J MED, V346, P16, DOI 10.1056/NEJMoa002028; Csernansky JG, 2002, NEW ENGL J MED, V346, P1424; DAVIS JM, 1984, TREATMENT CARE SCHIZ; Dickey B, 1996, ARCH GEN PSYCHIAT, V53, P945; Donohue JM, 2000, HARVARD REV PSYCHIAT, V8, P231, DOI 10.1093/hrp/8.5.231; ESSOCK SM, 1995, HEALTH AFFAIR, V14, P34, DOI 10.1377/hlthaff.14.3.34; FRANK RG, 1995, HEALTH AFFAIR, V14, P50, DOI 10.1377/hlthaff.14.3.50; Garnick DW, 2001, PSYCHIAT SERV, V52, P1502, DOI 10.1176/appi.ps.52.11.1502; Hodgkin D, 2000, J BEHAV HEALTH SER R, V27, P178, DOI 10.1007/BF02287312; HUTTUNEN M, 1995, J CLIN PSYCHOPHARM, V15, pS4, DOI 10.1097/00004714-199502001-00002; Iglehart JK, 1996, NEW ENGL J MED, V334, P131, DOI 10.1056/NEJM199601113340221; JOHNSON DAW, 1988, SCHIZOPHRENIA MAJOR, P158; JOHNSON RE, 1991, J AM GERIATR SOC, V39, P1079, DOI 10.1111/j.1532-5415.1991.tb02872.x; KANE JM, 1993, SCHIZOPHRENIA BULL, V19, P287, DOI 10.1093/schbul/19.2.287; Kane JM, 1998, SCHIZOPHRENIA BULL, V24, P20, DOI 10.1093/oxfordjournals.schbul.a033310; Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P1; Lehman AF, 1999, HEALTH AFFAIR, V18, P52, DOI 10.1377/hlthaff.18.5.52; LEISTER KA, 1981, MED CARE, V19, P658, DOI 10.1097/00005650-198106000-00008; Manning WG, 1999, J BEHAV HEALTH SER R, V26, P442, DOI 10.1007/BF02287304; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; Owens DGC, 1996, DRUGS, V51, P895; Ray WA, 1997, ANN INTERN MED, V127, P712, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00055; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; Stoner T, 1997, HEALTH CARE FINANC R, V18, P73; STROM BL, 1990, EPIDEMIOL REV, V12, P87, DOI 10.1093/oxfordjournals.epirev.a036064; WEST SL, 1995, AM J EPIDEMIOL, V142, P1103, DOI 10.1093/oxfordjournals.aje.a117563	32	42	42	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1885	1894		10.1056/NEJMsa020584	http://dx.doi.org/10.1056/NEJMsa020584			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675FY	12736282				2023-01-03	WOS:000182684100008
J	Kovacs, MJ; Rodger, M; Anderson, DR; Morrow, B; Kells, G; Kovacs, J; Boyle, E; Wells, PS				Kovacs, MJ; Rodger, M; Anderson, DR; Morrow, B; Kells, G; Kovacs, J; Boyle, E; Wells, PS			Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatmeny of acute venous thromboembolism - A randomized, double-blind, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; ORAL ANTICOAGULATION; THERAPY; HOME	Background: The optimal means of achieving therapeutic oral anticoagulation in the outpatient setting has not been determined. Objective: To compare a 10-mg dosing nomogram with a 5-mg nomogram that has been suggested to be sufficient for warfarin initiation. Design: Randomized, controlled clinical trial. Setting: Outpatient venous thromboembolism services of four tertiary care hospitals. Patients: 201 of 210 consecutive patients with objectively confirmed diagnoses of acute venous thromboembolism. Intervention: All patients were treated with subcutaneous low-molecular-weight heparin for a minimum of 5 days until a therapeutic international normalized ratio (INR) was achieved. Patients were randomly assigned to initially receive a 10-mg or 5-mg dose of warfarin. Measurements: The primary end point was time in days to therapeutic INR. Secondary end points were the proportion of patients who had achieved a therapeutic INR by day 5, the total number of INR assessments, the number of INR measurements greater than 5.0, incidence of recurrent venous thromboembolism and major bleeding, and survival. Results: 210 consecutive patients met the inclusion criteria. Of these, 9 were excluded and 201 were randomly assigned to study groups (104 to the 10-mg group and 97 to the 5-mg group). Demographic characteristics of both groups were similar. Patients in the 10-mg group achieved therapeutic INR 1.4 days earlier than patients in the 5-mg group (P < 0.001). Eighty-three percent of patients in the 10-mg group achieved a therapeutic INR by day 5 versus 46% in the 5-mg group (P < 0.001). Fewer INR assessments were performed in the 10-mg group than in the 5-mg group (8.1 vs. 9.1; P = 0.04). There were no significant differences between the two groups in recurrent events, major bleeding, survival, and number of INR measurements greater than 5.0. Conclusion: The 10-mg warfarin initiation nomogram is superior to the 5-mg nomogram because it allows more rapid achievement of a therapeutic INR.	London Hlth Sci Ctr, Dept Hematol, London, ON N6A 4G5, Canada; Ottawa Hlth Res Inst, Ottawa, ON, Canada; Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada	London Health Sciences Centre; University of Ottawa; Ottawa Hospital Research Institute; Queen Elizabeth II Health Sciences Centre	Kovacs, MJ (corresponding author), London Hlth Sci Ctr, Dept Hematol, 800 Commissioners Rd E, London, ON N6A 4G5, Canada.	michael.kovacs@lhsc.on.ca	Boyle, Eleanor/G-4567-2016; Kovacs, Michael/G-3315-2011	Boyle, Eleanor/0000-0002-9012-9128; Rodger, Marc/0000-0001-8166-3487				Crowther MA, 1997, ANN INTERN MED, V127, P333, DOI 10.7326/0003-4819-127-4-199708150-00019; Crowther MA, 1999, ARCH INTERN MED, V159, P46, DOI 10.1001/archinte.159.1.46; Harrison L, 1997, ANN INTERN MED, V126, P133, DOI 10.7326/0003-4819-126-2-199701150-00006; Hirsh J, 2002, BLOOD, V99, P3102, DOI 10.1182/blood.V99.9.3102; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Kovacs MJ, 1998, HAEMOSTASIS, V28, P62; Kovacs MJ, 2002, PATHOPHYSIOL HAEMO T, V32, P131, DOI 10.1159/000065215; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; tenCate JW, 1997, NEW ENGL J MED, V337, P657; WEINMANN EE, 1994, NEW ENGL J MED, V331, P1630, DOI 10.1056/NEJM199412153312407; Wells PS, 1998, ARCH INTERN MED, V158, P1809, DOI 10.1001/archinte.158.16.1809	11	158	161	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					714	719		10.7326/0003-4819-138-9-200305060-00007	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729425				2023-01-03	WOS:000182661400003
J	Kerner, M; Hohenberg, H; Ertl, S; Reckermann, M; Spitzy, A				Kerner, M; Hohenberg, H; Ertl, S; Reckermann, M; Spitzy, A			Self-organization of dissolved organic matter to micelle-like microparticles in river water	NATURE			English	Article							PARTICLES; COLLOIDS; CARBON; ACID	In aquatic systems, the concept of the 'microbial loop' is invoked to describe the conversion of dissolved organic matter to particulate organic matter by bacteria(1). This process mediates the transfer of energy and matter from dissolved organic matter to higher trophic levels, and therefore controls (together with primary production) the productivity of aquatic systems. Here we report experiments on laboratory incubations of sterile filtered river water in which we find that up to 25% of the dissolved organic carbon (DOC) aggregates abiotically to particles of diameter 0.4-0.8 micrometres, at rates similar to bacterial growth. Diffusion drives aggregation of low- to high-molecular-mass DOC and further to larger micelle-like microparticles. The chemical composition of these microparticles suggests their potential use as food by planktonic bacterivores. This pathway is apparent from differences in the stable carbon isotope compositions of picoplankton and the microparticles. A large fraction of dissolved organic matter might therefore be channelled through microparticles directly to higher trophic levels-bypassing the microbial loop-suggesting that current concepts of carbon conversion in aquatic systems require revision.	Univ Hamburg, Inst Hydrobiol & Fishery Sci, D-22765 Hamburg, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Hamburg, Inst Biogeochem & Marine Chem, D-20146 Hamburg, Germany; Univ Kiel, Res & Technol Ctr Westcoast, D-25761 Busum, Hafentorn, Germany	University of Hamburg; Heinrich Pette Institute; University of Hamburg; University of Hamburg; University of Kiel	Kerner, M (corresponding author), Univ Hamburg, Inst Hydrobiol & Fishery Sci, Zeiseweg 9, D-22765 Hamburg, Germany.							AZAM F, 1983, MAR ECOL PROG SER, V10, P257, DOI 10.3354/meps010257; Bianchi A, 1996, APPL ENVIRON MICROB, V62, P174, DOI 10.1128/AEM.62.1.174-177.1996; Chin WC, 1998, NATURE, V391, P568, DOI 10.1038/35345; Ducklow Hugh W., 1993, P261; Fukuda R, 1998, APPL ENVIRON MICROB, V64, P3352; GREENSPAN P, 1985, J LIPID RES, V26, P781; HARRIS JR, 1997, NEGATIVE STAINING CR, P12; Hertkorn N, 2002, J ENVIRON QUAL, V31, P375, DOI 10.2134/jeq2002.0375; HOHENBERG H, 1994, J MICROSC-OXFORD, V175, P34, DOI 10.1111/j.1365-2818.1994.tb04785.x; HUBER SA, 1991, ANAL CHEM, V63, P2122, DOI 10.1021/ac00019a011; Hullar MAJ, 1996, APPL ENVIRON MICROB, V62, P2489, DOI 10.1128/AEM.62.7.2489-2493.1996; KEPKAY PE, 1994, MAR ECOL PROG SER, V109, P293, DOI 10.3354/meps109293; Kerner M, 2001, MICROBIAL ECOL, V41, P69; LEPPARD GG, 1995, SCI TOTAL ENVIRON, V165, P103, DOI 10.1016/0048-9697(95)04546-D; Nagata T, 1997, ADV MICROB ECOL, V15, P81; Nanny MA, 2001, ENVIRON SCI TECHNOL, V35, P379, DOI 10.1021/es0012927; Niedergesass R., 1995, WASSERWIRTSCHAFT WAS, V7, P22; Passow U, 1995, LIMNOL OCEANOGR, V40, P1326, DOI 10.4319/lo.1995.40.7.1326; POLLARD TD, 2002, CELL BIOL, P277; Posch T, 1996, AQUAT MICROB ECOL, V10, P45, DOI 10.3354/ame010045; RAIMBAULT P, 1991, LIMNOL OCEANOGR, V36, P405, DOI 10.4319/lo.1991.36.2.0405; RILEY GA, 1963, LIMNOL OCEANOGR, V8, P372, DOI 10.4319/lo.1963.8.4.0372; Santschi PH, 1998, LIMNOL OCEANOGR, V43, P896, DOI 10.4319/lo.1998.43.5.0896; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Volke F, 1997, CHEM PHYS LIPIDS, V85, P115, DOI 10.1016/S0009-3084(96)02649-7	25	118	127	5	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 13	2003	422	6928					150	154		10.1038/nature01469	http://dx.doi.org/10.1038/nature01469			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654HG	12634782				2023-01-03	WOS:000181488900041
J	Reinehr, R; Schliess, F; Haussinger, D				Reinehr, R; Schliess, F; Haussinger, D			Hyperosmolarity and CD95L trigger CD95/EGFR association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation	FASEB JOURNAL			English	Article						apoptosis; osmosignaling; oxidative stress; c-Jun-N-terminal kinase; protein kinase C	CELL-VOLUME; GROWTH-FACTOR; RECEPTOR; INHIBITION; ACTIVATION; FAS; SHRINKAGE; PROLIFERATION; INDUCTION; MECHANISM	The mechanisms underlying CD95 ligand (CD95L)- and hyperosmolarity-induced activation of the CD95 system [Reinehr, R., Graf, D., Fischer, R., Schliess, F., and Haussinger, D. (2002) Hepatology 36, 602-614] as initial steps of apoptosis were studied. Hyperosmotic exposure (405 mosmol/l) of rat hepatocytes induced within 1 min oxidative stress and antioxidant-sensitive activation of the epidermal growth factor receptor (EGFR) and c-Jun-N-terminal-kinase (JNK). After 30 min of hyperosmotic exposure EGFR associated with CD95 and CD95 became tyrosine phosphorylated. Inhibition of JNK or protein kinase C (PKC) had no effect on EGFR phosphorylation but abolished CD95/EGFR association, CD95-tyrosine phosphorylation, membrane targeting, and Fas-associated death domain/caspase 8 recruitment to CD95 [death-inducing signaling complex (DISC) formation]. Inhibition of EGFR tyrosine kinase activity prevented CD95 tyrosine phosphorylation and DISC formation but not hyperosmolarity-induced EGFR phosphorylation and EGFR association with CD95. Tyrosine-phosphorylated CD95 was enriched in the plasma membrane. All maneuvers preventing CD95 tyrosine phosphorylation inhibited CD95 membrane trafficking and DISC formation. Stimulation of EGFR by EGF induced EGFR phosphorylation but no association with CD95 or CD95 phosphorylation. Addition of CD95L also induced EGFR and JNK activation, EGFR/CD95 association, CD95 tyrosine phosphorylation, DISC formation, and CD95 membrane targeting with an inhibitor sensitivity profile similar to that of hyperosmotic CD95 activation, except that inhibition of PKC was ineffective. The data suggest that moderate hyperosmolarity or CD95L trigger oxidative stress and EGFR activation followed by a JNK-dependent EGFR/CD95association and CD95 tyrosine phosphorylation, probably through EGFR tyrosine kinase activity. This provides a signal for CD95 membrane trafficking and DISC formation.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-4000 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Klinikum Dusseldorf, Klin Gastroenterol Hepatol & Infektiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de	Reinehr, Roland/G-6118-2016					Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BORNER CD, 1996, AM J PHYSIOL-CELL PH, V40, pC950; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; GORG B, 2002, IN PRESS HEPATOLOGY; HALLBRUCKER C, 1993, EUR J BIOCHEM, V211, P449, DOI 10.1111/j.1432-1033.1993.tb17570.x; Haussinger D, 1996, BIOCHEM J, V313, P697; Haussinger D, 1999, BIOCHEM BIOPH RES CO, V255, P551, DOI 10.1006/bbrc.1998.9946; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KOH YH, 2001, FASEB J, DOI DOI 10.1096/FJ.00-572FJE; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Kurz AK, 1998, HEPATOLOGY, V28, P774, DOI 10.1002/hep.510280326; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 1998, PFLUG ARCH EUR J PHY, V436, P377, DOI 10.1007/s004240050646; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Lang F, 2000, PFLUG ARCH EUR J PHY, V440, P902, DOI 10.1007/s004240000358; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meves A, 2002, ARCH DERMATOL RES, V294, P243, DOI 10.1007/s00403-002-0315-1; Nobel CSI, 2000, APOPTOSIS, V5, P153, DOI 10.1023/A:1009684713784; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; Reinehr R, 2002, HEPATOLOGY, V36, P602, DOI 10.1053/jhep.2002.35447; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SAHA N, 1992, EUR J BIOCHEM, V209, P437, DOI 10.1111/j.1432-1033.1992.tb17307.x; SAHA N, 1993, BIOCHEM J, V296, P701, DOI 10.1042/bj2960701; Schlehr F, 1999, ATHLET THER TODAY, V4, P13, DOI 10.1123/att.4.4.13; Schliess F, 2002, BIOL CHEM, V383, P577, DOI 10.1515/BC.2002.059; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Wettstein M, 1997, HEPATOLOGY, V26, P1560; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3	37	97	98	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					731	+		10.1096/fj.02-0915fje	http://dx.doi.org/10.1096/fj.02-0915fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586732				2023-01-03	WOS:000181456900035
J	Golab, J; Nowis, D; Skrzycki, M; Czeczot, H; Baranczyk-Kuzma, A; Wilczynski, GM; Makowski, M; Mroz, P; Kozar, K; Kaminski, R; Jalili, A; Kopec, M; Grzela, T; Jakobisiak, M				Golab, J; Nowis, D; Skrzycki, M; Czeczot, H; Baranczyk-Kuzma, A; Wilczynski, GM; Makowski, M; Mroz, P; Kozar, K; Kaminski, R; Jalili, A; Kopec, M; Grzela, T; Jakobisiak, M			Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol - A superoxide dismutase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN METABOLITE; AMINOLEVULINIC ACID; HYDROGEN-PEROXIDE; BREAST-CANCER; FREE-RADICALS; GAMMA-RAYS; IN-VITRO; CARCINOMA; RADIATION; APOPTOSIS	Photodynamic therapy (PDT), a promising therapeutic modality for the management of solid tumors, is a two-phase treatment consisting of a photosensitizer and visible light. Increasing evidence indicates that tumor cells in regions exposed to sublethal doses of PDT can respond by rescue responses that lead to insufficient cell death. We decided to examine the role of superoxide dismutases (SODs) in the effectiveness of PDT and to investigate whether 2-methoxyestradiol (2-McOE(2)), an inhibitor of SODs, is capable of potentiating the antitumor effects of this treatment regimen. In the initial experiment we observed that PDT induced the expression of MnSOD but not Cu,Zn-SOD in cancer cells. Pretreatment of cancer cells with a cell-permeable SOD mimetic, Mn(II)-tetrakis(4-benzoic acid)porphyrin chloride, and transient transfection with the MnSOD gene resulted in a decreased effectiveness of PDT. Inhibition of SOD activity in tumor cells by preincubation with 2-MeOE2 produced synergistic antitumor effects when combined with PDT in 3 murine and 5 human tumor cell lines. The combination treatment was also effective in vivo producing retardation of the tumor growth and prolongation of the survival of tumor-bearing mice. We conclude that inhibition of MnSOD activity by 2-MeOE2 is an effective treatment modality capable of potentiating the antitumor effectiveness of PDT.	Med Univ Warsaw, Dept Immunol, Ctr Biostruct Res, PL-02004 Warsaw, Poland; Med Univ Warsaw, Dept Biochem, Ctr Biostruct Res, PL-02004 Warsaw, Poland; Med Univ Warsaw, Dept Pathol, Ctr Biostruct Res, PL-02004 Warsaw, Poland; Med Univ Warsaw, Dept Histol & Embryol, Ctr Biostruct Res, PL-02004 Warsaw, Poland; Med Univ Warsaw, Dept Gen & Vasc Surg & Transplantat, PL-02004 Warsaw, Poland	Medical University of Warsaw; Medical University of Warsaw; Medical University of Warsaw; Medical University of Warsaw; Medical University of Warsaw	Golab, J (corresponding author), Med Univ Warsaw, Dept Immunol, Ctr Biostruct Res, Chalubinskiego 5, PL-02004 Warsaw, Poland.	jgolab@ib.amwaw.edu.pl	Golab, Jakub/K-6974-2013; Nowis, Dominika/P-1213-2017; Nowis, Dominika/P-6866-2019; Skrzycki, Michał/X-3743-2018; Mroz, Pawel/P-1258-2019; CZECZOT, HANNA/ABB-6415-2020	Golab, Jakub/0000-0002-2830-5100; Nowis, Dominika/0000-0003-2748-9523; Nowis, Dominika/0000-0003-2748-9523; Skrzycki, Michał/0000-0001-7087-1037; Kaminski, Rafal/0000-0003-4552-3596; Mroz, Pawel/0000-0003-3838-4743; Wilczynski, Grzegorz/0000-0001-6667-0291; CZECZOT, HANNA/0000-0001-8541-6619; Kozar-Kaminska, Katarzyna/0000-0002-2397-2975				ALLARDICE JT, 1994, SURG ONCOL, V3, P1, DOI 10.1016/0960-7404(94)90018-3; Allison R, 2001, CANCER, V91, P1, DOI 10.1002/1097-0142(20010101)91:1<1::AID-CNCR1>3.0.CO;2-P; Amorino GP, 2000, RADIAT RES, V153, P384, DOI 10.1667/0033-7587(2000)153[0384:EOREIV]2.0.CO;2; ATHAR M, 1988, BIOCHEM BIOPH RES CO, V151, P1054, DOI 10.1016/S0006-291X(88)80472-8; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Berr F, 2000, HEPATOLOGY, V31, P291, DOI 10.1002/hep.510310205; Bown SG, 2002, GUT, V50, P549, DOI 10.1136/gut.50.4.549; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; Das Hiranmoy, 2000, International Journal of Clinical Oncology, V5, P97, DOI 10.1007/s101470050098; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Gilaberte Y, 1997, PHOTODERMATOL PHOTO, V13, P43, DOI 10.1111/j.1600-0781.1997.tb00107.x; Golab J, 2000, BRIT J CANCER, V82, P1485; Golab J, 2002, CLIN CANCER RES, V8, P1265; Golab J, 2001, LEUKEMIA, V15, P613; Goodell T T, 2001, J Neurosci Nurs, V33, P296; Hadjur C, 1997, J PHOTOCH PHOTOBIO B, V38, P196, DOI 10.1016/S1011-1344(96)07440-4; HENDERSON BW, 1987, CANCER RES, V47, P3110; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kachadourian R, 2001, ARCH BIOCHEM BIOPHYS, V392, P349, DOI 10.1006/abbi.2001.2455; Kashtan H, 1999, GASTROINTEST ENDOSC, V49, P760, DOI 10.1016/S0016-5107(99)70297-X; Kinuya S, 2001, EUR J NUCL MED, V28, P1306, DOI 10.1007/s002590100585; Klauber N, 1997, CANCER RES, V57, P81; Korbelik M, 2000, BRIT J CANCER, V82, P1835, DOI 10.1054/bjoc.2000.1157; Kuninaka S, 2000, BRIT J CANCER, V83, P928, DOI 10.1054/bjoc.2000.1367; Kuroda M, 2000, ANTICANCER RES, V20, P7; MacDonald IJ, 2001, J PORPHYR PHTHALOCYA, V5, P105, DOI 10.1002/jpp.328; MARTINEZCAYUELA M, 1995, BIOCHIMIE, V77, P147, DOI 10.1016/0300-9084(96)88119-3; Mimura S, 1996, LASER SURG MED, V19, P168; Moor ACE, 2000, J PHOTOCH PHOTOBIO B, V57, P1, DOI 10.1016/S1011-1344(00)00065-8; Morgan J, 2000, PHOTOCHEM PHOTOBIOL, V71, P747, DOI 10.1562/0031-8655(2000)071<0747:COPTIA>2.0.CO;2; Nakano T, 1996, CANCER RES, V56, P2771; RIGO A, 1975, BIOCHEM BIOPH RES CO, V63, P1013, DOI 10.1016/0006-291X(75)90670-1; Salet C, 1997, FREE RADICAL RES, V26, P201, DOI 10.3109/10715769709097800; Schumacher G, 1999, CLIN CANCER RES, V5, P493; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; Sharman WM, 2000, METHOD ENZYMOL, V319, P376; Ueta E, 1999, JPN J CANCER RES, V90, P555, DOI 10.1111/j.1349-7006.1999.tb00783.x; Ueta E, 2001, INT J CANCER, V94, P545, DOI 10.1002/ijc.1513; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; WHITE L, 1988, BRIT J CANCER, V57, P455, DOI 10.1038/bjc.1988.106; Wilson BC, 1997, PHOTOCHEM PHOTOBIOL, V65, P166, DOI 10.1111/j.1751-1097.1997.tb01894.x; Wood L, 2001, ANTI-CANCER DRUG DES, V16, P209; Wyss P, 2001, INT J CANCER, V93, P720, DOI 10.1002/ijc.1400; Zhang Y, 2002, CANCER RES, V62, P1205	46	103	110	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					407	414		10.1074/jbc.M209125200	http://dx.doi.org/10.1074/jbc.M209125200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12409296	hybrid			2023-01-03	WOS:000180255700054
J	Carroll, D; Ebrahim, S; Tilling, K; MacLeod, J; Smith, GD				Carroll, D; Ebrahim, S; Tilling, K; MacLeod, J; Smith, GD			Admissions for myocardial infarction and World Cup football: database survey	BRITISH MEDICAL JOURNAL			English	Article							EARTHQUAKE; DISEASE; STRESS; CIVILIANS; MORTALITY; TRIGGERS	Objectives To examine hospital admissions for a range of diagnoses on days surrounding England's 1998 World Cup football matches. Design Analysis of hospital admissions obtained from English hospital episode statistics. Setting England. Participants Population aged 15-64 years. Main outcome measures Ratio of number of admissions for acute myocardial infarction, stroke, deliberate self harm, and road traffic injuries on the day of and five days after England's World Cup matches, compared with admissions at die same time in previous and following years and in the month preceding the tournament. Results Risk of admission for acute myocardial infarction increased by 25% on 30 June 1998 (the day England lost to Argentina in a penalty shoot-out) and the following two days. No excess admissions occurred for other diagnoses or on the days of the other England matches. The effect was the same when only the two days after the match were treated as the exposed condition. Individual analyses of the day of and the two days after the Argentina match showed 55 extra admissions for myocardial infarctions compared with the number expected. Conclusion The increase in admissions suggests that myocardial infarction can be triggered by emotional upset, such as watching your football team lose an important match.	Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England; Univ Birmingham, Sch Sport & Exercise Sci, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Bristol; University of Birmingham; University of Birmingham	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England.		Tilling, Kate/AAY-1578-2021; Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Tilling, Kate/0000-0002-1010-8926				BERGOVEC M, 1992, LANCET, V339, P303, DOI 10.1016/0140-6736(92)91370-N; BRODKIN J, 1998, GUARDIAN        0702, P3; Brunekreef B, 2002, EPIDEMIOLOGY, V13, P491, DOI 10.1097/00001648-200207000-00022; Harrison LK, 2000, BIOL PSYCHOL, V52, P113, DOI 10.1016/S0301-0511(99)00033-2; Heslop P, 2001, BRIT J HEALTH PSYCH, V6, P167, DOI 10.1348/135910701169133; KATSOUYANNI K, 1986, INT J EPIDEMIOL, V15, P326, DOI 10.1093/ije/15.3.326; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Kondo N I, 1995, J Cardiovasc Risk, V2, P499, DOI 10.1097/00043798-199512000-00003; LEAR J, 1996, AM J CARDIOL, V77, P1230; Macleod J, 2002, BMJ-BRIT MED J, V324, P1247, DOI 10.1136/bmj.324.7348.1247; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; SUZUKI S, 1995, LANCET, V345, P981, DOI 10.1016/S0140-6736(95)90727-0; *TEL AUD RES INF S, 1999, UK TEL VID YB; TOFLER GH, 1990, AM J CARDIOL, V66, P22, DOI 10.1016/0002-9149(90)90729-K; TRICHOPOULOS D, 1983, LANCET, V1, P441; WITTE DR, 2000, BRIT MED J, V321, P1332; Zanobetti A, 2002, EPIDEMIOLOGY, V13, P87, DOI 10.1097/00001648-200201000-00014; 2002, GUARDIAN        0620, P11	19	143	148	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 21	2002	325	7378					1439	1442		10.1136/bmj.325.7378.1439	http://dx.doi.org/10.1136/bmj.325.7378.1439			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	631VX	12493655	Green Published, Green Accepted			2023-01-03	WOS:000180188600007
J	Graham, SM				Graham, SM			Prophylaxis against Pneumocystis carinii pneumonia for HIV-exposed infants in Africa	LANCET			English	Editorial Material							VIRUS-INFECTED CHILDREN; COTRIMOXAZOLE PROPHYLAXIS; TRIMETHOPRIM; RESISTANCE		Univ Malawi, Wellcome Trust Res Labs, Blantyre 3, Malawi; Univ Malawi, Coll Med, Dept Paediat, Blantyre 3, Malawi; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	University of Malawi; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool	Graham, SM (corresponding author), Univ Malawi, Wellcome Trust Res Labs, POB 30096, Blantyre 3, Malawi.	sgraham@mlw.medcol.mw		Graham, Stephen/0000-0003-3525-2294				Abdel-Haq N, 1999, PEDIATR INFECT DIS J, V18, P647, DOI 10.1097/00006454-199907000-00017; Chintu C, 2002, LANCET, V360, P985, DOI 10.1016/S0140-6736(02)11082-8; Chokephaibulkit K, 1999, PEDIATR INFECT DIS J, V18, P147, DOI 10.1097/00006454-199902000-00012; DOUNG T, 1999, BMJ-BRIT MED J, V319, P1227; Fisher RG, 2001, AIDS PATIENT CARE ST, V15, P263, DOI 10.1089/10872910152050784; GIBB DM, 1994, ARCH DIS CHILD, V70, P241, DOI 10.1136/adc.70.3.241; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Graham SM, 2000, LANCET, V355, P369, DOI 10.1016/S0140-6736(98)11074-7; Grimwade K, 2001, CURR OPIN INFECT DIS, V14, P507, DOI 10.1097/00001432-200110000-00002; Ikeogu MO, 1997, ARCH DIS CHILD, V76, P124, DOI 10.1136/adc.76.2.124; Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8; Jeena PM, 1996, ANN TROP PAEDIATR, V16, P361, DOI 10.1080/02724936.1996.11747852; JohannLiang R, 1997, PEDIATR INFECT DIS J, V16, P1145, DOI 10.1097/00006454-199712000-00009; Lucas SB, 1996, BRIT MED J, V312, P335, DOI 10.1136/bmj.312.7027.335; Ruffini DD, 2002, AIDS, V16, P105, DOI 10.1097/00002030-200201040-00013; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; *UNAIDS WHO, 2000, UNAIDS PROV WHO UNAI; Williams AJ, 2001, AIDS, V15, P335, DOI 10.1097/00002030-200102160-00006; Zachariah R, 2002, T ROY SOC TROP MED H, V96, P202, DOI 10.1016/S0035-9203(02)90306-8; Zar HJ, 2000, PEDIATR INFECT DIS J, V19, P603, DOI 10.1097/00006454-200007000-00004	20	19	19	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	2002	360	9349					1966	1968		10.1016/S0140-6736(02)11921-0	http://dx.doi.org/10.1016/S0140-6736(02)11921-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	626KC	12493279				2023-01-03	WOS:000179870200031
J	Orach, CG; Kolsteren, P				Orach, CG; Kolsteren, P			Outpatient care for severely malnourished children	LANCET			English	Editorial Material							SEVERE MALNUTRITION; MORTALITY; DISTRICT; REFUGEE		Makerere Univ, Inst Publ Hlth, Kampala, Uganda	Makerere University	Orach, CG (corresponding author), Makerere Univ, Inst Publ Hlth, Kampala, Uganda.	cgorach@hotmail.com						Ashworth A, 1997, HEALTH POLICY PLANN, V12, P115, DOI 10.1093/heapol/12.2.115; BENGOA JOSE M., 1967, J TROP PEDIAT, V13, P169; CALVALCANTE AAM, 1998, TROP DOCT, V28, P95; Centers for Disease Control and Prevention, 1992, MMWR RECOMM REP, V41, P1; Collins S, 2001, LANCET, V358, P498, DOI 10.1016/S0140-6736(01)05630-6; FERNANDEZCONCHA D, 1991, T ROY SOC TROP MED H, V85, P809, DOI 10.1016/0035-9203(91)90465-B; Husaini Y. K., 1986, Food and Nutrition Bulletin, V8, P55; *INT COMM RED CROS, 1996, HDB WAR PUBL HLTH, P353; KHANUM S, 1994, LANCET, V344, P1728; King M, 1966, MED CARE DEV COUNTRI; Orach CG, 1999, E AFR MED J, V76, P195; Puoane T, 2001, S AFR MED J, V91, P137; ROEMER MI, 1991, NATL HLTH SYSTEMS WO, P31; Schofield C, 1997, Afr Health, V19, P17; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; *UN CHILDR FUND, 1998, STAT WORLDS CHILDR F, P9; Van Damme W, 1998, LANCET, V351, P1609, DOI 10.1016/S0140-6736(97)10348-8; Van Damme W, 2002, LANCET, V359, P260, DOI 10.1016/S0140-6736(02)07422-6; Waterlow J, 1999, LANCET, V354, P1142, DOI 10.1016/S0140-6736(99)00329-3; 1997, MED SANS FRONTIERES, P37	20	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 7	2002	360	9348					1800	1801						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623MB	12480354				2023-01-03	WOS:000179706100004
J	Osrin, D; Tumbahangphe, KM; Shrestha, D; Mesko, N; Shtestha, BP; Manandhar, MK; Standing, H; Manandhar, DS; Costello, AMD				Osrin, D; Tumbahangphe, KM; Shrestha, D; Mesko, N; Shtestha, BP; Manandhar, MK; Standing, H; Manandhar, DS; Costello, AMD			Cross sectional, community based study of care of newborn infants in Nepal	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPOTHERMIA; DELIVERY; INDIA	Objective To determine home based newborn care practices in rural Nepal in order to inform strategies to improve neonatal outcome. Design Cross sectional, retrospective study using structured interviews. Setting Makwanpur district, Nepal. Participants 5411 married women aged 15 to 49 years who had given birth to a live baby in the past year. Main outcome measures Attendance at delivery, hygiene, thermal care, and early feeding practices. Results 4893 (90%) women gave birth at home. Attendance at delivery by skilled government health workers was low (334, 6%), as was attendance by traditional birth attendants (267, 5%). Only 461 (8%) women had used a clean home delivery kit, and about half of attendants had washed their,hands. Only 3482 (64%) newborn infants had been wrapped within half an hour of birth, and 4992 (92%) had been bathed within the first hour. 99% (5362) of babies were breast fed, 91% (4939) within six hours of birth. Practices with respect to colostrum and prelacteals were not a cause for anxiety. Conclusions Health promotion interventions most likely to improve newborn health in this setting include increasing attendance at delivery by skilled service providers, improving information for families about basic perinatal care, promotion of clean delivery practices, early cord cutting and wrapping of the baby, and avoidance of early bathing.	UCL, Inst Child Hlth, Int Perinatal Care Unit, London WC1N 1EH, England; Mother Infant Res Act, Kathmandu, Nepal; Nepal Adm Staff Coll, Ctr Local Governance, Kathmandu, Nepal; Univ Sussex, Inst Dev Studies, Hlth & Social Change Unit, Brighton BN1 9RH, E Sussex, England	University of London; University College London; University of Sussex	Costello, AMD (corresponding author), UCL, Inst Child Hlth, Int Perinatal Care Unit, London WC1N 1EH, England.	ipu@ich.ucl.ac.uk		Osrin, David/0000-0001-9691-9684				[Anonymous], 2002, WORLD DEV REP 2002; Bang A T, 2001, Indian Pediatr, V38, P952; BHAVE S A, 1989, Indian Pediatrics, V26, P1094; *CENTR BUR STAT, 2001, STAT YB NEP 2001; Claeson M, 2000, B WORLD HEALTH ORGAN, V78, P1192; *DEP HLTH SERV, 2001, 205657 DEP HLTH SERV; Ellis M, 1996, ARCH DIS CHILD-FETAL, V75, pF42, DOI 10.1136/fn.75.1.F42; *FAM HLTH DIV, 1998, CONTR TRAIN TBAS NEP; GOODBURN EA, 1995, STUD FAMILY PLANN, V26, P22, DOI 10.2307/2138048; IYENGAR SD, 1991, TROP GEOGR MED, V43, P293; JUSTICE J, 1983, SOC SCI MED, V17, P967, DOI 10.1016/0277-9536(83)90223-X; MANANDHAR M, 1999, BIRTHING PRACTICES S; *NAT PLANN COMM SE, 1998, FURTH AN REP AN DEL; *NAT PLANN COMM SE, 1998, FURTH AN REP ANT DEL; *NAT PLANN COMM SE, 1998, CAR PREGN DEL IMPL P; *NEP S AS CTR, 1998, NEP HUM DEV REP 1998; NICHTER M, 1983, HUM ORGAN, V42, P235, DOI 10.17730/humo.42.3.43081445235366lk; Pradhan A., 1997, NEPAL FAMILY HLTH SU; Pradhan A, 1997, NEP FAM HLTH SURV 19; Tamang S, 2001, CONTRIBUTIONS NEPALE, V28, P10; Thapa N, 2000, SOC SCI MED, V51, P1447, DOI 10.1016/S0277-9536(00)00045-9; TRAVERSO HP, 1989, LANCET, V1, P486; *UN CHILDR FUND, 1999, TRENDS CHILDH MORT D; *UN FUND POP ACT, 2000, STAT WORLDS POP 2000; *WHO, 1993, THERM CONTR NEWB PRA; World Bank, 2002, WORLD DEV REP 2002 B; World Health Organization, 1996, ESS NEWB CAR REP TEC	27	84	84	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2002	325	7372					1063	1066		10.1136/bmj.325.7372.1063	http://dx.doi.org/10.1136/bmj.325.7372.1063			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424164	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000179415700017
J	Joyce, GF; Escarce, JJ; Solomon, MD; Goldman, DP				Joyce, GF; Escarce, JJ; Solomon, MD; Goldman, DP			Employer drug benefit plans and spending on prescription drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATION; COST-CONTAINMENT; MEDICAID; PAYMENT; FORMULARY; MEMBERS; IMPACT	Context With drug spending rising rapidly for working-aged adults, many employers and health insurance providers have changed benefits packages to encourage use of fewer or less expensive drugs. It is unknown how these initiatives affect drug costs. Objective To examine how innovations in benefits packages, such as those that include multitier formularies and mandatory generic substitution, affect total cost to insurance providers for generic and brand drugs and out-of-pocket payments to beneficiaries. Design and Participants Retrospective study from 1997 to 1999 linking claims data of 420786 primary beneficiaries aged 18 through 64 years who worked at large firms (n = 25) with health insurance benefits that included outpatient drugs. Main Outcome Measures Overall drug costs; generic, single-source brand, and multisource brand costs; and drug expenditures by health insurance providers and out-of-pocket costs for beneficiaries. Results For a 1-tier plan with a $5 co-payment for all drugs,,the average annual spending was $725 per member. Doubling co-payments to $10 for all drugs reduced the annual average drug cost from $725 to $563 per member (22.3%, P<.001). Doubling co-payments in a 2-tier plan from $5 for generics and $10 for brand drugs to $10 for generics and $20 for brand drugs reduced costs from $678 to $455 (32.9%, P<.001). Adding an additional co-payment of $30 for nonpreferred brand drugs to a 2-tier plan ($10 generics; $20 brand) lowered overall drug spending by 4% (P<.001). Requiring mandatory generic substitution in a 2-tier plan reduced drug spending by 8% (P<.001). Doubling co-payments in a 2-tier plan increased the fraction beneficiaries' paid out-of-pocket from 17.6% to 25.6%. Conclusions Adding an additional level of co-payment, increasing existing co-, payments or coinsurance rates, and requiring mandatory generic substitution all reduced plan payments and overall drug spending among working-age enrollees with employer-provided drug coverage. The reduction in drug spending largely benefited health insurance plans because the percentage of drug expenses beneficiaries paid out-of-pocket rose significantly.	RAND Hlth, Santa Monica, CA 90407 USA	RAND Corporation	Joyce, GF (corresponding author), RAND Hlth, 1700 Main St, Santa Monica, CA 90407 USA.		Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396				Berndt ER, 2001, HEALTH AFFAIR, V20, P100, DOI 10.1377/hlthaff.20.2.100; BYMARK L, 2002, PRESCRIPTION DRUG US; *CA HEALTHC FDN FO, 2002, PRESCR DRUG COV FORM; Duan N., 1983, J BUSINESS EC STAT, V1, P115, DOI [DOI 10.1080/07350015.1983.10509330, DOI 10.2307/1391852]; Dubois RW, 2000, HEALTH AFFAIR, V19, P231, DOI 10.1377/hlthaff.19.2.231; Ernst ME, 2000, ARCH FAM MED, V9, P1002, DOI 10.1001/archfami.9.10.1002; Goldman DP, 1998, J AM STAT ASSOC, V93, P54, DOI 10.2307/2669602; HARRIS BL, 1990, MED CARE, V28, P907, DOI 10.1097/00005650-199010000-00005; HILLMAN AL, 1999, HLTH AFF MILLWOOD, V18, P188; Horn SD, 1998, AM J MANAG CARE, V4, P1105; Johnson RE, 1997, HEALTH SERV RES, V32, P103; Johnson RE, 1997, MED CARE, V35, P1119, DOI 10.1097/00005650-199711000-00004; LEIBOWITZ A, 1985, SOC SCI MED, V21, P1063, DOI 10.1016/0277-9536(85)90161-3; Levit K, 2000, HEALTH AFFAIR, V19, P124, DOI 10.1377/hlthaff.19.1.124; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Motheral B, 2001, MED CARE, V39, P1293, DOI 10.1097/00005650-200112000-00005; Motheral BR, 1999, INQUIRY-J HEALTH CAR, V36, P481; Mullahy J, 1998, J HEALTH ECON, V17, P247, DOI 10.1016/S0167-6296(98)00030-7; *NIH CAR MAN FDN, 2001, PRESCR DRUG EXP 2000; PENNA P, 2000, J MANAGE CARE PHARM, V6, P351; REEDER CE, 1985, INQUIRY-J HEALTH CAR, V22, P396; REISSMAN D, 2001, DRUG BENEFIT TRENDS, V13, P24; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; SMITH DG, 1993, INQUIRY-J HEALTH CAR, V30, P189; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Stuart B, 1999, HEALTH AFFAIR, V18, P201, DOI 10.1377/hlthaff.18.2.201; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Walser BL, 1996, HEALTH AFFAIR, V15, P95, DOI 10.1377/hlthaff.15.3.95	30	183	184	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2002	288	14					1733	1739		10.1001/jama.288.14.1733	http://dx.doi.org/10.1001/jama.288.14.1733			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	602BJ	12365957	Bronze			2023-01-03	WOS:000178484700026
J	Pradhan, AD; Manson, JE; Rossouw, JE; Siscovick, DS; Mouton, CP; Rifai, N; Wallace, RB; Jackson, RD; Pettinger, MB; Ridker, PM				Pradhan, AD; Manson, JE; Rossouw, JE; Siscovick, DS; Mouton, CP; Rifai, N; Wallace, RB; Jackson, RD; Pettinger, MB; Ridker, PM			Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease - Prospective analysis from the Women's Health Initiative observational study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; PLASMA-CONCENTRATION; UNSTABLE ANGINA; INSULIN-RESISTANCE; ADIPOSE-TISSUE; RISK; INTERLEUKIN-6; OBESITY	Context Postmenopausal hormone replacement therapy (HRT) has been shown to elevate C-reactive protein (CRP) levels. Several inflammatory biomarkers, including CRP, are associated with increased cardiovascular risk. However, whether the,effect of HRT on CRP represents a clinical hazard is unknown. Objectives To assess the association between baseline levels of CRP and interleukin 6 (IL-6) and incident coronary heart disease (CHD) and to examine the relationship between baseline use of HRT, CRP, and IL-6 levels as they relate to subsequent vascular risk. Design, Setting, and Participants Prospective, nested case-control study of postmenopausal women, forming part of the Women's Health Initiative, a large, nationwide, observational study. Among 75343 women with no history of cardiovascular disease or cancer, 304 women who developed incident CHD were defined as cases and matched by age, smoking status, ethnicity, and follow-up time with 304 study participants who remained event free during a median observation period of 2.9 years. Main Outcome Measure Incidence of first myocardial infarction or death from CHD. Results Median baseline levels of CRP (0.33 vs 0.25 mg/dL; interquartile range [IQR], 0.14-0.71 vs 0.10-0.47; P < 001) and IL-6 (1.81 vs 1.47 pg/mL; IQR, 1.30-2.75 vs 1.05-2.15; P < .001) were significantly higher among cases compared with controls. In matched analyses, the odds ratio (OR) for incident CHD in the highest vs lowest quartile was 2.3 for CRP (95% confidence interval [CI], 1.4-3.7; P for trend = .002) and 3.3 for IL-6 (95% 10, 2.0-5.5; P for trend <.001), After additional adjustment for lipid and nonlipid risk factors, both inflammatory markers were significantly associated with a 2-fold increase in odds for CHD events. As anticipated, current use of HRT was associated with significantly elevated median CRP levels. However, there was no association between HRT and IL-6. In analyses comparing individuals with comparable baseline levels of either CRP or IL-6, those taking or not taking HRT had similar CHD ORs. In analyses stratified by HRT, we observed a positively graded relationship between plasma CRP levels and the OR for CHD among both users and nonusers of HRT across the full spectrum of baseline CRP. Conclusions These prospective findings indicate that CRP and IL-6 independently predict vascular events among apparently healthy postmenopausal women and that HRT increases CRP. However, use or nonuse of HRT had less importance as a predictor of cardiovascular risk than did baseline levels of either CRP or IL-6.	Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Div Prevent Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Div Cardiol, Boston, MA 02215 USA; Brigham & Womens Hosp, Leducq Ctr Mol & Genet Epidemiol Cardiovasc Disor, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; NHLBI, Bethesda, MD 20892 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Texas, Hlth Sci Ctr, Dept Family & Community Med, Div Community Geriatr, San Antonio, TX USA; Childrens Hosp, Med Ctr, Dept Pathol, Boston, MA 02115 USA; Univ Iowa, Coll Med, Dept Epidemiol, Iowa City, IA USA; Ohio State Univ, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA; Fred Hutchinson Canc Res Ctr, Womens Hlth Initiat Clin Coordinating Ctr, Seattle, WA 98104 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health San Antonio; Harvard University; Boston Children's Hospital; University of Iowa; University System of Ohio; Ohio State University; Fred Hutchinson Cancer Center	Ridker, PM (corresponding author), Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063293] Funding Source: NIH RePORTER; WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH [N01WH032109] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63293, HL 07575] Funding Source: Medline; WHI NIH HHS [N01-WH-3-2109] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); WHI NIH HHS		Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Barinas-Mitchell E, 2001, AM J EPIDEMIOL, V153, P1094, DOI 10.1093/aje/153.11.1094; Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Cushman M, 1999, ARTERIOSCL THROM VAS, V19, P893, DOI 10.1161/01.ATV.19.4.893; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Hak AE, 1999, ARTERIOSCL THROM VAS, V19, P1986, DOI 10.1161/01.ATV.19.8.1986; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hastie T., 1990, GEN ADDITIVE MODELS, DOI DOI 10.1201/9780203753781; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Lowe GDO, 2001, THROMB HAEMOSTASIS, V86, P550; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Morrow DA, 1998, J AM COLL CARDIOL, V31, P1460, DOI 10.1016/S0735-1097(98)00136-3; Nakagomi A, 2000, CIRCULATION, V101, P1785, DOI 10.1161/01.CIR.101.15.1785; Ockene IS, 2001, CLIN CHEM, V47, P444; Rexrode KM, 1996, CURR OPIN CARDIOL, V11, P490, DOI 10.1097/00001573-199609000-00007; Ridker PM, 1999, CIRCULATION, V100, P713, DOI 10.1161/01.CIR.100.7.713; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sattar N, 1999, LANCET, V354, P487, DOI 10.1016/S0140-6736(99)02079-6; Straub RH, 2000, J CLIN ENDOCR METAB, V85, P1340, DOI 10.1210/jc.85.3.1340; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; van Baal WM, 1999, THROMB HAEMOSTASIS, V81, P925, DOI 10.1055/s-0037-1614600; Walsh BW, 2000, J CLIN ENDOCR METAB, V85, P214, DOI 10.1210/jc.85.1.214; Weinhold B, 1997, BIOCHEM J, V327, P425, DOI 10.1042/bj3270425; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972	38	525	536	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	2002	288	8					980	987		10.1001/jama.288.8.980	http://dx.doi.org/10.1001/jama.288.8.980			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	587RM	12190368	Bronze			2023-01-03	WOS:000177656400023
J	Sanz, EJ				Sanz, EJ			Concordance and children's use of medicines	BRITISH MEDICAL JOURNAL			English	Article								Concordance is usually established between two people, doctor and patient, but the use of drugs in children always involves a third partner, the parents. Developing concordance with children in their health care raises several questions with no straightforward answers. For example, should children have a more active role in taking decisions about health and drugs than they currently do? Should greater emphasis be placed on informing parents about the disease and its treatment or on direct communication with their sick child? From what age should children be addressed directly about their illness? What is really relevant for them? Do children's and parents' perceptions about the usefulness and risks (efficacy), rules, and use of drugs coincide? This article, based on qualitative studies of children's perceptions and attitudes to health, disease, and drug use, presents information that, though by no means providing the "right" answers to the above questions, might be useful when considering the options.	Univ La Laguna, Sch Med, Dept Pharmacol, Tenerife 38071, Spain	Universidad de la Laguna	Sanz, EJ (corresponding author), Univ La Laguna, Sch Med, Dept Pharmacol, Tenerife 38071, Spain.		Sanz Alvarez, Emilio J/M-3535-2019; Sanz, Emilio J/C-9793-2009	Sanz Alvarez, Emilio J/0000-0001-6788-4435; Sanz, Emilio J/0000-0001-6788-4435				ARAMBURUZABALA P, 1997, CHILDREN MED CULTURE, P155; Bluebond-Langner M, 1978, PRIVATE WORLDS DYING; Bush PJ, 1999, CLIN THER, V21, P1280, DOI 10.1016/S0149-2918(00)80030-2; BUSH PJ, 1996, CHILDREN MED CULTURE; Garcia M, 1997, CHILDREN MED CULTURE, P193; Haynes R B, 2002, Cochrane Database Syst Rev, pCD000011; Lewin SA, 2001, COCHRANE DB SYST REV, V4, DOI [DOI 10.1002/14651858, DOI 10.1002/14651858.CD003267]; Sanz E., 1997, CHILDREN MED CULTURE, P77; SCOTT JT, 2001, COCHRANE DATABASE SY, DOI UNSP CD002969; Trakas DJ, 1992, STUDYING CHILDHOOD M; TRAKAS DJ, 1996, CHILDHOOD MED USE CR	11	36	36	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					858	860		10.1136/bmj.327.7419.858	http://dx.doi.org/10.1136/bmj.327.7419.858			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551105	Green Published			2023-01-03	WOS:000185921200027
J	Riley, SG; Chess, J; Donovan, KL; Williams, JD				Riley, SG; Chess, J; Donovan, KL; Williams, JD			Lesson of the week - Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RENAL-FAILURE		Univ Wales Hosp, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Riley, SG (corresponding author), Univ Wales Hosp, Inst Nephrol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	steveriley65@hotmail.com						ANSELL D, 2000, UK RENAL REGISTRY RE; Coles GA, 1998, KIDNEY INT, V54, P2234, DOI 10.1046/j.1523-1755.1998.00183.x; Gokal R, 2002, KIDNEY INT, V62, pS62, DOI 10.1046/j.1523-1755.62.s81.9.x; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Mehmet S, 2001, DIABETIC MED, V18, P679, DOI 10.1046/j.0742-3071.2001.00556.x; Ritz E, 1999, AM J KIDNEY DIS, V34, P795, DOI 10.1016/S0272-6386(99)70035-1; Wens R, 1998, PERITON DIALYSIS INT, V18, P603; Wilkie ME, 1997, PERITON DIALYSIS INT, V17, P84	8	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2003	327	7415					608	609		10.1136/bmj.327.7415.608	http://dx.doi.org/10.1136/bmj.327.7415.608			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969932	Green Published			2023-01-03	WOS:000185358700028
J	Patrick, DL; Curtis, JR; Engelberg, RA; Nielsen, E; McCown, E				Patrick, DL; Curtis, JR; Engelberg, RA; Nielsen, E; McCown, E			Measuring and improving the quality of dying and death	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				OF-LIFE CARE; END; PHYSICIANS; FAMILY; ILLNESS	Improving end-of-life experience is a major challenge to successful aging. Deaths that are reasonably free of discomfort, in accordance with patients' wishes, and within acceptable professional and ethical standards are high-quality deaths. The authors developed a 31-item measure of the quality of dying and death and applied it in a community sample and a sample of hospice enrollees. Scores on the Quality of Dying and Death Instrument and measures of perceived quality of care were collected from patients' loved ones after death. Higher overall after-death ratings of the quality of care received from all providers and from physicians were associated with higher-quality dying and death. How well patients' symptoms were controlled in the community study and how well wishes were followed and treatments were explained in the hospice study were associated with higher-quality dying. Major challenges to end-of-life research include recruiting representative population samples, given widespread reluctance of patients and loved ones to participate in research at the end of life; important variation in evaluations among different reporters after death; reluctance of loved ones to assign negative evaluations to dying experiences after death; and the highly individual and dynamic nature of dying experiences. Overcoming these challenges is of great importance in the search for the social, organizational, and individual determinants of high-quality dying in the U.S. cultural and health care context.	Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle	Patrick, DL (corresponding author), Univ Washington, Dept Hlth Serv, Box 357660,1959 NE Pacific St, Seattle, WA 98195 USA.	donald@u.washington.edu	Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492	AHRQ HHS [R03 HS09540] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS009540] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Curtis JR, 2002, J PAIN SYMPTOM MANAG, V24, P17, DOI 10.1016/S0885-3924(02)00419-0; Curtis JR, 2001, J GEN INTERN MED, V16, P41; Desbiens NA, 2000, J AM GERIATR SOC, V48, pS183, DOI 10.1111/j.1532-5415.2000.tb03130.x; Field MJ, 1997, APPROACHING DEATH IM; Fowler FJ, 1999, J PAIN SYMPTOM MANAG, V17, P114, DOI 10.1016/S0885-3924(98)00133-X; Hinton J, 1996, SOC SCI MED, V43, P1229, DOI 10.1016/0277-9536(95)00437-8; *I MED, 2001, CROSS QUAL CHASM NEW, P300; KASSBARTELMES BL, 2003, AHRQ PUB; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Patrick DL, 2001, J PAIN SYMPTOM MANAG, V22, P717, DOI 10.1016/S0885-3924(01)00333-5; Pierson CM, 2002, AIDS CARE, V14, P587, DOI 10.1080/0954012021000005416; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Stewart AL, 1999, J PAIN SYMPTOM MANAG, V17, P93, DOI 10.1016/S0885-3924(98)00131-6; Teno JM, 1999, J PAIN SYMPTOM MANAG, V17, P75, DOI 10.1016/S0885-3924(98)00134-1; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P738, DOI 10.1016/S0885-3924(01)00335-9; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; RW JOHNSON FDN LAST	22	118	118	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			410	415		10.7326/0003-4819-139-5_Part_2-200309021-00006	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965967				2023-01-03	WOS:000185133800006
J	Foster, GD; Wyatt, HR; Hill, JO; McGuckin, BG; Brill, C; Mohammed, BS; Szapary, PO; Rader, DJ; Edman, JS; Klein, S				Foster, GD; Wyatt, HR; Hill, JO; McGuckin, BG; Brill, C; Mohammed, BS; Szapary, PO; Rader, DJ; Edman, JS; Klein, S			A randomized trial of a low-carbohydrate diet for obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; WEIGHT-LOSS; PLASMA-LIPOPROTEINS; INSULIN SENSITIVITY; RISK FACTOR; NUTRITION; PREVALENCE; REDUCTION; DISEASE; ADULTS	BACKGROUND: Despite the popularity of the low-carbohydrate, high-protein, high-fat (Atkins) diet, no randomized, controlled trials have evaluated its efficacy. METHODS: We conducted a one-year, multicenter, controlled trial involving 63 obese men and women who were randomly assigned to either a low-carbohydrate, high-protein, high-fat diet or a low-calorie, high-carbohydrate, low-fat (conventional) diet. Professional contact was minimal to replicate the approach used by most dieters. RESULTS: Subjects on the low-carbohydrate diet had lost more weight than subjects on the conventional diet at 3 months (mean [+/-SD], -6.8+/-5.0 vs. -2.7+/-3.7 percent of body weight; P=0.001) and 6 months (-7.0+/-6.5 vs. -3.2+/-5.6 percent of body weight, P=0.02), but the difference at 12 months was not significant (-4.4+/-6.7 vs. -2.5+/-6.3 percent of body weight, P=0.26). After three months, no significant differences were found between the groups in total or low-density lipoprotein cholesterol concentrations. The increase in high-density lipoprotein cholesterol concentrations and the decrease in triglyceride concentrations were greater among subjects on the low-carbohydrate diet than among those on the conventional diet throughout most of the study. Both diets significantly decreased diastolic blood pressure and the insulin response to an oral glucose load. CONCLUSIONS: The low-carbohydrate diet produced a greater weight loss (absolute difference, approximately 4 percent) than did the conventional diet for the first six months, but the differences were not significant at one year. The low-carbohydrate diet was associated with a greater improvement in some risk factors for coronary heart disease. Adherence was poor and attrition was high in both groups. Longer and larger studies are required to determine the long-term safety and efficacy of low-carbohydrate, high-protein, high-fat diets.	Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Washington Univ, Sch Med, St Louis, MO USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	University of Pennsylvania; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Washington University (WUSTL); Jefferson University	Foster, GD (corresponding author), Univ Penn, Sch Med, 3535 Market St,Suite 3027, Philadelphia, PA 19104 USA.	fosterg@mail.med.upenn.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042549, P30DK056341, R01DK042549, K23DK002703, R01DK037948, P30DK048520] Funding Source: NIH RePORTER; NCCIH NIH HHS [AT00058, AT1103] Funding Source: Medline; NCRR NIH HHS [RR00036, RR00051, RR00040] Funding Source: Medline; NIDDK NIH HHS [DK48520, DK02703, DK 37948, DK42549, DK 56341] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; [Anonymous], 1997, J AM DIET ASSOC, V97, P71; Atkins RC, 1998, ATKINS NEW DIET REVO; Blackburn GL, 2001, CLEV CLIN J MED, V68, P761, DOI 10.3949/ccjm.68.9.761; Boden WE, 2000, AM J CARDIOL, V86, p19L; Brownell K. D., 2000, LEARN PROGRAM WEIGHT; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; *DEP AGR, 1992, 252 DEP AGR; Department of Health and Human Services, 2001, SURG GEN CALL ACT PR; EADES MR, 1999, PROTEIN POWER; Ferrannini E, 1997, J CLIN INVEST, V100, P1166, DOI 10.1172/JCI119628; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Forrester JS, 2001, CURR OPIN CARDIOL, V16, P261, DOI 10.1097/00001573-200107000-00007; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARG A, 1992, DIABETES, V41, P1278, DOI 10.2337/diabetes.41.10.1278; Golay A, 1996, INT J OBESITY, V20, P1067; Golay A, 1996, AM J CLIN NUTR, V63, P174, DOI 10.1093/ajcn/63.2.174; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; LAROSA JC, 1980, J AM DIET ASSOC, V77, P264; LEWIS SB, 1977, AM J CLIN NUTR, V30, P160, DOI 10.1093/ajcn/30.2.160; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Ornish D, 1999, JAMA-J AM MED ASSOC, V281, P1380; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Potteiger JA, 2002, INT J OBESITY, V26, P87, DOI 10.1038/sj.ijo.0801839; RABAST U, 1978, NUTR METAB, V22, P269; Schaefer EJ, 2002, AM J CLIN NUTR, V75, P191, DOI 10.1093/ajcn/75.2.191; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; *SPSS, 2000, SPSS 11 0 WIND; STEWARD HL, 1995, SUGAR BUSTERS; Szapary Philippe O., 2001, Current Opinion in Pharmacology, V1, P113, DOI 10.1016/S1471-4892(01)00028-5; Thomas PR, 1995, WEIGHING OPTIONS CRI; Wadden TA, 2000, MED CLIN N AM, V84, P441, DOI 10.1016/j.psc.2004.09.008; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; YANG MU, 1976, J CLIN INVEST, V58, P722, DOI 10.1172/JCI108519; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586; 2002, CONSUMER REPORTS JUN, P26; 1998, OBES RES, V6, P464	41	1127	1156	2	178	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2082	2090		10.1056/NEJMoa022207	http://dx.doi.org/10.1056/NEJMoa022207			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761365	Bronze			2023-01-03	WOS:000183008300005
J	Korthals-de Bos, IBC; Hoving, JL; van Tulder, MW; Rutten-Van Molken, MPMH; Ader, HJ; de Vet, HCW; Koes, BW; Vondeling, H; Bouter, LM				Korthals-de Bos, IBC; Hoving, JL; van Tulder, MW; Rutten-Van Molken, MPMH; Ader, HJ; de Vet, HCW; Koes, BW; Vondeling, H; Bouter, LM			Cost effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							DISABILITY INDEX; RATIOS	Objective To evaluate the cost effectiveness of physiotherapy, manual therapy, and care by a general practitioner for patients with neck pain. Design Economic evaluation alongside a randomised controlled trial. Setting Primary care. Participants 183 patients with neck pain for at least two weeks recruited by 42 general practitioners and randomly allocated to manual therapy (n = 60, spinal mobilisation), physiotherapy (n = 59, mainly exercise), or general practitioner care (n = 64, counselling, education, and drugs). Main outcome measures Clinical outcomes were perceived recovery, intensity of pain, functional disability, and quality of life. Direct and indirect costs were measured by means of cost diaries that were kept by patients for one year. Differences in mean costs between. groups, cost effectiveness, and cost utility ratios were evaluated by applying non-parametric bootstrapping techniques. Results The manual therapy group showed a faster improvement than the physiotherapy group and the general practitioner care group up to 26 weeks, but differences were negligible by follow up at 52 weeks. The total costs of manual therapy (C447; pound273; $402) were around one third of the costs of physiotherapy (C1297) and general practitioner care (C1379). These differences were significant: P < 0.01 for manual therapy versus physiotherapy and manual therapy versus general practitioner care and P = 0.55 for general practitioner care versus physiotherapy. The cost effectiveness ratios and the cost utility ratios showed that manual therapy was less costly and more effective than physiotherapy or general practitioner care. Conclusions Manual therapy (spinal mobilisation) is more effective and less costly for treating neck pain than physiotherapy or care by a general practitioner.	VU Univ, Inst Res Extramural Med, Med Ctr, NL-1081 BT Amsterdam, Netherlands; Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands; Erasmus Med Ctr, Dept Gen Practice, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	Korthals-de Bos, IBC (corresponding author), VU Univ, Inst Res Extramural Med, Med Ctr, Van Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		van Tulder, Maurits/AAB-9785-2022; Molken, Maureen Rutten-van/X-8712-2019; Koes, Bart w/K-4614-2016; Hoving, Jan/C-3744-2017; Hoving, Jan L/O-2235-2013; Molken, Maureen PMH Rutten-van/G-8481-2014	van Tulder, Maurits/0000-0002-7589-8471; Molken, Maureen Rutten-van/0000-0001-8706-3159; Koes, Bart w/0000-0002-0450-9969; Hoving, Jan L/0000-0002-0461-4013; Molken, Maureen PMH Rutten-van/0000-0001-8706-3159; Bouter, Lex/0000-0002-2659-5482				BORGHOUTS JA, 2000, THESIS WAGENINGEN; Borghouts JAJ, 1999, PAIN, V80, P629, DOI 10.1016/S0304-3959(98)00268-1; Chaudhary MA, 1996, STAT MED, V15, P1447; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; *DUTCH CENTR ORG H, 1996, TAR MED SPEC EXCL PS; Efron B., 1993, INTRO BOOTSTRAP; Goossens MEJB, 2000, J CLIN EPIDEMIOL, V53, P688, DOI 10.1016/S0895-4356(99)00177-8; GROSS AR, 1996, ONLINE J CURR CLIN T; Hains F, 1998, J MANIP PHYSIOL THER, V21, P75; Harms-Ringdahl K, 2000, NECK BACK PAIN SCI E, P327; Hoving JL, 2002, ANN INTERN MED, V136, P713, DOI 10.7326/0003-4819-136-10-200205210-00006; Koopmanschap MA, 1996, PHARMACOECONOMICS, V10, P460, DOI 10.2165/00019053-199610050-00003; Lanser K, 1994, NEKKLACHTEN VOORKOME; LANSER K, 1994, NEKKLACHLEN WOORKOME; OOSTENBRINK JB, 2000, HANDLEIDING KOSTENUN; PICAVET HS, 2000, 266807002 RIVM NAT I; Skargren EI, 1998, SPINE, V23, P1875, DOI 10.1097/00007632-199809010-00016; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; Stratford P.W., 1999, PHYSIOTHER CANADA, V51, P107; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; VANTULDER MW, 2000, NECK BACK PAIN SCI E, P339; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; 2000, TAXE REPORT	23	171	173	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 26	2003	326	7395					911	914B						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	673WQ	12714472				2023-01-03	WOS:000182603600018
J	Yueh, MF; Huang, YH; Hiller, A; Chen, SJ; Nguyen, N; Tukey, RH				Yueh, MF; Huang, YH; Hiller, A; Chen, SJ; Nguyen, N; Tukey, RH			Involvement of the xenobiotic response element (XRE) in ah receptor-mediated induction of human UDP-glucuronosyltransferase 1A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; CACO-2 CELLS; HUMAN BILIRUBIN; GASTROINTESTINAL-TRACT; METABOLIZING-ENZYMES; FLAVONOID CHRYSIN; NUCLEAR RECEPTOR; COMPLEX LOCUS; CYP1A1 GENE; EXPRESSION	UDP-glucuronosyltransferase 1A1 (UGT1A1) plays an important physiological role by contributing to the metabolism of endogenous substances such as bilirubin in addition to xenobiotics and drugs. The UGT1A1 gene has been shown to be inducible by nuclear receptors steroid xenobiotic receptor (SXR) and the constitutive active receptor, CAR. In this report, we show that in human hepatoma HepG2 cells the UGT1A1 gene is also inducible with aryl hydrocarbon receptor (Ah receptor) ligands such as 2,3,7,8-tetrachlodibenzo-p-dioxin (TCDD), beta-naphthoflavone, and benzo[a]pyrene metabolites. Induction was monitored by increases in protein and catalytic activity as well as UGT1A1 mRNA. To examine the molecular interactions that control UGT1A1 expression, the gene was characterized and induction by Ah receptor ligands was regionalized to bases -3338 to -3287. Nucleotide sequence analysis of this UGT1A1 enhancer region revealed a xenobiotic response element (XRE) at -3381/-3299. The dependence of the XRE on UGT1A1-luciferase activity was demonstrated by a loss of Ah receptor ligand inducibility when the XRE core region (CACGCA) was deleted or mutated. Gel mobility shift analysis confirmed that TCDD induction of nuclear proteins specifically bound to the UGT1A1-XRE, and competition experiments with Ah receptor and Arnt antibodies demonstrated that the nuclear protein was the Ah receptor. These observations reveal that the Ah receptor is involved in human UGT1A1 induction.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Lab Environm Toxicol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tukey, RH (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES10337] Funding Source: Medline; NIGMS NIH HHS [GM49135] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen SW, 2001, DRUG METAB DISPOS, V29, P1074; Anderson JW, 1999, MAR ENVIRON RES, V48, P389, DOI 10.1016/S0141-1136(99)00054-9; BANSAL SK, 1980, ANAL BIOCHEM, V109, P321, DOI 10.1016/0003-2697(80)90655-7; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bock KW, 2000, BIOCHEM PHARMACOL, V59, P467, DOI 10.1016/S0006-2952(99)00366-4; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; Dutton G.F., 1980, GLUCURONIDATION DRUG; Galijatovic A, 2000, PHARMACEUT RES, V17, P21, DOI 10.1023/A:1007506222436; Galijatovic A, 2001, PHARMACEUT RES, V18, P374, DOI 10.1023/A:1011019417236; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Grams B, 2000, ARCH BIOCHEM BIOPHYS, V377, P255, DOI 10.1006/abbi.2000.1777; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kashfi K, 1995, CLIN PHARMACOL THER, V58, P625, DOI 10.1016/0009-9236(95)90018-7; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MERCHANT M, 1992, ARCH BIOCHEM BIOPHYS, V292, P250, DOI 10.1016/0003-9861(92)90076-9; MINERS JO, 1991, PHARMACOL THERAPEUT, V51, P347, DOI 10.1016/0163-7258(91)90065-T; Munzel PA, 1999, DRUG METAB DISPOS, V27, P569; Munzel PA, 1998, ARCH BIOCHEM BIOPHYS, V350, P72, DOI 10.1006/abbi.1997.0485; PETERS WHM, 1987, GASTROENTEROLOGY, V93, P162, DOI 10.1016/0016-5085(87)90329-5; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504; Ritter JK, 1999, HEPATOLOGY, V30, P476, DOI 10.1002/hep.510300205; RITTER JK, 1992, J BIOL CHEM, V267, P3257; Soucek P, 1995, BIOCHEMISTRY-US, V34, P16013, DOI 10.1021/bi00049a015; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489; Strassburg CP, 2000, J BIOL CHEM, V275, P36164, DOI 10.1074/jbc.M002180200; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tukey RH, 2001, MOL PHARMACOL, V59, P405, DOI 10.1124/mol.59.3.405; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Walle T, 2000, DRUG METAB DISPOS, V28, P1077; Walle UK, 2002, DRUG METAB DISPOS, V30, P564, DOI 10.1124/dmd.30.5.564; Whitlock JP, 1997, DRUG METAB REV, V29, P1107, DOI 10.3109/03602539709002245; XIE W, 2003, IN PRESS P NATL ACAD; Ziccardi MH, 2002, ENVIRON TOXICOL CHEM, V21, P2027, DOI 10.1897/1551-5028(2002)021<2027:AOTLRC>2.0.CO;2	38	139	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15001	15006		10.1074/jbc.M300645200	http://dx.doi.org/10.1074/jbc.M300645200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12566446	hybrid			2023-01-03	WOS:000182516100056
J	Klausberger, T; Magill, PJ; Marton, LF; Roberts, JDB; Cobden, PM; Buzsaki, G; Somogyi, P				Klausberger, T; Magill, PJ; Marton, LF; Roberts, JDB; Cobden, PM; Buzsaki, G; Somogyi, P			Brain-state- and cell-type-specific firing of hippocampal interneurons in vivo	NATURE			English	Article							PYRAMIDAL CELLS; RAT HIPPOCAMPUS; THETA-RHYTHM; IN-VIVO; NEURONS	Neural-network oscillations at distinct frequencies have been implicated in the encoding, consolidation and retrieval of information in the hippocampus. Some GABA (gamma-aminobutyric acid)-containing interneurons fire phase-locked to theta oscillations (4-8 Hz) or to sharp-wave-associated ripple oscillations (120-200 Hz), which represent different behavioural states(1-6). Interneurons also entrain pyramidal cells in vitro(7). The large diversity of interneurons(8-10) poses the question of whether they have specific roles in shaping distinct network activities in vivo. Here we report that three distinct interneuron types-basket, axo-axonic and oriens-lacunosum-moleculare cells-visualized and defined by synaptic connectivity as well as by neurochemical markers, contribute differentially to theta and ripple oscillations in anaesthetized rats. The firing patterns of individual cells of the same class are remarkably stereotyped and provide unique signatures for each class. We conclude that the diversity of interneurons, innervating distinct domains of pyramidal cells 11, emerged to coordinate the activity of pyramidal cells in a temporally distinct and brain-state-dependent manner.	Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England; Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA	University of Oxford; Rutgers State University Newark; Rutgers State University New Brunswick	Klausberger, T (corresponding author), Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Mansfield Rd, Oxford OX1 3TH, England.	thomas.klausberger@pharm.ox.ac.uk		Magill, Peter/0000-0001-7141-7071; Buzsaki, Gyorgy/0000-0002-3100-4800				Ali AB, 1998, J PHYSIOL-LONDON, V507, P185, DOI 10.1111/j.1469-7793.1998.185bu.x; Brun VH, 2002, SCIENCE, V296, P2243, DOI 10.1126/science.1071089; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; Csicsvari J, 1999, J NEUROSCI, V19, P274, DOI 10.1523/JNEUROSCI.19-01-00274.1999; FOX SE, 1989, EXP BRAIN RES, V77, P283, DOI 10.1007/BF00274985; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Fricker D, 2001, NEURON, V32, P771, DOI 10.1016/S0896-6273(01)00528-1; Gillies MJ, 2002, J PHYSIOL-LONDON, V543, P779, DOI 10.1113/jphysiol.2002.024588; Harris KD, 2002, NATURE, V417, P738, DOI 10.1038/nature00808; Harris KD, 2001, NEURON, V32, P141, DOI 10.1016/S0896-6273(01)00447-0; Katona I, 1999, NEUROSCIENCE, V88, P37, DOI 10.1016/S0306-4522(98)00302-9; Losonczy A, 2002, J PHYSIOL-LONDON, V542, P193, DOI 10.1113/jphysiol.2002.020024; Maccaferri G, 2000, J PHYSIOL-LONDON, V524, P91, DOI 10.1111/j.1469-7793.2000.t01-3-00091.x; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; McBain CJ, 2001, NAT REV NEUROSCI, V2, P11, DOI 10.1038/35049047; Mehta MR, 2002, NATURE, V417, P741, DOI 10.1038/nature00807; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; OKeefe J., 1978, HIPPOCAMPUS COGNITIV, DOI DOI 10.1101/LM.321006; Pinault D, 1996, J NEUROSCI METH, V65, P113, DOI 10.1016/0165-0270(95)00144-1; SIK A, 1995, J NEUROSCI, V15, P6651; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; Traub RD, 2002, REV NEUROSCIENCE, V13, P1; VANDERWOLF CH, 1988, INT REV NEUROBIOL, V30, P225; YLINEN A, 1995, HIPPOCAMPUS, V5, P78, DOI 10.1002/hipo.450050110; YLINEN A, 1995, J NEUROSCI, V15, P30; Zar J., 1999, PEARSON, V4th ed.	30	944	995	2	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	2003	421	6925					844	848		10.1038/nature01374	http://dx.doi.org/10.1038/nature01374			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	646QA	12594513				2023-01-03	WOS:000181044700048
J	Friedman, MA; den Besten, H; Attaran, A				Friedman, MA; den Besten, H; Attaran, A			Out-licensing: a practical approach for improvement of access to medicines in poor countries	LANCET			English	Editorial Material									Harvard Univ, John F Kennedy Sch Govt, Carr Ctr Human Rights Policy, Cambridge, MA 02138 USA; Int Dispensary Assoc, Amsterdam, Netherlands; Pharmacia Corp, Peapack, NJ USA	Harvard University; Pfizer	Attaran, A (corresponding author), Harvard Univ, John F Kennedy Sch Govt, Carr Ctr Human Rights Policy, 79 JFK St, Cambridge, MA 02138 USA.	amir_attaran@harvard.edu						ACHMAT Z, 2002, 14 INT AIDS C BARC; ACHMAT Z, 2001, GUARDIAN        1201; *ACT UP, 2002, ACT UP DEM BREAK PAT; *AIDS HEALTHC FDN, 2002, US LARG AIDS ORG CAL; Attaran A, 2001, JAMA-J AM MED ASSOC, V286, P1886, DOI 10.1001/jama.286.15.1886; BAKER BK, 2001, TRIPS REFORM VOLUNTA; BOOKER S, 2001, NATION          0709; BOSELEY S, 2002, GUARDIAN        1004; *BRIST MYERS SQUIB, 2001, BRIST SQUIBB ANN ACC; COHEN M, 2001, ASS PRESS WORLD 0516; *CONS PROJ TECHN H, 2001, JOINT STAT WTO WHO D; *HLTH GAP, 2002, WHAT IS HLTH GAP; *MED SANS FRONT, 2002, DURB BARC OV TREATM; *MERCK, 2000, HIV AIDS DEV WORLD M; Murray CJL, 1996, GLOBAL BURDEN DIS CO; PEARL D, 2001, WALL STREET J   0216; *PFIZER, 2002, ALL BUILD 1ST LARG S; *TREATM ACT CAMP, 2002, DEF CAMP QUEST ANSW; *UNAIDS, 2002, 12 M GEN MAY 28; WALDHOLZ M, 2002, WALL STREET J   0627; *WHO COMM MACR HLT, 2002, MACR HLTH INV HLTH E; *WHO WORLD TRADE O, 2002, WORKSH DIFF PRIC FIN; World Health Organization, 2002, SEL US ESS MED REP W; 2002, OXFAM IMPLAUSIBLE DE; 2002, REUTERS MED NEW 1115	25	16	16	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	2003	361	9354					341	344		10.1016/S0140-6736(03)12331-8	http://dx.doi.org/10.1016/S0140-6736(03)12331-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639RV	12559883				2023-01-03	WOS:000180643900029
J	Ellershaw, J; Ward, C				Ellershaw, J; Ward, C			Care of the dying patient: the last hours or days of life	BRITISH MEDICAL JOURNAL			English	Review									Marie Curie Ctr Liverpool, Liverpool L25 8QA, Merseyside, England; Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Dundee DD2 9SY, Scotland	University of Dundee	Ellershaw, J (corresponding author), Marie Curie Ctr Liverpool, Speke Rd, Liverpool L25 8QA, Merseyside, England.		Ram, Prem/K-4511-2012	Ellershaw, John/0000-0001-9789-3180				Anderson H, 2001, PALLIATIVE MED, V15, P279, DOI 10.1191/026921601678320269; *BRIT MED ASS, 1995, ADV STAT MED TREATM; Campbell H, 1998, BMJ-BRIT MED J, V316, P133; Clark D, 2002, BRIT MED J, V324, P905, DOI 10.1136/bmj.324.7342.905; *DEP HLTH, 2000, NAT SERV FRAM COR HE, pCH6; *DEP HLTH, 2000, NAT SERV FRAM COR HE, pCH7; DYER C, 1992, BRIT MED J, V305, P1311; Ellershaw J, 2001, J PAIN SYMPTOM MANAG, V21, P12, DOI 10.1016/S0885-3924(00)00240-2; Ellershaw J., 1997, EUR J PALLIAT CARE, V4, P203; Fallowfield LJ, 2002, PALLIATIVE MED, V16, P297, DOI 10.1191/0269216302pm575oa; FIELD D, IN PRESS MED ED; *GEN MED COUNC, 2002, TOM DOCT REC UND MED; Hanks GW, 1996, BRIT MED J, V312, P823; Higgs R, 1999, J ROY COLL PHYS LOND, V33, P110; HINTON JM, 1963, Q J MED, V32, P1; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; McCarthy M, 1996, J ROY COLL PHYS LOND, V30, P325; *NAT COUNC HOSP SP, 1997, J EUR ASS PALLIATIVE, V4, P203; *NAT COUNC HOSP SP, 2002, ETH DEC MAK PALL CAR; NHS Beacon Programme, 2001, NHS BEAC LEARN HDB S, V4, P128; Office of National Statistics, 2000, ANN REV REG GEN DEAT; Thomas K., 2003, CARING DYING HOME CO; TWYCROSS R, 1998, OXFORD BOOK PALLIATI, pCH17; *WORK PART CLIN GU, 1997, CHANG GEAR GUID MAN	24	351	359	1	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 4	2003	326	7379					30	34		10.1136/bmj.326.7379.30	http://dx.doi.org/10.1136/bmj.326.7379.30			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	633UP	12511460				2023-01-03	WOS:000180302000024
J	Weis, CP; Intrepido, AJ; Miller, AK; Cowin, PG; Durno, MA; Gebhardt, JS; Bull, R				Weis, CP; Intrepido, AJ; Miller, AK; Cowin, PG; Durno, MA; Gebhardt, JS; Bull, R			Secondary aerosolization of viable Bacillus anthracis spores in a contaminated US Senate Office	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PCR	Context Bioterrorist attacks involving letters and mail-handling systems in Washington, DC, resulted in Bacillus anthracis (anthrax) spore contamination in the Hart Senate Office Building and other facilities in the US Capitol's vicinity. Objective To provide information about the nature and extent of indoor secondary aerosolization of B anthracis spores. Design Stationary and personal air samples, surface dust, and swab samples were collected under semiquiescent (minimal activities) and then simulated active office conditions to estimate secondary aerosolization of B anthracis spores. Nominal size characteristics, airborne concentrations, and surface contamination of a anthracis particles (colony-forming units) were evaluated. Results Viable B anthracis spores reaerosolized under semiquiescent conditions, with a marked increase in reaerosolization during simulated active office conditions. Increases were observed for B anthracis collected on open sheep blood agar plates (P<.001) and personal air monitors (P=.01) during active office conditions. More than 80% of the B anthracis particles collected on stationary monitors were within an alveolar respirable size range of 0.95 to 3.5 &mu;m. Conclusions Bacillus anthracis spores used in a recent terrorist incident reaerosolized under common office activities. These findings have important implications for appropriate respiratory protection, remediation, and reoccupancy of contaminated office environments.	US EPA, Natl Enforcement Invest Ctr, Denver Fed Ctr, Denver, CO 80225 USA; USA, Ctr Hlth Promot & Prevent Med, Aberdeen Proving Ground, MD USA; US PHS, Denver, CO USA; US EPA, Cleveland Off, Westlake, OH USA; Naval Med Res Ctr, Biol Def Directorate, Silver Spring, MD USA	United States Environmental Protection Agency; United States Public Health Service; United States Environmental Protection Agency; Naval Medical Research Center (NMRC)	Weis, CP (corresponding author), US EPA, Natl Enforcement Invest Ctr, Denver Fed Ctr, Bldg 53,POB 25227, Denver, CO 80225 USA.		Weis, Christopher/GWR-1351-2022					Barakat LA, 2002, JAMA-J AM MED ASSOC, V287, P863, DOI 10.1001/jama.287.7.863; Brachman P S, 1980, Ann N Y Acad Sci, V353, P83, DOI 10.1111/j.1749-6632.1980.tb18910.x; BRACHMAN PS, 1966, BACTERIOL REV, V30, P646, DOI 10.1128/MMBR.30.3.646-659.1966; CHINN KS, 1996, REAEROSOLIZATION HAZ; DAVIDS DE, 1981, 321 DEF RES EST SUFF; DRUETT HA, 1953, J HYG-CAMBRIDGE, V51, P359, DOI 10.1017/S0022172400015795; FELLER W, 1950, INTRO PROBABILITY TH, P324; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Inglesby TV, 2002, JAMA-J AM MED ASSOC, V287, P2236, DOI 10.1001/jama.287.17.2236; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Keim M, 1999, ANN EMERG MED, V34, P177, DOI 10.1016/S0196-0644(99)70227-1; Linn William S., 1993, Journal of Occupational Medicine and Toxicology, V2, P1; LINN WS, 1993, J CLEAN TECHNOL ENV, V3, P101; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Marple V.A., 1986, CASCADE IMPACTOR SAM, P79; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; PARKER JS, 2001, TERRORISM MAIL PROTE; PATRICK WC, 1999, RISK ASSESSMENT BIOL; Peters CJ, 2002, LANCET, V359, P710, DOI 10.1016/S0140-6736(02)07792-9; Resnick IG, 1990, EVALUATION NEED DETE; WATSON A, 1994, EPIDEMIOL INFECT, V113, P47	21	91	97	2	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	2002	288	22					2853	2858		10.1001/jama.288.22.2853	http://dx.doi.org/10.1001/jama.288.22.2853			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623YM	12472327				2023-01-03	WOS:000179732600030
J	Zandi, PP; Carlson, MC; Plassman, BL; Welsh-Bohmer, KA; Mayer, LS; Steffens, DC; Breitner, JCS				Zandi, PP; Carlson, MC; Plassman, BL; Welsh-Bohmer, KA; Mayer, LS; Steffens, DC; Breitner, JCS		Cache County Memory Study Investig	Hormone replacement therapy and incidence of Alzheimer disease in older women - The Cache County Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COGNITIVE DECLINE; CONTROLLED TRIAL; ESTROGEN; RISK; DEMENTIA; AD; POPULATION; PREVALENCE; AGE	Context Previous studies have shown a sex-specific increased risk of Alzheimer disease (AD) in women older than 80 years. Basic neuroscience findings suggest that hormone replacement therapy (HRT) could reduce a woman's risk of AD. Epidemiologic findings on AD and HRT are mixed. Objective To examine the relationship between use of HRT and risk of AD among elderly women. Design, Setting, and Participants Prospective study of incident dementia among 1357 men (mean age, 73.2 years) and 1889 women (mean age, 74.5 years) residing in a single county in Utah. Participants were first assessed in 1995-1997, with follow-up conducted in 1998-2000. History of women's current and former use of HRT, as well as of calcium and multivitamin supplements, was ascertained at the initial contact. Main Outcome Measure Diagnosis of incident AD. Results Thirty-five men (2.6%) and 88 women (4.7%) developed AD between the initial interview and time of the follow-up Q years). Incidence among women increased after age 80 years and exceeded the risk among men of similar age (adjusted hazard ratio [HR], 2.11.; 95% confidence interval [CI], 1.22-3.86). Women who used HRT had a reduced risk of AD (26 cases among 1066 women) compared with non-HRT users (58 cases among 800 women) (adjusted HR, 0.59; 95% CI, 0.36-0.96). Risk varied with duration of HRT use, so that a woman's sex-specific increase in risk disappeared entirely with more than 10 years of treatment Q cases among 427 women). Adjusted HRs were 0.41 (95% CI, 0.17-0.86) for HRT users compared with non users and 0.77 (95% CI, 0.31-1.67) compared with men. No similar effect was seen with calcium or multivitamin use. Almost all of the HRT-related reduction in incidence reflected former use of HRT (9 cases among 490 women; adjusted HR, 0.33 [95% CI, 0.15-0.65]). There was no effect with current HRT use (17 cases among 576 women; adjusted HR, 1.08 [95% CI, 0.59-1.91]) unless duration of treatment exceeded 10 years (6 cases among 344 women; adjusted HR, 0.55 [95% CI, 0.21-1.23]). Conclusions Prior HRT use is associated with reduced risk of AD, but there is no apparent benefit with current HRT use unless such use has exceeded 10 years.	VA Puget Sound Hlth Care Syst, GRECC S182, Seattle, WA 98108 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Ment Hyg, Baltimore, MD USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA; Banner Hlth Syst, Phoenix, AZ USA; Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Johns Hopkins University; Duke University; Duke University; Banner Research; Banner Health; University of Washington; University of Washington Seattle	Breitner, JCS (corresponding author), VA Puget Sound Hlth Care Syst, GRECC S182, 1660 S Columbian Way, Seattle, WA 98108 USA.	jcsb@u.washington.edu	Plassman, Brenda L/K-2620-2015; Welsh-Bohmer, Kathleen/AAA-3178-2020		NIA NIH HHS [R01-AG-11380] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011380] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allison Paul D., 1984, EVENT HIST ANAL REGR; AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; Andersen K, 1999, NEUROLOGY, V53, P1992, DOI 10.1212/WNL.53.9.1992; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; Baldereschi M, 1998, NEUROLOGY, V50, P996, DOI 10.1212/WNL.50.4.996; Breitner JCS, 1999, NEUROLOGY, V53, P321, DOI 10.1212/WNL.53.2.321; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Lerner A, 1997, LANCET, V349, P403, DOI 10.1016/S0140-6736(97)80025-6; Marder K, 2000, NEUROLOGY, V54, P2035, DOI 10.1212/WNL.54.11.2035; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Miech RA, 2002, NEUROLOGY, V58, P209, DOI 10.1212/WNL.58.2.209; MORTEL KF, 1995, J NEUROPSYCH CLIN N, V7, P334; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; RINCH CE, 2000, CHANCE DEV AGING; Seshadri S, 2001, ARCH NEUROL-CHICAGO, V58, P435, DOI 10.1001/archneur.58.3.435; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; SILVERMAN JM, 1986, AM J PSYCHIAT, V143, P1279; Skoog I, 1999, J Epidemiol Biostat, V4, P227; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965	32	695	711	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2123	2129		10.1001/jama.288.17.2123	http://dx.doi.org/10.1001/jama.288.17.2123			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413371	Bronze			2023-01-03	WOS:000179048100022
J	Hanratty, B; Hibbert, D; Mair, F; May, C; Ward, C; Capewell, S; Litva, A; Corcoran, G				Hanratty, B; Hibbert, D; Mair, F; May, C; Ward, C; Capewell, S; Litva, A; Corcoran, G			Doctors' perceptions of palliative care for heart failure: focus group study	BRITISH MEDICAL JOURNAL			English	Article							OF-LIFE; DISEASE; END; COMMUNICATION; FAMILY; CANCER	Objectives To identify doctors' perceptions of the need for palliative care for heart failure and barriers to change. Design Qualitative study with focus groups. Setting North west England. Participants General practitioners and consultants in cardiology, geriatrics, palliative care, and general medicine. Results Doctors supported the development of palliative care for patients with heart failure with the general practitioner as a central figure. They were reluctant to endorse expansion of specialist palliative care services. Barriers to developing approaches to palliative care in heart failure related to three main areas: the organisation of health care, the unpredictable course of heart failure, and the doctors' understanding of roles. The health system was thought to work against provision of holistic care, exacerbated by issues of professional rivalry and control. The priorities identified for the future were developing the role of the nurse, better community support for primary care, and enhanced communication between all the health professionals involved in the care of patients with heart failure. Conclusions Greater consideration should be given to the care of patients dying with heart failure, clarifying the roles of doctors and nurses in different specialties, and reshaping the services provided for them. Many of the organisational and professional issues are not peculiar to patients dying with heart failure, and addressing such concerns as the lack of coordination and continuity in medical care would benefit all patients.	Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England; Univ Liverpool, Dept Primary Care, Liverpool L69 3GB, Merseyside, England; Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE3 1SX, Tyne & Wear, England; Wythenshawe Hosp, Dept Cardiol, Manchester M23 9LT, Lancs, England; Univ Hosp Aintree, Dept Palliat Care, Liverpool L9 7AL, Merseyside, England	University of Liverpool; University of Liverpool; Newcastle University - UK; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Hanratty, B (corresponding author), Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England.		May, Carl/A-8502-2011; Hanratty, Barbara/AAH-1801-2019	May, Carl/0000-0002-0451-2690; Hanratty, Barbara/0000-0002-3122-7190; Mair, Frances/0000-0001-9780-1135				ADDINGTONHALL J, 1995, STROKE, V26, P2242, DOI 10.1161/01.STR.26.12.2242; Anderson H, 2001, PALLIATIVE MED, V15, P279, DOI 10.1191/026921601678320269; Blue L, 2001, BRIT MED J, V323, P715, DOI 10.1136/bmj.323.7315.715; Davis RC, 2000, BRIT MED J, V320, P39, DOI 10.1136/bmj.320.7226.39; *DEP HLTH, 2000, NAT SERV FRAM COR HE; FRASER D, 1999, QSR NVIVO REFERENCE; Gibbs LME, 1998, BRIT MED J, V317, P961, DOI 10.1136/bmj.317.7164.961; Gore JM, 2000, THORAX, V55, P1000, DOI 10.1136/thorax.55.12.1000; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lloyd-Williams M, 2002, FAM PRACT, V19, P219, DOI 10.1093/fampra/19.3.219; McCarthy M, 1996, J ROY COLL PHYS LOND, V30, P325; *NAT COUNC HOSP SP, 1998, 14 NCHSPC; Rich MW, 1995, NEW ENGL J MED, V333, P1213; Rogers AE, 2000, BMJ-BRIT MED J, V321, P605, DOI 10.1136/bmj.321.7261.605; Silverman D., 1985, QUALITATIVE METHODOL; Skilbeck J, 1998, PALLIATIVE MED, V12, P245, DOI 10.1191/026921698677124622; Sloan RH, 2002, BRIT MED J, V324, P1035, DOI 10.1136/bmj.324.7344.1035; Stewart S, 2001, EUR J HEART FAIL, V3, P315, DOI 10.1016/S1388-9842(00)00141-0; Tobin Terry, 2002, Health Serv J, V112, P22; Ward C, 2002, HEART, V87, P294, DOI 10.1136/heart.87.3.294; 2001, 52001 BRIT HEART FDN	22	126	127	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 14	2002	325	7364					581	585		10.1136/bmj.325.7364.581	http://dx.doi.org/10.1136/bmj.325.7364.581			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	595JJ	12228136	Green Published, Bronze			2023-01-03	WOS:000178105200023
J	Smith, IE				Smith, IE			New drugs for breast cancer	LANCET			English	Review							FIRST-LINE THERAPY; PHASE-III; POSTMENOPAUSAL WOMEN; TAMOXIFEN; LETROZOLE; SUPERIOR; EFFICACY; CHEMOTHERAPY; CAPECITABINE; TRASTUZUMAB		Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Smith, IE (corresponding author), Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England.	ian.smith@rmh.nthames.nhs.uk						Baum M, 2002, LANCET, V359, P2131; Biganzoli L, 2002, J CLIN ONCOL, V20, P3114, DOI 10.1200/JCO.2002.11.005; Blum JL, 1999, J CLIN ONCOL, V17, P485, DOI 10.1200/JCO.1999.17.2.485; Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; Chan S, 1999, J CLIN ONCOL, V17, P2341, DOI 10.1200/JCO.1999.17.8.2341; Coleman RE, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.25427; Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601; Eiermann W, 2001, ANN ONCOL, V12, P1527, DOI 10.1023/A:1013128213451; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Hamilton A, 1999, ANN ONCOL, V10, P377, DOI 10.1023/A:1008368300827; HENDERSON IC, 1998, P AN M AM SOC CLIN, V17, P101; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; Klijn JGM, 2001, J CLIN ONCOL, V19, P343, DOI 10.1200/JCO.2001.19.2.343; Klijn JGM, 2000, JNCI-J NATL CANCER I, V92, P903, DOI 10.1093/jnci/92.11.903; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758, DOI 10.1200/JCO.2000.18.22.3758; NABHOLTZ JM, 2002, P ASCO, V21, P141; O'Shaughnessy J, 2002, J CLIN ONCOL, V20, P2812, DOI 10.1200/JCO.2002.09.002; Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080; Saarto T, 2001, J CLIN ONCOL, V19, P10, DOI 10.1200/JCO.2001.19.1.10; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719	24	23	26	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 7	2002	360	9335					790	792		10.1016/S0140-6736(02)09903-8	http://dx.doi.org/10.1016/S0140-6736(02)09903-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12241842				2023-01-03	WOS:000177933000025
J	Church, C; Junor, B				Church, C; Junor, B			Sclerosing peritonitis during continuous ambulatory peritoneal dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Western Infirm & Associated Hosp, Glasgow G11, Lanark, Scotland		Church, C (corresponding author), Western Infirm & Associated Hosp, Glasgow G11, Lanark, Scotland.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	2002	347	10					737	737		10.1056/NEJMicm010754	http://dx.doi.org/10.1056/NEJMicm010754			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	589NH	12213945				2023-01-03	WOS:000177765800007
J	Russell, MJ				Russell, MJ			The importance of being alkaline	SCIENCE			English	Editorial Material							ORIGIN; PEPTIDES; LIFE		Scottish Univ Environm Res Ctr, Glasgow G75 0QF, Lanark, Scotland	Scottish Universities Research & Reactor Center	Russell, MJ (corresponding author), Scottish Univ Environm Res Ctr, Glasgow G75 0QF, Lanark, Scotland.							Ferris JP, 2002, ORIGINS LIFE EVOL B, V32, P311, DOI 10.1023/A:1020543312109; Geptner A, 2002, CLAY CLAY MINER, V50, P174, DOI 10.1346/000986002760832775; Hanczyc MM, 2003, SCIENCE, V302, P618, DOI 10.1126/science.1089904; Huber C, 2003, SCIENCE, V301, P938, DOI 10.1126/science.1086501; Huber C, 1998, SCIENCE, V281, P670, DOI 10.1126/science.281.5377.670; Kelley DS, 2001, NATURE, V412, P145, DOI 10.1038/35084000; Martin W, 2003, PHILOS T R SOC LON B, V358, P27; Mellersh A, 2000, ORIGINS LIFE EVOL B, V30, P3, DOI 10.1023/A:1006620421068; MELLERSH AR, 1993, ORIGINS LIFE EVOL B, V23, P261, DOI 10.1007/BF01581903; Russell MJ, 2002, GEOCHEM NEWS, V113, P6; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; Woese C.R., 1967, GENETIC CODE MOL BAS	12	62	65	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					580	581		10.1126/science.1091765	http://dx.doi.org/10.1126/science.1091765			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576411	Green Accepted			2023-01-03	WOS:000186119900035
J	Dickinson, D; Raynor, DKT				Dickinson, D; Raynor, DKT			Ask the patients - they may want to know more than you think	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; MEDICINES		Consumation, Consumer Informat Design, London SW17 7QW, England; Univ Leeds, Pharm Practice & Med Management, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Dickinson, D (corresponding author), Consumation, Consumer Informat Design, 53 Hosack Rd, London SW17 7QW, England.		Sturchio, Jeffrey/GWZ-3472-2022					Berry DC, 1997, PSYCHOL HEALTH, V12, P467, DOI 10.1080/08870449708406723; Berry DC, 2002, LANCET, V359, P853, DOI 10.1016/S0140-6736(02)07923-0; Blenkinsopp A, 1998, BRIT MED J, V317, P413; Coulter A, 1999, BRIT MED J, V318, P318, DOI 10.1136/bmj.318.7179.318; Dickinson D, 2001, PATIENT EDUC COUNS, V43, P147, DOI 10.1016/S0738-3991(00)00156-7; RAYNOR DK, IN PRESS PATIENT ED	6	71	74	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					861	861		10.1136/bmj.327.7419.861-a	http://dx.doi.org/10.1136/bmj.327.7419.861-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732BP	14551106	Green Published, Green Accepted			2023-01-03	WOS:000185921200028
J	Petitti, DB				Petitti, DB			Combination estrogen-progestin oral contraceptives	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL-VEIN-THROMBOSIS; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; OVARIAN-CANCER; YOUNG-WOMEN; CERVICAL-CANCER; CARDIOVASCULAR-DISEASE; ETHINYL ESTRADIOL; UTERINE FIBROIDS; SINUS THROMBOSIS		Kaiser Permanente So Calif, Res & Evaluat Dept, Pasadena, CA 91188 USA	Kaiser Permanente	Petitti, DB (corresponding author), Kaiser Permanente So Calif, Res & Evaluat Dept, 100 S Los Robles,2nd Fl, Pasadena, CA 91188 USA.	diana.b.petitti@kp.org						[Anonymous], 2001, INT J GYNECOL OBSTET, V75, P93; [Anonymous], 1998, Contraception, V58, P262; Bloemenkamp KWM, 1999, ARCH INTERN MED, V159, P65, DOI 10.1001/archinte.159.1.65; Bloemenkamp KWM, 2000, ARCH INTERN MED, V160, P49, DOI 10.1001/archinte.160.1.49; Burkman RT, 2001, CLIN OBSTET GYNECOL, V44, P62, DOI 10.1097/00003081-200103000-00010; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Chang CL, 1999, BMJ-BRIT MED J, V318, P13; Chang Jeani, 2003, MMWR Surveill Summ, V52, P1; Chiaffarino F, 1999, BRIT J OBSTET GYNAEC, V106, P857, DOI 10.1111/j.1471-0528.1999.tb08409.x; Cosmi B, 2003, ARCH INTERN MED, V163, P1105, DOI 10.1001/archinte.163.9.1105; Davis A, 2000, OBSTET GYNECOL, V96, P913, DOI 10.1016/S0029-7844(00)01029-2; de Bruijn SFTM, 1998, BRIT MED J, V316, P589, DOI 10.1136/bmj.316.7131.589; de Bruijn SFTM, 1998, LANCET, V351, P1404, DOI 10.1016/S0140-6736(05)79442-3; de Bruijn SFTM, 1998, BRIT MED J, V316, P822; DELGADORODRIGUEZ M, 1992, ACTA OBSTET GYN SCAN, V71, P368, DOI 10.3109/00016349209021075; Dunn N, 1999, BRIT MED J, V318, P1579, DOI 10.1136/bmj.318.7198.1579; Farley TMM, 1998, CONTRACEPTION, V57, P211, DOI 10.1016/S0010-7824(98)00019-5; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; Fernandez E, 1998, EPIDEMIOLOGY, V9, P295, DOI 10.1097/00001648-199805000-00014; Fu HS, 1999, FAM PLANN PERSPECT, V31, P56, DOI 10.2307/2991640; Gabrick DM, 2000, JAMA-J AM MED ASSOC, V284, P1791, DOI 10.1001/jama.284.14.1791; Hannaford P, 2000, DRUG SAFETY, V22, P361, DOI 10.2165/00002018-200022050-00004; Heimdal K, 2002, CANCER DETECT PREV, V26, P23, DOI 10.1016/S0361-090X(02)00004-1; Heinemann L A, 1998, Eur J Contracept Reprod Health Care, V3, P194; Heinemann LAJ, 1997, CONTRACEPTION, V56, P275, DOI 10.1016/S0010-7824(97)00158-3; Heinemann LAJ, 1998, CONTRACEPTION, V57, P29, DOI 10.1016/S0010-7824(97)00204-7; Hennessy S, 2001, CONTRACEPTION, V64, P125, DOI 10.1016/S0010-7824(01)00234-7; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; Kemmeren JM, 2002, STROKE, V33, P1202, DOI 10.1161/01.STR.0000015345.61324.3F; Koulianos GT, 2000, CUTIS, V66, P281; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Lewis MA, 1996, BRIT MED J, V312, P88; Lidegaard O, 1998, CONTRACEPTION, V57, P291, DOI 10.1016/S0010-7824(98)00033-X; Marchbanks PA, 2002, NEW ENGL J MED, V346, P2025, DOI 10.1056/NEJMoa013202; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; Martinelli I, 1998, LANCET, V352, P326, DOI 10.1016/S0140-6736(05)60307-8; Milman N, 1998, ANN HEMATOL, V77, P13, DOI 10.1007/s002770050405; Modan B, 2001, NEW ENGL J MED, V345, P235, DOI 10.1056/NEJM200107263450401; Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3; Narod SA, 2002, JNCI-J NATL CANCER I, V94, P1773, DOI 10.1093/jnci/94.23.1773; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Ness RB, 2000, AM J EPIDEMIOL, V152, P233, DOI 10.1093/aje/152.3.233; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; Olson WH, 1998, INT J FERTIL WOMEN M, V43, P286; Parkin L, 2000, LANCET, V355, P2133, DOI 10.1016/S0140-6736(00)02382-5; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; RIVERA R, 1983, CONTRACEPTION, V27, P311, DOI 10.1016/0010-7824(83)90009-4; Royar J, 2001, INT J CANCER, V95, P370, DOI 10.1002/1097-0215(20011120)95:6<370::AID-IJC1065>3.0.CO;2-T; Samadi AR, 1996, AM J PUBLIC HEALTH, V86, P858, DOI 10.2105/AJPH.86.6.858; Schwartz SM, 1998, STROKE, V29, P2277, DOI 10.1161/01.STR.29.11.2277; Sidney S, 1998, CIRCULATION, V98, P1058, DOI 10.1161/01.CIR.98.11.1058; Spitzer WO, 1996, BRIT MED J, V312, P83; STAMPFER MJ, 1990, AM J OBSTET GYNECOL, V163, P285, DOI 10.1016/0002-9378(90)90569-S; Tanis BC, 2001, NEW ENGL J MED, V345, P1787, DOI 10.1056/NEJMoa003216; Thomas DB, 2001, AM J EPIDEMIOL, V153, P723, DOI 10.1093/aje/153.8.723; Thorneycroft IH, 1999, AM J OBSTET GYNECOL, V180, pS280, DOI 10.1016/S0002-9378(99)70719-2; Thorneycroft IH, 1999, CONTRACEPTION, V60, P255, DOI 10.1016/S0010-7824(99)00093-1; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; Tzourio C, 2000, CEPHALALGIA, V20, P190, DOI 10.1046/j.1468-2982.2000.00041.x; Ursin G, 1997, CANCER RES, V57, P3678; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; Walker GR, 2002, AM J OBSTET GYNECOL, V186, P8, DOI 10.1067/mob.2002.118657; *WHO, 2000, IMPR ACC QUAL CAR FA, P1	65	179	191	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1443	1450		10.1056/NEJMcp030751	http://dx.doi.org/10.1056/NEJMcp030751			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534338				2023-01-03	WOS:000185769500009
J	Anderson, GL; Judd, HL; Kaunitz, AM; Barad, DH; Beresford, SAA; Pettinger, M; Liu, J; McNeeley, SG; Lopez, AM				Anderson, GL; Judd, HL; Kaunitz, AM; Barad, DH; Beresford, SAA; Pettinger, M; Liu, J; McNeeley, SG; Lopez, AM		Women's Hlth Initiative Investigat	Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures - The Women's Health Initiative randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; EPITHELIAL OVARIAN-CANCER; ENDOMETRIAL CANCER; POSTMENOPAUSAL WOMEN; RISK; PREVENTION; PIPELLE	Context The effects of continuous combined hormone therapy on gynecologic cancers have not been investigated previously in a randomized trial setting. Objective To determine the possible associations of estrogen plus progestin on gynecologic cancers and related diagnostic procedures. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial of 16608 postmenopausal women, who had not had a hysterectomy at baseline and who had been recruited from 40 US clinical centers between September 1993 and October 1998 (average follow-up, 5.6 years). Intervention One tablet per day containing 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate (n=8506) or placebo (n=8102). Main Outcome Measure Incident invasive cancer of the ovary and endometrium. Results In 5.6 years of follow-up, there were 32 cases of invasive ovarian cancer, 58 cases of endometrial cancer, 1 case of nonendometrial uterine cancer, 13 cases of cervical cancer, and 7 cases of other gynecologic cancers. The hazard ratio (HR) for invasive ovarian cancer in women assigned to estrogen plus progestin compared with placebo Was 1.58 (95% confidence interval [CI], 0.77-3.24). The HR for endometrial cancer was 0.81 (95% Cl, 0.48-1.36). No appreciable differences were found in the distributions of tumor histology, stage, or grade for either cancer site. The incidence of other gynecologic cancers was low and did not differ by randomization assignment. More women taking estrogen plus progestin required endometrial biopsies (33% vs 6%; P<.001) Conclusions This randomized trial suggests that continuous combined estrogen plus progestin therapy may increase the risk of ovarian cancer while producing endometrial cancer rates similar to placebo. The increased burden of endometrial biopsies required to assess vaginal bleeding further limits the acceptability of this regimen. These data provide additional support for caution in the use of continuous combined hormones.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA; Univ Florida, Hlth Sci Ctr, Dept Obstet & Gynecol, Jacksonville, FL 32209 USA; Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA; Case Western Reserve Univ, Dept Reprod Biol, Cleveland, OH 44106 USA; Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA; Univ Arizona, Ctr Canc, Dept Internal Med, Tucson, AZ USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; State University System of Florida; University of Florida; Yeshiva University; Albert Einstein College of Medicine; Case Western Reserve University; Wayne State University; University of Arizona	Anderson, GL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,MP-1002, Seattle, WA 98109 USA.		Barad, David/AAF-4332-2021; Kaunitz, Andrew/AAL-8448-2020	Anderson, Garnet/0000-0001-5087-7837; Lopez, Ana Maria/0000-0002-2759-5353				*AM COLL OBST GYN, HORM THER QUEST ANSW; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; BOOTH M, 1989, BRIT J CANCER, V60, P592, DOI 10.1038/bjc.1989.320; Cramer Daniel W., 1995, Annals of Epidemiology, V5, P310, DOI 10.1016/1047-2797(94)00098-E; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; FATHALLA MF, 1971, LANCET, V2, P163; Freedman L, 1996, CONTROL CLIN TRIALS, V17, P509, DOI 10.1016/S0197-2456(96)00016-5; GARDNER WU, 1961, J NATL CANCER I, V26, P829; Hill DA, 2000, AM J OBSTET GYNECOL, V183, P1456, DOI 10.1067/mob.2000.108081; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; KAUNITZ AM, 1988, J REPROD MED, V33, P427; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; *NAT CANC I, 1992, SEER PROGR COD MAN R; *NAT CANC I, 1973, SURV EP END RES SEER; Ness RB, 1999, JNCI-J NATL CANCER I, V91, P1459, DOI 10.1093/jnci/91.17.1459; Ness RB, 2000, AM J EPIDEMIOL, V152, P233, DOI 10.1093/aje/152.3.233; Percy C., 1990, INT CLASSIFICATION D; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; PURDIE D, 1995, INT J CANCER, V62, P678, DOI 10.1002/ijc.2910620606; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Risch HA, 1996, GYNECOL ONCOL, V63, P254, DOI 10.1006/gyno.1996.0315; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Rodriguez GC, 1998, J SOC GYNECOL INVEST, V5, P271, DOI 10.1016/S1071-5576(98)00017-3; Smith-Bindman R, 1998, JAMA-J AM MED ASSOC, V280, P1510, DOI 10.1001/jama.280.17.1510; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; Stadel B V, 1975, Am J Obstet Gynecol, V123, P772; STOVALL TG, 1991, OBSTET GYNECOL, V77, P954; Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131; WEISS NS, 1982, J NATL CANCER I, V68, P95; WHITTEMORE AS, 1993, CANCER-AM CANCER SOC, V71, P558; *WOM HLTH IN STUD, 1998, JAMA-J AM MED ASSOC, V19, P61; WOODRUFF JD, 1994, AM J OBSTET GYNECOL, V170, P1213	34	352	375	2	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1739	1748		10.1001/jama.290.13.1739	http://dx.doi.org/10.1001/jama.290.13.1739			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519708	Bronze			2023-01-03	WOS:000185606100023
J	Barr, RG; Rowe, BH; Camargo, CA				Barr, RG; Rowe, BH; Camargo, CA			Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RELEASE THEOPHYLLINE; AIRWAYS OBSTRUCTION; AMINOPHYLLINE; SALBUTAMOL; THERAPY; MANAGEMENT	Objective To evaluate the addition of methylxanthines to standard treatments in patients presenting with acute exacerbations of chronic obstructive pulmonary disease (COPD). Design Meta-analysis of randomised controlled trials. Data source The Cochrane air-ways review group's COPD register. Two reviewers independently selected articles for inclusion, assessed methodological quality, and extracted data. Selection of studies Four trials met the inclusion criteria, with 169 patients. Main outcome measures Mean change in spirometry, clinical end points, symptom scores, and adverse events. Results Mean change in forced expiratory volume at one second at two hours was similar in methylxanthine and placebo groups but transiently increased with methylxanthines at three days. Non-significant reductions in admissions to hospital and length of stay were offset by a non-significant increase in relapses at one week. Changes in symptom scores did not reach significance. Methylxanthines caused more nausea and vomiting than placebo (odds ratio 4.6,95% confidence interval 1.7 to 12.6), and non-significant increases in tremor, palpitations, and arrhythmias were also observed. Conclusions The available data do not support the use of methylxanthines for the treatment of exacerbations of chronic obstructive pulmonary disease. Potential benefits of methylxanthines for lung function and symptoms were generally not confirmed at standard levels of significance, whereas the potentially important adverse events of nausea and vomiting were significantly increased in patients receiving methylxanthines.	Columbia Presbyterian Med Ctr, Div Gen Med, New York, NY 10032 USA; Univ Alberta, Div Emergency Med, Edmonton, AB T6G 2B7, Canada; Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA	Columbia University; NewYork-Presbyterian Hospital; University of Alberta; Harvard University; Massachusetts General Hospital	Barr, RG (corresponding author), Columbia Presbyterian Med Ctr, Div Gen Med, New York, NY 10032 USA.	rgb9@columbia.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NHLBI NIH HHS [HL-07427, HL-63841] Funding Source: Medline; BHP HRSA HHS [PE-11001] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063841, T32HL007427] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BHP HRSA HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONE RC, 1980, ARCH INTERN MED, V140, P1018, DOI 10.1001/archinte.140.8.1018; Brantingham P, 1970, Br J Clin Pract, V24, P165; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CHIAPPINI F, 1990, Clinica Terapeutica, V135, P121; CHIN R, 1983, CRIT CARE Q, V6, P1; DOLCETTI A, 1988, J INT MED RES, V16, P264, DOI 10.1177/030006058801600403; DONNER C, 1980, G ITAL MAL TORACE, V34, P307; DOROW P, 1978, ARZNEIMITTELFORSCH, V28-1, P853; FURUKAWA CT, 1988, ANN ALLERGY, V60, P472; HOLFORD N, 1993, CLIN PHARMACOKINET, V25, P495, DOI 10.2165/00003088-199325060-00007; HOLFORD N, 1993, CLIN PHARMACOKINET, V25, P506, DOI 10.2165/00003088-199325060-00008; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JENKINS PF, 1982, BRIT J DIS CHEST, V76, P57; JONSSON S, 1988, CHEST, V94, P723, DOI 10.1378/chest.94.4.723; LIGHT RW, 1983, RESP CARE, V28, P561; LLOBERES P, 1988, EUR RESPIR J, V1, P536; MORANDINI GC, 1989, CLIN TRIALS J, V26, P163; MUSIL J, 1998, PRAKT LEK, V78, P319; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pearson MG, 1997, THORAX, V52, pS1; Peleman RA, 1998, CLIN EXP ALLERGY, V28, P53; PERRET L, 1980, FINSKA LAKARESALLSKA, V124, P101; RAM FSF, 2000, AM J RESP CRIT CAR S, V161, pA489; Ram FSF., 2002, COCHRANE DB SYST REV, V2002, pCD003902, DOI DOI 10.1002/14651858.CD003902; REINECKE T, 1986, ANN EMERG MED, V15, P147, DOI 10.1016/S0196-0644(86)80009-9; RICE KL, 1987, ANN INTERN MED, V107, P305, DOI 10.7326/0003-4819-107-2-305; SAHAY JN, 1984, CURR MED RES OPIN, V9, P1, DOI 10.1185/03007998409109551; SAHAY JN, 1986, BRIT J CLIN PRACT, V40, P198; Schmidt E W, 1988, Prax Klin Pneumol, V42, P600; SEIDENFELD JJ, 1984, ANN EMERG MED, V13, P248, DOI 10.1016/S0196-0644(84)80472-2; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Snow V, 2001, ANN INTERN MED, V134, P595, DOI 10.7326/0003-4819-134-7-200104030-00015; TANSER AR, 1982, PRACTITIONER, V226, P569; TEDDERS JG, 1976, BRIT J CLIN PRACT, V30, P212; THOMAS P, 1992, CHEST, V101, P160, DOI 10.1378/chest.101.1.160; VOZEH S, 1982, AM REV RESPIR DIS, V125, P181; Weinberger M, 1996, NEW ENGL J MED, V334, P1380, DOI 10.1056/NEJM199605233342107; WRENN K, 1991, ANN INTERN MED, V115, P241, DOI 10.7326/0003-4819-115-4-241	38	70	75	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2003	327	7416					643	646A		10.1136/bmj.327.7416.643	http://dx.doi.org/10.1136/bmj.327.7416.643			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500434	Bronze, Green Published			2023-01-03	WOS:000185463100014
J	Adachi, M; Saito, H; Kobayashi, H; Horie, Y; Kato, S; Yoshioka, M; Ishii, H				Adachi, M; Saito, H; Kobayashi, H; Horie, Y; Kato, S; Yoshioka, M; Ishii, H			Hepatic injury in 12 patients taking the herbal weight loss aids Chaso or Onshido	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATOTOXICITY; SUPPLEMENTS; REMEDIES	Background: The Chinese herbal dietary supplements Chaso and Onshido are marketed for weight loss in Japan. The safety of these weight loss aids is unknown. Objective: To describe patients who developed liver injury while taking Chaso or Onshido. Design: Case series. Setting: Keio University Hospital, Tokyo, Japan, and other hospitals in Japan. Patients: 6 patients who took Chaso and 6 patients who took Onshido before presenting with liver injury. Measurements: Pathologic, clinical, and laboratory evaluations and chemical analysis of the herbal weight loss aids. Results: All 12 patients developed acute liver injury characterized by a marked increase in serum liver chemistry values (mean alanine aminotransferase level, 1978 U/L [range, 283 to 4074 U/L]) after ingesting these products. Two patients developed fulminant hepatic failure: 1 patient required liver transplantation, and the other patient died. N-nitroso-fenfluramine, a variant of the appetite-depressant drug fenfluramine, was present in these products. Conclusions: The use of the weight loss aids Chaso and Onshido may be associated with acute liver injury. N-nitroso-fenfluramine is a possible hepatotoxic ingredient.	Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Ishii, H (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.							Allison DB, 2001, CRIT REV FOOD SCI, V41, P1, DOI 10.1080/20014091091661; Barnes J, 1998, BRIT J CLIN PHARMACO, V45, P496, DOI 10.1046/j.1365-2125.1998.00715.x; Chitturi S, 2000, J GASTROEN HEPATOL, V15, P1093, DOI 10.1046/j.1440-1746.2000.02349.x; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; ELIASON BC, 1994, J FAM PRACTICE, V38, P287; Favreau JT, 2002, ANN INTERN MED, V136, P590, DOI 10.7326/0003-4819-136-8-200204160-00008; HANAWA N, 2003, ACTAZ HEPATOLOGICA J, V44, P21; Hasegawa R, 1998, CANCER LETT, V123, P185, DOI 10.1016/S0304-3835(97)00417-5; Hutchins GM, 2001, NEW ENGL J MED, V344, P1095; KATO Y, 1979, Gastroenterologia Japonica, V14, P216; Nadir A, 1996, AM J GASTROENTEROL, V91, P1436; Shaw D, 1997, DRUG SAFETY, V17, P342, DOI 10.2165/00002018-199717050-00006; Sheikh NM, 1997, ARCH INTERN MED, V157, P913, DOI 10.1001/archinte.157.8.913; Trey C, 1970, Prog Liver Dis, V3, P282; Zimmerman H J, 2000, Clin Liver Dis, V4, P73, DOI 10.1016/S1089-3261(05)70097-0	16	59	60	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					488	492		10.7326/0003-4819-139-6-200309160-00012	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679326				2023-01-03	WOS:000185324100005
J	van der Heide, A; Deliens, L; Faisst, K; Nilstun, T; Norup, M; Paci, E; van der Wal, G; van der Maas, PJ				van der Heide, A; Deliens, L; Faisst, K; Nilstun, T; Norup, M; Paci, E; van der Wal, G; van der Maas, PJ		EURELD Consortium	End-of-life decision-making in six European countries: descriptive study	LANCET			English	Article							PALLIATIVE-CARE; MEDICAL-PRACTICE; NATIONAL SURVEY; INTENSIVE-CARE; ILL PATIENTS; EUTHANASIA; PHYSICIANS; ATTITUDES; SUPPORT	Background Empirical data about end-of-life decision-making practices are scarce. We aimed to investigate frequency and characteristics of end-of-life decision-making practices in six European countries: Belgium, Denmark, Italy, the Netherlands, Sweden, and Switzerland. Methods In all participating countries, deaths reported to death registries were stratified for cause (apart from in Switzerland), and samples were drawn from every stratum. Reporting doctors received a mailed questionnaire about the medical decision-making that had preceded the death of the patient. The data-collection procedure precluded identification of any of the doctors or patients. All deaths arose between June, 2001, and February, 2002. We weighted data to correct for stratification and to make results representative for all deaths: results were presented as weighted percentages. Findings The questionnaire response rate was 75% for the Netherlands, 67% for Switzerland, 62% for Denmark, 61% for Sweden, 59% for Belgium, and 44% for Italy. Total number of deaths studied was 20 480. Death happened suddenly and unexpectedly in about a third of cases in all countries. The proportion of deaths that were preceded by any end-of-life decision ranged between 23% (Italy) and 51% (Switzerland). Administration of drugs with the explicit intention of hastening death varied between countries: about 1% or less in Denmark, Italy, Sweden, and Switzerland, 1.82% in Belgium, and 3.40% in the Netherlands. Large variations were recorded in the extent to which decisions were discussed with patients, relatives, and other caregivers. Interpretation Medical end-of-life decisions frequently precede dying in all participating countries. Patients and relatives are generally involved in decision-making in countries in which the frequency of making these decisions is high.	Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Free Univ Brussels, Dept Med Sociol & Hlth Sci, Brussels, Belgium; Univ Zurich, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland; Lund Univ, Dept Med Eth, Lund, Sweden; Univ Copenhagen, Dept Med Philosophy & Clin Theory, Copenhagen, Denmark; Ctr Study & Prevent Canc, Epidemiol Unit, Florence, Italy; Vrije Univ Amsterdam, Med Ctr, Dept Social Med, Amsterdam, Netherlands; Inst Res Extramural Med, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Zurich; Lund University; University of Copenhagen; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	van der Heide, A (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.			Deliens, Luc/0000-0002-8158-2422				[Anonymous], 1993, HIST PUBLIC HLTH; BERNARD HR, 1984, ANNU REV ANTHROPOL, V13, P495, DOI 10.1146/annurev.an.13.100184.002431; Bittel N, 2002, SUPPORT CARE CANCER, V10, P265, DOI 10.1007/s00520-001-0325-0; Cuttini M, 2000, LANCET, V355, P2112, DOI 10.1016/S0140-6736(00)02378-3; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; DiMola G, 1996, ANN ONCOL, V7, P907, DOI 10.1093/oxfordjournals.annonc.a010792; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; Folker AP, 1996, BIOETHICS, V10, P233, DOI 10.1111/j.1467-8519.1996.tb00122.x; Forde R, 1997, SOC SCI MED, V45, P887, DOI 10.1016/S0277-9536(96)00430-3; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; Kuhse H, 1997, MED J AUSTRALIA, V166, P191, DOI 10.5694/j.1326-5377.1997.tb140074.x; Nilstun T, 1996, Lakartidningen, V93, P1350; Parens E, 1996, HASTINGS CENT REP, V26, P13, DOI 10.2307/3527601; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Shah N, 1998, LANCET, V352, P1360, DOI 10.1016/S0140-6736(05)60751-9; Sjokvist P, 1999, INTENS CARE MED, V25, P949, DOI 10.1007/s001340050987; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; TENO J, 2001, CLIN EPIDEMIOLOGICAL; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERWAL G, 1996, EUTHANASIA OTHER MED; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; WEHKAMP KH, 1998, BERLINER MEDIZINETHI; Weiss SC, 2001, LANCET, V357, P1311, DOI 10.1016/S0140-6736(00)04515-3	25	483	488	3	76	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 2	2003	362	9381					345	350		10.1016/S0140-6736(03)14019-6	http://dx.doi.org/10.1016/S0140-6736(03)14019-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	707FB	12907005				2023-01-03	WOS:000184498700006
J	Goode, PS; Burgio, KL; Locher, JL; Roth, DL; Umlauf, MG; Richter, HE; Varner, RE; Lloyd, LK				Goode, PS; Burgio, KL; Locher, JL; Roth, DL; Umlauf, MG; Richter, HE; Varner, RE; Lloyd, LK			Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-INCONTINENCE; OLDER WOMEN; VAGINAL CONES; BIOFEEDBACK; MANAGEMENT; BLIND	Context Pelvic floor electrical stimulation (PFES) has been shown to be effective for stress incontinence. However, its role in a multicomponent behavioral training program has not been defined. Objective To determine if PFES increases efficacy of behavioral training for community-dwelling women with stress incontinence. Design and Setting Prospective randomized controlled trial conducted from October 1, 1995, through May 1, 2001, at a university-based outpatient continence clinic in the United States. Patients Volunteer sample of 200 ambulatory, nondemented, community-dwelling women aged 40 to 78 years with stress or mixed incontinence with stress as the predominant pattern; stratified by race, type of incontinence (stress only vs mixed), and severity (frequency of episodes). Interventions Patients were randomly assigned to 8 weeks (4 visits) of behavioral training, 8 weeks (4 visits) of the behavioral training plus home PFES, or 8 weeks of self-administered behavioral treatment using a self-help booklet (control condition). Main Outcome Measures Primary outcome was percentage reduction in the number of incontinent episodes as documented in bladder diaries. Secondary outcomes were patient satisfaction and changes in quality of life. Results Intention-to-treat analysis showed that incontinence was reduced a mean of 68.6% with behavioral training, 71.9% with behavioral training plus PFES, and 52.5% with the self-help booklet (P=.005). In comparison with the self-help booklet, behavioral training (P=.02) and behavioral training plus PFES (P=.002) were significantly more effective, but they were not significantly different from each other (P=.60). The PFES group had significantly better patient self-perception of outcome (P<.001) and satisfaction with progress (P=.02). Significant improvements were seen across all 3 groups on the Incontinence Impact Questionnaire but with no between-group differences. Conclusions Treatment with PFES did not increase effectiveness of a comprehensive behavioral program for women with stress incontinence. A self-help booklet reduced incontinence and improved quality of life but not as much as the clinic-based programs.	Univ Alabama, Sch Med, Birmingham, AL USA; Univ Alabama, Ctr Aging, Birmingham, AL USA; Univ Alabama, Sch Nursing, Birmingham, AL USA; Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA; Dept Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Geriatric Research Education & Clinical Center	Goode, PS (corresponding author), Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, 11G,700 19th St S, Birmingham, AL 35233 USA.		Umlauf, Mary Grace/A-5021-2015	Locher, Julie/0000-0002-2639-6459; Richter, Holly E/0000-0001-7741-5771	NIDDK NIH HHS [1R01DK49472] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049472] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrams P., 1990, INT UROGYNECOL J, V1, P45, DOI [10.1007/BF00373608, DOI 10.1007/BF00373608]; *AM MED ASS, 2001, BEH THER TREATM UR I, P12; Blowman C, 1991, PHYSIOTHERAPY, V77, P661; Bo K, 1999, BMJ-BRIT MED J, V318, P487, DOI 10.1136/bmj.318.7182.487; BURGIO KL, 1985, ANN INTERN MED, V103, P507, DOI 10.7326/0003-4819-103-4-507; Burgio KL, 2002, JAMA-J AM MED ASSOC, V288, P2293, DOI 10.1001/jama.288.18.2293; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; Burgio KL, 1989, STAYING DRY PRACTICA; CAPUTO RM, 1993, J REPROD MED, V38, P667; *DEP HHS, 2000, MED COV ISS MAN; Derogatis L.R., 1983, SCL 90 R ADM SCORING; ENGEL BT, 1974, NEW ENGL J MED, V290, P646, DOI 10.1056/NEJM197403212901202; ERIKSEN BC, 1987, BRIT J UROL, V59, P45, DOI 10.1111/j.1464-410X.1987.tb04577.x; ERLANDSON BE, 1977, SCAND J UROL NEPHR S, V44, P49; Fall M, 1978, SCAND J UROL NEPHR S, V44, P41; FISCHER W, 1983, ACTA OBSTET GYN SCAN, V62, P579, DOI 10.3109/00016348309156252; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GODEC CJ, 1981, INVEST UROL, V18, P239; HAHN I, 1991, NEUROUROL URODYNAM, V10, P545, DOI 10.1002/nau.1930100604; HUFFMAN J W, 1952, Arch Phys Med Rehabil, V33, P674; KARRAM MM, 1988, OBSTET GYNECOL, V71, P807; KRALJ B, 1991, UROGYNECOLOGY URODYN, P508; Locher JL, 2001, J GERONTOL A-BIOL, V56, pM32, DOI 10.1093/gerona/56.1.M32; Montgomery E, 1983, Physiotherapy, V69, P112; MOORE T, 1967, BMJ-BRIT MED J, V3, P150, DOI 10.1136/bmj.3.5558.150; OLAH KS, 1990, AM J OBSTET GYNECOL, V162, P87, DOI 10.1016/0002-9378(90)90827-T; PLEVNIK S, 1977, MED BIOL ENG COMPUT, V15, P155, DOI 10.1007/BF02442959; SAND PK, 1995, AM J OBSTET GYNECOL, V173, P72, DOI 10.1016/0002-9378(95)90172-8; SHUMAKER SA, 1994, QUAL LIFE RES, V3, P291, DOI 10.1007/BF00451721; Sung MS, 2000, J KOREAN MED SCI, V15, P303, DOI 10.3346/jkms.2000.15.3.303; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yamanishi T, 1997, J UROLOGY, V158, P2127, DOI 10.1016/S0022-5347(01)68176-X	32	118	127	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2003	290	3					345	352		10.1001/jama.290.3.345	http://dx.doi.org/10.1001/jama.290.3.345			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	699WK	12865375	Bronze			2023-01-03	WOS:000184078800028
J	Anakk, S; Kalsotra, A; Shen, Q; Vu, MT; Staudinger, JL; Davies, PJA; Strobel, HW				Anakk, S; Kalsotra, A; Shen, Q; Vu, MT; Staudinger, JL; Davies, PJA; Strobel, HW			Genomic characterization and regulation of CYP3a13: role of xenobiotics and nuclear receptors	FASEB JOURNAL			English	Article						cytochrome P4503A; drug metabolism; sexual dimorphism; nuclear receptors	RETINOID-X-RECEPTOR; TATA-LESS; HUMAN HEPATOCYTES; CDNA CLONING; EXPRESSION; GENE; INDUCTION; LIVER; TRANSCRIPTION; DEXAMETHASONE	We report that CYP3a13 gene, located on mouse chromosome 5, spans 27.5 Kb and contains 13 exons. The transcription start site is 35 bp upstream of the coding region and results in a 109 bp 5' untranslated region. CYP3a13 promoter shows putative binding sites for retinoid X receptor, pregnane X receptor, and estrogen receptor. CYP3a13 shows a broad tissue distribution with predominant expression in liver. Although CYP3a13 shares 92% nucleotide identity with the female-specific rat CYP3A9, its expression does not exhibit sexual dimorphism. Ligand activation of peroxisomal proliferator-activated receptor-gamma and retinoid X receptor inhibit expression of CYP3a13 at the transcription level in a tissue-specific manner. Another novel finding is hepatic induction of CYP3a13 by dexamethasone occurring only in pregnane X receptor null mice. We also report that pregnane X receptor is essential to maintain robust in vivo basal levels of CYP3a13 in contrast to CYP3a11. CYP3a13 protein expressed in vitro can metabolize clinically active drugs ethylmorphine and erythromycin, as well as benzphetamine. We conclude that CYP3a13 is regulated differentially by various nuclear receptors. In humans this may lead to altered drug metabolism, as many of the newly synthesized ligands/drugs targeted toward these nuclear receptors could influence CYP3A gene expression.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77225 USA; Univ Kansas, Med Ctr, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA	University of Texas System; University of Texas System; University of Kansas; University of Kansas Medical Center	Strobel, HW (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	henry.w.strobel@uth.tmc.edu		Kalsotra, Auinash/0000-0002-1011-0006				Balthazart J, 1998, TRENDS NEUROSCI, V21, P243, DOI 10.1016/S0166-2236(97)01221-6; Bernard P, 1999, MOL PHARMACOL, V56, P526, DOI 10.1124/mol.56.3.526; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; BURGER HJ, 1992, P NATL ACAD SCI USA, V89, P2145, DOI 10.1073/pnas.89.6.2145; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Cui XM, 2002, GENE, V297, P179, DOI 10.1016/S0378-1119(02)00885-5; Dai D, 2001, J BIOCHEM MOL TOXIC, V15, P90, DOI 10.1002/jbt.4; Davies PJA, 2001, MOL PHARMACOL, V59, P170, DOI 10.1124/mol.59.2.170; Domanski TL, 2001, MOL PHARMACOL, V59, P386, DOI 10.1124/mol.59.2.386; El-Sankary W, 2002, DRUG METAB DISPOS, V30, P1029, DOI 10.1124/dmd.30.9.1029; Finta C, 2000, GENE, V260, P13, DOI 10.1016/S0378-1119(00)00470-4; Goodwin B, 2002, ANNU REV PHARMACOL, V42, P1, DOI 10.1146/annurev.pharmtox.42.111901.111051; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Howell SR, 1998, DRUG METAB DISPOS, V26, P234; Huber R, 1998, GENE, V214, P35, DOI 10.1016/S0378-1119(98)00233-9; ITOH S, 1994, EUR J BIOCHEM, V226, P877, DOI 10.1111/j.1432-1033.1994.t01-1-00877.x; JANIKAMJORN K, 2001, BIOCHEM PHARMACOL, V62, P161; JOUNAIDI Y, 1994, BIOCHEM BIOPH RES CO, V205, P1741, DOI 10.1006/bbrc.1994.2870; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KATO R, 1993, HORMONAL REGULATION; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; LeCluyse EL, 2001, CHEM-BIOL INTERACT, V134, P283, DOI 10.1016/S0009-2797(01)00163-6; Lenhard JM, 1999, DIABETOLOGIA, V42, P545, DOI 10.1007/s001250051193; Mahnke Z, 1997, ARCH BIOCHEM BIOPHYS, V337, P62, DOI 10.1006/abbi.1996.9752; MOLOWA DT, 1986, P NATL ACAD SCI USA, V83, P5311, DOI 10.1073/pnas.83.14.5311; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Pascussi JM, 2000, MOL PHARMACOL, V58, P361, DOI 10.1124/mol.58.2.361; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Pereira TM, 1998, DNA CELL BIOL, V17, P39, DOI 10.1089/dna.1998.17.39; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Robertson GR, 1998, BIOCHEM BIOPH RES CO, V242, P57, DOI 10.1006/bbrc.1997.7904; Rubin GL, 2002, ENDOCRINOLOGY, V143, P2863, DOI 10.1210/en.143.8.2863; Sakuma T, 2002, ARCH BIOCHEM BIOPHYS, V404, P234, DOI 10.1016/S0003-9861(02)00329-6; Sakuma T, 2000, ARCH BIOCHEM BIOPHYS, V377, P153, DOI 10.1006/abbi.2000.1747; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Skak K, 1999, GENE, V236, P231, DOI 10.1016/S0378-1119(99)00286-3; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Thummel KE, 2001, MOL PHARMACOL, V60, P1399, DOI 10.1124/mol.60.6.1399; Toide K, 1997, ARCH BIOCHEM BIOPHYS, V338, P43, DOI 10.1006/abbi.1996.9792; VandenBroek PJA, 1996, EXPERIENTIA, V52, P851; Wang HM, 2000, MOL CELL BIOCHEM, V213, P127, DOI 10.1023/A:1007124417566; Wang HM, 1997, ARCH BIOCHEM BIOPHYS, V344, P365, DOI 10.1006/abbi.1997.0230; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Yamada H, 2000, BIOCHEM BIOPH RES CO, V277, P66, DOI 10.1006/bbrc.2000.3620; YANAGIMOTO T, 1994, BBA-GEN SUBJECTS, V1201, P405, DOI 10.1016/0304-4165(94)90069-8; Yanagimoto T, 1997, ARCH BIOCHEM BIOPHYS, V340, P215, DOI 10.1006/abbi.1997.9900	53	27	27	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1736	+		10.1096/fj.02-1004fje	http://dx.doi.org/10.1096/fj.02-1004fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958193				2023-01-03	WOS:000184471600022
J	Krieg, AM				Krieg, AM			CpG motifs: the active ingredient in bacterial extracts?	NATURE MEDICINE			English	Article							HEPATITIS-B-VACCINE; TOLL-LIKE RECEPTORS; T-CELL RESPONSES; IMMUNE-RESPONSE; DENDRITIC CELLS; ESTABLISHED TUMORS; MURINE MODEL; DNA; OLIGODEOXYNUCLEOTIDES; ANTIGEN	The use of bacteria and bacterial extracts for immunotherapy has a checkered past. Recent developments in immunology reveal that these nonspecific immune activators actually work by triggering specific receptors that are expressed by subsets of immune cells. Identification of these receptors and the molecular signaling pathways that they activate has enabled a new era of specific targeted immunotherapy using chemically synthesized mimics of pathogen molecules.	Coley Pharmaceut Grp, Wellesley, MA 02481 USA	Coley Pharmaceutical Group	Krieg, AM (corresponding author), Coley Pharmaceut Grp, Wellesley, MA 02481 USA.	akrieg@coleypharma.com	Krieg, Art/R-6166-2019; Krieg, Arthur M/K-8109-2019					Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Ahonen CL, 1999, CELL IMMUNOL, V197, P62, DOI 10.1006/cimm.1999.1555; Ambrosch F, 2000, VACCINE, V18, P2095, DOI 10.1016/S0264-410X(99)00566-6; Ballas ZK, 2001, J IMMUNOL, V167, P4878, DOI 10.4049/jimmunol.167.9.4878; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Biron CA, 2002, CURR TOP MICROBIOL, V263, P7; Blazar BR, 2001, BLOOD, V98, P1217, DOI 10.1182/blood.V98.4.1217; Brown WC, 1998, INFECT IMMUN, V66, P5423, DOI 10.1128/IAI.66.11.5423-5432.1998; Carpentier AF, 2000, CLIN CANCER RES, V6, P2469; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Coley W.B, 1893, AM J MED SCI, V105, P487, DOI [DOI 10.1097/00000441-189305000-00001, 10.1097/00000441-189305000-00001]; Creticos PS, 2002, J ALLERGY CLIN IMMUN, V109, P743; Davila E, 2000, J IMMUNOL, V165, P539, DOI 10.4049/jimmunol.165.1.539; Davis HL, 2000, VACCINE, V18, P1920, DOI 10.1016/S0264-410X(99)00443-0; Davis HL, 2000, CURR TOP MICROBIOL, V247, P171; Egeter O, 2000, CANCER RES, V60, P1515; Ferguson TA, 2002, J IMMUNOL, V168, P5589, DOI 10.4049/jimmunol.168.11.5589; Goeckeritz BE, 1999, INT IMMUNOL, V11, P1693, DOI 10.1093/intimm/11.10.1693; Grossmann ME, 2001, J IMMUNOTHER, V24, P237, DOI 10.1097/00002371-200105000-00007; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Heckelsmiller K, 2002, EUR J IMMUNOL, V32, P3235, DOI 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Ito T, 2002, J EXP MED, V195, P1507, DOI 10.1084/jem.20020207; Jain VV, 2002, J ALLERGY CLIN IMMUN, V110, P867, DOI 10.1067/mai.2002.129371; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jones TR, 1999, VACCINE, V17, P3065, DOI 10.1016/S0264-410X(99)00145-0; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kawarada Y, 2001, J IMMUNOL, V167, P5247, DOI 10.4049/jimmunol.167.9.5247; Kim SK, 1999, VACCINE, V18, P597, DOI 10.1016/S0264-410X(99)00316-3; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1999, IMMUNITY, V11, P123, DOI 10.1016/S1074-7613(00)80087-4; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 2002, NAT IMMUNOL, V3, P423, DOI 10.1038/ni0502-423; Krieg AM, 1998, P NATL ACAD SCI USA, V95, P12631, DOI 10.1073/pnas.95.21.12631; Krieg Arthur M., 2002, Trends in Immunology, V23, P64, DOI 10.1016/S1471-4906(01)02150-0; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Kuwana M, 2001, EUR J IMMUNOL, V31, P2547, DOI 10.1002/1521-4141(200109)31:9<2547::AID-IMMU2547>3.0.CO;2-J; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lenert P, 2001, ANTISENSE NUCLEIC A, V11, P247, DOI 10.1089/108729001317022241; Lipford GB, 1997, EUR J IMMUNOL, V27, P2340, DOI 10.1002/eji.1830270931; Liu HM, 1998, BLOOD, V92, P3730, DOI 10.1182/blood.V92.10.3730.422k20_3730_3736; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; Martin P, 2002, BLOOD, V100, P383, DOI 10.1182/blood.V100.2.383; Miconnet I, 2002, J IMMUNOL, V168, P1212, DOI 10.4049/jimmunol.168.3.1212; Mor G, 1997, HUM GENE THER, V8, P293, DOI 10.1089/hum.1997.8.3-293; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51; Sandler AD, 2003, CANCER RES, V63, P394; Sethi S, 2002, LANCET, V360, P229, DOI 10.1016/S0140-6736(02)09513-2; Sfondrini L, 2002, FASEB J, V16, P1749, DOI 10.1096/fj.02-0383com; Smith JB, 1998, J NATL CANCER I, V90, P1146, DOI 10.1093/jnci/90.15.1146; Sparwasser T, 2000, EUR J IMMUNOL, V30, P3591, DOI 10.1002/1521-4141(200012)30:12<3591::AID-IMMU3591>3.0.CO;2-J; Stacey KJ, 2003, J IMMUNOL, V170, P3614, DOI 10.4049/jimmunol.170.7.3614; Stern BV, 2002, J IMMUNOL, V168, P6099, DOI 10.4049/jimmunol.168.12.6099; Thoelen S, 1998, VACCINE, V16, P708, DOI 10.1016/S0264-410X(97)00254-5; Tokunaga T, 1999, JPN J INFECT DIS, V52, P1; VANOJIK H, 2003, ANN ONCOL, V13, P157; Vasilakos JP, 2000, CELL IMMUNOL, V204, P64, DOI 10.1006/cimm.2000.1689; Wang YQ, 2003, INT IMMUNOL, V15, P223, DOI 10.1093/intimm/dxg020; Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833; WIEMANN B, 1994, PHARMACOL THERAPEUT, V64, P529, DOI 10.1016/0163-7258(94)90023-X; Wild J, 1999, J IMMUNOL, V163, P1880; Yamaji M, 2002, PHOTOCH PHOTOBIO SCI, V1, P169, DOI 10.1039/b110092k; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yi AK, 1998, J IMMUNOL, V160, P4755; Zeuner RA, 2002, ARTHRITIS RHEUM, V46, P2219, DOI 10.1002/art.10423; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625; Zwaveling S, 2002, J IMMUNOL, V169, P350, DOI 10.4049/jimmunol.169.1.350	75	234	342	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2003	9	7					831	835		10.1038/nm0703-831	http://dx.doi.org/10.1038/nm0703-831			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	698CD	12835699				2023-01-03	WOS:000183979300020
J	McGlynn, EA; Asch, SM; Adams, J; Keesey, J; Hicks, J; DeCristofaro, A; Kerr, EA				McGlynn, EA; Asch, SM; Adams, J; Keesey, J; Hicks, J; DeCristofaro, A; Kerr, EA			The quality of health care delivered to adults in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ELDERLY MEDICARE BENEFICIARIES; STANDARDIZED PATIENTS; UNDERUSE; APPROPRIATENESS; OUTCOMES; TRIALS; WOMEN	BACKGROUND: We have little systematic information about the extent to which standard processes involved in health care -- a key element of quality -- are delivered in the United States. METHODS: We telephoned a random sample of adults living in 12 metropolitan areas in the United States and asked them about selected health care experiences. We also received written consent to copy their medical records for the most recent two-year period and used this information to evaluate performance on 439 indicators of quality of care for 30 acute and chronic conditions as well as preventive care. We then constructed aggregate scores. RESULTS: Participants received 54.9 percent (95 percent confidence interval, 54.3 to 55.5) of recommended care. We found little difference among the proportion of recommended preventive care provided (54.9 percent), the proportion of recommended acute care provided (53.5 percent), and the proportion of recommended care provided for chronic conditions (56.1 percent). Among different medical functions, adherence to the processes involved in care ranged from 52.2 percent for screening to 58.5 percent for follow-up care. Quality varied substantially according to the particular medical condition, ranging from 78.7 percent of recommended care (95 percent confidence interval, 73.3 to 84.2) for senile cataract to 10.5 percent of recommended care (95 percent confidence interval, 6.8 to 14.6) for alcohol dependence. CONCLUSIONS: The deficits we have identified in adherence to recommended processes for basic care pose serious threats to the health of the American public. Strategies to reduce these deficits in care are warranted.	RAND Corp, Santa Monica, CA 90407 USA; Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; VA Ann Arbor Hlth Care Syst, VA Ctr Practice Management & Outcomes Res, Ann Arbor, MI USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	McGlynn, EA (corresponding author), RAND Corp, 1700 Main St,POB 2138, Santa Monica, CA 90407 USA.	beth_mcglynn@rand.org	Wilkins, Thad/G-2541-2010; Greiver, Michelle/N-8764-2015; Young, Alexander/A-1523-2009	Greiver, Michelle/0000-0001-8957-0285; Young, Alexander/0000-0002-9367-9213				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Asch SM, 2000, JAMA-J AM MED ASSOC, V284, P2325, DOI 10.1001/jama.284.18.2325; Asch SM, 2001, ARCH INTERN MED, V161, P1329, DOI 10.1001/archinte.161.10.1329; Asch SM, 2001, J ACQ IMMUN DEF SYND, V28, P340, DOI 10.1097/00126334-200112010-00006; Asch SM, 2000, QUALITY CARE ONCOLOG; Berwick DM, 2003, MED CARE, V41, pI30; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; Brook R. H., 1994, AHCPR PUB, P59; CHERRY DK, 1999, ADV DATA VITAL HLTH, V322; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cunningham PJ, 2002, MED CARE RES REV, V59, P79, DOI 10.1177/107755870205900104; Draper DA, 2002, HEALTH AFFAIR, V21, P11, DOI 10.1377/hlthaff.21.1.11; Dresselhaus TR, 2002, J MED ETHICS, V28, P293, DOI 10.1136/jme.28.5.291; Efron B., 1993, INTRO BOOTSTRAP; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; HYMAN DJ, 2002, NEW ENGL J MED, V346, P544; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; Kemper P, 1996, INQUIRY-J HEALTH CAR, V33, P195; Kerr EA, 2000, QUALITY CARE CARDIOP; KERR EA, 2000, QUALITY CARE GEN MED; Kravitz RL, 1997, HEALTH POLICY, V42, P135, DOI 10.1016/S0168-8510(97)00064-X; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Luck J, 2002, BMJ-BRIT MED J, V325, P679, DOI 10.1136/bmj.325.7366.679; McGlynn E A, 1998, Jt Comm J Qual Improv, V24, P470; McGlynn EA, 2001, HEALTH AFFAIR, V20, P82, DOI 10.1377/hlthaff.20.3.82; McGlynn EA, 1999, WOMEN HEALTH ISS, V9, P184, DOI 10.1016/S1049-3867(99)00009-2; McGlynn EA, 2000, QUALITY CARE WOMEN; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Murata PJ, 1994, ARCH FAM MED, V3, P41; *NAT COMM QUAL ASS, 2002, STAT HLTH CAR QUAL; Nelson DE, 2002, JAMA-J AM MED ASSOC, V287, P2659, DOI 10.1001/jama.287.20.2659; PAYNE SMC, 1995, ARCH PEDIAT ADOL MED, V149, P162, DOI 10.1001/archpedi.1995.02170140044006; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Saaddine JB, 2002, ANN INTERN MED, V136, P565, DOI 10.7326/0003-4819-136-8-200204160-00005; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022; Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607; STARFIELD B, 1994, JAMA-J AM MED ASSOC, V272, P1903, DOI 10.1001/jama.272.24.1903; STRUNK BC, 2001, TRACKING HLTH CARE C; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; Woolf SH, 1999, JAMA-J AM MED ASSOC, V282, P2358, DOI 10.1001/jama.282.24.2358	50	3441	3469	3	154	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2635	2645		10.1056/NEJMsa022615	http://dx.doi.org/10.1056/NEJMsa022615			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	693PN	12826639				2023-01-03	WOS:000183726400008
J	Assendelft, WJJ; Morton, SC; Yu, EI; Suttorp, MJ; Shekelle, PG				Assendelft, WJJ; Morton, SC; Yu, EI; Suttorp, MJ; Shekelle, PG			Spinal manipulative therapy for low back pain - A meta-analysis of effectiveness relative to other therapies	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CLINICAL-TRIAL; SYSTEMATIC REVIEWS; MANUAL THERAPY; NECK COMPLAINTS; FOLLOW-UP; OUTCOME MEASURES; PRIMARY-CARE; HEALTH-CARE; CONSERVATIVE TREATMENT; MULTICENTER TRIAL	Background: Low back pain is a costly illness for which spinal manipulative therapy is commonly recommended. Previous systematic reviews and practice guidelines have reached discordant results on the effectiveness of this therapy for low back pain. Purpose: To resolve the discrepancies related to use of spinal manipulative therapy and to update previous estimates of effectiveness by comparing spinal manipulative therapy with other therapies and then incorporating data from recent high-quality randomized, controlled trials (RCTs) into the analysis. Data Sources: MEDLINE, EMBASE, CINAHL, the Cochrane Controlled Trials Register, and previous systematic reviews. Study Selection: Randomized, controlled trials of patients with low back pain that evaluated spinal manipulative therapy with at least 1 day of follow-up and at least one clinically relevant outcome measure. Data Extraction: Two authors, who served as the reviewers for all stages of the meta-analysis, independently extracted data from unmasked articles. Comparison treatments were classified into the following seven categories: sham, conventional general practitioner care, analgesics, physical therapy, exercises, back school, or a collection of therapies judged to be ineffective or even harmful (traction, corset, bed rest, home care, topical gel, no treatment, diathermy, and minimal massage). Data Synthesis: Thirty-nine RCTs were identified. Meta-regression models were developed for acute or chronic pain and short-term and long-term pain and function. For patients with acute low back pain, spinal manipulative therapy was superior only to sham therapy (10-mm difference [95% CI, 2 to 17 mm] on a 100-mm visual analogue scale) or therapies judged to be ineffective or even harmful. Spinal manipulative therapy had no statistically or clinically significant advantage over general practitioner care, analgesics, physical therapy, exercises, or back school. Results for patients with chronic low back pain were similar. Radiation of pain, study quality, profession of manipulator, and use of manipulation alone or in combination with other therapies did not affect these results. Conclusions: There is no evidence that spinal manipulative therapy is superior to other standard treatments for patients with acute or chronic low back pain.	RAND Corp, Santa Monica, CA 90407 USA; Cochrane Back Review Grp, Toronto, ON, Canada; Dutch Coll Gen Practitioners, Utrecht, Netherlands; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Shekelle, PG (corresponding author), RAND Corp, 1700 Main St,POB 2138, Santa Monica, CA 90407 USA.	shekelle@rand.org	Assendelft, W.J.J./H-8008-2014; assendelft, willem/AAW-1854-2021	Assendelft, W.J.J./0000-0002-2966-3778; assendelft, willem/0000-0002-2966-3778				ANDERSON R, 1992, J MANIP PHYSIOL THER, V15, P181; Andersson GBJ, 1999, NEW ENGL J MED, V341, P1426, DOI 10.1056/NEJM199911043411903; ARKUSZEWSKI Z, 1986, MANUAL MED, V2, P68; Assendelft W J, 1996, J Manipulative Physiol Ther, V19, P499; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND, P9; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; Blomberg S, 1994, Eur Spine J, V3, P246, DOI 10.1007/BF02226573; BLOMBERG S, 1994, SPINE, V19, P569, DOI 10.1097/00007632-199403000-00013; BLOMBERG S, 1992, Scandinavian Journal of Primary Health Care, V10, P170, DOI 10.3109/02813439209014057; Blomberg S, 1993, CLIN REHABIL, V7, P49; Blomberg Stefan, 1993, Scandinavian Journal of Primary Health Care, V11, P83, DOI 10.3109/02813439308994908; BRENNAN PC, 1994, J MANIP PHYSIOL THER, V17, P219; Bronfort G, 1996, J Manipulative Physiol Ther, V19, P570; Bronfort G, 1999, NEUROL CLIN, V17, P91, DOI 10.1016/S0733-8619(05)70116-X; BRONFORT G, 1997, EFFICACY MANUAL THER; Bronfort G., 1989, AM J CHIROPRACTIC ME, V2, P145; BUERGER AA, 1980, MANUAL MED, V2, P17; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Cherkin DC, 1998, SPINE, V23, P607, DOI 10.1097/00007632-199803010-00015; CIBULKA MT, 1988, PHYS THER, V68, P1359, DOI 10.1093/ptj/68.9.1359; COTE P, 1994, J MANIP PHYSIOL THER, V17, P364; COXHEAD CE, 1981, LANCET, V1, P1065; COYER AB, 1955, BRIT MED J, V1, P705, DOI 10.1136/bmj.1.4915.705; CRAMER GD, 1993, J MANIP PHYSIOL THER, V16, P7; DELITTO A, 1993, PHYS THER, V73, P216, DOI 10.1093/ptj/73.4.216; DEYO RA, 1994, SPINE, V19, pS2032, DOI 10.1097/00007632-199409151-00003; DICKERSIN K, 1996, COCHRANE LIB; DIFABIO RP, 1992, PHYS THER, V72, P853, DOI 10.1093/ptj/72.12.853; DORAN DML, 1975, BRIT MED J, V2, P161, DOI 10.1136/bmj.2.5964.161; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; ELLESTAD SM, 1988, J AM OSTEOPATH ASSOC, V88, P991; ELLESTAD SM, 1990, MANUELLE MED, V28, P7; ERHARD RE, 1994, PHYS THER, V74, P1093, DOI 10.1093/ptj/74.12.1093; Ernst E, 2001, J PAIN SYMPTOM MANAG, V22, P879, DOI 10.1016/S0885-3924(01)00337-2; Ernst E, 2000, FAM PRACT, V17, P554, DOI 10.1093/fampra/17.6.554; EVANS DP, 1978, RHEUMATOL REHABIL, V17, P46, DOI 10.1093/rheumatology/17.1.46; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; Ferreira ML, 2002, AUST J PHYSIOTHER, V48, P277, DOI 10.1016/S0004-9514(14)60167-7; GEMMELL HA, 1995, J MANIP PHYSIOL THER, V18, P453; GIBSON T, 1985, LANCET, V1, P1258; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; GLOVER JR, 1974, BRIT J IND MED, V31, P59; GODFREY CM, 1984, SPINE, V9, P301, DOI 10.1097/00007632-198404000-00015; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; Haas M, 1995, J MANIP PHYSIOL THER, V18, P582; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; Hadler NM, 1990, MANUELLE MED, P2; HEDGES LV, 1984, PSYCHOL BULL, V96, P573, DOI 10.1037/0033-2909.96.3.573; HEDGES LV, 1985, STAT METHODS META AN; Helliwell PS, 1987, PHYSICIAN        APR, P187; Hemmila HM, 1997, ARCH PHYS MED REHAB, V78, P571, DOI 10.1016/S0003-9993(97)90420-2; HERZOG W, 1991, J MANIP PHYSIOL THER, V14, P104; HOEHLER FK, 1981, JAMA-J AM MED ASSOC, V245, P1535; HSIEH CYJ, 1992, J MANIP PHYSIOL THER, V15, P4; Hunt DL, 1997, ANN INTERN MED, V126, P532, DOI 10.7326/0003-4819-126-7-199704010-00006; INDAHL A, 1995, SPINE, V20, P473, DOI 10.1097/00007632-199502001-00011; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; KHALIL TM, 1992, SPINE, V17, P311, DOI 10.1097/00007632-199203000-00012; Kinalski R, 1989, J MANUAL MED, V4, P44; KOES BW, 1992, J MANIP PHYSIOL THER, V15, P16; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; KOES BW, 1993, J MANIP PHYSIOL THER, V16, P211; KOKJOHN K, 1992, J MANIP PHYSIOL THER, V15, P279; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; MACDONALD RS, 1990, SPINE, V15, P364, DOI 10.1097/00007632-199005000-00005; Maher, 1993, J MANUAL MANIPULATIV, V1, P142, DOI 10.1179/jmt.1993.1.4.142; MATHEWS JA, 1987, BRIT J RHEUMATOL, V26, P416; McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Mood A.M., 1974, INTRO THEORY STAT; NWUGA VCB, 1982, AM J PHYS MED REHAB, V61, P273; ONGLEY MJ, 1987, LANCET, V2, P143; OTTENBACHER K, 1985, SPINE, V10, P833, DOI 10.1097/00007632-198511000-00010; Pengel HM, 2002, CLIN REHABIL, V16, P811, DOI 10.1191/0269215502cr562oa; Petty N J, 1995, Man Ther, V1, P25, DOI 10.1054/math.1995.0246; POPE MH, 1994, SPINE, V19, P2571, DOI 10.1097/00007632-199411001-00013; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; Rasmussen G. G., 1979, MANUAL MED, V17, P8; Rosenthal R., 1991, METAANALYTIC PROCEDU, V6; RUPERT RL, 1985, ICA INT REV CHIR WIN, P58; SANDERS GE, 1990, J MANIP PHYSIOL THER, V13, P391; *SAS I INC, 1999, SAS STAT SOFTW MAN; SCHEER SJ, 1995, ARCH PHYS MED REHAB, V76, P966, DOI 10.1016/S0003-9993(95)80076-X; Scheer SJ, 1997, ARCH PHYS MED REHAB, V78, P414, DOI 10.1016/S0003-9993(97)90235-5; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; Siehl D, 1971, J Am Osteopath Assoc, V70, P433; SIMSWILLIAMS H, 1978, BMJ-BRIT MED J, V2, P1338, DOI 10.1136/bmj.2.6148.1338; SIMSWILLIAMS H, 1979, BMJ-BRIT MED J, V2, P1318, DOI 10.1136/bmj.2.6201.1318; Skargren EI, 1998, SPINE, V23, P1875, DOI 10.1097/00007632-199809010-00016; Skargren EI, 1998, PAIN, V77, P201, DOI 10.1016/S0304-3959(98)00101-8; Skargren EI, 1997, SPINE, V22, P2167, DOI 10.1097/00007632-199709150-00015; *STAT CORP, 1999, STAT STAT SOFTW MAN; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; TERRETT ACJ, 1984, AM J PHYS MED REHAB, V63, P217; TIMM KE, 1994, J ORTHOP SPORT PHYS, V20, P276, DOI 10.2519/jospt.1994.20.6.276; TOBIS JS, 1983, B NEW YORK ACAD MED, V59, P660; TRIANO JJ, 1995, SPINE, V20, P948, DOI 10.1097/00007632-199504150-00013; vanderWeide WE, 1997, SCAND J WORK ENV HEA, V23, P165, DOI 10.5271/sjweh.195; VANTULDER M, 2002, CLIN EVIDENCE; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; VANTULDER MW, 1995, PAIN, V62, P233, DOI 10.1016/0304-3959(94)00272-G; Waagen GN, 1986, MANUAL MED, V2, P63; Waddell G, 1996, SPINE, V21, P2820, DOI 10.1097/00007632-199612150-00002; WATERWORTH RF, 1985, NEW ZEAL MED J, V98, P372; Wreje Ullacarin, 1992, Scandinavian Journal of Primary Health Care, V10, P310, DOI 10.3109/02813439209014080; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176	117	253	257	3	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					871	881		10.7326/0003-4819-138-11-200306030-00008	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AB	12779297				2023-01-03	WOS:000183296400002
J	Vlot, A				Vlot, A			The lost patient	LANCET			English	Editorial Material									Univ Med Ctr, Dept Haematol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Vlot, A (corresponding author), Univ Med Ctr, Dept Haematol, NL-6500 HB Nijmegen, Netherlands.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1367	1367		10.1016/S0140-6736(03)13074-7	http://dx.doi.org/10.1016/S0140-6736(03)13074-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711485				2023-01-03	WOS:000182346100026
J	Forster, AJ; Murff, HJ; Peterson, JF; Gandhi, TK; Bates, DW				Forster, AJ; Murff, HJ; Peterson, JF; Gandhi, TK; Bates, DW			The incidence and severity of adverse events affecting patients after discharge from the hospital	ANNALS OF INTERNAL MEDICINE			English	Article							DRUG EVENTS; CARE; PREVENTABILITY; INFECTIONS; QUALITY	Background: Studies of hospitalized patients identify safety as a significant problem, but few data are available regarding injuries occurring after discharge. Patients may be vulnerable during this transition period. Objective: To describe the incidence, severity, preventability, and "ameliorability" of adverse events affecting patients after discharge from the hospital and to develop strategies for improving patient safety during this interval. Design: Prospective cohort study. Setting: A tertiary care academic hospital. Patients: 400 consecutive patients discharged home from the general medical service. Measurements: The three main outcomes were adverse events, defined as injuries occurring as a result of medical management; preventable adverse events, defined as adverse events judged to have been caused by an error; and ameliorable adverse events, defined as adverse events whose severity could have been decreased. Posthospital course was determined by performing a medical record review and a structured telephone interview approximately 3 weeks after each patient's discharge. Outcomes were determined by independent physician reviews. Results: Seventy-six patients had adverse events after discharge (19% [95% Cl, 15% to 23%]). Of these, 23 had preventable adverse events (6% [Cl, 4% to 9%]) and 24 held ameliorable adverse events (6% [Cl, 4% to 9%]). Three percent of injuries were serious laboratory abnormalities, 65% were symptoms, 30% were symptoms associated with a nonpermanent disability, and 3% were permanent disabilities. Adverse drug events were the most common type of adverse event (66% [Cl, 55% to 76%]), followed by procedure-related injuries (17% [Cl, 86% to 26%]). Of the 25 adverse events resulting in at least a nonpermanent disability, 12 were preventable (48% [Cl, 28% to 68%]) and 6 were ameliorable (24% [Cl, 7% to 41%]). Conclusion: Adverse events occurred frequently in the peridischarge period, and many could potentially have been prevented or ameliorated with simple strategies.	Univ Ottawa, Ottawa, ON K1N 6N5, Canada; Harvard Univ, Sch Med, Boston, MA USA	University of Ottawa; Harvard University; Harvard Medical School	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Med, 75 Francis St,PBB-A3, Boston, MA 02115 USA.	dbates@partners.org	Bates, David/AAE-7283-2019					BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; Benbassat J, 2000, ARCH INTERN MED, V160, P1074, DOI 10.1001/archinte.160.8.1074; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; Cook RI, 2000, BRIT MED J, V320, P791, DOI 10.1136/bmj.320.7237.791; Delgado-Rodriguez M, 2001, INFECT CONT HOSP EP, V22, P24, DOI 10.1086/501820; Gandhi TK, 2000, J GEN INTERN MED, V15, P149, DOI 10.1046/j.1525-1497.2000.04199.x; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; *I MED, 2000, ERR HUM BUILD SAF HL; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Kelley MA, 1999, ANN INTERN MED, V130, P373, DOI 10.7326/0003-4819-130-4-199902161-00009; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Mitchell DH, 1999, AUST NZ J SURG, V69, P117, DOI 10.1046/j.1440-1622.1999.01500.x; PARKES J, 2000, COCHRANE DATABASE SY; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003	18	1203	1226	1	46	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 4	2003	138	3					161	167		10.7326/0003-4819-138-3-200302040-00007	http://dx.doi.org/10.7326/0003-4819-138-3-200302040-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646DB	12558354				2023-01-03	WOS:000181018600001
J	Shan, H; Wang, JX; Ren, FR; Zhang, YZ; Zhao, HY; Gao, GJ; Ji, Y; Ness, PM				Shan, H; Wang, JX; Ren, FR; Zhang, YZ; Zhao, HY; Gao, GJ; Ji, Y; Ness, PM			Blood banking in China	LANCET			English	Article							INFECTION	While transfusion-transmissible diseases, including AIDS and viral hepatitis, continue to spread especially in developing countries, the issue of safeguarding the world's blood supply is of paramount importance. China houses more than 20% of the earth's population, and thus its blood supply has the potential to affect the global community. In recent years, Chinese blood centres have tried to improve the nation's blood safety. Although substantial progress has already been made, many daunting difficulties remain. Traditional cultural barriers need to be overcome to successfully mobilise volunteer blood donors. Gaps in information and technology still need to be closed. Insufficiency of economic resources also restrict the blood bank industry. Other developing countries face many of the same challenges as China.	Johns Hopkins Med Inst, Dept Pathol, Div Blood Transfus, HIV Specialty Testing Lab, Baltimore, MD 21287 USA; Chinese Acad Med Sci, Inst Blood Transfus, Chengdu, Sichuan, Peoples R China; Beijing Red Cross Blood Ctr, Beijing, Peoples R China; Xinjiang Autonomous Reg Ctr Dis Control & Prevent, Urumqi, Xinjiang, Peoples R China	Johns Hopkins University; Johns Hopkins Medicine; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Blood Transfusion - CAMS	Shan, H (corresponding author), Johns Hopkins Med Inst, Dept Pathol, Div Blood Transfus, HIV Specialty Testing Lab, Baltimore, MD 21287 USA.				FIC NIH HHS [5D43 TW00010] Funding Source: Medline; NIAID NIH HHS [U01 AI48011] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI048011] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAY F, 1998, WHY ITS REALLY DRAW; Beach MV, 2001, LANCET, V357, P49, DOI 10.1016/S0140-6736(05)71551-8; DAI ZC, 1999, VIRAL HEPATITIS CHIN; FENG G, 2001, CHIN J BLOOD TRANSFU, V14, P205; JANG T, 2000, CHIN J BLOOD TRANSFU, V13, P44; Ji Y, 1996, TRANSFUSION MED, V6, P291, DOI 10.1111/j.1365-3148.1996.tb00082.x; JI Y, 1998, ACTA ACAD MED, V20, P240; JI Y, 1992, CHIN J BLOOD TRANSFU, V4, P184; JI Y, 1995, VOX SANG, V9, P255; LEI W, 1999, CHIN J BLOOD TRANSFU, V12, P31; LIU Y, 1999, CHIN J BLOOD TRANSFU, V12, P33; LUI Z, 2000, CHIN J EPIDEMIOL, V21, P466; MA J, 1995, CHIN J LIVER DIS S, V3, P28; SHAN H, 1998, 51 ANN M AM ASS BLOO; Shi XL, 1999, TRANSFUSION, V39, P913, DOI 10.1046/j.1537-2995.1999.39080913.x; Weinberg PD, 2002, ANN INTERN MED, V136, P312, DOI 10.7326/0003-4819-136-4-200202190-00011; XIAO H, 2000, CHIN J BLOOD TRANS S, V13, P72; Xiwen Zheng, 2000, CHIN J EPIDEMIOL, V21; YAN J, 2000, CHIN J EPIDEMIOL, V21, P10; YANG C, 2001, 1 FOG WORKSH BLOOD S; Zhang Y, 2000, 53 ANN M AM ASS BLOO; ZHAO H, 1992, CHIN J BLOOD TRANSFU, V4, P176; ZHENG X, 2000, CHIN J EPIDEMIOL, V21, P13; ZHENG X, 2000, CHIN J EPIDEMIOL, V21, P253; ZHENG XW, 1999, CHINESE J EPIDEMIOLO, V20, P131; ZHU P, 2000, CHIN J EPIDEMIOL, V21, P140; 2000, PEOPLES DAILY   1101; 2002, NEW CHINA NEWS A APR; 1998, HEALTH          0922	29	117	123	2	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 30	2002	360	9347					1770	1775		10.1016/S0140-6736(02)11669-2	http://dx.doi.org/10.1016/S0140-6736(02)11669-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622FU	12480443				2023-01-03	WOS:000179636800027
J	Kronenberg, F; Fugh-Berman, A				Kronenberg, F; Fugh-Berman, A			Complementary and alternative medicine for menopausal symptoms: A review of randomized, controlled trials	ANNALS OF INTERNAL MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; BREAST-CANCER SURVIVORS; QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; HOT FLASHES; VASOMOTOR SYMPTOMS; DOUBLE-BLIND; TRANSDERMAL PROGESTERONE; BEHAVIORAL TREATMENT; SOY PHYTOESTROGENS	Background: women commonly use soy products, herbs, and other complementary and alternative medicine (CAM) therapies for menopausal symptoms. Randomized, controlled trials have evaluated the efficacy and short-term safety of these therapies. Purpose: To review randomized, controlled trials of CAM therapies for menopausal symptoms in order to better inform practice and guide future research. Data Sources: Searches of MEDLINE for articles published from January 1966 through March 2002, of the Alternative and Complementary Database (AMED) of the British Library for articles published from January 1985 through December 2000, and of the authors' own extensive files. Search terms were hot flash/flush, menopause, and climacteric, combined with phytoestrogens, alternative medicine, herbal medicine, traditional medicine, Traditional Chinese Medicine (TCM), Ayuneda, naturopathy, chiropractic, osteopathy, massage, yoga, relaxation therapy, homeopathy, aromatherapy, and therapeutic touch. Study Selection: 29 randomized, controlled clinical trials of CAM therapies for hot flashes and other menopausal symptoms were identified; of these, 12 dealt with soy or soy extracts, 10 with herbs, and 7 with other CAM therapies. Data Extraction: Each author extracted information from half of the studies on the number of patients, study design, outcome measures, and results; the other author then checked these results. Data Synthesis: Soy seems to have modest benefit for hot flashes, but studies are not conclusive. Isoflavone preparations seem to be less effective than soy foods. Black cohosh may be effective for menopausal symptoms, especially hot flashes, but the lack of adequate long-term safety data (mainly on estrogenic stimulation of the breast or endometrium) precludes recommending long-term use. Single clinical trials have found that dong quai, evening primrose oil, a Chinese herb mixture, vitamin E, and acupuncture do not affect hot flashes; two trials have shown that red clover has no benefit for treating hot flashes. Conclusions: Black cohosh and foods that contain phytoestrogens show promise for the treatment of menopausal symptoms. Clinical trials do not support the use of other herbs or CAM therapies. Long-term safety data on individual isoflavones or isoflavone concentrates are not available.	George Washington Univ, Dept Hlth Care Sci, Sch Med, Washington, DC 20037 USA; Columbia Univ, New York, NY USA	George Washington University; Columbia University	Fugh-Berman, A (corresponding author), George Washington Univ, Dept Hlth Care Sci, Sch Med, 2300 K St NW, Washington, DC 20037 USA.	fk@columbia.edu			NCCIH NIH HHS [P50 AT00090] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P50AT000090] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ADLERCREUTZ H, 1992, LANCET, V339, P1233, DOI 10.1016/0140-6736(92)91174-7; Albertazzi P, 1998, OBSTET GYNECOL, V91, P6, DOI 10.1016/S0029-7844(97)00597-8; Amato P, 2002, MENOPAUSE, V9, P145, DOI 10.1097/00042192-200203000-00010; AVINA RL, 1978, WESTERN J MED, V128, P366; Baber R J, 1999, Climacteric, V2, P85, DOI 10.3109/13697139909025571; BAIRD DD, 1995, J CLIN ENDOCR METAB, V80, P1685, DOI 10.1210/jc.80.5.1685; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; Beal MW, 1998, J NURSE-MIDWIFERY, V43, P224, DOI 10.1016/S0091-2182(98)00009-3; BLATT MHG, 1953, ARCH INTERN MED, V91, P792, DOI 10.1001/archinte.1953.00240180101012; Brzezinski A, 1997, MENOPAUSE, V4, P89; CHENOY R, 1994, BRIT MED J, V308, P501, DOI 10.1136/bmj.308.6927.501; Cooper A, 1998, LANCET, V351, P1255, DOI 10.1016/S0140-6736(05)79323-5; CORNEY RH, 1991, J PSYCHOSOM RES, V35, P471, DOI 10.1016/0022-3999(91)90042-M; Dalais F S, 1998, Climacteric, V1, P124, DOI 10.3109/13697139809085527; Davis SR, 2001, MED J AUSTRALIA, V174, P68, DOI 10.5694/j.1326-5377.2001.tb143156.x; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1997, PAIN, V71, P123, DOI 10.1016/S0304-3959(97)03368-X; Foster S., 1999, TYLERS HONEST HERBAL; FREEDMAN RR, 1992, AM J OBSTET GYNECOL, V167, P436, DOI 10.1016/S0002-9378(11)91425-2; FREEDMAN RR, 1995, MENOPAUSE, V2, P211, DOI 10.1097/00042192-199502040-00005; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; GREENSPAN EM, 1983, JAMA-J AM MED ASSOC, V249, P2018, DOI 10.1001/jama.1983.03330390026012; Han KK, 2002, OBSTET GYNECOL, V99, P389, DOI 10.1016/S0029-7844(01)01744-6; HARE ML, 1993, MED ANTHROPOL Q, V7, P30, DOI 10.1525/maq.1993.7.1.02a00030; HIMMEL W, 1993, BRIT J GEN PRACT, V43, P232; Hirata JD, 1997, FERTIL STERIL, V68, P981, DOI 10.1016/S0015-0282(97)00397-X; HOPKINS MP, 1988, AM J OBSTET GYNECOL, V159, P1121, DOI 10.1016/0002-9378(88)90426-7; Irvin JH, 1996, J PSYCHOSOM OBST GYN, V17, P202, DOI 10.3109/01674829609025684; Jacobson JS, 2001, J CLIN ONCOL, V19, P2739, DOI 10.1200/JCO.2001.19.10.2739; JARRY H, 1985, PLANTA MED, V51, P316, DOI 10.1055/s-2007-969500; Kennelly EJ, 2002, PHYTOMEDICINE, V9, P461, DOI 10.1078/09447110260571733; Knight D C, 1999, Climacteric, V2, P79, DOI 10.3109/13697139909025570; Komesaroff P A, 2001, Climacteric, V4, P144; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; Kronenberg F, 1994, MENOPAUSE, V1, P171; Lee J., 1993, NATURAL PROGESTERONE; LEHMANNWILLENBROCK E, 1988, ZBL GYNAKOL, V110, P611; Leonetti HB, 1999, OBSTET GYNECOL, V94, P225, DOI 10.1016/S0029-7844(99)00266-5; Lewis JG, 2002, MATURITAS, V41, P1, DOI 10.1016/S0378-5122(01)00250-X; LOCK M, 1988, MATURITAS, V10, P317, DOI 10.1016/0378-5122(88)90067-9; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MCCOY J, 1996, P 212 AM CHEM SOC NA; MURKIES AL, 1995, MATURITAS, V21, P189, DOI 10.1016/0378-5122(95)00899-V; PUNNONEN R, 1980, BRIT MED J, V281, P1110, DOI 10.1136/bmj.281.6248.1110; Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068; Scambia G, 2000, MENOPAUSE, V7, P105, DOI 10.1097/00042192-200007020-00006; St Germain A, 2001, MENOPAUSE, V8, P17, DOI 10.1097/00042192-200101000-00005; Stoll W., 1987, THERAPEUTIKON, V1, P23; Struck D, 1997, PLANTA MED, V63, P289, DOI 10.1055/s-2006-957682; THOMPSON LU, 1991, NUTR CANCER, V16, P43, DOI 10.1080/01635589109514139; Upmalis DH, 2000, MENOPAUSE, V7, P236, DOI 10.1097/00042192-200007040-00005; Van Patten CL, 2002, J CLIN ONCOL, V20, P1449, DOI 10.1200/JCO.20.6.1449; WARNECKE G, 1985, MED WELT, V36, P871; Washburn S, 1999, MENOPAUSE, V6, P7; Wiklund IK, 1999, INT J CLIN PHARM RES, V19, P89; Wren BG, 1999, LANCET, V354, P1447, DOI 10.1016/S0140-6736(99)03430-3; WYON Y, 1995, MENOPAUSE, V2, P3; Zava DT, 1998, P SOC EXP BIOL MED, V217, P369	58	363	376	1	134	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					805	813		10.7326/0003-4819-137-10-200211190-00009	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616VE	12435217	Green Published			2023-01-03	WOS:000179323400004
J	Raff, JP; Dobson, CE; Tsai, HM				Raff, JP; Dobson, CE; Tsai, HM			Transfusion of polymerised human haemoglobin in a patient with severe sickle-cell anaemia	LANCET			English	Article							BLOOD SUBSTITUTE; ACUTE TRAUMA; HEMOGLOBIN; SURGERY; ANEMIA	Many patients with sickle-cell anaemia have red-cell alloantibodies. We could not obtain compatible blood for a 40-year-old woman with a sickle-cell crisis after a hip operation. We transfused a polymerised human haemoglobin solution, after which the patient's pain was alleviated. This treatment, in combination with erythropoietin, resulted in a rise in our patient's haemoglobin concentration, and her eventual recovery. Increased oxygen delivery to the microcirculation might have contributed to the rapid resolution of pain after the transfusion.	Montefiore Med Ctr, Div Haematol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Tsai, HM (corresponding author), Montefiore Med Ctr, Div Haematol, 111 E 210th St, Bronx, NY 10467 USA.							Gould SA, 1997, J TRAUMA, V43, P325, DOI 10.1097/00005373-199708000-00019; Gould SA, 1998, J AM COLL SURGEONS, V187, P113, DOI 10.1016/S1072-7515(98)00095-7; Mullon J, 2000, NEW ENGL J MED, V342, P1638, DOI 10.1056/NEJM200006013422204; STEINBERG MH, 2001, DISORDERS HEMOGLOBIN, V4; VICHINSKY EP, 1990, NEW ENGL J MED, V322, P1617, DOI 10.1056/NEJM199006073222301	5	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 10	2002	360	9331					464	465		10.1016/S0140-6736(02)09640-X	http://dx.doi.org/10.1016/S0140-6736(02)09640-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	582GZ	12241723				2023-01-03	WOS:000177342900017
J	Sinha, A; Nightingale, JMD; West, KP; Berlanga-Acosta, J; Playford, RJ				Sinha, A; Nightingale, JMD; West, KP; Berlanga-Acosta, J; Playford, RJ			Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							5-AMINOSALICYLIC ACID; EXPERIMENTAL-MODEL; FACTOR-RECEPTOR; EXPRESSION; UROGASTRONE; APPEARANCES; STABILITY; PEPTIDES; THERAPY	Background: Epidermal growth factor (EGF) is a potent mitogenic peptide produced by salivary glands. We examined whether EGF enemas are an effective treatment for active left-sided ulcerative colitis and ulceration limited to the rectum (proctitis). Methods: In a randomized, double-blind clinical trial conducted at Leicester Royal Infirmary, 12 patients with mild-to-moderate left-sided ulcerative colitis received daily enemas of 5 microg of EGF in 100 ml of an inert carrier and 12 received daily enemas with carrier alone for 14 days. All also began to receive 1.2 g of oral mesalamine per day or had their dose increased by 1.2 g per day. Patients were assessed clinically at 0, 2, 4, and 12 weeks and by sigmoidoscopy and biopsy at 0, 2, and 4 weeks. The primary end point was disease remission (defined by a St. Marks score of 4 or less without sigmoidoscopic evidence of inflammation) at two weeks. Secondary end points were clinically significant improvements in disease activity (defined by a decrease of more than 3 points in the St. Marks score or the ulcerative colitis disease-activity index) at two and four weeks. Analyses were performed according to the intention-to-treat principle. Results: After two weeks, 10 of the 12 patients given EGF enemas were in remission, as compared with 1 of 12 in the control group (83 percent vs. 8 percent, P<0.001). At the 2-week assessment, disease-activity scores, sigmoidoscopic score, and histologic scores were all significantly better in the EGF group than in the placebo group (P<0.01 for all comparisons), and this benefit was maintained at 4 weeks and at 12 weeks. Conclusions: This study provides preliminary data suggesting that EGF enemas are an effective treatment for active left-sided ulcerative colitis.	Leicester Royal Infirm, Gastroenterol Ctr, Dept Gastroenterol, Leicester LE1 5WW, Leics, England; Leicester Royal Infirm, Dept Pathol, Leicester LE1 5WW, Leics, England; Ctr Genet Engn & Biotechnol, Havana, Cuba; Univ London Imperial Coll Sci Technol & Med, Fac Med, Gastroenterol Sect, London, England	University of Leicester; University of Leicester; Centro de Ingenieria Genetica y Biotecnologia; Imperial College London	Nightingale, JMD (corresponding author), Leicester Royal Infirm, Gastroenterol Ctr, Dept Gastroenterol, Leicester LE1 5WW, Leics, England.	jeremy.nightingale@uhl-tr.nhs.uk		Playford, Raymond/0000-0003-1235-8504				ARAKI F, 1989, CHEM PHARM BULL, V37, P404; BARON JH, 1964, BRIT MED J, V1, P89, DOI 10.1136/bmj.1.5375.89; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; Berlanga J, 2002, AM J PATHOL, V161, P373, DOI 10.1016/S0002-9440(10)64192-2; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; Calnan DP, 2000, GUT, V47, P622, DOI 10.1136/gut.47.5.622; CHINERY R, 1995, CLIN SCI, V88, P401, DOI 10.1042/cs0880401; DRUMM B, 1988, LANCET, V1, P111; Farrell RJ, 2002, LANCET, V359, P331, DOI 10.1016/S0140-6736(02)07499-8; HANAUER SB, 1993, LANCET, V342, P412, DOI 10.1016/0140-6736(93)92819-F; HEITZ PU, 1978, GUT, V19, P408, DOI 10.1136/gut.19.5.408; Hoffmann P, 2000, SCAND J GASTROENTERO, V35, P1174; ITOH M, 1992, J CLIN GASTROENTEROL, V14, pS127, DOI 10.1097/00004836-199206001-00022; KELLY SM, 1994, GUT, V35, P611, DOI 10.1136/gut.35.5.611; Klotz U, 2000, EUR J CLIN PHARMACOL, V56, P353, DOI 10.1007/s002280000163; MEYERS S, 1989, J CLIN GASTROENTEROL, V11, P33, DOI 10.1097/00004836-198902000-00008; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Playford RJ, 1997, GUT, V40, P286, DOI 10.1136/gut.40.2.286; PLAYFORD RJ, 1993, LANCET, V341, P843, DOI 10.1016/0140-6736(93)93057-8; PLAYFORD RJ, 1995, GASTROENTEROLOGY, V108, P92, DOI 10.1016/0016-5085(95)90012-8; PLAYFORD RJ, 1995, GUT, V37, P595, DOI 10.1136/gut.37.5.595; Playford RJ, 1996, GUT, V39, P262, DOI 10.1136/gut.39.2.262; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; POWELLTUCK J, 1982, DIGEST DIS SCI, V27, P533, DOI 10.1007/BF01296733; PROCACCINO F, 1994, GASTROENTEROLOGY, V107, P12, DOI 10.1016/0016-5085(94)90055-8; Safdi M, 1997, AM J GASTROENTEROL, V92, P1867; Sinha A, 2000, GASTROENTEROLOGY, V118, pA316, DOI 10.1016/S0016-5085(00)83352-1; SULLIVAN PB, 1991, LANCET, V338, P53, DOI 10.1016/0140-6736(91)90042-N; SUTHERLAND LR, 1987, GASTROENTEROLOGY, V92, P1894, DOI 10.1016/0016-5085(87)90621-4; SUTHERLAND LR, 1993, ANN INTERN MED, V118, P540, DOI 10.7326/0003-4819-118-7-199304010-00009; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6	31	229	241	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	2003	349	4					350	357		10.1056/NEJMoa013136	http://dx.doi.org/10.1056/NEJMoa013136			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	703ZH	12878742	Green Published, Bronze			2023-01-03	WOS:000184312800008
J	Parmar, MKB; Ledermann, JA; Colombo, N; du Bois, A; Delaloye, JF; Kristensen, GB; Wheeler, S; Swart, AM; Qian, W; Torri, V; Floriani, I; Jayson, G; Lamont, A; Trope, C; Lederman, JA; Parmar, MKB; Mangioni, C; Torri, V; Sandercock, J; Dubois, A				Parmar, MKB; Ledermann, JA; Colombo, N; du Bois, A; Delaloye, JF; Kristensen, GB; Wheeler, S; Swart, AM; Qian, W; Torri, V; Floriani, I; Jayson, G; Lamont, A; Trope, C; Lederman, JA; Parmar, MKB; Mangioni, C; Torri, V; Sandercock, J; Dubois, A		ICON Collaborators; AGO Collaborators	Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial	LANCET			English	Article							2ND-LINE THERAPY; STAGE-III; CISPLATIN; CYCLOPHOSPHAMIDE; CARBOPLATIN; CARCINOMA	Background Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment. Methods In parallel international, multicentre, randomised trials, between January, 1996, and March, 2002, 802 patients with platinum-sensitive ovarian cancer relapsing after 6 months of being treatment-free were enrolled from 119 hospitals in five countries. Patients were randomly assigned paclitaxel plus platinum chemotherapy or conventional platinum-based chemotherapy. Analysis was by intention to treat, except for toxic effects. Findings With a median follow-up of 42 months, 530 patients have died. Survival curves showed a difference in favour of paclitaxel plus platinum (hazard ratio 0.82 [95% Cl 0.69-0.97], p=0.02), corresponding to an absolute difference in 2-year survival of 7% between the paclitaxel and conventional treatment groups (57 vs 50% [95% Cl for difference 1-12]), and median survival of 5 months (29 vs 24 months [1-11). 717 patients developed progressive disease or died. The progress ion-free survival curves show a difference in favour of paclitaxel plus platinum (hazard ratio 0.76 [0.66-0.89], p=0.0004), corresponding to an absolute difference in 1-year progression-free survival of 10% (50 vs 40% [4-15]) and in median progress ion-free survival of 3 months (13 vs 10 months [1-5]). Interpretation Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy.	MRC, Trials Unit, Canc Div, ICON Trial 4, London NW1 2DA, England	Medical Research Council Clinical Trials Unit	Parmar, MKB (corresponding author), MRC, Trials Unit, Canc Div, ICON Trial 4, 222 Euston Rd, London NW1 2DA, England.		Torri, Valter/H-7550-2015; Colombo, Nicoletta/AAB-8319-2019; Jayson, Gordon C/O-8224-2015	Torri, Valter/0000-0001-9541-9354; Jayson, Gordon C/0000-0002-8515-8944				Aabo K, 1998, BRIT J CANCER, V78, P1479, DOI 10.1038/bjc.1998.710; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; Cantu MG, 2002, J CLIN ONCOL, V20, P1232, DOI 10.1200/JCO.20.5.1232; Dizon DS, 2002, J CLIN ONCOL, V20, P1238, DOI 10.1200/JCO.20.5.1238; Fayers P, 2001, EORTC QLQ C30 SCORIN, P86; Girling D.J., 2003, CLIN TRIALS CANC; MARKMAN M, 1991, J CLIN ONCOL, V9, P389, DOI 10.1200/JCO.1991.9.3.389; MARTIN AAG, 2003, P ASCO, V22; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Muggia FM, 2000, J CLIN ONCOL, V18, P106, DOI 10.1200/JCO.2000.18.1.106; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; PARMAR M, 1995, SURVIVAL ANAL PRACTI; Parmar MKB, 2002, LANCET, V360, P505; Parmar MKB, 1998, LANCET, V352, P1571; Piccart MJ, 2000, JNCI-J NATL CANCER I, V92, P699, DOI 10.1093/jnci/92.9.699; Rose PG, 1998, J CLIN ONCOL, V16, P1494, DOI 10.1200/JCO.1998.16.4.1494; Sandercock J, 2002, BRIT J CANCER, V87, P815, DOI 10.1038/sj.bjc.6600567; TRIMBLE EL, 1993, J CLIN ONCOL, V11, P2405, DOI 10.1200/JCO.1993.11.12.2405; Van Warmerdam Laurence J. C., 1997, Seminars in Oncology, V24, P97	19	845	886	2	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2099	2106						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826431				2023-01-03	WOS:000183654200007
J	Kmietowicz, Z				Kmietowicz, Z			Commentary: Information for patients: removal of lice and eggs by combing	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ Publishing Grp, BestTreatments, London WC1H 9JR, England	BMJ Publishing Group Ltd	Kmietowicz, Z (corresponding author), BMJ Publishing Grp, BestTreatments, London WC1H 9JR, England.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1258	1258		10.1136/bmj.326.7401.1258	http://dx.doi.org/10.1136/bmj.326.7401.1258			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791747	Green Published			2023-01-03	WOS:000183480700023
J	Rosenberg, AL; Hofer, TP; Strachan, C; Watts, CM; Hayward, RA				Rosenberg, AL; Hofer, TP; Strachan, C; Watts, CM; Hayward, RA			Accepting critically ill transfer patients: Adverse effect on a referral center's outcome and benchmark measures	ANNALS OF INTERNAL MEDICINE			English	Article							INTENSIVE-CARE-UNIT; QUALITY-OF-CARE; ACADEMIC-MEDICAL-CENTER; LEAD-TIME BIAS; MANAGED CARE; HOSPITAL MORTALITY; INTERHOSPITAL TRANSFERS; ACUTE PHYSIOLOGY; RISK ADJUSTMENT; SCORING SYSTEM	Background: Common methods of benchmarking clinical performance rarely, if ever, account for admission source and, in particular, the effect of a patient being transferred from one medical center to another. Small biases in comparisons of observed versus expected deaths can substantially affect how high-quality institutions compare with peer hospitals. With the most sophisticated and validated set of case-mix measures available for patients, the intensive care unit is an ideal setting in which to study the effect of a patient's being transferred from another hospital. Objective: To determine the extent of bias in benchmarking outcomes when performance measures do not account for transfer patients' greater severity of illness. Design: Prospectively developed cohort study. Setting: Medical intensive care unit (MICU) at a tertiary care university hospital. Patients: 4579 consecutive admissions for 4208 patients from 1 January 1994 to 1 April 1998. Measurements: MICU and hospital lengths of stay, MICU readmission, and hospital mortality rates. Results: Compared with directly admitted patients, MICU patients transferred from another hospital had significantly higher Acute Physiology Scores at the time of admission and discharge (P = 0.001). Even after full adjustment for case mix and severity of illness, transfer patients had a 38% longer MICU stay (95% CI, 32% to 45%), a 41% longer hospital stay (CI, 34% to 50%), and a 2.2 times greater odds of hospital mortality (CI, 1.7 to 2.8) than directly admitted patients. With identical efficiency and quality, a referral hospital with a 25% MICU transfer rate compared with another with a 0% transfer rate would be penalized by 14 excess deaths per 1000 admissions when a benchmarking program adjusts only for case mix and severity of illness and not for the source of admission. Conclusions: In a setting with the most thorough diagnostic-based, case-mix adjustment and the most physiologically precise severity-of-illness information, accepting transfer patients can adversely affect efficiency and quality benchmarks. Benchmarking and profiling efforts beyond intensive care units must also recognize and account for this phenomenon; otherwise, referral centers may have an incentive to refuse care for patients who could benefit from being transferred to their facility.	Univ Michigan, Ctr Med, Dept Anesthesiol & Crit Care, Ann Arbor, MI 48109 USA; Vet Affairs Ann Arbor Healthcare Syst, Dept Vet Affairs Hlth Serv Res & Dev Serv, Ann Arbor, MI USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Rosenberg, AL (corresponding author), Univ Michigan, Ctr Med, Dept Anesthesiol & Crit Care, Room 1G323,Box 0048, Ann Arbor, MI 48109 USA.	arosen@umich.edu	Hofer, Timothy Philip/AAC-9238-2022	Hofer, Timothy/0000-0003-0434-8787				Albertson GA, 2000, J GEN INTERN MED, V15, P242, DOI 10.1111/j.1525-1497.2000.02208.x; Angus DC, 2000, CRIT CARE MED, V28, P2145, DOI 10.1097/00003246-200006000-00088; Bailey JE, 1999, JAMA-J AM MED ASSOC, V282, P1067, DOI 10.1001/jama.282.11.1067; Bernard AM, 1996, ACAD MED, V71, P262, DOI 10.1097/00001888-199603000-00019; Bindman AB, 1999, JAMA-J AM MED ASSOC, V281, P2142, DOI 10.1001/jama.281.22.2142; Blumenthal D, 1996, NEW ENGL J MED, V335, P891, DOI 10.1056/NEJM199609193351213; BORLASE BC, 1991, J TRAUMA, V31, P915, DOI 10.1097/00005373-199107000-00006; Chernew ME, 1998, MED CARE RES REV, V55, P259, DOI 10.1177/107755879805500301; CLEMMITT M, 2001, MED HLTH S, V55, P1; DRAGSTED L, 1989, CRIT CARE MED, V17, P418, DOI 10.1097/00003246-198905000-00008; DUNCAN RP, 1988, HOSP HEALTH SERV ADM, V33, P237; ESCARCE JJ, 1990, JAMA-J AM MED ASSOC, V264, P2389, DOI 10.1001/jama.264.18.2389; Fihn SD, 2000, JAMA-J AM MED ASSOC, V283, P1740, DOI 10.1001/jama.283.13.1740; FRANKLIN C, 1983, CRIT CARE MED, V11, P61, DOI 10.1097/00003246-198302000-00001; Goodman DC, 1996, JAMA-J AM MED ASSOC, V276, P1811, DOI 10.1001/jama.276.22.1811; Gordon HS, 1996, MED CARE, V34, P295, DOI 10.1097/00005650-199604000-00002; Green J, 1997, JAMA-J AM MED ASSOC, V277, P1152, DOI 10.1001/jama.277.14.1152; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HAYWARD RA, 1995, J GEN INTERN MED, V10, P504, DOI 10.1007/BF02602402; Hofer T P, 1997, Jt Comm J Qual Improv, V23, P455; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; Hofer TP, 1996, MED CARE, V34, P737, DOI 10.1097/00005650-199608000-00002; Huerta J A, 1995, J Clin Eng, V20, P48; HURLEY J, 1990, HEALTH SERV RES, V25, P239; Iezzoni LI, 1996, AM J PUBLIC HEALTH, V86, P1379, DOI 10.2105/AJPH.86.10.1379; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; JENCKS SF, 1988, MED CARE, V26, P948, DOI 10.1097/00005650-198810000-00003; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS W, 1989, CRIT CARE MED, V17, pS176, DOI 10.1097/00003246-198912001-00005; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Krakauer H, 1998, J Eval Clin Pract, V4, P11, DOI 10.1046/j.1365-2753.1998.t01-1-00002.x; Kulu-Glasgow I, 1998, HEALTH POLICY, V45, P221, DOI 10.1016/S0168-8510(98)00045-1; Langenbrunner J C, 1989, Health Care Financ Rev, V10, P91; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1994, JAMA-J AM MED ASSOC, V272, P1049, DOI 10.1001/jama.272.13.1049; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; MILLER MG, 1994, JAMA-J AM MED ASSOC, V271, P1493, DOI 10.1001/jama.271.19.1493; OBREMSKEY W, 1994, J TRAUMA, V36, P373, DOI 10.1097/00005373-199403000-00016; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; *PHC4, 1995, FOC HEART ATT W PENN; RAPOPORT J, 1990, CRIT CARE MED, V18, P1231, DOI 10.1097/00003246-199011000-00009; RAPOPORT J, 1992, ARCH INTERN MED, V152, P2207, DOI 10.1001/archinte.152.11.2207; ROMANO PS, 1994, J CLIN EPIDEMIOL, V47, P249, DOI 10.1016/0895-4356(94)90006-X; Rosenberg AL, 2001, CRIT CARE MED, V29, P511, DOI 10.1097/00003246-200103000-00008; Rosenthal G E, 1997, Am J Med Qual, V12, P103, DOI 10.1177/0885713X9701200204; ROSENTHAL GE, 1994, JOINT COMM J QUAL IM, V20, P425, DOI 10.1016/S1070-3241(16)30088-8; Rubenfeld GD, 1999, AM J RESP CRIT CARE, V160, P358, DOI 10.1164/ajrccm.160.1.9807118; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; Schroeder J, 1996, Am J Med Qual, V11, pS58; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SHAPIRO MF, 1994, HEALTH SERV RES, V29, P95; Spoeri RK, 1997, ANN INTERN MED, V127, P726, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00058; TERES D, 1993, CRIT CARE CLIN, V9, P543, DOI 10.1016/S0749-0704(18)30184-2; Tunnell RD, 1998, ANAESTHESIA, V53, P1045, DOI 10.1046/j.1365-2044.1998.00566.x; Weissman NW, 1999, J EVAL CLIN PRACT, V5, P269, DOI 10.1046/j.1365-2753.1999.00203.x; ZIMMERMAN JE, 1994, CRIT CARE MED, V22, P1373, DOI 10.1097/00003246-199409000-00005; Zimmerman JE, 1998, CRIT CARE MED, V26, P1317, DOI 10.1097/00003246-199808000-00012; Zimmerman JE, 2000, CRIT CARE MED, V28, P258, DOI 10.1097/00003246-200001000-00048; 2001, MED HEALTHC S, P6	62	171	172	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					882	890		10.7326/0003-4819-138-11-200306030-00009	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	686AB	12779298				2023-01-03	WOS:000183296400003
J	Lorenz, K; Lynn, J				Lorenz, K; Lynn, J			Moral and practical challenges of physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OREGON; EUTHANASIA; DEATH		Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA; Washington Home Ctr Palliat Care Studies, Washington, DC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lorenz, K (corresponding author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.							Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; CRENSHAW A, 2000, WASHINGTON POST 0425, P1; Drought Theresa S, 2002, Gerontologist, V42 Spec No 3, P114; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; FIELD MJ, 1997, APPRAOCHING DEATH IM; Foley KM, 2001, IMPROVING PALLIATIVE; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Iwashyna TJ, 2002, HEALTH SERV RES, V37, P1531, DOI 10.1111/1475-6773.10562; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 2003, ANN INTERN MED, V138, P208, DOI 10.7326/0003-4819-138-3-200302040-00013; *RW JOHNS FDN, 2003, ACC REP; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Veldink JH, 2002, NEW ENGL J MED, V346, P1638, DOI 10.1056/NEJMsa012739; Virnig BA, 2000, J AM GERIATR SOC, V48, P1117, DOI 10.1111/j.1532-5415.2000.tb04789.x; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	17	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2282	2282		10.1001/jama.289.17.2282	http://dx.doi.org/10.1001/jama.289.17.2282			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675ET	12734143				2023-01-03	WOS:000182680700034
J	Jonas, WB; Kaptchuk, TJ; Linde, K				Jonas, WB; Kaptchuk, TJ; Linde, K			A critical overview of homeopathy	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN BASOPHIL DEGRANULATION; DILUTE ANTISERUM; CLINICAL-TRIALS; PLACEBO; METAANALYSIS; GLUTAMATE; EFFICACY; MEDICINE; ARNICA	Homeopathy is a 200-year-old therapeutic system that uses small doses of various substances to stimulate autoregulatory and self-healing processes. Homeopathy selects substances by matching a patient's symptoms with symptoms produced by these substances in healthy individuals. Medicines are prepared by serial dilution and shaking, which proponents claim imprints information into water. Although many conventional physicians find such notions implausible, homeopathy had a prominent place in 19th-century health care and has recently undergone a worldwide revival. In the United States, patients who seek homeopathic care are more affluent and younger and more often seek treatment for subjective symptoms than those who seek conventional care. Homeopathic remedies were allowed by the 1939 Pure Food and Drug Act and are available over the counter. Some data-both from randomized, controlled trials and laboratory research-show effects from homeopathic remedies that contradict the contemporary rational basis of medicine. Three independent systematic reviews of placebo-controlled trials on homeopathy reported that its effects seem to be more than placebo, and one review found its effects consistent with placebo. There is also evidence from randomized, controlled trials that homeopathy may be effective for the treatment of influenza, allergies, postoperative ileus, and childhood diarrhea. Evidence suggests that homeopathy is ineffective for migraine, delayed-onset muscle soreness, and influenza prevention. There is a lack of conclusive evidence on the effectiveness of homeopathy for most conditions. Homeopathy deserves an open-minded opportunity to demonstrate its value by using evidence-based principles, but it should not be substituted for proven therapies.	Samueli Inst Informat Biol, Bethesda, MD USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Tech Univ Munich, Ctr Complementary Med Res, D-8000 Munich, Germany	Uniformed Services University of the Health Sciences - USA; Harvard University; Harvard Medical School; Technical University of Munich	Jonas, WB (corresponding author), Samueli Inst, 121 S St Asaph St,Suite 200, Alexandria, VA 22314 USA.	wjonas@siib.org		Linde, Klaus/0000-0002-2902-970X	NCCIH NIH HHS [AT00178-01, AT00270-01] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT000178, R21AT000270] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Barnes J, 1997, J CLIN GASTROENTEROL, V25, P628, DOI 10.1097/00004836-199712000-00016; Belon P, 1999, INFLAMM RES, V48, pS17; Cassedy James H., 1984, AM MED STAT THINKING; COULTER HL, 1981, CONFLICT HOMEOPATHY, V3; Cucherat M, 2000, EUR J CLIN PHARMACOL, V56, P27, DOI 10.1007/s002280050716; DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0; EGGER M, 2001, ARE CLIN EFFECTS HOM; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1999, J PAIN SYMPTOM MANAG, V18, P353, DOI 10.1016/S0885-3924(99)00095-0; Ernst E, 1996, ARCH INTERN MED, V156, P2162, DOI 10.1001/archinte.156.19.2162; Ernst E, 1999, PERFUSION, V12, P13; Ernst E, 1998, ARCH SURG-CHICAGO, V133, P1187, DOI 10.1001/archsurg.133.11.1187; Ernst E, 1997, PERFUSION, V10, P293; FYE WB, 1986, CIRCULATION, V73, P21, DOI 10.1161/01.CIR.73.1.21; HAEHL R, 1922, S HAHNEMANN HIS LIFE; HAHNEMANN S, 1982, ORGANON MED; HIRST SJ, 1993, NATURE, V366, P525, DOI 10.1038/366525a0; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Jacobs J, 1998, ARCH FAM MED, V7, P537, DOI 10.1001/archfami.7.6.537; JACOBS J, 1994, PEDIATRICS, V93, P719; JACOBS J, 2003, IN PRESS PEDIAT INFE; Jacobs J W, 1991, Ned Tijdschr Geneeskd, V135, P317; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; Jonas W, 1999, PERFUSION-GERMANY, V12, P452; Jonas W, 2001, NEUROREPORT, V12, P335, DOI 10.1097/00001756-200102120-00031; Jonas W B, 2001, BMC Complement Altern Med, V1, P12, DOI 10.1186/1472-6882-1-12; Jonas WB, 2000, J ALTERN COMPLEM MED, V6, P213, DOI 10.1089/acm.2000.6.213; Jonas WB, 2000, RHEUM DIS CLIN N AM, V26, P117, DOI 10.1016/S0889-857X(05)70125-3; JONAS WB, 1996, HEALING HOMEOPATHY C; Jonas WB, 2000, J SCI EXPLOR, V14, P35; JONAS WB, 1999, ESSENTIALS COMPLEMEN, P167; JOSLIN BF, 1849, ECLECTIC MED J, V8, P363; Kaptchuk TJ, 1998, B HIST MED, V72, P389, DOI 10.1353/bhm.1998.0159; KAPTCHUK TJ, 1996, BRIT HOMEOPATHIC J, V85, P237; KENT JT, 1885, HOMOEOPATHIC PHYSICI, V5, P346; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LEARY B, 1994, BRIT HOMEOPATHIC J, V83, P117; LELAND PW, 1852, BOSTON MED SURG J, V47, P283; LEWIN DI, 1996, J NIH RES, V8, P30; Lewith GT, 2002, BMJ-BRIT MED J, V324, P520, DOI 10.1136/bmj.324.7336.520; LINDE K, 1994, HUM EXP TOXICOL, V13, P481, DOI 10.1177/096032719401300706; Linde K, 1998, J ALTERN COMPLEM MED, V4, P371, DOI 10.1089/acm.1998.4.371; Linde K, 2003, J ROY SOC MED, V96, P17, DOI 10.1258/jrsm.96.1.17; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Linde K., 1999, ESSENTIALS COMPLEMEN, P57; Linde K, 2000, COCHRANE DB SYST REV; LUDTKE R, 1999, JB K V CARSTENSSTIFT, V5, P97; MADDOX J, 1988, NATURE, V334, P287, DOI 10.1038/334287a0; MUKHERJEE JK, 1964, HAHN GLEAN, V31, P163; Nicholls Phillip A., 1988, HOMEOPATHY MED PROFE; OVELGONNE JH, 1992, EXPERIENTIA, V48, P504, DOI 10.1007/BF01928175; PARKER WW, 1886, JHAMA, P7; PERSONS S, 1991, B HIST MED, V65, P74; ROBERTS WH, 1986, B HIST MED, V60, P73; Rogers Naomi, 1998, ALTERNATIVE PATH MAK; ROTHSTEIN WG, 1992, AM PHYSICIANS 19 CEN; Taylor MA, 2000, BMJ-BRIT MED J, V321, P471, DOI 10.1136/bmj.321.7259.471; Vickers AJ, 1999, FORSCH KOMPLEMENTMED, V6, P311, DOI 10.1159/000021286; VICKERS AJ, 2000, COCHRANE DB SYST REV; WALACH H, 1997, THESIS A LUDWIGS U F; Wiesenauer M, 1996, FORSCH KOMPLEMENTMED, V3, P230; 1882, HOMOEOPATHIC PHYSICI, V2, P73	62	115	145	2	61	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 4	2003	138	5					393	399		10.7326/0003-4819-138-5-200303040-00009	http://dx.doi.org/10.7326/0003-4819-138-5-200303040-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650HJ	12614092				2023-01-03	WOS:000181257300005
J	Solomon, CG; Dluhy, RG				Solomon, CG; Dluhy, RG			Rethinking postmenopausal hormone therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Solomon, CG (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.								0	44	49	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	2003	348	7					579	580		10.1056/NEJMp030006	http://dx.doi.org/10.1056/NEJMp030006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644HY	12584364				2023-01-03	WOS:000180912900001
J	Antlsperger, DSM; Dirsch, VM; Ferreira, D; Su, JL; Kuo, ML; Vollmar, AM				Antlsperger, DSM; Dirsch, VM; Ferreira, D; Su, JL; Kuo, ML; Vollmar, AM			Ajoene-induced cell death in human promyeloleukemic cells does not require JNK but is amplified by the inhibition of ERK	ONCOGENE			English	Article						ajoene; apoptosis; mitogen-activated protein kinase; c-Jun NH2-terminal kinase; extracellular signal-regulated kinases	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; JUN NH2-TERMINAL KINASE; INDUCED APOPTOSIS; SIGNALING PATHWAYS; CANCER CELLS; CYTOCHROME-C; HL-60 CELLS; KAPPA-B; T-CELLS	Treatment of human promyeloleukemic HL-60 cells with the experimental antileukemic drug ajoene induces the activation of the mitogen-activated protein kinases (MAPKs) c-Jun NH2-terminal kinase (JNK), p38 and extracellular signal-regulated kinases (ERK) 1/2 as well as the survival kinase Akt. JNK activation occurred in HL-60/neo, HL-60/bcl-x(L), and in HL-60 cells pretreated with the pan-caspase inhibitor zVAD-fmk, indicating that JNK activation is not dependent on ajoene-induced mitochondria perturbation and subsequent caspase activation. Cells overexpressing a dominant-negative JNK showed no altered sensitivity towards ajoene suggesting that the activation of JNK is not necessary for ajoene-induced cell death. Inhibition of p38 MAPK by SB 203580 had no influence on ajoene-mediated apoptosis. In contrast, inhibition of ERK1/2 vastly enhanced ajoene-induced cell death. The survival kinase Akt, in contrast, did not participate in ajoene-induced death signaling as shown by the use of the phosphatidylinositol-3-kinase inhibitor wortmannin. Thus in contrast to the previous findings regarding stress-induced cell death, ajoene-mediated activation of JNK and p38 has no impact on ajoene-induced apoptosis in HL-60 cells. Blockade of ERK1/2 but not Akt pathways leads to sensitization of cells against ajoene-mediated apoptosis supporting the view that inhibition of ERK1/2 is a valuable strategy to increase the sensitivity of promyeloleukemic cells towards ajoene.	Univ Munich, Ctr Drug Res, Dept Pharm, D-81377 Munich, Germany; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan	University of Munich; National Taiwan University	Dirsch, VM (corresponding author), Univ Munich, Ctr Drug Res, Dept Pharm, Butenandtstr 5-13, D-81377 Munich, Germany.		Kuo, Min-Liang/C-4872-2009	Dirsch, Verena/0000-0002-9261-5293				Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; Bamford M, 2000, EXP CELL RES, V256, P1, DOI 10.1006/excr.2000.4837; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dirsch VM, 2001, CANCER RES, V61, P5817; Dirsch VM, 1998, MOL PHARMACOL, V53, P402, DOI 10.1124/mol.53.3.402; Dirsch VM, 2002, LEUKEMIA, V16, P74, DOI 10.1038/sj.leu.2402337; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Eilers A, 2001, J NEUROCHEM, V76, P1439, DOI 10.1046/j.1471-4159.2001.00150.x; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hancock JT, 2001, BIOCHEM SOC T, V29, P345, DOI 10.1042/0300-5127:0290345; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Ibrado AM, 1996, CANCER RES, V56, P4743; Jarvis WD, 1999, J PHARMACOL EXP THER, V290, P1384; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Mandlekar S, 2000, CANCER RES, V60, P5995; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Shiah SG, 2001, MOL PHARMACOL, V59, P254, DOI 10.1124/mol.59.2.254; Shiah SG, 1999, CANCER RES, V59, P391; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen A, 1998, CANCER RES, V58, P3163; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	44	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					582	589		10.1038/sj.onc.1206161	http://dx.doi.org/10.1038/sj.onc.1206161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555071				2023-01-03	WOS:000180538200011
J	Bodenheimer, T; Lorig, K; Holman, H; Grumbach, K				Bodenheimer, T; Lorig, K; Holman, H; Grumbach, K			Patient self-management of chronic disease in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; HEALTH-STATUS; RHEUMATOID-ARTHRITIS; EDUCATION-PROGRAM; OLDER-ADULTS; OSTEOARTHRITIS; ADHERENCE; PEOPLE; PARTNERSHIP	Patients with chronic conditions make day-to-day, decisions about-self-manage-their illnesses. This reality introduces a new chronic disease paradigm: the patient-professional partnership, involving collaborative care and self-management education. Self-management education complements traditional patient education in supporting patients to live the best possible quality of life with their chronic condition. Whereas traditional patient education offers information and technical skills, self-management education teaches problem-solving skills. A central concept in self-management is self-efficacy-confidence to carry out a behavior necessary to reach a desired goal. Self-efficacy is enhanced when patients succeed in solving patient-identified problems. Evidence from controlled clinical trials suggests that (1) programs teaching self-management skills are more effective than information-only patient education in improving clinical outcomes; (2) in some circumstances, self-management education improves outcomes and can reduce costs for arthritis and probably for adult asthma patients; and (3) in initial studies, a self-management education program bringing together patients with a variety of chronic conditions may improve outcomes and reduce costs. Self-management education for chronic illness may soon become an integral part of high-quality primary care.	Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Stanford Univ, Dept Med, Palo Alto, CA 94304 USA	University of California System; University of California San Francisco; Stanford University	Bodenheimer, T (corresponding author), San Francisco Gen Hosp, Ward 83,1001 Potrero Ave, San Francisco, CA 94110 USA.	tbodie@earthlink.net	Grumbach, Kevin/L-9222-2016; Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				Anderson RM, 2000, DIABETES EDUCATOR, V26, P597, DOI 10.1177/014572170002600405; ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943; ANDERSON RM, 1996, PRACTICAL PSYCHOL DI; ARNOLD MS, 1995, DIABETES EDUCATOR, V21, P308, DOI 10.1177/014572179502100408; Bailey WC, 1999, ARCH INTERN MED, V159, P2422, DOI 10.1001/archinte.159.20.2422; Bandura A, 1997, EFFICACY EXERCISE CO; Barlow JH, 1996, PATIENT EDUC COUNS, V27, P257, DOI 10.1016/0738-3991(95)00844-6; Barlow JH, 2000, HEALTH EDUC RES, V15, P665, DOI 10.1093/her/15.6.665; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Brus H, 1999, PATIENT EDUC COUNS, V36, P57, DOI 10.1016/S0738-3991(98)00087-1; CLEMENT S, 1995, DIABETES CARE, V18, P1204, DOI 10.2337/diacare.18.8.1204; Corbin J.M., 1988, UNENDING WORK CARE M; Cote J, 2000, Can Respir J, V7, P395; D'Zurilla TJ., 1999, PROBLEM SOLVING THER; *DEP HLTH, 2002, HLTH IN WEB SIT; Edworthy SM, 1999, J RHEUMATOL, V26, P1793; Elasy TA, 2001, PATIENT EDUC COUNS, V43, P121, DOI 10.1016/S0738-3991(00)00150-6; Fries JF, 1997, J RHEUMATOL, V24, P1378; Funnell M M, 1991, Diabetes Educ, V17, P37, DOI 10.1177/014572179101700108; Funnell MM, 2000, JAMA-J AM MED ASSOC, V284, P1709, DOI 10.1001/jama.284.13.1709; Gallefoss F, 1999, AM J RESP CRIT CARE, V159, P812, DOI 10.1164/ajrccm.159.3.9804047; GIBSON PG, 2001, LTD INFORMATION ONLY; GIBSON PG, 2001, SELF MANAGEMENT ED R; Glasgow RE, 1999, DIABETES CARE, V22, P2090, DOI 10.2337/diacare.22.12.2090; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Glasgow RE, 1997, PATIENT EDUC COUNS, V32, P175, DOI 10.1016/S0738-3991(97)00039-6; Glasgow RE, 1996, DIABETES EDUCATOR, V22, P573, DOI 10.1177/014572179602200605; Gotler RS, 2000, MED CARE, V38, P1200, DOI 10.1097/00005650-200012000-00007; Groessl EJ, 2000, AM J COMMUN PSYCHOL, V28, P455, DOI 10.1023/A:1005184414241; Hammond A, 2001, RHEUMATOLOGY, V40, P1044, DOI 10.1093/rheumatology/40.9.1044; Helliwell PS, 1999, RHEUMATOLOGY, V38, P303, DOI 10.1093/rheumatology/38.4.303; Holman H, 2000, BRIT MED J, V320, P526, DOI 10.1136/bmj.320.7234.526; Hopman-Rock M, 2000, J RHEUMATOL, V27, P1947; *I FUT, 2000, HLTH HLTH CAR 2010; Kauppinen R, 2001, RESP MED, V95, P56, DOI 10.1053/rmed.2000.0971; Keefe FJ, 1999, ARTHRIT CARE RES, V12, P101, DOI 10.1002/1529-0131(199904)12:2<101::AID-ART5>3.0.CO;2-9; Leveille SG, 1998, J AM GERIATR SOC, V46, P1191, DOI 10.1111/j.1532-5415.1998.tb04533.x; Levy ML, 2000, RESP MED, V94, P900, DOI 10.1053/rmed.2000.0861; Lindroth Y, 1997, ARTHRIT CARE RES, V10, P325, DOI 10.1002/art.1790100507; Lorig K., 1994, LIVING HLTH LIFE CHR; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Mazzuca SA, 1997, ARTHRITIS RHEUM-US, V40, P1466, DOI 10.1002/art.1780400815; *MICH DIAB TRAIN C, 2002, WEB SIT; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; Parker JC, 1995, ARTHRITIS RHEUM, V38, P1807, DOI 10.1002/art.1780381214; Riemsma RP, 1997, ARTHRIT CARE RES, V10, P238, DOI 10.1002/art.1790100405; Simeoni E, 1995, ARTHRIT CARE RES, V8, P102, DOI 10.1002/art.1790080208; *STANDF PAT ED RES, 2002, WEB SIT; *STANF PAT ED RES, 1997, CHRON DIS SELF MAN L; TAAL E, 1993, PATIENT EDUC COUNS, V20, P177, DOI 10.1016/0738-3991(93)90131-F; Van der Palen J, 1998, RESP MED, V92, P668, DOI 10.1016/S0954-6111(98)90516-9; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; 2001, DIABETES ED, V27, P899	55	2120	2169	8	320	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2002	288	19					2469	2475		10.1001/jama.288.19.2469	http://dx.doi.org/10.1001/jama.288.19.2469			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	616FB	12435261				2023-01-03	WOS:000179292300031
J	Blackman, MB; Sorkin, JD; Munzer, T; Bellantoni, MF; Busby-Whitehead, J; Stevens, TE; Jayme, J; O'Connor, KG; Christmas, C; Tobin, JD; Stewart, KJ; Cottrell, E; St Clair, C; Pabst, KM; Harman, SM				Blackman, MB; Sorkin, JD; Munzer, T; Bellantoni, MF; Busby-Whitehead, J; Stevens, TE; Jayme, J; O'Connor, KG; Christmas, C; Tobin, JD; Stewart, KJ; Cottrell, E; St Clair, C; Pabst, KM; Harman, SM			Growth hormone and sex steroid administration in healthy aged women and men - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; MUSCLE STRENGTH; FACTOR-I; TESTOSTERONE REPLACEMENT; BODY-COMPOSITION; HYPOGONADAL MEN; OLDER MEN; ESTROGEN REPLACEMENT; RESISTANCE EXERCISE	Context Hormone administration to elderly individuals can increase lean body mass (LBM) and decrease fat, but interactive effects of growth hormone (GH) and sex steroids and their influence on strength and endurance are unknown. Objective To evaluate the effects of recombinant human GH and/or sex steroids on body composition, strength, endurance, and adverse outcomes in aged persons. Design, Setting, and Participants A 26-week randomized, double-blind, placebo-controlled parallel-group trial in healthy, ambulatory, community-dwelling US women (n=57) and men (n=74) aged 65 to 88 years recruited between June 1992 and July 1998. Interventions Participants were randomized to receive GH (starting dose, 30 mug/kg reduced to 20 mug/kg, subcutaneously 3 times/wk) + sex steroids (women: transdermal estradiol,100 mug/d, plus oral medroxyprogesterone acetate, 10 mg/d, during the last 10 days of each 28-day cycle [HRT]; men: testosterone enanthate, biweekly intramuscular injections of 100 mg) (n=35); GH + placebo sex steroid (n=30); sex steroid + placebo GH (n=35); or placebo GH + placebo sex steroid (n=31) in a 2 x 2 factorial design. Main Outcome Measures Lean body mass, fat mass, muscle strength, maximum oxygen uptake ((V) over doto(2)max) during treadmill test, and adverse effects. Results In women, LBM increased by 0.4 kg with placebo, 1.2 kg with HRT (P=.09), 1.0 kg with GH (P=.001), and 2.1 kg with GH+HRT (P<.001). Fat mass decreased significantly in the GH and GH+HRT groups. In men, LBM increased by 0.1 kg with placebo, 1.4 kg with testosterone (P=.06), 3.1 kg with GH (P<.001), and 4.3 kg with GH+testosterone (P<.001). Fat mass decreased significantly with GH and GH+testosterone. Women's strength decreased in the placebo group and increased's strength nonsignificantly with HRT (P=.09), GH (P=.29), and GH+HRT (P=.14). Men also did not increase significantly except for a marginally significant increase of 13.5 kg with GH+testosterone (P=.05). Women's (V) over dot o(2)max declined by 0.4 mL/min/kg in the placebo and HRT groups but increased with GH (P=.07) and GH+HRT (P=.06). 3 Men's (V) over dot o(2)max declined by 1.2 mL/min/kg with placebo and by 0.4 mL/min/kg with testosterone (P=.49) but increased with GH (P=.11) and with GH+testosterone (P<.001). Changes in strength (r=0.355; P<.001) and in (V) over dot o(2)max (r=0.320; P=.002) were directly related to changes in LBM. Edema was significantly more common in women taking GH (39% vs 0%) and GH+HRT (38% vs 0%). Carpal tunnel symptoms were more common in men taking GH+testosterone (32% vs 0%) and arthralgias were more common in men taking GH (41% vs 0%). Diabetes or glucose intolerance occurred in 18 GH-treated men vs 7 not receiving GH (P=.006). Conclusions In this study, GH with or without sex steroids in healthy, aged women and men increased LBM and decreased fat mass. Sex steroid + GH increased muscle strength marginally and (V) over dot o(2)max in men, but women had no significant change in strength or cardiovascular endurance. Because adverse effects were frequent (importantly, diabetes and glucose intolerance), GH interventions; in the elderly should be confined to controlled studies.	Natl Ctr Complementary & Alternat Med, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA; NIA, Endocrine Sect, NIH, Lab Clin Invest,Intramural Res Program, Bethesda, MD 20892 USA; NIA, Metab Sect, NIH, Lab Clin Invest,Intramural Res Program, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Burgerspital, St Gallen, Switzerland; Univ N Carolina, Sch Med, Div Geriatr Med, Chapel Hill, NC USA; Univ S Alabama, Sch Med, Div Geriatr Med, Mobile, AL USA; Louth Hosp, Louth, Ireland; Kronos Res Inst, Phoenix, AZ USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Baltimore; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of South Alabama	Blackman, MB (corresponding author), Natl Ctr Complementary & Alternat Med, NIH, 8 West Dr,Bldg 15 B-1, Bethesda, MD 20892 USA.			Bellantoni, Michele/0000-0001-8525-2247	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NCRR NIH HHS [M0-1-RR-02719] Funding Source: Medline; NIA NIH HHS [R0-1 AG11005] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abs R, 1999, CLIN ENDOCRINOL, V50, P703, DOI 10.1046/j.1365-2265.1999.00695.x; Barbulescu K, 2001, MOL ENDOCRINOL, V15, P1803, DOI 10.1210/me.15.10.1803; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BELLANTONI MF, 1991, J CLIN ENDOCR METAB, V72, P172, DOI 10.1210/jcem-72-1-172; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P407, DOI 10.1210/jc.82.2.407; BLACKMAN MR, 1999, SEX STEROID INTERACT, P44; BLACKMAN MR, 1995, ENDOCRINOLOGY, P2702; BRUCE RA, 1966, AM HEART J, V71, P455, DOI 10.1016/0002-8703(66)90210-9; Burman P, 1997, J CLIN ENDOCR METAB, V82, P550, DOI 10.1210/jc.82.2.550; Cappola AR, 2001, J CLIN ENDOCR METAB, V86, P4139, DOI 10.1210/jc.86.9.4139; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; Cefalu WT, 1998, METABOLISM, V47, P401, DOI 10.1016/S0026-0495(98)90050-6; Christmas C, 2002, J GERONTOL A-BIOL, V57, pM12, DOI 10.1093/gerona/57.1.M12; COHN L, 1993, CLIN ENDOCRINOL, V39, P417, DOI 10.1111/j.1365-2265.1993.tb02388.x; CUNEO RC, 1991, J APPL PHYSIOL, V70, P688, DOI 10.1152/jappl.1991.70.2.688; Cuttica CM, 1997, AGING CLIN EXP RES, V9, P193, DOI 10.1007/BF03340149; DAWSONHUGHES B, 1986, J CLIN ENDOCR METAB, V63, P424, DOI 10.1210/jcem-63-2-424; Dobs AS, 2002, J CLIN ENDOCR METAB, V87, P1509, DOI 10.1210/jc.87.4.1509; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Ferrando AA, 2002, AM J PHYSIOL-ENDOC M, V282, pE601, DOI 10.1152/ajpendo.00362.2001; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; Friend KE, 1996, J CLIN ENDOCR METAB, V81, P2250, DOI 10.1210/jc.81.6.2250; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gentili A, 2002, J CLIN ENDOCR METAB, V87, P825, DOI 10.1210/jc.87.2.825; HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W; Hajjar RR, 1997, J CLIN ENDOCR METAB, V82, P3793, DOI 10.1210/jc.82.11.3793; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Hayes VY, 2001, J CLIN ENDOCR METAB, V86, P2211, DOI 10.1210/jc.86.5.2211; Ho Ken K. Y., 1996, Endocrine Journal, V43, pS57; HULKA BS, 1980, JAMA-J AM MED ASSOC, V244, P2419; Johnston D. G., 1999, Journal of Endocrinological Investigation, V22, P37; KLATZ R, 1997, GROW YOUNG HGH AMAZI; KRITZSILVERSTEIN D, 1994, J BONE MINER RES, V9, P45, DOI 10.1002/jbmr.5650090107; Lasco A, 2000, DIABETES CARE, V23, P422, DOI 10.2337/diacare.23.3.422; Lindle RS, 1997, J APPL PHYSIOL, V83, P1581, DOI 10.1152/jappl.1997.83.5.1581; MALOZOWSKI S, 1993, NEW ENGL J MED, V329, P665, DOI 10.1056/NEJM199308263290917; MARDH G, 1994, ENDOCRINOLOGY MET SA, V1, P43; Marin P, 1992, Eur J Med, V1, P329; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; Miller MM, 1999, EXP GERONTOL, V34, P587, DOI 10.1016/S0531-5565(99)00032-7; Munzer T, 2001, J CLIN ENDOCR METAB, V86, P3604, DOI 10.1210/jc.86.8.3604; O'Connor KG, 1998, J GERONTOL A-BIOL, V53, pM176, DOI 10.1093/gerona/53A.3.M176; O'Sullivan AJ, 1998, J CLIN INVEST, V102, P1035, DOI 10.1172/JCI2773; Papadakis MA, 1996, ANN INTERN MED, V124, P708, DOI 10.7326/0003-4819-124-8-199604150-00002; Rosenfalck AM, 1999, GROWTH HORM IGF RES, V9, P96, DOI 10.1054/ghir.1999.0091; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Roy TA, 2002, AM J PHYSIOL-ENDOC M, V283, pE284, DOI 10.1152/ajpendo.00334.2001; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; Savine R, 2000, HORM RES, V53, P37, DOI 10.1159/000023531; SHIMOKATA H, 1989, INT J OBESITY, V13, P455; Sih R, 1997, J CLIN ENDOCR METAB, V82, P1661, DOI 10.1210/jc.82.6.1661; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647; Snyder PJ, 2000, J CLIN ENDOCR METAB, V85, P2670, DOI 10.1210/jc.85.8.2670; Sorensen MB, 2001, OBES RES, V9, P622, DOI 10.1038/oby.2001.81; Swerdlow AJ, 2002, LANCET, V360, P273, DOI 10.1016/S0140-6736(02)09519-3; Taaffe DR, 1999, J AM GERIATR SOC, V47, P1208, DOI 10.1111/j.1532-5415.1999.tb05201.x; TAAFFE DR, 1994, J CLIN ENDOCR METAB, V79, P1361, DOI 10.1210/jc.79.5.1361; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; Vitiello MV, 1997, J GERONTOL A-BIOL, V52, pM149, DOI 10.1093/gerona/52A.3.M149; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4	62	325	351	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2282	2292		10.1001/jama.288.18.2282	http://dx.doi.org/10.1001/jama.288.18.2282			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425705	Bronze			2023-01-03	WOS:000179186400027
J	Eyber, C; Ager, A				Eyber, C; Ager, A			Conselho: psychological healing in displaced communities in Angola	LANCET			English	Editorial Material									Queen Margaret Univ Coll, Ctr Int Hlth Studies, Edinburgh EH12 8TS, Midlothian, Scotland	Queen Margaret University	Eyber, C (corresponding author), Queen Margaret Univ Coll, Ctr Int Hlth Studies, Edinburgh EH12 8TS, Midlothian, Scotland.			Ager, Alastair/0000-0002-9474-3563					0	17	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					871	871		10.1016/S0140-6736(02)09961-0	http://dx.doi.org/10.1016/S0140-6736(02)09961-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243936				2023-01-03	WOS:000178053500026
J	Linster, CL; Van Schaftingen, E				Linster, CL; Van Schaftingen, E			Rapid stimulation of free glucuronate formation by non-glucuronidable xenobiotics in isolated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ASCORBIC-ACID; FRUCTOSE 2,6-BISPHOSPHATE; METABOLISM; PYROPHOSPHATASE; DEHYDROGENASE; BIOSYNTHESIS; PURIFICATION; TRANSFERASE; MECHANISM; REDUCTASE	Vitamin C synthesis in rat liver is enhanced by several xenobiotics, including aminopyrine and chloretone. The effect of these agents has been linked to induction of enzymes potentially involved in the formation of glucuronate, a precursor of vitamin C. Using isolated rat hepatocytes as a model, we show that a series of agents ( aminopyrine, antipyrine, chloretone, clotrimazole, metyrapone, proadifen, and barbital) induced in a few minutes an up to 15-fold increase in the formation of glucuronate, which was best observed in the presence of sorbinil, an inhibitor of glucuronate reductase. They also caused an similar to2-fold decrease in the concentration of UDP-glucuronate but little if any change in the concentration of UDP-glucose. Depletion of UDP-glucuronate with resorcinol or D-galactosamine markedly decreased the formation of glucuronate both in the presence and in the absence of aminopyrine, confirming the precursor-product relationship between UDP-glucuronate and free glucuronate. Most of the agents did not induce the formation of detectable amounts of glucuronides, indicating that the formation of glucuronate is not due to a glucuronidation-deglucuronidation cycle. With the exception of barbital ( which inhibits glucuronate reductase), all of the above mentioned agents also caused an increase in the concentration of ascorbic acid. They had little effect on glutathione concentration, and their effect on glucuronate and vitamin C formation was not mimicked by glutathione-depleting agents such as diamide and buthionine sulfoximine. It is concluded that the stimulation of vitamin C synthesis exerted by some xenobiotics is mediated through a rapid increase in the conversion of UDP-glucuronate to glucuronate, which does not apparently involve a glucuronidation-deglucuronidation cycle.	Catholic Univ Louvain, Physiol Chem Lab, B-1200 Brussels, Belgium; Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	Universite Catholique Louvain	Van Schaftingen, E (corresponding author), Catholic Univ Louvain, Physiol Chem Lab, B-1200 Brussels, Belgium.	vanschaftingen@bchm.ucl.ac.be	Van+Schaftingen, Emile/AAF-5532-2020	Linster, Carole/0000-0001-7143-0719; Van Schaftingen, Emile/0000-0002-6199-7647				ASHWELL G, 1960, J BIOL CHEM, V235, P1559; BARTRONS R, 1983, BIOCHEM J, V214, P829, DOI 10.1042/bj2140829; Braun L, 1996, FEBS LETT, V388, P173, DOI 10.1016/0014-5793(96)00548-0; BURNS JJ, 1956, J BIOL CHEM, V223, P897; BURNS JJ, 1957, J BIOL CHEM, V227, P785; EVANS C, 1960, BIOCHIM BIOPHYS ACTA, V41, P9, DOI 10.1016/0006-3002(60)90362-0; GINSBURG V, 1958, BIOCHIM BIOPHYS ACTA, V28, P649, DOI 10.1016/0006-3002(58)90538-9; GRIFFITH OW, 1990, METHOD ENZYMAT AN, V8, P521; HIATT HH, 2001, METABOLIC MOL BASES, V1, P1589; HICKMAN J, 1960, J BIOL CHEM, V235, P1566; HOCHMAN Y, 1984, J BIOL CHEM, V259, P5521; HOLLMANN S, 1962, BIOCHIM BIOPHYS ACTA, V62, P338, DOI 10.1016/0006-3002(62)90048-3; HORIO F, 1993, J NUTR, V123, P2075; HORIO F, 1983, J NUTR SCI VITAMINOL, V29, P233, DOI 10.3177/jnsv.29.233; Horio F, 1997, BIOSCI BIOTECH BIOCH, V61, P109, DOI 10.1271/bbb.61.109; IYANAGI T, 1989, J BIOL CHEM, V264, P21302; KEPPLER DOR, 1970, EUR J BIOCHEM, V17, P246, DOI 10.1111/j.1432-1033.1970.tb01160.x; LEWIS DF, 2001, GUIDE CYTOCHROMES P4, P118; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Margolis JJ, 1929, AM J MED SCI, V177, P348, DOI 10.1097/00000441-192903000-00005; Omaye S T, 1979, Methods Enzymol, V62, P3, DOI 10.1016/0076-6879(79)62181-X; POGELL BM, 1961, J BIOL CHEM, V236, P293; PUHAKAINEN E, 1976, EUR J BIOCHEM, V61, P165, DOI 10.1111/j.1432-1033.1976.tb10007.x; Radominska-Pandya A, 1999, DRUG METAB REV, V31, P817, DOI 10.1081/DMR-100101944; RODRIGUES AD, 1987, BIOCHEM PHARMACOL, V36, P4277, DOI 10.1016/0006-2952(87)90670-8; SATO K, 1993, ARCH BIOCHEM BIOPHYS, V307, P286, DOI 10.1006/abbi.1993.1591; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Smirnoff N, 2001, VITAM HORM, V61, P241; SRIVASTAVA SK, 1982, CURR EYE RES, V2, P407, DOI 10.3109/02713688209000786; Tanaka E, 1997, J CLIN PHARM THER, V22, P237, DOI 10.1046/j.1365-2710.1997.10875108.x; Trautschold I., 1985, METHODS ENZYMATIC AN, V3rd, P346; VANSCHAFTINGEN E, 1995, EUR J BIOCHEM, V234, P301; VANSCHAFTINGEN E, 1987, EUR J BIOCHEM, V166, P653	33	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36328	36333		10.1074/jbc.M306593200	http://dx.doi.org/10.1074/jbc.M306593200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12865420	Green Published, hybrid			2023-01-03	WOS:000185318300058
J	Li, PKT; Chow, KM; Wong, TYH; Leung, CB; Szeto, CC				Li, PKT; Chow, KM; Wong, TYH; Leung, CB; Szeto, CC			Effects of an angiotensin-converting renal function in patients receiving enzyme inhibitor on residual peritoneal dialysis - A randomized, controlled study	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the American-Society-of-Nephrology	OCT 30-NOV 06, 2002	PHILADELPHIA, PA	Amer Soc Nephrol			CONTROLLED-TRIAL; ADEQUACY; MORTALITY; CAPD; PRESERVATION; PROGRESSION; CLEARANCES; MORBIDITY; CAPTOPRIL; RAMIPRIL	Background: Residual renal function is an important determinant of mortality and morbidity in patients receiving peritoneall dialysis. However, few studies have evaluated therapeutic approaches for preserving residual renal function after the initiation of dialysis. Objective: To test the hypothesis that the angiotensin-converting enzyme (ACE) inhibitor ramipril slows the decline in residual renal function in patients with end-stage renal failure treated with peritoneal dialysis. Design: Randomized, open-label, controlled trial. Setting: Single-center study in the dialysis unit of a university teaching hospital. Patients: 60 patients receiving peritoneal dialysis. Measurements: Patients were randomly assigned to ramipril (5 mg daily) or no treatment. The target blood pressure was 135/85 mm Hg or less. Rate of decline in residual glomerular filtration rate (GFR) and development of complete anuria were compared among groups. Results: Over 12 months, average residual GFR declined by 2.07 mUmin per 1.73 m(2) in the ramipril group versus 3.00 mL/min per 1.73 m(2) in the control group (P = 0.03). The difference between the average changes in residual GFR in the ramipril and control groups from baseline to 12 months was 0.93 mL/min per 1.73 m(2) (95% CI, 0.09 to 1.78 mL/min per 1.73 m(2)). At 12 months, 14 patients in the ramipril group and 22 in the control group developed anuria. With intention-to-treat multivariable analysis using the Cox model, it was estimated that at 3, 6, and 9 months, patients assigned to ramipril had a higher adjusted hazard of complete anuria than did patients assigned to no treatment. Of the 25 patients who still did not have complete anuria at 12 months, those assigned to ramipril had a better prognosis than did those assigned to no treatment (adjusted hazard ratio, 0.58 [CI, 0.36 to 0.94]). The rates of death from any cause, duration of hospitalization, and cardiovascular events did not differ significantly between groups. Conclusions: Although the trial was small and had a limited ability to exclude effects of potential confounding factors, the angiotensin-converting enzyme inhibitor ramipril may reduce the rate of decline of residual renal function in patients with end-stage renal failure treated with peritoneal dialysis.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Li, PKT (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	philipli@cuhk.edu.hk	Wong, Tien Yin/AAC-9724-2020; Szeto, Cheuk Chun/N-4954-2015; Li, Philip K. T./D-4051-2017; Ming, Chow Kai/Y-5568-2019	Wong, Tien Yin/0000-0002-8448-1264; Szeto, Cheuk Chun/0000-0002-8898-8505; Ming, Chow Kai/0000-0001-5310-5197				Andersen S, 2000, KIDNEY INT, V57, P601, DOI 10.1046/j.1523-1755.2000.t01-1-00880.x; Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; BAUER JH, 1992, AM J KIDNEY DIS, V20, P443, DOI 10.1016/S0272-6386(12)70256-1; Blake P G, 1996, Perit Dial Int, V16 Suppl 1, pS143; Blake PG, 1996, PERITON DIALYSIS INT, V16, P243; CANCARINI GC, 1986, PERITON DIALYSIS INT, V6, P77; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Diaz-Buxo JA, 1999, AM J KIDNEY DIS, V33, P523, DOI 10.1016/S0272-6386(99)70190-3; Fogo AB, 2000, AM J KIDNEY DIS, V35, P179, DOI 10.1016/S0272-6386(00)70324-6; Gokal R, 2000, PERITON DIALYSIS INT, V20, P386; Hiroshige K, 1996, PERITON DIALYSIS INT, V16, P307; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LI PK, 2000, HONG KONG J NEPHROLO, V2, P61; Li PKT, 2001, PERITON DIALYSIS INT, V21, pS378; Li PKT, 2001, PERITON DIALYSIS INT, V21, pS307; Maiorca R, 1995, NEPHROL DIAL TRANSPL, V10, P2295, DOI 10.1093/ndt/10.12.2295; Mathiesen ER, 1999, BRIT MED J, V319, P24, DOI 10.1136/bmj.319.7201.24; Medcalf JF, 2001, KIDNEY INT, V59, P1128, DOI 10.1046/j.1523-1755.2001.0590031128.x; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; Nolph K D, 1992, ASAIO J, V38, pM139, DOI 10.1097/00002480-199207000-00004; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Ruggenenti P, 1999, LANCET, V354, P359, DOI 10.1016/S0140-6736(98)10363-X; Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X; Stack AG, 2001, J AM SOC NEPHROL, V12, P1516, DOI 10.1681/ASN.V1271516; Szeto CC, 2000, KIDNEY INT, V58, P400, DOI 10.1046/j.1523-1755.2000.00179.x; Szeto CC, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341040; Szeto CC, 1999, AM J KIDNEY DIS, V34, P1056, DOI 10.1016/S0272-6386(99)70011-9; TATTERSALL JE, 1993, NEPHROL DIAL TRANSPL, V8, P535, DOI 10.1093/ndt/8.6.535; TREVISAN R, 1995, AM J HYPERTENS, V8, P876, DOI 10.1016/0895-7061(95)00162-I; Van Biesen W, 2000, PERITON DIALYSIS INT, V20, P375; vanOlden RW, 1996, J AM SOC NEPHROL, V7, P745; Venkataraman V, 2000, PERITON DIALYSIS INT, V20, P392; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275	36	198	218	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2003	139	2					105	112		10.7326/0003-4819-139-2-200307150-00010	http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	701HX	12859160				2023-01-03	WOS:000184163100004
J	Bunch, TJ; White, RD; Gersh, BJ; Meverden, RA; Hodge, DO; Ballman, KV; Hammill, SC; Shen, WK; Packer, DL				Bunch, TJ; White, RD; Gersh, BJ; Meverden, RA; Hodge, DO; Ballman, KV; Hammill, SC; Shen, WK; Packer, DL			Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL-SERVICES SYSTEM; VENTRICULAR-FIBRILLATION; RAPID DEFIBRILLATION; HEALTH-STATUS; PRIMARY-CARE; SURVIVORS; LIFE; RESUSCITATION; TECHNICIANS; PARAMEDICS	BACKGROUND: Mortality after out-of-hospital cardiac arrest from ventricular fibrillation is high. Programs focusing on early defibrillation have improved the rate of survival to hospital discharge. We conducted a population-based analysis of the long-term outcome and quality of life of survivors. METHODS: All patients who had an out-of-hospital cardiac arrest between November 1990 and January 2001 who received early defibrillation for ventricular fibrillation in Olmsted County, Minnesota, were included. The survival rate was compared with that of an age-, sex-, and disease-matched (2:1) control population of residents who had not had an out-of-hospital cardiac arrest and with that of age- and sex-matched controls from the general U.S. population. The quality of life was assessed with use of the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36) and compared with U.S. population norms. RESULTS: Of 200 patients who presented with an out-of-hospital cardiac arrest with ventricular fibrillation, 145 (72 percent) survived to hospital admission (7 died in the emergency department) and 79 (40 percent) were neurologically intact (good overall capability or moderate overall disability) at discharge. The mean (+/-SD) length of follow-up was 4.8+/-3.0 years. Nineteen patients died after discharge from the hospital. The expected five-year survival rate (79 percent) was identical to that among age-, sex-, and disease-matched controls (P=0.68) but lower than that among the age- and sex-matched U.S. population (86 percent, P=0.02). Fifty patients completed SF-36 surveys at the end of follow-up, and the majority had a nearly normal quality of life, with the exception of reduced vitality. CONCLUSIONS: Long-term survival among patients who have undergone rapid defibrillation after out-of-hospital cardiac arrest is similar to that among age-, sex-, and disease-matched patients who did not have out-of-hospital cardiac arrest. The quality of life among the majority of survivors is similar to that of the general population.	Mayo Clin & Mayo Fdn, Dept Anesthesiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Div Biostat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	White, RD (corresponding author), Mayo Clin & Mayo Fdn, Dept Anesthesiol, 200 1St St SW, Rochester, MN 55905 USA.			Ballman, Karla/0000-0002-4492-0357				American Heart Association, 2000, 2001 HEART STROK STA; BERGNER L, 1985, AM J PUBLIC HEALTH, V75, P1321, DOI 10.2105/AJPH.75.11.1321; Bergner L, 1983, Am J Emerg Med, V1, P259, DOI 10.1016/0735-6757(83)90101-8; BERGNER L, 1984, AM J PUBLIC HEALTH, V74, P508, DOI 10.2105/AJPH.74.5.508; BERTINI G, 1990, Journal of Emergency Medicine, V8, P407, DOI 10.1016/0736-4679(90)90166-S; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; Graves JR, 1997, RESUSCITATION, V35, P117; Herbst JH, 1999, PACE, V22, P915, DOI 10.1111/j.1540-8159.1999.tb06816.x; HOLMES DR, 1986, CIRCULATION, V73, P1254, DOI 10.1161/01.CIR.73.6.1254; Hsu JWY, 1996, ANN EMERG MED, V28, P597, DOI 10.1016/S0196-0644(96)70080-X; JENNETT B, 1975, LANCET, V1, P480; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; Kuck KH, 2000, CIRCULATION, V102, P748, DOI 10.1161/01.CIR.102.7.748; Kuilman M, 1999, RESUSCITATION, V41, P25, DOI 10.1016/S0300-9572(99)00016-7; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; MYERBURG RJ, 1992, CIRCULATION, V85, P2; Nichol G, 1999, ACAD EMERG MED, V6, P95, DOI 10.1111/j.1553-2712.1999.tb01044.x; PARADIS NA, 1996, CARDIAC ARREST SCI P, P867; Smith HJ, 2000, HEART, V84, P390, DOI 10.1136/heart.84.4.390; Stratton S, 1998, ANN EMERG MED, V31, P471, DOI 10.1016/S0196-0644(98)70256-2; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; Sunnerhagen KS, 1996, RESUSCITATION, V31, P135, DOI 10.1016/0300-9572(95)00903-5; SWOR RA, 1995, ANN EMERG MED, V25, P780, DOI 10.1016/S0196-0644(95)70207-5; VALENZUELA TD, 1993, ANN EMERG MED, V22, P1678, DOI 10.1016/S0196-0644(05)81305-8; Ware J.E., 1993, SF 36 HLTH SURVEY MA; White R D, 2001, Curr Opin Crit Care, V7, P145, DOI 10.1097/00075198-200106000-00002; White RD, 1996, ANN EMERG MED, V28, P480, DOI 10.1016/S0196-0644(96)70109-9; White RD, 1998, RESUSCITATION, V39, P145, DOI 10.1016/S0300-9572(98)00135-X; White RD, 2001, RESUSCITATION, V49, P9, DOI 10.1016/S0300-9572(00)00338-5; 1994, JAMA, V271, P984; [No title captured]	35	270	278	0	11	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2626	2633		10.1056/NEJMoa023053	http://dx.doi.org/10.1056/NEJMoa023053			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826637				2023-01-03	WOS:000183726400006
J	Gandhi, TK; Weingart, SN; Borus, J; Seger, AC; Peterson, J; Burdick, E; Seger, DL; Shu, K; Federico, F; Leape, LL; Bates, DW				Gandhi, TK; Weingart, SN; Borus, J; Seger, AC; Peterson, J; Burdick, E; Seger, DL; Shu, K; Federico, F; Leape, LL; Bates, DW			Adverse drug events in ambulatory care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITALIZED-PATIENTS; RISK-FACTORS; OUTPATIENTS; PREVENTION; COSTS	BACKGROUND: Adverse events related to drugs occur frequently among inpatients, and many of these events are preventable. However, few data are available on adverse drug events among outpatients. We conducted a study to determine the rates, types, severity, and preventability of such events among outpatients and to identify preventive strategies. METHODS: We performed a prospective cohort study, including a survey of patients and a chart review, at four adult primary care practices in Boston (two hospital-based and two community-based), involving a total of 1202 outpatients who received at least one prescription during a four-week period. Prescriptions were computerized at two of the practices and handwritten at the other two. RESULTS: Of the 661 patients who responded to the survey (response rate, 55 percent), 162 had adverse drug events (25 percent; 95 percent confidence interval, 20 to 29 percent), with a total of 181 events (27 per 100 patients). Twenty-four of the events (13 percent) were serious, 51 (28 percent) were ameliorable, and 20 (11 percent) were preventable. Of the 51 ameliorable events, 32 (63 percent) were attributed to the physician's failure to respond to medication-related symptoms and 19 (37 percent) to the patient's failure to inform the physician of the symptoms. The medication classes most frequently involved in adverse drug events were selective serotonin-reuptake inhibitors (10 percent), beta-blockers (9 percent), angiotensin-converting-enzyme inhibitors (8 percent), and nonsteroidal antiinflammatory agents (8 percent). On multivariate analysis, only the number of medications taken was significantly associated with adverse events. CONCLUSIONS: Adverse events related to drugs are common in primary care, and many are preventable or ameliorable. Monitoring for and acting on symptoms are important. Improving communication between outpatients and providers may help prevent adverse events related to drugs.	Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Risk Management Fdn, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health	Gandhi, TK (corresponding author), Brigham & Womens Hosp, Div Gen Med, 75 Francis St, Boston, MA 02115 USA.	tgandhi@partners.org						Bates DW, 1999, ARCH INTERN MED, V159, P2553, DOI 10.1001/archinte.159.21.2553; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Borowitz SM, 1998, JAMA-J AM MED ASSOC, V280, P1321, DOI 10.1001/jama.280.15.1321; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; FOLLI HL, 1987, PEDIATRICS, V79, P718; Gandhi TK, 2000, J GEN INTERN MED, V15, P149, DOI 10.1046/j.1525-1497.2000.04199.x; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Hanlon JT, 1997, J AM GERIATR SOC, V45, P945, DOI 10.1111/j.1532-5415.1997.tb02964.x; HUTCHINSON TA, 1986, J CHRON DIS, V39, P533, DOI 10.1016/0021-9681(86)90198-0; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Li YC, 2001, INT J MED INFORM, V61, P241, DOI 10.1016/S1386-5056(01)00146-0; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; SANDS DZ, 2001, HIMSS P, V3; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	17	913	935	1	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1556	1564		10.1056/NEJMsa020703	http://dx.doi.org/10.1056/NEJMsa020703			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700376	Bronze			2023-01-03	WOS:000182248900007
J	Emanuel, EJ; Young-Xu, Y; Levinsky, NG; Gazelle, G; Saynina, O; Ash, AS				Emanuel, EJ; Young-Xu, Y; Levinsky, NG; Gazelle, G; Saynina, O; Ash, AS			Chemotherapy use among medicare beneficiaries at the end of life	ANNALS OF INTERNAL MEDICINE			English	Article							CELL LUNG-CANCER; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; EXPECTATIONS; CISPLATIN; ATTITUDES; MITOMYCIN; SURVIVAL	Background: Although many observers believe that cancer chef motherapy is overused at the end of life, there are no published data on this. Objective: To determine the frequency and duration of chemotherapy use in the last 6 months of life stratified by type of cancer, age, and sex. Design: Retrospective cohort Analysis. Setting: Administrative databases from Massachusetts and California. Patients: All Medicare patients Who died of cancer in Massachusetts and 5% of Medicare cancer decedents in California in 1996. Measurements: Use of intravenous chemotherapy agents, chemotherapy administration, or medical evaluation for chemotherapy from Medicare billing data for each patient in 30-day periods from the date of death backward. Results: in Massachusetts, 33% of cancer decedents older than 65 years of age received chemotherapy in the last 6 months of life, 23% in the last 3 months, and 9% in the last month. In California, the percentages were 26%, 20%, and 9%, respectively. Chemotherapy use greatly declined with age. Chemotherapy use was similar for patients with breast, colon, and ovarian cancer and those with cancer generally considered unresponsive to chemotherapy, such as pancreatic, hepatocellular, or renal-cell cancer or melanoma. Patients with types of cancer that are unresponsive to chemotherapy had shorter duration of chemotherapy use. Conclusion: Among patients who died of cancer, chemotherapy was used frequently in the last 3 months of life. The cancer's responsiveness to chemotherapy does not seem to influence whether dying patients receive chemotherapy at the end of life.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Natl Bur Econ Res, Palo Alto, CA USA; Harvard Vanguard Associates, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA	National Institutes of Health (NIH) - USA; National Bureau of Economic Research; Harvard Vanguard Medical Associates; Boston University	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253	CLINICAL CENTER [Z01CL010508] Funding Source: NIH RePORTER	CLINICAL CENTER		ABELOFF DM, 2000, CLIN ONCOLOGY, P1681; Annas G J, 1992, Health Matrix Clevel, V2, P119; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cullen MH, 1999, J CLIN ONCOL, V17, P3188, DOI 10.1200/JCO.1999.17.10.3188; Cullen M, 2001, LANCET ONCOL, V2, P173, DOI 10.1016/S1470-2045(00)00260-6; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; DEVITA WT, 2001, CANC PRINCIPLES PRAC, V1126, P1262; Doyle C, 2001, J CLIN ONCOL, V19, P1266, DOI 10.1200/JCO.2001.19.5.1266; Earle CC, 2000, CHEST, V117, P1239, DOI 10.1378/chest.117.5.1239; ELLIS PA, 1995, BRIT J CANCER, V71, P366, DOI 10.1038/bjc.1995.74; FIELD MJ, 1997, APPROACHING DEATH IM, P12; GOUGH IR, 1981, CLIN ONCOL, V7, P5; MCKHANN CF, 1999, TIME DIE, P1; Miller M, 2000, HASTINGS CENT REP, V30, P34, DOI 10.2307/3527646; Schrag D, 2001, J NATL CANCER I, V93, P850, DOI 10.1093/jnci/93.11.850; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SONTAG S, 1978, ILLNES METAPHOR; Wan GJ, 1997, PSYCHO-ONCOL, V6, P1; YELLEN SB, 1995, J CLIN ONCOL, V13, P1255, DOI 10.1200/JCO.1995.13.5.1255; 1997, CANC EC          MAR, P1	20	217	219	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					639	643		10.7326/0003-4819-138-8-200304150-00011	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693886				2023-01-03	WOS:000182173800006
J	Li, CI; Anderson, BO; Daling, JR; Moe, RE				Li, CI; Anderson, BO; Daling, JR; Moe, RE			Trends in incidence rates of invasive lobular and ductal breast carcinoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; ESTROGEN; CANCER; WOMEN; MANAGEMENT; DIAGNOSIS; PROGESTIN; PATTERNS; RISK	Context Research has suggested that use of combined estrogen and progestin hormone replacement therapy (CHRT) increases breast cancer risk and that CHRT use more strongly associated with the risk of invasive lobular breast carcinoma than that invasive ductal carcinoma. Lobular carcinoma is less common than ductal carcinoma can be more difficult to diagnose because of its subtle elusive. infiltrative pattern. Objective To evaluate trends in invasive lobular and ductal carcinoma incidence from 1987 through 1999, during which time use of CHRT increased in the United Design Descriptive epidemiologic study. Setting Nine cancer registries that participate in the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute and that cover Atlanta, Ga; Detroit, Mich; San Francisco-Oakland, Calif; Seattle, Wash; and Connecticut, Hawaii, Iowa, New Mexico, and Utah., Population Women 30 years of age and older residing in the areas covered by the 9 SEER registries. Main Outcome Measures Proportional changes in incidence rates of invasive lobular and ductal carcinoma among women with no prior history of breast cancer. Results A total of 190458 women were included in this analysis who were identified through the registries as having invasive breast cancer; 7682 of the 198140 potentially eligible women (ie, those identified as not having in situ breast cancer) were I excluded from this analysis because stage of cancer was unknown. Invasive breast cancer incidence rates adjusted for age and for SEER historic stage increased 1.04-fold (95% confidence interval [CI], 1.004-1.07) from 1987-1999 (206.7/100000 to 214.1/100000, age-adjusted). However, incidence rates of tumors classified as lobular increased 1.52-fold (95% CI, 1.42-1.63), and those classified as mixed ductal-lobular increased 1.96-fold (95% CI, 1.80-2.14); rates of these types combined increased 1.65-fold (95% CI, 1.55-1.78) (19.8/100000 to 33.4/100000, age-adjusted). In contrast, ductal carcinoma rates remained largely constant (153.8/100000 to 155.3/100000, age-adjusted; proportional change, 1.03 [95% CI, 0.99-1.061). The proportion of breast cancers with a lobular component increased from 9.5% in 1987 to 15.6% in 1999. Conclusions Ductal carcinoma incidence rates remained essentially constant from 1987-1999 while lobular carcinoma rates increased steadily. This increase presents a clinical challenge given that lobular carcinoma is more difficult to detect than ductal carcinoma by both physical examination and mammography.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Li, CI (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,MP 381,POB 19024, Seattle, WA 98109 USA.				NATIONAL CANCER INSTITUTE [T32CA009168, R01CA085913] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 85913, T32 CA 09168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Brett KM, 1997, AM J EPIDEMIOL, V145, P536; Carr BR, 1996, EUR J OBSTET GYN R B, V64, pS17, DOI 10.1016/0301-2115(95)02351-8; Chen CL, 2002, JAMA-J AM MED ASSOC, V287, P734, DOI 10.1001/jama.287.6.734; Daling JR, 2002, CANCER-AM CANCER SOC, V95, P2455, DOI 10.1002/cncr.10984; DAVIS RP, 1979, ARCH SURG-CHICAGO, V114, P485; DIXON JM, 1982, HISTOPATHOLOGY, V6, P149, DOI 10.1111/j.1365-2559.1982.tb02712.x; DUTOIT RS, 1991, EUR J SURG ONCOL, V17, P251; Evans N, 2000, CLIN RADIOL, V55, P261, DOI 10.1053/crad.1999.0291; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; Li CI, 2000, CANCER, V88, P2561, DOI 10.1002/1097-0142(20000601)88:11<2561::AID-CNCR19>3.3.CO;2-O; Li CI, 2000, CANCER, V88, P2570, DOI 10.1002/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O; Munot K, 2002, BRIT J SURG, V89, P1296, DOI 10.1046/j.1365-2168.2002.02208.x; *NAT CANC I, SEER DAT QUAL; *NAT CANC I, ABOUT SEER; *NAT CANC I, CHAR SEER POP COMP T; Newcomb PA, 2002, CANCER EPIDEM BIOMAR, V11, P593; Newcomer LM, 1999, AM J EPIDEMIOL, V149, pS79; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SILVERSTEIN MJ, 1994, CANCER-AM CANCER SOC, V73, P1673, DOI 10.1002/1097-0142(19940315)73:6<1673::AID-CNCR2820730620>3.0.CO;2-B; Skaane P, 1999, ACTA RADIOL, V40, P369, DOI 10.3109/02841859909177749; STIERER M, 1993, ANN SURG, V218, P13, DOI 10.1097/00000658-199307000-00004; Weinstein SP, 2001, AM J ROENTGENOL, V176, P399, DOI 10.2214/ajr.176.2.1760399; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; YEATMAN TJ, 1995, ANN SURG, V222, P549	28	350	361	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	2003	289	11					1421	1424		10.1001/jama.289.11.1421	http://dx.doi.org/10.1001/jama.289.11.1421			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656PM	12636465	Bronze			2023-01-03	WOS:000181616200034
J	Grodstein, F; Clarkson, TB; Manson, JE				Grodstein, F; Clarkson, TB; Manson, JE			Understanding the divergent data on postmenopausal hormone therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ESTROGEN REPLACEMENT THERAPY; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; CORONARY EVENTS; WOMEN; ATHEROSCLEROSIS; MORTALITY; RISK; INFLAMMATION		Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA.							Albert CM, 2002, NEW ENGL J MED, V346, P1113, DOI 10.1056/NEJMoa012918; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Cline JM, 1996, AM J OBSTET GYNECOL, V174, P93, DOI 10.1016/S0002-9378(96)70379-4; Collaborative Group on Hormonal Factors in Breast Cancer, 1997, LANCET, V350, P1484; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, NEW ENGL J MED, V335, P1406; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Grodstein F, 2001, ANN INTERN MED, V135, P1, DOI 10.7326/0003-4819-135-1-200107030-00003; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; GRODSTEIN F, 2002, THROMBOSIS THROMBOEM; Heckbert SR, 2001, ARCH INTERN MED, V161, P1709, DOI 10.1001/archinte.161.14.1709; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Herrington DM, 2001, ARTERIOSCL THROM VAS, V21, P1955, DOI 10.1161/hq1201.100241; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Manson JE, 2001, NEW ENGL J MED, V345, P34, DOI 10.1056/NEJM200107053450106; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; MCGILL HC, 1979, ATHER REV, V4, P157; Mikkola TS, 2002, CARDIOVASC RES, V53, P605, DOI 10.1016/S0008-6363(01)00466-7; Petitti Diana B., 1994, Annals of Epidemiology, V4, P115; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Rimm EB, 2000, MED CLIN N AM, V84, P239, DOI 10.1016/S0025-7125(05)70216-9; Rodriguez C, 2001, AM J EPIDEMIOL, V153, P145, DOI 10.1093/aje/153.2.145; ROSENBERG L, 1993, AM J EPIDEMIOL, V137, P54, DOI 10.1093/oxfordjournals.aje.a116602; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; Sourander L, 1999, LANCET, V353, P330; Sourander L, 1998, LANCET, V352, P1965, DOI 10.1016/S0140-6736(98)05066-1; Strong JP, 1999, JAMA-J AM MED ASSOC, V281, P727, DOI 10.1001/jama.281.8.727; TEJADA C, 1968, LAB INVEST, V18, P509; Zanger D, 2000, J AM COLL CARDIOL, V36, P1797, DOI 10.1016/S0735-1097(00)00952-9	40	258	265	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	2003	348	7					645	650		10.1056/NEJMsb022365	http://dx.doi.org/10.1056/NEJMsb022365			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644HY	12584376				2023-01-03	WOS:000180912900012
J	Hurst, SA; Mauron, A				Hurst, SA; Mauron, A			Assisted suicide and euthanasia in Switzerland: allowing a role for non-physicians	BRITISH MEDICAL JOURNAL			English	Article							VOLUNTARY EUTHANASIA		NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA; Univ Geneva, Fac Med, Unite Rech & Enseignement Bioeth, Geneva, Switzerland	National Institutes of Health (NIH) - USA; University of Geneva	Hurst, SA (corresponding author), NIH, Dept Clin Bioeth, Bldg 10, Bethesda, MD 20892 USA.		Hurst, Samia A./A-9661-2008	Hurst, Samia A./0000-0002-1980-5226				*ASS DROIT MOUR DI, SOND ASS SUIC EUTH A; Bittel N, 2002, SUPPORT CARE CANCER, V10, P265, DOI 10.1007/s00520-001-0325-0; CASSANI U, 1997, MED HYG, V55, P616; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL EJ, 1994, ANN INTERN MED, V121, P793, DOI 10.7326/0003-4819-121-10-199411150-00010; Hunziker A, 1999, Praxis (Bern 1994), V88, P1235; Kerridge IH, 1996, J MED ETHICS, V22, P273, DOI 10.1136/jme.22.5.273; Malacrida R, 1996, SCHWEIZ MED WSCHR, V126, P2149; MAURON A, 1997, MED HYG, V55, P617; ROY DJ, 1994, EUR J PALLIAT CARE, V1, P1; Sayid Mustafa D, 1983, Boston College Int Comp Law Rev, V6, P533; Sheldon T, 2001, BRIT MED J, V322, P947, DOI 10.1136/bmj.322.7292.947; Sobel J, 2001, Rev Med Suisse Romande, V121, P163; STIEFEL F, 2001, B SWISS PHYS, V82, P1611; STRATENWERTH G, 1983, SCHWEIZERISCHES STRA; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; *SWISS AC MED SCI, 1995, MED ETH GUID MED CAR; *SWISS FED STAT OF, 2001, ANN POP STAT 2001; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; WATSON R, 2001, BRIT MED J, V323, P1024	20	112	115	3	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2003	326	7383					271	273		10.1136/bmj.326.7383.271	http://dx.doi.org/10.1136/bmj.326.7383.271			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644FY	12560284	Green Published			2023-01-03	WOS:000180908300027
J	Ellis, M; Zwaan, F; Hedstrom, U; Poynton, C; Kristensen, J; Jumaa, P; Wassell, J; al-Ramadi, B				Ellis, M; Zwaan, F; Hedstrom, U; Poynton, C; Kristensen, J; Jumaa, P; Wassell, J; al-Ramadi, B			Recombinant human interleukin 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial	LANCET			English	Article							C-REACTIVE PROTEIN; GROWTH-FACTOR; CELLS; MICE	Background Bacteraemia in patients with haemological malignant disease causes substantial morbidity. Recombinant human interleukin 11 (rhIL-11) prevents gastrointestinal epithelial disintegrity and has immunomodulatory actions. Our aim was to ascertain whether or not treatment with rhIL-11 can prevent gut-associated infections. Methods We did a double-blind placebo-controlled randomised trial, to which we enrolled 40 patients with haemological malignant disease who were undergoing chemotherapy. Patients received either rhIL-11 50 mug/kg (n=20) or placebo (n=20) daily by subcutaneous injection from the day before the start of chemotherapy until resolution of neutropenia or for 2:1 days, whichever was longer. Our primary outcome measure was a reduction in bacteraemia. Analysis was by intention to treat. Findings Significantly fewer patients who received rhIL-11 rather than placebo developed bacteraemia, particularly of gastrointestinal origin: the proportion of patients with at least one positive blood culture was 0.65 and 0.25, respectively (p=0.02). The numbers of patients (placebo vs rhIL-11) for each number of distinct isolates were: no organism isolated seven versus 15, one organism nine versus four, two organisms two versus one, three organisms one versus none, and four organisms one versus none (p=0.01), suggesting a lower bacterial load in the rhIL-11 than in the placebo group. Time to first bacteraemic event was longer in patients who received rhIL-11 (p=0.03) than in those who received placebo. Interpretation rhIL-11 reduces the frequency and load of bacteraemia in patients with haemological malignant disease undergoing chemotherapy, possibly by gastrointestinal cytoprotective or immunological mechanisms.	United Arab Emirates Univ, Dept Med & Hlth Sci, Fac Med & Hlth Sci, Al Ain, U Arab Emirates; Tawam Hosp, Al Ain, U Arab Emirates; Karolinska Inst, Huddinge Hosp, S-10401 Stockholm, Sweden; Univ Wales Coll Cardiff, Cardiff CF1 3NS, S Glam, Wales	United Arab Emirates University; Karolinska Institutet; Cardiff University	Ellis, M (corresponding author), United Arab Emirates Univ, Dept Med & Hlth Sci, Fac Med & Hlth Sci, POB 17666, Al Ain, U Arab Emirates.							Antin JH, 2002, BONE MARROW TRANSPL, V29, P373, DOI 10.1038/sj.bmt.1703394; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; COX DR, 1972, J R STAT SOC B, V34, P187; Culley FJ, 1997, BIOCHEM SOC T, V25, pS286, DOI 10.1042/bst025286s; Curti A, 2001, BLOOD, V97, P2758, DOI 10.1182/blood.V97.9.2758; DU XX, 1994, BLOOD, V83, P33; FEGAN C, 1990, BONE MARROW TRANSPL, V5, P373; Gordon MS, 1996, BLOOD, V87, P3615, DOI 10.1182/blood.V87.9.3615.bloodjournal8793615; Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Mahboubi K, 2000, J IMMUNOL, V164, P3837, DOI 10.4049/jimmunol.164.7.3837; MOLD C, 1981, J EXP MED, V154, P1703, DOI 10.1084/jem.154.5.1703; Opal SM, 1999, BLOOD, V93, P3467, DOI 10.1182/blood.V93.10.3467.410k10_3467_3472; Opal SM, 2000, J INFECT DIS, V181, P754, DOI 10.1086/315247; Peterson RL, 1998, LAB INVEST, V78, P1503; Sonis ST, 2000, ORAL ONCOL, V36, P373, DOI 10.1016/S1368-8375(00)00012-9; Szalai AJ, 2000, INFECT IMMUN, V68, P5652, DOI 10.1128/IAI.68.10.5652-5656.2000; TREPICCHIO WL, 1996, J IMMUNOL, V157, P1705; Weiser JN, 1998, J EXP MED, V187, P631, DOI 10.1084/jem.187.4.631	19	39	45	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 25	2003	361	9354					275	280		10.1016/S0140-6736(03)12322-7	http://dx.doi.org/10.1016/S0140-6736(03)12322-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639RV	12559860				2023-01-03	WOS:000180643900007
J	Roberts, SE; Goldacre, MJ				Roberts, SE; Goldacre, MJ			Case fatality rates after admission to hospital with stroke: linked database study	BRITISH MEDICAL JOURNAL			English	Article								Population based mortality for stroke has declined in most Western countries during the past few decades.' This is probably because of a decrease in both the incidence of and case fatality from stroke over this period.(2-4) Routine statistics generally do not provide long term trends in case fatality, and few studies have looked at differences in case fatality rates between hospitals.(5) We used routine hospital data, which had been linked to mortality data in the former Oxford health region of England, to study case fatality rates after admission for stroke and to compare rates between different periods and different hospitals.	Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.							BONITA R, 1993, LANCET, V342, P1470, DOI 10.1016/0140-6736(93)92938-P; Charlton J., 1997, HLTH ADULT BRITAIN 1, VVolume 2, P60; MALMGREN R, 1987, LANCET, V2, P1196; Wolfe CDA, 1999, STROKE, V30, P350, DOI 10.1161/01.STR.30.2.350; 1983, LANCET, V1, P1195	5	13	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 25	2003	326	7382					193	194		10.1136/bmj.326.7382.193	http://dx.doi.org/10.1136/bmj.326.7382.193			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	640LD	12543834	Green Published, Bronze			2023-01-03	WOS:000180689600016
J	Lip, GYH; Kamath, S; Hart, RG				Lip, GYH; Kamath, S; Hart, RG			ABC of antithrombotic therapy - Antithrombotic therapy for cerebrovascular disorders	BRITISH MEDICAL JOURNAL			English	Article									City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	University of Birmingham; University of Texas System; University of Texas Health San Antonio	Lip, GYH (corresponding author), City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England.							Adams HP, 2002, STROKE, V33, P856, DOI 10.1161/hs0302.104628; Albers CW, 2001, CHEST, V119, p300S, DOI 10.1378/chest.119.1_suppl.300S; Atkinson RP, 2000, THROMB RES, V98, pV97; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Sandercock P, 1997, LANCET, V349, P1569	8	8	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2002	325	7373					1161	1163		10.1136/bmj.325.7373.1161	http://dx.doi.org/10.1136/bmj.325.7373.1161			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433770	Green Published			2023-01-03	WOS:000179443100027
J	Dinsmore, AD; Hsu, MF; Nikolaides, MG; Marquez, M; Bausch, AR; Weitz, DA				Dinsmore, AD; Hsu, MF; Nikolaides, MG; Marquez, M; Bausch, AR; Weitz, DA			Colloidosomes: Selectively permeable capsules composed of colloidal particles	SCIENCE			English	Article							EMULSION DROPLETS; LATEX-PARTICLES; ENCAPSULATION; TEMPLATES; CELLS; MICROENCAPSULATION; ENDOSTATIN; INTERFACES	We present an approach to fabricate solid capsules with precise control of size, permeability, mechanical strength, and compatibility. The capsules are fabricated by the self-assembly of colloidal particles onto the interface of emulsion droplets. After the particles are locked together to form elastic shells, the emulsion droplets are transferred to a fresh continuous-phase fluid that is the same as that inside the droplets. The resultant structures, which we call "colloidosomes", are hollow, elastic shells whose permeability and elasticity can be precisely controlled. The generality and robustness of these structures and their potential for cellular immunoisolation are demonstrated by the use of a variety of solvents, particles, and contents.	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Harvard Univ, DEAS, Cambridge, MA 02138 USA; Los Alamos Natl Lab, Div Chem, Los Alamos, NM 87545 USA; Kraft Foods R&D, Nanotechnol Lab, Glenview, IL 60025 USA	Harvard University; Harvard University; United States Department of Energy (DOE); Los Alamos National Laboratory; Kraft Heinz	Dinsmore, AD (corresponding author), Univ Massachusetts, Dept Phys, Amherst, MA 01003 USA.	dinsmore@physics.umass.edu; abausch@ph.atum.de; weitz@deas.harvard.edu						BAUSCH AR, UNPUB; Berg Howard C., 1993, RANDOM WALKS BIOL; Binks BP, 2002, LANGMUIR, V18, P1270, DOI 10.1021/la011420k; Bowick MJ, 2000, PHYS REV B, V62, P8738, DOI 10.1103/PhysRevB.62.8738; Caruso F, 2000, LANGMUIR, V16, P8932, DOI 10.1021/la000401s; Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111; Chaikof EL, 1999, ANNU REV BIOMED ENG, V1, P103, DOI 10.1146/annurev.bioeng.1.1.103; Cohen I, 2001, SCIENCE, V292, P265, DOI 10.1126/science.1059175; Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232; Desai TA, 2000, BIOMOL ENG, V17, P23, DOI 10.1016/S1389-0344(00)00063-0; Ganan-Calvo AM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.274501; Gibbs BF, 1999, INT J FOOD SCI NUTR, V50, P213, DOI 10.1080/096374899101256; GORDON V, UNPUB; HURD AJ, 1985, J PHYS A-MATH GEN, V18, P1055; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; Kralchevsky PA, 2000, ADV COLLOID INTERFAC, V85, P145, DOI 10.1016/S0001-8686(99)00016-0; Lanza R.P., 2000, PRINCIPLES TISSUE EN; Leoni L, 2001, IEEE T BIO-MED ENG, V48, P1335, DOI 10.1109/10.959329; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Lin Y. P., UNPUB; Loscertales IG, 2002, SCIENCE, V295, P1695, DOI 10.1126/science.1067595; Lowe KC, 1999, ARTIF CELL BLOOD SUB, V27, P255, DOI 10.3109/10731199909117698; Marinakos SM, 1999, J AM CHEM SOC, V121, P8518, DOI 10.1021/ja990945k; NIKOLAIDES MG, IN PRESS NATURE; ONODA GY, 1985, PHYS REV LETT, V55, P226, DOI 10.1103/PhysRevLett.55.226; Park JK, 2000, BIOTECHNOL ADV, V18, P303, DOI 10.1016/S0734-9750(00)00040-9; PIERANSKI P, 1980, PHYS REV LETT, V45, P569, DOI 10.1103/PhysRevLett.45.569; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; Read TA, 2001, NAT BIOTECHNOL, V19, P29, DOI 10.1038/83471; RODRIGUEZ BE, 1994, MACROMOLECULES, V27, P6642, DOI 10.1021/ma00100a058; Sukhorukov GB, 1999, J PHYS CHEM B, V103, P6434, DOI 10.1021/jp990095v; Tiarks F, 2001, LANGMUIR, V17, P908, DOI 10.1021/la001276n; Umbanhowar PB, 2000, LANGMUIR, V16, P347, DOI 10.1021/la990101e; Velev OD, 2000, SCIENCE, V287, P2240, DOI 10.1126/science.287.5461.2240; Velev OD, 1996, LANGMUIR, V12, P2385, DOI 10.1021/la950679y; Velev OD, 1996, LANGMUIR, V12, P2374, DOI 10.1021/la9506786; Velev OD, 1997, LANGMUIR, V13, P1856, DOI 10.1021/la960652u; Willaert RG, 1996, REV CHEM ENG, V12, P5	38	1759	1864	19	912	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	2002	298	5595					1006	1009		10.1126/science.1074868	http://dx.doi.org/10.1126/science.1074868			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411700	Green Submitted			2023-01-03	WOS:000178932000050
J	Gill, TM; Baker, DI; Gottschalk, M; Peduzzi, PN; Allore, H; Byers, A				Gill, TM; Baker, DI; Gottschalk, M; Peduzzi, PN; Allore, H; Byers, A			A program to prevent functional decline in physically frail, elderly persons who live at home	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OLDER PERSONS; CARE; DISABILITY; DEPENDENCE; STRATEGIES; EXERCISE; PEOPLE; ADULTS; RISK; AGE	Background: Functional decline in physically frail, elderly persons is associated with substantial morbidity. It is uncertain whether such functional decline can be prevented. Methods: We randomly assigned 188 persons 75 years of age or older who were physically frail and living at home to undergo a six-month, home-based intervention program that included physical therapy and that focused primarily on improving underlying impairments in physical abilities, including balance, muscle strength, ability to transfer from one position to another, and mobility, or to undergo an educational program (as a control). The primary outcome was the change between base line and 3, 7, and 12 months in the score on a disability scale based on eight activities of daily living: walking, bathing, upper- and lower-body dressing, transferring from a chair, using the toilet, eating, and grooming. Scores on the scale ranged from 0 to 16, with higher scores indicating more severe disability. Results: Participants in the intervention group had less functional decline over time, according to their disability scores, than participants in the control group. The disability scores in the intervention and control groups were 2.3 and 2.8, respectively, at base line; 2.0 and 3.6 at 7 months (P=0.008 for the comparison between the groups in the change from base line); and 2.7 and 4.2 at 12 months (P=0.02). The benefit of the intervention was observed among participants with moderate frailty but not those with severe frailty. The frequency of admission to a nursing home did not differ significantly between the intervention group and the control group (14 percent and 19 percent, respectively; P=0.37). Conclusions: A home-based program targeting underlying impairments in physical abilities can reduce the progression of functional decline among physically frail, elderly persons who live at home.	Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Internal Med, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Yale New Haven Med Ctr, Dept Rehabil Serv, New Haven, CT 06504 USA; Connecticut Healthcare Syst, Dept Vet Affairs, West Haven, CT USA	Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Gill, TM (corresponding author), Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Internal Med, TMP 17B,20 York St, New Haven, CT 06504 USA.	gill@ynhh.org	Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368; Allore, Heather/0000-0001-7685-8175	NATIONAL INSTITUTE ON AGING [P60AG010469, K23AG000759] Funding Source: NIH RePORTER; NIA NIH HHS [P60AG10469, K23AG00759] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315; COUGHLIN TA, 1992, HEALTH SERV RES, V27, P453; *DEP HLTH HUM SERV, 1990, DHHS PUBL; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 1998, ANN INTERN MED, V128, P96, DOI 10.7326/0003-4819-128-2-199801150-00004; Gill TM, 1999, J GERONTOL A-BIOL, V54, pM377, DOI 10.1093/gerona/54.7.M377; Gill TM, 2001, J AM GERIATR SOC, V49, P1039, DOI 10.1046/j.1532-5415.2001.49206.x; GILL TM, IN PRESS ARCH PHYS M; GILL TM, IN PRESS ARCH INTERN; GILL TM, 1995, J GERONTOL MED SCI, V50, pM325; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Guralnik JM, 2002, AM J PUBLIC HEALTH, V92, P1244, DOI 10.2105/AJPH.92.8.1244; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Jette AM, 1999, AM J PUBLIC HEALTH, V89, P66, DOI 10.2105/AJPH.89.1.66; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KEMPER P, 1992, HEALTH SERV RES, V27, P421; KING AC, 1988, AM J CARDIOL, V61, P628, DOI 10.1016/0002-9149(88)90778-3; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Levine C, 1999, NEW ENGL J MED, V340, P1587, DOI 10.1056/NEJM199905203402013; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; Manton KG, 2001, P NATL ACAD SCI USA, V98, P6354, DOI 10.1073/pnas.111152298; McCullagh P., 1989, GEN LINEAR MODELS; MCKINLAY JB, 1995, J AGING HEALTH, V7, P497, DOI 10.1177/089826439500700403; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002	31	557	567	1	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1068	1074		10.1056/NEJMoa020423	http://dx.doi.org/10.1056/NEJMoa020423			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	599KD	12362007				2023-01-03	WOS:000178332900003
J	Prigerson, HG				Prigerson, HG			Costs to society of family caregiving for patients with end-stage Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Yale Univ, Dept Psychiat, New Haven, CT 06520 USA	Yale University	Prigerson, HG (corresponding author), Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.		Prigerson, Holly/L-3800-2019; Prigerson, Holly/GWV-3283-2022	Prigerson, Holly/0000-0002-7075-4268; 				CHISHOLM D, 2001, INT J METH PSYCH RES, V10, P59, DOI DOI 10.1002/MPR.101	1	41	42	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1891	1892		10.1056/NEJMp038157	http://dx.doi.org/10.1056/NEJMp038157			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614164				2023-01-03	WOS:000186502400003
J	Block, BM; Liu, SS; Rowlingson, AJ; Cowan, AR; Cowan, JA; Wu, CL				Block, BM; Liu, SS; Rowlingson, AJ; Cowan, AR; Cowan, JA; Wu, CL			Efficacy of postoperative epidural analgesia - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PATIENT-CONTROLLED ANALGESIA; CONTROLLED OPIOID ANALGESIA; PAIN OUTCOME MEASURES; REGIONAL ANESTHESIA; RANDOMIZED-TRIALS; PROSPECTIVE EXPERIENCE; MORPHINE ANALGESIA; SURGICAL-PATIENTS; CLINICAL-TRIALS; AORTIC-SURGERY	Context Whether epidural analgesia is a better method than parenteral opioids for postoperative pain control remains controversial. Objective To systematically review the efficacy of postoperative epidural analgesia vs parenteral opioids, the primary alternative technique. Data Sources Studies were identified primarily by searching the National Library of Medicine's PubMed database (1966 to April 25, 2002) and other sources for studies related to postoperative epidural analgesia. Study Selection Inclusion criteria were a comparison of epidural therapy vs parenteral opioids for postoperative analgesia, measurement of pain using a visual analog scale (VAS) or numeric rating scale, randomization of patients to either therapy, and adult patients (greater than or equal to18 years). A total of 1404 abstracts were identified, 100 of which met all inclusion criteria. Data Extraction Each article was reviewed and data extracted from tables, text, or extrapolated from figures as needed. Weighted mean pain scores, weighted mean differences in pain score, and weighted incidences of complications were determined by using a fixed-effect model. Data Synthesis Epidural analgesia provided better postoperative analgesia compared with parenteral opioids (mean [SE], 19,40 mm [0.17] vs 29.40 mm [0.20] on the VAS; P<.001). When analyzed by postoperative day, epidural analgesia was better than parenteral opioids on each postoperative day (P<.001 for each day after surgery). For all types of surgery and pain assessments, all forms of epidural analgesia provided significantly better postoperative analgesia compared with parenteral opioid analgesia (P<.001 for all), with the exception of thoracic epidural analgesia vs opioids for rest pain after thoracic surgery (weighted mean difference, 0.6 mm; 95% confidence interval, -0.3 to 1.5 mm; P = .12). The complication rates were lower than expected for nausea or vomiting and pruritus but comparable with existing data for lower extremity motor block. Conclusion Epidural analgesia, regardless of analgesic agent, location of catheter placement, and type and time of pain assessment, provided better postoperative analgesia compared with parenteral opioids.	Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; Univ Washington, Virginia Mason Med Ctr, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA	Johns Hopkins University; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Wu, CL (corresponding author), Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Carnegie 280,600 N Wolfe St, Baltimore, MD 21287 USA.			Wu, Christopher/0000-0002-4484-0787				Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Barratt SM, 2002, REGION ANESTH PAIN M, V27, P15, DOI 10.1053/rapm.2002.27850; Basse L, 2002, BRIT J SURG, V89, P446, DOI 10.1046/j.0007-1323.2001.02044.x; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Bois S, 1997, ANESTH ANALG, V85, P1233, DOI 10.1097/00000539-199712000-00010; Boylan JF, 1998, ANESTHESIOLOGY, V89, P585, DOI 10.1097/00000542-199809000-00006; Brodner G, 2000, EUR J ANAESTH, V17, P566, DOI 10.1046/j.1365-2346.2000.00738.x; Brodner G, 2001, ANESTH ANALG, V92, P1594, DOI 10.1097/00000539-200106000-00049; Bucklin BA, 2002, REGION ANESTH PAIN M, V27, P23, DOI 10.1053/rapm.2002.29111; CADE L, 1993, ANAESTH INTENS CARE, V21, P696, DOI 10.1177/0310057X9302100537; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; Carr DB, 2001, EUR J PAIN, V5, P91, DOI 10.1053/eujp.2001.0288; Cassady JF, 2000, REGION ANESTH PAIN M, V25, P246; Correll DJ, 2001, REGION ANESTH PAIN M, V26, P444, DOI 10.1053/rapm.2001.26219; DELEONCASASOLA OA, 1994, ANESTHESIOLOGY, V81, P368, DOI 10.1097/00000542-199408000-00015; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Gedney JA, 1998, ANAESTHESIA, V53, P1148, DOI 10.1046/j.1365-2044.1998.00636.x; Gottschalk A, 1998, JAMA-J AM MED ASSOC, V279, P1076, DOI 10.1001/jama.279.14.1076; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Horlocker TT, 1998, REGION ANESTH PAIN M, V23, P129, DOI 10.1016/S1098-7339(98)90137-7; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; Kahn L, 1999, CAN J ANAESTH, V46, P415, DOI 10.1007/BF03012939; Kampe S, 2001, ANAESTHESIA, V56, P1189; KANEKO M, 1994, ANESTHESIOLOGY, V80, P137, DOI 10.1097/00000542-199401000-00021; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046/j.0265-0215.2000.00826.x; Kopacz DJ, 1999, ANESTH ANALG, V89, P1497, DOI 10.1097/00000539-199912000-00034; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Nakata K, 2002, J CLIN ANESTH, V14, P121, DOI 10.1016/S0952-8180(01)00366-X; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; ROSENTHAL R, 1991, PSYCHOSOM MED, V53, P247, DOI 10.1097/00006842-199105000-00001; SCOTT DA, 1995, ANESTHESIOLOGY, V83, P727, DOI 10.1097/00000542-199510000-00012; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Wheatley RG, 2001, BRIT J ANAESTH, V87, P47, DOI 10.1093/bja/87.1.47; WHITE MJ, 1992, CAN J ANAESTH, V39, P576, DOI 10.1007/BF03008321; Wigfull J, 2001, ANAESTHESIA, V56, P70, DOI 10.1046/j.1365-2044.2001.01763-6.x; Wu CL, 2000, ANESTH ANALG, V91, P1232, DOI 10.1097/00000539-200011000-00035; Wu CL, 2001, REGION ANESTH PAIN M, V26, P196, DOI 10.1053/rapm.2001.22257	52	613	665	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2455	2463		10.1001/jama.290.18.2455	http://dx.doi.org/10.1001/jama.290.18.2455			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742LH	14612482				2023-01-03	WOS:000186518300032
J	Dickinson, D; Raynor, DKT; Kennedy, JG; Bonaccorso, S; Sturchio, JL				Dickinson, D; Raynor, DKT; Kennedy, JG; Bonaccorso, S; Sturchio, JL			What information do patients need about medicines?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Consumation, Consumer Informat Design, London SW17 7QW, England; Univ Leeds, Pharm Practice & Med Management Grp, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Dickinson, D (corresponding author), Consumation, Consumer Informat Design, 53 Hosack Rd, London SW17 7QW, England.		Sturchio, Jeffrey/GWZ-3472-2022						0	71	74	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					861	861		10.1136/bmj.327.7419.861-a	http://dx.doi.org/10.1136/bmj.327.7419.861-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551106	Green Published, Green Accepted			2023-01-03	WOS:000185921200029
J	Szapary, PO; Wolfe, ML; Bloedon, LT; Cucchiara, AJ; DerMarderosian, AH; Cirigliano, MD				Szapary, PO; Wolfe, ML; Bloedon, LT; Cucchiara, AJ; DerMarderosian, AH; Cirigliano, MD			Guggulipid for the treatment of hypercholesterolemia - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMIPHORA-MUKUL; NATURAL PRODUCT; BILE-ACID; CHOLESTEROL; GUM; ANTAGONIST; RECEPTOR; HYPERLIPIDEMIA; GUGGULSTERONE; THERAPY	Context Herbal extracts from Commiphora mukul (guggul) have been widely used in Asia as cholesterol-lowering agents, and their popularity is increasing in the United States. Recently, guggulsterones, the purported bioactive compounds of guggul, have been shown to be potent antagonists of 2 nuclear hormone receptors involved in cholesterol metabolism, establishing a plausible mechanism of action for the hypolipidemic effects of these extracts. However, there are currently no published safety or efficacy data on the use of guggul extracts in Western populations. Objective To study the short-term safety and efficacy of 2 doses of a standardized guggul extract (guggulipid, containing 2.5% guggulsterones) in healthy adults with hyperlipidemia. eating a typical Western diet. Design Double-blind, randomized, placebo-controlled trial using a parallel design, conducted March 2000-August 2001. Participants and Setting A total of 103 ambulatory, community-dwelling, healthy adults with hypercholesterolemia in the Philadelphia, Pa, metropolitan area. Intervention Oral, 3 times daily doses of standard-dose guggulipid (1000 mg), high-dose guggulipid (2000 mg), or matching placebo. Main Outcome Measures Percentage change in levels of directly measured low-density lipoprotein cholesterol (LDL-C) after 8 weeks of therapy. Secondary outcome measures included levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, and directly measured very low-density lipoprotein cholesterol (VLDL-C), as well as adverse events reports and laboratory safety measures including electrolyte levels and hepatic and renal function. Results Compared with participants randomized to placebo (n=36), in whom levels of LDL-C decreased by 5%,both standard-dose guggulipid (n = 33) and high -dose guggulipid (n=34) raised levels of LDL-C by 4% (P=.01 vs placebo) and 5% (P=.006 vs placebo), respectively, at 8 weeks, for a net positive change of 9% to 10%. There were no significant changes in levels of total cholesterol, HDL-C, triglycerides, or VLDL-C in response to treatment with guggulipid in the intention-to-treat analysis. While guggulipid was generally well tolerated, 6 participants treated with guggulipid developed a hypersensitivity rash compared with none in the placebo group. Conclusions Despite plausible mechanisms of action, guggulipid did not appear to improve levels of serum cholesterol over the short term in this population of adults with hypercholesterolemia, and might in fact raise levels of LDL-C. Guggulipid also appeared to cause a dermatologic hypersensitivity reaction in some patients.	Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Gen Clin Res Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Sci, Dept Med & Biol Chem, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Szapary, PO (corresponding author), Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, 1222 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.				NCCIH NIH HHS [K-23 AT-00058] Funding Source: Medline; NCRR NIH HHS [M01-RR00040] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K23AT000058] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGARWAL RC, 1986, INDIAN J MED RES, V84, P626; ARORA RB, 1972, INDIAN J MED RES, V60, P929; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; Cui J, 2003, J BIOL CHEM, V278, P10214, DOI 10.1074/jbc.M209323200; Das Gupta R, 1990, J Assoc Physicians India, V38, P186; DASGUPTA R, 1990, J ASSOC PHYSICIAN I, V38, P598; De Smet PAGM, 2002, NEW ENGL J MED, V347, P2046, DOI 10.1056/NEJMra020398; Dev S, 1997, CURR SCI INDIA, V73, P909; DUWIEJUA M, 1993, PLANTA MED, V59, P12, DOI 10.1055/s-2006-959594; Ghorai M, 2000, PHYTOTHER RES, V14, P200, DOI 10.1002/(SICI)1099-1573(200005)14:3&lt;200::AID-PTR548&gt;3.0.CO;2-T; Goldman P, 2001, ANN INTERN MED, V135, P594, DOI 10.7326/0003-4819-135-8_Part_1-200110160-00010; Gopal K, 1986, J Assoc Physicians India, V34, P249; Kuppurajan K, 1978, J Assoc Physicians India, V26, P367; MALHOTRA SC, 1971, INDIAN J MED RES, V59, P1621; MALHOTRA SC, 1977, INDIAN J MED RES, V65, P390; Nagarajan M, 2001, J AOAC INT, V84, P24; Nityanand S, 1989, J Assoc Physicians India, V37, P323; NITYANAND S, 1973, INDIAN J EXP BIOL, V11, P395; Panda S, 1999, LIFE SCI, V65, pPL137, DOI 10.1016/S0024-3205(99)00369-0; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; SATYAVATI GV, 1988, INDIAN J MED RES, V87, P327; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; SINGH RB, 1994, CARDIOVASC DRUG THER, V8, P659, DOI 10.1007/BF00877420; TRIPATHI YB, 1984, PLANTA MED, V1, P78; Urizar NL, 2002, SCIENCE, V296, P1703, DOI 10.1126/science.1072891; VERMA SK, 1988, INDIAN J MED RES, V87, P356; Wu J, 2002, MOL ENDOCRINOL, V16, P1590, DOI 10.1210/me.16.7.1590	27	156	165	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2003	290	6					765	772		10.1001/jama.290.6.765	http://dx.doi.org/10.1001/jama.290.6.765			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709VU	12915429	Bronze			2023-01-03	WOS:000184647700027
J	Stein, C; Schafer, M; Machelska, H				Stein, C; Schafer, M; Machelska, H			Attacking pain at its source: new perspectives on opioids	NATURE MEDICINE			English	Review							PERIPHERAL MORPHINE ANALGESIA; RECEPTORS MEDIATING ANTINOCICEPTION; INTERCELLULAR-ADHESION MOLECULE-1; CORTICOTROPIN-RELEASING FACTOR; RAT SENSORY NEURONS; DORSAL-ROOT GANGLIA; INTRAARTICULAR MORPHINE; INFLAMMATORY PAIN; INFLAMED TISSUE; IMMUNE CELLS	The treatment of severe pain with opioids has thus far been limited by their unwanted central side effects. Recent research promises new approaches, including opioid analgesics acting outside the central nervous system, targeting of opioid peptide-containing immune cells to peripheral damaged tissue, and gene transfer to enhance opioid production at sites of injury.	Free Univ Berlin, Klinikum Benjamin Franklin, Klin Anaesthesiol & Operat Intens Med, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stein, C (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Klin Anaesthesiol & Operat Intens Med, Hindenburgdamm 30, D-12200 Berlin, Germany.			Stein, Christoph/0000-0001-5240-6836; Schaefer, Michael/0000-0002-1581-706X; Machelska, Halina/0000-0001-6315-2958				AKINS PT, 1993, NEUROSCIENCE, V56, P759, DOI 10.1016/0306-4522(93)90372-M; Aley KO, 1995, J NEUROSCI, V15, P8031; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; Averbeck B, 2001, NEUROREPORT, V12, P2097, DOI 10.1097/00001756-200107200-00011; BARBER A, 1994, BRIT J PHARMACOL, V113, P1317, DOI 10.1111/j.1476-5381.1994.tb17142.x; Bickel A, 1998, PAIN, V76, P317, DOI 10.1016/S0304-3959(98)00062-1; Binder W, 2000, J PHARMACOL EXP THER, V292, P303; Binder W, 2001, ANESTHESIOLOGY, V94, P1034, DOI 10.1097/00000542-200106000-00018; Borgland SL, 2001, J PHYSIOL-LONDON, V536, P35, DOI 10.1111/j.1469-7793.2001.t01-1-00035.x; Borner C, 2002, MOL PHARMACOL, V61, P800, DOI 10.1124/mol.61.4.800; Braz J, 2001, J NEUROSCI, V21, P7881, DOI 10.1523/JNEUROSCI.21-20-07881.2001; Brower V, 2000, NAT BIOTECHNOL, V18, P387, DOI 10.1038/74438; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Cabot PJ, 2001, PAIN, V93, P207, DOI 10.1016/S0304-3959(01)00322-0; CHAO CC, 1993, INT J IMMUNOPHARMACO, V15, P447, DOI 10.1016/0192-0561(93)90057-6; Coggeshall RE, 1997, BRAIN RES, V764, P126, DOI 10.1016/S0006-8993(97)00446-0; Dehaven-Hudkins DL, 1999, J PHARMACOL EXP THER, V289, P494; Dionne RA, 2001, CLIN PHARMACOL THER, V70, P66, DOI 10.1067/mcp.2001.116443; Duckett JW, 1997, J UROLOGY, V157, P1407, DOI 10.1016/S0022-5347(01)65001-8; Eisenach JC, 2003, PAIN, V101, P89, DOI 10.1016/S0304-3959(02)00259-2; FERREIRA SH, 1984, EUR J PHARMACOL, V99, P23, DOI 10.1016/0014-2999(84)90428-X; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; Gold MS, 1996, NEUROSCI LETT, V212, P83, DOI 10.1016/0304-3940(96)12791-9; HASSAN AHS, 1993, NEUROSCIENCE, V55, P185, DOI 10.1016/0306-4522(93)90465-R; Honore P, 1997, PAIN, V71, P99, DOI 10.1016/S0304-3959(97)03345-9; Houghton AK, 1998, ANESTHESIOLOGY, V89, P190, DOI 10.1097/00000542-199807000-00026; INGRAM SL, 1994, NEURON, V13, P179, DOI 10.1016/0896-6273(94)90468-5; JEANJEAN AP, 1995, NEUROSCIENCE, V68, P151, DOI 10.1016/0306-4522(95)00106-S; Ji RR, 1995, J NEUROSCI, V15, P8156; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3269, DOI 10.1073/pnas.95.6.3269; Jonker JW, 1999, BRIT J PHARMACOL, V127, P43, DOI 10.1038/sj.bjp.0702497; JORIS JL, 1987, ANESTH ANALG, V66, P1277; Kalso E, 2002, PAIN, V98, P269, DOI 10.1016/S0304-3959(02)00019-2; Khodorova A, 2003, NAT MED, V9, P1055, DOI 10.1038/nm885; KHOURY GF, 1992, ANESTHESIOLOGY, V77, P263, DOI 10.1097/00000542-199208000-00007; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; King M, 2001, NAT NEUROSCI, V4, P268, DOI 10.1038/85115; Kolesnikov Y, 1999, J PHARMACOL EXP THER, V290, P247; Koppert W, 1999, ANESTH ANALG, V88, P117, DOI 10.1097/00000539-199901000-00022; Krajnik M, 1999, PAIN, V80, P121, DOI 10.1016/S0304-3959(98)00211-5; Kraus J, 2001, J BIOL CHEM, V276, P43901, DOI 10.1074/jbc.M107543200; Laird JMA, 2002, J NEUROSCI, V22, P8352; Lewanowitsch T, 2002, EUR J PHARMACOL, V445, P61, DOI 10.1016/S0014-2999(02)01715-6; Likar R, 1997, ANESTH ANALG, V84, P1313, DOI 10.1097/00000539-199706000-00025; Likar R, 2001, J PAIN SYMPTOM MANAG, V21, P330, DOI 10.1016/S0885-3924(01)00251-2; Likar R, 1999, BRIT J ANAESTH, V83, P241, DOI 10.1093/bja/83.2.241; Lu CY, 2002, GENE THER, V9, P1008, DOI 10.1038/sj.gt.3301774; Machelska H, 1999, J PHARMACOL EXP THER, V290, P354; Machelska H, 1998, NAT MED, V4, P1425, DOI 10.1038/4017; Machelska H, 2002, ANESTH ANALG, V95, P1002, DOI 10.1213/01.ANE.0000024213.38319.27; Machelska H, 2002, J NEUROSCI, V22, P5588; MINAMI M, 1995, MOL BRAIN RES, V30, P203, DOI 10.1016/0169-328X(94)00290-U; MOINICHE S, 1993, ACTA ANAESTH SCAND, V37, P710, DOI 10.1111/j.1399-6576.1993.tb03795.x; Mousa SA, 2000, J NEUROIMMUNOL, V108, P160, DOI 10.1016/S0165-5728(00)00284-8; Mousa SA, 2001, J NEUROIMMUNOL, V115, P71, DOI 10.1016/S0165-5728(01)00271-5; Mousa SA, 2002, J NEUROIMMUNOL, V126, P5, DOI 10.1016/S0165-5728(02)00049-8; Murphy DB, 2000, ANESTH ANALG, V90, P1122, DOI 10.1097/00000539-200005000-00023; Nozaki-Taguchi N, 1999, ANESTHESIOLOGY, V90, P225, DOI 10.1097/00000542-199901000-00029; Pan ZZ, 1998, TRENDS PHARMACOL SCI, V19, P94, DOI 10.1016/S0165-6147(98)01169-9; Pare M, 2001, J NEUROSCI, V21, P7236, DOI 10.1523/JNEUROSCI.21-18-07236.2001; PARSONS CG, 1990, PAIN, V41, P81, DOI 10.1016/0304-3959(90)91112-V; Pertovaara A, 2001, EUR J PHARMACOL, V429, P139, DOI 10.1016/S0014-2999(01)01315-2; PEYMAN GA, 1994, BRIT J OPHTHALMOL, V78, P138, DOI 10.1136/bjo.78.2.138; Picard PR, 1997, PAIN, V72, P309, DOI 10.1016/S0304-3959(97)00040-7; Polydefkis M, 2002, NEUROLOGY, V58, P115, DOI 10.1212/WNL.58.1.115; Poonyachoti S, 2002, CELL TISSUE RES, V307, P23, DOI 10.1007/s00441-001-0480-0; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; Reuben SS, 2001, ANESTHESIOLOGY, V95, P390, DOI 10.1097/00000542-200108000-00021; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; Rorarius M, 1999, PAIN, V79, P83, DOI 10.1016/S0304-3959(98)00157-2; Rosseland LA, 1999, ACTA ANAESTH SCAND, V43, P252, DOI 10.1034/j.1399-6576.1999.430303.x; Sandner-Kiesling A, 2002, PAIN, V96, P13, DOI 10.1016/S0304-3959(01)00398-0; Schafer M, 1996, P NATL ACAD SCI USA, V93, P6096, DOI 10.1073/pnas.93.12.6096; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Schmitt TK, 2003, ANESTHESIOLOGY, V98, P195, DOI 10.1097/00000542-200301000-00030; SCHULTESTEINBERG H, 1995, ANESTHESIOLOGY, V82, P634, DOI 10.1097/00000542-199503000-00004; SELLEY DE, 1993, MOL PHARMACOL, V44, P731; Sengupta JN, 1999, PAIN, V79, P175, DOI 10.1016/S0304-3959(98)00175-4; Shannon HE, 2002, NEUROPHARMACOLOGY, V42, P253, DOI 10.1016/S0028-3908(01)00173-3; SIMON P, 1986, NEPHROLOGIE, V5, P185; Smith EM, 2003, ADV EXP MED BIOL, V521, P51; Stein A, 1999, PAIN, V83, P525, DOI 10.1016/S0304-3959(99)00156-6; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; Stein C, 1996, J CLIN INVEST, V98, P793, DOI 10.1172/JCI118852; STEIN C, 1988, NEUROSCI LETT, V84, P225, DOI 10.1016/0304-3940(88)90412-0; STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602; Stein C, 2001, Z RHEUMATOL, V60, P416, DOI 10.1007/s003930170004; STEIN C, 1993, ANESTH ANALG, V76, P182; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; TADDESE A, 1995, SCIENCE, V270, P1366, DOI 10.1126/science.270.5240.1366; Taguchi A, 2001, NEW ENGL J MED, V345, P935, DOI 10.1056/NEJMoa010564; Truong W, 2003, ANN NEUROL, V53, P366, DOI 10.1002/ana.10465; Ueda H, 1999, NEUROSCI LETT, V266, P105, DOI 10.1016/S0304-3940(99)00285-2; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Walker J, 1999, PAIN, V83, P509, DOI 10.1016/S0304-3959(99)00158-X; Wenk HN, 1999, J COMP NEUROL, V408, P567, DOI 10.1002/(SICI)1096-9861(19990614)408:4<567::AID-CNE10>3.0.CO;2-Q; Wilson JL, 1998, J RHEUMATOL, V25, P499; YAKSH TL, 1988, BRAIN RES, V458, P319, DOI 10.1016/0006-8993(88)90474-X; YOUNG WS, 1980, SCIENCE, V210, P76, DOI 10.1126/science.6158097; Zhou L, 1998, J PHARMACOL EXP THER, V286, P1000; ZOLLNER C, IN PRESS MOL PHARM	103	440	457	0	42	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2003	9	8					1003	1008		10.1038/nm908	http://dx.doi.org/10.1038/nm908			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	706ZL	12894165				2023-01-03	WOS:000184484900022
J	Madden, JM; Soumerai, SB; Lieu, TA; Mandl, KD; Zhang, F; Ross-Degnan, D				Madden, JM; Soumerai, SB; Lieu, TA; Mandl, KD; Zhang, F; Ross-Degnan, D			Effects of a law against early postpartum discharge on newborn follow-up, adverse events, and HMO expenditures.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Academy-of-Health-Services-Research-and-Health-Policy	JUN, 2002	WASHINGTON, D.C.	Acad Hlth Serv Res & Hlth Policy			HOSPITAL READMISSION; STAY; LENGTH; MORTALITY; MEDICAID; MOTHERS; PROGRAM; CARE	Background: Concern about harm to newborns from early postpartum discharges led to laws establishing minimum hospital stays in the mid-1990s. We evaluated the effects of an early-discharge protocol (a hospital stay of one postpartum night plus a home visit) in a health maintenance organization (HMO) and a subsequent state law guaranteeing a 48-hour hospital stay. Methods: Using interrupted-time-series analysis and data on 20,366 mother-infant pairs with normal vaginal deliveries, we measured changes in length of stay, newborn examinations on the third or fourth day of life, and office visits, emergency department visits, and hospital readmissions for newborns. We also examined expenditures for hospitalizations and home-based care. Results: The early-discharge program increased the rate of stays of less than two nights from 29.0 percent to 65.6 percent (P<0.001). The rate declined to 13.7 percent after the state mandate (P<0.001). The rate of newborn examinations on the third or fourth day of life increased from 24.5 percent to 64.4 percent with the program (P<0.001), then dropped to 53.0 percent after the mandate (P<0.001) -- changes that primarily reflected changes in the rate of home visits. The rate of nonurgent visits to a health center increased from 33.4 percent to 44.7 percent (P<0.001) after the reduced-stay program was implemented. There were no significant changes in the rate of emergency department visits (quarterly mean, 1.1 percent) or rehospitalizations (quarterly mean, 1.5 percent). Results were similar for a vulnerable subgroup with lower incomes, younger maternal age, a lower level of education, or some combination of these characteristics. Average HMO expenditures on hospital and home-based services decreased by $90 per delivery with the early-discharge program and increased by $100 after the mandate. Conclusions: Neither policy appears to have affected the health outcomes of newborns. After the mandate, newborns were less likely to be examined as recommended on day 3 or 4. Because of changes in hospital prices, the two policies had minimal effects on HMO expenditures for hospital and home-based services.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Boston Children's Hospital	Ross-Degnan, D (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 133 Brookline Ave,6th Fl, Boston, MA 02215 USA.				AHRQ HHS [5R01HS10060] Funding Source: Medline; PHS HHS [H16MC00050] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010060] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 2001, Jt Comm Perspect, V21, P10; Braveman P, 1997, JAMA-J AM MED ASSOC, V278, P334; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRITTON JR, 1994, PEDIATRICS, V94, P291; Brumfield CG, 1998, CLIN OBSTET GYNECOL, V41, P611, DOI 10.1097/00003081-199809000-00016; CARTY EM, 1990, BIRTH-ISS PERINAT C, V17, P199, DOI 10.1111/j.1523-536X.1990.tb00021.x; CHARLES S, 1995, PEDIATRICS, V96, P746; Cook T.D., 1979, QUASIEXPERIMENTATION; Declercq E, 1997, MILBANK Q, V75, P175, DOI 10.1111/1468-0009.00051; Eaton AP, 2001, PEDIATRICS, V107, P400, DOI 10.1542/peds.107.2.400; Edmonson MB, 1997, JAMA-J AM MED ASSOC, V278, P299, DOI 10.1001/jama.278.4.299; Gagnon AJ, 1997, AM J OBSTET GYNECOL, V176, P205, DOI 10.1016/S0002-9378(97)80037-3; Gartner LM, 1997, PEDIATRICS, V100, P1035, DOI 10.1542/peds.100.6.1035; GILLINGS D, 1981, AM J PUBLIC HEALTH, V71, P38, DOI 10.2105/AJPH.71.1.38; Kotagal UR, 1999, JAMA-J AM MED ASSOC, V282, P1150, DOI 10.1001/jama.282.12.1150; LAWRENCE RA, 1999, BREASTFEEDING GUIDE; Liu LL, 1997, JAMA-J AM MED ASSOC, V278, P2067; MADDEN JM, 2000, 6 ANN HMO RES NETW C; Maisels MJ, 1998, PEDIATRICS, V101, P995, DOI 10.1542/peds.101.6.995; Malkin JD, 2000, OBSTET GYNECOL, V96, P183, DOI 10.1016/S0029-7844(00)00894-2; Mandl KD, 1997, ARCH PEDIAT ADOL MED, V151, P915, DOI 10.1001/archpedi.1997.02170460053009; Mandl KD, 2000, PEDIATRICS, V106, P937; Martin S, 2000, INDEX CENSORSHIP, V29, P72, DOI 10.1080/03064220008536766; OH W, 1995, PEDIATRICS, V96, P788; Platt R., 1994, PHARMACOEPIDEM DR S, P277; ROSSDEGNAN D, 1993, JAMA-J AM MED ASSOC, V270, P1937, DOI 10.1001/jama.270.16.1937; SAS Institute, 1993, SAS ETS US GUID VERS SAS ETS US GUID VERS, V2nd; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Thilo EH, 1998, CLIN PERINATOL, V25, P257, DOI 10.1016/S0095-5108(18)30114-3; 1995, MMWR MORB MORTAL WKL, V44, P335	30	62	66	0	7	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	2002	347	25					2031	2038		10.1056/NEJMsa020408	http://dx.doi.org/10.1056/NEJMsa020408			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	626LT	12490685	Green Submitted, Green Published			2023-01-03	WOS:000179874500007
J	McDonald, HP; Garg, AX; Haynes, RB				McDonald, HP; Garg, AX; Haynes, RB			Interventions to enhance patient adherence to medication prescriptions - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED-TRIAL; SELF-MANAGEMENT; BLOOD-PRESSURE; SCHIZOPHRENIC-PATIENTS; COMPLIANCE THERAPY; FOLLOW-UP; EDUCATION; HYPERTENSION; STRATEGIES; PUBLICATION	Context Low adherence with prescribed treatments is ubiquitous and undermines treatment benefits. Objective To systematically review published randomized controlled trials (RCTs) of interventions to assist patients' adherence to prescribed medications. Data Sources A search of MEDLINE, CINAHL, PSYCHLIT, SOCIOFILE, IPA, EMBASE, The Cochrane Library databases, and bibliographies was performed for records from 1967 through August 2001 to identify relevant articles of all RCTs of interventions intended to improve adherence to self-administered medications. Study Selection and Data Extraction Studies were included if they reported an unconfounded RCT of an intervention to improve adherence with prescribed medications for a medical or psychiatric disorder; both adherence and treatment outcome were measured; follow-up of at least 80% of each study group was reported; and the duration of follow-up for studies with positive initial findings was at least 6 months. Information on study design features, interventions, controls, and findings (adherence rates and patient outcomes) were extracted for each article. Data Synthesis Studies were too disparate to warrant meta-analysis. Forty-nine percent of the interventions tested (19 of 39 in 33 studies) were associated with statistically significant increases in medication adherence and only 17 reported statistically significant improvements in treatment outcomes. Almost all the interventions that were effective for long-term care were complex, including combinations of more convenient care, information, counseling, reminders, self-monitoring, reinforcement, family therapy, and other forms of additional supervision or attention. Even the most effective interventions had modest effects. Conclusions Current methods of improving medication adherence for chronic health problems are mostly complex, labor-intensive, and not predictably effective. The full benefits of medications cannot be realized at currently achievable levels of adherence; therefore, more studies of innovative approaches to assist patients to follow prescriptions for medications are needed.	McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Fac Hlth Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Sch Grad Studies, Hlth Res Methodol Program, Hamilton, ON, Canada; McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Haynes, RB (corresponding author), McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Fac Hlth Sci, Room 2C10B,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	bhaynes@mcmaster.ca	Garg, Amit X/G-3295-2011	Haynes, Robert Brian/0000-0002-1453-3196				BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BAIRD MG, 1984, CLIN INVEST MED, V7, P95; Bandura A., 1971, SOCIAL LEARNING THEO; BECKER LA, 1986, J FAM PRACTICE, V22, P357; Brown BG, 1997, AM J CARDIOL, V80, P111, DOI 10.1016/S0002-9149(97)00303-2; Brus HLM, 1998, ANN RHEUM DIS, V57, P146, DOI 10.1136/ard.57.3.146; Burke LE, 1997, ANN BEHAV MED, V19, P239, DOI 10.1007/BF02892289; Chaplin R, 1998, BRIT J PSYCHIAT, V172, P78, DOI 10.1192/bjp.172.1.78; COLCHER IS, 1972, J AMER MED ASSOC, V222, P657, DOI 10.1001/jama.222.6.657; Cote J, 1997, AM J RESP CRIT CARE, V155, P1509, DOI 10.1164/ajrccm.155.5.9154850; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Friedman RH, 1996, AM J HYPERTENS, V9, P285, DOI 10.1016/0895-7061(95)00353-3; Gallefoss F, 1999, AM J RESP CRIT CARE, V160, P2000, DOI 10.1164/ajrccm.160.6.9901028; Gallefoss F, 1999, AM J RESP CRIT CARE, V159, P812, DOI 10.1164/ajrccm.159.3.9804047; GIBSON PG, 1999, LTD PATIENT ED PROGR; Girvin B, 1999, J HYPERTENS, V17, P1627, DOI 10.1097/00004872-199917110-00017; Gordis L, 1979, COMPLIANCE HLTH CARE, P23; HARVEY EL, 1999, IMPROVING HLTH PROFE; Haynes R., 2002, INTERVENTIONS HELPIN; Haynes RB, 2001, AM HEART MONOGR S, P3; HAYNES RB, 1976, LANCET, V1, P1265; HAYNES RB, 1987, CONTROL CLIN TRIALS, V8, P12, DOI 10.1016/0197-2456(87)90021-3; Henry A, 1999, AM J GASTROENTEROL, V94, P811, DOI 10.1111/j.1572-0241.1999.00856.x; HOWLAND JS, 1990, J FAM PRACTICE, V31, P62; Inzucchi SE, 2002, JAMA-J AM MED ASSOC, V287, P360, DOI 10.1001/jama.287.3.360; Irvine J, 1999, PSYCHOSOM MED, V61, P566, DOI 10.1097/00006842-199907000-00023; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOHNSON AL, 1978, CAN MED ASSOC J, V119, P1034; Katon W, 2001, ARCH GEN PSYCHIAT, V58, P241, DOI 10.1001/archpsyc.58.3.241; Kemp R, 1996, BRIT MED J, V312, P345; Kemp R, 1998, BRIT J PSYCHIAT, V172, P413, DOI 10.1192/bjp.172.5.413; Knobel H, 1999, Enferm Infecc Microbiol Clin, V17, P78; LANCASTER T, 1999, SELF HELP INTERVENTI; Levy ML, 2000, RESP MED, V94, P900, DOI 10.1053/rmed.2000.0861; LOGAN AG, 1981, HYPERTENSION, V3, P211, DOI 10.1161/01.HYP.3.2.211; LOGAN AG, 1979, LANCET, V2, P1175; LUMLEY J, 1999, INTERVENTIONS PROMOT; MACHARIA WM, 1992, JAMA-J AM MED ASSOC, V267, P1813, DOI 10.1001/jama.267.13.1813; Merinder LB, 1999, SOC PSYCH PSYCH EPID, V34, P287, DOI 10.1007/s001270050146; Miller NH, 1997, CIRCULATION, V95, P1085; PETERSON GM, 1984, EPILEPSIA, V25, P412, DOI 10.1111/j.1528-1157.1984.tb03436.x; Peveler R, 1999, BRIT MED J, V319, P612, DOI 10.1136/bmj.319.7210.612; Piette JD, 2000, AM J MED, V108, P20, DOI 10.1016/S0002-9343(99)00298-3; Razali S, 2000, J MENTAL HLTH, V9, P283, DOI DOI 10.1080/713680246; SACKETT DL, 1975, LANCET, V1, P1205; Sackett DL, 1979, COMPLIANCE HLTH CARE; SILAGY C, 1999, NICOTINE REPLACEMENT; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; STRANG J S, 1981, Psychopharmacology Bulletin, V17, P87; Tuldra A, 2000, J ACQ IMMUN DEF SYND, V25, P221, DOI 10.1097/00126334-200011010-00003; van Es SM, 2001, PATIENT EDUC COUNS, V44, P193, DOI 10.1016/S0738-3991(00)00195-6; VOLMINK J, 1999, INTERVENTIONS PROMOT; Wysocki T, 2001, DIABETES CARE, V24, P441, DOI 10.2337/diacare.24.3.441; XIONG W, 1994, BRIT J PSYCHIAT, V165, P239, DOI 10.1192/bjp.165.2.239; ZHANG ML, 1994, BRIT J PSYCHIAT, V165, P96, DOI 10.1192/S0007125000293045; [No title captured]	58	825	843	0	91	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	2002	288	22					2868	2879		10.1001/jama.288.22.2868	http://dx.doi.org/10.1001/jama.288.22.2868			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623YM	12472329	Bronze			2023-01-03	WOS:000179732600032
J	Lincoff, AM; Califf, RM; Van de Werf, F; Willerson, JT; White, HD; Armstrong, PW; Guetta, V; Gibler, WB; Hochman, JS; Bode, C; Vahanian, A; Steg, PG; Ardissino, D; Savonitto, S; Bar, F; Sadowski, Z; Betriu, A; Booth, JE; Wolski, K; Waller, M; Topol, EJ				Lincoff, AM; Califf, RM; Van de Werf, F; Willerson, JT; White, HD; Armstrong, PW; Guetta, V; Gibler, WB; Hochman, JS; Bode, C; Vahanian, A; Steg, PG; Ardissino, D; Savonitto, S; Bar, F; Sadowski, Z; Betriu, A; Booth, JE; Wolski, K; Waller, M; Topol, EJ		GUSTO V Investigators	Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction - GUSTO V randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; RECEPTOR BLOCKADE; REPERFUSION; ABCIXIMAB; ANGIOPLASTY	Context Among patients with acute myocardial infarction, combination reperfusion therapy with a platelet glycoprotein IIb/IIIa receptor inhibitor (abciximab) and a half dose of a plasminogen activator (reteplase) did not significantly reduce mortality at 30 days compared with a full dose of reteplase. Rates of nonfatal ischemic complications were significantly diminished. Objective To determine if the beneficial effects of abciximab and reteplase (combination therapy) on early nonfatal complications would translate into a reduction in the risk of death by 1 year. Design, Setting, and Patients One-year follow-up of a randomized controlled trial (Global Use of Strategies To Open Coronary Arteries [GUSTO] V). Of 16588 patients who had been treated in 820 community and referral hospitals in 20 countries between July 1999 and February 2001, mortality data were available for 16453 (99.2%). Intervention Patients were randomly assigned to receive (intravenously) a standard dose of reteplase (two 10-U boluses, 30 minutes apart) or the combination of a standard dose of abdximab (0.25 mg/kg bolus, 0.125 mug/kg per minute infusion [maximum 10 mug/min for 12 hours]) and a half dose of reteplase (two 5-U boluses, 30 minutes apart). Main Outcome Measure One-year all-cause mortality rates. Results All-cause mortality at 1 year occurred in 692 (8.38%) of 8260 patients in the reteplase group and 698 (8.38%) of the 8328 patients in the combination therapy group (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.90-1.11; P>.99). Reinfarction within the first 7 days occurred in 3.5% of patients in the reteplase group and 2.3% of patients in the combination therapy group, and was significantly associated with 1-year mortality (22.6% in patients with reinfarction vs 8.0% in patients without reinfarction; HR, 3.08; 95% CI, 2.53-3.75; P<.001). However, treatment assignment did not significantly influence time of mortality regardless of reinfarction status. Conclusion Combination therapy (abciximab and reteplase) did not reduce mortality over 1 year compared with fibrinolytic therapy with reteplase alone.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Dike Clin Res Inst, Durham, NC USA; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Houston Med Ctr, Houston, TX USA; Green Lane Hosp, Auckland 3, New Zealand; Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; Chaim Sheba Med Ctr, Ramat Gan, Israel; Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; St Lukes Hosp, New York, NY USA; Univ Freiburg, Med Klin, D-7800 Freiburg, Germany; Hop Bichat Claude Bernard, F-75877 Paris, France; Hop Tenon, F-75970 Paris, France; Azienda Osped Parma, Parma, Italy; Osped Niguarda Ca Granda, Milan, Italy; Acad Ziekenhuis Maastricht, Maastricht, Netherlands; Natl Inst Cardiol, Warsaw, Poland; Univ Barcelona Hosp Clin, Barcelona, Spain; Centocor Inc, Malvern, PA 19355 USA	Cleveland Clinic Foundation; KU Leuven; University Hospital Leuven; University of Alberta; Chaim Sheba Medical Center; University System of Ohio; University of Cincinnati; Mount Sinai St. Luke's; University of Freiburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Parma; University Hospital of Parma; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Maastricht University; Maastricht University Medical Centre (MUMC); Institute of Cardiology - Poland; University of Barcelona; Hospital Clinic de Barcelona; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Lincoff, AM (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	lincofa@ccf.org	Ardissino, Diego/AAC-4041-2022; STEG, Philippe Gabriel/Z-1567-2019	Hochman, Judith/0000-0002-5889-5981; STEG, Philippe Gabriel/0000-0001-6896-2941; solinas, emilia/0000-0003-3532-1317; Armstrong, Paul/0000-0002-0460-3445; Van de Werf, Frans/0000-0001-9479-7767; Topol, Eric/0000-0002-1478-4729				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; de Lemos JA, 2000, CIRCULATION, V101, P239, DOI 10.1161/01.CIR.101.3.239; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; *GUSTO 5 INV, 2000, LANCET, V357, P1905; Harrington RA, 1998, J AM COLL CARDIOL, V32, P2003; Hudson MP, 2001, CIRCULATION, V104, P1229, DOI 10.1161/hc3601.095717; KLEIMAN NS, 1991, CIRCULATION S2, V84, P522; LINCOFF AM, 1993, CIRCULATION, V88, P1361, DOI 10.1161/01.CIR.88.3.1361; LINCOFF AM, 1993, CIRCULATION, V87, P1792; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Neumann FJ, 2000, J AM COLL CARDIOL, V35, P915, DOI 10.1016/S0735-1097(99)00635-X; Ohman EM, 1997, CIRCULATION, V95, P846; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SAVONITTO S, IN PRESS EUR HEART J; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2000, CIRCULATION, V101, P2788; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2001, LANCET, V358, P605; White HD, 2001, LANCET, V358, P1855	25	90	93	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2130	2135		10.1001/jama.288.17.2130	http://dx.doi.org/10.1001/jama.288.17.2130			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413372				2023-01-03	WOS:000179048100023
J	Overgaard, J; Hansen, HS; Specht, L; Overgaard, M; Grau, C; Andersen, E; Bentzen, J; Bastholt, L; Hansen, O; Johansen, J; Andersen, L; Evensen, JF				Overgaard, J; Hansen, HS; Specht, L; Overgaard, M; Grau, C; Andersen, E; Bentzen, J; Bastholt, L; Hansen, O; Johansen, J; Andersen, L; Evensen, JF		Danish Head Neck Canc Study Grp	Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial	LANCET			English	Article							GROWTH-FACTOR RECEPTOR; SPLIT-COURSE RADIOTHERAPY; ACCELERATED FRACTIONATION; ALTERED FRACTIONATION; PHARYNX CARCINOMA; PHASE-III; CANCER; LARYNX; HYPERFRACTIONATION; ONCOLOGY	Background Although head and neck cancer can be cured by radiotherapy, the optimum treatment time for locoregional control is unclear. We aimed to find out whether shortening of treatment time by use of six instead of five radiotherapy fractions per week improves the tumour response in squamous-cell carcinoma. Methods We did a multicentre, controlled, randomised trial. Between January, 1992, and December, 1999, of 1485 patients treated with primary radiotherapy alone, 1476 eligible patients were randomly assigned five (n=726) or six (n=750) fractions per week at the same total dose and fraction number (66-68 Gy in 33-34 fractions to all tumour sites except well-differentiated T1 glottic tumours, which were treated with 62 Gy). All patients, except those with glottic cancers, also received the hypoxic radiosensitiser nimorazole. Analysis was by intention to treat. Findings More than 97% of the patients received the planned total dose. Median overall treatment times were 39 days (six-fraction group) and 46 days (five-fraction group). Overall 5-year locoregional control rates were 70% and 60% for the six-fraction and five-fraction groups, respectively (p=0.0005). The whole benefit of shortening of treatment time was seen for primary tumour control (76 vs 64% for six and five fractions, p=0.0001), but was non-significant for neck-node control. Six compared with five fractions per week improved preservation of the voice among patients with laryngeal cancer (80 vs 68%, p=0.007). Disease-specific survival improved (73 vs 66% for six and five fractions, p=0.01) but not overall survival. Acute morbidity was significantly more frequent with six than with five fractions, but was transient. Interpretation The shortening of overall treatment time by increase of the weekly number of fractions is beneficial in patients with head and neck cancer. The six-fractions-weekly regimen has become the standard treatment in Denmark.	Aarhus Univ Hosp, Dept Expt Clin Oncol, DK-8000 Aarhus C, Denmark; Rigshosp, Finsen Ctr, Dept Oncol, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus C, Denmark; Herlev Hosp, Dept Oncol, Copenhagen, Denmark; Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark; Aaborg Hosp, Dept Oncol, Aaborg, Denmark; Norwegian Radium Hosp, Oslo, Norway	Aarhus University; Rigshospitalet; University of Copenhagen; Aarhus University; University of Copenhagen; Herlev & Gentofte Hospital; University of Southern Denmark; Odense University Hospital; University of Oslo	Overgaard, J (corresponding author), Aarhus Univ Hosp, Dept Expt Clin Oncol, Norrebrogade 44,Bldg 5, DK-8000 Aarhus C, Denmark.		Johansen, Jørgen/I-6816-2013; Grau, Cai/I-8161-2014; Specht, Lena/J-6422-2019; Andersen, Elo/A-1639-2016; Hansen, Olfred/D-1432-2012	Johansen, Jørgen/0000-0003-3911-3929; Grau, Cai/0000-0003-3548-3527; Specht, Lena/0000-0002-6902-2190; Andersen, Elo/0000-0002-2476-1037; Hansen, Olfred/0000-0003-0396-1424; Bastholt, Lars/0000-0001-5478-9826				Ang KK, 2002, CANCER RES, V62, P7350; Bernier J, 2003, EUR J CANCER, V39, P560, DOI 10.1016/S0959-8049(02)00838-9; Bourhis J., 2002, International Journal of Radiation Oncology Biology Physics, V54, P71, DOI 10.1016/S0360-3016(02)03180-2; BOURHIS J, 2000, P AN M AM SOC CLIN, V19, pA412; Cummings BJ, 1999, ACTA ONCOL, V38, P131, DOI 10.1080/028418699431528; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Dische S, 1997, RADIOTHER ONCOL, V44, P123, DOI 10.1016/S0167-8140(97)00094-7; Dobrowsky W, 2000, RADIOTHER ONCOL, V57, P119, DOI 10.1016/S0167-8140(00)00233-4; ERIKSEN JG, IN PRESS INT J RAD O; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Groome PA, 2003, J CLIN ONCOL, V21, P496, DOI 10.1200/JCO.2003.10.106; Hansen O, 1997, RADIOTHER ONCOL, V43, P47, DOI 10.1016/S0167-8140(97)01904-X; Hliniak A, 2002, RADIOTHER ONCOL, V62, P1, DOI 10.1016/S0167-8140(01)00494-7; HORIOT JC, 1992, RADIOTHER ONCOL, V25, P231, DOI 10.1016/0167-8140(92)90242-M; Horiot JC, 1997, RADIOTHER ONCOL, V44, P111, DOI 10.1016/S0167-8140(97)00079-0; Jackson SM, 1997, RADIOTHER ONCOL, V43, P39, DOI 10.1016/S0167-8140(97)01944-0; Kaanders JHAM, 2002, LANCET ONCOL, V3, P728, DOI 10.1016/S1470-2045(02)00929-4; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Nguyen LN, 2002, LANCET ONCOL, V3, P693, DOI 10.1016/S1470-2045(02)00906-3; OVERGAARD J, 1989, INT J RADIAT ONCOL, V16, P1065, DOI 10.1016/0360-3016(89)90917-6; Overgaard J, 1996, SEMIN RADIAT ONCOL, V6, P10, DOI 10.1016/S1053-4296(96)80032-4; Overgaard J, 1998, RADIOTHER ONCOL, V46, P135, DOI 10.1016/S0167-8140(97)00220-X; OVERGAARD J, 1988, ACTA ONCOL, V27, P147, DOI 10.3109/02841868809090334; OVERGAARD J, 1986, INT J RADIAT ONCOL, V12, P515, DOI 10.1016/0360-3016(86)90058-1; Overgaard Jens, 2000, Rays (Rome), V25, P313; Peters, 1992, Semin Radiat Oncol, V2, P180, DOI 10.1016/1053-4296(92)90007-8; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Poulsen MG, 2001, RADIOTHER ONCOL, V60, P113, DOI 10.1016/S0167-8140(01)00347-4; Skladowski K, 2000, RADIOTHER ONCOL, V55, P101, DOI 10.1016/S0167-8140(00)00139-0; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333	30	493	501	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					933	940		10.1016/S0140-6736(03)14361-9	http://dx.doi.org/10.1016/S0140-6736(03)14361-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511925				2023-01-03	WOS:000185489600006
J	Bai, XH; Cerimele, F; Ushio-Fukai, M; Waqas, M; Campbell, PM; Govindarajan, B; Der, CJ; Battle, T; Frank, DA; Ye, KQ; Murad, E; Dubiel, W; Soff, G; Arbiser, JL				Bai, XH; Cerimele, F; Ushio-Fukai, M; Waqas, M; Campbell, PM; Govindarajan, B; Der, CJ; Battle, T; Frank, DA; Ye, KQ; Murad, E; Dubiel, W; Soff, G; Arbiser, JL			Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL PROLIFERATION; RIE-1 EPITHELIAL-CELLS; INDUCED APOPTOSIS; DIETARY CURCUMIN; MELANOMA-CELLS; MAGNOLIA BARK; COLON-CANCER; ACTIVATION; KINASE; TRAIL	Natural products comprise a major source of small molecular weight angiogenesis inhibitors. We have used the transformed endothelial cell line SVR as an effective screen of natural product extracts to isolate anti-angiogenesis and anti-tumor compounds. Aqueous extracts of Magnolia grandiflora exhibit potent activity in our SVR proliferation assays. We found that the small molecular weight compound honokiol is the active principle of magnolia extract. Honokiol exhibited potent anti-proliferative activity against SVR cells in vitro. In addition, honokiol demonstrated preferential inhibition of primary human endothelial cells compared with fibroblasts and this inhibition was antagonized by antibodies against TNF alpha-related apoptosis-inducing ligand. In vivo, honokiol was highly effective against angiosarcoma in nude mice. Our preclinical data suggests that honokiol is a systemically available and non-toxic inhibitor of angiogenesis and should be further evaluated as a potential chemotherapeutic agent.	Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Cardiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Univ N Carolina, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Humboldt Univ, Dept Surg, Berlin, Germany; Humboldt Univ, Fac Med Charite, Div Mol Biol, Berlin, Germany; Northwestern Univ, Sch Med, Evanston, IL 60208 USA	Emory University; Emory University; Emory University; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Northwestern University	Arbiser, JL (corresponding author), Emory Univ, Sch Med, Dept Dermatol, WMB 5309,1639 Pierce Dr, Atlanta, GA 30322 USA.	jarbise@emory.edu		Campbell, Paul/0000-0002-3345-5007; Dubiel, Wolfgang/0000-0002-3393-0701; Der, Channing/0000-0002-7751-2747	NIAMS NIH HHS [AR44947, AR02030, AR42687] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR042687, R03AR044947] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ai JL, 2001, PHARMACOLOGY, V63, P34, DOI 10.1159/000056110; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Arbiser JL, 1999, J AM ACAD DERMATOL, V40, P925, DOI 10.1016/S0190-9622(99)70080-0; Arbiser JL, 1998, MOL MED, V4, P376, DOI 10.1007/BF03401744; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Daneker GW, 1998, IN VITRO CELL DEV-AN, V34, P370, DOI 10.1007/s11626-998-0018-9; Dinkova-Kostova AT, 1999, CARCINOGENESIS, V20, P911, DOI 10.1093/carcin/20.5.911; Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; FUJITA M, 1973, YAKUGAKU ZASSHI, V93, P429, DOI 10.1248/yakushi1947.93.4_429; Gupta S, 2001, P NATL ACAD SCI USA, V98, P10350, DOI 10.1073/pnas.171326098; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; HUANG MT, 1994, CANCER RES, V54, P5841; HUANG MT, 1991, CANCER RES, V51, P813; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Kuribara H, 2000, J PHARM PHARMACOL, V52, P1425, DOI 10.1211/0022357001777432; Kuribara H, 1999, J PHARM PHARMACOL, V51, P97; LaMontagne KR, 2000, AM J PATHOL, V157, P1937, DOI 10.1016/S0002-9440(10)64832-8; LaVallee TM, 2003, CANCER RES, V63, P468; Lin WW, 1997, J CHIN INST CHEM ENG, V28, P29; Maruyama Y, 1998, J NAT PROD, V61, P135, DOI 10.1021/np9702446; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Pieri L, 2003, BBA-GEN SUBJECTS, V1621, P76, DOI 10.1016/S0304-4165(03)00048-5; Pollmann C, 2001, CANCER RES, V61, P8416; Pruitt K, 2000, J BIOL CHEM, V275, P40916, DOI 10.1074/jbc.M006682200; Rao CV, 1995, ANN NY ACAD SCI, V768, P201, DOI 10.1111/j.1749-6632.1995.tb12122.x; Samaha HS, 1997, CANCER RES, V57, P1301; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Thaloor D, 1998, CELL GROWTH DIFFER, V9, P305; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	42	304	333	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35501	35507		10.1074/jbc.M302967200	http://dx.doi.org/10.1074/jbc.M302967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12816951	hybrid, Green Published			2023-01-03	WOS:000185164400092
J	Bravata, DM; Sanders, L; Huang, J; Krumholz, HM; Olkin, I; Gardner, CD; Bravata, DM				Bravata, DM; Sanders, L; Huang, J; Krumholz, HM; Olkin, I; Gardner, CD; Bravata, DM			Efficacy and safety of low-carbohydrate diets - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-CALORIE DIET; RESTING METABOLIC-RATE; LOW-FAT DIET; DEPENDENT DIABETES-MELLITUS; RANDOMIZED CONTROLLED TRIAL; CARDIOVASCULAR RISK-FACTORS; ENERGY-RESTRICTED DIETS; WEIGHT-LOSS; BODY-COMPOSITION; MONOUNSATURATED FAT	Context Low-carbohydrate diets have been popularized without detailed evidence of their efficacy or safety. The literature has no clear consensus as to what amount of carbohydrates per day constitutes a low-carbohydrate diet. Objective To evaluate changes in weight, serum lipids, fasting serum glucose, and fasting serum insulin levels, and blood pressure among adults using low-carbohydrate diets in the outpatient setting. Data Sources We performed MEDLINE and bibliographic searches for English-language studies published between January 1, 1966, and February 15, 2003, with key words such as low carbohydrate, ketogenic, and diet. Study Selection We included articles describing adult, outpatient recipients of low-carbohydrate diets of 4 days or more in duration and 500 kcal/d or more, and which reported both carbohydrate content and total calories consumed. Literature searches identified 2609 potentially relevant articles of low-carbohydrate diets. We included 107 articles describing 94 dietary interventions reporting data for 3268 participants; 663 participants received diets of 60 g/d or less of carbohydrates-of whom only 71 received 20 g/d or less of carbohydrates. Study variables (eg, number of participants, design of dietary evaluation), participant variables (eg, age, sex, baseline weight, fasting serum glucose level), diet variables (eg, carbohydrate content, caloric content, duration) were abstracted from each study. Data Extraction Two authors independently reviewed articles meeting inclusion criteria and abstracted data onto pretested abstraction forms. Data Synthesis The included studies were highly heterogeneous with respect to design, carbohydrate content (range, 0-901 g/d), total caloric content (range, 5254629 kcal/d), diet duration (range, 4-365 days), and participant characteristics (eg, baseline weight range, 57-217 kg). No study evaluated diets of 60 g/d or less of carbohydrates in participants with a mean age older than 53.1 years. Only 5 studies (non-randomized and no comparison groups) evaluated these diets for more than 90 days. Among obese patients, weight loss was associated with longer diet duration (P=.002), restriction of calorie intake (P=.03), but not with reduced carbohydrate content (P=.90). Low-carbohydrate diets had no significant adverse effect on serum lipid, fasting serum glucose, and fasting serum insulin levels, or blood pressure. Conclusions There is insufficient evidence to make recommendations for or against the use of low-carbohydrate diets, particularly among participants older than age 50 years, for use longer than 90 days, or for diets of 20 g/d or less of carbohydrates. Among the published studies, participant,weight loss while using low-carbohydrate diets was principally associated with decreased caloric intake and increased diet duration but not with reduced carbohydrate content.	Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Stanford Univ, Sch Educ, Dept Stat, Stanford, CA 94305 USA; Stanford Univ, Stanford Ctr Res Dis Prevent, Stanford, CA 94305 USA; Calif Pacific Med Ctr, San Francisco, CA USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA	Stanford University; Stanford University; Stanford University; California Pacific Medical Center; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Bravata, DM (corresponding author), Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, 117 Encina Commons, Stanford, CA 94305 USA.	bravata@healthpolicy.stanford.edu	, Harlan/AAI-2875-2020; Biguzzi, Felipe A/E-4724-2015					ALFORD BB, 1990, J AM DIET ASSOC, V90, P534; *AM HEART ASS, HIGH PROT DIETS AHA; *AM HEART ASS, 2002, SCI SESS AM HEART AS; APFELBAUM M, 1981, INT J OBESITY, V5, P117; Atkins RC, 1998, ATKINS NEW DIET REVO; Banting W., 1863, LETT CORPULENCE ADDR; BARON JA, 1986, AM J PUBLIC HEALTH, V76, P1293, DOI 10.2105/AJPH.76.11.1293; BENOIT FL, 1965, ANN INTERN MED, V63, P604, DOI 10.7326/0003-4819-63-4-604; BETTENS C, 1989, INT J OBESITY, V13, P113; BIALKOWSKA M, 1977, Materia Medica Polona, V9, P244; BONANOME A, 1991, AM J CLIN NUTR, V54, P586, DOI 10.1093/ajcn/54.3.586; Brown RC, 2000, MED SCI SPORT EXER, V32, P690, DOI 10.1097/00005768-200003000-00021; BRUSSAARD JH, 1982, ATHEROSCLEROSIS, V42, P205, DOI 10.1016/0021-9150(82)90151-4; Buffenstein R, 2000, PHYSIOL BEHAV, V68, P439, DOI 10.1016/S0031-9384(99)00222-X; CALLEPASCUAL AL, 1995, HORM METAB RES, V27, P499, DOI 10.1055/s-2007-980011; CANGIANO C, 1992, AM J CLIN NUTR, V56, P863, DOI 10.1093/ajcn/56.5.863; Carey AL, 2001, J APPL PHYSIOL, V91, P115, DOI 10.1152/jappl.2001.91.1.115; CATTRAN DC, 1980, CLIN NEPHROL, V13, P177; COMI D, 1995, EUR J CLIN NUTR, V49, pS242; CORDERA R, 1985, DIABETES METAB, V11, P137; Coyle EF, 2001, AM J PHYSIOL-ENDOC M, V280, pE391, DOI 10.1152/ajpendo.2001.280.3.E391; De Lorenzo A, 2001, DIABETES NUTR METAB, V14, P181; DONNELLY JE, 1991, AM J CLIN NUTR, V54, P56, DOI 10.1093/ajcn/54.1.56; EKSTEDT B, 1991, SCAND J CLIN LAB INV, V51, P437, DOI 10.3109/00365519109091637; Engelhart M, 1996, CLIN EXP RHEUMATOL, V14, P289; EVANS E, 1974, NUTR METAB, V17, P360; FAGERBERG B, 1984, INT J OBESITY, V8, P237; FERY F, 1982, DIABETES METAB, V8, P299; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fleming Richard M, 2002, Prev Cardiol, V5, P110, DOI 10.1111/j.1520-037X.2002.01231.x; FOSTER GD, 1992, AM J CLIN NUTR, V55, P811, DOI 10.1093/ajcn/55.4.811; FOSTER GD, 1990, AM J CLIN NUTR, V51, P167, DOI 10.1093/ajcn/51.2.167; GAFFNEY T, 1981, MED J AUSTRALIA, V1, P237; Gleser L.J., 1994, HDB RES SYNTHESIS, P339, DOI DOI 10.7758/9781610448864.16; Golay A, 1996, INT J OBESITY, V20, P1067; Grande F, 1967, Nutr Rev, V25, P189; GREENHAFF PL, 1988, EUR J APPL PHYSIOL, V57, P531, DOI 10.1007/BF00418458; GREENHAFF PL, 1988, EUR J APPL PHYSIOL, V57, P583, DOI 10.1007/BF00418466; Gumbiner B, 1998, DIABETES CARE, V21, P9, DOI 10.2337/diacare.21.1.9; HALLAK MH, 1988, AM J CLIN NUTR, V48, P1197, DOI 10.1093/ajcn/48.5.1197; HAMMER RL, 1989, AM J CLIN NUTR, V49, P77, DOI 10.1093/ajcn/49.1.77; HARVEY J, 1993, APPETITE, V21, P105, DOI 10.1016/0195-6663(93)90003-3; Haulrik N, 2002, AM J CLIN NUTR, V76, P1202, DOI 10.1093/ajcn/76.6.1202; HEDGES L, 1985, STAT METHODS METAANA, V1; Heilbronn LK, 1999, DIABETES CARE, V22, P889, DOI 10.2337/diacare.22.6.889; Heilbronn LK, 2002, J AM COLL NUTR, V21, P120, DOI 10.1080/07315724.2002.10719204; Helge JW, 2002, INT J OBESITY, V26, P1118, DOI 10.1038/sj.ijo.0802058; HELLER RF, 1993, CARBOHYDRATE ADDICTS; HOCKADAY TDR, 1978, BRIT J NUTR, V39, P357, DOI 10.1079/BJN19780045; Holmback U, 2002, J NUTR, V132, P1892, DOI 10.1093/jn/132.7.1892; HULLEY SB, 1972, LANCET, V2, P551; IRELAND P, 1992, DIABETES CARE, V15, P1499, DOI 10.2337/diacare.15.11.1499; Jenkins DJA, 2001, AM J CLIN NUTR, V74, P57; Jeor STS, 2001, CIRCULATION, V104, P1869, DOI 10.1161/hc4001.096152; KIRBY R K, 1985, Carle Selected Papers, V37, P14; KOGON MM, 1994, AM J CLIN NUTR, V60, P488, DOI 10.1093/ajcn/60.4.488; Kratz M, 2002, J CLIN ENDOCR METAB, V87, P5008, DOI 10.1210/jc.2002-020496; KROTKIEWSKI M, 1990, AM J CLIN NUTR, V51, P321, DOI 10.1093/ajcn/51.3.321; KWAN RMF, 1986, J NUTR, V116, P2393, DOI 10.1093/jn/116.12.2393; LAROSA JC, 1980, J AM DIET ASSOC, V77, P264; Lean MEJ, 1997, EUR J CLIN NUTR, V51, P243, DOI 10.1038/sj.ejcn.1600391; Lousley S E, 1984, Diabet Med, V1, P21; Low CC, 1996, DIABETES, V45, P569, DOI 10.2337/diabetes.45.5.569; LUNTZ GRWN, 1975, POSTGRAD MED J, V51, P133; Luscombe ND, 2002, DIABETES CARE, V25, P652, DOI 10.2337/diacare.25.4.652; Luscombe ND, 1999, EUR J CLIN NUTR, V53, P473, DOI 10.1038/sj.ejcn.1600779; MARSOOBIAN V, 1990, 74 ANN M FED AM SOC; MATHIESON RA, 1986, METABOLISM, V35, P394, DOI 10.1016/0026-0495(86)90126-5; Mezzano D, 2001, EUR J CLIN NUTR, V55, P444, DOI 10.1038/sj.ejcn.1601202; Miller ER, 2002, HYPERTENSION, V40, P612, DOI 10.1161/01.HYP.0000037217.96002.8E; Mogul H R, 2001, Heart Dis, V3, P285; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Muller H, 2003, J NUTR, V133, P78, DOI 10.1093/jn/133.1.78; NAGY R, 1974, VA MED, V101, P383; NOBELS F, 1989, NETH J MED, V35, P295; ODEA K, 1989, J AM DIET ASSOC, V89, P1076; Parker B, 2002, DIABETES CARE, V25, P425, DOI 10.2337/diacare.25.3.425; PETERSON CM, 1995, J AM COLL NUTR, V14, P369; Pieke B, 2000, INT J OBESITY, V24, P1286, DOI 10.1038/sj.ijo.0801440; POMERLEAU J, 1993, DIABETOLOGIA, V36, P829, DOI 10.1007/BF00400358; RABAST U, 1978, MED KLIN, V73, P55; RACETTE SB, 1995, AM J CLIN NUTR, V61, P486, DOI 10.1093/ajcn/61.3.486; ROSEN JC, 1985, AM J CLIN NUTR, V42, P371, DOI 10.1093/ajcn/42.3.371; Saltzman E, 2001, J AM COLL NUTR, V20, P50, DOI 10.1080/07315724.2001.10719014; Saltzman E, 2001, J NUTR, V131, P1465, DOI 10.1093/jn/131.5.1465; SCHLUNDT DG, 1993, INT J OBESITY, V17, P623; SCOTT CB, 1992, MED SCI SPORT EXER, V24, P814; Sears B., 1995, ZONE DIETARY ROAD MA; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; SEROG P, 1982, AM J CLIN NUTR, V35, P24, DOI 10.1093/ajcn/35.1.24; SHAH M, 1994, AM J CLIN NUTR, V59, P980, DOI 10.1093/ajcn/59.5.980; Sharman MJ, 2002, J NUTR, V132, P1879, DOI 10.1093/jn/132.7.1879; SIMONYI J, 1969, Cor et Vasa, V11, P251; SIMPSON RW, 1979, BRIT MED J, V1, P1753, DOI 10.1136/bmj.1.6180.1753; Skov AR, 1999, INT J OBESITY, V23, P1170, DOI 10.1038/sj.ijo.0801048; Skov AR, 2002, OBES RES, V10, P432, DOI 10.1038/oby.2002.60; SKOV R, 1999, INT J OBES RELAT MET, V23, P528; SPAULDING SW, 1976, J CLIN ENDOCR METAB, V42, P197, DOI 10.1210/jcem-42-1-197; SPILLER GA, 1992, J AM COLL NUTR, V11, P126; Staudacher HM, 2001, INT J SPORT NUTR EXE, V11, P273, DOI 10.1123/ijsnem.11.3.273; Stein K, 2000, J AM DIET ASSOC, V100, P760, DOI 10.1016/S0002-8223(00)00219-4; Straznicky NE, 1999, HYPERTENSION, V34, P580, DOI 10.1161/01.HYP.34.4.580; THOMPSON PD, 1984, METABOLISM, V33, P1003, DOI 10.1016/0026-0495(84)90228-2; VANSTRATUM P, 1978, AM J CLIN NUTR, V31, P206, DOI 10.1093/ajcn/31.2.206; VASWANI AN, 1983, J AM COLL NUTR, V2, P123; Vessby B, 2001, DIABETOLOGIA, V44, P312, DOI 10.1007/s001250051620; Volek JS, 2002, METABOLISM, V51, P864, DOI 10.1053/meta.2002.32037; Volek JS, 2001, METABOLISM, V50, P1351, DOI 10.1053/meta.2001.25648; Volek JS, 2000, J AM COLL NUTR, V19, P383, DOI 10.1080/07315724.2000.10718935; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V264, P707, DOI 10.1001/jama.264.6.707; WALBERG JL, 1988, MED SCI SPORT EXER, V20, P34, DOI 10.1249/00005768-198802000-00005; WEINSIER RL, 1974, ANN INTERN MED, V80, P332, DOI 10.7326/0003-4819-80-3-332; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; Whitehead JM, 1996, INT J OBESITY, V20, P727; Wolever TMS, 2002, BRIT J NUTR, V87, P477, DOI 10.1079/BJN2002568; WOLFE BM, 1991, METABOLISM, V40, P338, DOI 10.1016/0026-0495(91)90142-J; Wolfe BMJ, 1999, CLIN INVEST MED, V22, P140; YOUNG CM, 1971, AM J CLIN NUTR, V24, P290; 2000, MED LETT DRUGS THER, V42, P52; 1966, NUTR REV, V24, P133	121	366	374	3	151	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1837	1850		10.1001/jama.289.14.1837	http://dx.doi.org/10.1001/jama.289.14.1837			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZJ	12684364				2023-01-03	WOS:000182094900031
J	Quinlivan, JA; Box, H; Evans, SF				Quinlivan, JA; Box, H; Evans, SF			Postnatal home visits in teenage mothers: a randomised controlled trial	LANCET			English	Article							ADOLESCENT PREGNANCY; MATERNAL AGE; PROGRAM; CHILDBEARING; PREVENTION; VISITATION; INFANCY; NURSES; RISK	Background Teenage pregnancies are associated with negative socioeconomic effects. Our aim was to ascertain whether a postnatal home-visiting service for teenage mothers younger than age 18 years could reduce the frequency of adverse neonatal outcomes and improve knowledge of contraception, breastfeeding, and infant vaccination schedules in this parent group. Methods We enrolled 139 adolescents, attending a teenage pregnancy clinic, in a randomised controlled trial. After completing an antenatal questionnaire designed to assess their knowledge of contraception, infant vaccination, and breastfeeding, we assigned participants to either receive five structured postnatal home visits by nurse-midwives (n=65) or not (n=71). Assessment interviews were done 6 months postpartum. Our primary endpoint was unadjusted difference in knowledge between groups, and incidence of predefined adverse neonatal outcomes. Analysis was by intention to treat. Findings Three women withdrew before randomisation because of late fetal loss, 11 mothers withdrew because of adverse neonatal outcomes (adverse neonatal outcome was a primary endpoint, but resulted in withdrawal from the study for knowledge outcomes), and one left voluntarily. Follow-up data were, therefore, available for 124 teenagers. Postnatal home visits were associated with a reduction in adverse neonatal outcomes (intervention: 2; control: 9; relative risk 0.24, 95% CI 0.05-1.08), and a significant increase in contraception knowledge (mean difference 0.92, 95% CI 0.32-1.52). However, there was no significant increase in knowledge with respect to breastfeeding or infant vaccination schedules associated with the home visits. Interpretation Postnatal home-visiting services by nurse-midwives reduce adverse neonatal events and improve contraception outcomes, but do not affect breastfeeding or infant vaccination knowledge or compliance.	Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic 3052, Australia; King Edward Mem Hosp, Obstet Clin Care Unit, Perth, WA, Australia; Univ Western Australia, Dept Obstet & Gynaecol, Nedlands, WA 6009, Australia; Univ Western Australia, Womens & Infants Res Fdn, Nedlands, WA 6009, Australia	University of Melbourne; King Edward Memorial Hospital; University of Western Australia; University of Western Australia; University of Western Australia	Quinlivan, JA (corresponding author), Univ Melbourne, Royal Womens Hosp, Univ Dept Obstet & Gynaecol, Carlton, Vic 3053, Australia.	julieq@unimelb.edu.au		Quinlivan, Julie/0000-0003-4706-2412				Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408; [Anonymous], 1973, OB GYN NEWS, V8, P1; BABSON SG, 1983, J PEDIATR-US, V103, P391, DOI 10.1016/S0022-3476(83)80409-0; Chase-Lansdale PL, 2002, FUTURE CHILD, V12, P167; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; FURSTENBERG FF, 1989, AM PSYCHOL, V44, P313, DOI 10.1037/0003-066X.44.2.313; Gueorguieva RV, 2001, AM J EPIDEMIOL, V154, P212, DOI 10.1093/aje/154.3.212; Guyatt GH, 2000, J CLIN EPIDEMIOL, V53, P167, DOI 10.1016/S0895-4356(99)00160-2; Hippisley-Cox J, 2000, BRIT MED J, V320, P842, DOI 10.1136/bmj.320.7238.842; HOBBS CJ, 1999, CHILD ABUSE NEGLECT; Kitzman H, 1997, JAMA-J AM MED ASSOC, V278, P644, DOI 10.1001/jama.278.8.644; Korfmacher J, 1999, AM J PUBLIC HEALTH, V89, P1847, DOI 10.2105/AJPH.89.12.1847; Magann EF, 1996, AM J OBSTET GYNECOL, V175, P182, DOI 10.1016/S0002-9378(96)70272-7; MCANARNEY ER, 1987, AM J DIS CHILD, V141, P1053, DOI 10.1001/archpedi.1987.04460100031017; Miller F C, 2000, J Pediatr Adolesc Gynecol, V13, P5, DOI 10.1016/S1083-3188(99)00035-2; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; Nair P, 1997, CHILD ABUSE NEGLECT, V21, P1039, DOI 10.1016/S0145-2134(97)00064-1; OLDS DL, 1986, PEDIATRICS, V78, P65; Pierre Natalie, 1997, Current Opinion in Pediatrics, V9, P310, DOI 10.1097/00008480-199708000-00003; POLIT DF, 1986, AM J PUBLIC HEALTH, V76, P167, DOI 10.2105/AJPH.76.2.167; Quinlivan J A, 2001, J Pediatr Adolesc Gynecol, V14, P17, DOI 10.1016/S1083-3188(00)00078-4; Quinlivan JA, 1999, AUST NZ J PSYCHIAT, V33, P864, DOI 10.1046/j.1440-1614.1999.00592.x; Social Exclusion Unit, 1999, TEEN PREGN REP PARL; Stevens-Simon C, 1998, ARCH PEDIAT ADOL MED, V152, P893; Stevens-Simon C, 2001, CHILD ABUSE NEGLECT, V25, P753, DOI 10.1016/S0145-2134(01)00237-X; StevensSimon C, 1997, JAMA-J AM MED ASSOC, V277, P977, DOI 10.1001/jama.277.12.977; WILLIAMS S, 1987, BRIT MED J, V294, P20, DOI 10.1136/bmj.294.6563.20-a; 1989, HOME VISITING OPENIN	28	83	83	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	2003	361	9361					893	900		10.1016/S0140-6736(03)12770-5	http://dx.doi.org/10.1016/S0140-6736(03)12770-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	658VP	12648967				2023-01-03	WOS:000181741600006
J	O'Brien, SG; Guilhot, F; Larson, RA; Gathmann, I; Baccarani, M; Cervantes, F; Cornelissen, JJ; Fischer, T; Hochhaus, A; Hughes, T; Lechner, K; Nielsen, JL; Rousselot, P; Reiffers, J; Saglio, G; Shepherd, J; Simonsson, B; Gratwohl, A; Goldman, JM; Kantarjian, H; Taylor, K; Verhoef, G; Bolton, AE; Capdeville, R; Druker, BJ; Durrant, S; Schwarer, A; Joske, D; Seymour, J; Grigg, A; Ma, D; Arthur, C; Bradstock, K; Joshua, D; Louwagie, A; Martiat, P; Straetmans, N; Bosly, A; Shustik, C; Lipton, J; Forrest, D; Walker, I; Roy, DC; Rubinger, M; Bence-Bruckler, I; Kovacs, M; Turner, AR; Birgens, H; Bjerrum, O; Facon, T; Harousseau, JL; Tulliez, M; Guerci, A; Blaise, D; Maloisel, F; Michallet, M; Hossfeld, D; Mertelsmann, R; Andreesen, R; Nerl, C; Freund, M; Gattermann, N; Hoeffken, K; Ehninger, G; Deininger, M; Ottmann, O; Peschel, C; Fruehauf, S; Neubauer, A; Le Coutre, P; Aulitzky, W; Fanin, R; Rosti, G; Mandelli, F; Morra, E; Carella, A; Lazzarino, M; Petrini, M; Ferrini, PR; Nobile, F; Liso, V; Ferrara, F; Rizzoli, V; Fioritoni, G; Martinelli, G; Ossenkoppele, G; Browett, P; Gedde-Dahl, T; Tangen, JM; Dahl, I; Odriozola, J; Boluda, JCH; Steegmann, JL; Canizo, C; Sureda, A; Diaz, J; Granena, A; Fernandez, MN; Stenke, L; Paul, C; Bjoreman, M; Malm, C; Wadenvik, H; Nilsson, PG; Turesson, I; Hess, U; Solenthaler, M; Russel, N; Mufti, G; Cavenagh, J; Clark, RE; Green, AR; Holyoake, TL; Lucas, GS; Smith, G; Milligan, DW; Rule, SJ; Burnett, AK; Moroose, R; Wetzler, M; Bearden, J; Brown, R; Lobell, M; Cataland, S; Rabinowitz, I; Meisenberg, B; Gabrilove, J; Thompson, K; Graziano, S; Emanuel, P; Gross, H; Cobb, P; Bhatia, R; Dakhil, S; Irwin, D; Issell, B; Pavletic, S; Kuebler, P; Layhe, E; Butera, P; Glass, J; Moore, J; Grant, B; Niell, H; Herzig, R; Burris, H; Peterson, B; Powell, B; Kalaycio, M; Stirewalt, D; Samlowski, W; Berman, E; Limentani, S; Seay, T; Shea, T; Akard, L; Smith, G; Becker, P; DeVine, S; Hart, R; Veith, R; Wade, J; Brunvand, M; Silver, R; Kalman, L; Strickland, D; Shurafa, M; Bashey, A; Shadduck, R; Cooper, S; Safah, H; Rubenstein, M; Collins, R; Keller, A; Stone, R; Tallman, M; Stevens, D; Pecora, A; Agha, M; Holmes, H; Druker, BJ; Guilhot, F; Larson, RA; O'Brien, SG; Rowe, J; Schiffer, CA; Buyse, M; Baccarani, M; Cervantes, F; Cornelissen, J; Fischer, T; Hochhaus, A; Hughes, T; Kantarjian, H; Lechner, K; Nielsen, JL; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Simonsson, B; Gratwohl, A; Goldman, JM; Taylor, K; Verhoef, G				O'Brien, SG; Guilhot, F; Larson, RA; Gathmann, I; Baccarani, M; Cervantes, F; Cornelissen, JJ; Fischer, T; Hochhaus, A; Hughes, T; Lechner, K; Nielsen, JL; Rousselot, P; Reiffers, J; Saglio, G; Shepherd, J; Simonsson, B; Gratwohl, A; Goldman, JM; Kantarjian, H; Taylor, K; Verhoef, G; Bolton, AE; Capdeville, R; Druker, BJ; Durrant, S; Schwarer, A; Joske, D; Seymour, J; Grigg, A; Ma, D; Arthur, C; Bradstock, K; Joshua, D; Louwagie, A; Martiat, P; Straetmans, N; Bosly, A; Shustik, C; Lipton, J; Forrest, D; Walker, I; Roy, DC; Rubinger, M; Bence-Bruckler, I; Kovacs, M; Turner, AR; Birgens, H; Bjerrum, O; Facon, T; Harousseau, JL; Tulliez, M; Guerci, A; Blaise, D; Maloisel, F; Michallet, M; Hossfeld, D; Mertelsmann, R; Andreesen, R; Nerl, C; Freund, M; Gattermann, N; Hoeffken, K; Ehninger, G; Deininger, M; Ottmann, O; Peschel, C; Fruehauf, S; Neubauer, A; Le Coutre, P; Aulitzky, W; Fanin, R; Rosti, G; Mandelli, F; Morra, E; Carella, A; Lazzarino, M; Petrini, M; Ferrini, PR; Nobile, F; Liso, V; Ferrara, F; Rizzoli, V; Fioritoni, G; Martinelli, G; Ossenkoppele, G; Browett, P; Gedde-Dahl, T; Tangen, JM; Dahl, I; Odriozola, J; Boluda, JCH; Steegmann, JL; Canizo, C; Sureda, A; Diaz, J; Granena, A; Fernandez, MN; Stenke, L; Paul, C; Bjoreman, M; Malm, C; Wadenvik, H; Nilsson, PG; Turesson, I; Hess, U; Solenthaler, M; Russel, N; Mufti, G; Cavenagh, J; Clark, RE; Green, AR; Holyoake, TL; Lucas, GS; Smith, G; Milligan, DW; Rule, SJ; Burnett, AK; Moroose, R; Wetzler, M; Bearden, J; Brown, R; Lobell, M; Cataland, S; Rabinowitz, I; Meisenberg, B; Gabrilove, J; Thompson, K; Graziano, S; Emanuel, P; Gross, H; Cobb, P; Bhatia, R; Dakhil, S; Irwin, D; Issell, B; Pavletic, S; Kuebler, P; Layhe, E; Butera, P; Glass, J; Moore, J; Grant, B; Niell, H; Herzig, R; Burris, H; Peterson, B; Powell, B; Kalaycio, M; Stirewalt, D; Samlowski, W; Berman, E; Limentani, S; Seay, T; Shea, T; Akard, L; Smith, G; Becker, P; DeVine, S; Hart, R; Veith, R; Wade, J; Brunvand, M; Silver, R; Kalman, L; Strickland, D; Shurafa, M; Bashey, A; Shadduck, R; Cooper, S; Safah, H; Rubenstein, M; Collins, R; Keller, A; Stone, R; Tallman, M; Stevens, D; Pecora, A; Agha, M; Holmes, H; Druker, BJ; Guilhot, F; Larson, RA; O'Brien, SG; Rowe, J; Schiffer, CA; Buyse, M; Baccarani, M; Cervantes, F; Cornelissen, J; Fischer, T; Hochhaus, A; Hughes, T; Kantarjian, H; Lechner, K; Nielsen, JL; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Simonsson, B; Gratwohl, A; Goldman, JM; Taylor, K; Verhoef, G		IRIS Investigators	Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; BCR-ABL; CYTOGENETIC RESPONSES; IN-VITRO; C-KIT; INHIBITION; BUSULFAN; GROWTH; ALPHA	Background: Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML. Methods: We randomly assigned 1106 patients to receive imatinib (553 patients) or interferon alfa plus low-dose cytarabine (553 patients). Crossover to the alternative group was allowed if stringent criteria defining treatment failure or intolerance were met. Patients were evaluated for hematologic and cytogenetic responses, toxic effects, and rates of progression. Results: After a median follow-up of 19 months, the estimated rate of a major cytogenetic response (0 to 35 percent of cells in metaphase positive for the Philadelphia chromosome) at 18 months was 87.1 percent (95 percent confidence interval, 84.1 to 90.0) in the imatinib group and 34.7 percent (95 percent confidence interval, 29.3 to 40.0) in the group given interferon alfa plus cytarabine (P<0.001). The estimated rates of complete cytogenetic response were 76.2 percent (95 percent confidence interval, 72.5 to 79.9) and 14.5 percent (95 percent confidence interval, 10.5 to 18.5), respectively (P<0.001). At 18 months, the estimated rate of freedom from progression to accelerated-phase or blast-crisis CML was 96.7 percent in the imatinib group and 91.5 percent in the combination-therapy group (P<0.001). Imatinib was better tolerated than combination therapy. Conclusions: In terms of hematologic and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML.	Univ Newcastle, Newcastle, NSW 2308, Australia; CHU Poitiers, Poitiers, France; Univ Chicago, Chicago, IL 60637 USA; Novartis, Basel, Switzerland; St Orsola Marcello Malpighi Hosp, Bologna, Italy; Hosp Clin Barcelona, Barcelona, Spain; Erasmus MC, Dr Daniel Den Hoed Canc Ctr, Rotterdam, Netherlands; Johannes Gutenberg Univ Mainz, D-6500 Mainz, Germany; Heidelberg Univ, Klinikum Mannheim, Mannheim, Germany; Royal Adelaide Hosp, Adelaide, SA 5000, Australia; Univ Vienna, Innere Med Klin 1, Vienna, Austria; Aarhus Kommune Hosp, DK-8000 Aarhus, Denmark; Hop St Louis, Paris, France; CHU Bordeaux, Pessac, France; Azienda Osped S Luigi Gonzaga, Orbassano, Italy; Vancouver Hosp, Vancouver, BC, Canada; Uppsala Univ, Akad Sjukhuset, Uppsala, Sweden; Kantonsspital Basel, Basel, Switzerland; Hammersmith Hosp, London, England; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Mater Misericordiae Publ Hosp, Brisbane, Qld, Australia; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Oregon Hlth & Sci Univ, Inst Canc, Portland, OR USA	University of Newcastle; CHU Poitiers; Universite de Poitiers; University of Chicago; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Barcelona; Hospital Clinic de Barcelona; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Johannes Gutenberg University of Mainz; Ruprecht Karls University Heidelberg; Royal Adelaide Hospital; University of Vienna; Aarhus University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; University of British Columbia; Uppsala University; Uppsala University Hospital; Imperial College London; University of Texas System; UTMD Anderson Cancer Center; KU Leuven; University Hospital Leuven; Oregon Health & Science University	O'Brien, SG (corresponding author), Univ Newcastle, Newcastle, NSW 2308, Australia.		Bjerrum, Ole Weis/AAF-9999-2019; Yang, Chen/G-1379-2010; Blaise, Didier/R-2483-2016; Devine, Steven/AAS-7644-2021; Seymour, John/K-7326-2019; Fernandez, Manuel/M-9168-2013; Larson, Richard A./AAE-7223-2019; Kovacs, Michael/G-3315-2011; Agha, Mounzer/AAC-2520-2022; Arthur, Chris/ABG-7286-2022	Blaise, Didier/0000-0002-5684-9447; Seymour, John/0000-0003-2188-6835; Larson, Richard A./0000-0001-9168-3203; Arthur, Chris/0000-0002-9147-9090; Saglio, Giuseppe/0000-0002-1046-3514; Guilhot, Francois/0000-0001-7222-487X; Druker, Brian/0000-0001-8331-8206; Hochhaus, Andreas/0000-0003-0626-0834				ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Baccarani M, 2002, BLOOD, V99, P1527, DOI 10.1182/blood.V99.5.1527; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Delannoy A, 1997, J NATL CANCER I, V89, P1616; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; Gratwohl A, 2002, LANCET, V359, P712, DOI 10.1016/S0140-6736(02)07831-5; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hasford J, 1998, JNCI-J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLIHER M, 1990, P NATL ACAD SCI USA, V87, P9072; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Kluin-Nelemans JC, 1998, BLOOD, V91, P2713; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; NOWELL PC, 1960, SCIENCE, V132, P1497; OHNISHI K, 1995, BLOOD, V86, P906; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Silver RT, 1999, BLOOD, V94, P1517; SOKAL JE, 1988, SEMIN HEMATOL, V25, P49; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; TURA S, 1994, NEW ENGL J MED, V330, P820	37	2627	2729	8	163	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					994	1004		10.1056/NEJMoa022457	http://dx.doi.org/10.1056/NEJMoa022457			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637609				2023-01-03	WOS:000181465200004
J	Busch, MP; Kleinman, SH; Nemo, GJ				Busch, MP; Kleinman, SH; Nemo, GJ			Current and emerging infectious risks of blood transfusions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; SAFETY; CONTAMINATION; BACK; NAT		Blood Ctr Pacific, San Francisco, CA 94118 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Blood Syst Inc, Scottsdale, AZ USA; Westat Corp, Rockville, MD USA; Univ British Columbia, Victoria, BC, Canada; NHLBI, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; Vitalant; Westat; University of British Columbia; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Busch, MP (corresponding author), Blood Ctr Pacific, 270 Masonic Ave, San Francisco, CA 94118 USA.	mpbusch@itsa.ucsf.edu			NHLBI NIH HHS [N01-HB-97077] Funding Source: Medline; PHS HHS [47114-97082, 47114-77078, 47114-97081, 47114-97079, 47114-97080] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097077] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AuBuchon JP, 1997, TRANSFUSION, V37, P1211, DOI 10.1046/j.1537-2995.1997.37111298088055.x; Blajchman Morris A., 2001, Transfusion Medicine Reviews, V15, P108, DOI 10.1053/tm.2001.22614; Busch M, 1999, VOX SANG, V77, P67, DOI 10.1159/000031079; Busch MP, 2000, TRANSFUSION, V40, P1157, DOI 10.1046/j.1537-2995.2000.40101157.x; Busch MP, 2001, BLOOD SAFETY IN THE NEW MILLENNIUM, P33; Cannon MJ, 2001, NEW ENGL J MED, V344, P637, DOI 10.1056/NEJM200103013440904; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P879; Chamberland ME, 2002, CLIN INFECT DIS, V34, P797, DOI 10.1086/338787; CHAMBERLAND ME, 2001, AIDS REV, V3, P24; DELWART EL, IN PRESS TRANSFUSION; *DEP HLTH, CREUTZF J DIS CJD BO; Dodd RY, 2002, TRANSFUSION, V42, P509, DOI 10.1046/j.1537-2995.2002.00143.x; JACKSON BR, IN PRESS TRANSFUSION; Jacobs MR, 2001, TRANSFUSION, V41, P1331, DOI 10.1046/j.1537-2995.2001.41111331.x; Klein HG, 2000, JAMA-J AM MED ASSOC, V284, P238, DOI 10.1001/jama.284.2.238; Kleinman S, 2001, TRANSFUS MED REV, V15, P201, DOI 10.1053/tmrv.2001.24589; Kleinman SH, 2000, BEST PRACT RES CL HA, V13, P631, DOI 10.1053/beha.2000.0104; Kleinman SH, 2001, TRANSFUSION, V41, P1081, DOI 10.1046/j.1537-2995.2001.41091081.x; Kopko PM, 2002, JAMA-J AM MED ASSOC, V287, P1968, DOI 10.1001/jama.287.15.1968; Leiby DA, 1997, J INFECT DIS, V176, P1047, DOI 10.1086/516534; Leiby DA, 2001, BLOOD SAFETY IN THE NEW MILLENNIUM, P55; Mungai M, 2001, NEW ENGL J MED, V344, P1973, DOI 10.1056/NEJM200106283442603; Popovsky MA, 2000, CURR OPIN HEMATOL, V7, P402, DOI 10.1097/00062752-200011000-00014; Schmidt I, 2001, VOX SANG, V81, P228, DOI 10.1046/j.1423-0410.2001.00120.x; Sibinga CTS, 2000, TRANSFUS MED REV, V14, P269, DOI 10.1053/tm.2000.7396; Stramer SL, 2000, TRANSFUSION, V40, P1165, DOI 10.1046/j.1537-2995.2000.40101165.x; Turner ML, 2000, TRANSFUS MED REV, V14, P216, DOI 10.1053/tm.2000.7357; Weinberg PD, 2002, ANN INTERN MED, V136, P312, DOI 10.7326/0003-4819-136-4-200202190-00011	28	206	217	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	2003	289	8					959	962		10.1001/jama.289.8.959	http://dx.doi.org/10.1001/jama.289.8.959			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	648BK	12597733				2023-01-03	WOS:000181129800002
J	Way, J; Back, AL; Curtis, JR				Way, J; Back, AL; Curtis, JR			Withdrawing life support and resolution of conflict with families	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTENSIVE-CARE-UNIT; MEDICAL FUTILITY RATIONALE; CRITICALLY ILL PATIENTS; SUSTAINING TREATMENT; RESUSCITATION PREFERENCES; MECHANICAL VENTILATION; PATIENTS EXPERIENCE; END; DECISIONS; COMMUNICATION		Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Curtis, JR (corresponding author), Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, Box 359762,325 9th Ave, Seattle, WA 98104 USA.	jrc@u.washington.edu			NINR NIH HHS [R01 NR005226, R01 NR-05226-01] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR005226] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Abbott KH, 2001, CRIT CARE MED, V29, P197, DOI 10.1097/00003246-200101000-00040; American Thoracic Society, 1991, Ann Intern Med, V115, P478; Asch DA, 1996, MED CARE, V34, P103, DOI 10.1097/00005650-199602000-00002; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Azoulay E, 2000, CRIT CARE MED, V28, P3044, DOI 10.1097/00003246-200008000-00061; BERGBOMENGBERG I, 1989, CRIT CARE MED, V17, P1068, DOI 10.1097/00003246-198910000-00021; Breen CM, 2001, J GEN INTERN MED, V16, P283, DOI 10.1046/j.1525-1497.2001.00419.x; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; CAMPBELL ML, 1992, AM J CRIT CARE, V1, P152; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; *COUNC ETH JUD AFF, 1989, PRINC MED ETH; Covinsky KE, 2000, J AM GERIATR SOC, V48, pS187, DOI 10.1111/j.1532-5415.2000.tb03131.x; CURTIS J, 2001, MANAGING DEATH ICU T; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; Curtis JR, 2000, ARCH INTERN MED, V160, P1597, DOI 10.1001/archinte.160.11.1597; Curtis JR, 2002, J CRIT CARE, V17, P147, DOI 10.1053/jcrc.2002.35929; Daly B J, 1996, Am J Crit Care, V5, P331; Danis M, 1997, CRIT CARE MED, V25, P887; Eidelman LA, 1998, INTENS CARE MED, V24, P162, DOI 10.1007/s001340050539; Esteban A, 2001, INTENS CARE MED, V27, P1744, DOI 10.1007/s00134-001-1111-7; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN.K, 1996, AM J RESP CRIT CARE, V109, P852; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Fetters MD, 2001, CRIT CARE MED, V29, P921, DOI 10.1097/00003246-200105000-00001; Goold SD, 2000, JAMA-J AM MED ASSOC, V283, P909, DOI 10.1001/jama.283.7.909; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Helft PR, 2000, NEW ENGL J MED, V343, P293, DOI 10.1056/NEJM200007273430411; HICKEY M, 1990, HEART LUNG, V19, P401; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; Keenan SP, 1998, CRIT CARE MED, V26, P245, DOI 10.1097/00003246-199802000-00018; KIRKLAND L, 1994, J CLIN ETHIC, V5, P38; LANTOS JD, 1989, AM J MED, V87, P81; Lilly CM, 2000, AM J MED, V109, P469, DOI 10.1016/S0002-9343(00)00524-6; Luce JM, 1997, AM J RESP CRIT CARE, V156, P1715, DOI 10.1164/ajrccm.156.6.9705004; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MOLTER NC, 1979, HEART LUNG, V8, P332; Nelson JE, 2001, CRIT CARE MED, V29, P277, DOI 10.1097/00003246-200102000-00010; Plows CW, 1999, JAMA-J AM MED ASSOC, V281, P937; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Puchalski CM, 2000, J AM GERIATR SOC, V48, pS84, DOI 10.1111/j.1532-5415.2000.tb03146.x; Rushton C H, 1995, Am J Crit Care, V4, P112; Schneiderman LJ, 1996, ANN INTERN MED, V125, P669, DOI 10.7326/0003-4819-125-8-199610150-00007; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Somogyi-Zalud E, 2000, J AM GERIATR SOC, V48, pS140, DOI 10.1111/j.1532-5415.2000.tb03123.x; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V274, P1591; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; Truog RD, 2001, CRIT CARE MED, V29, P2332, DOI 10.1097/00003246-200112000-00017; Truog RD, 2000, NEW ENGL J MED, V342, P508, DOI 10.1056/NEJM200002173420712; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; UHLMANN RF, 1989, WESTERN J MED, V150, P705; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; Wenger NS, 2000, J AM GERIATR SOC, V48, pS44, DOI 10.1111/j.1532-5415.2000.tb03140.x; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	61	77	80	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	2002	325	7376					1342	1345		10.1136/bmj.325.7376.1342	http://dx.doi.org/10.1136/bmj.325.7376.1342			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	625LC	12468486	Green Published			2023-01-03	WOS:000179817100024
J	Mwinga, A; Nunn, A; Ngwira, B; Chintu, C; Warndorff, D; Fine, P; Darbyshire, J; Zumla, A				Mwinga, A; Nunn, A; Ngwira, B; Chintu, C; Warndorff, D; Fine, P; Darbyshire, J; Zumla, A		LUSKAR Collaboration	Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; IMMUNIZATION; HEALTHY	Background Mortality rates of HIV-infected patients treated for tuberculosis remain high. This study aimed to assess the effect on mortality of immunotherapy with single-dose SRL172 added to standard antituberculosis chemotherapy in such patients. Methods The double-blind trial enrolled 1229 patients aged 18-60 years, who had never received antiretroviral treatment and who presented with newly diagnosed, sputum-smear-positive pulmonary tuberculosis to referral centres in Lusaka, Zambia, and Karonga, Malawi. Both HIV-positive and HIV-negative patients were enrolled, to avoid stigmatisation. Participants were randomly assigned a single injection of SRL172 or matching placebo within 2 weeks of starting 8 months of antituberculosis chemotherapy and followed up for at least 12 months. The primary endpoint was time to death in the HIV-infected population. Analyses were based on 760 HIV-positive patients after exclusion of 84 patients with errors in storage of the injection, no bacteriological confirmation, or no HIV result. Findings Of 760 HIV-infected patients, 374 received SRL172 and 386 received placebo. SRL172 did not cause any serious adverse events. The follow-up rate was 88% at 12 months in both groups. Of the HIV-positive patients, 109 (19.5 per 100 person-years) of 372 assigned SRL172 and 107 (19.3 per 100 person-years) of 386 assigned placebo died. In the Cox's regression analysis, stratified by centre, the hazard ratio of deaths (SRL172/placebo) was 1.03 (95% CI 0.79-1.35). There was no evidence of benefit to the group assigned SRL172. Interpretation Immunotherapy with single-dose SRL172 as an adjunct to standard antituberculosis treatment in HIV-positive adults with pulmonary tuberculosis had no significant effect on survival or bacteriological outcome, though the treatment was safe and well tolerated.	Univ Zambia, Univ Coll London, TB HIV Res & Training Project, Lusaka, Zambia; Univ Teaching Hosp, Lusaka, Zambia; MRC, Clin Trials Unit, London, England; Karonga Prevent Study, Karonga, Malawi; London Sch Hyg & Trop Med, London WC1, England; Royal Free & UCL Med Sch, Ctr Infect Dis & Int Hlth, London, England; UCL Hosp NHS Trust, London, England	University of Zambia; University of Zambia; Medical Research Council Clinical Trials Unit; Malawi Epidemiology and Intervention Research Unit; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Zumla, A (corresponding author), UCL, Windeyer Inst Med Sci, Ctr Infect Dis & Int Hlth, Room G41,46 Cleveland St, London W1P 6DB, England.	a.zumla@ucl.ac.uk	ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735; Nunn, Andrew/0000-0002-9158-4595				AbouZeid C, 1997, INFECT IMMUN, V65, P1856, DOI 10.1128/IAI.65.5.1856-1862.1997; Ahmed Y, 1999, INT J TUBERC LUNG D, V3, P675; BAHR GM, 1990, TUBERCLE, V71, P259, DOI 10.1016/0041-3879(90)90038-A; Corlan E, 1997, RESP MED, V91, P13, DOI 10.1016/S0954-6111(97)90132-3; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Glynn JR, 1998, B WORLD HEALTH ORGAN, V76, P295; Johnson JL, 2000, J INFECT DIS, V181, P1304, DOI 10.1086/315393; LUO C, 1994, TUBERCLE LUNG DIS, V75, P110, DOI 10.1016/0962-8479(94)90039-6; Luo SJ, 2001, IEEE T COMPON PACK T, V24, P43, DOI 10.1109/6144.910801; LUO Y, 2000, CHUNG HUA CHIEH HO H, V23, P85; Marsh BJ, 1997, AM J MED SCI, V313, P377, DOI 10.1097/00000441-199706000-00011; ONYEBUJOH PC, 1995, RESP MED, V89, P199, DOI 10.1016/0954-6111(95)90248-1; Onyebujoh PC, 1999, LANCET, V354, P116, DOI 10.1016/S0140-6736(98)10448-8; Skinner MA, 1997, INFECT IMMUN, V65, P4525, DOI 10.1128/IAI.65.11.4525-4530.1997; Vacirca A., 1994, Tubercle and Lung Disease, V75, P47, DOI 10.1016/0962-8479(94)90857-5; von Reyn CF, 1998, CLIN INFECT DIS, V27, P1517, DOI 10.1086/515024; vonReyn CF, 1997, CLIN INFECT DIS, V24, P843, DOI 10.1093/clinids/24.5.843; Waddell RD, 2000, CLIN INFECT DIS, V30, pS309, DOI 10.1086/313880; Wang CC, 1998, IMMUNOLOGY, V93, P307; World Health Organization, 2002, WHOCDSTB2002295	21	62	64	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	2002	360	9339					1050	1055		10.1016/S0140-6736(02)11141-X	http://dx.doi.org/10.1016/S0140-6736(02)11141-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383985				2023-01-03	WOS:000178485200010
J	Pell, JP; Sirel, JM; Marsden, AK; Ford, I; Walker, NL; Cobbe, SM				Pell, JP; Sirel, JM; Marsden, AK; Ford, I; Walker, NL; Cobbe, SM			Potential impact of public access defibrillators on survival after out of hospital cardiopulmonary arrest: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							AMERICAN-HEART-ASSOCIATION; CARDIAC-ARREST; AIRLINE	Objective To estimate the potential impact of public access defibrillators on overall survival after out of hospital cardiac arrest. Design Retrospective cohort study using data from an electronic register. A statistical model was used to estimate the effect on survival of placing public access defibrillators at suitable or possibly suitable sites. Setting Scottish Ambulance Service. Subjects Records of all out of hospital cardiac arrests due to heart disease in Scotland in 1991-8. Main outcome measures Observed and predicted survival to discharge from hospital. Results Of 15 189 arrests, 12 004 (79.0%) occurred in sites not suitable for the location of public access defibrillators, 453 (3.0%) in sites where they may be suitable, and 2732 (18.0%) in suitable sites. Defibrillation was given in 67.9% of arrests that occurred in possibly suitable sites for locating defibrillators and in 72.9% of arrests that occurred in suitable sites. Compared with an actual overall survival of 744 (5.0%), the predicted survival with public access defibrillators ranged from 942 (6.3%) to 959 (6.5%), depending on the assumptions made regarding defibrillator coverage. Conclusions The predicted increase in survival from targeted provision of public access defibrillators is less than the increase achievable through expansion of first responder defibrillation to non-ambulance personnel, such as police or firefighters, or of bystander cardiopulmonary resuscitation. Additional resources for wide scale coverage of public access defibrillators are probably not justified by the marginal improvement in survival.	Univ Glasgow, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland; Scottish Ambulance Serv Headquarters, Edinburgh EH10 5UU, Midlothian, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow	Cobbe, SM (corresponding author), Univ Glasgow, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland.		Ford, Ian/ABE-6145-2020	Pell, Jill/0000-0002-8898-7035				CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Nichol G, 1998, CIRCULATION, V97, P1309, DOI 10.1161/01.CIR.97.13.1309; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Pell JP, 2001, BRIT MED J, V322, P1385, DOI 10.1136/bmj.322.7299.1385; *SECR STAT HLTH, 1999, SAV LIV OUR HLTH NAT; SEDGWICK ML, 1994, RESUSCITATION, V27, P55, DOI 10.1016/0300-9572(94)90022-1; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WILCOXGOK VL, 1991, MED CARE, V29, P104, DOI 10.1097/00005650-199102000-00003	11	58	61	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 7	2002	325	7363					515	517		10.1136/bmj.325.7363.515	http://dx.doi.org/10.1136/bmj.325.7363.515			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	593NJ	12217989	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000177997800015
J	Fraaije, MW; Kamerbeek, NM; Heidekamp, AJ; Fortin, R; Janssen, DB				Fraaije, MW; Kamerbeek, NM; Heidekamp, AJ; Fortin, R; Janssen, DB			The prodrug activator EtaA from Mycobacterium tuberculosis is a Baeyer-Villiger monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACIDS; 4-HYDROXYACETOPHENONE MONOOXYGENASE; DRUG ETHIONAMIDE; GENE-CLUSTER; IDENTIFICATION; SUBSTRATE; OXIDATION; SEQUENCE; CHEMOTHERAPY; BIOSYNTHESIS	EtaA is a newly identified FAD-containing monooxygenase that is responsible for activation of several thioamide prodrugs in Mycobacterium tuberculosis. It was found that purified EtaA displays a remarkably low activity with the antitubercular prodrug ethionamide. Hinted by the presence of a Baeyer-Villiger monooxygenase sequence motif in the EtaA sequence, we have been able to identify a large number of novel EtaA substrates. It was discovered that the enzyme converts a wide range of ketones to the corresponding esters or lactones via a Baeyer-Villiger reaction, indicating that EtaA represents a Baeyer-Villiger monooxygenase. With the exception of aromatic ketones (phenylacetone and benzylacetone), long-chain ketones (e.g. 2-hexanone and 2-dodecanone) also are converted. EtaA is also able to catalyze enantioselective sulfoxidation of methyl-p-tolylsulfide. Conversion of all of the identified substrates is relatively slow with typical k(cat) values of around 0.02 s(-1). The best substrate identified so far is phenylacetone (K-m=61 muM, k(cat)=0.017 s(-1)). Redox monitoring of the flavin cofactor during turnover of phenylacetone indicates that a step in the reductive half-reaction is limiting the rate of catalysis. Intriguingly, EtaA activity could be increased by one order of magnitude by adding bovine serum albumin. This reactivity and substrate acceptance-profiling study provides valuable information concerning this newly identified prodrug activator from M. tuberculosis.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Biochem Lab, NL-9747 AG Groningen, Netherlands	University of Groningen	Fraaije, MW (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Biochem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	m.w.fraaije@chem.rug.nl	Fraaije, Marco/E-8421-2014	Fraaije, Marco/0000-0001-6346-5014				Asselineau C, 2002, PROG LIPID RES, V41, P501, DOI 10.1016/S0163-7827(02)00008-5; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Baulard AR, 2000, J BIOL CHEM, V275, P28326; BRITTON LN, 1977, J BIOL CHEM, V252, P8561; Chakraborty S, 2002, J BIOL CHEM, V277, P41507, DOI 10.1074/jbc.M205432200; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; DeBarber AE, 2000, P NATL ACAD SCI USA, V97, P9677, DOI 10.1073/pnas.97.17.9677; Duetz WA, 2001, CURR OPIN BIOTECH, V12, P419, DOI 10.1016/S0958-1669(00)00237-8; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; EINARSDOTTIR GH, 1989, BIOCHEMISTRY-US, V28, P4161, DOI 10.1021/bi00436a006; Fraaije MW, 2002, FEBS LETT, V518, P43, DOI 10.1016/S0014-5793(02)02623-6; Grosset JH, 2001, LEPROSY REV, V72, P429; HARTMANS S, 1986, FEMS MICROBIOL LETT, V36, P155; Howard ST, 2002, MICROBIOL-SGM, V148, P2987, DOI 10.1099/00221287-148-10-2987; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; Kamerbeek NM, 2003, ADV SYNTH CATAL, V345, P667, DOI 10.1002/adsc.200303014; Kamerbeek NM, 2003, APPL ENVIRON MICROB, V69, P419, DOI 10.1128/AEM.69.1.419-426.2003; Kamerbeek NM, 2001, EUR J BIOCHEM, V268, P2547, DOI 10.1046/j.1432-1327.2001.02137.x; Kostichka K, 2001, J BACTERIOL, V183, P6478, DOI 10.1128/JB.183.21.6478-6486.2001; LANEELLE MA, 1970, EUR J BIOCHEM, V12, P296, DOI 10.1111/j.1432-1033.1970.tb00850.x; Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x; Liang XY, 2001, J BACTERIOL, V183, P843, DOI 10.1128/JB.183.3.843-853.2001; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; Meyer A, 2002, J BIOL CHEM, V277, P5575, DOI 10.1074/jbc.M110018200; Pattyn S R, 1978, Lepr Rev, V49, P324; Phetsuksiri B, 1999, ANTIMICROB AGENTS CH, V43, P1042, DOI 10.1128/AAC.43.5.1042; POULSEN LL, 1995, CHEM-BIOL INTERACT, V96, P57, DOI 10.1016/0009-2797(94)03583-T; Rivera-Marrero CA, 1998, MICROB PATHOGENESIS, V25, P307, DOI 10.1006/mpat.1998.0235; RYERSON CC, 1982, BIOCHEMISTRY-US, V21, P2644, DOI 10.1021/bi00540a011; Sheng DW, 2001, BIOCHEMISTRY-US, V40, P11156, DOI 10.1021/bi011153h; Souter A, 2000, J CHEM TECHNOL BIOT, V75, P933, DOI 10.1002/1097-4660(200010)75:10<933::AID-JCTB301>3.0.CO;2-C; Suh JK, 2000, ARCH BIOCHEM BIOPHYS, V381, P317, DOI 10.1006/abbi.2000.1965; THIERRY D, 1993, J CLIN MICROBIOL, V31, P1048, DOI 10.1128/JCM.31.5.1048-1054.1993; TORIYAMA S, 1982, BIOCHIM BIOPHYS ACTA, V712, P427, DOI 10.1016/0005-2760(82)90363-0; Vannelli TA, 2002, J BIOL CHEM, V277, P12824, DOI 10.1074/jbc.M110751200; *WHO IUATLD GLOB P, 2002, 2 WHOIUATLD GLOB PRO; Yu J, 2000, APPL MICROBIOL BIOT, V53, P583, DOI 10.1007/s002530051660; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	38	123	128	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3354	3360		10.1074/jbc.M307770200	http://dx.doi.org/10.1074/jbc.M307770200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14610090	Green Published, hybrid			2023-01-03	WOS:000188379600027
J	Sigurdson, AJ; Jones, IM				Sigurdson, AJ; Jones, IM			Second cancers after radiotherapy: any evidence for radiation-induced genomic instability?	ONCOGENE			English	Article						second primary cancer; radiation therapy; genomic instability; chromosomal instability; review	DNA-REPAIR GENES; THERAPY-RELATED LEUKEMIA; HODGKINS-DISEASE; IONIZING-RADIATION; LUNG-CANCER; P53 MUTATIONS; SOLID TUMORS; MICROSATELLITE INSTABILITY; CHROMOSOMAL-ABERRATIONS; MARROW TRANSPLANTATION	Do second primary cancers in humans arise from radiation-induced somatic genomic instability after radiotherapy for the first malignancy? The amount of truly pertinent human information on this issue is sparse, leading to the conclusion that we cannot confirm or refute that instability induction by radiation is involved. However, the in vitro findings of radiation-induced genomic instability through bystander effects or increased mutation rates in cell progeny of apparently normal but irradiated cells are provocative and their transferability to human in vivo biology deserves further investigation. We describe possible animal and human studies to stimulate ideas, but the collaborative commitment of multiple large institutions to tumor tissue procurement and retrieval will be essential. In addition, detecting the temporal progression of genomic instability and identifying the salient genetic events as being radiation-induced will be pivotal. Execution of some of the studies suggested is not possible now, but applying next-generation methods could bring the concepts to fruition. As nearly one in 10 cancer diagnoses are second (or higher) malignancies, it is important to understand the contribution of radiotherapy to second cancer induction and pursue well-coordinated efforts to determine the role of induced genomic instability.	NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Sigurdson, AJ (corresponding author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, 6120 Execut Blvd,EPS 7092,MSC 7238, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01CP010131, ZIACP010131] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTER BP, 1998, HEMATOLOGY INFANCY C, V1, P259; Backlund MG, 2001, CANCER RES, V61, P6577; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; Bauchinger M, 1998, MUTAT RES-FUND MOL M, V404, P89, DOI 10.1016/S0027-5107(98)00098-0; Behrens C, 2000, CANCER EPIDEM BIOMAR, V9, P1027; BenYehuda D, 1996, BLOOD, V88, P4296; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; BERWICK M, 2002, BIOMARKERS ENV ASS D, P84; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; BOICE JD, 1988, RADIAT RES, V116, P3, DOI 10.2307/3577477; BOICE JD, 1987, J NATL CANCER I, V79, P1295; Boice Jr JD, 1996, CANC EPIDEMIOLOGY PR, P319; BOIVIN JF, 1995, JNCI-J NATL CANCER I, V87, P732, DOI 10.1093/jnci/87.10.732; Brat DJ, 1999, AM J PATHOL, V154, P1431, DOI 10.1016/S0002-9440(10)65397-7; Chauveinc L, 1999, CANCER GENET CYTOGEN, V114, P1, DOI 10.1016/S0165-4608(99)00038-2; Chen Z, 2002, AM J MED GENET, V115, P130, DOI 10.1002/ajmg.10689; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; de Vathaire F, 1999, ARCH INTERN MED, V159, P2713, DOI 10.1001/archinte.159.22.2713; DeBenedetti VMG, 1996, CANCER EPIDEM BIOMAR, V5, P93; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; Dores GM, 2002, J CLIN ONCOL, V20, P3484, DOI 10.1200/JCO.2002.09.038; Fang NY, 2003, P NATL ACAD SCI USA, V100, P5372, DOI 10.1073/pnas.0831102100; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Finnon P, 1999, INT J RADIAT BIOL, V75, P1215, DOI 10.1080/095530099139368; Friedberg EC, 2003, DNA REPAIR, V2, P501, DOI 10.1016/S1568-7864(03)00005-3; Gafanovich A, 1999, CANCER-AM CANCER SOC, V85, P504; Gilbert ES, 2003, RADIAT RES, V159, P161, DOI 10.1667/0033-7587(2003)159[0161:LCATFH]2.0.CO;2; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Horiike S, 1999, LEUKEMIA, V13, P1235, DOI 10.1038/sj.leu.2401466; Inskip PD, 1999, MULTIPLE PRIMARY CANCERS, P91; KALDOR JM, 1992, INT J CANCER, V52, P677, DOI 10.1002/ijc.2910520502; KLEINERMAN RA, 1990, RADIAT RES, V123, P93, DOI 10.2307/3577663; Kodama Y, 2001, RADIAT RES, V156, P337, DOI 10.1667/0033-7587(2001)156[0337:SCAIAB]2.0.CO;2; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; MENDELSOHN ML, 1995, MODELING BIOL EFFECT, P185; Mertens F, 2000, CANCER GENET CYTOGEN, V116, P89, DOI 10.1016/S0165-4608(99)00105-3; Mohrenweiser HW, 2003, MUTAT RES-FUND MOL M, V526, P93, DOI 10.1016/S0027-5107(03)00049-6; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Platz EA, 2000, INT J RADIAT BIOL, V76, P955, DOI 10.1080/09553000050050963; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; Ronen A, 2001, ENVIRON MOL MUTAGEN, V37, P241, DOI 10.1002/em.1033; Shoshan Y, 2000, J NEUROPATH EXP NEUR, V59, P614, DOI 10.1093/jnen/59.7.614; SWERDLOW AJ, 1992, BRIT MED J, V304, P1137, DOI 10.1136/bmj.304.6835.1137; Tarkkanen M, 2001, CANCER, V92, P1992, DOI 10.1002/1097-0142(20011001)92:7<1992::AID-CNCR1719>3.0.CO;2-2; Travis LB, 2000, JNCI-J NATL CANCER I, V92, P1165, DOI 10.1093/jnci/92.14.1165; Travis LB, 2002, JNCI-J NATL CANCER I, V94, P182, DOI 10.1093/jnci/94.3.182; TUCKER JD, 1993, INT J RADIAT BIOL, V64, P27, DOI 10.1080/09553009314551081; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; TUCKER MA, 1991, CANCER RES, V51, P2885; Ullrich RL, 1998, INT J RADIAT BIOL, V74, P747, DOI 10.1080/095530098141023; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P312, DOI 10.1200/JCO.1994.12.2.312; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Yu YJ, 2001, CANCER RES, V61, P1820; Zablotska LB, 2003, CANCER, V97, P1404, DOI 10.1002/cncr.11214	61	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7018	7027		10.1038/sj.onc.1206989	http://dx.doi.org/10.1038/sj.onc.1206989			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557806				2023-01-03	WOS:000185903900006
J	Manson, JE; Hsia, J; Johnson, KC; Rossouw, JE; Assaf, AR; Lasser, NL; Trevisan, M; Black, HR; Heckbert, SR; Detrano, R; Strickland, OL; Wong, ND; Crouse, JR; Stein, E; Cushman, M; Alving, B; Rossouw, JE; Pottern, L; Ludlam, S; McGowan, JA; Prentice, R; Anderson, G; LaCroix, A; Patterson, R; McTiernan, A; Cochrane, B; Hunt, J; Tinker, L; Kooperberg, C; McIntosh, M; Wang, CY; Chen, C; Bowen, D; Kristal, A; Stanford, J; Urban, N; Weiss, N; White, E; Shumaker, S; Rautaharju, P; Prineas, R; Naughton, M; Stein, E; Laskarzewski, P; Cummings, S; Nevitt, M; Dockrell, M; Harnack, L; Cammarata, F; Lindenfelser, S; Psaty, B; Heckbert, S; Wassertheil-Smoller, S; Frishman, W; Wylie-Rosett, J; Barad, D; Freeman, R; Hays, J; Young, R; Anderson, J; Lithgow, S; Bray, P; Manson, J; Buring, J; Gaziano, JM; Rexrode, K; Chae, C; Assaf, AR; Carleton, R; Wheeler, C; Eaton, C; Cyr, M; Phillips, L; Pedersen, M; Strickland, O; Huber, M; Porter, V; Beresford, SAA; Taylor, VM; Woods, NF; Henderson, M; Kestin, M; Hsia, J; Gaba, N; Ascensao, J; Laowattana, S; Chlebowski, R; Detrano, R; Nelson, A; Heiner, J; Marshall, J; Ritenbaugh, C; Valanis, B; Elmer, P; Stevens, V; Karanja, N; Caan, B; Sidney, S; Bailey, G; Hirata, J; Kotchen, JM; Barnabei, V; Kotchen, TA; Gilligan, MAC; Neuner, J; Howard, BV; Adams-Campbell, L; Passaro, M; Rainford, M; Agurs-Collins, T; Van Horn, L; Greenland, P; Khandekar, J; Liu, K; Rosenberg, C; Black, H; Powell, L; Mason, E; Stefanick, ML; Hlatky, MA; Chen, B; Stafford, RS; Giudice, LC; Lane, D; Granek, I; Lawson, W; San Roman, G; Messina, C; Jackson, R; Harris, R; Frid, D; Mysiw, WJ; Blumenfeld, M; Lewis, CE; Oberman, A; Fouad, MN; Shikany, JM; West, DS; Bassford, T; Mattox, J; Ko, M; Lohman, T; Trevisan, M; Wactawski-Wende, J; Graham, S; Chang, J; Smit, E; Robbins, J; Yasmeen, S; Lindfors, K; Stern, J; Hubbell, A; Frank, G; Wong, N; Greep, N; MoOnk, B; Judd, H; Heber, D; Elashoff, R; Langer, RD; Criqui, MH; Talavera, GT; Garland, CF; Hanson, RE; Gass, M; Wernke, S; Watts, N; Limacher, M; Perri, M; Kaunitz, A; Williams, RS; Brinson, Y; Curb, D; Petrovitch, H; Rodriguez, B; Masaki, K; Sharma, S; Wallace, R; Torner, J; Johnson, S; Snetselaar, L; VanVoorhis, B; Ockene, I; Yood, R; Aronson, P; Lasser, N; Hymowitz, N; Lasser, V; Safford, M; Kostis, J; O'Sullivan, MJ; Parker, L; Estape, R; Fernandez, D; Margolis, KL; Grimm, RH; Hunninghake, DB; LaValleur, J; Hall, KM; Brunner, R; St Jeor, S; Graettinger, W; Oujevolk, V; Heiss, G; Haines, P; Ontjes, D; Sueta, C; Wells, E; Kuller, L; Caggiula, A; Cauley, J; Berga, S; Milas, NC; Johnson, KC; Satterfield, S; Ke, TW; Vile, J; Tylavsky, F; Brzyski, R; Schenken, R; Trabal, J; Rodriguez-Sifuentes, M; Mouton, C; Allen, C; Laube, D; McBride, P; Mares-Perlman, J; Loevinger, B; Burke, G; Crouse, R; Parsons, L; Vitolins, M; Hendrix, S; Simon, M; McNeeley, G; Gordon, P; Makela, P				Manson, JE; Hsia, J; Johnson, KC; Rossouw, JE; Assaf, AR; Lasser, NL; Trevisan, M; Black, HR; Heckbert, SR; Detrano, R; Strickland, OL; Wong, ND; Crouse, JR; Stein, E; Cushman, M; Alving, B; Rossouw, JE; Pottern, L; Ludlam, S; McGowan, JA; Prentice, R; Anderson, G; LaCroix, A; Patterson, R; McTiernan, A; Cochrane, B; Hunt, J; Tinker, L; Kooperberg, C; McIntosh, M; Wang, CY; Chen, C; Bowen, D; Kristal, A; Stanford, J; Urban, N; Weiss, N; White, E; Shumaker, S; Rautaharju, P; Prineas, R; Naughton, M; Stein, E; Laskarzewski, P; Cummings, S; Nevitt, M; Dockrell, M; Harnack, L; Cammarata, F; Lindenfelser, S; Psaty, B; Heckbert, S; Wassertheil-Smoller, S; Frishman, W; Wylie-Rosett, J; Barad, D; Freeman, R; Hays, J; Young, R; Anderson, J; Lithgow, S; Bray, P; Manson, J; Buring, J; Gaziano, JM; Rexrode, K; Chae, C; Assaf, AR; Carleton, R; Wheeler, C; Eaton, C; Cyr, M; Phillips, L; Pedersen, M; Strickland, O; Huber, M; Porter, V; Beresford, SAA; Taylor, VM; Woods, NF; Henderson, M; Kestin, M; Hsia, J; Gaba, N; Ascensao, J; Laowattana, S; Chlebowski, R; Detrano, R; Nelson, A; Heiner, J; Marshall, J; Ritenbaugh, C; Valanis, B; Elmer, P; Stevens, V; Karanja, N; Caan, B; Sidney, S; Bailey, G; Hirata, J; Kotchen, JM; Barnabei, V; Kotchen, TA; Gilligan, MAC; Neuner, J; Howard, BV; Adams-Campbell, L; Passaro, M; Rainford, M; Agurs-Collins, T; Van Horn, L; Greenland, P; Khandekar, J; Liu, K; Rosenberg, C; Black, H; Powell, L; Mason, E; Stefanick, ML; Hlatky, MA; Chen, B; Stafford, RS; Giudice, LC; Lane, D; Granek, I; Lawson, W; San Roman, G; Messina, C; Jackson, R; Harris, R; Frid, D; Mysiw, WJ; Blumenfeld, M; Lewis, CE; Oberman, A; Fouad, MN; Shikany, JM; West, DS; Bassford, T; Mattox, J; Ko, M; Lohman, T; Trevisan, M; Wactawski-Wende, J; Graham, S; Chang, J; Smit, E; Robbins, J; Yasmeen, S; Lindfors, K; Stern, J; Hubbell, A; Frank, G; Wong, N; Greep, N; MoOnk, B; Judd, H; Heber, D; Elashoff, R; Langer, RD; Criqui, MH; Talavera, GT; Garland, CF; Hanson, RE; Gass, M; Wernke, S; Watts, N; Limacher, M; Perri, M; Kaunitz, A; Williams, RS; Brinson, Y; Curb, D; Petrovitch, H; Rodriguez, B; Masaki, K; Sharma, S; Wallace, R; Torner, J; Johnson, S; Snetselaar, L; VanVoorhis, B; Ockene, I; Yood, R; Aronson, P; Lasser, N; Hymowitz, N; Lasser, V; Safford, M; Kostis, J; O'Sullivan, MJ; Parker, L; Estape, R; Fernandez, D; Margolis, KL; Grimm, RH; Hunninghake, DB; LaValleur, J; Hall, KM; Brunner, R; St Jeor, S; Graettinger, W; Oujevolk, V; Heiss, G; Haines, P; Ontjes, D; Sueta, C; Wells, E; Kuller, L; Caggiula, A; Cauley, J; Berga, S; Milas, NC; Johnson, KC; Satterfield, S; Ke, TW; Vile, J; Tylavsky, F; Brzyski, R; Schenken, R; Trabal, J; Rodriguez-Sifuentes, M; Mouton, C; Allen, C; Laube, D; McBride, P; Mares-Perlman, J; Loevinger, B; Burke, G; Crouse, R; Parsons, L; Vitolins, M; Hendrix, S; Simon, M; McNeeley, G; Gordon, P; Makela, P		Women's Hlth Initiative Investigat	Estrogen plus progestin and the risk of coronary heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE-REPLACEMENT THERAPY; ESTROGEN/PROGESTIN INTERVENTIONS PEPI; RANDOMIZED CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR-DISEASE; CLINICAL-TRIAL; ATHEROSCLEROSIS; PREVENTION; INFLAMMATION; PROGRESSION	BACKGROUND: Recent randomized clinical trials have suggested that estrogen plus progestin does not confer cardiac protection and may increase the risk of coronary heart disease (CHD). In this report, we provide the final results with regard to estrogen plus progestin and CHD from the Women's Health Initiative (WHI). METHODS: The WHI included a randomized primary-prevention trial of estrogen plus progestin in 16,608 postmenopausal women who were 50 to 79 years of age at base line. Participants were randomly assigned to receive conjugated equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo. The primary efficacy outcome of the trial was CHD (nonfatal myocardial infarction or death due to CHD). RESULTS: After a mean follow-up of 5.2 years (planned duration, 8.5 years), the data and safety monitoring board recommended terminating the estrogen-plus-progestin trial because the overall risks exceeded the benefits. Combined hormone therapy was associated with a hazard ratio for CHD of 1.24 (nominal 95 percent confidence interval, 1.00 to 1.54; 95 percent confidence interval after adjustment for sequential monitoring, 0.97 to 1.60). The elevation in risk was most apparent at one year (hazard ratio, 1.81 [95 percent confidence interval, 1.09 to 3.01]). Although higher base-line levels of low-density lipoprotein cholesterol were associated with an excess risk of CHD among women who received hormone therapy, higher base-line levels of C-reactive protein, other biomarkers, and other clinical characteristics did not significantly modify the treatment-related risk of CHD. CONCLUSIONS: Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use. This treatment should not be prescribed for the prevention of cardiovascular disease.	Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; George Washington Univ, Dept Med, Washington, DC USA; Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA; NHLBI, Program Off, Bethesda, MD 20892 USA; Brown Univ, Mem Hosp, Sch Med, Pawtucket, RI USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Prevent Cardiol Program, Newark, NJ 07103 USA; Univ Buffalo, Dept Social & Prevent Med, Buffalo, NY USA; Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Calif Los Angeles, Div Cardiol, Harbor Res & Educ Inst, Torrance, CA USA; Emory Univ, Woodruff Sch Nursing, Atlanta, GA 30322 USA; Univ Calif Irvine, Heart Dis Prevent Program, Irvine, CA 92717 USA; Wake Forest Univ, Dept Med, Winston Salem, NC 27109 USA; Med Res Labs Int, Highland Hts, KY USA; Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; George Washington University; University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Brown University; Rutgers State University New Brunswick; Rutgers State University Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Rush University; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Emory University; University of California System; University of California Irvine; Wake Forest University; University of Vermont; University of Vermont; Harvard University; Harvard Medical School	Manson, JE (corresponding author), Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth Ave, Boston, MA 02215 USA.		Wactawski-Wende, Jean/AGH-5457-2022; Kristal, Alan/A-8779-2008; Kaunitz, Andrew/AAL-8448-2020; Sueta, Carla/AAH-8100-2021; Mysiw, Walter/E-3724-2011; Cauley, Jane A/N-4836-2015; Barad, David/AAF-4332-2021; West, Delia Smith/GWV-5839-2022; Greenland, Philip/ABD-5528-2021; Rexrode, Kathryn M/I-1177-2018; Stafford, Randall/F-3974-2017	Wactawski-Wende, Jean/0000-0003-3096-9595; Cauley, Jane A/0000-0003-0752-4408; West, Delia Smith/0000-0002-4375-2785; Stafford, Randall/0000-0003-1805-1271				Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; CHAE CU, 1999, CLIN TRIALS CARDIOVA, P399; Cherry N, 2002, LANCET, V360, P2001; Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x; COX DR, 1972, J R STAT SOC B, V34, P187; Cushman M, 1999, ARTERIOSCL THROM VAS, V19, P893, DOI 10.1161/01.ATV.19.4.893; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; *ESTR PROG INT PEP, 1995, JAMA-J AM MED ASSOC, V274, P1676; Furberg CD, 2002, CIRCULATION, V105, P917, DOI 10.1161/hc0802.104280; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 2002, JAMA-J AM MED ASSOC, V288, P1064; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Manson JE, 2001, NEW ENGL J MED, V345, P34, DOI 10.1056/NEJM200107053450106; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; *N AM MEN SOC NAMS, 2002, REP NAMS ADV PAN POS; Pilon D, 2001, OBSTET GYNECOL, V97, P97, DOI 10.1016/S0029-7844(00)01104-2; Psaty BM, 2001, JAMA-J AM MED ASSOC, V285, P906, DOI 10.1001/jama.285.7.906; Rautaharju PM, 1998, J ELECTROCARDIOL, V31, P157, DOI 10.1016/S0022-0736(98)90132-7; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shlipak MG, 2000, JAMA-J AM MED ASSOC, V283, P1845, DOI 10.1001/jama.283.14.1845; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; 2002, JAMA, V288, P2819	34	1511	1555	1	73	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 7	2003	349	6					523	534		10.1056/NEJMoa030808	http://dx.doi.org/10.1056/NEJMoa030808			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	708JL	12904517				2023-01-03	WOS:000184563500003
J	Hack, M				Hack, M			Uses of error - Continuity of neonatal care	LANCET			English	Editorial Material									Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Hack, M (corresponding author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, 11,100 Euclid Ave, Cleveland, OH 44106 USA.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1809	1809		10.1016/S0140-6736(03)13406-X	http://dx.doi.org/10.1016/S0140-6736(03)13406-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781552				2023-01-03	WOS:000183074800022
J	Greenspan, SL; Resnick, NM; Parker, RA				Greenspan, SL; Resnick, NM; Parker, RA			Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN/PROGESTIN REPLACEMENT; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; VERTEBRAL FRACTURES; NONVERTEBRAL FRACTURES; ESTROGEN REPLACEMENT; DISEASE OUTCOMES; RISK; HEART; OSTEOPOROSIS	Context Therapy with individual antiresorptive agents has been shown to be effective for prevention and treatment of postmenopausal osteoporosis, but whether combination antiresorptive therapy with hormones and bisphosphonates is safe or efficacious or how these agents compare in elderly women is unknown. Objective To determine whether hormone replacement and the bisphosphonate alendronate sodium in combination are efficacious and safe, and how they compare with monotherapy in community-dwelling elderly women. Design Randomized, double-blind, placebo-controlled, clinical trial. Setting and Participants Five hundred seventy-three community-dwelling women age 65 years or older were screened: 485 completed screening and 373 (aged 65 to 90 years) were randomized following a 3-month, open-label, run-in phase with hormone replacement and alendronate placebo. The trial was conducted at a single academic US medical center from January 1996 to May 2001. Interventions Participants were randomly assigned in a 2 x 2 factorial design to receive hormone replacement (conjugated equine estrogen, 0.625 mg/d, with or without medroxyprogesterone, 2.5 mg/d) and alendronate, 10 mg daily, both agents, or neither. All participants received calcium and vitamin D supplements. Main Outcome Measures Annualized change in bone mineral density of the hip and spine and occurrence of adverse events. Results Bone mineral density at 3 years was significantly greater at all femoral and vertebral sites in women treated with combination therapy than with monotherapy, with mean (SD) increases of 5.9% (3.8) at the total hip, 10.4% (5.4) at the posteroanterior lumbar spine, and 11.8% (6.8) at the lateral lumbar spine. Mean (SD) increases in bone mass at the hip in women treated with alendronate alone were significantly greater than in those treated with hormone replacement therapy alone (4.2% [3.8] vs 3.0% [4.9]; P<.05, respectively), and alendronate resulted in more responders to therapy. All therapies were well tolerated and participant retention was 90% at 3 years. Conclusions Combination therapy with hormone replacement and alendronate was efficacious and well tolerated in this cohort. Alendronate was superior to hormone replacement, and combination therapy was superior to either therapy alone. Combination therapy may represent an option for women with more severe disease or for those who have failed to achieve an adequate response to monotherapy.	Univ Pittsburgh, Med Ctr, Div Endocrinol & Metab, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Div Geriatr Med, Pittsburgh, PA USA; Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard T.H. Chan School of Public Health	Greenspan, SL (corresponding author), Osteoporosis Prevent & Treatment Ctr, Kaufmann Med Bldg,Suite 1110,3471 5th Ave, Pittsburgh, PA 15213 USA.	griffithsd@msx.dept-med.pitt.edu			NCRR NIH HHS [M01-RR1032] Funding Source: Medline; NIA NIH HHS [R01 AG13069-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013069] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002-9343(01)01124-X; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; DAWSONHUGHES B, 1987, AM J CLIN NUTR, V46, P685, DOI 10.1093/ajcn/46.4.685; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Faulkner KG, 2000, J BONE MINER RES, V15, P183, DOI 10.1359/jbmr.2000.15.2.183; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Greendale GA, 2000, ARCH INTERN MED, V160, P3065, DOI 10.1001/archinte.160.20.3065; Greenspan SL, 1998, J BONE MINER RES, V13, P1431, DOI 10.1359/jbmr.1998.13.9.1431; Greenspan SL, 1996, CALCIFIED TISSUE INT, V58, P409, DOI 10.1007/BF02509439; GREENSPAN SL, 1994, J BONE MINER RES, V9, P1959, DOI 10.1002/jbmr.5650091216; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Harris ST, 2001, J CLIN ENDOCR METAB, V86, P1890, DOI 10.1210/jc.86.5.1890; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Kuchel GA, 2001, J WOMEN HEALTH GEN-B, V10, P109, DOI 10.1089/152460901300039449; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LOOKER AC, 1995, J BONE MINER RES, V10, P796; Lu Y, 1996, J BONE MINER RES, V11, P626; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; *NIH CONS, 2000, OSTEOPOROSIS REP, V16, P1; Palomba S, 2002, J CLIN ENDOCR METAB, V87, P1502, DOI 10.1210/jc.87.4.1502; Regan MM, 2001, J WOMEN HEALTH GEN-B, V10, P343, DOI 10.1089/152460901750269661; Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Villareal DT, 2001, JAMA-J AM MED ASSOC, V286, P815, DOI 10.1001/jama.286.7.815; Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231; Wilson PWF, 2003, ANN INTERN MED, V138, P69, DOI 10.7326/0003-4819-138-1-200301070-00015	41	89	102	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2003	289	19					2525	2533		10.1001/jama.289.19.2525	http://dx.doi.org/10.1001/jama.289.19.2525			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680KL	12759324	Bronze			2023-01-03	WOS:000182976500021
J	Saal, D; Dong, Y; Bonci, A; Malenka, RC				Saal, D; Dong, Y; Bonci, A; Malenka, RC			Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons	NEURON			English	Article							VENTRAL TEGMENTAL AREA; LONG-TERM POTENTIATION; GLUCOCORTICOID RECEPTORS; ADDICTION; PLASTICITY; COCAINE; GLUTAMATE; NEUROBIOLOGY; HIPPOCAMPUS; MECHANISMS	Drug seeking and drug self-administration in both animals and humans can be triggered by drugs of abuse themselves or by stressful events. Here, we demonstrate that in vivo administration of drugs of abuse with different molecular mechanisms of action as well as acute stress both increase strength at excitatory synapses on midbrain dopamine neurons. Psychoactive drugs with minimal abuse potential do not cause this change. The synaptic effects of stress, but not of cocaine, are blocked by the glucocorticoid receptor antagonist RU486. These results suggest that plasticity at excitatory synapses on dopamine neurons may be a key neural adaptation contributing to addiction and its interactions with stress and thus may be an attractive therapeutic target for reducing the risk of addiction.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Nancy Pritzker Lab, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Dept Neurol, Ernest Gallo Clin & Res Ctr, San Francisco, CA 94110 USA; Univ Calif San Francisco, Wheeler Ctr Neurobiol Addict, San Francisco, CA 94110 USA	Stanford University; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco	Malenka, RC (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Nancy Pritzker Lab, Palo Alto, CA 94304 USA.		Dong, Yan/A-4154-2016	Dong, Yan/0000-0003-0016-9028				Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Cadepond F, 1997, ANNU REV MED, V48, P129; Cameron DL, 1997, NEUROSCIENCE, V77, P155, DOI 10.1016/S0306-4522(96)00444-7; Carlezon WA, 2002, TRENDS NEUROSCI, V25, P610, DOI 10.1016/S0166-2236(02)02289-0; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; Douma BRK, 1998, PSYCHONEUROENDOCRINO, V23, P33, DOI 10.1016/S0306-4530(97)00091-7; Everitt BJ, 2002, J NEUROSCI, V22, P3312; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; Georges F, 2002, J NEUROSCI, V22, P5173, DOI 10.1523/JNEUROSCI.22-12-05173.2002; HEIKINHEIMO O, 1993, ANN MED, V25, P71, DOI 10.3109/07853899309147861; Horger BA, 1996, CRIT REV NEUROBIOL, V10, P395; Huber JD, 2001, PHARMACOL BIOCHEM BE, V69, P451, DOI 10.1016/S0091-3057(01)00521-4; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Kelley AE, 2002, J NEUROSCI, V22, P3306; Kim JJ, 1996, P NATL ACAD SCI USA, V93, P4750, DOI 10.1073/pnas.93.10.4750; Koob GF, 1996, MOL PSYCHIATR, V1, P186; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kullmann DM, 2000, PROG BRAIN RES, V125, P339; Lu WX, 2002, NEUROPSYCHOPHARMACOL, V26, P1, DOI 10.1016/S0893-133X(01)00272-X; Marinelli M, 1998, P NATL ACAD SCI USA, V95, P7742, DOI 10.1073/pnas.95.13.7742; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Nestler E.J., 2015, MOL NEUROPHARMACOLOG; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Neuhoff H, 2002, J NEUROSCI, V22, P1290, DOI 10.1523/JNEUROSCI.22-04-01290.2002; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; Piazza PV, 1998, TRENDS PHARMACOL SCI, V19, P67, DOI 10.1016/S0165-6147(97)01115-2; PIERETTI S, 1991, GEN PHARMACOL, V22, P929, DOI 10.1016/0306-3623(91)90232-U; Robinson TE, 2000, ADDICTION, V95, pS91; Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2; SHORS TJ, 1989, SCIENCE, V244, P224, DOI 10.1126/science.2704997; Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077; Waelti P, 2001, NATURE, V412, P43, DOI 10.1038/35083500; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; Xu L, 1997, NATURE, V387, P497, DOI 10.1038/387497a0; Xu L, 1998, P NATL ACAD SCI USA, V95, P3204, DOI 10.1073/pnas.95.6.3204; Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699	36	817	837	0	89	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0896-6273			NEURON	Neuron	FEB 20	2003	37	4					577	582		10.1016/S0896-6273(03)00021-7	http://dx.doi.org/10.1016/S0896-6273(03)00021-7			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	648EH	12597856	Bronze			2023-01-03	WOS:000181136500007
J	Wetzel, MS; Kaptchuk, TJ; Haramati, A; Eisenberg, DM				Wetzel, MS; Kaptchuk, TJ; Haramati, A; Eisenberg, DM			Complementary and alternative medical therapies: Implications for medical education	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; JOHNS WORT; SCHOOLS; TRENDS; CARE	Increased use of complementary and alternative medicine (CAM) has made it imperative that these topics be included in medical education from the preclinical years through residency and beyond. There has been progress in this direction in recent years, with a steady increase in the number of medical schools that include CAM therapies in their curricula. There remains, however, a lack of clear goals and concrete suggestions for implementing these changes. This article examines the questions that arise when medical educators consider how to incorporate CAM therapies as an integral part of the medical curriculum. It offers practical suggestions for finding time in an already packed curriculum, getting started, including faculty and students in the process, and sustaining the initiative with the necessary administrative and institutional support.	Harvard Univ, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Georgetown Univ, Sch Med, Washington, DC 20057 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Georgetown University	Wetzel, MS (corresponding author), Harvard Univ, Sch Med, 10 Shattuck St,Suite 612, Boston, MA 02115 USA.		Haramati, Aviad/ABB-1587-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR 43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*AM ASS MED COLL, 1998, LEARN OBJ MED STUD E, V6, P8; *AM MED ASS COUNC, 1997, ENC MED STUD ED COMP; Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Barzansky B, 2000, JAMA-J AM MED ASSOC, V284, P1114, DOI 10.1001/jama.284.9.1114; Berman BM, 2001, BRIT MED J, V322, P121, DOI 10.1136/bmj.322.7279.121; Carlston M, 1997, Fam Med, V29, P559; Caspi O, 2000, ARCH INTERN MED, V160, P3193, DOI 10.1001/archinte.160.21.3193; Coulter I, 1998, ALTERN THER HEALTH M, V4, P64; DESAINTONGE DMC, 1994, LANCET, V344, P995, DOI 10.1016/S0140-6736(94)91647-0; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Frenkel M, 2001, ACAD MED, V76, P251, DOI 10.1097/00001888-200103000-00012; *HARV MED SCH CTR, 2000, WOM HLTH 10 CURR THE, V2, P1; *HARV MED SCH OFF, 2000, NEW HMS DIV PROB COM; JENSEN CB, 1997, ALTERN COMPLEMENT TH, V3, P276; Kligler B, 2000, FAM MED, V32, P30; Laken M P, 1995, J Altern Complement Med, V1, P93, DOI 10.1089/acm.1995.1.93; Marshall E, 2000, SCIENCE, V288, P1571, DOI 10.1126/science.288.5471.1571; MUEHSAM PA, 2000, GEA CORRESPONDENT, V13, P8; MUEHSAM PA, 1999, GEA CORRESPONDENT, V12, P13; *NAT CTR COMPL ALT, 1999, REQ PROP CAM ED GRAN; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; OH VMS, 1994, BRIT MED J, V309, P69, DOI 10.1136/bmj.309.6947.69; Pelletier KR, 1999, AM J HEALTH PROMOT, V14, P125, DOI 10.4278/0890-1171-14.2.125; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; SLOAN DA, 1995, ANN SURG, V222, P735, DOI 10.1097/00000658-199512000-00007; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784	30	106	109	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 4	2003	138	3					191	196		10.7326/0003-4819-138-3-200302040-00011	http://dx.doi.org/10.7326/0003-4819-138-3-200302040-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646DB	12558358				2023-01-03	WOS:000181018600005
J	Manciu, L; Chang, XB; Buyse, F; Hou, YX; Gustot, A; Riordan, JR; Ruysschaert, JM				Manciu, L; Chang, XB; Buyse, F; Hou, YX; Gustot, A; Riordan, JR; Ruysschaert, JM			Intermediate structural states involved in MRP1-mediated drug transport - Role of glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; TRANSFORM INFRARED-SPECTROSCOPY; TERTIARY STRUCTURE CHANGES; CONJUGATE EXPORT PUMP; AMINO-ACID RESIDUE; TUMOR-CELL-LINES; P-GLYCOPROTEIN; ATPASE ACTIVITY; CONFORMATIONAL-CHANGES; SECONDARY STRUCTURE	Human multidrug resistance protein 1 (MRP1) is a member of the ATP-binding cassette transporter family and transports chemotherapeutic drugs as well as diverse organic anions such as leukotriene LTC4. The transport of chemotherapeutic drugs requires the presence of reduced GSH. By using hydrogen/deuterium exchange kinetics and limited trypsin digestion, the structural changes associated with each step of the drug transport process are analyzed. Purified MRP1 is reconstituted into lipid vesicles with an inside-out orientation, exposing its cytoplasmic region to the external medium. The resulting proteoliposomes have been shown previously to exhibit both ATP-dependent drug transport and drug-stimulated ATPase activity. Our results show that during GSH-dependent drug transport, MRP1 does not undergo secondary structure changes but only modifications in its accessibility toward the external environment. Drug binding induces a restructuring of MRP1 membrane-embedded domains that does not affect the cytosolic domains, including the nucleotide binding domains, responsible for ATP hydrolysis. This demonstrates that drug binding to MRP1 is not sufficient to propagate an allosteric signal between the membrane and the cytosolic domains. On the other hand, GSH binding induces a conformational change that affects the structural organization of the cytosolic domains and enhances ATP binding and/or hydrolysis suggesting that GSH-mediated conformational changes are required for the coupling between drug transport and ATP hydrolysis. Following ATP binding, the protein adopts a conformation characterized by a decreased stability and/or an increased accessibility toward the aqueous medium. No additional change in the accessibility toward the solvent and/or the stability of this specific conformational state and no change of the transmembrane helices orientation are observed upon ATP hydrolysis. Binding of a non-transported drug affects the dynamic changes occurring during ATP binding and hydrolysis and restricts the movement of the drug and its release.	Free Univ Brussels, Lab Struct & Fonct Membranes Biol, Ctr Struct Biol & Bioinformat, B-1050 Brussels, Belgium; Mayo Clin, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Ruysschaert, JM (corresponding author), Free Univ Brussels, Lab Struct & Fonct Membranes Biol, Ctr Struct Biol & Bioinformat, CP 206-2,Bd Triomphe, B-1050 Brussels, Belgium.							Bakker M, 1997, INT J CANCER, V73, P362, DOI 10.1002/(SICI)1097-0215(19971104)73:3<362::AID-IJC10>3.0.CO;2-F; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Bechinger B, 1999, BIOPHYS J, V76, P552, DOI 10.1016/S0006-3495(99)77223-1; Blackmore CG, 2001, MOL MEMBR BIOL, V18, P97, DOI 10.1080/09687680010030200; BREUNINGER LM, 1995, CANCER RES, V55, P5342; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Daoud R, 2000, BIOCHEMISTRY-US, V39, P15344, DOI 10.1021/bi0020574; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; Ding GY, 1999, ANTICANCER RES, V19, P3243; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; GOORMAGHTIGH E, 1994, SPECTROCHIM ACTA A, V50, P2137; Goormaghtigh E, 1996, APPL SPECTROSC, V50, P1519, DOI 10.1366/0003702963904610; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Goormaghtigh E, 1994, Subcell Biochem, V23, P363; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; Grimard V, 2001, BIOCHEMISTRY-US, V40, P11876, DOI 10.1021/bi010017+; HELMICHDEJONG ML, 1987, BIOCHIM BIOPHYS ACTA, V905, P358, DOI 10.1016/0005-2736(87)90464-0; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hooijberg JH, 2000, FEBS LETT, V469, P47, DOI 10.1016/S0014-5793(00)01238-2; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Jedlitschky G, 1996, CANCER RES, V56, P988; Jedlitschky G, 1997, BIOCHEM J, V327, P305, DOI 10.1042/bj3270305; Kashiwayama Y, 2002, BIOCHEM BIOPH RES CO, V291, P1245, DOI 10.1006/bbrc.2002.6588; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; Manciu L, 2000, BIOCHEMISTRY-US, V39, P13026, DOI 10.1021/bi001043v; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; Marsh D, 2000, BIOPHYS J, V78, P2499, DOI 10.1016/S0006-3495(00)76795-6; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Rappa G, 1997, CANCER RES, V57, P5232; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Rhee KH, 2002, EMBO J, V21, P3582, DOI 10.1093/emboj/cdf385; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; Vanhoefer U, 1996, CLIN CANCER RES, V2, P1961; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; Vigano C, 2002, J BIOL CHEM, V277, P5008, DOI 10.1074/jbc.M107928200; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Wang GC, 1998, EUR J BIOCHEM, V255, P383, DOI 10.1046/j.1432-1327.1998.2550383.x; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zhang DW, 2002, J BIOL CHEM, V277, P20934, DOI 10.1074/jbc.M201311200; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	67	53	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3347	3356		10.1074/jbc.M207963200	http://dx.doi.org/10.1074/jbc.M207963200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12424247	hybrid			2023-01-03	WOS:000180915000074
J	Neuberger, J				Neuberger, J			Commentary: a "good death" is possible in the NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Fund, London W1M 0AN, England		Neuberger, J (corresponding author), Kings Fund, London W1M 0AN, England.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 4	2003	326	7379					34	34						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	633UP	12516617				2023-01-03	WOS:000180302000025
J	Van Gelder, IC; Hagens, VE; Bosker, HA; Kingma, JH; Kamp, O; Kingma, T; Said, SA; Darmanata, JI; Timmermans, AJM; Tijssen, JGP; Crijns, HJGM				Van Gelder, IC; Hagens, VE; Bosker, HA; Kingma, JH; Kamp, O; Kingma, T; Said, SA; Darmanata, JI; Timmermans, AJM; Tijssen, JGP; Crijns, HJGM		Rate Control Versus Elect Cardiove	A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPY; STROKE; CARDIOVERSION; PROGRESS; SAFETY	Background: Maintenance of sinus rhythm is the main therapeutic goal in patients with atrial fibrillation. However, recurrences of atrial fibrillation and side effects of antiarrhythmic drugs offset the benefits of sinus rhythm. We hypothesized that ventricular rate control is not inferior to the maintenance of sinus rhythm for the treatment of atrial fibrillation. Methods: We randomly assigned 522 patients who had persistent atrial fibrillation after a previous electrical cardioversion to receive treatment aimed at rate control or rhythm control. Patients in the rate-control group received oral anticoagulant drugs and rate-slowing medication. Patients in the rhythm-control group underwent serial cardioversions and received antiarrhythmic drugs and oral anticoagulant drugs. The end point was a composite of death from cardiovascular causes, heart failure, thromboembolic complications, bleeding, implantation of a pacemaker, and severe adverse effects of drugs. Results: After a mean (+/-SD) of 2.3+/-0.6 years, 39 percent of the 266 patients in the rhythm-control group had sinus rhythm, as compared with 10 percent of the 256 patients in the rate-control group. The primary end point occurred in 44 patients (17.2 percent) in the rate-control group and in 60 (22.6 percent) in the rhythm-control group. The 90 percent (two-sided) upper boundary of the absolute difference in the primary end point was 0.4 percent (the prespecified criterion for noninferiority was 10 percent or less). The distribution of the various components of the primary end point was similar in the rate-control and rhythm-control groups. Conclusions: Rate control is not inferior to rhythm control for the prevention of death and morbidity from cardiovascular causes and may be appropriate therapy in patients with a recurrence of persistent atrial fibrillation after electrical cardioversion.	Univ Groningen Hosp, Thoraxctr, Dept Cardiol, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Trial Coordinat Ctr, NL-9700 RB Groningen, Netherlands; Rijnstate Hosp, Arnhem, Netherlands; St Antonius Hosp, Nieuwegein, Netherlands; Free Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; Hosp Midden Twente, Hengelo, Netherlands; Twenteborg Hosp, Almelo, Netherlands; Med Spectrum Twente, Enschede, Netherlands; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	University of Groningen; University of Groningen; Rijnstate Hospital; St. Antonius Hospital Utrecht; Vrije Universiteit Amsterdam; Medical Spectrum Twente; University of Amsterdam; Academic Medical Center Amsterdam	Van Gelder, IC (corresponding author), Univ Groningen Hosp, Thoraxctr, Dept Cardiol, POB 30-001, NL-9700 RB Groningen, Netherlands.	i.c.van.gelder@thorax.azg.nl	Said, Salah Ali Mohamed/I-6656-2019	kamp, otto/0000-0003-2707-2090				ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; [Anonymous], 2001, CIRCULATION, V104, P2118; COPLEN SE, 1991, CIRCULATION, V83, P714; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; Falk RH, 2001, NEW ENGL J MED, V344, P1067, DOI 10.1056/NEJM200104053441407; Gallagher MM, 1998, AM J CARDIOL, V82, p18N, DOI 10.1016/S0002-9149(98)00736-X; GROGAN M, 1992, AM J CARDIOL, V69, P1570, DOI 10.1016/0002-9149(92)90705-4; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 1999, ANN INTERN MED, V131, P688, DOI 10.7326/0003-4819-131-9-199911020-00010; Hart RG, 2000, J AM COLL CARDIOL, V35, P183, DOI 10.1016/S0735-1097(99)00489-1; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; HOHNLOSER SH, 1995, J CARDIOVASC ELECTR, V6, P920, DOI 10.1111/j.1540-8167.1995.tb00368.x; Levy S, 1999, CIRCULATION, V99, P3028, DOI 10.1161/01.CIR.99.23.3028; PACKER DL, 1986, AM J CARDIOL, V57, P563, DOI 10.1016/0002-9149(86)90836-2; VanGelder IC, 1996, ARCH INTERN MED, V156, P2585, DOI 10.1001/archinte.156.22.2585; WELLENS HJJ, 1994, NEW ENGL J MED, V331, P944, DOI 10.1056/NEJM199410063311413; Wyse DG, 1997, AM J CARDIOL, V79, P1198	18	1598	1651	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	2002	347	23					1834	1840		10.1056/NEJMoa021375	http://dx.doi.org/10.1056/NEJMoa021375			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	621NW	12466507				2023-01-03	WOS:000179596900003
J	Baqui, AH; Black, RE; El Arifeen, S; Yunus, M; Chakraborty, Y; Ahmed, S; Vaughan, JP				Baqui, AH; Black, RE; El Arifeen, S; Yunus, M; Chakraborty, Y; Ahmed, S; Vaughan, JP			Effect of zinc supplementation started during diarrhoea on morbidity and mortality in Bangladeshi children: community randomised trial	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-INFECTIONS; DOUBLE-BLIND; DEFICIENCY; INFANTS	Objective To evaluate the effect on morbidity and mortality of providing daily zinc for 14 days to children with diarrhoea. Design Cluster randomised comparison. Setting Matlab field site of International Center for Diarrhoeal Disease Research, Bangladesh. Participants 8070 children aged 3-59 months contributed 11 881 child years of observation during a two year period. Intervention Children with diarrhoea in the intervention clusters were treated with zinc (20 mg per day for 14 days); all children with diarrhoea were treated with oral rehydration therapy. Main outcome measures Duration of episode of diarrhoea, incidence of diarrhoea and acute lower respiratory infections, admission to hospital for diarrhoea or acute lower respiratory infections, and child mortality. Results About 40% (399/1007) of diarrhoeal episodes were treated with zinc in the first four months of the trial; the rate rose to 67% (350/526) in month 5 and to >80% (364/434) in month 7 and was sustained at that level. Children in the intervention cluster received. zinc for about seven days on average during each episode of diarrhoea. They had a shorter duration (hazard ratio 0.76, 95% confidence interval 0.65 to 0.90) and lower incidence of diarrhoea (rate ratio 0.85, 0.76 to 0.96) than children in the comparison group. Incidence of acute lower respiratory infection was reduced in the-intervention group but hot in the comparison group. Admission to hospital of children with diarrhoea was lower in the intervention group than in the comparison group (0.76, 0.59 to 0.98). Admission for acute lower respiratory infection was lower in the intervention group, but this was not statistically significant (0.81, 0.53 to 1.23). The rate of non-injury deaths in the intervention clusters was considerably lower (0.49, 0.25 to 0.94). Conclusions The lower rates of child morbidity and mortality with zinc treatment represent substantial benefits from a simple and inexpensive intervention that can be incorporated in existing efforts to control diarrhoeal disease.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat & Family Hlth, Baltimore, MD 21205 USA; Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Child Hlth Program, Dhaka 1000, Bangladesh; Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Matlab Hlth Res Program, Dhaka 1000, Bangladesh; London Sch Hyg & Trop Med, London WC1A 7HT, England	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); University of London; London School of Hygiene & Tropical Medicine	Baqui, AH (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.			Black, Robert/0000-0001-9926-7984; Arifeen, Shams/0000-0002-5372-5932				Baqui AH, 1998, B WORLD HEALTH ORGAN, V76, P161; BETTGER WJ, 1981, LIFE SCI, V28, P1425, DOI 10.1016/0024-3205(81)90374-X; Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7; Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516; CASTILLODURAN C, 1988, J PEDIATR-US, V113, P452, DOI 10.1016/S0022-3476(88)80627-9; FENWICK PK, 1990, AM J CLIN NUTR, V52, P166, DOI 10.1093/ajcn/52.1.166; GEBHARD RL, 1983, J NUTR, V113, P855, DOI 10.1093/jn/113.4.855; GOLDEN BE, 1985, TRACE ELEMENTS MAN A, V5, P228; *HLTH DEM SURV SYS, 2000, 87 ICDDR HLTH DEM SU; Rosado JL, 1997, AM J CLIN NUTR, V65, P13, DOI 10.1093/ajcn/65.1.13; Roy SK, 1997, ARCH DIS CHILD, V77, P196, DOI 10.1136/adc.77.3.196; Ruel MT, 1997, PEDIATRICS, V99, P808, DOI 10.1542/peds.99.6.808; SANDSTEAD HH, 1991, AM J DIS CHILD, V145, P853, DOI 10.1001/archpedi.1991.02160080029016; Sazawal S, 1998, PEDIATRICS, V102, P1, DOI 10.1542/peds.102.1.1; Sazawal S, 1997, AM J CLIN NUTR, V66, P413, DOI 10.1093/ajcn/66.2.413; SAZAWAL S, 1995, NEW ENGL J MED, V333, P839, DOI 10.1056/NEJM199509283331304; Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S	17	212	219	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2002	325	7372					1059	1062		10.1136/bmj.325.7372.1059	http://dx.doi.org/10.1136/bmj.325.7372.1059			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424162	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000179415700015
J	Brugha, R				Brugha, R			Antiretroviral treatment in developing countries: the peril of neglecting private providers	BRITISH MEDICAL JOURNAL			English	Article							HEALTH	Increased access to antiretroviral drugs is vital to maintain developing countries with high rates of HIV infection. But unless treatment is properly controlled, these drugs could rapidly become useless	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Brugha, R (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England.		Brugha, Ruairi/C-8420-2012	Brugha, Ruairi/0000-0003-0729-0197				Balambal R., 2001, Indian Journal of Tuberculosis, V48, P73; Benjarattanaporn P, 1997, AIDS, V11, pS87; Berman P, 2000, B WORLD HEALTH ORGAN, V78, P791; Brugha R, 1998, HEALTH POLICY PLANN, V13, P107, DOI 10.1093/heapol/13.2.107; Brugha Ruairi, 2002, HLTH POLICY GLOBALIS, P63; *BUS FIGHTS AIDS, MEMB PROF ABB LAB WO; EGROT M, 2002, P 14 INT AIDS C 7 12; Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145; International HIV Treatment Access Coalition, 2002, COMM ACT EXP ACC HIV; KAMAT VR, 1997, PRIVATE HLTH PROVIDE, P124; Nyazema N. Z., 2000, Central African Journal of Medicine, V46, P89; SAPLE DG, 2002, P 14 INT AIDS C 7 12; SEBULIME G, 2002, P 14 INT AIDS C 7 12; SMITH E, 2001, WORK PRIVATE SECTOR; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization, 2002, SCAL ANT THER RES LT	16	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1382	1384		10.1136/bmj.326.7403.1382	http://dx.doi.org/10.1136/bmj.326.7403.1382			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816829	Green Accepted, Green Published			2023-01-03	WOS:000183756400027
J	Guevara, JP; Wolf, FM; Grum, CM; Clark, NM				Guevara, JP; Wolf, FM; Grum, CM; Clark, NM			Learning about asthma - Educational programmes improve the ability of children and teenagers to manage their asthma	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INNER-CITY CHILDREN; HEALTH-EDUCATION; CHILDHOOD ASTHMA; PEDIATRIC ASTHMA; CONTROLLED TRIAL; YOUNG-CHILDREN; INTERVENTION; IMPACT; POPULATION; PARENTS		Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Washington, Sch Med, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA	University of Pennsylvania; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guevara, JP (corresponding author), Childrens Hosp Philadelphia, Div Gen Pediat, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	guevara@email.chop.edu	Praena-Crespo, Manuel/E-7172-2010	Praena-Crespo, Manuel/0000-0002-1928-9663; Guevara, James/0000-0003-1665-4503	FOGARTY INTERNATIONAL CENTER [F06TW002123] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH065696] Funding Source: NIH RePORTER; FIC NIH HHS [1 F06 TW02123] Funding Source: Medline; NHLBI NIH HHS [1 K07 HL 03046] Funding Source: Medline; NIMH NIH HHS [K23 MH065696] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alexander J S, 1988, J Pediatr Nurs, V3, P312; Carswell F, 1989, Bristol Med Chir J, V104, P11; CHARLTON I, 1994, ARCH DIS CHILD, V70, P313, DOI 10.1136/adc.70.4.313; Christiansen SC, 1997, J ALLERGY CLIN IMMUN, V100, P613, DOI 10.1016/S0091-6749(97)70164-7; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; COLLAND VT, 1993, PATIENT EDUC COUNS, V22, P141, DOI 10.1016/0738-3991(93)90094-D; DAHL J, 1990, J ASTHMA, V27, P41, DOI 10.3109/02770909009073293; DEAVES DM, 1993, J ADV NURS, V18, P354, DOI 10.1046/j.1365-2648.1993.18030354.x; EVANS D, 1987, HEALTH EDUC QUART, V14, P267, DOI 10.1177/109019818701400302; FIREMAN P, 1981, PEDIATRICS, V68, P341; HILL R, 1991, BRIT MED J, V303, P1169, DOI 10.1136/bmj.303.6811.1169; Holzheimer L, 1998, CHILD CARE HLTH DEV, V24, P85; HUGHES DM, 1991, PEDIATRICS, V87, P54; Kubly L S, 1984, Issues Compr Pediatr Nurs, V7, P121, DOI 10.3109/01460868409009050; LEBARON S, 1985, ANN ALLERGY, V55, P811; LEWIS CE, 1984, PEDIATRICS, V74, P478; Madge P, 1997, THORAX, V52, P223, DOI 10.1136/thx.52.3.223; MCNABB WL, 1985, AM J PUBLIC HEALTH, V75, P1219, DOI 10.2105/AJPH.75.10.1219; MITCHELL EA, 1986, ARCH DIS CHILD, V61, P1184, DOI 10.1136/adc.61.12.1184; Parcel G S, 1980, J Dev Behav Pediatr, V1, P128; PERRIN JM, 1992, J DEV BEHAV PEDIATR, V13, P241; Persaud DI, 1996, J ASTHMA, V33, P37, DOI 10.3109/02770909609077761; RAKOS RF, 1985, J PSYCHOSOM RES, V29, P101, DOI 10.1016/0022-3999(85)90014-5; Ronchetti R, 1997, EUR RESPIR J, V10, P1248, DOI 10.1183/09031936.97.10061248; RUBIN DH, 1986, PEDIATRICS, V77, P1; SHIELDS MC, 1990, AM J PUBLIC HEALTH, V80, P36, DOI 10.2105/AJPH.80.1.36; Szczepanski R, 1996, Pneumologie, V50, P544; TALABERE LR, 1993, KEY ASPECTS CARING C, P319; TOELLE BG, 1993, MED J AUSTRALIA, V158, P742, DOI 10.5694/j.1326-5377.1993.tb121954.x; WEINGARTEN MA, 1985, J ASTHMA, V22, P261, DOI 10.3109/02770908509077458; WHITMAN N, 1985, HEALTH EDUC QUART, V12, P333, DOI 10.1177/109019818501200312; Wilson SR, 1996, J ASTHMA, V33, P239, DOI 10.3109/02770909609055365	32	340	356	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2003	326	7402					1308	1309		10.1136/bmj.326.7402.1308	http://dx.doi.org/10.1136/bmj.326.7402.1308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	691VK	12805167	Green Published, Bronze			2023-01-03	WOS:000183626500031
J	Cherkin, DC; Sherman, KJ; Deyo, RA; Shekelle, PG				Cherkin, DC; Sherman, KJ; Deyo, RA; Shekelle, PG			A review of the evidence for the effectiveness, safety, and cost of acupuncture, massage therapy, and spinal manipulation for back pain	ANNALS OF INTERNAL MEDICINE			English	Article							SYSTEMATIC REVIEWS; TRIAL; HEALTH; CARE; COMPLICATIONS; EXPECTATIONS; METAANALYSIS; MANAGEMENT; QUALITY; NECK	Background: Few treatments for back pain are supported by strong scientific evidence. Conventional treatments, although widely used, have had limited success. Dissatisfied patients have, therefore, turned to complementary and alternative medical therapies and providers for care for back pain. Purpose: To provide a rigorous and balanced summary of the best available evidence about the effectiveness, safety, and costs of the most popular complementary and alternative medical therapies used to treat back pain. Data Sources: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Study Selection: Systematic reviews of randomized, controlled trials (RCTs) that were published since 1995 and that evaluated acupuncture, massage therapy, or spinal manipulation for nonspecific back pain and RCTs published since the reviews were conducted. Data Extraction: Two authors independently extracted data from the reviews (including number of RCTs, type of back pain, quality assessment, and conclusions) and original articles (including type of pain, comparison treatments, sample size, outcomes, follow-up intervals, loss to follow-up, and authors' conclusions). Data Synthesis: Because the quality of the 20 RCTs that evaluated acupuncture was generally poor, the effectiveness of acupuncture for treating acute or chronic back pain is unclear. The three RCTs that evaluated massage reported that this therapy is effective for subacute and chronic back pain. A meta-regression analysis of the results of 26 RCTs evaluating spinal manipulation for acute and chronic back pain reported that spinal manipulation was superior to sham therapies and therapies judged to have no evidence of a benefit but was not superior to effective conventional treatments. Conclusions: Initial studies have found massage to be effective for persistent back pain. Spinal manipulation has small clinical benefits that are equivalent to those of other commonly used therapies. The effectiveness of acupuncture remains unclear. All of these treatments seem to be relatively safe. Preliminary evidence suggests that massage, but not acupuncture or spinal manipulation, may reduce the costs of care after an initial course of therapy.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Seattle, WA 98195 USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA; RAND Corp, Santa Monica, CA USA	Group Health Cooperative; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; RAND Corporation	Cherkin, DC (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009989] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000606, R01AT000622] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS 09989] Funding Source: Medline; NCCIH NIH HHS [AT00622, AT00606] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Assendelft WJJ, 1996, J FAM PRACTICE, V42, P475; Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; Bigos SJ, 1994, AHCPR PUBLICATION, V95-0642; Bronfort G, 1999, NEUROL CLIN, V17, P91, DOI 10.1016/S0733-8619(05)70116-X; Carlsson CPO, 2001, CLIN J PAIN, V17, P296, DOI 10.1097/00002508-200112000-00003; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P463; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; Coulter ID, 2002, SPINE, V27, P291, DOI 10.1097/00007632-200202010-00018; Crow R., 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.3310/HTA3030, DOI 10.3310/hta3030]; DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1999, J PAIN SYMPTOM MANAG, V17, P65, DOI 10.1016/S0885-3924(98)00129-8; Ernst E, 1998, ARCH INTERN MED, V158, P2235, DOI 10.1001/archinte.158.20.2235; Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9; ERNST E, 2001, DESKTOP GUIDE COMPLE, P60; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; FURLAN AD, 2000, COCHRANE DB SYST REV, P1929; Giles LGF, 1999, J MANIP PHYSIOL THER, V22, P376, DOI 10.1016/S0161-4754(99)70082-5; Grant DJ, 1999, PAIN, V82, P9, DOI 10.1016/S0304-3959(99)00027-5; Hernandez-Reif M, 2001, INT J NEUROSCI, V106, P131, DOI 10.3109/00207450109149744; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jensen GA, 1998, MED CARE, V36, P544, DOI 10.1097/00005650-199804000-00010; Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005; Kittang G, 2001, Tidsskr Nor Laegeforen, V121, P1207; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; Lytle C, 1993, OVERVIEW ACUPUNCTURE; MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486; MILNE S, 2001, COCHRANE DB SYST REV; Mondloch MV, 2001, CAN MED ASSOC J, V165, P174; Nyiendo J, 2001, J MANIP PHYSIOL THER, V24, P92, DOI 10.1067/mmt.2001.112565; Odsberg A, 2001, COMPLEMENT THER MED, V9, P17, DOI 10.1054/ctim.2000.0418; Preyde M, 2000, CAN MED ASSOC J, V162, P1815; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; SANDEFUR R, 1997, AHCPR PUBLICATION, P33; Senstad O, 1997, SPINE, V22, P435, DOI 10.1097/00007632-199702150-00017; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; Skargren EI, 1998, SPINE, V23, P1875, DOI 10.1097/00007632-199809010-00016; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; Sternbach RA, 1986, CLIN J PAIN, V2, P49, DOI DOI 10.1097/00002508-198602010-00008; van Tulder MW, 1999, SPINE, V24, P1113, DOI 10.1097/00007632-199906010-00011; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485; 1995, CONSUMER REPORTS FEB, P81	47	259	269	0	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					898	906		10.7326/0003-4819-138-11-200306030-00011	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AB	12779300				2023-01-03	WOS:000183296400005
J	Reynolds, SJ; Bartlett, JG; Quinn, TC; Beyrer, C; Bollinger, RC				Reynolds, SJ; Bartlett, JG; Quinn, TC; Beyrer, C; Bollinger, RC			Antiretroviral therapy where resources are limited	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DRUG-RESISTANCE; POOR SETTINGS; COTE-DIVOIRE; HIV; ADULTS; TUBERCULOSIS; INFECTION; SURVIVAL; ABIDJAN; AFRICA		Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA; NIAID, NIH, Bethesda, MD 20892 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Reynolds, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA.		safaiee, malihe/C-5045-2018; Zolfigol, Mohammad Ali/AAH-9281-2020; Habibi, Davood/AAH-3062-2020	Habibi, Davood/0000-0002-2386-8502; Bollinger, Robert/0000-0002-6798-6834; Reynolds, Steven/0000-0002-5403-2759	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000361, Z01AI000361] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adje C, 2001, J ACQ IMMUN DEF SYND, V26, P501, DOI 10.1097/00126334-200104150-00018; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Attaran A, 2001, LANCET, V357, P57, DOI 10.1016/S0140-6736(00)03576-5; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Bell JC, 1999, AIDS, V13, P1549, DOI 10.1097/00002030-199908200-00016; Brenner B, 2000, INT J ANTIMICROB AG, V16, P429, DOI 10.1016/S0924-8579(00)00270-3; *BRIT HIV ASS, 2002, GUID TREATM HIV INF; Casseb J, 1999, AIDS PATIENT CARE ST, V13, P213, DOI 10.1089/apc.1999.13.213; *DEP HLTH HUM SERV, 2002, GUID US ANT AG HIV I; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; *GLOB FUND FIGHT A, 2002, PROP COMP APPR FUND; Kam KM, 1998, CLIN IMMUNOL IMMUNOP, V89, P11, DOI 10.1006/clin.1998.4570; Kannangai R, 2000, J CLIN VIROL, V17, P101, DOI 10.1016/S1386-6532(00)00080-9; Kebba A, 2002, AIDS RES HUM RETROV, V18, P1181, DOI 10.1089/08892220260387922; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Mbewu A, 2001, B WORLD HEALTH ORGAN, V79, P1152; Porter K, 2001, BRIT MED J, V322, P1087, DOI 10.1136/bmj.322.7294.1087; Rabkin M, 2002, LANCET, V360, P1503, DOI 10.1016/S0140-6736(02)11478-4; Vergne L, 2002, J ACQ IMMUN DEF SYND, V29, P165, DOI 10.1097/00042560-200202010-00009; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; *WHO, 2002, SCAL ANT THER RES LI; *WHO UNAIDS, 2000, WHO UNAIDS HAIL CONS; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	25	24	25	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1806	1809		10.1056/NEJMsb035366	http://dx.doi.org/10.1056/NEJMsb035366			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724489	Bronze			2023-01-03	WOS:000182543500012
J	Wik, L; Hansen, TB; Fylling, F; Steen, T; Vaagenes, P; Auestad, BH; Steen, PA				Wik, L; Hansen, TB; Fylling, F; Steen, T; Vaagenes, P; Auestad, BH; Steen, PA			Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREHOSPITAL CARDIAC-ARREST; IMMEDIATE COUNTERSHOCK; SURVIVAL; MODEL; QUALITY; LIFE; STATEMENT; THERAPY; SUCCESS; TIME	Context Defibrillation as soon as possible is standard treatment for patients with ventricular fibrillation. A nonrandomized study indicates that after a few minutes of ventricular fibrillation, delaying defibrillation to give cardiopulmonary resuscitation (CPR) first might improve the outcome. Objective To determine the effects of CPR before defibrillation on outcome in patients with ventricular fibrillation and with response times either up to or longer than 5 minutes. Design, Setting, and Patients Randomized trial of 200 patients with out-of-hospital ventricular fibrillation in Oslo, Norway, between June 1998 and May 2001. Patients received either standard care with immediate defibrillation (n = 96) or CPR first with 3 minutes of basic CPR by ambulance personnel prior to defibrillation (n = 104). If initial defibrillation was unsuccessful, the standard group received 1 minute of CPR, before additional defibrillation attempts compared with 3 minutes in the CPR first group. Main Outcome Measure Primary end point was survival to hospital discharge. Secondary end points were hospital admission with return of spontaneous circulation (ROSC), 1-year survival, and neurological outcome. A prespecified analysis examined subgroups with response times either up to or longer than 5 minutes. Results In the standard group, 14 (15%) of 96 patients survived to hospital discharge vs 23 (22%) of 104 in the CPR first group (P=.17). There were no differences in ROSC rates between the standard group (56% [58/104]) and the CPR first group (46% [44/96]; P=.16); or in 1-year survival (20% [21/104] and 15% [14/96], respectively ; P=.30). In subgroup analysis or patients with ambulance response times of either up to 5 minutes or shorter, there were no differences in any outcome variables between the CPR first group (n=40) and the standard group (n=41). For patients with response intervals of longer than 5 minutes, more patients achieved ROSC in the CPR first group (58% [37/64]) compared with the standard group (38% [21/55]; odds ratio [OR], 2.22; 95% confidence interval [CI], 1.06-4.63; P=.04); survival to hospital discharge (22% [14/64] vs 4% [2/55]; OR, 7.42; 95% CI, 1.61-34.3; P=.006); and 1-year survival (20% [13/64] vs 4% [2/55]; OR, 6.76; 95% CI, 1.42-31.4; P=.01). Thirty-three (89%) of 37 patients Who survived to hospital discharge had no or minor reductions in neurological status with no difference between the groups. Conclusions Compared with standard care for ventricular fibrillation, CPR first prior to defibrillation offered no advantage in improving outcomes for this entire study population or for patients with ambulance response times shorter than 5 minutes. However, the patients with ventricular fibrillation and ambulance response intervals longer than 5 minutes had better outcomes with CPR first before defibrillation was attempted. These results require confirmation in additional randomized trials.	Ullevaal Univ Hosp, Expt Med Res Inst, Div Surg, N-0407 Oslo, Norway; Norwegian Competence Ctr Emergency Med, Expt Med Res Inst, Oslo, Norway; Norwegian Def Res Estab, Div Protect & Mat, N-2007 Kjeller, Norway; Stavanger Univ Coll, Dept Technol & Nat Sci, Stavanger, Norway	University of Oslo; Norwegian Defence Research Establishment; Equinor; Universitetet i Stavanger	Wik, L (corresponding author), Ullevaal Univ Hosp, Expt Med Res Inst, Div Surg, N-0407 Oslo, Norway.							[Anonymous], 2000, Resuscitation, V46, P73; *AUT EXT DEF ACLS, 1991, AM J EMERG MED, V9, P91; Brown CG, 1996, ANN EMERG MED, V27, P184, DOI 10.1016/S0196-0644(96)70346-3; CAMPBELL JP, 1995, ANN EMERG MED, V26, P590, DOI 10.1016/S0196-0644(95)70009-9; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DYBVIK T, 1995, RESUSCITATION, V29, P89, DOI 10.1016/0300-9572(95)00850-S; Eftestol T, 2002, CIRCULATION, V105, P2270, DOI 10.1161/01.CIR.0000016362.42586.FE; Graves JR, 1997, RESUSCITATION, V35, P117; Holmberg M, 1998, RESUSCITATION, V36, P29, DOI 10.1016/S0300-9572(97)00089-0; Hsu JWY, 1996, ANN EMERG MED, V28, P597, DOI 10.1016/S0196-0644(96)70080-X; IDRIS AH, 1994, CIRCULATION, V90, P3063, DOI 10.1161/01.CIR.90.6.3063; KERN KB, 1990, RESUSCITATION, V20, P221, DOI 10.1016/0300-9572(90)90005-Y; Kloeck W, 1997, CIRCULATION, V95, P2180, DOI 10.1161/01.CIR.95.8.2180; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; MALDONADO FA, 1993, ANESTHESIOLOGY, V78, P343, DOI 10.1097/00000542-199302000-00019; Niemann JT, 2000, ANN EMERG MED, V36, P543, DOI 10.1067/mem.2000.109441; NIEMANN JT, 1992, CIRCULATION, V85, P281, DOI 10.1161/01.CIR.85.1.281; Robertson C, 1998, RESUSCITATION, V37, P81, DOI 10.1016/S0300-9572(98)00035-5; Robinson JS, 1998, EUR J ANAESTH, V15, P702, DOI 10.1097/00003643-199811000-00012; SAFAR P, 1988, BASIC ADV CARDIAC TR, P267; SAKLAYEN M, 1995, MEDICINE, V74, P163, DOI 10.1097/00005792-199507000-00001; STUEVEN HA, 1989, RESUSCITATION, V17, P251, DOI 10.1016/0300-9572(89)90041-5; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; Sunde K, 1999, RESUSCITATION, V41, P237, DOI 10.1016/S0300-9572(99)00059-3; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7; World Medical Association, 1964, DECL HELS; YAKAITIS RW, 1980, CRIT CARE MED, V8, P157, DOI 10.1097/00003246-198003000-00014	32	457	484	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	2003	289	11					1389	1395		10.1001/jama.289.11.1389	http://dx.doi.org/10.1001/jama.289.11.1389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656PM	12636461	Bronze			2023-01-03	WOS:000181616200030
J	Moreno, MA				Moreno, MA			The cross-cover resident	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	2003	289	8					956	957		10.1001/jama.289.8.956	http://dx.doi.org/10.1001/jama.289.8.956			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	648BK	12597732				2023-01-03	WOS:000181129800001
J	Sehgal, AR				Sehgal, AR			Impact of quality improvement efforts on race and sex disparities in hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALBUMIN CONCENTRATION; ETHNIC DISPARITIES; OF-LIFE; HEALTH; PREDICTORS; CARE; INEQUALITY; MORTALITY; SURVIVAL; DIALYSIS	Context By improving the process of care, quality improvement efforts have the potential to reduce race and sex disparities. However, little is known about whether reductions actually occur. National quality improvement activities targeting hemodialysis patients provide an opportunity to examine this issue. Objective To determine the effect of quality improvement efforts on race and sex disparities among hemodialysis patients. Design, Setting, and Subjects Longitudinal study of 58700 randomly selected hemodialysis patients from throughout the United States in 1993 through 2000. Intervention Medicare-funded quality improvement project involving monitoring of patient outcomes, feedback of performance data, and education of clinicians at dialysis centers. Main Outcome Measures Changes in hemodialysis dose (Kt/V), anemia management (hemoglobin level), and nutritional status (albumin level). Results The proportion of all patients with an adequate hemodialysis dose increased 2-fold. In 1993, 46% of white patients and 36% of black patients received an adequate hemodialysis dose compared with 2000 when the proportions were 87% and 84%, respectively. Thus, the gap between white and black patients decreased from 10% to 3% (P<.001). The gap between female and male patients decreased from 23% to 9% over the same period (P=.008). The proportion of all patients with adequate hemoglobin levels increased 3-fold. The proportion of all patients with adequate albumin levels remained unchanged. Race and sex disparities in anemia management and nutritional status did not change significantly. Conclusions Quality improvement efforts have a variable impact on race and sex disparities in health outcomes. Further work is needed to determine how quality improvement methods can be targeted to reduce health disparities.	Case Western Reserve Univ, Metrohlth Med Ctr, Div Nephrol, 2500 Metrohlth Dr, Cleveland, OH 44109 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Ctr Hlth Care Res & Policy, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Biomed Eth, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Sehgal, AR (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Div Nephrol, 2500 Metrohlth Dr, Cleveland, OH 44109 USA.	axs81@po.cwru.edu			NIDDK NIH HHS [DK54178, DK51472] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051472, P50DK054178] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; [Anonymous], 1997, Am J Kidney Dis, V30, pS15; [Anonymous], 1997, Am J Kidney Dis, V30, pS192; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Bierman A S, 2001, J Am Med Womens Assoc (1972), V56, P155; COLLINS AJ, 1994, AM J KIDNEY DIS, V23, P272, DOI 10.1016/S0272-6386(12)80984-X; Cooper LA, 2002, J GEN INTERN MED, V17, P477, DOI 10.1046/j.1525-1497.2002.10633.x; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Hakim RM, 2001, HDB DIALYSIS, V3rd, P236; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; *HLTH CAR FIN ADM, 1994, ANN REP END STAG REN; IGLEHART JK, 1993, NEW ENGL J MED, V328, P366, DOI 10.1056/NEJM199302043280528; Kaysen GA, 1997, AM J KIDNEY DIS, V29, P658, DOI 10.1016/S0272-6386(97)90117-7; KEPPEL KG, 2002, HLTH PEOPLE 2000 STA, V23, P1; Leggat JE, 1998, AM J KIDNEY DIS, V32, P139, DOI 10.1053/ajkd.1998.v32.pm9669435; Leon JB, 2001, AM J NEPHROL, V21, P200, DOI 10.1159/000046248; Leon JB, 2001, J RENAL NUTR, V11, P9, DOI 10.1016/S1051-2276(01)79890-1; Lynch JW, 2000, BMJ-BRIT MED J, V320, P1200, DOI 10.1136/bmj.320.7243.1200; McClellan WM, 1999, AM J KIDNEY DIS, V34, P1075, DOI 10.1016/S0272-6386(99)70013-2; McClellan WM, 1998, AM J KIDNEY DIS, V31, P584, DOI 10.1053/ajkd.1998.v31.pm9531173; *NAT KIDN FDN, 2000, AM J KIDNEY DIS S, V35, pS1, DOI DOI 10.1053/KD.2000.6671; Owen WF, 1998, JAMA-J AM MED ASSOC, V280, P1764, DOI 10.1001/jama.280.20.1764; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; SCHOENBACH VJ, 2002, AM PUBL HLTH ASS ANN; Sehgal A R, 1998, J Ren Nutr, V8, P179, DOI 10.1016/S1051-2276(98)90016-4; Sehgal AR, 2002, JAMA-J AM MED ASSOC, V287, P1961, DOI 10.1001/jama.287.15.1961; Sehgal AR, 2001, AM J KIDNEY DIS, V37, P1223, DOI 10.1053/ajkd.2001.24526; Smith JL, 2001, MED CARE, V39, P910, DOI 10.1097/00005650-200109000-00002; Stamler R, 1987, HYPERTENSION, V9, P641; *US DEPT HHS, 1998, 1998 ANN REP END STA; *US DEPT HHS, 1996, 1995 ANN REP END STA; *US DEPT HHS, 1999, 1999 ANN REP END STA; *US DEPT HHS, 1997, 1997 ANN REP END STA; *US DEPT HHS, 2000, 2000 ANN REP END STA; *US DEPT HHS, 1997, 1996 ANN REP END STA; *US DHHS, 2001, 2001 ANN REP END STA; *USRDS, 2002, 2002 ANN DAT REP; Williams DR, 2000, HEALTH CARE FINANC R, V21, P75	40	143	145	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	2003	289	8					996	1000		10.1001/jama.289.8.996	http://dx.doi.org/10.1001/jama.289.8.996			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	648BK	12597751	Bronze			2023-01-03	WOS:000181129800025
J	Golin, J; Ambudkar, SV; Gottesman, MM; Habib, AD; Sczepanski, J; Ziccardi, W; May, L				Golin, J; Ambudkar, SV; Gottesman, MM; Habib, AD; Sczepanski, J; Ziccardi, W; May, L			Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-DRUG RESISTANCE; P-GLYCOPROTEIN; GENE	The yeast (Saccharomyces cerevisiae) multidrug transporter Pdr5p effluxes a broad range of substrates that are variable in structure and mode of action. Previous work suggested that molecular size and ionization could be important parameters. In this study, we compared the relative sensitivity of isogenic PDR5 and pdr5 strains toward putative substrates that are similar in chemical structure. Three series were used: imidazole-containing compounds, trialkyltin chlorides, and tetraalkyltin compounds. We demonstrate that the Pdr5p transporter is capable of mediating transport of substrates that neither ionize nor have electron pair donors and that are much simpler in structure than those transported by the human MDR1-encoded P-glycoprotein. Furthermore, the size of the substrate is critical and independent of any requirement for hydrophobicity. Substrates have surface volumes greater than 90 Angstrom(3) with an optimum response at similar to200-225 A(3) as determined by molecular modeling. Assays measuring the efflux from cells of [H-3]chloramphenicol and [H-3]tritylimidazole were used. A concentration-dependent inhibition of chloramphenicol transport was observed with imidazole derivatives but not with either the organotin compounds or the antitumor agent doxorubicin. In contrast, several of the organotin compounds were potent inhibitors of tritylimidazole efflux, but the Pdr5p substrate tetrapropyltin was ineffective in both assays. This argues for the existence of at least three substrate-binding sites on Pdr5p that differ in behavior from those of the mammalian P-glycoprotein. Evidence also indicates that some substrates are capable of interacting at more than one site. The surprising observation that Pdr5p mediates resistance to tetraalkyltins suggests that one of the sites might use only hydrophobic interactions to bind substrates.	Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA; Catholic Univ Amer, Dept Chem, Washington, DC 20064 USA; NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Dept Chem, Waukesha, WI 53188 USA	Catholic University of America; Catholic University of America; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System	Golin, J (corresponding author), NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	golin@cua.edu	Ambudkar, Suresh V/L-1317-2016; Ambudkar, Suresh V/B-5964-2008		NATIONAL CANCER INSTITUTE [Z01BC005598, Z01BC010030, ZIABC010030, ZIABC005598] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldabbagh F, 1999, TETRAHEDRON, V55, P4109, DOI 10.1016/S0040-4020(99)00104-0; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; Golin J, 2000, ANTIMICROB AGENTS CH, V44, P134, DOI 10.1128/AAC.44.1.134-138.2000; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; LEONARD PJ, 1994, ANTIMICROB AGENTS CH, V38, P2492, DOI 10.1128/AAC.38.10.2492; LEPPERT G, 1990, GENETICS, V125, P13; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Mealey KL, 2002, ANTIMICROB AGENTS CH, V46, P755, DOI 10.1128/AAC.46.3.755-761.2002; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Rogers B, 2001, J MOL MICROB BIOTECH, V3, P207; Salerno M, 2002, BIOCHEM PHARMACOL, V63, P1471, DOI 10.1016/S0006-2952(02)00895-X; Seelig A, 2000, EUR J PHARM SCI, V12, P31, DOI 10.1016/S0928-0987(00)00177-9; Seelig A, 1998, INT J CLIN PHARM TH, V36, P50	15	67	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5963	5969		10.1074/jbc.M210908200	http://dx.doi.org/10.1074/jbc.M210908200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12496287	hybrid			2023-01-03	WOS:000181129400060
J	McGregor, CL; Chen, L; Pomroy, NC; Hwang, P; Go, S; Chakrabartty, A; Prive, GG				McGregor, CL; Chen, L; Pomroy, NC; Hwang, P; Go, S; Chakrabartty, A; Prive, GG			Lipopeptide detergents designed for the structural study of membrane proteins	NATURE BIOTECHNOLOGY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; ESCHERICHIA-COLI; RELAXATION; MICELLES; PURIFICATION; TRANSPORTERS; BIOCHEMISTRY; PEPTIDES; HOMOLOG	The structural study of membrane proteins requires detergents that can effectively mimic lipid bilayers, and the choice of detergent is often a compromise between detergents that promote protein stability and detergents that form small micelles. We describe lipopeptide detergents (LPDs), a new class of amphiphile consisting of a peptide scaffold that supports two alkyl chains, one anchored to each end of an alpha-helix. The goal was to design a molecule that could self-assemble into a cylindrical micelle with a rigid outer hydrophilic shell surrounding an inner lipidic core. Consistent with this design, LPDs self-assemble into small micelles, can disperse phospholipid membranes, and are gentle, nondenaturing detergents that preserve the structure of the membrane proteins in solution for extended periods of time. The LPD design allows for a membrane-like packing of the alkyl chains in the core of the molecular assemblies, possibly explaining their superior properties relative to traditional detergents in stabilizing membrane protein structures.	Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Hlth Network, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Prive, GG (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.		Privé, Gilbert G/A-3039-2008	Prive, Gilbert/0000-0002-0712-4319; Chakrabartty, Avi/0000-0001-7002-8381				Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Arora A, 2001, NAT STRUCT BIOL, V8, P334, DOI 10.1038/86214; Bogusz S, 2000, J PHYS CHEM B, V104, P5462, DOI 10.1021/jp000159y; Boulter JM, 2001, PROTEIN EXPRES PURIF, V22, P337, DOI 10.1006/prep.2001.1440; Bowie JU, 2001, CURR OPIN STRUC BIOL, V11, P397, DOI 10.1016/S0959-440X(00)00223-2; CASEY JR, 1993, BIOCHEMISTRY-US, V32, P1172, DOI 10.1021/bi00055a023; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; DAprano A, 1996, J MOL STRUCT, V383, P177, DOI 10.1016/S0022-2860(96)09283-6; DILL KA, 1981, P NATL ACAD SCI USA, V78, P676, DOI 10.1073/pnas.78.2.676; DOIG AJ, 1994, BIOCHEMISTRY-US, V33, P3396, DOI 10.1021/bi00177a033; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Edelstein S J, 1973, Methods Enzymol, V27, P82; EDELSTEIN SJ, 1967, J BIOL CHEM, V242, P306; Engel CK, 2002, BBA-BIOMEMBRANES, V1564, P47, DOI 10.1016/S0005-2736(02)00397-8; Engel CK, 2002, BBA-BIOMEMBRANES, V1564, P38, DOI 10.1016/S0005-2736(02)00398-X; Fernandez C, 2001, FEBS LETT, V504, P173, DOI 10.1016/S0014-5793(01)02742-9; Garavito RM, 2001, J BIOL CHEM, V276, P32403, DOI 10.1074/jbc.R100031200; Gennis R.B., 1989, BIOMEMBRANES MOL STR, DOI DOI 10.1007/978-1-4757-2065-5; HJELMELAND LM, 1980, P NATL ACAD SCI-BIOL, V77, P6368, DOI 10.1073/pnas.77.11.6368; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; LAUTERWEIN J, 1979, BIOCHIM BIOPHYS ACTA, V556, P244, DOI 10.1016/0005-2736(79)90046-4; le Coutret J, 2000, BIOPOLYMERS, V55, P297, DOI 10.1002/1097-0282(2000)55:4<297::AID-BIP1003>3.0.CO;2-H; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; LORBER B, 1990, BIOCHIM BIOPHYS ACTA, V1023, P254, DOI 10.1016/0005-2736(90)90421-J; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MICHEL H, 2001, INT TABLES CRYSTALLO, VF, P94; Michel H., 1991, CRYSTALLIZATION MEMB, P73; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; ROSEVEAR P, 1980, BIOCHEMISTRY-US, V19, P4108, DOI 10.1021/bi00558a032; SCHAFMEISTER CE, 1993, SCIENCE, V262, P734, DOI 10.1126/science.8235592; Tieleman DP, 2000, J PHYS CHEM B, V104, P6380, DOI 10.1021/jp001268f; Tribet C, 1996, P NATL ACAD SCI USA, V93, P15047, DOI 10.1073/pnas.93.26.15047; Walker S, 1996, P NATL ACAD SCI USA, V93, P1585, DOI 10.1073/pnas.93.4.1585; Yu SM, 2000, PROTEIN SCI, V9, P2518, DOI 10.1110/ps.9.12.2518; Zhou YF, 2000, J BIOL CHEM, V275, P6975, DOI 10.1074/jbc.275.10.6975; Zhou YF, 2001, PROTEIN SCI, V10, P378, DOI 10.1110/ps.34201	42	150	159	0	39	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2003	21	2					171	176		10.1038/nbt776	http://dx.doi.org/10.1038/nbt776			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	642KE	12524549				2023-01-03	WOS:000180802000030
J	Suckfull, M				Suckfull, M		Hearing Loss Study Grp	Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial	LANCET			English	Article							PRECIPITATION HELP; BLOOD-VISCOSITY; DOUBLE-BLIND; HYPERCHOLESTEROLEMIA; DEAFNESS; DISEASE; HYPERLIPIDEMIA; IMPROVEMENT; EXPERIENCE; THERAPY	Background Sudden sensorineural hearing loss (SSHL) is thought to have many different origins, including disturbances of microcirculation, autoimmune pathology, and viral infection. We aimed to determine whether acute reduction of plasma fibrinogen and serum LDL is effective for treatment of SSHL of suspected vascular origin. Methods Between January, 2000, and June, 2001, we recruited 201 patients with sudden hearing loss from four otorhinolaryngology clinics in Germany. Patients were randomly allocated to single fibrinogen/LDL apheresis or standard treatment (250 mg prednisolone reduced by 25 mg per day, 500 mL 6% hydroxyethyl starch, 400 mg pentoxifylline per day). The primary outcome was recovery of hearing as measured by pure-tone audiometry 48 h after the start of treatment. Secondary outcomes were recovery of hearing 6 weeks after treatment, improvement of speech audiometry, tinnitus, and frequency of side-effects. Analysis was done per protocol. Findings Overall improvement of pure-tone thresholds was slightly but not significantly better in patients given apheresis than in those given standard treatment (difference 7.7, 95% Cl -8.2 to 23.6). However, the mean sound level at which 50% of recorded digits were recognised was significantly lower after 48 h in the apheresis group (21.6 dB, SD 20.8) than in the standard group (29.3 dB, 29.4; p=0.034). After 6 weeks, the mean 50% speech perception was at 13.6 dB (SD 14.3) in the apheresis group and at 20.8 dB (25.4) in those on standard treatment (p=0.059). At 48 h, in patients with plasma fibrinogen concentrations of more than 295 mg/dL, speech perception was improved much more in those on apheresis (15.3 dB, 17.3) than in those on standard treatment (6.1 dB, 10.4; p=0.005). Interpretation A single fibrinogen/LDL apheresis lasting for 2 h could be used as an alternative to conventional infusion treatment and prednisolone for 10 days. Patients with a plasma fibrinogen of more than 8.68 mumol/L improve much better when treated with apheresis, especially if serum LDL concentrations are also raised.	Univ Munich, Klinikum Grosshadern, D-81377 Munich, Germany	University of Munich	Suckfull, M (corresponding author), Univ Munich, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.	suckfuell@hno.med.uni-muenchen.de						Alexiou C, 2001, ARCH OTOLARYNGOL, V127, P253, DOI 10.1001/archotol.127.3.253; AXELSSON A, 1985, ACTA OTO-LARYNGOL, V100, P379, DOI 10.3109/00016488509126561; BYL FM, 1984, LARYNGOSCOPE, V94, P647; CIUFFETTI G, 1991, LARYNGOSCOPE, V101, P65; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Fessenden JD, 1998, HEARING RES, V118, P168, DOI 10.1016/S0378-5955(98)00027-6; Fetterman BL, 1996, AM J OTOL, V17, P529; GATEHOUSE S, 1989, ARCH OTOLARYNGOL, V115, P1227; GATES GA, 1993, ARCH OTOLARYNGOL, V119, P156; John S, 1998, CIRCULATION, V98, P211, DOI 10.1161/01.CIR.98.3.211; KAWAKAMI M, 1992, ACTA OTO-LARYNGOL, V112, P991, DOI 10.3109/00016489209137500; Kojima Y, 2001, ANN OTO RHINOL LARYN, V110, P105, DOI 10.1177/000348940111000202; MATTOX DE, 1977, ANN OTO RHINOL LARYN, V86, P463, DOI 10.1177/000348947708600406; Megighian D, 2000, GERONTOLOGY, V46, P199, DOI 10.1159/000022160; Mellwig KP, 1998, ATHEROSCLEROSIS, V139, P173, DOI 10.1016/S0021-9150(98)00055-0; MILLER JM, 1988, AM J OTOLARYNG, V9, P302, DOI 10.1016/S0196-0709(88)80038-3; MOSKOWITZ D, 1984, LARYNGOSCOPE, V94, P664; Nguyen TVN, 1998, OTOLARYNG HEAD NECK, V119, P14, DOI 10.1016/S0194-5998(98)70167-6; OHINATA Y, 1994, ACTA OTO-LARYNGOL, V114, P601, DOI 10.3109/00016489409126112; Pfefferkorn TK, 1999, STROKE, V30, P1802, DOI 10.1161/01.STR.30.9.1802; PROBST R, 1992, ACTA OTO-LARYNGOL, V112, P435, DOI 10.3109/00016489209137424; PYYKKO I, 1988, ACTA OTO-LARYNGOL, P155; SAITO T, 1994, ORL J OTO-RHINO-LARY, V56, P315, DOI 10.1159/000276683; SCHUFFWERNER P, 1989, EUR J CLIN INVEST, V19, P30, DOI 10.1111/j.1365-2362.1989.tb00303.x; Seidel D, 1996, ARTIF ORGANS, V20, P303, DOI 10.1111/j.1525-1594.1996.tb04449.x; SHIRAISHI T, 1993, ACTA OTO-LARYNGOL, P46; Suckfull M, 1999, ACTA OTO-LARYNGOL, V119, P763, DOI 10.1080/00016489950180397; Suzuki K, 2000, LARYNGOSCOPE, V110, P1736, DOI 10.1097/00005537-200010000-00033; WILSON WR, 1980, ARCH OTOLARYNGOL, V106, P772; ZEIHER AM, 1993, J CLIN INVEST, V92, P652, DOI 10.1172/JCI116634	30	136	144	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 7	2002	360	9348					1811	1817		10.1016/S0140-6736(02)11768-5	http://dx.doi.org/10.1016/S0140-6736(02)11768-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623MB	12480357				2023-01-03	WOS:000179706100007
J	Lip, GYH; Chin, BSP; Prasad, N				Lip, GYH; Chin, BSP; Prasad, N			ABC of antithrombotic therapy - Antithrombotic therapy in myocardial infarction and stable angina	BMJ-BRITISH MEDICAL JOURNAL			English	Review							THROMBOLYSIS		City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Univ Dept Med, Birmingham, W Midlands, England	University of Birmingham	Lip, GYH (corresponding author), City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Univ Dept Med, Birmingham, W Midlands, England.							[Anonymous], 1988, LANCET, V2, P349; Cairns JA, 2001, CHEST, V119, p228S, DOI 10.1378/chest.119.1_suppl.228S; Collins R, 1996, BMJ-BRIT MED J, V313, P652; MOUNSEY JP, 1995, BRIT HEART J, V74, P348; *NAT I CLIN EXC, 2002, TECHN APPR GUID 52 G; Ohman EM, 2001, CHEST, V119, p253S, DOI 10.1378/chest.119.1_suppl.253S; Oldroyd KG, 2000, HEART, V84, P113, DOI 10.1136/heart.84.2.113; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	8	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	2002	325	7375					1287	1289		10.1136/bmj.325.7375.1287	http://dx.doi.org/10.1136/bmj.325.7375.1287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458252	Green Published			2023-01-03	WOS:000179696300022
J	Di Bisceglie, AM				Di Bisceglie, AM			An error rationalised is still a mistake	LANCET			English	Editorial Material									St Louis Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, St Louis, MO 63110 USA	Saint Louis University	Di Bisceglie, AM (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, 3635 Vista Ave, St Louis, MO 63110 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 23	2002	360	9346					1688	1688		10.1016/S0140-6736(02)11609-6	http://dx.doi.org/10.1016/S0140-6736(02)11609-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457806				2023-01-03	WOS:000179393900028
J	Hanczyc, MM; Fujikawa, SM; Szostak, JW				Hanczyc, MM; Fujikawa, SM; Szostak, JW			Experimental models of primitive cellular compartments: Encapsulation, growth, and division	SCIENCE			English	Article							MURCHISON CARBONACEOUS CHONDRITE; LARGE UNILAMELLAR VESICLES; FATTY-ACID MEMBRANES; MONTMORILLONITE CATALYSIS; SIZE DISTRIBUTION; EXTRUSION; SURFACE; RNA; POLYMERIZATION; COMPONENTS	The clay montmorillonite is known to catalyze the polymerization of RNA from activated ribonucleotides. Here we report that montmorillonite accelerates the spontaneous conversion of fatty acid micelles into vesicles. Clay particles often become encapsulated in these vesicles, thus providing a pathway for the prebiotic encapsulation of catalytically active surfaces within membrane vesicles. In addition, RNA adsorbed to clay can be encapsulated within vesicles. Once formed, such vesicles can grow by incorporating fatty acid supplied as micelles and can divide without dilution of their contents by extrusion through small pores. These processes mediate vesicle replication through cycles of growth and division. The formation, growth, and division of the earliest cells may have occurred in response to similar interactions with mineral particles and inputs of material and energy.	Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital	Szostak, JW (corresponding author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA.			Hanczyc, Martin/0000-0002-5453-2139	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Apel CL, 2002, BBA-BIOMEMBRANES, V1559, P1, DOI 10.1016/S0005-2736(01)00400-X; Aranda-Espinoza H, 1999, SCIENCE, V285, P394, DOI 10.1126/science.285.5426.394; Berclaz N, 2001, J PHYS CHEM B, V105, P1056, DOI 10.1021/jp001298i; Blochliger E, 1998, J PHYS CHEM B, V102, P10383, DOI 10.1021/jp981234w; CLERC SG, 1994, BIOPHYS J, V67, P475, DOI 10.1016/S0006-3495(94)80503-X; DEAMER DW, 1985, NATURE, V317, P792, DOI 10.1038/317792a0; DEAMER DW, 1989, ORIGINS LIFE EVOL B, V19, P21, DOI 10.1007/BF01808285; Dworkin JP, 2001, P NATL ACAD SCI USA, V98, P815, DOI 10.1073/pnas.98.3.815; Ertem G, 1997, J AM CHEM SOC, V119, P7197, DOI 10.1021/ja970422h; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; FERRIS JP, 1992, SCIENCE, V257, P1387, DOI 10.1126/science.1529338; Franchi M, 2003, ORIGINS LIFE EVOL B, V33, P1, DOI 10.1023/A:1023982008714; Frisken BJ, 2000, LANGMUIR, V16, P928, DOI 10.1021/la9905113; GEBICKI JM, 1973, NATURE, V243, P232, DOI 10.1038/243232a0; GEBICKI JM, 1976, CHEM PHYS LIPIDS, V16, P142, DOI 10.1016/0009-3084(76)90006-2; HAINES TH, 1983, P NATL ACAD SCI-BIOL, V80, P160, DOI 10.1073/pnas.80.1.160; HARGREAVES WR, 1978, BIOCHEMISTRY-US, V17, P3759, DOI 10.1021/bi00611a014; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hunter DG, 1998, BIOPHYS J, V74, P2996, DOI 10.1016/S0006-3495(98)78006-3; Johnston WK, 2001, SCIENCE, V292, P1319, DOI 10.1126/science.1060786; Korgel BA, 1998, BIOPHYS J, V74, P3264, DOI 10.1016/S0006-3495(98)78033-6; Malinin VS, 2001, BIOCHEMISTRY-US, V40, P8292, DOI 10.1021/bi010570r; MAYER L, 1986, BIOCHIM BIOPHYS ACTA, V858, P61; McCollom TM, 1999, ORIGINS LIFE EVOL B, V29, P153, DOI 10.1023/A:1006592502746; Monnard PA, 2002, ASTROBIOLOGY, V2, P139, DOI 10.1089/15311070260192237; MUI BLS, 1995, BIOPHYS J, V69, P930, DOI 10.1016/S0006-3495(95)79967-2; NAYER R, 1989, BIOCHIM BIOPHYS ACTA, V986, P200; Ramos L, 1999, SCIENCE, V286, P2325, DOI 10.1126/science.286.5448.2325; Rushdi AI, 2001, ORIGINS LIFE EVOL B, V31, P103, DOI 10.1023/A:1006702503954; SMITH R, 1973, P NATL ACAD SCI USA, V70, P289, DOI 10.1073/pnas.70.2.289; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Szostak JW, 2001, NATURE, V409, P387, DOI 10.1038/35053176; Traikia M, 2002, BIOPHYS J, V83, P1443, DOI 10.1016/S0006-3495(02)73915-5; WALDE P, 1994, J AM CHEM SOC, V116, P11649, DOI 10.1021/ja00105a004	34	576	593	11	215	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					618	622		10.1126/science.1089904	http://dx.doi.org/10.1126/science.1089904			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576428	Green Accepted			2023-01-03	WOS:000186119900051
J	Kearns, GL; Abdel-Rahman, SM; Alander, SW; Blowey, DL; Leeder, JS; Kauffman, RE				Kearns, GL; Abdel-Rahman, SM; Alander, SW; Blowey, DL; Leeder, JS; Kauffman, RE			Developmental pharmacology - Drug disposition, action, and therapy in infants and children	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BLOOD-FLOW-VELOCITY; HUMAN LIVER; METABOLIZING-ENZYMES; CIRCULATORY ADAPTATION; NEWBORN-INFANTS; GESTATIONAL-AGE; RENAL-FUNCTION; PHARMACOKINETICS; PRETERM; ONTOGENY		Childrens Mercy Hosp & Clin, Dept Pediat, Div Pediat Pharmacol & Med Toxicol, Kansas City, MO 64108 USA; Childrens Mercy Hosp & Clin, Div Emergency Med, Kansas City, MO 64108 USA; Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA; Univ Missouri, Dept Pharmacol, Kansas City, MO 64110 USA; Univ Missouri, Dept Pharm Practice, Kansas City, MO 64110 USA; Childrens Mercy Hosp & Clin, Div Nephrol, Kansas City, MO 64108 USA	Children's Mercy Hospital; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; Children's Mercy Hospital	Kearns, GL (corresponding author), Childrens Mercy Hosp & Clin, Dept Pediat, Div Pediat Pharmacol & Med Toxicol, 2401 Gillham Rd, Kansas City, MO 64108 USA.	gkearns@cmh.edu	Leeder, James Steven/ABD-5438-2021	Leeder, James Steven/0000-0001-6688-0504	NICHD NIH HHS [U01 HD044239-01, 5 U01 HD31313-10] Funding Source: Medline; NIEHS NIH HHS [R01 ES10855-04] Funding Source: Medline; NIGMS NIH HHS [R01 GM58883-04] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD044239, U01HD031313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058883] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUNOD M, 1969, AM J DIG DIS, V14, P400, DOI 10.1007/BF02239360; Alcorn J, 2002, CLIN PHARMACOKINET, V41, P1077, DOI 10.2165/00003088-200241130-00005; AMATO M, 1992, AM J PERINAT, V9, P431, DOI 10.1055/s-2007-999282; ARANDA JV, 1979, ARCH DIS CHILD, V54, P946, DOI 10.1136/adc.54.12.946; ARANT BS, 1978, J PEDIATR-US, V92, P705, DOI 10.1016/S0022-3476(78)80133-4; Bajpai M, 1996, DRUG METAB DISPOS, V24, P1401; Barrett DA, 1996, BRIT J CLIN PHARMACO, V41, P531, DOI 10.1046/j.1365-2125.1996.03539.x; BERSETH CL, 1989, J PEDIATR-US, V115, P646, DOI 10.1016/S0022-3476(89)80302-6; Blanco JG, 2000, DRUG METAB DISPOS, V28, P379; BOURGEOIS BFD, 1983, NEUROLOGY, V33, P173, DOI 10.1212/WNL.33.2.173; BRION LP, 1991, PEDIATR NEPHROL, V5, P675, DOI 10.1007/BF00857868; CARRY MR, 1986, MUSCLE NERVE, V9, P445, DOI 10.1002/mus.880090510; Chen H, 2000, DRUG METAB DISPOS, V28, P1051; CHIBA K, 1980, J PEDIATR-US, V96, P479; Coulthard KP, 1998, J PAEDIATR CHILD H, V34, P425, DOI 10.1046/j.1440-1754.1998.00267.x; de Wildt SN, 2003, CLIN DRUG INVEST, V23, P27, DOI 10.2165/00044011-200323010-00004; de Wildt SN, 1999, CLIN PHARMACOKINET, V37, P485, DOI 10.2165/00003088-199937060-00004; DILORENZO C, 1995, J PEDIATR-US, V127, P593, DOI 10.1016/S0022-3476(95)70120-6; EHRNEBO M, 1971, EUR J CLIN PHARMACOL, V3, P189, DOI 10.1007/BF00565004; Engel G, 1996, CLIN PHARMACOL THER, V59, P613, DOI 10.1016/S0009-9236(96)90001-6; Fluhr JW, 2000, PEDIATR DERMATOL, V17, P436, DOI 10.1046/j.1525-1470.2000.01815.x; FREDHOLM BB, 1975, PEDIATR RES, V9, P26, DOI 10.1203/00006450-197509010-00005; FRIISHANSEN B, 1983, ACTA PAEDIATR SCAND, P7; Gibbs JP, 1999, DRUG METAB DISPOS, V27, P1466; GRAND RJ, 1976, GASTROENTEROLOGY, V70, P790; GREENBLATT DJ, 1976, NEW ENGL J MED, V295, P542; GUPTA M, 1978, PEDIATRICS, V62, P26; Hall Stephen D., 1999, Drug Metabolism and Disposition, V27, P161; Halpern S, 1988, AM PEDIAT SOCIAL DYN, P52; HEIMANN G, 1980, EUR J CLIN PHARMACOL, V18, P43, DOI 10.1007/BF00561477; Hines RN, 2002, J PHARMACOL EXP THER, V300, P355, DOI 10.1124/jpet.300.2.355; HUANG NN, 1953, J PEDIATR-US, V42, P657, DOI 10.1016/S0022-3476(53)80422-1; ITTMANN PI, 1992, DIGEST DIS SCI, V37, P14, DOI 10.1007/BF01308336; Jadcherla SR, 2002, J PEDIATR GASTR NUTR, V34, P16, DOI 10.1097/00005176-200201000-00005; James LP, 2000, J CLIN PHARMACOL, V40, P1298; James LP, 1998, J CLIN PHARMACOL, V38, P1089; KAFETZIS DA, 1979, ACTA PAEDIATR SCAND, V68, P419, DOI 10.1111/j.1651-2227.1979.tb05030.x; Kauffman R E, 2000, Paediatr Drugs, V2, P411, DOI 10.2165/00128072-200002060-00001; Kearns GL, 2000, J ALLERGY CLIN IMMUN, V106, pS128; KERR BM, 1994, BIOCHEM PHARMACOL, V47, P1969, DOI 10.1016/0006-2952(94)90071-X; Kinirons MT, 1999, CLIN PHARMACOL THER, V66, P224, DOI 10.1016/S0009-9236(99)70029-9; KITADA M, 1987, J BIOL CHEM, V262, P13534; KRAUS DM, 1993, CLIN PHARMACOL THER, V54, P351, DOI 10.1038/clpt.1993.160; Lacroix D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/j.1432-1033.1997.00625.x; LAMBERT GH, 1986, DEV PHARMACOL THERAP, V9, P375, DOI 10.1159/000457262; Leeder J. S., 2002, Pharmacogenomics Journal, V2, P141, DOI 10.1038/sj.tpj.6500104; Leeder JS, 2001, CURR THER RES CLIN E, V62, P900, DOI 10.1016/S0011-393X(01)80094-1; Lin JH, 2003, CLIN PHARMACOKINET, V42, P59, DOI 10.2165/00003088-200342010-00003; LINDAY L, 1987, PEDIATRICS, V79, P544; LOUGHNAN PM, 1977, ARCH DIS CHILD, V52, P302, DOI 10.1136/adc.52.4.302; Marshall J, 2000, J CLIN PHARMACOL, V40, P578; Marshall JD, 1999, CLIN PHARMACOL THER, V66, P66, DOI 10.1016/S0009-9236(99)70055-X; Martinussen M, 1996, PEDIATR RES, V39, P275, DOI 10.1203/00006450-199602000-00015; MARTINUSSEN M, 1994, PEDIATR RES, V36, P334, DOI 10.1203/00006450-199409000-00011; McCarver DG, 2002, J PHARMACOL EXP THER, V300, P361, DOI 10.1124/jpet.300.2.361; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; MILLER RP, 1976, CLIN PHARMACOL THER, V19, P284; MORSELLI PL, 1977, DRUG DISPOSITION DEV, P311; MURRY DJ, 1995, DRUG METAB DISPOS, V23, P1110; OKAH FA, 1995, PEDIATRICS, V96, P688; PAINTER MJ, 1981, NEUROLOGY, V31, P1107, DOI 10.1212/WNL.31.9.1107; POLEY JR, 1964, J LAB CLIN MED, V63, P838; Pui CH, 2001, LANCET ONCOL, V2, P597, DOI 10.1016/S1470-2045(01)00516-2; PYNNONEN S, 1977, EUR J CLIN PHARMACOL, V11, P129, DOI 10.1007/BF00562904; RITSCHEL WA, 1999, HDB BASIC PHARMACOKI, P318; RITSCHEL WA, 1980, HDB BASIC PHARMACOKI, P296; RIVA R, 1985, CLIN PHARMACOKINET, V10, P524, DOI 10.2165/00003088-198510060-00005; Robillard JE, 1999, PEDIAT NEPHROLOGY, P21; RODBRO PAUL, 1967, SCAND J GASTROENTEROL, V2, P209; RUTTER N, 1987, CLIN PERINATOL, V14, P911, DOI 10.1016/S0095-5108(18)30740-1; SCHILLERSCOTLAND CF, 1994, TOXICOL LETT, V72, P137, DOI 10.1016/0378-4274(94)90020-5; Scott CS, 1999, J PEDIATR-US, V135, P423, DOI 10.1016/S0022-3476(99)70163-0; Sharer JE, 1996, DRUG METAB DISPOS, V24, P487; SHENG KT, 1964, ANTIMICROBIAL AGENTS, P200; SIBER GR, 1975, J INFECT DIS, V132, P637, DOI 10.1093/infdis/132.6.637; Silver L, 2001, VOICES, V27, P37; Sonnier M, 1998, EUR J BIOCHEM, V251, P893, DOI 10.1046/j.1432-1327.1998.2510893.x; Stahl G, 1999, HUNG J IND CHEM, V27, P9; Steinbrook R, 2002, NEW ENGL J MED, V347, P1462, DOI 10.1056/NEJMhpr021646; Stratchunsky L S, 1991, Eur J Drug Metab Pharmacokinet, VSpec No 3, P321; SUCHY FJ, 1981, GASTROENTEROLOGY, V80, P1037; SZEFLER SJ, 1980, J PEDIATR-US, V97, P312, DOI 10.1016/S0022-3476(80)80506-3; Takahashi H, 2000, CLIN PHARMACOL THER, V68, P541, DOI 10.1067/mcp.2000.110977; Taketomo CH, 2000, PEDIAT DOSAGE HDB; Thorsson L, 2001, BRIT J CLIN PHARMACO, V52, P529, DOI 10.1046/j.0306-5251.2001.01493.x; TRELUYER JM, 1991, EUR J BIOCHEM, V202, P583, DOI 10.1111/j.1432-1033.1991.tb16411.x; Treluyer JM, 1997, PHARMACOGENETICS, V7, P441, DOI 10.1097/00008571-199712000-00002; Tsai C, 2000, PEDIATR RES, V47, p436A; van Lingen RA, 1999, ARCH DIS CHILD-FETAL, V80, pF59, DOI 10.1136/fn.80.1.F59; vandenAnker JN, 1995, CLIN PHARMACOL THER, V58, P650, DOI 10.1016/0009-9236(95)90021-7; VANDENANKER JN, 1994, PEDIATR RES, V36, P578, DOI 10.1203/00006450-199411000-00006; Vieira I, 1996, EUR J BIOCHEM, V238, P476, DOI 10.1111/j.1432-1033.1996.0476z.x; WEAVER LT, 1991, GUT, V32, P1321, DOI 10.1136/gut.32.11.1321; WEISS CF, 1960, NEW ENGL J MED, V262, P787, DOI 10.1056/NEJM196004212621601; WEST DP, 1981, J INVEST DERMATOL, V76, P147, DOI 10.1111/1523-1747.ep12525553; WINDORFE.A, 1974, EUR J CLIN PHARMACOL, V7, P227, DOI 10.1007/BF00560385; Yanowitz TD, 1999, J APPL PHYSIOL, V87, P370, DOI 10.1152/jappl.1999.87.1.370; YOUNG WS, 1978, J PHARMACOL EXP THER, V204, P203	98	1456	1512	3	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1157	1167		10.1056/NEJMra035092	http://dx.doi.org/10.1056/NEJMra035092			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679531				2023-01-03	WOS:000185369700011
J	Keeling, P; Hughes, D; Price, L; Shaw, S; Barton, A				Keeling, P; Hughes, D; Price, L; Shaw, S; Barton, A			Safety and feasibility of prehospital thrombolysis carried out by paramedics	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION		S Devon Healthcare Trust, Torquay TQ2 7AA, England; Peninsula Med Sch, Res & Dev Support Unit, Plymouth PL6 8BX, Devon, England; Univ Plymouth, Dept Math & Stat, Plymouth PL4 8AA, Devon, England	University of Plymouth; University of Plymouth	Keeling, P (corresponding author), S Devon Healthcare Trust, Lawes Bridge, Torquay TQ2 7AA, England.			barton, andy/0000-0003-2245-1446				Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; *DEP HLTH, 2001, NAT SERV FRAM COR HE; Morrison LJ, 2000, JAMA-J AM MED ASSOC, V283, P2686, DOI 10.1001/jama.283.20.2686; *NAT I CLIN EXC, 2002, GUID US DRUGS EARL T; *ROYAL COLL AMB LI, 2001, TECHN APPR PROC SER, V4	5	27	29	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 5	2003	327	7405					27	28		10.1136/bmj.327.7405.27	http://dx.doi.org/10.1136/bmj.327.7405.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842952	Bronze, Green Published			2023-01-03	WOS:000184062700022
J	Imai, Y; Parodo, J; Kajikawa, O; de Perrot, M; Fischer, S; Edwards, V; Cutz, E; Liu, MY; Keshavjee, S; Martin, TR; Marshall, JC; Ranieri, VM; Slutsky, AS				Imai, Y; Parodo, J; Kajikawa, O; de Perrot, M; Fischer, S; Edwards, V; Cutz, E; Liu, MY; Keshavjee, S; Martin, TR; Marshall, JC; Ranieri, VM; Slutsky, AS			Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL TUBULAR CELLS; INDUCED LUNG INJURY; SOLUBLE FAS-LIGAND; DEATH; FAILURE; SEPSIS; EXPRESSION; INDUCTION; CYTOKINES; ISCHEMIA	Context Recent clinical trials have demonstrated a decrease in multiple organ dysfunction syndrome (MODS) and mortality in patients with acute respiratory distress syndrome (ARDS) treated with a protective ventilatory strategy. Objective To examine the hypothesis that an injurious ventilatory strategy may lead to end-organ epithelial cell apoptosis and organ dysfunction. Design and Setting In vivo animals: 24 rabbits with acid-aspiration lung injury were ventilated with injurious or noninjurious ventilatory strategies. In vitro:,rabbit epithelial cells were exposed to plasma from in vivo rabbit studies. In vivo human: plasma samples from patients included in a previous randomized controlled trial examining a lung protective strategy were analyzed (lung protection group, n=9 and controls, n=11). Main Outcome Measures In vivo animals: biochemical markers of liver and renal dysfunction; apoptosis in end organs. In vitro: induction of apoptosis in LLC-RK1 renal tubular epithelial cells. In vivo human: correlation of plasma creatinine and soluble Fas ligand. Results The injurious ventilatory strategy led to increased rates of epithelial cell apoptosis in the kidney (mean [SE]: injurious, 10.9% [0.88%]; noninjurious, 1.86% [0.17%]; P<001) and small intestine villi (injurious, 6.7% [0.66%]; noninjurious, 0.97% [0.14%]; P<001), and led to the elevation of biochemical markers indicating renal dysfunction in vivo. Induction of apoptosis was increased in LLC-RK1 cells incubated with plasma from rabbits ventilated with injurious ventilatory strategy at 4 hours (P=.03) and 8 hours (P=.002). The Fas:Ig, a fusion protein that blocks soluble Fas ligand, attenuated induction of apoptosis in vitro. There was a significant correlation between changes in soluble Fas ligand and changes in creatinine in patients with ARDS (R=0.64, P=.002). Conclusions Mechanical ventilation can lead to epithelial cell apoptosis in the kidney and small intestine, Accompanied by biochemical evidence of organ dysfunction. This may partially explain the high rate of MODS observed in patients with ARDS and the decrease in morbidity and mortality in patients treated with a lung protective strategy.	Univ Toronto, St Michaels Hosp, Dept Crit Care, Toronto, ON M5B 1W8, Canada; Univ Hlth Network, Res Lab, Toronto, ON, Canada; Seattle Vet Adm Med Ctr, Seattle, WA USA; Hosp Sick Children, Res Inst, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Turin, Osped S Giovanni Battista, Sez Anestesiol & Rianimaz, Dipartimento Discipline Medicochirurg Div, Turin, Italy	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin	Slutsky, AS (corresponding author), Univ Toronto, St Michaels Hosp, Dept Crit Care, 30 Bond St,Queen Wing,Room 4-042, Toronto, ON M5B 1W8, Canada.	arthur.slutsky@utoronto.ca	Ranieri, Marco/AFX-8152-2022; Slutsky, Arthur/M-3325-2019; Imai, Yumiko/GXW-1144-2022; Slutsky, Arthur S/A-6013-2008	Slutsky, Arthur S/0000-0002-6063-3876; Liu, Mingyao/0000-0002-9188-8417; Keshavjee, Shaf/0000-0003-4547-8094; de Perrot, Marc/0000-0003-2000-9427				Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; [Anonymous], 1999, INTENS CARE MED, V25, P1444; BALK RA, 1995, JAMA-J AM MED ASSOC, V274, P127, DOI 10.1001/jama.1995.03530020045021; Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; Coopersmith CM, 2002, JAMA-J AM MED ASSOC, V287, P1716, DOI 10.1001/jama.287.13.1716; Daemen MARC, 2001, TRANSPLANTATION, V71, P1007; de Perrot M, 2002, J THORAC CARDIOV SUR, V124, P1137, DOI 10.1067/mtc.2002.125056; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Fink M P, 2000, Minerva Anestesiol, V66, P337; Fischer S, 2000, ANN SURG, V231, P424, DOI 10.1097/00000658-200003000-00016; Fry DE, 2000, AM SURGEON, V66, P126; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237, DOI 10.1164/ajrccm.161.1.9810007; Healy E, 1998, KIDNEY INT, V54, P1955, DOI 10.1046/j.1523-1755.1998.00202.x; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; Hotchkiss RS, 2000, CRIT CARE MED, V28, P3207, DOI 10.1097/00003246-200009000-00016; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; Hudson LD, 1999, JAMA-J AM MED ASSOC, V282, P77, DOI 10.1001/jama.282.1.77; Imai Y, 2001, J APPL PHYSIOL, V91, P1836, DOI 10.1152/jappl.2001.91.4.1836; Iwama H, 2000, AM J EMERG MED, V18, P348, DOI 10.1016/S0735-6757(00)90141-4; Kajikawa O, 1997, J IMMUNOL METHODS, V205, P135, DOI 10.1016/S0022-1759(97)00066-5; Kajikawa O, 1996, J IMMUNOL METHODS, V197, P19, DOI 10.1016/0022-1759(96)00101-9; Koide N, 1996, FEMS IMMUNOL MED MIC, V16, P205, DOI 10.1111/j.1574-695X.1996.tb00137.x; Krammer P H, 1999, Adv Immunol, V71, P163; LeGall JR, 1996, JAMA-J AM MED ASSOC, V276, P802, DOI 10.1001/jama.276.10.802; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; Matute-Bello G, 2001, AM J PHYSIOL-LUNG C, V281, pL328, DOI 10.1152/ajplung.2001.281.2.L328; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OrtizArduan A, 1996, AM J PHYSIOL-RENAL, V271, pF1193; Papathanassoglou EDE, 2000, CRIT CARE MED, V28, P537, DOI 10.1097/00003246-200002000-00042; Perianayagam MC, 2000, J LAB CLIN MED, V136, P320, DOI 10.1067/mlc.2000.109318; Rana A, 2001, APOPTOSIS, V6, P83, DOI 10.1023/A:1009680229931; Ranieri VM, 2000, JAMA-J AM MED ASSOC, V284, P43, DOI 10.1001/jama.284.1.43; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; SCHUMER M, 1992, AM J PATHOL, V140, P831; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; Tesch GH, 1999, J CLIN INVEST, V103, P73, DOI 10.1172/JCI4876; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tremblay LN, 1998, P ASSOC AM PHYSICIAN, V110, P482; Ueda N, 1998, KIDNEY INT, V54, P399, DOI 10.1046/j.1523-1755.1998.00008.x; WARDLE EN, 1994, NEPHROL DIAL TRANSPL, V9, P104; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Watson RWG, 1997, J IMMUNOL, V158, P945; Wyncoll DLA, 1999, LANCET, V354, P497, DOI 10.1016/S0140-6736(98)08129-X	51	446	488	2	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2104	2112		10.1001/jama.289.16.2104	http://dx.doi.org/10.1001/jama.289.16.2104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709468	Bronze			2023-01-03	WOS:000182374300026
J	Grier, HE; Krailo, MD; Tarbell, NJ; Link, MP; Fryer, CJH; Pritchard, DJ; Gebhardt, MC; Dickman, PS; Perlman, EJ; Meyers, PA; Donaldson, SS; Moore, S; Rausen, AR; Vietti, TJ; Miser, JS				Grier, HE; Krailo, MD; Tarbell, NJ; Link, MP; Fryer, CJH; Pritchard, DJ; Gebhardt, MC; Dickman, PS; Perlman, EJ; Meyers, PA; Donaldson, SS; Moore, S; Rausen, AR; Vietti, TJ; Miser, JS			Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YOUNG-ADULTS; PEDIATRIC ONCOLOGY; NO BENEFIT; CHILDREN; CYCLOPHOSPHAMIDE; VINCRISTINE; DOXORUBICIN; COMBINATION; EXPERIENCE; CHILDHOOD	BACKGROUND: Ewing's sarcoma and primitive neuroectodermal tumor of bone are closely related, highly malignant tumors of children, adolescents, and young adults. A new drug combination, ifosfamide and etoposide, was highly effective in patients with Ewing's sarcoma or primitive neuroectodermal tumor of bone who had a relapse after standard therapy. We designed a study to test whether the addition of these drugs to a standard regimen would improve the survival of patients with newly diagnosed disease. METHODS: Patients 30 years old or younger with Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone were eligible. The patients were randomly assigned to receive 49 weeks of standard chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin or experimental therapy with these four drugs alternating with courses of ifosfamide and etoposide. RESULTS: A total of 518 patients met the eligibility requirements. Of 120 patients with metastatic disease, 62 were randomly assigned to the standard-therapy group and 58 to the experimental-therapy group. There was no significant difference in five-year event-free survival between the treatment groups (P=0.81). Among the 398 patients with nonmetastatic disease, the mean (+/-SE) five-year event-free survival among the 198 patients in the experimental-therapy group was 69+/-3 percent, as compared with 54+/-4 percent among the 200 patients in the standard-therapy group (P=0.005). Overall survival was also significantly better among patients in the experimental-therapy group (72+/-3.4 percent vs. 61+/-3.6 percent in the standard-therapy group, P=0.01). CONCLUSIONS: The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone.	Dana Farber Canc Inst, Dept Pediat Hematol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Oncol, Boston, MA 02115 USA; Childrens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; King Khalid Natl Hosp, Dept Pediat, Jeddah, Saudi Arabia; Mayo Clin, Rochester, MN USA; Childrens Hosp Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Childrens Hosp, Dept Radiol, Los Angeles, CA 90027 USA; NYU Med Ctr, Dept Pediat, New York, NY 10016 USA; Washington Univ, Med Ctr, Div Pediat Hematol & Oncol, St Louis, MO USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; City Hope Natl Med Ctr, Dept Pediat, Duarte, CA 91010 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; University of Southern California; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Stanford University; Stanford University; Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center; Children's Hospital Los Angeles; New York University; Washington University (WUSTL); Washington University (WUSTL); City of Hope	Grier, HE (corresponding author), Dana Farber Canc Inst, Dept Pediat Hematol, 44 Binney St, Boston, MA 02115 USA.			Donaldson, Sarah/0000-0001-7125-3118; Perlman, Elizabeth/0000-0001-6853-6221; Meyers, Paul/0000-0001-6146-6101				ANTMAN KH, 1989, J CLIN ONCOL, V7, P126, DOI 10.1200/JCO.1989.7.1.126; ANTMAN KH, 1989, J CLIN ONCOL, V7, P1369; Bacci G, 1998, CANCER-AM CANCER SOC, V82, P1174, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1174::AID-CNCR24>3.0.CO;2-2; Craft A, 1998, J CLIN ONCOL, V16, P3628, DOI 10.1200/JCO.1998.16.11.3628; DEHNER LP, 1994, ARCH PATHOL LAB MED, V118, P606; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HUSTU HO, 1972, CANCER, V30, P1522, DOI 10.1002/1097-0142(197212)30:6<1522::AID-CNCR2820300617>3.0.CO;2-J; JURGENS H, 1988, CANCER, V61, P23, DOI 10.1002/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M; Jurgens H, 1989, Cancer Chemother Pharmacol, V24 Suppl 1, pS40; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; KAMEN BA, 1995, J CLIN ONCOL, V13, P307, DOI 10.1200/JCO.1995.13.2.307; KUNG FH, 1993, CANCER-AM CANCER SOC, V71, P1898, DOI 10.1002/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO;2-Q; KUSHNER BH, 1995, J CLIN ONCOL, V13, P2796, DOI 10.1200/JCO.1995.13.11.2796; MAGRATH I, 1986, CANCER CHEMOTH PHARM, V18, pS25, DOI 10.1007/BF00647446; MEYER WH, 1992, J CLIN ONCOL, V10, P1737, DOI 10.1200/JCO.1992.10.11.1737; MISER JS, 1987, J CLIN ONCOL, V5, P1191, DOI 10.1200/JCO.1987.5.8.1191; Nesbit M E, 1976, CA Cancer J Clin, V26, P174, DOI 10.3322/canjclin.26.3.174; NESBIT ME, 1990, J CLIN ONCOL, V8, P1664, DOI 10.1200/JCO.1990.8.10.1664; OBERLIN O, 1992, J CLIN ONCOL, V10, P1407, DOI 10.1200/JCO.1992.10.9.1407; Paulussen M, 2001, J CLIN ONCOL, V19, P1818, DOI 10.1200/JCO.2001.19.6.1818; Rosito P, 1999, CANCER-AM CANCER SOC, V86, P421, DOI 10.1002/(SICI)1097-0142(19990801)86:3<421::AID-CNCR10>3.0.CO;2-O; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Wexler LH, 1996, CANCER, V78, P901; Wexler LH, 1997, CANCER, V79, P867; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4	26	823	896	0	56	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	2003	348	8					694	701		10.1056/NEJMoa020890	http://dx.doi.org/10.1056/NEJMoa020890			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646BF	12594313				2023-01-03	WOS:000181014400004
J	Moore, L; Campbell, R; Whelan, A; Mills, N; Lupton, P; Misselbrook, E; Frohlich, J				Moore, L; Campbell, R; Whelan, A; Mills, N; Lupton, P; Misselbrook, E; Frohlich, J			Self help smoking cessation in pregnancy: cluster randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							STOPPING SMOKING; INTERVENTION; WOMEN; PROGRAM; SMOKERS; CARE	Objectives To evaluate the effectiveness of a self help approach to smoking cessation in pregnancy. Design Pragmatic cluster randomised controlled trial with community midwife as the unit of randomisation. Setting Three NHS hospital trusts in England. Participants 1527 women who smoked at the start of pregnancy. Intervention A series of five self help booklets comprising a step by step programme to increase motivation for quitting smoking and to teach strategies for cessation and relapse prevention. The first booklet was given to the women by a midwife at the earliest opportunity in antenatal care, together with a booklet for partners, family members, and friends. The remaining four booklets were mailed directly to die women. Main outcome measures The primary outcome was smoking cessation validated by cotinine measurement at the end of the second trimester of pregnancy. Other outcomes were self reported smoking status and cigarette consumption among daily smokers. Qualitative data exploring the acceptability of the intervention and the way that smoking cessation advice was delivered in both trial arms were also collected. Results Smoking cessation rates were low: the cotinine validated rates were 18.8% (113/600) in the intervention group and 20.7% (144/695) in the normal care group (difference 1.9%, 95% confidence intervals -3.5% to 7.3%). Self reported quit rates were higher. In the intervention group, 156 (25.6%), women reported not smoking for at least seven days, compared with 207 (29.1%) in the normal care group. In both groups, median self reported daily cigarette consumption among daily smokers was 10 cigarettes per day. Pregnant women and midwives approved of the intervention, but the way in which it was delivered varied considerably. For the primary smoking outcome, the degree of clustering at the midwife level was non-trivial (intracluster correlation coefficient 0.031). Conclusion The self help intervention was acceptable but ineffective when implemented during routine antenatal care. More intensive and complex interventions, appropriately targeted and tailored, need to be developed and evaluated. Validated smoking cessation rates among pregnant women are substantially lower than the self reported rates on which current smoking policy is based.	Cardiff Univ, Sch Social Sci, Cardiff CF10 3WT, S Glam, Wales; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ W England, Ctr Res Innovat & Grad Studies, Bristol BS16 1QD, Avon, England; Poole Hosp NHS Trust, Poole BH15 2JB, Dorset, England; St Michaels Hosp, United Bristol Healthcare Trust, Bristol BS2 8EG, Avon, England; Southmead Gen Hosp, N Bristol NHS Trust, Bristol BS10 5NB, Avon, England	Cardiff University; University of Bristol; University of West England; North Bristol NHS Trust; Southmead Hospital	Moore, L (corresponding author), Cardiff Univ, Sch Social Sci, Cardiff CF10 3WT, S Glam, Wales.			Mills, Nicola/0000-0002-2960-2940; Moore, Laurence/0000-0003-2182-823X				ADAMS C, 2000, UNPUB LEADING WAY SM; [Anonymous], 2002, INFANT FEEDING 2000; DOLANMULLEN P, 1994, AM J OBSTET GYNECOL, V171, P1328, DOI 10.1016/0002-9378(94)90156-2; ERSHOFF DH, 1989, AM J PUBLIC HEALTH, V79, P182, DOI 10.2105/AJPH.79.2.182; Fitzmaurice DA, 2001, BRIT MED J, V322, P1193, DOI 10.1136/bmj.322.7296.1193; Gielen AC, 1997, HEALTH EDUC RES, V12, P247, DOI 10.1093/her/12.2.247; Hajek P, 2001, ADDICTION, V96, P485, DOI 10.1046/j.1360-0443.2001.96348511.x; HJALMARSON AIM, 1991, BRIT J OBSTET GYNAEC, V98, P260, DOI 10.1111/j.1471-0528.1991.tb13390.x; *HLTH ED AUTH, 1993, SMOK PREGN GUID PURC; KENDRICK JS, 1995, AM J PUBLIC HEALTH, V85, P217, DOI 10.2105/AJPH.85.2.217; LUMLEY J, 1998, COCHRANE LIB; LUMLEY J, 1994, PREGNANCY CHILDBIRTH; MANT D, 1996, SCI BASIS HLTH SERVI, P170; Owen L, 1998, BRIT MED J, V317, P728, DOI 10.1136/bmj.317.7160.728; Owen L, 2001, ADDICTION, V96, P1001, DOI 10.1046/j.1360-0443.2001.96710019.x; PETERSEN L, 1992, OBSTET GYNECOL, V79, P924; Secretary of State for Health, 1998, SMOK KILLS WHIT PAP; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; WALSH R, 1993, HEALTH PROMOT INT, V8, P111; WINDSOR RA, 1985, AM J PUBLIC HEALTH, V75, P1389, DOI 10.2105/AJPH.75.12.1389; WINDSOR RA, 1993, AM J PUBLIC HEALTH, V83, P201, DOI 10.2105/AJPH.83.2.201; Wisborg K, 1998, BRIT J OBSTET GYNAEC, V105, P1171, DOI 10.1111/j.1471-0528.1998.tb09970.x; [No title captured]	23	49	51	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 14	2002	325	7377					1383	1386A		10.1136/bmj.325.7377.1383	http://dx.doi.org/10.1136/bmj.325.7377.1383			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	628CP	12480850	Green Published			2023-01-03	WOS:000179975000016
J	Ayanian, JZ; Landrum, MB; Guadagnoli, E; Gaccione, P				Ayanian, JZ; Landrum, MB; Guadagnoli, E; Gaccione, P			Specialty of ambulatory care physicians and mortality among elderly patients after myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; RIGHT HEART CATHETERIZATION; MEDICARE PATIENTS; PROPENSITY SCORE; CARDIOLOGISTS; GENERALIST; QUALITY; OUTCOMES; ASSOCIATION; MANAGEMENT	Background: The outcome after myocardial infarction may be influenced by the type of physician providing ambulatory care. Methods: We studied 35,520 patients 65 years of age or older who were hospitalized for myocardial infarction in seven states during 1994 and 1995 and who survived for at least three months after discharge. From Medicare claims, we identified ambulatory visits to cardiologists, internists, and family practitioners. Using propensity scores to adjust for demographic, clinical, and hospital characteristics, we analyzed treatment and mortality at two years among patients matched according to their estimated propensity to receive care from a cardiologist within three months after discharge. Results: As compared with patients who saw only an internist or a family practitioner in the three months after discharge, patients who saw a cardiologist were younger, were more likely to be white, were more likely to be male, had fewer coexisting conditions, and were more likely to have undergone invasive cardiac procedures while hospitalized (P<0.01 for all comparisons). Patients who saw a cardiologist were more likely to undergo cardiac procedures and rehabilitation after discharge. Patients who saw a cardiologist had a lower two-year mortality rate than matched patients who saw only an internist or a family practitioner (14.6 percent vs. 18.3 percent, P<0.001). Patients who saw both a cardiologist and an internist or a family practitioner had a lower mortality rate than matched patients who saw only a cardiologist (11.1 percent vs. 12.1 percent, P=0.02). Conclusions: Ambulatory visits to cardiologists were associated with greater use of cardiac procedures and decreased mortality after myocardial infarction. Concurrent care by an internist or a family practitioner was associated with a further reduction in mortality.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.				AHRQ HHS [R01 HS09718, R01 HS08071] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009718, R01HS008071] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM MED ASS, 1997, PHYS CURR PROC TERM; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; Ayanian JZ, 2000, AM J MED, V108, P259, DOI 10.1016/S0002-9343(99)00455-6; Ayanian JZ, 2002, ARCH INTERN MED, V162, P1013, DOI 10.1001/archinte.162.9.1013; Baldwin LM, 2002, MED CARE, V40, P82; Casale PN, 1998, J AM COLL CARDIOL, V32, P885, DOI 10.1016/S0735-1097(98)00325-8; Chen J, 2000, AM J MED, V108, P460, DOI 10.1016/S0002-9343(00)00331-4; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Donohoe MT, 1998, ARCH INTERN MED, V158, P1596, DOI 10.1001/archinte.158.15.1596; Frances CD, 1999, ARCH INTERN MED, V159, P1429, DOI 10.1001/archinte.159.13.1429; Frances CD, 2000, HEALTH SERV RES, V35, P1093; Go AS, 2000, AM J MED, V108, P216, DOI 10.1016/S0002-9343(99)00430-1; Hardarson T, 2001, J INTERN MED, V249, P495, DOI 10.1046/j.1365-2796.2001.00834.x; Harrold LR, 1999, J GEN INTERN MED, V14, P499, DOI 10.1046/j.1525-1497.1999.08168.x; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; LANDRUM MB, 2001, HLTH SERV OUTCOMES R, V2, P221, DOI DOI 10.1023/A:1020367111374; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; Majumdar SR, 2001, J GEN INTERN MED, V16, P351, DOI 10.1046/j.1525-1497.2001.016006351.x; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Nash IS, 1999, AM J CARDIOL, V83, P650, DOI 10.1016/S0002-9149(98)00961-8; Nash IS, 1997, J AM COLL CARDIOL, V29, P475, DOI 10.1016/S0735-1097(96)00528-1; O'Connor GT, 1999, JAMA-J AM MED ASSOC, V281, P627, DOI 10.1001/jama.281.7.627; Petersen LA, 2000, NEW ENGL J MED, V343, P1934, DOI 10.1056/NEJM200012283432606; Polanczyk CA, 2001, JAMA-J AM MED ASSOC, V286, P309, DOI 10.1001/jama.286.3.309; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Seddon ME, 2001, AM J MED, V111, P24, DOI 10.1016/S0002-9343(01)00741-0; Sundararajan V, 2002, ANN INTERN MED, V136, P349, DOI 10.7326/0003-4819-136-5-200203050-00007; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Willison DJ, 1998, ARCH INTERN MED, V158, P1778, DOI 10.1001/archinte.158.16.1778	34	163	164	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1678	1686		10.1056/NEJMsa020080	http://dx.doi.org/10.1056/NEJMsa020080			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444183	Bronze			2023-01-03	WOS:000179339900007
J	Crowther, C; Henderson-Smart, D				Crowther, C; Henderson-Smart, D			Prenatal phenobarbital before very-preterm birth and neurodevelopmental outcome	LANCET			English	Editorial Material							HEMORRHAGE; NEWBORN; INFANTS		Univ Adelaide, Dept Obstet & Gynaecol, Maternal Perinatal Clin Trials Unit, Adelaide, SA 5001, Australia; Univ Sydney, Neonatal Med Royal Prince Alfred Hosp, NSW Ctr Perinatal Serv Res, Sydney, NSW 2006, Australia	University of Adelaide; University of Sydney	Crowther, C (corresponding author), Univ Adelaide, Dept Obstet & Gynaecol, Maternal Perinatal Clin Trials Unit, Adelaide, SA 5001, Australia.							CROWLEY P, 2002, COCHRANE LIB; Doyle L, 1996, LANCET, V348, P975, DOI 10.1016/S0140-6736(05)64922-7; Early Supported Discharge Trialists, 2002, COCHRANE LIB; GODDARDFINEGOLD J, 1987, PEDIATRICS, V79, P901; Shankaran S, 1997, NEW ENGL J MED, V337, P466, DOI 10.1056/NEJM199708143370705; Shankaran S, 2002, AM J OBSTET GYNECOL, V187, P171, DOI 10.1067/mob.2002.122445; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; WIMBERLEY PD, 1982, ACTA PAEDIATR SCAND, V71, P537, DOI 10.1111/j.1651-2227.1982.tb09471.x; 2002, COCHRANE LIB, V3	9	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1529	1530		10.1016/S0140-6736(02)11578-9	http://dx.doi.org/10.1016/S0140-6736(02)11578-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443587				2023-01-03	WOS:000179292400005
J	Spronk, PE; Ince, C; Gardien, MJ; Mathura, KR; Oudemans-van Straaten, HM; Zandstra, DF				Spronk, PE; Ince, C; Gardien, MJ; Mathura, KR; Oudemans-van Straaten, HM; Zandstra, DF			Nitroglycerin in septic shock after intravascular volume resuscitation	LANCET			English	Article							MICROCIRCULATION; SEPSIS	In patients with septic shock, oxygen consumption is increased, but oxygen delivery and extraction is impaired, partly because of microcirculatory shutdown and shunting. Orthogonal polarisation spectral (OPS) imaging allows visualisation of the microcirculation. We used this technique to assess microcirculatory flow in septic-shock patients who had a mean arterial blood pressure of more than 60 mm Hg and central venous pressure greater than 12 mm Hg. The infusion of 0.5 mg of nitroglycerin intravenously then resulted in a marked increase in microvascular flow on OPS imaging. Improved recruitment of the microcirculation could be a new resuscitation endpoint in septic shock.	Onze Lieve Vrouw Hosp, Dept Intens Care Med, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Anesthesiol, NL-1105 AZ Amsterdam, Netherlands	Onze Lieve Vrouwe Gasthuis Hospital; University of Amsterdam; Academic Medical Center Amsterdam	Spronk, PE (corresponding author), Gelre Ziekenhuizen, Dept Intens Care Med, Locatie Lukas,Albert Schweitzerlaan 31, NL-7334 DZ Apeldoorn, Netherlands.							Ince C, 1999, CRIT CARE MED, V27, P1369, DOI 10.1097/00003246-199907000-00031; Lehr HA, 2000, J PATHOL, V190, P373, DOI 10.1002/(SICI)1096-9896(200002)190:3&lt;373::AID-PATH593&gt;3.0.CO;2-3; Mathura KR, 2001, J APPL PHYSIOL, V91, P74, DOI 10.1152/jappl.2001.91.1.74; Mathura KR, 2001, LANCET, V358, P1698, DOI 10.1016/S0140-6736(01)06722-8; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307	5	383	406	1	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1395	1396		10.1016/S0140-6736(02)11393-6	http://dx.doi.org/10.1016/S0140-6736(02)11393-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423989				2023-01-03	WOS:000179081600016
J	Weaver, LK; Hopkins, RO; Chan, KJ; Churchill, S; Elliott, CG; Clemmer, TP; Orme, JF; Thomas, FO; Morris, AH				Weaver, LK; Hopkins, RO; Chan, KJ; Churchill, S; Elliott, CG; Clemmer, TP; Orme, JF; Thomas, FO; Morris, AH			Hyperbaric oxygen for acute carbon monoxide poisoning	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NORMOBARIC OXYGEN; PROGRESS	Background: Patients with acute carbon monoxide poisoning commonly have cognitive sequelae. We conducted a double-blind, randomized trial to evaluate the effect of hyperbaric-oxygen treatment on such cognitive sequelae. Methods: We randomly assigned patients with symptomatic acute carbon monoxide poisoning in equal proportions to three chamber sessions within a 24-hour period, consisting of either three hyperbaric-oxygen treatments or one normobaric-oxygen treatment plus two sessions of exposure to normobaric room air. Oxygen treatments were administered from a high-flow reservoir through a face mask that prevented rebreathing or by endotracheal tube. Neuropsychological tests were administered immediately after chamber sessions 1 and 3, and 2 weeks, 6 weeks, 6 months, and 12 months after enrollment. The primary outcome was cognitive sequelae six weeks after carbon monoxide poisoning. Results: The trial was stopped after the third of four scheduled interim analyses, at which point there were 76 patients in each group. Cognitive sequelae at six weeks were less frequent in the hyperbaric-oxygen group (19 of 76 [25.0 percent]) than in the normobaric-oxygen group (35 of 76 [46.1 percent], P=0.007), even after adjustment for cerebellar dysfunction and for stratification variables (adjusted odds ratio, 0.45 [95 percent confidence interval, 0.22 to 0.92]; P=0.03). The presence of cerebellar dysfunction before treatment was associated with the occurrence of cognitive sequelae (odds ratio, 5.71 [95 percent confidence interval, 1.69 to 19.31]; P=0.005) and was more frequent in the normobaric-oxygen group (15 percent vs. 4 percent, P=0.03). Cognitive sequelae were less frequent in the hyperbaric-oxygen group at 12 months, according to the intention-to-treat analysis (P=0.04). Conclusions: Three hyperbaric-oxygen treatments within a 24-hour period appeared to reduce the risk of cognitive sequelae 6 weeks and 12 months after acute carbon monoxide poisoning.	Latter Day St Hosp, Dept Internal Med, Div Pulm & Crit Care, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Stat Data Ctr, Salt Lake City, UT 84143 USA; Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA	Utah System of Higher Education; University of Utah; Brigham Young University	Weaver, LK (corresponding author), Latter Day St Hosp, Crit Care Div, 8th Ave & C St, Salt Lake City, UT 84143 USA.	lweaver@ihc.com	Isbister, Geoffrey K/G-8052-2015	Isbister, Geoffrey K/0000-0003-1519-7419				Brown S D, 1989, Adv Exp Med Biol, V248, P747; BROWN SD, 1989, LANCET, V2, P1032; CHOI IS, 1983, ARCH NEUROL-CHICAGO, V40, P433, DOI 10.1001/archneur.1983.04050070063016; CLARK JM, 1993, PHYSL MED DIVING, P121; Denman SB., 1984, DENMAN NEUROPSYCHOLO; DUCASSE JL, 1995, UNDERSEA HYPERBAR M, V22, P9; Ernst A, 1998, NEW ENGL J MED, V339, P1603, DOI 10.1056/NEJM199811263392206; GORMAN DF, 1992, ANAESTH INTENS CARE, V20, P311, DOI 10.1177/0310057X9202000306; Hampson NB, 1996, UNDERSEA HYPERBAR M, V23, P215; HAMPSON NB, 1999, HYPERBARIC OXYGEN TH; Hampson Neil B., 1995, Journal of Emergency Medicine, V13, P227, DOI 10.1016/0736-4679(94)00144-8; Heaton R., 1992, COMPREHENSIVE NORMS; Heaton RK, 1991, COMPREHENSIVE NORMS; HOPKINS RO, 1991, UNDERSEA BIOMED RES, V18, P34; JUURLINK DN, 2000, COCHRANE DB SYST REV, V2, P2041; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; Kindwall EP, 1988, HYPERBARIC MED PROCE, P32; Lezak M.D., 2012, NEUROPSYCHOLOGICAL A; MESSIER LD, 1991, J CLIN PSYCHOL, V47, P675, DOI 10.1002/1097-4679(199109)47:5<675::AID-JCLP2270470508>3.0.CO;2-H; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; NOTERMANS NC, 1994, J NEUROL NEUROSUR PS, V57, P22, DOI 10.1136/jnnp.57.1.22; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PACE N, 1950, SCIENCE, V111, P652, DOI 10.1126/science.111.2894.652; Piantadosi C A, 1999, Respir Care Clin N Am, V5, P183; RAPHAEL JC, 1989, LANCET, V2, P414; Reitan R., 1993, HALSTEAD REITAN NEUR; Scheinkestel CD, 1999, MED J AUSTRALIA, V170, P203, DOI 10.5694/j.1326-5377.1999.tb140318.x; Spilker B., 1991, GUIDE CLIN TRIALS; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; THOM SR, 1993, TOXICOL APPL PHARM, V123, P248, DOI 10.1006/taap.1993.1243; THOM SR, 1990, TOXICOL APPL PHARM, V105, P340, DOI 10.1016/0041-008X(90)90195-Z; THOM SR, 1997, UNDERSEA HYPER MED S, V24, P20; THOM SR, 1992, UNDERSEA BIOMED RES, V19, P47; THORN SR, 1995, ANN EMERG MED, V25, P474, DOI 10.1016/S0196-0644(95)70261-X; TIBBLES PM, 1994, ANN EMERG MED, V24, P269, DOI 10.1016/S0196-0644(94)70141-5; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; TOMASZEWSKI C, 1992, ANN EMERG MED, V21, P1308, DOI 10.1016/S0196-0644(05)81892-X; Weaver LK, 2000, CHEST, V117, P801, DOI 10.1378/chest.117.3.801; Weaver LK, 1999, CRIT CARE CLIN, V15, P297, DOI 10.1016/S0749-0704(05)70056-7; Weaver LK, 1997, UNDERSEA HYPERB ME S, V24, P36; Wechsler D, 2008, WECHSLER ADULT INTEL; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	42	605	636	0	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1057	1067		10.1056/NEJMoa013121	http://dx.doi.org/10.1056/NEJMoa013121			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362006	Bronze			2023-01-03	WOS:000178332900002
J	Bertheau, P; Plassa, F; Espie, M; Turpin, E; de Roquancourt, A; Marty, M; Lerebours, F; Beuzard, Y; Janin, A; de The, H				Bertheau, P; Plassa, F; Espie, M; Turpin, E; de Roquancourt, A; Marty, M; Lerebours, F; Beuzard, Y; Janin, A; de The, H			Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy	LANCET			English	Article							P53	TP53 activation by genotoxic drugs can induce apoptosis or cell-cycle arrest. Thus, whether the gene is mutated or wild type could affect the response of a tumour to chemotherapy. Clinical data are unclear, possibly as a result of heterogeneity of tumours, drugs, methods of assessing response, or TP53 status. We studied 50 non-inflammatory, locally advanced breast cancers that had been treated with high doses of a combination of epirubicin and cyclophosphamide. We noted eight complete responses, which all occurred in the 14 patients with tumours containing mutated TP53 (p<0.0001). In high-grade, advanced breast cancers, inactivation of the TP53 pathway could greatly improve the response to this chemotherapy regimen.	Hop St Louis, Serv Biochim B, F-75475 Paris 10, France; Hop St Louis, CNRS, UPR 9051, F-75475 Paris, France; Hop St Louis, INSERM, ERM 0220, F-75475 Paris 10, France; Hop St Louis, Serv Pathol, F-75475 Paris 10, France; Hop St Louis, Serv Oncol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	de The, H (corresponding author), Hop St Louis, Serv Biochim B, 1 Ave C Vellefaux, F-75475 Paris 10, France.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Lavarino C, 2000, J CLIN ONCOL, V18, P3936, DOI 10.1200/JCO.2000.18.23.3936; MAKRIS A, 1995, LANCET, V345, P1181, DOI 10.1016/S0140-6736(95)91014-X; McGill G, 1999, J CLIN INVEST, V104, P223, DOI 10.1172/JCI7861	5	114	119	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					852	854		10.1016/S0140-6736(02)09969-5	http://dx.doi.org/10.1016/S0140-6736(02)09969-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243922				2023-01-03	WOS:000178053500013
J	McLeod, H; Ham, C; Kipping, R				McLeod, H; Ham, C; Kipping, R			Booking patients for hospital admissions: evaluation of a pilot programme for day cases	BRITISH MEDICAL JOURNAL			English	Article								Problem NHS patients requiring elective surgery usually have to wait before being treated and are usually told when a date becomes available. Design 18 month pilot programme to enable day case patients to book date of hospital admission at time of decision to operate. Background and setting 24 pilot sites in England with relatively short waiting times and some experience of booking appointments. Key measures for improvement Proportion of patients with booked or "to come in" date during and after pilot programme, proportion not attending for admission, and proportion waiting greater than or equal to6 months. Comparison of pilot sites with non-pilot sites. Strategies for change National Patients' Access Team established to help pilot sites enable patients to book admission dates. Provision of pound9.9m to pilot sites to employ project managers, purchase equipment, buy extra time from clinical and other staff, and invest in information and communications technology. Effects of change Proportion of patients with booked or "to come in" date increased from 51.1% to 72.7% between end of March 1999 and end of March 2000, and then fell to 66.2% by end of March 2001. Over the same periods, the proportion of patients waiting 6 months fell from 10.9% to 10.5% and then increased to 11.9%. The proportion of patients failing to attend fell from 5.7% to 3.1% between the first quarter of 1999 and the first quarter of 2000, and then increased to 4.0% in the first quarter of 2001. Pilot sites varied widely in performance during and after the pilot phase. Pilot sites had higher proportions of patients with booked or "to come in" date than non-pilot sites at end of each period. Lessons learnt Increasing the proportion of patients who book their date of hospital admission is possible, but there are difficulties in sustaining this. Several factors facilitated or hindered the implementation of booking, and the roll out of the programme across the NHS is seeking to incorporate these factors.	Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham	McLeod, H (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.			Kipping, Ruth/0000-0002-5446-8077; McLeod, Hugh/0000-0002-2266-7303				[Anonymous], IMPR EXP REF NEXT 3; Armitage P., 1987, STAT METHODS MED RES; BEECHAM L, 1991, BRIT MED J, V302, P929; COX AG, 1977, LANCET, V1, P301; Department of Health, 2002, IMPR EXP REF NEXT 3; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; Fraser G, 1993, WAITING LISTS WAITIN; HAM C, 2002, CAPACITY CULTURE LEA; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; *S W REG HLTH AUTH, 1991, PROV HIGH QUAL SERV; *SECR STAT HLTH, 2000, NHS PLAN PLAN INV PL; YATES JM, 1998, BOOKING SYSTEMS SCOR	12	5	5	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1147	+		10.1136/bmj.327.7424.1147	http://dx.doi.org/10.1136/bmj.327.7424.1147			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615342	Green Published			2023-01-03	WOS:000186622100023
J	Ball, C; Kirkby, M; Williams, S				Ball, C; Kirkby, M; Williams, S			Effect of the critical care outreach team on patient survival to discharge from hospital and readmission to critical care: non-randomised population based study	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL EMERGENCY TEAM; INTENSIVE-CARE; MORTALITY; ADMISSIONS; ARRESTS; DEATHS; UNITS	Objectives To determine the effect of the critical care outreach team on patient survival to discharge from hospital after discharge from critical care and readmission to critical care. Design Non-randomised population based study. Setting Tertiary referral teaching hospital with 1200 beds. Participants Patients discharged from the critical care unit after their first or only admission for two study periods, 26 February 2000 to 25 February 2001 and 26 February 2001 to 25 February 2002. Main outcome measures Survival to discharge from hospital after discharge from critical care and readmission to critical care. Results The introduction of a critical care outreach team increased survival to discharge from hospital after discharge from critical care by 6.8% (risk ratio 1.08). Readmission to critical care decreased by 6.4% (0.48). Conclusions The activity of the critical care outreach team seems to improve patient survival to discharge from hospital and may reduce the number of readmissions to critical care.	Royal Free Hampstead NHS Trust, Crit Care Unit, London NW3 2QG, England	University of London; University College London	Ball, C (corresponding author), Royal Free Hampstead NHS Trust, Crit Care Unit, London NW3 2QG, England.							Bristow PJ, 2000, MED J AUSTRALIA, V173, P236, DOI 10.5694/j.1326-5377.2000.tb125627.x; Buist MD, 2002, BRIT MED J, V324, P387, DOI 10.1136/bmj.324.7334.387; Cuthbertson BH, 2003, BRIT J ANAESTH, V90, P4, DOI 10.1093/bja/aeg004; DALY K, 2001, BRIT MED J, V322, P1; *DEP HLTH, 2001, COMPR CRIT CAR; Garrard C, 1998, BMJ-BRIT MED J, V316, P1841; Goldhill DR, 1999, ANAESTHESIA, V54, P853; Goldhill DR, 1996, INTENS CARE MED, V22, P415, DOI 10.1007/BF01712157; Goldhill DR, 2002, CURR ANAESTH CRIT CA, V13, P356, DOI DOI 10.1054/cacc.2003.0433; Hillman K, 2003, BRIT J ANAESTH, V90, P808, DOI 10.1093/bja/aeg573; *ICNARC, 1997, INT CAR NAT AUD RES; *INT CAR NAT AUD R, 1997, INT CAR NAT AUD RES; Leary T, 2003, ANAESTHESIA, V58, P328, DOI 10.1046/j.1365-2044.2003.03077.x; McGloin H, 1999, J ROY COLL PHYS LOND, V33, P255; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; Metnitz PGH, 2003, INTENS CARE MED, V29, P241, DOI 10.1007/s00134-002-1584-z; Patel PA, 1999, INTENS CARE MED, V25, P977, DOI 10.1007/s001340050992; Rosenberg AL, 2000, CHEST, V118, P492, DOI 10.1378/chest.118.2.492; *SCOTT EX HLTH DEP, 2000, BETT CRIT CAR REP SH; Trivedi M, 2001, ANAESTHESIA, V56, P841, DOI 10.1046/j.1365-2044.2001.02174.x	20	174	177	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1014	1016A		10.1136/bmj.327.7422.1014	http://dx.doi.org/10.1136/bmj.327.7422.1014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593033	Bronze, Green Published			2023-01-03	WOS:000186294100017
J	Bonaccorso, S; Sturchio, JL				Bonaccorso, S; Sturchio, JL			Perspectives from the pharmaceutical industry	BRITISH MEDICAL JOURNAL			English	Article									Merck & Co Inc, Mkt & Med Serv, Whitehouse Stn, NJ 08889 USA; Merck & Co Inc, External Affairs Europe Middle E & Africa, Whitehouse Stn, NJ 08889 USA	Merck & Company; Merck & Company	Bonaccorso, S (corresponding author), Merck & Co Inc, Mkt & Med Serv, 1 Merck Dr, Whitehouse Stn, NJ 08889 USA.							Bonaccorso SN, 2002, BRIT MED J, V324, P910, DOI 10.1136/bmj.324.7342.910; Calfee JE, 2002, J LAW ECON, V45, P673, DOI 10.1086/374704; Coulter A, 2003, EUROPEAN PATIENT FUT; *EUR FED PHARM IND, 2001, GUID INT WEB SIT AV; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; Organization WH, 2003, ADHERENCE LONG TERM	6	14	14	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					863	864		10.1136/bmj.327.7419.863	http://dx.doi.org/10.1136/bmj.327.7419.863			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551109	Green Published			2023-01-03	WOS:000185921200031
J	Cook, D; Rocker, G; Marshall, J; Sjokvist, P; Dodek, P; Griffith, L; Freitag, A; Varon, J; Bradley, C; Levy, M; Finfer, S; Hamielec, C; McMullin, J; Weaver, B; Walter, S; Guyatt, G				Cook, D; Rocker, G; Marshall, J; Sjokvist, P; Dodek, P; Griffith, L; Freitag, A; Varon, J; Bradley, C; Levy, M; Finfer, S; Hamielec, C; McMullin, J; Weaver, B; Walter, S; Guyatt, G		Level Care Study Investigators; Canadian Critical Care Trials Grp	Withdrawal of mechanical ventilation in anticipation of death in the intensive care unit	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENTS; CRITICALLY ILL; CARDIOPULMONARY-RESUSCITATION; DECISION-MAKING; SUPPORT; PHYSICIAN; PREFERENCES; END; DIRECTIVES; HOSPITALS	BACKGROUND: In critically ill patients who are receiving mechanical ventilation, the factors associated with physicians' decisions to withdraw ventilation in anticipation of death are unclear. The objective of this study was to examine the clinical determinants that were associated with the withdrawal of mechanical ventilation. METHODS: We studied adults who were receiving mechanical ventilation in 15 intensive care units, recording base-line physiological characteristics, daily Multiple Organ Dysfunction Scores, the patient's decision-making ability, the type of life support administered, the use of do-not-resuscitate orders, the physician's prediction of the patient's status, and the physician's perceptions of the patient's preferences about the use of life support. We examined the relation between these factors and withdrawal of mechanical ventilation, using Cox proportional-hazards regression analysis. RESULTS: Of 851 patients who were receiving mechanical ventilation, 539 (63.3 percent) were successfully weaned, 146 (17.2 percent) died while receiving mechanical ventilation, and 166 (19.5 percent) had mechanical ventilation withdrawn. The need for inotropes or vasopressors was associated with withdrawal of the ventilator (hazard ratio, 1.78; 95 percent confidence interval, 1.20 to 2.66; P=0.004), as were the physician's prediction that the patient's likelihood of survival in the intensive care unit was less than 10 percent (hazard ratio, 3.49; 95 percent confidence interval, 1.39 to 8.79; P=0.002), the physician's prediction that future cognitive function would be severely impaired (hazard ratio, 2.51; 95 percent confidence interval, 1.28 to 4.94; P=0.04), and the physician's perception that the patient did not want life support used (hazard ratio, 4.19; 95 percent confidence interval, 2.57 to 6.81; P<0.001). CONCLUSIONS: Rather than age or the severity of the illness and organ dysfunction, the strongest determinants of the withdrawal of ventilation in critically ill patients were the physician's perception that the patient preferred not to use life support, the physician's predictions of a low likelihood of survival in the intensive care unit and a high likelihood of poor cognitive function, and the use of inotropes or vasopressors.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Dalhousie Univ, Dept Med, Halifax, NS, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Huddinge Univ, Dept Anesthesia & Intens Care, Stockholm, Sweden; Univ British Columbia, Program Crit Care Med, Vancouver, BC V5Z 1M9, Canada; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Brown Univ, Dept Med, Providence, RI 02912 USA; Univ Sydney, Royal N Shore Hosp, Intens Therapy Unit, Sydney, NSW 2006, Australia; Toronto Hosp, Toronto, ON M5T 2S8, Canada; London Hlth Sci Ctr, London, ON, Canada; Hamilton Hlth Sci Ctr, Hamilton, ON, Canada	McMaster University; McMaster University; Dalhousie University; University of Toronto; University of British Columbia; Baylor College of Medicine; Brown University; Royal North Shore Hospital; University of Sydney; University of Toronto; University Toronto Affiliates; University Health Network Toronto; London Health Sciences Centre; McMaster University	Cook, D (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.		Walter, Stephen/AAB-5548-2022; Varon, Joseph/R-5198-2019; Varon, Joseph/T-9481-2019	Walter, Stephen/0000-0003-4157-8928; Finfer, Simon/0000-0002-2785-5864; Varon, Joseph/0000-0002-7622-9974				Asch DA, 1996, MED CARE, V34, P103, DOI 10.1097/00005650-199602000-00002; CHRISTAKIS NA, 1993, LANCET, V342, P642, DOI 10.1016/0140-6736(93)91759-F; CHRISTAKIS NA, 1995, J GEN INTERN MED, V10, P491, DOI 10.1007/BF02602399; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Cook DJ, 2001, LANCET, V358, P1941, DOI 10.1016/S0140-6736(01)06960-4; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; Esteban A, 2001, INTENS CARE MED, V27, P1744, DOI 10.1007/s00134-001-1111-7; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Hall RI, 2000, CHEST, V118, P1424, DOI 10.1378/chest.118.5.1424; Hamel Mary Beth, 1995, JAMA (Journal of the American Medical Association), V273, P1842, DOI 10.1001/jama.273.23.1842; JAYES RL, 1993, JAMA-J AM MED ASSOC, V270, P2213, DOI 10.1001/jama.270.18.2213; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Keenan SP, 1998, CRIT CARE MED, V26, P245, DOI 10.1097/00003246-199802000-00018; Keenan SP, 1997, CRIT CARE MED, V25, P1324, DOI 10.1097/00003246-199708000-00019; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANKEN PN, 1991, ANN INTERN MED, V115, P478; LEE DKP, 1994, JAMA-J AM MED ASSOC, V271, P1358, DOI 10.1001/jama.271.17.1358; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McLean RF, 2000, CRIT CARE MED, V28, P100, DOI 10.1097/00003246-200001000-00016; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; SLOMKA J, 1992, SOC SCI MED, V35, P251, DOI 10.1016/0277-9536(92)90021-H; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Smucker WD, 2000, MED DECIS MAKING, V20, P271, DOI 10.1177/0272989X0002000303; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; WOOD GG, 1995, CAN J ANAESTH, V42, P186, DOI 10.1007/BF03010673	36	298	304	0	19	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1123	1132		10.1056/NEJMoa030083	http://dx.doi.org/10.1056/NEJMoa030083			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679526	Bronze			2023-01-03	WOS:000185369700005
J	Manisty, C; Waxman, J				Manisty, C; Waxman, J			For and against - Doctors should not discuss resuscitation with terminally ill patients - For	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC-ARREST; CANCER		Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Canc Med, London W12 0NN, England	Imperial College London	Waxman, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Canc Med, Hammersmith Campus, London W12 0NN, England.		Manisty, Charlotte/AAN-3723-2021	Manisty, Charlotte/0000-0003-0245-7090				BMA Resuscitation Council UK and Royal College of Nursing, DEC REL CARD RES; Ewer MS, 2001, CANCER, V92, P1905, DOI 10.1002/1097-0142(20011001)92:7<1905::AID-CNCR1708>3.0.CO;2-6; Haidet P, 1998, AM J MED, V105, P222, DOI 10.1016/S0002-9343(98)00242-3; Varon J, 1998, RESUSCITATION, V36, P165, DOI 10.1016/S0300-9572(98)00015-X	4	20	21	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					614	615		10.1136/bmj.327.7415.614	http://dx.doi.org/10.1136/bmj.327.7415.614			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969934	Green Published			2023-01-03	WOS:000185358700030
J	Sprung, CL; Cohen, SL; Sjokvist, P; Baras, M; Bulow, HH; Hovilehto, S; Ledoux, D; Lippert, A; Maia, P; Phelan, D; Schobersberger, W; Wennberg, E; Woodcock, T				Sprung, CL; Cohen, SL; Sjokvist, P; Baras, M; Bulow, HH; Hovilehto, S; Ledoux, D; Lippert, A; Maia, P; Phelan, D; Schobersberger, W; Wennberg, E; Woodcock, T		Ethicus Study Grp	End-of-life practices in European intensive care units - The ethicus study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSTAINING TREATMENT; SUPPORT; WITHDRAWAL; DECISIONS; STATES	Context While the adoption of practice guidelines is standardizing many aspects of patient care, ethical dilemmas are occurring because of forgoing life-sustaining therapies in intensive care and are dealt with in diverse ways between different countries and cultures. Objectives To determine the frequency and types of actual end-of-life practices in European intensive care units (ICUs) and to analyze the similarities and differences. Design and Setting A prospective, observational study of European ICUs. Participants Consecutive patients who died or had any limitation of therapy. Intervention Prospectively defined end-of-life practices in 37 ICUs in 17 European countries were studied from January 1, 1999, to June 30, 2000. Main Outcome Measures Comparison and analysis of the frequencies and patterns of end-of-life care by geographic regions and different patients and professionals. Results Of 31417 patients admitted to ICUs, 4248 patients (13.5%) died or had a limitation of life-sustaining therapy. Of these, 3086 patients (72.6%) had limitations of treatments (10% of admissions). Substantial intercountry variability was found in the limitations and the manner of dying: unsuccessful cardiopulmonary resuscitation in 20% (range, 5%-48%), brain death in 8% (range, 0%-15%), withholding therapy in 38% (range, 16%-70%), withdrawing therapy in 33% (range, 5%-69%), and active shortening of the dying process in 2% (range, 0%-19%). Shortening of the dying process was reported in 7 countries. Doses of opioids and benzodiazepines reported for shortening of the dying process were in the same range as those used for symptom relief in previous studies. Limitation of therapy vs continuation of life-sustaining therapy was associated with patient age, acute and chronic diagnoses, number of days in ICU, region, and religion (P<.001). Conclusion The limiting of life-sustaining treatment in European ICUs is common and variable. Limitations were associated with patient age, diagnoses, ICU stay, and geographic and religious factors. Although shortening of the dying process is rare, clarity between withdrawing therapies and shortening of the dying process and between therapies intended to relieve pain and suffering and those intended to shorten the dying process may be lacking.	Hadassah Hebrew Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Gen Intens Care Unit, IL-91120 Jerusalem, Israel; UCL, Dept Med, London, England; Orebro Univ Hosp, Dept Anesthesiol, Orebro, Sweden; Hadassah Hebrew Univ, Med Ctr, Dept Social Med, IL-91120 Jerusalem, Israel; Univ Hosp Glostrup, Dept Anesthesiol, Glostrup, Denmark; S Karelia Cent Hosp, Dept Anesthesiol, Lappeenranta, Finland; Univ Liege, Dept Anesthesiol & Intens Care Med, Liege, Belgium; Herlev Univ Hosp, Dept Anesthesiol, DK-2730 Herlev, Denmark; Hosp Geral Santo Antonio, Dept Intens Care, Oporto, Portugal; Mater Hosp Univ Coll, Dept Intens Care, Dublin, Ireland; Univ Innsbruck Hosp, Div Gen & Surg Intens Care Med, A-6020 Innsbruck, Austria; Sahlgrens Univ Hosp, Dept Anesthesia & Intens Care, S-41345 Gothenburg, Sweden; Southampton Univ Hosp NHS Trust, Crit Care Directorate, Southampton, Hants, England	Hebrew University of Jerusalem; Hadassah University Medical Center; University of London; University College London; Orebro University; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Copenhagen; University of Liege; University of Copenhagen; Herlev & Gentofte Hospital; Mater Misericordiae University Hospital; Medical University of Innsbruck; Sahlgrenska University Hospital; University of Southampton; University Hospital Southampton NHS Foundation Trust	Sprung, CL (corresponding author), Hadassah Hebrew Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Gen Intens Care Unit, POB 12000, IL-91120 Jerusalem, Israel.		Bouza, Carmen/F-4626-2016; Ledoux, Didier/ABA-8401-2021	Bouza, Carmen/0000-0002-8089-9866; Ledoux, Didier/0000-0002-9314-6564; Woodcock, Thomas/0000-0001-5878-4379				[Anonymous], 1991, Am Rev Respir Dis, V144, P726; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Cook DJ, 2001, LANCET, V358, P1941, DOI 10.1016/S0140-6736(01)06960-4; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; Eidelman LA, 1998, INTENS CARE MED, V24, P162, DOI 10.1007/s001340050539; Esteban A, 2001, INTENS CARE MED, V27, P1744, DOI 10.1007/s00134-001-1111-7; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Hall RI, 2000, CHEST, V118, P1424, DOI 10.1378/chest.118.5.1424; Keenan SP, 1998, CRIT CARE MED, V26, P245, DOI 10.1097/00003246-199802000-00018; Keenan SP, 1997, CRIT CARE MED, V25, P1324, DOI 10.1097/00003246-199708000-00019; KLESSIG J, 1992, WESTERN J MED, V157, P316; McHaffie HE, 1999, J MED ETHICS, V25, P440, DOI 10.1136/jme.25.6.440; *PC STUD ETH PROBL, 1983, DEC FOR LIF SUST TRE; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; Richter J, 2001, J MED ETHICS, V27, P186, DOI 10.1136/jme.27.3.186; *SOC CRIT CAR MED, 1990, CRIT CARE MED, V18, P1435; SPRUNG CL, 1992, CRIT CARE MED, V20, P320; Sprung CL, 1996, INTENS CARE MED, V22, P1003; Sprung CL, 1997, CRIT CARE MED, V25, P383, DOI 10.1097/00003246-199703000-00002; Sprung CL, 1996, MAYO CLIN PROC, V71, P512, DOI 10.4065/71.5.512; TERES D, 1993, INTENS CARE MED, V19, P316, DOI 10.1007/BF01694704; Truog RD, 2001, CRIT CARE MED, V29, P2332, DOI 10.1097/00003246-200112000-00017; Turner JS, 1996, INTENS CARE MED, V22, P1020, DOI 10.1007/s001340050207; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VINCENT JL, 1989, CRIT CARE MED, V17, P530, DOI 10.1097/00003246-198906000-00009; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	30	703	722	2	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2003	290	6					790	797		10.1001/jama.290.6.790	http://dx.doi.org/10.1001/jama.290.6.790			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709VU	12915432				2023-01-03	WOS:000184647700030
J	deFilippi, C; Wasserman, S; Rosanio, S; Tiblier, E; Sperger, H; Tocchi, M; Christenson, R; Uretsky, B; Smiley, M; Gold, J; Muniz, H; Badalamenti, J; Herzog, C; Henrich, W				deFilippi, C; Wasserman, S; Rosanio, S; Tiblier, E; Sperger, H; Tocchi, M; Christenson, R; Uretsky, B; Smiley, M; Gold, J; Muniz, H; Badalamenti, J; Herzog, C; Henrich, W			Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR MASS; STAGE RENAL-DISEASE; CARDIOVASCULAR MORTALITY; ARTERY-DISEASE; ALL-CAUSE; INFLAMMATION; MARKERS; DEATH; DIALYSIS; EVENTS	Context Cardiac troponin T (cTnT) and C-reactive protein (CRP) are prognostic markers in acute coronary syndromes. However, for patients with end-stage renal disease (ESRD) the ability of combinations of these markers to predict outcomes, and their association with cardiac pathology, are unclear. Objective To investigate the association between levels of cTnT and CRP and long-term risk of cardiac pathology and death in patients with ESRD. Design, Setting, and Participants A prospective cohort study initiated February through June 1998 and enrolling 224 patients with ESRD from 5 hemodialysis centers in the Houston-Galveston region of Texas. Levels of cTnT and CRP were analyzed at study entry in patients without ischemic symptoms. Main Outcome Measures All-cause mortality during a mean follow-up of 827 (range, 29-1327) days. Secondary outcomes in predefined substudies were coronary artery disease (CAD), decreased (less than or equal to40%) left ventricular ejection fraction (LVEF), and presence of left ventricular hypertrophy (LVH). Results One hundred seventeen (52%) patients died during follow-up. For levels of cTnT and CRP, progressively higher levels predicted increased risk of death compared with the lowest quartile (for cTnT quartile 2: unadjusted hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.2-4.1; quartile 3: HR, 2.7; 95% Cl, 1.5-4.9; quartile 4: HR, 3.0; 95% Cl, 1.6-5.3. For CRP quartile 2: HR, 0.9; 95% Cl, 0.5-1.6; quartile 3: HR, 1.8; 95% Cl, 1.1-3.1; quartile 4: HR, 1.8; 95% Cl, 1.1-3.2). Both cTnT and CRP remained independent predictors of death after adjusting for a number of potential confounders. The combination of cTnT and CRP results provided prognostic information when patients were divided into groups at or above and below the biomarker medians (high cTnT high CRP levels vs low cTnT/low CRP levels for risk of death: HR, 2.5; 95% Cl, 1.5-4.0). Elevated levels of cTnT, but not CRP, were strongly associated with diffuse CAD (n=67; 0%, 25%, 50%, and 62% prevalence of multivessel CAD across progressive cTnT quartiles, P<.001). An LVEF of 40% or less was identified in 4 (9%), 3 (8%), 10 (27%), and 7 (19%) of patients across cTnT quartiles (P=.07). No trend for cTnT levels was found among patients with LVH (P=.45); similarly, no trend for CRP was found among patients with LVH (P=.65) or an LVEF of 40% or less (P=.75). Conclusions Among stable patients with ESRD, increasing levels of cTnT and CRP are associated with increased risk of death. Furthermore, higher levels of cTnT may identify patients with severe angiographic coronary disease.	Univ Maryland, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; San Raffaele Univ Hosp, Dept Cardiol, Milan, Italy; Univ Texas, Med Branch, Dept Med, Galveston, TX 77550 USA; Renal Care Grp, Angleton, TX USA; Renal Specialists, Houston, TX USA; Univ Minnesota, Sch Med, Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55455 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Texas System; University of Texas Medical Branch Galveston; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	deFilippi, C (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Cardiol, 22 S Greene St, Baltimore, MD 21201 USA.	cdefilip@medicine.umaryland.edu	Schulz, Sandra/F-6238-2012					Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Apple FS, 2002, CIRCULATION, V106, P2941, DOI 10.1161/01.CIR.0000041254.30637.34; Arici M, 2001, KIDNEY INT, V59, P407, DOI 10.1046/j.1523-1755.2001.059002407.x; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; deFilippi CR, 2000, J AM COLL CARDIOL, V35, P1827, DOI 10.1016/S0735-1097(00)00628-8; DEPNER TA, 1999, PRINCIPLES PRACTICE, P97; Dierkes J, 2000, CIRCULATION, V102, P1964, DOI 10.1161/01.CIR.102.16.1964; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Felker GM, 2002, J AM COLL CARDIOL, V39, P210, DOI 10.1016/S0735-1097(01)01738-7; FOLEY RN, 1995, KIDNEY INT, V47, P186, DOI 10.1038/ki.1995.22; Freda BJ, 2002, J AM COLL CARDIOL, V40, P2065, DOI 10.1016/S0735-1097(02)02608-6; Heidenreich PA, 2001, J AM COLL CARDIOL, V38, P478, DOI 10.1016/S0735-1097(01)01388-2; HOSMER DW, 2000, WILEY PS TX, P1; Iliou MC, 2001, NEPHROL DIAL TRANSPL, V16, P1452, DOI 10.1093/ndt/16.7.1452; Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; Mallamaci F, 2002, AM J KIDNEY DIS, V40, P68, DOI 10.1053/ajkd.2002.33914; Mallamaci F, 2002, KIDNEY INT, V62, P1884, DOI 10.1046/j.1523-1755.2002.00641.x; Ooi DS, 1999, CLIN BIOCHEM, V32, P647, DOI 10.1016/S0009-9120(99)00064-8; Owen WF, 1998, KIDNEY INT, V54, P627, DOI 10.1046/j.1523-1755.1998.00032.x; Park S H, 1996, J Am Soc Echocardiogr, V9, P119, DOI 10.1016/S0894-7317(96)90019-X; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Redberg RF, 2000, J AM COLL CARDIOL, V36, P39, DOI 10.1016/S0735-1097(00)00680-X; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Rocco MV, 2002, AM J KIDNEY DIS, V39, P146, DOI 10.1053/ajkd.2002.29905; Roppolo LP, 1999, J AM COLL CARDIOL, V34, P448, DOI 10.1016/S0735-1097(99)00207-7; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAS Institute, 1997, SAS STAT SOFTW CHANG; Stenvinkel P, 2002, KIDNEY INT, V62, P1791, DOI 10.1046/j.1523-1755.2002.00637.x; Stolear JC, 1999, NEPHROL DIAL TRANSPL, V14, P1961, DOI 10.1093/ndt/14.8.1961; *US REN DATA SYST, 2000, USRDS ANN DAT REP, P581; Wanner C, 2002, KIDNEY INT, V61, pS99, DOI 10.1046/j.1523-1755.61.s80.18.x; Wayand D, 2000, CLIN CHEM, V46, P1345; Yeun JY, 2000, AM J KIDNEY DIS, V35, P469, DOI 10.1016/S0272-6386(00)70200-9; Zebrack JS, 2002, J AM COLL CARDIOL, V39, P632, DOI 10.1016/S0735-1097(01)01804-6; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	36	307	315	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2003	290	3					353	359		10.1001/jama.290.3.353	http://dx.doi.org/10.1001/jama.290.3.353			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699WK	12865376				2023-01-03	WOS:000184078800029
J	Bonow, RO; Eckel, RH				Bonow, RO; Eckel, RH			Diet, obesity, and cardiovascular risk	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Northwestern University; Feinberg School of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Bonow, RO (corresponding author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.							Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; DiabetesPrev D. Prog Res. Group, 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801	3	79	84	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2057	2058		10.1056/NEJMp030053	http://dx.doi.org/10.1056/NEJMp030053			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761363				2023-01-03	WOS:000183008300002
J	Rosenkranz, AA; Lunin, VG; Gulak, PV; Sergienko, OV; Shumiantseva, MA; Voronina, OL; Gilyazova, DG; John, AP; Kofner, AA; Mironov, AF; Jans, DA; Sobolev, AS				Rosenkranz, AA; Lunin, VG; Gulak, PV; Sergienko, OV; Shumiantseva, MA; Voronina, OL; Gilyazova, DG; John, AP; Kofner, AA; Mironov, AF; Jans, DA; Sobolev, AS			Recombinant modular transporters for cell-specific nuclear delivery of locally acting drugs enhance photosensitizer activity	FASEB JOURNAL			English	Article						targeted drug delivery; intracellular transport; nucleo-cytoplasmic transport; cancer; melanoma	TARGETED INTRACELLULAR DELIVERY; VIVO PROTEIN TRANSDUCTION; GENE-TRANSFER; PHOTODYNAMIC ACTIVITY; IN-VITRO; RECEPTOR; HORMONE; FUSION; TOXIN; PEPTIDES	The search for new pharmaceuticals that are specific for diseased rather than normal cells in the case of cancer and viral disease has raised interest in locally acting drugs that act over short distances within the cell and for which different cell compartments have distinct sensitivities. Thus, photo sensitizers (PSs) used in anti-cancer therapy should ideally be transported to the most sensitive subcellular compartments in order for their action to be most pronounced. Here we describe the design, production, and characterization of the effects of bacterially expressed modular recombinant transporters for PSs comprising 1) a-melanocyte-stimulating hormone as an internalizable, cell-specific ligand; 2) an optimized nuclear localization sequence of the SV40 large T-antigen; 3) an Escherichia coli hemoglobin-like protein as a carrier; and 4) an endosomolytic amphipathic polypeptide, the translocation domain of diphtheria toxin. These modular transporters delivered PSs into the nuclei, the most vulnerable sites for the action of PSs, of murine melanoma cells, but not non-MSH receptor-overexpressing cells, to result in cytotoxic effects several orders of magnitude greater than those of nonmodified PSs. The modular fusion proteins described here for the first time, capable of cell-specific targeting to particular subcellular compartments to increase drug efficacy, represent new pharmaceuticals with general application.	Russian Acad Sci, Inst Gene Biol, Dept Mol Genet Intracellular Transport, Moscow 119334, Russia; Moscow MV Lomonosov State Univ, Fac Biol, Dept Biophys, Moscow 119899, Russia; Russian Acad Agr Sci, All Russia Inst Agr Biotechnol, Lab Mol Diagnost & Gene Engn Constructs, Moscow 127550, Russia; Russian Acad Sci, Bach Inst Biochem, Lab Enzyme Syst, Moscow 119071, Russia; Australian Natl Univ, John Curtin Sch Med Res, Nucl Signaling Lab, Canberra, ACT 2601, Australia; Moscow Acad Fine Chem Technol, Dept Chem & Technol Fine Organ Chem, Moscow 117571, Russia; Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Clayton, Vic 3168, Australia	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Lomonosov Moscow State University; All-Russia Research Institute of Agricultural Biotechnology; Research Center of Biotechnology RAS; Russian Academy of Sciences; Australian National University; John Curtin School of Medical Research; Monash University	Sobolev, AS (corresponding author), Russian Acad Sci, Inst Gene Biol, Dept Mol Genet Intracellular Transport, 34-5 Vavilov St, Moscow 119334, Russia.	asobol@l.biophys.bio.msu.ru	Rosenkranz, Andrey A/J-3514-2015; Voronina, Olga L/F-4959-2018; Sobolev, Alexander S./P-6302-2015; Mironov, Andrey/ABB-3245-2021	Rosenkranz, Andrey A/0000-0001-9941-6118; Voronina, Olga L/0000-0001-7206-3594; Sobolev, Alexander S./0000-0001-8315-7764; Jans, David/0000-0001-5115-4745; Mironov, Andrey F./0000-0001-8353-1904				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AKHLYNINA TV, 1995, CANCER RES, V55, P1014; AKHLYNINA TV, 1990, B EXP BIOL MED+, V109, P183, DOI 10.1007/BF00841665; Akhlynina TV, 1997, J BIOL CHEM, V272, P20328, DOI 10.1074/jbc.272.33.20328; AKHLYNINA TV, 1993, PHOTOCHEM PHOTOBIOL, V58, P45, DOI 10.1111/j.1751-1097.1993.tb04901.x; Akhlynina TV, 1999, INT J CANCER, V81, P734, DOI 10.1002/(SICI)1097-0215(19990531)81:5<734::AID-IJC12>3.0.CO;2-J; Atkins JH, 2002, NAT REV DRUG DISCOV, V1, P491, DOI 10.1038/nrd842; Barati S, 2002, EXP NEUROL, V177, P75, DOI 10.1006/exnr.2002.7999; Bisland SK, 1999, BIOCONJUGATE CHEM, V10, P982, DOI 10.1021/bc990020u; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chan CK, 2001, GENE THER, V8, P166, DOI 10.1038/sj.gt.3301366; Chenal A, 2002, PROTEIN ENG, V15, P383, DOI 10.1093/protein/15.5.383; de Jong M, 2002, SEMIN NUCL MED, V32, P133, DOI 10.1053/snuc.2002.31027; FINLAY GJ, 1984, ANAL BIOCHEM, V139, P272, DOI 10.1016/0003-2697(84)90002-2; Frankel AE, 2002, CLIN CANCER RES, V8, P1004; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Hamblin MR, 2000, PHOTOCHEM PHOTOBIOL, V72, P533, DOI 10.1562/0031-8655(2000)072<0533:SRTPT>2.0.CO;2; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jiang J, 1996, Exp Dermatol, V5, P325, DOI 10.1111/j.1600-0625.1996.tb00136.x; Kwekkeboom DJ, 2002, SEMIN NUCL MED, V32, P84, DOI 10.1053/snuc.2002.31022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273; Liang H, 2000, LASER MED SCI, V15, P109, DOI 10.1007/s101030050056; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mironov A. F., 1992, P SOC PHOTO-OPT INS, V1922, P204; Nir S, 2000, PROG LIPID RES, V39, P181, DOI 10.1016/S0163-7827(00)00004-7; O'Hare KB, 1993, J DRUG TARGET, V1, P217, DOI 10.3109/10611869308996079; PLANK C, 1994, J BIOL CHEM, V269, P12918; Poul MA, 2000, J MOL BIOL, V301, P1149, DOI 10.1006/jmbi.2000.4026; *QIAGEN, 2001, QIAEXPR; Ramage JG, 2003, LEUKEMIA RES, V27, P79, DOI 10.1016/S0145-2126(02)00077-2; Rosenkranz AA, 1997, BIOCHEM BIOPH RES CO, V236, P750, DOI 10.1006/bbrc.1997.7040; Rosenkranz AA, 2000, IMMUNOL CELL BIOL, V78, P452, DOI 10.1046/j.1440-1711.2000.00925.x; SAHM UG, 1994, PEPTIDES, V15, P441, DOI 10.1016/0196-9781(94)90202-X; Salazar-Onfray F, 2002, BRIT J CANCER, V87, P414, DOI 10.1038/sj.bjc.6600441; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; SIEGRIST W, 1986, ANAL BIOCHEM, V159, P191, DOI 10.1016/0003-2697(86)90327-1; Silver RB, 1998, METHOD CELL BIOL, V56, P237, DOI 10.1016/S0091-679X(08)60429-X; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Sobolev AS, 2000, PROG BIOPHYS MOL BIO, V73, P51, DOI 10.1016/S0079-6107(00)00002-X; Trail PA, 1999, CURR OPIN IMMUNOL, V11, P584, DOI 10.1016/S0952-7915(99)00012-6; Uherek C, 1998, J BIOL CHEM, V273, P8835, DOI 10.1074/jbc.273.15.8835; WEN ZL, 1991, J BIOL CHEM, V266, P12289; Wikberg JES, 2000, PHARMACOL RES, V42, P393, DOI 10.1006/phrs.2000.0725; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wong WS, 1996, INT J BIOCHEM CELL B, V28, P1223, DOI 10.1016/S1357-2725(96)00074-X	48	50	58	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1121	+		10.1096/fj.02-0888fje	http://dx.doi.org/10.1096/fj.02-0888fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692081				2023-01-03	WOS:000182580100041
J	Harrod, HL				Harrod, HL			An essay on desire	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	2003	289	7					813	814		10.1001/jama.289.7.813	http://dx.doi.org/10.1001/jama.289.7.813			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647BW	12588245				2023-01-03	WOS:000181072200001
J	Tirona, RG; Lee, W; Leake, BF; Lan, LB; Cline, CB; Lamba, V; Parviz, F; Duncan, SA; Inoue, Y; Gonzalez, FJ; Schuetz, EG; Kim, RB				Tirona, RG; Lee, W; Leake, BF; Lan, LB; Cline, CB; Lamba, V; Parviz, F; Duncan, SA; Inoue, Y; Gonzalez, FJ; Schuetz, EG; Kim, RB			The orphan nuclear receptor HNF4 alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4	NATURE MEDICINE			English	Article							PREGNANE-X-RECEPTOR; HUMAN CYP2B6 GENE; TRANSCRIPTIONAL REGULATION; VISCERAL ENDODERM; ACTIVATION; EXPRESSION; HNF-4; GASTRULATION; REQUIRES; EMBRYOS	The drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is thought to be involved in the metabolism of nearly 50% of all the drugs currently prescribed. Alteration in the activity or expression of this enzyme seems to be a key predictor of drug responsiveness and toxicity(1). Currently available studies indicate that the ligand-activated nuclear receptors pregnane X receptor (PXR; NR1I2) and constitutive androstane receptor (CAR; NR1I3) regulate CYP3A4 expression(2,3). However, in cell-based reporter assays, CYP3A4 promoter activity was most pronounced in liver-derived cells and minimal or modest in non-hepatic cells(2), indicating that a liver-specific factor is required for physiological transcriptional response. Here we show that the orphan nuclear receptor hepatocyte nuclear factor-4alpha (HNF4alpha; HNF4A) is critically involved in the PXR- and CAR-mediated transcriptional activation of CYP3A4. We identified a specific cis-acting element in the CYP3A4 gene enhancer that confers HNF4alpha binding and thereby permits PXR- and CAR-mediated gene activation. Fetal mice with conditional deletion of Hnf4alpha had reduced or absent expression of CYP3A. Furthermore, adult mice with conditional hepatic deletion of Hnf4alpha had reduced basal and inducible expression of CYP3A. These data identify HNF4alpha as an important regulator of coordinate nuclear-receptor-mediated response to xenobiotics.	Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA; Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; NCI, Lab Metab, Div Basic Sci, Bethesda, MD 20892 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA	Vanderbilt University; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Kim, RB (corresponding author), Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA.	richard.kim@vanderbilt.edu	Inoue, Yusuke/O-6207-2018; Kim, Richard/D-6971-2011; Cline, Cynthia D/F-7065-2012; Schuetz, Erin/N-8087-2018; Lee, Wooin/K-7789-2012	Inoue, Yusuke/0000-0002-9710-7482; Kim, Richard/0000-0001-8148-1632; Lee, Wooin/0000-0001-7805-869X; Duncan, Stephen/0000-0002-2507-7827	NIEHS NIH HHS [ES08658] Funding Source: Medline; NIGMS NIH HHS [GM31304, GM54724, GM60346] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM054724, P01GM031304, R01GM054724, R01GM060346] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Duncan SA, 1997, DEVELOPMENT, V124, P279; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 2002, MOL PHARMACOL, V62, P359, DOI 10.1124/mol.62.2.359; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Huss JM, 1998, J BIOL CHEM, V273, P16155, DOI 10.1074/jbc.273.26.16155; Jover R, 2001, HEPATOLOGY, V33, P668, DOI 10.1053/jhep.2001.22176; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Li JX, 2000, GENE DEV, V14, P464; Ogino M, 1999, ARCH BIOCHEM BIOPHYS, V362, P32, DOI 10.1006/abbi.1998.1012; Parviz F, 2002, GENESIS, V32, P130, DOI 10.1002/gene.10058; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Saito T, 2001, J BIOL CHEM, V276, P38010; Schuetz E, 2002, MOL PHARMACOL, V62, P439, DOI 10.1124/mol.62.3.439; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Thummel KE, 2001, MOL PHARMACOL, V60, P1399, DOI 10.1124/mol.60.6.1399; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zhang J, 2001, PHARMACOGENETICS, V11, P555, DOI 10.1097/00008571-200110000-00003	23	374	381	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2003	9	2					220	224		10.1038/nm815	http://dx.doi.org/10.1038/nm815			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	642KD	12514743				2023-01-03	WOS:000180801900027
J	Lightowler, JV; Wedzicha, JA; Elliott, MW; Ram, FSF				Lightowler, JV; Wedzicha, JA; Elliott, MW; Ram, FSF			Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STANDARD MEDICAL THERAPY; MECHANICAL VENTILATION; NOSOCOMIAL PNEUMONIA; LUNG-DISEASE; SUPPORT; TRIAL; RISK	Objectives To determine the effectiveness of non-invasive positive pressure ventilation (NPPV) in the management of respiratory failure secondary to acute exacerbation of chronic obstructive pulmonary disease. Design Systematic review of randomised controlled trials that compared NPPV and usual medical care with usual medical care alone in patients admitted to hospital with respiratory failure resulting from an exacerbation of chronic obstructive pulmonary disease and with PaCO2 > 6 kPa. Results The eight studies included in the review showed that, compared with usual care alone, NPPV as an adjunct to usual care was associated with a lower mortality (relative risk 0.41 (95% confidence interval 0.26 to 0.64)), a lower need for intubation (relative risk 0.42 (0.31 to 0.59)), lower likelihood of treatment failure (relative risk 0.51 (0.38 to 0.67)), and greater improvements at 1 hour in pH (weighted mean difference 0.03 (0.02 to 0.04)), PaCO2 (weighted mean difference - 0.40 kPa (- 0.78 to - 0.03)), and respiratory rate (weighted mean difference - 3.08 breaths per minute (- 4.26 to - 1.89)). NPPV resulted in fewer complications associated with treatment (relative risk 0.32 (0.18 to 0.56)) and shorter duration of stay in hospital (weighted mean difference - 3.24 days (- 4.42 to - 2.06)). Conclusions NPPV should be the first line intervention in addition to usual medical care to manage respiratory failure secondary to an acute exacerbation of chronic obstructive pulmonary disease in all suitable patients. NPPV should be tried early in the course of respiratory failure and before severe acidosis, to reduce mortality, avoid endotracheal intubation, and decrease treatment failure.	Univ London St Georges Hosp, Sch Med, Dept Med Physiol, London SW17 0RE, England; St James Univ Hosp, Dept Resp Med, Leeds LS9 7TF, W Yorkshire, England; St Bartholomews Sch, London EC1A 7BE, England; Royal London Sch Med & Dent, London EC1A 7BE, England	St Georges University London; Saint James's University Hospital; University of London; Queen Mary University London; University of London; Queen Mary University London	Ram, FSF (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Med Physiol, London SW17 0RE, England.	fram@sghms.ac.uk		Ram, Felix Simon Francis/0000-0002-5437-4089				Avdeev S N, 1998, Anesteziol Reanimatol, P45; AVDEEV SN, 1998, ANESTEZIOL REANIMATO; Barbe F, 1996, EUR RESPIR J, V9, P1240, DOI 10.1183/09031936.96.09061240; Baudouin S, 2002, THORAX, V57, P192; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; Dikensoy O, 2002, INT J CLIN PRACT, V56, P85; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FOGLIO C, 1992, CHEST, V101, P1533, DOI 10.1378/chest.101.6.1533; Guerin C, 1997, INTENS CARE MED, V23, P1024, DOI 10.1007/s001340050452; HOO GWS, 1994, CRIT CARE MED, V22, P1253, DOI 10.1097/00003246-199408000-00009; JEFFREY AA, 1992, THORAX, V47, P34, DOI 10.1136/thx.47.1.34; Kramer B, 1999, ANN INTERN MED, V130, P1027, DOI 10.7326/0003-4819-130-12-199906150-00025; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; Moretti M, 2000, THORAX, V55, P819, DOI 10.1136/thorax.55.10.819; Nourdine K, 1999, INTENS CARE MED, V25, P567, DOI 10.1007/s001340050904; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0	22	513	551	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	2003	326	7382					185	187		10.1136/bmj.326.7382.185	http://dx.doi.org/10.1136/bmj.326.7382.185			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	640LD	12543832	Bronze, Green Published			2023-01-03	WOS:000180689600014
J	Pinhu, L; Whitehead, T; Evans, T; Griffiths, M				Pinhu, L; Whitehead, T; Evans, T; Griffiths, M			Ventilator-associated lung injury	LANCET			English	Review							RESPIRATORY-DISTRESS SYNDROME; HIGH AIRWAY PRESSURE; HYALINE-MEMBRANE FORMATION; ALVEOLAR EPITHELIAL-CELLS; SURFACTANT-DEPLETED LUNG; END-EXPIRATORY PRESSURE; NECROSIS-FACTOR-ALPHA; ISOLATED RAT LUNGS; MECHANICAL VENTILATION; TIDAL VOLUME	Mechanical ventilation is indispensable in support of patients with respiratory failure who are critically ill. However, use of this technique has adverse effects, including increased risk of pneumonia, impaired cardiac performance, and difficulties associated with sedation and paralysis. Moreover, application of pressure to the lung, whether positive or negative, can cause damage known as ventilator-associated lung injury (VALI). Despite difficulties in distinguishing the effects of mechanical ventilation from those of the underlying disorder, VALI greatly assists patients with the most severe form of lung injury, acute respiratory distress syndrome (ARDS). Moreover, modification of mechanical ventilation so that VALI is kept to a minimum improves survival of patients with ARDS. Here, we outline the effects of mechanical ventilation on injured lungs and explore the underlying mechanisms.	Royal Brompton Hosp, Adult Intens Care Unit, London SW3 6NP, England; Imperial Coll Sch Med, Dept Intens Care Med, London, England; Imperial Coll Sch Med, Crit Care Unit, London, England; Imperial Coll Sch Med, Natl Heart & Lung Inst, London, England; Royal Brompton Hosp, Dept Resp Med, London SW3 6LY, England	Royal Brompton Hospital; Imperial College London; Imperial College London; Imperial College London; Royal Brompton Hospital	Griffiths, M (corresponding author), Royal Brompton Hosp, Adult Intens Care Unit, London SW3 6NP, England.			Griffiths, Mark/0000-0002-1615-1896				ADAMSON IYR, 1991, EXP LUNG RES, V17, P821, DOI 10.3109/01902149109062880; AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; *ARDS CLIN NETW, 2002, ASSESSMENT LOW TIDAL; ARGIRAS EP, 1987, BRIT J ANAESTH, V59, P1278, DOI 10.1093/bja/59.10.1278; ARTIGAS A, 2002, EUROPEAN RESP MONOGR, P1; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; Broccard AF, 1998, AM J RESP CRIT CARE, V157, P1935, DOI 10.1164/ajrccm.157.6.9612006; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Carmichael LC, 1996, J CRIT CARE, V11, P9, DOI 10.1016/S0883-9441(96)90015-5; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; Cheng JJ, 1996, HYPERTENSION, V28, P386, DOI 10.1161/01.HYP.28.3.386; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; Dries DJ, 2002, CRIT CARE MED, V30, P1159, DOI 10.1097/00003246-200205000-00036; Eisner MD, 2002, AM J RESP CRIT CARE, V165, P978, DOI 10.1164/ajrccm.165.7.2109059; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; FELDHERR CM, 1990, J CELL BIOL, V111, P1, DOI 10.1083/jcb.111.1.1; FU ZX, 1992, J APPL PHYSIOL, V73, P123, DOI 10.1152/jappl.1992.73.1.123; GATTINONI L, 1987, AM REV RESPIR DIS, V136, P730, DOI 10.1164/ajrccm/136.3.730; Grembowicz KP, 1999, MOL BIOL CELL, V10, P1247, DOI 10.1091/mbc.10.4.1247; Gunther A, 1996, AM J RESP CRIT CARE, V153, P176; GUNTHER A, 2002, EUROPEAN RESP SOC MO, P119; Guo YH, 2001, AM J PHYSIOL-LUNG C, V280, pL191, DOI 10.1152/ajplung.2001.280.2.L191; Harris RS, 2000, AM J RESP CRIT CARE, V161, P432; Held HD, 2001, AM J RESP CRIT CARE, V163, P711, DOI 10.1164/ajrccm.163.3.2003001; HERNANDEZ LA, 1989, J APPL PHYSIOL, V66, P2364, DOI 10.1152/jappl.1989.66.5.2364; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; IMAI Y, 1994, AM J RESP CRIT CARE, V150, P1550, DOI 10.1164/ajrccm.150.6.7952613; Imai Y, 1999, J APPL PHYSIOL, V87, P510, DOI 10.1152/jappl.1999.87.2.510; Imanaka H, 2001, ANESTH ANALG, V92, P428; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; KAWANO T, 1987, J APPL PHYSIOL, V62, P27, DOI 10.1152/jappl.1987.62.1.27; Ko KS, 2001, J BIOL CHEM, V276, P35967, DOI 10.1074/jbc.M104106200; LIU MY, 1994, J CELL PHYSIOL, V161, P501, DOI 10.1002/jcp.1041610313; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; LIU MY, 1995, AM J PHYSIOL-LUNG C, V269, pL178, DOI 10.1152/ajplung.1995.269.2.L178; Liu MY, 1999, AM J PHYSIOL-LUNG C, V277, pL667, DOI 10.1152/ajplung.1999.277.4.L667; LOICK HM, 1993, J APPL PHYSIOL, V75, P301, DOI 10.1152/jappl.1993.75.1.301; Maggiore S M, 2001, Minerva Anestesiol, V67, P228; MATHIEUCOSTELLO OA, 1994, CHEST, V105, pS102, DOI 10.1378/chest.105.3_Supplement.102S; Matsuoka H, 2002, AM J PHYSIOL-LUNG C, V283, pL103, DOI 10.1152/ajplung.00187.2001; MATSUOKA T, 1994, J APPL PHYSIOL, V76, P539, DOI 10.1152/jappl.1994.76.2.539; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; Mourgeon E, 2000, AM J PHYSIOL-LUNG C, V279, pL699, DOI 10.1152/ajplung.2000.279.4.L699; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Murphy DB, 2000, AM J RESP CRIT CARE, V162, P27, DOI 10.1164/ajrccm.162.1.9908110; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Nahum A, 1997, CRIT CARE MED, V25, P1733, DOI 10.1097/00003246-199710000-00026; Nakamura T, 2001, J APPL PHYSIOL, V91, P811, DOI 10.1152/jappl.2001.91.2.811; NARIMANBEKOV IO, 1995, EXP LUNG RES, V21, P239, DOI 10.3109/01902149509068830; NAURECKAS ET, 1994, J APPL PHYSIOL, V76, P1372, DOI 10.1152/jappl.1994.76.3.1372; PARK J, 2000, AM J RESP CRIT CARE, V161, pA47; Parker JC, 1998, J APPL PHYSIOL, V84, P1113, DOI 10.1152/jappl.1998.84.4.1113; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; Pugin J, 1998, AM J PHYSIOL-LUNG C, V275, pL1040, DOI 10.1152/ajplung.1998.275.6.L1040; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; Quinn D, 1999, CHEST, V116, p89S, DOI 10.1378/chest.116.suppl_1.89S; RAGHU G, 1985, AM REV RESPIR DIS, V131, P281, DOI 10.1164/ajrccm/138.3.703; Ranieri VM, 2000, JAMA-J AM MED ASSOC, V284, P43, DOI 10.1001/jama.284.1.43; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Ricard JD, 2001, AM J RESP CRIT CARE, V163, P1176, DOI 10.1164/ajrccm.163.5.2006053; ROUBY JJ, 1993, INTENS CARE MED, V19, P383, DOI 10.1007/BF01724877; ROUPIE E, 1995, AM J RESP CRIT CARE, V152, P121, DOI 10.1164/ajrccm.152.1.7599810; Sanchez-Esteban J, 2001, J APPL PHYSIOL, V91, P589, DOI 10.1152/jappl.2001.91.2.589; SANDHAR BK, 1988, INTENS CARE MED, V14, P538, DOI 10.1007/BF00263527; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tschumperlin DJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1173, DOI 10.1152/ajplung.1998.275.6.L1173; TSUKIMOTO K, 1991, J APPL PHYSIOL, V71, P573, DOI 10.1152/jappl.1991.71.2.573; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; Uhal BD, 1997, AM J PHYSIOL-LUNG C, V272, pL1031, DOI 10.1152/ajplung.1997.272.6.L1031; Verbrugge SJC, 1999, ANESTHESIOLOGY, V91, P1834, DOI 10.1097/00000542-199912000-00038; Vlahakis NE, 2000, J APPL PHYSIOL, V89, P2490, DOI 10.1152/jappl.2000.89.6.2490; Vlahakis NE, 1999, AM J PHYSIOL-LUNG C, V277, pL167, DOI 10.1152/ajplung.1999.277.1.L167; von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052; Wang N, 2001, P NATL ACAD SCI USA, V98, P7765, DOI 10.1073/pnas.141199598; Ward NS, 2002, CRIT CARE MED, V30, P963, DOI 10.1097/00003246-200205000-00002; Weg JG, 1998, NEW ENGL J MED, V338, P341, DOI 10.1056/NEJM199802053380601; Wirtz HR, 2000, RESP PHYSIOL, V119, P1, DOI 10.1016/S0034-5687(99)00092-4; WIRTZ HRW, 1990, SCIENCE, V250, P1266, DOI 10.1126/science.2173861; WOO SW, 1972, J APPL PHYSIOL, V33, P14, DOI 10.1152/jappl.1972.33.1.14	91	258	295	2	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 25	2003	361	9354					332	340		10.1016/S0140-6736(03)12329-X	http://dx.doi.org/10.1016/S0140-6736(03)12329-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639RV	12559881				2023-01-03	WOS:000180643900027
J	Schmidt, PJ; Leacock, AG				Schmidt, PJ; Leacock, AG			Forgotten transfusion history: John Leacock of Barbados	BRITISH MEDICAL JOURNAL			English	Article								A sugar planter's son from Barbados who graduated at Edinburgh was one of the first people to experiment with transfusing blood, in the early 19th century, nearly 100 years before the discovery of blood groups made transfusion routinely practicable.	Florida Blood Serv, Transfus Med Acad Ctr, St Petersburg, FL 33742 USA		Schmidt, PJ (corresponding author), 913 Mooring Circle, Tampa, FL 33602 USA.							Blundell J, 1818, Med Chir Trans, V9, P56; Blundell J., 1825, RES PHYSL PATHOLOGIC, P63; CASTLE T, 1984, PRINCIPLES PRACTICE; Leacock JH, 1817, MED CHIR J REV, V3, P276; Porter R., 1998, GREATEST BENEFIT MAN, P291; Schmidt PJ, 2002, TRANSFUSION, V42, P275, DOI 10.1046/j.1537-2995.2002.00033.x; SCHMIDT PJ, 1968, NEW ENGL J MED, V279, P1319, DOI 10.1056/NEJM196812122792406	7	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 21	2002	325	7378					1485	1487		10.1136/bmj.325.7378.1485	http://dx.doi.org/10.1136/bmj.325.7378.1485			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	631VX	12493676	Green Published			2023-01-03	WOS:000180188600029
J	Straus, SE				Straus, SE			Perspective - Herbal medicines - What's in the bottle?.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Straus, SE (corresponding author), Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA.								0	54	55	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	2002	347	25					1997	1998		10.1056/NEJMp020148	http://dx.doi.org/10.1056/NEJMp020148			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	626LT	12490680				2023-01-03	WOS:000179874500002
J	Pichichero, ME; Cernichiari, E; Lopreiato, J; Treanor, J				Pichichero, ME; Cernichiari, E; Lopreiato, J; Treanor, J			Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study	LANCET			English	Article							METHYLMERCURY EXPOSURE; VACCINATION; SEYCHELLES; HAIR	Background Thiomersal is a preservative containing small amounts of ethylmercury that is used in routine vaccines for infants and children. The effect of vaccines containing thiomersal on concentrations of mercury in infants' blood has not been extensively assessed, and the metabolism of ethylmercury in infants is unknown. We aimed to measure concentrations of mercury in blood, urine, and stools of infants who received such vaccines. Methods 40 full-term infants aged 6 months and younger were given vaccines that contained thiomersal (diptheria-tetanus-acellular pertussis vaccine, hepatitis B vaccine, and in some children Haemophilus influenzae type B vaccine). 21 control infants received thiomersal-free vaccines. We obtained samples of blood, urine, and stools 3-28 days after vaccination. Total mercury (organic and inorganic) in the samples was measured by cold vapour atomic absorption. Findings Mean mercury doses in infants exposed to thiomersal were 45.6 mug (range 37.5-62.5) for 2-month-olds and 111.3 mug (range 87.5-175.0) for 6-month-olds. Blood mercury in thiomersal-exposed 2-month-olds ranged from less than 3.75 to 20.55 nmol/L (parts per billion); in 6-month-olds all values were lower than 7.50 nmol/L. Only one of 15 blood samples from controls contained quantifiable mercury. Concentrations of mercury were low in urine after vaccination but were high in stools of thiomersal-exposed 2-month-olds (mean 82 ng/g dry weight) and in 6-month-olds (mean 58 ng/g dry weight). Estimated blood half-life of ethylmercury was 7 days (95% CI 4-10 days). Interpretation Administration of vaccines containing thiomersal does not seem to raise blood concentrations of mercury above safe values in infants. Ethylmercury seems to be eliminated from blood rapidly via the stools after parenteral administration of thiomersal in vaccines.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Dept Environm Med, Rochester, NY 14642 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA; Natl Naval Med Res Inst, Bethesda, MD USA	University of Rochester; University of Rochester; University of Rochester; Naval Medical Research Center (NMRC)	Pichichero, ME (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14642 USA.	michael_pichichero@urmc.rochester.edu	Pichichero, Michael E/AID-7886-2022		ACF HHS [1 AF-45248] Funding Source: Medline	ACF HHS		Abramson JS, 1999, PEDIATRICS, V104, P570, DOI 10.1542/peds.104.3.570; AXTON JH, 1972, POSTGRAD MED J, V561, P417; Ball LK, 2001, PEDIATRICS, V107, P1147, DOI 10.1542/peds.107.5.1147; Cernichiari E, 1995, NEUROTOXICOLOGY, V16, P705; Cernichiari E, 1995, NEUROTOXICOLOGY, V16, P613; Clarkson TW, 1997, CRIT REV CL LAB SCI, V34, P369, DOI 10.3109/10408369708998098; Clements CJ, 2000, LANCET, V355, P1279, DOI 10.1016/S0140-6736(05)74714-0; COX NH, 1988, CONTACT DERMATITIS, V18, P229, DOI 10.1111/j.1600-0536.1988.tb02809.x; Davidson PW, 1998, JAMA-J AM MED ASSOC, V280, P701, DOI 10.1001/jama.280.8.701; FAGAN DG, 1977, ARCH DIS CHILD, V52, P962, DOI 10.1136/adc.52.12.962; Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4; Lowell J A, 1996, Liver Transpl Surg, V2, P475, DOI 10.1002/lt.500020612; MATHESON DS, 1980, J PEDIATR-US, V97, P153, DOI 10.1016/S0022-3476(80)80159-4; National Academy of Sciences, 2000, TOX EFF METH; NIELSEN JB, 1994, ARCH TOXICOL, V68, P317, DOI 10.1007/s002040050075; Pfab R, 1996, J TOXICOL-CLIN TOXIC, V34, P453, DOI 10.3109/15563659609013818; Shenker BJ, 1998, ENVIRON RES, V77, P149, DOI 10.1006/enrs.1997.3816; Stajich GV, 2000, J PEDIATR-US, V136, P679, DOI 10.1067/mpd.2000.105133; YESS NJ, 1993, J AOAC INT, V76, P36; [No title captured]	20	157	170	0	32	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 30	2002	360	9347					1737	1741		10.1016/S0140-6736(02)11682-5	http://dx.doi.org/10.1016/S0140-6736(02)11682-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622FU	12480426				2023-01-03	WOS:000179636800010
J	Nelson, LE; Guo, TZ; Lu, J; Saper, CB; Franks, NP; Maze, M				Nelson, LE; Guo, TZ; Lu, J; Saper, CB; Franks, NP; Maze, M			The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway	NATURE NEUROSCIENCE			English	Article							FOS-LIKE IMMUNOREACTIVITY; C-FOS; TUBEROMAMMILLARY NUCLEUS; NITROUS-OXIDE; RAT-BRAIN; NEURONS; PROPOFOL; ACTIVATION; HYPOTHALAMUS; WAKEFULNESS	We investigated the role of regionally discrete GABA (gamma-aminobutyric acid) receptors in the sedative response to pharmacological agents that act on GABA(A) receptors (muscimol, propofol and pentobarbital; 'GABAergic agents') and to ketamine, a general anesthetic that does not affect GABA(A) receptors. Behavioral studies in rats showed that the sedative response to centrally administered GABAergic agents was attenuated by the GABA(A) receptor antagonist gabazine (systemically administered). The sedative response to ketamine, by contrast, was unaffected by gabazine. Using c-Fos as a marker of neuronal activation, we identified a possible role for the tuberomammillary nucleus (TMN): when gabazine was microinjected directly into the TMN, it attenuated the sedative response to GABAergic agents. Furthermore, the GABA(A) receptor agonist muscimol produced a dose-dependent sedation when it was administered into the TMN. We conclude that the TMN is a discrete neural locus that has a key role in the sedative response to GABAergic anesthetics.	Chelsea & Westminster Hosp, Imperial Coll Sch Med, Dept Anaesthet & Intens Care, London SW10 9NH, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Blackett Lab, Biophys Sect, London SW7 2BW, England; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA	Imperial College London; Imperial College London; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Franks, NP (corresponding author), Chelsea & Westminster Hosp, Imperial Coll Sch Med, Dept Anaesthet & Intens Care, London SW10 9NH, England.	n.franks@ic.ac.uk	Saper, Clifford/L-3815-2019	Franks, Nicholas/0000-0003-4874-4212	NHLBI NIH HHS [HL60292] Funding Source: Medline; NIA NIH HHS [AG09975] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009975] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; AIRAKSINEN MS, 1992, J COMP NEUROL, V323, P103, DOI 10.1002/cne.903230109; AKAIKE N, 1990, AM J PHYSIOL, V258, pC452, DOI 10.1152/ajpcell.1990.258.3.C452; ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; ANIS NA, 1983, BRIT J PHARMACOL, V79, P565, DOI 10.1111/j.1476-5381.1983.tb11031.x; BARKER JL, 1973, SCIENCE, V182, P720, DOI 10.1126/science.182.4113.720; Belelli D, 1999, TRENDS PHARMACOL SCI, V20, P496, DOI 10.1016/S0165-6147(99)01405-4; CHENG SC, 1985, ANESTHESIOLOGY, V63, P147, DOI 10.1097/00000542-198508000-00005; Chou TC, 2002, J NEUROSCI, V22, P977, DOI 10.1523/JNEUROSCI.22-03-00977.2002; CIRELLI C, 1993, ARCH ITAL BIOL, V131, P327; Cirelli C, 2000, SLEEP, V23, P453; COLLINGRIDGE GL, 1984, J PHYSIOL-LONDON, V356, P551, DOI 10.1113/jphysiol.1984.sp015482; CORREASALES C, 1992, ANESTHESIOLOGY, V76, P948, DOI 10.1097/00000542-199206000-00013; Depczynski B, 1998, ANN NY ACAD SCI, V863, P120, DOI 10.1111/j.1749-6632.1998.tb10689.x; Devor M, 2001, PAIN, V94, P101, DOI 10.1016/S0304-3959(01)00345-1; Elmquist JK, 1996, J COMP NEUROL, V371, P85, DOI 10.1002/(SICI)1096-9861(19960715)371:1<85::AID-CNE5>3.0.CO;2-H; ERICSON H, 1991, J COMP NEUROL, V305, P462, DOI 10.1002/cne.903050309; Fiset P, 1999, J NEUROSCI, V19, P5506; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; GAGE PW, 1985, BRIT J PHARMACOL, V85, P229, DOI 10.1111/j.1476-5381.1985.tb08851.x; Gallopin T, 2000, NATURE, V404, P992, DOI 10.1038/35010109; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HARA M, 1993, ANESTHESIOLOGY, V79, P781, DOI 10.1097/00000542-199310000-00021; HOFFMAN GE, 1993, FRONT NEUROENDOCRIN, V14, P173, DOI 10.1006/frne.1993.1006; Jevtovic-Todorovic V, 1998, NAT MED, V4, P460, DOI 10.1038/nm0498-460; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; Lam DW, 1998, BRAIN RES, V784, P179, DOI 10.1016/S0006-8993(97)01334-6; Lin JS, 1996, J NEUROSCI, V16, P1523; LIN JS, 1988, NEUROPHARMACOLOGY, V27, P111, DOI 10.1016/0028-3908(88)90159-1; LIN LH, 1993, J NEUROCHEM, V60, P1548, DOI 10.1111/j.1471-4159.1993.tb03320.x; MONTI JM, 1993, LIFE SCI, V53, P1331, DOI 10.1016/0024-3205(93)90592-Q; Nitz D, 1996, AM J PHYSIOL-REG I, V271, pR1707, DOI 10.1152/ajpregu.1996.271.6.R1707; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pompeiano M, 1995, NEUROPHYSIOL CLIN, V25, P329, DOI 10.1016/0987-7053(96)84906-9; SAPER CB, 1985, J COMP NEUROL, V237, P21, DOI 10.1002/cne.902370103; Sawamura S, 2000, J NEUROSCI, V20, P9242; Sherin JE, 1998, J NEUROSCI, V18, P4705; Sherin JE, 1996, SCIENCE, V271, P216, DOI 10.1126/science.271.5246.216; Steininger TL, 1999, BRAIN RES, V840, P138, DOI 10.1016/S0006-8993(99)01648-0; Steininger TL, 2001, J COMP NEUROL, V429, P638; Stell BM, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0003.2002; TANELIAN DL, 1993, ANESTHESIOLOGY, V78, P757, DOI 10.1097/00000542-199304000-00020; VILLAR MJ, 1990, NEUROSCIENCE, V36, P181, DOI 10.1016/0306-4522(90)90361-7; WAUD DR, 1972, J PHARMACOL EXP THER, V183, P577	45	422	436	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	OCT	2002	5	10					979	984		10.1038/nn913	http://dx.doi.org/10.1038/nn913			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	597VV	12195434				2023-01-03	WOS:000178242200017
J	Lassen, A; Hallas, J; de Muckadell, OBS				Lassen, A; Hallas, J; de Muckadell, OBS			Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		Odense Univ Hosp, Dept Med Gastroenterol, DK-5000 Odense, Denmark; Odense Univ Hosp, Dept Internal Med, DK-5000 Odense, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital	Lassen, A (corresponding author), Odense Univ Hosp, Dept Med Gastroenterol, DK-5000 Odense, Denmark.		Lassen, Annmarie/AAA-5816-2019	Schaffalitzky de Muckadell, Ove B/0000-0003-1969-2329; Hallas, Jesper/0000-0002-8097-8708; Lassen, Annmarie/0000-0003-4942-6152				De Boer WA, 2001, GUT, V48, P567, DOI 10.1136/gut.48.4.567; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; Gaist D, 1997, DAN MED BULL, V44, P445; Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x; McColl KEL, 2000, AM J GASTROENTEROL, V95, P101	5	10	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					603	603		10.1136/bmj.327.7415.603	http://dx.doi.org/10.1136/bmj.327.7415.603			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969930	Green Published, Bronze			2023-01-03	WOS:000185358700026
J	Fudala, PJ; Bridge, TP; Herbert, S; Williford, WO; Chiang, CN; Jones, K; Collins, J; Raisch, D; Casadonte, P; Goldsmith, RJ; Ling, W; Malkerneker, U; McNicholas, L; Renner, J; Stine, S; Tusel, D				Fudala, PJ; Bridge, TP; Herbert, S; Williford, WO; Chiang, CN; Jones, K; Collins, J; Raisch, D; Casadonte, P; Goldsmith, RJ; Ling, W; Malkerneker, U; McNicholas, L; Renner, J; Stine, S; Tusel, D		Buprenorphine Naloxone Collaborati	Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED CLINICAL-TRIAL; DRUG-ABUSE TREATMENT; OPIOID DEPENDENCE; INTRAVENOUS BUPRENORPHINE; CRIMINAL ACTIVITY; VOLUNTEERS; COMBINATIONS; PREVALENCE; METHADONE	Background: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone has been proposed, but its efficacy and safety have not been well studied. Methods: We conducted a multicenter, randomized, placebo-controlled trial involving 326 opiate-addicted persons who were assigned to office-based treatment with sublingual tablets consisting of buprenorphine (16 mg) in combination with naloxone (4 mg), buprenorphine alone (16 mg), or placebo given daily for four weeks. The primary outcome measures were the percentage of urine samples negative for opiates and the subjects' self-reported craving for opiates. Safety data were obtained on 461 opiate-addicted persons who participated in an open-label study of buprenorphine and naloxone (at daily doses of up to 24 mg and 6 mg, respectively) and another 11 persons who received this combination only during the trial. Results: The double-blind trial was terminated early because buprenorphine and naloxone in combination and buprenorphine alone were found to have greater efficacy than placebo. The proportion of urine samples that were negative for opiates was greater in the combined-treatment and buprenorphine groups (17.8 percent and 20.7 percent, respectively) than in the placebo group (5.8 percent, P<0.001 for both comparisons); the active-treatment groups also reported less opiate craving (P<0.001 for both comparisons with placebo). Rates of adverse events were similar in the active-treatment and placebo groups. During the open-label phase, the percentage of urine samples negative for opiates ranged from 35.2 percent to 67.4 percent. Results from the open-label follow-up study indicated that the combined treatment was safe and well tolerated. Conclusions: Buprenorphine and naloxone in combination and buprenorphine alone are safe and reduce the use of opiates and the craving for opiates among opiate-addicted persons who receive these medications in an office-based setting.	Univ Penn, Sch Med, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; NIDA, Div Treatment Res & Dev, NIH, Bethesda, MD 20892 USA; VA Cooperat Studies Program, Coordinating Ctr, Perry Point, MD USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Univ New Mexico, VA Cooperat Studies Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM 87131 USA; NYU, Sch Med, New York Harbor Hlth Care Syst, VA Med Ctr, New York, NY USA; VA Med Ctr, Cincinnati, OH USA; VA Med Ctr, Los Angeles, CA USA; VA Med Ctr, Hines, IL USA; Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02118 USA; VA Med Ctr, West Haven, CT USA; Univ Calif San Francisco, VA Med Ctr, San Francisco, CA 94143 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University System of Maryland; University of Maryland Baltimore; University of New Mexico; New York University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; University of California System; University of California San Francisco	Fudala, PJ (corresponding author), VA Med Ctr, Psychiat Serv, Ward 7E 116-7E,Univ & Woodland Aves, Philadelphia, PA 19104 USA.			, Walter/0000-0003-0664-5099; Stine, Susan/0000-0001-5426-4448	NIDA NIH HHS [3Y01-DA-30011-04] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		American Psychiatric Association, 1994, DSM 4; Bates M, 1996, SCOT MED J, V41, P173, DOI 10.1177/003693309604100606; BROWN BS, 1989, AM J DRUG ALCOHOL AB, V15, P261, DOI 10.3109/00952998908993407; CHILDRESS AR, 1991, RES MONOGRAPH NAT I, V106, P167; Comer SD, 2002, J PHARMACOL EXP THER, V301, P266, DOI 10.1124/jpet.301.1.266; DEMETS DL, 1987, STAT MED, V6, P753, DOI 10.1002/sim.4780060706; FRENCH MT, 1993, AM J DRUG ALCOHOL AB, V19, P19, DOI 10.3109/00952999309002663; Fudala PJ, 1998, DRUG ALCOHOL DEPEN, V50, P1, DOI 10.1016/S0376-8716(98)00008-8; Harling R, 1998, BRIT MED J, V317, P431; Harris DS, 2000, DRUG ALCOHOL DEPEN, V61, P85, DOI 10.1016/S0376-8716(00)00126-5; HARTNOLL RL, 1994, ADDICTION, V89, P1377, DOI 10.1111/j.1360-0443.1994.tb03733.x; HUGHES PH, 1995, EPIDEMIOL REV, V17, P66, DOI 10.1093/oxfordjournals.epirev.a036186; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; JOHNSON RE, 1995, DRUG ALCOHOL DEPEN, V40, P17, DOI 10.1016/0376-8716(95)01186-2; Johnson RE, 2000, NEW ENGL J MED, V343, P1290, DOI 10.1056/NEJM200011023431802; Kakko J, 2003, LANCET, V361, P662, DOI 10.1016/S0140-6736(03)12600-1; Knolle H, 1997, SUBST USE MISUSE, V32, P1349, DOI 10.3109/10826089709039382; Krook AL, 2002, ADDICTION, V97, P533, DOI 10.1046/j.1360-0443.2002.00090.x; LEANDER JD, 1987, NEUROPHARMACOLOGY, V26, P1445, DOI 10.1016/0028-3908(87)90112-2; Ling W, 1998, ADDICTION, V93, P475, DOI 10.1046/j.1360-0443.1998.9344753.x; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Mendelson J, 1999, PSYCHOPHARMACOLOGY, V141, P37, DOI 10.1007/s002130050804; Mendelson J, 1996, CLIN PHARMACOL THER, V60, P105, DOI 10.1016/S0009-9236(96)90173-3; Mendelson J, 2003, DRUG ALCOHOL DEPEN, V70, pS29, DOI 10.1016/S0376-8716(03)00057-7; Merrill J, 1999, J SUBST ABUSE TREAT, V17, P313, DOI 10.1016/S0740-5472(99)00012-4; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Nath RP, 1999, J CLIN PHARMACOL, V39, P619, DOI 10.1177/00912709922008236; *OFF DRUG CONTR PO, 1997, WHAT AM US SPEND ILL; Pani PP, 2000, DRUG ALCOHOL DEPEN, V60, P39, DOI 10.1016/S0376-8716(99)00140-4; PICKWORTH WB, 1993, CLIN PHARMACOL THER, V53, P570, DOI 10.1038/clpt.1993.72; Strain EC, 1997, PSYCHOPHARMACOLOGY, V129, P329, DOI 10.1007/s002130050199; 2001, FED REG, V66, P4075	32	407	414	0	32	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					949	958		10.1056/NEJMoa022164	http://dx.doi.org/10.1056/NEJMoa022164			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717HJ	12954743	Bronze			2023-01-03	WOS:000185081400006
J	Chirita, CN; Necula, M; Kuret, J				Chirita, CN; Necula, M; Kuret, J			Anionic micelles and vesicles induce tau fibrillization in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; BETA-AMYLOID PEPTIDE; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; FATTY-ACIDS; SULFATED GLYCOSAMINOGLYCANS; TERMINAL DOMAIN; BINDING	Alzheimer's disease is defined in part by the intraneuronal accumulation of filaments comprised of the microtubule-associated protein tau. In vitro, fibrillization of recombinant tau can be induced by treatment with various agents, including phosphotransferases, polyanionic compounds, and fatty acids. Here we characterize the structural features required for the fatty acid class of tau fibrillization inducer using recombinant full-length tau protein, arachidonic acid, and a series of straight chain anionic, cationic, and nonionic detergents. Induction of measurable tau fibrillization required an alkyl chain length of at least 12 carbons and a negative charge consisting of carboxylate, sulfonate, or sulfate moieties. All detergents and fatty acids were micellar at active concentrations, due to a profound, tau-dependent depression of their critical micelle concentrations. Anionic surfaces larger than detergent micelles, such as those supplied by phosphatidylserine vesicles, also induced tau fibrillization with resultant filaments originating from their surface. These data suggest that anionic surfaces presented as micelles or vesicles can serve to nucleate tau fibrillization, that this mechanism underlies the activity of fatty acid inducers, and that anionic membranes may serve this function in vivo.	Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Ctr Biotechnol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Biophys Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kuret, J (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Ctr Biotechnol, 1060 Carmack Rd, Columbus, OH 43210 USA.				NATIONAL INSTITUTE ON AGING [R01AG014452] Funding Source: NIH RePORTER; NIA NIH HHS [AG14452] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Bales BL, 2001, J PHYS CHEM B, V105, P6798, DOI 10.1021/jp004576m; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; Bondareff W, 1998, J NEUROSCI RES, V52, P498, DOI 10.1002/(SICI)1097-4547(19980601)52:5<498::AID-JNR2>3.0.CO;2-7; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITO RMM, 1986, ANAL BIOCHEM, V152, P250, DOI 10.1016/0003-2697(86)90406-9; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; CORRIN ML, 1947, J AM CHEM SOC, V69, P683, DOI 10.1021/ja01195a065; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Farooqui AA, 1997, NEUROCHEM RES, V22, P523, DOI 10.1023/A:1027380331807; Feany MB, 1996, ANN NEUROL, V40, P139, DOI 10.1002/ana.410400204; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Ghoshal N, 2002, EXP NEUROL, V177, P475, DOI 10.1006/exnr.2002.8014; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GomezIsla T, 1996, J NEUROSCI, V16, P4491; GRAY EG, 1987, NEUROPATH APPL NEURO, V13, P91, DOI 10.1111/j.1365-2990.1987.tb00174.x; GUNNARSSON G, 1980, J PHYS CHEM-US, V84, P3114, DOI 10.1021/j100460a029; Hasegawa M, 1997, J BIOL CHEM, V272, P33118, DOI 10.1074/jbc.272.52.33118; Huibers PDT, 1997, J COLLOID INTERF SCI, V187, P113, DOI 10.1006/jcis.1996.4680; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KING MD, 1987, BIOCHEMISTRY-US, V26, P1224, DOI 10.1021/bi00379a004; King ME, 1999, BIOCHEMISTRY-US, V38, P14851, DOI 10.1021/bi9911839; King ME, 2000, J NEUROCHEM, V74, P1749, DOI 10.1046/j.1471-4159.2000.0741749.x; Koyama Y, 1996, BIOCONJUGATE CHEM, V7, P298, DOI 10.1021/bc9600123; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Lins L, 2002, PROTEIN ENG, V15, P513, DOI 10.1093/protein/15.6.513; Martinez-Senac MD, 1999, EUR J BIOCHEM, V265, P744, DOI 10.1046/j.1432-1327.1999.00775.x; Perez M, 1996, J NEUROCHEM, V67, P1183; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Pillot T, 1997, J MOL BIOL, V274, P381, DOI 10.1006/jmbi.1997.1382; Pillot T, 1996, J BIOL CHEM, V271, P28757, DOI 10.1074/jbc.271.46.28757; Ranganathan R, 2000, J PHYS CHEM B, V104, P2260, DOI 10.1021/jp993917x; RAY A, 1971, NATURE, V231, P313, DOI 10.1038/231313a0; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; SUN GY, 1985, PHOSPHOLIPIDS NERVOU, P79; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TESSARI M, 1993, BIOPOLYMERS, V33, P1877, DOI 10.1002/bip.360331213; TROJANOWSKI JQ, 1995, NEUROBIOL AGING, V16, P335, DOI 10.1016/0197-4580(94)00176-2; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; Wells K, 1995, NEUROCHEM RES, V20, P1329, DOI 10.1007/BF00992508; Wilson DM, 1997, AM J PATHOL, V150, P2181; Yen S, 2002, NEUROBIOL AGING, V23, pS490	60	181	187	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25644	25650		10.1074/jbc.M301663200	http://dx.doi.org/10.1074/jbc.M301663200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730214	hybrid			2023-01-03	WOS:000183920200047
J	Mann, E				Mann, E			Managing pain	BRITISH MEDICAL JOURNAL			English	Article									Poole Hosp NHS Trust, Poole BH21 2JB, Dorset, England; Bournemouth Univ, IHCS, Poole BH21 2JB, Dorset, England	Bournemouth University	Mann, E (corresponding author), Poole Hosp NHS Trust, Poole BH21 2JB, Dorset, England.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1320	1321		10.1136/bmj.326.7402.1320	http://dx.doi.org/10.1136/bmj.326.7402.1320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805176	Green Published			2023-01-03	WOS:000183626500039
J	Abol-Enein, H; Bono, AV; Boyer, M; Clarke, NW; Coppin, CML; Cortesi, E; Goebell, PJ; Groshen, S; Hall, RR; Horwich, A; Malmstrom, PU; Martinez-Pineiro, JA; Parmar, MKB; Raghavan, D; Roberts, JTG; Sengelov, L; Sherif, A; Stewart, LA; Stockle, M; Sylvester, R; Tierney, JF; Torti, FM; Vale, CL; Wallace, DMA				Abol-Enein, H; Bono, AV; Boyer, M; Clarke, NW; Coppin, CML; Cortesi, E; Goebell, PJ; Groshen, S; Hall, RR; Horwich, A; Malmstrom, PU; Martinez-Pineiro, JA; Parmar, MKB; Raghavan, D; Roberts, JTG; Sengelov, L; Sherif, A; Stewart, LA; Stockle, M; Sylvester, R; Tierney, JF; Torti, FM; Vale, CL; Wallace, DMA		ABC Meta-Anal Collaboration	Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis	LANCET			English	Article							TRANSITIONAL-CELL-CARCINOMA; RADICAL CYSTECTOMY; PROSPECTIVE TRIAL; CISPLATIN; THERAPY	Background Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment 06 survival in patients with this disease. Methods We analysed updated data for 2688 individual patients from ten available randomised trials. Findings Platinum-based combination chemotherapy showed a significant benefit to overall survival (combined hazard ratio [HR] 0.87 [95% Cl 0.78-0.98, p=0.016]; 13% reduction in risk of death; 5% absolute benefit at 5 years [1-7]; overall survival increased from 45% to 50%). This effect was observed irrespective of the type of local treatment, and did not vary between subgroups of patients. The HR for all trials, including those using single-agent cisplatin, tended to favour neoadjuvant chemotherapy (HR=0.91, 95% Cl 0.83-1.01) although this tendency was not significant (p=0.084). Although platinum based combination chemotherapy was beneficial, there was no evidence to support the use of single-agent platinum; indeed, there was a significant difference in the effect between these groups of trials (p=0.044). Interpretation This improvement in survival encourages the use of platinum-based combination chemotherapy for patients with invasive bladder cancer.	MRC, Clin Trials Unit, Metaanal Grp, London NW1 2DA, England; Urol & Nephrol Ctr, Mansoura, Egypt; Univ Padua, Sch Med, Padua, Italy; Osped Circolo & Fdn Macchi, Varese, Italy; Sydney Canc Ctr, Sydney, NSW, Australia; Christie Hosp, Manchester, Lancs, England; Fraser Valley Canc Ctr, Surrey, BC, Canada; Univ Roma La Sapienza, Rome, Italy; Univ Essen Gesamthsch, Urol Clin, Essen, Germany; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Freeman Rd Hosp, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Royal Marsden NHS Trust, Surrey, England; Univ Uppsala Hosp, Uppsala, Sweden; La Luz Clin, Madrid, Spain; No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England; Herlev Univ Hosp, DK-2730 Herlev, Denmark; Univ Uppsala Hosp, Uppsala, Sweden; Biostat Abt, Mannheim, Germany; EORTC Data Ctr, Brussels, Belgium; Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England	Medical Research Council Clinical Trials Unit; University of Padua; Ospedale Circolo & Fondazione Macchi; University of Sydney; Christie NHS Foundation Trust; Christie Hospital; Sapienza University Rome; University of Duisburg Essen; University of Southern California; Newcastle Freeman Hospital; Newcastle University - UK; Royal Marsden NHS Foundation Trust; Uppsala University; Uppsala University Hospital; University of Copenhagen; Herlev & Gentofte Hospital; Uppsala University; Uppsala University Hospital; European Organisation for Research & Treatment of Cancer; Wake Forest University; University of Birmingham	Vale, CL (corresponding author), MRC, Clin Trials Unit, Metaanal Grp, 222 Euston Rd, London NW1 2DA, England.	cv@ctu.mrc.ac.uk	Cortesi, Enrico/AAA-2983-2019	Tierney, Jayne/0000-0002-4734-3014; Stewart, Lesley/0000-0003-0287-4724; Vale, Claire/0000-0001-5157-0634				ABOLENEIN H, 1997, BR J UROL S4, V79, P174; *ADV OV CANC TRIAL, 1991, BMJ-BRIT MED J, V303, P844; [Anonymous], 1999, Lancet, V354, P533; Bassi P, 1999, J UROLOGY, V161, P1494, DOI 10.1016/S0022-5347(05)68936-7; Clarke M, 1998, ANN ONCOL, V9, P827, DOI 10.1023/A:1008468705492; Coppin CML, 1996, J CLIN ONCOL, V14, P2901, DOI 10.1200/JCO.1996.14.11.2901; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; FAGG SL, 1984, BRIT J UROL, V56, P296, DOI 10.1111/j.1464-410X.1984.tb05390.x; GHERSI D, 1995, BRIT J UROL, V75, P206; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Malmstrom PU, 1996, J UROLOGY, V155, P1903, DOI 10.1016/S0022-5347(01)66042-7; Martinez-Pineiro JA, 1998, BRIT J UROL, V82, P33; MARTINEZPINEIRO JA, 1995, J UROLOGY, V153, P964, DOI 10.1016/S0022-5347(01)67614-6; Millikan R, 2001, J CLIN ONCOL, V19, P4005, DOI 10.1200/JCO.2001.19.20.4005; NATALE RB, 2001, P AN M AM SOC CLIN, V20, P3; OZONO S, 1991, UROL INT, V47, P116, DOI 10.1159/000282268; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; PARMAR M, 1995, SURVIVAL ANAL PRACTI; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; PARMAR MKB, 1999, CLIN MANAGEMENT BLAD, P249; RAGHAVAN D, 1984, MED J AUSTRALIA, V140, P276, DOI 10.5694/j.1326-5377.1984.tb104036.x; Sengelov L, 2002, ACTA ONCOL, V41, P447, DOI 10.1080/028418602320405041; SHEARER RJ, 1988, BRIT J UROL, V62, P558, DOI 10.1111/j.1464-410X.1988.tb04426.x; Sherif A, 2002, SCAND J UROL NEPHROL, V36, P419, DOI 10.1080/003655902762467567; Shipley WU, 1998, J CLIN ONCOL, V16, P3576, DOI 10.1200/JCO.1998.16.11.3576; SOLOWAY MS, 1981, CANCER, V47, P476, DOI 10.1002/1097-0142(19810201)47:3<476::AID-CNCR2820470309>3.0.CO;2-8; Sternberg CN, 2001, J CLIN ONCOL, V19, p21S; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; STEWART LA, 1993, LANCET, V341, P964; WALLACE DMA, 1991, BRIT J UROL, V67, P608, DOI 10.1111/j.1464-410X.1991.tb15225.x; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	31	472	481	1	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2003	361	9373					1927	1934						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801735				2023-01-03	WOS:000183359700007
J	Shumaker, SA; Legault, C; Rapp, SR; Thal, L; Wallace, RB; Ockene, JK; Hendrix, SL; Jones, BN; Assaf, AR; Jackson, RD; Kotchen, JM; Wassertheil-Smoller, S; Wactawski-Wende, J				Shumaker, SA; Legault, C; Rapp, SR; Thal, L; Wallace, RB; Ockene, JK; Hendrix, SL; Jones, BN; Assaf, AR; Jackson, RD; Kotchen, JM; Wassertheil-Smoller, S; Wactawski-Wende, J		WHIMS Investigators	Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women - The Women's Health Initiative Memory Study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; CEREBRAL-BLOOD-FLOW; ALZHEIMERS-DISEASE; DIABETES-MELLITUS; OLDER WOMEN; RISK-FACTORS; POPULATION; ACQUISITION; PREVALENCE; ESTRADIOL	Context Postmenopausal women have a greater risk than men of developing Alzheimer disease, but studies of the effects of estrogen therapy on Alzheimer disease have been inconsistent. On July 8, 2002, the study drugs, estrogen plus progestin, in the Women's Health Initiative (WHI) trial were discontinued because of certain increased health risks in women receiving combined hormone therapy. Objective To evaluate the effect of estrogen plus progestin on the incidence of dementia and mild cognitive impairment compared with placebo. Design, Setting, and Participants The Women's Health Initiative Memory Study (WHIMS), a randomized, double-blind, placebo-controlled clinical trial, began enrolling participants from the Women's Health Initiative (WHI) estrogen plus progestin trial in May 1996. Of the 4894 eligible participants of the WHI study, 4532 (92.6%) postmenopausal women free of probable dementia, aged 65 years or older, and recruited from 39 of 40 WHI clinical centers were enrolled in the WHIMS. Intervention Participants received either 1 daily tablet of 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate (n=2229), ora matching placebo (n=2303). Main Outcome Measures incidence of probable dementia (primary outcome) and mild cognitive impairment (secondary outcome) were identified through a structured clinical assessment. Results The mean (SD) time between the date of randomization into WHI and the last Modified Mini-Mental State Examination (3MSE) for all WHIMS participants was 4.05 (1.19) years. Overall, 61 women were diagnosed with probable dementia, 40 (66%) in the estrogen plus progestin group compared with 21 (34%) in the placebo group. The hazard ratio (HR) for probable dementia was 2.05 (95% confidence interval [CI], 1.21-3.48; 45 vs 22 per 10000 person-years; P=.01). This increased risk would result in an additional 23 cases of dementia per 10000 women per year. Alzheimer disease was the most common classification of dementia in both study groups. Treatment effects on mild cognitive impairment did not differ between groups (HR, 1.07; 95% CI, 0.74-1.55; 63 vs 59 cases per 10000 person-years; P=.72). Conclusions Estrogen plus progestin therapy increased the risk for probable dementia in postmenopausal women aged 65 years or older. In addition, estrogen plus progestin therapy did not prevent mild cognitive impairment in these women. These findings, coupled with previously reported WHI data, support the conclusion that the risks of estrogen plus progestin outweigh the benefits.	Wake Forest Univ Hlth Sci, Dept Publ Hlth Sci, Winston Salem, NC 27104 USA; Wake Forest Univ Hlth Sci, Dept Psychiat & Behav Med, Winston Salem, NC USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; Univ Iowa, Dept Epidemiol, Iowa City, IA USA; Univ Massachusetts, Div Prevent & Behav Med, Worcester, MA 01605 USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Obstet & Gynecol, Detroit, MI USA; Brown Univ, Ctr Primary Care & Div, Providence, RI 02912 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Med Coll Wisconsin, Dept Epidemiol & Med, Milwaukee, WI 53226 USA; Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; University of California System; University of California San Diego; University of Iowa; University of Massachusetts System; University of Massachusetts Worcester; Wayne State University; Brown University; University System of Ohio; Ohio State University; Medical College of Wisconsin; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Shumaker, SA (corresponding author), Wake Forest Univ Hlth Sci, Dept Publ Hlth Sci, 200 W 1st St,Piedmont Plaza 2, Winston Salem, NC 27104 USA.	sshumake@wfubmc.edu	Wactawski-Wende, Jean/AGH-5457-2022	Wactawski-Wende, Jean/0000-0003-3096-9595				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; ATKINSON RC, 1971, SCI AM, V225, P82, DOI 10.1038/scientificamerican0871-82; Baldereschi M, 1998, NEUROLOGY, V50, P996, DOI 10.1212/WNL.50.4.996; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; BIRGE SJ, 1997, AM J MED, V103, P15; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; Brinton RD, 2000, NEUROBIOL AGING, V21, P475, DOI 10.1016/S0197-4580(00)00109-3; Burke W J, 1991, J Geriatr Psychiatry Neurol, V4, P173, DOI 10.1177/089198879100400310; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; Chen JG, 2002, J NEUROPSYCH CLIN N, V14, P58, DOI 10.1176/appi.neuropsych.14.1.58; Chesler EJ, 2000, HORM BEHAV, V38, P234, DOI 10.1006/hbeh.2000.1626; Coker LH, 2003, J PSYCHOSOM RES, V54, P129, DOI 10.1016/S0022-3999(02)00523-8; COX DR, 1972, J R STAT SOC B, V34, P187; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; Freedman L, 1996, CONTROL CLIN TRIALS, V17, P509, DOI 10.1016/S0197-2456(96)00016-5; Gibbs RB, 1999, HORM BEHAV, V36, P222, DOI 10.1006/hbeh.1999.1541; Gibbs RB, 1998, HORM BEHAV, V34, P98, DOI 10.1006/hbeh.1998.1451; Gibbs RB, 2000, NEUROSCIENCE, V101, P931, DOI 10.1016/S0306-4522(00)00433-4; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Hajjar L, 2002, J GERONTOL A-BIOL, V57, pM414, DOI 10.1093/gerona/57.7.M414; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HERBISON AE, 1995, NEUROENDOCRINOLOGY, V61, P1, DOI 10.1159/000126810; Hogervorst E, 2000, NEUROSCIENCE, V101, P485, DOI 10.1016/S0306-4522(00)00410-3; HOGERVORST E, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003799; ISAACS B, 1973, BRIT J PSYCHIAT, V123, P467, DOI 10.1192/bjp.123.4.467; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; Jellinger KA, 2002, J NEURAL TRANSM, V109, P329, DOI 10.1007/s007020200027; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; JUDD HL, 1974, J CLIN ENDOCR METAB, V39, P1020, DOI 10.1210/jcem-39-6-1020; Kalaria RN, 1996, NEUROBIOL AGING, V17, P687; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Kaplan EF., 1983, BOSTON NAMING TEST, V2; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kawas CH, 2003, NEUROLOGY, V60, P1089, DOI 10.1212/01.WNL.0000055813.36504.BF; Kuller LH, 2003, NEUROEPIDEMIOLOGY, V22, P13, DOI 10.1159/000067109; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Leibson CL, 1997, AM J EPIDEMIOL, V145, P301; Maki PM, 2002, NEUROPSYCHOLOGIA, V40, P518, DOI 10.1016/S0028-3932(01)00126-9; Maki PM, 2000, NEUROBIOL AGING, V21, P373, DOI 10.1016/S0197-4580(00)00123-8; Marriott LK, 2002, BEHAV NEUROSCI, V116, P902, DOI 10.1037//0735-7044.116.5.902; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Nilsen J, 2002, NEUROREPORT, V13, P825, DOI 10.1097/00001756-200205070-00018; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; REITAN RM, 1992, J CLIN PSYCHOL, V48, P521, DOI 10.1002/1097-4679(199207)48:4<521::AID-JCLP2270480414>3.0.CO;2-C; Resnick SM, 1998, HORM BEHAV, V34, P171, DOI 10.1006/hbeh.1998.1476; Resnick SM, 2002, JAMA-J AM MED ASSOC, V288, P2170, DOI 10.1001/jama.288.17.2170; Rice MM, 2000, ARCH INTERN MED, V160, P1641, DOI 10.1001/archinte.160.11.1641; Rodriguez EG, 2002, J AM GERIATR SOC, V50, P1852, DOI 10.1046/j.1532-5415.2002.50515.x; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Steffens DC, 1999, J AM GERIATR SOC, V47, P1171, DOI 10.1111/j.1532-5415.1999.tb05195.x; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TENG EL, 1990, PSYCHOGERIATRICS BIO, P189; Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Wang PN, 2000, NEUROLOGY, V54, P2061, DOI 10.1212/WNL.54.11.2061; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; Warren SG, 1997, BEHAV NEUROSCI, V111, P259, DOI 10.1037/0735-7044.111.2.259; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123	82	1521	1562	1	90	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2651	2662		10.1001/jama.289.20.2651	http://dx.doi.org/10.1001/jama.289.20.2651			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	682DG	12771112				2023-01-03	WOS:000183075600024
J	Nagamori, S; Vazquez-Ibar, JL; Weinglass, AB; Kaback, HR				Nagamori, S; Vazquez-Ibar, JL; Weinglass, AB; Kaback, HR			In vitro synthesis of lactose permease to probe the mechanism of membrane insertion and folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; LAC CARRIER PROTEIN; THIOL CROSS-LINKING; ESCHERICHIA-COLI; PROJECTION STRUCTURE; ANGSTROM RESOLUTION; TRANSPORT PROTEINS; SUBSTRATE-BINDING; HELIX PACKING; TRANSLOCATION	Insertion and folding of polytopic membrane proteins is an important unsolved biological problem. To study this issue, lactose permease, a membrane transport protein from Escherichia coli, is transcribed, translated, and inserted into inside-out membrane vesicles in vitro. The protein is in a native conformation as judged by sensitivity to protease, binding of a monoclonal antibody directed against a conformational epitope, and importantly, by functional assays. By exploiting this system it is possible to express the N-terminal six helices of the permease (N-6) and probe changes in conformation during insertion into the membrane. Specifically, when N-6 remains attached to the ribosome it is readily extracted from the membrane with urea, whereas after release from the ribosome or translation of additional helices, those polypeptides are not urea extractable. Furthermore, the accessibility of an engineered Factor Xa site to Xa protease is reduced significantly when N-6 is released from the ribosome or more helices are translated. Finally, spontaneous disulfide formation between Cys residues at positions 126 (Helix IV) and 144 (Helix V) is observed when N-6 is released from the ribosome and inserted into the membrane. Moreover, in contrast to full-length permease, N-6 is degraded by FtsH protease in vivo, and N-6 with a single Cys residue at position 148 does not react with N-ethylmaleimide. Taken together, the findings indicate that N-6 remains in a hydrophilic environment until it is released from the ribosome or additional helices are translated and continues to fold into a quasi-native conformation after insertion into the bilayer. Furthermore, there is synergism between N-6 and the C-terminal half of permease during assembly, as opposed to assembly of the two halves as independent domains.	Univ Calif Los Angeles, HHMI, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Physiol & Microbiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Mol Genet, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kaback, HR (corresponding author), Univ Calif Los Angeles, HHMI, 5-748 Macdonald Res Labs,Box 951662, Los Angeles, CA 90095 USA.		Vazquez-Ibar, Jose-Luis/AAD-8827-2021; Nagamori, Shushi/P-4530-2018	Vazquez-Ibar, Jose-Luis/0000-0002-8314-3378; Nagamori, Shushi/0000-0003-0203-2754	NIDDK NIH HHS [DK51131:08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHREM B, 1989, J CELL BIOL, V108, P1637, DOI 10.1083/jcb.108.5.1637; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Bernstein HD, 2000, CURR OPIN MICROBIOL, V3, P203, DOI 10.1016/S1369-5274(00)00076-X; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Bochkareva E, 1996, J BIOL CHEM, V271, P22256, DOI 10.1074/jbc.271.36.22256; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; Dalbey RE, 2000, CURR OPIN CELL BIOL, V12, P435, DOI 10.1016/S0955-0674(00)00113-7; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRILLINGOS S, 1995, BIOCHEMISTRY-US, V34, P9368, DOI 10.1021/bi00029a012; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GOLDKORN T, 1983, P NATL ACAD SCI-BIOL, V80, P3322, DOI 10.1073/pnas.80.11.3322; Guan L, 2002, P NATL ACAD SCI USA, V99, P3475, DOI 10.1073/pnas.052703699; Guan L, 2002, P NATL ACAD SCI USA, V99, P6613, DOI 10.1073/pnas.102178299; Hacksell I, 2002, EMBO J, V21, P3569, DOI 10.1093/emboj/cdf378; Herskovits AA, 2002, J CELL BIOL, V159, P403, DOI 10.1083/jcb.200204144; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; KONINGS WN, 1996, HDB BIOL PHYSICS TRA; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; Nagamori S, 2000, J BIOCHEM-TOKYO, V128, P129, DOI 10.1093/oxfordjournals.jbchem.a022723; Nishiyama K, 2000, BIOSCI BIOTECH BIOCH, V64, P2121, DOI 10.1271/bbb.64.2121; Nouwen N, 2002, MOL MICROBIOL, V44, P1397, DOI 10.1046/j.1365-2958.2002.02972.x; Ogura T, 1999, MOL MICROBIOL, V31, P833, DOI 10.1046/j.1365-2958.1999.01221.x; Prinz WA, 1998, J BIOL CHEM, V273, P8419, DOI 10.1074/jbc.273.14.8419; Sahin-Toth M, 2002, BIOCHEMISTRY-US, V41, P13039, DOI 10.1021/bi0203076; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; SahinToth M, 1996, BIOCHEMISTRY-US, V35, P2016, DOI 10.1021/bi952496g; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; SAHINTOTH M, 1995, BIOCHEMISTRY-US, V34, P1107, DOI 10.1021/bi00004a001; Saier MH, 2000, MOL MICROBIOL, V35, P699, DOI 10.1046/j.1365-2958.2000.01759.x; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SCHULDINER S, 1975, J BIOL CHEM, V250, P1361; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Seluanov A, 1997, J BIOL CHEM, V272, P2053; SHORT SA, 1974, P NATL ACAD SCI USA, V71, P1461, DOI 10.1073/pnas.71.4.1461; Sorgen PL, 2002, P NATL ACAD SCI USA, V99, P14037, DOI 10.1073/pnas.182552199; STOCHAJ U, 1987, EUR J BIOCHEM, V163, P653, DOI 10.1111/j.1432-1033.1987.tb10914.x; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P274, DOI 10.1021/bi962292f; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P11959, DOI 10.1021/bi971172k; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; van Voorst F, 2000, BIOCHEM J, V347, P601, DOI 10.1042/bj3470601; Vazquez-Ibar JL, 2002, P NATL ACAD SCI USA, V99, P3487, DOI 10.1073/pnas.052703599; Venkatesan P, 1998, P NATL ACAD SCI USA, V95, P9802, DOI 10.1073/pnas.95.17.9802; VIITANEN P, 1984, P NATL ACAD SCI-BIOL, V81, P1629, DOI 10.1073/pnas.81.6.1629; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; Weinglass AB, 2000, P NATL ACAD SCI USA, V97, P8938, DOI 10.1073/pnas.140224497; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; WILLIAMS RW, 1986, METHOD ENZYMOL, V130, P311; Wolin CD, 2000, BIOCHEMISTRY-US, V39, P6130, DOI 10.1021/bi0001269; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; WU JH, 1995, P NATL ACAD SCI USA, V92, P9186, DOI 10.1073/pnas.92.20.9186; YAMADA H, 1989, J BIOL CHEM, V264, P1723; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005; ZEN KH, 1995, BIOCHEMISTRY-US, V34, P3430, DOI 10.1021/bi00010a035; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	79	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14820	14826		10.1074/jbc.M300332200	http://dx.doi.org/10.1074/jbc.M300332200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590141	hybrid			2023-01-03	WOS:000182516100032
J	Iglehart, JK				Iglehart, JK			Medicare and drug pricing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRENDS											ALBERT H, 2001, COMMUNICATION   0620; *AM SOC CLIN ONC, 2002, AN WAYS MEANS STAFF; American Society of Clinical Oncology, 2001, REF MED PAYM METH CA; [Anonymous], 2001, GAO011118; BURTON TM, 2002, WALL STREET J   0313, pB1; CLOUD DJ, 2000, WALL STREET J   0927, pB1; *CTR MED MED SERV, 2003, DMEPOS COMP BIDD DEM; *DEP HLTH HUM SERV, 2000, OEI030000311 DEP HLT; *DEP HLTH HUM SERV, 2001, OEI030000310 DEP HLT; *DEP HLTH HUM SERV, 2000, OEI030000020 DEP HLT; *DEP HLTH HUM SERV, 1997, OEI039700290 DEP HLT; *DEP HLTH HUM SERV, 1998, OEI039700510 DEP HLT; *DEP HLTH HUM SERV, 1996, OEI039500420 DEP HLT; FREUDENHEIM M, 2002, NY TIMES        0513, pC5; FUHRMANS V, 2001, WALL STREET J   1213, pB4; FUHRMANS V, 2002, WALL STREET J   0607, P1; Gabel J, 2002, HEALTH AFFAIR, V21, P143, DOI 10.1377/hlthaff.21.5.143; *GEN ACC OFF, 2001, GAO0253; Gencarelli DM, 2002, AVERAGE WHOLESALE PR; Iglehart JK, 2002, NEW ENGL J MED, V347, P956, DOI 10.1056/NEJMhpr022143; Iglehart JK, 2002, NEW ENGL J MED, V346, P1924, DOI 10.1056/NEJMhpr020324; JAPSEN B, 2001, CHICAGO TRIBUNE 1122; KOWALCZYK L, 2001, BOSTON GLOBE    1221; Levit K, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.1.154; MCGINLEY L, 2000, WALL STREET J   0602, pB6; NAIK G, 2002, WALL STREET J   1226, pA8; NICOLA TJ, 2001, REGULATORY LEGISLATI; Pear Robert, 2003, N Y Times Web, pA15; Pear Robert, 2002, NY TIMES        0517, pA1; STRUNK BC, 2001, HLTH AFFAIRS    0926; TAUZIN B, 2001, COMMUNICATION   1114; 2002, FED REG, V67, P79973	32	19	19	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1590	1597		10.1056/NEJMhpr035135	http://dx.doi.org/10.1056/NEJMhpr035135			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700381				2023-01-03	WOS:000182248900012
J	Murray, SA; Grant, E; Grant, A; Kendall, M				Murray, SA; Grant, E; Grant, A; Kendall, M			Dying from cancer in developed and developing countries: lessons from two qualitative interview studies of patients and their carers	BRITISH MEDICAL JOURNAL			English	Article								Objective To describe the experiences of illness and needs and use of services in two groups of patients with incurable cancer, one in a developed country and the other in a developing country. Design Scotland: longitudinal study with qualitative interviews. Kenya: cross sectional study with qualitative interviews. Settings Lothian region, Scotland, and Meru District, Kenya. Participants Scotland: 20 patients with inoperable lung cancer and their carers. Kenya: 24 patients with common advanced cancers and their main informal carers. Main outcome measures Descriptions of experiences, needs, and available services. Results 67 interviews were conducted in Scotland and 46 in Kenya. The emotional pain of facing death was the prime concern of Scottish patients and their carers, while physical pain and financial worries dominated the lives of Kenyan patients and their carers. In Scotland, free health and social services (including financial assistance) were available, but sometimes underused. In Kenya, analgesia, essential equipment, suitable food, and assistance in care were often inaccessible and unaffordable, resulting in considerable unmet physical needs. Kenyan patients thought that their psychological, social, and spiritual needs were met by their families, local community, and religious groups. Some Scottish patients thought that such non-physical needs went unmet. Conclusions In patients living in developed and developing countries there are differences not only in resources available for patients dying from cancer but also in their lived experience of illness. The expression of needs and how they are met in different cultural contexts can inform local assessment of needs and provide insights for initiatives in holistic cancer care.	Univ Edinburgh, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland; Chogoria Hosp, Chogoria, Meru, Kenya	University of Edinburgh	Murray, SA (corresponding author), Univ Edinburgh, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland.							Coffey A., 1996, MAKING SENSE QUALITA; DEBOER CN, 1989, SOC SCI MED, V28, P1007, DOI 10.1016/0277-9536(89)90383-3; Defilippi K, 2000, Int J Palliat Nurs, V6, P108; GRANT E, IN PRESS J PALLIAT C; Green J, 1998, BMJ-BRIT MED J, V316, P1230, DOI 10.1136/bmj.316.7139.1230; Haines A, 2000, BRIT MED J, V320, P1, DOI 10.1136/bmj.320.7226.1; Isichei Elizabeth, 1995, HIST CHRISTIANITY AF; Lincoln Y.S., 2000, HDB QUALITATIVE RES; Maslow A., 1954, MOTIVATION PERSONALI; Mbiti John S., 1969, AFRICAN RELIG PHILOS; MURRAY JL, 1996, GLOBAL BURDEN DIS; Murray SA, 2002, BRIT MED J, V325, P929, DOI 10.1136/bmj.325.7370.929; OLWENY C, 1996, OXFORD TXB PALLIATIV; Olweny C L, 1994, J Palliat Care, V10, P17; Ramsay S, 2001, LANCET, V358, P734, DOI 10.1016/S0140-6736(01)05942-6; Scottish Executive Health Department, 2001, CANC SCEN AID PLANN; Singer PA, 2002, BMJ-BRIT MED J, V324, P1291, DOI 10.1136/bmj.324.7349.1291; Smith R, 2000, BMJ-BRIT MED J, V320, P129, DOI 10.1136/bmj.320.7228.129; WESTPHUAL VB, 1990, MONOGRAPH 6 HOME CAR; *WHO, 1979, HDB REPRESENTING RES; WHO, 2001, MACR HLTH INV HLTH E; World Health Organization, 1990, CANC PAIN REL PALL C	22	99	100	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 15	2003	326	7385					368	371		10.1136/bmj.326.7385.368	http://dx.doi.org/10.1136/bmj.326.7385.368			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	648RZ	12586671	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000181165500021
J	Evans, WE; McLeod, HL				Evans, WE; McLeod, HL			Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONVERTING ENZYME-INHIBITOR; SINGLE-NUCLEOTIDE POLYMORPHISMS; S-METHYLTRANSFERASE DEFICIENCY; APOLIPOPROTEIN-E POLYMORPHISM; LEFT-VENTRICULAR HYPERTROPHY; SEROTONIN TRANSPORTER GENE; MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN; BETA(2)-ADRENERGIC RECEPTOR; CORONARY ATHEROSCLEROSIS		St Jude Childrens Res Hosp, Memphis, TN 38101 USA; Univ Tennessee, Coll Pharm, Memphis, TN USA; Univ Tennessee, Coll Med, Memphis, TN USA; Washington Univ, Sch Med, St Louis, MO USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Washington University (WUSTL)	Evans, WE (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38101 USA.	william.evans@stjude.org	McLeod, Howard/ABD-8364-2021; Evans, William E./C-2069-2012	McLeod, Howard/0000-0002-9004-9232; Evans, William E./0000-0002-9333-5322	NCI NIH HHS [R37 CA36401, R01 CA78224, CA21765, CA091842] Funding Source: Medline; NIGMS NIH HHS [U01 GM61394, U01 GM63340, U01 GM61393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078224, R37CA036401, P30CA021765, P30CA091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061394, U01GM063340, U01GM061393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Ameyaw MM, 2001, PHARMACOGENETICS, V11, P217, DOI 10.1097/00008571-200104000-00005; Arranz MJ, 2000, LANCET, V355, P1615, DOI 10.1016/S0140-6736(00)02221-2; Ballantyne CM, 2000, J AM COLL CARDIOL, V36, P1572, DOI 10.1016/S0735-1097(00)00918-9; Basile VS, 1999, NEUROPSYCHOPHARMACOL, V21, P17, DOI 10.1016/S0893-133X(98)00114-6; Black AJ, 1998, ANN INTERN MED, V129, P716, DOI 10.7326/0003-4819-129-9-199811010-00007; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Brinkmann U, 2001, DRUG DISCOV TODAY, V6, P835, DOI 10.1016/S1359-6446(01)01892-X; Cargill M, 2000, Pharmacogenomics, V1, P27, DOI 10.1517/14622416.1.1.27; CARSON PE, 1956, SCIENCE, V124, P484, DOI 10.1126/science.124.3220.484-a; Choo EF, 2000, DRUG METAB DISPOS, V28, P655; Cockcroft JR, 2000, HYPERTENSION, V36, P371, DOI 10.1161/01.HYP.36.3.371; de Maat MPM, 1999, AM J CARDIOL, V83, P852, DOI 10.1016/S0002-9149(98)01073-X; Dishy V, 2001, NEW ENGL J MED, V345, P1030, DOI 10.1056/NEJMoa010819; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Eichhammer P, 2000, AM J MED GENET, V96, P187, DOI 10.1002/(SICI)1096-8628(20000403)96:2<187::AID-AJMG13>3.0.CO;2-8; Esteller M, 2000, NEW ENGL J MED, V343, P1740; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; EVANS DAP, 1960, BRIT MED J, V2, P485, DOI 10.1136/bmj.2.5197.485; Evans WE, 2001, J CLIN ONCOL, V19, P2293, DOI 10.1200/JCO.2001.19.8.2293; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Evans WE, 2001, ANNU REV GENOM HUM G, V2, P9, DOI 10.1146/annurev.genom.2.1.9; Farlow MR, 1998, NEUROLOGY, V50, P669, DOI 10.1212/WNL.50.3.669; Fellay J, 2002, LANCET, V359, P30, DOI 10.1016/S0140-6736(02)07276-8; Gerdes LU, 2000, CIRCULATION, V101, P1366, DOI 10.1161/01.CIR.101.12.1366; Herrington DM, 2002, NEW ENGL J MED, V346, P967, DOI 10.1056/NEJMoa012952; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Hitzl M, 2001, PHARMACOGENETICS, V11, P293, DOI 10.1097/00008571-200106000-00003; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; HUGHES HB, 1954, AM REV TUBERC PULM, V70, P266; Hwu HG, 1998, BIOL PSYCHIAT, V44, P483, DOI 10.1016/S0006-3223(98)00134-6; Ingelman-Sundberg M, 1999, TRENDS PHARMACOL SCI, V20, P342, DOI 10.1016/S0165-6147(99)01363-2; Israel E, 2001, INT ARCH ALLERGY IMM, V124, P183, DOI 10.1159/000053705; Issa AM, 2000, CAN J PSYCHIAT, V45, P917, DOI 10.1177/070674370004501007; Jacobsen P, 1998, KIDNEY INT, V53, P1002, DOI 10.1046/j.1523-1755.1998.00847.x; Kaiser R, 2000, MOL PSYCHIATR, V5, P418, DOI 10.1038/sj.mp.4000729; Kalow W, 1998, PHARMACOGENETICS, V8, P283; KALOW W, 1956, LANCET, V2, P576; Kim DK, 2000, NEUROREPORT, V11, P215, DOI 10.1097/00001756-200001170-00042; Kim RB, 2001, CLIN PHARMACOL THER, V70, P189, DOI 10.1067/mcp.2001.117412; Kohno M, 1999, AM J MED, V106, P544, DOI 10.1016/S0002-9343(99)00067-4; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; Liggett SB, 2000, AM J RESP CRIT CARE, V161, pS197, DOI 10.1164/ajrccm.161.supplement_2.a1q4-10; Lima JJ, 1999, CLIN PHARMACOL THER, V65, P519, DOI 10.1016/S0009-9236(99)70071-8; Liotta LA, 2001, JAMA-J AM MED ASSOC, V286, P2211, DOI 10.1001/jama.286.18.2211; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Marian AJ, 2000, J AM COLL CARDIOL, V35, P89, DOI 10.1016/S0735-1097(99)00535-5; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; McDonald OG, 2002, PHARMACOGENETICS, V12, P93, DOI 10.1097/00008571-200203000-00003; McLeod HL, 2002, LANCET, V359, P78, DOI 10.1016/S0140-6736(02)07296-3; McLeod HL, 2001, ANNU REV PHARMACOL, V41, P101, DOI 10.1146/annurev.pharmtox.41.1.101; Meyer UA, 2000, LANCET, V356, P1667, DOI 10.1016/S0140-6736(00)03167-6; Michelson AD, 2000, CIRCULATION, V101, P1013, DOI 10.1161/01.CIR.101.9.1013; Mukae S, 2000, HYPERTENSION, V36, P127, DOI 10.1161/01.HYP.36.1.127; Napolitano C, 2000, J CARDIOVASC ELECTR, V11, P691, DOI 10.1111/j.1540-8167.2000.tb00033.x; NESTRUCK AC, 1987, METABOLISM, V36, P743, DOI 10.1016/0026-0495(87)90110-7; Ohmichi N, 1997, AM J HYPERTENS, V10, P951, DOI 10.1016/S0895-7061(97)00121-0; Okamura A, 1999, ANGIOLOGY, V50, P811, DOI 10.1177/000331979905001005; Ongphiphadhanakul B, 2000, CLIN ENDOCRINOL, V52, P581, DOI 10.1046/j.1365-2265.2000.00979.x; ORDOVAS JM, 1995, ATHEROSCLEROSIS, V113, P157, DOI 10.1016/0021-9150(94)05439-P; Pedro-Botet J, 2001, ATHEROSCLEROSIS, V158, P183, DOI 10.1016/S0021-9150(01)00410-5; Penno G, 1998, DIABETES, V47, P1507, DOI 10.2337/diabetes.47.9.1507; Perna A, 2000, KIDNEY INT, V57, P274, DOI 10.1046/j.1523-1755.2000.00818.x; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; Prasad A, 2000, CIRCULATION, V102, P35, DOI 10.1161/01.CIR.102.1.35; Psaty BM, 2002, JAMA-J AM MED ASSOC, V287, P1680, DOI 10.1001/jama.287.13.1680; Rao VV, 1999, P NATL ACAD SCI USA, V96, P3900, DOI 10.1073/pnas.96.7.3900; Relling MV, 1999, JNCI-J NATL CANCER I, V91, P2001, DOI 10.1093/jnci/91.23.2001; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; Richard F, 1997, LANCET, V349, P539, DOI 10.1016/S0140-6736(97)80089-X; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sakaeda T, 2001, PHARMACEUT RES, V18, P1400, DOI 10.1023/A:1012244520615; Sasaki M, 1996, J HYPERTENS, V14, P1403, DOI 10.1097/00004872-199612000-00003; Sata F, 2000, CLIN PHARMACOL THER, V67, P48, DOI 10.1067/mcp.2000.104391; Schaeffeler E, 2001, LANCET, V358, P383, DOI 10.1016/S0140-6736(01)05579-9; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sham P, 2001, PHARMACOGENOMICS, V2, P195, DOI 10.1517/14622416.2.3.195; Siest G, 2000, CLIN CHEM LAB MED, V38, P841, DOI 10.1515/CCLM.2000.122; Smeraldi E, 1998, MOL PSYCHIATR, V3, P508, DOI 10.1038/sj.mp.4000425; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Stavroulakis GA, 2000, CARDIOVASC DRUG THER, V14, P427, DOI 10.1023/A:1007820401377; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; VESELL ES, 1989, PHARMACOL THERAPEUT, V41, P535, DOI 10.1016/0163-7258(89)90130-7; WATANABE J, 1993, DIABETES RES CLIN PR, V20, P21, DOI 10.1016/0168-8227(93)90018-Z; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; Whale R, 2000, PSYCHOPHARMACOLOGY, V150, P120, DOI 10.1007/s002130000432; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	95	1212	1343	2	151	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	2003	348	6					538	549		10.1056/NEJMra020526	http://dx.doi.org/10.1056/NEJMra020526			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642JY	12571262				2023-01-03	WOS:000180801400008
J	Stewart, KJ; Hiatt, WR; Regensteiner, JG; Hirsch, AT				Stewart, KJ; Hiatt, WR; Regensteiner, JG; Hirsch, AT			Medical progress: Exercise training for claudication	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PERIPHERAL ARTERIAL-DISEASE; MUSCLE BLOOD-FLOW; INTERMITTENT CLAUDICATION; SKELETAL-MUSCLE; NITRIC-OXIDE; FUNCTIONAL STATUS; AEROBIC EXERCISE; ENDOTHELIAL REACTIVITY; VASCULAR REACTIVITY; RESISTANCE EXERCISE		Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Univ Colorado, Hlth Sci Ctr, Sect Vasc Med, Div Cardiol, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Sect Vasc Med, Div Geriatr, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Sect Vasc Med, Dept Internal Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Colorado Prevent Ctr, Denver, CO USA; Univ Minnesota, Sch Med, Minnesota Vasc Dis Ctr, Cardiovasc Div,Vasc Med Program, Minneapolis, MN 55455 USA	Johns Hopkins University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Minnesota System; University of Minnesota Twin Cities	Stewart, KJ (corresponding author), Johns Hopkins Bayview Med Ctr, 4940 Eastern Ave, Baltimore, MD 21224 USA.	kstewart@mail.jhmi.edu						Albright A, 2000, MED SCI SPORT EXER, V32, P1345; ALPERT JS, 1969, CIRCULATION, V39, P353, DOI 10.1161/01.CIR.39.3.353; *AM ASS CARD PULM, 1999, GUID CARD REH SEC PR; [Anonymous], 2001, ACSMS RESOURCE MANUA; Arosio E, 2001, LIFE SCI, V69, P421, DOI 10.1016/S0024-3205(01)01134-1; Baron AD, 1999, AM J CARDIOL, V84, p25J; Beebe HG, 1999, ARCH INTERN MED, V159, P2041, DOI 10.1001/archinte.159.17.2041; Brass EP, 2001, AM J PHYSIOL-HEART C, V280, pH603, DOI 10.1152/ajpheart.2001.280.2.H603; Brass EP, 2000, VASC MED, V5, P225, DOI 10.1191/135886300701568513; Brass EP, 2000, VASC MED, V5, P55, DOI 10.1177/1358836X0000500109; Brendle DC, 2001, AM J CARDIOL, V87, P324, DOI 10.1016/S0002-9149(00)01367-9; BRUSH JE, 1992, J AM COLL CARDIOL, V19, P809, DOI 10.1016/0735-1097(92)90522-O; Caballero AE, 1999, DIABETES, V48, P1856, DOI 10.2337/diabetes.48.9.1856; Capecchi PL, 1997, ANGIOLOGY, V48, P469, DOI 10.1177/000331979704800601; Clarkson P, 1996, J AM COLL CARDIOL, V28, P573, DOI 10.1016/0735-1097(96)82380-1; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; CLIFFORD PC, 1980, BRIT MED J, V280, P1503, DOI 10.1136/bmj.280.6230.1503; COFFMAN JD, 1991, NEW ENGL J MED, V325, P577, DOI 10.1056/NEJM199108223250810; Creager M A, 2001, Cardiol Rev, V9, P238, DOI 10.1097/00045415-200107000-00010; Creasy T S, 1990, Eur J Vasc Surg, V4, P135, DOI 10.1016/S0950-821X(05)80427-X; Criqui MH, 2001, VASC MED, V6, P3, DOI 10.1177/1358836X0100600i102; Crosby F E, 1993, J Vasc Nurs, V11, P5; Dawson DL, 2000, AM J MED, V109, P523, DOI 10.1016/S0002-9343(00)00569-6; Dawson DL, 1998, CIRCULATION, V98, P678, DOI 10.1161/01.CIR.98.7.678; de Vries SO, 2002, RADIOLOGY, V222, P25, DOI 10.1148/radiol.2221001743; Deschenes MR, 1999, MED SCI SPORT EXER, V31, P1599, DOI 10.1097/00005768-199911000-00016; DESPRES JP, 1993, NUTRITION, V9, P452; Dormer S, 2000, IIC-INT REV IND PROP, V31, P1; ENGLAND JD, 1995, MUSCLE NERVE, V18, P380, DOI 10.1002/mus.880180403; ERNST E, 1994, ANGIOLOGY, V45, P339, DOI 10.1177/000331979404500502; ERNST EEW, 1987, CIRCULATION, V76, P1110, DOI 10.1161/01.CIR.76.5.1110; Feinglass J, 2000, J VASC SURG, V31, P93, DOI 10.1016/S0741-5214(00)70071-1; Franklin BA, 2000, ACSMS GUIDELINES EXE; Gardner Andrew W, 2002, J Cardiopulm Rehabil, V22, P192, DOI 10.1097/00008483-200205000-00011; Gardner AW, 2001, J AM GERIATR SOC, V49, P755, DOI 10.1046/j.1532-5415.2001.49152.x; GARDNER AW, 1995, JAMA-J AM MED ASSOC, V274, P975, DOI 10.1001/jama.274.12.975; Gardner AW, 2001, VASC MED, V6, P31, DOI 10.1191/135886301677047365; Gardner AW, 2000, J GERONTOL A-BIOL, V55, pM570, DOI 10.1093/gerona/55.10.M570; Gavin TP, 2001, J APPL PHYSIOL, V90, P1219, DOI 10.1152/jappl.2001.90.4.1219; Gibellini R, 2000, INT ANGIOL, V19, P8; Girolami B, 1999, ARCH INTERN MED, V159, P337, DOI 10.1001/archinte.159.4.337; Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, pH679, DOI 10.1152/ajpheart.1999.276.2.H679; Gustafsson T, 2001, EUR J CLIN INVEST, V31, P362, DOI 10.1046/j.1365-2362.2001.00816.x; Gustafsson T, 2001, FRONT BIOSCI-LANDMRK, V6, pD75, DOI 10.2741/gustafss; Hagberg JM, 2000, SPORTS MED, V30, P193, DOI 10.2165/00007256-200030030-00004; Hambrecht R, 1998, CIRCULATION, V98, P2709, DOI 10.1161/01.CIR.98.24.2709; Hardman AE, 1999, INT J OBESITY, V23, pS64, DOI 10.1038/sj.ijo.0800886; HARRIS LM, 1995, AM J CARDIOL, V76, P207, DOI 10.1016/S0002-9149(99)80066-6; HIATT WR, 1994, CIRCULATION, V90, P1866, DOI 10.1161/01.CIR.90.4.1866; HIATT WR, 1990, CIRCULATION, V81, P602, DOI 10.1161/01.CIR.81.2.602; HIATT WR, 1992, J APPL PHYSIOL, V73, P346, DOI 10.1152/jappl.1992.73.1.346; Hiatt WR, 1996, J APPL PHYSIOL, V81, P780, DOI 10.1152/jappl.1996.81.2.780; HIATT WR, 1989, J CLIN INVEST, V84, P1167, DOI 10.1172/JCI114281; HIATT WR, 1995, CIRCULATION, V91, P1472, DOI 10.1161/01.CIR.91.5.1472; Hiatt WR, 2001, NEW ENGL J MED, V344, P1608, DOI 10.1056/NEJM200105243442108; Higashi Y, 1999, HYPERTENSION, V33, P591, DOI 10.1161/01.HYP.33.1.591; Higashi Y, 1999, CIRCULATION, V100, P1194, DOI 10.1161/01.CIR.100.11.1194; Hirsch AT, 2001, VASC MED, V6, P9, DOI 10.1177/1358836X0100600i103; Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317; Hood SC, 1996, CAN MED ASSOC J, V155, P1053; Hooi JD, 1998, SCAND J PRIM HEALTH, V16, P177; John S, 2000, J HYPERTENS, V18, P363, DOI 10.1097/00004872-200018040-00002; JOHNSON EC, 1989, CIRCULATION, V80, P59; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; Kelley G A, 2001, Prev Cardiol, V4, P73, DOI 10.1111/j.1520-037X.2001.00529.x; Kelley GA, 2001, PREV MED, V33, P120, DOI 10.1006/pmed.2001.0860; Killewich LA, 1998, J VASC SURG, V27, P645, DOI 10.1016/S0741-5214(98)70229-0; Kingwell BA, 2000, CLIN EXP PHARMACOL P, V27, P239, DOI 10.1046/j.1440-1681.2000.03232.x; Lavrencic A, 2000, ARTERIOSCL THROM VAS, V20, P551, DOI 10.1161/01.ATV.20.2.551; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; LENG GC, 2000, COCHRANE DB SYST REV, V2; Libby P, 2000, INT J CARDIOL, V74, pS3, DOI 10.1016/S0167-5273(99)00105-9; Lloyd PG, 2001, AM J PHYSIOL-HEART C, V281, pH2528, DOI 10.1152/ajpheart.2001.281.6.H2528; LUNDGREN F, 1989, ANN SURG, V209, P346, DOI 10.1097/00000658-198903000-00016; LUNDGREN F, 1989, CLIN SCI, V77, P45; Maiorana A, 2001, J AM COLL CARDIOL, V38, P860, DOI 10.1016/S0735-1097(01)01439-5; MATHIEN GM, 1990, AM J PHYSIOL, V258, pH759, DOI 10.1152/ajpheart.1990.258.3.H759; Maxwell AJ, 2002, NITRIC OXIDE-BIOL CH, V6, P101, DOI 10.1006/niox.2001.0394; MCALLISTER RM, 1995, MED SCI SPORT EXER, V27, P1145; McCully K, 1999, J GERONTOL A-BIOL, V54, pB291, DOI 10.1093/gerona/54.7.B291; McDermott MM, 2001, J AM GERIATR SOC, V49, P747, DOI 10.1046/j.1532-5415.2001.49151.x; MCVEIGH GE, 1992, DIABETOLOGIA, V35, P771; Money SR, 1998, J VASC SURG, V27, P267, DOI 10.1016/S0741-5214(98)70357-X; Mustonen P, 1998, ARTERIOSCL THROM VAS, V18, P244, DOI 10.1161/01.ATV.18.2.244; *NAT COMM PREV DET, 1997, NIH PUBL; Nehler MR, 1999, ANN VASC SURG, V13, P109, DOI 10.1007/s100169900228; Niebauer J, 1996, J AM COLL CARDIOL, V28, P1652, DOI 10.1016/S0735-1097(96)00393-2; NIEBAUER J, 1999, AM J PHYSL, V276; Ouriel K, 2001, LANCET, V358, P1257, DOI 10.1016/S0140-6736(01)06351-6; Paterick T E, 2001, Cardiol Rev, V9, P282, DOI 10.1097/00045415-200109000-00008; Patterson RB, 1997, J VASC SURG, V25, P312, DOI 10.1016/S0741-5214(97)70352-5; Pollock ML, 2000, CIRCULATION, V101, P828, DOI 10.1161/01.CIR.101.7.828; PRIEBE M, 1991, WESTERN J MED, V154, P598; RADACK K, 1990, ANN INTERN MED, V113, P135, DOI 10.7326/0003-4819-113-2-135; Regensteiner J G, 1997, Vasc Med, V2, P238; Regensteiner JG, 1996, J VASC SURG, V23, P104, DOI 10.1016/S0741-5214(05)80040-0; Regensteiner JG, 2002, AM J MED, V112, P49, DOI 10.1016/S0002-9343(01)01034-8; REGENSTEINER JG, 1993, ANGIOLOGY, V44, P1, DOI 10.1177/000331979304400101; Regensteiner JG, 1997, ANGIOLOGY, V48, P291, DOI 10.1177/000331979704800402; Robeer GG, 1998, EUR J VASC ENDOVASC, V15, P36, DOI 10.1016/S1078-5884(98)80070-1; RUDERMAN N, 2000, HDB EXERCISE DIABETE; Ryan AS, 2000, J GERONTOL A-BIOL, V55, pB302, DOI 10.1093/gerona/55.6.B302; Scherer SA, 1998, ARCH PHYS MED REHAB, V79, P529, DOI 10.1016/S0003-9993(98)90067-3; SCHWARTZ RS, 1991, METABOLISM, V40, P545, DOI 10.1016/0026-0495(91)90239-S; SCHWARTZ RS, 1992, METABOLISM, V41, P649, DOI 10.1016/0026-0495(92)90058-I; Sieminski D J, 1997, Vasc Med, V2, P286; STEWART KJ, 1990, MED SCI SPORT EXER, V22, P171; TERJUNG RL, 1988, AM J CARDIOL, V62, pE15, DOI 10.1016/S0002-9149(88)80004-3; Tisi PV, 1998, EUR J VASC ENDOVASC, V16, P169, DOI 10.1016/S1078-5884(98)80161-5; Tisi PV, 1997, EUR J VASC ENDOVASC, V14, P344, DOI 10.1016/S1078-5884(97)80283-3; Tisi PV, 1998, EUR J VASC ENDOVASC, V15, P7, DOI 10.1016/S1078-5884(98)80066-X; Tomoike H, 1996, DIABETES RES CLIN PR, V30, pS55, DOI 10.1016/S0168-8227(96)80038-6; Treat-Jacobson D, 2002, J NURS SCHOLARSHIP, V34, P55, DOI 10.1111/j.1547-5069.2002.00055.x; VOGT MT, 1994, J AM GERIATR SOC, V42, P923, DOI 10.1111/j.1532-5415.1994.tb06581.x; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006; Whyman MR, 1997, J VASC SURG, V26, P551, DOI 10.1016/S0741-5214(97)70052-1; Williams SB, 1996, J AM COLL CARDIOL, V27, P567, DOI 10.1016/0735-1097(95)00522-6; Womack CJ, 2001, MED SCI SPORT EXER, V33, P214; Womack CJ, 1997, MED SCI SPORT EXER, V29, P1286, DOI 10.1097/00005768-199710000-00002; WOMACK CJ, 1997, FVASC MED, V2, P174; YANG HT, 1995, AM J PHYSIOL-HEART C, V268, pH1174, DOI 10.1152/ajpheart.1995.268.3.H1174; Yataco AR, 1999, AM J CARDIOL, V83, P754, DOI 10.1016/S0002-9149(98)00984-9	122	336	351	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 12	2002	347	24					1941	1951		10.1056/NEJMra021135	http://dx.doi.org/10.1056/NEJMra021135			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	623ZX	12477945				2023-01-03	WOS:000179735800007
J	Greenspan, SL; Emkey, RD; Bone, HG; Weiss, SR; Bell, NH; Downs, RW; McKeever, C; Miller, SS; Davidson, M; Bolognese, MA; Mulloy, AL; Heyden, N; Wu, M; Kaur, A; Lombardi, A				Greenspan, SL; Emkey, RD; Bone, HG; Weiss, SR; Bell, NH; Downs, RW; McKeever, C; Miller, SS; Davidson, M; Bolognese, MA; Mulloy, AL; Heyden, N; Wu, M; Kaur, A; Lombardi, A			Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; HIP FRACTURE; WOMEN; TURNOVER; RISK; MARKERS; DENSITY	Background: Combination therapy with alendronate and estrogen for 2 years increases bone mineral density at the spine and hip more than does therapy with either agent alone. Changes in bone mineral density after discontinuation of therapy have not been compared directly. Objective: To determine the rate of bone loss when therapy with alendronate, estrogen, or both agents is discontinued. Design: Double-blind, placebo-controlled discontinuation trial. Setting: 18 U.S. centers. Patients: 244 postmenopausal, hysterectomized women 44 to 77 years of age. Intervention: 2 years of therapy with alendronate, 10 mg/d (n = 92); conjugated estrogen, 0.625 mg/d (n = 143); alendronate and conjugated estrogen (n = 140); or placebo (n = 50). At year 3, women were allocated into five groups: Twenty-eight women continued to take placebo and 44 women continued to take combination therapy, but 50 women taking alendronate, 81 taking conjugated estrogen, and 41 taking combination therapy were switched to placebo. Measurements: Bone mineral density and biochemical markers of bone turnover. Results: Women taking alendronate or combination therapy who were switched to placebo for year 3 of the study maintained bone mass. Bone mineral density in these women was 4.1 % (Cl, 2.6% to 5.7%) and 6.6% (Cl, 5.0% to 8.2%) higher, respectively, at the spine (P < 0.001 for both treatment comparisons) and 3.5% (Cl, 2.3% to 4.6%) and 3.0% (Cl, 1.8% to 4.2%) higher, respectively, at the trochanter (P < 0.001 for both treatment comparisons) than that in women previously taking estrogen who were switched to placebo. in contrast, women who were taking estrogen and were switched to placebo during year 3 experienced a 4.5% decrease at the spine (95% Cl, -5.0% to -4.0%) and a 2.4% decrease at the trochanter (Cl, -2.7% to -2.1 %) (P < 0.001 for both changes). Compared with women who took placebo for 3 years, women who took estrogen for 2 years and were then switched to placebo had a bone mineral density that was 2.9% higher (Cl, 1.2% to 4.6%) at the spine (P < 0.05) and 2.9% higher (Cl, 1.6% to 4.2%) at the trochanter (P < 0.001). Changes in biochemical markers during year 3 did not differ among the groups that discontinued active treatment. Conclusions: Accelerated bone loss is seen after withdrawal of estrogen therapy but not after withdrawal of alendronate or combination therapy. The differential effects after withdrawal of therapy should be considered in the management of postmenopausal osteoporosis.	Univ Pittsburgh, Osteoporosis Prevent & Treatment Ctr, Pittsburgh, PA 15213 USA; Radiant Res Reading, Wyomissing, PA USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Michigan Bone & Mineral Clin, Detroit, MI USA; San Diego Endocrinol & Med Clin, San Diego, CA USA; Med Univ S Carolina, Charleston, SC 29425 USA; Virginia Commonwealth Univ, Richmond, VA 23298 USA; Res Hlth, Houston, TX USA; SAM Clin Res Ctr, San Antonio, TX USA; Chicago Ctr Clin Res, Chicago, IL USA; Bethesda Hlth Res, Bethesda, MD USA; Med Coll Georgia, Augusta, GA 30912 USA; Merck & Co Inc, Rahway, NJ 07065 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Beth Israel Deaconess Medical Center; Medical University of South Carolina; Virginia Commonwealth University; University System of Georgia; Augusta University; Merck & Company	Greenspan, SL (corresponding author), Univ Pittsburgh, Osteoporosis Prevent & Treatment Ctr, Kaufmann Med Bldg,Suite 1110,3471 5th Ave, Pittsburgh, PA 15213 USA.	GriffithsD@msx.dept-med.pitt.edu						Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1981, LANCET, V1, P459; Eastell R, 2000, J BONE MINER RES, V15, P594, DOI 10.1359/jbmr.2000.15.3.594; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; Garnero P, 1996, J BONE MINER RES, V11, P1531; Greenspan SL, 1997, CALCIFIED TISSUE INT, V60, P419, DOI 10.1007/s002239900256; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Hochberg MC, 1999, ARTHRITIS RHEUM-US, V42, P1246, DOI 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LINDSAY R, 1980, LANCET, V2, P1151; Lindsay R, 1999, J CLIN ENDOCR METAB, V84, P3076, DOI 10.1210/jc.84.9.3076; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; Miller PD, 1999, J CLIN DENSITOM, V2, P323, DOI 10.1385/JCD:2:3:323; Neter John, 1990, APPL LINEAR STAT MOD; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; Stock JL, 1997, AM J MED, V103, P291, DOI 10.1016/S0002-9343(97)00130-7; Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231	21	152	158	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					875	883		10.7326/0003-4819-137-11-200212030-00008	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622GY	12458987				2023-01-03	WOS:000179639700003
J	Comin-Anduix, B; Boros, LG; Marin, S; Boren, J; Callol-Massot, C; Centelles, JJ; Torres, JL; Agell, N; Bassilian, S; Cascante, M				Comin-Anduix, B; Boros, LG; Marin, S; Boren, J; Callol-Massot, C; Centelles, JJ; Torres, JL; Agell, N; Bassilian, S; Cascante, M			Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL COLON CARCINOGENESIS; FATTY-ACID SYNTHESIS; ADENOCARCINOMA CELLS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; PROTEINS; RELEASE; RIBOSE; GROWTH; CANCER; DEATH	The fermented extract of wheat germ, trade name Avemar, is a complex mixture of biologically active molecules with potent anti-metastatic activities in various human malignancies. Here we report the effect of Avemar on Jurkat leukemia cell viability, proliferation, cell cycle distribution, apoptosis, and the activity of key glycolytic/pentose cycle enzymes that control carbon flow for nucleic acid synthesis. The cytotoxic IC50 concentration of Avemar for Jurkat tumor cells is 0.2 mg/ml, and increasing doses of the crude powder inhibit Jurkat cell proliferation in a dose-dependent fashion. At concentrations higher than 0.2 mg/ml, Avemar inhibits cell growth by more than 50% (72 h of incubation), which is preceded by the appearance of a sub-G(1) peak on flow histograms at 48 h. Laser scanning cytometry of propidium iodide and annexin V-stained cells indicated that the growth-inhibiting effect of Avemar was consistent with a strong induction of apoptosis. Inhibition by benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone of apoptosis but increased proteolysis of poly(ADP-ribose) indicate caspases mediate the cellular effects of Avemar. Activities of glucose-6-phosphate dehydrogenase and transketolase were inhibited in a dose-dependent fashion, which correlated with decreased C-13 incorporation and pentose cycle substrate flow into RNA ribose. This decrease in pentose cycle enzyme activities and carbon flow toward nucleic acid precursor synthesis provide the mechanistic understanding of the cell growth-controlling and apoptosis-inducing effects of fermented wheat germ. Avemar exhibits about a 50-fold higher IC50 (10.02 mg/ml) for peripheral blood lymphocytes to induce a biological response, which provides the broad therapeutic window for this supplemental cancer treatment modality with no toxic effects.	Univ Barcelona, Dept Biochem & Mol Biol, IDIBAPS, CeRQT PCB, E-08028 Barcelona, Spain; Univ Calif Los Angeles, Sch Med, Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA; CSIC, Dept Peptide & Prot Chem, Inst Chem & Environm Res, IIQAB, ES-08034 Barcelona, Spain; Univ Barcelona, Dept Cell Biol, IDIBAPS, Fac Med, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Consejo Superior de Investigaciones Cientificas (CSIC); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Cascante, M (corresponding author), Univ Barcelona, Dept Biochem & Mol Biol, IDIBAPS, CeRQT PCB, Barcelona Sci Pk,1 Marti & Franques, E-08028 Barcelona, Spain.		CASCANTE, MARTA/AAG-4355-2022; CASCANTE, MARTA/AFK-5991-2022; Torres, Josep Lluís/N-7256-2013; Boren, Joan/A-8515-2012; Centelles, Josep J./K-2972-2014; Marin, Silvia/C-5492-2017; Agell, Neus/E-9640-2016	CASCANTE, MARTA/0000-0002-2062-4633; CASCANTE, MARTA/0000-0002-2062-4633; Torres, Josep Lluís/0000-0002-5072-8265; Centelles, Josep J./0000-0002-6289-9678; Marin, Silvia/0000-0003-0693-2207; Agell, Neus/0000-0002-1205-6074	NATIONAL CANCER INSTITUTE [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42710] Funding Source: Medline; NCRR NIH HHS [M01-RR00425] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Boren J, 2001, J BIOL CHEM, V276, P37747; Boros LG, 2002, NEW ENGL J MED, V347, P67, DOI 10.1056/NEJM200207043470116; Boros LG, 2002, DRUG DISCOV TODAY, V7, P364, DOI 10.1016/S1359-6446(02)02179-7; Boros LG, 2001, PANCREAS, V23, P141, DOI 10.1097/00006676-200108000-00004; Boros LG, 1997, CANCER RES, V57, P4242; BOYUM A, 1968, SCAND J CLIN LAB S21, V97, P51; Cascante M, 2002, NAT BIOTECHNOL, V20, P243, DOI 10.1038/nbt0302-243; Castano E, 1999, BRIT J CANCER, V81, P294, DOI 10.1038/sj.bjc.6990690; Comin-Anduix B, 2001, MOL PHARMACOL, V60, P1235; de la HABA G., 1955, JOUR BIOL CHEM, V214, P409; DEMIDOV L, 2002, 18 UICC INT CANC C O; Fajka-Boja R, 2002, INT J ONCOL, V20, P563; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; Haridas V, 2001, P NATL ACAD SCI USA, V98, P5821, DOI 10.1073/pnas.101619098; Hidvegi M, 1998, ANTICANCER RES, V18, P2353; Hidvegi M, 1999, IMMUNOPHARMACOLOGY, V41, P183, DOI 10.1016/S0162-3109(99)00002-8; Inayat-Hussain SH, 2001, TOXICOL APPL PHARM, V175, P95, DOI 10.1006/taap.2001.9221; Jakab F, 2000, HEPATO-GASTROENTEROL, V47, P393; JAKAB F, 2001, HEPATAGASTROENTER S1, V48; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; MOMMSEN TP, 1980, CAN J ZOOL, V58, P1785, DOI 10.1139/z80-246; Orosz F, 1999, BRIT J CANCER, V79, P1356, DOI 10.1038/sj.bjc.6690218; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Pique M, 2000, FEBS LETT, V480, P193, DOI 10.1016/S0014-5793(00)01922-0; Reddy BS, 2000, CANCER RES, V60, P4792; SUTTLE S, 2000, RADIAT RES, V153, P781; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; TIAN WN, 1994, J BIOL CHEM, V269, P14798; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Zalatnai A, 2001, CARCINOGENESIS, V22, P1649, DOI 10.1093/carcin/22.10.1649	32	79	81	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46408	46414		10.1074/jbc.M206150200	http://dx.doi.org/10.1074/jbc.M206150200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351627	hybrid, Green Published, Green Submitted			2023-01-03	WOS:000179529300092
J	Goldhaber, SZ				Goldhaber, SZ			Perspective: Thrombolysis for pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldhaber, SZ (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.								0	51	53	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1131	1132		10.1056/NEJMp020107	http://dx.doi.org/10.1056/NEJMp020107			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374871				2023-01-03	WOS:000178465100001
J	Teri, L; Gibbons, LE; McCurry, SM; Logsdon, RG; Buchner, DM; Barlow, WE; Kukull, WA; LaCroix, AZ; McCormick, W; Larson, EB				Teri, L; Gibbons, LE; McCurry, SM; Logsdon, RG; Buchner, DM; Barlow, WE; Kukull, WA; LaCroix, AZ; McCormick, W; Larson, EB			Exercise plus behavioral management in patients with Alzheimer disease - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED CLINICAL-TRIAL; NURSING-HOME RESIDENTS; OLDER ADULTS; DEPRESSIVE SYMPTOMS; DEMENTIA PATIENTS; PHYSICAL-ACTIVITY; FUNCTIONAL REACH; FALLS; REHABILITATION; ASSOCIATION	Context Exercise training for patients with Alzheimer disease combined with teaching caregivers how to manage behavioral problems may help decrease the frailty and behavioral impairment that are often prevalent in patients with Alzheimer disease. Objective To determine whether a home-based exercise program combined with caregiver training in behavioral management techniques would reduce functional dependence and delay institutionalization among patients with Alzheimer disease. Design, Setting, and Patients Randomized controlled trial of 153 community-dwelling patients meeting National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer Disease and Related Disorders Association criteria for Alzheimer disease, conducted between June 1994 and April 1999. Interventions Patient-caregiver dyads were randomly assigned to the combined exercise and caregiver training progam, Reducing Disability in Alzheimer Disease (RDAD), or to routine medical care (RMC). The RDAD program was conducted in the patients' home over 3 months. Main Outcome Measures Physical health and function (36-item Short-Form Health Survey's [SF-36] physical functioning and physical role functioning subscales and Sickness Impact Profile's Mobility subscale), and affective status (Hamilton Depression Rating Scale and Cornell Depression Scale for Depression in Dementia). Results At 3 months, in comparison with the routine care patients, more patients in the RDAD group exercised at least 60 min/wk (odds ratio [OR], 2.82; 95% confidence interval [CI], 1.25-6.39; P=.01) and had fewer days of restricted activity (OR, 3.10; 95% Cl, 1.08-8.95; P<.001). Patients in the RDAD group also had improved scores for physical role functioning compared with worse scores for patients in the RMC group (mean difference, 19.29; 95% Cl, 8.75-29.83; P<.001). Patients in the RDAD group had improved Cornell Depression Scale for Depression in Dementia scores while the patients in the RMC group had worse scores (mean difference, -1.03; 95% Cl, -0.17 to -1.91; P=.02). At 2 years, the RDAD patients continued to have better physical role functioning scores than the RMC patients (mean difference, 10.89; 95% Cl, 3.62-18.16; P=.003) and showed a trend (19% vs 50%) for less institutionalization due to behavioral disturbance. For patients with higher depression scores at baseline, those in the RDAD group improved significantly more at 3 months on the Hamilton Depression Rating Scale (mean difference, 2.21; 95% Cl, 0.22-4.20; P=.04) and maintained that improvement at 24 months (mean difference, 2.14; 95% Cl, 0.14-4.17; P=.04). Conclusion Exercise training combined with teaching caregivers behavioral management techniques improved physical health and depression in patients with Alzheimer disease.	Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA; Group Health Cooperative	Teri, L (corresponding author), Univ Washington, Dept Psychosocial & Community Hlth, POB 358733, Seattle, WA 98195 USA.	lteri@u.washington.edu	McCurry, Susan M/E-4731-2015; Janson, Patrick/AAC-7581-2022	McCurry, Susan M/0000-0001-8624-3772; Kukull, Walter/0000-0001-8761-9014	NATIONAL INSTITUTE ON AGING [R01AG014777, R01AG010845] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; Arkin SM, 1999, GERONTOLOGIST, V39, P729, DOI 10.1093/geront/39.6.729; Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349; BRILL PA, 1995, GERONTOLOGIST, V35, P263; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P321, DOI 10.1111/j.1532-5415.1993.tb06711.x; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Dvorak RV, 1998, NEUROLOGY, V51, P1386, DOI 10.1212/WNL.51.5.1386; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; KRENZ C, 1988, MED CARE, V26, P453, DOI 10.1097/00005650-198805000-00002; Larson E B, 1990, Aging (Milano), V2, P404; Lazowski DA, 1999, J GERONTOL A-BIOL, V54, pM621, DOI 10.1093/gerona/54.12.M621; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIANG MH, 1985, ARTHRITIS RHEUM, V28, P542, DOI 10.1002/art.1780280513; LOGSDON RG, 1995, J AM GERIATR SOC, V43, P150, DOI 10.1111/j.1532-5415.1995.tb06380.x; MacRae PG, 1996, J AM GERIATR SOC, V44, P175, DOI 10.1111/j.1532-5415.1996.tb02435.x; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; Mather AS, 2002, BRIT J PSYCHIAT, V180, P411, DOI 10.1192/bjp.180.5.411; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Meuleman JR, 2000, ARCH PHYS MED REHAB, V81, P312, DOI 10.1053/apmr.2000.0810312; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MORRIS JC, 1987, J GERONTOL, V42, P412, DOI 10.1093/geronj/42.4.412; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM494, DOI 10.1093/gerona/54.10.M494; *NAT CTR HLTH STAT, 1986, VIT HLTH STAT, V10; OLESKE DM, 1995, J AM GERIATR SOC, V43, P741, DOI 10.1111/j.1532-5415.1995.tb07042.x; Penninx BWJH, 2002, J GERONTOL B-PSYCHOL, V57, pP124, DOI 10.1093/geronb/57.2.P124; SCHOLES D, 1991, AM J PUBLIC HEALTH, V81, P485, DOI 10.2105/AJPH.81.4.485; Singh NA, 2001, J GERONTOL A-BIOL, V56, pM497, DOI 10.1093/gerona/56.8.M497; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TERI L, 1992, J CONSULT CLIN PSYCH, V60, P379, DOI 10.1037/0022-006X.60.3.379; Teri L, 1998, PSYCHOTHERAPY, V35, P436, DOI 10.1037/h0087766; Teri L, 2000, NEUROLOGY, V55, P1271, DOI 10.1212/WNL.55.9.1271; Teri L, 2002, MED CLIN N AM, V86, P641, DOI 10.1016/S0025-7125(02)00006-8; Teri L, 1997, J GERONTOL B-PSYCHOL, V52, pP159, DOI 10.1093/geronb/52B.4.P159; TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622; Teri L, 1998, J REHABIL RES DEV, V35, P411; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; WAGNER EH, 1993, J AM GERIATR SOC, V41, P241, DOI 10.1111/j.1532-5415.1993.tb06700.x; WEINER DK, 1993, ARCH PHYS MED REHAB, V74, P796, DOI 10.1016/0003-9993(93)90003-S; Wolf-Klein G P, 1994, Int Psychogeriatr, V6, P135, DOI 10.1017/S1041610294001705	44	505	532	2	74	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2015	2022		10.1001/jama.290.15.2015	http://dx.doi.org/10.1001/jama.290.15.2015			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CX	14559955	Green Published			2023-01-03	WOS:000185924200025
J	Heath, I				Heath, I			A wolf in sheep's clothing: a critical look at the ethics of drug taking	BRITISH MEDICAL JOURNAL			English	Article							CONCORDANCE; WOMEN	In 1997 a report of a working party of the Royal Pharmaceutical Society of Great Britain acknowledged that prescribing is "a technically difficult, and morally complex, problem" and that compliance is an ethically dubious aspiration.(1) The report proposed the use of a new term-concordance-which was intended to describe the creation, during the process of prescribing, of an agreement that respected the beliefs and wishes of the patient.(2) The intention of the working party was to foster a distinct change in culture in the relation between prescribing and drug taking and between patient and prescriber. The intention was honourable, but the initiative seems to be foundering.	Caversham Grp Practice, London NW5 2UP, England		Heath, I (corresponding author), Caversham Grp Practice, Kentish Town, London NW5 2UP, England.							Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Bashir A, 2001, INT J PHARM PRACT S, V9, pR78; Butler CC, 2001, J ANTIMICROB CHEMOTH, V48, P435, DOI 10.1093/jac/48.3.435; Carter S, 2003, QUESTION CHOICE COMP; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; DONALDSON MR, 1992, ALL ER, V4, P649; Dowell J, 2002, BRIT J GEN PRACT, V52, P24; Hodgkin P, 1996, BRIT MED J, V313, P1568, DOI 10.1136/bmj.313.7072.1568; Marinker M, 2003, BRIT MED J, V326, P348, DOI 10.1136/bmj.326.7385.348; METCALFE D, 1986, J ROY COLL GEN PRACT, V36, P349; POLLOCK AM, 2003, BRIT MED J, V377, P571; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; Royal Pharmaceutical Society of Great Britain, 1997, COMPL CONC ACH SHAR; Thornton H, 2003, BMJ-BRIT MED J, V327, P101, DOI 10.1136/bmj.327.7406.101; Tuckett D., 1985, M EXPERTS APPROACH S; ZBIGNIEW H, 1983, REPORT BESIEGED CITY	16	23	23	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					856	858		10.1136/bmj.327.7419.856	http://dx.doi.org/10.1136/bmj.327.7419.856			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551104	Green Published			2023-01-03	WOS:000185921200026
J	Higginson, I				Higginson, I			For and against - Doctors should not discuss resuscitation with terminally ill patients - Against	BRITISH MEDICAL JOURNAL			English	Article							CARE; PHYSICIANS; LIFE; COMMUNICATION; PREFERENCES; CANCER; END		Kings Coll London, Weston Educ Ctr, Dept Palliat Care & Policy, London SE5 9RJ, England	University of London; King's College London	Higginson, I (corresponding author), Kings Coll London, Weston Educ Ctr, Dept Palliat Care & Policy, London SE5 9RJ, England.	irene.higginson@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				Davies E, 2003, SUPPORT CARE CANCER, V11, P21, DOI 10.1007/s00520-002-0392-x; Edmonds P, 2003, CLIN MED, V3, P149, DOI 10.7861/clinmedicine.3-2-149; Fallowfield LJ, 2002, PALLIATIVE MED, V16, P297, DOI 10.1191/0269216302pm575oa; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; GYSELS M, 2003, IMPROVING SUPPORTIVE; Koffman J, 2001, PALLIATIVE MED, V15, P337, DOI 10.1191/026921601678320322; MURRAY E, 2001, BRIT MED J, V323, P496; *NAT CANC RES I, 2002, STRAT AN 2002 OV CAN; Perron NJ, 2002, SWISS MED WKLY, V132, P562; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Teno JM, 1998, J GEN INTERN MED, V13, P439, DOI 10.1046/j.1525-1497.1998.00132.x	12	12	13	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					615	616		10.1136/bmj.327.7415.615	http://dx.doi.org/10.1136/bmj.327.7415.615			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969935	Green Published			2023-01-03	WOS:000185358700031
J	Tseng, CW; Brook, RH; Keeler, E; Mangione, CM				Tseng, CW; Brook, RH; Keeler, E; Mangione, CM			Impact of an annual dollar limit or "cap" on prescription drug benefits for medicare patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BENEFICIARIES; COVERAGE; COST	Context Annual dollar limits, or "caps," on drug benefits are common in Medicare managed care (Medicare + Choice) and have been part of several proposals for a national Medicare drug benefit. Objectives To determine how cap levels affect the percentage of patients exceeding the cap and their out-of-pocket drug costs and to identify the medications that contribute most to prescription costs. Design and Setting Cross-sectional analysis of 2001 pharmacy claims data from a large Medicare + Choice plan in a mature market with caps of $750 to $2000 per year applied to the plan's share of prescription costs. Participants Patients who filled at least 1 prescription in 2001 (n=438802). Main Outcome Measures Percentages of patients exceeding caps, identified from prescription claims; out-of-pocket patient costs before exceeding caps, calculated from patients' co-payments; and out-of-pocket patient costs after exceeding caps, estimated from total prescription costs before exceeding the cap. Each unique drug was ranked by total expenditures, which included spending by patients who exceeded caps and by the plan for that drug. Results A total of 22%, 14%, and 4% of Medicare patients exceeded caps of $750, $1000, and $2000, respectively. Across caps, patients faced a potential 2- to 3-fold increase in median out-of-pocket costs after exceeding caps ($179-$305/mo) to continue the same prescription use as before exceeding caps ($794100/mo). For patients who exceeded a cap of $750, yearly out-of-pocket drug costs ranged from $564 to $4201 (5th-95th percentiles). Fifteen of the 20 medications with the highest total prescription expenditures for patients who exceeded the cap were for chronic conditions. Seven had lower-cost generic versions or a generic medication available in the same treatment class. Conclusions At lower caps, a substantial proportion of Medicare patients exceeded their annual drug benefit. To continue the same medication use as before exceeding caps, these patients faced potentially high increases in out-of-pocket costs for medications used primarily to treat chronic conditions. Generic options were not available for many of these drugs.	Univ Hawaii, Dept Family Practice & Community Hlth, Honolulu, HI 96822 USA; Pacific Hlth Res Inst, Honolulu, HI USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, Los Angeles, CA USA; RAND Corp, Hlth, Santa Monica, CA USA	University of Hawaii System; Pacific Health Research & Education Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Robert Wood Johnson Foundation (RWJF); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation	Tseng, CW (corresponding author), 846 S Hotel St,Suite 303, Honolulu, HI 96813 USA.				NIA NIH HHS [AG-02-004] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams AS, 2001, HEALTH AFFAIR, V20, P276, DOI 10.1377/hlthaff.20.1.276; *C BUDG OFF, 2002, ISS DES PRESCR DRUG; *COMM FUND, 1999, TRENDS MED PLUS CHOI; Cox ER, 2001, MED CARE, V39, P296, DOI 10.1097/00005650-200103000-00009; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; *HJ KAIS FAM FDN C, SEN PRESCR DRUGS FIN; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P1733, DOI 10.1001/jama.288.14.1733; LASCHOBER MA, 1996, TRENDS MEDICARE S IN; Lichtenberg FR, 2001, HEALTH AFFAIR, V20, P241, DOI 10.1377/hlthaff.20.5.241; McClellan M, 2000, HEALTH AFFAIR, V19, P26, DOI 10.1377/hlthaff.19.2.26; Poisal JA, 2001, HEALTH AFFAIR, V20, P74, DOI 10.1377/hlthaff.20.2.74; Rector TS, 2000, JAMA-J AM MED ASSOC, V283, P2163, DOI 10.1001/jama.283.16.2163; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; Steinman MA, 2001, J GEN INTERN MED, V16, P793, DOI 10.1046/j.1525-1497.2001.10412.x; Stuart B, 1998, MED CARE, V36, P202, DOI 10.1097/00005650-199802000-00009; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; 2002, HJ KAISER FAMILY FDN	18	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					222	227		10.1001/jama.290.2.222	http://dx.doi.org/10.1001/jama.290.2.222			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698GH	12851277	Green Submitted			2023-01-03	WOS:000183989800027
J	Li, CI; Malone, KE; Porter, PL; Weiss, NS; Tang, MTC; Cushing-Haugen, KL; Daling, JR				Li, CI; Malone, KE; Porter, PL; Weiss, NS; Tang, MTC; Cushing-Haugen, KL; Daling, JR			Relationship between long durations and different regimens of hormone therapy and risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; RECEPTOR STATUS; ESTROGEN USE; CARCINOMA; PROGESTIN; HEALTH; METAANALYSIS; INFORMATION; RELIABILITY	Context Women using combined estrogen and progestin hormone replacement therapy (CHRT) have an increased risk of breast cancer; however, data on use for long durations and on risk associated with patterns of use are lacking. Objective To evaluate relationships between durations and patterns of CHRT use and risk of breast cancer by histological type and hormone receptor status. Design Population-based case-control study. Setting Three counties in western Washington State. Participants Nine hundred seventy-five women 65-79 years of age diagnosed with invasive breast cancer from April 1, 1997, through May 31, 1999 (histology: 196 lobular cases, 656 ductal cases, 114 cases with other histological type, and 9 cases with an unspecified histological type; estrogen receptor (ER)/progesterone receptor (PR) status: 646 ER+/PR+ cases, 147 ER+/PR- cases, and 101 ER-/PR- cases [6 ER-/PR+ cases and 75 cases with unknown ER/PR status were not included in the analyses herein]) and 1007 population controls. Main Outcome Measures Risks of invasive lobular, ductal, ER+/PR+, ER+/PR-, and ER-/PR- breast carcinomas. Results Women using unopposed estrogen replacement therapy (ERT) (exclusive ERT use), even for 25 years or longer, had no appreciable increase in risk of breast cancer, although the associated odds ratios were not inconsistent with a possible small effect. Ever users of CHRT (includes CHRT users who also had used ERT) had a 1.7-fold (95% confidence interval (01, 1.3-2.2) increased risk of breast cancer, including a 2.7-fold (95% Cl, 1.7-4.3) increased risk of invasive lobular carcinoma, a 1.5-fold (95% Cl, 1.1-2.0) increased risk of invasive ductal carcinoma, and a 2.0-fold (95% Cl, 1.5-2.7) increased risk of ER+/PR+ breast cancers. The increase in risk was greatest in those using CHRT for longer durations (users for 5-14.9 years and 15 years had 1.5-fold [95% Cl, 1.0-2.3] and 1.6-fold [95% Cl, 1.0-2.6] increases in risk of invasive ductal carcinoma, respectively, and 3.7-fold [95% Cl, 2.0-6.6] and 2.6-fold [95% Cl, 1.3-5.3] increases in risk of invasive lobular carcinoma, respectively. Associations of similar magnitudes were seen among users of both sequential and continuous CHRT. Risks of ER+/PR- and ER-/ PR- tumors were not increased by use of any form of hormone replacement therapy; however,,small numbers of these tumors limited power to detect possible associations. Conclusion These data suggest that use of CHRT is associated with an increased risk of breast cancer, particularly invasive lobular tumors, whether the progestin component was taken in a sequential or in a continuous manner.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Li, CI (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,MP 381,POB 19024, Seattle, WA 98109 USA.				NCI NIH HHS [R01 CA072787] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072787] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEGG CB, 1984, BIOMETRIKA, V71, P11, DOI 10.2307/2336391; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Breslow NE, 1980, ANAL CASE CONTROL ST; Chen CL, 2002, JAMA-J AM MED ASSOC, V287, P734, DOI 10.1001/jama.287.6.734; Cobleigh MA, 1999, JAMA-J AM MED ASSOC, V281, P1528, DOI 10.1001/jama.281.16.1528; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Daling JR, 2002, CANCER-AM CANCER SOC, V95, P2455, DOI 10.1002/cncr.10984; DIXON JM, 1982, HISTOPATHOLOGY, V6, P149, DOI 10.1111/j.1365-2559.1982.tb02712.x; DUTOIT RS, 1991, EUR J SURG ONCOL, V17, P251; *F HUTCH CANC RES, CSS REP PUBL FAQS; GOODMAN MT, 1990, AM J EPIDEMIOL, V131, P815, DOI 10.1093/oxfordjournals.aje.a115572; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Jain MG, 1999, EPIDEMIOLOGY, V10, P260, DOI 10.1097/00001648-199905000-00012; Kirsh V, 2002, CANCER CAUSE CONTROL, V13, P583, DOI 10.1023/A:1016330024268; Li CI, 2000, CANCER, V88, P2561, DOI 10.1002/1097-0142(20000601)88:11<2561::AID-CNCR19>3.3.CO;2-O; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421; Li CI, 2000, CANCER, V88, P2570, DOI 10.1002/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O; Lower EE, 1999, BREAST CANCER RES TR, V58, P205, DOI 10.1023/A:1006315607241; *NCI, 2003, SEER; Newcomb PA, 2002, CANCER EPIDEM BIOMAR, V11, P593; Newcomer LM, 1999, AM J EPIDEMIOL, V149, pS79; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PERSSON I, 1987, INT J EPIDEMIOL, V16, P222, DOI 10.1093/ije/16.2.222; POTTER JD, 1995, CANCER EPIDEM BIOMAR, V4, P319; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; STEINBERG KK, 1994, EPIDEMIOLOGY, V5, P415, DOI 10.1097/00001648-199407000-00007; STIERER M, 1993, ANN SURG, V218, P13, DOI 10.1097/00000658-199307000-00004; WHO, 2000, INT CLASSIFICATION D, V3rd	31	296	313	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3254	3263		10.1001/jama.289.24.3254	http://dx.doi.org/10.1001/jama.289.24.3254			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693EX	12824206	Bronze			2023-01-03	WOS:000183704600018
J	Baldwin, E				Baldwin, E			Time for a fresh look at complementary medicine	BRITISH MEDICAL JOURNAL			English	Article									House Lords, London SW1A 0PW, England		Baldwin, E (corresponding author), House Lords, London SW1A 0PW, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1322	1322		10.1136/bmj.326.7402.1322	http://dx.doi.org/10.1136/bmj.326.7402.1322			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805177	Green Published			2023-01-03	WOS:000183626500041
J	Shimokawa, I; Higami, Y; Tsuchiya, T; Otani, H; Komatsu, T; Chiba, T; Yamaza, H				Shimokawa, I; Higami, Y; Tsuchiya, T; Otani, H; Komatsu, T; Chiba, T; Yamaza, H			Lifespan extension by reduction of the growth hormone-insulin-like growth factor-1 axis: relation to caloric restriction	FASEB JOURNAL			English	Article						longevity; transgenic rat; dwarf; pathology	DIETARY RESTRICTION; GENE-EXPRESSION; SPAN EXTENSION; DWARF MICE; LONGEVITY; RATS	A reduced growth hormone (GH)-insulin-like growth factor (IGF)-1 axis is associated with an extension of lifespan in laboratory rodents. Several phenotypes of such animal models resemble those induced by caloric restriction (CR). Using a transgenic male Wistar rat model whose GH-IGF-1 axis was moderately suppressed by overexpression of the antisense GH transgene (tg), we elucidated a relationship between the effects of a reduced GH-IGF-1 axis and CR for some biomarkers of aging, lifespan, and pathologies. Heterozygous (tg/-) rats fed ad libitum (AL) had a dwarf phenotype similar to that of control nontransgenic (-/-) rats subjected to 30% CR from 6 wk of age. Both the reduced GH-IGF-1 axis and CR extended lifespan to a similar extent, although the effect of CR seemed to be greater. There was an additive effect of CR to lifespan extension when tg/- rats were subjected to CR. Pathologic analyses indicated that the preventive effect of CR on selected diseases was greater than that of the reduced GH-IGF-1 axis. The present study suggests that CR affects aging and longevity by mechanisms other than suppression of the GH-IGF-1 axis, although CR might exhibit its effects partly through the reduced GH-IGF-1 axis.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol & Gerontol, Nagasaki 8528523, Japan	Nagasaki University	Shimokawa, I (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol & Gerontol, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	shimo@net.nagasaki-u.ac.jp	Yamaza, Haruyoshi/AAD-4011-2019	Yamaza, Haruyoshi/0000-0003-1138-3943; Higami, Yoshikazu/0000-0003-1381-0777; Tsuchiya, Tomoshi/0000-0002-8419-1478				Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; BIELSCHOWSKY F, 1961, BRIT J CANCER, V15, P257, DOI 10.1038/bjc.1961.32; BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; CHEN HW, 1972, JNCI-J NATL CANCER I, V49, P1145; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; Dominici FP, 2000, J ENDOCRINOL, V166, P579, DOI 10.1677/joe.0.1660579; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Hsieh CC, 2002, MECH AGEING DEV, V123, P1229, DOI 10.1016/S0047-6374(02)00036-2; MAEDA H, 1985, J GERONTOL, V40, P671, DOI 10.1093/geronj/40.6.671; MASORO EJ, 1992, J GERONTOL, V47, pB202, DOI 10.1093/geronj/47.6.B202; MATSUMOTO K, 1993, MOL REPROD DEV, V36, P53, DOI 10.1002/mrd.1080360109; Mattison JA, 2000, J AM AGING ASSOC, V23, P9, DOI 10.1007/s11357-000-0002-0; OOKA H, 1983, MECH AGEING DEV, V22, P113, DOI 10.1016/0047-6374(83)90104-5; RENNELS EG, 1965, TEX REP BIOL MED, V23, P776; Shimokawa I, 2002, AM J PATHOL, V160, P2259, DOI 10.1016/S0002-9440(10)61173-X; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; WEINDRUCH R, 1988, RETARDATION AGING DI	20	94	99	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1108	+		10.1096/fj.02-0819fje	http://dx.doi.org/10.1096/fj.02-0819fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692087				2023-01-03	WOS:000182580100033
J	Langewitz, W; Denz, M; Keller, A; Kiss, A; Ruttimann, S; Wossmer, B				Langewitz, W; Denz, M; Keller, A; Kiss, A; Ruttimann, S; Wossmer, B			Spontaneous talking time at start of consultation in outpatient clinic: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Univ Basel Hosp, Dept Internal Med, Div Psychosomat Med, CH-4031 Basel, Switzerland; Univ Hosp, Zurich, Switzerland; Forel Klin, Ellikon An Der Thur, Switzerland; Kantonsspital, Dept Internal Med, Schaffhausen, Switzerland	University of Basel; University of Zurich; University Zurich Hospital; Kantonsspital Aarau AG (KSA)	Langewitz, W (corresponding author), Univ Basel Hosp, Dept Internal Med, Div Psychosomat Med, CH-4031 Basel, Switzerland.							BLAU JN, 1989, BRIT MED J, V298, P39, DOI 10.1136/bmj.298.6665.39; Martina B, 1994, Schweiz Rundsch Med Prax, V83, P147; Martina B, 1997, J GEN INTERN MED, V12, P459, DOI 10.1046/j.1525-1497.1997.00083.x; Marvel MK, 1999, JAMA-J AM MED ASSOC, V281, P283, DOI 10.1001/jama.281.3.283	4	100	104	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 28	2002	325	7366					682	+		10.1136/bmj.325.7366.682	http://dx.doi.org/10.1136/bmj.325.7366.682			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351359	Bronze, Green Published			2023-01-03	WOS:000178387600019
J	Dybul, M; Fauci, AS; Bartlett, JG; Kaplan, JE; Pau, AK				Dybul, M; Fauci, AS; Bartlett, JG; Kaplan, JE; Pau, AK			Guidelines for using antiretroviral agents among HIV-infected adults and adolescents - The panel on clinical practices for treatment of HIV	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITOR; PNEUMOCYSTIS-CARINII-PNEUMONIA; PLACEBO-CONTROLLED TRIAL; TYPE-1 RNA LEVELS; CD4 CELL COUNTS; BONE-MINERAL LOSS; VIRAL LOAD; PROTEASE-INHIBITOR; RISK-FACTORS	The availability of an increasing number of antiretroviral agents and the rapid evolution of new information have introduced substantial complexity into treatment regimens for persons infected with human immunodeficiency virus (HIV). In 1996, the Department of Health and Human Services and the Henry J. Kaiser Family Foundation convened the Panel on Clinical Practices for the Treatment of HIV to develop guidelines for clinical management of HIV-infected adults and adolescents (CDC. Report of the NIH Panel To Define Principles of Therapy of HIV Infection and Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR. 1998;47[RR-5]:1-41). This report, which updates the 1998 guidelines, addresses 1) using testing for plasma HIV ribonucleic acid levels (i.e., viral load) and CD4(+) T cell count; 2) using testing for antiretroviral drug resistance; 3) considerations for when to initiate therapy; 4) adherence to antiretroviral therapy; 5) considerations for therapy among patients with advanced disease; 6) therapy-related adverse events; 7) interruption of therapy, 8) considerations for changing therapy and available therapeutic options; 9) treatment for acute HIV infection; 10) considerations for antiretroviral therapy among adolescents; 11) considerations for antiretroviral therapy among pregnant women; and 12) concerns related to transmission of HIV to others. Antiretroviral regimens are complex, have serious side effects, pose difficulty with adherence, and carry serious potential consequences from the development of viral resistance because of non-adherence to the drug regimen or suboptimal levels of antiretroviral agents. Patient education and involvement in therapeutic decisions are critical. Treatment should usually be offered to all patients with symptoms ascribed to HIV infection. Recommendations for offering antiretroviral therapy among asymptomatic patients require analysis of real and potential risks and benefits. In general, treatment should be offered to persons who have <350 CD4(+) T cells/mm(3) or plasma HIV ribonucleic acid (RNA) levels of >55,000 copies/mL (by b-deoxyribonucleic acid [bDNA] or reverse transcriptase-polymerase chain reaction [RT-PCR] assays). The recommendation to treat asymptomatic patients should be based on the willingness and readiness of the pet-son to begin therapy; the degree of existing immunodeficiency as determined by the CD4(+) T cell count; the risk for disease progression as determined by the CD4(+) T cell count and level of plasma HIV RNA; the potential benefits and risks of initiating therapy in an asymptomatic person; and the likelihood, after counseling and education, of adherence to the prescribed treatment regimen. Treatment goals should be maximal and durable suppression of viral load, restoration and preservation of immunologic function, improvement of quality of life, and reduction of HIV-related morbidity and mortality. Results of therapy are evaluated through plasma HIV RNA levels, which are expected to indicate a 1.0 log(10) decrease at 2-8 weeks and no detectable virus (<50 copies/mL) at 4-6 months after treatment initiation. Failure of therapy at 4-6 months might be ascribed to nonadherence, inadequate potency of drugs or suboptimal levels of antiretroviral agents, viral resistance, and other factors that are poorly understood. Patients whose therapy fails in spite of a high level of adherence to the regimen should have their regimen changed; this change should be guided by a thorough drug treatment history and the results of drug-resistance testing. Because of limitations in Me available alternative antiretroviral regimens Mat have documented efficacy optimal changes in therapy might be difficult to achieve for patients in whom the preferred regimen has failed. These decisions are further confounded by problems with adherence, toxicity, and resistance. For certain patients, participating in a clinical trial with or without access to new drugs or using a regimen that might not achieve complete suppression of viral replication might be preferable. Because concepts regarding HIV management are evolving rapidly, readers should check regularly for additional information and updates at the HIV/AIDS Treatment Information Service website (http://www.hivatis.org).	NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Baltimore, MD USA; CDC, Atlanta, GA 30333 USA	National Institutes of Health (NIH) - USA; Johns Hopkins University; Centers for Disease Control & Prevention - USA	Dybul, M (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.							Acosta EP, 1999, PHARMACOTHERAPY, V19, P708, DOI 10.1592/phco.19.9.708.31544; AHDIEH L, 2000, 13 INT AIDS C DURB S; ANASTOS K, 1999, 6 C RETR OPP INF CHI, P1208; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Antinori A, 2001, AIDS, V15, P1579, DOI 10.1097/00002030-200108170-00018; ARNSTEN J, 2000, 7 C RETR OPP INF, P88; Aukrust P, 1999, J CLIN ENDOCR METAB, V84, P145, DOI 10.1210/jc.84.1.145; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BAETEN J, 2000, 13 INT AIDS C DURB S; Bailey A, 1999, AIDS, V13, P1377, DOI 10.1097/00002030-199907300-00016; BAILEY R, 2001, 8 C RETR OPP INF CHI; Bangsberg D, 1997, JAMA-J AM MED ASSOC, V278, P63, DOI 10.1001/jama.278.1.63; BANGSBERG DR, 2000, 7 C RETR OPP INF SAN, P88; Barry MG, 1996, AIDS, V10, P1361, DOI 10.1097/00002030-199610000-00008; Bartlett J, 2001, 8 C RETR OPP INF CHI; BARTLETT J, 2000, 13 INT AIDS C DURB S; BAXTER JD, 1999, 6 C RETR OPP INF CHI, P206; Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001; Bersoff-Matcha SJ, 2001, CLIN INFECT DIS, V32, P124, DOI 10.1086/317536; BINGHAM T, 2001, 8 C RETR OPP INF CHI; BLAIR J, 2000, 7 C RETR OPP INF SAN, P112; Blake M, 2000, CLIN INFECT DIS, V30, pS96, DOI 10.1086/313859; Boden D, 1999, JAMA-J AM MED ASSOC, V282, P1135, DOI 10.1001/jama.282.12.1135; *BOEHR ING ROX LAB, 2000, DEAR HLTH CAR PROF L; Bonfanti P, 2001, J ACQ IMMUN DEF SYND, V27, P316; Bossi P, 2000, CLIN INFECT DIS, V30, P227, DOI 10.1086/313629; BOUBAKER K, 2000, 7 C RETR OPP INF SAN; Bourezane Y, 1998, CLIN INFECT DIS, V27, P1321, DOI 10.1086/517713; BOXWELL DE, 1999, 39 INT C ANT AG CHEM, P496; Brinkman K, 2000, CLIN INFECT DIS, V31, P167, DOI 10.1086/313921; Brinkman K, 1999, LANCET, V354, P1112, DOI 10.1016/S0140-6736(99)06102-4; *BRIST MYERS SQUIB, 2001, HEALTHC PROV IMP DRU; BUKUSI E, 2000, 13 INT AIDS C DURB S; Bush CE, 1996, J CLIN MICROBIOL, V34, P970, DOI 10.1128/JCM.34.4.970-972.1996; BUVE A, 2000, 13 INT AIDS C DURB S; CAHN P, 2000, 40 INT C ANT AG CHEM; Cameron DW, 1999, AIDS, V13, P213, DOI 10.1097/00002030-199902040-00009; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carmona A, 2000, 13 INT AIDS C DURB S; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P185; Chaisson RE, 2000, JAMA-J AM MED ASSOC, V284, P3128, DOI 10.1001/jama.284.24.3128; CHEEVER L, 1999, ADHERENCE HIV THERAP, P10; Chen R, 2001, 8 C RETR OPP INF CHI; Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849; Chodock R, 1999, NEPHROL DIAL TRANSPL, V14, P2484, DOI 10.1093/ndt/14.10.2484; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Clarke S, 2000, CLIN INFECT DIS, V31, P806, DOI 10.1086/314026; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; COHEN C, 2000, 7 C RETR OPP INF SAN, P120; Control CfD Prevention, 1998, MMWR-MORBID MORTAL W, V47, pi, DOI DOI 10.1001/jamahealthforum.2021.0325; COODLEY GO, 1994, J ACQ IMMUN DEF SYND, V7, P681; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; Crespo-Fierro M, 1997, J Assoc Nurses AIDS Care, V8, P43, DOI 10.1016/S1055-3290(97)80012-X; CUNNEY RJ, 1999, 37 INF DIS SOC AM M; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Deeks SG, 1999, J INFECT DIS, V179, P1375, DOI 10.1086/314775; den Brinker M, 2000, AIDS, V14, P2895, DOI 10.1097/00002030-200012220-00011; Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Dube M P, 1998, AIDS Clin Care, V10, P41; Dube MP, 2000, CLIN INFECT DIS, V31, P1216; Dunlop MBV, 1999, B RHEUM DIS, V48, P1; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; DYBUL M, 2001, 8 C RETR OPP INF CHI; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; Eastone JA, 1997, ANN INTERN MED, V127, P948, DOI 10.7326/0003-4819-127-10-199711150-00017; EGGER M, 2001, 41 INT C ANT AG CHEM; Evans JS, 1997, J INFECT DIS, V175, P795, DOI 10.1086/513973; FAGARD C, 2001, 8 C RETR OPP INF CHI; Fagot JP, 2001, AIDS, V15, P1843, DOI 10.1097/00002030-200109280-00014; Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FISCHL M, 2000, 7 C RETR OPP INF SAN; FLAKS R, 2001, 8 C RETR OPP INF CHI; FLANIGAN T, 1999, ADHERENCE HIV THERAP, P21; FORTGANG IS, 1995, AM J GASTROENTEROL, V90, P1433; Fowler M E, 1998, J Assoc Nurses AIDS Care, V9, P72, DOI 10.1016/S1055-3290(98)80021-6; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; GAUGHAN DM, 2001, 8 C RETR OPP INF CHI; Gervasoni C, 1999, AIDS, V13, P465, DOI 10.1097/00002030-199903110-00004; Gisolf EH, 2000, CLIN INFECT DIS, V31, P1234, DOI 10.1086/317449; GLESBY M, 2000, ANTIVIR THER, V5, P21; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; GRAY R, 2000, 13 INT AIDS C DURB S; GREENBERG RN, 1984, CLIN THER, V6, P592; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hadigan C, 2000, JAMA-J AM MED ASSOC, V284, P472, DOI 10.1001/jama.284.4.472; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARRIS M, 2000, ANTIVIR THER S, V5, P31; Hart CE, 1999, J INFECT DIS, V179, P871, DOI 10.1086/314656; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hoen B, 1999, J INFECT DIS, V180, P1342, DOI 10.1086/315002; HOFFMAN I, 2000, 13 INT AIDS C DURB S; Hogg R, 2000, 13 INT AIDS C DURB S; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; HOY J, 2000, 7 C RETR OPP INF SAN; Hsu A, 1998, CLIN PHARMACOL THER, V63, P453, DOI 10.1016/S0009-9236(98)90041-8; Human rabies-New York, 1993, MMWR MORB MORTAL WKL, V42, P806; Ibdah JA, 1999, NEW ENGL J MED, V340, P1723, DOI 10.1056/NEJM199906033402204; Ibdah JA, 2000, MOL GENET METAB, V71, P182, DOI 10.1006/mgme.2000.3065; Ickovics JR, 1997, J CLIN EPIDEMIOL, V50, P385, DOI 10.1016/S0895-4356(97)00041-3; Ioannidis JPA, 2001, J INFECT DIS, V183, P539, DOI 10.1086/318530; Iversen AKN, 1998, J INFECT DIS, V177, P1214, DOI 10.1086/515266; Joffe BI, 2001, LANCET, V357, P1379, DOI 10.1016/S0140-6736(00)04616-X; John M, 2001, AIDS, V15, P717, DOI 10.1097/00002030-200104130-00007; Junghans C, 1999, LANCET, V353, P589, DOI 10.1016/S0140-6736(05)75645-2; Kakuda TN, 1999, AIDS, V13, P2311, DOI 10.1097/00002030-199911120-00019; Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3; Kalichman SC, 1999, J GEN INTERN MED, V14, P267, DOI 10.1046/j.1525-1497.1999.00334.x; KALISH LA, 1999, 39 INT C ANT AG CHEM, P532; Kaplan J, 2000, 13 INT AIDS C DURB S; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; KILBY M, 2000, 40 INT C ANT AG CHEM, P336; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Knobel H, 2001, J ACQ IMMUN DEF SYND, V28, P14, DOI 10.1097/00042560-200109010-00003; KNOBEL H, 1998, 12 INT AIDS C GEN SW; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; Kotler DP, 1999, J ACQ IMMUN DEF SYND, V20, P228, DOI 10.1097/00042560-199903010-00003; Kourtis AP, 2001, JAMA-J AM MED ASSOC, V285, P709, DOI 10.1001/jama.285.6.709; Kovacs A, 2001, LANCET, V358, P1593, DOI 10.1016/S0140-6736(01)06653-3; KUROWSKI M, 2000, 40 INT C ANT AG CHEM, P333; Lafeuillade A, 1997, J INFECT DIS, V175, P1051, DOI 10.1086/516442; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; LIBMAN H, 2000, HIV; LICHTENSTEIN K, 2000, 13 INT AIDS C DURB S; Lillo FB, 1999, AIDS, V13, P791, DOI 10.1097/00002030-199905070-00007; Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; Lonergan JT, 2000, CLIN INFECT DIS, V31, P162, DOI 10.1086/313912; LUBER AD, 2000, 40 INT C ANT AG CHEM, P297; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Luzzati R, 1999, LANCET, V353, P901, DOI 10.1016/S0140-6736(99)00523-1; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; MALLAL S, 1999, 1 INT WORKSH ADV DRU; Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002; MANNHERHEIMER S, 2000, 13 INT AIDS C DURB S; MANNUCCI PM, 1994, BRIT J HAEMATOL, V86, P174, DOI 10.1111/j.1365-2141.1994.tb03270.x; Martinez E, 2000, CLIN INFECT DIS, V31, P1266, DOI 10.1086/317426; Martinez E, 2001, AIDS, V15, P1261, DOI 10.1097/00002030-200107060-00007; MARX P, 2000, 13 INT AIDS C DURB S; Masur H, 2002, ANN INTERN MED, V137, P435, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00002; MASUR H, 2000, 38 INF DIS SOC AM M; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; McPherson-Baker S., 2000, AIDS Care, V12, P399, DOI 10.1080/09540120050123792; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MILLER J, 2001, 8 C RETR OPP INF CHI; Miller KD, 2000, ANN INTERN MED, V133, P192, DOI 10.7326/0003-4819-133-3-200008010-00010; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Miller V, 1999, J INFECT DIS, V180, P530, DOI 10.1086/314890; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P478, DOI 10.1016/S0002-9378(97)70519-2; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Mokrzycki MH, 2000, CLIN INFECT DIS, V30, P198, DOI 10.1086/313594; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MOORE R, 2000, 7 C RETR OPP INF SAN; Moore RD, 1999, LANCET, V353, P463, DOI 10.1016/S0140-6736(98)05379-3; Mora S, 2001, AIDS, V15, P1823, DOI 10.1097/00002030-200109280-00011; Moroni M, 1999, LANCET, V353, P589, DOI 10.1016/S0140-6736(05)75646-4; MOYLE GJ, 2000, 40 INT C ANT AG CHEM; MULDER JW, 1994, AIDS, V8, P313, DOI 10.1097/00002030-199403000-00004; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; Mulligan K, 2001, J ACQ IMMUN DEF SYND, V26, P443, DOI 10.1097/00126334-200104150-00006; MURATA H, 2001, 3 INT WORKSH ADV DRU; Murphy RL, 2001, AIDS, V15, pF1, DOI 10.1097/00002030-200101050-00002; NIEUWKERK P, 2000, 13 INT AIDS C DURB S; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; Nunez M, 2001, J ACQ IMMUN DEF SYND, V27, P426, DOI 10.1097/00126334-200108150-00002; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OPRAVIL M, 2001, 8 C RETR OPP INF CHI; Overbaugh J, 1996, AIDS RES HUM RETROV, V12, P107, DOI 10.1089/aid.1996.12.107; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PALUMBO R, 1999, GLOB STRAT PREV HIV; Pantaleo G, 1998, NAT MED, V4, P341, DOI 10.1038/nm0398-341; PARIENTI JJ, 2000, 40 INT C ANT AG CHEM; Parkin NT, 1999, J INFECT DIS, V180, P865, DOI 10.1086/314928; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Paton NIJ, 1997, CALCIFIED TISSUE INT, V61, P30, DOI 10.1007/s002239900288; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PISCITELLI S, 2000, 7 C RETR OPP INF SAN; Powderly WG, 1999, AIDS, V13, P1873, DOI 10.1097/00002030-199910010-00009; POWDERLY WG, 2000, 40 INT C ANT AG CHEM; Prins M, 1999, AIDS, V13, P2361, DOI 10.1097/00002030-199912030-00007; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Raboud JM, 1996, J INFECT DIS, V174, P191, DOI 10.1093/infdis/174.1.191; Racoosin JA, 1999, HAEMOPHILIA, V5, P266; Raffi F, 2000, CLIN INFECT DIS, V31, P1274, DOI 10.1086/317424; RAPPAPORT E, 1999, ADHERENCE HIV THERAP, P31; Rodman JH, 1996, J INFECT DIS, V174, P490, DOI 10.1093/infdis/174.3.490; ROGERS A, 1999, ADHERENCE HIV THERAP, P16; ROMEAU J, 1999, 39 INT C ANT AG CHEM; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Ruiz L, 2001, J ACQ IMMUN DEF SYND, V27, P229, DOI 10.1097/00126334-200107010-00003; SAAH A, 1999, 6 C RETR OPP INF CHI; Saint-Marc T, 2000, AIDS, V14, P37, DOI 10.1097/00002030-200001070-00005; Saves M, 2000, ANTIMICROB AGENTS CH, V44, P3451, DOI 10.1128/AAC.44.12.3451-3455.2000; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; Schramm C, 1999, EUR J ANAESTH, V16, P733; Scribner AN, 2000, J ACQ IMMUN DEF SYND, V25, P19, DOI 10.1097/00126334-200009010-00003; Sellmeyer DE, 1996, ENDOCR REV, V17, P518, DOI 10.1210/er.17.5.518; Shaheen F, 1999, J HUMAN VIROL, V2, P154; Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218; Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305; Sherer R, 1998, JAMA-J AM MED ASSOC, V280, P567, DOI 10.1001/jama.280.6.567; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; Soriano V, 2000, AIDS, V14, P1672, DOI 10.1097/00002030-200007280-00032; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; SQUIRES K, 2001, 8 C RETR OPP INF CHI; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 1999, AIDS, V13, P951, DOI 10.1097/00002030-199905280-00011; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; STENZEL MS, 2000, 13 INT AIDS C DURB S; Sterling TR, 2001, NEW ENGL J MED, V344, P720, DOI 10.1056/NEJM200103083441003; Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967; STERLING TR, 2001, 8 C RETR OPP INF CHI; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030-200003100-00005; TEBAS P, 2000, ANTIVIR THER, V5, P18; ter Hofstede HJM, 2000, INT J STD AIDS, V11, P611; Thiebaut R, 2000, CLIN INFECT DIS, V31, P1482, DOI 10.1086/317477; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; TOFFALETTI JG, 1991, CRIT REV CL LAB SCI, V28, P253, DOI 10.3109/10408369109106865; Tsiodras S, 2000, ARCH INTERN MED, V160, P2050, DOI 10.1001/archinte.160.13.2050; TYNDALL M, 2000, 13 INT AIDS C DURB S; *US DEP HHS, 2002, PHS TASK FORC REC US; Valleroy LA, 2000, JAMA-J AM MED ASSOC, V284, P198, DOI 10.1001/jama.284.2.198; Visnegarwala F, 1997, ANN INTERN MED, V127, P947, DOI 10.7326/0003-4819-127-10-199711150-00016; Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623; WABWIREMANGEN F, 2000, 13 INT AIDS C DURB S; WALSH JC, 2000, 40 INT C ANT AG CHEM, P294; Webber MP, 1999, AIDS, V13, P257, DOI 10.1097/00002030-199902040-00014; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; Williams A, 1997, AIDS Clin Care, V9, P51; Williams A, 1997, AIDS CLIN CARE, V9, P58; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YARASHESKI K, 2001, 3 INT WORKSH ADV DRU; Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6; 1996, MMWR MORB MORTAL WKL, V45, P468; 1998, MMWR MORB MORTAL WKL, V47, P1521	252	249	267	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 3	2002	137	5	2				381	433		10.7326/0003-4819-137-5_Part_2-200209031-00001	http://dx.doi.org/10.7326/0003-4819-137-5_Part_2-200209031-00001			53	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592TJ	12617573				2023-01-03	WOS:000177952700001
J	Liddle, R; Davies, CS; Colquhoun, M; Handley, AJ				Liddle, R; Davies, CS; Colquhoun, M; Handley, AJ			ABC of resuscitation - The automated external defibrillator	BRITISH MEDICAL JOURNAL			English	Review							ADVANCED-LIFE-SUPPORT; WORKING GROUP; EXECUTIVE-COMMITTEE; STATEMENT; COUNCIL; GUIDELINES		Wythenshawe Hosp, Manchester M23 9LT, Lancs, England; Natl Defibrillator Programme, London, England; Univ Wales Coll Med, Wales Heart Res Inst, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Coll Med, Prehosp Emergency Res Unit, Cardiff CF4 4XN, S Glam, Wales	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Cardiff University; Cardiff University	Liddle, R (corresponding author), Wythenshawe Hosp, Manchester M23 9LT, Lancs, England.							[Anonymous], 2000, RESUSCITATION, V46, P73; BOSSAERT L, 1992, RESUSCITATION, V24, P211, DOI 10.1016/0300-9572(92)90181-B; CUMMINS RO, 1989, ANN EMERG MED, V18, P1269, DOI 10.1016/S0196-0644(89)80257-4; Davies CS, 2002, RESUSCITATION, V52, P13; Kloeck W, 1997, RESUSCITATION, V34, P109, DOI 10.1016/S0300-9572(97)01100-3; Monsieurs KG, 2001, RESUSCITATION, V48, P207, DOI 10.1016/S0300-9572(00)00378-6; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; *RES COUNC UK, 2002, IMM LIF SUPP MAN; Robertson C, 1998, RESUSCITATION, V37, P81, DOI 10.1016/S0300-9572(98)00035-5; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701	10	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 22	2003	327	7425					1216	1218		10.1136/bmj.327.7425.1216	http://dx.doi.org/10.1136/bmj.327.7425.1216			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630761	Green Published			2023-01-03	WOS:000186784300024
J	Howard, RF				Howard, RF			Current status of pain management in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECURRENT ABDOMINAL-PAIN; POSTOPERATIVE PAIN; SENSORY HYPERINNERVATION; CHRONIC MUSCULOSKELETAL; PRELIMINARY VALIDATION; INITIAL VALIDATION; TONSILLECTOMY PAIN; NEWBORN-INFANTS; ANALGESIA; SURGERY	Many changes have taken place in pediatric pain management since the undertreatment of children's pain was first reported. Notable advances include an increase in understanding pain during development and improvements in the management of acute pain. Although much more about the safe and effective management of pain in children is now known, this knowledge has not been widely or effectively translated into routine clinical practice. Lack of suitable research on which to firmly establish evidence-based care is likely to have contributed to this situation. A subject of considerable interest recently is the discovery that the experience of pain in early life may lead to long-term consequences. New research findings from laboratory and clinical studies have clearly identified possible mechanisms and provided evidence that long-term behavioral changes can extend far beyond what would be considered the normal period of postinjury recovery. Timing, degree of injury, and administered analgesia and its nature may be important determinants of the long-term outcome of infant pain. Chronic pain, including neuropathic pain, is far more common in children than was thought. The assessment and treatment of this pain and its functional consequences present a considerable unmet challenge. There is a pressing need for further research and clinical development in the management of pain in children.	Great Ormond St Hosp Sick Children, Dept Anaesthesia, London WC1N 2JH, England; Great Ormond St Hosp Sick Children, Children Nationwide Pain Res Ctr, London WC1N 2JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Howard, RF (corresponding author), Great Ormond St Hosp Sick Children, Dept Anaesthesia, Great Ormond St, London WC1N 2JH, England.	r.howard@ich.ucl.ac.uk		Howard, Richard/0000-0001-9271-0074				Alvares D, 1999, PAIN, pS71, DOI 10.1016/S0304-3959(99)00140-2; *AM PAIN SOC, PED CHRON PAIN POS S; Anand KJS, 2000, NAT MED, V6, P971, DOI 10.1038/79658; Anand KJS, 1999, PHYSIOL BEHAV, V66, P627, DOI 10.1016/S0031-9384(98)00338-2; ANAND KJS, 1989, PEDIATR CLIN N AM, V36, P795; Anderson BJ, 1999, ANESTHESIOLOGY, V90, P411, DOI 10.1097/00000542-199902000-00014; Andrews K, 2002, PAIN, V99, P185, DOI 10.1016/S0304-3959(02)00100-8; Andrews KA, 2002, PAIN, V100, P35, DOI 10.1016/S0304-3959(02)00288-9; [Anonymous], 1979, Pain, V6, P249; Asprey J R, 1994, J Pediatr Nurs, V9, P150; Beland B, 2001, PAIN, V90, P143, DOI 10.1016/S0304-3959(00)00397-3; BELLMAN MH, 1993, BRIT MED J, V307, P1563, DOI 10.1136/bmj.307.6918.1563; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Berde CB, 2003, PAIN INFANTS CHILDRE, P620; BIERI D, 1990, PAIN, V41, P139, DOI 10.1016/0304-3959(90)90018-9; Blass EM, 1999, PAIN, V83, P611, DOI 10.1016/S0304-3959(99)00166-9; Breau LM, 2000, DEV MED CHILD NEUROL, V42, P609, DOI 10.1017/S0012162200001146; Campo JV, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e1; Chambers CT, 1996, PAIN, V68, P307, DOI 10.1016/S0304-3959(96)03209-5; Chambers CT, 1998, PAIN, V78, P27, DOI 10.1016/S0304-3959(98)00112-2; Chambliss C Robert, 2002, Paediatr Drugs, V4, P737, DOI 10.2165/00148581-200204110-00005; CHAMPION DG, 1998, PROGR PAIN RES MANAG, P123; Collins JJ, 2002, HEMATOL ONCOL CLIN N, V16, P657, DOI 10.1016/S0889-8588(02)00020-5; Conroy S, 2000, BRIT J CLIN PHARMACO, V49, P93, DOI 10.1046/j.1365-2125.2000.00125.x; Cox T H, 1995, Hosp Pharm, V30, P980; COX TH, 1995, HOSP PHARM, V30, P995; CRAIG KD, 1984, SOC SCI MED, V19, P1331, DOI 10.1016/0277-9536(84)90021-2; De Lima J, 1999, BRIT J ANAESTH, V83, P662, DOI 10.1093/bja/83.4.662; DI LC, 2001, J PEDIAT, V139, P838; DOYLE E, 1993, BRIT J ANAESTH, V71, P670, DOI 10.1093/bja/71.5.670; Eland JM, 1977, PAIN SOURCE BOOK NUR, P453; Ellis JA, 2002, CLIN J PAIN, V18, P262, DOI 10.1097/00002508-200207000-00007; Fearon I, 1997, J DEV BEHAV PEDIATR, V18, P222; Finley GA, 1996, PAIN, V64, P83, DOI 10.1016/0304-3959(95)00091-7; Fitzgerald M, 2001, NEUROSCIENTIST, V7, P246, DOI 10.1177/107385840100700309; Fitzgerald M, 2003, PROG PAIN RES MANAG, V24, P185; FITZGERALD M, 1989, PAIN, V39, P31, DOI 10.1016/0304-3959(89)90172-3; Flato B, 1997, CLIN EXP RHEUMATOL, V15, P569; Franck LS, 2000, PEDIATR CLIN N AM, V47, P487, DOI 10.1016/S0031-3955(05)70222-4; GEDALYDUFF V, 1994, PAIN, V57, P293, DOI 10.1016/0304-3959(94)90004-3; Giaufre E, 1996, ANESTH ANALG, V83, P904, DOI 10.1097/00000539-199611000-00003; GOODMAN JE, 1991, PAIN, V46, P247, DOI 10.1016/0304-3959(91)90108-A; GRUNAU RE, 2000, PAIN NEONATES, P55; Gunter Joel B, 2002, Paediatr Drugs, V4, P649, DOI 10.2165/00128072-200204100-00003; Hadden KL, 2002, PAIN, V99, P281, DOI 10.1016/S0304-3959(02)00123-9; Herod J, 2002, PAEDIATR ANAESTH, V12, P388, DOI 10.1046/j.1460-9592.2002.00768.x; HESTER NKO, 1979, NURS RES, V28, P250; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; Holden EW, 1998, J DEV BEHAV PEDIATR, V19, P109; Hotopf M, 1998, BRIT MED J, V316, P1196, DOI 10.1136/bmj.316.7139.1196; Howard RF, 2001, ANESTHESIOLOGY, V95, P421, DOI 10.1097/00000542-200108000-00026; Hunt A, 2003, INT J NURS STUD, V40, P171, DOI 10.1016/S0020-7489(02)00058-5; JAY S, 1995, PAIN, V62, P3, DOI 10.1016/0304-3959(94)00216-2; *JOINT COMM ACCR H, HOSP ACCR STAND 2000; Kart T, 1997, PAEDIATR ANAESTH, V7, P93; Kokinsky E, 1999, PAEDIATR ANAESTH, V9, P243; Lee BH, 2002, J PEDIATR-US, V141, P135, DOI 10.1067/mpd.2002.124380; LEHMANN HP, 1990, J DEV BEHAV PEDIATR, V11, P128; LLOYDTHOMAS AR, 1994, PAEDIATRIC ANAESTHES, V4, P3; Malleson PN, 2001, ARCH DIS CHILD, V84, P189, DOI 10.1136/adc.84.3.189; McGrath P, 1996, PAIN, V64, P435, DOI 10.1016/0304-3959(95)00171-9; MCINTOSH N, 1994, ARCH DIS CHILD-FETAL, V70, pF177, DOI 10.1136/fn.70.3.F177; Meier PM, 2001, MUSCLE NERVE, V24, P1339, DOI 10.1002/mus.1153; Morton NS, 1999, BRIT J ANAESTH, V83, P118, DOI 10.1093/bja/83.1.118; MURAT I, 1987, BRIT J ANAESTH, V59, P1441, DOI 10.1093/bja/59.11.1441; Murray CS, 2000, ARCH DIS CHILD, V82, P231, DOI 10.1136/adc.82.3.231; MURRAY WB, 1987, S AFR MED J, V72, P839; *NAT HLTH MRC AUST, AC PAIN MAN SCI EV; Nishina K, 1999, PAEDIATR ANAESTH, V9, P187; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; Perquin CW, 2000, CLIN J PAIN, V16, P229, DOI 10.1097/00002508-200009000-00008; Perquin CW, 2000, PAIN, V87, P51, DOI 10.1016/S0304-3959(00)00269-4; Peters JWB, 2003, PEDIATRICS, V111, P129, DOI 10.1542/peds.111.1.129; Porter FL, 1997, PEDIATRICS, V100, P626, DOI 10.1542/peds.100.4.626; REYNOLDS ML, 1995, J COMP NEUROL, V358, P487, DOI 10.1002/cne.903580403; ROWBOTHAM DJ, 1998, GUIDELINES USE NONST; *ROYAL COLL NURS I, CLIN GUID REC ASS AC; Ruda MA, 2000, SCIENCE, V289, P628, DOI 10.1126/science.289.5479.628; Schanberg LE, 2003, ARTHRITIS RHEUM-US, V48, P1390, DOI 10.1002/art.10986; SCHECHTER N, 1988, AM J NURS, V88, P719, DOI 10.2307/3425945; SCHECHTER NL, 1986, PEDIATRICS, V77, P11; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Schreiner MS, 2002, ANESTH ANALG, V94, P1; Semple D, 1996, ANAESTHESIA, V51, P1170, DOI 10.1111/j.1365-2044.1996.tb15063.x; Sepponen K, 1999, PHARM WORLD SCI, V21, P168, DOI 10.1023/A:1008793223756; SHAPIRO BS, 1991, PEDIATRICS, V88, P1226; Simons J, 2001, J ADV NURS, V36, P591, DOI 10.1046/j.1365-2648.2001.02012.x; Small E, 2002, PEDIATR CLIN N AM, V49, P655, DOI 10.1016/S0031-3955(02)00008-1; Stallard P, 2001, ARCH DIS CHILD, V85, P460, DOI 10.1136/adc.85.6.460; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; Taddio A, 2002, JAMA-J AM MED ASSOC, V288, P857, DOI 10.1001/jama.288.7.857; Voepel-Lewis T, 2002, ANESTH ANALG, V95, P1224, DOI 10.1097/00000539-200211000-00020; Weydert JA, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.1.e1; WILDER RT, 1992, J BONE JOINT SURG AM, V74A, P910, DOI 10.2106/00004623-199274060-00013; Williams DG, 2001, BRIT J ANAESTH, V86, P413, DOI 10.1093/bja/86.3.413; WOLF AR, 1993, BRIT J ANAESTH, V70, P654, DOI 10.1093/bja/70.6.654; Wong D L, 1988, Pediatr Nurs, V14, P9; YASTER M, 1994, J PEDIATR-US, V124, P165, DOI 10.1016/S0022-3476(94)70300-0	98	165	174	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2464	2469		10.1001/jama.290.18.2464	http://dx.doi.org/10.1001/jama.290.18.2464			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742LH	14612483				2023-01-03	WOS:000186518300033
J	Duyk, G				Duyk, G			Attrition and translation	SCIENCE			English	Article							DRUG DEVELOPMENT; UNITED-STATES	The recently published NIH Roadmap proposes that public-sector science should place increased emphasis on the development of new therapeutics and diagnostics based on the fruits of fundamental research. Such "translational research" activities, traditionally the province of the private sector, have long been compromised by high rates of attrition (failure during the course of preclinical or clinical development of therapeutics). Attrition has led to growing financial costs, as well as opportunity costs. The new focus offers a way to reverse these trends, especially if the scientific community can improve on its ability to reconcile molecular genetic research with integrative organ- and organism-based research.	Exelixis Inc, San Francisco, CA 94083 USA	Exelixis, Inc.	Duyk, G (corresponding author), Exelixis Inc, 170 Harbor Way, San Francisco, CA 94083 USA.							*BILL MEL GAT FDN, GLOB HLTH PROGR; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Collins FS, 2003, SCIENCE, V300, P286, DOI 10.1126/science.1084564; DiMasi JA, 2001, CLIN PHARMACOL THER, V69, P286, DOI 10.1067/mcp.2001.115132; DIMASI JA, 1991, CLIN PHARMACOL THER, V50, P471, DOI 10.1038/clpt.1991.172; DiMasi Joseph A., 1996, Am J Ther, V3, P647, DOI 10.1097/00045391-199609000-00008; Eisenberg RS, 2003, SCIENCE, V299, P1018, DOI 10.1126/science.1081790; FALK M, 2003, STATUS FUTURE INTEGR; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; KAITIN KI, 2003, TUFTS CTR STUDY DRUG, V5; *LEHM BROTH, 2001, FRUITS GEN DRUG PIP; Malakoff D, 2003, SCIENCE, V300, P1635; MCCLELLAN MB, 2003, COMMUNICATION   0609; MILNE CP, 2002, PHARMACOECONOMICS S3, V20; Wellcome Trust, 2003, SHAR DAT LARG SCAL B; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867	16	72	74	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					603	605		10.1126/science.1090521	http://dx.doi.org/10.1126/science.1090521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576424				2023-01-03	WOS:000186119900047
J	Baumgart, T; Hess, ST; Webb, WW				Baumgart, T; Hess, ST; Webb, WW			Imaging coexisting fluid domains in biomembrane models coupling curvature and line tension	NATURE			English	Article							GIANT PHOSPHOLIPID-VESICLES; INTRAMEMBRANE DOMAINS; MEMBRANES; SHAPE; FISSION; TRANSITIONS; MONOLAYERS; DYNAMICS	Lipid bilayer membranes - ubiquitous in biological systems and closely associated with cell function - exhibit rich shape-transition behaviour, including bud formation(1) and vesicle fission(2). Membranes formed from multiple lipid components can laterally separate into coexisting liquid phases, or domains, with distinct compositions. This process, which may resemble raft formation in cell membranes, has been directly observed in giant unilamellar vesicles(3,4). Detailed theoretical frameworks(5-11) link the elasticity of domains and their boundary properties to the shape adopted by membranes and the formation of particular domain patterns, but it has been difficult to experimentally probe and validate these theories. Here we show that high-resolution fluorescence imaging using two dyes preferentially labelling different fluid phases directly provides a correlation between domain composition and local membrane curvature. Using freely suspended membranes of giant unilamellar vesicles, we are able to optically resolve curvature and line tension interactions of circular, stripe and ring domains. We observe long-range domain ordering in the form of locally parallel stripes and hexagonal arrays of circular domains, curvature-dependent domain sorting, and membrane fission into separate vesicles at domain boundaries. By analysing our observations using available membrane theory, we are able to provide experimental estimates of boundary tension between fluid bilayer domains.	Cornell Univ, Ithaca, NY 14853 USA; NICHHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Webb, WW (corresponding author), Cornell Univ, Ithaca, NY 14853 USA.		Webb, Watt W./B-5905-2011					ANDELMAN D, 1992, EUROPHYS LETT, V19, P57, DOI 10.1209/0295-5075/19/1/010; ANDELMAN D, 1987, J CHEM PHYS, V86, P3673, DOI 10.1063/1.451970; BARZIV R, 1994, PHYS REV LETT, V73, P1392, DOI 10.1103/PhysRevLett.73.1392; BENVEGNU DJ, 1992, J PHYS CHEM-US, V96, P6820, DOI 10.1021/j100195a053; Chen CM, 1997, PHYS REV LETT, V79, P1579, DOI 10.1103/PhysRevLett.79.1579; Debregeas G, 1998, SCIENCE, V279, P1704, DOI 10.1126/science.279.5357.1704; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; DOBEREINER HG, 1993, BIOPHYS J, V65, P1396; DUWE HP, 1990, PHYSICA A, V163, P410, DOI 10.1016/0378-4371(90)90349-W; HELFRICH W, 1984, NUOVO CIMENTO D, V3, P137, DOI 10.1007/BF02452208; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; Huttner WB, 2001, CURR OPIN CELL BIOL, V13, P478, DOI 10.1016/S0955-0674(00)00239-8; JENKINS JT, 1977, J MATH BIOL, V4, P149, DOI 10.1007/BF00275981; Jiang Y, 2000, PHYS REV E, V61, pR57, DOI 10.1103/PhysRevE.61.R57; Julicher F, 1996, PHYS REV E, V53, P2670, DOI 10.1103/PhysRevE.53.2670; KAS J, 1991, BIOPHYS J, V60, P825, DOI 10.1016/S0006-3495(91)82117-8; Kumar PBS, 2001, PHYS REV LETT, V86, P3911, DOI 10.1103/PhysRevLett.86.3911; LEIBLER S, 1987, J PHYS-PARIS, V48, P2013, DOI 10.1051/jphys:0198700480110201300; LIPOWSKY R, 1992, J PHYS II, V2, P1825, DOI 10.1051/jp2:1992238; Lipowsky R, 2003, J PHYS-CONDENS MAT, V15, pS31, DOI 10.1088/0953-8984/15/1/304; Mathivet L, 1996, BIOPHYS J, V70, P1112, DOI 10.1016/S0006-3495(96)79693-5; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/jphys:019840045090145700; SEIFERT U, 1993, PHYS REV LETT, V70, P1335, DOI 10.1103/PhysRevLett.70.1335; SEUL M, 1995, SCIENCE, V267, P476, DOI 10.1126/science.267.5197.476; Veatch SL, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.268101; Wintz W, 1996, EUROPHYS LETT, V33, P403, DOI 10.1209/epl/i1996-00353-8	29	1230	1254	7	325	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					821	824		10.1038/nature02013	http://dx.doi.org/10.1038/nature02013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574408				2023-01-03	WOS:000186118500041
J	Porter, K; Babiker, AG; Darbyshire, JH; Pezzotti, P; Bhaskaran, K; Walker, AS				Porter, K; Babiker, AG; Darbyshire, JH; Pezzotti, P; Bhaskaran, K; Walker, AS		CASCADE Collaboration	Determinants of survival following HIV-1 seroconversion after the introduction of HAART	LANCET			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; DRUG-USE; MORTALITY; AIDS; ADHERENCE; PROGRESSION; PREDICTORS; INFECTION; RECOVERY; OUTCOMES	Background Highly active antiretroviral therapy (HAART) was introduced in 1997. We aimed to assess the continuing effect of this treatment on survival and progression to AIDS after HIV-1 seroconversion. Methods We used Cox models to estimate the effect of calendar year on time to AIDS and death in 22 cohorts of people from Europe, Australia, and Canada who had seroconverted. Retrospective and prospective data were used. We compared the effects of age at seroconversion, exposure category, sex, and presentation during acute HIV-1 infection pre-1997 (pre-HAART), in 1997-98 (limited use of HAART), and 1999-2001 (widespread use of HAART). Findings Of 7740 seroconverters, 2000 (26%) had died. Compared with pre-1997 data, the hazard ratio (HR) for death fell sharply to 0.47 [95% Cl 0.39-0-56] in 1997, dropping further to 0.16 [0.12-0.22] in 2001. Correspondingly, the proportion of person-time on HAART increased from 22% in 1997 to 57% in 2001. By contrast with the pre-HAART era, injecting drug users had significantly higher mortality in 1999-2001 than did men infected through sex with men (HR 4.28 [2.86-6.41]). However, whereas pre-1997 the risk of AIDS was higher in those aged 45 years or older at seroconversion than in people who were 16-24 years (2.03 [1.67-2.47]), in 1999-2001 there was little evidence of a difference in risk by age (HR=1.17 [0.60-2.30]; interaction p=0.06). No such attenuation in the effect of age on survival was observed (p=0.63). Interpretation Predicted survival for people with HIV-1 has continued to increase, since the introduction of HAART; however. the importance of age and exposure category as determinants of progression seems to have changed.	MRC, Clin Trials Unit, London NW1 2DA, England	Medical Research Council Clinical Trials Unit	Porter, K (corresponding author), MRC, Clin Trials Unit, 222 Euston Rd, London NW1 2DA, England.	kp@ctu.mrc.ac.uk	PEZZOTTI, PATRIZIO/C-6480-2016; VALLET, Yannick/F-9979-2011	PEZZOTTI, PATRIZIO/0000-0002-0805-2927; Johnson, Anne/0000-0003-1330-7100; Bhaskaran, Krishnan/0000-0001-5364-8757; Porter, Kholoud/0000-0002-9226-6206				Babiker A, 2000, LANCET, V355, P1131, DOI 10.1016/S0140-6736(00)02061-4; BROOKMEYER R, 1987, AM J EPIDEMIOL, V126, P14, DOI 10.1093/oxfordjournals.aje.a114646; CASCADE Collaboration, 2000, LANCET, V355, P1158, DOI 10.1016/S0140-6736(00)02069-9; CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration, 2000, HIV Med, V1, P224; Celentano DD, 2001, AIDS, V15, P1707, DOI 10.1097/00002030-200109070-00015; Centers for Disease Control and Prevention, 1992, MMWR RECOMM REP, V41, P1; CLAYTON C, 1993, STAT MODELS EPIDEMIO; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; Cunningham WE, 2000, J ACQ IMMUN DEF SYND, V25, P115, DOI 10.1097/00126334-200010010-00005; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Gordillo V, 1999, AIDS, V13, P1763, DOI 10.1097/00002030-199909100-00021; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Jacobson LP, 2001, J CLIN EPIDEMIOL, V54, P149, DOI 10.1016/S0895-4356(00)00274-2; Le Moing V, 2001, J ACQ IMMUN DEF SYND, V27, P372, DOI 10.1097/00126334-200108010-00007; Lindsey J. K., 1996, PARAMETRIC STAT INFE; Lucas GM, 2002, AIDS, V16, P767, DOI 10.1097/00002030-200203290-00012; Lucas GM, 2001, J ACQ IMMUN DEF SYND, V27, P251, DOI 10.1097/00126334-200107010-00006; Mocroft A, 1999, J ACQ IMMUN DEF SYND, V22, P369; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 1997, BRIT MED J, V314, P409, DOI 10.1136/bmj.314.7078.409; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; PEREZHOYOZ S, 2002, 14 INT AIDS C BARC J; PEZZOTTI P, 14 INT AIDS C BARC J, P2; Porta D, 1999, AIDS, V13, P2125, DOI 10.1097/00002030-199910220-00016; Porter K, 1999, AIDS, V13, P1943, DOI 10.1097/00002030-199910010-00018; Porter K, 2000, AIDS, V14, P1899; Poundstone KE, 2001, AIDS, V15, P1115, DOI 10.1097/00002030-200106150-00006; Sabin CA, 2001, EPIDEMIOL INFECT, V127, P91; Steinmann G G, 1986, Curr Top Pathol, V75, P43; Strathdee SA, 1998, JAMA-J AM MED ASSOC, V280, P547, DOI 10.1001/jama.280.6.547; Tarwater PM, 2001, AM J EPIDEMIOL, V154, P675, DOI 10.1093/aje/154.7.675; Turner BJ, 2001, J GEN INTERN MED, V16, P625, DOI 10.1046/j.1525-1497.2001.016009625.x; Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678; Whitman S, 2000, ARCH INTERN MED, V160, P365, DOI 10.1001/archinte.160.3.365; Wilson TE, 2002, CLIN INFECT DIS, V34, P529, DOI 10.1086/338397	38	280	294	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1267	1274						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575971				2023-01-03	WOS:000186036900010
J	Stelfox, HT; Bates, DW; Redelmeier, DA				Stelfox, HT; Bates, DW; Redelmeier, DA			Safety of patients isolated for infection control	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; ADVERSE; EVENTS; STOP; CARE	Context Hospital infection control policies that use patient isolation prevent nosocomial transmission of infectious diseases, but may inadvertently lead to patient neglect and errors. Objective To examine the quality of medical care received by patients isolated for infection control. Design, Setting, and Patients We identified consecutive adults who were isolated for methicillin-resistant Staphylococcus aureus colonization or infection at 2 large North American teaching hospitals: a general cohort (patients admitted with all diagnoses between January 1, 1999, and January 1, 2000; n = 78); and a disease-specific cohort (patients admitted with a diagnosis of congestive heart failure between January 1, 1999, and July 1, 2002; n = 72). Two matched controls were selected for each isolated patient (n = 156 general cohort controls and n = 144 disease-specific cohort controls). Main Outcome Measures Quality-of-care measures encompassing processes, outcomes, and satisfaction. Adjustments for study cohort and patient demographic, hospital, and clinical characteristics were conducted using multivariable regression. Results Isolated and control patients generally had similar baseline characteristics; however, isolated patients were twice as likely as control patients to experience adverse events during their hospitalization (31 vs 15 adverse events per 1000 days; P<.001). This difference in adverse events reflected preventable events (20 vs 3 adverse events per 1000 days; P<.001) as opposed to nonpreventable events (11 vs 12 adverse events per 1000 days; P=.98). Isolated patients were also more likely to formally complain to the hospital about their care than control patients (8% vs 1%; P<.001), to have their vital signs not recorded as ordered (51% vs 31%; P<.001), and more likely to have days with no physician progress note (26% vs 13%; P<.001). No differences in hospital mortality were observed for the 2 groups (17% vs 10%; P=16). Conclusion Compared with controls, patients isolated for infection control precautions experience more preventable adverse events, express greater dissatisfaction with their treatment, and have less documented care.	Brigham & Womens Hosp, Div Gen Med, Boston, MA 02120 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02120 USA; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Clin Epidemiol Unit, Toronto, ON, Canada; Harvard Univ, Grad Sch Arts & Sci, Cambridge, MA 02138 USA; Partners HealthCare Syst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Harvard University; Partners Healthcare System	Stelfox, HT (corresponding author), Brigham & Womens Hosp, Div Gen Med, 1620 Tremont St, Boston, MA 02120 USA.	stelfox@fas.harvard.edu		Stelfox, Henry/0000-0003-1231-1490	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS011534] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Brown L H, 1997, Prehosp Emerg Care, V1, P145, DOI 10.1080/10903129708958808; Burke JP, 2003, NEW ENGL J MED, V348, P651, DOI 10.1056/NEJMhpr020557; Centers for Disease Control and Prevention, SEV AC RESP SYNDR SA; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Garner Julia S., 1996, Infection Control and Hospital Epidemiology, V17, P53; Gawande AA, 2003, NEW ENGL J MED, V348, P229, DOI 10.1056/NEJMsa021721; Harvard Medical Practice study, 1990, PAT DOCT LAW STUD ME, VI; HICKSON G, 1997, LAW CONTEMP PROBL, V27, P8; Hickson GB, 2002, JAMA-J AM MED ASSOC, V287, P2951, DOI 10.1001/jama.287.22.2951; HIGGINS L, 2001, J GEN INTERN MED S1, V16, P200; Kirkland KB, 1999, LANCET, V354, P1177, DOI 10.1016/S0140-6736(99)04196-3; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Knowles H E, 1993, Nurs Times, V89, P53; Kohn LT, 2000, ERR IS HUMAN BUILDIN; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Krumholz HM, 2000, CIRCULATION, V101, pE122, DOI 10.1161/01.CIR.101.12.e122; Krumholz HM, 2000, CIRCULATION, V101, P1483; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Montecalvo MA, 1999, ANN INTERN MED, V131, P269, DOI 10.7326/0003-4819-131-4-199908170-00006; Nettleman M D, 1994, Clin Perform Qual Health Care, V2, P67; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; Ostrowsky BE, 2001, NEW ENGL J MED, V344, P1427, DOI 10.1056/NEJM200105103441903; Peel RK, 1997, BRIT MED J, V315, P58; Perrow C., 1984, NORMAL ACCIDENTS LIV; Pichert J W, 1999, Jt Comm J Qual Improv, V25, P288; Reason J., 1997, MANAGING RISKS ORG A; Reason J., 1990, HUMAN ERROR; Rosenberg AL, 2000, CHEST, V118, P492, DOI 10.1378/chest.118.2.492; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; Sobie J M, 2000, J Emerg Nurs, V26, P549, DOI 10.1067/men.2000.110891; Teare EL, 1997, BRIT MED J, V314, P665, DOI 10.1136/bmj.314.7081.665; WEICK KE, 1987, CALIF MANAGE REV, V29, P112, DOI 10.2307/41165243; World Health Organization, HOSP INF CONTR GUID; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	36	405	406	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1899	1905		10.1001/jama.290.14.1899	http://dx.doi.org/10.1001/jama.290.14.1899			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	729CB	14532319	Bronze			2023-01-03	WOS:000185752600031
J	Hennessy, S; Bilker, WB; Zhou, L; Weber, AL; Brensinger, C; Wang, YL; Strom, BL				Hennessy, S; Bilker, WB; Zhou, L; Weber, AL; Brensinger, C; Wang, YL; Strom, BL			Retrospective drug utilization review, prescribing errors, and clinical outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICARE BENEFICIARIES; INTERVENTION; DATABASES; DISEASE	Context Retrospective drug utilization review is required of all state Medicaid programs and is performed by most private-sector prescription programs. However, it has not been shown to improve clinical outcomes or reduce the rate of potential prescribing errors, known as "exceptions." Objective To look for an effect of retrospective drug utilization review on the rate of exceptions and of clinical outcomes in patients with an exception. Design, Setting, and Participants Longitudinal ecologic study of the rate of exceptions, controlling for preintervention trends and calendar time; and a cohort study of all-cause and cause-specific hospitalizations in patients with an exception, controlling for potential individual-level confounders in 6 Medicaid programs using the same software in the mid-1990s. Main Outcome Measures The rate of exceptions was examined as a function of retrospective drug utilization review implementation. In addition, before-after comparisons were made of the incidence of all-cause and cause-specific hospitalization in patients with exceptions. Results We found no reduction in the rate of exceptions coincident with retrospective drug utilization review implementation (rate increase, 0.064 exceptions per 1000 prescriptions per month; 95% confidence interval [CI], -0.006 to 0.133). We also found no effect of retrospective drug utilization review on the incidence of all-cause hospitalization (odds ratio, 0.99; 95% Cl, 0.98-1.00) or cause-specific hospitalization. These results persisted in multiple subgroup analyses. Study states intervened using physician alerts in between 1% and 25% of exceptions. Conclusions We were unable to identify an effect of retrospective drug utilization review on the rate of exceptions or on clinical outcomes. Given the lack of evidence for effectiveness, and suggestions from previous research of possible harm, policy-makers should consider withdrawing the legislative mandate for retrospective drug utilization review.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Hennessy, S (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, 803 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.		Bilker, Warren/AAS-3515-2021		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG000987, R01AG014601] Funding Source: NIH RePORTER; AHRQ HHS [U18-HS10399] Funding Source: Medline; NIA NIH HHS [1K23AG000987, 1R01 AG14601] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*ABT ASS INC, 1998, EV DRUG US REV DEM P; Agresti A., 1990, CATEGORICAL DATA ANA; Carson JL, 2000, PHARMACOEPIDEM DR S, P307; CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Coleman CI, 2003, AM J HEALTH-SYST PH, V60, P1142, DOI 10.1093/ajhp/60.11.1142; Hennessey S, 2000, PHARMACOEPIDEM DR S, P505; Hennessy S, 2003, PHARMACOEPIDEM DR S, V12, P103, DOI 10.1002/pds.765; JAY DE, 1991, MED CAL THERAPEUTIC; Kleinbaum DG, 1988, APPL REGRESSION ANAL; Krumholz HM, 1998, J AM COLL CARDIOL, V31, P957, DOI 10.1016/S0735-1097(98)00106-5; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Raiford DS, 1996, EPIDEMIOLOGY, V7, P101, DOI 10.1097/00001648-199601000-00018; Ray WA, 1997, ANN INTERN MED, V127, P712, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00055; Smith DH, 1998, MED CARE, V36, P1013, DOI 10.1097/00005650-199807000-00008; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; STROM BL, 1995, AM J MED, V99, P282, DOI 10.1016/S0002-9343(99)80161-2; STROM BL, 1990, EPIDEMIOL REV, V12, P87, DOI 10.1093/oxfordjournals.epirev.a036064; Strom BL, 1997, ARCH INTERN MED, V157, P2626, DOI 10.1001/archinte.157.22.2626; *US CTR MED MED SE, MED DUALL EL POP; *US CTR MED MED SE, MED ENR BEN SEL FISC; West SL, 2000, PHARMACOEPIDEMIOLOGY, V3rd edn, P661; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; ZIMMERMAN DR, 1994, INQUIRY-J HEALTH CAR, V31, P89; 1969, FINAL REPORT TASK FO	27	38	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1494	1499		10.1001/jama.290.11.1494	http://dx.doi.org/10.1001/jama.290.11.1494			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129990				2023-01-03	WOS:000185329000032
J	Mitchell, K; Owens, RG				Mitchell, K; Owens, RG			National survey of medical decisions at end of life made by New Zealand general practitioners	BRITISH MEDICAL JOURNAL			English	Article									Univ Auckland, Dept Psychol, Auckland, New Zealand; Univ Wales, Bangor LL57 2AS, Gwynedd, Wales	University of Auckland; Bangor University	Mitchell, K (corresponding author), Univ Auckland, Dept Psychol, Private Bag 92019, Auckland, New Zealand.							Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; GILLETT GR, 1991, NZ LAW J         APR; Kuhse H, 1997, MED J AUSTRALIA, V166, P191, DOI 10.5694/j.1326-5377.1997.tb140074.x; van der Maas PJ, 1992, HEALTH POLICY, V22, P1; Zylicz Z, 2000, PATIENT EDUC COUNS, V41, P47, DOI 10.1016/S0738-3991(00)00114-2	5	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 26	2003	327	7408					202	203		10.1136/bmj.327.7408.202	http://dx.doi.org/10.1136/bmj.327.7408.202			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	706DL	12881263	Bronze, Green Published			2023-01-03	WOS:000184437300019
J	Suzuki, M; Suzuki, H; Sugimoto, Y; Sugiyama, Y				Suzuki, M; Suzuki, H; Sugimoto, Y; Sugiyama, Y			ABCG2 transports sulfated conjugates of steroids and xenobiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	53rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases	NOV 01-05, 2002	BOSTON, MA	Amer Assoc Study Liver Dis			BREAST-CANCER RESISTANCE; BILE CANALICULAR MEMBRANE; PRIMARY ACTIVE-TRANSPORT; SUBSTRATE-SPECIFICITY; KINETIC-ANALYSIS; STEM-CELLS; PROTEIN; GENE; OVEREXPRESSION; MITOXANTRONE	The mechanism for the cellular extrusion of sulfated conjugates is still unknown. In the present study, we investigated whether human wild type ABCG2 transports estrone 3-sulfate (E1S) using membrane vesicles from cDNA-transfected mouse lymphoma cell line (P388 cells). The uptake of [H-3]E1S into ABCG2-expressing membrane vesicles was stimulated by ATP, and the Km value for [H-3]E1S was determined to be 16.6 muM. The ABCG2-mediated transport of [H-3]E1S was potently inhibited by SN-38 and many sulfate conjugates but not by glucuronide and glutathione conjugates or other anionic compounds. Other sulfate conjugates such as [H-3] dehydroepiandrosterone sulfate (DHEAS) and [S-35]4-methylumbelliferone sulfate (K-m = 12.9 muM) and [S-35]6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate (K-m = 26.9 muM) were also transported by ABCG2. Although [H-3]methotrexate, [H-3]17beta-estradiol-17beta-D-glucuronide, [H-3]2,4-dinitrophenyl-S-glutathione, and [C-14]4-methylumbelliferone glucuronide were transported by ABCG2, this took place to a much lesser extent compared with [H-3]E1S. It was suggested that ABCG2 preferentially transports sulfate conjugates and that E1S and DHEAS are the potential physiological substrates for this transporter.	Univ Tokyo, Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Biotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Suzuki, H (corresponding author), Univ Tokyo, Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	suzukihi-tky@umin.ac.jp						Akita H, 2001, BBA-BIOMEMBRANES, V1511, P7, DOI 10.1016/S0005-2736(00)00355-2; Allikmets R, 1998, CANCER RES, V58, P5337; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Cui YH, 2001, MOL PHARMACOL, V60, P934, DOI 10.1124/mol.60.5.934; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Hirohashi T, 2000, J PHARMACOL EXP THER, V292, P265; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Honjo Y, 2001, CANCER RES, V61, P6635; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Jonker JW, 2000, JNCI-J NATL CANCER I, V92, P1651, DOI 10.1093/jnci/92.20.1651; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Keppler D, 2000, SEMIN LIVER DIS, V20, P265, DOI 10.1055/s-2000-9391; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Litman T, 2000, J CELL SCI, V113, P2011; Maliepaard M, 1999, CANCER RES, V59, P4559; Maliepaard M, 2001, CANCER RES, V61, P3458; Miyake K, 1999, CANCER RES, V59, P8; Nakatomi K, 2001, BIOCHEM BIOPH RES CO, V288, P827, DOI 10.1006/bbrc.2001.5850; Niinuma K, 1999, AM J PHYSIOL-GASTR L, V276, pG1153, DOI 10.1152/ajpgi.1999.276.5.G1153; Niinuma K, 1997, J PHARMACOL EXP THER, V282, P866; Ozvegy C, 2001, BIOCHEM BIOPH RES CO, V285, P111, DOI 10.1006/bbrc.2001.5130; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Scheffer GL, 2000, CANCER RES, V60, P2589; Suzuki H, 2002, HEPATOLOGY, V36, p218A; Suzuki H, 2000, EUR J PHARM SCI, V12, P3, DOI 10.1016/S0928-0987(00)00178-0; Suzuki H, 1999, Pharm Biotechnol, V12, P387; Suzuki H, 1998, SEMIN LIVER DIS, V18, P359, DOI 10.1055/s-2007-1007170; TAKENAKA O, 1995, PHARMACEUT RES, V12, P1746, DOI 10.1023/A:1016278008658; Volk EL, 2002, CANCER RES, V62, P5035; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	35	279	282	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22644	22649		10.1074/jbc.M212399200	http://dx.doi.org/10.1074/jbc.M212399200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	689QF	12682043	hybrid			2023-01-03	WOS:000183503900063
J	Lunney, JR; Lynn, J; Foley, DJ; Lipson, S; Guralnik, JM				Lunney, JR; Lynn, J; Foley, DJ; Lipson, S; Guralnik, JM			Patterns of functional decline at the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OLDER PERSONS; DISABILITY; SERVICES; HOSPICE; DISEASE; HEALTH; ADULTS; HEART	Context Clinicians have observed various patterns of functional decline at the end of life, but few empirical data have tested these patterns in large populations. Objective To determine if functional decline differs among 4 types of illness trajectories: sudden death, cancer death, death from organ failure, and frailty. Design, Setting, and Participants Cohort analysis of data from 4 US regions in the prospective, longitudinal Established Populations for Epidemiologic Studies of the Elderly (EPESE) study. Of the 14456 participants aged 65 years or older who provided interviews at baseline (1981-1987), 4871 died during the first 6 years of follow-up; 4190 (86%) of these provided interviews within 1 year before dying. These decedents were evenly distributed in 12 cohorts based on the number of months between the final interview and death. Main Outcome Measures Self-or proxy-reported physical function (performance of 7 activities of daily living [ADLs]) within 1 year prior to death; predicted ADL dependency prior to death. Results Mean function declined across the 12 cohorts, simulating individual decline in the final year of life. Sudden death decedents were highly functional even in the last month before death (mean [95% confidence interval {CI}] numbers of ADL dependencies: 0.69 [0.19-1.19] at 12 months before death vs 1.22 [0.59-1.85] at the final month of life, P=.20); cancer decedents were highly functional early in their final year but markedly more disabled 3-months prior to death (0.77 [0.30-1.24] vs 4.09 [3.37-4.81], P<.001); organ failure decedents experienced a fluctuating. pattern of decline, with substantially poorer function during the last 3 months before death (2.10 [1.49-2.70] vs 3.66 [2.94-4.38], P<.001); and frail decedents were relatively more disabled in the final year and especially dependent during the last month (2.92 [2.24-3.60] vs 5.84 [5.33-6.35], P<.001). After controlling for age, sex, race, education, marital status, interval between final interview and death, and other demographic differences, frail decedents were more than 8 times more likely than sudden death decedents to be ADL dependent (OR, 8.32 [95% CI, 6.46-10.73); cancer decedents, one and a half times more likely (OR, 1.57 [95% CI, 1.25-1.96]); and organ failure decedents, 3 times more likely (OR, 3.00 [95% CI, 2.39-3.77]). Conclusions Trajectories of functional decline at the end of life are quite variable. Differentiating among expected trajectories and related needs would help shape tailored strategies and better programs of care prior to death.	NIA, Lab Epidemiol Demog & Biometry, NIH, Bethesda, MD 20892 USA; Washington Home Ctr Palliat Care Studies, Washington, DC USA; Hebrew Home Greater Washington, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Lunney, JR (corresponding author), NIA, Lab Epidemiol Demog & Biometry, NIH, Gateway Bldg,Suite 3C-309, Bethesda, MD 20892 USA.		Ram, Prem/K-4511-2012		NATIONAL INSTITUTE OF NURSING RESEARCH [K22NR007967] Funding Source: NIH RePORTER; NINR NIH HHS [K22-NR07967] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		CORNONIHUNTLEY J, 1986, NIH PUBLICATION; CORNONIHUNTLEY J, NIH PUBLICATION, V2; *FED INT FOR AG RE, 2000, OLD AM 2000 KEY IND; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; Ferrucci L, 1996, J GERONTOL A-BIOL, V51, pM123, DOI 10.1093/gerona/51A.3.M123; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Glaser B., 1968, TIME DYING, DOI DOI 10.1097/00000446-196812000-00048; GURALNIK JM, 1991, AM J PUBLIC HEALTH, V81, P443, DOI 10.2105/AJPH.81.4.443; Guralnik JM, 2001, J AM GERIATR SOC, V49, pS12; Haan MN, 1997, J AM GERIATR SOC, V45, P667, DOI 10.1111/j.1532-5415.1997.tb01468.x; *I MED, 1997, APPR DEATH IMPR CAR; LAWTON MP, 1990, MILBANK Q, V68, P1, DOI 10.2307/3350075; Lunney JR, 2002, J AM GERIATR SOC, V50, P1108, DOI 10.1046/j.1532-5415.2002.50268.x; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Magaziner J, 2000, J GERONTOL A-BIOL, V55, pM498, DOI 10.1093/gerona/55.9.M498; MCNEIL J, 2001, AM DISABILITIES 1997; Minino A M, 2001, Natl Vital Stat Rep, V49, P1; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; VERBRUGGE LM, 1994, J HEALTH SOC BEHAV, V35, P97, DOI 10.2307/2137359; Visser M, 1998, AM J CLIN NUTR, V68, P584, DOI 10.1093/ajcn/68.3.584; Wolinsky FD, 1997, MED CARE, V35, P1031, DOI 10.1097/00005650-199710000-00005; Wolinsky FD, 1998, J GERONTOL B-PSYCHOL, V53, pS336, DOI 10.1093/geronb/53B.6.S336; Wolinsky FD, 1996, J AGING HEALTH, V8, P155, DOI 10.1177/089826439600800201	23	821	829	1	61	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2387	2392		10.1001/jama.289.18.2387	http://dx.doi.org/10.1001/jama.289.18.2387			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	677WF	12746362	Bronze			2023-01-03	WOS:000182831200028
J	Lucas, G; Hendolin, P; Harkany, T; Agerman, K; Paratcha, G; Holmgren, C; Zilberter, Y; Sairanen, M; Minichiello, L; Castren, E; Ernfors, P				Lucas, G; Hendolin, P; Harkany, T; Agerman, K; Paratcha, G; Holmgren, C; Zilberter, Y; Sairanen, M; Minichiello, L; Castren, E; Ernfors, P			Neurotrophin-4 mediated TrkB activation reinforces morphine-induced analgesia	NATURE NEUROSCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; AUTOPHOSPHORYLATION SITES; TYROSINE PHOSPHORYLATION; RECEPTORS; LOCALIZATION; EFFICACY; NEURONS; KINASE; RAT		Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Univ Kuopio, Dept Neurobiol, AI Virtanen Inst, FIN-70211 Kuopio, Finland; European Mol Biol Lab, I-00016 Monterotondo, Rome, Italy	Karolinska Institutet; Karolinska Institutet; University of Eastern Finland; European Molecular Biology Laboratory (EMBL)	Ernfors, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.		Lucas, Guilherme/N-8827-2014; Castrén, Eero/A-4618-2010; Minichiello, Liliana/AAA-7190-2022	Lucas, Guilherme/0000-0002-1656-9571; Ernfors, Patrik/0000-0002-1140-3986; Paratcha, Gustavo/0000-0002-0804-4433; Castren, Eero/0000-0002-1402-2791				Appleyard SM, 2000, J BIOL CHEM, V275, P38281, DOI 10.1074/jbc.M006756200; Ding YQ, 1996, J COMP NEUROL, V367, P375; GUITON M, 1995, BIOCHEM SOC T, V23, pS176, DOI 10.1042/bst023176s; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; McLaughlin JP, 2001, MOL PHARMACOL, V59, P1360, DOI 10.1124/mol.59.6.1360; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; Minichiello L, 1998, NEURON, V21, P335, DOI 10.1016/S0896-6273(00)80543-7; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Saarelainen T, 2000, MOL CELL NEUROSCI, V16, P87, DOI 10.1006/mcne.2000.0863; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; SIUCIAK JA, 1994, BRAIN RES, V633, P326, DOI 10.1016/0006-8993(94)91556-3; Yan Q, 1997, J COMP NEUROL, V378, P135	14	16	16	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1097-6256			NAT NEUROSCI	Nat. Neurosci.	MAR	2003	6	3					221	222		10.1038/nn1021	http://dx.doi.org/10.1038/nn1021			2	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	648YB	12601381				2023-01-03	WOS:000181178300009
J	Hope, MD				Hope, MD			Pain and forgetting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Hope, MD (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	2003	289	5					617	617		10.1001/jama.289.5.617	http://dx.doi.org/10.1001/jama.289.5.617			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642CV	12578502	Bronze			2023-01-03	WOS:000180787500036
J	Bonetti, A				Bonetti, A			Hepatic artery infusion for liver metastases from colorectal cancer	LANCET			English	Editorial Material							5-FLUOROURACIL; LEUCOVORIN		ASL 21 Reg Veneto Osped Legnago, Dept Oncol, I-37045 Legnago, VR, Italy	ULSS 9 Scaligera; Ospedale Mater Salutis di Legnago	Bonetti, A (corresponding author), ASL 21 Reg Veneto Osped Legnago, Dept Oncol, I-37045 Legnago, VR, Italy.		Bonetti, Andrea/AAL-6623-2020	BONETTI, Andrea/0000-0003-2329-6628				ACKERMAN NB, 1974, SURGERY, V75, P589; Buyse M, 1996, J NATL CANCER I, V88, P252; ENSMINGER WD, 1978, CANCER RES, V38, P3784; Estey E, 1997, CLIN CANCER RES, V3, P2591; Giacchetti S, 1999, ANN ONCOL, V10, P663, DOI 10.1023/A:1008347829017; GROTHEY A, 2002, P AN M AM SOC CLIN, V21, P512; Kemeny N, 2001, J CLIN ONCOL, V19, P2687, DOI 10.1200/JCO.2001.19.10.2687; Lorenz M, 2000, J CLIN ONCOL, V18, P243, DOI 10.1200/JCO.2000.18.2.243; Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X; SALTZ LB, 2000, P ASCO, V19, P242; THERNEAU TM, 1993, CONTROL CLIN TRIALS, V14, P98, DOI 10.1016/0197-2456(93)90013-4	11	11	12	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 1	2003	361	9355					358	359		10.1016/S0140-6736(03)12439-7	http://dx.doi.org/10.1016/S0140-6736(03)12439-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642CP	12573366				2023-01-03	WOS:000180787000002
J	Shelke, RRJ; Leeuwenburgh, C				Shelke, RRJ; Leeuwenburgh, C			Life-long calorie restriction (CR) increases expression of apoptosis repressor with a caspase recruitment domain (ARC) in the brain	FASEB JOURNAL			English	Article						oxidative stress; Bcl-2 family; cytochrome c; mitochondria.	HUMAN SUBSTANTIA-NIGRA; DIETARY RESTRICTION; SKELETAL-MUSCLE; CYTOCHROME-C; OXIDATIVE-STRESS; MITOCHONDRIA; RELEASE; NEURONS; HEART; ACTIVATION	Aging may increase apoptotic events and the susceptibility of the central nervous system to apoptosis. Calorie restriction has been shown to have neuroprotective effects, but the mechanisms in vivo are unknown. We investigated apoptosis and apoptotic regulatory proteins in the brain frontal cortex of 12-month-old ad libitum fed, 26-month-old ad libitum fed, and 26-month-old calorie-restricted (CR) male Fischer 344 rats (CR = 40% restricted compared to ad libitum). We found that specific DNA fragmentation indicative of apoptosis was increased with age (+124%) in the cortices of the brain and that calorie restriction attenuated this increase significantly (-36%). We determined levels of ARC (apoptosis repressor with a caspase recruitment domain), which inhibits caspase-2 activity and also attenuates cytochrome c release from the mitochondria. We found a significant age-associated decline in ARC level, which was attenuated in the brains of the CR rats. In accordance with the changes in ARC expression observed, calorie restriction attenuated the increases in cytosolic cytochrome c and caspase-2 activity with age and suppressed the age-associated rise in cleaved caspase-9 and cleaved caspase-3. However, neither age nor calorie restriction had any effect on caspase-3 and caspase-9 activities. This data provides evidence for an increased incidence of apoptosis in rat brain with age and evidence that calorie restriction has the ability to attenuate this. Furthermore, our data suggest that calorie restriction provides neuroprotection through ARC by suppressing cytochrome c release and caspase-2 activity.	Univ Florida, Coll Hlth & Human Performance, Biochem Aging Lab, FLG 25, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Leeuwenburgh, C (corresponding author), Univ Florida, Coll Hlth & Human Performance, Biochem Aging Lab, FLG 25, Stadium Rd,POB 118206, Gainesville, FL 32611 USA.	cleeuwen@ufl.edu		Leeuwenburgh, Christiaan/0000-0003-0826-4257				Adams SM, 2001, BIOMARKERS, V6, P1, DOI 10.1080/135475001452724; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLEMAN PD, 1987, NEUROBIOL AGING, V8, P521, DOI 10.1016/0197-4580(87)90127-8; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dirks A, 2002, AM J PHYSIOL-REG I, V282, pR519, DOI 10.1152/ajpregu.00458.2001; Drew B, 2002, ANN NY ACAD SCI, V959, P66, DOI 10.1111/j.1749-6632.2002.tb02084.x; Ekhterae D, 1999, CIRC RES, V85, pE70; Engidawork E, 2001, BIOCHEM BIOPH RES CO, V281, P84, DOI 10.1006/bbrc.2001.4306; Floyd RA, 2000, ADV RES NEURODEGENER, V8, P387; Floyd RA, 2000, ANN NY ACAD SCI, V899, P222; GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gulesserian T, 2001, J NEURAL TRANSM-SUPP, P163; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Ingram DK, 2001, ANN NY ACAD SCI, V928, P316; Itoh K, 1996, NEUROBIOL AGING, V17, P843, DOI 10.1016/S0197-4580(96)00168-6; Kajstura J, 1996, AM J PHYSIOL-HEART C, V271, pH1215, DOI 10.1152/ajpheart.1996.271.3.H1215; Kaufmann JA, 2001, J NEUROCHEM, V76, P1099, DOI 10.1046/j.1471-4159.2001.00118.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Kretsch MJ, 1997, INT J OBESITY, V21, P14, DOI 10.1038/sj.ijo.0800353; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Lee BJ, 2001, MATER RES INNOV, V4, P97, DOI 10.1007/PL00010786; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mattson MP, 2002, AGEING RES REV, V1, P155, DOI 10.1016/S1568-1637(01)00003-4; Mayhew M, 1998, BIOCHEM BIOPH RES CO, V251, P95, DOI 10.1006/bbrc.1998.9438; MEANS LW, 1993, PHYSIOL BEHAV, V54, P503, DOI 10.1016/0031-9384(93)90243-9; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Numata T, 2002, BIOCHEM BIOPH RES CO, V297, P517, DOI 10.1016/S0006-291X(02)02155-1; Pahlavani MA, 2000, P SOC EXP BIOL MED, V223, P163, DOI 10.1046/j.1525-1373.2000.22322.x; Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x; Pollack M, 2001, J GERONTOL A-BIOL, V56, pB475, DOI 10.1093/gerona/56.11.B475; Pollack M, 1999, HDB OXIDANTS ANTIOXI, P881; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Renganathan M, 1998, FEBS LETT, V434, P346, DOI 10.1016/S0014-5793(98)01009-6; Sayre LM, 2001, CURR MED CHEM, V8, P721, DOI 10.2174/0929867013372922; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; SOHAL RS, 1992, MUTAT RES, V275, P295, DOI 10.1016/0921-8734(92)90033-L; SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Spaulding CC, 1997, MECH AGEING DEV, V93, P87, DOI 10.1016/S0047-6374(96)01824-6; Strasser H, 2000, J UROLOGY, V164, P1781, DOI 10.1016/S0022-5347(05)67106-6; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Suzuki Y, 2000, EXP NEUROL, V165, P35, DOI 10.1006/exnr.2000.7465; Viel JJ, 2001, J NEUROSCI RES, V64, P454, DOI 10.1002/jnr.1097; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Weindruch R., 1988, RETARDATION AGING DI; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	55	48	49	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					494	+		10.1096/fj.02-0803fje	http://dx.doi.org/10.1096/fj.02-0803fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514107				2023-01-03	WOS:000181453700027
J	Agrawal, M; Emanuel, EJ				Agrawal, M; Emanuel, EJ			Death and dignity: dogma disputed	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; OF-LIFE; ILL PATIENTS; CARE; QUALITY; END		NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Agrawal, M (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA.							ABIVEN M, 1991, World Health Forum, V12, P375; ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; Chochinov HM, 2002, SOC SCI MED, V54, P433, DOI 10.1016/S0277-9536(01)00084-3; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 2002, ARCH INTERN MED, V162, P142, DOI 10.1001/archinte.162.2.142; *I MED, 1997, APPR DEATH IMPR CARE; Jordhoy MS, 2001, J CLIN ONCOL, V19, P3884, DOI 10.1200/JCO.2001.19.18.3884; KANE RL, 1984, LANCET, V1, P890; Lynn J, 1997, J AM GERIATR SOC, V45, P526; MADAN TN, 1992, SOC SCI MED, V35, P425, DOI 10.1016/0277-9536(92)90335-N; Payne SA, 1996, PALLIATIVE MED, V10, P307, DOI 10.1177/026921639601000406; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser Karen E, 2002, J Palliat Med, V5, P407, DOI 10.1089/109662102320135298; Weiss SC, 2001, LANCET, V357, P1311, DOI 10.1016/S0140-6736(00)04515-3	18	6	6	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 21	2002	360	9350					1997	1998		10.1016/S0140-6736(02)12031-9	http://dx.doi.org/10.1016/S0140-6736(02)12031-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	628CH	12504390				2023-01-03	WOS:000179974200003
J	Chochinov, HM; Hack, T; Hassard, T; Kristjanson, LJ; McClement, S; Harlos, M				Chochinov, HM; Hack, T; Hassard, T; Kristjanson, LJ; McClement, S; Harlos, M			Dignity in the terminally ill: a cross-sectional, cohort study	LANCET			English	Article							PHYSICIAN-ASSISTED SUICIDE; CANCER-PATIENTS; EUTHANASIA; EXPERIENCES; DEPRESSION; ATTITUDES; ILLNESS; OREGON; DEATH; LIFE	Background Considerations of dignity are often raised in reference to the care of dying patients. However, little research that addresses this issue has been done. Our aim was to identify the extent to which dying patients perceive they are able to maintain a sense of dignity, and to ascertain how demographic and disease-specific variables relate to the issue of dignity in these individuals. Methods We did a cross-sectional study of a cohort of terminally ill patients with cancer, who had a life expectancy of less than 6 months. We enrolled 213 patients from two palliative care units in Winnipeg, Canada, and asked them to rate their sense of dignity. Our main outcome measures included: a 7-point sense of dignity item; the symptom distress scale; the McGill pain questionnaire; the index of independence in activities of daily living (IADL); a quality of life scale; a brief battery of self-report measures, including screening for desire for death, anxiety, hopelessness, and will to live; burden to others; and requirement for social support. Findings 16 of 213 patients (7.5%; 95% Cl 4-11) indicated that loss of dignity was a great concern. These patients were far more than likely than the rest of the cohort to report psychological distress and symptom distress, heightened dependency needs, and loss of will to live. Interpretation Loss of dignity is closely associated with certain types of distress often seen among the terminally ill. Preservation of dignity should be an overall aim of treatment and care in patients who are nearing death.	Univ Manitoba, Dept Psychiat, Winnipeg, MB R3E 3N4, Canada; Univ Manitoba, Fac Nursing, Winnipeg, MB R3E 3N4, Canada; CancerCare Manitoba, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada; Edith Cowan Univ, Perth, WA, Australia	University of Manitoba; University of Manitoba; CancerCare Manitoba Foundation; University of Manitoba; Children's Hospital Research Institute of Manitoba; Edith Cowan University	Chochinov, HM (corresponding author), Univ Manitoba, Dept Psychiat, Winnipeg, MB R3E 3N4, Canada.	chochin@cc.UManitoba.CA	Hack, Thomas/C-5174-2012; McClement, Susan E/H-7031-2016	Hack, Thomas/0000-0002-6913-8732; McClement, Susan E/0000-0002-9537-9900; Chochinov, Harvey/0000-0003-2656-4704				Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BRORSSON B, 1984, SCAND J REHABIL MED, V16, P125; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Chochinov HM, 2000, PSYCHOSOMATICS, V41, P500, DOI 10.1176/appi.psy.41.6.500; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; Chochinov HM, 1998, PSYCHOSOMATICS, V39, P366, DOI 10.1016/S0033-3182(98)71325-8; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; Chochinov HM, 2002, SOC SCI MED, V54, P433, DOI 10.1016/S0277-9536(01)00084-3; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; CRAIG TJ, 1974, AM J PSYCHIAT, V131, P1323; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; GRAHAM KY, 1987, CANCER NURS, V10, P338; KATHOL RG, 1990, PSYCHOSOMATICS, V31, P434, DOI 10.1016/S0033-3182(90)72140-8; LEVINE PM, 1978, CANCER, V42, P1385, DOI 10.1002/1097-0142(197809)42:3<1385::AID-CNCR2820420349>3.0.CO;2-0; MADAN TN, 1992, SOC SCI MED, V35, P425, DOI 10.1016/0277-9536(92)90335-N; McCorkle R, 1978, Cancer Nurs, V1, P373; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; NOYES R, 1990, PSYCHOSOMATICS, V31, P321, DOI 10.1016/S0033-3182(90)72170-6; Pannuti F, 1993, World Health Forum, V14, P172; Pullman D, 1996, Health Law J, V4, P197; Quill TE, 2000, ANN INTERN MED, V132, P488, DOI 10.7326/0003-4819-132-6-200003210-00011; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Wilson KG, 2000, ARCH INTERN MED, V160, P2454, DOI 10.1001/archinte.160.16.2454	29	246	257	3	40	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	2002	360	9350					2026	2030		10.1016/S0140-6736(02)12022-8	http://dx.doi.org/10.1016/S0140-6736(02)12022-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	628CH	12504398				2023-01-03	WOS:000179974200010
J	Eisenberg, DM; Cohen, MH; Hrbek, A; Grayzel, J; Van Rompay, MI; Cooper, RA				Eisenberg, DM; Cohen, MH; Hrbek, A; Grayzel, J; Van Rompay, MI; Cooper, RA			Credentialing complementary and alternative medical providers	ANNALS OF INTERNAL MEDICINE			English	Article							NONPHYSICIAN CLINICIAN; UNITED-STATES; THERAPIES; CARE; HOMEOPATHY; TRENDS	Since the late 19th century, state legislatures and professional medical organizations have developed mechanisms to license physicians and other conventional nonphysician providers, establish standards of practice, and protect health care consumers by establishing standardized credentials as markers of competence. The popularity of complementary and alternative medical (CAM) therapies presents new challenges. This article describes the current status of, and central issues in, efforts to create models for health care credentialing of chiropractors, acupuncturists, naturopaths, massage therapists, and other CAM practitioners. It also suggests a strategy of CAM provider credentialing for use by physicians, health care administrators, insurance companies, and national professional organizations. The credentialing debate reflects fundamental questions about who determines which providers and therapies will be accepted as safe, effective, appropriate, and reimbursable. More nationally uniform credentialing mechanisms are necessary to ensure high standards of care and more generalizable clinical research. However, the result of more uniform licensure and credentialing may be excessive standardization and a decrease in individualization of services. Thus, increased standardization of credentialing for CAM practitioners may alter CAM practice substantially. Furthermore, even credentialed providers can deliver ineffective therapy. The suggested framework balances the desire to protect the public from dangerous practices against the wish to grant patients access to reasonably safe and effective therapies.	Harvard Univ, Sch Med, Osher Inst, Div Res & Educ Complementary & Integrat Med Therap, Boston, MA 02215 USA; Univ Massachusetts, Med Ctr, Worcester, MA 01655 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Medical College of Wisconsin	Eisenberg, DM (corresponding author), Harvard Univ, Sch Med, Osher Inst, Div Res & Educ Complementary & Integrat Med Therap, Suite 22A,401 Pk Dr, Boston, MA 02215 USA.	Osher_Institute@hms.harvard.edu	Van Rompay, Maria/G-9452-2012		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NCCIH NIH HHS [AT00144] Funding Source: Medline; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams KE, 2002, ANN INTERN MED, V137, P660, DOI 10.7326/0003-4819-137-8-200210150-00010; *AM ASS NAT PHYS, 1998, NAT MED WHAT IT IS W; *AM ASS NAT PHYS, 1989, 20 QUEST NAT MED; *AM ASS NAT PHYS, 1997, MEMB RES DIR; *AM CHIR ASS, 2002, HOT TOP; *AM MASS THER ASS, 2002, DEM MASS THER; [Anonymous], 2000, LANCET, V356, P2023; CHAPMAN EH, 1997, J AM I HOMEOPATH, V90, P5; COHEN M, 2000, COMPLEMENTARY MED LE; Cohen MH, 2002, ANN INTERN MED, V136, P596, DOI 10.7326/0003-4819-136-8-200204160-00009; Cohen Michael, 1998, COMPLEMENTARY ALTERN; Cooper RA, 1996, HEALTH AFFAIR, V15, P226, DOI 10.1377/hlthaff.15.3.226; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P788, DOI 10.1001/jama.280.9.788; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P795, DOI 10.1001/jama.280.9.795; COOPER RA, IN PRESS MILLBANK Q; Diehl D L, 1997, J Altern Complement Med, V3, P119, DOI 10.1089/acm.1997.3.119; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ELLISON MS, 1999, PHYSICIANS FINANCE S, V17, pS30; Ernst E, 2002, ANN INTERN MED, V136, P42, DOI 10.7326/0003-4819-136-1-200201010-00010; Goldman P, 2001, ANN INTERN MED, V135, P594, DOI 10.7326/0003-4819-135-8_Part_1-200110160-00010; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; Leake R, 1999, ALTERN THER HEALTH M, V5, P94; Lee ACC, 2000, ARCH PEDIAT ADOL MED, V154, P75; MITCHELL BB, 2001, ACUPUNCTURE ORIENTAL; MITCHELL BB, 1998, LEGISLATIVE UPDATE F; O'Neale J, 2000, BRIT MED J, V321, P1365, DOI 10.1136/bmj.321.7273.1365; ROBBINS DA, 2000, MANAGED HEALTHCARE, P38; Ullman D, 1999, J ALTERN COMPLEM MED, V5, P65, DOI 10.1089/acm.1999.5.65; ULLMAN D, 1995, CONSUMERS GUIDE HOME; WEEKS J, 1998, CHALLENGES CREDENTIA, P2; 1997, OFFICIAL DIRECTORY C; 1998, DICT HLTH CARE TERMS, P59; 1998, DICT HLTH CARE TERMS, P46; 1998, DICT HLTH CARE TERMS, P211; 2002, NCCAOM CERTIFICATION	35	90	91	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 17	2002	137	12					965	973		10.7326/0003-4819-137-12-200212170-00010	http://dx.doi.org/10.7326/0003-4819-137-12-200212170-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	626DR	12484712				2023-01-03	WOS:000179857500005
J	Fromm, RE; Weltge, A; Varon, J				Fromm, RE; Weltge, A; Varon, J			Public use of automatic defibrillators: a bolt from the blue	LANCET			English	Editorial Material									Univ Texas, Hlth Sci Ctr, Dept Emergency Med, Houston, TX 77225 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine	Fromm, RE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Emergency Med, Houston, TX 77225 USA.		Varon, Joseph/R-5198-2019; Varon, Joseph/T-9481-2019	Varon, Joseph/0000-0002-7622-9974				[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P123; Becker LB, 1991, AM J EMERG MED, V20, P335; Bigger JT, 2002, NEW ENGL J MED, V346, P931, DOI 10.1056/NEJMe020011; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; CUMMINS RO, 1984, ANN EMERG MED, V13, P798, DOI 10.1016/S0196-0644(84)80441-2; DIACK AW, 1979, MED INSTRUM, V13, P78; Fromm RE, 1997, RESUSCITATION, V33, P219, DOI 10.1016/S0300-9572(96)01036-2; WALTERS G, 1994, RESUSCITATION, V27, P39, DOI 10.1016/0300-9572(94)90020-5; 2000, CIRCULATION S1, V102, P60	9	0	0	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 30	2002	360	9347					1712	1712		10.1016/S0140-6736(02)11724-7	http://dx.doi.org/10.1016/S0140-6736(02)11724-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622FU	12480420				2023-01-03	WOS:000179636800004
J	Burgio, KL; Goode, PS; Locher, JL; Umlauf, MG; Roth, DL; Richter, HE; Varner, RE; Lloyd, LK				Burgio, KL; Goode, PS; Locher, JL; Umlauf, MG; Roth, DL; Richter, HE; Varner, RE; Lloyd, LK			Behavioral training with and without biofeedback in the treatment of urge incontinence in older women - A Randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-INCONTINENCE; BLADDER; EFFICACY	Context Previous research on urge urinary incontinence has demonstrated that multicomponent behavioral training with biofeedback is safe and effective, yet it has not been established whether biofeedback is an essential component that heightens therapeutic efficacy. Objective To examine the role of biofeedback in a multicomponent behavioral training program for urge incontinence in community-dwelling older women. Design Prospective, randomized controlled trial conducted from April 1, 1995, to March 30, 2001. Setting University-based outpatient continence clinic in the United States. Patients A volunteer sample of 222 ambulatory, nondemented, community-dwelling women aged 55 to 92 years with urge incontinence or mixed incontinence with urge as the predominant pattern. Patients were stratified by race, type of incontinence (urge only vs mixed), and severity (frequency of accidents). Interventions Patients were randomly assigned to receive 8 weeks (4 visits) of bio-feedback-assisted behavioral training (n=73), 8 weeks (4 visits) of behavioral training fee without biofeedback (verbal feedback based on vaginal palpation; n=74), or 8 weeks, of self-administered behavioral treatment using a self-help booklet (control condition; n=75). Main Outcome Measures Reduction in the number of incontinence episodes as documented in bladder diaries, patients' perceptions and satisfaction, and changes in quality of life. Results Intention-to-treat analysis showed that behavioral training with biofeedback yielded a mean 63.1% reduction (SD, 42.7%) in incontinence, verbal feedback a mean 69.4% reduction (SD; 32.7%), and the self-help booklet a mean 58.6% reduction (SD, 38.8%). The 3 groups were not significantly different from each other (P=.23). The groups differed significantly regarding patient satisfaction: 75.0% of the biofeedback group, 85.5% of the verbal feedback group, and 55.7% of the self-help booklet group reported being completely satisfied with treatment (P=.001). Significant improvements were seen across all 3 groups on 3 quality-of-life instruments, with no significant between-group differences. Conclusions Biofeedback to teach pelvic floor muscle control, verbal feedback based on vaginal palpation, and a self-help booklet in a first-line behavioral training program all;achieved comparable improvements in urge incontinence in community-dwelling older women. Patients' perceptions of treatment were significantly better for the 2 behavioral training interventions.	Dept Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA; Univ Alabama, Sch Med, Birmingham, AL USA; Univ Alabama, Ctr Aging, Birmingham, AL USA; Univ Alabama, Sch Nursing, Birmingham, AL USA; Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA	Geriatric Research Education & Clinical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Burgio, KL (corresponding author), Birmingham Vet Affairs Med Ctr, GRECC-11G,700 19th St S, Birmingham, AL 35233 USA.		Umlauf, Mary Grace/A-5021-2015	Locher, Julie/0000-0002-2639-6459; Richter, Holly E/0000-0001-7741-5771	NATIONAL INSTITUTE ON AGING [R01AG008010] Funding Source: NIH RePORTER; NIA NIH HHS [AG R0108010] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAIGISSMITH J, 1989, GERONTOLOGIST, V29, P229, DOI 10.1093/geront/29.2.229; Berghmans LCM, 1996, NEUROUROL URODYNAM, V15, P37, DOI 10.1002/(SICI)1520-6777(1996)15:1<37::AID-NAU4>3.0.CO;2-G; BUMP RC, 1993, OBSTET GYNECOL, V81, P421; BURGIO KL, 1985, ANN INTERN MED, V103, P507, DOI 10.7326/0003-4819-103-4-507; BURGIO KL, 1986, AM J OBSTET GYNECOL, V154, P58; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; BURGIO KL, 1989, J UROLOGY, V141, P303, DOI 10.1016/S0022-5347(17)40747-6; Burgio KL, 1989, STAYING DRY PRACTICA; BURTON JR, 1988, J AM GERIATR SOC, V36, P693, DOI 10.1111/j.1532-5415.1988.tb07170.x; CARDOZO LD, 1978, BRIT J UROL, V50, P521, DOI 10.1111/j.1464-410X.1978.tb06204.x; Derogatis L.R, 1983, SCL 90 R ADM SCORING, VII; DIOKNO AC, 1986, J UROLOGY, V136, P1022; Elser DM, 1999, NEUROUROL URODYNAM, V18, P427, DOI 10.1002/(SICI)1520-6777(1999)18:5<427::AID-NAU3>3.0.CO;2-0; ENGEL BT, 1974, NEW ENGL J MED, V290, P646, DOI 10.1056/NEJM197403212901202; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Howard D, 2000, OBSTET GYNECOL, V96, P622, DOI 10.1016/S0029-7844(00)00956-X; Hunskaar S, 2000, INT UROGYNECOL J, V11, P301, DOI 10.1007/s001920070021; Locher JL, 2001, J GERONTOL A-BIOL, V56, pM32, DOI 10.1093/gerona/56.1.M32; Shepherd A M, 1983, Physiotherapy, V69, P113; SHUMAKER SA, 1994, QUAL LIFE RES, V3, P291, DOI 10.1007/BF00451721; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wein AJ, 1998, UROLOGY, V51, P43, DOI 10.1016/S0090-4295(98)90009-7; [No title captured]	24	190	191	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2293	2299		10.1001/jama.288.18.2293	http://dx.doi.org/10.1001/jama.288.18.2293			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425706	Bronze			2023-01-03	WOS:000179186400028
J	Wells, AW; Mounter, PJ; Chapman, CE; Stainsby, D; Wallis, JP				Wells, AW; Mounter, PJ; Chapman, CE; Stainsby, D; Wallis, JP			Where does blood go? Prospective observational study of red cell transfusion in north England	BRITISH MEDICAL JOURNAL			English	Article							HOSPITALS	Objective To collect population based information on transfusion of red blood cells. Design Prospective observational study over 28 days. Setting Hospital blood banks in the north of England (population 2.9 million). Main outcome measures Indications for transfusion, number of units given, and the age and sex of transfusion recipients. Participants All patients who received a red cell transfusion during the study period. Data completed by hospital blood bank staff. Results The destination of 9848 units was recorded (97% of expected blood use). In total 9774 units were transfused: 5047 (51.6%) units were given to medical patients, 3982 (40.7%) to surgical patients, and 612 (6.3%) to obstetric and gynaecology patients. Nearly half (49.3%) of all blood is given to female recipients, and the mean age of recipients of individual units was 62.7 years. The most common surgical indications for transfusion were total hip replacement (4.6% of all blood transfused) and coronary artery bypass grafting (4.1%). Haematological disorders accounted for 15.5% of use. Overall use was 4274 units per 100 000 population per year. Conclusion In the north east of England more than half of red cell units are transfused for medical indications. Demand for red cell transfusion increases with age. With anticipated changes in the age structure of the population the demand for blood will increase by 4.9% by 2008.	Freeman Rd Hosp, Newcastle Tyne Hosp NHS Trust, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Newcastle Ctr, Natl Blood Serv, Newcastle Upon Tyne NE2 4NQ, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Wallis, JP (corresponding author), Freeman Rd Hosp, Newcastle Tyne Hosp NHS Trust, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.							Barrett-Lee PJ, 2000, BRIT J CANCER, V82, P93, DOI 10.1054/bjoc.1999.0883; Chapman J., 2001, British Journal of Haematology, V113, P58; Charlton BG, 1997, QJM-MON J ASSOC PHYS, V90, P147, DOI 10.1093/qjmed/90.2.147; Chiavetta JA, 1996, TRANSFUSION, V36, P699, DOI 10.1046/j.1537-2995.1996.36896374373.x; COOK SS, 1991, TRANSFUSION, V31, P355, DOI 10.1046/j.1537-2995.1991.31491213303.x; Mathoulin-Pelissier S, 2000, TRANSFUSION, V40, P1140, DOI 10.1046/j.1537-2995.2000.40091140.x; *NHS EX, 1998, 1998224 NHS EX HSC; SIRCHIA G, 1994, TRANSFUSION MED, V4, P251; Stover EP, 1998, ANESTHESIOLOGY, V88, P327, DOI 10.1097/00000542-199802000-00009; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; VAMVAKAS EC, 1994, TRANSFUSION, V34, P464, DOI 10.1046/j.1537-2995.1994.34694295059.x; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; WALLIS JP, 2000, TRANSFUSION MED, V10, P15	13	165	169	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 12	2002	325	7368					803	U7		10.1136/bmj.325.7368.803	http://dx.doi.org/10.1136/bmj.325.7368.803			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376439	Green Published, Bronze			2023-01-03	WOS:000178648700016
J	Stewart, KJ				Stewart, KJ			Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension - Plausible mechanisms for improving cardiovascular health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LEFT-VENTRICULAR FUNCTION; BODY-FAT DISTRIBUTION; C-REACTIVE PROTEIN; NITRIC-OXIDE SYNTHESIS; BLOOD-PRESSURE; DIASTOLIC DYSFUNCTION; AEROBIC EXERCISE; ARTERIAL STIFFNESS; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY	The coexistence of type 2 diabetes and hypertension is especially damaging to cardiovascular health. Most trials of exercise training for these conditions have focused on glycemic control and blood pressure reduction. Less is known about the effects of exercise on the cardiovascular consequences of diabetes and hypertension. This article reviews the available evidence and plausible mechanisms by which exercise training may improve the cardiovascular health of persons with type 2 diabetes and hypertension and provides practical guidelines for exercise prescription. A MEDLINE search was performed for January 1985 to June 2002. Bibliographies from relevant articles, professional society clinical practice guidelines, and books were also reviewed. Because few large, randomized trials exist on these topics, meta-analyses, smaller trials, nonrandomized trials, and animal studies were also considered. Data quality was determined by publication in peer-reviewed journals or professional society literature. Type 2 diabetes and hypertension result in abnormalities in central and peripheral parameters of cardiovascular structure and function. Evidence for an exercise training benefit is strongest for improvements in endothelial vasodilator function and left ventricular diastolic function. The data for exercise training's improvement of arterial stiffness and system inflammation and reduction of left ventricular mass are less robust. However, this assertion is based more on a lack of randomized controlled trials rather than data to the contrary. Exercise training also reduces total and abdominal fat. These changes in body composition mediate improvements in insulin sensitivity and blood pressure and may improve endothelial vasodilator function. The current evidence, albeit not fully confirmed in randomized trials, suggests that the benefits of exercise training go beyond the recognized benefits of glycemic control and blood pressure reduction.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA	Johns Hopkins University	Stewart, KJ (corresponding author), Johns Hopkins Bayview Med Ctr, Johns Hopkins Heart Hlth, 4940 Eastern Ave, Baltimore, MD 21224 USA.	kstewart@mail.jhmi.edu						Abete P, 2000, J AM COLL CARDIOL, V36, P643, DOI 10.1016/S0735-1097(00)00722-1; Abramson JL, 2002, HYPERTENSION, V39, P197, DOI 10.1161/hy0202.104270; ACSM, 2000, GUID EX TEST PRESCR; Adamopoulos S, 2001, EUR HEART J, V22, P791, DOI 10.1053/euhj.2000.2285; Aiello LP, 2002, HDB EXERCISE DIABETE, P401; Albright A, 2000, MED SCI SPORT EXER, V32, P1345; *AM DIAB ASS, 2002, DIABETES CARE S1, V52, pS64; American College of Sports Medicine, 1993, MED SCI SPORTS EXERC, V25, pi, DOI DOI 10.1249/00005768-199310000-00024; American Diabetes Association, 2002, DIABETES CARE, V25, ps64; Arad Y, 2001, ARTERIOSCL THROM VAS, V21, P2051, DOI 10.1161/hq1201.100257; Arcaro G, 1999, INT J OBESITY, V23, P936, DOI 10.1038/sj.ijo.0801022; BADENHOP DT, 2001, CLIN EXERCISE PHYSL, V3, P71; Baron AD, 1999, AM J CARDIOL, V84, p25J; BELJIC T, 1994, ACTA DIABETOL, V31, P147, DOI 10.1007/BF00570369; Berger M, 2002, HDB EXERCISE DIABETE, P365; BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; Boule NG, 2001, JAMA-J AM MED ASSOC, V286, P1218, DOI 10.1001/jama.286.10.1218; Brenner DA, 2001, CIRCULATION, V104, P221, DOI 10.1161/01.CIR.104.2.221; Brubaker P. H, 2002, CORONARY ARTERY DIS; BRUSH JE, 1992, J AM COLL CARDIOL, V19, P809, DOI 10.1016/0735-1097(92)90522-O; Caballero AE, 1999, DIABETES, V48, P1856, DOI 10.2337/diabetes.48.9.1856; Chae CU, 2001, HYPERTENSION, V38, P399, DOI 10.1161/01.HYP.38.3.399; Chipkin Stuart R., 2001, Cardiology Clinics, V19, P489, DOI 10.1016/S0733-8651(05)70231-9; Clarkson P, 1996, J AM COLL CARDIOL, V28, P573, DOI 10.1016/0735-1097(96)82380-1; Cockcroft JR, 2000, J HUM HYPERTENS, V14, P377, DOI 10.1038/sj.jhh.1001023; DEFRONZO RA, 1920, J CARDIOVASC PHA S11, V20, pS1; DESPRES JP, 1991, AM J PHYSIOL, V261, pE159, DOI 10.1152/ajpendo.1991.261.2.E159; DESPRES JP, 1993, NUTRITION, V9, P452; Devereux RB, 2000, CIRCULATION, V101, P2271, DOI 10.1161/01.CIR.101.19.2271; Duncan B B, 2001, Sao Paulo Med J, V119, P122; Estacio RO, 1998, DIABETES CARE, V21, P291, DOI 10.2337/diacare.21.2.291; Fang TC, 2001, J HYPERTENS, V19, P1255, DOI 10.1097/00004872-200107000-00010; Feigenbaum MS, 1999, MED SCI SPORT EXER, V31, P38, DOI 10.1097/00005768-199901000-00008; Ferrier KE, 2001, HYPERTENSION, V38, P222, DOI 10.1161/01.HYP.38.2.222; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; FORMAN DE, 1992, J GERONTOL, V47, pM56, DOI 10.1093/geronj/47.2.M56; Garvey W T, 1998, Clin Cornerstone, V1, P13, DOI 10.1016/S1098-3597(98)90015-1; Geffken DF, 2001, AM J EPIDEMIOL, V153, P242, DOI 10.1093/aje/153.3.242; GOUGH SCL, 1995, ACTA DIABETOL, V32, P110, DOI 10.1007/BF00569568; Grossman E, 2000, ARCH INTERN MED, V160, P2447, DOI 10.1001/archinte.160.16.2447; Haffner SM, 2000, BRIT J NUTR, V83, pS67; Higashi Y, 1999, HYPERTENSION, V33, P591, DOI 10.1161/01.HYP.33.1.591; Higashi Y, 1999, CIRCULATION, V100, P1194, DOI 10.1161/01.CIR.100.11.1194; HIRAI J, 1992, INTERNAL MED, V31, P725, DOI 10.2169/internalmedicine.31.725; HODES RJ, 1995, J AM GERIATR SOC, V43, P581, DOI 10.1111/j.1532-5415.1995.tb06111.x; HORNSBY WG, 2002, HDB EXERCISE DIABETE, P311; Huang ES, 2001, AM J MED, V111, P633, DOI 10.1016/S0002-9343(01)00978-0; Irace L, 1998, CLIN CARDIOL, V21, P567, DOI 10.1002/clc.4960210807; Jensen-Urstad K, 1999, SCAND J MED SCI SPOR, V9, P88; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; KELEMEN MH, 1990, JAMA-J AM MED ASSOC, V263, P2766, DOI 10.1001/jama.263.20.2766; Kelley DE, 2001, MED SCI SPORT EXER, V33, pS495, DOI 10.1097/00005768-200106001-00020; Kelley G A, 2001, Prev Cardiol, V4, P73, DOI 10.1111/j.1520-037X.2001.00529.x; Kelley GA, 2001, PREV MED, V33, P120, DOI 10.1006/pmed.2001.0860; Kingwell BA, 1998, J HYPERTENS, V16, P181, DOI 10.1097/00004872-199816020-00008; Kuzuya M, 2001, DIABETOLOGIA, V44, P433, DOI 10.1007/s001250051640; LagadicGossmann D, 1996, AM J PHYSIOL-HEART C, V270, pH1529, DOI 10.1152/ajpheart.1996.270.5.H1529; LANGER A, 1991, AM J CARDIOL, V67, P1073, DOI 10.1016/0002-9149(91)90868-L; Lavrencic A, 2000, ARTERIOSCL THROM VAS, V20, P551, DOI 10.1161/01.ATV.20.2.551; LEVY WC, 1993, CIRCULATION, V88, P116, DOI 10.1161/01.CIR.88.1.116; London GM, 1999, J HYPERTENS, V17, pS3; Maiorana A, 2001, J AM COLL CARDIOL, V38, P860, DOI 10.1016/S0735-1097(01)01439-5; Maiorana A, 2001, MED SCI SPORT EXER, V33, P2022, DOI 10.1097/00005768-200112000-00008; Marks JB, 2000, J DIABETES COMPLICAT, V14, P108, DOI 10.1016/S1056-8727(00)00065-9; Mattusch F, 2000, INT J SPORTS MED, V21, P21; MCALLISTER RM, 1995, MED SCI SPORT EXER, V27, P1145; MCVEIGH GE, 1992, DIABETOLOGIA, V35, P771; Missault L H, 1993, Blood Press, V2, P284, DOI 10.3109/08037059309077169; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Morgan CL, 2000, DIABETIC MED, V17, P146, DOI 10.1046/j.1464-5491.2000.00222.x; Mourier A, 1997, DIABETES CARE, V20, P385, DOI 10.2337/diacare.20.3.385; *NAT HIGH BLOOD PR, 1997, PUBL NIH; Osei K, 1999, AM J CARDIOL, V84, p33J; Otis CL, 1997, MED SCI SPORT EXER, V29, pR1, DOI 10.1097/00005768-199705000-00037; Paterick T E, 2001, Cardiol Rev, V9, P282, DOI 10.1097/00045415-200109000-00008; Pi-Sunyer FX, 1999, MED SCI SPORT EXER, V31, pS602, DOI 10.1097/00005768-199911001-00019; Poirier P, 2001, DIABETES CARE, V24, P5, DOI 10.2337/diacare.24.1.5; Poirier P, 2000, AM J CARDIOL, V85, P473, DOI 10.1016/S0002-9149(99)00774-2; Pollock ML, 2000, CIRCULATION, V101, P828, DOI 10.1161/01.CIR.101.7.828; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; RAEV DC, 1994, DIABETES CARE, V17, P633, DOI 10.2337/diacare.17.7.633; Rakowski H, 1996, J Am Soc Echocardiogr, V9, P736, DOI 10.1016/S0894-7317(96)90076-0; Ray NF, 1998, DIABETES CARE, V21, P296; ROBILLON JF, 1994, DIABETES METAB, V20, P473; Rodriguez-Moran M, 2000, ARCH MED RES, V31, P399, DOI 10.1016/S0188-4409(00)00089-8; Ross R, 2000, ANN INTERN MED, V133, P92, DOI 10.7326/0003-4819-133-2-200007180-00008; Ruderman N, 2002, HDB EXERCISE DIABETE, P269; RUDERMAN N, 2002, HDB EXERCISE DIABETE; SACHS R N, 1985, Revue de Medecine Interne, V6, P68, DOI 10.1016/S0248-8663(85)80082-5; Sakamoto S, 1998, DIABETES, V47, P82, DOI 10.2337/diabetes.47.1.82; SALOMAA V, 1995, CIRCULATION, V91, P1432, DOI 10.1161/01.CIR.91.5.1432; Scherrer U, 2000, EUR J ENDOCRINOL, V142, P315, DOI 10.1530/eje.0.1420315; SCHWARTZ RS, 1991, METABOLISM, V40, P545, DOI 10.1016/0026-0495(91)90239-S; SCHWARTZ RS, 1992, METABOLISM, V41, P649, DOI 10.1016/0026-0495(92)90058-I; STERN MP, 1986, ARTERIOSCLEROSIS, V6, P123, DOI 10.1161/01.ATV.6.2.123; STEWART K, 2001, ACSMS RESOURCE MANUA; STEWART KJ, 1990, MED SCI SPORT EXER, V22, P171; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; TAKEMOTO KA, 1992, AM HEART J, V124, P143, DOI 10.1016/0002-8703(92)90932-L; TAKENAKA K, 1988, AM J CARDIOL, V61, P1140, DOI 10.1016/0002-9149(88)90149-X; TARUMI N, 1993, CARDIOLOGY, V83, P316, DOI 10.1159/000175987; Tisi PV, 1997, EUR J VASC ENDOVASC, V14, P344, DOI 10.1016/S1078-5884(97)80283-3; Tomoike H, 1996, DIABETES RES CLIN PR, V30, pS55, DOI 10.1016/S0168-8227(96)80038-6; Turner MJ, 2000, J GERONTOL A-BIOL, V55, pM245, DOI 10.1093/gerona/55.4.M245; UUSITUPA M, 1983, ACTA MED SCAND, V213, P363; UUSITUPA MIJ, 1990, ANN MED, V22, P377, DOI 10.3109/07853899009147274; VAITKEVICIUS PV, 1993, CIRCULATION, V88, P1456, DOI 10.1161/01.CIR.88.4.1456; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006; Williams SB, 1996, J AM COLL CARDIOL, V27, P567, DOI 10.1016/0735-1097(95)00522-6; YAMADA J, 1991, J NUTR SCI VITAMINOL, V37, pS17; Yasuda I, 1992, J Cardiol, V22, P427; Zabalgoitia M, 2001, AM J CARDIOL, V87, P320, DOI 10.1016/S0002-9149(00)01366-7	112	183	188	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1622	1631		10.1001/jama.288.13.1622	http://dx.doi.org/10.1001/jama.288.13.1622			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350193				2023-01-03	WOS:000178314000023
J	Townsend, A; Hunt, K; Wyke, S				Townsend, A; Hunt, K; Wyke, S			Managing multiple morbidity in mid-life: a qualitative study of attitudes to drug use	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PRIMARY-CARE; MEDICATIONS; DECISIONS; MEDICINES	Objective To examine attitudes towards drug use among middle aged respondents with high levels of chronic morbidity. Design Qualitative study with detailed interviews. Setting West of Scotland. Participants 23 men and women aged about 50 years with four or more chronic illnesses. Main outcome measure Participants' feelings about long term use of drugs to manage chronic multiple morbidity. Results Drugs occupied a central place in the way people managed their comorbidities. Respondents expressed an aversion to taking drugs, despite acknowledging that they depended on drugs to live as "normal" a life as possible. Respondents expressed ambivalence to their drugs in various ways. Firstly, they adopted both regular and more flexible regimens and might adhere to a regular regimen in treating one condition (such as hypertension) while adopting a flexible regimen in relation to others, in response to their experience of symptoms or varying demands of their daily life. Secondly, they expressed reluctance to take drugs, but an inability to be free of them. Thirdly, drugs both facilitated performance of social roles and served as evidence of an inability to perform such roles. Conclusions Insight into the considerable tension experienced by people managing complex drug regimens to manage multiple chronic illness may help medical carets to support self care practices among patients and to optimise concordance in their use of prescribed drugs.	Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; NHS Educ Scotland, Scottish Sch Primary Care, Edinburgh EH8 9DR, Midlothian, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; NHS Education for Scotland	Hunt, K (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.			Hunt, Kate/0000-0002-5873-3632				Benson J, 2002, BRIT MED J, V325, P873, DOI 10.1136/bmj.325.7369.873; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; BRITTEN N, 1994, BRIT J GEN PRACT, V44, P465; BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; Britten N, 1996, MODERN MED LAY PERSP, P48; Britten Nicky, 2002, Health Expect, V5, P256, DOI 10.1046/j.1369-6513.2002.00187.x; CONRAD P, 1985, SOC SCI MED, V20, P29, DOI 10.1016/0277-9536(85)90308-9; Corbin J., 1998, BASICS QUALITATIVE R; Department of Health, 2001, EXP PAT NEW APPR CHR; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; FORD G, 1994, SOC SCI MED, V39, P1037, DOI 10.1016/0277-9536(94)90375-1; Haynes RB, 1996, LANCET, V348, P383; HUNT K, 2000, J EPIDEMIOL COMMUNIT, V54, P786; Macintyre S, 1999, SOC SCI MED, V48, P89, DOI 10.1016/S0277-9536(98)00292-5; Macintyre S, 1989, READINGS NEW PUBLIC, P56; Marinker M, 2003, BRIT MED J, V326, P348, DOI 10.1136/bmj.326.7385.348; Morgan M., 1996, MODERN MED LAY PERSP, P95; *OFF NAT STAT, 2000, LIV BRIT RES 1998 GE; Rogers A, 1998, SOC SCI MED, V47, P1313, DOI 10.1016/S0277-9536(98)00209-3; Royal Pharmaceutical Society of Great Britain, 1997, COMPL CONC ACH SHAR; Starfield B, 2001, BRIT J GEN PRACT, V51, P303; VAN DER GEEST SJAAK, 1989, MED ANTHROPOL Q, V3, P345, DOI DOI 10.1525/maq.1989.3.4.02a00030; Wyke Sally, 2003, Eur J Gen Pract, V9, P48	23	118	120	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					837	840		10.1136/bmj.327.7419.837	http://dx.doi.org/10.1136/bmj.327.7419.837			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732BP	14551097	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000185921200017
J	Drazen, JM				Drazen, JM			Decisions at the end of life	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material													Drazen, Jeffrey M/E-5841-2012	Drazen, Jeffrey/0000-0003-2715-9890					0	18	20	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1109	1110		10.1056/NEJMp038146	http://dx.doi.org/10.1056/NEJMp038146			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679523				2023-01-03	WOS:000185369700002
J	Viljanen, M; Malmivaara, A; Uitti, J; Rinne, M; Palmroos, R; Laippala, P				Viljanen, M; Malmivaara, A; Uitti, J; Rinne, M; Palmroos, R; Laippala, P			Effectiveness of dynamic muscle training, relaxation training, or ordinary activity for chronic neck pain: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE	Objective To determine the effectiveness of dynamic muscle training and relaxation training for chronic neck pain. Design Randomised controlled trial. Setting Five occupational healthcare centres, Tampere, Finland. Participants 393 female office workers (mean age 45 years) with chronic non-specific neck pain randomly assigned to 12 weeks of dynamic muscle training (n=135) or relaxation training (n=128), plus one week of reinforcement training six months after baseline; or ordinary activity (control group; n=130). Main outcome measure Change in intensity of neck pain at three, six, and 12 months. Results No significant difference was found in neck pain between the groups at follow up. However, the range of motion for cervical rotation and lateral flexion increased more in the training groups than in the control group. Conclusions Dynamic muscle training and relaxation training do not lead to better improvements in neck pain compared with ordinary activity.	Tampere Reg Inst Occupat Hlth, FIN-33101 Tampere, Finland; Natl Res & Dev Ctr Welf & Hlth, Finnish Off Hlth Technol Assessment, Helsinki, Finland; Kekkonen Inst Hlth Promot Res, Tampere, Finland; Tampere Univ Hosp, Res Unit, Tampere, Finland; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland	Finland National Institute for Health & Welfare; Tampere University; Tampere University Hospital; Tampere University	Viljanen, M (corresponding author), Tampere Reg Inst Occupat Hlth, POB 486, FIN-33101 Tampere, Finland.		salimi, mehdi/D-1192-2009					ALTMAN DG, 1989, STATISTICS CONFIDENC, P20; Borghouts JAJ, 1999, PAIN, V80, P629, DOI 10.1016/S0304-3959(98)00268-1; Borghouts JAJ, 1998, PAIN, V77, P1, DOI 10.1016/S0304-3959(98)00058-X; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; Cote P, 1998, SPINE, V23, P1689, DOI 10.1097/00007632-199808010-00015; DENNER I, 1992, RETEST RELIABILITY C; DYRSSEN T, 1989, LAKARTIDNINGEN, V86, P116; ELO AL, 1994, OCCUPATIONAL MED, P945; GROSS AR, 2000, COCHRANE LIB; HAGBERG M, 1987, BRIT J IND MED, V44, P602; HERTLING D, 1990, MANAGEMENT COMMON MU, P144; Kjellman GV, 1999, SCAND J REHABIL MED, V31, P139; LEVOSKA S, 1993, ARCH PHYS MED REHAB, V74, P425; MOSSTON M, 1994, TEACHING PHYSICAL ED; Randlov A, 1998, CLIN REHABIL, V12, P200, DOI 10.1191/026921598666881319; RINNE M, 1998, PATIENT ED COUNSE S1, V334, P69; SALOKANGAS RKR, 1995, ACTA PSYCHIAT SCAND, V92, P10, DOI 10.1111/j.1600-0447.1995.tb09536.x; Taimela S, 2000, SPINE, V25, P1021, DOI 10.1097/00007632-200004150-00018; TOIVANEN H, 1993, J OCCUP ENVIRON MED, V35, P1123, DOI 10.1097/00043764-199311000-00015; VANTULDER MW, 2000, NECK BACK PAIN	20	146	146	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2003	327	7413					475	477		10.1136/bmj.327.7413.475	http://dx.doi.org/10.1136/bmj.327.7413.475			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LA	12946968	Green Published, Bronze			2023-01-03	WOS:000185088900014
J	Brennan, TA; Mello, MM				Brennan, TA; Mello, MM			Patient safety and medical malpractice: A case study	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE EVENTS; CLAIMS; CARE; LITIGATION; PERCEPTIONS; NEGLIGENCE; PHYSICIANS; DISCLOSURE; SEVERITY; INJURIES	The system of tort liability for medical malpractice is frequently criticized for poorly performing its theoretical functions of compensating injured patients, deterring negligence, and dispensing corrective justice. Working from an actual malpractice case involving serious injury but no apparent negligence, the authors explore these criticisms from the perspectives of both the plaintiff-patient and the defendant-physician. They then examine the tort system through the lens of patient safety and conclude that the tensions between the system and patient safety initiatives suggest a need to reexamine our attachment to adversarial dispute resolution in health care. They propose targeted reforms that could improve the functioning of the system and create incentives to improve safety and quality.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Brennan, TA (corresponding author), Brigham & Womens Hosp, 75 Francis St,PBB4, Boston, MA 02115 USA.			Mello, Michelle/0000-0003-2877-4270				ABEL RL, 1990, UCLA LAW REV, V37, P785; ALBERT T, 2002, AM MED NEWS     1014, P5; BELL PA, 1984, SYRACUSE LAW REV, V35, P939; Bovbjerg RR, 1989, UC DAVIS LAW REV, V22, P499; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 1996, NEW ENGL J MED, V335, P1963, DOI 10.1056/NEJM199612263352606; Calabresi G, 1970, COSTS ACCIDENTS LEGA; CLINES FS, 2002, NY TIMES        0613, pA24; CONN LT, 2000, ERR IS HUMAN BUILDIN; DANZON P, 1984, J LAW ECON, V27, P115, DOI 10.1086/467060; Dubay L, 1999, J HEALTH ECON, V18, P491, DOI 10.1016/S0167-6296(99)00004-1; ENTMAN SS, 1994, JAMA-J AM MED ASSOC, V272, P1588, DOI 10.1001/jama.272.20.1588; FARBER HS, 1991, RAND J ECON, V22, P199, DOI 10.2307/2601017; FURROW BR, 2001, LAW HLTH CARE ORG FI; GORMAN T, 2002, LOS ANGELES TIM 0301, P1; *HARV MED PRACT ST, 1990, PAT DOCT LAW MED INJ; Hupert N, 1996, SOC SCI MED, V43, P1, DOI 10.1016/0277-9536(95)00314-2; Hyman DA, 2002, TEX LAW REV, V80, P1639; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; *JOINT COMM ACCR H, FACTS PAT SAF; KINNEY ED, 1995, J HEALTH POLIT POLIC, V20, P99, DOI 10.1215/03616878-20-1-99; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Lamb RM, 2003, HEALTH AFFAIR, V22, P73, DOI 10.1377/hlthaff.22.2.73; LAWTHERS AG, 1992, J HEALTH POLIT POLIC, V17, P463, DOI 10.1215/03616878-17-3-463; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; LOCALIO AR, 1993, JAMA-J AM MED ASSOC, V269, P366, DOI 10.1001/jama.269.3.366; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; Mello MM, 2003, NEW ENGL J MED, V348, P2281, DOI 10.1056/NEJMp030064; Mello MM, 2002, TEX LAW REV, V80, P1595; Moore PJ, 2000, WESTERN J MED, V173, P244, DOI 10.1136/ewjm.173.4.244; *NAT AC STAT HLTH, 2002, STAT RESP PROBL MED; *OFF TECHN ASS, 1994, DEF MED MED MALP; Peterson L M, 1990, J Clin Ethics, V1, P207; SCHEUTZOW SO, 1992, J LAW HLTH, V7, P169; SCHWARTZ GT, 1994, UCLA LAW REV, V42, P377; Shavell S, 2009, EC ANAL ACCIDENT LAW, P3; SLOAN FA, 1995, MED CARE, V33, P700, DOI 10.1097/00005650-199507000-00006; SLOAN FA, 1985, J HEALTH POLIT POLIC, V9, P629, DOI 10.1215/03616878-9-4-629; SLOAN FA, 1991, INSURING MED MALPRAC; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; Studdert DM, 2000, MED CARE, V38, P250, DOI 10.1097/00005650-200003000-00002; Studdert DM, 2001, JAMA-J AM MED ASSOC, V286, P217, DOI 10.1001/jama.286.2.217; TARAGIN MI, 1992, ANN INTERN MED, V117, P780, DOI 10.7326/0003-4819-117-9-780; Thomas EJ, 1999, INQUIRY-J HEALTH CAR, V36, P255; Thomas EJ, 2002, ANN INTERN MED, V136, P812, DOI 10.7326/0003-4819-136-11-200206040-00009; WEILER PC, 1991, MED MALPRACTICE TRIA; Weiler PC, 1993, MEASURE MALPRACTICE; Wu AW, 1999, ANN INTERN MED, V131, P970, DOI 10.7326/0003-4819-131-12-199912210-00012; Wu AW, 1997, J GEN INTERN MED, V12, P770, DOI 10.1046/j.1525-1497.1997.07163.x	49	30	30	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2003	139	4					267	273		10.7326/0003-4819-139-4-200308190-00009	http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	712JY	12965982				2023-01-03	WOS:000184795600005
J	Lagro-Janssen, T; Rosser, WW; van Wee, C				Lagro-Janssen, T; Rosser, WW; van Wee, C			Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces	LANCET			English	Editorial Material							HEALTHY POSTMENOPAUSAL WOMEN; ESTROGEN PLUS PROGESTIN; TRIAL; RISK		Univ Med Ctr Nijmegen, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands; Queens Univ, Dept Family Med, Kingston, ON, Canada	Radboud University Nijmegen; Queens University - Canada	van Wee, C (corresponding author), Univ Med Ctr Nijmegen, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands.		Lagro, A.L.M./H-8066-2014; van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				[Anonymous], 2003, LANCET, V361, P977; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; *DUTCH COLL GEN PR, 2003, PRACT GUID NHG PRACT; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P3254, DOI 10.1001/jama.289.24.3254; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sackett DL, 2002, CAN MED ASSOC J, V167, P363; van Weel C, 1999, LANCET, V353, P916, DOI 10.1016/S0140-6736(98)08024-6; VANWEEL C, IN PRESS ANN FAMILY; Wilson RA, 1966, FEMININE FOREVER	12	33	33	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					414	415		10.1016/S0140-6736(03)14095-0	http://dx.doi.org/10.1016/S0140-6736(03)14095-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927422				2023-01-03	WOS:000184651100002
J	Hodis, HN; Mack, WJ; Azen, SP; Lobo, RA; Shoupe, D; Mahrer, PR; Faxon, DP; Cashin-Hemphill, L; Sanmarco, ME; French, WJ; Shook, TL; Gaarder, TD; Mehra, AO; Rabbani, R; Sevanian, A; Shil, AB; Torres, M; Vogelbach, KH; Selzer, RH; Hodis, HN; Azen, SP; Faxon, DP; Lobo, RA; Mack, WJ; Charlson, M; Gesselman, C; Morales, T; Torres, M; Watcher, F; Zurbrugg, L; Faxon, DP; Mehra, AO; Rabbani, R; Agra, B; Coria, I; Ee, J; Johnson, S; Reyes, L; Stolicky, C; Mahrer, PR; Aharonian, VJ; Browning, RA; Jackimowicz, P; Scutella, PJ; Velasco, A; Williams, C; French, WJ; Shook, TL; Matthews, RV; Vogelbach, KH; Ujiiye, DL; Selzer, RH; Shil, AB; Shircore, A; Mack, WJ; Azen, SP; Ying-Lai, M; Morales, O; Xiang, M; Sevanian, A; Hwang, J; Bolusan, O; Ramirez, A; Cashin-Hemphill, L; Sanmarco, ME; Faxon, DP; French, WJ; Gaarder, TD; Mahrer, PR; Mehra, AO; Rabbani, R; Shook, TL; Mezrow, G; Shoupe, D; Stanczyk, FZ; Felix, JC; Parisky, Y; Brown, BG; Chaudhuri, G; Malloy, M; Odom-Maryon, T; Wilson-Ross, J; Gordon, DJ				Hodis, HN; Mack, WJ; Azen, SP; Lobo, RA; Shoupe, D; Mahrer, PR; Faxon, DP; Cashin-Hemphill, L; Sanmarco, ME; French, WJ; Shook, TL; Gaarder, TD; Mehra, AO; Rabbani, R; Sevanian, A; Shil, AB; Torres, M; Vogelbach, KH; Selzer, RH; Hodis, HN; Azen, SP; Faxon, DP; Lobo, RA; Mack, WJ; Charlson, M; Gesselman, C; Morales, T; Torres, M; Watcher, F; Zurbrugg, L; Faxon, DP; Mehra, AO; Rabbani, R; Agra, B; Coria, I; Ee, J; Johnson, S; Reyes, L; Stolicky, C; Mahrer, PR; Aharonian, VJ; Browning, RA; Jackimowicz, P; Scutella, PJ; Velasco, A; Williams, C; French, WJ; Shook, TL; Matthews, RV; Vogelbach, KH; Ujiiye, DL; Selzer, RH; Shil, AB; Shircore, A; Mack, WJ; Azen, SP; Ying-Lai, M; Morales, O; Xiang, M; Sevanian, A; Hwang, J; Bolusan, O; Ramirez, A; Cashin-Hemphill, L; Sanmarco, ME; Faxon, DP; French, WJ; Gaarder, TD; Mahrer, PR; Mehra, AO; Rabbani, R; Shook, TL; Mezrow, G; Shoupe, D; Stanczyk, FZ; Felix, JC; Parisky, Y; Brown, BG; Chaudhuri, G; Malloy, M; Odom-Maryon, T; Wilson-Ross, J; Gordon, DJ		WELL-HART Res Grp	Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGENS; COLESTIPOL-NIACIN THERAPY; REPLACEMENT THERAPY; HEART-DISEASE; PREVENTION; REGRESSION; RECEPTOR; EVENTS; STATIN	BACKGROUND: In postmenopausal women with coronary artery disease, conjugated equine estrogen with or without continuous administration of medroxyprogesterone acetate has failed to slow the progression of atherosclerosis. Whether 17(beta)-estradiol (the endogenous estrogen molecule) alone or administered sequentially with medroxyprogesterone acetate can slow the progression of atherosclerosis is unknown. METHODS: We conducted a double-blind, placebo-controlled trial in 226 postmenopausal women (mean age, 63.5 years) who had at least one coronary-artery lesion. Participants were randomly assigned to usual care (control group), estrogen therapy with micronized 17(beta)-estradiol alone (estrogen group), or 17(beta)-estradiol plus sequentially administered medroxyprogesterone acetate (estrogen-progestin group). In all patients the low-density lipoprotein (LDL) cholesterol level was reduced to a target of less than 130 mg per deciliter. The primary outcome was the average per-participant change between base-line and follow-up coronary angiograms in the percent stenosis measured by quantitative coronary angiography. RESULTS: After a median of 3.3 years of follow-up, the mean (+/-SE) change in the percent stenosis in the 169 participants who had a pair of matched angiograms was 1.89+/-0.78 percentage points in the control group, 2.18+/-0.76 in the estrogen group, and 1.24+/-0.80 in the estrogen-progestin group (P=0.66 for the comparison among the three groups). The mean difference in the percent stenosis between the estrogen group and the control group was 0.29 percentage point (95 percent confidence interval, -1.88 to 2.46), and the mean difference between the estrogen-progestin group and the control group was -0.65 (95 percent confidence interval, -2.87 to 1.57). CONCLUSIONS: In older postmenopausal women with established coronary-artery atherosclerosis, 17(beta)-estradiol either alone or with sequentially administered medroxyprogesterone acetate had no significant effect on the progression of atherosclerosis.	Univ So Calif, Keck Sch Med, Atherosclerosis Res Unit, Los Angeles, CA 90033 USA; Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Sch Pharm, Los Angeles, CA 90033 USA; Univ So Calif, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA; Univ So Calif, Div Cardiovasc Med, Los Angeles, CA 90033 USA; Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA; Kaiser Permanente Med Ctr, Los Angeles, CA 90034 USA; Univ Chicago, Div Cardiol, Chicago, IL USA; Boston Heart Fdn, Boston, MA USA; Lakewood Reg Med Ctr, Lakewood, CA USA; Univ Calif Los Angeles, Harbor Med Ctr, Div Cardiol, Torrance, CA 90509 USA; Good Samaritan Hosp, Los Angeles, CA USA; Presbyterian Intercommunity Hosp, Whittier, CA USA; So Calif Heart Specialits, Pasadena, CA USA; CALTECH, Jet Prop Lab, Pasadena, CA USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; Columbia University; Kaiser Permanente; University of Chicago; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Hodis, HN (corresponding author), Univ So Calif, Keck Sch Med, Atherosclerosis Res Unit, 2250 Alcazar St,CSC132, Los Angeles, CA 90033 USA.	watcher@usc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049298] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01-HL-49298] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams MR, 1997, ARTERIOSCL THROM VAS, V17, P217, DOI 10.1161/01.ATV.17.1.217; Angerer P, 2001, ARTERIOSCL THROM VAS, V21, P262, DOI 10.1161/01.ATV.21.2.262; AZEN SP, 1991, ARTERIOSCLER THROMB, V11, P385, DOI 10.1161/01.ATV.11.2.385; Azen SP, 1996, CIRCULATION, V93, P34, DOI 10.1161/01.CIR.93.1.34; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BLANKENHORN DH, 1992, CIRCULATION, V86, P1701, DOI 10.1161/01.CIR.86.6.1701; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1987, CONTROL CLIN TRIALS, V8, P354, DOI 10.1016/0197-2456(87)90156-5; BLANKENHORN DH, 1988, JAMA-J AM MED ASSOC, V259, P2698; Byington RP, 2002, ARTERIOSCL THROM VAS, V22, P1692, DOI 10.1161/01.ATV.0000033514.79653.04; Campisi R, 2002, CIRCULATION, V105, P425, DOI 10.1161/hc0402.102860; CASHINHEMPHILL L, 1992, ONLINE J CURR C 1023; CASHINHEMPHILL L, 1992, ONLINE J CURR C 1114; Cherry N, 2002, LANCET, V360, P2001; Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x; Clarkson TB, 1998, J CLIN ENDOCR METAB, V83, P721, DOI 10.1210/jc.83.3.721; Clarkson TB, 2001, J CLIN ENDOCR METAB, V86, P41, DOI 10.1210/jc.86.1.41; ESPELAND MA, 1995, AM J EPIDEMIOL, V142, P1011, DOI 10.1093/oxfordjournals.aje.a117553; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Herrington DM, 2002, CIRCULATION, V105, P2962, DOI 10.1161/01.CIR.0000019406.74017.B2; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; Hodis Howard N, 2003, Curr Atheroscler Rep, V5, P56, DOI 10.1007/s11883-003-0069-z; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; *LIP RES CLIN PROG, 1974, DHEW PUBL NIH; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; Luan ZX, 2003, ARTERIOSCL THROM VAS, V23, P769, DOI 10.1161/01.ATV.0000068646.76823.AE; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4; Rosenfeld ME, 2002, ATHEROSCLEROSIS, V164, P251, DOI 10.1016/S0021-9150(02)00178-8; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SELZER RH, 1989, J CLIN INVEST, V83, P520, DOI 10.1172/JCI113913; Son JW, 2003, INT J CARDIOL, V88, P77, DOI 10.1016/S0167-5273(02)00368-6; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; WEI LJ, 1977, J AM STAT ASSOC, V72, P382, DOI 10.2307/2286803; WILLIAMS JK, 1995, ARTERIOSCL THROM VAS, V15, P827, DOI 10.1161/01.ATV.15.7.827; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V274, P1676; Zanger D, 2000, J AM COLL CARDIOL, V36, P1797, DOI 10.1016/S0735-1097(00)00952-9	40	282	288	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 7	2003	349	6					535	545		10.1056/NEJMoa030830	http://dx.doi.org/10.1056/NEJMoa030830			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	708JL	12904518				2023-01-03	WOS:000184563500004
J	Onwuteaka-Philipsen, BD; van der Heide, A; Koper, D; Keij-Deerenberg, I; Rietjens, JAC; Rurup, ML; Vrakking, AM; Georges, JJ; Muller, MT; van der Wal, G; van der Maas, PJ				Onwuteaka-Philipsen, BD; van der Heide, A; Koper, D; Keij-Deerenberg, I; Rietjens, JAC; Rurup, ML; Vrakking, AM; Georges, JJ; Muller, MT; van der Wal, G; van der Maas, PJ			Euthanasia and other end-of-life decisions in the Netherlands in 1990, 1995, and 2001	LANCET			English	Article							PHYSICIAN-ASSISTED SUICIDE	Empirical data on the rate of euthanasia, physician-assisted suicide, and other end-of-life decisions have greatly contributed to the debate about the role of such practices in modern health care. In the Netherlands, the continuing debate about whether and when physician-assisted dying is acceptable seems to be resulting in a gradual stabilisation of end-of-life practices. We replicated interview and death-certificate studies done in 1990 and 1995 to investigate whether end-of-life practices had altered between 1995 and 2001. Since 1995, the demand for physician-assisted death has not risen among patients and physicians, who seem to have become somewhat more reluctant in their attitude towards this practice.	Free Univ Amsterdam, Med Ctr, Dept Social Med, NL-1081 BT Amsterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; Stat Netherlands, Voorburg, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC	Onwuteaka-Philipsen, BD (corresponding author), Free Univ Amsterdam, Med Ctr, Dept Social Med, van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.							Asch DA, 1999, AM J MED, V107, P153, DOI 10.1016/S0002-9343(99)00198-9; Groenewoud JH, 2000, NEW ENGL J MED, V342, P551, DOI 10.1056/NEJM200002243420805; Groenewoud JH, 2000, ARCH INTERN MED, V160, P357, DOI 10.1001/archinte.160.3.357; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; Morita T, 2001, J PAIN SYMPTOM MANAG, V21, P282, DOI 10.1016/S0885-3924(01)00258-5; OnwuteakaPhilipsen BD, 1997, J AM GERIATR SOC, V45, P1208, DOI 10.1111/j.1532-5415.1997.tb03771.x; *ROYAL DUTCH MED A, 1995, VIS EUTH; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; TENO J, 2001, CLIN EPIDEMIOLOGICAL; Thorns A, 2000, LANCET, V356, P398, DOI 10.1016/S0140-6736(00)02534-4; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; Van Der Maas PJ, 1996, EUTHANASIA OTHER MED; VANDERMAAS PJ, 1992, HLTH POLICY, V21, P1; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; Weiss SC, 2001, LANCET, V357, P1311, DOI 10.1016/S0140-6736(00)04515-3	18	168	169	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 2	2003	362	9381					395	399		10.1016/S0140-6736(03)14029-9	http://dx.doi.org/10.1016/S0140-6736(03)14029-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	707FB	12907015				2023-01-03	WOS:000184498700023
J	Neuberger, J				Neuberger, J			A healthy view of dying	BRITISH MEDICAL JOURNAL			English	Article									Kings Fund, London W1G 0AN, England		Neuberger, J (corresponding author), Kings Fund, London W1G 0AN, England.							*COUNS CAR, 1995, LAST RIGHTS STUD DEA; Ellershaw J, 2003, BRIT MED J, V326, P30, DOI 10.1136/bmj.326.7379.30; Finlay I, 2003, CLIN MED, V3, P102, DOI 10.7861/clinmedicine.3-2-102; HIGGINSON IJ, 2002, PALLIATIVE CARE PROG; Kafetz K, 2002, J ROY SOC MED, V95, P536, DOI 10.1258/jrsm.95.11.536; *NAT COUNC HOSP SP, 2001, PALL CAR SERV DIFF E; SHIPMAN C, 2002, PSYCHOSOCIAL SUPPORT	7	7	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 26	2003	327	7408					207	208		10.1136/bmj.327.7408.207	http://dx.doi.org/10.1136/bmj.327.7408.207			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	706DL	12881266	Green Published			2023-01-03	WOS:000184437300022
J	Kaji, T; Hachimura, S; Ise, W; Kaminogawa, S				Kaji, T; Hachimura, S; Ise, W; Kaminogawa, S			Proteome analysis reveals caspase activation in hyporesponsive CD4 T lymphocytes induced in vivo by the oral administration of antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TRANSGENIC MICE; CELL-RECEPTOR; ADAPTER PROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; PHOSPHOLIPASE C-GAMMA-1; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; POLYACRYLAMIDE-GELS; MEDIATED ACTIVATION; ACTIVE SUPPRESSION	The oral administration of antigen can lead to systemic antigen-specific hyporesponsiveness, also known as oral tolerance. This phenomenon is a representative form of immune tolerance to exogenous antigen under physiological conditions. We have previously reported that long term feeding of dietary antigen to ovalbumin-specific T cell receptor (TCR) transgenic mice induced oral tolerance of peripheral T cells with impairment in their TCR-induced calcium-signaling pathway. In this study, we utilized two-dimensional electrophoresis to compare intracellular protein expression patterns of orally tolerant and unsensitized CD4 T cells. We detected 26 increased and 16 decreased protein spots and identified 35 of these by mass spectrometry. The results indicated that the expression of caspases was up-regulated and that the protein levels of intact proteins susceptible to caspase cleavage, such as Grb2-related adaptor downstream of Shc (GADS), were decreased in orally tolerant CD4 T cells. Western blotting experiments confirmed that expression of the active form of caspase-3 and the antiapoptotic factor, X-linked inhibitor of apoptosis, were both up-regulated in orally tolerant CD4 T cells, which were found to be nonapoptotic. We further demonstrated that orally tolerant CD4 T cells could not form normal TCR signaling complexes associated with GADS and showed down-regulated phospholipase C-gamma1 activation, which is likely to contribute to the impairment of TCR-induced calcium signaling. Our findings indicate that orally tolerant CD4 T cells up-regulate caspase activation and show decreased levels of caspase-targeted proteins, including TCR signaling-associated molecules, while up-regulating antiapoptotic factors, all of which appear to contribute to their unique tolerant characteristics.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 113, Japan; Nihon Univ, Coll Bioresource Sci, Dept Food Sci & Technol, Fujisawa, Kanagawa 2528510, Japan	University of Tokyo; Nihon University	Hachimura, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.							Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Alpan O, 2001, J IMMUNOL, V166, P4843, DOI 10.4049/jimmunol.166.8.4843; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Asai K, 2002, J IMMUNOL, V169, P4723, DOI 10.4049/jimmunol.169.9.4723; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P2375, DOI 10.1073/pnas.92.6.2375; Berggren K, 2000, ELECTROPHORESIS, V21, P2509, DOI 10.1002/1522-2683(20000701)21:12<2509::AID-ELPS2509>3.3.CO;2-0; Berry DM, 2001, ONCOGENE, V20, P1203, DOI 10.1038/sj.onc.1204218; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Chen YH, 1996, P NATL ACAD SCI USA, V93, P388, DOI 10.1073/pnas.93.1.388; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Chen YHH, 1996, ANN NY ACAD SCI, V778, P111, DOI 10.1111/j.1749-6632.1996.tb21120.x; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DUBOIS PM, 1994, EUR J IMMUNOL, V24, P348, DOI 10.1002/eji.1830240212; Faria AMC, 1999, ADV IMMUNOL, V73, P153, DOI 10.1016/S0065-2776(08)60787-7; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; Garside P, 1996, AM J PATHOL, V149, P1971; GARSIDE P, 1995, J IMMUNOL, V154, P5649; Garside P, 2001, SEMIN IMMUNOL, V13, P177, DOI 10.1006/smim.2001.0310; Gavin MA, 2002, NAT IMMUNOL, V3, P33, DOI 10.1038/ni743; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.3.CO;2-Y; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hanninen A, 2000, SCAND J IMMUNOL, V52, P217; HIRAHARA K, 1995, J IMMUNOL, V154, P6238; Kaji T, 2002, NITRIC OXIDE-BIOL CH, V6, P125, DOI 10.1006/niox.2001.0389; Kang B, 1999, IMMUNOBIOLOGY, V200, P264, DOI 10.1016/S0171-2985(99)80075-8; Kimura M, 2000, INT IMMUNOL, V12, P817, DOI 10.1093/intimm/12.6.817; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lechner O, 2001, CURR BIOL, V11, P587, DOI 10.1016/S0960-9822(01)00160-9; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu SKW, 2001, ONCOGENE, V20, P6284, DOI 10.1038/sj.onc.1204771; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MELAMED D, 1993, EUR J IMMUNOL, V23, P935, DOI 10.1002/eji.1830230426; MIGITA K, 1995, J IMMUNOL, V155, P5083; MIGITA K, 1994, EUR J IMMUNOL, V24, P2081, DOI 10.1002/eji.1830240922; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SATO T, 1994, EUR J IMMUNOL, V24, P1512, DOI 10.1002/eji.1830240708; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Shen R, 2002, MOL CELL BIOL, V22, P3230, DOI 10.1128/MCB.22.10.3230-3236.2002; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Strobel S, 2002, ANN NY ACAD SCI, V958, P47; Strober W, 1998, J CLIN IMMUNOL, V18, P1, DOI 10.1023/A:1023222003039; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thorstenson KM, 2001, J IMMUNOL, V167, P188, DOI 10.4049/jimmunol.167.1.188; Tsuji NM, 2001, IMMUNOLOGY, V103, P458, DOI 10.1046/j.1365-2567.2001.01265.x; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; VanHouten N, 1996, J IMMUNOL, V157, P1337; Vaughan ATM, 2002, APOPTOSIS, V7, P173, DOI 10.1023/A:1014374717773; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yankee TM, 2001, P NATL ACAD SCI USA, V98, P6789, DOI 10.1073/pnas.111158598; Yoshida T, 1997, CLIN IMMUNOL IMMUNOP, V82, P207, DOI 10.1006/clin.1996.4319; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245	67	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27836	27843		10.1074/jbc.M212820200	http://dx.doi.org/10.1074/jbc.M212820200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736267	hybrid			2023-01-03	WOS:000184242700065
J	Hansel, TT; Kharitonov, SA; Donnelly, LE; Erin, EM; Currie, MG; Moore, WM; Manning, PT; Recker, DP; Barnes, PJ				Hansel, TT; Kharitonov, SA; Donnelly, LE; Erin, EM; Currie, MG; Moore, WM; Manning, PT; Recker, DP; Barnes, PJ			A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics	FASEB JOURNAL			English	Article						respiratory; pharmacology; tolerability	OBSTRUCTIVE PULMONARY-DISEASE; INOS INHIBITOR; AIRWAYS; LUNG; MICE; AIR; BRONCHODILATOR; NITROTYROSINE; PEROXYNITRITE; INFLAMMATION	The inducible isoenzyme of nitric oxide synthase (iNOS) generates nitric oxide (NO) in inflammatory diseases such as asthma. The prodrug L-N-6-(1-iminoethyl)lysine 5-tetrazole amide (SC-51) is rapidly converted in vivo to the active metabolite L-N-6-(1-iminoethyl)lysine (L-NIL). Initially, we performed in vitro experiments in human primary airway epithelial cells to demonstrate that L-NIL causes inhibition of iNOS. In a randomized double-blind placebo-controlled crossover trial, SC-51 was administered as a single oral dose (20 or 200 mg) in separate cohorts of healthy volunteers (two groups of n=12) and mild asthmatic patients (two groups of n=12). SC-51 (200 mg) reduced exhaled breath NO levels to <2 ppb in both healthy volunteers (P<0.001) and mild asthmatics (P<0.001) within 15 min, representing >90% inhibition of baseline levels of NO in asthmatic patients, with the effects lasting at least 72 h. There were no significant effects on blood pressure, pulse rate, or respiratory function (FEV1). This study demonstrates that an inhibitor of iNOS produces marked inhibition of exhaled breath NO in normal and asthmatic subjects without producing the side effects observed following the systemic administration of non-selective NOS inhibitors, and thus provides support for the potential use of iNOS inhibitors to treat a range of inflammatory clinical disorders.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Clin Studies Unit, London, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London, England; Pharmacia Corp, Skokie, IL USA; Pharmacia Corp, St Louis, MO USA	Imperial College London; Imperial College London; Pfizer; Pfizer	Hansel, TT (corresponding author), Royal Brompton Hosp, NHLI Clin Studies Unit, London SW3 6HP, England.	t.hansel@imperial.ac.uk		Barnes, Peter/0000-0002-5122-4018; Donnelly, Louise/0000-0002-0753-5425				Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ALVING K, 1993, EUR RESPIR J, V6, P1368; Amin Ashok R., 1999, Current Opinion in Rheumatology, V11, P202, DOI 10.1097/00002281-199905000-00009; Ashina M, 1999, LANCET, V353, P287, DOI 10.1016/S0140-6736(98)01079-4; Ashutosh K, 2000, THORAX, V55, P109, DOI 10.1136/thorax.55.2.109; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BRYNE J, 2001, BR J CARDIOL, V8, P570; Clini E, 1998, THORAX, V53, P881, DOI 10.1136/thx.53.10.881; CONNOR JR, 1995, EUR J PHARMACOL, V273, P15, DOI 10.1016/0014-2999(94)00672-T; Corradi M, 1999, THORAX, V54, P572, DOI 10.1136/thx.54.7.572; Donnelly LE, 2001, AM J RESP CELL MOL, V24, P295, DOI 10.1165/ajrcmb.24.3.4001; Dworski R, 2000, THORAX, V55, pS51, DOI 10.1136/thorax.55.suppl_2.S51; Gomez FP, 1998, EUR RESPIR J, V12, P865, DOI 10.1183/09031936.98.12040865; Hallinan EA, 2002, J MED CHEM, V45, P1686, DOI 10.1021/jm010420e; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273, DOI 10.1164/ajrccm.162.4.9912064; Hart CM, 1999, CHEST, V115, P1407, DOI 10.1378/chest.115.5.1407; Hickey MJ, 2001, CLIN SCI, V100, P1, DOI 10.1042/CS20000135; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747, DOI 10.1016/S0091-6749(99)70283-6; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Koarai A, 2000, PULM PHARMACOL THER, V13, P267, DOI 10.1006/pupt.2000.0254; KUO HP, 1992, EUR J PHARMACOL, V221, P385; Leckie MJ, 2000, EXPERT OPIN INV DRUG, V9, P3, DOI 10.1517/13543784.9.1.3; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; Lopez-Jaramillo P, 1998, LANCET, V351, P1176, DOI 10.1016/S0140-6736(05)79119-4; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998, DOI 10.1164/ajrccm.157.3.97-05009; MISKO TP, 1993, ANAL BIOCHEM, V214, P1; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; Moncada S, 1999, J ROY SOC MED, V92, P164, DOI 10.1177/014107689909200402; Moore WM, 1996, J MED CHEM, V39, P669, DOI 10.1021/jm950766n; Perner A, 1999, ALIMENT PHARM THERAP, V13, P135; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; RITTER J, 2001, BR J CARDIOL, V8, P564; Rutgers SR, 1999, THORAX, V54, P576, DOI 10.1136/thx.54.7.576; Sadeghi-Hashjin G, 1998, CLIN EXP ALLERGY, V28, P1464; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; Shah AM, 2000, PHARMACOL THERAPEUT, V86, P49, DOI 10.1016/S0163-7258(99)00072-8; Singh S, 1997, EUR RESPIR J, V10, P699; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Stirling RG, 1998, THORAX, V53, P1030, DOI 10.1136/thx.53.12.1030; Szabo C, 1999, SHOCK, V12, P1, DOI 10.1097/00024382-199907000-00001; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99, DOI 10.1164/ajrccm.158.1.9709091; Thomsen LL, 1998, CLIN NEUROSCI, V5, P28; Torreilles J, 2001, FRONT BIOSCI-LANDMRK, V6, pD1161, DOI 10.2741/Torreill; Trifilieff A, 2000, J IMMUNOL, V165, P1526, DOI 10.4049/jimmunol.165.3.1526; Tulic MK, 2000, EUR RESPIR J, V15, P870, DOI 10.1183/09031936.00.15587000; VALLANCE P, 1989, LANCET, V2, P997; WARD JK, 1995, AM J RESP CELL MOL, V13, P175, DOI 10.1165/ajrcmb.13.2.7542897; Weinberger B, 1999, PHARMACOL THERAPEUT, V84, P401, DOI 10.1016/S0163-7258(99)00044-3; Xiong YL, 1999, J IMMUNOL, V162, P445; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247, DOI 10.1164/ajrccm.154.1.8680689	59	151	161	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1298	+		10.1096/fj.02-0633fje	http://dx.doi.org/10.1096/fj.02-0633fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738811				2023-01-03	WOS:000183165000030
J	Bower, P; Roland, M; Campbell, J; Mead, N				Bower, P; Roland, M; Campbell, J; Mead, N			Setting standards based on patients' views on access and continuity: secondary analysis of data from the general practice assessment survey	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; QUALITY; PRIORITIES	Objectives To examine patients' views on access and continuity in general practice to derive quality standards. Design Secondary analysis of data from general practice research studies and routine quality assessment activities undertaken by practices and primary care trusts. Setting General practice. Participants General practice patients. Results Satisfactory standards of access were next day appointments with general practitioners and a 6-10 minute wait for consultations to begin. A satisfactory level of continuity was seeing the same general practitioner "a lot of the time." Standards varied with the analytic method used and by sociodemographic group. Conclusions Standards expected by patients in primary care can be derived from linked report-assessment pairs. Patients may have expectations of access that are in excess of government targets. Patients also have high expectations of continuity of care. It is unclear the degree to which such standards are reliable or valid, how conflicts between access and continuity should be resolved, or how these standards relate to other priorities of patients such as high quality interpersonal care.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Peninsula Med Sch, Dept Gen Practice & Primary Care, Exeter EX2 5DW, Devon, England	University of Manchester; University of Exeter	Bower, P (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.		Bower, Peter/A-1508-2011	Bower, Peter/0000-0001-9558-3349; Campbell, John/0000-0002-6752-3493				Bamford C, 1992, Qual Health Care, V1, P153, DOI 10.1136/qshc.1.3.153; Bower P, 2002, FAM PRACT, V19, P489, DOI 10.1093/fampra/19.5.489; Campbell JL, 2001, QUAL HEALTH CARE, V10, P90, DOI 10.1136/qhc.10.2.90; Campbell SM, 2001, BMJ-BRIT MED J, V323, P784, DOI 10.1136/bmj.323.7316.784; Campbell SM, 2000, SOC SCI MED, V51, P1611, DOI 10.1016/S0277-9536(00)00057-5; GROL R, 2000, PATIENTS EVALUATE GE; Gulliford Martin, 2002, J Health Serv Res Policy, V7, P186, DOI 10.1258/135581902760082517; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Kearley KE, 2001, BRIT J GEN PRACT, V51, P712; Little P, 2001, BRIT MED J, V323, P908, DOI 10.1136/bmj.323.7318.908; MEAD N, 2002, THESIS U MANCHESTER; Neuberger J, 1998, BMJ-BRIT MED J, V317, P260, DOI 10.1136/bmj.317.7153.260; *NHS EX, 1998, 1 CLASS SERV QUAL NE; *NHS EX, 1999, NAT SURV NHS PAT; *PMS NAT EV TEAM, 2000, NAT EV 1 WAV NHS PER; Ramsay J, 2000, FAM PRACT, V17, P372, DOI 10.1093/fampra/17.5.372; Roland M., 2002, GEN PRACTICE ASSESSM; Salisbury C, 2002, BRIT J GEN PRACT, V52, P554; Scott A, 1999, SCOT J POLIT ECON, V46, P111, DOI 10.1111/1467-9485.00124; Scott A., 2001, EVIDENCE BASED PATIE, P66; Secretary of State for Health, 2000, NHS PLAN; SMITH CH, 1989, BRIT MED J, V299, P494, DOI 10.1136/bmj.299.6697.494; Stewart M, 2001, BRIT MED J, V322, P444, DOI 10.1136/bmj.322.7284.444; Vick S, 1998, J HEALTH ECON, V17, P587, DOI 10.1016/S0167-6296(97)00035-0; Wensing M, 1998, SOC SCI MED, V47, P1573, DOI 10.1016/S0277-9536(98)00222-6; Williamson C, 2000, QUAL HEALTH CARE, V9, P190, DOI 10.1136/qhc.9.3.190	26	57	60	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2003	326	7383					258	260A		10.1136/bmj.326.7383.258	http://dx.doi.org/10.1136/bmj.326.7383.258			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644FY	12560279	Bronze, Green Published			2023-01-03	WOS:000180908300022
J	Eda, S; Maseda, H; Nakae, T				Eda, S; Maseda, H; Nakae, T			An elegant means of self-protection in gram-negative bacteria by recognizing and extruding xenobiotics from the periplasmic space	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG EFFLUX PUMPS; SUBSTRATE-SPECIFICITY; PSEUDOMONAS-AERUGINOSA; ANTIBIOTIC EXTRUSION; ESCHERICHIA-COLI; DRUG EXTRUSION; TRANSPORTER; RESISTANCE; VECTORS; SUBUNIT	Infection of Pseudomonas aeruginosa in cystic fibrosis patients is a major cause of mortality. This organism shows wide ranging antibiotic resistance that is largely attributable to the expression of xenobiotic efflux pump(s). Here, we show a novel mechanism by which the resistance-nodulation-division-type xenobiotic transporter expels potential hazards and protects the interior of the cells. The xenobiotic transporters MexB and MexY preferentially export beta-lactam and aminoglycoside antibiotics, respectively. When two large extramembrane loops of MexY were replaced by the corresponding loops of MexB, the hybrid protein exhibited P-lactam selectivity (MexB-type), but failed to recognize aminoglycoside. As the transmembrane segment of MexB was replaced with a corresponding transmembrane segment of MexY, one-by-one for all 12 segments, all the hybrid proteins showed MexB-type antibiotic selectivity. These results clearly demonstrated that the resistance-nodulation-division-type efflux pump in P. aeruginosa selects and transports substrates via the domains that largely protrude over the cytoplasmic membrane. The transmerabrane segments were unlikely to have been involved in substrate selectivity. These observations led us to propose a novel mechanism by which the xenobiotic transporters in Gram-negative bacteria select and expel substrates from the periplasmic space before potential hazards penetrate into the cytoplasmic membrane.	Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan	Tokai University	Nakae, T (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	nakae@is.icc.u-tokai.ac.jp						Bibi E, 2001, J MOL MICROB BIOTECH, V3, P171; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Brown MH, 2001, J MOL MICROB BIOTECH, V3, P163; Elkins CA, 2002, J BACTERIOL, V184, P6490, DOI 10.1128/JB.184.23.6490-6499.2002; Gotoh N, 1999, FEBS LETT, V458, P32, DOI 10.1016/S0014-5793(99)01116-3; Guan L, 1999, J BIOL CHEM, V274, P10517, DOI 10.1074/jbc.274.15.10517; Guan L, 2001, J BACTERIOL, V183, P1734, DOI 10.1128/JB.183.5.1734-1739.2001; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; Klyachko KA, 1997, J BACTERIOL, V179, P2189, DOI 10.1128/jb.179.7.2189-2193.1997; Mao WM, 2002, MOL MICROBIOL, V46, P889, DOI 10.1046/j.1365-2958.2002.03223.x; Masuda N, 2000, ANTIMICROB AGENTS CH, V44, P3322, DOI 10.1128/AAC.44.12.3322-3327.2000; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Nakae Taiji, 1997, J Infect Chemother, V3, P173, DOI 10.1007/BF02490031; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ocaktan A, 1997, J BIOL CHEM, V272, P21964, DOI 10.1074/jbc.272.35.21964; Poole K, 2001, J MOL MICROB BIOTECH, V3, P255; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; SIMON R, 1986, METHOD ENZYMOL, V118, P640; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506	23	47	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2085	2088		10.1074/jbc.C200661200	http://dx.doi.org/10.1074/jbc.C200661200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12460990	hybrid			2023-01-03	WOS:000180562000002
J	Blann, AD; Fitzmaurice, DA; Lip, GYH				Blann, AD; Fitzmaurice, DA; Lip, GYH			ABC of antithrombotic therapy - Anticoagulation in hospitals and general practice	BRITISH MEDICAL JOURNAL			English	Review							COMPUTERIZED DECISION-SUPPORT; PRIMARY-CARE; MANAGEMENT; PHARMACIST; INR		City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England	University of Birmingham	Blann, AD (corresponding author), City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England.							Baglin T, 1997, BRIT J HAEMATOL, V96, P431, DOI 10.1046/j.1365-2141.1997.d01-2079.x; Blann A, 1999, BRIT J HAEMATOL, V107, P207, DOI 10.1046/j.1365-2141.1999.01672.x; *BRIT COMM STAND H, 1998, BRIT J HAEMATOL, V101, P374; Fitzmaurice DA, 1998, BRIT J HAEMATOL, V102, P907; Fitzmaurice DA, 2000, ARCH INTERN MED, V160, P2343, DOI 10.1001/archinte.160.15.2343; Fitzmaurice DA, 2002, J CLIN PATHOL, V55, P845, DOI 10.1136/jcp.55.11.845; Macgregor SH, 1996, BRIT MED J, V312, P560, DOI 10.1136/bmj.312.7030.560; PELL JP, 1993, BRIT J GEN PRACT, V43, P152; RADLEY AS, 1995, J CLIN PATHOL, V48, P545, DOI 10.1136/jcp.48.6.545	9	20	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 18	2003	326	7381					153	156		10.1136/bmj.326.7381.153	http://dx.doi.org/10.1136/bmj.326.7381.153			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	638MY	12531851	Green Published			2023-01-03	WOS:000180575900030
J	Hurley, AC; Volicer, L				Hurley, AC; Volicer, L			Alzheimer disease - "It's okay, mama, if you want to go, it's okay"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NURSING-HOME PLACEMENT; RANDOMIZED CONTROLLED TRIAL; TERMINALLY ILL PATIENTS; END-STAGE DEMENTIA; LONG-TERM-CARE; COGNITIVE IMPAIRMENT; FEVER-MANAGEMENT; UNITED-STATES; HOSPICE; PAIN		Northeastern Univ, Bouve Coll Hlth Sci, Brigham & Womens Hosp, Ctr Excellence Nursing Practice,Sch Nursing, Boston, MA 02115 USA; Edith Nourse Rogers Mem Vet Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA	Harvard University; Brigham & Women's Hospital; Northeastern University; Geriatric Research Education & Clinical Center; Boston University	Hurley, AC (corresponding author), Northeastern Univ, Bouve Coll Hlth Sci, Brigham & Womens Hosp, Ctr Excellence Nursing Practice,Sch Nursing, 75 Francis St, Boston, MA 02115 USA.	Ahurley@partners.org	Volicer, Ladislav/K-7576-2019	Volicer, Ladislav/0000-0002-6939-7531	NIA NIH HHS [P30AG13846] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG013846] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahronheim JC, 1996, CLIN GERIATR MED, V12, P379; *ALZH ASS, 2002, STAT ALZH DIS; Benedetti F, 1999, PAIN, V80, P377, DOI 10.1016/S0304-3959(98)00228-0; Berger JT, 2000, J CLIN ETHIC, V11, P304; BIRKS JS, 1997, DONEPEZIL MILD MODER; BLASI ZV, 2002, J AM MED DIR ASSOC, V13, P57; Brown J., 1988, CLIN MANAGEMENT ALZH, P29; Casarett D, 2002, ALZ DIS ASSOC DIS, V16, P116, DOI 10.1097/00002093-200204000-00009; Cook AKR, 1999, INT J GERIATR PSYCH, V14, P421, DOI 10.1002/(SICI)1099-1166(199906)14:6<421::AID-GPS932>3.0.CO;2-Y; Doody RS, 2001, ARCH NEUROL-CHICAGO, V58, P449, DOI 10.1001/archneur.58.3.449; Dooneief G, 1996, NEUROLOGY, V46, P1746, DOI 10.1212/WNL.46.6.1746; DRICKAMER MA, 1992, NEW ENGL J MED, V326, P947, DOI 10.1056/NEJM199204023261410; EPPIS L, 1999, HOME CARE FINANC FAL, P207; FABISZEWSKI KJ, 1990, JAMA-J AM MED ASSOC, V263, P3168, DOI 10.1001/jama.263.23.3168; FELD MJ, 1997, APPROACHING DEATH IM; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried TR, 1997, J AM GERIATR SOC, V45, P302, DOI 10.1111/j.1532-5415.1997.tb00944.x; FRISSONI GB, 1998, SPR S ETH LAW AG, P48; Gaugler JE, 2000, J GERONTOL B-PSYCHOL, V55, pP247, DOI 10.1093/geronb/55.4.P247; HANRAHAN P, 1995, J AM GERIATR SOC, V43, P56, DOI 10.1111/j.1532-5415.1995.tb06243.x; Hebert LE, 2001, ALZ DIS ASSOC DIS, V15, P169, DOI 10.1097/00002093-200110000-00002; HELMES E, 1995, ARCH NEUROL-CHICAGO, V52, P306, DOI 10.1001/archneur.1995.00540270102026; HIRATADULAS CAI, 1991, J AM GERIATR SOC, V39, P979, DOI 10.1111/j.1532-5415.1991.tb04044.x; Huang ZB, 2000, CLIN GERIATR MED, V16, P313, DOI 10.1016/S0749-0690(05)70058-6; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; HURLEY A, 1996, FED PRACTITIONER, V13, P16; HURLEY AC, 1993, ADV NURS SCI, V16, P21, DOI 10.1097/00012272-199309000-00004; Hurley AC, 1996, ALZ DIS ASSOC DIS, V10, P5, DOI 10.1097/00002093-199601010-00003; HURLEY AC, 1992, RES NURS HEALTH, V15, P369, DOI 10.1002/nur.4770150506; Hurley AC, 1999, ALZ DIS ASSOC DIS, V13, pS6, DOI 10.1097/00002093-199904001-00004; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; Kayser-Jones J, 1996, J Gerontol Nurs, V22, P26; Komaromy C, 2000, Int J Palliat Nurs, V6, P192; Kovach CR, 2001, APPL NURS RES, V14, P193, DOI 10.1053/apnr.2001.26784; Kovach CR, 1999, J PAIN SYMPTOM MANAG, V18, P412, DOI 10.1016/S0885-3924(99)00094-9; KOVACH CR, 1998, SPR S ETH LAW AG, P276; KUKULL WA, 1994, J AM GERIATR SOC, V42, P723, DOI 10.1111/j.1532-5415.1994.tb06531.x; Leff B, 2001, J GERONTOL A-BIOL, V56, pM603, DOI 10.1093/gerona/56.10.M603; Leff B, 2000, J AM GERIATR SOC, V48, P943, DOI 10.1111/j.1532-5415.2000.tb06892.x; Luchins DJ, 1997, J AM GERIATR SOC, V45, P1054, DOI 10.1111/j.1532-5415.1997.tb05966.x; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Lynn J, 2001, WESTERN J MED, V175, P299, DOI 10.1136/ewjm.175.5.299; Mahoney E. K., 2000, MANAGEMENT CHALLENGI; Mahoney EK, 2000, MANAGEMENT CHALLENGI, P155; MAHONEY M, 1992, FAMILY DECISION MAKI; MAHONEY MA, 1998, SPR S ETH LAW AG, P169; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; McConnell S, 1999, GENERATIONS, V23, P69; *MED EC CO INC, 2002, PHYS DESK REF; Meier DE, 2001, ARCH INTERN MED, V161, P594, DOI 10.1001/archinte.161.4.594; Menzin J, 1999, AM J GERIAT PSYCHIAT, V7, P300; MITTELMAN MS, 1993, GERONTOLOGIST, V33, P730, DOI 10.1093/geront/33.6.730; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MOSS MS, 2000, ANN REV GERONTOLOGY, P224; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; *NAT I AG, 2000, 2000 PROGR REP ALZH; Ostbye T, 1999, NEUROLOGY, V53, P521, DOI 10.1212/WNL.53.3.521; PAN CX, 2000, ANN REV GERONTOLOGY, P273; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; Rempusheski V F, 2000, J Gerontol Nurs, V26, P27; RHEAUME YL, 1998, SPR S ETH LAW AG, P189; Rice DP, 2001, AM J MANAG CARE, V7, P809; Robinson E M, 2000, J Nurs Law, V7, P21; ROBINSON EM, 1998, FED PRACT, V15, P26; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rovner B W, 1992, J Geriatr Psychiatry Neurol, V5, P102; Ryan AA, 2000, J ADV NURS, V32, P1187, DOI 10.1046/j.1365-2648.2000.01589.x; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Smith GE, 2001, NEUROLOGY, V57, P1467, DOI 10.1212/WNL.57.8.1467; SMITH SJ, 1998, SPR S ETH LAW AG, P247; SPECTOR WD, 2000, CHARACTERISTICS LONG; Stern Y, 1997, JAMA-J AM MED ASSOC, V277, P806, DOI 10.1001/jama.277.10.806; STUART B, 1995, MED GUIDELINES DETER; Teno JM, 2002, JAMA-J AM MED ASSOC, V287, P3211, DOI 10.1001/jama.287.24.3211; Teno JM, 2001, JAMA-J AM MED ASSOC, V285, P2081, DOI 10.1001/jama.285.16.2081-a; Thompson R S, 1997, J Am Board Fam Pract, V10, P82; VOLICER BJ, 1993, J AM GERIATR SOC, V41, P535, DOI 10.1111/j.1532-5415.1993.tb01891.x; VOLICER L, 1994, J GERIATR PSYCH NEUR, V7, P227, DOI 10.1177/089198879400700406; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; Volicer L, 1998, HOSPICE CARE PATIENT; VOLICER L, 1990, AM J ALZHEIMERS CARE, V5, P22; VOLICER L, 1989, J GERIATR PSYCHIAT, V2, P169; VOLICER L, 1998, SPR S ETH LAW AG, P29; VOLICER L, 1996, LATE STAGE DEMENTIA, P125; WARDEN VJ, 1989, GERIATR NURS, V10, P210; Wilson SA, 1996, GERIATR NURS, V17, P6, DOI 10.1016/S0197-4572(96)80004-8; Wolfson C, 2001, NEW ENGL J MED, V344, P1111, DOI 10.1056/NEJM200104123441501; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090	90	35	35	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2324	2331		10.1001/jama.288.18.2324	http://dx.doi.org/10.1001/jama.288.18.2324			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	614JZ	12425711				2023-01-03	WOS:000179186400033
J	Main, CJ; Williams, ACD				Main, CJ; Williams, ACD			ABC of psychological medicine - Musculoskeletal pain	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Hope Hosp, Dept Behav Med, Salford M6 8HD, Lancs, England; Univ London, Guys Kings & St Thomass Sch Med, London WC1E 7HU, England	University of London; King's College London	Main, CJ (corresponding author), Hope Hosp, Dept Behav Med, Salford M6 8HD, Lancs, England.		de C Williams, Amanda C/C-7816-2009	Williams, Amanda/0000-0003-3761-8704				Accident Compensation Corporation Ministry of Health Health Quality & Safety Commission New Zealand New Zealand Government, 2022, LIV STRONG LONG PREV; *CLIN STAND ADV GR, 1994, CLIN STAND ADV GROUP; ROLAND M, 2002, BACK BOOK; *ROYAL COLL GEN PR, 1996, CLIN GUID MAN AC LOW; Waddell G, 2000, OCCUPATIONAL HLTH GU	5	73	75	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 7	2002	325	7363					534	537		10.1136/bmj.325.7363.534	http://dx.doi.org/10.1136/bmj.325.7363.534			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	593NJ	12217996	Green Published			2023-01-03	WOS:000177997800022
J	Duke, T				Duke, T			Sources of error: from procedures to end-of-life decisions	LANCET			English	Editorial Material									Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia	University of Melbourne	Duke, T (corresponding author), Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1313	1313		10.1016/S0140-6736(03)14575-8	http://dx.doi.org/10.1016/S0140-6736(03)14575-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575978				2023-01-03	WOS:000186036900026
J	Cauley, JA; Robbins, J; Chen, Z; Cummings, SR; Jackson, RD; LaCroix, AZ; LeBoff, M; Lewis, CE; McGowan, J; Neuner, J; Pettinger, M; Stefanick, ML; Wactawski-Wende, J; Watts, NB				Cauley, JA; Robbins, J; Chen, Z; Cummings, SR; Jackson, RD; LaCroix, AZ; LeBoff, M; Lewis, CE; McGowan, J; Neuner, J; Pettinger, M; Stefanick, ML; Wactawski-Wende, J; Watts, NB		Women's Hlth Initiative Investigat	Effects of estrogen plus progestin on risk of fracture and bone mineral density - The Women's Health Initiative randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; VERTEBRAL FRACTURES; POSTMENOPAUSAL WOMEN; OLDER WOMEN; ESTROGEN/PROGESTIN REPLACEMENT; OSTEOPOROTIC FRACTURES; NONVERTEBRAL FRACTURES; ELDERLY WOMEN; HIP FRACTURE; PREVENTION	Context In the Women's Health Initiative trial of estrogen-plus-progestin therapy, women assigned to active treatment had fewer fractures. Objective To test the hypothesis that the relative risk reduction of estrogen plus progestin on fractures differs according to risk factors for fractures. Design, Setting, and Participants Randomized controlled trial (September 1993-July 2002) in which 16608 postmenopausal women aged 50 to 79 years with an intact uterus at baseline were recruited at 40 US clinical centers and followed up for an average of 5.6 years. Intervention Women were randomly assigned to receive conjugated equine estrogen, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n=8506) or placebo (n = 8102). Main Outcome Measures All confirmed osteoporotic fracture events that occurred from enrollment to discontinuation of the trial (July 7, 2002); bone mineral density (BMD), measured in a subset of women (n = 1024) at baseline and years 1 and 3; and a global index, developed to summarize the balance of risks and benefits to test whether the risk-benefit profile differed across tertiles of fracture risk. Results Seven hundred thirty-three women (8.6%) in the estrogen-plus-progestin group and 896 women (11.1%) in the placebo group experienced a fracture (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.69-0.83). The effect did not differ in women stratified by age, body mass index, smoking status, history of falls, personal and family history of fracture, total calcium intake, past use of hormone therapy, BMD, or summary fracture risk score. Total hip BMD increased 3.7% after 3 years of treatment with estrogen plus progestin compared with 0.14% in the placebo group (P<.001). The HR for the global index was similar across tertiles of the fracture risk scale (lowest fracture risk tertile, HR, 1.20; 95% CI, 0.93-1.58; middle tertile, HR, 1,23; 95% Cl, 1.04-1.46; highest tertile, HR, 1.03; 95% Cl, 0.88-1.24) (P for interaction =.54). Conclusions This study demonstrates that estrogen plus progestin increases BMD and reduces the risk of fracture in healthy postmenopausal women. The decreased risk of fracture attributed to estrogen plus progestin appeared to be present in all subgroups of women examined. When considering the effects of hormone therapy on other important disease outcomes in a global model, there was no net benefit, even in women considered to be at high risk of fracture.	Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Univ Calif Davis, Sch Med, Dept Internal Med, Sacramento, CA 95817 USA; Univ Arizona, Mel & Enid Zuckerman Arizona Coll Publ Hlth, Div Epidemiol & Biostat, Tucson, AZ USA; Univ Calif San Francisco, Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA; Ohio State Univ, Dept Internal Med, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA; Fred Hutchinson Canc Res Ctr, Womens Hlth Initiat Clin Coordinating Ctr, Seattle, WA 98104 USA; Brigham & Womens Hosp, Div Endocrine Hypertens, Boston, MA 02115 USA; Univ Alabama, Div Prevent Med, Birmingham, AL USA; NIAMSD, Bethesda, MD 20892 USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Ctr Patient Care & Outcomes Res, Milwaukee, WI 53226 USA; Stanford Univ, Dept Med, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA; SUNY Buffalo, Buffalo, NY 14260 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Davis; University of Arizona; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Ohio; Ohio State University; Fred Hutchinson Cancer Center; Harvard University; Brigham & Women's Hospital; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Medical College of Wisconsin; Medical College of Wisconsin; Stanford University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University System of Ohio; University of Cincinnati	Cauley, JA (corresponding author), Univ Pittsburgh, Dept Epidemiol, Crabtree Hall A524,130 DeSoto St, Pittsburgh, PA 15261 USA.		Cauley, Jane A/N-4836-2015; Wactawski-Wende, Jean/AGH-5457-2022	Cauley, Jane A/0000-0003-0752-4408; Wactawski-Wende, Jean/0000-0003-3096-9595				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Black DM, 2001, OSTEOPOROSIS INT, V12, P519, DOI 10.1007/s001980170072; Black DM, 1999, J BONE MINER RES, V14, P821, DOI 10.1359/jbmr.1999.14.5.821; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BROWN BW, 1997, J GERONTOL A-BIOL, V52, pB166; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; Cauley JA, 2001, AM J MED, V110, P442, DOI 10.1016/S0002-9343(01)00647-7; COOPER C, 1993, BONE, V14, pS89; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; ENSRUD KE, 1995, J BONE MINER RES, V10, P1778; Grady D, 2001, JAMA-J AM MED ASSOC, V285, P2909, DOI 10.1001/jama.285.22.2909; Handa VL, 1996, J AM GERIATR SOC, V44, P1; Hannan EL, 2001, JAMA-J AM MED ASSOC, V285, P2736, DOI 10.1001/jama.285.21.2736; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JACOBSEN SJ, 1992, AM J PUBLIC HEALTH, V82, P1147, DOI 10.2105/AJPH.82.8.1147; Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755; Kado DM, 1999, ARCH INTERN MED, V159, P1215, DOI 10.1001/archinte.159.11.1215; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KRISTAL AR, 1994, P 17 NAT NUTR DAT C, P110; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205; Melton LJ, 1999, OSTEOPOROSIS INT, V9, P29, DOI 10.1007/s001980050113; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Nelson HD, 2002, ANN INTERN MED, V137, P529, DOI 10.7326/0003-4819-137-6-200209170-00015; Nevitt MC, 1998, ANN INTERN MED, V128, P793, DOI 10.7326/0003-4819-128-10-199805150-00001; Pi-Sunyer FX, 1998, AM J CLIN NUTR, V68, P899; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SEELEY DG, 1995, ARCH INTERN MED, V155, P293, DOI 10.1001/archinte.155.3.293; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002	36	772	806	1	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1729	1738		10.1001/jama.290.13.1729	http://dx.doi.org/10.1001/jama.290.13.1729			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519707	Bronze			2023-01-03	WOS:000185606100022
J	Pedley, DK; Bissett, K; Connolly, EM; Goodman, CG; Golding, I; Pringle, TH; McNeill, GP; Pringle, SD; Jones, MC				Pedley, DK; Bissett, K; Connolly, EM; Goodman, CG; Golding, I; Pringle, TH; McNeill, GP; Pringle, SD; Jones, MC			Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics	BRITISH MEDICAL JOURNAL			English	Article							EARLY ANISTREPLASE TRIAL; NEEDLE TIMES; THERAPY; MORTALITY; CALL	Objectives To evaluate a system of prehospital thrombolysis, delivered by paramedics, in meeting the national service framework's targets for the management of acute myocardial infarction. Design Prospective observational cohort study comparing patients with suspected acute myocardial infarction considered for thrombolysis in the prehospital environment With patients treated in hospital. Setting The catchment area of a large teaching hospital, including urban and rural areas. Participants 201 patients presenting concurrently over a 12 month period who had changes to the electrocardiogram that were diagnostic of acute myocardial infarction or who received thrombolysis for suspected acute myocardial infarction. Main outcome measures Time from first medical contact to initiation of thrombolysis (call to needle time), number of patients given thrombolysis appropriately, and all cause mortality in hospital. Results The median call to needle time for patients treated before arriving in hospital (n=28) was 52 (95% confidence interval 41 to 62) minutes. Patients from similar rural areas who were treated in hospital (n=43) had a median time of 125 (104 to 140) minutes. This represents a median time saved of 73 minutes (P < 0.001). Sixty minutes after medical contact 64% of, patients (18/28) treated before arrival in hospital had received thrombolysis; this compares with 4% of patients (2/43) in a cohort from similar areas. Median call to needle time for patients from urban areas (n=107) was 80 (78 to 93) minutes. Myocardial infarction was confirmed in 89% of patients (25/28) who had received prehospital thrombolysis; this compares with 92% (138/150) in the two groups of patients receiving thrombolysis in hospital. Conclusions Thrombolysis delivered by paramedics with support from the base hospital can meet the national targets for early thrombolysis. The system has been shown to work well and can be introduced without delay.	Univ Dundee, Ninewells Hosp & Med Sch, Chest Pain Serv, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Med & Cardiovasc Grp, Dundee DD1 9SY, Scotland; Scottish Ambulance Serv, Dundee DD3 8PQ, Scotland	University of Dundee; University of Dundee	Pedley, DK (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Chest Pain Serv, Dundee DD1 9SY, Scotland.							[Anonymous], 1988, LANCET, V332, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; *DEP HLTH, 2000, NAT SERV FRAM COR HE; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; Morrison LJ, 2000, JAMA-J AM MED ASSOC, V283, P2686, DOI 10.1001/jama.283.20.2686; Rawles J, 1998, BRIT MED J, V317, P576, DOI 10.1136/bmj.317.7158.576; Rawles J, 1999, BRIT MED J, V318, P1554; Rawles JM, 1997, J AM COLL CARDIOL, V30, P1181, DOI 10.1016/S0735-1097(97)00299-4; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767; 2002, J AM COLL CARDIOL, V3, P71	13	53	54	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 5	2003	327	7405					22	26		10.1136/bmj.327.7405.22	http://dx.doi.org/10.1136/bmj.327.7405.22			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842951	Green Published, Bronze			2023-01-03	WOS:000184062700018
J	Mileykovskaya, E; Fishov, I; Fu, XY; Corbin, BD; Margolin, W; Dowhan, W				Mileykovskaya, E; Fishov, I; Fu, XY; Corbin, BD; Margolin, W; Dowhan, W			Effects of phospholipid composition on MinD-membrane interactions in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL DIVISION; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ESCHERICHIA-COLI; LIPID DOMAINS; SITE PLACEMENT; Z-RING; PROTEIN; LOCALIZATION; FTSZ; ATP	The peripheral membrane ATPase MinD is a component of the Min system responsible for correct placement of the division site in Escherichia coli cells. By rapidly migrating from one cell pole to the other, MinD helps to block unwanted septation events at the poles. MinD is an amphitropic protein that is localized to the membrane in its ATP-bound form. A C-terminal domain essential for membrane localization is predicted to be an amphipathic alpha-helix with hydrophobic residues interacting with lipid acyl chains and cationic residues on the opposite face of the helix interacting with the head groups of anionic phospholipids (Szeto, T. H., Rowland, S. L., Rothfield, L. I., and King, G. F. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 15693 - 15698). To investigate whether E. coli MinD displays a preference for anionic phospholipids, we first examined the localization dynamics of a green fluorescent protein-tagged derivative of MinD expressed in a mutant of E. coli that lacks phosphatidylethanolamine. In these cells, which contain only anionic phospholipids ( phosphatidylglycerol and cardiolipin), green fluorescent protein-MinD assembled into dynamic focal clusters instead of the broad zones typical of cells with normal phospholipid content. In experiments with liposomes composed of only zwitterionic, only anionic, or a mixture of anionic and zwitterionic phospholipids, purified MinD bound to these liposomes in the presence of ATP with positive cooperativity with respect to the protein concentration and exhibited Hill coefficients of about 2. Oligomerization of MinD on the liposome surface also was detected by fluorescence resonance energy transfer between MinD molecules labeled with different fluorescent probes. The affinity of MinD-ATP for anionic liposomes as well as liposomes composed of both anionic and zwitterionic phospholipids increased 9- and 2-fold, respectively, relative to zwitterionic liposomes. The degree of acyl chain unsaturation contributed positively to binding strength. These results suggest that MinD has a preference for anionic phospholipids and that MinD oscillation behavior, and therefore cell division site selection, may be regulated by membrane phospholipid composition.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77225 USA; Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	University of Texas System; University of Texas System; Ben Gurion University	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	William.Dowhan@uth.tmc.edu	FISHOV, ITZHAK/F-2264-2012	Fishov, Itzhak/0000-0002-2125-0012; Mileykovskaya, Eugenia/0000-0002-8775-4467	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061074] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20487, GM61074] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addinall SG, 2002, J MOL BIOL, V318, P219, DOI 10.1016/S0022-2836(02)00024-4; AKERLUND T, 1992, MOL MICROBIOL, V6, P2073, DOI 10.1111/j.1365-2958.1992.tb01380.x; Christensen H, 1999, MOL MICROBIOL, V31, P1561, DOI 10.1046/j.1365-2958.1999.01304.x; Corbin BD, 2002, EMBO J, V21, P1998, DOI 10.1093/emboj/21.8.1998; Cordell SC, 2001, FEBS LETT, V492, P160, DOI 10.1016/S0014-5793(01)02216-5; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Drobnies AE, 2002, BBA-BIOMEMBRANES, V1564, P82, DOI 10.1016/S0005-2736(02)00404-2; EISENBERG D, 1989, PREDICTION PROTEIN S, P635; Fishov I, 1999, MOL MICROBIOL, V32, P1166, DOI 10.1046/j.1365-2958.1999.01425.x; Haiens TH, 2002, FEBS LETT, V528, P35, DOI 10.1016/S0014-5793(02)03292-1; Hu ZL, 1999, P NATL ACAD SCI USA, V96, P14819, DOI 10.1073/pnas.96.26.14819; Hu ZL, 2003, MOL MICROBIOL, V47, P345, DOI 10.1046/j.1365-2958.2003.03321.x; Hu ZL, 2003, J BACTERIOL, V185, P196, DOI 10.1128/JB.185.1.196-203.2003; Hu ZL, 2002, P NATL ACAD SCI USA, V99, P6761, DOI 10.1073/pnas.102059099; Hu ZL, 2000, J BACTERIOL, V182, P3965, DOI 10.1128/JB.182.14.3965-3971.2000; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; Johnson JE, 2003, J BIOL CHEM, V278, P514, DOI 10.1074/jbc.M206072200; KARNOVSKY MJ, 1982, J CELL BIOL, V94, P1, DOI 10.1083/jcb.94.1.1; Koppelman CM, 2001, J BACTERIOL, V183, P6144, DOI 10.1128/JB.183.20.6144-6147.2001; Lackner LL, 2003, J BACTERIOL, V185, P735, DOI 10.1128/JB.185.3.735-749.2003; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Margolin W, 2001, CURR OPIN MICROBIOL, V4, P647, DOI 10.1016/S1369-5274(01)00264-8; Margolin W, 2001, CURR BIOL, V11, pR395, DOI 10.1016/S0960-9822(01)00217-2; Meinhardt H, 2001, P NATL ACAD SCI USA, V98, P14202, DOI 10.1073/pnas.251216598; METCALF TN, 1986, P NATL ACAD SCI USA, V83, P95, DOI 10.1073/pnas.83.1.95; Mileykovskaya E, 1998, J BACTERIOL, V180, P4252, DOI 10.1128/JB.180.16.4252-4257.1998; Mileykovskaya E, 2000, J BACTERIOL, V182, P1172, DOI 10.1128/JB.182.4.1172-1175.2000; Phoenix DA, 2002, MOL MEMBR BIOL, V19, P1, DOI 10.1080/09687680110103631; Raskin DM, 1999, P NATL ACAD SCI USA, V96, P4971, DOI 10.1073/pnas.96.9.4971; Rothfield L, 1999, ANNU REV GENET, V33, P423, DOI 10.1146/annurev.genet.33.1.423; Rothfield LI, 2001, CELL, V106, P13, DOI 10.1016/S0092-8674(01)00432-9; Rye HS, 2001, METHODS, V24, P278, DOI 10.1006/meth.2001.1188; Sakai N, 2001, STRUCTURE, V9, P817, DOI 10.1016/S0969-2126(01)00638-4; Shih YL, 2002, EMBO J, V21, P3347, DOI 10.1093/emboj/cdf323; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Suefuji K, 2002, P NATL ACAD SCI USA, V99, P16776, DOI 10.1073/pnas.262671699; Szeto TH, 2002, P NATL ACAD SCI USA, V99, P15693, DOI 10.1073/pnas.232590599; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Weiss DS, 1999, J BACTERIOL, V181, P508, DOI 10.1128/JB.181.2.508-520.1999; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	42	133	136	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22193	22198		10.1074/jbc.M302603200	http://dx.doi.org/10.1074/jbc.M302603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12676941	hybrid			2023-01-03	WOS:000183503900003
J	Berman, B				Berman, B			Integrative approaches to pain management: how to get the best of both worlds	BRITISH MEDICAL JOURNAL			English	Article									Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Berman, B (corresponding author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.				NCCIH NIH HHS [N0 5-P50-AT00084-02] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P50AT000084] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)			0	9	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1320	+		10.1136/bmj.326.7402.1320-a	http://dx.doi.org/10.1136/bmj.326.7402.1320-a			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805175	Green Published			2023-01-03	WOS:000183626500040
J	Steinman, MA; Gonzales, R; Linder, JA; Landefeld, CS				Steinman, MA; Gonzales, R; Linder, JA; Landefeld, CS			Changing use of antibiotics in community-based outpatient practice, 1991-1999	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; RESPIRATORY-TRACT INFECTIONS; ACUTE OTITIS-MEDIA; ANTIMICROBIAL RESISTANCE; JUDICIOUS USE; PHARMACEUTICAL-INDUSTRY; UNITED-STATES; PRIMARY-CARE; INCREASING PREVALENCE; PHYSICIANS BEHAVIOR	Background: Judicious use of antibiotics can slow the spread of antimicrobial resistance. However, overall patterns of antibiotic use among ambulatory patients are not well understood. Objective: To study patterns of outpatient antibiotic use in the United States, focusing on broad-spectrum antibiotics. Design: Cross-sectional survey in three 2-year periods (1991-1992, 1994-1995, and 1998-1999). Setting: The National Ambulatory Medical Care Survey, a nationally representative sample of community-based outpatient visits. Patients: Patients visiting community-based outpatient clinics. Measurements: Rates of overall antibiotic use and use of broad-spectrum antibiotics (azithromycin and clarithromycin, quinolones, amoxicillin-clavulanate, and second- and third-generation cephalosporins). All comparisons were made between the first study period (1991-1992) and the final study period (1998-1999). Results: Between 1991-1992 and 1998-1999, antibiotics were used less frequently to treat acute respiratory tract infections, such as the common cold and pharyngitis. However, use of broad-spectrum agents increased from 24% to 48% of antibiotic prescriptions in adults (P < 0.001) and from 23% to 40% in children (P < 0.001). Use of broad-spectrum antibiotics increased across many conditions, increasing two- to threefold as a percentage of total antibiotic use for a variety of diagnoses in both adults and children. By 1998-1999, 22% of adult and 14% of pediatric prescriptions for broad-spectrum antibiotics were for the common cold, unspecified upper respiratory tract infections, and acute bronchitis, conditions that are primarily viral. Conclusions: Antibiotic use in ambulatory patients is decreasing in the United States. However, physicians are increasingly turning to expensive, broad-spectrum agents, even when there is little clinical rationale for their use.	Univ Calif San Francisco, Vet Adm Med Ctr, Div Geriatr, San Francisco, CA 94121 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Steinman, MA (corresponding author), Univ Calif San Francisco, Vet Adm Med Ctr, Div Geriatr, Box 18-G,4150 Clement St, San Francisco, CA 94121 USA.	mstein@itsa.ucsf.edu	Linder, Jeffrey/AAF-3424-2021	Linder, Jeffrey/0000-0003-2217-184X	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE011001] Funding Source: NIH RePORTER; BHP HRSA HHS [5T32PE11001-12] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); BHP HRSA HHS		Appelbaum PC, 2000, CLIN INFECT DIS, V31, pS29, DOI 10.1086/314057; Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152; Avorn J, 2000, ANN INTERN MED, V133, P128, DOI 10.7326/0003-4819-133-2-200007180-00012; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; Bell RA, 1999, J GEN INTERN MED, V14, P651, DOI 10.1046/j.1525-1497.1999.01049.x; Bloom BS, 2001, BMJ-BRIT MED J, V323, P647, DOI 10.1136/bmj.323.7314.647; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P800; Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; Chew LD, 2000, J GEN INTERN MED, V15, P478, DOI 10.1046/j.1525-1497.2000.08014.x; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; ClavoSanchez AJ, 1997, CLIN INFECT DIS, V24, P1052, DOI 10.1086/513628; Doern GV, 2001, CLIN INFECT DIS, V33, pS187, DOI 10.1086/321847; Donskey CJ, 2000, NEW ENGL J MED, V343, P1925, DOI 10.1056/NEJM200012283432604; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P1, DOI 10.1097/00006454-199901000-00002; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; Gonzales R, 1999, J GEN INTERN MED, V14, P151, DOI 10.1046/j.1525-1497.1999.00306.x; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; Gupta K, 2001, ANN INTERN MED, V135, P41, DOI 10.7326/0003-4819-135-1-200107030-00012; Gupta K, 2001, CLIN INFECT DIS, V33, P89, DOI 10.1086/320880; Hamm RM, 1996, J FAM PRACTICE, V43, P56; HEMMINKI E, 1975, SOC SCI MED, V9, P111, DOI 10.1016/0037-7856(75)90103-1; Huang ES, 2002, ARCH INTERN MED, V162, P41, DOI 10.1001/archinte.162.1.41; Hyde TB, 2001, JAMA-J AM MED ASSOC, V286, P1857, DOI 10.1001/jama.286.15.1857; Ioannidis JPA, 2001, J ANTIMICROB CHEMOTH, V48, P677, DOI 10.1093/jac/48.5.677; Jain A, 1999, BRIT MED J, V318, P1596, DOI 10.1136/bmj.318.7198.1596; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; Linder JA, 2001, JAMA-J AM MED ASSOC, V286, P1181, DOI 10.1001/jama.286.10.1181; Low DE, 2001, CLIN INFECT DIS, V33, pS206, DOI 10.1086/321849; LURIE N, 1990, J GEN INTERN MED, V5, P240, DOI 10.1007/BF02600542; Marshall WF, 1999, MAYO CLIN PROC, V74, P187, DOI 10.4065/74.2.187; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; *MED EC, 1999, DRUG TOP RED BOOK; *NAT CTR HLTH STAT, 2001, PUBL US MICR FIL DOC; *NAT CTR HLTH STAT, 1994, PUBL US DAT TAP DOC; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; O'Brien KL, 1998, PEDIATRICS, V101, P178; O'Brien KL, 1998, PEDIATRICS, V101, P174; Piccirillo JF, 2001, JAMA-J AM MED ASSOC, V286, P1849, DOI 10.1001/jama.286.15.1849; *PRACT MAN INF, 1998, INT CLASS DIS; Rosenstein N, 1998, PEDIATRICS, V101, P181; SABLE CA, 1993, GERIATRICS, V48, P41; Sargent J, 2001, Eff Clin Pract, V4, P136; Schwartz B, 1998, PEDIATRICS, V101, P171; SENSAKOVIC JW, 1995, MED CLIN N AM, V79, P695, DOI 10.1016/S0025-7125(16)30033-5; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Snow V, 2001, ANN INTERN MED, V134, P518, DOI 10.7326/0003-4819-134-6-200103200-00020; Snow V, 2001, ANN INTERN MED, V134, P506, DOI 10.7326/0003-4819-134-6-200103200-00018; Snow V, 2001, ANN INTERN MED, V134, P495, DOI 10.7326/0003-4819-134-6-200103200-00016; Snow V, 2001, ANN INTERN MED, V134, P487, DOI 10.7326/0003-4819-134-6-200103200-00014; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; *STAT CORP, 1999, OV SURV EST STAT US, P321; Steinman MA, 2003, JAMA-J AM MED ASSOC, V289, P719, DOI 10.1001/jama.289.6.719; Steinman MA, 2001, AM J MED, V110, P551, DOI 10.1016/S0002-9343(01)00660-X; Takata GS, 2001, PEDIATRICS, V108, P239, DOI 10.1542/peds.108.2.239; Walker S, 2000, CAN MED ASSOC J, V163, P273; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; Wright AJ, 1999, MAYO CLIN PROC, V74, P290, DOI 10.4065/74.3.290; 2000, RESIDENT POPULATION	63	235	244	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					525	533		10.7326/0003-4819-138-7-200304010-00008	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667022				2023-01-03	WOS:000181872100001
J	Bradley, DJ; Bradley, EA; Baughman, KL; Berger, RD; Calkins, H; Goodman, SN; Kass, DA; Powe, NR				Bradley, DJ; Bradley, EA; Baughman, KL; Berger, RD; Calkins, H; Goodman, SN; Kass, DA; Powe, NR			Cardiac resynchronization and death from progressive heart failure - A meta-analysis of randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BUNDLE-BRANCH-BLOCK; DILATED CARDIOMYOPATHY; VENTRICULAR-TACHYCARDIA; MULTISITE STIMULATION; EXERCISE PERFORMANCE; SUDDEN-DEATH; THERAPY; MORTALITY; DEFIBRILLATOR; IMPLANTATION	Context Progressive heart failure is the most common mechanism of death among patients with advanced heart failure. Cardiac resynchronization, a pacemaker-based therapy for heart failure, enhances cardiac performance and quality of life, but its effect on mortality is uncertain. Objective To determine whether cardiac resynchronization reduces mortality from progressive heart failure. Data Sources MEDLINE (1966-2002), EMBASE (1980-2002), the Cochrane Controlled Trials Register (Second Quarter, 2002), The National Institutes of Health ClinicalTrials.gov database, the US Food and Drug Administration Web site, and reports presented at scientific meetings (1994-2002). Search terms included pacemaker, pacing, heart failure, dual-site, multisite, biventricular, resynchronization, and left ventricular preexcitation. Study Selection Eligible studies were randomized controlled trials of cardiac resynchronization for the treatment of chronic symptomatic left ventricular dysfunction. Eligible studies reported death, hospitalization for heart failure, or ventricular arrhythmia as outcomes. Of the 6883 potentially relevant reports initially identified, 11 reports of 4 randomized trials with 1634 total patients were included in the meta-analysis. Data Extraction Trial reports were reviewed independently by 2 investigators in an unblinded standardized manner. Data Synthesis Follow-up in the included trials ranged from 3 to 6 months. Pooled data from the 4 selected studies showed that cardiac resynchronization reduced death from progressive heart failure by 51% relative to controls (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.25-0.93). Progressive heart failure mortality was 1.7% for cardiac resynchronization patients and 3.5% for controls. Cardiac resynchronization also reduced heart failure hospitalization by 29% (OR, 0.71; 95% CI, 0.53-0.96) and showed a trend toward reducing all-cause mortality (OR, 0.77; 95% CI, 0.51-1.18). Cardiac resynchronization was not associated with a statistically significant effect on non-heart failure mortality (OR, 1.15; 95% CI, 0.65-2.02). Among patients with implantable cardioverter defibrillators, cardiac resynchronization had no clear impact on ventricular tachycardia or ventricular fibrillation (OR, 0.92; 95% CI, 0.67-1.27). Conclusions Cardiac resynchronization reduces mortality from progressive heart failure inpatients with symptomatic left ventricular dysfunction. This finding suggests that cardiac resynchronization may have a substantial impact on the most common mechanism of death among patients with advanced heart failure. Cardiac resynchronization also reduces heart failure hospitalization and shows a trend toward reducing all-cause mortality.	Johns Hopkins Sch Med, Dept Med, Div Cardiol, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA; Johns Hopkins Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Sch Med, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; Johns Hopkins Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; Mayo Clin & Mayo Fdn, Dept Ophthalmol, Rochester, MN 55905 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Mayo Clinic	Bradley, DJ (corresponding author), Johns Hopkins Univ Hosp, Div Cardiol, Carnegie 568,600 N Wolfe St, Baltimore, MD 21287 USA.	DBradley@jhmi.edu		Goodman, Steven/0000-0002-3872-5723				Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Abraham WT, 2000, J CARD FAIL, V6, P369, DOI 10.1054/jcaf.2000.20841; *AM HEART ASS, 2001, 2002 HEART STROK STA; Ansalone G, 2002, J AM COLL CARDIOL, V39, P489, DOI 10.1016/S0735-1097(01)01772-7; Auricchio A, 2002, J AM COLL CARDIOL, V39, P1163, DOI 10.1016/S0735-1097(02)01727-8; Auricchio A, 2002, AM J CARDIOL, V89, P198, DOI 10.1016/S0002-9149(01)02200-7; Auricchio A, 1999, CIRCULATION, V99, P2993, DOI 10.1161/01.CIR.99.23.2993; AURICCHIO A, 2001, N AM SOC PAC EL 22 A; AURICCHIO A, 2001, PACE, V24, P540; Baldasseroni S, 2002, AM HEART J, V143, P398, DOI 10.1067/mhj.2002.121264; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; BAROLD HS, 2002, US FOOD DRUG ADM CTR; BAROLD HS, 2001, PRELIMINARY CLIN REV; Barold SS, 2000, PACE, V23, P2117, DOI 10.1111/j.1540-8159.2000.tb00786.x; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; Birnie D, 2001, HEART, V86, P703, DOI 10.1136/heart.86.6.703; Braunwald E, 2000, CIRCULATION, V102, P14; Breithardt OA, 2002, AM HEART J, V143, P34, DOI 10.1067/mhj.2002.119616; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; CLARKE M, 2002, COCHRANE REV HDB 4 1; Cleland JGF, 1999, EUR J HEART FAIL, V1, P41, DOI 10.1016/S1388-9842(99)00009-4; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; Daubert JC, 2000, CIRCULATION, V102, P693; DAUBERT JC, 2002, PACING CLIN ELECTROP, V25, P558; De Sutter J, 2000, PACE, V23, P1718; de Teresa E, 2000, AM J CARDIOL, V86, p126K, DOI 10.1016/S0002-9149(00)01192-9; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; EGGER M, 2001, SYSTEMATIC REV HLTH, P51; Farwell D, 2000, EUR HEART J, V21, P1246, DOI 10.1053/euhj.1999.1985; Garrigue S, 2000, PACE, V23, P1700, DOI 10.1046/j.1460-9592.2000.01700.x; GOLDMAN S, 1993, CIRCULATION, V87, P24; Gottlieb SS, 1997, LANCET, V349, P662, DOI 10.1016/S0140-6736(97)22010-6; Gras D, 2002, EUR J HEART FAIL, V4, P311, DOI 10.1016/S1388-9842(02)00018-1; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; GRINES CL, 1989, CIRCULATION, V79, P845, DOI 10.1161/01.CIR.79.4.845; Guyomar Y, 2001, AM J CARDIOL, V88, P688, DOI 10.1016/S0002-9149(01)01819-7; Hare JM, 2002, NEW ENGL J MED, V346, P1902, DOI 10.1056/NEJMed020028; Healthcare Cost and Utilization Project, HEALTHC COST UT PROJ; Higgins SL, 2000, J AM COLL CARDIOL, V36, P824, DOI 10.1016/S0735-1097(00)00795-6; HILL AB, 1971, PRINCIPLES MED STATI, P313; Hjalmarson A, 1999, LANCET, V353, P2001; Huth C, 2001, Z KARDIOL, V90, P10; Kass DA, 1999, CIRCULATION, V99, P1567, DOI 10.1161/01.CIR.99.12.1567; Krahn AD, 2002, CAN J CARDIOL, V18, P380; Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8; Lechat P, 1999, LANCET, V353, P9; Leclercq C, 2002, J AM COLL CARDIOL, V39, P194, DOI 10.1016/S0735-1097(01)01747-8; Leclercq C, 2000, AM J CARDIOL, V85, P1154, DOI 10.1016/S0002-9149(00)00716-5; LEDERCQ C, 2002, N AM SOC PAC EL 23 A, V25, P601; Linde C, 2002, J AM COLL CARDIOL, V40, P111, DOI 10.1016/S0735-1097(02)01932-0; LINDE C, 2001, 23 ANN M EUR SOC CAR; Lozano I, 2000, PACE, V23, P1711; Lunati M, 2002, J CARDIOVASC ELECTR, V13, pS63, DOI 10.1111/j.1540-8167.2002.tb01956.x; Martinelli Filho Martino, 2002, Arq. Bras. Cardiol., V78, P110, DOI 10.1590/S0066-782X2002000100010; McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0; *MEDTR CORP, 2001, US FOOD DRUG ADM CTR, P236; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Murkofsky RL, 1998, J AM COLL CARDIOL, V32, P476, DOI 10.1016/S0735-1097(98)00242-3; Nelson GS, 2000, CIRCULATION, V102, P3053; Nelson GS, 2000, CIRCULATION, V101, P2703, DOI 10.1161/01.CIR.101.23.2703; Oguz E, 2002, EUR J HEART FAIL, V4, P83, DOI 10.1016/S1388-9842(01)00188-X; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer Milton, 2001, American Journal of Medicine, V110, p81S; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Saxon LA, 2002, CIRCULATION, V105, P1304, DOI 10.1161/hc1102.105730; *STAT CORP, 2001, STAT STAT SOFTW COMP; Stellbrink C, 2001, J AM COLL CARDIOL, V38, P1957, DOI 10.1016/S0735-1097(01)01637-0; Stellbrink C, 1999, AM J CARDIOL, V83, p143D; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; *US FDA, 2001, US FOOD DRUG ADM CTR; *US FDA, SUMM SAF EFF GUID CO; *US FDA, 2002, US FOOD DRUG ADM CTR; Walker S, 2000, AM J CARDIOL, V86, P231, DOI 10.1016/S0002-9149(00)00865-1; Werling C, 2002, THORAC CARDIOV SURG, V50, P67, DOI 10.1055/s-2002-26702; Yu CM, 2002, CIRCULATION, V105, P438, DOI 10.1161/hc0402.102623; Zagrodzky JD, 2001, AM J CARDIOL, V87, P1208, DOI 10.1016/S0002-9149(01)01498-9; 2001, SUMMARY SAFETY EFFEC	79	521	571	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	2003	289	6					730	740		10.1001/jama.289.6.730	http://dx.doi.org/10.1001/jama.289.6.730			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	643WP	12585952				2023-01-03	WOS:000180886000028
J	Goodnough, LT; Shander, A; Brecher, ME				Goodnough, LT; Shander, A; Brecher, ME			Transfusion medicine: looking to the future	LANCET			English	Review							FACTOR-CLEAVING PROTEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED-STATES; PHOTOCHEMICAL INACTIVATION; BACTERIAL-CONTAMINATION; PATIENT IDENTIFICATION; RETROSPECTIVE ANALYSIS; TRYPANOSOMA-CRUZI; BOVINE HEMOGLOBIN; HEMATOCRIT VALUES	The evolution of transfusion medicine into a clinically oriented discipline emphasising patient care has been accompanied by challenges that need to be faced as specialists look to the future. Emerging issues that affect blood safety and blood supply, such as pathogen inactivation and more stringent donor screening questions, bring new pressures on the availability of an affordable blood supply. Imminent alternatives for management of anaemia, such as oxygen carriers, hold great promise but, if available, will require close oversight. With current estimates of HIV or hepatitis C viral (HCV) transmission approaching one in 2 000 000 units transfused, keeping to a minimum bacterial contamination of platelet products (one in 2000) and errors in transfusion, with its estimated one in 800 000 mortality rate, assume great urgency. Finally, serious difficulties in blood safety and availability for poor, developing countries require innovative strategies and commitment of resources.	Washington Univ, Sch Med, Div Lab Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; Mt Sinai Sch Med, Dept Anesthesiol, New York, NY USA; Englewood Med Ctr, Dept Anesthesiol Crit Care & Hyperbar Med, Englewood, NJ USA; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA	Washington University (WUSTL); Washington University (WUSTL); Icahn School of Medicine at Mount Sinai; Englewood Hospital & Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Goodnough, LT (corresponding author), Washington Univ, Sch Med, Div Lab Med, Dept Med, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	goodnough@labmed.wustl.edu						*AM ASS BLOOD BANK, 1996, ASS B AM ASS BLOOD B, V966; [Anonymous], 2001, ASS B AM ASS BLOOD B; AuBuchon JP, 1997, ANN INTERN MED, V127, P904, DOI 10.7326/0003-4819-127-10-199711150-00009; AuBuchon JP, 2001, TRANSFUSION, V41, p1S; AuBuchon JP, 2001, TRANSFUSION, V41, P964, DOI 10.1046/j.1537-2995.2001.41070964.x; Bandarenko N, 1998, J CLIN APHERESIS, V13, P133, DOI 10.1002/(SICI)1098-1101(1998)13:3<133::AID-JCA7>3.0.CO;2-Z; Battles JB, 1998, ARCH PATHOL LAB MED, V122, P231; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Brecher ME, 2000, TRANSFUSION, V40, P1308, DOI 10.1046/j.1537-2995.2000.40111308.x; Brecher ME, 1999, TRANSFUSION, V39, P396, DOI 10.1046/j.1537-2995.1999.39499235673.x; Brecher ME, 2001, TRANSFUSION, V41, P477, DOI 10.1046/j.1537-2995.2001.41040477.x; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; *C HLTH, MILL NEED ACC SAF BL; Callum JL, 2001, TRANSFUSION, V41, P1204, DOI 10.1046/j.1537-2995.2001.41101204.x; CANNELLA G, 1991, NEPHROL DIAL TRANSPL, V6, P31, DOI 10.1093/ndt/6.1.31; Cardoso MD, 2000, TRANSFUSION, V40, P1422, DOI 10.1046/j.1537-2995.2000.40111422.x; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; CHAPMAN J, 2001, 16 M JAN 31 202, V1; Cimo P L, 1993, Tex Med, V89, P48; Clark WF, 1999, ANN INTERN MED, V131, P453, DOI 10.7326/0003-4819-131-6-199909210-00011; Collins A., 1998, Journal of the American Society of Nephrology, V9, p204A; Collins AJ, 2000, SEMIN NEPHROL, V20, P345; Collins AJ, 2001, J AM SOC NEPHROL, V12, P2465, DOI 10.1681/ASN.V12112465; Consulting Pathologists Group Committee, 1953, BRIT MED J, V2, P390; Corash L, 1997, BLOOD, V90, P1171; Cothren C, 2002, NEW ENGL J MED, V346, P1097, DOI 10.1056/NEJM200204043461420; Dodd RY, 1998, TRANSFUSION, V38, P221, DOI 10.1046/j.1537-2995.1998.38398222863.x; DYSKSTRA A, 1998, TRANSFUSION S, V38, pS104; Eschbach J, 1997, AM J KIDNEY DIS, V30, pS192; *FDA, REV PREV MEAS RED PO; Foley RN, 1996, AM J KIDNEY DIS, V28, P53, DOI 10.1016/S0272-6386(96)90130-4; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; GILCHER R, 2002, 16 M JAN 31 2002, V1; GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6; Goldman M, 1997, TRANSFUSION, V37, P523, DOI 10.1046/j.1537-2995.1997.37597293885.x; Goodnough LT, 1999, NEW ENGL J MED, V340, P525, DOI 10.1056/NEJM199902183400706; Goodnough LT, 2001, NEW ENGL J MED, V345, P1272, DOI 10.1056/NEJM200110253451711; Goodnough LT, 1999, NEW ENGL J MED, V340, P438, DOI 10.1056/NEJM199902113400606; Goodnough LT, 1999, TRANSFUSION, V39, P1031, DOI 10.1046/j.1537-2995.1999.39091031.x; GUERRERO IC, 1983, ANN INTERN MED, V99, P221, DOI 10.7326/0003-4819-99-2-221; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; Hedner U, 2002, TRANSFUSION, V42, P114, DOI 10.1046/j.1537-2995.2002.00017.x; Jacobs MR, 2001, TRANSFUSION, V41, P1331, DOI 10.1046/j.1537-2995.2001.41111331.x; Jensen NJ, 1996, TRANSFUSION, V36, P216, DOI 10.1046/j.1537-2995.1996.36396182138.x; JONES JA, 1995, BRIT J ANAESTH, V74, P697, DOI 10.1093/bja/74.6.697; Kasper SM, 1998, ANESTH ANALG, V87, P284, DOI 10.1097/00000539-199808000-00009; KEIPERT PE, 1995, ARTIF CELL BLOOD SUB, V23, P381, DOI 10.3109/10731199509117954; Klein HG, 2001, TRANSFUSION, V41, P1179, DOI 10.1046/j.1537-2995.2001.41101179.x; Kleinman S. H., 2002, Vox Sanguinis, V83, P106; Knutson F, 2000, VOX SANG, V78, P209, DOI 10.1159/000031183; Laan E, 1999, TRANSFUSION, V39, p5S; Leiby DA, 1997, TRANSFUSION, V37, P259, DOI 10.1046/j.1537-2995.1997.37397240206.x; LENFANT C, 1992, TRANSFUSION, V32, P873, DOI 10.1046/j.1537-2995.1992.32993110764.x; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Lin L, 1997, TRANSFUSION, V37, P423, DOI 10.1046/j.1537-2995.1997.37497265344.x; Linden JV, 2000, TRANSFUSION, V40, P1207, DOI 10.1046/j.1537-2995.2000.40101207.x; Ma JZ, 1999, J AM SOC NEPHROL, V10, P610; Ma ZM, 1997, CLIN CHEM, V43, P1732; Maguire PJ, 2000, CRIT CARE CLIN, V16, P681, DOI 10.1016/S0749-0704(05)70140-8; McCullough J, 2001, BLOOD, V98, p450A; McDonald C. P., 2000, Vox Sanguinis, V78, pP375; McQuiston JH, 2000, TRANSFUSION, V40, P274, DOI 10.1046/j.1537-2995.2000.40030274.x; Mullon J, 2000, NEW ENGL J MED, V342, P1638, DOI 10.1056/NEJM200006013422204; Mungai M, 2001, NEW ENGL J MED, V344, P1973, DOI 10.1056/NEJM200106283442603; NAHLEN BL, 1991, TRANSFUSION, V31, P798, DOI 10.1046/j.1537-2995.1991.31992094665.x; Ness P, 2001, TRANSFUSION, V41, P857, DOI 10.1046/j.1537-2995.2001.41070857.x; NIGHTINGALE S, 2002, 16 M JAN 31 2002, V1; NOEL L, 2000, SAFE BLOOD STARTS ME; Ollgaard M., 1998, Vox Sanguinis, V74, P1126; OUELLETTE G, 2002, 16 M JAN 31 2002, V1; RIOUX F, 1995, J CARDIOVASC PHARM, V25, P587, DOI 10.1097/00005344-199504000-00012; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; Sazama K, 2001, TRANSFUSION, V41, P577, DOI 10.1046/j.1537-2995.2001.41050577.x; Schmidt PJ, 2002, NEW ENGL J MED, V346, P617, DOI 10.1056/NEJM200202213460813; SCHMUNIS GA, 1991, TRANSFUSION, V31, P547, DOI 10.1046/j.1537-2995.1991.31691306255.x; Schmunis GA, 2001, AM J TROP MED HYG, V65, P924, DOI 10.4269/ajtmh.2001.65.924; Scott MG, 1997, CLIN CHEM, V43, P1724; Shulman IA, 1997, TRANSFUSION, V37, P727, DOI 10.1046/j.1537-2995.1997.37797369449.x; Silverberg DS, 2001, J AM COLL CARDIOL, V37, P1775, DOI 10.1016/S0735-1097(01)01248-7; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; SNYDER E, 2001, 16 M JAN 31 2002; SPAHN DR, 1994, ANESTH ANALG, V78, P1000; Spahn DR, 1999, ANESTHESIOLOGY, V91, P1195, DOI 10.1097/00000542-199911000-00009; Stowell CP, 2001, TRANSFUSION, V41, P287, DOI 10.1046/j.1537-2995.2001.41020287.x; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Valeri CR, 2001, TRANSFUSION, V41, P933, DOI 10.1046/j.1537-2995.2001.41070933.x; VUETIC D, 2000, VOX SANG S, V78, pP371; WENZ B, 1991, TRANSFUSION, V31, P401, DOI 10.1046/j.1537-2995.1991.31591263193.x; Williamson LM, 1999, BRIT MED J, V319, P16, DOI 10.1136/bmj.319.7201.16; WINSLOW RM, 1995, NAT MED, V1, P1212, DOI 10.1038/nm1195-1212; Winslow RM, 2002, CURR OPIN HEMATOL, V9, P146, DOI 10.1097/00062752-200203000-00011; Wu WC, 2001, NEW ENGL J MED, V345, P1230, DOI 10.1056/NEJMoa010615; YOMTOVIAN R, 1993, TRANSFUSION, V33, P902, DOI 10.1046/j.1537-2995.1993.331194082380.x; Zayas CF, 2002, JAMA-J AM MED ASSOC, V287, P1795; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200	98	182	199	1	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 11	2003	361	9352					161	169		10.1016/S0140-6736(03)12195-2	http://dx.doi.org/10.1016/S0140-6736(03)12195-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	635YP	12531595				2023-01-03	WOS:000180428000026
J	Haynes, RB; McDonald, HP; Garg, AX				Haynes, RB; McDonald, HP; Garg, AX			Helping patients follow prescribed treatment - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADHERENCE	Low adherence to prescribed medical regimens is a ubiquitous problem. Typical adherence rates are about 50% for medications and are much lower for lifestyle prescriptions and other more behaviorally demanding regimens. In addition, many patients with medical problems do not seek care or drop out of care prematurely. Although accurate measures of low adherence are lacking for many regimens, simple measures, such as directly asking patients and watching for appointment nonattendance and treatment nonresponse, will detect most problems. For short-term regimens (less than or equal to2 weeks), adherence to medications is readily achieved by giving clear instructions. On the other hand, improving adherence to long-term regimens requires combinations of information about the regimen, counseling about the importance of adherence and how to organize medication taking, reminders about appointments and adherence, rewards and recognition for the patient's efforts to follow the regimen, and enlisting social support from family and friends. Successful interventions for long-term regimens are all labor-intensive but ultimately can be cost-effective.	McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Fac Hlth Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Sch Grad Studies, Hlth Res Methodol Program, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University	Haynes, RB (corresponding author), McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Fac Hlth Sci, Room 2C10B,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Garg, Amit X/G-3295-2011	Haynes, Robert Brian/0000-0002-1453-3196				BOWEN RG, 1961, NURS RES, V10, P151, DOI 10.1097/00006199-196101030-00005; DICKEY FF, 1975, HOSPITALS, V49, P85; GILBERT JR, 1980, CAN MED ASSOC J, V123, P119; Girvin B, 1999, J HYPERTENS, V17, P1627, DOI 10.1097/00004872-199917110-00017; GORDIS L, 1969, PEDIATRICS, V43, P173; Haynes RB, 2001, AM HEART MONOGR S, P3; Holmboe ES, 2002, JAMA-J AM MED ASSOC, V287, P373, DOI 10.1001/jama.287.3.373; Inzucchi SE, 2002, JAMA-J AM MED ASSOC, V287, P360, DOI 10.1001/jama.287.3.360; JONSEN AR, 1979, COMPLIANCE HLTH CARE, P113; LEVINE RJ, 1994, AM J RESP CRIT CARE, V149, P287, DOI 10.1164/ajrccm.149.2.8306018; LINKEWICH JA, 1974, DRUG INTEL CLIN PHAR, V8, P10, DOI 10.1177/106002807400800102; LOGAN AG, 1981, HYPERTENSION, V3, P211, DOI 10.1161/01.HYP.3.2.211; MACHARIA WM, 1992, JAMA-J AM MED ASSOC, V267, P1813, DOI 10.1001/jama.267.13.1813; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; SACKETT DL, 1979, ADHERENCE HLTH CARE, P11; SHARPE TR, 1974, AM J HOSP PHARM, V31, P479, DOI 10.1093/ajhp/31.5.479; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; Wright A, 1998, ANN INTERN MED, V128, P165, DOI 10.7326/0003-4819-128-3-199802010-00001; Yusuf S, 2000, NEW ENGL J MED, V342, P145; [No title captured]	20	560	593	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	2002	288	22					2880	2883		10.1001/jama.288.22.2880	http://dx.doi.org/10.1001/jama.288.22.2880			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623YM	12472330	Bronze			2023-01-03	WOS:000179732600033
J	Mallet, L; Mesnage, V; Houeto, JL; Pelissolo, A; Yelnik, J; Behar, C; Gargiulo, M; Welter, ML; Bonnet, AM; Pillon, B; Cornu, P; Dormont, D; Pidoux, B; Allilaire, JF; Agid, Y				Mallet, L; Mesnage, V; Houeto, JL; Pelissolo, A; Yelnik, J; Behar, C; Gargiulo, M; Welter, ML; Bonnet, AM; Pillon, B; Cornu, P; Dormont, D; Pidoux, B; Allilaire, JF; Agid, Y			Compulsions, Parkinson's disease, and stimulation	LANCET			English	Article								Pathophysiological models suggest that obsessive compulsive disorder (OCD) might be associated with dysfunctions in cortico-striato-pallido-thalamo-corticaI neuronal circuits. We implanted subthalamic electrodes to alleviate parkinsonian symptoms in two patients who had Parkinson's disease and a history of severe OCD. Parkinsonian disability improved postoperatively in both patients, and 2 weeks after the procedure, their compulsions had disappeared and obsessive symptoms improved (58% improvement for patient I on the Yale-Brown obsessive compulsive scale, 64% for patient 2). The improvements in these two patients suggest that high-frequency stimulation could improve function in the subcortical-limbic circuitry in patients with severe OCD.	Hop La Pitie Salpetriere, Assistance Publ Hop Paris, CNRS, UMR 7593, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, GH Pitie Salpetriere, F-75651 Paris, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Ctr Invest Clin, Federat Neurol, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, INSERM, U289, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, EPI 007, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Serv Neurochirurg, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Serv Neuroradiol, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Serv Neurophysiol, F-75651 Paris 13, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite	Mallet, L (corresponding author), Hop La Pitie Salpetriere, Assistance Publ Hop Paris, CNRS, UMR 7593, F-75651 Paris 13, France.		dormont, didier/B-2175-2012; Mallet, Luc/F-7156-2013; Dormont, Didier/F-5492-2012; Yelnik, Jérôme/F-7153-2013	Mallet, Luc/0000-0001-8061-1167; PELISSOLO, Antoine/0000-0003-0465-5648; Gargiulo, Marcela/0000-0003-1056-0653; YELNIK, Jerome/0000-0003-4814-708X				Alegret M, 2001, ARCH NEUROL-CHICAGO, V58, P1223, DOI 10.1001/archneur.58.8.1223; Benabid AL, 1998, MOVEMENT DISORD, V13, P119; Houeto JL, 2002, J NEUROL NEUROSUR PS, V72, P701, DOI 10.1136/jnnp.72.6.701; RAUCH SL, 2001, TOURETTE SYNDROME, P207; Yelnik J, 2000, NEUROSCIENCE, V101, P77, DOI 10.1016/S0306-4522(00)00364-X	5	251	255	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1302	1304		10.1016/S0140-6736(02)11339-0	http://dx.doi.org/10.1016/S0140-6736(02)11339-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414208				2023-01-03	WOS:000178827200015
J	Grimes, DA				Grimes, DA			Switching emergency contraception to over-the-counter status	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVANCE PROVISION; NICOTINE PATCH; SAFETY; LABEL		Family Hlth Int, Res Triangle Pk, NC 27713 USA		Grimes, DA (corresponding author), Family Hlth Int, Res Triangle Pk, NC 27713 USA.							AUBENY E, 2000, EUR J CONTRACEPT  S1, V5, P41; Davidson M, 1998, ARCH FAM MED, V7, P569, DOI 10.1001/archfami.7.6.569; EC Hughes, 1972, OBSTETRIC GYNECOLOGI, P327; Ellertson C, 1998, J Am Med Womens Assoc (1972), V53, P226; Ellertson C, 2001, OBSTET GYNECOL, V98, P570, DOI 10.1016/S0029-7844(01)01506-X; ELLERTSON C, 1998, J AM MED WOM ASS S2, V53, P232; Glasier A, 1998, NEW ENGL J MED, V339, P1, DOI 10.1056/NEJM199807023390101; Grimes D, 1998, LANCET, V352, P428; Grimes DA, 1997, NEW ENGL J MED, V337, P1078, DOI 10.1056/NEJM199710093371510; Grimes DA, 2001, OBSTET GYNECOL, V98, P151, DOI 10.1016/S0029-7844(01)01412-0; Grimes DA, 2001, WOMEN HEALTH ISS, V11, P397, DOI 10.1016/S1049-3867(01)00126-8; GRIMES DA, 1992, NEW ENGL J MED, V327, P1088, DOI 10.1056/NEJM199210083271509; GRIMES DA, 1992, AM J OBSTET GYNECOL, V166, P1950, DOI 10.1016/0002-9378(92)91394-P; Grimes DA, 2000, LANCET, V356, P1013, DOI 10.1016/S0140-6736(00)02699-4; Hays JT, 1999, AM J PUBLIC HEALTH, V89, P1701, DOI 10.2105/AJPH.89.11.1701; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; *HJ KAIS FAM FDN, 2000, EM CONTR PRESCR COUN, P1; Lovvorn A, 2000, CONTRACEPTION, V61, P287, DOI 10.1016/S0010-7824(00)00107-4; Matheson CI, 1998, FAM PRACT, V15, P38, DOI 10.1093/fampra/15.1.38; Mullen WH, 1997, ANN EMERG MED, V29, P255, DOI 10.1016/S0196-0644(97)70277-4; Piaggio G, 1999, LANCET, V353, P721, DOI 10.1016/S0140-6736(98)05718-3; Raine T, 2000, OBSTET GYNECOL, V96, P1, DOI 10.1016/S0029-7844(00)00830-9; RAMANWILMS L, 1995, OBSTET GYNECOL, V85, P141, DOI 10.1016/0029-7844(94)00341-A; Raymond EG, 2002, OBSTET GYNECOL, V100, P342, DOI 10.1016/S0029-7844(02)02086-0; ROWLANDS S, 1991, BR J FAM PLANN, V17, P23; Soller RW, 1999, DRUG INF J, V33, P799, DOI 10.1177/009286159903300320; Trussell J, 2000, OBSTET GYNECOL, V95, P267, DOI 10.1016/S0029-7844(99)00518-9; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; Ventura S J, 1999, Natl Vital Stat Rep, V47, P1; von Hertzen H, 2000, CONTRACEPTION, V61, P303, DOI 10.1016/S0010-7824(00)00116-5; Wearn AM, 1999, J CLIN PHARM THER, V24, P313, DOI 10.1046/j.1365-2710.1999.00234.x; WEBB A, 1994, BRIT MED J, V308, P135, DOI 10.1136/bmj.308.6921.135; *WHO, 2000, IMPR ACC QUAL CAR FA; WILLS SE, 2002, NATL REV         MAR; 2002, COUNTER MED WHATS RI; 1987, WHO TECH REP SER, V753, P7; 2002, TAKING EC COUNTER	37	35	35	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	2002	347	11					846	849		10.1056/NEJMsb020913	http://dx.doi.org/10.1056/NEJMsb020913			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592DK	12226159				2023-01-03	WOS:000177921300013
J	Royston, D; Cox, F				Royston, D; Cox, F			Anaesthesia: the patient's point of view	LANCET			English	Review							AUDITORY-EVOKED-RESPONSE; POSTOPERATIVE COGNITIVE DYSFUNCTION; ARTERY BYPASS-SURGERY; THORACIC EPIDURAL-ANESTHESIA; RANDOMIZED CONTROLLED TRIAL; GENERAL-ANESTHESIA; CARDIAC-SURGERY; PULSE OXIMETRY; COHERENT FREQUENCY; BISPECTRAL INDEX	Patients scheduled for surgical procedures continue to express concerns about their safety, outcome, and comfort. All medical interventions carry risks, but the patient often considers anaesthesia as the intervention with the greatest risk. Many still worry that they will not wake up after their surgery, or that they will be awake during the operation. Such events have received attention from the media, but are very rare. Challenges to Improve the comfort of patients continue, especially with regard to the almost universal problems of nausea, vomiting, and pain after surgery. A newer concern is that patients will develop some degree of mental impairment that may delay return to a full work and social lifestyle for days and weeks. Developments in technology, education, and training have had a major effect on anaesthetic practice, so that anaesthesia is increasingly regarded as safe for the patient. This article explores patients' concerns, and considers whether science and technology help to provide solutions to these complex difficulties.	Harefield Hosp, Royal Brompton & Harefield NHS Trust, Harefield UB9 6JH, Middx, England	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton Hospital	Royston, D (corresponding author), Harefield Hosp, Royal Brompton & Harefield NHS Trust, Hill End Rd, Harefield UB9 6JH, Middx, England.	Dave@tharg.demon.co.uk						Ancelin ML, 2000, REV EPIDEMIOL SANTE, V48, P459; Andrade J, 1996, ANESTH ANALG, V83, P1279, DOI 10.1097/00000539-199612000-00026; Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Audit Commission, 1997, AN EX EFF EFF AN PAI; Baguley WA, 1997, ANESTH ANALG, V84, P1380, DOI 10.1097/00000539-199706000-00038; Borowicz L, 2002, PSYCHOSOMATICS, V43, P464, DOI 10.1176/appi.psy.43.6.464; Bosek V, 2000, ANESTHESIOLOGY, V92, P885, DOI 10.1097/00000542-200003000-00040; BRESSLER SL, 1990, TRENDS NEUROSCI, V13, P161, DOI 10.1016/0166-2236(90)90039-D; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Chen PP, 2001, ANESTH ANALG, V92, P224; Chew S. T. H., 1998, SMJ, V39, P399; Christensen H, 2001, AUST NZ J PSYCHIAT, V35, P768, DOI 10.1046/j.1440-1614.2001.00966.x; Coloma M, 2002, ANESTHESIOLOGY, V96, P1346, DOI 10.1097/00000542-200206000-00013; Coloma M, 2002, ANESTHESIOLOGY, V97, P1387, DOI 10.1097/00000542-200212000-00009; COOPER JB, 1978, ANESTHESIOLOGY, V49, P399, DOI 10.1097/00000542-197812000-00004; Cooper JB, 2002, ANESTHESIOLOGY, V97, P1335, DOI 10.1097/00000542-200212000-00003; CRICK F, 1990, COLD SPRING HARB SYM, V55, P953; Di Carlo G, 2003, EXPERT OPIN INV DRUG, V12, P39, DOI 10.1517/eoid.12.1.39.21246; Dijkstra JB, 1999, BRIT J ANAESTH, V82, P867, DOI 10.1093/bja/82.6.867; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; EICHHORN JH, 1993, ANESTHESIOLOGY, V78, P423; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; Eriksson H, 1997, CURR OPIN ANAESTH, V10, P438; Gaba DM, 2000, BRIT MED J, V320, P785, DOI 10.1136/bmj.320.7237.785; Gal J, 2000, J CARDIOTHOR VASC AN, V14, P22; GALAMBOS R, 1981, P NATL ACAD SCI-BIOL, V78, P2643, DOI 10.1073/pnas.78.4.2643; Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233; GHONEIM MM, 1992, ANESTHESIOLOGY, V76, P279; Ghoneim MM, 2000, ACTA ANAESTH SCAND, V44, P133, DOI 10.1034/j.1399-6576.2000.440202.x; Ghoneim MM, 1997, ANESTHESIOLOGY, V87, P387, DOI 10.1097/00000542-199708000-00027; Gillies MAM, 2001, EUR J ANAESTH, V18, P620, DOI 10.1046/j.1365-2346.2001.00891.x; Golembiewski Julie A, 2002, J Perianesth Nurs, V17, P364, DOI 10.1053/jpan.2002.36596; Greif R, 1999, ANESTHESIOLOGY, V91, P1246, DOI 10.1097/00000542-199911000-00014; Grichnik KP, 1999, ANN THORAC SURG, V68, P1786, DOI 10.1016/S0003-4975(99)00992-3; Harter R L, 2000, Curr Opin Anaesthesiol, V13, P469, DOI 10.1097/00001503-200008000-00012; HENEGHAN CPH, 1987, BRIT J ANAESTH, V59, P277, DOI 10.1093/bja/59.3.277; Henzi I, 1999, BRIT J ANAESTH, V83, P761, DOI 10.1093/bja/83.5.761; Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038; HUME MA, 1994, ANAESTHESIA, V49, P715, DOI 10.1111/j.1365-2044.1994.tb04408.x; John ER, 2002, BRAIN RES REV, V39, P1, DOI 10.1016/S0165-0173(02)00142-X; Johnson T, 2002, ANESTHESIOLOGY, V96, P1351, DOI 10.1097/00000542-200206000-00014; Kalkman CJ, 2002, ANESTHESIOLOGY, V96, P784, DOI 10.1097/00000542-200204000-00003; KEATS AS, 1961, ANESTHESIOLOGY   MAR, P213; Keenan R L, 1991, J Clin Anesth, V3, P354; KEEP PJ, 1978, ANAESTHESIA, V33, P43, DOI 10.1111/j.1365-2044.1978.tb08277.x; KEHLET H, IN PRESS LANCET; Knoerl D V, 1999, Medsurg Nurs, V8, P25; Kochs E, 1999, ANESTH ANALG, V88, P1412, DOI 10.1097/00000539-199906000-00039; Kochs E, 2001, ANESTHESIOLOGY, V95, P1141, DOI 10.1097/00000542-200111000-00018; Kranke P, 2002, ANESTH ANALG, V95, P133, DOI 10.1097/00000539-200207000-00024; Kranke P, 2001, ACTA ANAESTH SCAND, V45, P160, DOI 10.1034/j.1399-6576.2001.450205.x; Lagasse RS, 2002, ANESTHESIOLOGY, V97, P1609, DOI 10.1097/00000542-200212000-00038; LASSEN HCA, 1953, LANCET, V264, P37; LIU WHD, 1991, ANAESTHESIA, V46, P435, DOI 10.1111/j.1365-2044.1991.tb11677.x; Loewen PS, 2002, EXPERT OPIN INV DRUG, V11, P801, DOI 10.1517/13543784.11.6.801; LUNN JN, 1987, LANCET, V2, P1384; Lyketsos CG, 1999, AM J PSYCHIAT, V156, P58, DOI 10.1176/ajp.156.1.58; Matthey P, 2001, CAN J ANAESTH, V48, P333, DOI 10.1007/BF03014959; McGaw CD, 1998, W INDIAN MED J, V47, P64; Meehan D A, 1995, Am J Crit Care, V4, P435; Miaskowski C, 1999, PAIN, V80, P23, DOI 10.1016/S0304-3959(98)00192-4; Millar K, 2001, BRIT J ANAESTH, V86, P63, DOI 10.1093/bja/86.1.63; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P445, DOI 10.1097/00000542-199303000-00007; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P436, DOI 10.1097/00000542-199303000-00006; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; MUNGLANI R, 1993, BRIT J ANAESTH, V71, P633, DOI 10.1093/bja/71.5.633; Myles PS, 2002, MED J AUSTRALIA, V177, P536, DOI 10.5694/j.1326-5377.2002.tb04947.x; Nay PG, 1996, ANAESTHESIA, V51, P741, DOI 10.1111/j.1365-2044.1996.tb06198.x; NEWMAN S, 1989, J PSYCHOSOM RES, V33, P227, DOI 10.1016/0022-3999(89)90050-0; NEWTON DEF, 1990, BRIT J ANAESTH, V65, P609, DOI 10.1093/bja/65.5.609; NIELSON WR, 1990, ANESTHESIOLOGY, V73, P1103, DOI 10.1097/00000542-199012000-00006; Nordstrom O, 1997, ACTA ANAESTH SCAND, V41, P978, DOI 10.1111/j.1399-6576.1997.tb04823.x; Nyssen AS, 2002, ANESTH ANALG, V94, P1560, DOI 10.1097/00000539-200206000-00035; Oddby-Muhrbeck E, 2002, ANESTHESIOLOGY, V96, P1109, DOI 10.1097/00000542-200205000-00013; Priestley MC, 2002, ANESTH ANALG, V94, P275, DOI 10.1097/00000539-200202000-00009; Pusch F, 2002, ANESTH ANALG, V94, P1652; RAMSAY MAE, 1972, ANAESTHESIA, V27, P396, DOI 10.1111/j.1365-2044.1972.tb08244.x; Reilly JG, 2000, LANCET, V355, P1048, DOI 10.1016/S0140-6736(00)02035-3; Rodig G, 1999, ANAESTHESIA, V54, P826; Rowbotham DJ, 2001, BRIT J ANAESTH, V87, P1, DOI 10.1093/bja/87.1.1; Sala Blanch X, 2000, REV ESP ANESTESIOL R, V47, P10; Sandin RH, 2000, LANCET, V355, P707, DOI 10.1016/S0140-6736(99)11010-9; SCHACTER DL, 1994, INT REV NEUROBIOL, V37, P271; SCHWENDER D, 1994, ANESTHESIOLOGY, V80, P493, DOI 10.1097/00000542-199403000-00004; Schwid HA, 2002, ANESTHESIOLOGY, V97, P1434, DOI 10.1097/00000542-200212000-00015; Schwid HA, 2001, TEACH LEARN MED, V13, P92, DOI 10.1207/S15328015TLM1302_4; Scott NB, 2001, ANESTH ANALG, V93, P528, DOI 10.1097/00000539-200109000-00003; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; SHEVDE K, 1991, ANESTH ANALG, V73, P190; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SMITH PLC, 1986, LANCET, V1, P823; Struys MMRF, 2002, ANESTHESIOLOGY, V96, P803, DOI 10.1097/00000542-200204000-00006; Sung YF, 1996, DRUG SAFETY, V14, P181, DOI 10.2165/00002018-199614030-00005; Svensson I, 2001, EUR J PAIN, V5, P125, DOI 10.1053/eujp.2001.0227; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; TAYLOR G, 1976, JAMA-J AM MED ASSOC, V236, P2758, DOI 10.1001/jama.236.24.2758; Thomas R, 2002, ANAESTHESIA, V57, P1119, DOI 10.1046/j.1365-2044.2002.02782_4.x; Thornton C, 1998, BRIT J ANAESTH, V81, P771, DOI 10.1093/bja/81.5.771; THORNTON C, 1989, BRIT J ANAESTH, V63, P113, DOI 10.1093/bja/63.1.113; THORNTON C, 1983, BRIT J ANAESTH, V55, P479, DOI 10.1093/bja/55.6.479; THORNTON C, 1986, BRIT J ANAESTH, V58, P422, DOI 10.1093/bja/58.4.422; THORNTON C, 1984, BRIT J ANAESTH, V56, P315, DOI 10.1093/bja/56.4.315; Timmons M E, 1993, Orthop Nurs, V12, P23, DOI 10.1097/00006416-199301000-00007; Tramer M, 1997, BRIT J ANAESTH, V78, P247, DOI 10.1093/bja/78.3.247; Tramer M, 1996, BRIT J ANAESTH, V76, P186, DOI 10.1093/bja/76.2.186; Tramer MR, 2001, ACTA ANAESTH SCAND, V45, P14, DOI 10.1034/j.1399-6576.2001.450103.x; Tzourio C, 1999, NEUROLOGY, V53, P1948, DOI 10.1212/WNL.53.9.1948; UTTING JE, 1979, CAN ANAESTH SOC J, V26, P472, DOI 10.1007/BF03006159; VANWIJK MGF, 1990, ANAESTHESIA, V45, P679; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684; Wang DX, 2002, ANESTH ANALG, V95, P1134, DOI 10.1097/00000539-200211000-00002; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; Werner MU, 2002, ANESTH ANALG, V95, P1361, DOI 10.1097/00000539-200211000-00049; White PF, 1999, ANESTH ANALG, V89, P1337, DOI 10.1097/00000539-199912000-00001; White PF, 2002, ANESTHESIOLOGY, V97, P1075, DOI 10.1097/00000542-200211000-00008; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44	119	31	31	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2003	362	9396					1648	1658		10.1016/S0140-6736(03)14800-3	http://dx.doi.org/10.1016/S0140-6736(03)14800-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630448				2023-01-03	WOS:000186637400025
J	Reynolds, EE; Singer, DE				Reynolds, EE; Singer, DE			A 60-year-old woman with atrial fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; ORAL ANTICOAGULATION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ANTITHROMBOTIC THERAPY; STROKE PREVENTION; RHYTHM MANAGEMENT; MAZE PROCEDURE; WARFARIN; THROMBOEMBOLISM; ASPIRIN		Massachusetts Gen Hosp, Clin Epidemiol Unit, Div Gen Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Reynolds, EE (corresponding author), Massachusetts Gen Hosp, Clin Epidemiol Unit, Div Gen Med, S 50-9, Boston, MA 02114 USA.				NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER; NIA NIH HHS [AG15478] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Al-Khatib SM, 2000, AM HEART J, V140, P142, DOI 10.1067/mhj.2000.107547; Al-Saady NM, 1999, HEART, V82, P547, DOI 10.1136/hrt.82.5.547; Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; [Anonymous], 2001, CIRCULATION, V104, P2118; [Anonymous], 1997, Arch Intern Med, V157, P1237; Ansell JE, 1997, ANN PHARMACOTHER, V31, P604, DOI 10.1177/106002809703100516; ANSELL JE, 2003, MANAGING ORAL ANTICO, pCH44; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; Blackshear JL, 1996, LANCET, V348, P633; Blackshear JL, 1996, ANN THORAC SURG, V61, P755, DOI 10.1016/0003-4975(95)00887-X; Brugada R, 1997, NEW ENGL J MED, V336, P905, DOI 10.1056/NEJM199703273361302; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P128; CHEVALIER H, 1979, AM HEART J, V98, P361, DOI 10.1016/0002-8703(79)90049-8; Cox JL, 1998, AM HEART J, V136, P934, DOI 10.1016/S0002-8703(98)70143-7; Cox JL, 1999, J THORAC CARDIOV SUR, V118, P833, DOI 10.1016/S0022-5223(99)70052-8; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Epstein AE, 2002, J CARDIOVASC ELECTR, V13, P667, DOI 10.1046/j.1540-8167.2002.00667.x; EVANS W, 1954, BRIT HEART J, V16, P189; Ezekowitz M, 1998, ARCH INTERN MED, V158, P1316; Falk RH, 2001, NEW ENGL J MED, V344, P1067, DOI 10.1056/NEJM200104053441407; FLAKER GC, 1995, AM J CARDIOL, V76, P355, DOI 10.1016/S0002-9149(99)80100-3; Francis CW, 2002, ANN INTERN MED, V137, P648, DOI 10.7326/0003-4819-137-8-200210150-00008; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Go AS, 2002, CIRCULATION, V106, P515; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004; Go AS, 2000, CIRCULATION, V102, P11, DOI 10.1161/01.CIR.102.1.11; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 2000, J AM COLL CARDIOL, V35, P183, DOI 10.1016/S0735-1097(99)00489-1; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; JOSEPHSON ME, 1994, HARRISONS PRINCIPLES, P1022; Klein AL, 2001, NEW ENGL J MED, V344, P1411, DOI 10.1056/NEJM200105103441901; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Levy S, 1999, CIRCULATION, V99, P3028, DOI 10.1161/01.CIR.99.23.3028; Longstreth WT, 2001, NEUROLOGY, V56, P368, DOI 10.1212/WNL.56.3.368; Man-Son-Hing M, 2000, MED DECIS MAKING, V20, P394, DOI 10.1177/0272989X0002000403; Manning WJ, 1996, PROG CARDIOVASC DIS, V39, P33, DOI 10.1016/S0033-0620(96)80039-9; MANNING WJ, 1995, ARCH INTERN MED, V155, P2193, DOI 10.1001/archinte.155.20.2193; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; Monette J, 1997, J AM GERIATR SOC, V45, P1060, DOI 10.1111/j.1532-5415.1997.tb05967.x; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; Ommen SR, 1997, NEW ENGL J MED, V336, P1429, DOI 10.1056/NEJM199705153362006; Page RL, 2003, CIRCULATION, V107, P1141, DOI 10.1161/01.CIR.0000051455.44919.73; PAGE RL, 1994, CIRCULATION, V89, P224, DOI 10.1161/01.CIR.89.1.224; Ricard P, 1997, AM J CARDIOL, V79, P815, DOI 10.1016/S0002-9149(96)00879-X; Saksena S, 2002, J AM COLL CARDIOL, V40, P1140, DOI 10.1016/S0735-1097(02)02068-5; SANDLER G, 1959, Q J MED, V28, P347; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145; Sievert H, 2002, CIRCULATION, V105, P1887, DOI 10.1161/01.CIR.0000015698.54752.6D; Stein PD, 2001, CHEST, V119, p220S, DOI 10.1378/chest.119.1_suppl.220S; Stollberger C, 1998, ANN INTERN MED, V128, P630, DOI 10.7326/0003-4819-128-8-199804150-00004; Stroke Prevention in Atrial Fibrillation Investigators, 1995, J Stroke Cerebrovasc Dis, V5, P147, DOI 10.1016/S1052-3057(10)80166-1; Umana E, 2003, AM J MED, V114, P51, DOI 10.1016/S0002-9343(02)01472-9; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; WALDO AL, 1995, AM HEART MONOGR S, P213; Wang TJ, 2003, JAMA-J AM MED ASSOC, V290, P1049, DOI 10.1001/jama.290.8.1049; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; Williams Mathew R, 2002, Semin Thorac Cardiovasc Surg, V14, P232; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Zabalgoitia M, 1998, ANN INTERN MED, V128, P639, DOI 10.7326/0003-4819-128-8-199804150-00005; Zabalgoitia M, 1998, J AM COLL CARDIOL, V31, P1622, DOI 10.1016/S0735-1097(98)00146-6	71	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2003	290	16					2182	2189						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CB	14570954				2023-01-03	WOS:000186036700028
J	Markowitz, JS; Donovan, JL; DeVane, CL; Taylor, RM; Ruan, Y; Wang, JS; Chavin, KD				Markowitz, JS; Donovan, JL; DeVane, CL; Taylor, RM; Ruan, Y; Wang, JS; Chavin, KD			Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERICUM-PERFORATUM; MAJOR DEPRESSION; PHARMACOKINETICS; ALPRAZOLAM; EXTRACT; DEXTROMETHORPHAN; INHIBITION; PLASMA; IMIPRAMINE; PLACEBO	Context St John's wort is a popular herbal product used to treat depression but it has been implicated in drug interactions. Objective To assess the potential of St John's wort administration to alter the activity of the cytochrome P450 (CYP) enzymes extensively involved in drug metabolism. Design, Setting, and Participants Open-label crossover study with fixed treatment order conducted March 2002 to February 2003 in a US general clinical research center involving 12 healthy volunteers (6 men and 6 women) aged 22 to 38 years before and after 14 days of administration of St John's wort. Intervention Participants were given probe drugs (30 mg of dextromethorphan and 2 mg of alprazolam) to establish baseline CYP 3A4 and CYP 2D6 activity. After a minimum 7-day washout period, participants began taking one 300-mg tablet 3 times per day. After 14 days of St John's wort administration, participants were given the probe drugs along with 1 St John's wort tablet to establish postadministration CYP activity; the St John's wort dosing regimen was continued for 48 hours. Main Outcome Measures Changes in plasma pharmacokinetics of alprazolam as a probe for CYP 3A4 activity and the ratio of dextromethorphan to its metabolite, dextrorphan, in urine as a probe for CYP 2D6 activity. Results A 2-fold decrease in the area under the curve for alprazolam plasma concentration vs time (P<.001) and a 2-fold increase in alprazolam clearance (P<.001) were observed following St John's wort administration. Alprazolam elimination half life was shortened from a mean (SD) of 12.4 (3.9) hours to 6.0 (2.4) hours (P<.001). The mean (SD) urinary ratio of dextromethorphan to its metabolite was 0.006 (0.010) at baseline and 0.014 (0.025) after St John's wort administration (P=.26). Conclusions A 14-day course of St John's wort administration significantly induced the activity of CYP 3A4 as measured by changes in alprazolam pharmacokinetics. This suggests that long-term administration of St John's wort may result in diminished clinical effectiveness or increased dosage requirements for all CYP 3A4 substrates, which represent at least 50% of all marketed medications.	Med Univ S Carolina, Inst Psychiat, Lab Drug Disposit & Pharmacogenet, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Surg, Div Transplantat, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Markowitz, JS (corresponding author), Med Univ S Carolina, Inst Psychiat, Lab Drug Disposit & Pharmacogenet, Dept Pharmaceut Sci, RM 246 N,67 President St, Charleston, SC 29425 USA.	markowij@musc.edu	DeVane, Lindsay/B-6645-2012		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT000511] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001070] Funding Source: NIH RePORTER; NCCIH NIH HHS [R21 AT00511] Funding Source: Medline; NCRR NIH HHS [M01 RR01070-18] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barnes J, 2001, J PHARM PHARMACOL, V53, P583, DOI 10.1211/0022357011775910; BLUMENTHAL M, 2003, HERBALGRAM, V58, P71; Brosen K, 1996, THER DRUG MONIT, V18, P393, DOI 10.1097/00007691-199608000-00014; Constantine GH, 1998, PHARM BIOL, V36, P365, DOI 10.1076/phbi.36.5.365.4651; Cui YY, 2002, J CHROMATOGR B, V780, P129, DOI 10.1016/S1570-0232(02)00439-7; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; de Maat MMR, 2001, AIDS, V15, P420, DOI 10.1097/00002030-200102160-00019; Donovan JL, 2003, FOOD CHEM TOXICOL, V41, P1199, DOI 10.1016/S0278-6915(03)00112-1; Donovan JL, 2003, DRUG METAB DISPOS, V31, P519, DOI 10.1124/dmd.31.5.519; Durr D, 2000, CLIN PHARMACOL THER, V68, P598, DOI 10.1067/mcp.2000.112240; Furukori H, 1998, NEUROPSYCHOPHARMACOL, V18, P364; Gorski JC, 1999, XENOBIOTICA, V29, P931, DOI 10.1080/004982599238173; Greeson JM, 2001, PSYCHOPHARMACOLOGY, V153, P402, DOI 10.1007/s002130000625; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; HENDERSON L, 2003, BR J CLIN PHARM, V55, P112; Hoskins JM, 1997, J CHROMATOGR B, V696, P81, DOI 10.1016/S0378-4347(97)00225-9; Johne A, 2002, J CLIN PSYCHOPHARM, V22, P46, DOI 10.1097/00004714-200202000-00008; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; Kerb R, 1996, ANTIMICROB AGENTS CH, V40, P2087, DOI 10.1128/AAC.40.9.2087; Lecrubier Y, 2002, AM J PSYCHIAT, V159, P1361, DOI 10.1176/appi.ajp.159.8.1361; Liston HL, 2002, J CLIN PSYCHOPHARM, V22, P169, DOI 10.1097/00004714-200204000-00010; Mai I, 2003, NEPHROL DIAL TRANSPL, V18, P819, DOI 10.1093/ndt/gfg002; Markowitz J S, 2001, Psychopharmacol Bull, V35, P53; MARKOWITZ JS, IN PRESS J CLIN PSYC; Markusen A, 2001, ANTIPODE, V33, P39, DOI 10.1111/1467-8330.00160; MILLER RL, 1988, J CHROMATOGR-BIOMED, V430, P180, DOI 10.1016/S0378-4347(00)83150-3; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Obach RS, 2000, J PHARMACOL EXP THER, V294, P88; Perloff MD, 2001, BRIT J PHARMACOL, V134, P1601, DOI 10.1038/sj.bjp.0704399; Perloff MD, 1999, BIOCHEM PHARMACOL, V57, P1227, DOI 10.1016/S0006-2952(99)00054-4; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; SCHMID B, 1985, CLIN PHARMACOL THER, V38, P618, DOI 10.1038/clpt.1985.235; Schmider J, 1999, PHARMACOGENETICS, V9, P725, DOI 10.1097/01213011-199912000-00007; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; Simmen U, 2003, EUR J PHARMACOL, V458, P251, DOI 10.1016/S0014-2999(02)02818-2; Smith DA, 1998, XENOBIOTICA, V28, P1095, DOI 10.1080/004982598238859; SMITH RB, 1984, PSYCHOPHARMACOLOGY, V84, P452, DOI 10.1007/BF00431449; Sugimoto K, 2001, CLIN PHARMACOL THER, V70, P518, DOI 10.1067/mcp.2001.120025; Venkatakrishnan K, 1998, J CLIN PSYCHOPHARM, V18, P256, DOI 10.1097/00004714-199806000-00015; Wang ZQ, 2002, CLIN PHARMACOL THER, V71, P414, DOI 10.1067/mcp.2002.124080; Wang ZQ, 2001, CLIN PHARMACOL THER, V70, P317, DOI 10.1067/mcp.2001.118522; Woelk H, 2000, BMJ-BRIT MED J, V321, P536, DOI 10.1136/bmj.321.7260.536; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; ZHANG Y, 1992, CLIN PHARMACOL THER, V51, P647, DOI 10.1038/clpt.1992.77	46	265	274	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1500	1504		10.1001/jama.290.11.1500	http://dx.doi.org/10.1001/jama.290.11.1500			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129991				2023-01-03	WOS:000185329000033
J	Peretti-Watel, P; Bendiane, MK; Pegliasco, H; Lapiana, JM; Favre, R; Galinier, A; Moatti, JP				Peretti-Watel, P; Bendiane, MK; Pegliasco, H; Lapiana, JM; Favre, R; Galinier, A; Moatti, JP			Doctors' opinions on euthanasia, end of life care, and doctor-patient communication: telephone survey in France	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN-ASSISTED SUICIDE; ATTITUDES		Reg Ctr Dis Control SE, F-13006 Marseille, France; Inst J Paoli I Calmettes, Hlth & Med Res Natl Inst, Unit 379, F-13009 Marseille, France; Departmental Ctr Private Profess, Marseille, France; Assistance Publ Hop Marseille, Med Oncol Serv, Marseille, France; Assistance Publ Hop Marseille, Dept Penitentiary Care, Marseille, France; Univ Aix Marseille 2, Dept Econ, F-13284 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite	Peretti-Watel, P (corresponding author), Reg Ctr Dis Control SE, F-13006 Marseille, France.		Bendiane, Marc-Karim/M-7060-2019; Peretti-Watel, Patrick/P-4535-2017; Bendiane, Marc-Karim K/F-5414-2010	Bendiane, Marc-Karim K/0000-0003-4329-8807				Ben Diane MK, 2003, PRESSE MED, V32, P488; Emanuel EJ, 2000, ANN INTERN MED, V133, P527, DOI 10.7326/0003-4819-133-7-200010030-00011; Grassi L, 1999, J PAIN SYMPTOM MANAG, V17, P188, DOI 10.1016/S0885-3924(98)00155-9; Hermsen MA, 2002, J PAIN SYMPTOM MANAG, V23, P517, DOI 10.1016/S0885-3924(02)00401-3; Seale C, 2000, SOC SCI MED, V51, P917, DOI 10.1016/S0277-9536(00)00071-X	5	39	40	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					595	596		10.1136/bmj.327.7415.595	http://dx.doi.org/10.1136/bmj.327.7415.595			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969926	Bronze, Green Published			2023-01-03	WOS:000185358700022
J	Atmane, N; Dairou, J; Paul, A; Dupret, JM; Rodrigues-Lima, F				Atmane, N; Dairou, J; Paul, A; Dupret, JM; Rodrigues-Lima, F			Redox regulation of the human xenobiotic metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) - Reversible inactivation by hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SULFENIC ACID; N-ACETYLTRANSFERASE; OXIDATIVE STRESS; ACTIVE-SITE; FUNCTIONAL-CHARACTERIZATION; CATALYTIC MECHANISM; AMINO-ACIDS; DNA-DAMAGE; IDENTIFICATION; RAT	Oxidative stress is increasingly recognized as a key mechanism in the biotransformation and/or toxicity of many xenobiotics. Human arylamine N-acetyltransferase 1 (NAT1) is a polymorphic ubiquitous phase II xenobiotic metabolizing enzyme that catalyzes the biotransformation of primary aromatic amine or hydrazine drugs and carcinogens. Functional and structural studies have shown that NAT1 catalytic activity is based on a cysteine protease-like catalytic triad, containing a reactive cysteine residue. Reactive protein cysteine residues are highly susceptible to oxidation by hydrogen peroxide (H2O2) generated within the cell. We, therefore, investigated whether human NAT1 activity was regulated by this cellular oxidant. Using purified recombinant NAT1, we show here that NAT1 is rapidly (k(inact) = 420 M-1.min(-1)) inactivated by physiological concentrations of H2O2. Reducing agents, such as reduced glutathione (GSH), reverse the H2O2-dependent inactivation of NAT1. Kinetic analysis and protection experiments with acetyl-CoA, the physiological acetyl-donor substrate of the enzyme, suggested that the H2O2-dependent inactivation reaction targets the active-site cysteine residue. Finally, we show that the reversible inactivation of NAT1 by H2O2 is due to the formation of a stable sulfenic acid group at the active-site cysteine. Our results suggest that, in addition to known genetically controlled interindividual variations in NAT1 activity, oxidative stress and cellular redox status may also regulate NAT1 activity. This may have important consequences with regard to drug biotransformation and cancer risk.	Univ Paris 06, CNRS, UMR 7000, F-75013 Paris, France; Univ Paris 07, UFR Biochim, F-75005 Paris, France; Inst Canc Res, CRUK Ctr Cell & Mol Biol, London SW3 6JB, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Rodrigues-Lima, F (corresponding author), Univ Paris 06, CNRS, UMR 7000, F-75013 Paris, France.	rlima@ext.jussieu.fr						ANDRES HH, 1988, J BIOL CHEM, V263, P7521; Barbouti A, 2002, FREE RADICAL BIO MED, V33, P691, DOI 10.1016/S0891-5849(02)00967-X; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; Boelsterli, 2003, MECH TOXICOLOGY MOL; Borutaite V, 2001, FEBS LETT, V500, P114, DOI 10.1016/S0014-5793(01)02593-5; Butcher N. J., 2002, Pharmacogenomics Journal, V2, P30, DOI 10.1038/sj.tpj.6500053; Butcher NJ, 2000, MOL PHARMACOL, V57, P468, DOI 10.1124/mol.57.3.468; Butcher NJ, 2000, BIOCHEM PHARMACOL, V60, P1829, DOI 10.1016/S0006-2952(00)00501-3; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Culotta VC, 2000, CURR TOP CELL REGUL, V36, P117; Delgoda R, 2003, BBA-GEN SUBJECTS, V1620, P8, DOI 10.1016/S0304-4165(02)00500-7; Delomenie C, 2001, J BACTERIOL, V183, P3417, DOI 10.1128/JB.183.11.3417-3427.2001; Demasi M, 2003, J BIOL CHEM, V278, P679, DOI 10.1074/jbc.M209282200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DUPRET JM, 1992, J BIOL CHEM, V267, P7381; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Feinendegen LE, 2002, HUM EXP TOXICOL, V21, P85, DOI 10.1191/0960327102ht216oa; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Fretland AJ, 2001, PHARMACOGENETICS, V11, P511, DOI 10.1097/00008571-200108000-00006; Georgiou G, 2002, CELL, V111, P607, DOI 10.1016/S0092-8674(02)01165-0; Gergel D, 1997, ARCH BIOCHEM BIOPHYS, V337, P239, DOI 10.1006/abbi.1996.9765; Giles NM, 2003, BIOCHEM BIOPH RES CO, V300, P1, DOI 10.1016/S0006-291X(02)02770-5; Goodfellow GH, 2000, BIOCHEM J, V348, P159, DOI 10.1042/0264-6021:3480159; GRANT DM, 1991, MOL PHARMACOL, V39, P184; Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9; Hampton MB, 2002, FEBS LETT, V517, P229, DOI 10.1016/S0014-5793(02)02629-7; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HEIN D, 2002, MUTAT RES, V65, P506; Hein DW, 2000, TOXICOL LETT, V112, P349, DOI 10.1016/S0378-4274(99)00226-X; Hightower LE, 1998, BIOL CHEM, V379, P1213; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; Matas N, 1997, CYTOGENET CELL GENET, V77, P290, DOI 10.1159/000134601; Meisel P, 2002, PHARMACOGENOMICS, V3, P349, DOI 10.1517/14622416.3.3.349; Morel Y, 1999, BIOCHEM J, V342, P481, DOI 10.1042/0264-6021:3420481; Mueller S, 2001, J BIOL CHEM, V276, P23192, DOI 10.1074/jbc.M100654200; Mushtaq A, 2002, J BIOL CHEM, V277, P12175, DOI 10.1074/jbc.M104365200; Pagano G, 2002, HUM EXP TOXICOL, V21, P77, DOI 10.1191/0960327102ht214oa; Panayiotidis R, 1999, FREE RADICAL BIO MED, V26, P548, DOI 10.1016/S0891-5849(98)00249-4; Penning TM, 1996, CHEM RES TOXICOL, V9, P84, DOI 10.1021/tx950055s; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; Pompeo F, 2002, PHARMACOGENOMICS, V3, P19, DOI 10.1517/14622416.3.1.19; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Rodrigues-Lima F, 2000, J BIOL CHEM, V275, P28316; Rodrigues-Lima F., 2002, Pharmacogenomics Journal, V2, P152, DOI 10.1038/sj.tpj.6500114; Rodrigues-Lima F, 2002, BIOCHEM BIOPH RES CO, V291, P116, DOI 10.1006/bbrc.2002.6414; Rodrigues-Lima F, 2002, BIOCHEM BIOPH RES CO, V293, P783, DOI 10.1016/S0006-291X(02)00299-1; Rodrigues-Lima F, 2001, BIOCHEM J, V356, P327, DOI 10.1042/0264-6021:3560327; Sandy J, 2002, J MOL BIOL, V318, P1071, DOI 10.1016/S0022-2836(02)00141-9; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR-100102336; Sinclair J, 1997, BIOCHEM PHARMACOL, V53, P11, DOI 10.1016/S0006-2952(96)00592-8; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Upton A, 2001, TRENDS PHARMACOL SCI, V22, P140, DOI 10.1016/S0165-6147(00)01639-4; Wong PSY, 2001, ARCH BIOCHEM BIOPHYS, V394, P216, DOI 10.1006/abbi.2001.2532; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X	63	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35086	35092		10.1074/jbc.M303813200	http://dx.doi.org/10.1074/jbc.M303813200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832400	hybrid			2023-01-03	WOS:000185164400043
J	Wallentin, L; Wilcox, RG; Weaver, WD; Emanuelsson, H; Goodvin, A; Nystrom, P; Bylock, A				Wallentin, L; Wilcox, RG; Weaver, WD; Emanuelsson, H; Goodvin, A; Nystrom, P; Bylock, A		ESTEEM Investigators	Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial	LANCET			English	Article							DIRECT THROMBIN INHIBITOR; ACUTE CORONARY SYNDROMES; UNSTABLE ANGINA; NO INFLUENCE; ACTIVE FORM; PHARMACODYNAMICS; PHARMACOKINETICS; MELAGATRAN; PREVENTION; MANAGEMENT	Background Despite important advances in treatment, the risk of recurrent ischaemic events is high both early and late after an acute coronary syndrome. We aimed to assess the effectiveness of ximelagatran and acetylsalicylic acid for prevention of death, non-fatal myocardial infarction, and severe recurrent ischaemia after a recent myocardial infarction. Methods In this placebo-controlled, double-blind, multicentre, multinational dose-guiding study we assessed 1883 patients who had had recent ST-elevation or non-ST-elevation myocardial infarction. Within 14 days after the index event we randomised the participants in the proportions 1/1/1/1/2 to oral ximelagatran at doses of 24 mg, 36 mg, 48 mg, or 60 mg twice daily, or placebo, respectively for 6 months. All patients received acetylsalicylic acid 160 mg once daily. The primary efficacy outcome was the dose response of ximelagatran by comparison with placebo for the occurrence of all-cause death, non-fatal myocardial infarction, and severe recurrent ischaemia. Analysis was by intention to treat. Findings Oral ximelagatran significantly reduced the risk for the primary endpoint compared with placebo from 16.3% (102 of 638) to 12.7% (154 of 1245) (hazard ratio 0.76, 95% CI 0.59-0.98, p=0.036) for the combined ximelagatran groups versus placebo. There was no indication of a dose response between the ximelagatran groups. Major bleeding events were rare, 1.8 % (23 of 1245) and 0.9 % (six of 638) (hazard ratio 1.97, 95% CI 0.80-4.84) in the combined ximelagatran and placebo groups, respectively. We recorded no serious clinically adverse outcomes judged related to the investigational drug. Interpretation Oral direct thrombin inhibition with ximelagatran and acetylsalicylic acid is more effective than acetylsalicylic acid alone in preventing major cardiovascular events during 6 months of treatment in patients who have had a recent myocardial infarction.	Univ Uppsala Hosp, Uppsala Clin Res Ctr, S-75185 Uppsala, Sweden; Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England; Henry Ford Hosp, Detroit, MI 48202 USA; AstraZeneca, Charnwood, England; AstraZeneca, Molndal, Sweden	Uppsala University; Uppsala University Hospital; University of Nottingham; Henry Ford Health System; Henry Ford Hospital; AstraZeneca	Wallentin, L (corresponding author), Univ Uppsala Hosp, Uppsala Clin Res Ctr, S-75185 Uppsala, Sweden.	lars.wallentin@ucr.uu.se						Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305; Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; *ASS SAF EFF NEW T, 2002, LANCET, V358, P605; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bertrand ME, 2002, EUR HEART J, V23, P1809, DOI 10.1053/euhj.2002.3385; Braunwald E, 2002, CIRCULATION, V106, P1893, DOI 10.1161/01.CIR.0000037106.76139.53; Cairns JA, 2001, CHEST, V119, p228S, DOI 10.1378/chest.119.1_suppl.228S; Eriksson B, 2002, LANCET, V360, P1441, DOI 10.1016/S0140-6736(02)11469-3; Eriksson H, 2002, BLOOD, V100, p81A; Eriksson H, 2003, J THROMB HAEMOST, V1, P41, DOI 10.1046/j.1538-7836.2003.00034.x; Eriksson UG, 2003, DRUG METAB DISPOS, V31, P294, DOI 10.1124/dmd.31.3.294; Eriksson UG, 2003, EUR J CLIN PHARMACOL, V59, P35, DOI 10.1007/s00228-003-0565-7; ERIKSSONLEPKOWS.M, 2002, PATHOPHYSIOL HAEMO T, V32, P130; Fager G, 2000, EUR HEART J, V21, P441; Grip L, 1997, EUR HEART J, V18, P1416; Hurlen M, 2002, NEW ENGL J MED, V347, P969, DOI 10.1056/NEJMoa020496; Johansson LC, 2003, CLIN PHARMACOKINET, V42, P475, DOI 10.2165/00003088-200342050-00005; Johansson LC, 2003, CLIN PHARMACOKINET, V42, P381, DOI 10.2165/00003088-200342040-00006; OHLSSON BS, IN PRESS LANCET; Petersen P, 2003, J AM COLL CARDIOL, V41, P1445, DOI 10.1016/S0735-1097(03)00255-9; Sarich TC, 2003, CLIN PHARMACOKINET, V42, P485, DOI 10.2165/00003088-200342050-00006; Sarich TC, 2002, THROMB HAEMOSTASIS, V87, P300; THEROUX P, 1992, NEW ENGL J MED, V327, P141, DOI 10.1056/NEJM199207163270301; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; van Es RF, 2002, LANCET, V360, P109, DOI 10.1016/S0140-6736(02)09409-6; Wallentin L, 1996, LANCET, V347, P561; Wallentin L, 1999, LANCET, V354, P701; Wallentin L, 2003, EUR HEART J, V24, P897, DOI 10.1016/S0195-668X(03)00006-X; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2002, LANCET, V359, P294	30	297	308	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2003	362	9386					789	797		10.1016/S0140-6736(03)14287-0	http://dx.doi.org/10.1016/S0140-6736(03)14287-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678873				2023-01-03	WOS:000185188500012
J	Burgess, I				Burgess, I			Commentary: How to advise a patient when over the counter products have failed	BRITISH MEDICAL JOURNAL			English	Editorial Material									Insect Res & Dev Ltd, Cambridge CB1 5EL, England		Burgess, I (corresponding author), Insect Res & Dev Ltd, Cambridge CB1 5EL, England.		Burgess, Ian/E-4049-2016; Burgess, Ian/N-2977-2013	Burgess, Ian/0000-0001-9348-2915; Burgess, Ian/0000-0003-0747-3938					0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1257	1257		10.1136/bmj.326.7401.1257	http://dx.doi.org/10.1136/bmj.326.7401.1257			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791745	Green Published			2023-01-03	WOS:000183480700022
J	Lack, G; Fox, D; Northstone, K; Golding, J				Lack, G; Fox, D; Northstone, K; Golding, J		Avon Longitudinal Study Parents Ch	Factors associated with the development of peanut allergy in childhood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATOPIC-DERMATITIS; FOOD HYPERSENSITIVITY; CHILDREN; SENSITIZATION; SKIN; FORMULAS; INFANTS; PROTEIN; ANTIGEN; SOY	Background: The prevalence of peanut allergy appears to have increased in recent decades. Other than a family history of peanut allergy and the presence of atopy, there are no known risk factors. Methods: We used data from the Avon Longitudinal Study of Parents and Children, a geographically defined cohort study of 13,971 preschool children, to identify those with a convincing history of peanut allergy and the subgroup that reacted to a double-blind peanut challenge. We first prospectively collected data on the whole cohort and then collected detailed information retrospectively by interview from the parents of children with peanut reactions and of children from two groups of controls (a random sample from the cohort and a group of children whose mothers had a history of eczema and who had had eczema themselves in the first six months of life). Results: Forty-nine children had a history of peanut allergy; peanut allergy was confirmed by peanut challenge in 23 of 36 children tested. There was no evidence of prenatal sensitization from the maternal diet, and peanut-specific IgE was not detectable in the cord blood. Peanut allergy was independently associated with intake of soy milk or soy formula (odds ratio, 2.6; 95 percent confidence interval, 1.3 to 5.2), rash over joints and skin creases (odds ratio, 2.6; 95 percent confidence interval, 1.4 to 5.0), and oozing, crusted rash (odds ratio, 5.2; 95 percent confidence interval, 2.7 to 10.2). Analysis of interview data showed a significant independent relation of peanut allergy with the use of skin preparations containing peanut oil (odds ratio, 6.8; 95 percent confidence interval, 1.4 to 32.9). Conclusions: Sensitization to peanut protein may occur in children through the application of peanut oil to inflamed skin. The association with soy protein could arise from cross-sensitization through common epitopes. Confirmation of these risk factors in future studies could lead to new strategies to prevent sensitization in infants who are at risk for subsequent peanut allergy.	Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Paediat Allergy & Immunol, London W2 1NY, England; Univ Bristol, Unit Paediat & Perinatal Epidemiol, Bristol, Avon, England	Imperial College London; University of Bristol	Lack, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Paediat Allergy & Immunol, Ground Floor,Salton House,Praed St, London W2 1NY, England.		Northstone, Kate/A-8165-2011	Northstone, Kate/0000-0002-0602-1983; Golding, Jean/0000-0003-2826-3307; Lack, Gideon/0000-0001-7350-4021				ASSEM ESK, 1990, BRIT MED J, V300, P1377, DOI 10.1136/bmj.300.6736.1377; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BURKS AW, 1989, ALLERGY PROC, V10, P265, DOI 10.2500/108854189778960045; CARSWELL F, 1986, LANCET, V2, P13, DOI 10.1016/S0140-6736(86)92560-2; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; DEKRUYFF RH, 1992, J IMMUNOL, V149, P3468; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1996, BRIT MED J, V313, P1046; Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204; Lever LR, 1996, BRIT MED J, V313, P299, DOI 10.1136/bmj.313.7052.299; Moneret-Vautrin D A, 1994, Pediatr Allergy Immunol, V5, P184, DOI 10.1111/j.1399-3038.1994.tb00236.x; Moneret-Vautrin DA, 1998, CLIN EXP ALLERGY, V28, P1113, DOI 10.1046/j.1365-2222.1998.00370.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4, DOI 10.1136/adc.77.1.4; Olszewski A, 1998, CLIN EXP ALLERGY, V28, P850, DOI 10.1046/j.1365-2222.1998.00325.x; RENZ H, 1993, J IMMUNOL, V151, P7206; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65, DOI 10.1164/ajrccm.149.1.8111600; Sampson HA, 1998, J ALLERGY CLIN IMMUN, V101, pS240; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2000, ALLERGY, V55, P515, DOI 10.1034/j.1398-9995.2000.00119.x; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; *U BRIST, 2003, ALSPAC; van Reijsen FC, 1998, J ALLERGY CLIN IMMUN, V101, P207, DOI 10.1016/S0091-6749(98)70410-5; ZIMMERMAN B, 1989, J ALLERGY CLIN IMMUN, V83, P764, DOI 10.1016/0091-6749(89)90012-2	29	648	661	2	68	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					977	985		10.1056/NEJMoa013536	http://dx.doi.org/10.1056/NEJMoa013536			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637607				2023-01-03	WOS:000181465200002
J	Du, XLL; Key, CR; Osborne, C; Mahnken, JD; Goodwin, JS				Du, XLL; Key, CR; Osborne, C; Mahnken, JD; Goodwin, JS			Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer	ANNALS OF INTERNAL MEDICINE			English	Article							OLDER WOMEN; CLINICAL GUIDELINES; CONSERVING SURGERY; RADIATION-THERAPY; LINKED MEDICARE; NATIONAL SURVEY; AGE; CARCINOMA; CARE; DETERMINANTS	Background: Although the efficacy of adjuvant chemotherapy in prolonging survival for women with breast cancer has been well documented, limited population-based information is available on the actual use of chemotherapy. Objective: To examine the relationship between age and chemotherapy use. Design: Cohort study. Setting: New Mexico. Patients: 5101 women 20 years of age or older receiving a diagnosis of stage 1, stage 11, or stage IIIA breast cancer from 1991 through 1997. Measurements: Pattern of chemotherapy use by age; logistic regression analysis to generate the odds and probabilities of receiving chemotherapy; and sensitivity analysis to estimate potential effects of unmeasured confounders. Results: Overall, 29% of women received chemotherapy. The rate of chemotherapy use for women with stage I, stage II, or stage IIIA breast cancer was 11%, 47%, and 68%, respectively. Across all tumor stages, the use of chemotherapy decreased substantially with increasing age (P < 0.001). overall, 66% of women younger than 45 years of age received chemotherapy compared with 44% of women between 50 and 54 years of age, 31% of women between 55 and 59 years of age, and 18% of women between 60 and 64 years of age. The decreasing pattern of chemotherapy use with age continued after adjustment for prognostic factors and was relatively insensitive to changes in unmeasured factors. Conclusions: There is considerable discrepancy between the 1990 National Institutes of Health Consensus Conference recommendations for chemotherapy administration in women with breast cancer and the actual use of chemotherapy in the community. The decrease in use with age may relate to the decreasing efficacy of chemotherapy with age, as reported in clinical trials. Outcomes studies should address whether the recommendations are overly aggressive or whether practicing oncologists are too conservative in their use of chemotherapy.	Univ Texas, Dept Internal Med, Med Branch, Galveston, TX 77555 USA; Univ New Mexico, Albuquerque, NM 87131 USA	University of Texas System; University of Texas Medical Branch Galveston; University of New Mexico	Du, XLL (corresponding author), Univ Texas, Dept Internal Med, Med Branch, 3-134 Jennie Sealy Hosp, Galveston, TX 77555 USA.	xdu@utmb.edu			NATIONAL CANCER INSTITUTE [R01CA090626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024832] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA090626-02S1, R01 CA090626, R01 CA090626-03, R01 CA090626-04, R01-CA90626, R01-CA871773, R01 CA090626-02, R01 CA090626-01, R01 CA090626-03S1] Funding Source: Medline; NIA NIH HHS [P30 AG024832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1985, JAMA-J AM MED ASSOC, V254, P3461; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; [Anonymous], 1992, Lancet, V339, P1; Athas WF, 2000, J NATL CANCER I, V92, P269, DOI 10.1093/jnci/92.3.269; Carlson RW, 2000, ONCOLOGY-NY, V14, P33; CHRISTMAN K, 1992, JAMA-J AM MED ASSOC, V268, P57, DOI 10.1001/jama.268.1.57; CHU J, 1987, J GERONTOL, V42, P185, DOI 10.1093/geronj/42.2.185; Du XL, 1999, J CLIN EPIDEMIOL, V52, P463, DOI 10.1016/S0895-4356(99)00011-6; Du XL, 2001, CANCER-AM CANCER SOC, V92, P730, DOI 10.1002/1097-0142(20010815)92:4<730::AID-CNCR1376>3.0.CO;2-P; Du XL, 2001, J CLIN ONCOL, V19, P1455, DOI 10.1200/JCO.2001.19.5.1455; Du XL, 1999, J GERONTOL A-BIOL, V54, pM474, DOI 10.1093/gerona/54.9.M474; Du XLL, 2002, J CLIN ONCOL, V20, P4636, DOI 10.1200/JCO.2002.05.088; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; Field MJ., 1992, GUIDELINES CLIN PRAC; Fisher B, 2001, J Natl Cancer Inst Monogr, P62; Fisher B, 1999, CA-CANCER J CLIN, V49, P159, DOI 10.3322/canjclin.49.3.159; FISHER B, 1998, LANCET, V352, P930; GOODWIN JS, 1993, CANCER-AM CANCER SOC, V72, P594, DOI 10.1002/1097-0142(19930715)72:2<594::AID-CNCR2820720243>3.0.CO;2-#; Goodwin JS, 1996, JNCI-J NATL CANCER I, V88, P1031, DOI 10.1093/jnci/88.15.1031; GOODWIN JS, 1988, ARCH INTERN MED, V148, P2258, DOI 10.1001/archinte.148.10.2258; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GREENLAND S, 1998, EPIDEMIOLOGY, P343; HALL WH, 1991, JAMA-J AM MED ASSOC, V265, P391; Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407; HOSMER DW, 2000, WILEY PS TX, P1; Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; MUSS HB, 1994, CANCER, V74, P2165, DOI 10.1002/1097-0142(19941001)74:7+<2165::AID-CNCR2820741727>3.0.CO;2-6; MUSS HB, 1995, SEMIN ONCOL, V22, P14; National Cancer Institute, 1994, NIH PUBLICATION; NERENZ DR, 1986, HEALTH SERV RES, V20, P961; *NEW MEX TUM REG, 2002, NEW MEX TUM REG; OSTEEN RT, 1994, J AM COLL SURGEONS, V178, P213; POTOSKY AL, 1993, MED CARE, V31, P732; RIES LA, 1997, NIH PUBLICAITON; RIES LAG, 1997, NIH PUBLICATION; SAMET J, 1986, JAMA-J AM MED ASSOC, V255, P3385, DOI 10.1001/jama.255.24.3385; Shekelle P, 2001, BMJ-BRIT MED J, V323, P155, DOI 10.1136/bmj.323.7305.155; Shekelle PG, 2001, JAMA-J AM MED ASSOC, V286, P1461, DOI 10.1001/jama.286.12.1461; *STEER COMM CLIN P, 1998, CAN MED ASSOC J S, V158, pS52; *STEER COMM CLIN P, 1998, CAN MED ASSOC J S, V158, pS43; WETLE T, 1987, JAMA-J AM MED ASSOC, V258, P516, DOI 10.1001/jama.1987.03400040114035; WILSON RE, 1984, SURG GYNECOL OBSTET, V159, P309; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; [No title captured]	46	81	82	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 21	2003	138	2					90	97		10.7326/0003-4819-138-2-200301210-00009	http://dx.doi.org/10.7326/0003-4819-138-2-200301210-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646CY	12529090	Green Accepted			2023-01-03	WOS:000181018300002
J	van de Put, W				van de Put, W			Addressing mental health in Afghanistan	LANCET			English	Article									HealthNet Int, NL-1062 GL Amsterdam, Netherlands		van de Put, W (corresponding author), HealthNet Int, Maassluisstr 258, NL-1062 GL Amsterdam, Netherlands.								0	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2002	360			S			S41	S42		10.1016/S0140-6736(02)11816-2	http://dx.doi.org/10.1016/S0140-6736(02)11816-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	629TG	12504499				2023-01-03	WOS:000180064500020
J	Chen, WY; Colditz, GA; Rosner, B; Hankinson, SE; Hunter, DJ; Manson, JE; Stampfer, MJ; Willett, WC; Speizer, FE				Chen, WY; Colditz, GA; Rosner, B; Hankinson, SE; Hunter, DJ; Manson, JE; Stampfer, MJ; Willett, WC; Speizer, FE			Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer	ANNALS OF INTERNAL MEDICINE			English	Article							REPLACEMENT THERAPY; BEVERAGE CONSUMPTION; MEASUREMENT ERROR; WOMEN; ESTROGENS	Background: Physiologic evidence suggests that use of alcohol increases the risk for breast cancer through a hormonal mechanism, but the relationship among breast cancer, alcohol, and postmenopausal hormones (PMH) remains unclear. Objective: To examine the relation between concurrent use of alcohol and PMH and invasive breast cancer. Design: Prospective cohort study Setting: Nurses' Health Study. Participants: 44187 postmenopausal women. Measurements: Self-reported data on PMH use and breast cancer obtained from biennial questionnaires completed from 1980 to 1994 and average alcohol consumption in 1980, 1984, 1986, and 1990. Results: 1722 women developed invasive breast cancer. Risk for breast cancer was elevated in women who currently used PMH for 5 or more years and did not drink alcohol (relative risk, 1.32 [95% CI, 1.05 to 1.66]) and those who never used PMH but drank 20 or more g (1.5 to 2 drinks) of alcohol daily (relative risk, 1.28 [Cl, 0.97 to 1.69]). Current users of PMH for 5 or more years who consumed 20 or more g of alcohol daily had a relative risk for breast cancer nearly twice (1.99 [Cl, 1.42 to 2.79]) that of non-drinking nonusers of PMH. A hypothetical postmenopausal woman whose lifetime risk for breast cancer is 4% could increase her risk to 8% with 5 or more years of current PMH use and consumption of more than one alcoholic drink daily. Conclusions: Both alcohol consumption and PMH use were associated with an increased incidence of breast cancer. Women who are currently taking PMH may want to consider the added risks of regular alcohol consumption.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Chen, WY (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [5-R25-CA577011-08, CA40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Dawson D A, 1995, J Subst Abuse, V7, P331, DOI 10.1016/0899-3289(95)90026-8; Flanders W D, 1990, Epidemiology, V1, P239, DOI 10.1097/00001648-199005000-00010; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GAPSTUR SM, 1992, AM J EPIDEMIOL, V136, P1221, DOI 10.1093/oxfordjournals.aje.a116430; Ginsburg ES, 1996, JAMA-J AM MED ASSOC, V276, P1747, DOI 10.1001/jama.276.21.1747; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HARVEY EB, 1987, J NATL CANCER I, V78, P657; LONGNECKER MP, 1995, CANCER EPIDEM BIOMAR, V4, P721; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MIDANIK LT, 1994, AM J PUBLIC HEALTH, V84, P1218, DOI 10.2105/AJPH.84.8.1218; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; PAGANINIHILL A, 1983, LANCET, V2, P626; Pike MC, 1998, AM J EPIDEMIOL, V147, P718; REICHMAN ME, 1993, J NATL CANCER I, V85, P722, DOI 10.1093/jnci/85.9.722; Rockhill B, 2000, AM J EPIDEMIOL, V151, P404; ROSENBERG L, 1990, AM J EPIDEMIOL, V131, P6, DOI 10.1093/oxfordjournals.aje.a115486; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Rosner BA, 1996, STAT MED, V15, P293, DOI 10.1002/(SICI)1097-0258(19960215)15:3<293::AID-SIM166>3.0.CO;2-E; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; *USDA, 1997, USDA NUTR DAT STAND; WILLIAMS GD, 1992, BRIT J ADDICT, V87, P643; WILLIAMS RR, 1977, JNCI-J NATL CANCER I, V58, P525, DOI 10.1093/jnci/58.3.525	28	67	68	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					798	804		10.7326/0003-4819-137-10-200211190-00008	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616VE	12435216				2023-01-03	WOS:000179323400003
J	Rabow, MW; Markowitz, AJ				Rabow, MW; Markowitz, AJ			Responding to requests for physician-assisted suicide - "These are uncharted waters for both of us ..."	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Bascom PB, 2002, JAMA-J AM MED ASSOC, V288, P91, DOI 10.1001/jama.288.1.91	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2332	2332		10.1001/jama.288.18.2332	http://dx.doi.org/10.1001/jama.288.18.2332			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425712				2023-01-03	WOS:000179186400034
J	Singh, RB; Dubnov, G; Niaz, MA; Ghosh, S; Singh, R; Rastogi, SS; Manor, O; Pella, D; Berry, EM				Singh, RB; Dubnov, G; Niaz, MA; Ghosh, S; Singh, R; Rastogi, SS; Manor, O; Pella, D; Berry, EM			Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial	LANCET			English	Article							POLYUNSATURATED FATTY-ACIDS; ACUTE MYOCARDIAL-INFARCTION; SOCIAL-CLASS; CHOLESTEROL; FISH; ATHEROSCLEROSIS; ASSOCIATION; STYLE; OIL	Background The rapid emergence of coronary artery disease (CAD) in south Asian people is not explained by conventional risk factors. In view of card ioprotective effects of a Mediterranean style diet rich in alpha-linolenic acid, we assessed the benefits of this diet for patients at high risk of CAD. Methods We did a randomised, single-blind trial in 1000 patients with angina pectoris, myocardial infarction, or surrogate risk factors for CAD. 499 patients were allocated to a diet rich in whole grains, fruits, vegetables, walnuts, and almonds. 501 controls consumed a local diet similar to the step I National Cholesterol Education Program (NCEP) prudent diet. Findings The intervention group consumed more fruits, vegetables, legumes, walnuts, and almonds than did controls (573 g [SD 127] vs 231 g [19] per day p<0.001). The intervention group had an increased intake of whole grains and mustard or soy bean oil. The mean intake of alpha-linolenic acid was two-fold greater in the intervention group (1.8 g [SD 0.4] vs 0.8 g [0.2] per day, p<0.001). Total cardiac end points were significantly fewer in the intervention group than the controls (39 vs 76 events, p<0.001). Sudden cardiac deaths were also reduced (6 vs 16, p=0.015), as were non-fatal myocardial infarctions (21 vs 43, p<0.001). We noted a significant reduction in serum cholesterol concentration and other risk factors in both groups; but especially in the intervention diet group. In the treatment group, patients with pre-existing CAD had significantly greater benefits compared with such patients in the control group. Interpretation An Indo-Mediterranean diet that is rich in alpha-linolenic acid might be more effective in primary and secondary prevention of CAD than the conventional step I NCEP prudent diet.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel; Med Hosp & Res Ctr, Ctr Nutr & Heart, Moradabad, India; Hebrew Univ Jerusalem, Hadassah Med Sch, Sch Publ Hlth & Community Med, IL-91120 Jerusalem, Israel; Safarik Univ, Kosice, Slovakia	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Pavol Jozef Safarik Kosice	Berry, EM (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel.	berry@md.huji.ac.il	Dubnov-Raz, Gal/L-3297-2016	Dubnov-Raz, Gal/0000-0003-1469-8043				[Anonymous], 1968, LANCET, V2, P693; Berry EM, 1999, MED HYPOTHESES, V53, P397, DOI 10.1054/mehy.1998.0786; Berry EM, 2001, NUTR METAB CARDIOVAS, V11, P181; BURR ML, 1989, LANCET, V2, P757; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Indian Consensus Group, 1996, J NUTR ENV MED, V6, P309, DOI DOI 10.3109/13590849609007257; JACOBSON MS, 1987, LANCET, V2, P656, DOI 10.1016/S0140-6736(87)92443-3; Janus ED, 1996, CIRCULATION, V94, P2671, DOI 10.1161/01.CIR.94.11.2671; Johansen O, 1999, ARTERIOSCL THROM VAS, V19, P1681, DOI 10.1161/01.ATV.19.7.1681; Joshipura KJ, 2001, ANN INTERN MED, V134, P1106, DOI 10.7326/0003-4819-134-12-200106190-00010; Kris-Etherton P, 2001, CIRCULATION, V103, P1823, DOI 10.1161/01.CIR.103.13.1823; Mori TA, 1997, ARTERIOSCL THROM VAS, V17, P279, DOI 10.1161/01.ATV.17.2.279; NASINGARAO BS, 1989, NUTR COMPOSITION IND; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333; REGNSTROM J, 1992, LANCET, V339, P1183, DOI 10.1016/0140-6736(92)91129-V; Robertson RM, 2001, CIRCULATION, V103, P1821, DOI 10.1161/01.CIR.103.13.1821; Rose G, 1982, CARDIOVASCULAR SURVE; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; Singh R. B., 2001, Journal of Nutritional and Environmental Medicine (Abingdon), V11, P43, DOI 10.1080/13590840020030258; Singh RB, 2000, ASIA PAC J CLIN NUTR, V9, P298, DOI 10.1046/j.1440-6047.2000.00177.x; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; Singh RB, 1997, CARDIOVASC DRUG THER, V11, P485, DOI 10.1023/A:1007757724505; Singh RB, 1999, LANCET, V353, P154, DOI 10.1016/S0140-6736(05)76196-1; SINGH RB, 1995, AM J CARDIOL, V76, P1233, DOI 10.1016/S0002-9149(99)80348-8; SINGH RB, 1995, LANCET, V346, P778, DOI 10.1016/S0140-6736(95)91537-0; SINGH RB, 1992, AM J CARDIOL, V70, P869, DOI 10.1016/0002-9149(92)90729-I; Singh RB, 1997, J ASSOC PHYSICIAN I, V45, P603; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; VANHANDEL E, 1957, J LAB CLIN MED, V50, P152; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; WILSON DE, 1973, J LAB CLIN MED, V82, P473; World Health Organization Study Group, 1990, DIET NUTR PREV CHRON; Yusuf S, 2000, NEW ENGL J MED, V342, P145	35	396	416	0	43	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	2002	360	9344					1455	1461		10.1016/S0140-6736(02)11472-3	http://dx.doi.org/10.1016/S0140-6736(02)11472-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433513				2023-01-03	WOS:000179186000010
J	Vincent, JL; Baron, JF; Reinhart, K; Gattinoni, L; Thijs, L; Webb, A; Meier-Hellmann, A; Nollet, G; Peres-Bota, D				Vincent, JL; Baron, JF; Reinhart, K; Gattinoni, L; Thijs, L; Webb, A; Meier-Hellmann, A; Nollet, G; Peres-Bota, D		ABC Investigators	Anemia and blood transfusion in critically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; INTENSIVE-CARE-UNIT; ELECTIVE COLORECTAL SURGERY; LEUKOCYTE DEPLETION; CARDIAC-SURGERY; CLINICAL-TRIAL; WHOLE-BLOOD; MORTALITY; SEPSIS; SCORE	Context Anemia is a common problem in critically ill patients admitted to intensive care units (ICUs), but the consequences of anemia on morbidity and mortality in the. critically ill is poorly defined. Objectives To prospectively define the incidence of anemia and use of red blood cell (RBC) transfusions in critically ill patients and to explore the potential benefits and risks associated with transfusion in the ICU. Design Prospective observational study conducted November 1999, with 2. components: a blood sampling study and an, anemia and blood transfusion study. Setting and Patients The blood sampling study included 1136 patients from 145 western European ICUs, and the anemia and blood transfusion study included 3534 patients from 146 western European ICUs. Patients were followed up for 28 days or until hospital discharge, interinstitutional transfer, or death. Main Outcome Measures Frequency of blood drawing and associated volume of blood drawn, collected over a 24-hour period; hemoglobin levels, transfusion rate, organ dysfunction (assessed using the Sequential Organ Failure Assessment score), and mortality, collected throughout a 2-week period. Results The mean (SD) volume per blood draw was 10.3 (6.6) mL, with an average total volume of 41.1 (39.7) mL during the 24-hour period. There was a positive correlation between organ dysfunction and the number of blood draws (r=0.34; P<.001) and total volume drawn (r=0.28; P<.001). The mean hemoglobin concentration at ICU admission was 11.3 (2.3) g/dL, with 29% (963/3295) having a concentration of less than 10 g/dL. The transfusion rate during the ICU period was 37.0% (1307/3534). Older patients and those with a longer ICU length of stay were more commonly transfused. Both ICU and overall mortality rates were significantly higher in patients who had vs had not received a transfusion (ICU rates: 18.5% vs 10.1%, respectively; chi(2)=50.1; P<.001; overall rates: 29.0% vs 14.9%, respectively; chi(2) =88.1; P<.001). For similar degrees of organ dysfunction, patients who had a transfusion had a higher mortality rate. For matched patients in the propensity analysis, the 28-day mortality was 22.7% among patients with transfusions and 17.1% among those without (P=.02); the Kaplan-Meier log-rank test confirmed this difference. Conclusions This multicenter observational study reveals the common occurrence of anemia and the large use of blood transfusion in critically ill patients. Additionally, this epidemiologic study provides evidence of an association between transfusions and diminished organ function as well as between transfusions and mortality.	Erasme Univ Hosp, Dept Intens Care, B-1070 Brussels, Belgium; Hop Broussais, Dept Anesthesiol, F-75674 Paris, France; Klinikum FSU Jena, Dept Anesthesiol, Jena, Germany; Osped Maggiore, Ist Anestesia & Rianimaz, Milan, Italy; VU Ziekenhuis, Med Intens Care Unit, Amsterdam, Netherlands; UCL Hosp, Dept Intens Care, London, England; Onze Lieve Vrouw Hosp, Dept Anesthesiol & Intens Care, Aalst, Belgium	Universite Libre de Bruxelles; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Friedrich Schiller University of Jena; University College London Hospitals NHS Foundation Trust; University of London; University College London	Vincent, JL (corresponding author), Erasme Univ Hosp, Dept Intens Care, Route Lennik 808, B-1070 Brussels, Belgium.	jlvincen@ulb.ac.be		Vincent, Jean-Louis/0000-0001-6011-6951; Gattinoni, Luciano/0000-0001-5380-2494				Ania BJ, 1997, J AM GERIATR SOC, V45, P825, DOI 10.1111/j.1532-5415.1997.tb01509.x; Balducci, 1998, Cancer Control, V5, P17; Blumberg N, 1996, AM J MED, V101, P299, DOI 10.1016/S0002-9343(96)00124-6; BLUMBERG N, 1986, BRIT MED J, V293, P530, DOI 10.1136/bmj.293.6546.530; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; BURNUM JF, 1986, NEW ENGL J MED, V314, P1250, DOI 10.1056/NEJM198605083141910; CORWIN HL, 1995, CHEST, V108, P767, DOI 10.1378/chest.108.3.767; Corwin HL, 1999, CRIT CARE MED, V27, P2346, DOI 10.1097/00003246-199911000-00004; DALE JC, 1993, MAYO CLIN PROC, V68, P249, DOI 10.1016/S0025-6196(12)60044-5; Gabriel A, 1998, J TRAUMA, V44, P361, DOI 10.1097/00005373-199802000-00023; GOODNOUGH LT, 1995, ANN THORAC SURG, V60, P473, DOI 10.1016/0003-4975(95)98960-3; Gott JP, 1998, ANN THORAC SURG, V66, P747, DOI 10.1016/S0003-4975(98)00695-X; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; Gum PA, 2001, JAMA-J AM MED ASSOC, V286, P1187, DOI 10.1001/jama.286.10.1187; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; Jensen LS, 1996, BRIT J SURG, V83, P973, DOI 10.1002/bjs.1800830727; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; NELSON AH, 1993, CRIT CARE MED, V21, P860, DOI 10.1097/00003246-199306000-00013; Rogiers P, 1997, INTENS CARE MED, V23, P159, DOI 10.1007/s001340050310; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Schallom L, 1999, Crit Care Nurs Clin North Am, V11, P99; SILVER MJ, 1993, CHEST, V104, P1711, DOI 10.1378/chest.104.6.1711; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; Tartter PI, 1998, AM J SURG, V176, P462, DOI 10.1016/S0002-9610(98)00245-1; van de Watering LMG, 1998, CIRCULATION, V97, P562; van Iperen CE, 2000, CRIT CARE MED, V28, P2773, DOI 10.1097/00003246-200008000-00015; VILJOEN M, 1994, HAEMATOLOGICA, V79, P19; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; von Ahsen N, 1999, CRIT CARE MED, V27, P2630, DOI 10.1097/00003246-199912000-00005	32	1102	1173	1	56	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2002	288	12					1499	1507		10.1001/jama.288.12.1499	http://dx.doi.org/10.1001/jama.288.12.1499			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AT	12243637				2023-01-03	WOS:000178142000021
J	Parmar, MKB; Adams, M; Balestrino, M; Bertelsen, K; Bonazzi, C; Calvert, H; Colombo, N; Delaloye, JF; Durando, A; Guthrie, D; Hagen, B; Harper, P; Mangioni, C; Perren, T; Poole, C; Qian, W; Rustin, G; Sandercock, J; Tumolo, S; Torri, V; Vecchione, F				Parmar, MKB; Adams, M; Balestrino, M; Bertelsen, K; Bonazzi, C; Calvert, H; Colombo, N; Delaloye, JF; Durando, A; Guthrie, D; Hagen, B; Harper, P; Mangioni, C; Perren, T; Poole, C; Qian, W; Rustin, G; Sandercock, J; Tumolo, S; Torri, V; Vecchione, F		ICON Grp	Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial	LANCET			English	Article							STAGE-III	Background Previously, we have shown that the combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) and single-agent carboplatin produce similar survival and progression-free survival rates in women with ovarian cancer. Subsequently, paclitaxel combined with platinum has become a widely accepted treatment for the disease. We aimed to compare the safety and efficacy of paclitaxel plus carboplatin with a control of either CAP or carboplatin alone. Methods Between February, 1995, and October, 1998, we enrolled 2074 patients from 130 centres in eight countries. Women were randomly assigned paclitaxel plus carboplatin or control, the control (CAP or single-agent carboplatin) being chosen by the patient and clinician before randomisation. The primary outcome measure was overall survival. Secondary outcomes were progression-free survival and toxicity. Analysis was by intention to treat. Findings With a median follow-up of 51 months, 1265 patients had died, and survival curves showed no evidence of a difference in overall survival between paclitaxel plus carboplatin and control (hazard ratio 0.98, 95% Cl 0.87-1.10, p=0.74). The median overall survival was 36.1 months on paclitaxel plus carboplatin and 35.4 months on control (difference 0.7 months, 95% CI -3.6 to 4.7). 1538 patients had progressive disease or died, and again, Kaplan-Meier curves showed no evidence of a difference between the groups (hazard ratio 0.93, 95% Cl 0.84-1.03, p=0.16). Median progression-free survival was 17.3 months on paclitaxel plus carboplatin and 16.1 months on control (difference 1.2 months, 95% Cl -0.5 to 2.8). Paclitaxel plus carboplatin caused more alopecia, fever, and sensory neuropathy than carboplatin alone, and more sensory neuropathy than CAP. CAP was associated with more fever than paclitaxel plus carboplatin. Interpretation Single-agent carboplatin and CAP are as effective as paclitaxel plus carboplatin as first-line treatment for women requiring chemotherapy for ovarian cancer. The favourable toxicity profile of single-agent carboplatin suggests that this drug is a reasonable option as first-line chemotherapy for ovarian cancer.	ICON Trials, Canc Div, MRC, Clin Trials Unit, London NW1 2DA, England	Medical Research Council Clinical Trials Unit	Parmar, MKB (corresponding author), ICON Trials, Canc Div, MRC, Clin Trials Unit, London NW1 2DA, England.		Perren, Timothy J/D-5387-2013; Rustin, Gordon J. S./J-9763-2019; Colombo, Nicoletta/AAB-8319-2019; Torri, Valter/H-7550-2015	Perren, Timothy J/0000-0001-8472-8856; Torri, Valter/0000-0001-9541-9354; Sandercock, Josie/0000-0001-7337-8635				Aabo K, 1998, BRIT J CANCER, V78, P1479, DOI 10.1038/bjc.1998.710; Adams M, 1998, BRIT J CANCER, V78, P1404, DOI 10.1038/bjc.1998.699; AHERN RP, 1995, J CLIN ONCOL, V13, P726, DOI 10.1200/JCO.1995.13.3.726; BUYSE M, 1991, J CLIN ONCOL, V9, P1668; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; DUBOIS A, 1998, P AN M AM SOC CLIN, V17, P1395; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Muggia FM, 2000, J CLIN ONCOL, V18, P106, DOI 10.1200/JCO.2000.18.1.106; NEIJT JP, 1997, SEMIN ONCOL, V39, pS15; OZOLS RF, 1999, P AN M AM SOC CLIN, V18, P1373; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; PARMAR M, 1995, SURVIVAL ANAL PRACTI; Parmar MKB, 1998, LANCET, V352, P1571; Piccart MJ, 2000, EUR J CANCER, V36, P10, DOI 10.1016/S0959-8049(99)00210-5; Piccart MJ, 2000, JNCI-J NATL CANCER I, V92, P699, DOI 10.1093/jnci/92.9.699; Pisani P, 1999, INT J CANCER, V83, P870; Sandercock J, 1998, BRIT J CANCER, V78, P1471, DOI 10.1038/bjc.1998.709; SANDERCOCK J, IN PRESS BR J CANC; WARWICK J, 1995, BRIT J CANCER, V72, P1513, DOI 10.1038/bjc.1995.539	19	394	400	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 17	2002	360	9332					505	515						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	585EZ	12241653				2023-01-03	WOS:000177512800007
J	Monsonego, A; Weiner, HL				Monsonego, A; Weiner, HL			Immunotherapeutic approaches to Alzheimer's disease	SCIENCE			English	Review							CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA-PEPTIDE; REGULATORY T-CELLS; NITRIC-OXIDE; MOUSE MODEL; IN-VITRO; NEGATIVE SELECTION; PRECURSOR PROTEIN; CLONAL SELECTION; GAMMA-SECRETASE	Although neurodegenerative diseases such as Alzheimer's disease are not classically considered mediated by inflammation or the immune system, in some instances the immune system may play an important role in the degenerative process. Furthermore, it has become clear that the immune system itself may have beneficial effects in nervous system diseases considered neurodegenerative. Immunotherapeutic approaches designed to induce a humoral immune response have recently been developed for the treatment of Alzheimer's disease. These studies have led to human trials that resulted in both beneficial and adverse effects. In animal models, it has also been shown that immunotherapy designed to induce a cellular immune response may be of benefit in central nervous system injury, although T cells may have either a beneficial or detrimental effect depending on the type of T cell response induced. These areas provide a new avenue for exploring immune system based therapy of neurodegenerative diseases and will be discussed here with a primary focus on Alzheimer's disease. We will also discuss how these approaches affect microglia activation, which plays a key role in therapy of such diseases.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Monsonego, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.	amonsonego@rics.bwh.harvard.edu; hweiner@rics.bwh.harvard.edu						Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bauer J, 1998, AM J PATHOL, V153, P715, DOI 10.1016/S0002-9440(10)65615-5; Becher B, 2000, GLIA, V29, P293; Becker KJ, 1997, P NATL ACAD SCI USA, V94, P10873, DOI 10.1073/pnas.94.20.10873; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; Cohen IR, 2001, J AUTOIMMUN, V16, P337, DOI 10.1006/jaut.2000.0481; Cooper NR, 2000, NEUROBIOL AGING, V21, P451, DOI 10.1016/S0197-4580(00)00148-2; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; ElKhoury J, 1996, NATURE, V382, P716; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717; Ford AL, 1996, J EXP MED, V184, P1737, DOI 10.1084/jem.184.5.1737; Frenkel D, 2000, P NATL ACAD SCI USA, V97, P11455, DOI 10.1073/pnas.97.21.11455; FRENKEL D, 2002, CLIN IMMUNOL S, V1, P411; GAMMON G, 1989, NATURE, V342, P183, DOI 10.1038/342183a0; Haas J, 2002, NEUROSCI LETT, V322, P121, DOI 10.1016/S0304-3940(02)00095-2; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Heneka MT, 2002, J NEUROSCI, V22, P2434, DOI 10.1523/JNEUROSCI.22-07-02434.2002; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Husemann J, 2001, J NEUROIMMUNOL, V114, P142, DOI 10.1016/S0165-5728(01)00239-9; Janeway CA, 1999, CURR BIOL, V9, pR342, DOI 10.1016/S0960-9822(99)80209-7; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kawahata K, 2002, J IMMUNOL, V168, P4399, DOI 10.4049/jimmunol.168.9.4399; Kim HJ, 2002, CLIN IMMUNOL, V104, P105, DOI 10.1006/clim.2002.5258; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Kitani A, 2000, J IMMUNOL, V165, P691, DOI 10.4049/jimmunol.165.2.691; Lemere CA, 2000, ANN NY ACAD SCI, V920, P328; Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072; McGeer EG, 1998, EXP GERONTOL, V33, P371, DOI 10.1016/S0531-5565(98)00013-8; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207, DOI 10.1096/fasebj.13.10.1207; Monsonego A, 2003, J IMMUNOL, V171, P2216, DOI 10.4049/jimmunol.171.5.2216; Monsonego A, 2003, J CLIN INVEST, V112, P415, DOI 10.1172/JCI200318104; Monsonego A, 2001, P NATL ACAD SCI USA, V98, P10273, DOI 10.1073/pnas.191118298; MONSONEGO A, UNPUB; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Peterson DA, 1999, IMMUNITY, V11, P453, DOI 10.1016/S1074-7613(00)80120-X; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Phillips LM, 1999, J NEUROIMMUNOL, V96, P218, DOI 10.1016/S0165-5728(99)00034-X; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Santambrogio L, 2001, P NATL ACAD SCI USA, V98, P6295, DOI 10.1073/pnas.111152498; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schwartz M, 2002, TRENDS IMMUNOL, V23, P530, DOI 10.1016/S1471-4906(02)02322-0; Seguin R, 2003, GLIA, V42, P36, DOI 10.1002/glia.10201; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Spooner ET, 2002, VACCINE, V21, P290, DOI 10.1016/S0264-410X(02)00464-4; Tarkowski E, 2001, ACTA NEUROL SCAND, V103, P166, DOI 10.1034/j.1600-0404.2001.103003166.x; van der Veen RC, 2001, INT IMMUNOPHARMACOL, V1, P1491, DOI 10.1016/S1567-5769(01)00093-5; van Exel E, 2002, STROKE, V33, P1135, DOI 10.1161/01.STR.0000014206.05597.9E; Weiner HL, 2000, ANN NEUROL, V48, P567, DOI 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.3.CO;2-N; WEKERLE H, 1993, INTERVIROLOGY, V35, P95, DOI 10.1159/000150299; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Williams K, 2001, GLIA, V36, P156, DOI 10.1002/glia.1105; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	73	181	221	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					834	838		10.1126/science.1088469	http://dx.doi.org/10.1126/science.1088469			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593170				2023-01-03	WOS:000186258000040
J	Lawton, B; Rose, S; McLeod, D; Dowell, A				Lawton, B; Rose, S; McLeod, D; Dowell, A			Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users	BRITISH MEDICAL JOURNAL			English	Editorial Material									Wellington Sch Med & Hlth Sci, Dept Gen Practice, Wellington, New Zealand	University of Otago	Lawton, B (corresponding author), Wellington Sch Med & Hlth Sci, Dept Gen Practice, POB 7343, Wellington, New Zealand.			Lawton, Beverley/0000-0003-2447-8386				Ballard K, 2002, BRIT J GEN PRACT, V52, P835; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; International Menopause Society, INT MEN SOC DEV CONS; North FM, 2001, NEW ZEAL MED J, V114, P250; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321	5	106	107	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					845	846		10.1136/bmj.327.7419.845	http://dx.doi.org/10.1136/bmj.327.7419.845			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551101	Green Published, Bronze			2023-01-03	WOS:000185921200021
J	Harris, CL; Hughes, CE; Williams, AS; Goodfellow, I; Evans, DJ; Caterson, B; Morgan, BP				Harris, CL; Hughes, CE; Williams, AS; Goodfellow, I; Evans, DJ; Caterson, B; Morgan, BP			Generation of anti-complement "prodrugs" - Cleavable reagents for specific delivery of complement regulators to disease sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE CLEAVAGE; INTERGLOBULAR DOMAIN; SYNOVIAL-FLUID; CARTILAGE PROTEOGLYCAN; SEGMENTAL FLEXIBILITY; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; RECOMBINANT AGGRECAN; CHIMERIC HUMAN; CATABOLISM	Expression of biologically active molecules as fusion proteins with antibody Fc can substantially extend the plasma half-life of the active agent but may also influence function. We have previously generated a number of fusion proteins comprising a complement regulator coupled to Fc and shown that the hybrid molecule has a long plasma half-life and retains biological activity. However, several of the fusion proteins generated had substantially reduced biological activity when compared with the native regulator or regulator released from the Fc following papain cleavage. We have taken advantage of this finding to engineer a prodrug with low complement regulatory activity that is cleaved at sites of inflammation to release active regulator. Two model prodrugs, comprising, respectively, the four short consensus repeats of human decay accelerating factor (CD55) linked to IgG(4) Fc and the three NH2-terminal short consensus repeats of human decay accelerating factor linked to IgG(2) Fc have been developed. In each, specific cleavage sites for matrix metalloproteinases and/or aggrecanases have been incorporated between the complement regulator and the Fc. These prodrugs have markedly decreased complement inhibitory activity when compared with the parent regulator in vitro. Exposure of the prodrugs to the relevant enzymes, either purified, or in supernatants of cytokine-stimulated chondrocytes or in synovial fluid, efficiently cleaved the prodrug, releasing active regulator. Such agents, having negligible systemic effects but active at sites of inflammation, represent a paradigm for the next generation of anti-C therapeutics.	Cardiff Univ, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales; Cardiff Univ, Dept Rheumatol, Cardiff CF14 4XN, S Glam, Wales; Cardiff Univ, Cardiff Sch Biosci, Connect Tissue Biol Labs, Cardiff CF10 3US, S Glam, Wales; Univ Glasgow, Fac Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland	Cardiff University; Cardiff University; Cardiff University; University of Glasgow	Harris, CL (corresponding author), Cardiff Univ, Dept Med Biochem & Immunol, Tenovus Bldg,Heath Pk, Cardiff CF14 4XX, S Glam, Wales.	HarrisCL@cardiff.ac.uk	Caterson, Bruce/A-8085-2010; Hughes, Clare E/A-4526-2010; Evans, David/C-7553-2012	Morgan, Paul/0000-0003-4075-7676; Evans, David J./0000-0002-1315-4258; Hughes, Clare/0000-0003-4726-5877; Goodfellow, Ian/0000-0002-9483-510X; Caterson, Bruce/0000-0001-6016-0661				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; BREKKE OH, 1995, IMMUNOL TODAY, V16, P85, DOI 10.1016/0167-5699(95)80094-8; BRODEUR JP, 1991, ARTHRITIS RHEUM, V34, P1531; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Caterson B, 1995, ACTA ORTHOP SCAND, V66, P121, DOI 10.3109/17453679509157666; CHARREAU B, 1994, TRANSPLANTATION, V58, P1222, DOI 10.1097/00007890-199412150-00015; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; Daniels GL, 1998, TRANSFUSION, V38, P332, DOI 10.1046/j.1537-2995.1998.38498257370.x; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1991, MATRIX, V11, P17, DOI 10.1016/S0934-8832(11)80223-4; Goodfellow RM, 2000, CLIN EXP IMMUNOL, V119, P210, DOI 10.1046/j.1365-2249.2000.01129.x; Goodfellow RM, 1997, CLIN EXP IMMUNOL, V110, P45; Harris CL, 2002, BIOCHEM SOC T, V30, P1019, DOI 10.1042/bst0301019; Harris CL, 2002, CLIN EXP IMMUNOL, V129, P198, DOI 10.1046/j.1365-2249.2002.01924.x; Harris CL, 2002, J IMMUNOL METHODS, V268, P245, DOI 10.1016/S0022-1759(02)00207-7; Horber C, 2000, MATRIX BIOL, V19, P533, DOI 10.1016/S0945-053X(00)00113-X; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; Hughes CE, 1997, J BIOL CHEM, V272, P20269, DOI 10.1074/jbc.272.32.20269; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; Ishiguro N, 2001, ARTHRITIS RHEUM, V44, P2503, DOI 10.1002/1529-0131(200111)44:11<2503::AID-ART430>3.0.CO;2-P; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; Little CB, 2002, MATRIX BIOL, V21, P271, DOI 10.1016/S0945-053X(02)00004-5; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Matsuno H, 2001, J RHEUMATOL, V28, P22; Mercuri FA, 2000, J BIOL CHEM, V275, P33038, DOI 10.1074/jbc.275.42.33038; MORGAN BP, 1988, CLIN EXP IMMUNOL, V73, P473; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; Morgan BP., 1999, COMPLEMENT REGULATOR; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; OLEESKY DA, 1991, CLIN EXP IMMUNOL, V84, P250; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; Quigg RJ, 1998, J IMMUNOL, V160, P4553; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Rioux P, 2001, Curr Opin Investig Drugs, V2, P364; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2	44	22	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36068	36076		10.1074/jbc.M306351200	http://dx.doi.org/10.1074/jbc.M306351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12842884	Green Accepted, hybrid			2023-01-03	WOS:000185318300026
J	DeVita, VT				DeVita, VT			Hodgkin's disease - Clinical trials and travails	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06510 USA; Yale New Haven Med Ctr, New Haven, CT 06504 USA	Yale University; Yale University	DeVita, VT (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, 333 Cedar St, New Haven, CT 06510 USA.								0	24	24	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2375	2376		10.1056/NEJMp030049	http://dx.doi.org/10.1056/NEJMp030049			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802021				2023-01-03	WOS:000183428900001
J	Laing, R; Waning, B; Gray, A; Ford, N; 't Hoen, E				Laing, R; Waning, B; Gray, A; Ford, N; 't Hoen, E			25 years of the WHO essential medicines lists: progress and challenges	LANCET			English	Review								The first WHO essential drugs list, published in 1977, was described as a peaceful revolution in international public health. The list helped to establish the principle that some medicines were more useful than others and that essential medicines were often inaccessible to many populations. Since then, the essential medicines list (EML) has increased in size; defining an essential medicine has moved from an experience to an evidence-based process, including criteria such as public-health relevance, efficacy, safety, and cost-effectiveness. High priced medicines such as antiretrovirals are now included. Differences exist between the WHO model EML and national EMLs since countries face varying challenges relating to costs, drug effectiveness, morbidity patterns, and rationality of prescribing. Ensuring equitable access to and rational use of essential medicines has been promoted through WHO's revised drug strategy. This approach has required an engagement by WHO on issues such as the effect of international trade agreements on access to essential medicines and research and development to ensure availability of new essential medicines.	Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA; Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA; Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Expt & Clin Pharmacol, Congella, South Africa; Med Sans Frontieres, London, England; Med Sans Frontieres, Paris, France	Boston University; University of Kwazulu Natal; Doctors Without Borders; Doctors Without Borders	Laing, R (corresponding author), Boston Univ, Sch Publ Hlth, 715 Albany St,T4W, Boston, MA 02118 USA.	richardl@bu.edu	Gray, Andrew/F-2104-2013	Gray, Andrew/0000-0001-7815-8180; 't Hoen, Ellen/0000-0003-4477-6866; Waning, Brenda/0000-0001-5773-1558				CHETLEY A, 1990, HLTH BUSINESS WORLD, P75; *DEP HLTH S AFR, 1996, NAT DRUG POL S AFR; *DEP HLTH S AFR, POL GUID MAN TRANSM; Gray A, 1999, S AFRICAN HLTH REV 1, P161; GRAY A, 1997, S AFRICAN HLTH REV 1, P99; GRAY A, POLICY CHANGE CONTEX; HOGERZEIL HV, 1984, TROPICAL DOCTOR, V16, P113; HOWARD NJ, 1991, LANCET, V338, P743, DOI 10.1016/0140-6736(91)91455-4; *INT FED PHARM MAN, 1997, ESS DRUGS; Kanji N, 1992, DRUGS POLICY DEV COU; MARITOUX J, 2002, ESSENTIAL DRUGS PRAC; QUICK JD, 1981, MANAGING DRUG SUPPLY; Quick JD, 1997, DC2018020003 DEP EN; SCHOLTZ M, 1999, C AIDS ESS MED COMP; STEIGER W, 2001, COMMENTS RECOMMENDAT; t Hoen Ellen F. M., 2002, CHICAGO J INT LAW, V3, P27; THOEN E, 1993, LANCET, V342, P308, DOI 10.1016/0140-6736(93)91856-H; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; Velasquez G., 1999, GLOBALIZATION ACCESS; *WHO, 2001, IPCW305ADD3 WHO; WHO, 1986, WHA3927 WHO; WHO, 2000, WHO MED STRAT 2000 2; *WHO, 1987, RAT US DRUGS REP; *WHO, 2001, WHOCDSRBM200135; *WHO, 2002, EB1098 WHO; *WHO, 1997, TECH REP SER WHO, V867; *WHO, 1977, TECH REP SER WHO, V615; *WHO, 1997, WHOMAL961075; *WHO, 2002, REP 12 EXP COMM SEL; *WHO, 1996, 4914 WHO WHA; *WHO, 1988, TECH REP SER WHO, V770; *WHO, 2002, WHO MOD FORM; *WHO, 2000, TECHN REP SERI WHO, V895; *WHO, 1979, TECH REP SER WHO, V641; *WHO, 2001, 54102001 WHO WHA; *WHO, 2001, 5411 WHO WHA; *WHO, 2002, TECH REP SER WHO, V914; *WHO, 1990, TECH REP SER WHO, V805; *WHO, 2002, WHO CHILD AD HLTH DE; *WHO, 2002, DRUG PRIC INF SERV W; *WHO EDM DEP ESS D, 2001, UPD DISS WHO MOD LIS; *WHO EX BOARD, 2001, EB108INFDOC2 WHO; *WHO UNICEF, 1978, HLTH ALL SER, V1; WHO (World Health Organization), 1988, WORLD DRUG SIT; *WORLD HLTH ASS, 1975, WHA2866 WHO; World Trade Organization, 2001, WTMIN01DEC2 WTO; 1998, DEV ESSENTIAL DRUGS; 2003, LANCET, V361, P269; 1999, COMMON WORKING PAPER, V3; 1998, 1D3BWD98 EUR COMM DG; 1999, WTGCW282; 1987, SCRIP, V256, P1; 2001, WHO ESSEN DRUGS MON, P23	53	191	214	2	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1723	1729		10.1016/S0140-6736(03)13375-2	http://dx.doi.org/10.1016/S0140-6736(03)13375-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767751				2023-01-03	WOS:000182919700025
J	Free, C; Lee, RM; Ogden, J				Free, C; Lee, RM; Ogden, J			Young women's accounts of factors influencing their use and non-use of emergency contraception: in-depth interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							KNOWLEDGE	Objectives To explore young women's accounts of their use and non-use of emergency contraception. Design Qualitative study using in-depth interviews. Participants 30 women aged 16-25; participants from socially deprived inner city areas were specifically included. Setting Community, service, and educational settings in the London area. Results Young women's accounts of their non-use of emergency contraception principally concerned evaluations of the risk conferred by different contraceptive behaviours, their evaluations of themselves in needing emergency contraception, and personal difficulties in asking for emergency contraception. Conclusions The attitudes and concerns of young women, especially those from disadvantaged backgrounds, may make them less able or willing than others to take advantage of recent increases in access to emergency contraception. Interventions that aim to increase the use of emergency contraception need to address the factors that influence young women's non-use of emergency contraception.	Guys Kings & St Thomas Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England; Royal Holloway Univ London, Dept Social & Polit Sci, Egham TW20 0EX, Surrey, England	University of London; King's College London; University of London; Royal Holloway University London	Free, C (corresponding author), Guys Kings & St Thomas Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England.	caroline.free@kcl.ac.uk		Ogden, Jane/0000-0003-4271-5621; Free, Caroline/0000-0003-1711-0006				ANDERSON C, 2001, LAMBETH SOUTHWORK LE; Barrett G, 2000, SOCIOL HEALTH ILL, V22, P197, DOI 10.1111/1467-9566.00199; Beck U., 1992, RISK SOC NEW MODERNI; Crosier A, 1996, BRIT J FAM PLAN, V22, P87; Crosier A., 1997, EMERGENCY CONTRACEPT; Department of the Environment Transport and the Regions, 2000, IND DEPR 2000 REG RE; Glasier A, 1998, NEW ENGL J MED, V339, P1, DOI 10.1056/NEJM199807023390101; Graham A, 1996, BRIT MED J, V312, P1567, DOI 10.1136/bmj.312.7046.1567; HALPER C, 1995, FAM PLANN PERSPECT, V27, P149, DOI 10.2307/2136258; Harrison-Woolrych M, 2001, BRIT MED J, V322, P186; Irwin MR, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P269, DOI 10.2307/2135857; Trussell J, 1998, J Am Med Womens Assoc (1972), V53, P247; WEINSTEIN ND, 1984, HEALTH PSYCHOL, V3, P431, DOI 10.1037/0278-6133.3.5.431; Ziebland S, 1996, BRIT J FAM PLAN, V22, P84	15	75	77	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 14	2002	325	7377					1393	1396		10.1136/bmj.325.7377.1393	http://dx.doi.org/10.1136/bmj.325.7377.1393			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	628CP	12480855	Green Published, Green Accepted			2023-01-03	WOS:000179975000024
J	Weiger, WA; Smith, M; Boon, H; Richardson, MA; Kaptchuk, TJ; Eisenberg, DM				Weiger, WA; Smith, M; Boon, H; Richardson, MA; Kaptchuk, TJ; Eisenberg, DM			Advising patients who seek complementary and alternative medical therapies for cancer	ANNALS OF INTERNAL MEDICINE			English	Review							STRUCTURED PSYCHIATRIC INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; CHINESE HERBAL PREPARATION; VITAMIN-E SUPPLEMENTATION; METASTATIC BREAST-CANCER; PINEAL HORMONE MELATONIN; MANUAL LYMPH-DRAINAGE; DIETARY-FAT INTAKE; CELL LUNG-CANCER; ST-JOHNS WORT	Many patients with cancer use complementary and alternative medical (CAM) therapies. Physicians need authoritative information on CAM therapies to responsibly advise patients who seek these interventions. This article summarizes current evidence on the efficacy and safety of selected CAM therapies that are commonly used by patients with cancer. The following major categories of interventions are covered: dietary modification and supplementation, herbal products and other biological agents, acupuncture, massage, exercise, and psychological and mind-body therapies. Two categories of evidence on efficacy are considered: possible effects on disease progression and survival and possible palliative effects. In evaluating evidence on safety, two types of risk are considered: the risk for direct adverse effects and the risk for interactions with conventional treatments. For each therapy, the current balance of evidence on efficacy and safety points to whether the therapy may be reasonably recommended, accepted (for example, dietary fat reduction in well-nourished patients with breast or prostate cancer), or discouraged (for example, high-dose vitamin A supplementation). This strategy allows the development of an approach for providing responsible, evidence-based, patient-centered advice to persons with cancer who seek CAM therapies.	Harvard Univ, Sch Med, Landmark Ctr,Osher Inst, Div Res & Educ Complementary & Integrat Med Thera, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Canadian Col Naturopath Med, Toronto, ON, Canada; Univ Toronto, Toronto, ON, Canada; NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Weiger, WA (corresponding author), Harvard Univ, Sch Med, Landmark Ctr,Osher Inst, Div Res & Educ Complementary & Integrat Med Thera, 2nd Floor W,Suite 22A,401 Pk Dr, Boston, MA 02215 USA.	wendy_weiger@hms.harvard.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR 43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADLERCREUTZ CHT, 1995, J NUTR, V125, pS757, DOI 10.1093/jn/125.3_Suppl.757S; ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; Ahles TA, 1999, J PAIN SYMPTOM MANAG, V18, P157, DOI 10.1016/S0885-3924(99)00061-5; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Alimi D, 2000, J PAIN SYMPTOM MANAG, V19, P81, DOI 10.1016/S0885-3924(99)00140-2; Allred CD, 2001, CANCER RES, V61, P5045; Amato P, 2002, MENOPAUSE, V9, P145, DOI 10.1097/00042192-200203000-00010; [Anonymous], 1993, CA-CANCER J CLIN, V43, P309; [Anonymous], 2001, DIETARY REFERENCE IN; [Anonymous], 2001, MED EC; Awad AB, 2001, EUR J CANCER PREV, V10, P507, DOI 10.1097/00008469-200112000-00005; Bairati I, 1998, J UROLOGY, V159, P1271, DOI 10.1016/S0022-5347(01)63579-1; BAIRD DD, 1995, J CLIN ENDOCR METAB, V80, P1685, DOI 10.1210/jc.80.5.1685; BATIST G, 1995, ALTERNATIVE COMPLEME, V1, P243; BINDEMANN S, 1991, EUR J CANCER, V27, P170, DOI 10.1016/0277-5379(91)90480-2; Bogliun G, 1996, INT J GYNECOL CANCER, V6, P415, DOI 10.1046/j.1525-1438.1996.06050415.x; Bonham M, 2002, CANCER RES, V62, P3920; BOON H, 1999, BOT PHARM PHARM 47 C; BORDIA A, 1985, CLIN CARDIOL, V8, P552, DOI 10.1002/clc.4960081012; BORDIA AK, 1980, ATHEROSCLEROSIS, V35, P181, DOI 10.1016/0021-9150(80)90083-0; BOWMAN BB, 1984, J CLIN ONCOL, V2, P702, DOI 10.1200/JCO.1984.2.6.702; BROWN V, 1985, MACROBIOTIC MIRACLE; Calzada C, 1997, ATHEROSCLEROSIS, V128, P97, DOI 10.1016/S0021-9150(96)05974-6; CARTER JP, 1993, J AM COLL NUTR, V12, P209; Cascinu S, 2002, J CLIN ONCOL, V20, P3478, DOI 10.1200/JCO.2002.07.061; CASCINU S, 1995, J CLIN ONCOL, V13, P26, DOI 10.1200/JCO.1995.13.1.26; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; CHLEBOWSKI RT, 1992, BREAST CANCER RES TR, V20, P73; Classen C, 2001, ARCH GEN PSYCHIAT, V58, P494, DOI 10.1001/archpsyc.58.5.494; Cohen MH, 2002, ANN INTERN MED, V136, P596, DOI 10.7326/0003-4819-136-8-200204160-00009; CONNORS T. A., 1966, EUR J CANCER, V2, P293, DOI 10.1016/0014-2964(66)90042-9; CREAGAN ET, 1979, NEW ENGL J MED, V301, P687, DOI 10.1056/NEJM197909273011303; Cunningham AJ, 1998, PSYCHO-ONCOL, V7, P508, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<508::AID-PON376>3.0.CO;2-7; CURTIES D, 1998, MASSAGE THERAPY CANC; Darzynkiewicz Z, 2000, INT J ONCOL, V17, P729; Davis NB, 2002, J UROLOGY, V167, P1793, DOI 10.1016/S0022-5347(05)65209-3; de la Taille A, 1999, BJU INT, V84, P845; De la Taille A, 2000, J UROLOGY, V164, P1229, DOI 10.1097/00005392-200010000-00021; DeVita VT, 1997, CANC PRINCIPLES PRAC; Dimeo F, 1997, BLOOD, V90, P3390, DOI 10.1182/blood.V90.9.3390; Dimeo FC, 1999, CANCER, V85, P2273, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2273::AID-CNCR24>3.0.CO;2-B; DiPaola RS, 1998, NEW ENGL J MED, V339, P785, DOI 10.1056/NEJM199809173391201; Duda RB, 1999, J SURG ONCOL, V72, P230, DOI 10.1002/(SICI)1096-9098(199912)72:4<230::AID-JSO9>3.0.CO;2-2; Duncan AM, 1999, J CLIN ENDOCR METAB, V84, P192, DOI 10.1210/jc.84.1.192; Duncan AM, 1999, J CLIN ENDOCR METAB, V84, P3479, DOI 10.1210/jc.84.10.3479; DUNDEE JW, 1987, LANCET, V1, P1083; DVORKIN L, 2000, SHARK CARTILAGE; Edelman S, 1999, PSYCHO-ONCOL, V8, P474, DOI 10.1002/(SICI)1099-1611(199911/12)8:6<474::AID-PON427>3.0.CO;2-A; Edelman S, 1999, PSYCHO-ONCOL, V8, P295, DOI 10.1002/(SICI)1099-1611(199907/08)8:4<295::AID-PON386>3.3.CO;2-P; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; Ernst E, 2002, ARCH SURG-CHICAGO, V137, P316, DOI 10.1001/archsurg.137.3.316; EVANS BAJ, 1995, J ENDOCRINOL, V147, P295, DOI 10.1677/joe.0.1470295; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720; FILSHIE J, 1985, EUR J SURG ONCOL, V11, P389; FILSHIE J, 1988, CANCER SURV, V7, P161; FLETCHER RH, 2001, VITAMIN SUPPLEMANTAT; *FOOD NUTR BOARD I, 2002, DIET REF INT TABL; FORESTER B, 1985, AM J PSYCHIAT, V142, P22; Fotsis T, 1997, CANCER RES, V57, P2916; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; FREI B, 1994, AM J MED, V97, pS5, DOI 10.1016/0002-9343(94)90292-5; Frei B, 1994, AM J MED, V97, p22S; Fukui S, 2000, CANCER, V89, P1026, DOI 10.1002/1097-0142(20000901)89:5<1026::AID-CNCR12>3.0.CO;2-5; Giese S, 1998, PLAST RECONSTR SURG, V102, P1778, DOI 10.1097/00006534-199810000-00101; Goldman P, 2001, ANN INTERN MED, V135, P594, DOI 10.7326/0003-4819-135-8_Part_1-200110160-00010; Goodwin PJ, 2001, NEW ENGL J MED, V345, P1719, DOI 10.1056/NEJMoa011871; Grealish L, 2000, CANCER NURS, V23, P237, DOI 10.1097/00002820-200006000-00012; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Habito RC, 2000, BRIT J NUTR, V84, P557, DOI 10.1017/S0007114500001872; Halicka HD, 1997, INT J ONCOL, V11, P437; Hargreaves DF, 1999, J CLIN ENDOCR METAB, V84, P4017, DOI 10.1210/jc.84.11.4017; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HERSKOVITZ S, 1992, MUSCLE NERVE, V15, P1215; Holmes MD, 1999, CANCER, V86, P826, DOI 10.1002/(SICI)1097-0142(19990901)86:5&lt;826::AID-CNCR19&gt;3.0.CO;2-0; HOPKINS MP, 1988, AM J OBSTET GYNECOL, V159, P1121, DOI 10.1016/0002-9378(88)90426-7; Hospers GAP, 1999, BRIT J CANCER, V80, P629, DOI 10.1038/sj.bjc.6690404; Hsieh TC, 1998, INT J ONCOL, V13, P1199; Hsieh TC, 1997, BIOCHEM MOL BIOL INT, V42, P535; Ikezoe T, 2001, PROSTATE, V49, P285, DOI 10.1002/pros.10024; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Johansson K, 1999, LYMPHOLOGY, V32, P103; Johansson K, 1998, LYMPHOLOGY, V31, P56; Ju YH, 2002, CANCER RES, V62, P2474; KAGERUD A, 1981, ACTA RADIOL ONCOL, V20, P97; Kane GC, 2000, MAYO CLIN PROC, V75, P933, DOI 10.4065/75.9.933; Kaptchuk TJ, 2001, ANN INTERN MED, V135, P196, DOI 10.7326/0003-4819-135-3-200108070-00012; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010; Kerr H D, 1997, WMJ, V96, P57; Kim DJ, 2000, CANCER CAUSE CONTROL, V11, P65, DOI 10.1023/A:1008913620344; Kristal AR, 2002, CANCER EPIDEM BIOMAR, V11, P719; Kubota T, 2000, PROSTATE, V42, P163; KUCERA H, 1982, FORTSCHR MED, V100, P760; Kuchler T, 1999, HEPATO-GASTROENTEROL, V46, P322; Kumar NB, 2002, CANCER-AM CANCER SOC, V94, P1166, DOI 10.1002/cncr.10320; KUSHI M, 1983, CANC PREVENTION DIET; KUSHI M, 1991, MACROBIOTIC APPROACH; Labriola D, 1999, ONCOLOGY-NY, V13, P1003; Labriola D, 1999, ONCOLOGY HUNTINGT, V13, P1008; Lamson D W, 1999, Altern Med Rev, V4, P304; LAWVERE S, 2002, MASSAGE THERAPY EVID, P57; Leitner S. P., 1998, P AN M AM SOC CLIN, V17, pA; Li DH, 1999, J NUTR, V129, P1075, DOI 10.1093/jn/129.5.1075; LINN MW, 1982, CANCER, V49, P1048, DOI 10.1002/1097-0142(19820301)49:5<1048::AID-CNCR2820490534>3.0.CO;2-G; Lissoni P, 1997, J PINEAL RES, V23, P15, DOI 10.1111/j.1600-079X.1997.tb00329.x; Lissoni P, 1999, EUR J CANCER, V35, P1688, DOI 10.1016/S0959-8049(99)00159-8; Lissoni P, 1996, ONCOLOGY, V53, P43; Lund EL, 1998, FOLIA MICROBIOL, V43, P505, DOI 10.1007/BF02820805; MACKINNON S, 2000, EVERYDAY REFERENCE H, P191; MacPherson H, 1999, J ALTERN COMPLEM MED, V5, P47, DOI 10.1089/acm.1999.5.47; MACVICAR MG, 1989, NURS RES, V38, P348; MANN F, 1973, LANCET, V2, P57; MARCUS R, 1996, PHARMACOL BASIS THER, P1573; MARKOVITS J, 1989, CANCER RES, V49, P5111; Martini MC, 1999, NUTR CANCER, V34, P133, DOI 10.1207/S15327914NC3402_2; Mathijssen RHJ, 2002, J NATL CANCER I, V94, P1247, DOI 10.1093/jnci/94.16.1247; MCMILLAN C, 1991, BRIT J CANCER, V64, P971, DOI 10.1038/bjc.1991.439; Messina MJ, 2001, J NUTR, V131, p3095S, DOI 10.1093/jn/131.11.3095S; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; Meyer F, 1999, CANCER CAUSE CONTROL, V10, P245, DOI 10.1023/A:1008913307947; Mikhail A, 1997, NEPHROL DIAL TRANSPL, V12, P797, DOI 10.1093/ndt/12.4.797; Miller DR, 1998, J CLIN ONCOL, V16, P3649, DOI 10.1200/JCO.1998.16.11.3649; MILLS EED, 1988, BRIT J CANCER, V57, P416, DOI 10.1038/bjc.1988.94; Mock V, 1997, Oncol Nurs Forum, V24, P991; MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301; MOUSAVI Y, 1993, STEROIDS, V58, P301, DOI 10.1016/0039-128X(93)90088-5; Moyad MA, 1999, UROLOGY, V54, P319, DOI 10.1016/S0090-4295(99)00216-2; MYERS C, 1983, SEMIN ONCOL, V10, P53; Nagata C, 2001, CANCER EPIDEM BIOMAR, V10, P179; Nagata C, 1998, JNCI-J NATL CANCER I, V90, P1830, DOI 10.1093/jnci/90.23.1830; *OFF TECHN ASS, 1990, OTAH405 OFF TECHN AS; Oh MK, 2001, UROLOGY, V57, P122, DOI 10.1016/S0090-4295(00)00986-9; Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; Pearl ML, 1999, CANCER NURS, V22, P307, DOI 10.1097/00002820-199908000-00008; Peng A T, 1974, Am Surg, V40, P50; Persky VW, 2002, AM J CLIN NUTR, V75, P145, DOI 10.1093/ajcn/75.1.145; Petrakis NL, 1996, CANCER EPIDEM BIOMAR, V5, P785; Peuker ET, 1999, ARCH FAM MED, V8, P553, DOI 10.1001/archfami.8.6.553; Pfeifer BL, 2000, BJU INT, V85, P481, DOI 10.1046/j.1464-410x.2000.00476.x; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; PRICE H, 1991, COMPLEMENT MED RES, V5, P93; PUNNONEN R, 1980, BRIT MED J, V281, P1110, DOI 10.1136/bmj.281.6248.1110; Rafi MM, 2000, ANTICANCER RES, V20, P2653; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; RATCLIFFE MA, 1995, PSYCHO-ONCOL, V4, P39, DOI 10.1002/pon.2960040105; RICHARDSON JL, 1990, J CLIN ONCOL, V8, P356, DOI 10.1200/JCO.1990.8.2.356; RICO RC, 1982, J MED, V13, P247; Riviere M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P46; Rosenbluth R. J., 1999, P ANN M AM SOC CLIN, V18, pA; SAKAMOTO K, 1973, BRIT J RADIOL, V46, P538, DOI 10.1259/0007-1285-46-547-538; Santell RC, 2000, J NUTR, V130, P1665, DOI 10.1093/jn/130.7.1665; Santibanez JF, 1997, ANTICANCER RES, V17, P1199; SATTILARO A, 1982, RECALLED LIFE; Segal R, 2001, J CLIN ONCOL, V19, P657, DOI 10.1200/JCO.2001.19.3.657; SHEN J, 1997, P AN M AM SOC CLIN, V16, pA148; Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755; SINGH CV, 1978, J INDIAN MED ASSOC, V11, P108; Sloman R, 1994, Contemp Nurse, V3, P6; Small EJ, 2000, J CLIN ONCOL, V18, P3595, DOI 10.1200/JCO.2000.18.21.3595; SMALL EJ, 2002, P AN M AM SOC CLIN, V21, pA709; Smith M, 1999, PATIENT EDUC COUNS, V38, P109, DOI 10.1016/S0738-3991(99)00058-0; Smyth JF, 1997, ANN ONCOL, V8, P569, DOI 10.1023/A:1008211226339; Sovak M, 2002, J NATL CANCER I, V94, P1275, DOI 10.1093/jnci/94.17.1275; Speca M, 2000, PSYCHOSOM MED, V62, P613, DOI 10.1097/00006842-200009000-00004; Speyer J, 1998, SEMIN ONCOL, V25, P525; SPIEGEL D, 1989, LANCET, V2, P888; SPIEGEL D, 1981, ARCH GEN PSYCHIAT, V38, P527; SPIEGEL D, 1983, PSYCHOSOM MED, V45, P333, DOI 10.1097/00006842-198308000-00007; STELLING K, 2000, EVERYDAY REFERENCE H, P110; SYRJALA KL, 1995, PAIN, V63, P189, DOI 10.1016/0304-3959(95)00039-U; SYRJALA KL, 1992, PAIN, V48, P137, DOI 10.1016/0304-3959(92)90049-H; TEICHER BA, 1994, CANCER CHEMOTH PHARM, V34, P235; TELCH CF, 1986, J CONSULT CLIN PSYCH, V54, P802, DOI 10.1037/0022-006X.54.6.802; Trotter JF, 1999, NEW ENGL J MED, V341, P2019, DOI 10.1056/NEJM199912233412616; Upmalis DH, 2000, MENOPAUSE, V7, P236, DOI 10.1097/00042192-200007040-00005; *US PREV SERV TASK, 1989, GUID CLIN PREV SERV, P388; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; WALKER C, 1998, PC WEEK, V15, P34; Walker LG, 1999, BRIT J CANCER, V80, P262, DOI 10.1038/sj.bjc.6690349; Walker LG, 1999, EUR J CANCER, V35, P1783, DOI 10.1016/S0959-8049(99)00169-0; Wang CF, 1998, NUTR CANCER, V31, P90, DOI 10.1080/01635589809514686; Wang CF, 1997, NUTR CANCER, V28, P236, DOI 10.1080/01635589709514582; Weinerman, 1994, ANNU ROYAL COLL PHYS, V27, P93; Weinrobe MC, 2001, NEW ENGL J MED, V345, P1213, DOI 10.1056/NEJM200110183451616; Weitzman S, 1998, INT J CANCER, V78, P69; WEN HL, 1977, MOD MED ASIA, V0013, P00012; WIERNIK PH, 1992, CANCER INVEST, V10, P1, DOI 10.3109/07357909209032783; Wilkie D J, 2000, Hosp J, V15, P31; Wilkinson IB, 1999, J CARDIOVASC PHARM, V34, P690, DOI 10.1097/00005344-199911000-00010; Williams JC, 1997, INT J EXP PATHOL, V78, P259, DOI 10.1046/j.1365-2613.1997.260359.x; Williams JK, 1998, CORONARY ARTERY DIS, V9, P759, DOI 10.1097/00019501-199809110-00009; Wiseman H, 1996, BIOCHEM SOC T, V24, P795, DOI 10.1042/bst0240795; WISSEL PS, 1987, EUR J CLIN PHARMACOL, V33, P403, DOI 10.1007/BF00637638; Wu AH, 1999, J NATL CANCER I, V91, P529, DOI 10.1093/jnci/91.6.529; Yeo T. C., 1994, Singapore Medical Journal, V35, P319; Yip I, 1996, ADV EXP MED BIOL, V399, P173; Zava DT, 1997, NUTR CANCER, V27, P31, DOI 10.1080/01635589709514498; 1999, CATILAGE; 2000, ESSIAC 1999	205	143	147	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					889	903		10.7326/0003-4819-137-11-200212030-00010	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00010			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	622GY	12458989				2023-01-03	WOS:000179639700005
J	Kapur, N; House, A; Dodgson, K; May, C; Creed, F				Kapur, N; House, A; Dodgson, K; May, C; Creed, F			Effect of general hospital management on repeat episodes of deliberate self poisoning: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ERYSIPELAS; CELLULITIS; ADULTS; PRISTINAMYCIN; PENICILLIN; INFECTIONS; THERAPY		Manchester Royal Infirm, Dept Psychiat & Behav Sci, Manchester M13 9WL, Lancs, England; Univ Leeds, Acad Univ Psychiat & Behav Sci, Leeds LS2 9JT, W Yorkshire, England	University of Manchester; University of Leeds	Kapur, N (corresponding author), Univ Manchester, 7th Floor,Williamson Bldg, Manchester M13 9PL, Lancs, England.	nav.kapur@man.ac.uk		House, Allan/0000-0001-8721-8026				[Anonymous], 2000, Ann Dermatol Venereol, V127, P1118; Bergkvist PI, 1997, SCAND J INFECT DIS, V29, P377, DOI 10.3109/00365549709011834; BERNARD P, 1989, ARCH DERMATOL, V125, P779, DOI 10.1001/archderm.125.6.779; Bernard P, 1997, ANN DERMATOL VENER, V124, P384; BERNARD P, 1992, BRIT J DERMATOL, V127, P155, DOI 10.1111/j.1365-2133.1992.tb08048.x; Bernard P, 1996, ANN DERMATOL VENER, V123, P16; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; CHARTIER C, 1990, INT J DERMATOL, V29, P459, DOI 10.1111/j.1365-4362.1990.tb04833.x; Chartier C, 1996, INT J DERMATOL, V35, P779, DOI 10.1111/j.1365-4362.1996.tb02971.x; Committee for Proprietary Medicinal Products, 2000, POINTS CONS SWITCH S; Dupuy A, 1999, BRIT MED J, V318, P1591, DOI 10.1136/bmj.318.7198.1591; DUVANEL T, 1989, ARCH INTERN MED, V149, P293, DOI 10.1001/archinte.149.2.293; Eriksson B, 1996, CLIN INFECT DIS, V23, P1091, DOI 10.1093/clinids/23.5.1091; Gilbody S, 1997, J ROY COLL PHYS LOND, V31, P171; HAWTON K, 2001, COCHRANE DATABASE SY, P1764; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; JORUPRONSTROM C, 1986, SCAND J INFECT DIS, V18, P519, DOI 10.3109/00365548609021656; JORUPRONSTROM C, 1984, INFECTION, V12, P390, DOI 10.1007/BF01645222; JORUPRONSTROM C, 1982, SCAND J INFECT DIS S, V36, pS150; Kapur N, 1998, BRIT MED J, V316, P831, DOI 10.1136/bmj.316.7134.831; Kopp M, 2001, ANN DERMATOL VENER, V128, P338; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; REVERDY ME, 1994, MED MALADIES INFECT, V24, P898, DOI 10.1016/S0399-077X(05)80580-3; RONNEN M, 1985, INT J DERMATOL, V24, P169, DOI 10.1111/j.1365-4362.1985.tb05415.x; Royal College of Psychiatrists, 1994, GEN HOSP MAN AD DEL; Schmit JL, 2001, ANN DERMATOL VENER, V128, P334; Siegel JP, 2000, AM HEART J, V139, pS166, DOI 10.1016/S0002-8703(00)90066-8; [No title captured]; 1998, EFFECTIVE HLTH CARE, V4, P1	29	48	48	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 19	2002	325	7369					866	867		10.1136/bmj.325.7369.866	http://dx.doi.org/10.1136/bmj.325.7369.866			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386037	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000178793000019
J	Necula, M; Chirita, CN; Kuret, J				Necula, M; Chirita, CN; Kuret, J			Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRIL FORMATION; CENTRAL-NERVOUS-SYSTEM; A-BETA COMPONENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; LEWY BODIES; NEURODEGENERATIVE DISORDERS; PRECURSOR PROTEIN; FATTY-ACIDS; MEMBRANE INTERACTIONS	Parkinson's disease is characterized by the aggregation of alpha-synuclein into filamentous forms within affected neurons of the basal ganglia. Fibrillization of purified recombinant alpha-synuclein is inefficient in vitro but can be enhanced by the addition of various agents including glycosaminoglycans and polycations. Here we report that fatty acids and structurally related anionic detergents greatly accelerate fibrillization of recombinant alpha-synucleinat low micromolar concentrations with lag times as short as 11 min and apparent first order growth rate constants as fast as 10.4 h(-1). All detergents and fatty acids were micellar at active concentrations because of an alpha-synuclein-dependent depression of their critical micelle concentrations. Other anionic surfaces, such as those supplied by anionic phospholipid vesicles, also induced alpha-synuclein fibrillization, with resultant filaments originating from their surface. These data suggest that anionic surfaces presented as micelles or vesicles can serve to nucleate alpha-synuclein fibrillization, that this mechanism underlies the inducer activity of anionic surfactants, and that anionic membranes may serve this function in vivo.	Ohio State Univ, Coll Med & Publ Hlth, Ctr Biotechnol, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Biophys Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kuret, J (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Ctr Biotechnol, Dept Mol & Cellular Biochem, 1060 Carmack Rd, Columbus, OH 43210 USA.	kuret.3@osu.edu			NIA NIH HHS [AG 14452] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014452] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alim MA, 2002, J BIOL CHEM, V277, P2112, DOI 10.1074/jbc.M102981200; Antony T, 2003, J BIOL CHEM, V278, P3235, DOI 10.1074/jbc.M208249200; Arai Y, 2001, BRAIN RES, V888, P287, DOI 10.1016/S0006-8993(00)03082-1; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Baba M, 1998, AM J PATHOL, V152, P879; Bales BL, 2001, J PHYS CHEM B, V105, P6798, DOI 10.1021/jp004576m; BERGERON C, 1989, Alzheimer Disease and Associated Disorders, V3, P197, DOI 10.1097/00002093-198900000-00002; Bouchard M, 2000, PROTEIN SCI, V9, P1960, DOI 10.1110/ps.9.10.1960; BRITO RMM, 1986, ANAL BIOCHEM, V152, P250, DOI 10.1016/0003-2697(86)90406-9; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Chirita CN, 2003, J BIOL CHEM, V278, P25644, DOI 10.1074/jbc.M301663200; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; CORRIN ML, 1947, J AM CHEM SOC, V69, P683, DOI 10.1021/ja01195a065; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DICKSON DW, 2000, NEURODEGENERATIVE DE, P247; DUFFY PE, 1965, J NEUROPATH EXP NEUR, V24, P398, DOI 10.1097/00005072-196507000-00003; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Fezoui Y, 2000, NAT STRUCT BIOL, V7, P1095, DOI 10.1038/81937; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; GUNNARSSON G, 1980, J PHYS CHEM-US, V84, P3114, DOI 10.1021/j100460a029; Hagihara Y, 2002, BIOCHEMISTRY-US, V41, P1020, DOI 10.1021/bi015693q; Huibers PDT, 1997, J COLLOID INTERF SCI, V187, P113, DOI 10.1006/jcis.1996.4680; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAGER WAD, 1969, ARCH NEUROL-CHICAGO, V21, P615; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; KING MD, 1987, BIOCHEMISTRY-US, V26, P1224, DOI 10.1021/bi00379a004; King ME, 1999, BIOCHEMISTRY-US, V38, P14851, DOI 10.1021/bi9911839; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Mukaetova-Ladinska EB, 2000, J NEUROPATH EXP NEUR, V59, P408, DOI 10.1093/jnen/59.5.408; Naiki H, 1998, BIOCHEMISTRY-US, V37, P17882, DOI 10.1021/bi980550y; Naiki H, 1999, METHOD ENZYMOL, V309, P305; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Pertinhez TA, 2002, FEBS LETT, V529, P193, DOI 10.1016/S0014-5793(02)03333-1; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ranganathan R, 2000, J PHYS CHEM B, V104, P2260, DOI 10.1021/jp993917x; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Spillantini MG, 1999, ACTA NEUROPATHOL, V97, P585, DOI 10.1007/s004010051034; Takeda A, 1998, AM J PATHOL, V152, P367; TESSARI M, 1993, BIOPOLYMERS, V33, P1877, DOI 10.1002/bip.360331213; Trojanowski JQ, 2000, ANN NY ACAD SCI, V924, P62; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Wilson DM, 1997, AM J PATHOL, V150, P2181; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x; Yamabe T, 1999, J COLLOID INTERF SCI, V215, P58, DOI 10.1006/jcis.1999.6215; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200; Zhu M, 2002, J BIOL CHEM, V277, P50914, DOI 10.1074/jbc.M207225200	80	178	182	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46674	46680		10.1074/jbc.M308231200	http://dx.doi.org/10.1074/jbc.M308231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	14506232	hybrid			2023-01-03	WOS:000186569400057
J	Krack, P; Batir, A; Van Blercom, N; Chabardes, S; Fraix, V; Ardouin, C; Koudsie, A; Limousin, PD; Benazzouz, A; LeBas, JF; Benabid, AL; Pollak, P				Krack, P; Batir, A; Van Blercom, N; Chabardes, S; Fraix, V; Ardouin, C; Koudsie, A; Limousin, PD; Benazzouz, A; LeBas, JF; Benabid, AL; Pollak, P			Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-BRAIN-STIMULATION; RATING-SCALE; POSTEROVENTRAL PALLIDOTOMY; UNILATERAL PALLIDOTOMY; GLOBUS-PALLIDUS; MOTOR FUNCTION; LEVODOPA; FLUCTUATIONS; DEPRESSION; SPECTRUM	Background: Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown. Methods: We conducted a five-year prospective study of the first 49 consecutive patients whom we treated with bilateral stimulation of the subthalamic nucleus. Patients were assessed at one, three, and five years with levodopa (on medication) and without levodopa (off medication), with use of the Unified Parkinson's Disease Rating Scale. Seven patients did not complete the study: three died, and four were lost to follow-up. Results: As compared with base line, the patients' scores at five years for motor function while off medication improved by 54 percent (P<0.001) and those for activities of daily living improved by 49 percent (P<0.001). Speech was the only motor function for which off-medication scores did not improve. The scores for motor function on medication did not improve one year after surgery, except for the dyskinesia scores. On-medication akinesia, speech, postural stability, and freezing of gait worsened between year 1 and year 5 (P<0.001 for all comparisons). At five years, the dose of dopaminergic treatment and the duration and severity of levodopa-induced dyskinesia were reduced, as compared with base line (P<0.001 for each comparison). The average scores for cognitive performance remained unchanged, but dementia developed in three patients after three years. Mean depression scores remained unchanged. Severe adverse events included a large intracerebral hemorrhage in one patient. One patient committed suicide. Conclusions: Patients with advanced Parkinson's disease who were treated with bilateral stimulation of the subthalamic nucleus had marked improvements over five years in motor function while off medication and in dyskinesia while on medication. There was no control group, but worsening of akinesia, speech, postural stability, freezing of gait, and cognitive function between the first and the fifth year is consistent with the natural history of Parkinson's disease.	Univ Grenoble 1, Dept Clin & Biol Neurosci, Grenoble, France; Univ Grenoble 1, Dept Magnet Resonance Imaging, Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Krack, P (corresponding author), CHU Grenoble, Dept Neurol, Dept Clin & Biol Neurosci, BP 217, F-38043 Grenoble 9, France.	paul.krack@ujf-grenoble.fr	FRAIX, VALERIE/AAC-3616-2019; Benabid, Alim L/Q-3506-2017; Benazzouz, Abdelhamid/E-5050-2016	Krack, Paul/0000-0002-3508-7295				Albanese A, 2001, MOVEMENT DISORD, V16, P197, DOI 10.1002/mds.1069; Alkhani A, 2001, J NEUROSURG, V94, P43, DOI 10.3171/jns.2001.94.1.0043; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Berney A, 2002, NEUROLOGY, V59, P1427, DOI 10.1212/01.WNL.0000032756.14298.18; BONNET AM, 1987, NEUROLOGY, V37, P1539, DOI 10.1212/WNL.37.9.1539; De Bie RMA, 2002, MOVEMENT DISORD, V17, P533, DOI 10.1002/mds.10090; Doshi PK, 2002, MOVEMENT DISORD, V17, P1084, DOI 10.1002/mds.10198; Durif F, 2002, MOVEMENT DISORD, V17, P803, DOI 10.1002/mds.10128; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; Fine J, 2000, NEW ENGL J MED, V342, P1708, DOI 10.1056/NEJM200006083422304; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Funkiewiez A, 2003, MOVEMENT DISORD, V18, P524, DOI 10.1002/mds.10441; Ghika J, 1998, J NEUROSURG, V89, P713, DOI 10.3171/jns.1998.89.5.0713; Ghika J, 1999, J NEUROSURG, V91, P313, DOI 10.3171/jns.1999.91.2.0313; Goetz CG, 2002, MOVEMENT DISORD, V17, P283, DOI 10.1002/mds.10024; Goetz CG, 2000, NEUROLOGY, V54, P710, DOI 10.1212/WNL.54.3.710; GREENE P, 1993, ADV NEUROL, V60, P703; Hariz GM, 2003, MOVEMENT DISORD, V18, P373, DOI 10.1002/mds.10386; Hariz MI, 2001, J NEUROSURG, V94, P552, DOI 10.3171/jns.2001.94.4.0552; Hoehn MM, 1969, 3 S PARK DIS, P274; Houeto JL, 2002, J NEUROL NEUROSUR PS, V72, P701, DOI 10.1136/jnnp.72.6.701; Jahanshahi M, 2000, BRAIN, V123, P1142, DOI 10.1093/brain/123.6.1142; KLAWANS HL, 1986, MOVEMENT DISORD, V3, P187; Krack P, 2002, MOVEMENT DISORD, V17, pS188, DOI 10.1002/mds.10163; Krack P, 1997, LANCET, V350, P1676, DOI 10.1016/S0140-6736(05)64273-0; Krack P, 1999, BRAIN, V122, P1133, DOI 10.1093/brain/122.6.1133; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MARKHAM CH, 1986, ANN NEUROL, V19, P365, DOI 10.1002/ana.410190410; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Oh MY, 2002, NEUROSURGERY, V50, P1268; Pahwa R, 2003, J NEUROSURG, V99, P71, DOI 10.3171/jns.2003.99.1.0071; Pillon B, 2000, NEUROLOGY, V55, P411, DOI 10.1212/WNL.55.3.411; Rehncrona S, 2003, MOVEMENT DISORD, V18, P163, DOI 10.1002/mds.10309; RICHARDS M, 1994, MOVEMENT DISORD, V9, P89, DOI 10.1002/mds.870090114; RILEY DE, 1993, NEUROLOGY, V43, P1459, DOI 10.1212/WNL.43.8.1459; Romito LM, 2002, MOVEMENT DISORD, V17, P1371, DOI 10.1002/mds.10265; SCHMIDT R, 1994, NEUROLOGY, V44, P964, DOI 10.1212/WNL.44.5.964; Schwab R.S., 1969, 3 S PARK DIS, P152; Speelman JD, 1998, MOVEMENT DISORD, V13, P103; Valldeoriola F, 2002, J NEUROL, V249, P1671, DOI 10.1007/s00415-002-0897-8; Zhang H, 2003, NEUROSURGERY, V52, P89, DOI 10.1227/01.NEU.0000038933.95427.AE	46	1551	1583	1	188	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1925	1934		10.1056/NEJMoa035275	http://dx.doi.org/10.1056/NEJMoa035275			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614167	Green Published, Bronze			2023-01-03	WOS:000186502400007
J	Nordin, P; Zetterstrom, H; Gunnarsson, U; Nilsson, E				Nordin, P; Zetterstrom, H; Gunnarsson, U; Nilsson, E			Local, regional, or general anaesthesia in groin hernia repair: multicentre randomised trial	LANCET			English	Article							INGUINAL-HERNIA; HERNIORRHAPHY; OUTCOMES	Background In specialised centres, local anaesthesia is almost always used in groin hernia surgery; whereas in routine surgical practice, regional or general anaesthesia are the methods of choice. In this three-arm multicentre randomised trial, we aimed to compare the three methods of anaesthesia and to determine the extent to which general surgeons can reproduce the excellent results obtained with local anaesthesia in specialised hernia centres. Methods Between January, 1999, and December, 2001, 616 patients at ten hospitals, were randomly assigned to have either local, regional, or general anaesthesia. Primary endpoints were early and late postoperative complications. Secondary endpoints were duration of surgery and anaesthesia, length of postoperative hospital stay, and time to normal activity. Analysis was by intention to treat. Findings Intraoperative tolerance for local anaesthesia was high. In the early postoperative period, local anaesthesia was superior to the other two types with respect to almost all endpoints. At 8 days' and 30 days' follow-up, there were no significant differences between the three groups. Although the mean duration of surgery was longer, the total anaesthesia time-ie, time from the start of anaesthesia until the patient left the operating room-was significantly shorter than it was for regional or general anaesthesia. Interpretation Local anaesthesia has substantial advantages compared with regional or general anaesthesia, such as shorter duration of admission, less postoperative pain, and fewer micturition difficulties. The favourable results obtained with local anaesthesia in specialised hernia centres can, to a great extent, be reproduced by general surgeons in routine surgical practice.	Ostersund Hosp, Dept Surg, S-83183 Ostersund, Sweden; Ostersund Hosp, Dept Anaesthet, Ostersund, Sweden; Univ Uppsala, Mora Hosp, Dept Surg, S-75105 Uppsala, Sweden; Motala Hosp, Dept Surg, Motala, Sweden	Uppsala University	Nordin, P (corresponding author), Ostersund Hosp, Dept Surg, S-83183 Ostersund, Sweden.		Nordin, Pär/Y-6278-2019	Nordin, Par/0000-0001-6117-5777				Aasbo V, 2002, ACTA ANAESTH SCAND, V46, P674, DOI 10.1034/j.1399-6576.2002.460607.x; ALSARRAGE SAM, 1990, J KUWAIT MED ASSOC, V24, P31; AMID PK, 1994, ANN SURG, V220, P735, DOI 10.1097/00000658-199412000-00004; Amid PK, 1996, EUR J SURG, V162, P447; Bay-Nielsen M, 2001, LANCET, V358, P1124, DOI 10.1016/S0140-6736(01)06251-1; Bendavid R, 2001, ABDOMINAL WALL HERNI, P370; Callesen T, 2001, ANESTH ANALG, V93, P1373, DOI 10.1097/00000539-200112000-00004; CAMPBELL MJ, 1995, BRIT MED J, V311, P1145, DOI 10.1136/bmj.311.7013.1145; Cheek CM, 1998, ANN ROY COLL SURG, V80, pS1; Cushing H, 1900, ANN SURG, V31, P1, DOI 10.1097/00000658-190001000-00003; FINLEY RK, 1991, AM SURGEON, V57, P486; FLANAGAN L, 1984, SURG CLIN N AM, V64, P257; Friemert B, 2000, CHIRURG, V71, P52, DOI 10.1007/s001040051012; GODFREY PJ, 1981, BRIT J SURG, V68, P587, DOI 10.1002/bjs.1800680820; Gonullu N N, 2002, Hernia, V6, P29; HAAPANIEMI S, 2001, THESIS LINKOPING U S; Hair A, 2000, BRIT J SURG, V87, P1722, DOI 10.1046/j.1365-2168.2000.01598.x; Kark AE, 1998, J AM COLL SURGEONS, V186, P447, DOI 10.1016/S1072-7515(98)00057-X; Kingsnorth AN, 2000, HERNIA, V4, P1; KNAPP RW, 1976, AM SURGEON, V42, P908; MAKURIA T, 1979, ANN ROY COLL SURG, V61, P291; MERHAV H, 1993, INT SURG, V78, P257; NILSSON E, 2002, NYHUS CONDONS HERNIA, P567; O'Riordan DC, 1998, SURG CLIN N AM, V78, P1129, DOI 10.1016/S0039-6109(05)70374-1; PONKA JL, 1980, HERNIAS ABDOMINAL WA; Song DJ, 2000, ANESTH ANALG, V91, P876, DOI 10.1097/00000539-200010000-00020; TEASDALE C, 1982, ANN ROY COLL SURG, V64, P238; VANDERLINDEN W, 1983, CONTROVERSIES SURG, V2, P1; YOUNG DV, 1987, AM J SURG, V153, P560, DOI 10.1016/0002-9610(87)90154-1	29	155	165	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					853	858		10.1016/S0140-6736(03)14339-5	http://dx.doi.org/10.1016/S0140-6736(03)14339-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678971				2023-01-03	WOS:000185329400008
J	Swarte, NB; van der Lee, ML; van der Bom, JG; van den Bout, J; Heintz, APM				Swarte, NB; van der Lee, ML; van der Bom, JG; van den Bout, J; Heintz, APM			Effects of euthanasia on the bereaved family and friends: a cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN-ASSISTED SUICIDE; NATIONWIDE; LIFE; END	Objective To assess how euthanasia in terminally ill cancer patients affects the grief response of bereaved family and friends. Design Cross sectional study Setting Tertiary referral centre for oncology patients in Utrecht, the Netherlands. Participants 189 bereaved family members and close friends of terminally ill cancer patients who died by euthanasia and 316 bereaved family members and close friends of comparable cancer patients who died a natural death between 1992 and 1999. Main outcome measures Symptoms of traumatic grief assessed by the inventory of traumatic grief, current feelings of grief assessed by the Texas revised inventory of grief, and post-traumatic stress reactions assessed by the impact of event scale. Results The bereaved family and friends of cancer patients who died by euthanasia had less traumatic grief symptoms (adjusted difference - 5.29 (95% confidence interval - 8.44 to - 2.15)), less current feeling of grief (adjusted difference 2.93 (0.85 to 5.01)); and less post-traumatic stress reactions (adjusted difference - 2.79 (- 5.33 to - 0.25)) than the family and friends of patients who died of natural causes. These differences were independent of other risk factors. Conclusions The bereaved family and friends of cancer patients who died by euthanasia coped better with respect to grief symptoms and post-traumatic stress reactions than the bereaved of comparable cancer patients who died a natural death. These results should not be interpreted as a plea for euthanasia, but as a plea for the same level of care and openness in all patients who are terminally ill.	Univ Med Ctr Utrecht, Dept Gynaecol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Dept Clin Psychol, NL-3508 TC Utrecht, Netherlands; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University; Utrecht University Medical Center	Swarte, NB (corresponding author), Univ Med Ctr Utrecht, Dept Gynaecol, F05-829,POB 85500, NL-3508 GA Utrecht, Netherlands.	n.swarte@azu.nl	van der Bom, Johanna G./G-1965-2018	van der Bom, Johanna G./0000-0001-9095-2475				Arrindell WA, 1986, SCL 90 MANUAL MULTID; Boelen PA, 2003, DEATH STUD, V27, P227, DOI 10.1080/07481180302889; BrintzenhofeSzoc KM, 1999, CANCER PRACT, V7, P233, DOI 10.1046/j.1523-5394.1999.75006.x; Chochinov HM, 2000, PSYCHOSOMATICS, V41, P500, DOI 10.1176/appi.psy.41.6.500; Emanuel EJ, 2002, ARCH INTERN MED, V162, P142, DOI 10.1001/archinte.162.2.142; FASCHINGBAUER RRZ, 1987, BIOPSYCHOSOCIAL ASPE, P127; Goldstein H., 1998, USERS GUIDE MLWIN; Groenewoud JH, 2000, NEW ENGL J MED, V342, P551, DOI 10.1056/NEJM200002243420805; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Jacobs S, 2000, DEATH STUD, V24, P185, DOI 10.1080/074811800200531; Kelly BJ, 1996, AUST NZ J PSYCHIAT, V30, P3, DOI 10.3109/00048679609076068; Koop P M, 1997, Can J Nurs Res, V29, P33; LUBIN B, 1965, ARCH GEN PSYCHIAT, V12, P57; PIJNENBORG L, 1994, BMJ-BRIT MED J, V309, P1209, DOI 10.1136/bmj.309.6963.1209; SANDERMAN R, 1995, EYSENCK PERSONALITY; STROEBE MS, 1989, OMEGA-J DEATH DYING, V20, P1, DOI 10.2190/C3JE-C9L1-5R91-DWDU; STROEBE W, 2001, HDB BEREAVEMENT RES, P613; Swarte NB, 2001, BEST PRACT RES CL OB, V15, P313, DOI 10.1053/beog.2000.0171; Swarte NB, 1999, ANN MED, V31, P364, DOI 10.3109/07853899908998793; SWARTE NB, 2000, BAILLIERE CLIN OB GY, V15, P313; Valdimarsdottir U, 2002, BRIT J CANCER, V86, P1540, DOI 10.1038/sj.bjc.6600271; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vandenBoom F, 1995, AIDS CARE, V7, pS175; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; WEGNER M, 1993, MEASUREMENT PERCEIVE	25	64	64	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 26	2003	327	7408					189	192		10.1136/bmj.327.7408.189	http://dx.doi.org/10.1136/bmj.327.7408.189			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	706DL	12881258	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000184437300014
J	Mitchell, SL; Teno, JM; Roy, J; Kabumoto, G; Mor, V				Mitchell, SL; Teno, JM; Roy, J; Kabumoto, G; Mor, V			Clinical and organizational factors associated with feeding tube use among nursing home residents with advanced cognitive impairment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCED DEMENTIA; PREFERENCES; DIRECTIVES; ATTITUDES; FACILITY; RISK	Context Empiric data and expert opinion suggest that use of feeding tubes is not beneficial for older persons with advanced dementia. Previous research has shown a 10-fold variation in this practice across the United States. Objective To identify the facility and resident characteristics associated with feeding tube use among US nursing homes residents with severe cognitive impairment. Design, Setting, and Participants Cross-sectional study of all residents with advanced cognitive impairment who had Minimum Data Set assessments within 60 days of April 1, 1999, (N = 186835) and who resided in Medicare- or Medicaid-certified US nursing homes. Main Outcomes Measures Facility and resident characteristics described in the 1999 On-line Survey Certification of Automated Records and the 1999 Minimum Data Set. Multivariate analysis using generalized estimating equations determined the facility and resident factors independently associated with feeding tube use. Results Thirty-four percent of residents with advanced cognitive impairment had feeding tubes (N = 63 101). Resident characteristics associated with a greater likelihood of feeding tube use included younger age, nonwhite race, male sex, divorced marital status, lack of advance directives, a recent decline in functional status, and no diagnosis of Alzheimer disease. Controlling for these patient factors, residents living in facilities that were for profit (adjusted odds ratio (OR], 1.09; 95% confidence interval [Cl], 1.06-1.12); located in an urban area (OR, 1.14; 95% Cl, 1.11-1.16); having more than 100 beds (OR, 1.04; 95% Cl, 1.01-1.07); and lacking a special dementia care unit (OR, 1.11; 95% Cl, 1.07-1.15) had a higher likelihood of having a feeding tube. Additionally, feeding tube use was more likely among residents living in facilities that had a smaller proportion of residents with do-not-resuscitate orders, had a higher prevalence of non-white residents, and lacked a nurse practitioner or physician assistant on staff. Conclusions More than one third of severely cognitively impaired residents in US nursing homes have feeding tubes. Feeding tube use is independently associated with both the residents' clinical characteristics and the nursing homes' fiscal, organizational, and demographic features.	Beth Israel Deaconess Med Ctr, Hebrew Rehabil Ctr Aged, Res & Training Inst, Dept Med, Boston, MA 02131 USA; Harvard Univ, Sch Med, Div Aging, Boston, MA 02115 USA; Brown Univ, Sch Med, Dept Community Hlth, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Brown University	Mitchell, SL (corresponding author), Beth Israel Deaconess Med Ctr, Hebrew Rehabil Ctr Aged, Res & Training Inst, Dept Med, 1200 Ctr St, Boston, MA 02131 USA.				NATIONAL INSTITUTE ON AGING [K23AG020054, R37AG011624] Funding Source: NIH RePORTER; NIA NIH HHS [AG-11624, K23AG20054-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahronheim JC, 2001, J AM GERIATR SOC, V49, P148, DOI 10.1046/j.1532-5415.2001.49035.x; BATCHELOR AJ, 1992, J AM GERIATR SOC, V40, P679, DOI 10.1111/j.1532-5415.1992.tb01959.x; Blackhall LJ, 1999, SOC SCI MED, V48, P1779, DOI 10.1016/S0277-9536(99)00077-5; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; FRIES BE, 1994, MED CARE, V32, P668, DOI 10.1097/00005650-199407000-00002; Gessert CE, 2000, J AM GERIATR SOC, V48, P1593, DOI 10.1111/j.1532-5415.2000.tb03869.x; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; GRADY D, 2000, NY TIMES        0120, pA13; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; Intrator O, 1999, MED CARE, V37, P228, DOI 10.1097/00005650-199903000-00003; Kayser-Jones J, 1999, J AM GERIATR SOC, V47, P1187, DOI 10.1111/j.1532-5415.1999.tb05198.x; Kiely DK, 2001, J AM GERIATR SOC, V49, P1346, DOI 10.1046/j.1532-5415.2001.49263.x; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; Meier DE, 2002, NEW ENGL J MED, V346, P1087, DOI 10.1056/NEJM200204043461413; Meier DE, 2001, ARCH INTERN MED, V161, P594, DOI 10.1001/archinte.161.4.594; Mitchell S L, 2001, J Am Med Dir Assoc, V2, P10, DOI 10.1097/00130535-200101000-00003; Mitchell SL, 1997, ARCH INTERN MED, V157, P327, DOI 10.1001/archinte.157.3.327; Mitchell SL, 2003, J AM GERIATR SOC, V51, P75, DOI 10.1034/j.1601-5215.2002.51021.x; Mitchell SL, 2003, J AM GERIATR SOC, V51, P129, DOI 10.1034/j.1601-5215.2002.51021.x; Mitchell Susan L, 2003, J Am Med Dir Assoc, V4, P27, DOI 10.1097/00130535-200301000-00005; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; SAS Institute, 2014, SAS STAT SOFTW CHANG; Teno JM, 2002, JAMA-J AM MED ASSOC, V287, P3211, DOI 10.1001/jama.287.24.3211; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	26	236	240	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					73	80		10.1001/jama.290.1.73	http://dx.doi.org/10.1001/jama.290.1.73			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	696CR	12837714	Bronze			2023-01-03	WOS:000183868600022
J	Wald, NJ; Law, MR				Wald, NJ; Law, MR			A strategy to reduce cardiovascular disease by more than 80%	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; RISK-FACTOR; HOMOCYSTEINE; CHOLESTEROL; STROKE	Objectives To determine the combination of drugs and vitamins, and their doses, for use in a single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse effects. The strategy was to simultaneously reduce four cardiovascular risk factors (low density lipoprotein cholesterol, blood pressure, serum homocysteine, and platelet function) regardless of pretreatment levels. Design We quantified the efficacy and adverse effects of the proposed formulation from published meta-analyses of randomised trials and cohort studies and a meta-analysis of 15 trials of low dose (50-125 mg/day) aspirin. Outcome measures Proportional reduction in ischaemic heart disease (IHD) events and strokes; life years gained; and prevalence of adverse effects. Results The formulation which met our objectives was: a statin (for example, atorvastatin (daily dose 10 mg) or simvastatin (40 mg); three blood pressure lowering drugs (for example, a thiazide, a P blocker, and an angiotensin converting enzyme inhibitor), each at half standard dose; folic acid (0.8 mg); and aspirin (75 mg). We estimate that the combination (which we call the Polypill) reduces IHD events by 88% (95% confidence interval 84% to 91%) and stroke by 80% (71% to 87%). One third of people taking this pill from age 55 would benefit, gaining on average about I I years of life free from an IHD event or stroke. Summing the adverse effects of the components observed in randomised trials shows that the Polypill would cause symptoms in 8-15% of people (depending on the precise formulation). Conclusion The Polypill strategy could largely prevent heart attacks and stroke if taken by everyone aged 55 and older and everyone with existing cardiovascular disease. It would be acceptably safe and with widespread use would have a greater impact on the prevention of disease in the Western world than an), other single intervention.	Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Wald, NJ (corresponding author), Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England.	n.j.wald@qmul.ac.uk	Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; *BRIT MED ASS, 2002, 44 BMA RPS; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Law MR, 2002, ARCH INTERN MED, V162, P2405, DOI 10.1001/archinte.162.21.2405; Law MR, 2002, BMJ-BRIT MED J, V324, P1570, DOI 10.1136/bmj.324.7353.1570; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; LAW MR, IN PRESS HLTH TECHNO; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; LIU LS, 1995, CHINESE MED J-PEKING, V108, P710; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Wald DS, 2001, ARCH INTERN MED, V161, P695, DOI 10.1001/archinte.161.5.695; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; Wald NJ, 1999, BMJ-BRIT MED J, V319, P1562, DOI 10.1136/bmj.319.7224.1562; WALD NJ, 2000, Patent No. 000879162000; 2001, J MED SCREEN, V8, P220	25	1046	1116	3	67	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	2003	326	7404					1419	1423		10.1136/bmj.326.7404.1419	http://dx.doi.org/10.1136/bmj.326.7404.1419			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697FP	12829553	Bronze, Green Published			2023-01-03	WOS:000183931800015
J	McIntyre, LA; Fergusson, DA; Hebert, PC; Moher, D; Hutchison, JS				McIntyre, LA; Fergusson, DA; Hebert, PC; Moher, D; Hutchison, JS			Prolonged therapeutic hypothermia after traumatic brain injury in adults - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MILD HYPOTHERMIA; INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; TRIALS; TEMPERATURE; BARBITURATE; EXPERIENCE; EFFICACY; QUALITY	Context The benefits of therapeutic hypothermia as a treatment for traumatic brain injury (TBI) remain unclear. Objective To explore the effects of depth, duration, and rate of rewarming after discontinuation of hypothermia on mortality and neurologic outcome in adults after TBI. Data Sources An electronic search of MEDLINE (OVID), EMBASE, Current Contents, the Cochrane library and a hand search of key journals were performed. Corresponding authors of identified studies were contacted for additional unpublished or ongoing clinical trials. Study Selection All randomized controlled trials of therapeutic hypothermia for at least 24 hours vs normothermia in adults with TBI. Data Extraction Demographic and clinical data, hypothermia interventions and cointerventions, mortality and neurologic outcomes, and methodological quality were abstracted by 2 independent reviewers. Data Synthesis Twelve trials met eligibility criteria and were included in the analysis. We also performed subanalyses by different hypothermia interventions (ie, depth, duration, and rapidity of rewarming after hypothermia) and methodological quality. Therapeutic hypothermia was associated with a 19% reduction in the risk of death (95% confidence interval [CI], 0.69-0.96) and a 22% reduction in the risk of poor neurologic outcome (95% CI, 0.63-0.98) compared with normothermia. Hypothermia longer than 48 hours was associated with a reduction in the risks of death and of poor neurologic outcome (relative risk [RR], 0.70; 95% CI, 0.56-0.87 and RR, 0.65; 95% CI, 0.48-0.89, respectively) compared with normothermia. Hypothermia to a target temperature between 32degreesC and 33degreesC, a duration of 24 hours, and rewarming within 24 hours were all associated with reduced risks of poor neurologic outcome compared with normothermia. Assessment of methodological quality did not reveal evidence of bias. Conclusions Therapeutic hypothermia may reduce the risks of mortality and poor neurologic outcome in adults with TBI. Outcomes were influenced, however, by depth and duration of hypothermia as well as rate of rewarming (less than or equal to24 hours) after discontinuation of hypothermia. Nonetheless, the evidence is not yet sufficient to recommend routine use of therapeutic hypothermia for TBI outside of research settings.	Univ Ottawa, Ottawa Hosp, Dept Med, Div Intens Care, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ctr Transfus Res, Clin Epidemiol Program, Hlth Res Inst, Ottawa, ON, Canada; Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Chalmers Res Grp, Ottawa, ON, Canada; Univ Ottawa, Dept Pediat, Ottawa, ON, Canada; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada; Univ Toronto, Hosp Sick Children, Dept Crit Care, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	McIntyre, LA (corresponding author), Univ Ottawa, Ottawa Hosp, Dept Med, Div Intens Care, Gen Campus, 501 Smyth Rd,Box 201, Ottawa, ON K1H 8L6, Canada.	lmcintyre@ottawahospital.on.ca	McIntyre, Lauralyn/AAR-7710-2021	McIntyre, Lauralyn/0000-0001-7421-1407; Fergusson, Dean/0000-0002-3389-2485; Moher, David/0000-0003-2434-4206				Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Bernard S, 1996, ANAESTH INTENS CARE, V24, P382, DOI 10.1177/0310057X9602400315; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernard SA, 1999, CRIT CARE, V3, P167, DOI 10.1186/cc371; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; *COCHR LIB, 2002, COCHR CONTR TRIALS R; DRAKE CG, 1962, CAN MED ASSOC J, V87, P887; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; Gadkary CS, 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001048; Ginsberg MD, 2002, CRIT CARE MED, V30, P935, DOI 10.1097/00003246-200204000-00040; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; Hedges LV, 2002, STAT METHODS METAANA; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; Heyland DK, 2001, JAMA-J AM MED ASSOC, V286, P944, DOI 10.1001/jama.286.8.944; Hirayama TKY, 1994, INTRACRANIAL PRESSUR, VIX, P233; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Mouritzen CV, 1966, J THORAC CARDIOVASC, V51, P579; Nakamura T, 1998, ACT NEUR S, V71, P85; Nara I, 1998, ACT NEUR S, V71, P22; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schwab S, 1998, STROKE, V29, P305; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHEN JH, 2000, HEIBEL MED J, V6, P498; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vespa PM, 2001, CRIT CARE MED, V29, P2224; Yan Y, 2001, Chin J Traumatol, V4, P8; Zhang K, 2000, INNER MONGOLIA MED J, V32, P4	58	239	248	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2003	289	22					2992	2999		10.1001/jama.289.22.2992	http://dx.doi.org/10.1001/jama.289.22.2992			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687XZ	12799408				2023-01-03	WOS:000183403400023
J	Keenan, SP; Sinuff, T; Cook, DJ; Hill, NS				Keenan, SP; Sinuff, T; Cook, DJ; Hill, NS			Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE RESPIRATORY-FAILURE; STANDARD MEDICAL THERAPY; NASAL MASK VENTILATION; MECHANICAL VENTILATION; FACE MASK; METAANALYSIS; MORTALITY; SUPPORT; TRIAL; COPD	Background: Over the past decade, noninvasive positive-pressure ventilation (NPPV) in the setting of acute exacerbations of chronic obstructive pulmonary disease (COPD) has increased in popularity. Although several trials have been published on the relative effectiveness of this treatment, apparent inconsistencies in study results remain. Purpose: To assess the effect of NPPV on rate of endotracheal intubation, length of hospital stay, and in-hospital mortality rate in patients with an acute exacerbation of COPD and to determine the effect of exacerbation severity on these outcomes. Data Sources: MEDLINE (1966 to 2002) and EMBASE (1990 to 2002). Additional data sources included the Cochrane Library, personal files, abstract proceedings, reference lists of selected articles, and expert contact. There were no language restrictions. Study Selection: The researchers selected randomized, controlled trials that 1) examined patients with acute exacerbation of COPD; 2) compared noninvasive ventilation and standard therapy with standard therapy alone; and 3) included need for endotracheal intubation, length of hospital stay, or hospital survival as an outcome. Data Extraction: Methodologic quality and results were abstracted independently and in duplicate. Data Synthesis: The addition of NPPV to standard care in patients with an acute exacerbation of COPD decreased the rate of endotracheal intubation (risk reduction, 28% [95% CI, 15% to 40%]), length of hospital stay (absolute reduction, 4.57 days [CI, 2.30 to 6.83 days]), and in-hospital mortality rate (risk reduction, 10% [CI, 5% to 15%]). However, subgroup analysis showed that these beneficial effects occurred only in patients with severe exacerbations, not in those with milder exacerbations. Conclusions: Patients with severe exacerbations of COPD benefit from the addition of NPPV to standard therapy. However, NPPV has not been shown to benefit hospitalized patients with milder COPD exacerbations.	Royal Columbian Hosp, New Westminster, BC, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; McMaster Fac Sci, Hamilton, ON, Canada; Tufts Univ New England Med Ctr, Boston, MA USA	University of British Columbia; St. Paul's Hospital; University of Saskatchewan; McMaster University; Tufts Medical Center	Keenan, SP (corresponding author), Suite 103,250 Keary St, New Westminster, BC V3L 5E7, Canada.	Sean_Keenan@telus.net						AbouShala N, 1996, CRIT CARE MED, V24, P705, DOI 10.1097/00003246-199604000-00025; Ambrosino N, 1996, EUR RESPIR J, V9, P795, DOI 10.1183/09031936.96.09040795; Ambrosino N, 1993, Monaldi Arch Chest Dis, V48, P144; Angus RM, 1996, THORAX, V51, P1048, DOI 10.1136/thx.51.10.1048; Antonelli M, 2000, CRIT CARE, V4, P15, DOI 10.1186/cc645; Avdeev S N, 1998, Anesteziol Reanimatol, P45; Barbe F, 1996, EUR RESPIR J, V9, P1240, DOI 10.1183/09031936.96.09061240; Bardi G, 2000, EUR RESPIR J, V15, P98, DOI 10.1034/j.1399-3003.2000.15a18.x; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; Clark HE, 1997, LUNG, V175, P143, DOI 10.1007/PL00007562; Confalonieri M, 1999, AM J RESP CRIT CARE, V160, P1585, DOI 10.1164/ajrccm.160.5.9903015; Daskalopoulou E, 1993, CHEST, V103, p271S; Dikensoy O, 2002, INT J CLIN PRACT, V56, P85; ELLIOTT MW, 1990, BRIT MED J, V300, P358, DOI 10.1136/bmj.300.6721.358; FOGLIO C, 1992, CHEST, V101, P1533, DOI 10.1378/chest.101.6.1533; HILL NS, 1993, AM REV RESPIR DIS, V147, P1050, DOI 10.1164/ajrccm/147.4.1050; HOO GWS, 1994, CRIT CARE MED, V22, P1253, DOI 10.1097/00003246-199408000-00009; Jasmer RM, 1997, CHEST, V111, P1672, DOI 10.1378/chest.111.6.1672; Keenan SP, 2000, CRIT CARE MED, V28, P2094, DOI 10.1097/00003246-200006000-00072; Keenan SP, 1998, CRIT CARE CLIN, V14, P359, DOI 10.1016/S0749-0704(05)70005-1; Keenan SP, 1997, CRIT CARE MED, V25, P1685, DOI 10.1097/00003246-199710000-00018; Keenan SP, 2001, AM J RESP CRIT CARE, V163, pA250; Khilnani G.C., 2002, AM J RESP CRIT CARE, V165, pA387; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; MARINO W, 1991, CHEST, V99, P681, DOI 10.1378/chest.99.3.681; Martin TJ, 2000, AM J RESP CRIT CARE, V161, P807, DOI 10.1164/ajrccm.161.3.9808143; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; Meduri GU, 1997, CRIT CARE MED, V25, P1631, DOI 10.1097/00003246-199710000-00008; Meduri GU, 1996, CLIN CHEST MED, V17, P513, DOI 10.1016/S0272-5231(05)70330-0; MEDURI GU, 1991, CHEST, V100, P445, DOI 10.1378/chest.100.2.445; Mehta S, 2001, AM J RESP CRIT CARE, V163, P540, DOI 10.1164/ajrccm.163.2.9906116; Mehta S, 1996, Respir Care Clin N Am, V2, P267; MEYER TJ, 1994, ANN INTERN MED, V120, P760, DOI 10.7326/0003-4819-120-9-199405010-00008; Nicholson D, 1998, Curr Opin Pulm Med, V4, P66, DOI 10.1097/00063198-199803000-00003; Pang D, 1998, CHEST, V114, P1185, DOI 10.1378/chest.114.4.1185; Peter JV, 2002, CRIT CARE MED, V30, P555, DOI 10.1097/00003246-200203000-00010; Plant PK, 2001, THORAX, V56, P708, DOI 10.1136/thorax.56.9.708; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Porta R, 2000, Monaldi Arch Chest Dis, V55, P509; SERVERA E, 1995, CHEST, V108, P1572, DOI 10.1378/chest.108.6.1572; SERVILLO G, 1994, INTENS CARE MED, V50, pS54; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8	46	256	282	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					861	870		10.7326/0003-4819-138-11-200306030-00007	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AB	12779296				2023-01-03	WOS:000183296400001
J	Ylinen, J; Takala, EP; Nykanen, M; Hakkinen, A; Malkia, E; Pohjolainen, T; Karppi, SL; Kautiainen, H; Airaksinen, O				Ylinen, J; Takala, EP; Nykanen, M; Hakkinen, A; Malkia, E; Pohjolainen, T; Karppi, SL; Kautiainen, H; Airaksinen, O			Active neck muscle training in the treatment of chronic neck pain in women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; ISOMETRIC STRENGTH; CERVICAL-SPINE; HEALTHY-VOLUNTEERS; SHOULDER PAIN; MRI CHANGES; PHYSIOTHERAPY; DISABILITY; REHABILITATION; INTERVENTION	Context Active physical training is commonly recommended for patients with chronic neck pain; however, its efficacy has not been demonstrated in randomized studies. Objective To evaluate the efficacy of intensive isometric neck strength training and lighter endurance training of neck muscles on pain and disability in women with chronic, nonspecific neck pain. Design Examiner-blinded randomized controlled trial conducted between February 2000 and March 2002. Setting Participants were recruited from occupational health care systems in southern and eastern Finland. Patients A total of 180 female office workers between the ages of 25 and 53 years with chronic, nonspecific neck pain. Interventions Patients were randomly assigned to either 2 training groups or to a control group, with 60 patients in each group. The endurance training group performed dynamic neck exercises, which included lifting the head up from the supine and prone positions. The strength training group performed high-intensity isometric neck strengthening and stabilization exercises with an elastic band. Both training groups performed dynamic exercises for the shoulders and upper extremities with dumbbells. All groups were advised to do aerobic and stretching exercises regularly 3 times a week. Main Outcome Measures Neck pain and disability were assessed by a visual ana, log scale, the neck and shoulder pain and disability index, and the Vernon neck disability index. Intermediate outcome measures included mood assessed by a short depression inventory and by maximal isometric neck strength and range of motion measures. Results At the 12-month follow-up visit, both neck pain and disability had decreased in both training groups compared with the control group (P<.001). Maximal isometric neck strength had improved flexion by 110%, rotation by 76%, and extension by 69% in the strength training group. The respective improvements in the endurance training group were 28%, 29%, and 16% and in the control group were 10%, 10%, and 7%. Range of motion had also improved statistically significantly in both training groups compared with the control group in rotation, but only the strength training group had statistically significant improvements in lateral flexion and in flexion and extension. Conclusions Both strength and endurance training for 12 months were effective methods for decreasing pain and disability in women with chronic, nonspecific neck pain. Stretching and fitness training are commonly advised for patients with chronic neck pain, but stretching and aerobic exercising alone proved to be a much less effective form of training than strength training.	Jyvaskyla Cent Hosp, Dept Phys Med & Rehabil, Jyvaskyla 40620, Finland; Finnish Inst Occupat Hlth, Helsinki, Finland; Punkaharju Rehabil Ctr, Punkaharju, Finland; Univ Jyvaskyla, Dept Hlth Sci, Jyvaskyla, Finland; Social Insurance Inst, Helsinki, Finland; Rheumatism Fdn Hosp, SF-18120 Heinola, Finland; Kuopio Univ Hosp, Dept Phys Med & Rehabil, SF-70210 Kuopio, Finland	Central Finland Central Hospital; Finnish Institute of Occupational Health; University of Jyvaskyla; Rheumatism Foundation Hospital; Kuopio University Hospital; University of Eastern Finland	Ylinen, J (corresponding author), Jyvaskyla Cent Hosp, Dept Phys Med & Rehabil, Keskussairaalantie 19, Jyvaskyla 40620, Finland.	jari.ylinen@ksshp.fi		Hakkinen, Arja/0000-0002-5779-1259				Aker PD, 1996, BMJ-BRIT MED J, V313, P1291; ANDERSSEN KL, 1971, FUNDAMENTALS EXERCIS; AROMAA A, 2002, PUBLICATION NATL PUB; Chiu TTW, 2002, CLIN REHABIL, V16, P772, DOI 10.1191/0269215502cr552oa; Conley MS, 1997, J APPL PHYSIOL, V83, P2105, DOI 10.1152/jappl.1997.83.6.2105; Cote P, 2000, SPINE, V25, P1109; Ertzgaard S., 2000, PHYSIOTHER CAN, V52, P233; FORSETH KO, 1992, SCAND J RHEUMATOL, V21, P74, DOI 10.3109/03009749209095071; FRIEDENBERG ZB, 1963, J BONE JOINT SURG AM, V45, P1171, DOI 10.2106/00004623-196345060-00004; GOLDIE I, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P117; Gore DR, 2001, SPINE, V26, P2463, DOI 10.1097/00007632-200111150-00013; GORE DR, 1987, SPINE, V12, P1, DOI 10.1097/00007632-198701000-00001; GROSS AR, 1996, ONLINE J CURR C0730; Horneij E, 2002, J REHABIL MED, V34, P176, DOI 10.1080/16501970213235; Jordan A, 1998, SPINE, V23, P311, DOI 10.1097/00007632-199802010-00005; Jordan A, 1999, SPINE, V24, P1343, DOI 10.1097/00007632-199907010-00012; Karjalainen K, 2001, SPINE, V26, P174, DOI 10.1097/00007632-200101150-00012; KELTIKANGASJARVINEN L, 1987, PSYCHOL REP, V60, P111, DOI 10.2466/pr0.1987.60.1.111; LEHTO IJ, 1994, NEURORADIOLOGY, V36, P49, DOI 10.1007/BF00599196; LEVOSKA S, 1993, ARCH PHYS MED REHAB, V74, P425; Lundblad I, 1999, J OCCUP REHABIL, V9, P179, DOI 10.1023/A:1021301801292; Mantyselka PT, 2002, EUR J PAIN, V6, P141, DOI 10.1053/eujp.2001.0311; MANTYSELKA PT, 1998, PATIENT PAIN GEN PRA; Mathiowetz Virgil, 2002, Occup Ther Int, V9, P201, DOI 10.1002/oti.165; Randlov A, 1998, CLIN REHABIL, V12, P200, DOI 10.1191/026921598666881319; REKOLA K, 1993, ACTA U OUL D, V259, P53; RUSH PJ, 1994, BRIT J RHEUMATOL, V33, P566; Siivola SM, 2002, EUR SPINE J, V11, P358, DOI 10.1007/s00586-001-0370-x; Sjogaard G, 2000, EUR J APPL PHYSIOL, V83, P99, DOI 10.1007/s004210000285; Staudte H W, 1994, Eur Spine J, V3, P155, DOI 10.1007/BF02190578; Taimela S, 2000, SPINE, V25, P1021, DOI 10.1097/00007632-200004150-00018; TAKALA EP, 1994, SCAND J REHABIL MED, V26, P17; TAKALA EP, 1992, SCAND J WORK ENV HEA, V18, P257, DOI 10.5271/sjweh.1580; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; VIIKARIJUNTURA E, 1988, SCAND J REHABIL MED, V20, P167; Waling K, 2002, SPINE, V27, P789, DOI 10.1097/00007632-200204150-00002; WULFF HR, 1981, ANN RHEUM DIS, V40, P87; YLINEN J, 1994, ARCH PHYS MED REHAB, V75, P465, DOI 10.1016/0003-9993(94)90173-2; Ylinen JJ, 1999, CLIN BIOMECH, V14, P217, DOI 10.1016/S0268-0033(98)00063-1	39	330	343	0	62	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2003	289	19					2509	2516		10.1001/jama.289.19.2509	http://dx.doi.org/10.1001/jama.289.19.2509			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680KL	12759322	Bronze			2023-01-03	WOS:000182976500019
J	Waldmann, TA				Waldmann, TA			Immunotherapy: past, present and future	NATURE MEDICINE			English	Review							B-CELL LYMPHOMA; COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; MONOCLONAL-ANTIBODY; IN-VIVO; INTERLEUKIN-2 RECEPTOR; RECOMBINANT IMMUNOTOXIN; METASTATIC MELANOMA; ANTITUMOR IMMUNITY; CHEMOTHERAPY PLUS	Harnessing the immune system to treat chronic infectious diseases or cancer is a major goal of immunotherapy. Among others, impediments to this aim include host failure to identify tumor antigens, tolerance to self and negative immunoregulatory mechanisms. But with recent progress, active and passive immunotherapy are proving themselves as effective therapeutic strategies.	NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Waldmann, TA (corresponding author), NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.		Waldmann, Thomas/AAT-5972-2021	Waldmann, Thomas/0000-0003-4500-6660	NATIONAL CANCER INSTITUTE [ZIASC004002, Z01SC004002] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlers JD, 1997, J IMMUNOL, V158, P3947; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Axworthy DB, 2000, P NATL ACAD SCI USA, V97, P1802, DOI 10.1073/pnas.97.4.1802; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Baselga J, 1998, CANCER RES, V58, P2825; Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; Berzofsky JA, 2001, NAT REV IMMUNOL, V1, P209, DOI 10.1038/35105075; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; COLEY WB, 1896, J HOPKINS HOSP B, V7, P157; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; El-Gabalawy HS, 2002, ARTHRITIS RES THER, V4, pS297, DOI 10.1186/ar568; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337; Gura T, 2002, NATURE, V417, P584, DOI 10.1038/417584a; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Krackhardt AM, 2002, BLOOD, V100, P2123, DOI 10.1182/blood-2002-02-0513; Kreitman RJ, 1999, BLOOD, V94, P3340, DOI 10.1182/blood.V94.10.3340.422k19_3340_3348; Kreitman RJ, 2000, J CLIN ONCOL, V18, P1622, DOI 10.1200/JCO.2000.18.8.1622; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; La Rosa C, 2001, BLOOD, V97, P1776; Labeur MS, 1999, J IMMUNOL, V162, P168; Lenardo MJ, 1996, J EXP MED, V183, P721, DOI 10.1084/jem.183.3.721; LYNCH RG, 1972, P NATL ACAD SCI USA, V69, P1540, DOI 10.1073/pnas.69.6.1540; MALONEY DG, 1994, BLOOD, V84, P2457; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; Onizuka S, 1999, CANCER RES, V59, P3128; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3; Press OW, 2001, BLOOD, V98, P2535, DOI 10.1182/blood.V98.8.2535; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; Ramshaw IA, 2000, IMMUNOL TODAY, V21, P163, DOI 10.1016/S0167-5699(00)01612-1; ROBBINS PF, 1996, CURR OPIN IMMUNOL, V8, P626; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907; ROSENBERG SA, 1996, J IMMUNOTHER, V19, P8; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sarobe P, 1998, J CLIN INVEST, V102, P1239, DOI 10.1172/JCI3714; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shimizu J, 1999, J IMMUNOL, V163, P5211; Shimizu K, 2001, CANCER RES, V61, P2618; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Srivastava PK, 2000, NAT IMMUNOL, V1, P363, DOI 10.1038/80795; STEVENSON GT, 1977, FED PROC, V36, P2268; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(01)00093-0; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Zhang ML, 2002, BLOOD, V100, P208, DOI 10.1182/blood-2002-01-0107; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	70	418	494	0	90	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2003	9	3					269	277		10.1038/nm0303-269	http://dx.doi.org/10.1038/nm0303-269			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	651GN	12612576	Green Published			2023-01-03	WOS:000181312300026
J	Quill, TE; Cassel, CK				Quill, TE; Cassel, CK			Professional organizations' position statements on physician-assisted suicide: A case for studied neutrality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							VOLUNTARY ACTIVE EUTHANASIA; OF-LIFE CARE; TERMINALLY-ILL; WASHINGTON-STATE; UNITED-STATES; OREGON DEATH; DIGNITY ACT; ATTITUDES; EXPERIENCES; DEPRESSION	Position statements opposing legalization of physician-assisted suicide by organizations such as the American College of Physicians-American Society of Internal Medicine rightly emphasize that palliative care should be the standard of care for the dying, and that the inadequacies that exist in its delivery should be remedied. But such position statements generally understate the limitations of palliative care to alleviate some end-of-life suffering, and they do not provide adequate guidance about how physicians should approach patients with intractable suffering who are prepared to die. In this manuscript, we briefly present. data about severe suffering before death for terminally ill patients, including those enrolled in hospice programs. We also review some of what is known about requests and responses for physician-assisted suicide in Oregon and in the rest of the United States. Preliminary data from Oregon suggest that legally sanctioned access to physician-assisted suicide is used by a very small number of patients and seems to be associated with improved delivery of hospice and palliative care. Physicians of good will, deep religious convictions, and considerable palliative care experience exist on both sides of the debate about legalization of physician-assisted suicide. In an effort to respect this diversity, and to encourage out profession to continue to struggle with the genuine dilemmas faced by some patients toward the end of their lives and by their families, we argue in favor of medical organizations' taking a position of studied neutrality on this contentious issue.	Univ Rochester, Med Ctr, Rochester, NY 14642 USA; Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA	University of Rochester; Oregon Health & Science University	Quill, TE (corresponding author), Univ Rochester, Med Ctr, 601 Elmwood Ave,Box 601, Rochester, NY 14642 USA.							[Anonymous], 1995, J Am Geriatr Soc, V43, P577; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BATTIN MP, 1995, ACAD MED, V70, P583; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; CHOCHINOV HM, 1994, AM J PSYCHIAT, V151, P537; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; Coyle N, 1990, J Pain Symptom Manage, V5, P83; DONNELLY S, 1995, SEMIN ONCOL, V22, P67; DUBERSEIN PR, 1995, J AM GERIATR SOC, V43, P395, DOI 10.1111/j.1532-5415.1995.tb05814.x; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; FOLEY KM, 1995, PAIN FORUM, V4, P163; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; Ingham JM, 1996, HEMATOL ONCOL CLIN N, V10, P21, DOI 10.1016/S0889-8588(05)70325-7; JACOBSON JA, 1995, J CLIN ETHIC, V6, P149; KANE RL, 1985, JAMA-J AM MED ASSOC, V253, P2683, DOI 10.1001/jama.253.18.2683; KASTING GA, 1993, PHYSICIAN ASSISTED D, P25; KATHOL RG, 1990, PSYCHOSOMATICS, V31, P434, DOI 10.1016/S0033-3182(90)72140-8; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; *NAT AC, 1997, APPR DEATH IMPR CAR; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Quill TE, 1998, ANN INTERN MED, V128, P552, DOI 10.7326/0003-4819-128-7-199804010-00006; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Sachs GA, 2000, JAMA-J AM MED ASSOC, V284, P2423, DOI 10.1001/jama.284.19.2423; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; Snyder L, 2001, ANN INTERN MED, V135, P209, DOI 10.7326/0003-4819-135-3-200108070-00015; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Sullivan AD, 2001, NEW ENGL J MED, V344, P605, DOI 10.1056/NEJM200102223440811; *TASK FORC IMPR CA, 2002, OR DEATH DIG ACT GUI; Tolle SW, 1999, ANN INTERN MED, V130, P681, DOI 10.7326/0003-4819-130-8-199904200-00015; Ventafridda V, 1990, J Palliat Care, V6, P7; Whitney SN, 2001, J GEN INTERN MED, V16, P290, DOI 10.1046/j.1525-1497.2001.04159.x; 1996, BRIEF AMICUS CURIAE	46	28	28	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 4	2003	138	3					208	211		10.7326/0003-4819-138-3-200302040-00013	http://dx.doi.org/10.7326/0003-4819-138-3-200302040-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646DB	12558360				2023-01-03	WOS:000181018600007
J	Bawaskar, HS				Bawaskar, HS			Mistakes are lessons of the past	LANCET			English	Editorial Material									Bawaskar Hosp & Res Ctr, Mahad 402301, Maharashtra, India		Bawaskar, HS (corresponding author), Bawaskar Hosp & Res Ctr, Mahad 402301, Maharashtra, India.								0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 4	2003	361	9351					59	59		10.1016/S0140-6736(03)12163-0	http://dx.doi.org/10.1016/S0140-6736(03)12163-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	631WX	12517471				2023-01-03	WOS:000180191600025
J	Shevell, M				Shevell, M			Hallervorden and history.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Div Pediat Neurol, Montreal, PQ H3H 1P3, Canada	McGill University; McGill University; McGill University	Shevell, M (corresponding author), McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada.								0	40	43	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	2003	348	1					3	4		10.1056/NEJMp020158	http://dx.doi.org/10.1056/NEJMp020158			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	630WY	12510036				2023-01-03	WOS:000180134400001
J	De Smet, PAGM				De Smet, PAGM			Drug therapy - Herbal remedies.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ST-JOHNS-WORT; GINKGO-BILOBA EXTRACT; BENIGN PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIAL; PLACEBO-CONTROLLED TRIALS; HYPERICUM-PERFORATUM; DOUBLE-BLIND; INTERMITTENT CLAUDICATION; MAJOR DEPRESSION; CLINICAL-TRIALS		Sci Inst Dutch Pharmacists, NL-2514 JL The Hague, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands	Radboud University Nijmegen	De Smet, PAGM (corresponding author), Sci Inst Dutch Pharmacists, Alexanderstr 11, NL-2514 JL The Hague, Netherlands.	pdesmet@winap.nl	Smet, P.A.G.M./L-4654-2015					Ackermann RT, 2001, ARCH INTERN MED, V161, P813, DOI 10.1001/archinte.161.6.813; AMMON HPT, 1981, PLANTA MED, V43, P209, DOI 10.1055/s-2007-971502; Ang-Lee MK, 2001, JAMA-J AM MED ASSOC, V286, P208, DOI 10.1001/jama.286.2.208; Arenz A, 1996, PLANTA MED, V62, P548, DOI 10.1055/s-2006-957967; Behnke K, 2002, ADV THER, V19, P43, DOI 10.1007/BF02850017; Benjamin J, 2001, POSTGRAD MED J, V77, P112, DOI 10.1136/pmj.77.904.112; Benninger J, 1999, GASTROENTEROLOGY, V117, P1234, DOI 10.1016/S0016-5085(99)70410-5; Bhattacharya SK, 1998, PHARMACOPSYCHIATRY, V31, P22, DOI 10.1055/s-2007-979342; Blumenthal M., 1998, COMPLETE GERMAN COMM; Bove GM, 1998, LANCET, V352, P1121, DOI 10.1016/S0140-6736(05)79763-4; BRAQUET P, 1991, J ETHNOPHARMACOL, V32, P135, DOI 10.1016/0378-8741(91)90111-P; BRAQUET P, 1993, AM J GASTROENTEROL, V88, P2138; Brenner R, 2000, CLIN THER, V22, P411, DOI 10.1016/S0149-2918(00)89010-4; Brown TM, 2000, AM J EMERG MED, V18, P231, DOI 10.1016/S0735-6757(00)90030-5; Budeiri D, 1996, CONTROL CLIN TRIALS, V17, P60, DOI 10.1016/0197-2456(95)00082-8; Burkard G, 1991, MUNCH MED WSCHR S1, V133, P38; Burstein AH, 2000, CLIN PHARMACOL THER, V68, P605, DOI 10.1067/mcp.2000.111530; Carraro JC, 1996, PROSTATE, V29, P231, DOI 10.1002/(SICI)1097-0045(199610)29:4&lt;231::AID-PROS4&gt;3.0.CO;2-E; Chatterjee SS, 1998, LIFE SCI, V63, P499, DOI 10.1016/S0024-3205(98)00299-9; Chatterjee SS, 1997, ARZNEIMITTEL-FORSCH, V47, P821; Cheema P, 2001, J INTERN MED, V250, P167, DOI 10.1046/j.1365-2796.2001.00851.x; Crowe S, 2002, ANESTHESIOLOGY, V96, P1025, DOI 10.1097/00000542-200204000-00035; Davidson JRT, 2001, J CLIN PSYCHOPHARM, V21, P635, DOI 10.1097/00004714-200112000-00026; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; Davydov Liya, 2001, Journal of Herbal Pharmacotherapy, V1, P65, DOI 10.1080/J157v01n03_06; De Backer TL, 2000, EUR J CLIN PHARMACOL, V56, P199, DOI 10.1007/s002280000114; Debruyne F, 2002, EUR UROL, V41, P497, DOI 10.1016/S0302-2838(02)00066-0; DESMET PAG, 1992, ADVERSE EFFECTS HERB, V1, P1; DESMET PAG, 1999, ESSENTIALS COMPLEMEN, P108; DESMET PAGM, 1995, DRUG SAFETY, V13, P81, DOI 10.2165/00002018-199513020-00003; DeSmet PAGM, 1996, BMJ-BRIT MED J, V313, P241, DOI 10.1136/bmj.313.7052.241; Di Silverio F, 1998, PROSTATE, V37, P77, DOI 10.1002/(SICI)1097-0045(19981001)37:2<77::AID-PROS3>3.0.CO;2-I; DISILVERIO F, 1992, EUR UROL, V21, P309; Drew S, 2001, BRIT MED J, V322, P73, DOI 10.1136/bmj.322.7278.73; Drieu K., 2000, GINKGO BILOBA, P303; Durr D, 2000, CLIN PHARMACOL THER, V68, P598, DOI 10.1067/mcp.2000.112240; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2000, BRIT J ANAESTH, V84, P367, DOI 10.1093/oxfordjournals.bja.a013442; Ernst E, 1997, NATURE, V385, P480, DOI 10.1038/385480c0; Ernst E, 2000, Public Health Nutr, V3, P509, DOI 10.1017/S1368980000000598; Ernst E, 1998, EUR J CLIN PHARMACOL, V54, P589, DOI 10.1007/s002280050519; Ernst E, 1999, CLIN DRUG INVEST, V17, P301, DOI 10.2165/00044011-199917040-00006; Ernst E, 1999, CLIN OTOLARYNGOL, V24, P164, DOI 10.1046/j.1365-2273.1999.00243.x; Ernst E, 2002, COCHRANE DATABASE SY, V2; Escher M, 2001, BRIT MED J, V322, P139, DOI 10.1136/bmj.322.7279.139; ESCHER M, 2001, BRIT MED J, V322, P1097; *EUR HERB PRACT AS, 2002, PROV MCA ASS REL STR; Felker GM, 2001, AM HEART J, V142, P393, DOI 10.1067/mhj.2001.117606; Ferko N, 2001, PHARMACOTHERAPY, V21, P1574, DOI 10.1592/phco.21.20.1574.34483; Flausino OA, 2002, PHARMACOL BIOCHEM BE, V71, P251, DOI 10.1016/S0091-3057(01)00665-7; Fornal CA, 2001, NEUROPSYCHOPHARMACOL, V25, P858, DOI 10.1016/S0893-133X(01)00297-4; Galluzzi S, 2000, J NEUROL NEUROSUR PS, V68, P679; Gaster B, 2000, ARCH INTERN MED, V160, P152, DOI 10.1001/archinte.160.2.152; Gerber GS, 2000, J UROLOGY, V163, P1408, DOI 10.1016/S0022-5347(05)67631-8; Gerber GS, 2001, UROLOGY, V58, P960, DOI 10.1016/S0090-4295(01)01442-X; Gilbert GJ, 1997, NEUROLOGY, V48, P1137, DOI 10.1212/WNL.48.4.1137; Giles JT, 2000, PHARMACOTHERAPY, V20, P690, DOI 10.1592/phco.20.7.690.35173; Gobbi M, 2001, PHARMACOPSYCHIATRY, V34, pS45, DOI 10.1055/s-2001-15458; Golsch S, 1997, HAUTARZT, V48, P249, DOI 10.1007/s001050050578; Granger AS, 2001, AGE AGEING, V30, P523, DOI 10.1093/ageing/30.6.523; Gregory PJ, 2001, ANN INTERN MED, V134, P344, DOI 10.7326/0003-4819-134-4-200102200-00026; Gundling K, 1999, WESTERN J MED, V171, P191; Gurley BJ, 2000, AM J HEALTH-SYST PH, V57, P963, DOI 10.1093/ajhp/57.10.963; Harrer G, 1999, ARZNEIMITTELFORSCH, V49, P289; Holubarsch CJ, 2000, EUR J HEART FAIL, V2, P431, DOI 10.1016/S1388-9842(00)00109-4; Irefin S, 2000, J CLIN ANESTH, V12, P498, DOI 10.1016/S0952-8180(00)00199-9; Joseph G, 1995, ARZNEIMITTEL-FORSCH, V45-2, P1261; Kajiyama Y, 2002, PEDIATRICS, V109, P325, DOI 10.1542/peds.109.2.325; Kanowski S, 1996, PHARMACOPSYCHIATRY, V29, P47, DOI 10.1055/s-2007-979544; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kitts D, 2000, Public Health Nutr, V3, P473, DOI 10.1017/S1368980000000550; Lacaille-Dubois MA, 2001, PHYTOMEDICINE, V8, P47, DOI 10.1078/0944-7113-00003; Lal S, 2000, CAN MED ASSOC J, V163, P262; Lane-Brown MM, 2000, MED J AUSTRALIA, V172, P302, DOI 10.5694/j.1326-5377.2000.tb123965.x; Le Bars PL, 2000, DEMENT GERIATR COGN, V11, P230, DOI 10.1159/000017242; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; LINDE K, 2000, COCHRANE DB SYST REV, V2; Lord GM, 1999, LANCET, V354, P481, DOI 10.1016/S0140-6736(99)03380-2; Lord GM, 2001, LANCET, V358, P1515, DOI 10.1016/S0140-6736(01)06576-X; *MED CONTR AG, 2002, HERB SAF NEWS; Melchart D., 2000, COCHRANE DB SYST REV; Miwa H, 2001, EPILEPSIA, V42, P280, DOI 10.1046/j.1528-1157.2001.4220280.x; Moher D, 2000, DRUGS, V59, P1057, DOI 10.2165/00003495-200059050-00003; Moses EL, 2000, J CLIN PSYCHOPHARM, V20, P115, DOI 10.1097/00004714-200002000-00027; Mossabeb R, 2001, WIEN KLIN WOCHENSCHR, V113, P580; MULROW C, 2000, AHRQ PUBLICATION; Nahrstedt A, 1997, PHARMACOPSYCHIATRY, V30, P129, DOI 10.1055/s-2007-979533; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; OYAMA Y, 1994, BRAIN RES, V635, P125, DOI 10.1016/0006-8993(94)91431-1; Parker V, 2001, CAN J PSYCHIAT, V46, P77, DOI 10.1177/070674370104600112; Patel S, 2002, AM J MED, V112, P507, DOI 10.1016/S0002-9343(01)01134-2; Perloff MD, 2001, BRIT J PHARMACOL, V134, P1601, DOI 10.1038/sj.bjp.0704399; Peters H, 1998, VASA-J VASCULAR DIS, V27, P106; *PHARM CONV, 2002, SAW PALM; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; PHILIPP M, 2000, BMJ-BRIT MED J, V320, P361; Pittler MH, 2000, J CLIN EPIDEMIOL, V53, P485, DOI 10.1016/S0895-4356(99)00220-6; Pittler MH, 2000, AM J MED, V108, P276, DOI 10.1016/S0002-9343(99)00454-4; Roby CA, 2000, CLIN PHARMACOL THER, V67, P451, DOI 10.1067/mcp.2000.106793; Rothfuss MA, 2001, ARZNEIMITTEL-FORSCH, V51, P24; Schempp CM, 2001, ARCH DERMATOL, V137, P512; Schmidt U., 1998, Z PHYTOTHER, V19, P22; Schrader E, 2000, INT CLIN PSYCHOPHARM, V15, P61, DOI 10.1097/00004850-200015020-00001; Schulz V., 2004, RATIONAL PHYTOTHERAP, P1; Schwinger RHG, 2000, J CARDIOVASC PHARM, V35, P700, DOI 10.1097/00005344-200005000-00004; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; Sherwin BB, 2000, J AM GERIATR SOC, V48, P431, DOI 10.1111/j.1532-5415.2000.tb04703.x; Snow V, 2000, ANN INTERN MED, V132, P738, DOI 10.7326/0003-4819-132-9-200005020-00010; Steuer-Vogt MK, 2001, EUR J CANCER, V37, P23, DOI 10.1016/S0959-8049(00)00360-9; Stevinson C, 2000, SLEEP MED, V1, P91, DOI 10.1016/S1389-9457(99)00015-5; Tauchert M, 2002, AM HEART J, V143, P910, DOI 10.1067/mhj.2002.121463; TAUCHERT M, 1999, HERZ, V24, P586; Tauchert R, 1999, HERZ, V24, P465; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Vacherot F, 2000, PROSTATE, V45, P259, DOI 10.1002/1097-0045(20001101)45:3<259::AID-PROS9>3.0.CO;2-G; Vale S, 1998, LANCET, V352, P36, DOI 10.1016/S0140-6736(05)79516-7; van Dongen MCJM, 2000, J AM GERIATR SOC, V48, P1183, DOI 10.1111/j.1532-5415.2000.tb02589.x; van Gurp G, 2002, CAN FAM PHYSICIAN, V48, P905; Vogler BK, 1999, EUR J CLIN PHARMACOL, V55, P567, DOI 10.1007/s002280050674; Vorbach EU, 1997, PHARMACOPSYCHIATRY, V30, P81, DOI 10.1055/s-2007-979524; Wang ZQ, 2001, CLIN PHARMACOL THER, V70, P317, DOI 10.1067/mcp.2001.118522; Weihmayr T, 1996, Fortschr Med, V114, P27; Wentworth JM, 2000, J ENDOCRINOL, V166, pR11, DOI 10.1677/joe.0.166R011; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; Whiskey E, 2001, INT CLIN PSYCHOPHARM, V16, P239, DOI 10.1097/00004850-200109000-00001; Williams JW, 2000, ANN INTERN MED, V132, P743, DOI 10.7326/0003-4819-132-9-200005020-00011; WILT T, 2001, COCHRANE DATABASE SY, V2; Woelk H, 2000, BMJ-BRIT MED J, V321, P536, DOI 10.1136/bmj.321.7260.536; 2002, MED LETT DRUGS THER, V44, P29; 1994, PHARM ZTG, V139, P986	130	391	425	0	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	2002	347	25					2046	2056		10.1056/NEJMra020398	http://dx.doi.org/10.1056/NEJMra020398			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	626LT	12490687				2023-01-03	WOS:000179874500009
J	Barrett, BP; Brown, RL; Locken, K; Maberry, R; Bobula, JA; D'Alessio, D				Barrett, BP; Brown, RL; Locken, K; Maberry, R; Bobula, JA; D'Alessio, D			Treatment of the common cold with unrefined echinacea - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							EXPERIMENTAL RHINOVIRUS COLDS; VIRAL RESPIRATORY-INFECTIONS; IMPORTANT DIFFERENCE; CLINICAL-TRIALS; EFFICACY; ANTIBIOTICS; PREVENTION; SEVERITY; PURPUREA; SYMPTOMS	Background: Echinacea preparations are widely used to treat the common cold. Objective: To assess the efficacy of dried, encapsulated, whole-plant echinacea as early treatment for the common cold. Design: Randomized, double-blind, placebo-controlled community-based trial. Setting: University of Wisconsin-Madison, Madison, Wisconsin. Participants: 148 registered students with common colds of recent onset. Intervention: An encapsulated mixture of unrefined Echinacea purpurea herb (25%) and root (25%) and E angustifolia root (50%) taken in 1-g doses six times on the first day of illness and three times on each subsequent day of illness for a maximum of 10 days. Measurements: severity and duration of self-reported symptoms of upper respiratory tract infection. Results: No statistically significant differences were detected between the echinacea and placebo groups for any of the measured outcomes. Trajectories of severity over time were nearly identical in the two groups. Mean cold duration was 6.01 days in both groups as a whole, 5.75 days in the placebo group, and 6.27 days in the echinacea group (between-group difference, -0.52 day [95% Cl, -1.09 to 0.22 days]). After controlling for severity and duration of symptoms before study entry, sex, date of enrollment, and use of nonprotocol medications, researchers found no statistically significant treatment effect (adjusted hazard ratio, 1.24 [Cl, 0.86 to 1.78]). Multivariable regression models assessing severity scores over time failed to detect statistically significant differences between the echinacea and placebo groups. Conclusion: Compared with placebo, unrefined echinacea provided no detectable benefit or harm in these college students who had the common cold.	Univ Wisconsin, Dept Family Med, Madison, WI 53715 USA	University of Wisconsin System; University of Wisconsin Madison	Barrett, BP (corresponding author), Univ Wisconsin, Dept Family Med, 777 S Mills St, Madison, WI 53715 USA.				NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K23AT000051] Funding Source: NIH RePORTER; NCCIH NIH HHS [K23 AT00051-01] Funding Source: Medline; PHS HHS [T-32 HP 10010-09] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLISON PD, 1995, SURVIVAL ANAL USING, P175; Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997; Barrett B, 1999, J FAM PRACTICE, V48, P628; BARRETT B, 2000, HLTH NOTES REV COMPL, V7, P211; BARRETT B, 2003, IN PRESS PHYTOMEDICI, P10; Barrett Bruce, 2002, J Fam Pract, V51, P265; Bauer R., 1999, Journal of Herbs, Spices & Medicinal Plants, V6, P51, DOI 10.1300/J044v06n03_05; BAUER R, 1998, PHYTOMEDICINES EUROP, P140; Bauer R, 1999, IMMUNOMODULATORY AGE, P41, DOI DOI 10.1007/978-3-0348-8763-22; Bone K., 1997, Alternative Medicine Review, V2, P87; BRAUNIG B, 1992, Z PHYTOTHER, V13, P7; Brinkeborn RM, 1999, PHYTOMEDICINE, V6, P1; BROWN RL, 1989, EDUC PSYCHOL MEAS, V49, P26; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS CS, 1991, STAT MED, V10, P1959, DOI 10.1002/sim.4780101210; Dillon WilliamR., 1984, MULTIVARIATE ANAL ME; Dorn M., 1997, COMPLEMENT THER MED, V5, P40, DOI [DOI 10.1016/S0965-2299(97)80089-1, 10.1016/S0965-2299(97)80089-1]; DORN M, 1989, NATUR GANZHEITSMEDIZ, V2, P314; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Fahey T, 1998, BRIT MED J, V316, P906, DOI 10.1136/bmj.316.7135.906; Fischer D, 1999, JAMA-J AM MED ASSOC, V282, P1157, DOI 10.1001/jama.282.12.1157; Flannery M A, 1999, Pharm Hist, V41, P52; Forth H, 1981, ZFA (Stuttgart), V57, P2272; FOSTER S, 1996, ECHINACEA PURPLE CON; Friedman L. M., 1998, FUNDAMENTALS CLIN TR; Giles JT, 2000, PHARMACOTHERAPY, V20, P690, DOI 10.1592/phco.20.7.690.35173; Grimm W, 1999, AM J MED, V106, P138, DOI 10.1016/S0002-9343(98)00406-9; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; GWALTNEY J M JR, 1985, Rhinology (Utrecht), V23, P265; Gwaltney JM, 1996, ANTIVIR RES, V29, P287, DOI 10.1016/0166-3542(95)00935-3; Henneicke-Von Zepelin HH, 1999, CURR MED RES OPIN, V15, P214, DOI 10.1185/03007999909114094; Hoheisel O., 1997, EUR J CLIN RES, V9, P261; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Juniper EF., 1996, QUALITY LIFE PHARAMA, V2nd; Jû┬reskog KG., 1993, LISREL 8 USERS REFER; Lindenmuth GF, 2000, J ALTERN COMPLEM MED, V6, P327, DOI 10.1089/10755530050120691; Littell R.C., 1996, SAS SYSTEMS MIXED MO; LITTLE PS, 1994, BRIT MED J, V309, P1010, DOI 10.1136/bmj.309.6960.1010; Mainous AG, 1996, J FAM PRACTICE, V42, P357; McDowell I, 1996, J NUTR EDUC, DOI DOI 10.1016/S0022-3182(88)80070-0; Melchart D, 1998, ARCH FAM MED, V7, P541, DOI 10.1001/archfami.7.6.541; MELCHART D, 2000, COCHRANE DATABASE SY; MELCHART D, 1999, IMMUNOMODULATORY AGE, P105; Monto AS, 1995, AM J MED, V99, pS24, DOI 10.1016/S0002-9343(99)80307-6; Parnham MJ, 1999, IMMUNOMODULATORY AGE, P119; RAO SS, 1995, AM J RHINOL, V9, P49, DOI 10.2500/105065895781874114; Redelmeier DA, 1996, J CLIN EPIDEMIOL, V49, P1215, DOI 10.1016/S0895-4356(96)00206-5; REITZ HD, 1990, NOTABENE MED, V20, P362; SCHMID M, 1990, J HYPERTENS, V8, P277; Schulten B, 2001, ARZNEIMITTELFORSCH, V51, P563; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; STOKES M, 1995, CATEGORICAL DATA ANA; Streiner DL, 1995, HLTH MEASUREMENT SCA, V2nd; Turner RB, 2000, ANTIMICROB AGENTS CH, V44, P1708, DOI 10.1128/AAC.44.6.1708-1709.2000; Turner RB, 2001, ANTIVIR RES, V49, P1, DOI 10.1016/S0166-3542(00)00135-2; VORBERG G, 1984, ARZTLICHE PRAXIS, V36, P97; VORBERG G, 1989, ARZTL FORSCH, V36, P3; WALKER TA, 1994, PEDIATR CLIN N AM, V41, P1365; WITTENBORN JR, 1972, J NERV MENT DIS, V154, P79, DOI 10.1097/00005053-197202000-00001; 2002, DIAGNOSIS TREATMENT	60	90	96	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 17	2002	137	12					939	946		10.7326/0003-4819-137-12-200212170-00006	http://dx.doi.org/10.7326/0003-4819-137-12-200212170-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	626DR	12484708				2023-01-03	WOS:000179857500001
J	Wyse, DG; Waldo, AL; DiMarco, JP; Domanski, MJ; Rosenberg, Y; Schron, EB; Kellen, JC; Greene, HL; Mickel, MC; Dalquist, JE; Corley, SD				Wyse, DG; Waldo, AL; DiMarco, JP; Domanski, MJ; Rosenberg, Y; Schron, EB; Kellen, JC; Greene, HL; Mickel, MC; Dalquist, JE; Corley, SD		Atrial Fibrillation Follow Investi	A comparison of rate control and rhythm control in patients with atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINUS RHYTHM; ANTITHROMBOTIC THERAPY; RISK-FACTORS; STROKE; MANAGEMENT; ANTICOAGULATION; CARDIOVERSION; MAINTENANCE; PREVALENCE; CONVERSION	Background: There are two approaches to the treatment of atrial fibrillation: one is cardioversion and treatment with antiarrhythmic drugs to maintain sinus rhythm, and the other is the use of rate-controlling drugs, allowing atrial fibrillation to persist. In both approaches, the use of anticoagulant drugs is recommended. Methods: We conducted a randomized, multicenter comparison of these two treatment strategies in patients with atrial fibrillation and a high risk of stroke or death. The primary end point was overall mortality. Results: A total of 4060 patients (mean [+/-SD] age, 69.7+/-9.0 years) were enrolled in the study; 70.8 percent had a history of hypertension, and 38.2 percent had coronary artery disease. Of the 3311 patients with echocardiograms, the left atrium was enlarged in 64.7 percent and left ventricular function was depressed in 26.0 percent. There were 356 deaths among the patients assigned to rhythm-control therapy and 310 deaths among those assigned to rate-control therapy (mortality at five years, 23.8 percent and 21.3 percent, respectively; hazard ratio, 1.15 [95 percent confidence interval, 0.99 to 1.34]; P=0.08). More patients in the rhythm-control group than in the rate-control group were hospitalized, and there were more adverse drug effects in the rhythm-control group as well. In both groups, the majority of strokes occurred after warfarin had been stopped or when the international normalized ratio was subtherapeutic. Conclusions: Management of atrial fibrillation with the rhythm-control strategy offers no survival advantage over the rate-control strategy, and there are potential advantages, such as a lower risk of adverse drug effects, with the rate-control strategy. Anticoagulation should be continued in this group of high-risk patients.	AFFIRM Clin Trial Ctr, Axio Res, Seattle, WA 98121 USA		Wyse, DG (corresponding author), AFFIRM Clin Trial Ctr, Axio Res, 2601 4th Ave,Ste 200, Seattle, WA 98121 USA.	leong@axioresearch.com		Corley, Scott/0000-0001-5288-9188	NHLBI NIH HHS [N01-HC-55139] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055139] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		*AFFIRM INV, 2002, N AM SOC PAC EL LAT; Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; ANTMAN E, 1993, J AM COLL CARDIOL, V22, P1830; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; BRODSKY MA, 1987, AM J CARDIOL, V60, P572, DOI 10.1016/0002-9149(87)90307-9; COX DR, 1972, J R STAT SOC B, V34, P187; Cox J L, 2000, Semin Thorac Cardiovasc Surg, V12, P15; CRIJNS HJ, 1991, AM J CARDIOL, V68, P335, DOI 10.1016/0002-9149(91)90828-9; Dries DL, 1998, J AM COLL CARDIOL, V32, P695, DOI 10.1016/S0735-1097(98)00297-6; Epstein AE, 2002, J CARDIOVASC ELECTR, V13, P667, DOI 10.1046/j.1540-8167.2002.00667.x; Epstein AE, 2002, AM HEART J, V143, P991, DOI 10.1067/mhj.2002.122875; Falk RH, 2001, NEW ENGL J MED, V344, P1067, DOI 10.1056/NEJM200104053441407; FLEGEL KM, 1987, LANCET, V1, P878; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Gage BF, 2000, STROKE, V31, P822, DOI 10.1161/01.STR.31.4.822; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Hart RG, 1999, ANN INTERN MED, V131, P688, DOI 10.7326/0003-4819-131-9-199911020-00010; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAHN AD, 1995, AM J MED, V98, P476, DOI 10.1016/S0002-9343(99)80348-9; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LIPKIN DP, 1986, BRIT MED J, V292, P653, DOI 10.1136/bmj.292.6521.653; MANOLIO TA, 1994, J AM COLL CARDIOL, V23, P916, DOI 10.1016/0735-1097(94)90638-6; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; Miller MR, 2000, J FAM PRACTICE, V49, P1033; Narasimhan C, 1998, J CARDIOVASC ELECTR, V9, pS146; Nichol G, 2002, HEART, V87, P535, DOI 10.1136/heart.87.6.535; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Oral H, 2002, CIRCULATION, V105, P1077, DOI 10.1161/hc0902.104712; Roger VL, 2002, ANN INTERN MED, V136, P341, DOI 10.7326/0003-4819-136-5-200203050-00005; Scheinman MM, 2001, CIRCULATION, V103, P2120; Stewart S, 2002, INT J CARDIOL, V82, P229, DOI 10.1016/S0167-5273(01)00626-X; Taylor FC, 2001, BMJ-BRIT MED J, V322, P321, DOI 10.1136/bmj.322.7282.321; VanGelder IC, 1996, ARCH INTERN MED, V156, P2585, DOI 10.1001/archinte.156.22.2585; Waldo AL, 1999, AM J CARDIOL, V84, P698; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; Wood MA, 2000, CIRCULATION, V101, P1138, DOI 10.1161/01.CIR.101.10.1138; Wyse DG, 1997, AM J CARDIOL, V79, P1198; Wyse DG, 2001, J INTERV CARD ELECTR, V5, P267, DOI 10.1023/A:1011460631369	43	2896	3045	0	94	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	2002	347	23					1825	1833		10.1056/nejmoa021328	http://dx.doi.org/10.1056/nejmoa021328			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	621NW	12466506	Bronze			2023-01-03	WOS:000179596900002
J	Caffrey, SL; Willoughby, PJ; Pepe, PE; Becker, LB				Caffrey, SL; Willoughby, PJ; Pepe, PE; Becker, LB			Public use of automated external defibrillators	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; ACCESS DEFIBRILLATION; VENTRICULAR-FIBRILLATION; UNITED-STATES; SURVIVAL; OUTCOMES; DEATH; AIRLINE	Background: Automated external defibrillators save lives when they are used by designated personnel in certain public settings. We performed a two-year prospective study at three Chicago airports to assess whether random bystanders witnessing out-of-hospital cardiac arrests would retrieve and successfully use automated external defibrillators. Methods: Defibrillators were installed a brisk 60-to-90-second walk apart throughout passenger terminals at O'Hare, Midway, and Meigs Field airports, which together serve more than 100 million passengers per year. The use of defibrillators was promoted by public-service videos in waiting areas, pamphlets, and reports in the media. We assessed the time from notification of the dispatchers to defibrillation, survival rate at 72 hours and at one year among persons with cardiac arrest, their neurologic status, and the characteristics of rescuers. Results: Over a two-year period, 21 persons had nontraumatic cardiac arrest, 18 of whom had ventricular fibrillation. With two exceptions, defibrillator operators were good Samaritans, acting voluntarily. In the case of four patients with ventricular fibrillation, defibrillators were neither nearby nor used within five minutes, and none of these patients survived. Three others remained in fibrillation and eventually died, despite the rapid use of a defibrillator (within five minutes). Eleven patients with ventricular fibrillation were successfully resuscitated, including eight who regained consciousness before hospital admission. No shock was delivered in four cases of suspected cardiac arrest, and the device correctly indicated that the problem was not due to ventricular fibrillation. The rescuers of 6 of the 11 successfully resuscitated patients had no training or experience in the use of automated defibrillators, although 3 had medical degrees. Ten of the 18 patients with ventricular fibrillation were alive and neurologically intact at one year. Conclusions: Automated external defibrillators deployed in readily accessible, well-marked public areas in Chicago airports were used effectively to assist patients with cardiac arrest. In the cases of survivors, most of the users had no duty to act and no prior training in the use of these devices.	City Chicago Dept Aviat, Chicago, IL USA; Chicago Fire Dept, Chicago, IL USA; Univ Texas, SW Med Ctr, Sch Publ Hlth, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA; Univ Chicago, Div Emergency Med, Chicago, IL 60637 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Chicago	Caffrey, SL (corresponding author), OHare Int Airport, Dept Aviat, POB 66142, Chicago, IL 60666 USA.	sherord@aol.com						*AM HEART ASS, 2002, 2002 HEART STROK STA; Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; Becker L, 1996, CARDIAC ARREST SCI P, P28; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BECKER LB, 1993, ANN EMERG MED, V22, P354, DOI 10.1016/S0196-0644(05)80465-2; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P123; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; Cummins RO, 1997, ACAD EMERG MED, V4, P603; Domanovits H, 1998, RESUSCITATION, V39, P47, DOI 10.1016/S0300-9572(98)00114-2; Eisenberg MS, 2000, JAMA-J AM MED ASSOC, V284, P1435, DOI 10.1001/jama.284.11.1435; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; GREENE HL, 1990, AM J CARDIOL, V65, pB4; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; Hallstrom AP, 1996, CIRCULATION, V93, P2019, DOI 10.1161/01.CIR.93.11.2019; Hossack KF, 1982, J CARDIAC REHABIL, V2, P402; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; KERBER RE, 1981, CIRCULATION, V63, P676, DOI 10.1161/01.CIR.63.3.676; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; MacDonald Russell D, 2002, Prehosp Emerg Care, V6, P1; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Safar P, 1983, Am J Emerg Med, V1, P198, DOI 10.1016/0735-6757(83)90089-X; SoRelle R, 1999, CIRCULATION, V99, P2606, DOI 10.1161/01.CIR.99.20.2606; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Wassertheil J, 2000, RESUSCITATION, V44, P97, DOI 10.1016/S0300-9572(99)00168-9; White RD, 1998, RESUSCITATION, V39, P145, DOI 10.1016/S0300-9572(98)00135-X; White RD, 2001, RESUSCITATION, V49, P9, DOI 10.1016/S0300-9572(00)00338-5; Zheng ZJ, 2001, CIRCULATION, V104, P2158, DOI 10.1161/hc4301.098254; 2000, CIRCULATION S1, V102, P60	36	551	566	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1242	1247		10.1056/NEJMoa020932	http://dx.doi.org/10.1056/NEJMoa020932			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393821				2023-01-03	WOS:000178598300005
J	Thomas, KS; Muir, KR; Doherty, M; Jones, AC; O'Reilly, SC; Bassey, EJ				Thomas, KS; Muir, KR; Doherty, M; Jones, AC; O'Reilly, SC; Bassey, EJ		Community Osteoarthritis Res Grp	Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OSTEO-ARTHRITIS; THERAPY; ADULTS; TREAT; HIP	Objectives To determine whether a home based exercise programme can improve outcomes in patients with knee pain. Design Pragmatic, factorial randomised controlled trial of two years' duration. Setting Two general practices in Nottingham. Participants 786 men and women aged greater than or equal to45 years with self reported knee pain. Interventions Participants were randomised to four groups to receive exercise therapy, monthly telephone contact, exercise therapy plus telephone contact, or no intervention. Patients in the no intervention and combined exercise and telephone groups were randomised to receive or not receive a placebo health food tablet. Main outcome measures Primary outcome was self reported score for knee pain on the Western Ontario and McMaster universities (WOMAC) osteoarthritis index at two years. Secondary outcomes included knee specific physical function and stiffness (scored on WOMAC index), general physical function (scored on SF-36 questionnaire), psychological outlook (scored on hospital anxiety and depression scale), and isometric muscle strength. Results 600 (76.3%) participants completed the study. At 24 months, highly significant reductions in knee pain were apparent for the pooled exercise groups compared with the non-exercise groups (mean difference -0.82, 95% confidence interval -1.3 to -0.3). Similar improvements were observed at 6, 12, and 18 months. Regular telephone contact alone did not reduce pain. The reduction in pain was greater the closer patients adhered to the exercise plan. Conclusions A simple home based exercise programme can significantly reduce knee pain. The lack of improvement in patients who received only telephone contact suggests that improvements are not just due to psychosocial effects because of contact with the therapist.	City Hosp, Nottingham NG5 1PB, England; Queens Med Ctr, Dept Epidemiol & Publ Hlth Med, Nottingham NG7 2UH, England; Queens Med Ctr, Sch Biomed Sci, Nottingham, England	University of Nottingham; University of Nottingham; University of Nottingham	Doherty, M (corresponding author), City Hosp, Nottingham NG5 1PB, England.	michael.doherty@nottingham.ac.uk		Doherty, Michael/0000-0002-5763-8326; Thomas, Kim/0000-0001-7785-7465				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; ALTMAN RD, 1995, OSTEOARTHR CARTILAGE, V3, P3; BADLEY EM, 1993, BRIT J RHEUMATOL, V32, P601; Bellamy N, 1988, J ORTHOP RHEUMATOL, V1, P95; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; DAVIS MA, 1992, J RHEUMATOL, V19, P1943; Deyle GD, 2000, ANN INTERN MED, V132, P173, DOI 10.7326/0003-4819-132-3-200002010-00002; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; Maurer BT, 1999, ARCH PHYS MED REHAB, V80, P1293, DOI 10.1016/S0003-9993(99)90032-1; O'Reilly SC, 1999, ANN RHEUM DIS, V58, P15, DOI 10.1136/ard.58.1.15; OReilly SC, 1996, ANN RHEUM DIS, V55, P931, DOI 10.1136/ard.55.12.931; TORNVALL G, 1963, ACTA PHYSIOL SCAND, V58, P5; TORNVALL G, 1963, ACTA PHYSIOL SCAND S, V58, P201; van Baar ME, 2001, ANN RHEUM DIS, V60, P1123, DOI 10.1136/ard.60.12.1123; Van Baar ME, 1998, J RHEUMATOL, V25, P2432; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	21	258	264	2	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2002	325	7367					752	755		10.1136/bmj.325.7367.752	http://dx.doi.org/10.1136/bmj.325.7367.752			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603AU	12364304	Green Accepted, Green Published, Green Submitted, Bronze			2023-01-03	WOS:000178537300018
J	Beral, V; Banks, E; Reeves, G				Beral, V; Banks, E; Reeves, G			Evidence from randomised trials on the long-term effects of hormone replacement therapy	LANCET			English	Review							ESTROGEN; RISK; PROGESTIN; DISEASE; STROKE; HEART		Radcliffe Infirm, Canc Res UK Epidemiol Unit, Oxford OX2 6HE, England	Cancer Research UK; Radcliffe Infirmary	Beral, V (corresponding author), Radcliffe Infirm, Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.			Banks, Emily/0000-0002-4617-1302				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beral V, 1999, J Epidemiol Biostat, V4, P191; Collins N, 2002, CLIMACTERIC S1, V5, P133; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Hoibraaten E, 2000, THROMB HAEMOSTASIS, V84, P961; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KAHN MA, 2000, Q J MED, V93, P699; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Meade T W, 1999, J Epidemiol Biostat, V4, P165; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	17	354	369	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					942	944		10.1016/S0140-6736(02)11032-4	http://dx.doi.org/10.1016/S0140-6736(02)11032-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354487				2023-01-03	WOS:000178142200024
J	Kaufman, YJ; Tanre, D; Boucher, O				Kaufman, YJ; Tanre, D; Boucher, O			A satellite view of aerosols in the climate system	NATURE			English	Review							BIOMASS BURNING AEROSOLS; SINGLE-SCATTERING ALBEDO; INDIAN-OCEAN EXPERIMENT; OPTICAL-PROPERTIES; TROPOSPHERIC AEROSOLS; MINERAL DUST; CLOUD MICROPHYSICS; SULFATE AEROSOLS; LIQUID WATER; BLACK CARBON	Anthropogenic aerosols are intricately linked to the climate system and to the hydrologic cycle. The net effect of aerosols is to cool the climate system by reflecting sunlight. Depending on their composition, aerosols can also absorb sunlight in the atmosphere, further cooling the surface but warming the atmosphere in the process. These effects of aerosols on the temperature profile, along with the role of aerosols as cloud condensation nuclei, impact the hydrologic cycle, through changes in cloud cover, cloud properties and precipitation. Unravelling these feedbacks is particularly difficult because aerosols take a multitude of shapes and forms, ranging from desert dust to urban pollution, and because aerosol concentrations vary strongly over time and space. To accurately study aerosol distribution and composition therefore requires continuous observations from satellites, networks of ground-based instruments and dedicated field experiments. Increases in aerosol concentration and changes in their composition, driven by industrialization and an expanding population, may adversely affect the Earth's climate and water supply.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Lille, CNRS, Opt Atmospher Lab, Villeneuve Dascq, France	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Kaufman, YJ (corresponding author), NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.	kaufman@climate.gsfc.nasa.gov	Boucher, Olivier/J-5810-2012; Keyes, Dennis/AAZ-9285-2021; Boucher, Olivier/K-7483-2012	Boucher, Olivier/0000-0003-2328-5769; Boucher, Olivier/0000-0003-2328-5769				Ackerman AS, 2000, SCIENCE, V288, P1042, DOI 10.1126/science.288.5468.1042; ACKERMAN TP, 1981, APPL OPTICS, V20, P3661, DOI 10.1364/AO.20.003661; ALBRECHT BA, 1989, SCIENCE, V245, P1227, DOI 10.1126/science.245.4923.1227; Alpert P, 1998, NATURE, V395, P367, DOI 10.1038/26456; ANDREAE MO, 1986, SCIENCE, V232, P1620, DOI 10.1126/science.232.4758.1620; Artaxo P, 1998, J GEOPHYS RES-ATMOS, V103, P31837, DOI 10.1029/98JD02346; Bates TS, 1998, J GEOPHYS RES-ATMOS, V103, P16297, DOI 10.1029/97JD03741; Bond TC, 1998, GEOPHYS RES LETT, V25, P337, DOI 10.1029/98GL00039; BOUCHER O, 1995, J CLIMATE, V8, P1403, DOI 10.1175/1520-0442(1995)008<1403:GEOTIA>2.0.CO;2; Boucher O, 2001, CLIM DYNAM, V18, P297, DOI 10.1007/s003820100185; Breon FM, 2002, SCIENCE, V295, P834, DOI 10.1126/science.1066434; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; Charlson RJ, 2001, SCIENCE, V292, P2025, DOI 10.1126/science.1060096; Chin M, 2002, J ATMOS SCI, V59, P461, DOI 10.1175/1520-0469(2002)059<0461:TAOTFT>2.0.CO;2; CHOU MD, 1992, J ATMOS SCI, V49, P762, DOI 10.1175/1520-0469(1992)049<0762:ASRMFU>2.0.CO;2; Chowdhary J, 2002, J ATMOS SCI, V59, P383, DOI 10.1175/1520-0469(2002)059<0383:CSOARO>2.0.CO;2; Christopher SA, 1996, J GEOPHYS RES-ATMOS, V101, P21265, DOI 10.1029/96JD02161; CHU DA, IN PRESS GEOPHYS RES; Claquin T, 1998, TELLUS B, V50, P491, DOI 10.1034/j.1600-0889.1998.t01-2-00007.x; Clarke AD, 2002, J ATMOS SCI, V59, P363, DOI 10.1175/1520-0469(2002)059<0363:APASPI>2.0.CO;2; CLARKE AD, 1985, SCIENCE, V229, P263, DOI 10.1126/science.229.4710.263; COAKLEY JA, 1987, SCIENCE, V237, P1020, DOI 10.1126/science.237.4818.1020; Collins WD, 2001, J GEOPHYS RES-ATMOS, V106, P7313, DOI 10.1029/2000JD900507; Delene DJ, 2002, J ATMOS SCI, V59, P1135, DOI 10.1175/1520-0469(2002)059<1135:VOAOPA>2.0.CO;2; Deuze JL, 2000, J GEOPHYS RES-ATMOS, V105, P15329, DOI 10.1029/2000JD900148; Diner DJ, 2001, GEOPHYS RES LETT, V28, P3127, DOI 10.1029/2001GL013188; Dubovik O, 2002, J ATMOS SCI, V59, P590, DOI 10.1175/1520-0469(2002)059<0590:VOAAOP>2.0.CO;2; Eck TF, 1998, J GEOPHYS RES-ATMOS, V103, P31865, DOI 10.1029/98JD00399; Eck TF, 2001, J GEOPHYS RES-ATMOS, V106, P3425, DOI 10.1029/2000JD900555; Feingold G, 1999, J ATMOS SCI, V56, P4100, DOI 10.1175/1520-0469(1999)056<4100:TIOGCC>2.0.CO;2; Feingold G, 2002, J ATMOS SCI, V59, P2006, DOI 10.1175/1520-0469(2002)059<2006:AOTIOF>2.0.CO;2; Feingold G, 2001, J GEOPHYS RES-ATMOS, V106, P22907, DOI 10.1029/2001JD000732; Formenti P, 2001, J GEOPHYS RES-ATMOS, V106, P9807, DOI 10.1029/2000JD900609; FOUQUART Y, 1987, J CLIM APPL METEOROL, V26, P28, DOI 10.1175/1520-0450(1987)026<0028:OOSARO>2.0.CO;2; FRASER RS, 1984, ATMOS ENVIRON, V18, P2577, DOI 10.1016/0004-6981(84)90322-6; FRASER RS, 1985, IEEE J GEOSCI REM GE, V23, P525; Gao Y, 2001, GEOPHYS RES LETT, V28, P29, DOI 10.1029/2000GL011926; Gobbi GP, 2000, ATMOS ENVIRON, V34, P5119, DOI 10.1016/S1352-2310(00)00194-1; HAN QY, 1994, J CLIMATE, V7, P465, DOI 10.1175/1520-0442(1994)007<0465:NGSOED>2.0.CO;2; Hansen J, 1997, J GEOPHYS RES-ATMOS, V102, P6831, DOI 10.1029/96JD03436; Haywood J, 2000, REV GEOPHYS, V38, P513, DOI 10.1029/1999RG000078; Hegg DA, 1997, J GEOPHYS RES-ATMOS, V102, P25293, DOI 10.1029/97JD02293; Herman JR, 1997, J GEOPHYS RES-ATMOS, V102, P16911, DOI 10.1029/96JD03680; Herman M, 1997, J GEOPHYS RES-ATMOS, V102, P17039, DOI 10.1029/96JD02109; Heymsfield AJ, 2001, J GEOPHYS RES-ATMOS, V106, P28653, DOI 10.1029/2000JD900776; Holben BN, 2001, J GEOPHYS RES-ATMOS, V106, P12067, DOI 10.1029/2001JD900014; HOPPEL WA, 1990, J GEOPHYS RES-ATMOS, V95, P3659, DOI 10.1029/JD095iD04p03659; Hsu NC, 2000, J GEOPHYS RES-ATMOS, V105, P20649, DOI 10.1029/2000JD900150; Husar RB, 1997, J GEOPHYS RES-ATMOS, V102, P16889, DOI 10.1029/96JD04009; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Jacobson MZ, 2001, NATURE, V409, P695, DOI 10.1038/35055518; Kaufman YJ, 1998, J GEOPHYS RES-ATMOS, V103, P31783, DOI 10.1029/98JD02281; Kaufman YJ, 1997, SCIENCE, V277, P1636, DOI 10.1126/science.277.5332.1636; Kaufman YJ, 1997, J GEOPHYS RES-ATMOS, V102, P17051, DOI 10.1029/96JD03988; KAUFMAN YJ, 1993, J APPL METEOROL, V32, P729, DOI [10.1175/1520-0450(1993)032<0729:EOASOC>2.0.CO;2, 10.1175/1520-0450(1993)032&lt;0729:EOASOC&gt;2.0.CO;2]; Kaufman YJ, 2001, GEOPHYS RES LETT, V28, P1479, DOI 10.1029/2000GL012647; KEELING CD, 1960, TELLUS, V12, P200, DOI 10.1111/j.2153-3490.1960.tb01300.x; Khain AP, 2001, GEOPHYS RES LETT, V28, P3887, DOI 10.1029/2000GL012662; KIEHL JT, 1993, SCIENCE, V260, P311, DOI 10.1126/science.260.5106.311; King MD, 1999, B AM METEOROL SOC, V80, P2229, DOI 10.1175/1520-0477(1999)080<2229:RSOTAF>2.0.CO;2; Kreidenweis SM, 2001, J GEOPHYS RES-ATMOS, V106, P4831, DOI 10.1029/2000JD900488; Leon JF, 2001, J GEOPHYS RES-ATMOS, V106, P28427, DOI 10.1029/2001JD900023; Levin Z, 1996, J APPL METEOROL, V35, P1511, DOI 10.1175/1520-0450(1996)035<1511:TEODPC>2.0.CO;2; Li ZQ, 1998, TELLUS B, V50, P543, DOI 10.1034/j.1600-0889.1998.00010.x; Liao H, 1998, J GEOPHYS RES-ATMOS, V103, P3781, DOI 10.1029/97JD03455; Liousse C, 1996, J GEOPHYS RES-ATMOS, V101, P19411, DOI 10.1029/95JD03426; Liu M, 2001, J GEOPHYS RES-ATMOS, V106, P18099, DOI 10.1029/2000JD900711; Lohmann U, 1997, J GEOPHYS RES-ATMOS, V102, P13685, DOI 10.1029/97JD00631; Luo YF, 2001, J GEOPHYS RES-ATMOS, V106, P14501, DOI 10.1029/2001JD900030; Martins JV, 1998, J GEOPHYS RES-ATMOS, V103, P32041, DOI 10.1029/98JD02593; Mishchenko MI, 1997, J GEOPHYS RES-ATMOS, V102, P16989, DOI 10.1029/96JD02425; Moulin C, 1997, NATURE, V387, P691, DOI 10.1038/42679; Nakajima T, 2001, GEOPHYS RES LETT, V28, P1171, DOI 10.1029/2000GL012186; Novakov T, 1997, J GEOPHYS RES-ATMOS, V102, P30023, DOI 10.1029/97JD02793; PENNER JE, 1992, SCIENCE, V256, P1432, DOI 10.1126/science.256.5062.1432; Prospero JM, 1999, J GEOPHYS RES-ATMOS, V104, P15917, DOI 10.1029/1999JD900072; PROSPERO JM, 1986, NATURE, V320, P735, DOI 10.1038/320735a0; PROSPERO JM, IN PRESS GEOPHYS REV; Ramanathan V, 2001, J GEOPHYS RES-ATMOS, V106, P28371, DOI 10.1029/2001JD900133; Ramanathan V, 2001, SCIENCE, V294, P2119, DOI 10.1126/science.1064034; Reiner T, 2001, J GEOPHYS RES-ATMOS, V106, P28497, DOI 10.1029/2000JD900695; Remer LA, 1997, J GEOPHYS RES-ATMOS, V102, P16849, DOI 10.1029/96JD01932; REMER LA, IN PRESS GEOPHYS RES; Rosenfeld D, 1999, GEOPHYS RES LETT, V26, P3105, DOI 10.1029/1999GL006066; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; Rosenfeld D, 2000, NATURE, V405, P440, DOI 10.1038/35013030; Ross JL, 1998, J GEOPHYS RES-ATMOS, V103, P31925, DOI 10.1029/97JD03677; Rotstayn LD, 2000, GEOPHYS RES LETT, V27, P3045, DOI 10.1029/2000GL011737; Satheesh SK, 1999, J GEOPHYS RES-ATMOS, V104, P27421, DOI 10.1029/1999JD900478; Satheesh SK, 2000, NATURE, V405, P60, DOI 10.1038/35011039; Smirnov A, 2002, J ATMOS SCI, V59, P501, DOI 10.1175/1520-0469(2002)059<0501:OPOAAI>2.0.CO;2; Sokolik IN, 1996, NATURE, V381, P681, DOI 10.1038/381681a0; Takemura T, 2002, J CLIMATE, V15, P333, DOI 10.1175/1520-0442(2002)015<0333:SSAARF>2.0.CO;2; Tanre D, 1997, J GEOPHYS RES-ATMOS, V102, P16971, DOI 10.1029/96JD03437; Tanre D, 2001, J GEOPHYS RES-ATMOS, V106, P18205, DOI 10.1029/2000JD900663; Torres O, 2002, J ATMOS SCI, V59, P398, DOI 10.1175/1520-0469(2002)059<0398:ALTROA>2.0.CO;2; TWOMEY SA, 1984, TELLUS B, V36, P356, DOI 10.1111/j.1600-0889.1984.tb00254.x; Veefkind JP, 1998, GEOPHYS RES LETT, V25, P3135, DOI 10.1029/98GL02264; Wielicki BA, 1996, B AM METEOROL SOC, V77, P853, DOI 10.1175/1520-0477(1996)077<0853:CATERE>2.0.CO;2; Winker DM, 1996, P IEEE, V84, P164, DOI 10.1109/5.482227	100	1581	1683	27	520	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	2002	419	6903					215	223		10.1038/nature01091	http://dx.doi.org/10.1038/nature01091			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	592HK	12226676				2023-01-03	WOS:000177931200051
J	Ganzini, L; Harvath, TA; Jackson, A; Goy, ER; Miller, LL; Delorit, MA				Ganzini, L; Harvath, TA; Jackson, A; Goy, ER; Miller, LL; Delorit, MA			Experiences of Oregon nurses and social workers with hospice patients who requested assistance with suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERMINALLY ILL PATIENTS; DEATH; EUTHANASIA; DESIRE; ATTITUDES	Background Oregon's 1997 Death with Dignity Act legalizes physician-assisted suicide. To date, information about patients who have requested this option has come from surveys of physicians. Although 78 percent of the 91 Oregonians who have died by assisted suicide were enrolled in hospice programs, there is little information about the experiences of hospice practitioners with these patients. Methods In 2001, we mailed a questionnaire to all hospice nurses and social workers in Oregon. Results Of 545 eligible hospice nurses and social workers, 397 (73 percent) returned the survey, including 71 percent of nurses and 78 percent of social workers. Since November 1997,179 of the respondents (45 percent) had cared for a patient who requested assistance with suicide. Hospice nurses reported on 82 patients who had received prescriptions for lethal medication. Ninety-eight percent of the nurses had discussed the request with a coworker, and 77 percent of the requests had been presented at a hospice interdisciplinary conference on patient care. A very important reason for the request was to control the circumstances of death. The least important reasons included depression, lack of social support, and fear of being a financial drain on family members. Although the patients were concerned about burdening others, only 11 percent of hospice nurses rated their family caregivers as more burdened than family caregivers for other hospice patients. Conclusions Since assisted suicide was legalized in Oregon, many hospice nurses and social workers have provided care for a patient who requested assistance with suicide. They rated desire for control as a very important reason for these requests.	Vet Affairs Med Ctr, Div Mental Hlth, Portland, OR 97207 USA; Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA; Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR USA; Oregon Hospice Assoc, Portland, OR USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon Health & Science University	Ganzini, L (corresponding author), Vet Affairs Med Ctr, Div Mental Hlth, P3MHDC,POB 1034, Portland, OR 97207 USA.		Harvath, Theresa/L-1115-2019					Breitbart W, 1996, AM J PSYCHIAT, V153, P238; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; DANIEL WW, 1999, BIOSTATISTICS FDN AN; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; Foley K, 1999, HASTINGS CENT REP, V29, P37, DOI 10.2307/3528194; Ganzini L, 2000, NEW ENGL J MED, V342, P1538; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Hamilton NG, 2000, HASTINGS CENT REP, V30, P4; Hedberg K, 2002, NEW ENGL J MED, V346, P450, DOI 10.1056/NEJM200202073460614; Miller FG, 1997, CAMB Q HEALTHC ETHIC, V6, P78, DOI 10.1017/S0963180100007635; Rosenfeld B, 2000, NEW ENGL J MED, V343, P151; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Sullivan AD, 2001, NEW ENGL J MED, V344, P605, DOI 10.1056/NEJM200102223440811; Wilson KG, 2000, ARCH INTERN MED, V160, P2454, DOI 10.1001/archinte.160.16.2454	18	113	114	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	2002	347	8					582	588		10.1056/NEJMsa020562	http://dx.doi.org/10.1056/NEJMsa020562			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	587ZR	12192019				2023-01-03	WOS:000177675400008
J	Simons, SHP; van Dijk, M; van Lingen, R; Roofthooft, D; Duivenvoorden, HJ; Jongeneel, N; Bunkers, C; Smink, E; Anand, KJS; van den Anker, JN; Tibboel, D				Simons, SHP; van Dijk, M; van Lingen, R; Roofthooft, D; Duivenvoorden, HJ; Jongeneel, N; Bunkers, C; Smink, E; Anand, KJS; van den Anker, JN; Tibboel, D			Routine morphine infusion in preterm newborns who received ventilatory support - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT INFANTS; BIOBEHAVIORAL PAIN RESPONSES; WEEKS POSTCONCEPTIONAL AGE; INTRAVENTRICULAR HEMORRHAGE; BETA-ENDORPHIN; PREMATURE-INFANTS; BRAIN ULTRASOUND; RECOMMENDED USE; CHILDREN; ANALGESIA	Context Newborns admitted to neonatal intensive care units (NICUs) undergo a variety of painful procedures and stressful events. Because the effect of continuous morphine infusion in preterm neonates has not been investigated systematically, there is confusion regarding whether morphine should be used routinely in this setting. Objective To evaluate the effects of continuous intravenous morphine infusion on pain responses, incidence of intraventricular hemorrhage (IVH), and poor neurologic outcome (severe IVH, periventricular leukomalacia, or death). Design, Setting, and Patients A randomized, double-blind, placebo-controlled trial conducted between December 2000 and October 2002 in 2 level III NICUs in the Netherlands of 150 newborns who had received ventilatory support (inclusion criteria: postnatal age younger than 3 days and ventilation for less than 8 hours; exclusion criteria: severe asphyxia, severe IVH; major congenital malformations, and administration of neuromuscular blockers). Interventions Intravenous morphine (100 mug/kg and 10 mug/kg per hour) or placebo infusion was given for 7 days (or less because of clinical necessity in several cases). Main Outcome Measures The analgesic effect of morphine, as assessed using validated scales; the effect of morphine on the incidence of IVH; and poor neurologic outcome. Results The analgesic effect did not differ between the morphine and placebo groups, judging from the following median (interquartile range) pain scores: Premature Infant Pain Profile, 10.1,(8.2-11.6) vs 10.0 (8.2-12.0) (P=.94); Neonatal Infant Pain Scale, 4.8 (3.7-6.0) vs 4.8 (3.2-6.0) (P=.58); and visual analog scale, 2.8 (2.0-3.9) vs 2.6 (1.8-4.3) (P=.14), respectively. Routine morphine infusion decreased the incidence of IVH (23% vs 40%, P=.04) but did not influence poor neurologic outcome (10% vs 16%, P=.66). In addition, analyses were adjusted for the use of additional open-label morphine (27% of morphine group vs 40% of placebo group, P=.10). Conclusions Lack of a measurable analgesic effect and absence of a beneficial effect on poor neurologic outcome do not support the routine-use of morphine infusions as a standard of care in preterm newborns who have received ventilatory support. Follow-up is needed to evaluate the long-term effects of morphine infusions on the neurobehavioral outcomes of prematurity.	Erasmus MC Sophia, Dept Pediat Surg, NL-3015 GJ Rotterdam, Netherlands; Erasmus MC Sophia, Dept Pediat, NL-3015 GJ Rotterdam, Netherlands; Erasmus MC Sophia, Div Neonatol, NL-3015 GJ Rotterdam, Netherlands; Erasmus MC, Dept Med Psychol, Rotterdam, Netherlands; Isala Clin, Dept Pediat, Div Neonatol, Zwolle, Netherlands; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Arkansas Childrens Hosp, Little Rock, AR 72202 USA; George Washington Univ, Dept Pediat, Div Pediat Clin Pharmacol, Washington, DC 20052 USA; George Washington Univ, Dept Pharmacol, Div Pediat Clin Pharmacol, Washington, DC 20052 USA	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Isala Clinics; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; George Washington University; George Washington University	Tibboel, D (corresponding author), Erasmus MC Sophia, Dept Pediat Surg Pediat, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.		simons, sinno/AAC-7442-2019; van Dijk, Monique/B-6327-2009; Anand, Kanwaljeet/B-3287-2014	Anand, Kanwaljeet/0000-0001-6498-1483; Simons, Sinno/0000-0001-5219-5696; van Dijk, Monique/0000-0002-9856-0318				Ambalavanan N, 1999, J PEDIATR-US, V135, P403, DOI 10.1016/S0022-3476(99)70156-3; Anand KJS, 1999, PHYSIOL BEHAV, V66, P627, DOI 10.1016/S0031-9384(98)00338-2; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; ANAND KJS, 2000, PAIN NEONATES, V10, P180; ANDREWS K, 1994, PAIN, V56, P95, DOI 10.1016/0304-3959(94)90154-6; BACIGALUPO G, 1987, J PERINAT MED, V15, P45, DOI 10.1515/jpme.1987.15.1.45; Ballantyne M, 1999, CLIN J PAIN, V15, P297, DOI 10.1097/00002508-199912000-00006; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Bhutta AT, 2001, PHYSIOL BEHAV, V73, P51, DOI 10.1016/S0031-9384(01)00432-2; Blauer T, 1998, CLIN J PAIN, V14, P39, DOI 10.1097/00002508-199803000-00006; DEVRIES LS, 1992, BEHAV BRAIN RES, V49, P1, DOI 10.1016/S0166-4328(05)80189-5; DUBOWITZ LMS, 1984, J PEDIATR-US, V105, P452, DOI 10.1016/S0022-3476(84)80028-1; Evans J C, 1997, Neonatal Netw, V16, P33; Feingold E, 2002, J ADOLESCENT HEALTH, V31, P234, DOI 10.1016/S1054-139X(01)00407-4; FITZGERALD M, 1988, LANCET, V1, P292; FITZGERALD M, 1989, PAIN, V39, P31, DOI 10.1016/0304-3959(89)90172-3; Franck LS, 1998, J PAIN SYMPTOM MANAG, V15, P41, DOI 10.1016/S0885-3924(97)00272-8; GhaziBirry HS, 1997, AM J NEURORADIOL, V18, P219; GREISEN G, 1985, ACTA PAEDIATR SCAND, V74, P525, DOI 10.1111/j.1651-2227.1985.tb11022.x; Grunau RE, 2000, CLIN J PAIN, V16, P37, DOI 10.1097/00002508-200003000-00007; Grunau RE, 2001, PEDIATRICS, V107, P105, DOI 10.1542/peds.107.1.105; HANDELMANN GE, 1985, PEPTIDES, V6, P29, DOI 10.1016/0196-9781(85)90131-7; HARTLEY R, 1993, ARCH DIS CHILD-FETAL, V69, P55, DOI 10.1136/adc.69.1_Spec_No.55; Johnston C C, 1999, J Obstet Gynecol Neonatal Nurs, V28, P587, DOI 10.1111/j.1552-6909.1999.tb02167.x; JOHNSTON CC, 1995, PAIN, V61, P471, DOI 10.1016/0304-3959(94)00213-X; Kahn DJ, 1998, ARCH PEDIAT ADOL MED, V152, P844; Kart T, 1997, PAEDIATR ANAESTH, V7, P93; Kart T, 1997, PAEDIATR ANAESTH, V7, P5, DOI 10.1046/j.1460-9592.1997.d01-30.x; Kennedy KA, 1999, J PEDIATR-US, V134, P127, DOI 10.1016/S0022-3476(99)70399-9; KOREN G, 1985, VET HUM TOXICOL, V27, P519; Lawrence J, 1993, Neonatal Netw, V12, P59; Lemons JA, 2000, PEDIATRICS, V105, P454; LYNN AM, 1993, ANESTH ANALG, V77, P695; MacGregor R, 1998, ARCH DIS CHILD-FETAL, V79, pF40, DOI 10.1136/fn.79.1.F40; MCCULLOCH KM, 1995, EARLY HUM DEV, V41, P147, DOI 10.1016/0378-3782(95)01617-C; Oberlander TF, 2002, PEDIATRICS, V110, P570, DOI 10.1542/peds.110.3.570; Oh W, 1996, PEDIATRICS, V98, P141; PAPILE LA, 1983, J PEDIATR-US, V103, P273, DOI 10.1016/S0022-3476(83)80366-7; PERLMAN JM, 1983, NEW ENGL J MED, V309, P204, DOI 10.1056/NEJM198307283090402; Peters JWB, 2003, PEDIATRICS, V111, P129, DOI 10.1542/peds.111.1.129; POHJAVUORI M, 1986, BIOL RES PREG PERIN, V7, P1; POKELA ML, 1994, PEDIATRICS, V93, P379; POKELA ML, 1994, ACTA PAEDIATR, V83, P151, DOI 10.1111/j.1651-2227.1994.tb13040.x; Porter FL, 1999, J DEV BEHAV PEDIATR, V20, P253, DOI 10.1097/00004703-199908000-00008; Quinn MW, 1998, ARCH DIS CHILD-FETAL, V78, pF195, DOI 10.1136/fn.78.3.F195; QUINN MW, 1993, LANCET, V342, P324, DOI 10.1016/0140-6736(93)91472-X; RAISANEN I, 1986, OBSTET GYNECOL, V67, P384; Rutter N, 2000, ARCH DIS CHILD-FETAL, V83, pF101, DOI 10.1136/fn.83.2.F101; Saarenmaa E, 1996, ARCH DIS CHILD-FETAL, V75, pF103, DOI 10.1136/fn.75.2.F103; Saarenmaa E, 2000, CLIN PHARMACOL THER, V68, P160, DOI 10.1067/mcp.2000.108947; Sabatino G, 1997, EARLY HUM DEV, V47, P263, DOI 10.1016/S0378-3782(96)01781-1; Scott CS, 1999, J PEDIATR-US, V135, P423, DOI 10.1016/S0022-3476(99)70163-0; SHANKARAN S, 1982, J PEDIATR-US, V100, P469, DOI 10.1016/S0022-3476(82)80462-9; SKOV L, 1992, ACTA PAEDIATR, V81, P389, DOI 10.1111/j.1651-2227.1992.tb12255.x; SMITH WL, 1983, RADIOLOGY, V147, P445, DOI 10.1148/radiology.147.2.6836123; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; STEWART AL, 1983, ARCH DIS CHILD, V58, P598, DOI 10.1136/adc.58.8.598; TEMPEL A, 1991, DEV BRAIN RES, V64, P19, DOI 10.1016/0165-3806(91)90204-V; THORBURN RJ, 1981, LANCET, V1, P1119; USHER R, 1969, J PEDIATR-US, V74, P901, DOI 10.1016/S0022-3476(69)80224-6; van Dijk M, 2002, CLIN PERINATOL, V29, P469, DOI 10.1016/S0095-5108(02)00015-5; van Dijk M, 2002, CLIN J PAIN, V18, P310, DOI 10.1097/00002508-200209000-00006; VOHR B, 1992, J PEDIATR-US, V121, P280, DOI 10.1016/S0022-3476(05)81204-1; Volpe J. J., 2000, NEUROLOGY NEWBORN, P428; WAY WL, 1965, CLIN PHARMACOL THER, V6, P454; Wood CM, 1998, ARCH DIS CHILD-FETAL, V79, pF34, DOI 10.1136/fn.79.1.F34	67	200	204	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2419	2427		10.1001/jama.290.18.2419	http://dx.doi.org/10.1001/jama.290.18.2419			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742LH	14612478	Bronze			2023-01-03	WOS:000186518300028
J	Hutin, YJF; Hauri, AM; Armstrong, GL				Hutin, YJF; Hauri, AM; Armstrong, GL			Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEPATITIS-B-VIRUS; UNSAFE INJECTIONS; RURAL TANZANIA; HIV-INFECTION; RISK-FACTORS; TRANSMISSION; CONTAMINATION; COMMUNITY; SAFETY; TRIAL	Objective To describe injection practices worldwide in terms of frequency and safety. Design Literature review The global burden of disease project of the World Health Organization defined 14 regions on the basis of geography and mortality patterns. Data sources included published studies and unpublished WHO reports. Studies were reviewed by using a standardised decision making algorithm to generate region specific estimates. Setting Healthcare facilities, both formal and informal. Data sources: General population and users of healthcare facilities. Main outcome measure Annual number of injections per person and proportion of injections administered with syringes and needles that are reused in the absence of sterilisation. Results The analysis excluded four regions (predominantly affluent, developed nations) where reuse of injection equipment in the absence of sterilisation was assumed to be negligible. In the 10 other regions, the annual ratio of injections per person ranged from 1.7 to 11.3. Of these, the proportion administered with equipment reused in the absence of sterilisation ranged from 1.2% to 75.0%. Reuse was highest in the South East Asia region "D" (seven countries, mostly located in South Asia), the eastern Mediterranean region "D" (nine countries, mostly located in the Middle East crescent), and the western Pacific region "B" (22 countries). No information regarding injection safety was available for Latin America. Conclusions Overuse of injections and unsafe practices are still common in developing and transitional countries. An urgent need exists to use injections safely and appropriately, to prevent healthcare associated infections with HIV and other bloodborne pathogens.	WHO, Dept Blood Safety & Clin Technol, Ave Appia 20, CH-1211 Geneva, Switzerland; Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	World Health Organization; Centers for Disease Control & Prevention - USA	Hutin, YJF (corresponding author), WHO, Dept Blood Safety & Clin Technol, Ave Appia 20, CH-1211 Geneva, Switzerland.	hutiny@who.int						Abulrahi HA, 1997, LANCET, V349, P23, DOI 10.1016/S0140-6736(96)03508-8; ALTAF A, 2002, 14 INT AIDS C 2002 B; ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; Archibald LK, 1998, J PEDIATR-US, V133, P640, DOI 10.1016/S0022-3476(98)70104-0; AYLWARD B, 1995, INT J EPIDEMIOL, V24, P446, DOI 10.1093/ije/24.2.446; BASS A, 2000, B WORLD HEALTH ORGAN, V18, P277; Birungi H, 1998, SOC SCI MED, V47, P1455, DOI 10.1016/S0277-9536(98)00194-4; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Centers for Disease Control, 2001, Morbidity and Mortality Weekly Report, V50, P59; Centers for Disease Control, 1999, Morbidity and Mortality Weekly Report, V48, P271; Chang Shun-Jen, 1996, Kaohsiung Journal of Medical Sciences, V12, P241; Deivanayagam N, 1993, Indian Pediatr, V30, P335; *DEM HLTH SURV, 2000, MEAS DHS PLUS; Dicko M, 2000, B WORLD HEALTH ORGAN, V78, P163; Drucker E, 2001, LANCET, V358, P1989, DOI 10.1016/S0140-6736(01)06967-7; ELSAKKA H, 1997, EP INT SERV C ATL GA; Ferry B, 1995, SEXUAL BEHAV AIDS DE; FISHERHOCH SP, 1995, BRIT MED J, V311, P857, DOI 10.1136/bmj.311.7009.857; Flaskerud JH, 1996, AIDS CARE, V8, P95, DOI 10.1080/09540129650126028; GROSSKURTH H, 1995, AIDS, V9, P927, DOI 10.1097/00002030-199508000-00015; GUYER B, 1980, B WORLD HEALTH ORGAN, V58, P285; Hadiyono JEP, 1996, SOC SCI MED, V42, P1177, DOI 10.1016/0277-9536(95)00391-6; HERSH BS, 1993, AIDS, V7, P1617, DOI 10.1097/00002030-199312000-00012; HOFMANN CA, 2001, ANN M 30 31 AUG; Hutin YJF, 1999, INT J EPIDEMIOL, V28, P782, DOI 10.1093/ije/28.4.782; Hutin YJF, 1999, B WORLD HEALTH ORGAN, V77, P787; Jain P, 2001, NATL MED J INDIA, V14, P143; JANSZEN E, 1993, IMPACT INJECTIONS DA, P43; Kane A, 1999, B WORLD HEALTH ORGAN, V77, P801; Khan AJ, 2000, B WORLD HEALTH ORGAN, V78, P956; KO Y-C, 1991, Kaohsiung Journal of Medical Sciences, V7, P313; KO Y-C, 1991, Kaohsiung Journal of Medical Sciences, V7, P358; KO YC, 1991, AM J EPIDEMIOL, V133, P1015, DOI 10.1093/oxfordjournals.aje.a115810; KOSEN S, 1999, ASSESSMENT SAFETY EP; Lakshman M, 2000, SOC SCI MED, V51, P11, DOI 10.1016/S0277-9536(99)00426-8; Logez S., 2001, ACCESSIBILITY INJECT; Luby SP, 1997, EPIDEMIOL INFECT, V119, P349, DOI 10.1017/S0950268897007899; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Murray CJL, 1999, EPIDEMIOLOGY, V10, P594, DOI 10.1097/00001648-199909000-00029; Organization WH, 2002, WHO TRAD MED STRAT 2, P74; OTU AA, 1987, CANCER, V60, P2581, DOI 10.1002/1097-0142(19871115)60:10<2581::AID-CNCR2820601039>3.0.CO;2-G; PAPE JW, 1985, ANN INTERN MED, V103, P674, DOI 10.7326/0003-4819-103-5-674; PRIOTTO G, 2001, INJECTION USE POPULA; Quick JD, 1997, MANAGING DRUG SUPPLY, P430; Quigley M, 1997, AIDS, V11, P237, DOI 10.1097/00002030-199702000-00015; REELER AV, 1990, SOC SCI MED, V31, P1119, DOI 10.1016/0277-9536(90)90233-I; REELER AV, WHODAP948, P94; SCHNURR A, 1999, TECH NET M 1999 HAR; Simonsen L, 1999, B WORLD HEALTH ORGAN, V77, P789; SOETERS R, 1989, TROP DOCT, V19, P124, DOI 10.1177/004947558901900310; STOICA A, 1999, ANN M SOC HEALTHC EP; Talaat M, 2003, TROP MED INT HEALTH, V8, P234, DOI 10.1046/j.1365-3156.2003.01015.x; UGALDE A, 1988, CONTEXT MED DEV COUN, P57; van Staa A, 1996, WHODAP964; Villanueva A, 1997, CLIN INFECT DIS, V24, P1147, DOI 10.1086/513656; VONG S, 2002, 51 EP INT SERV C CDC; *WHO, 2001, WHOBCT0211; *WHO, 1994, WHODAP9412; *WHO, 2001, WHOVB0130; *WHO, 1999, WKLY EPIDEMIOL REC, V11, P84; *WHO, 2000, WHO FACT SHEET, P204; World Health Organization, 2000, AID MEM NAT STRAT SA; WYAU HV, 1984, SOC SCI MED, V19, P911; 1945, LANCET          0728, P116	64	176	185	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	2003	327	7423					1075	+		10.1136/bmj.327.7423.1075	http://dx.doi.org/10.1136/bmj.327.7423.1075			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742QW	14604927	Bronze, Green Published			2023-01-03	WOS:000186530400016
J	Lloyd-Williams, M; Dennis, M; Taylor, F; Baker, I				Lloyd-Williams, M; Dennis, M; Taylor, F; Baker, I			Is asking patients in palliative care, "Are you depressed?" appropriate? Prospective study	BRITISH MEDICAL JOURNAL			English	Article							SINGLE QUESTION; TERMINALLY ILL		Univ Liverpool, Sch Med, Dept Primary Care, Liverpool L69 3GB, Merseyside, England; Univ Leicester, Leicester Gen Hosp, Dept Psychiat, Leicester LE5 4PW, Leics, England; LOROS Hospice, Leicester LE3 9QE, Leics, England	University of Liverpool; University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester	Lloyd-Williams, M (corresponding author), Univ Liverpool, Sch Med, Dept Primary Care, Liverpool L69 3GB, Merseyside, England.							Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; Hotopf M, 2002, PALLIATIVE MED, V16, P81, DOI 10.1191/02169216302pm507oa; Lloyd-Williams M, 1999, PALLIATIVE MED, V13, P243, DOI 10.1191/026921699676753309; MAHONEY J, 1994, J AM GERIATR SOC, V42, P1006; Watkins C, 2001, BRIT MED J, V323, P1159, DOI 10.1136/bmj.323.7322.1159	5	54	54	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					372	373		10.1136/bmj.327.7411.372	http://dx.doi.org/10.1136/bmj.327.7411.372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919988	Green Published, Bronze			2023-01-03	WOS:000184864200018
J	Scarabin, PY; Oger, E; Plu-Bureau, G				Scarabin, PY; Oger, E; Plu-Bureau, G		ESTHER Study Grp	Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; HORMONE REPLACEMENT; POSTMENOPAUSAL WOMEN; PULMONARY-EMBOLISM; COAGULATION; USERS; PHARMACOKINETICS; FIBRINOLYSIS; ESTRADIOL	Background Oral oestrogen-replacement therapy (ERT) activates blood coagulation and increases the risk of venous thromboembolism (VTE) in postmenopausal women. Transdermal ERT has little effect on haemostasis, but data assessing its effect on thrombotic process are scarce. We aimed to examine the effect of the route of oestrogen administration on VTE risk. Methods We did a multicentre hospital-based case-control study of postmenopausal women in France. During 1999-2002, we recruited 155 consecutive cases with a first documented episode of idiopathic VTE (92 with pulmonary embolisms and 63 with deep venous thrombosis), and 381 controls matched for centre, age, and time of recruitment. Findings Overall, 32 (21%) cases and 27 (7%) controls were current users of oral ERT, whereas 30 (19%) cases and 93 (24%) controls were current users of transdermal ERT. After adjustment for potential confounding variables, the odds ratio for VTE in current users of oral and transdermal ERT compared with non-users was 3.5 (95% CI 1.8-6.8) and 0.9 (0.5-1.6), respectively. Estimated risk for VTE in current users of oral ERT compared with transdermal ERT users was 4.0 (1.9-8.3). Interpretation- Oral but not transdermal ERT is associated with risk of VTE in postmenopausal women. These data suggest that transdermal ERT might be safer than oral ERT with respect to thrombotic risk.	INSERM, U258, F-94807 Villejuif, France; Hop Cavale Blanche, Dept Internal Med, Brest, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Brest; Universite de Bretagne Occidentale	Scarabin, PY (corresponding author), INSERM, U258, Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	scarabin@vjf.inserm.fr						Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; CAINE YG, 1992, THROMB HAEMOSTASIS, V68, P392; CONARD J, 1983, THROMB HAEMOSTASIS, V49, P252; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DELIGNIERES B, 1986, J CLIN ENDOCR METAB, V62, P536, DOI 10.1210/jcem-62-3-536; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hoibraaten E, 2001, BRIT J HAEMATOL, V115, P415, DOI 10.1046/j.1365-2141.2001.03111.x; Holbraaten E, 1999, THROMB HAEMOSTASIS, V82, P1218; JAMA, 1970, JAMA, V214, P1303, DOI DOI 10.1001/JAMA.1970.03180070069012; JICK H, 1978, AM J EPIDEMIOL, V107, P1; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Le Gal G, 2003, ATHEROSCLEROSIS, V166, P163, DOI 10.1016/S0021-9150(02)00325-8; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Oger E, 1999, DRUG AGING, V14, P55, DOI 10.2165/00002512-199914010-00004; OGER E, 2003, IN PRESS ARTERIOSCLE; POWERS MS, 1985, AM J OBSTET GYNECOL, V152, P1099, DOI 10.1016/0002-9378(85)90569-1; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Scarabin PY, 1997, ARTERIOSCL THROM VAS, V17, P3071, DOI 10.1161/01.ATV.17.11.3071; SCOTT RT, 1991, OBSTET GYNECOL, V77, P758; Seradour B, 1999, J MED SCREEN, V6, P99, DOI 10.1136/jms.6.2.99; Teede HJ, 2000, ARTERIOSCL THROM VAS, V20, P1404, DOI 10.1161/01.ATV.20.5.1404; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; 1990, JAMA, V263, P2753	24	502	515	2	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					428	432		10.1016/S0140-6736(03)14066-4	http://dx.doi.org/10.1016/S0140-6736(03)14066-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927428				2023-01-03	WOS:000184651100008
J	Kikule, E				Kikule, E			A good death in Uganda: survey of needs for palliative care for terminally ill people in urban areas	BRITISH MEDICAL JOURNAL			English	Article								Objective To identify the palliative care needs of terminally ill people in Uganda. Design Descriptive cross sectional study. Setting Home care programmes in and around Kampala that look after terminally ill people in their homes. Participants 173 terminally ill patients registered with the home care programmes. Results Most of the participants had either HIV/AIDS or cancer or both; 145 were aged under 50 years, and 107 were women. Three main needs were identified: the control or relief of pain and other symptoms; counselling; and financial assistance for basic needs such as food, shelter, and school fees for their children. The preferred site of care was the home, though all these people lived in urban areas with access to healthcare services within 5 kin of their homes. Conclusion A "good death" in a developing country occurs when the dying person is being cared for at home, is free from pain or other distressing symptoms, feels no stigma, is at peace, and has their basic needs met without feeling dependent on others.	Hospice Africa Uganda, Kampala, Uganda		Kikule, E (corresponding author), Hospice Africa Uganda, POB 7757, Kampala, Uganda.							KATABIRA E, 1998, WORLD HLTH, P16; Kish L., 1965, SURVEY SAMPLING; *MIN ENV, 1999, POLL CHECK RES 98 EV, P10; Murray SA, 2003, BRIT MED J, V326, P368, DOI 10.1136/bmj.326.7385.368; OKUONZI SA, 2003, UGANDA HLTH B J  JAN, P9; REGNARD FBC, 1998, GUIDE SYMPTOM RELIEF; SIMS R, 1995, TERMINAL CARE PEOPLE, P1; *UN DEV PROGR, 2000, UG HUM DEV REP; *UNAIDS WHO, 1998, AIDS EP UPD DEC, P1; 1990, WHO TECH REP SER, V804, P1	10	72	73	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 26	2003	327	7408					192	194		10.1136/bmj.327.7408.192	http://dx.doi.org/10.1136/bmj.327.7408.192			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	706DL	12881259	Green Published, Bronze			2023-01-03	WOS:000184437300015
J	Markowitz, AJ; Rabow, MW				Markowitz, AJ; Rabow, MW			Alzheimer disease: "It's okay, mama, if you want to go, it's okay"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Hurley AC, 2002, JAMA-J AM MED ASSOC, V288, P2324, DOI 10.1001/jama.288.18.2324	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					105	105		10.1001/jama.290.1.105	http://dx.doi.org/10.1001/jama.290.1.105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837718				2023-01-03	WOS:000183868600026
J	Coulter, A				Coulter, A			Killing the goose that laid the golden egg?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Picker Inst Europe, Oxford OX1 1RX, England		Coulter, A (corresponding author), Picker Inst Europe, Oxford OX1 1RX, England.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375					0	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1280	1280		10.1136/bmj.326.7402.1280	http://dx.doi.org/10.1136/bmj.326.7402.1280			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805130	Green Published			2023-01-03	WOS:000183626500006
J	Moeckel, GW; Zhang, L; Fogo, AB; Hao, CM; Pozzi, A; Breyer, MD				Moeckel, GW; Zhang, L; Fogo, AB; Hao, CM; Pozzi, A; Breyer, MD			COX2 activity promotes organic osmolyte accumulation and adaptation of renal medullary interstitial cells to hypertonic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE-2; EXPRESSION; INHIBITORS; SURVIVAL; CLONING; CULTURE; BETAINE; KIDNEY	The mechanism by which COX2 inhibition decreases renal cell survival is poorly understood. In the present study we examined the effect of COX2 activity on organic osmolyte accumulation in renal medulla and in cultured mouse renal medullary interstitial cells (MMICs) and its role in facilitating cell survival. Hypertonicity increased accumulation of the organic osmolytes inositol, sorbitol, and betaine in cultured mouse medullary interstitial cells. Pretreatment of MMICs with a COX2-specific inhibitor (SC58236, 10 mumol/liter) dramatically reduced osmolyte accumulation ( by 79 +/- 9, 57 +/- 12, and 96 +/- 10% for inositol, sorbitol, and betaine respectively, p < 0.05). Similarly, 24 h of dehydration increased inner medullary inositol, sorbitol, and betaine concentrations in vivo by 85 +/- 10, 197 +/- 28, and 190 +/- 24 pmol/&mu;g of protein, respectively, but this increase was also blunted ( by 100 +/- 5, 66 +/- 15, and 81 +/- 9% for inositol, sorbitol, and betaine, respectively, p < 0.05) by pretreatment with an oral COX2 inhibitor. Dehydrated COX2-/- mice also exhibited an impressive defect in sorbitol accumulation ( 88 +/- 9% less than wild type, p < 0.05) after dehydration. COX2 inhibition ( COX2 inhibitor-treated or COX2-/- MMICs) dramatically reduced the expression of organic osmolyte uptake mechanisms including betaine (BGT1) and sodium-myo-inositol transporter and aldose reductase mRNA expression under hypertonic conditions. Importantly, preincubation of COX2 inhibitor-treated MMICs with organic osmolytes restored their ability to survive hypertonic stress. In conclusion, osmolyte accumulation in the kidney inner medulla is dependent on COX2 activity, and providing exogenous osmolytes reverses COX2-induced cell death. These findings may have implications for the pathogenesis of analgesic nephropathy.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Pathol,Renal Pathol Div, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Moeckel, GW (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Pathol,Renal Pathol Div, MCN C-2317,1161 21st Ave So, Nashville, TN 37232 USA.			Breyer, Matthew/0000-0003-1880-371X; Moeckel, Gilbert/0000-0002-6059-0837	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, K08DK059975] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39261, K08 DK59975] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK FX, 1990, CELL VOLUME REGULATI, P132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burger-Kentischer A, 1999, KIDNEY INT, V55, P1417, DOI 10.1046/j.1523-1755.1999.00382.x; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Crofford LJ, 1997, J RHEUMATOL, V24, P15; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DUNN MJ, 1976, PROSTAG OTH LIPID M, V12, P37, DOI 10.1016/S0090-6980(76)80005-6; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; Grupp C, 1999, EXP NEPHROL, V7, P377; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF18, DOI 10.1152/ajprenal.1997.273.1.F18; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1991, J BIOL CHEM, V266, P24059; Horio M, 2001, NEPHROL DIAL TRANSPL, V16, P483, DOI 10.1093/ndt/16.3.483; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Komhoff M, 2000, KIDNEY INT, V57, P414; Komhoff M., 1997, AM J PHYSIOL, V272, P460; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; MACKNIGHT ADC, 1988, RENAL PHYSIOL BIOCH, V11, P114; MOECKEL GW, 1994, AM J PHYSIOL, V266, pF512, DOI 10.1152/ajprenal.1994.266.3.F512; Moeckel GW, 1997, AM J PHYSIOL-RENAL, V272, pF100, DOI 10.1152/ajprenal.1997.272.1.F100; Moeckel GW, 1997, AM J PHYSIOL-RENAL, V272, pF94, DOI 10.1152/ajprenal.1997.272.1.F94; MOLLAND EA, 1978, KIDNEY INT, V13, P5, DOI 10.1038/ki.1978.2; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; WEINHOLD PA, 1963, P SOC EXP BIOL MED, V112, P165; YANCEY PH, 1990, AM J PHYSIOL, V258, pC156, DOI 10.1152/ajpcell.1990.258.1.C156; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF1, DOI 10.1152/ajprenal.1999.277.1.F1	31	58	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19352	19357		10.1074/jbc.M302209200	http://dx.doi.org/10.1074/jbc.M302209200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637551	hybrid			2023-01-03	WOS:000182932200083
J	Fledelius, HC				Fledelius, HC			High atmospheric pressure and myopic shift in caisson workers	LANCET			English	Editorial Material							HYPERBARIC-OXYGEN THERAPY		Rigshosp, Univ Eye Dept, DK-2100 Copenhagen O, Denmark	Rigshospitalet	Fledelius, HC (corresponding author), Rigshosp, Univ Eye Dept, DK-2100 Copenhagen O, Denmark.							Anderson B Jr, 1978, Trans Am Ophthalmol Soc, V76, P116; CURTIN BJ, 1985, MYOPIAS BASIC SCI CL, P3; Fledelius HC, 2002, ACTA OPHTHALMOL SCAN, V80, P188, DOI 10.1034/j.1600-0420.2002.800213.x; Kindwall EP, 1994, HYPERBARIC MED, pS45; LYNE AJ, 1978, T OPHTHAL SOC UK, V98, P66; Onoo A, 2002, BRIT J OPHTHALMOL, V86, P1274, DOI 10.1136/bjo.86.11.1274; PALMQUIST BM, 1984, BRIT J OPHTHALMOL, V68, P113, DOI 10.1136/bjo.68.2.113; Ross ME, 1996, OPTOMETRY VISION SCI, V73, P487, DOI 10.1097/00006324-199607000-00006	8	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 1	2003	361	9355					362	362		10.1016/S0140-6736(03)12443-9	http://dx.doi.org/10.1016/S0140-6736(03)12443-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642CP	12573370				2023-01-03	WOS:000180787000006
J	van Grootheest, K; Vrieling, T				van Grootheest, K; Vrieling, T			Thromboembolism associated with the new contraceptive Yasmin	BRITISH MEDICAL JOURNAL			English	Letter									Netherlands Pharmacovigilance Ctr Lareb, NL-5237 MH Shertogenbosch, Netherlands		van Grootheest, K (corresponding author), Netherlands Pharmacovigilance Ctr Lareb, Goudsbloemvallei 7, NL-5237 MH Shertogenbosch, Netherlands.							Sheldon T, 2002, BRIT MED J, V324, P869, DOI 10.1136/bmj.324.7342.869; WINKLER UH, 2001, GYNAECOL FORUM, V6, P23	2	36	36	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2003	326	7383					257	257		10.1136/bmj.326.7383.257	http://dx.doi.org/10.1136/bmj.326.7383.257			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644FY	12560278	Bronze, Green Published			2023-01-03	WOS:000180908300021
J	Rogina, B; Helfand, SL; Frankel, S				Rogina, B; Helfand, SL; Frankel, S			Longevity regulation by Drosophila Rpd3 deacetylase and caloric restriction	SCIENCE			English	Article							HISTONE DEACETYLASE; LIFE-SPAN		Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, New Haven, CT 06536 USA; Univ Connecticut, Ctr Hlth, Sch Med, Dept Genet & Dev Biol, Farmington, CT 06030 USA	Yale University; University of Connecticut	Frankel, S (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, 295 Congress Ave, New Haven, CT 06536 USA.	stewart.frankel@yale.edu		Rogina, Blanka/0000-0003-1195-905X	NATIONAL INSTITUTE ON AGING [R37AG016667] Funding Source: NIH RePORTER; NIA NIH HHS [R37 AG016667] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; DORN R, 1986, CHROMOSOMA, V93, P398, DOI 10.1007/BF00285820; Kang HL, 2002, P NATL ACAD SCI USA, V99, P838, DOI 10.1073/pnas.022631999; Kim S, 1999, MOL BIOL CELL, V10, P3125, DOI 10.1091/mbc.10.10.3125; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; PLETCHER S, COMMUNICATION; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3	9	209	227	3	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1745	1745		10.1126/science.1078986	http://dx.doi.org/10.1126/science.1078986			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459580				2023-01-03	WOS:000179494800032
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Woolf, SH		US Preventive Services Task Force	Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale	ANNALS OF INTERNAL MEDICINE			English	Article							ESTROGEN-PROGESTIN REPLACEMENT; BREAST-CANCER; ESTROGEN/PROGESTIN REPLACEMENT; PLUS PROGESTIN; OVARIAN-CANCER; FOLLOW-UP; RISK; WOMEN; METAANALYSIS; DISEASE	This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations for use of hormone replacement therapy for the primary prevention of chronic conditions in postmenopausal women and updates the 1996 USPSTF recommendations on this topic. The complete information on which this statement is based, including evidence tables and references, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov) and through the National Guideline Clearinghouse (www.guideline.gov) The USPSTF reviewed the evidence on the use of postmenopausal hormone replacement therapy and the following outcomes: cardiovascular disease, including CHD and stroke; osteoporosis and fractures; thromboembolism; dementia and cognitive function; breast, colon, ovarian, and endometrial cancer; and cholecystitis. The USPSTF also reviewed evidence of the effects of hormone replacement therapy on phytoestrogens and osteoporosis and cardiovascular disease. The use of hormone replacement therapy for relieving active symptoms of menopause, such as hot flashes, urogenital symptoms, and mood and sleep disturbances, among others, is outside the scope of these USPSTF recommendations, and literature on this topic was not reviewed. Sources for estimates of benefits and harms cited in this Recommendation statement are described in the summary of the evidence available from the Agency for Healthcare Research and Quality.	US Prevent Serv Task Force, Agcy Hlth Care Res & Qual Publicat Clearinghouse, Rockville, MD USA		Berg, AO (corresponding author), US Prevent Serv Task Force, Agcy Hlth Care Res & Qual Publicat Clearinghouse, Rockville, MD USA.							*AM ASS CLIN END, 1999, ENDOCR PRACT, V5, P355; *AM COLL OBST GYN, 2002, GUID WOM HLTH CAR, P130; *AM HEART ASS, Q A HORM REPL THER; American Cancer Society, 2002, CANC FACTS FIG; *CAN TASK FORC PER, HLTH CAN; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; HUMPHREY L, 2002, SYSTEMATIC EVIDENCE; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; LEBLANC E, 2002, SYSTEMATIC EVIDENCE; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Miller J, 2002, SYSTEMATIC EVIDENCE, V11; *N AM MEN SOC, REP NAMS ADV PAN POS; Nawaz H, 1999, AM J PREV MED, V17, P250; Nelson HD, 2002, POSTMENOPAUSAL HORMO; Persson I, 1996, INT J CANCER, V67, P327, DOI 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.3.CO;2-J; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SADOVSKY R, 2002, RECENT ANAL HORMONE; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; STEINBERG KK, 1994, EPIDEMIOLOGY, V5, P415, DOI 10.1097/00001648-199407000-00007; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534	30	109	112	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					834	839		10.7326/0003-4819-137-10-200211190-00013	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00013			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616VE	12435221				2023-01-03	WOS:000179323400007
J	Shafran, SD; Mashinter, LD; Phillips, P; Lalonde, RG; Gill, MJ; Walmsley, SL; Toma, E; Conway, B; Fong, IW; Rachlis, AR; Williams, KE; Garber, GE; Schlech, WF; Smaill, F				Shafran, SD; Mashinter, LD; Phillips, P; Lalonde, RG; Gill, MJ; Walmsley, SL; Toma, E; Conway, B; Fong, IW; Rachlis, AR; Williams, KE; Garber, GE; Schlech, WF; Smaill, F			Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; SECONDARY PROPHYLAXIS; AIDS; RESOLUTION; BACTEREMIA; PATIENT; TRIAL	Background: Highly active antiretroviral therapy (HAART) is associated with improvement or resolution of several HIV-associated opportunistic infections. Although prophylaxis against disseminated Mycobacterium avium, complex infection may be successfully discontinued after a favorable response to HAART, the 1999 guidelines from the U.S. Public Health Service/infectious Diseases Society of America recommend continuing therapy for disseminated M. avium complex infection, regardless of the response to HAART. Objective: To examine the outcome among patients with disseminated M. avium complex infection whose antimycobacterial therapy was discontinued after a favorable response to HAART. Design: Retrospective chart review between May 2000 and May 2001. Setting: 13 Canadian HIV clinics. Patients: 52 HIV-infected adults (43 men; mean age, 37.3 years) in whom successful anti mycobacterial therapy for disseminated M. avium, complex infection was discontinued after a favorable virologic response to HAART. Measurements: Survival, survival free of disseminated M. avium complex infection, and CD4(+) cell count responses. Results: At the time of diagnosis of disseminated M. avium, complex infection, the median CD4(+) cell count was 0.016 x 109 cells/L, and the median plasma HIV RNA level was 90 000 copies/mL (plasma HIV RNA levels were available for only 21 patients). The patients received a median of 32 months of antimycobacterial therapy that included ethambutol plus either clarithromycin or azithromycin. When anti mycobacterial therapy was discontinued, the median CD4(+) cell count was 0.23 x 10(9) cells/L and the median plasma HIV RNA level was less than 50 copies/mL. A median of 20 months after discontinuation of antimycobacterial therapy, only 1 patient had developed recurrent M. avium complex disease (37 months after stopping antimycobacterial therapy). This patient had stopped HAART 2 months earlier because of uncontrolled HIV viremia. Twenty months after stopping anti mycobacterial therapy, the other 51 patients had a median CD4(+) cell count of 0.288 x 10(9) cells/L; 34 (67%) had undetectable plasma HIV RNA levels, and 8 (15%) had plasma HIV RNA levels of 50 to 1000 copies/mL. Conclusions: Discontinuation of successful disseminated M. avium complex therapy after a successful response to HAART is safe and reduces patients' pill burdens, potential drug adverse effects, drug interactions, and costs of therapy.	Univ Alberta, Edmonton, AB, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; McGill Univ, Montreal, PQ, Canada; Univ Montreal, Montreal, PQ, Canada; Univ Calgary, Calgary, AB, Canada; Univ Toronto, Toronto, ON, Canada; Univ Saskatchewan, Saskatoon, SK, Canada; Univ Ottawa, Ottawa, ON, Canada; Dalhousie Univ, Halifax, NS, Canada; McMaster Univ, Hamilton, ON, Canada	University of Alberta; University of British Columbia; McGill University; Universite de Montreal; University of Calgary; University of Toronto; University of Saskatchewan; University of Ottawa; Dalhousie University; McMaster University	Shafran, SD (corresponding author), Univ Alberta Hosp, Div Infect Dis, 8440 112 St,WMC 2E4-16, Edmonton, AB T6G 2B7, Canada.	shafran@uah.ualberta.ca	Dodsley, Maria/G-7083-2016; Gill, Michael John/G-7083-2016	Dodsley, Maria/0000-0001-7587-558X; Walmsley, Sharon/0000-0002-3959-5692; Gill, Michael John/0000-0002-8546-8790				Aberg JA, 1998, J INFECT DIS, V178, P1446, DOI 10.1086/314469; Carr A, 1998, LANCET, V351, P256, DOI 10.1016/S0140-6736(97)07529-6; Cinti SK, 2000, CLIN INFECT DIS, V30, P511, DOI 10.1086/313705; Currier JS, 2000, ANN INTERN MED, V133, P493, DOI 10.7326/0003-4819-133-7-200010030-00008; de Quiros JCLB, 2001, NEW ENGL J MED, V344, P159, DOI 10.1056/NEJM200101183440301; El-Sadr WM, 2000, NEW ENGL J MED, V342, P1085, DOI 10.1056/NEJM200004133421503; Guex AC, 2000, CLIN INFECT DIS, V30, P602, DOI 10.1086/313733; Hadad DJ, 1998, CLIN INFECT DIS, V26, P758, DOI 10.1086/514577; Hicks CB, 1997, CLIN INFECT DIS, V24, P1023, DOI 10.1093/clinids/24.5.1023; KAPLAN JE, 1995, CLIN INFECT DIS    S, V1, pS1; KEMPER CA, 1994, J INFECT DIS, V170, P488, DOI 10.1093/infdis/170.2.488; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; Martinez E, 1999, AIDS, V13, P147; Masur H, 1999, ANN INTERN MED, V131, P873, DOI 10.7326/0003-4819-131-11-199912070-00022; Miralles P, 1998, AIDS, V12, P2467, DOI 10.1097/00002030-199818000-00016; Murray R, 2001, EUR J CLIN MICROBIOL, V20, P199, DOI 10.1007/PL00011252; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Soriano V, 2000, AIDS, V14, P383, DOI 10.1097/00002030-200003100-00011; *USPHS IDSA PREV O, 2002, 2001 USPHS IDSA GUID; Zingman BS, 1996, NEW ENGL J MED, V334, P1674, DOI 10.1056/NEJM199606203342516	20	28	28	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2002	137	9					734	737		10.7326/0003-4819-137-9-200211050-00008	http://dx.doi.org/10.7326/0003-4819-137-9-200211050-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612BA	12416943				2023-01-03	WOS:000179052400004
J	Adams, KE; Cohen, MH; Eisenberg, D; Jonsen, AR				Adams, KE; Cohen, MH; Eisenberg, D; Jonsen, AR			Ethical considerations of complementary and alternative medical therapies in conventional medical settings	ANNALS OF INTERNAL MEDICINE			English	Article							ST JOHNS WORT; PHYSICIANS	Increasing use of complementary and alternative medical (CAM) therapies by patients, health care providers, and institutions has made it imperative that physicians consider their ethical obligations when recommending, tolerating, or proscribing these therapies. The authors present a risk-benefit framework that can be applied to determine the appropriateness of using CAM therapies in various clinical scenarios. The major relevant issues are the severity and acuteness of illness; the curability of the illness by conventional forms of treatment; the degree of invasiveness, associated toxicities, and side effects of the conventional treatment; the availability and quality of evidence of utility and safety of the desired CAM treatment; the level of understanding of risks and benefits of the CAM treatment combined with the patient's knowing and voluntary acceptance of those risks; and the patient's persistence of intention to use CAM therapies. Even in the absence of scientific evidence for CAM therapies, by considering these relevant issues, providers can formulate a plan that is clinically sound, ethically appropriate, and targeted to the unique circumstances of individual patients. Physicians are encouraged to remain engaged in problem-solving with their patients and to attempt to elucidate and clarify the patient's core values and beliefs when counseling about CAM therapies.	Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, UHNSO, Portland, OR 97239 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Med Ctr, Seattle, WA 98195 USA	Oregon Health & Science University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle	Adams, KE (corresponding author), Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, UHNSO, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	adamsk@ohsu.edu						Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; COHEN M, 2000, COMPLEMENTARY MED LE; Cohen MH, 2002, ANN INTERN MED, V136, P596, DOI 10.7326/0003-4819-136-8-200204160-00009; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; EISENBERG DM, IN PRESS ANN INTERN; EISENBERG DM, 1996, HARVARD MED ALUMNI B, V70, P20; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; FUGHBERMAN A, 1997, ALTERNATIVE MED WHAT; Jonsen A. R., 1992, CLIN ETHICS; JONSEN AR, 1995, KENNEDY INST ETHIC J, V5, P237; JONSEN AR, 1997, INTRO HIST METHODS P, P158; KOTTOW MH, 1992, J MED ETHICS, V18, P18, DOI 10.1136/jme.18.1.18; Kramer N, 1999, RHEUM DIS CLIN N AM, V25, P833, DOI 10.1016/S0889-857X(05)70104-6; Long L, 2001, COMPLEMENT THER MED, V9, P178, DOI 10.1054/ctim.2001.0453; MAY WF, 1983, PHYSICIANS COVENANT; National Institutes of Health, 1995, INT BEH REL APPR TRE, P1; ORNISH D, 1983, JAMA-J AM MED ASSOC, V249, P54, DOI 10.1001/jama.249.1.54; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Ramsey P., 1970, PATIENT PERSON EXPLO; Spencer JW, 1999, COMPLEMENTARY ALTERN, P3; SPIEGEL D, 1989, LANCET, V2, P888; Studdert DM, 1998, JAMA-J AM MED ASSOC, V280, P1610, DOI 10.1001/jama.280.18.1610	30	75	77	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2002	137	8					660	664		10.7326/0003-4819-137-8-200210150-00010	http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604WL	12379066				2023-01-03	WOS:000178644000005
J	Lowenberg, B; van Putten, W; Theobald, M; Gmur, J; Verdonck, L; Sonneveld, P; Fey, M; Schouten, H; de Greef, G; Ferrant, A; Kovacsovics, T; Gratwohl, A; Daenen, S; Huijgens, P; Boogaerts, M				Lowenberg, B; van Putten, W; Theobald, M; Gmur, J; Verdonck, L; Sonneveld, P; Fey, M; Schouten, H; de Greef, G; Ferrant, A; Kovacsovics, T; Gratwohl, A; Daenen, S; Huijgens, P; Boogaerts, M		HOVON Cooperative Grp; Swiss Grp Clin Canc Res	Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMATOPOIETIC GROWTH-FACTORS; ACUTE MYELOGENOUS LEUKEMIA; FACTOR GM-CSF; ACUTE MYELOBLASTIC-LEUKEMIA; DOSE ARA-C; CYTOSINE-ARABINOSIDE; INDUCTION CHEMOTHERAPY; EUROPEAN ORGANIZATION; ELDERLY PATIENTS; IN-VITRO	BACKGROUND Sensitization of leukemic cells with hematopoietic growth factors may enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML). METHODS In a multicenter randomized trial, we assigned patients (age range, 18 to 60 years) with newly diagnosed AML to receive cytarabine plus idarubicin (cycle 1) and cytarabine plus amsacrin (cycle 2) with granulocyte colony-stimulating factor (G-CSF) (321 patients) or without G-CSF (319). G-CSF was given concurrently with chemotherapy only. Idarubicin and amsacrin were given at the end of a cycle to allow the cell-cycle-dependent cytotoxicity of cytarabine in the context of G-CSF to have a greater effect. The effect of G-CSF on disease-free survival was assessed in all patients and in cytogenetically distinct prognostic subgroups. RESULTS After induction chemotherapy, the rates of response were not significantly different in the two groups. After a median follow-up of 55 months, patients in complete remission after induction chemotherapy plus G-CSF had a higher rate of disease-free survival than patients who did not receive G-CSF (42 percent vs. 33 percent at four years, P=0.02), owing to a reduced probability of relapse (relative risk, 0.77; 95 percent confidence interval, 0.61 to 0.99; P=0.04). G-CSF did not significantly improve overall survival (P=0.16). Although G-CSF did not improve the outcome in the subgroup with an unfavorable prognosis, the 72 percent of patients with standard-risk AML benefited from G-CSF therapy (overall survival at four years, 45 percent, as compared with 35 percent in the group that did not receive G-CSF [relative risk of death, 0.75; 95 percent confidence interval, 0.59 to 0.95; P=0.02]; disease-free survival, 45 percent vs. 33 percent [relative risk, 0.70]; 95 percent confidence interval, 0.55 to 0.90; P=0.006). CONCLUSIONS Sensitization of leukemic cells with growth factors is a clinically applicable means of enhancing the efficacy of chemotherapy in patients with AML.	Erasmus Univ, Med Ctr, Dept Hematol, NL-3000 CA Rotterdam, Netherlands; Erasmus Univ, Med Ctr, HOVON Data Ctr, NL-3000 CA Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Stat, NL-3000 CA Rotterdam, Netherlands; Johannes Gutenberg Univ Mainz, Univ Hosp, Dept Hematol & Oncol, D-6500 Mainz, Germany; Hirslanden Klin Pk, Onkozentrum, Zurich, Switzerland; Univ Med Ctr, Dept Hematol, Utrecht, Netherlands; Univ Bern, Inst Med Oncol, Bern, Switzerland; Univ Bern, Inselspital, CH-3010 Bern, Switzerland; Univ Hosp, Dept Internal Oncol & Hematol, Maastricht, Netherlands; Clin Univ St Luc, Dept Hematol, B-1200 Brussels, Belgium; Univ Hosp, Div Hematol, Lausanne, Switzerland; Kantonsspital, Div Hematol, CH-4031 Basel, Switzerland; Univ Groningen, Univ Med Ctr Groningen, Univ Hosp, Dept Hematol, Groningen, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands; Catholic Univ Louvain, Hosp Gasthuisberg, Dept Hematol, B-3000 Louvain, Belgium	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Johannes Gutenberg University of Mainz; University Hospital Mainz; Utrecht University; Utrecht University Medical Center; University of Bern; University of Bern; Maastricht University; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Kantonsspital Aarau AG (KSA); University of Basel; University of Groningen; Vrije Universiteit Amsterdam; Universite Catholique Louvain	Lowenberg, B (corresponding author), Erasmus Univ, Med Ctr, Dept Hematol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	b.lowenberg@erasmusmc.nl						Baer MR, 1996, BLOOD, V87, P1484, DOI 10.1182/blood.V87.4.1484.bloodjournal8741484; BHALLA K, 1991, BLOOD, V78, P2674; BHALLA K, 1988, LEUKEMIA, V2, P810; Bishop JF, 1996, BLOOD, V87, P1710, DOI 10.1182/blood.V87.5.1710.bloodjournal8751710; BOEKHORST PAWT, 1993, LEUKEMIA, V7, P1191; CANNISTRA SA, 1989, LEUKEMIA, V3, P328; CANNISTRA SA, 1991, LEUKEMIA, V5, P230; ESTEY E, 1992, BLOOD, V79, P2246; Estey EH, 1999, BLOOD, V93, P2478, DOI 10.1182/blood.V93.8.2478.408k04_2478_2484; FRENETTE PS, 1995, AM J HEMATOL, V49, P48, DOI 10.1002/ajh.2830490109; INATOMI Y, 1994, CANCER RES, V54, P455; LISTA P, 1988, BRIT J HAEMATOL, V70, P121, DOI 10.1111/j.1365-2141.1988.tb02444.x; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Lowenberg B, 1997, J CLIN ONCOL, V15, P3496; Lowenberg B, 2001, BEST PRACT RES CL HA, V14, P65, DOI 10.1053/beha.2000.0116; Lowenberg B, 1997, BLOOD, V90, P2952; LOWENBERG B, 1993, BLOOD, V81, P281; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; Mitelman F, 1995, ICSN 1995 INT SYSTEM; MIYAUCHI J, 1989, BLOOD, V73, P1272; Mrozek K, 1997, SEMIN ONCOL, V24, P17; Ohno R, 1998, LEUKEMIA RES, V22, P1143, DOI 10.1016/S0145-2126(98)00117-9; OHNO R, 1994, BLOOD, V83, P2086; REUTER C, 1994, LEUKEMIA, V8, P217; Rossi HA, 2002, LEUKEMIA, V16, P310, DOI 10.1038/sj.leu.2402368; Schiffer CA, 1996, BLOOD, V88, P3675, DOI 10.1182/blood.V88.10.3675.bloodjournal88103675; TANAKA M, 1993, LEUKEMIA RES, V17, P585, DOI 10.1016/0145-2126(93)90089-4; TEBOEKHORST PAW, 1994, LEUKEMIA, V8, P1480; Terpstra W, 1997, LEUKEMIA, V11, P315, DOI 10.1038/sj.leu.2400561; Wheatley K, 1999, BRIT J HAEMATOL, V107, P69, DOI 10.1046/j.1365-2141.1999.01684.x; Witz F, 1998, BLOOD, V91, P2722; Zittoun R, 1996, J CLIN ONCOL, V14, P2150, DOI 10.1200/JCO.1996.14.7.2150	32	308	322	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					743	752		10.1056/NEJMoa025406	http://dx.doi.org/10.1056/NEJMoa025406			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930926	Green Published, Bronze			2023-01-03	WOS:000184843300004
J	Grady, D				Grady, D			Postmenopausal hormones - Therapy for symptoms only	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							QUALITY-OF-LIFE; ESTROGEN/PROGESTIN REPLACEMENT; HEART; TRIAL; WOMEN		Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; San Francisco Vet Affairs Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Grady, D (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.							Grady D, 2002, AM J MED, V113, P543, DOI 10.1016/S0002-9343(02)01270-6; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; MacLennan A, 2001, Climacteric, V4, P58, DOI 10.1080/713605036; WIKLUND I, 1993, AM J OBSTET GYNECOL, V168, P824, DOI 10.1016/S0002-9378(12)90828-5	5	72	76	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1835	1837		10.1056/NEJMp030038	http://dx.doi.org/10.1056/NEJMp030038			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675FY	12642636				2023-01-03	WOS:000182684100001
J	Batlle, JC				Batlle, JC			Legal status of physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; EUTHANASIA; CONSULTATION; OREGON; DEATH		Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Batlle, JC (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							BAILE WF, 1993, CANCER, V72, P2786, DOI 10.1002/1097-0142(19931101)72:9<2786::AID-CNCR2820720942>3.0.CO;2-2; Cantor NL, 2001, J LAW MED ETHICS, V29, P182; Cohen-Almagor R, 2002, J LAW MED ETHICS, V30, P95, DOI 10.1111/j.1748-720X.2002.tb00725.x; *DEP JUST OFF ATT, 2001, 25342001 AG DEP JUST; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2002, ARCH INTERN MED, V162, P142, DOI 10.1001/archinte.162.2.142; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Hamerly JP, 1998, AM J HEALTH-SYST PH, V55, P543, DOI 10.1093/ajhp/55.6.543; Lindsay RA, 2002, J LAW MED ETHICS, V30, P6, DOI 10.1111/j.1748-720X.2002.tb00714.x; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; New York State Task Force on Life and the Law, 1994, DEATH IS SOUGHT ASS; Onwuteaka-Philipsen BD, 2001, J MED ETHICS, V27, P331; PRETTY D, RIGHT DIE CASE EUROP; Sullivan AD, 2001, NEW ENGL J MED, V344, P605, DOI 10.1056/NEJM200102223440811	14	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2279	2281		10.1001/jama.289.17.2279	http://dx.doi.org/10.1001/jama.289.17.2279			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675ET	12734142				2023-01-03	WOS:000182680700033
J	McCarthy, EP; Burns, RB; Ngo-Metzger, Q; Davis, RB; Phillips, RS				McCarthy, EP; Burns, RB; Ngo-Metzger, Q; Davis, RB; Phillips, RS			Hospice use among Medicare managed care and fee-for-service patients dying with cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	25th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 2002	ATLANTA, GEORGIA	Soc Gen Internal Med			ILL PATIENTS; PALLIATIVE CARE; LIFE; HMO; REIMBURSEMENT; OUTCOMES; SYSTEMS; DEATH; END	Context For most patients aged 65 years or older with cancer, hospice services are uniformly covered by Medicare. Hospice care is believed to improve care for patients at the end of life. However, few patients use hospice and others enroll too late to maximize the benefits of hospice services. Objectives Because type of insurance may affect use, we examined whether patients with Medicare managed care insurance enrolled in hospice earlier and had longer hospice stays than patients with Medicare fee-for-service (FFS) insurance. Design and Setting Retrospective analysis of the last year of life using the Linked Medicare-Tumor Registry Database in 1 of 9 Surveillance, Epidemiology, and End Results program coverage areas. Patients A total of 260090 Medicare beneficiaries aged 66 years or older diagnosed with first primary lung (n=62 117), colorectal (n=57 260), prostate (n=59 826), female breast (n =37 609), bladder (n =19 598), pancreatic (n =11 378), gastric (n =9599), or liver (n=2703) cancer between January 1, 1973, and December 31, 1996, and who died between January 1, 1988, and December 31, 1998. Main Outcome Measures Time from diagnosis to hospice entry and hospice length of stay for patients enrolled in FFS vs managed care plans after adjusting for patient demographics, tumor registry, year of hospice entry, and type and cancer stage. Results Of the 260090 patients, most were men (59%), white (85%), and enrolled in FFS (89.7%). Only 54937 patients (21.1%) received hospice care before death. Hospice use varied by type of primary cancer ranging from 31.8% of patients with pancreatic cancer to 15.6% with bladder cancer. Managed care patients were more likely to use hospice than FFS patients (32.4% vs 19.8%, P<.001). Among hospice patients, median (interquartile range) length of stay was longer for managed care vs FFS patients (32 days [11-82] vs 25 days [9-66], P<.001). After adjustment, managed care patients had higher rates of hospice enrollment (adjusted hazard ratio [HR], 1.38; 95% CI, 1.35-1.42) and had a longer length of stay (adjusted HR, 0.91; 95% CI, 0.88-0.94) vs FFS patients. Managed care patients were less likely to enroll in hospice within 7 days of their death (18.6% vs 22.6%, P<.001) and somewhat more likely to enroll in hospice more than 180 days before death (7.8% vs 6.1 %, P<.001); the results for each of the 8 cancer diagnoses were similar. Hospice enrollment and length of stay among managed care vs FFS patients differed significantly by region. Conclusion Medicare beneficiaries enrolled in managed care had consistently higher rates of hospice use and significantly longer hospice stays than those enrolled in FFS. Although these differences may reflect patient and family preferences, our findings raise the possibility that some managed care plans are more successful at facilitating or encouraging hospice use for patients dying with cancer.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	McCarthy, EP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, 330 Brookline Ave,Rose 139, Boston, MA 02215 USA.				NCI NIH HHS [5R29 CA79052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA079052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American Cancer Society, 2002, CANC FACTS FIG 2002; BULKIN W, 1988, NEW ENGL J MED, V318, P376, DOI 10.1056/NEJM198802113180609; Cher DJ, 1997, JAMA-J AM MED ASSOC, V278, P1001, DOI 10.1001/jama.278.12.1001; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Cleary JF, 1997, CANCER, V80, P1335, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1335::AID-CNCR21>3.3.CO;2-5; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; *CTR MED MED SERV, 2002, FACT SHEET PROT MED; *CTR MED MED SERV, 2002, US DEP HLTH HUM SERV; *CTR MED MED SERV, 2000, US DEP HLTH HUM SERV; Curtis JR, 1997, JAMA-J AM MED ASSOC, V278, P1025, DOI 10.1001/jama.278.12.1025; Emanuel EJ, 2002, ARCH INTERN MED, V162, P1722, DOI 10.1001/archinte.162.15.1722; *GEN ACC OFF, 2000, MED MOR BEN US HOSP; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; Kinzbrunner B M, 1998, J Palliat Med, V1, P127, DOI 10.1089/jpm.1998.1.127; Lamont EB, 2002, CANCER, V94, P2733, DOI 10.1002/cncr.10530; Lee E, 2013, STAT METHODS SURVIVA; LEVY MH, 1993, J NATL CANCER I, V85, P1283, DOI 10.1093/jnci/85.16.1283; McCarthy EP, 2003, J CLIN ONCOL, V21, P728, DOI 10.1200/JCO.2003.06.142; MILES SH, 1995, WESTERN J MED, V163, P302; Morgan RO, 1997, NEW ENGL J MED, V337, P169, DOI 10.1056/NEJM199707173370306; *NAT HOSP PALL CAR, 2002, DEV QUAL CAR COST EF; Neuman P, 1998, HEALTH AFFAIR, V17, P132, DOI 10.1377/hlthaff.17.4.132; POTOSKY AL, 1993, MED CARE, V31, P732; Randal J, 1996, J NATL CANCER I, V88, P860, DOI 10.1093/jnci/88.13.860; Riley G, 1996, HEALTH CARE FINANC R, V17, P65; Steinberg S M, 1998, J Palliat Med, V1, P387, DOI 10.1089/jpm.1998.1.387; SULMASY DP, 1995, ARCH INTERN MED, V155, P133, DOI 10.1001/archinte.155.2.133; Virnig B A, 1999, Hosp J, V14, P1; Virnig BA, 2001, AM J MANAG CARE, V7, P777; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027	32	107	108	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2238	2245		10.1001/jama.289.17.2238	http://dx.doi.org/10.1001/jama.289.17.2238			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675ET	12734135	Bronze			2023-01-03	WOS:000182680700026
J	Wormser, GP; Ramanathan, R; Nowakowski, J; McKenna, D; Holmgren, D; Visintainer, P; Dornbush, R; Singh, B; Nadelman, RB				Wormser, GP; Ramanathan, R; Nowakowski, J; McKenna, D; Holmgren, D; Visintainer, P; Dornbush, R; Singh, B; Nadelman, RB			Duration of antibiotic therapy for early Lyme disease - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ERYTHEMA MIGRANS; BORRELIA-BURGDORFERI; CEFUROXIME AXETIL; DOXYCYCLINE; INFECTION	Background: Treatment of patients with early Lyme disease has trended toward longer duration despite the absence of supporting clinical trials. Objective: To evaluate different durations of oral doxycycline treatment and the combination of oral doxycycline and a single intravenous dose of ceftriaxone for treatment of patients with early Lyme disease. Design: Randomized, double-blind, placebo-controlled trial. Setting: Single-center university hospital. Patients: 180 patients with erythema migrans. Intervention: Ten days of oral doxycycline, with or without a single intravenous dose of ceftriaxone, or 20 days of oral doxycycline. Measurements: Outcome was based on clinical observations and neurocognitive testing. Efficacy was assessed at 20 days, 3 months, 12 months, and 30 months. Results: At all time points, the complete response rate was similar for the three treatment groups in both on-study and intention-to-treat analyses. In the on-study analysis, the complete response rate at 30 months was 83.9% in the 20-day doxycycline group, 90.3% in the 10-day doxycycline group, and 86.5% in the doxycycline-ceftriaxone group (P > 0.2). The only patient with treatment failure (10-day doxycycline group) developed meningitis on day 18. There were no significant differences in the results of neurocognitive testing among the three treatment groups and a separate control group without Lyme disease. Diarrhea occurred significantly more often in the doxycycline-ceftriaxone group (35%) than in either of the other two groups (P < 0.001). Conclusions: Extending treatment with doxycycline from 10 to 20 days or adding one dose of ceftriaxone to the beginning of a 10-day course of doxycycline did not enhance therapeutic efficacy in patients with erythema migrans. Regardless of regimen, objective evidence of treatment failure was extremely rare.	New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA	New York Medical College	Wormser, GP (corresponding author), New York Med Coll, Div Infect Dis, Room 245,Munger Pavil, Valhalla, NY 10595 USA.		Ahluwalia, Brij/E-4614-2013	Visintainer, Paul/0000-0002-2491-1242	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041508] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR41508] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beck A.T., 1993, BECK DEPRESSION INVE; BUTLER T, 1978, J INFECT DIS, V137, P573, DOI 10.1093/infdis/137.5.573; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P800; Dattwyler RJ, 1997, NEW ENGL J MED, V337, P289, DOI 10.1056/NEJM199707313370501; DEFILIPPIS WA, 1979, BOOKLET CATEGORY TES; Delis D.C., 1987, CALIFORNIA VERBAL LE; Derogatis LR.., 1992, SCL 90 R ADM SCORING; FEKETY FR, 1990, AM J MED, V88, pS38, DOI 10.1016/0002-9343(90)90326-9; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Heaton RK, 1991, COMPREHENSIVE NORMS; Kaplan E., 1983, BOSTON NAMING TEST; Klempner MS, 2001, NEW ENGL J MED, V345, P85, DOI 10.1056/NEJM200107123450202; Luft BJ, 1996, ANN INTERN MED, V124, P785, DOI 10.7326/0003-4819-124-9-199605010-00002; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUGER SW, 1995, ANTIMICROB AGENTS CH, V39, P661, DOI 10.1128/AAC.39.3.661; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; NOWAKOWSKI J, 1995, J AM ACAD DERMATOL, V32, P223, DOI 10.1016/0190-9622(95)90130-2; Smith A., 1982, SYMBOL DIGIT MODALIT; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 2000, MANDELL DOUGLAS BENN, P2504; Strle F, 1999, ANN INTERN MED, V130, P32, DOI 10.7326/0003-4819-130-1-199901050-00006; Wechsler D, 1974, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL; Wormser GP, 1999, J INFECT DIS, V180, P720, DOI 10.1086/314922; WORMSER GP, 1995, MT SINAI J MED, V62, P188; 2001, MMWR MORB MORTAL WKL, V50, P181; 1997, MMWR MORB MO SRR10, V46, P20	27	167	173	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					697	704		10.7326/0003-4819-138-9-200305060-00005	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729423				2023-01-03	WOS:000182661400001
J	Hubbell, JA				Hubbell, JA			Enhancing drug function	SCIENCE			English	Editorial Material							COPOLYMER MICELLES; DELIVERY; TRANSDUCTION; CELLS; GENE		Swiss Fed Inst Technol, Inst Biomed Engn, CH-8044 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Mat Sci, CH-8044 Zurich, Switzerland; Univ Zurich, CH-8044 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Hubbell, JA (corresponding author), Swiss Fed Inst Technol, Inst Biomed Engn, Moussonstr 18, CH-8044 Zurich, Switzerland.		Hubbell, Jeffrey A/A-9266-2008	Hubbell, Jeffrey A/0000-0003-0276-5456				BADER H, 1984, ANGEW MAKROMOL CHEM, V123, P457, DOI 10.1002/apmc.1984.051230121; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; Jensen KD, 2003, J CONTROL RELEASE, V87, P89, DOI 10.1016/S0168-3659(02)00352-8; Kabanov AV, 2003, ADV DRUG DELIVER REV, V55, P151, DOI 10.1016/S0169-409X(02)00176-X; Kakizawa Y, 2002, ADV DRUG DELIVER REV, V54, P203, DOI 10.1016/S0169-409X(02)00017-0; Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c; Luo LB, 2002, BIOCONJUGATE CHEM, V13, P1259, DOI 10.1021/bc025524y; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0; Rapoport N, 2002, J PHARM SCI, V91, P157, DOI 10.1002/jps.10006; Savic R, 2003, SCIENCE, V300, P615, DOI 10.1126/science.1078192; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Wagner E, 1999, ADV DRUG DELIVER REV, V38, P279, DOI 10.1016/S0169-409X(99)00033-2; Zastre J, 2002, EUR J PHARM BIOPHARM, V54, P299, DOI 10.1016/S0939-6411(02)00119-4; Zuber G, 2001, ADV DRUG DELIVER REV, V52, P245, DOI 10.1016/S0169-409X(01)00213-7	15	162	167	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					595	596		10.1126/science.1083625	http://dx.doi.org/10.1126/science.1083625			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714733				2023-01-03	WOS:000182453700029
J	Eknoyan, G; Beck, GJ; Cheung, AK; Daugirdas, JT; Greene, T; Kusek, JW; Allon, M; Bailey, J; Delmez, JA; Depner, TA; Dwyer, JT; Levey, AS; Levin, NW; Milford, E; Ornt, DB; Rocco, MV; Schulman, G; Schwab, SJ; Teehan, BP; Toto, R				Eknoyan, G; Beck, GJ; Cheung, AK; Daugirdas, JT; Greene, T; Kusek, JW; Allon, M; Bailey, J; Delmez, JA; Depner, TA; Dwyer, JT; Levey, AS; Levin, NW; Milford, E; Ornt, DB; Rocco, MV; Schulman, G; Schwab, SJ; Teehan, BP; Toto, R		HEMO Study Grp	Effect of dialysis dose and membrane flux in maintenance hemodialysis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UREA REDUCTION RATIO; STAGE RENAL-DISEASE; MORTALITY; CLEARANCE; MORBIDITY; SURVIVAL; PRODUCT; MODELS; INDEX; REUSE	Background: The effects of the dose of dialysis and the level of flux of the dialyzer membrane on mortality and morbidity among patients undergoing maintenance hemodialysis are uncertain. Methods: We undertook a randomized clinical trial in 1846 patients undergoing thrice-weekly dialysis, using a two-by-two factorial design to assign patients randomly to a standard or high dose of dialysis and to a low-flux or high-flux dialyzer. Results: In the standard-dose group, the mean (+/-SD) urea-reduction ratio was 66.3+/-2.5 percent, the single-pool Kt/V was 1.32+/-0.09, and the equilibrated Kt/V was 1.16+/-0.08; in the high-dose group, the values were 75.2+/-2.5 percent, 1.71+/-0.11, and 1.53+/-0.09, respectively. Flux, estimated on the basis of beta(sub 2)-microglobulin clearance, was 3+/-7 ml per minute in the low-flux group and 34+/-11 ml per minute in the high-flux group. The primary outcome, death from any cause, was not significantly influenced by the dose or flux assignment: the relative risk of death in the high-dose group as compared with the standard-dose group was 0.96 (95 percent confidence interval, 0.84 to 1.10; P=0.53), and the relative risk of death in the high-flux group as compared with the low-flux group was 0.92 (95 percent confidence interval, 0.81 to 1.05; P=0.23). The main secondary outcomes (first hospitalization for cardiac causes or death from any cause, first hospitalization for infection or death from any cause, first 15 percent decrease in the serum albumin level or death from any cause, and all hospitalizations not related to vascular access) also did not differ significantly between either the dose groups or the flux groups. Possible benefits of the dose or flux interventions were suggested in two of seven prespecified subgroups of patients. Conclusions: Patients undergoing hemodialysis thrice weekly appear to have no major benefit from a higher dialysis dose than that recommended by current U.S. guidelines or from the use of a high-flux membrane.	Cleveland Clin Fdn, Dept Biostat & Epidemiol, HEMO Data Coordinating Ctr, Cleveland, OH 44195 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Utah, Salt Lake City, UT USA; Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA; Univ Illinois, Chicago, IL USA; Vet Affairs Chicago Hlth Care Syst, Chicago, IL USA; NIDDKD, Bethesda, MD 20892 USA; Univ Alabama Birmingham, Birmingham, AL USA; Emory Univ Hosp, Atlanta, GA 30322 USA; Washington Univ, St Louis, MO USA; Univ Calif Davis, Sacramento, CA 95817 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Beth Israel Deaconess Med Ctr, New York, NY 10003 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Rochester, Rochester, NY USA; Wake Forest Univ, Winston Salem, NC 27109 USA; Vanderbilt Univ, Nashville, TN USA; Duke Univ, Durham, NC USA; Lankenau Hosp & Med Res Ctr, Wynnewood, PA USA; Univ Texas, SW Med Ctr, Dallas, TX USA	Cleveland Clinic Foundation; Baylor College of Medicine; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Alabama System; University of Alabama Birmingham; Emory University; Washington University (WUSTL); University of California System; University of California Davis; Tufts Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; University of Rochester; Wake Forest University; Vanderbilt University; Duke University; Lankenau Medical Center; Lankenau Institute for Medical Research; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Beck, GJ (corresponding author), Cleveland Clin Fdn, Dept Biostat & Epidemiol, HEMO Data Coordinating Ctr, Wb4,9500 Euclid Ave, Cleveland, OH 44195 USA.	beckg@ccf.org	Dwyer, Johanna/AAI-5027-2020; Toto, Robert/AAQ-3336-2021	Dwyer, Johanna/0000-0002-0783-1769				Cheung AK, 1999, J AM SOC NEPHROL, V10, P117; COLLINS A, 1994, AM J KIDNEY DIS, V24, P157; COX DR, 1972, J R STAT SOC B, V34, P187; DAUGIRDAS JT, 1995, ASAIO J, V41, pM719, DOI 10.1097/00002480-199507000-00107; Depner TA., 1991, PRESCRIBING HEMODIAL, V2nd Ed.; Dunn D, 2002, CONTROL CLIN TRIALS, V23, P106, DOI 10.1016/S0197-2456(01)00200-8; Eknoyan G, 1997, KIDNEY INT, V52, P1395; Eknoyan G, 1996, SEMIN DIALYSIS, V9, P24, DOI 10.1111/j.1525-139X.1996.tb00897.x; Eknoyan G, 2001, AM J KIDNEY DIS, V37, P179, DOI 10.1016/S0272-6386(01)80074-3; Eknoyan G, 2001, AM J KIDNEY DIS, V37, pS5, DOI 10.1016/S0272-6386(01)70004-2; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Greene T, 2000, CONTROL CLIN TRIALS, V21, P502, DOI 10.1016/S0197-2456(00)00062-3; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; HORNBERGER JC, 1992, J AM SOC NEPHROL, V3, P1227; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Leypoldt JK, 1997, ASAIO J, V43, P904, DOI 10.1097/00002480-199711000-00011; Li ZS, 2000, AM J KIDNEY DIS, V35, P598, DOI 10.1016/S0272-6386(00)70004-7; Locatelli F, 1999, KIDNEY INT, V55, P286, DOI 10.1046/j.1523-1755.1999.00236.x; LOWRIE EG, 1981, NEW ENGL J MED, V305, P1176, DOI 10.1056/NEJM198111123052003; Lowrie EG, 1999, KIDNEY INT, V56, P729, DOI 10.1046/j.1523-1755.1999.00584.x; McCullagh P., 1989, GEN LINEAR MODELS; Miskulin DC, 2001, KIDNEY INT, V60, P1498, DOI 10.1046/j.1523-1755.2001.00954.x; Mohr PE, 2001, AM J KIDNEY DIS, V37, P777, DOI 10.1016/S0272-6386(01)80127-X; *NAT I DIAB DIG KI, 1999, HEMO STUD PROT; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Owen WF, 1998, JAMA-J AM MED ASSOC, V280, P1764, DOI 10.1001/jama.280.20.1764; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P50; Port FK, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341061; Port FK, 2001, AM J KIDNEY DIS, V37, P276, DOI 10.1053/ajkd.2001.21290; *REN DAT SYST, 2000, USRDS 2000 ANN DAT R; *REN DAT SYST, 2001, USRDS 2001 ANN DAT R; Rocco MV, 2002, AM J KIDNEY DIS, V39, P146, DOI 10.1053/ajkd.2002.29905; Shinzato T, 1997, NEPHROL DIAL TRANSPL, V12, P884, DOI 10.1093/ndt/12.5.884; Vos PF, 2001, AM J KIDNEY DIS, V37, pS99, DOI 10.1053/ajkd.2001.20761; Ward RA, 2000, J AM SOC NEPHROL, V11, P2344, DOI 10.1681/ASN.V11122344; Winchester JF, 2002, ADV RENAL REPLACE TH, V9, P19, DOI 10.1053/jarr.2002.30472; Wolfe RA, 2000, AM J KIDNEY DIS, V35, P80, DOI 10.1016/S0272-6386(00)70305-2	38	1363	1416	5	83	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	2002	347	25					2010	2019		10.1056/NEJMoa021583	http://dx.doi.org/10.1056/NEJMoa021583			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	626LT	12490682				2023-01-03	WOS:000179874500004
J	The, AM; Pasman, R; Onwuteaka-Philipsen, B; Ribbe, M; van der Wal, G				The, AM; Pasman, R; Onwuteaka-Philipsen, B; Ribbe, M; van der Wal, G			Withholding the artificial administration of fluids and food from elderly patients with dementia: ethnographic study	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE	Objective To clarify the practice of withholding the artificial administration of fluids and food from elderly patients with dementia in nursing homes. Design Qualitative, ethnographic study in two phases. Setting 10 wards in two nursing homes in the Netherlands. Participants 35 patients with dementia, eight doctors, 43 nurses, and 32 families. Results The clinical course of dementia was considered normal and was rarely reason to begin the artificial administration of fluids and food in advanced disease. Fluids and food seemed to be given mainly when there was an acute illness or a condition that needed medical treatment and which required hydration to be effective. The medical condition of the patient, the wishes of the family, and the interpretations of the patients' quality of life by their care providers were considered more important than living wills and policy agreements. Conclusions Doctors' decisions about withholding the artificial administration of fluids and food from elderly patients with dementia are influenced more by the clinical course of the illness, the presumed quality of life of the patient, and the patient's medical condition than they are by advanced planning of care. In an attempt to understand the wishes of the patient doctors try to create the broadest possible basis for the decision making process and its outcome, mainly by involving the family.	Free Univ Amsterdam, Med Ctr, Inst Res Extramural Med, Dept Social Med, NL-1081 BT Amsterdam, Netherlands; Inst Res Extramural Med, Dept Nursing Home Med, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	The, AM (corresponding author), Free Univ Amsterdam, Med Ctr, Inst Res Extramural Med, Dept Social Med, NL-1081 BT Amsterdam, Netherlands.		The, Anne-Mei/AAE-3468-2020					Ackerman TF, 1996, J AM GERIATR SOC, V44, P1265, DOI 10.1111/j.1532-5415.1996.tb01383.x; Dyer C, 1999, BRIT MED J, V318, P895; Dyer C, 1999, BRIT MED J, V318, P143, DOI 10.1136/bmj.318.7177.143; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; Huang ZB, 2000, CLIN GERIATR MED, V16, P313, DOI 10.1016/S0749-0690(05)70058-6; KMIETOWICZ Z, 1997, BRIT MED J, V314, P1501; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; ONWUTEAKA BD, 1998, WITHHOLDING ARTIFICI; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Savage J, 2000, BMJ-BRIT MED J, V321, P1400, DOI 10.1136/bmj.321.7273.1400; Sheiman SL, 1996, J AM GERIATR SOC, V44, P1268, DOI 10.1111/j.1532-5415.1996.tb01384.x; Sheldon T, 1997, BRIT MED J, V315, P327; Strauss A., 1990, BASICS GROUNDED THEO; VOLICER I, 1993, CARING MAGAZINE  NOV, P50	15	66	68	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 7	2002	325	7376					1326	1329		10.1136/bmj.325.7376.1326	http://dx.doi.org/10.1136/bmj.325.7376.1326			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	625LC	12468479	Green Published, Bronze			2023-01-03	WOS:000179817100016
J	Shore, B				Shore, B			Grace notes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2231	2231		10.1001/jama.288.18.2231	http://dx.doi.org/10.1001/jama.288.18.2231			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425682				2023-01-03	WOS:000179186400001
J	Hermiz, O; Comino, E; Marks, G; Daffurn, K; Wilson, S; Harris, M				Hermiz, O; Comino, E; Marks, G; Daffurn, K; Wilson, S; Harris, M			Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease	BRITISH MEDICAL JOURNAL			English	Article							AIR-FLOW LIMITATION; RESPIRATORY QUESTIONNAIRE; COPD; EXACERBATIONS; PROGRAM; ASTHMA	Objectives To evaluate usefulness of limited community based care for patients with chronic obstructive pulmonary disease after discharge from hospital. Design Randomised controlled trial. Setting Liverpool Health Service and Macarthur Health Service in outer metropolitan Sydney between September 1999 and July 2000. Participants 177 patients randomised into an intervention group (84 patients) and a control group (93 patients) which received current usual care. Interventions Home visits by community nurse at one and four weeks after discharge and preventive general practitioner care. Main outcome measures Frequency of patients' presentation and admission to hospital; changes in patients' disease-specific quality of life, measured with St George's respiratory questionnaire, over three months after discharge; patients' knowledge of illness, self management, and satisfaction with care at discharge and three months later; frequency of general practitioner and nurse visits and their satisfaction with care. Results Intervention and control groups showed no differences in presentation or admission to hospital or in overall functional status. However, the intervention group improved their activity scores and the control group worsened their symptom scores. While intervention group patients received more visits from community nurses and were more satisfied with their care, involvement of general practitioners was much less (with only 31% (22) remembering receiving a care plan). Patients in the intervention group had higher knowledge scores and were more satisfied. There were no differences in general practitioner visits or management. Conclusions This brief intervention after acute care improved patients' knowledge and some aspects of quality of life. However, it failed to prevent presentation and readmission to hospital.	Univ New S Wales, Sch Community Med, Sydney, NSW 2052, Australia; Liverpool Hlth Serv, Div Crit Care, Sydney, NSW, Australia; SW Sydney Area Hlth Serv, Macarthur Hlth Serv, Sydney, NSW, Australia	University of New South Wales Sydney	Harris, M (corresponding author), Univ New S Wales, Sch Community Med, Sydney, NSW 2052, Australia.		Marks, Guy B./F-5058-2013	Marks, Guy B./0000-0002-8976-8053				Blakeman T, 2001, Aust Fam Physician, V30, P75; Crockett AJ, 1996, QUAL LIFE RES, V5, P330, DOI 10.1007/BF00433917; Crockett AJ, 2000, INT J QUAL HEALTH C, V12, P41, DOI 10.1093/intqhc/12.1.41; Farrero E, 2001, CHEST, V119, P364, DOI 10.1378/chest.119.2.364; Fried TR, 1998, J GEN INTERN MED, V13, P522, DOI 10.1046/j.1525-1497.1998.00162.x; Gallefoss F, 1999, AM J RESP CRIT CARE, V159, P812, DOI 10.1164/ajrccm.159.3.9804047; Gibson P G, 1998, J Qual Clin Pract, V18, P125; GIBSON PG, 1988, J QUAL CLIN PRACT, V18, P125; Gravil JH, 1998, LANCET, V351, P1853, DOI 10.1016/S0140-6736(97)11048-0; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; Keenan SP, 2000, CRIT CARE MED, V28, P2094, DOI 10.1097/00003246-200006000-00072; Ketelaars CAJ, 1998, HEART LUNG, V27, P109, DOI 10.1016/S0147-9563(98)90018-8; Madison JM, 1998, LANCET, V352, P467, DOI 10.1016/S0140-6736(97)11081-9; Rutten-van Molken M, 1999, THORAX, V54, P995; *S W SYDN AR HLTH, 1998, EP UN REP COPD ASTHM; Skwarska E, 2000, THORAX, V55, P907, DOI 10.1136/thorax.55.11.907; SMITH B, 2000, COCHRANE DATABASE SY, DOI UNSP CD000994; Smith BJ, 1999, AUST NZ J MED, V29, P718, DOI 10.1111/j.1445-5994.1999.tb01621.x; Strijbos JH, 1996, CHEST, V109, P366, DOI 10.1378/chest.109.2.366; Tirimanna PRS, 1996, BRIT J GEN PRACT, V46, P277; TRAVER GA, 1988, HEART LUNG, V17, P689; 1987, AM REV RESP DIS, V136, P225	22	110	111	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					938	940C		10.1136/bmj.325.7370.938	http://dx.doi.org/10.1136/bmj.325.7370.938			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399344	Bronze, Green Published			2023-01-03	WOS:000178986300017
J	Falk, SJ; Girling, DJ; White, RJ; Hopwood, P; Harvey, A; Qian, WD; Stephens, RJ				Falk, SJ; Girling, DJ; White, RJ; Hopwood, P; Harvey, A; Qian, WD; Stephens, RJ		Med Res Council Lung Canc Working	Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							CARCINOMA	Objective To determine whether patients with locally advanced non-small cell lung cancer unsuitable for resection or radical radiotherapy, and with minimal thoracic symptoms, should be given palliative thoracic radiotherapy immediately or as needed to treat symptoms. Design Multicentre randomised controlled trial. Setting 23 centres in the United Kingdom, Ireland, and South Africa. Participants 230 patients with previously untreated, non-small cell lung cancer that is locally too advanced for resection or radical radiotherapy with curative intent, with minimal thoracic symptoms, and with no indication for immediate thoracic radiotherapy. Interventions All patients were given supportive treatment and were randomised to receive palliative thoracic radiotherapy either immediately or delayed until needed to treat symptoms. The recommended regimens were 17 Gy in two fractions one week apart or 10 Gy as a single dose. Main outcome measures Primary-patients alive and without moderate or severe cough, chest pain, haemoptysis, or dyspnoea six months from randomisation, as recorded by clinicians. Secondary-quality of life, adverse events, survival. Results From December 1992 to May 1999,230 patients were randomised. 104/115 of the patients in the immediate treatment group received thoracic radiotherapy (90 received one of the recommended regimens). In the delayed treatment group, 48/115 (42%) patients received thoracic radiotherapy (29 received one of the recommended regimens); 64 (56%) died without receiving thoracic radiotherapy; the remaining three (3%) were alive at the end of the study without having received the treatment. For patients who received thoracic radiotherapy, the median time to start was 15 days in the immediate treatment group and 125 days in the delayed treatment group. The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%,95% confidence interval -10.7% to 13.9%). No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients. Adverse events were more common in the immediate treatment group. Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71). Median survival was 8.3 months and 7.9 months, and the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively. Conclusion In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.	Bristol Oncol Ctr, Dept Oncol, Bristol BS2 8ED, Avon, England; MRC, Clin Trials Unit, Canc Div, London NW1 2DA, England; Frenchay Hosp, Dept Gen Med, Bristol BS16 1LE, Avon, England; Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England	Bristol Haematology & Oncology Centre; Medical Research Council Clinical Trials Unit; Christie NHS Foundation Trust; Christie Hospital	Stephens, RJ (corresponding author), Bristol Oncol Ctr, Dept Oncol, Bristol BS2 8ED, Avon, England.							ALBERTI W, 1995, BRIT MED J, V311, P899; BLEEHEN NM, 1992, BRIT J CANCER, V65, P934, DOI 10.1038/bjc.1992.196; BLISS JM, 1991, BRIT J CANCER, V63, P412; BRASHEAR RE, 1978, AM REV RESPIR DIS, V117, P411; CARROLL M, 1986, EUR J CANCER CLIN ON, V22, P1353, DOI 10.1016/0277-5379(86)90144-6; COHEN MH, 1983, CANCER TREAT REP, V67, P333; COX JD, 1983, CANCER TREAT REP, V67, P327; Cullen MH, 1999, J CLIN ONCOL, V17, P3188, DOI 10.1200/JCO.1999.17.10.3188; De Haes J, 1996, ROTTERDAM SYMPTOM CH; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; DURRANT KR, 1971, LANCET, V1, P715; GIRLING DJ, 1991, BRIT J CANCER, V63, P265; Medical Research Council Lung Cancer Working Party, 1996, CLIN ONCOL, V8, P167; PHILLIPS TL, 1978, AM REV RESPIR DIS, V117, P405; ROSWIT B, 1968, RADIOLOGY, V90, P688, DOI 10.1148/90.4.688; Saunders M, 1997, LANCET, V350, P161, DOI 10.1016/S0140-6736(97)06305-8; Timothy AR, 2001, CLIN ONCOL-UK, V13, P86, DOI 10.1053/clon.2001.9224; VANZANDWIJK N, 1985, P 4 WORLD C LUNG CAN, V21, pA355; World Health Organization, 1979, WHO HDB REP RES CANC; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	20	55	57	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 31	2002	325	7362					465	468		10.1136/bmj.325.7362.465	http://dx.doi.org/10.1136/bmj.325.7362.465			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592EZ	12202326	Green Published			2023-01-03	WOS:000177924900018
J	Johnson, AH; Peacock, JL; Greenough, A; Marlow, N; Limb, ES; Marston, L; Calvert, SA				Johnson, AH; Peacock, JL; Greenough, A; Marlow, N; Limb, ES; Marston, L; Calvert, SA		United Kingdom Oscillation Study G	High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; HYALINE-MEMBRANE DISEASE; PRETERM INFANTS; CONVENTIONAL VENTILATION; TRIAL; PRESSURE; INJURY; VOLUME	Background There remains uncertainty concerning the safety and efficacy of high-frequency oscillatory ventilation as compared with those of conventional ventilation for the respiratory support of very preterm infants. We conducted a multicenter trial to determine whether early intervention with high-frequency oscillatory ventilation reduced mortality and the incidence of chronic lung disease among newborns with a gestational age of 28 weeks or less. Methods We randomly assigned preterm infants with a gestational age of :23 to 28 weeks to either conventional ventilation or high-frequency oscillatory ventilation within one hour after birth. Randomization was stratified according to center and gestational age (23 to 25 weeks or 26 to 28 weeks). Results A total of 400 infants were assigned to high-frequency oscillatory ventilation, and 397 were assigned to conventional ventilation. The composite primary outcome (death or chronic lung disease, diagnosed at 36 weeks of postmenstrual age) occurred in 66 percent of the infants assigned to receive high-frequency oscillatory ventilation and 68 percent of those in the conventional-ventilation group (relative risk in the group assigned to high-frequency oscillatory ventilation, 0.98; 95 percent confidence interval, 0.89 to 1.08). Similar proportions of infants died or had chronic lung disease in each gestational-age group. In both treatment groups treatment failure occurred in 10 percent of infants (relative risk in the group assigned to high-frequency oscillatory ventilation, 0.99; 95 percent confidence interval, 0.66 to 1.50). There were no significant differences between the groups in a range of other secondary outcome measures, including serious brain injury and air leak. Conclusions The results obtained with high-frequency oscillatory ventilation and conventional ventilation do not differ significantly in the early treatment of respiratory disease in Very preterm infants. Assessment of long-term effects will require additional follow-up.	Univ London St Georges Hosp, Dept Child Hlth, Sch Med, London SW17 0QT, England; Univ London St Georges Hosp, Dept Publ Hlth Sci, Sch Med, London SW17 0QT, England; Kings Coll Hosp London, Dept Child Hlth, Sch Med, London, England; Univ Nottingham, Acad Div Child Hlth, Sch Human Dev, Nottingham NG7 2RD, England	St Georges University London; St Georges University London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of Nottingham	Calvert, SA (corresponding author), Univ London St Georges Hosp, Dept Child Hlth, Sch Med, 3rd Fl,Lanesborough Wing, London SW17 0QT, England.	scalvert@sghms.ac.uk	Marlow, Neil/D-2918-2009; Marston, Louise/A-8535-2012	Marlow, Neil/0000-0001-5890-2953; Marston, Louise/0000-0002-9973-1131; Greenough, Anne/0000-0002-8672-5349; Peacock, Janet/0000-0002-0310-2518				BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; BRYAN AC, 1991, PEDIATRICS, V87, P565; CLARK RH, 1992, PEDIATRICS, V89, P5; Courtney Sherry E., 2001, Pediatric Research, V49, p387A; DELEMOS RA, 1987, PEDIATR RES, V21, P594, DOI 10.1203/00006450-198706000-00018; Gerstmann DR, 1996, PEDIATRICS, V98, P1044; HAMILTON PP, 1983, J APPL PHYSIOL, V55, P131, DOI 10.1152/jappl.1983.55.1.131; Hatcher D, 1998, CRIT CARE MED, V26, P1081, DOI 10.1097/00003246-199806000-00032; HENDERSONSMART DJ, 2001, COCHRANE LIB; HIFI Study Group, 1989, N Engl J Med, V320, P88; Laubscher B, 1996, BR J INTENS CARE, V6, P148; Marlow N, 1998, ARCH DIS CHILD-FETAL, V78, pF1, DOI 10.1136/fn.78.1.F1; MCCULLOCH PR, 1988, AM REV RESPIR DIS, V137, P1185, DOI 10.1164/ajrccm/137.5.1185; MEREDITH KS, 1989, J APPL PHYSIOL, V66, P2150, DOI 10.1152/jappl.1989.66.5.2150; Moriette G, 2001, PEDIATRICS, V107, P363, DOI 10.1542/peds.107.2.363; OGAWA Y, 1993, EARLY HUM DEV, V32, P1, DOI 10.1016/0378-3782(93)90088-C; Plavka R, 1999, INTENS CARE MED, V25, P68, DOI 10.1007/s001340050789; Rettwitz-Volk W, 1998, J PEDIATR-US, V132, P249, DOI 10.1016/S0022-3476(98)70440-8; *STAT, 2001, STAT VERS 7 0; Thome U, 1999, J PEDIATR-US, V135, P39, DOI 10.1016/S0022-3476(99)70325-2; Thome U, 1998, AM J RESP CRIT CARE, V157, P1213, DOI 10.1164/ajrccm.157.4.9706030	21	216	237	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	2002	347	9					633	642		10.1056/NEJMoa020432	http://dx.doi.org/10.1056/NEJMoa020432			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	587ZT	12200550				2023-01-03	WOS:000177675500002
J	Fromme, E; Billings, JA				Fromme, E; Billings, JA			Care of the dying doctor - On the other end of the stethoscope	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-PATIENT; MEDICAL-PRACTICE; ROLE REVERSAL; HEAL THYSELF; PERSPECTIVE; FAMILIES; ANXIETY; SICK; ILLNESS; QUALITY	The challenges of caring for a dying doctor reflect both common issues in helping the terminally ill and unique problems in working with a physician-patient. The dying doctor must deal with a familiar environment and set of problems from a radically different perspective and must negotiate overlapping and conflicting personal and professional roles. Some of the cardinal virtues of physicians-professional identity, expertise, perfectionism, selflessness, and stoicism-may pose both strengths and liabilities in the patient's role. The treating physicians may also encounter new strains in caring for a colleague. They must guard against both overinvolvement and underinvolvement, and, as with all dying persons, they must serve as a guide through unfamiliar territory for dying patient and family-a companion who is not afraid to listen to or explore the most upsetting matters, a person who can speak frankly when others may be ignoring "the horse on the dining room table." The case of Dr B, an internist dying of myelofibrosis and congestive heart failure, whose son is also a physician, offers the reader the opportunity to reflect on these challenges and to draw lessons about how to best care for fellow physicians at a time of great need. We suggest strategies for negotiating the patient-physician relationship when the patient is also a physician.	Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Oregon Health & Science University; Harvard University; Harvard Medical School	Billings, JA (corresponding author), Massachusetts Gen Hosp, Palliat Care Serv, FND 600,55 Fruit St, Boston, MA 02114 USA.				NATIONAL CANCER INSTITUTE [R25CA082174, R25CA066818] Funding Source: NIH RePORTER; NCI NIH HHS [R25 CA 66818-04, R25 CA 82174-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLIBONE A, 1990, PRACTITIONER, V234, P984; Allibone A, 1981, J R Coll Gen Pract, V31, P728; *AM MED ASS, 1847, DUT PHYS EACH OTH PR, P9; AOUN H, 1992, ANN INTERN MED, V116, P335, DOI 10.7326/0003-4819-116-4-335; Back Anthony L, 2003, Ann Intern Med, V138, P439; Baldwin PJ, 1997, SOC SCI MED, V45, P41, DOI 10.1016/S0277-9536(96)00307-3; Bean RB, 1950, W OSLER APHORISMS HI; Bennet G, 1997, BRIT MED J, V314, P1908, DOI 10.1136/bmj.314.7098.1908; Berwick DM, 1996, ANN INTERN MED, V125, P839, DOI 10.7326/0003-4819-125-10-199611150-00009; BILLINGS J, IN PRESS CECIL TXB M; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P1931, DOI 10.1001/jama.276.24.1931; BONE RC, 1995, JAMA-J AM MED ASSOC, V274, P1656, DOI 10.1001/jama.274.21.1656; BOWES D, 1984, CAN MED ASSOC J, V131, P1343; British Medical Association, 1995, ETH RESP INV TREAT D; Cassell EJ, 1999, ANN INTERN MED, V131, P531, DOI 10.7326/0003-4819-131-7-199910050-00009; CASSELL EJ, 1991, MYSTERIOUS RELATIONS, P66; Chen FM, 2001, J FAM PRACTICE, V50, P762; Choa RG, 1998, BRIT MED J, V316, P1089; COHN KH, 1982, LANCET, V1, P1006; EDELSTEIN EL, 1982, PSYCHIAT CLIN, V15, P177, DOI 10.1159/000283938; ELLARD J, 1974, MED J AUSTRALIA, V2, P318, DOI 10.5694/j.1326-5377.1974.tb70807.x; ENDE J, 1990, J GEN INTERN MED, V5, P506, DOI 10.1007/BF02600881; ENGLISH TL, 1991, JAMA-J AM MED ASSOC, V265, P964, DOI 10.1001/jama.265.8.964; Forsythe M, 1999, BRIT MED J, V319, P605, DOI 10.1136/bmj.319.7210.605; GABBARD GO, 1985, JAMA-J AM MED ASSOC, V254, P2926, DOI 10.1001/jama.254.20.2926; GABBARD GO, 1995, JAMA-J AM MED ASSOC, V273, P1445, DOI 10.1001/jama.273.18.1445; Gallegos K V, 1990, Md Med J, V39, P1007; GLASS GS, 1975, PSYCHIATRY, V38, P132, DOI 10.1080/00332747.1975.11023843; GOLD N, 1972, AUST NZ J PSYCHIAT, V6, P209, DOI 10.3109/00048677209159712; Goldberger JJ, 1997, AM HEART J, V134, P119, DOI 10.1016/S0002-8703(97)70115-7; GROOPMAN J, 1998, NEW YORKER      1026, P78; Gross CP, 2000, ARCH INTERN MED, V160, P3209, DOI 10.1001/archinte.160.21.3209; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; HAEFNER HK, 1994, ANN INTERN MED, V120, P806, DOI 10.7326/0003-4819-120-9-199405010-00013; HEY S, 1994, BRIT MED J, V309, P1235, DOI 10.1136/bmj.309.6963.1235; Horn MO, 1999, ANN INTERN MED, V130, P940, DOI 10.7326/0003-4819-130-11-199906010-00020; HORN MO, 1996, AM J GASTROENTEROL, V91, P1299; INGELFINGER FJ, 1980, NEW ENGL J MED, V303, P1507, DOI 10.1056/NEJM198012253032604; KANE AC, 1985, OMEGA-J DEATH DYING, V16, P11; Kastenbaum R. J., 2001, DEATH SOC HUMAN EXPE; Klein MC, 1997, CAN MED ASSOC J, V156, P53; Lamberg L, 1999, JAMA-J AM MED ASSOC, V282, P13, DOI 10.1001/jama.282.1.13; LAPUMA J, 1992, JAMA-J AM MED ASSOC, V267, P1810, DOI 10.1001/jama.267.13.1810; MARZUK PM, 1987, NEW ENGL J MED, V317, P1409, DOI 10.1056/NEJM198711263172209; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Miller MN, 2000, SOUTH MED J, V93, P966; MOR S, 1995, COGNITIVE THER RES, V19, P207, DOI 10.1007/BF02229695; MORGAN P, 1997, CANC PERSONAL VOYAGE; Mount B M, 1994, J Palliat Care, V10, P24; MULLAN F, 1985, NEW ENGL J MED, V313, P270, DOI 10.1056/NEJM198507253130421; Mullan F, 1983, VITAL SIGNS YOUNG DO; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; OSLER W, 1932, AEQUANIMITAS OTHER A, P2; Poulson J, 1998, NEW ENGL J MED, V338, P1844, DOI 10.1056/NEJM199806183382512; PULLEN D, 1995, MED J AUSTRALIA, V162, P481, DOI 10.5694/j.1326-5377.1995.tb140011.x; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; RABIN D, 1982, NEW ENGL J MED, V307, P506, DOI 10.1056/NEJM198208193070827; ROBBINS GF, 1953, CANCER, V6, P624, DOI 10.1002/1097-0142(195305)6:3<624::AID-CNCR2820060320>3.0.CO;2-0; Rosen IM, 2000, J GEN INTERN MED, V15, P116, DOI 10.1046/j.1525-1497.2000.11218.x; ROSENBAUM EE, 1988, DOCTOR, P42; Scally G, 1996, LANCET, V347, P1059, DOI 10.1016/S0140-6736(96)90273-1; Schneck SA, 1998, JAMA-J AM MED ASSOC, V280, P2039, DOI 10.1001/jama.280.23.2039; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; Sontag Susan, 1983, ILLNESS METAPHOR AID, P59; Spiro HM, 1998, ANN INTERN MED, V128, P152, DOI 10.7326/0003-4819-128-2-199801150-00014; STETTEN D, 1981, NEW ENGL J MED, V305, P458, DOI 10.1056/NEJM198108203050811; STILLMAN AE, 1995, NEW ENGL J MED, V333, P1086, DOI 10.1056/NEJM199510193331618; STOUDEMIRE A, 1983, ANN INTERN MED, V98, P654, DOI 10.7326/0003-4819-98-5-654; Thompson WT, 2001, BRIT MED J, V323, P728, DOI 10.1136/bmj.323.7315.728; Tierney WM, 2002, MED CARE, V40, P20; Toyry S, 2000, ARCH FAM MED, V9, P1079, DOI 10.1001/archfami.9.10.1079; Vachon MLS, 2001, OXFORD TXB PALLIATIV, P919; VAILLANT GE, 1972, NEW ENGL J MED, V287, P372, DOI 10.1056/NEJM197208242870802; Villarosa L, 2001, NY TIMES; Viner E D, 1994, Trends Health Care Law Ethics, V9, P43; Waldron HA, 1996, LANCET, V347, P1558, DOI 10.1016/S0140-6736(96)90712-6; Waldron HA, 1996, ANN OCCUP HYG, V40, P391, DOI 10.1093/annhyg/40.4.391; WEINTRAUB W, 1964, J NERV MENT DIS, V138, P181, DOI 10.1097/00005053-196402000-00012; Wines AP, 1998, AUST NZ J SURG, V68, P778, DOI 10.1111/j.1445-2197.1998.tb04675.x; ZINN WM, 1988, JAMA-J AM MED ASSOC, V259, P3296, DOI 10.1001/jama.259.22.3296; ZINN WM, 1990, ANN INTERN MED, V113, P293, DOI 10.7326/0003-4819-113-4-293; 1972, MED WORLD NEWS, P56	84	23	24	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2048	2055		10.1001/jama.290.15.2048	http://dx.doi.org/10.1001/jama.290.15.2048			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CX	14559959				2023-01-03	WOS:000185924200029
J	Sox, CM; Cooper, WO; Koepsell, TD; DiGiuseppe, DL; Christakis, DA				Sox, CM; Cooper, WO; Koepsell, TD; DiGiuseppe, DL; Christakis, DA			Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPROVING PRIMARY-CARE; PENICILLIN PROPHYLAXIS; ORAL PENICILLIN; PRESCRIPTION; SERVICES; URBAN	Context It is recommended that children younger than 5 years with sickle cell disease (SCD) take daily prophylactic antibiotics to prevent pneumococcal infections; however, how much prophylactic medication they actually are dispensed is unclear. Objectives To measure the amount of prophylactic antibiotics dispensed to young children with SCD and to investigate factors associated with increased delivery of medication. Design, Setting, and Patients Retrospective longitudinal study conducted January 1995 through December 1999 using Tennessee and Washington State Medicaid administrative claims and encounter data. Children (N=261) who had 1 inpatient or 2 outpatient claims or encounters listing an International Classification of Diseases, Ninth Revision, Clinical Modification code for SCD, were younger than 4 years at study entry (mean age, 1.4 years), and were continuously enrolled in Medicaid for a 1-year period. Main Outcome Measure Number of days during a 365-day period covered by prescription fills for a penicillin or macrolide antibiotic, or for trimethoprimsulfamethoxazole. Results In a 365-day period, patients were dispensed a mean of 148.4 (SD, 121.3; median, 114; interquartile range [IQR], 39-247) days of prophylactic medication. The total amount of medication dispensed varied widely: 10.3% of patients received none and 21.5% received more than 270 days of medication. In a 365-day period, a mean of 12.7 (SD, 10.5; range, 0-40) prophylactic prescriptions were filled per patient. The median prescription duration was 10 days. In a multivariate linear regression model adjusting for state, sex, age at study entry, inclusion year, residence in urban community, outpatient inclusion encounter, required prescription co-payment, and number of outpatient visits for nonpreventive care, each preventive visit was associated with 12.0 (95% confidence interval [CI], 2.3-21.7) additional days of prophylactic antibiotics, and each emergency department visit was associated with 10.0 (95% CI, 1.2-18.8) additional days. Conclusions Publicly insured children with SCD may receive inadequate antibiotic prophylaxis against pneumococcal infections, placing them at increased risk of morbidity and mortality; however, increased numbers of outpatient visits for preventive care are associated with improved provision of prophylactic antibiotics.	Univ Washington, Robert Wood Johnson Clin Scholars Program, Hlth Sci Ctr H220, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Inst Child Hlth, Seattle, WA USA; Vanderbilt Univ, Dept Pediat, Nashville, TN USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Vanderbilt University	Sox, CM (corresponding author), Univ Washington, Robert Wood Johnson Clin Scholars Program, Hlth Sci Ctr H220, Dept Pediat, Box 357183, Seattle, WA 98195 USA.	colinsox@u.washington.edu		Sox, Colin/0000-0002-0249-9656				Abramson JS, 2000, PEDIATRICS, V106, P367, DOI 10.1542/peds.106.2.367; Abramson JS, 2000, PEDIATRICS, V106, P362; Berkovitch M, 1998, BRIT J CLIN PHARMACO, V45, P605, DOI 10.1046/j.1365-2125.1998.00730.x; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; BUCHANAN GR, 1982, PEDIATRICS, V70, P926; Carson JL, 2000, PHARMACOEPIDEM DR S, P307; Christakis DA, 2001, AMBUL PEDIATR, V1, P99, DOI 10.1367/1539-4409(2001)001<0099:CAQOCF>2.0.CO;2; Cooper WO, 2002, AMBUL PEDIATR, V2, P375, DOI 10.1367/1539-4409(2002)002<0375:OCUACI>2.0.CO;2; Cooper WO, 2002, OBSTET GYNECOL, V100, P101, DOI 10.1016/S0029-7844(02)02001-X; Cooper WO, 2001, ARCH PEDIAT ADOL MED, V155, P1111, DOI 10.1001/archpedi.155.10.1111; *COUNC REG NETW GE, 1995, NAT NEWB SCREEN REP; CUMMINS D, 1991, BRIT MED J, V302, P989, DOI 10.1136/bmj.302.6783.989; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; GURWITZ JH, 1993, AM J PUBLIC HEALTH, V83, P711, DOI 10.2105/AJPH.83.5.711; Haque A, 2000, J RURAL HEALTH, V16, P43, DOI 10.1111/j.1748-0361.2000.tb00435.x; JOHNSON RE, 1991, J AM GERIATR SOC, V39, P1079, DOI 10.1111/j.1532-5415.1991.tb02872.x; Kuhlthau K, 2001, PEDIATRICS, V108, P906, DOI 10.1542/peds.108.4.906; Lane PA, 2002, PEDIATRICS, V109, P526; Li STT, 2003, ARCH PEDIAT ADOL MED, V157, P475, DOI 10.1001/archpedi.157.5.475; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; MILNE RIG, 1990, BRIT MED J, V300, P371, DOI 10.1136/bmj.300.6721.371; Morrill R, 1999, URBAN GEOGR, V20, P727, DOI 10.2747/0272-3638.20.8.727; OVERTURF GD, 1977, AM J DIS CHILD, V131, P784, DOI 10.1001/archpedi.1977.02120200066014; PEGELOW CH, 1991, J PEDIATR-US, V118, P736, DOI 10.1016/S0022-3476(05)80036-8; STEINER JF, 1988, MED CARE, V26, P814, DOI 10.1097/00005650-198808000-00007; Teach SJ, 1998, ARCH PEDIAT ADOL MED, V152, P274	28	47	47	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1057	1061		10.1001/jama.290.8.1057	http://dx.doi.org/10.1001/jama.290.8.1057			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715FA	12941678	Bronze			2023-01-03	WOS:000184958900024
J	Banks, E; Beral, V; Bull, D; Reeves, G; Austoker, J; English, R; Patnick, J; Peto, R; Vessey, M; Wallis, M; Abbott, S; Bailey, E; Baker, K; Balkwill, A; Barnes, I; Black, J; Brown, A; Cameron, B; Canfell, K; Cliff, A; Crossley, B; Couto, E; Davies, S; Ewart, D; Ewart, S; Ford, D; Gerrard, L; Goodill, A; Green, J; Gray, W; Hilton, E; Hogg, A; Hooley, J; Hurst, A; Kan, SW; Keene, C; Langston, N; Roddam, A; Saunders, P; Sherman, E; Simmonds, M; Spencer, E; Strange, H; Timadjer, A				Banks, E; Beral, V; Bull, D; Reeves, G; Austoker, J; English, R; Patnick, J; Peto, R; Vessey, M; Wallis, M; Abbott, S; Bailey, E; Baker, K; Balkwill, A; Barnes, I; Black, J; Brown, A; Cameron, B; Canfell, K; Cliff, A; Crossley, B; Couto, E; Davies, S; Ewart, D; Ewart, S; Ford, D; Gerrard, L; Goodill, A; Green, J; Gray, W; Hilton, E; Hogg, A; Hooley, J; Hurst, A; Kan, SW; Keene, C; Langston, N; Roddam, A; Saunders, P; Sherman, E; Simmonds, M; Spencer, E; Strange, H; Timadjer, A		Million Women Study Collaborators	Breast cancer and hormone-replacement therapy in the Million Women Study	LANCET			English	Article							ESTROGEN; PROGESTIN; RISK	Background Current use of hormone-replacement therapy (HRT) increases the incidence of breast cancer. The Million Women Study was set up to investigate the effects of specific types of HRT on incident and fatal breast cancer. Methods 1084 110 UK women aged 50-64 years were recruited into the Million Women Study between 1996 and 2001, provided information about their use of HRT and other personal details, and were followed up for cancer incidence and death. Findings Half the women had used HRT; 9364 incident invasive breast cancers and 637 breast cancer deaths were registered after an average of 2.6 and 4.1 years of follow-up, respectively. Current users of HRT at recruitment were more likely than never users to develop breast cancer (adjusted relative risk 1.66 [95% CI 1.58-1-75], p<0.0001) and die from it (1.22 [1.00-1.48], p=0.05). Past users of HRT were, however, not at an increased risk of incident or fatal disease (1.01 [0.94-1.09] and 1.05 [0.82-1.34], respectively). Incidence was significantly increased for current users of preparations containing oestrogen only (1.30 [1.21-1.40], p<0.0001), oestrogen-progestagen (2.00 [1.88-2.12], p<0.0001), and tibolone (1.45 [1.25-1.68], p<0.0001), but the magnitude of the associated risk was substantially greater for oestrogen-progestagen than for other types of HRT (p<0.0001). Results varied little between specific oestrogens and progestagens or their doses; or between continuous and sequential regimens. The relative risks were significantly increased separately for oral, transdermal, and implanted oestrogen-only formulations (1.32 [1.21-1.45]; 1.24 [1.11-1.39]; and 1.65 [1.26-2.16], respectively; all p<0.0001). In current users of each type of HRT the risk of breast cancer increased with increasing total duration of use. 10 years' use of HRT is estimated to result in five (95% CI 3-7) additional breast cancers per 1000 users of oestrogen-only preparations and 19 (15-23) additional cancers per 1000 users of oestrogen-progestagen combinations. Use of HRT by women aged 50-64 years in the UK over the past decade has resulted in an estimated 20 000 extra breast cancers, 15 000 associated with oestrogen-progestagen; the extra deaths cannot yet be reliably estimated. Interpretation Current use of HRT is associated with an increased risk of incident and fatal breast cancer; the effect is substantially greater for oestrogen-progestagen combinations than for other types of HRT.	Radcliffe Infirm, Canc Res UK, Epidemiol Unit, Oxford OX2 6HE, England	Cancer Research UK; Radcliffe Infirmary	Beral, V (corresponding author), Radcliffe Infirm, Canc Res UK, Epidemiol Unit, Gibson Bldg,Woodstock Rd, Oxford OX2 6HE, England.		Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380				Abbott S, 2002, BJOG-INT J OBSTET GY, V109, P1319; Banks BA, 2001, SPACE TECHNOL PROC, V4, P1; Banks E, 2001, J Epidemiol Biostat, V6, P357; Banks E, 2001, J MED SCREEN, V8, P29, DOI 10.1136/jms.8.1.29; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beral V, 1999, J Epidemiol Biostat, V4, P191; BERQUIST L, 1989, NEW ENGL J MED, V32, P293; *BRIT MED ASS ROYA, 1999, BRIT NAT FORM; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P3254, DOI 10.1001/jama.289.24.3254; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; Newcomb PA, 2003, CANCER CAUSE CONTROL, V14, P195, DOI 10.1023/A:1023066304473; *OFF NAT STAT, 2000, KEY HLTH STAT GEN PR; Parkin D., 2002, IARC SCI PUBLICATION, VVIII; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131; World Health Organization, 2004, ICD 10 INT STAT CLAS	23	2280	2351	2	148	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					419	427		10.1016/s0140-6736(03)14065-2	http://dx.doi.org/10.1016/s0140-6736(03)14065-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927427	Green Submitted			2023-01-03	WOS:000184651100007
J	Martinez-Picado, J; Negredo, E; Ruiz, L; Shintani, A; Fumaz, CR; Zala, C; Domingo, P; Vilaro, J; Llibre, JM; Viciana, P; Hertogs, K; Boucher, C; D'Aquila, RT; Clotet, B				Martinez-Picado, J; Negredo, E; Ruiz, L; Shintani, A; Fumaz, CR; Zala, C; Domingo, P; Vilaro, J; Llibre, JM; Viciana, P; Hertogs, K; Boucher, C; D'Aquila, RT; Clotet, B		SWATCH Study Team	Alternation of antiretroviral drug regimens for HIV infection - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; STRUCTURED TREATMENT INTERRUPTION; HIV-1-INFECTED PATIENTS; SIMULTANEOUS ZIDOVUDINE; DIDANOSINE THERAPY; PROTEASE; ADHERENCE; INDINAVIR; SUPPRESSION; RESISTANCE	Background: Mathematical modeling has suggested that alternating antiretrovirall regimens while patients' viral load remains suppressed would minimize HIV resistance mutations. Objective: To compare alternation of antiretroviral regimens with the current standard of switching regimens after viral load rebound. Design: Randomized, multicenter, open-label, pilot trial. Setting: 15 outpatient HIV clinics in Spain and Argentina. Patients: 161 HIV-1-infected, antiretroviral-nalve persons. Intervention: Patients were assigned to continuously receive stavudine, didanosine, and efavirenz (standard of care, regimen A) or zidovudine, lamivudine, and nelfinavir (standard of care, regimen B) until virologic failure, or to alternate between those two regimens every 3 months while viral load was suppressed (regimen Q. Measurements: Time to virologic failure, percentage of patients with undetectable plasma viremia over 48 weeks, CD4 and CD8 cell counts, adverse events, emergence of drug resistance, drug adherence, and quality of life. Results: Patients receiving standard-of-care regimens A and B did not differ. Virologic failure over 48 weeks was delayed in the alternating therapy group compared with the pooled standard-of-cafe group (incidence rate, 1.2 events/1000 person-weeks [95% CI, 0.3 to 3.6 events/1000 person-weeks] vs. 4.8 events/1000 person-weeks [CI, 2.9 to 7.4 events/1000 person-weeks]; P = 0.01). Genotypic drug resistance emerged in 79% of patients in the standard-of-care group who experienced on-therapy treatment failure. Patients in the standard-of-care and alternating therapy groups had similar CD4 cell counts, frequency of adverse events, reported drug adherence, and quality of life. Conclusions: Virologic outcome was better with alternating therapy than with the current standard of care, while adverse events and adherence were similar. The strategy of alternating therapy merits further investigation.	Hosp Badalona Germans Trias & Pujol, IrsiCaixa Fdn, Barcelona 08916, Spain; Hosp Badalona Germans Trias & Pujol, Lluita SIDA Fdn, Barcelona 08916, Spain; Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; Huesped Fdn, Buenos Aires, DF, Argentina; Hosp Santa Creu & Sant Pau, E-08025 Barcelona, Spain; Hosp Vic, Vic, Spain; Hosp St Jaume Calella, Calella, Spain; Hosp Virgen Rocio, Seville, Spain; Tibotec Virco, Mechelen, Belgium; Univ Utrecht, Utrecht, Netherlands	Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; Hospital Germans Trias i Pujol; Vanderbilt University; Hospital of Santa Creu i Sant Pau; Virgen del Rocio University Hospital; Johnson & Johnson; Utrecht University	Martinez-Picado, J (corresponding author), Hosp Badalona Germans Trias & Pujol, IrsiCaixa Fdn, Carretera Canyet S-N, Barcelona 08916, Spain.	javiermp@ns.hugtip.scs.es	Domingo, Pere/AAP-7571-2021; Domingo, Pere/CAF-3577-2022; Martinez-Picado, Javier/G-5507-2012; IBIS, VIH/O-8856-2015; Torres, OH/D-2215-2012	Domingo, Pere/0000-0003-1138-5770; Martinez-Picado, Javier/0000-0002-4916-2129; Torres, OH/0000-0002-0305-8211; Negredo, Eugenia/0000-0001-5298-1734	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029193] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI29193] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; D'Amato RM, 1998, ANTIVIR THER, V3, P147; Deeks S G, 1997, AIDS Clin Rev, P145; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Fumaz CR, 2002, J ACQ IMMUN DEF SYND, V29, P244, DOI 10.1097/00042560-200203010-00004; Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 2001, AIDS, V15, P1671, DOI 10.1097/00002030-200109070-00010; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; KOJIMA E, 1995, J INFECT DIS, V171, P1152, DOI 10.1093/infdis/171.5.1152; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008; Norton L, 1997, SEMIN ONCOL, V24, P3; Oxenius A, 2002, P NATL ACAD SCI USA, V99, P13747, DOI 10.1073/pnas.202372199; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; ROBBINS G, 2002, P 14 INT AIDS C S BA, P26; Ruiz L, 2000, AIDS, V14, P397, DOI 10.1097/00002030-200003100-00013; SHAFER R, 2002, P 14 INT AIDS C S BA, P27; SKOWRON G, 1993, ANN INTERN MED, V118, P321, DOI 10.7326/0003-4819-118-5-199303010-00001; STASZEWSKI S, 2002, P 14 INT AIDS C S BA, P25; Tuldra A, 2000, J ACQ IMMUN DEF SYND, V25, P221, DOI 10.1097/00126334-200011010-00003; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; Weverling GJ, 1998, AIDS, V12, pF117, DOI 10.1097/00002030-199811000-00003; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9; 1999, AIDS, V13, P2209	33	36	37	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2003	139	2					81	89		10.7326/0003-4819-139-2-200307150-00007	http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701HX	12859157				2023-01-03	WOS:000184163100001
J	Mocroft, A; Ledergerber, B; Katlama, C; Kirk, O; Reiss, P; Monforte, AD; Knsyz, B; Dietrich, M; Phillips, AN; Lundgren, JD				Mocroft, A; Ledergerber, B; Katlama, C; Kirk, O; Reiss, P; Monforte, AD; Knsyz, B; Dietrich, M; Phillips, AN; Lundgren, JD		EuroSIDA Study Grp	Decline in the AIDS and death rates in the EuroSIDA study: an observational study	LANCET			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; VIRUS-INFECTED PATIENTS; CLINICAL PROGRESSION; VIROLOGICAL FAILURE; HIV-INFECTION; CELL COUNTS; EUROPE; RECOMMENDATIONS; INDIVIDUALS; PREDICTORS	Background Since the introduction of highly active antiretroviral therapy (HAART), little is known about whether changes in HIV-1-mortality and morbidity rates have been sustained. We aimed to assess possible changes in these rates across Europe. Methods We analysed data for 9803 patients in 70 European HIV centres including ones in Israel and Argentina. Incidence rates of AIDS or death were calculated for overall and most recent CD4 count in 6-monthly periods and in three treatment eras (pre-HAART, 1994-1995; early-HAART, 1996-1997; and late-HAART, 1998-2002). Findings The incidence of AIDS or death fell after September, 1998, by 8% per 6-month period (rate ratio 0.92, 95% CI 0.88-0.95, p<0.0001). When AIDS and death were analysed separately, the incidence of all deaths during the late-HAART era was significantly lower than that during the early-HAART era in patients whose latest CD4 count was 20 cells/mu L or less (0.43, 0.35-0.53, p<0.0001), but at higher CD4 counts, did not differ between early-HAART and late-HAART. Incidence of AIDS was about 50% lower in late-HAART than in early-HAART, irrespective of latest CD4 count (p<0.0001). In multivariate Cox's models, with early-HAART as the reference, there was an increased risk of AIDS (relative hazard 1.39; 95% CI 1.16-1.67, p=0.0004) and all deaths (1.29; 1.08-1.56, p=0.0065) in the pre-HAART era, and a reduced risk of AIDS (0.62; 0.50-0.77, p<0.0001) and all deaths (0.66; 0.53-0.82, p=0.0002) in the late-HAART era. Interpretation The initial drop in mortality and morbidity after the introduction of HAART has been sustained. Potential long-term adverse effects associated with HAART have not altered its effectiveness in treating AIDS.	UCL Royal Free & UCL Med Sch, Royal Free Ctr HIV Med, London NW3 2PF, England; UCL Royal Free & UCL Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; Univ Hosp, Zurich, Switzerland; Hop La Pitie Salpetriere, Paris, France; Univ Copenhagen, Hvidovre Hosp, DK-2650 Hvidovre, Denmark; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Osped L Sacco, Milan, Italy; Univ Wroclaw, Dept Infect Dis, PL-50138 Wroclaw, Poland; Bernhard Nocht Inst Trop Med, Hamburg, Germany	University of London; University College London; University of London; University College London; University of Zurich; University Zurich Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Copenhagen; University of Amsterdam; Academic Medical Center Amsterdam; University of Milan; Luigi Sacco Hospital; University of Wroclaw; Bernhard Nocht Institut fur Tropenmedizin	Mocroft, A (corresponding author), UCL Royal Free & UCL Med Sch, Royal Free Ctr HIV Med, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.	a.mocroft@pcps.ucl.ac.uk	Mocroft, Amanda/C-1527-2008; VALLET, Yannick/F-9979-2011; Ledergerber, Bruno/B-5656-2009; Phillips, Andrew N/B-4427-2008; kirk, ole/ABB-4746-2021; Lundgren, Jens/AAE-6876-2019; Mocroft, Amanda/G-8748-2011	Ledergerber, Bruno/0000-0002-6881-4401; Phillips, Andrew N/0000-0003-2384-4807; Mocroft, Amanda/0000-0001-8316-1122; Lundgren, Jens/0000-0001-8901-7850; Johnson, Anne/0000-0003-1330-7100				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Benson CA, 2002, J INFECT DIS, V185, P599, DOI 10.1086/339014; *BHIVA, 2001, HIV MED, V2, P276; Coakley EPG, 2000, AIDS, V14, P1147, DOI 10.1097/00002030-200006160-00011; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Flandre P, 2002, AIDS, V16, P561, DOI 10.1097/00002030-200203080-00007; Grulich AE, 2002, AIDS, V16, P1155, DOI 10.1097/00002030-200205240-00009; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Kirk O, 1998, AIDS, V12, P2031, DOI 10.1097/00002030-199815000-00015; Le Moing V, 2002, J INFECT DIS, V185, P471, DOI 10.1086/338929; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Lundgren JD, 2002, J INFECT DIS, V185, P178, DOI 10.1086/338267; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; Miller V, 2002, J INFECT DIS, V186, P189, DOI 10.1086/341466; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 2002, AIDS, V16, P1663, DOI 10.1097/00002030-200208160-00012; Mocroft A, 2000, LANCET, V356, P291, DOI 10.1016/S0140-6736(00)02504-6; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123; Piketty C, 2001, J INFECT DIS, V183, P1328, DOI 10.1086/319861; Selik RM, 2002, J ACQ IMMUN DEF SYND, V29, P378, DOI 10.1097/00126334-200204010-00009; Sterling TR, 2001, AIDS, V15, P2251, DOI 10.1097/00002030-200111230-00006; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	29	980	1011	1	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 5	2003	362	9377					22	29		10.1016/S0140-6736(03)13802-0	http://dx.doi.org/10.1016/S0140-6736(03)13802-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853195				2023-01-03	WOS:000184056900009
J	Kaye, SB				Kaye, SB			Chemotherapy for recurrent ovarian cancer	LANCET			English	Editorial Material							1ST-LINE		Royal Marsden Hosp, Canc Res UK Dept Med Oncol, Sutton SM2 5PT, Surrey, England	Cancer Research UK; Royal Marsden NHS Foundation Trust	Kaye, SB (corresponding author), Royal Marsden Hosp, Canc Res UK Dept Med Oncol, Downs Rd, Sutton SM2 5PT, Surrey, England.							GONZALEZMARTIN A, 2003, P ASCO, V22, P451; GORE ME, 1990, GYNECOL ONCOL, V36, P207, DOI 10.1016/0090-8258(90)90174-J; Kaye SB, 2002, BRIT J CANCER, V87, P813, DOI 10.1038/sj.bjc.6600568; Parmar MKB, 2002, LANCET, V360, P505; Sandercock J, 2002, BRIT J CANCER, V87, P815, DOI 10.1038/sj.bjc.6600567; VANDERBURG ME, 2002, BRIT J CANCER, V7, P19; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72	7	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2094	2095		10.1016/S0140-6736(03)13726-9	http://dx.doi.org/10.1016/S0140-6736(03)13726-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826426				2023-01-03	WOS:000183654200002
J	Heshka, S; Anderson, JW; Atkinson, RL; Greenway, FL; Hill, JO; Phinney, SD; Kolotkin, RL; Miller-Kovach, K; Pi-Sunyer, FX				Heshka, S; Anderson, JW; Atkinson, RL; Greenway, FL; Hill, JO; Phinney, SD; Kolotkin, RL; Miller-Kovach, K; Pi-Sunyer, FX			Weight loss with self-help compared with a structured commercial program - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; BLOOD-PRESSURE; OBESITY; OVERWEIGHT; REDUCTION; ADULTS; RISK	Context Although commercial weight loss programs provide treatment to millions of clients, their efficacy has not been evaluated in rigorous long-term trials. Objective To compare weight loss and health benefits achieved and maintained through self-help weight loss vs with a structured commercial program. Design and Setting A 2-year, multicenter randomized clinical trial with clinic visits at 12, 26, 52, 78, and 104 weeks conducted at 6 academic research centers in the United States between January 1998 and January 2001. Participants Overweight and obese men (n=65) and women (n=358) (body mass index, 27-40) aged 18 to 65 years. Intervention Random assignment to either a self-help program (n=212) consisting of two 20-minute counseling sessions with a nutritionist and provision of self-help resources or to a commercial weight loss program (n=211) consisting of a food plan, an activity plan, and a cognitive restructuring behavior modification plan, delivered at weekly meetings. Main Outcome Measures Weight change was the primary outcome measure. Secondary outcomes included waist circumference, body mass index, blood pressure, serum lipids, glucose, and insulin levels. Results At 2 years, 150 participants (71%)in the commercial group and 159 (75%) in the self-help group completed the study. In the intent-to-treat analysis, mean (SD) weight loss of participants in the commercial group was greater than in the self-help group at 1 year (-4.3 [6.1] kg vs -1.3 [6.1] kg, respectively; P<.001) and at 2 years (-2.9 [6.5] kg vs -0.2 [6.5] kg, respectively; P<.001). Waist circumference (P=.003) and body mass index (P<.001) decreased more in the commercial group. Changes in blood pressure, lipids, glucose, and insulin levels were related to changes in weight in both groups, but between group differences in biological parameters were mainly nonsignificant by year 2. Conclusion The structured commercial weight loss program provided modest weight loss but more than self-help over a 2-year period.	St Lukes Roosevelt Hosp, New York Obes Res Ctr, New York, NY 10025 USA; Columbia Univ, New York, NY USA; VA Med Ctr, Lexington, KY USA; Univ Kentucky, Lexington, KY 40506 USA; Univ Wisconsin, Madison, WI USA; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Univ Colorado, Boulder, CO 80309 USA; Univ Calif Davis, Dept Med, Davis, CA 95616 USA; Obes & Qual Life Consulting, Durham, NC USA; Weight Watchers Int, Woodbury, NY USA	Mount Sinai St. Luke's; Mount Sinai West; Columbia University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; University of Kentucky; University of Wisconsin System; University of Wisconsin Madison; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Colorado System; University of Colorado Boulder; University of California System; University of California Davis	Heshka, S (corresponding author), St Lukes Roosevelt Hosp, 1090 Amsterdam Ave,14C, New York, NY 10025 USA.		Atkinson, Richard/AAK-4953-2021; Greenway, Frank/N-1966-2017	Greenway, Frank/0000-0002-1766-6111; Atkinson, Richard L./0000-0003-1745-5645; phinney, stephen/0000-0002-3322-3978; Kolotkin, Ronette/0000-0002-1300-2131				Anderson JW, 2001, OBES RES, V9, p326S, DOI 10.1038/oby.2001.138; Ashley JM, 2001, OBES RES, V9, p312S, DOI 10.1038/oby.2001.136; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Gandek, 1997, SF 36 HLTH SURVEY MA; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; HEO M, IN PRESS STAT MED; Heshka S, 2000, AM J MED, V109, P282, DOI 10.1016/S0002-9343(00)00494-0; Janssen I, 2002, ARCH INTERN MED, V162, P2074, DOI 10.1001/archinte.162.18.2074; KANNEL WB, 1991, J CLIN EPIDEMIOL, V44, P183, DOI 10.1016/0895-4356(91)90265-B; Khaodhiar L., 2001, International textbook of obesity, P413; Klein S, 2001, OBES RES, V9, p354S, DOI 10.1038/oby.2001.142; Kolotkin RL, 2001, OBES RES, V9, P102, DOI 10.1038/oby.2001.13; LEVY AS, 1993, ANN INTERN MED, V119, P661, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00007; Lowe MR, 1999, OBES RES, V7, P51, DOI 10.1002/j.1550-8528.1999.tb00390.x; Lowe MR, 2001, INT J OBESITY, V25, P325, DOI 10.1038/sj.ijo.0801521; *MARK ENT INC, 2001, US WEIGHT LOSS DIET; Mertens IL, 2000, OBES RES, V8, P270, DOI 10.1038/oby.2000.32; *NAT AC SCI AC ADV, 1978, PREV SERV WELL POP; *NAT CATTL BEEF AS, 1996, EAT SMART; *NAT CATTL BEEF AS, 1996, FITT FITN; *NIH, 1995, PHYS ACT CARD HLTH; PERRI MG, 1989, J CONSULT CLIN PSYCH, V57, P450, DOI 10.1037/0022-006X.57.3.450; Rippe JM, 1998, OBES RES, V6, P208, DOI 10.1002/j.1550-8528.1998.tb00339.x; SERDULA MK, 1993, ANN INTERN MED, V119, P667, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00008; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; TAYLOR CB, 1993, OBESITY THEORY THERA, P335; Thomas PR, 1995, WEIGHING OPTIONS CRI; WADDEN TA, 1992, ARCH INTERN MED, V152, P961, DOI 10.1001/archinte.152.5.961	30	310	310	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1792	1798		10.1001/jama.289.14.1792	http://dx.doi.org/10.1001/jama.289.14.1792			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZJ	12684357	Bronze			2023-01-03	WOS:000182094900024
J	de Jong-van den Berg, L; Tobi, H; Bijker, B; van den Berg, P				de Jong-van den Berg, L; Tobi, H; Bijker, B; van den Berg, P			Influence of the third generation pill controversy on prescriptions for oral contraceptives among first time users: population based study	BRITISH MEDICAL JOURNAL			English	Article							3RD-GENERATION		Univ Groningen, Inst Drug Explorat, Dept Social Pharm Pharmacoepidemiol & Pharmacothe, NL-9713 AV Groningen, Netherlands	University of Groningen	de Jong-van den Berg, L (corresponding author), Univ Groningen, Inst Drug Explorat, Dept Social Pharm Pharmacoepidemiol & Pharmacothe, Antonius Deusinglaan 2, NL-9713 AV Groningen, Netherlands.		Tobi, Hilde/A-1512-2013	Tobi, Hilde/0000-0002-8804-0298				de Vries CS, 1998, CONTRACEPTION, V57, P247, DOI 10.1016/S0010-7824(98)00021-3; Drife JO, 2001, BRIT MED J, V323, P119, DOI 10.1136/bmj.323.7305.119; GEIJER RMM, 1996, HUISARTS WET, V39, P110; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; POULTER NR, 1995, LANCET, V346, P1575	5	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2003	326	7383					254	254		10.1136/bmj.326.7383.254	http://dx.doi.org/10.1136/bmj.326.7383.254			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644FY	12560275	Green Published, Bronze			2023-01-03	WOS:000180908300018
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; STIMULATED ATPASE ACTIVITY; TRANSMEMBRANE DOMAIN; CROSS-LINKING; CYSTEINE; MDR1; HYDROLYSIS; MUTATIONS; MUTANTS; SITES	The human multidrug resistance P-glycoprotein (P-gp, ABCB1) uses ATP to transport many structurally diverse compounds out of the cell. It is an ABC transporter with two nucleotide-binding domains (NBDs) and two transmembrane domains (TMDs). Recently, we showed that the "LSGGQ" motif in one NBD ((LS)-L-531-GGQ(535) in NBD1; (1176)SGGQ(1180) in NBD2) is adjacent to the "Walker A" sequence ((1070)GSSGCGKS(1077) in NBD2; (427)GNSGCGKS(434) in NBD1) in the other NBD (Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2002) J. Biol. Chem. 277, 41303-41306). Drug substrates can stimulate or inhibit the ATPase activity of P-gp. Here, we report the effect of drug binding on cross-linking between the LSGGQ signature and Walker A sites (Cys(431) (NBD1)/C1176C(NBD2) and Cys(1074) (NBD2)/L531C(NBD1), respectively). Seven drug substrates (calcein-AM, demecolcine, cis(Z)-flupentixol, verapamil, cyclosporin A, Hoechst 33342, and trans(E)-flupentixol) were tested for their effect on oxidative cross-linking. Substrates that stimulated the ATPase activity of P-gp (calcein-AM, demecolcine, cis(Z)-flupentixol, and verapamil) increased the rate of cross-linking between Cys(431) (NBD1-Walker A)/C1176C(NBD2-LSGGQ) and between CyS1074(NBD2-Walker A)/L531C(NBD1-LSGGQ) when compared with cross-linking in the absence of drug substrate. By contrast, substrates that inhibited ATPase activity (cyclosporin A, Hoechst 33342, and trans(E)-flupentixol) decreased the rate of cross-linking. These results indicate that interaction between the LSGGQ motifs and Walker A sites must be essential for coupling drug binding to ATP hydrolysis. Drug binding in the transmembrane domains can induce long range conformational changes in the NBDs, such that compounds that stimulate or inhibit ATPase activity must decrease and increase, respectively, the distance between the Walker A and LSGGQ sequences.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bakos E, 1997, BIOCHEM J, V323, P777, DOI 10.1042/bj3230777; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928-0987(00)00114-7; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Loo TW, 2000, JNCI-J NATL CANCER I, V92, P898, DOI 10.1093/jnci/92.11.898; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; SMITHPC, 2002, MOL CELL, V10, P139; Szakacs G, 2001, BIOCHEM J, V356, P71, DOI 10.1042/0264-6021:3560071; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020	38	111	114	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1575	1578		10.1074/jbc.M211307200	http://dx.doi.org/10.1074/jbc.M211307200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12421806	hybrid			2023-01-03	WOS:000180462200028
J	Mariano, NA				Mariano, NA			The changing room	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2091	2091		10.1001/jama.288.17.2091	http://dx.doi.org/10.1001/jama.288.17.2091			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413353				2023-01-03	WOS:000179048100001
J	Weaver, WD; Peberdy, MA				Weaver, WD; Peberdy, MA			Perspective: Defibrillators in public places - One step closer to home	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Henry Ford Heart & Vasc Inst, Detroit, MI 48202 USA; Virginia Commonwealth Univ, Hlth Syst, Richmond, VA 23298 USA	Henry Ford Health System; Virginia Commonwealth University	Weaver, WD (corresponding author), Henry Ford Heart & Vasc Inst, Detroit, MI 48202 USA.								0	33	34	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1223	1224		10.1056/NEJMp020108	http://dx.doi.org/10.1056/NEJMp020108			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393818				2023-01-03	WOS:000178598300001
J	Scribner, BH				Scribner, BH			Medical dilemmas: the old is new	NATURE MEDICINE			English	Editorial Material							DIALYSIS		Univ Washington, Dept Med, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle	Scribner, BH (corresponding author), Univ Washington, Dept Med, Seattle, WA 98104 USA.	Scrib@u.washington.edu						Blagg CR, 1998, NEPHROLOGY, V4, P295, DOI 10.1111/j.1440-1797.1998.tb00362.x; BRESCIA MJ, 1966, NEW ENGL J MED, V275, P1089, DOI 10.1056/NEJM196611172752002; Charra B, 1998, AM J KIDNEY DIS, V32, P720, DOI 10.1016/S0272-6386(98)70147-7; Charra Bernard, 1999, Home Hemodial Int, V3, P16, DOI 10.1111/hdi.1999.3.1.16; Fishbane SA, 2002, SEMIN DIALYSIS, V15, P144, DOI 10.1046/j.1525-139X.2002.00060.x; Jonsen A.R., 1998, BIRTH BIOETHICS; QUINTON W, 1960, T AM SOC ART INT ORG, V6, P104; Scribner B H, 1999, Nephrol News Issues, V13, P22; SCRIBNER BH, 1964, T AM SOC ART INT ORG, V10, P209; SCRIBNER BH, 1990, AM J KIDNEY DIS, V16, P511, DOI 10.1016/S0272-6386(12)81034-1; SCRIBNER BH, 1960, T AM SOC ART INT ORG, V6, P88; SCRIBNER BH, 1960, T AM SOC ART INT ORG, V6, P114; Scribner BH, 2002, DIALYSIS TRANSPLANT, V31, P13; Scribner BH, 1998, J AM SOC NEPHROL, V9, P899; SKEGGS LT, 1949, P SOC EXP BIOL MED, V72, P539	15	17	17	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1066	1067		10.1038/nm772	http://dx.doi.org/10.1038/nm772			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357234				2023-01-03	WOS:000178311000020
J	Bensafi, M; Porter, J; Pouliot, S; Mainland, J; Johnson, B; Zelano, C; Young, N; Bremner, E; Aframian, D; Khan, R; Sobel, N				Bensafi, M; Porter, J; Pouliot, S; Mainland, J; Johnson, B; Zelano, C; Young, N; Bremner, E; Aframian, D; Khan, R; Sobel, N			Olfactomotor activity during imagery mimics that during perception	NATURE NEUROSCIENCE			English	Article							MITRAL CELL-ACTIVITY; CORTEX	Neural representations created in the absence of external sensory stimuli are referred to as imagery(1), and such representations may be augmented by reenactment of sensorimotor processes(2). We measured nasal airflow in human subjects while they imagined sights, sounds and smells, and only during olfactory imagery did subjects spontaneously enact the motor component of olfaction-that is, they sniffed. Moreover, as in perception(3,4), imagery of pleasant odors involved larger sniffs than imagery of unpleasant odors, suggesting that the act of sniffing has a functional role in creating of olfactory percepts.	Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA; McGill Univ, Montreal Neurol Inst, Dept Psychol, Montreal, PQ, Canada	University of California System; University of California Berkeley; University of California System; University of California Berkeley; McGill University	Bensafi, M (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, 3210 Tolman Hall MC 1650, Berkeley, CA 94720 USA.		Mainland, Joel/C-5171-2009; Bensafi, Moustafa/H-6618-2017	Mainland, Joel/0000-0002-5056-4598; Bensafi, Moustafa/0000-0002-2991-3036; Sobel, Noam/0000-0002-3232-9391				Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; Elmes DG, 1998, CHEM SENSES, V23, P443, DOI 10.1093/chemse/23.4.443; Fontanini A, 2003, J NEUROSCI, V23, P7993; FREEMAN WJ, 1983, BIOL PSYCHIAT, V18, P1107; Friedrich RW, 2001, SCIENCE, V291, P889, DOI 10.1126/science.291.5505.889; Herz RS, 2000, MEM COGNITION, V28, P957, DOI 10.3758/BF03209343; Johnson B. N., 2003, J NEUROPHYSIOL; Kay LM, 1999, NAT NEUROSCI, V2, P1003, DOI 10.1038/14801; KOSSLYN SM, 1995, NEUROPSYCHOLOGIA, V33, P1335, DOI 10.1016/0028-3932(95)00067-D; Laeng B, 2002, COGNITIVE SCI, V26, P207, DOI 10.1016/S0364-0213(01)00065-9; LAING DG, 1983, PERCEPTION, V12, P99, DOI 10.1068/p120099; Leopold D, 2002, CHEM SENSES, V27, P611, DOI 10.1093/chemse/27.7.611; MACRIDES F, 1972, SCIENCE, V175, P84, DOI 10.1126/science.175.4017.84; SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P733, DOI 10.1152/jn.1995.74.2.733; TEGHTSOONIAN R, 1978, J EXP PSYCHOL HUMAN, V4, P144, DOI 10.1037/0096-1523.4.1.144	15	132	137	0	23	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1097-6256			NAT NEUROSCI	Nat. Neurosci.	NOV	2003	6	11					1142	1144		10.1038/nn1145	http://dx.doi.org/10.1038/nn1145			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	737KH	14566343				2023-01-03	WOS:000186229200012
J	Hviid, A; Stellfeld, M; Wohlfahrt, J; Melbye, M				Hviid, A; Stellfeld, M; Wohlfahrt, J; Melbye, M			Association between thimerosal-containing vaccine and autism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPULATION; REGISTER; MERCURY	Context Mercuric compounds are nephrotoxic and neurotoxic at high doses. Thimerosal, a preservative used widely in vaccine formulations, contains ethylmercury. Thus it has been suggested that childhood vaccination with thimerosal-containing vaccine could be causally related to neurodevelopmental disorders such as autism. Objective To determine whether vaccination with a thimerosal-containing vaccine is associated with development of autism. Design, Setting, and Participants Population-based cohort study of all children born in Denmark from January 1, 1990, until December 31, 1996 (N =467450) comparing children vaccinated with a thimerosal-containing vaccine with children vaccinated with a thimerosal-free formulation of the same vaccine. Main Outcome Measures Rate ratio (RR) for autism and other autistic-spectrum disorders, including trend with dose of ethylmercury. Results During 2986654 person-years, we identified 440 autism cases and 787 cases of other autistic-spectrum disorders. The risk of autism and other autistic-spectrum disorders did not differ significantly between children vaccinated with thimerosal-containing vaccine and children vaccinated with thimerosal-free vaccine (RR, 0.85 [95% confidence interval (0), 0.60-1.20] for autism; RR, 1.12 [95% Cl, 0.88-1.43] for other autistic-spectrum disorders). Furthermore, we found no evidence of a dose-response association (increase in RR per 25 mug of ethylmercury, 0.98 [95% Cl, 0.90-1.06] for autism and 1.03 [95% Cl, 0.98-1.09] for other autistic-spectrum disorders). Conclusion The results do not support a causal relationship between childhood vaccination with thimerosal-containing vaccines and development of autistic-spectrum disorders.	Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark; Statens Serum Inst, Dept Med, DK-2300 Copenhagen, Denmark	Aarhus University; Statens Serum Institut; Statens Serum Institut	Hviid, A (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.		Hviid, Anders/AAH-4319-2020	Hviid, Anders/0000-0002-7509-9127; melbye, mads/0000-0001-8264-6785				Andersen TF, 1999, DAN MED BULL, V46, P263; Ball LK, 2001, PEDIATRICS, V107, P1147, DOI 10.1542/peds.107.5.1147; Bertrand J, 2001, PEDIATRICS, V108, P1155, DOI 10.1542/peds.108.5.1155; Clarkson TW, 1997, CRIT REV CL LAB SCI, V34, P369, DOI 10.3109/10408369708998098; Hills, 1993, STAT MODELS EPIDEMIO; Knudsen LB, 1998, DAN MED BULL, V45, P320; Madsen KM, 2002, NEW ENGL J MED, V347, P1477, DOI 10.1056/NEJMoa021134; MALIG C, 1996, 6 IIVRS; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Pichichero ME, 2002, LANCET, V360, P1737, DOI 10.1016/S0140-6736(02)11682-5; Plesner A M, 1994, Ugeskr Laeger, V156, P7497; Ronne T, 1997, Ugeskr Laeger, V159, P1584; Stratton K, 2001, IMMUNIZATION SAFETY	13	175	183	0	108	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1763	1766		10.1001/jama.290.13.1763	http://dx.doi.org/10.1001/jama.290.13.1763			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519711				2023-01-03	WOS:000185606100026
J	Vaupel, JW; Carey, JR; Christensen, K				Vaupel, JW; Carey, JR; Christensen, K			It's never too late	SCIENCE			English	Editorial Material							DIETARY RESTRICTION; AGE; SELECTION; OLDER		Max Planck Inst Demog Res, D-18057 Rostock, Germany; Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Univ Calif Berkeley, Ctr Econ & Demog Aging, Berkeley, CA 94720 USA; Univ So Denmark, Inst Publ Hlth, DK-5000 Odense, Denmark	Max Planck Society; University of California System; University of California Davis; University of California System; University of California Berkeley; University of Southern Denmark	Vaupel, JW (corresponding author), Max Planck Inst Demog Res, Konrad Zuse Str 1, D-18057 Rostock, Germany.	jwv@demogr.mpg.de	Christensen, Kaare/C-2360-2009	Christensen, Kaare/0000-0002-5429-5292; Vaupel, James/0000-0003-0783-3905	NIA NIH HHS [AG-08761, P01 AG008761-130003, P01 AG008761] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aristotle, YOUTH OLD AGE LIFE D; Bergman B, 2002, ACTA OPHTHALMOL SCAN, V80, P598, DOI 10.1034/j.1600-0420.2002.800608.x; Carey J. R., 2003, LONGEVITY BIOL DEMOG, DOI [10.1515/9780691224084, DOI 10.1515/9780691224084]; Carey JR, 2002, AGING CELL, V1, P140, DOI 10.1046/j.1474-9728.2002.00019.x; Carey JR, 1998, SCIENCE, V281, P996, DOI 10.1126/science.281.5379.996; DOBLHAMMER G, LATE LIFE LEGACY VER; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; Gjonca Arjan, 2000, DEMOGR RES, V3, P1, DOI [10.4054/DemRes.2000.3.1, DOI 10.4054/DEMRES.2000.3.1]; Good TP, 2001, J INSECT PHYSIOL, V47, P1467, DOI 10.1016/S0022-1910(01)00138-X; HAMILTON WD, 1966, J THEOR BIOL, V12, P12, DOI 10.1016/0022-5193(66)90184-6; Kannisto Vaino., 1994, DEV OLDEST OLD MORTA; LaCroix A Z, 1992, Clin Geriatr Med, V8, P69; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675; Pagnano MW, 2003, MAYO CLIN PROC, V78, P285, DOI 10.4065/78.3.285; Riley J, 2001, RISING LIFE EXPECTAN; Vaupel JW, 1997, PHILOS T ROY SOC B, V352, P1799, DOI 10.1098/rstb.1997.0164; VAUPEL JW, 1985, AM STAT, V39, P176, DOI 10.2307/2683925; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; VAUPEL JW, 1995, EXCEPTIONAL LONGEVIT, P109	20	69	70	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1679	+		10.1126/science.1090529	http://dx.doi.org/10.1126/science.1090529			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500969	Green Accepted			2023-01-03	WOS:000185387700030
J	Askie, LM; Henderson-Smart, DJ; Irwig, L; Simpson, JM				Askie, LM; Henderson-Smart, DJ; Irwig, L; Simpson, JM			Oxygen-saturation targets and outcomes in extremely preterm infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIRTH-WEIGHT INFANTS; CHRONIC LUNG-DISEASE; BRONCHOPULMONARY DYSPLASIA; PREMATURE-INFANTS; SUPPLEMENTAL OXYGEN; TEMPERAMENT; REQUIREMENT; RETINOPATHY; SURVIVORS; DISCHARGE	Background: Physiological studies have shown that chronic hypoxemia may occur in preterm infants who require supplemental oxygen for extended periods and that this hypoxemia may contribute to poor growth and development. Anecdotal reports and uncontrolled observational studies have suggested that a higher oxygen-saturation range may be beneficial in terms of growth and development. Methods: We conducted a multicenter, double-blind, randomized, controlled trial involving 358 infants born at less than 30 weeks of gestation who remained dependent on supplemental oxygen at 32 weeks of postmenstrual age. They were randomly assigned to a target functional oxygen-saturation range of either 91 to 94 percent (standard-saturation group) or 95 to 98 percent (high-saturation group); this target was maintained for the duration of supplemental-oxygen therapy. The primary outcomes were growth and neurodevelopmental measures at a corrected age of 12 months. Results: There were no significant differences between the groups in weight, length, or head circumference at a corrected age of 12 months. The frequency of major developmental abnormalities also did not differ significantly between the standard-saturation group and the high-saturation group (24 percent and 23 percent, respectively, P=0.85). There were six deaths due to pulmonary causes in the high-saturation group and one such death in the standard-saturation group (P=0.12). The high-saturation group received oxygen for a longer period after randomization (median, 40 days vs. 18 days; P<0.001) and had a significantly higher rate of dependence on supplemental oxygen at 36 weeks of postmenstrual age and a significantly higher frequency of home-based oxygen therapy. Conclusions: Targeting a higher oxygen-saturation range in extremely preterm infants who were dependent on supplemental oxygen conferred no significant benefit with respect to growth and development and resulted in an increased burden on health services.	Univ Sydney, Queen Elizabeth II Res Inst, Ctr Perinatal Hlth Serv Res, Sydney, NSW 2006, Australia; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Askie, LM (corresponding author), Univ Sydney, Queen Elizabeth II Res Inst, Ctr Perinatal Hlth Serv Res, Bldg DO2, Sydney, NSW 2006, Australia.	lisa.askie@perinatal.usyd.edu.au						Askie LM, 2001, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001077; Bowen JR, 1996, J PAEDIATR CHILD H, V32, P25, DOI 10.1111/j.1440-1754.1996.tb01536.x; CAREY WB, 1978, PEDIATRICS, V61, P735; CHYE JK, 1995, J PAEDIATR CHILD H, V31, P105, DOI 10.1111/j.1440-1754.1995.tb00756.x; *COMM PROF HOSP AC, 1986, INT CLASS DIS, V1; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Daniel A.E., 1983, POWER PRIVILEGE PRES; DOYLE LW, 1995, MED J AUSTRALIA, V163, P11, DOI 10.5694/j.1326-5377.1995.tb126079.x; Duc Gabriel, 1992, P178; Ellsbury DL, 2002, J PEDIATR-US, V140, P247, DOI 10.1067/mpd.2002.121933; FOSTER J, 2002, NEONAT PAEDIAT CHILD, V5, P5; Gregoire MC, 1998, PEDIATRICS, V101, P856, DOI 10.1542/peds.101.5.856; Griffiths R., 1996, GRIFFITHS MENTAL DEV; GROOTHUIS JR, 1987, AM J DIS CHILD, V141, P992, DOI 10.1001/archpedi.1987.04460090069028; Hack M, 2000, Semin Neonatol, V5, P89, DOI 10.1053/siny.1999.0001; HAMILL PVV, 1977, VITAL HLTH STAT SERI, V11; HARRIS MA, 1995, LANCET, V345, P831, DOI 10.1016/S0140-6736(95)92966-5; HUDAK BB, 1989, AM J DIS CHILD, V143, P357, DOI 10.1001/archpedi.1989.02150150115028; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; KITCHEN W, 1987, J PEDIATR-US, V111, P761, DOI 10.1016/S0022-3476(87)80264-0; McIntosh N, 2001, ARCH DIS CHILD-FETAL, V84, pF149, DOI 10.1136/fn.84.3.F149; *NEON INT CAR STUD, 1997, NSW PUBL HLTH B S, V2; Phelps DL, 2000, PEDIATRICS, V105, P295; *PSYCH ASS RES, 1995, PAR STRESS IND SHORT; *ROP INT COMM CLAS, 1984, PEDIATRICS, V74, P127; Saugstad OD, 2001, PEDIATRICS, V108, P1203, DOI 10.1542/peds.108.5.1203; SAUVE RS, 1985, PEDIATRICS, V76, P725; SEKAR KC, 1991, PEDIATR PULM, V10, P112, DOI 10.1002/ppul.1950100213; SEWELL J, 1988, AUST PAEDIATR J, V24, P343; SHENNAN AT, 1988, PEDIATRICS, V82, P527; SIGNORINI DF, 1993, STAT MED, V12, P2343, DOI 10.1002/sim.4780122410; Simakajornboon N, 2002, PEDIATRICS, V110, P884, DOI 10.1542/peds.110.5.884; SINGER L, 1992, PEDIATRICS, V90, P380; SKIDMORE MD, 1990, DEV MED CHILD NEUROL, V32, P325; Solis A, 2002, EUR J PEDIATR, V161, P428, DOI 10.1007/s00431-002-0991-z; STEIN REK, 1980, MED CARE, V18, P465, DOI 10.1097/00005650-198004000-00010; Stevenson DK, 1998, AM J OBSTET GYNECOL, V179, P1632, DOI 10.1016/S0002-9378(98)70037-7; Tin W, 2002, PEDIATRICS, V110, P615, DOI 10.1542/peds.110.3.615; VOHR BR, 1991, DEV MED CHILD NEUROL, V33, P690; Weinberger B, 2002, TOXICOL APPL PHARM, V181, P60, DOI 10.1006/taap.2002.9387; WEINSTEIN MR, 1981, J PEDIATR-US, V99, P958, DOI 10.1016/S0022-3476(81)80032-7	41	329	345	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					959	967		10.1056/NEJMoa023080	http://dx.doi.org/10.1056/NEJMoa023080			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954744	Bronze			2023-01-03	WOS:000185081400007
J	Cohen, LM; Germain, MJ; Poppel, DM				Cohen, LM; Germain, MJ; Poppel, DM			Practical considerations in dialysis withdrawal "To have that option is a blessing"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; SERIOUSLY ILL PATIENTS; STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; PALLIATIVE CARE; SUPPORT TREATMENT; DECISION-MAKING; TERMINALLY ILL; END; DEPRESSION	Cessation of life-support treatment is an appropriate option for situations in which the burdens of therapy substantially outweigh the benefits. Decisions to withdraw dialysis now precede 1 in 4 deaths of patients who have end-stage renal disease. Guidelines have been recently published to assist clinicians in making these complex and emotionally charged determinations, and they include: relying on shared decision making by all participants, obtaining informed consent, estimating the prognosis on dialysis, adopting a systematic approach for conflict resolution of disagreements, honoring advance directives, and ensuring the provision of palliative care. These principles are discussed in relation to an elderly man with dementia whose family decided to terminate maintenance hemodialysis.	Baystate Med Ctr, Dept Psychiat, Springfield, MA 01199 USA; Baystate Med Ctr, Dept Med, Springfield, MA 01199 USA; Western New England Renal & Transplantat Associat, W Springfield, MA USA	Baystate Medical Center; Baystate Medical Center	Cohen, LM (corresponding author), Baystate Med Ctr, Dept Psychiat, 759 Chestnut St,S2669, Springfield, MA 01199 USA.							ALEXANDER S, 1962, LIFE            1109, P102; Beck DA, 1998, CLIN GERIATR MED, V14, P765; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; BUCKMAN R, 1992, HOW BREAK BADS NEWS; Cassell EJ, 1999, ANN INTERN MED, V131, P531, DOI 10.7326/0003-4819-131-7-199910050-00009; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; CHOCHINOV HM, 1994, AM J PSYCHIAT, V151, P537; Cohen L M, 2001, J Palliat Med, V4, P167, DOI 10.1089/109662101750290209; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; Cohen LM, 2002, PSYCHOSOM MED, V64, P889, DOI 10.1097/01.PSY.0000028828.64279.84; Cohen LM, 2000, ARCH INTERN MED, V160, P2513, DOI 10.1001/archinte.160.16.2513; Cohen LM, 2000, PSYCHOSOMATICS, V41, P195, DOI 10.1176/appi.psy.41.3.195; Cohen LM, 1998, ARCH INTERN MED, V158, P1973, DOI 10.1001/archinte.158.18.1973; Cohen LM, 2000, AM J KIDNEY DIS, V36, P140, DOI 10.1053/ajkd.2000.8286; COHEN LM, 2001, OXFORD TXB PALLIATIV, P103; COHEN LM, 2003, GERIATRIC PALLIATIVE, P192; COHEN LM, 2002, TXB CONSULTATION LIA, P537; COHEN LM, 2003, THERAPY NEPHROLOGY H, P753; COHEN LM, 2003, THERAPY NEPHROLOGY H, P731; Cotler M, 2000, HASTINGS CENT REP, V30, P24, DOI 10.2307/3528449; Coulehan JL, 2001, ANN INTERN MED, V135, P221, DOI 10.7326/0003-4819-135-3-200108070-00022; Crawley LM, 2002, ANN INTERN MED, V136, P673, DOI 10.7326/0003-4819-136-9-200205070-00010; CUMMINGS NB, 2001, DIS KIDNEY URINARY T, V3, P3007; Darrah J B, 1987, ASAIO Trans, V33, P791; Davison SN, 2002, SEMIN DIALYSIS, V15, P41, DOI 10.1046/j.1525-139x.2002.00015.x; DESSNER GH, 1986, NEW ENGL J MED, V314, P1449; Eiser AR, 1996, AM J KIDNEY DIS, V27, P451, DOI 10.1016/S0272-6386(96)90373-X; *END STAG REN DIS, REC FIELD; *ESRD NETW NEW ENG, 2002, 2001 ANN REP CTR MED, P60; FISHER SH, 1986, NEW ENGL J MED, V314, P1449; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; FRIEDMAN EA, 1987, ASAIO T, V33, P794; Galla JH, 2000, J AM SOC NEPHROL, V11, P1340, DOI 10.1681/ASN.V1171340; HIRSCH DJ, 1994, AM J KIDNEY DIS, V23, P463, DOI 10.1016/S0272-6386(12)81012-2; HOLLEY JL, 1991, J AM SOC NEPHROL, V1, P1284; Holley JL, 1997, AM J KIDNEY DIS, V30, P356, DOI 10.1016/S0272-6386(97)90279-1; Holley JL, 1999, AM J KIDNEY DIS, V33, P688, DOI 10.1016/S0272-6386(99)70220-9; Jansen LA, 2002, ANN INTERN MED, V136, P845, DOI 10.7326/0003-4819-136-11-200206040-00014; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; KAYE M, 1992, ETHICAL PROBLEMS DIA, P117; Leeman CP, 1999, GEN HOSP PSYCHIAT, V21, P112, DOI 10.1016/S0163-8343(98)00069-3; Leggat J E Jr, 1997, Adv Ren Replace Ther, V4, P22; Levinson W, 2001, ANN INTERN MED, V135, P386, DOI 10.7326/0003-4819-135-5-200109040-00027; Levy NB, 2001, TXB NEPHROLOGY, P1279; LOWANCE DC, 1993, AM J KIDNEY DIS, V21, P679, DOI 10.1016/S0272-6386(12)80045-X; LOWANCE DC, 1988, KIDNEY INT, V34, P124, DOI 10.1038/ki.1988.155; MCBRIDE P, 1990, CLIN DIALYSIS, P20; Meier DE, 2002, NEW ENGL J MED, V346, P1087, DOI 10.1056/NEJM200204043461413; Merkus MP, 1999, NEPHROL DIAL TRANSPL, V14, P1163, DOI 10.1093/ndt/14.5.1163; Moss A H, 2000, J Palliat Med, V3, P253, DOI 10.1089/jpm.2000.3.253; MOSS AH, 1993, J AM SOC NEPHROL, V4, P229; *NAT KIDN FDN, 1996, IN WITHDR DIAL END S; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; RABETOY CP, IN PRESS EDTNA ERCA; *REN PHYS ASS AM S, 2000, SHAR DEC MAK APPR IN, V2; Rettig RA, 1991, KIDNEY FAILURE FEDER; Ries LAG, 2002, SEER CANC STAT REV; Saunders C, 1989, TXB PAIN, P624; Sekkarie MA, 1998, AM J KIDNEY DIS, V31, P464, DOI 10.1053/ajkd.1998.v31.pm9506683; Shidler NR, 1998, AM J KIDNEY DIS, V32, P557, DOI 10.1016/S0272-6386(98)70017-4; Shuster JL, 1999, PSYCHOSOMATICS, V40, P1; Singer PA, 1999, AM J KIDNEY DIS, V33, P980; SINGER PA, 1992, J AM SOC NEPHROL, V2, P1235; SULLIVAN MD, 1994, AM J PSYCHIAT, V151, P971; *US REN DAT SYST, 2002, USRDS 2002 ANN DAT R; *US REN DAT SYST, 1999, AM J KIDNEY DIS S, V34, pS1; *US REN DAT SYST, 2001, USRDS 2001 ANN DAT R; Valderrabano F, 2001, AM J KIDNEY DIS, V38, P443, DOI 10.1053/ajkd.2001.26824; Weisbord SD, 2002, J AM SOC NEPHROL, V13, p706A; WEISBORD SD, IN PRESS NEPHROL DIA; Woods A, 1999, J NEPHROL SOCIAL WOR, V19, P9; World Health Organization, 1996, CANC PAIN REL; Zaubler TS, 2000, PSYCHOSOMATICS, V41, P193, DOI 10.1176/appi.psy.41.3.193	75	78	81	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2113	2119		10.1001/jama.289.16.2113	http://dx.doi.org/10.1001/jama.289.16.2113			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709469				2023-01-03	WOS:000182374300027
J	Hsu, STD; Breukink, E; Bierbaum, G; Sahl, HG; de Kruijff, B; Kaptein, R; van Nuland, NAJ; Bonvin, AMJJ				Hsu, STD; Breukink, E; Bierbaum, G; Sahl, HG; de Kruijff, B; Kaptein, R; van Nuland, NAJ; Bonvin, AMJJ			NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles - Conformational changes are a key to antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; MOLECULAR-DYNAMICS SIMULATION; LANTIBIOTIC MERSACIDIN; STEREOSPECIFIC ASSIGNMENTS; COUPLING-CONSTANTS; PORE FORMATION; PROTEINS; BIOSYNTHESIS; MECHANISM; NISIN	Mersacidin belongs to the type B lantibiotics (lanthionine-containing antibiotics) that contain post-translationally modified amino acids and cyclic ring structures. It targets the cell wall precursor lipid 11 and thereby inhibits cell wall synthesis. In light of the emerging antibiotics resistance problem, the understanding of the antibacterial activity on a structural basis provides a key to circumvent this issue. Here we present solution NMR studies of mersacidin-lipid II interaction in dodecylphosphocholine (DPC) micelles. Distinct solution structures of mersacidin were determined in three different states: in water/methanol solution and in DPC micelles with and without lipid II. The structures in various sample conditions reveal remarkable conformational changes in which the junction between Ala-12 and Abu-13 (where Abu is aminobutyric acid) effectively serves as the hinge for the opening and closure of the ring structures. The DPC micelle-bound form resembles the previously determined NMR and x-ray crystal structures of mersacidin in pure methanol but substantially deviates from the other two states in our current report. The structural changes delineate the large chemical shift perturbations observed during the course of a two-step N-15-H-1 heteronuclear single quantum coherence titration. They also modulate the surface charge distribution of mersacidin suggesting that electrostatics play a central role in the mersacidin-lipid II interaction. The observed conformational adaptability of mersacidin might be a general feature of lipid II-interacting antibiotics/peptides.	Univ Utrecht, Ctr Biomembrane & Lipid Enzymol, NMR Dept, Bijovet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Univ Bonn, Inst Med Microbiol & Immunol, D-53015 Bonn, Germany	Utrecht University; University of Bonn	Bonvin, AMJJ (corresponding author), Univ Utrecht, Ctr Biomembrane & Lipid Enzymol, NMR Dept, Bijovet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands.	abonvin@nmr.chem.uu.nl	Hsu, Shang-Te Danny/B-2324-2009; Breukink, Eefjan/I-3039-2016; Hsu, Shang-Te Danny/L-2826-2014; Bonvin, Alexandre M.J.J./A-5420-2009	Hsu, Shang-Te Danny/0000-0002-7231-0185; Breukink, Eefjan/0000-0002-7311-0660; Hsu, Shang-Te Danny/0000-0002-7231-0185; Bonvin, Alexandre M.J.J./0000-0001-7369-1322				ANGLISTER J, 1993, J BIOMOL NMR, V3, P121; Bader R, 2001, J MOL BIOL, V305, P307, DOI 10.1006/jmbi.2000.4264; BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; BIERBAUM G, 1995, FEMS MICROBIOL LETT, V127, P121, DOI 10.1016/0378-1097(95)00048-A; Bonvin AMJJ, 2001, J BIOMOL NMR, V21, P221, DOI 10.1023/A:1012935005256; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Brotz H, 2000, J ANTIMICROB CHEMOTH, V46, P1, DOI 10.1093/jac/46.1.1; Brotz H, 1998, MOL MICROBIOL, V30, P317, DOI 10.1046/j.1365-2958.1998.01065.x; Brotz H, 1997, EUR J BIOCHEM, V246, P193, DOI 10.1111/j.1432-1033.1997.t01-1-00193.x; Brotz H, 1998, ANTIMICROB AGENTS CH, V42, P154, DOI 10.1128/AAC.42.1.154; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cudic P, 2002, P NATL ACAD SCI USA, V99, P7384, DOI 10.1073/pnas.102192099; Dayie KT, 1996, ANNU REV PHYS CHEM, V47, P243, DOI 10.1146/annurev.physchem.47.1.243; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Feenstra KA, 1999, J COMPUT CHEM, V20, P786, DOI 10.1002/(SICI)1096-987X(199906)20:8<786::AID-JCC5>3.0.CO;2-B; Hsu ST, 2002, BIOCHEMISTRY-US, V41, P7670, DOI 10.1021/bi025679t; Jack RW, 2000, CURR OPIN CHEM BIOL, V4, P310, DOI 10.1016/S1367-5931(00)00094-6; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; KESSLER H, 1993, HELV CHIM ACTA, V76, P117, DOI 10.1002/hlca.19930760106; KESSLER H, 1992, BIOPOLYMERS, V32, P427, DOI 10.1002/bip.360320420; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LUDVIGSEN S, 1991, J MOL BIOL, V217, P731, DOI 10.1016/0022-2836(91)90529-F; Marrink SJ, 2000, J PHYS CHEM B, V104, P12165, DOI 10.1021/jp001898h; Mattos C, 2001, CURR OPIN STRUC BIOL, V11, P761, DOI 10.1016/S0959-440X(01)00278-0; NAGARJAN R, 1993, J ANTIBIOT, V46, P1181, DOI 10.7164/antibiotics.46.1181; Neidigh JW, 2001, BIOCHEMISTRY-US, V40, P13188, DOI 10.1021/bi010902s; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; Opella SJ, 2001, METHOD ENZYMOL, V339, P285, DOI 10.1016/S0076-6879(01)39319-9; Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129; Palmer AG, 1997, CURR OPIN STRUC BIOL, V7, P732, DOI 10.1016/S0959-440X(97)80085-1; Prasch T, 1997, EUR J BIOCHEM, V244, P501, DOI 10.1111/j.1432-1033.1997.00501.x; Schneider TR, 2000, ACTA CRYSTALLOGR D, V56, P705, DOI 10.1107/S0907444900003711; Vertesy L, 1999, J ANTIBIOT, V52, P730; Wand AJ, 1998, P NATL ACAD SCI USA, V95, P15299, DOI 10.1073/pnas.95.26.15299; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Williams KA, 1996, BIOCHEMISTRY-US, V35, P5145, DOI 10.1021/bi952897w; Wymore T, 1999, J MOL STRUCT, V485, P195, DOI 10.1016/S0022-2860(99)00090-3; XU RX, 1992, FEBS LETT, V305, P137, DOI 10.1016/0014-5793(92)80881-G; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zimmermann N, 1997, EUR J BIOCHEM, V246, P809, DOI 10.1111/j.1432-1033.1997.00809.x; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	50	110	114	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13110	13117		10.1074/jbc.M211144200	http://dx.doi.org/10.1074/jbc.M211144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562773	hybrid, Green Published			2023-01-03	WOS:000182189500067
J	Li, YY; Cunin, F; Link, JR; Gao, T; Betts, RE; Reiver, SH; Chin, V; Bhatia, SN; Sailor, MJ				Li, YY; Cunin, F; Link, JR; Gao, T; Betts, RE; Reiver, SH; Chin, V; Bhatia, SN; Sailor, MJ			Polymer replicas of photonic porous silicon for sensing and drug delivery applications	SCIENCE			English	Article							OPTICAL-PROPERTIES; FILTERS	Elaborate one-dimensional photonic crystals are constructed from a variety of organic and biopolymers, which can be dissolved or melted, by templating the solution-cast or injection-molded materials in porous silicon or porous silicon dioxide multilayer (rugate dielectric mirror) structures. After the removal of the template by chemical dissolution, the polymer castings replicate the photonic features and the nanostructure of the master. We demonstrate that these castings can be used as vapor sensors, as deformable and tunable optical filters, and as self-reporting, bioresorbable materials.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Li, YY (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr,Dept 0358, La Jolla, CA 92093 USA.		Sailor, Michael J/H-9044-2017; Li, Yang Yang/J-9243-2012	Sailor, Michael J/0000-0002-4809-9826; LI, Yang Yang/0000-0003-4153-9558				Allcock P, 2001, J APPL PHYS, V90, P5052, DOI 10.1063/1.1412268; Berger MG, 1997, THIN SOLID FILMS, V297, P237, DOI 10.1016/S0040-6090(96)09361-3; Cunin F, 2002, NAT MATER, V1, P39, DOI 10.1038/nmat702; Gao J, 2002, LANGMUIR, V18, P2229, DOI 10.1021/la015568f; HALIMAOUI A, 1997, PROPERTIES POROUS SI, P12; Haynes CL, 2001, J PHYS CHEM B, V105, P5599, DOI 10.1021/jp010657m; Hulteen JC, 1997, J MATER CHEM, V7, P1075, DOI 10.1039/a700027h; Lehmann V, 2001, APPL PHYS LETT, V78, P589, DOI 10.1063/1.1334943; Matthias S, 2002, ADV MATER, V14, P1618, DOI 10.1002/1521-4095(20021118)14:22<1618::AID-ADMA1618>3.0.CO;2-A; Moller K, 1998, CHEM MATER, V10, P2950, DOI 10.1021/cm980243e; Pavesi L, 1997, SEMICOND SCI TECH, V12, P570, DOI 10.1088/0268-1242/12/5/009; Polarz S, 2002, CHEM COMMUN, P2593, DOI 10.1039/b205708p; Reese CE, 2001, ANAL CHEM, V73, P5038, DOI 10.1021/ac010667j; Schmedake TA, 2002, ADV MATER, V14, P1270, DOI 10.1002/1521-4095(20020916)14:18<1270::AID-ADMA1270>3.0.CO;2-R; Snow PA, 1999, J APPL PHYS, V86, P1781, DOI 10.1063/1.370968; Thonissen M., 1997, PROPERTIES POROUS SI, V18, P30; Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u; VINCENT G, 1994, APPL PHYS LETT, V64, P2367, DOI 10.1063/1.111982; Wirtz M, 2002, CHEM-EUR J, V8, P3573; Xu XL, 2002, J AM CHEM SOC, V124, P13864, DOI 10.1021/ja026901k; Zangooie S, 1997, SENSOR ACTUAT B-CHEM, V43, P168, DOI 10.1016/S0925-4005(97)00148-2	21	341	395	4	162	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					2045	2047		10.1126/science.1081298	http://dx.doi.org/10.1126/science.1081298			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663921				2023-01-03	WOS:000181834200047
J	Kerr, DJ; McArdle, CS; Ledermann, J; Taylor, I; Sherlock, DJ; Schlag, PM; Buckels, J; Mayer, D; Cain, D; Stephens, RJ				Kerr, DJ; McArdle, CS; Ledermann, J; Taylor, I; Sherlock, DJ; Schlag, PM; Buckels, J; Mayer, D; Cain, D; Stephens, RJ		MRC EORTC Colorectal Canc Study Gr	Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial	LANCET			English	Article							QUALITY-OF-LIFE; INTRAARTERIAL FLOXURIDINE; SYSTEMIC FLUOROURACIL; HEPATIC METASTASES; PLUS LEUCOVORIN; CHEMOTHERAPY; INFUSION; CARCINOMA; FLUORODEOXYURIDINE; ONCOLOGY	Background The liver is the most frequent site for metastases of colorectal cancer, which is the second largest contributor to cancer deaths in Europe. We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver. Methods We randomly allocated 290 patients from 16 centres to receive either intravenous chemotherapy (folinic acid 200 mg/m(2), fluorouracil bolus 400 mg(2) and 22-h infusion 600 mg/m(2), day 1 and 2, repeated every 14 days), or IHA chemotherapy designed to be equitoxic (folinic acid 200 mg/m(2), fluorouracil 400 mg/m(2) over 15 mins and 22-h infusion 1600 mg/m(2), day 1 and 2, repeated every 14 days). The primary endpoint was overall survival, and analysis was by intention to treat. Findings 50 (37%) patients allocated to IHA did not start their treatment, and another 39 (29%) had to stop before receiving six cycles of treatment because of catheter failure. The IHA group received a median of two cycles (0-6), compared with 8.5 (6-12) for the intravenous group. 45 (51%) IHA patients who did not start or did not receive six cycles switched to intravenous treatment. In both groups, grade 3 or 4 toxicity was uncommon. Median overall survival was 14.7 months for the IHA group and 14.8 months for the intravenous group (hazard ratio 1.04 [95% CI 0.80-1.33], log-rank test p=0.79). Similarly, there was no significant difference in progression-free survival. Interpretation Our results showed no evidence of an advantage in progression-free survival or overall survival for the IHA group; thus continued use of this regimen cannot be recommended outside of a clinical trial.	Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England; Glasgow Royal Infirm, Dept Surg, Glasgow G4 0SF, Lanark, Scotland; UCL, Dept Surg & Oncol, London, England; N Manchester Grp Hosp, Manchester, Lancs, England; Humboldt Univ, Robert Roessle Klin, Dept Surg, Berlin, Germany; Univ Hosp Trust Birmingham, Liver Unit, Birmingham, W Midlands, England; MRC, Clin Trials Unit, Canc Div, London, England	Radcliffe Infirmary; University of Oxford; University of Glasgow; University of London; University College London; Humboldt University of Berlin; Medical Research Council Clinical Trials Unit	Kerr, DJ (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.	david.kerr@clinical-pharmacology.oxford.ac.uk		Sherlock, David/0000-0001-7630-0833				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; ALLENMERSH TG, 1994, LANCET, V344, P1255, DOI 10.1016/S0140-6736(94)90750-1; Anderson D, 1997, J CHROMATOGR B, V688, P87, DOI 10.1016/S0378-4347(97)88059-0; Blesing CH, 1996, J DRUG TARGET, V3, P341, DOI 10.3109/10611869608996825; BLESING CH, 1996, BRIT J RADIOL, V32, P14; Buyse M, 1996, J NATL CANCER I, V88, P252; CHANG AE, 1987, ANN SURG, V206, P685, DOI 10.1097/00000658-198712000-00001; Cohen AM, 1996, EUR J CANCER, V32A, P2195, DOI 10.1016/S0959-8049(96)00393-0; DETAKATS PG, 1994, BRIT J CANCER, V69, P372, DOI 10.1038/bjc.1994.68; Doci R, 1990, REG CANCER TREAT, V3, P13; HOHN DC, 1989, J CLIN ONCOL, V7, P1646, DOI 10.1200/JCO.1989.7.11.1646; KEMENY MM, 1986, CANCER, V57, P492, DOI 10.1002/1097-0142(19860201)57:3<492::AID-CNCR2820570315>3.0.CO;2-M; KEMENY N, 1987, ANN INTERN MED, V107, P459, DOI 10.7326/0003-4819-107-4-459; KERR DJ, 1995, J CLIN ONCOL, V13, P2968, DOI 10.1200/JCO.1995.13.12.2968; Koehne CH, 1999, ANN ONCOL, V10, P877, DOI 10.1023/A:1008348904180; Lorenz M, 2000, J CLIN ONCOL, V18, P243, DOI 10.1200/JCO.2000.18.2.243; MARTIN JK, 1990, ARCH SURG-CHICAGO, V125, P1022; Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X; Nicum S, 2000, J ROY SOC MED, V93, P416, DOI 10.1177/014107680009300807; O'Connell MJ, 1998, J CLIN ONCOL, V16, P2528, DOI 10.1200/JCO.1998.16.7.2528; ROUGIER P, 1992, J CLIN ONCOL, V10, P1112, DOI 10.1200/JCO.1992.10.7.1112; Seymour MT, 1996, J CLIN ONCOL, V14, P2280, DOI 10.1200/JCO.1996.14.8.2280; Sobrero A, 2000, EUR J CANCER, V36, P559, DOI 10.1016/S0959-8049(99)00314-7; Stephens R, 2001, LANCET ONCOL, V2, P9, DOI 10.1016/S1470-2045(00)00186-8; Wickremesekera JK, 2000, AUST NZ J SURG, V70, P496, DOI 10.1046/j.1440-1622.2000.01858.x; Young AN, 1999, CLIN PHARMACOKINET, V36, P391, DOI 10.2165/00003088-199936060-00001; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	27	189	195	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 1	2003	361	9355					368	373		10.1016/S0140-6736(03)12388-4	http://dx.doi.org/10.1016/S0140-6736(03)12388-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642CP	12573372				2023-01-03	WOS:000180787000008
J	Prendergast, TJ; Puntillo, KA				Prendergast, TJ; Puntillo, KA			Withdrawal of life support - Intensive caring at the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE-UNIT PATIENTS; SUSTAINING TREATMENT; ADVANCE DIRECTIVES; MECHANICAL VENTILATION; MEDICAL FUTILITY; DECISION-MAKING; FAMILY-MEMBERS; DYING PATIENTS; ILL PATIENTS; IMPACT	The technology and expertise of critical care practice support patients through life-threatehing illnesses. Most recover; some die quickly; others, however, linger-neither improving nor acutely dying, alive but with a dwindling capacity to recover from their injury or illness. Management of these patients is often dominated by the question: Is it appropriate to continue life-sustaining therapy? Patients rarely participate in these pivotal discussions because they are either too sick or too heavily sedated. As a result, the decision often falls to the family or the surrogate decision maker, in consultation with the medical team. Decisions of such import are emotionally stressful and are often a source of disagreement. Failure to resolve such disagreements may create conflict that compromises patient care, engenders guilt among family members, and creates dissatisfaction for health care professionals. However, the potential for strained communications is mitigated if clinicians provide timely clinical and prognostic information and support the patient and family with aggressive symptom control, a comfortable setting,and continuous psychosocial support. Effective communication includes sharing the burden of decision making with family members. This shift from individual responsibility to patient-focused consensus often permits the family to understand, perhaps reluctantly and with great sadness, that intensive caring may involve letting go of life-sustaining interventions.	Dartmouth Hitchcock Med Ctr, Dept Med, Sect Pulm & Crit Care Med 3D, Lebanon, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Dept Anesthesiol, Lebanon, NH 03766 USA; Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA	Dartmouth College; Dartmouth College; University of California System; University of California San Francisco	Prendergast, TJ (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Med, Sect Pulm & Crit Care Med 3D, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.j.prendergast@hitchcock.org						Abbott KH, 2001, CRIT CARE MED, V29, P197, DOI 10.1097/00003246-200101000-00040; *AM ASS COLL NURS, PEAC DEATH REC COMP; *AM NURS ASS, PROM COMF REL PAIN D; [Anonymous], 1990, CRIT CARE MED, V18, P1435; Asch DA, 1999, AM J MED, V107, P153, DOI 10.1016/S0002-9343(99)00198-9; Asch DA, 1996, MED CARE, V34, P103, DOI 10.1097/00005650-199602000-00002; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Azoulay E, 2000, CRIT CARE MED, V28, P3044, DOI 10.1097/00003246-200008000-00061; Azoulay E, 2002, AM J RESP CRIT CARE, V165, P438, DOI 10.1164/ajrccm.165.4.200108-006oc; BAGGS JG, 1993, NURS OUTLOOK, V41, P108; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; Campbell ML, 1999, CRIT CARE MED, V27, P73, DOI 10.1097/00003246-199901000-00029; CHRISTAKIS NA, 1995, J GEN INTERN MED, V10, P491, DOI 10.1007/BF02602399; Claessens MT, 2000, J AM GERIATR SOC, V48, pS146, DOI 10.1111/j.1532-5415.2000.tb03124.x; CLARKE DE, 1993, CHEST, V104, P1322, DOI 10.1378/chest.104.5.1322; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Cook DJ, 1999, CAN MED ASSOC J, V161, P1109; Cook DJ, 2001, MANAGING DEATH ICU, P59; Covinsky KE, 2000, J AM GERIATR SOC, V48, pS187, DOI 10.1111/j.1532-5415.2000.tb03131.x; Danis M, 1996, CRIT CARE MED, V24, P1811, DOI 10.1097/00003246-199611000-00009; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Desbiens NA, 1996, CRIT CARE MED, V24, P1953, DOI 10.1097/00003246-199612000-00005; Desbiens NA, 1999, J PAIN SYMPTOM MANAG, V17, P248, DOI 10.1016/S0885-3924(98)00149-3; Drought TS, 1996, CHEST, V110, P589, DOI 10.1378/chest.110.3.589; Ellershaw J, 2001, J PAIN SYMPTOM MANAG, V21, P12, DOI 10.1016/S0885-3924(00)00240-2; Faber-Langendoen K, 2000, ANN INTERN MED, V133, P886, DOI 10.7326/0003-4819-133-11-200012050-00013; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; Fisher R, 1991, GETTING YES; Foley KM, 2001, MANAGING DEATH INTEN, p[103, 127]; GIANAKOS D, 1995, CHEST, V108, P1405, DOI 10.1378/chest.108.5.1405; GILLIGAN T, 1995, CHEST, V108, P1407, DOI 10.1378/chest.108.5.1407; Goodman MD, 1998, CRIT CARE MED, V26, P701, DOI 10.1097/00003246-199804000-00018; Goold, 2000, JAMA, V283, P3199; Halevy A, 1996, JAMA-J AM MED ASSOC, V276, P571, DOI 10.1001/jama.276.7.571; Hall RI, 2000, CHEST, V118, P1424, DOI 10.1378/chest.118.5.1424; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Hansot E, 1996, ANN INTERN MED, V125, P149, DOI 10.7326/0003-4819-125-2-199607150-00016; HARPER R, 1991, PRESENCE VARIATIONS, P132; Harvey M A, 1996, Am J Crit Care, V5, P7; *HAST CTR, 1987, GUID TERM LIF SUST T; Huang ZB, 2000, CLIN GERIATR MED, V16, P313, DOI 10.1016/S0749-0690(05)70058-6; Kaplow R, 2000, Am J Crit Care, V9, P87; KAPP MB, 2001, MANAGING DEATH INTEN, P231; Keenan SP, 2000, J PALLIAT CARE, V16, pS40, DOI 10.1177/082585970001601S08; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KOLLEF MH, 2001, MANAGING DEATH ICU, P39; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; LANKEN PN, 1991, AM REV RESPIR DIS, V144, P726, DOI 10.1164/ajrccm/144.3_Pt_1.726; Lilly CM, 2000, AM J MED, V109, P469, DOI 10.1016/S0002-9343(00)00524-6; Luce JM, 2000, AM J RESP CRIT CARE, V162, P2029, DOI 10.1164/ajrccm.162.6.1-00; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Lynn J, 1997, New Horiz, V5, P56; McLean RF, 2000, CRIT CARE MED, V28, P100, DOI 10.1097/00003246-200001000-00016; Miles S., 2001, MANAGING DEATH INTEN, P207; MILLER DK, 1992, J GEN INTERN MED, V7, P475, DOI 10.1007/BF02599446; MURPHY DJ, 1990, JAMA-J AM MED ASSOC, V264, P2103, DOI 10.1001/jama.264.16.2103; Nelson HK, 2001, WILDLIFE SOC B, V29, P2; Nelson JE, 2001, CRIT CARE MED, V29, P277, DOI 10.1097/00003246-200102000-00010; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; Plows CW, 1999, JAMA-J AM MED ASSOC, V281, P937; POHLMAN AS, 1994, CRIT CARE MED, V22, P1241, DOI 10.1097/00003246-199408000-00007; Prendergast T J, 1997, New Horiz, V5, P62; Prendergast T. J, 2002, PRINCIPLES PRACTICE; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Prendergast TJ, 2001, CRIT CARE MED, V29, pN34, DOI 10.1097/00003246-200102001-00007; PRENDERGAST TJ, 1995, CHEST, V107, P836, DOI 10.1378/chest.107.3.836; Prendergast TJ, 2000, HOSP PRACT, V35, P91; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; Puchalski CM, 2000, J AM GERIATR SOC, V48, pS84, DOI 10.1111/j.1532-5415.2000.tb03146.x; PUNTILLO K, 1994, NURS RES, V43, P31; PUNTILLO K, 2000, P 9 WORLD C PAIN AUG, V16; Puntillo K A, 2001, Am J Crit Care, V10, P216; Puntillo KA, 1997, CRIT CARE MED, V25, P1159, DOI 10.1097/00003246-199707000-00017; Puntillo KA, 2001, MANAGING DEATH INTEN, P149; Quill TE, 2001, ANN INTERN MED, V135, P551, DOI 10.7326/0003-4819-135-7-200110020-00022; Rubenfeld G., 2001, MANAGING DEATH INTEN, P127; Schneiderman LJ, 1996, ANN INTERN MED, V125, P669, DOI 10.7326/0003-4819-125-8-199610150-00007; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; Schneiderman LJ, 2000, CRIT CARE MED, V28, P3920, DOI 10.1097/00003246-200012000-00033; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; Sulmasy DP, 1997, JAMA-J AM MED ASSOC, V277, P1854; Swigart V, 1996, HEART LUNG, V25, P483, DOI 10.1016/S0147-9563(96)80051-3; TENO JM, 1994, J AM GERIATR SOC, V42, P1202, DOI 10.1111/j.1532-5415.1994.tb06990.x; TILDEN VP, 1995, ARCH INTERN MED, V155, P633, DOI 10.1001/archinte.155.6.633; Tonelli MR, 1996, CHEST, V110, P816, DOI 10.1378/chest.110.3.816; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	97	84	87	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	2002	288	21					2732	2740		10.1001/jama.288.21.2732	http://dx.doi.org/10.1001/jama.288.21.2732			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	620UA	12460097				2023-01-03	WOS:000179549800033
J	Levinger, NE				Levinger, NE			Water in confinement	SCIENCE			English	Editorial Material							AQUEOUS REVERSE MICELLES; MOLECULAR SIMULATION; SOLVATION DYNAMICS; LIQUID WATER; SOLVENTS; SIZE		Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA	Colorado State University	Levinger, NE (corresponding author), Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.							Boyd JE, 2002, J PHYS CHEM B, V106, P6346, DOI 10.1021/jp0255740; Boyd JE, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.147401; Bursing H, 2001, PHYS CHEM CHEM PHYS, V3, P2378, DOI 10.1039/b009301g; DE TK, 1995, ADV COLLOID INTERFAC, V59, P95, DOI 10.1016/0001-8686(95)80005-N; Faeder J, 2000, J PHYS CHEM B, V104, P1033, DOI 10.1021/jp993076u; Faeder J, 2001, J PHYS CHEM B, V105, P11148, DOI 10.1021/jp010632n; Luisi P.L., 1984, REVERSE MICELLES BIO; OWRUTSKY JC, 1991, CHEM PHYS LETT, V184, P368, DOI 10.1016/0009-2614(91)80002-F; Pileni MP, 1997, BER BUNSEN PHYS CHEM, V101, P1578, DOI 10.1002/bbpc.19971011105; Salaniwal S, 1999, LANGMUIR, V15, P5188, DOI 10.1021/la9904556; Salaniwal S, 2001, LANGMUIR, V17, P1773, DOI 10.1021/la000554f; Senapati S, 2002, LANGMUIR, V18, P7371, DOI 10.1021/la025952s; Silber JJ, 1999, ADV COLLOID INTERFAC, V82, P189, DOI 10.1016/S0001-8686(99)00018-4; Venables DS, 2001, J PHYS CHEM B, V105, P9132, DOI 10.1021/jp0112065; Zhong Q, 2002, LANGMUIR, V18, P7401, DOI 10.1021/la0260234	15	282	284	1	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1722	1723		10.1126/science.1079322	http://dx.doi.org/10.1126/science.1079322			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459570				2023-01-03	WOS:000179494800023
J	Ball, K; Berch, DB; Helmers, KF; Jobe, JB; Leveck, MD; Marsiske, M; Morris, JN; Rebok, GW; Smith, DM; Tennstedt, SL; Unverzagt, FW; Willis, SL				Ball, K; Berch, DB; Helmers, KF; Jobe, JB; Leveck, MD; Marsiske, M; Morris, JN; Rebok, GW; Smith, DM; Tennstedt, SL; Unverzagt, FW; Willis, SL		ACTIVE Study Grp	Effects of cognitive training interventions with older adults - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI-MENTAL-STATE; MEMORY; AGE; PERFORMANCE; YOUNG; IMPAIRMENT; HEALTH; RECALL; CRASH; NORMS	Context Cognitive function in older adults is related to independent living and need for care. However, few studies have addressed whether improving cognitive functions might have short- or long-term effects on activities related to living independently: Objective To evaluate whether 3 cognitive training interventions improve mental abilities and daily functioning in older, independent-living adults. Design Randomized, controlled, single-blind trial with recruitment conducted from March 1998 to October 1999 and 2-year follow-up through December 2001. Setting and Participants Volunteer sample of 2832 persons aged 65 to 94 years recruited from senior housing, community centers, and hospital/clinics in 6 metropolitan areas in the United States. Interventions Participants were randomly assigned to 1 of 4 groups: 10-session group training for memory (verbal episodic memory; n=711), or reasoning (ability to solve problems that follow a serial pattern; n=705), or speed of processing (visual search and identification; n=712); or a no-contact control group (n=704). For the 3 treatment groups, 4-session booster training was offered to a 60% random sample 11 months later. Main Outcome Measures Cognitive function and cognitively demanding everyday functioning. Results Thirty participants were incorrectly randomized and were excluded from the analysis. Each intervention improved the targeted cognitive ability compared with baseline, durable to 2 years (P<.001 for all). Eighty-seven percent of speed-, 74% of reasoning-, and 26% of memory-trained participants demonstrated reliable cognitive improvement immediately after the intervention period. Booster training enhanced training gains in speed (P<.001) and reasoning (P<.001) interventions (speed booster, 92%; no booster, 68%; reasoning booster, 72%;. no booster, 49%), which were maintained at 2-year follow-up (P<.001 for both). No training effects on everyday functioning were detected at -2 years. Conclusions Results support the effectiveness and durability of the cognitive training interventions in improving targeted cognitive abilities: Training effects were of a magnitude equivalent to the amount of decline expected in elderly persons without dementia over 7- to 14-year intervals. Because of minimal functional decline across all groups, longer follow-up is likely required to observe training effects on everyday function.	Univ Alabama Birmingham, Dept Psychol, Ctr Res Appl Gerontol, Birmingham, AL 35294 USA; NIA, NIH, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Univ Florida, Inst Aging, Gainesville, FL USA; Univ Florida, Dept Hlth Policy & Epidemiol, Gainesville, FL USA; Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; Hebrew Rehabil Ctr Aged, Roslindale, MA USA; Johns Hopkins Univ, Dept Mental Hyg, Baltimore, MD USA; Indiana Univ, Sch Med, Dept Psychiat, Bloomington, IN USA; New England Res Inst, Watertown, MA 02172 USA; Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA	University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Johns Hopkins University; Maryland Department of Health & Mental Hygiene; Indiana University System; Indiana University Bloomington; HealthCore, Inc; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ball, K (corresponding author), Univ Alabama Birmingham, Dept Psychol, Ctr Res Appl Gerontol, 924 19th St S,101 Holley Mears Bldg, Birmingham, AL 35294 USA.	kball@uab.edu		Marsiske, Michael/0000-0001-5973-2116; Ball, Karlene/0000-0003-1811-9870	NATIONAL INSTITUTE OF NURSING RESEARCH [U01NR004507, U01NR004508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG014263, U01AG014289, U01AG014276, U01AG014260, U01AG014282] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; BALL K, 1988, Investigative Ophthalmology and Visual Science, V29, P448; Ball K., 2000, MOBILITY TRANSPORTAT, P213; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; Baltes P.B., 1982, AGING COGNITIVE PROC, P353, DOI DOI 10.1007/978-1-4684-4178-9_19; Blom G., 1958, STAT ESTIMATES TRANS; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Callahan CM, 1996, ARCH NEUROL-CHICAGO, V53, P134, DOI 10.1001/archneur.1996.00550020038013; CHURCHILL JD, IN PRESS NEUROBIOL A; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; COHEN GD, 1995, AM J GERIAT PSYCHIAT, V3, P1, DOI 10.1097/00019442-199524310-00001; Cohen J., 2013, STAT POWER ANAL BEHA; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; DIEHL M, 1995, PSYCHOL AGING, V10, P478, DOI 10.1037/0882-7974.10.3.478; Diehl M, 1998, ANN M GER SOC AM NOV; DUDEK FJ, 1979, PSYCHOL BULL, V86, P335, DOI 10.1037/0033-2909.86.2.335; EDWARDS JD, IN PRESS GERONTOLOGY; Ekstrom R. B., 1976, KIT FACTOR REFERENCE, VRev; *FED INT FOR AG RE, 2000, OLD AM 2000 KEY IND; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gonda J, 1985, SCHAIE THURSTONE MEN; GREENBERG C, 1987, ED GERONTOL, V12, P385; HOFLAND BF, 1981, J EDUC PSYCHOL, V73, P573, DOI 10.1037/0022-0663.73.4.573; Jobe JB, 2001, CONTROL CLIN TRIALS, V22, P453, DOI 10.1016/S0197-2456(01)00139-8; KLIEGL R, 1990, DEV PSYCHOL, V26, P894, DOI 10.1037/0012-1649.26.6.894; Krampe RT, 1996, J EXP PSYCHOL GEN, V125, P331, DOI 10.1037/0096-3445.125.4.331; LACHMAN ME, 1992, J GERONTOL, V47, pP293, DOI 10.1093/geronj/47.5.P293; LEIRER VO, 1988, J AM GERIATR SOC, V36, P877; LOWENTHAL MF, 1967, AGING MENTAL DISORDE; MCHORNEY CA, 1994, MED CARE, V32, P551, DOI 10.1097/00005650-199406000-00002; MORRIS J, 1997, MEASUREMENT ELDERLY; Morris JN, 1997, J AM GERIATR SOC, V45, P1017, DOI 10.1111/j.1532-5415.1997.tb02975.x; Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203; Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; OWSLEY C, IN PRESS GERONTOLOGY; Rasmusson DX, 1999, AGING NEUROPSYCHOL C, V6, P56, DOI 10.1076/anec.6.1.56.790; REBOK GW, 1989, DEV PSYCHOL, V25, P714, DOI 10.1037/0012-1649.25.5.714; RECANZONE GH, 2000, NEW COGNITIVE NEUROS, P237; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Schafer J.L., 1997, ANAL INCOMPLETE MULT; Schaie K. W., 1996, INTELLECTUAL DEV ADU; Small BJ, 1999, J GERONTOL B-PSYCHOL, V54, pP107, DOI 10.1093/geronb/54B.2.P107; Thurstone L. L., 1949, EXAMINER MANUAL SRA; WILLIS S, 1990, NEUROPSYCHOLOGY EVER, P183; Willis S L, 1986, Psychol Aging, V1, P239, DOI 10.1037/0882-7974.1.3.239; WILLIS SL, 1992, RES AGING, V14, P68, DOI 10.1177/0164027592141004; WILLIS SL, 1990, DEV PSYCHOL, V26, P905, DOI 10.1037/0012-1649.26.6.905; Willis SL., 1993, MANUAL EVERYDAY PROB; WILSON B, 1985, RIVER MEAD BEHAV MEM; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742; YESAVAGE JA, 1985, AM J PSYCHIAT, V142, P600; Zelinski EM, 1997, PSYCHOL AGING, V12, P503, DOI 10.1037/0882-7974.12.3.503	57	1298	1344	7	219	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2271	2281		10.1001/jama.288.18.2271	http://dx.doi.org/10.1001/jama.288.18.2271			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	614JZ	12425704	Green Accepted			2023-01-03	WOS:000179186400026
J	Strasburger, JF; Maron, BJ				Strasburger, JF; Maron, BJ			Commotio cordis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Childrens Mem Hosp, Chicago, IL 60614 USA; Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Minneapolis Heart Institute Foundation	Strasburger, JF (corresponding author), Childrens Mem Hosp, Chicago, IL 60614 USA.								0	19	19	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1248	1248		10.1056/NEJMicm020053	http://dx.doi.org/10.1056/NEJMicm020053			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393822				2023-01-03	WOS:000178598300006
J	Hohenleutner, U; Landthaler, M				Hohenleutner, U; Landthaler, M			Laser treatment of childhood haemangioma: progress or not?	LANCET			English	Editorial Material							PULSED DYE-LASER; HEMANGIOMAS; MANAGEMENT		Univ Regensburg Klinikum, Dermatol Klin & Poliklin, D-93042 Regensburg, Germany	University of Regensburg	Hohenleutner, U (corresponding author), Univ Regensburg Klinikum, Dermatol Klin & Poliklin, D-93042 Regensburg, Germany.							ASHINOFF R, 1993, PEDIATR DERMATOL, V10, P77, DOI 10.1111/j.1525-1470.1993.tb00021.x; ENJOLRAS O, 1993, PEDIATR DERMATOL, V10, P311, DOI 10.1111/j.1525-1470.1993.tb00393.x; Enjolras Odile, 1997, Journal of Dermatology (Tokyo), V24, P701; Frieden IJ, 1997, PEDIATR DERMATOL, V14, P57; GARDEN JM, 1992, J PEDIATR-US, V120, P555, DOI 10.1016/S0022-3476(05)82481-3; GRANTZOW R, 1995, MONATSSCHR KINDERH, V143, P369; Hohenleutner S, 2001, LASER SURG MED, V28, P273, DOI 10.1002/lsm.1050; MORELLI JG, 1993, MANAGEMENT TREATMENT, P124; Poetke M, 2000, ARCH DERMATOL, V136, P628, DOI 10.1001/archderm.136.5.628; WLOTZKE U, 1996, ZBL HAUT, V168, P21	10	13	13	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 17	2002	360	9332					502	503		10.1016/S0140-6736(02)09759-3	http://dx.doi.org/10.1016/S0140-6736(02)09759-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	585EZ	12241650				2023-01-03	WOS:000177512800004
J	Chastre, J; Wolff, M; Fagon, JY; Chevret, S; Thomas, F; Wermert, D; Clementi, E; Gonzalez, J; Jusserand, D; Asfar, P; Perrin, D; Fieux, F; Aubas, S				Chastre, J; Wolff, M; Fagon, JY; Chevret, S; Thomas, F; Wermert, D; Clementi, E; Gonzalez, J; Jusserand, D; Asfar, P; Perrin, D; Fieux, F; Aubas, S		PneumA Trial Grp	Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNITS; PSEUDOMONAS-AERUGINOSA; ANTIMICROBIAL RESISTANCE; ACINETOBACTER-BAUMANNII; NOSOCOMIAL PNEUMONIA; CONSENSUS CONFERENCE; ORGAN FAILURE; HOSPITALS; INFECTION; EPIDEMIOLOGY	Context The optimal duration of antimicrobial treatment for ventilator-associated pneumonia (VAP) is unknown. Shortening the length of treatment may help to contain the emergence of multiresistant bacteria in the intensive care unit (ICU). Objective To determine whether 8 days is as effective as 15 days of antibiotic treatment of patients with microbiologically proven VAP. Design, Setting, and Participants Prospective, randomized, double-blind (until day 8) clinical trial conducted in 51 French ICUs. A total of 401 patients diagnosed as having developed VAP by quantitative culture results of bronchoscopic specimens and who had received initial appropriate empirical antimicrobial therapy were enrolled between May 1999 and June 2002. Intervention A total of 197 patients were randomly assigned to receive 8 days and 204 to receive 15 days of therapy with an antibiotic regimen selected by the treating physician. Main Outcome Measures Primary outcome measures-death from any cause, microbiologically documented pulmonary infection recurrence, and antibiotic-free days-were assessed 28 days after VAP onset and analyzed on an intent-to-treat basis. Results Compared with patients treated for 15 days, those treated for 8 days had neither excess mortality (18.8% vs 17.2%; difference, 1.6%; 90% confidence interval [CI], -3.7% to 6.9%) nor more recurrent infections (28.9% vs 26.0%; difference, 2.9%; 90% CI, -3.2% to 9.1%), but they had more mean (SD) antibiotic-free days (13.1 [7.4] vs 8.7 [5.2] days, P<.001). The number of mechanical ventilation-free days, the number of organ failure-free days, the length of ICU stay, and mortality rates on day 60 for the 2 groups did not differ. Although patients with VAP caused by non-fermenting gram-negative bacilli, including Pseudomonas aeruginosa, did not have more unfavorable outcomes when antimicrobial therapy lasted only 8 days, they did have a higher pulmonary infection-recurrence rate compared with those receiving 15 days of treatment (40.6% vs; 25.4%; difference, 15.2%,90% CI, 3.9%-26.6%). Among patients who developed recurrent infections, multiresistant pathogens emerged less frequently in those who had received 8 days of antibiotics (42.1% vs 62.0% of pulmonary recurrences, P=.04). Conclusions Among patients who had received appropriate initial empirical therapy, with the possible exception of those developing nonfermenting gram-negative bacillus infections, comparable clinical effectiveness against VAP was obtained with the 8- and 15-day treatment regimens. The 8-day group had less antibiotic use.	Hop La Pitie Salpetriere, Serv Reanimat Med, Paris, France; Hop Bichat Claude Bernard, APHP, Serv Reanimat Med, F-75877 Paris 18, France; Hop Europeen Georges Pompidou, APHP, Serv Reanimat Med, Paris, France; Hop St Louis, APHP, Dept Biostat & Informat Med, Paris, France; Hop Diaconesses, Serv Reanimat, Paris, France; Hop Kremlin Bicetre, APHP, Serv Reanimat Med, Le Kremlin Bicetre, France; Hop Led Audaries, Serv Reanimat, La Roche Sur Yon, France; Hop Ray Poincare, APHP, Serv Reanimat Med, Garches, France; CHU Rouen, Dept Anesthesie & Reanimat, Rouen, France; CHU Angers, Serv Reanimat Med, Angers, France; Hop Courcouronne, Serv Reanimat, Evry, France; Hop St Louis, APHP, Serv Reanimat Med, Paris, France; CHU Montpellier, Dept Anesthesie & Reanimat, Montpellier, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Raymond-Poincare - APHP; CHU de Rouen; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Montpellier	Chastre, J (corresponding author), Grp Hosp Pitie Salpetriere, Inst Cardiol, Serv Reanimat Med, 47 Blvd Hop, F-75651 Paris 13, France.			chevret, sylvie/0000-0001-6449-4730				BASELSKI VS, 1994, CLIN MICROBIOL REV, V7, P533, DOI 10.1128/CMR.7.4.533-558.1994; Bergmans DCJJ, 1997, J ANTIMICROB CHEMOTH, V39, P527, DOI 10.1093/jac/39.4.527; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CHEST, V101, P1481, DOI 10.1378/chest.101.6.1481; Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; CHASTRE J, 1995, AM J RESP CRIT CARE, V152, P231, DOI 10.1164/ajrccm.152.1.7599829; Combes A, 2003, CRIT CARE MED, V31, P1102, DOI 10.1097/01.CCM.0000059313.31477.2C; Dennesen PJW, 2001, AM J RESP CRIT CARE, V163, P1371, DOI 10.1164/ajrccm.163.6.2007020; DURRLEMAN S, 1990, BIOMETRICS, V46, P329, DOI 10.2307/2531438; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; Fagon JY, 2000, ANN INTERN MED, V132, P621, DOI 10.7326/0003-4819-132-8-200004180-00004; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FINK MP, 1994, ANTIMICROB AGENTS CH, V38, P547, DOI 10.1128/AAC.38.3.547; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Fridkin SK, 1999, CLIN INFECT DIS, V29, P245, DOI 10.1086/520193; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; Gerberding J, 1999, AM J INFECT CONTROL, V27, P520; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; Ibrahim EH, 2001, CRIT CARE MED, V29, P1109, DOI 10.1097/00003246-200106000-00003; JENNISON C, 1984, CONTROL CLIN TRIALS, V5, P33, DOI 10.1016/0197-2456(84)90148-X; Kollef MH, 2001, ANN INTERN MED, V134, P298, DOI 10.7326/0003-4819-134-4-200102200-00014; Landman D, 2002, ARCH INTERN MED, V162, P1515, DOI 10.1001/archinte.162.13.1515; Lawton RM, 2000, INFECT CONT HOSP EP, V21, P256, DOI 10.1086/501754; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lepper PM, 2002, ANTIMICROB AGENTS CH, V46, P2920, DOI 10.1128/AAC.46.9.2920-2925.2002; Lipsitch M, 2000, P NATL ACAD SCI USA, V97, P1938, DOI 10.1073/pnas.97.4.1938; Mahgoub S, 2002, INFECT CONT HOSP EP, V23, P477, DOI 10.1086/502091; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Neuhauser MM, 2003, JAMA-J AM MED ASSOC, V289, P885, DOI 10.1001/jama.289.7.885; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; Rello J, 1998, AM J RESP CRIT CARE, V157, P912, DOI 10.1164/ajrccm.157.3.9703014; Shlaes DM, 1997, CLIN INFECT DIS, V25, P584, DOI 10.1086/513766; Singh N, 2000, AM J RESP CRIT CARE, V162, P505, DOI 10.1164/ajrccm.162.2.9909095; Trouillet JL, 1998, AM J RESP CRIT CARE, V157, P531, DOI 10.1164/ajrccm.157.2.9705064; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; WUNDERINK RG, 1992, CHEST, V102, pS580, DOI 10.1378/chest.102.5_Supplement_1.580S; 2002, MMWR MORB MORTAL WEE, V51, P565	41	853	911	0	42	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	2003	290	19					2588	2598		10.1001/jama.290.19.2588	http://dx.doi.org/10.1001/jama.290.19.2588			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744DQ	14625336				2023-01-03	WOS:000186613000029
J	Kenet, T; Bibitchkov, D; Tsodyks, M; Grinvald, A; Arieli, A				Kenet, T; Bibitchkov, D; Tsodyks, M; Grinvald, A; Arieli, A			Spontaneously emerging cortical representations of visual attributes	NATURE			English	Article							OBLIQUE CONTOURS; ONGOING ACTIVITY; IN-VIVO; CORTEX; VARIABILITY; RESPONSES; DYNAMICS; CELLS; SYNCHRONIZATION; CIRCUITS	Spontaneous cortical activity - ongoing activity in the absence of intentional sensory input - has been studied extensively(1), using methods ranging from EEG (electroencephalography)(2-4), through voltage sensitive dye imaging(5-7), down to recordings from single neurons(8,9). Ongoing cortical activity has been shown to play a critical role in development(10-14), and must also be essential for processing sensory perception, because it modulates stimulus-evoked activity(5,15,16), and is correlated with behaviour(17). Yet its role in the processing of external information and its relationship to internal representations of sensory attributes remains unknown. Using voltage sensitive dye imaging, we previously established a close link between ongoing activity in the visual cortex of anaesthetized cats and the spontaneous firing of a single neuron(6). Here we report that such activity encompasses a set of dynamically switching cortical states, many of which correspond closely to orientation maps. When such an orientation state emerged spontaneously, it spanned several hypercolumns and was often followed by a state corresponding to a proximal orientation. We suggest that dynamically switching cortical states could represent the brain's internal context, and therefore reflect or influence memory, perception and behaviour.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kenet, T (corresponding author), Univ Calif San Francisco, Keck Ctr Integrat Neurosci, 513 Parnassus Ave,Box 0732, San Francisco, CA 94143 USA.		tsodyks, misha/J-4430-2013; GRINVALD, AMIRAM/AAH-9919-2019	Tsodyks, Misha/0000-0002-5661-4349				Adrian ED, 1934, BRAIN, V57, P355, DOI 10.1093/brain/57.4.355; ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Azouz R, 1999, J NEUROSCI, V19, P2209; BENYISHAI R, 1995, P NATL ACAD SCI USA, V92, P3844, DOI 10.1073/pnas.92.9.3844; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; Chapman B, 1998, P NATL ACAD SCI USA, V95, P2609, DOI 10.1073/pnas.95.5.2609; Chiu CY, 2002, NEURON, V35, P1123, DOI 10.1016/S0896-6273(02)00867-X; Coppola DM, 1998, P NATL ACAD SCI USA, V95, P2621, DOI 10.1073/pnas.95.5.2621; CREUTZFELDT OD, 1966, ELECTROEN CLIN NEURO, V20, P19, DOI 10.1016/0013-4694(66)90137-4; Elul R, 1971, Int Rev Neurobiol, V15, P227; Ernst UA, 2001, NAT NEUROSCI, V4, P431, DOI 10.1038/86089; Fries P, 2001, NAT NEUROSCI, V4, P194, DOI 10.1038/84032; Grinvald A, 1999, MODERN TECHNIQUES NE, P893, DOI 10.1007/978-3-642-58552-4_34; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kisley MA, 1999, J NEUROSCI, V19, P10451; Kohonen T., 2000, SELF ORG MAPS; Lestienne R, 2001, PROG NEUROBIOL, V65, P545, DOI 10.1016/S0301-0082(01)00019-3; Li BW, 2003, J NEUROPHYSIOL, V90, P204, DOI 10.1152/jn.00954.2002; McCormick DA, 1999, SCIENCE, V285, P541, DOI 10.1126/science.285.5427.541; NODA H, 1970, BRAIN RES, V18, P513, DOI 10.1016/0006-8993(70)90134-4; Petersen CCH, 2003, J NEUROSCI, V23, P1298, DOI 10.1523/JNEUROSCI.23-04-01298.2003; Scherrer J, 1976, Prog Brain Res, V45, P309, DOI 10.1016/S0079-6123(08)60996-6; Shoham D, 1999, NEURON, V24, P791, DOI 10.1016/S0896-6273(00)81027-2; SOFTKY WR, 1993, J NEUROSCI, V13, P334; SOMERS DC, 1995, J NEUROSCI, V15, P5448; Sur M, 1999, J NEUROBIOL, V41, P33, DOI 10.1002/(SICI)1097-4695(199910)41:1<33::AID-NEU6>3.0.CO;2-1; Thompson I, 1997, CURR BIOL, V7, pR324, DOI 10.1016/S0960-9822(06)00150-3; Tsodyks M, 1999, SCIENCE, V286, P1943, DOI 10.1126/science.286.5446.1943; Wang G, 2003, NEUROSCI LETT, V338, P77, DOI 10.1016/S0304-3940(02)01355-1	30	617	622	3	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					954	956		10.1038/nature02078	http://dx.doi.org/10.1038/nature02078			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586468				2023-01-03	WOS:000186230600040
J	Murkofsky, RL; Phillips, RS; McCarthy, EP; Davis, RB; Hamel, MB				Murkofsky, RL; Phillips, RS; McCarthy, EP; Davis, RB; Hamel, MB			Length of stay in home care before and after the 1997 Balanced Budget Act	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE PAYMENT; FOR-PROFIT; OWNERSHIP; QUALITY; FACILITIES; MORTALITY; SERVICES	Context Prior to 1997, home health agencies (HHAs) were reimbursed on a fee-for-service basis and had incentives to provide more services. The 1997 Balanced Budget Act (BBA) reduced payments for home care services to help control Medicare spending. Objective To examine the length of stay in home care before and after the 1997 BBA. Design and Setting Cross-sectional study of home care patients in the 1996 and 1998 National Home and Hospice Care Surveys, which surveyed 1053 HHAs in 1996 and 1088 HHAs in 1998. Patients Nationally representative random sample of home care patients with Medicare coverage in 1996 (4127 patients) and 1998 (4051 patients). Main Outcome Measure Length of stay in home care (based on the number of days a patient was enrolled in home care services). Results From 1996 to 1998, unadjusted median length of stay decreased by 16 days for all home care patients (60-44 days, P=.002). The decrease affected for-profit HHAs more than not-for-profit HHAs (111-55 days [51% decrease, P=.002] vs 46-36 days [22% decrease, P=.042]). In a Cox proportional hazards model of time to discharge from home care, post-BBA year (1,998) was associated with a shorter length of stay in home care (adjusted hazard ratio [aHR] for home care discharge, 1.39 [95% confidence interval {CI}, 1.19-1.61]), and for-profit status was associated with a longer length of stay in home care (aHR, 0.82 [95% CI, 0.71-0.94]) after adjusting for patient demographics, diagnoses, and functional status. Conclusion After the 1997 BBA, length of stay in home care decreased among Medicare patients, particularly among those receiving care from for-profit HHAs.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Gerontol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Murkofsky, RL (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Gerontol, 1 Deaconess Rd,Palmer 119, Boston, MA 02215 USA.	rmurkofs@bidmc.harvard.edu			NIA NIH HHS [5K12AG00294] Funding Source: Medline; BHP HRSA HHS [5T32PE11001] Funding Source: Medline; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE011001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); BHP HRSA HHS; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Devereaux PJ, 2002, CAN MED ASSOC J, V166, P1399; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FREEMAN L, 1995, MON LABOR REV, V118, P3; Furth SL, 1999, PEDIATRICS, V104, P519, DOI 10.1542/peds.104.3.519; Garg PP, 1999, NEW ENGL J MED, V341, P1653, DOI 10.1056/NEJM199911253412205; Harrington C, 2001, AM J PUBLIC HEALTH, V91, P1452, DOI 10.2105/AJPH.91.9.1452; Himmelstein DU, 1999, JAMA-J AM MED ASSOC, V282, P159, DOI 10.1001/jama.282.2.159; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kominski G F, 1993, Health Care Financ Rev, V15, P121; McCall N, 2003, HEALTH SERV RES, V38, P85, DOI 10.1111/1475-6773.00106; MENKE T, 1990, INQUIRY-J HEALTH CAR, V27, P114; MULLER A, 1993, MED CARE, V31, P296, DOI 10.1097/00005650-199304000-00002; MUSHLIN AI, 1988, MED CARE, V26, P1081, DOI 10.1097/00005650-198811000-00006; *NAT CTR HLTH STAT, 1998, NAT HOM HOSP CAR SUR; *NAT CTR HLTH STAT, 1996, NAT HOM HOSP CAR SUR; *NAT CTR HLTH STAT, 2002, NAT HOM HOSP CAR SUR; *NAT CTR HLTH STAT, NAT HLTH CAR SURV; SCHEFFLER RM, 1994, MED CARE, V32, P471, DOI 10.1097/00005650-199405000-00006; SCHLESINGER M, 1989, MED CARE, V27, P244, DOI 10.1097/00005650-198903000-00003; Schlesinger M, 1997, MED CARE, V35, P974, DOI 10.1097/00005650-199709000-00009; Shah BV, 1996, SUDAAN USERS MANUAL; Thomas EJ, 2000, J GEN INTERN MED, V15, P211, DOI 10.1046/j.1525-1497.2000.015004211.x; Tu HT, 2002, NEW ENGL J MED, V346, P1288, DOI 10.1056/NEJMsa011250; *US DEP HHS, 1995, OEI049300260 US DEP; *US DEP HHS, 1995, OEI049300262 US DEP; *US DEP HHS, 1997, PUBL US DEP HHS; *US DEP HHS, 2000, PUBL US DEP HHS; *US DEP HHS, 1999, OEI029900530 US DEP; *US GAO, 1997, GAOHEHS97139R US GAO; *US GAO, 1998, MED HOM HLTH BEN IMP; *US GAO, 1996, GAOHEHS9616 US GAO; *US GAO, 2000, GAOHEHS00176 US GAO; *US GAO, 1998, SUBC HLTH COMM WAYS, P1; Yuan Z, 2000, MED CARE, V38, P231, DOI 10.1097/00005650-200002000-00012; 2002, FED REG         0628, V67, P43616; 1995, FED REG         0810, V60, P40847	37	34	34	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2003	289	21					2841	2848		10.1001/jama.289.21.2841	http://dx.doi.org/10.1001/jama.289.21.2841			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	684KH	12783915	Bronze			2023-01-03	WOS:000183205500033
J	Bogaty, P; Brophy, J				Bogaty, P; Brophy, J			Increasing burden of treatment in the acute coronary syndromes: is it justified?	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; CONSERVATIVE STRATEGIES; THROMBOLYSIS; MORTALITY; ASPIRIN		Univ Laval, Quebec Heart Inst, Quebec City, PQ, Canada; McGill Univ, Ctr Hlth, Montreal, PQ, Canada	Laval University; McGill University	Bogaty, P (corresponding author), Hop Laval, Quebec Heart Inst, 2725 Chemin St Foy, Ste Foy, PQ G1V 4G5, Canada.	Peter.Bogaty@med.ulaval.ca	brophy, james/H-6673-2019	brophy, james/0000-0001-8049-6875				ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boersma E, 2002, LANCET, V359, P189, DOI 10.1016/S0140-6736(02)07442-1; BRAUNWALD E, ACC AHA 2002 GUIDELI; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Choudhry NK, 2002, JAMA-J AM MED ASSOC, V287, P612, DOI 10.1001/jama.287.5.612; Erbel R, 1998, NEW ENGL J MED, V339, P1672, DOI 10.1056/NEJM199812033392304; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; Franzosi MG, 1998, CIRCULATION, V97, P2202, DOI 10.1161/01.CIR.97.22.2202; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Heidenreich PA, 2001, J AM COLL CARDIOL, V38, P478, DOI 10.1016/S0735-1097(01)01388-2; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; Liem AH, 2002, EUR HEART J, V23, P1931, DOI 10.1053/euhj.2002.3291; McPherson K, 2001, QUAL HEALTH CARE, V10, pI61; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Simoons ML, 2001, LANCET, V357, P1915; Topol E, 1998, NEW ENGL J MED, V339, P436; VOLPI A, 1993, CIRCULATION, V88, P416, DOI 10.1161/01.CIR.88.2.416; Wallentin L, 1999, LANCET, V354, P708; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2000, NEW ENGL J MED, V342, P145	26	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2003	361	9371					1813	1816		10.1016/S0140-6736(03)13407-1	http://dx.doi.org/10.1016/S0140-6736(03)13407-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781554				2023-01-03	WOS:000183074800024
J	Plant, PK; Owen, JL; Parrott, S; Elliott, MW				Plant, PK; Owen, JL; Parrott, S; Elliott, MW			Cost effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							POSITIVE PRESSURE VENTILATION; ACUTE RESPIRATORY-FAILURE; NONINVASIVE VENTILATION	Objective To evaluate the cost effectiveness of standard treatment with and without the addition of ward based non-invasive ventilation in patients admitted to hospital with all acute exacerbation of chronic obstructive pulmonary disease. Design Incremental cost effectiveness analysis of a randomised controlled trial. Setting Medical wards in 14 hospitals in the United Kingdom. Participants The trial comprised 236 patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease and mild to moderate acidosis (pH 7.25-7.35) secondary to respiratory failure. The economic analysis Compared the costs of treatment that these patients received after randomisation. Main outcome measure Incremental cost per in-hospital death. Results 24/118 died in the group receiving standard treatment and 12/118 in the group receiving non-invasive ventilation (P=0.05). Allocation to the group receiving non-invasive ventilation was associated with a reduction in costs of pound49362 ($78741; C73 109), mainly through reduced use of intensive care units. The incremental cost effectiveness ratio was -pound645 per death avoided (95% confidence interval -pound2310 to pound386), indicating a dominant (more effective and less costly) strategy. Modelling of these data indicates that a typical UK hospital providing a non-invasive ventilation service will avoid six deaths and three to nine admissions to intensive care units per year, with an associated cost reduction of pound112000-53000 per year. Conclusions Non-invasive ventilation is a highly cost, effective treatment that both reduced total costs and improved mortality in hospital.	St James Univ Hosp, Dept Resp Med, Leeds LS9 7TF, W Yorkshire, England; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	Saint James's University Hospital; University of York - UK	Plant, PK (corresponding author), St James Univ Hosp, Dept Resp Med, Leeds LS9 7TF, W Yorkshire, England.			Parrott, Steven James/0000-0002-0165-1150				Altman DG, 1991, PRACTICAL STAT MED R, P48; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; DRUMMOND MF, 1987, METHODS EC EVALUATIO, P74; DRUMMOND MF, 1987, METHODS EC EVALUATIO, P39; Keenan SP, 2000, CRIT CARE MED, V28, P2094, DOI 10.1097/00003246-200006000-00072; Kollef MH, 2000, LANCET, V356, P956, DOI 10.1016/S0140-6736(00)02708-2; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; Martin TJ, 2000, AM J RESP CRIT CARE, V161, P807, DOI 10.1164/ajrccm.161.3.9808143; Plant PK, 2000, THORAX, V55, P550, DOI 10.1136/thorax.55.7.550; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0	12	85	87	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 3	2003	326	7396					956	959		10.1136/bmj.326.7396.956	http://dx.doi.org/10.1136/bmj.326.7396.956			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676JC	12727767	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000182746700015
J	Savic, R; Luo, LB; Eisenberg, A; Maysinger, D				Savic, R; Luo, LB; Eisenberg, A; Maysinger, D			Micellar nanocontainers distribute to defined cytoplasmic organelles	SCIENCE			English	Article							BLOCK-COPOLYMER MICELLES; DRUG-DELIVERY; CELLS; NANOPARTICLES; DIBLOCK; TARGET; NERVE	Block copolymer micelles are water-soluble biocompatible nanocontainers with great potential for delivering hydrophobic drugs. An understanding of their cellular distribution is essential to achieving selective delivery of drugs at the subcellular level. Triple-labeling confocal microscopy in live cells revealed the localization of micelles in several cytoplasmic organelles, including mitochondria, but not in the nucleus. Moreover, micelles change the cellular distribution of and increase the amount of the agent delivered to the cells. These micelles may thus be worth exploring for their potential to selectively deliver drugs to specified subcellular targets.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Chem, Montreal, PQ H3A 2K6, Canada	McGill University; McGill University	Maysinger, D (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Eisenberg, Adi/B-8676-2008; Maysinger, Dusica/GYU-6332-2022					Allen C, 2000, DRUG DELIV, V7, P139; De Jaeghere F, 2000, J DRUG TARGET, V8, P143, DOI 10.3109/10611860008996860; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Haughland R.P., 1996, HDB FLUORESCENT PROB; Kabanov AV, 2002, CRIT REV THER DRUG, V19, P1, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10; Kakizawa Y, 2002, ADV DRUG DELIVER REV, V54, P203, DOI 10.1016/S0169-409X(02)00017-0; Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1; Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; Liaw J, 1999, PHARM RES-DORDR, V16, P213, DOI 10.1023/A:1012157906528; Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c; Luo LB, 2002, BIOCONJUGATE CHEM, V13, P1259, DOI 10.1021/bc025524y; MAYSINGER D, 2002, POLYM BIOMATERIALS, pCH42; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Rapoport N, 2002, J PHARM SCI, V91, P157, DOI 10.1002/jps.10006; Saltzman W. M., 2001, DRUG DELIVERY ENG PR; Szleifer I, 1997, CURR OPIN SOLID ST M, V2, P337, DOI 10.1016/S1359-0286(97)80125-8; Torchilin VP, 2002, ADV DRUG DELIVER REV, V54, P235, DOI 10.1016/S0169-409X(02)00019-4; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Webb RH, 1999, METHOD ENZYMOL, V307, P3; YOKOYAMA M, 1998, BIORELATED POLYM GEL, pCH6; Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777	23	978	1026	7	240	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					615	618		10.1126/science.1078192	http://dx.doi.org/10.1126/science.1078192			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714738				2023-01-03	WOS:000182453700034
J	Nichol, KL; Nordin, J; Mullooly, J; Lask, R; Fillbrandt, K; Iwane, M				Nichol, KL; Nordin, J; Mullooly, J; Lask, R; Fillbrandt, K; Iwane, M			Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXCESS MORTALITY; RISK-FACTOR; PREVENTING HOSPITALIZATION; PRECEDING INFECTION; COST-EFFECTIVENESS; BRAIN INFARCTION; REDUCED RISK; ASSOCIATION; EPIDEMIC; ADMISSIONS	BACKGROUND: Upper respiratory tract illnesses have been associated with an increased risk of ischemic heart disease and stroke. During two influenza seasons, we assessed the influence of vaccination against influenza on the risk of hospitalization for heart disease and stroke, hospitalization for pneumonia and influenza, and death from all causes. METHODS: Cohorts of community-dwelling members of three large managed-care organizations who were at least 65 years old were studied during the 1998-1999 and 1999-2000 influenza seasons. Administrative and clinical data were used to evaluate outcomes, with multivariable logistic regression to control for base-line demographic and health characteristics of the subjects. RESULTS: There were 140,055 subjects in the 1998-1999 cohort and 146,328 in the 1999-2000 cohort, of which 55.5 percent and 59.7 percent, respectively, were immunized. At base line, vaccinated subjects were on average sicker, having higher rates of most coexisting conditions, outpatient care, and prior hospitalization for pneumonia than unvaccinated subjects. Unvaccinated subjects, however, were more likely to have been given a prior diagnosis of dementia or stroke. Vaccination against influenza was associated with a reduction in the risk of hospitalization for cardiac disease (reduction of 19 percent during both seasons [P<0.001]), cerebrovascular disease (reduction of 16 percent during the 1998-1999 season [P<0.018] and 23 percent during the 1999-2000 season [P<0.001]), and pneumonia or influenza (reduction of 32 percent during the 1998-1999 season [P<0.001] and 29 percent during the 1999-2000 season [P<0.001]) and a reduction in the risk of death from all causes (reduction of 48 percent during the 1998-1999 season [P<0.001] and 50 percent during the 1999-2000 season [P<0.001]). In analyses according to age, the presence or absence of major medical conditions at base line, and study site, the findings were consistent across all subgroups. CONCLUSIONS: In the elderly, vaccination against influenza is associated with reductions in the risk of hospitalization for heart disease, cerebrovascular disease, and pneumonia or influenza as well as the risk of death from all causes during influenza seasons. These findings highlight the benefits of vaccination and support efforts to increase the rates of vaccination among the elderly.	Vet Affairs Med Ctr, Minneapolis, MN 55417 USA; Univ Minnesota, Minneapolis, MN USA; HealthPartners Res Fdn, Minneapolis, MN USA; Kaiser Permanente NW, Portland, OR USA; Oxford Hlth Plan, New York, NY USA; Ctr Dis Control & Prevent, Atlanta, GA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; HealthPartners Institute for Education & Research; Kaiser Permanente; UnitedHealth Group Incorporated; Centers for Disease Control & Prevention - USA	Nichol, KL (corresponding author), Vet Affairs Med Ctr, 1 Vet Dr, Minneapolis, MN 55417 USA.	nicho014@umn.edu		Nordin, James/0000-0002-3359-5843				*ADV COMM IMM PRAC, 2002, MMWR-MORBID MORTAL W, V51, P1; AHMED AEH, 1995, LANCET, V346, P591, DOI 10.1016/S0140-6736(95)91434-X; Ahmed AH, 1997, EPIDEMIOL INFECT, V118, P27, DOI 10.1017/S0950268896007121; ALLING DW, 1981, AM J EPIDEMIOL, V113, P30, DOI 10.1093/oxfordjournals.aje.a113063; [Anonymous], 1997, MMWR MORB MORT WKLY, V46, P1; BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; Becher H, 2000, J Epidemiol Biostat, V5, P277; Bova IY, 1996, STROKE, V27, P2204, DOI 10.1161/01.STR.27.12.2204; *CDCP, 2002, EARL REL SEL EST NAT; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P374; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P375; COLLINS S. D., 1932, Public Health Reports, V47, P2159, DOI 10.2307/4580606; COOK RJ, 1995, BRIT MED J, V310, P1056; Crocetti E, 2001, EUR J EPIDEMIOL, V17, P163, DOI 10.1023/A:1017978420601; *DEP HLTH HUM SERV, 2000, HLTH PEOPL 2010, V1; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; EPSEIN SE, 1999, CIRCULATION, V100, pE20; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V271, P1578; Fleming DM, 1995, EPIDEMIOL INFECT, V115, P581, DOI 10.1017/S095026880005874X; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; Gurfinkel EP, 2002, CIRCULATION, V105, P2143, DOI 10.1161/01.CIR.0000016182.85461.F4; Hak E, 2002, CLIN INFECT DIS, V35, P370, DOI 10.1086/341403; HOUSWORTH J, 1974, AM J EPIDEMIOL, V100, P40, DOI 10.1093/oxfordjournals.aje.a112007; Jackson LA, 2002, AM J EPIDEMIOL, V156, P634, DOI 10.1093/aje/kwf073; Jakovljevic D, 1996, STROKE, V27, P1774, DOI 10.1161/01.STR.27.10.1774; Lavallee P, 2002, STROKE, V33, P1172; Lavallee P, 2002, STROKE, V33, P513, DOI 10.1161/hs0202.102328; Mac Donald R, 1999, AM J PREV MED, V16, P173, DOI 10.1016/S0749-3797(98)00159-7; Macko RF, 1996, STROKE, V27, P1999, DOI 10.1161/01.STR.27.11.1999; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; Meier CR, 1998, LANCET, V351, P1467, DOI 10.1016/S0140-6736(97)11084-4; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; Naghavi M, 2000, CIRCULATION, V102, P3039; Nichol KL, 2001, ARCH INTERN MED, V161, P2702, DOI 10.1001/archinte.161.22.2702; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; NICHOL KL, 1998, TXB INFLUENZA, P358; Nordin J, 2001, J INFECT DIS, V184, P665, DOI 10.1086/323085; Ohmit SE, 1995, INT J EPIDEMIOL, V24, P1240, DOI 10.1093/ije/24.6.1240; PuigBarbera J, 1997, J EPIDEMIOL COMMUN H, V51, P526, DOI 10.1136/jech.51.5.526; Siscovick DS, 2000, AM J EPIDEMIOL, V152, P674, DOI 10.1093/aje/152.7.674; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; Stamboulian D, 1999, VACCINE, V17, pS53, DOI 10.1016/S0264-410X(99)00106-1; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; VALTONEN VV, 1991, ANN MED, V23, P539, DOI 10.3109/07853899109150515; Vu T, 2002, VACCINE, V20, P1831, DOI 10.1016/S0264-410X(02)00041-5	47	562	596	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1322	1332		10.1056/NEJMoa025028	http://dx.doi.org/10.1056/NEJMoa025028			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672859				2023-01-03	WOS:000181949100003
J	Bent, S; Tiedt, TN; Odden, MC; Shlipak, MG				Bent, S; Tiedt, TN; Odden, MC; Shlipak, MG			The relative safety of ephedra compared with other herbal products	ANNALS OF INTERNAL MEDICINE			English	Article							MA-HUANG; SUPPLEMENTS; TOXICITY; SYSTEM	Background: Ephedra is widely used in dietary supplements that are marketed to promote weight loss or increase energy; however, the safety of this product has been questioned because of numerous case reports of adverse events. Objective: To compare the risk for adverse events attributable to ephedra and other herbal products. Design: Comparative case series. Setting: American Association of Poison Control Centers Toxic Event Surveillance System Database Annual Report, 2001. Measurements: The relative risk and 95% confidence interval for experiencing an adverse reaction after ephedra. use compared with other herbs. This risk was defined as the ratio of adverse reactions to ephedra. versus other products, divided by the ratio of their relative use in the United States. Results: Products containing ephedra accounted for 64% of all adverse reactions to herbs in the United States, yet these products represented only 0.82% of herbal product sales. The relative risks for an adverse reaction in persons using ephedra compared with other herbs were extremely high, ranging from 100 (95% Cl, 83 to 140) for kava to 720 (Cl, 520 to 1100) for Ginkgo biloba. Conclusions: Ephedra use is associated with a greatly increased risk for adverse reactions compared with other herbs, and its use should be restricted.	San Francisco VA Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA; Med Tox Grp, Longboat Key, FL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco	Bent, S (corresponding author), San Francisco VA Med Ctr, 111-A1,4150 Clement St, San Francisco, CA 94121 USA.	bent@itsa.ucsf.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K08AT001338] Funding Source: NIH RePORTER; NCCIH NIH HHS [1 K08 AT01338-01] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Bloedorn WA, 1928, ARCH INTERN MED, V42, P322, DOI 10.1001/archinte.1928.00020020010002; Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539; Chen KK, 1930, MEDICINE, V9, P1, DOI 10.1097/00005792-193002000-00001; Foster S., 1999, TYLERS HONEST HERBAL; Gurley BJ, 1998, J PHARM SCI, V87, P1547, DOI 10.1021/js9801844; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; Hardman J.G., 2001, GOODMAN GILMANS PHAR, V10, DOI 10.1097/00000539-200205000-00085; KIMMEL SE, 2003, SUMMARY INCIDENCE SE; Litovitz TL, 2002, AM J EMERG MED, V20, P391, DOI 10.1053/ajem.2002.34955; RICHMAN A, 2001, 7 ANN HERB SALES SUR, P23; Rotblatt M, 2002, EVIDENCE BASED HERBA; Samenuk D, 2002, MAYO CLIN PROC, V77, P12, DOI 10.4065/77.1.12; Theoharides TC, 1997, J CLIN PSYCHOPHARM, V17, P437, DOI 10.1097/00004714-199710000-00025; TubertBitter P, 1996, J CLIN EPIDEMIOL, V49, P121, DOI 10.1016/0895-4356(95)00537-4; US Department of Health and Human Services Office of Inspector General, 2001, OEI010000180 US DEP; Vahedi K, 2000, J NEUROL NEUROSUR PS, V68, P112, DOI 10.1136/jnnp.68.1.112	16	94	102	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					468	471		10.7326/0003-4819-138-6-200303180-00010	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639079				2023-01-03	WOS:000181562400004
J	Druss, BG; Marcus, SC; Olfson, M; Tanielian, T; Pincus, HA				Druss, BG; Marcus, SC; Olfson, M; Tanielian, T; Pincus, HA			Trends in care by nonphysician clinicians in the United States.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NURSE PRACTITIONERS; PATIENT-CARE; PHYSICIAN ASSISTANTS; OUTCOMES	BACKGROUND: The 1990s saw rising numbers of graduates of training programs for nonphysician clinicians, passage of legislation expanding their scope of practice, and a proliferation of managed-care models that emphasized the use of these providers as a strategy for containing health care costs. METHODS: We used two nationally representative surveys to examine trends in outpatient care provided by physicians and nonphysician clinicians between 1987 and 1997, adjusting for the case mix. Analyses examined care provided by 10 categories of nonphysician clinicians: chiropractors, midwives, nurses or nurse practitioners, optometrists, podiatrists, physician assistants, physical or occupational therapists, psychologists, social workers, and others. RESULTS: Between 1987 and 1997, the proportion of patients who saw a nonphysician clinician rose from 30.6 percent to 36.1 percent (adjusted relative risk for 1997 as compared with 1987, 1.42 [95 percent confidence interval, 1.35 to 1.50]). The trend was driven by an increase in the proportion of persons who visited both a physician and a nonphysician clinician (from 23.5 percent to 30.9 percent; adjusted relative risk, 1.49 [95 percent confidence interval, 1.40 to 1.58]), rather than an increase in the proportion who saw only a nonphysician clinician (from 7.2 percent to 5.3 percent; adjusted relative risk, 0.81 [95 percent confidence interval, 0.70 to 0.93]). This pattern was consistent in analyses of specific medical conditions and specific types of nonphysician clinicians. There was an increase in the proportion of patients obtaining preventive services from nonphysician clinicians and a decline in the proportion receiving acute care services from such clinicians. CONCLUSIONS: From 1987 to 1997, there was a degree of differentiation between physicians and nonphysician clinicians with respect to the services they provided but not with respect to the patients they treated. The implications of these findings hinge on the degree to which the increase in conjoint service delivery represents growing coordination or fragmentation of care.	Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA; Univ Penn, Sch Social Work, Philadelphia, PA 19104 USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; RAND, Washington, DC USA; RAND, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA	Emory University; Rollins School Public Health; University of Pennsylvania; Columbia University; RAND Corporation; RAND Corporation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Druss, BG (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.		Olfson, Mark/AAA-8547-2021		NIMH NIH HHS [K08-MH01556-01A] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001556] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AG HEALTHC RES QU, 2002, CLIN CLASS SOFTW ICD; COHEN SB, 2000, AHRQ PUBLICATION; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P788, DOI 10.1001/jama.280.9.788; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P795, DOI 10.1001/jama.280.9.795; DIAL TH, 1995, HEALTH AFFAIR, V14, P168, DOI 10.1377/hlthaff.14.2.168; EDWARDS WS, 1989, DHHS PUBLICATION PHS; Glasgow RE, 2001, MILBANK Q, V79, P579, DOI 10.1111/1468-0009.00222; GOODE E, 2002, NY TIMES        0611, pF1; Grumbach K, 1998, JAMA-J AM MED ASSOC, V280, P825, DOI 10.1001/jama.280.9.825; *HLTH POL TRACK SE, 2002, NAT C STAT LEG JUN; HOFFMAN C, 1994, HEALTH AFFAIR, V13, P140, DOI 10.1377/hlthaff.13.4.140; Hooker RS, 2001, HEALTH AFFAIR, V20, P231, DOI 10.1377/hlthaff.20.4.231; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; KIRBY JB, 2001, AHRQ PUBLICATION; MELFI C, 1995, J CLIN EPIDEMIOL, V48, P917, DOI 10.1016/0895-4356(94)00202-2; Mundinger, 2000, JAMA, V283, P2521; SEKSCENSKI ES, 1994, NEW ENGL J MED, V331, P1266, DOI 10.1056/NEJM199411103311905; Shah BV, 1997, SUDAAN USERS MANUAL; SOX HC, 1979, ANN INTERN MED, V91, P459, DOI 10.7326/0003-4819-91-3-459; STARFIELD B, 1998, PRIMARY CARE BALANCI, P94; STARFIELD BH, 1976, MED CARE, V14, P625, DOI 10.1097/00005650-197607000-00008; Wagner EH, 2000, BMJ-BRIT MED J, V320, P569, DOI 10.1136/bmj.320.7234.569; *WHO, 1977, 9 REV C 1975 GEN WHO; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zuvekas SH, 2002, INQUIRY-J HEALTH CAR, V39, P76, DOI 10.5034/inquiryjrnl_39.1.76	25	117	118	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	2003	348	2					130	137		10.1056/NEJMsa020993	http://dx.doi.org/10.1056/NEJMsa020993			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	633DL	12519924				2023-01-03	WOS:000180263900006
J	Jafari, M; Forsberg, J; Gilcher, RO; Smith, JW; Crutcher, JM; McDermott, M; Brown, BR; George, JN				Jafari, M; Forsberg, J; Gilcher, RO; Smith, JW; Crutcher, JM; McDermott, M; Brown, BR; George, JN			Salmonella sepsis caused by a platelet transfusion from a donor with a pet snake	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; SEPTICEMIA		Univ Oklahoma, Hlth Sci Ctr, Hematol Oncol Sect, Dept Med, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA; Oklahoma Blood Inst, Oklahoma City, OK USA; Oklahoma Dept Hlth, Oklahoma City, OK USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	George, JN (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Hematol Oncol Sect, Dept Med, POB 26901, Oklahoma City, OK 73190 USA.							BRENNER FW, 1998, MODIFIED KAUFFMANNWH; CHIODINI RJ, 1981, AM J EPIDEMIOL, V113, P494, DOI 10.1093/oxfordjournals.aje.a113124; HEAL JM, 1987, TRANSFUSION, V27, P2, DOI 10.1046/j.1537-2995.1987.27187121466.x; Jacobs MR, 2001, TRANSFUSION, V41, P1331, DOI 10.1046/j.1537-2995.2001.41111331.x; Kuehnert MJ, 2001, TRANSFUSION, V41, P1493, DOI 10.1046/j.1537-2995.2001.41121493.x; Mermin J, 1997, PEDIATRICS, V99, P399, DOI 10.1542/peds.99.3.399; MERMIN J, 1998, 36 ANN M INF DIS SOC; Ness P, 2001, TRANSFUSION, V41, P857, DOI 10.1046/j.1537-2995.2001.41070857.x; RHAME FS, 1973, ANN INTERN MED, V78, P633, DOI 10.7326/0003-4819-78-5-633; SHANE SM, 1990, EPIDEMIOL INFECT, V105, P307, DOI 10.1017/S0950268800047907; Swaminathan B, 2001, EMERG INFECT DIS, V7, P382; VOETSCH D, 2002, 126 ANN M EXP AM PUB; Wollowitz S, 2001, SEMIN HEMATOL, V38, P4, DOI 10.1053/shem.2001.29495; 1999, MMWR MORB MORTAL WKL, V48, P1009; 1995, MMWR MORB MORTAL WKL, V44, P347; 1999, MMWR MORB MORTAL WKL, V48, P1051	16	40	41	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1075	1078		10.1056/NEJMoa021050	http://dx.doi.org/10.1056/NEJMoa021050			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362008				2023-01-03	WOS:000178332900004
J	Pierce, JP; Gilpin, EA				Pierce, JP; Gilpin, EA			Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALIFORNIA TOBACCO SURVEY; NICOTINE PATCH; TRANSDERMAL NICOTINE; DOUBLE-BLIND; TRIAL; POPULATION; TESTS	Context Successful smoking cessation is a major public health goal. In controlled clinical trials, nicotine replacement therapy (NRT) and the antidepressant bupropion have been shown to significantly increase cessation rates only for moderate to heavy smokers ( greater than or equal to15 cigarettes/d). Nicotine replacement therapy is heavily promoted to the general population by both the pharmaceutical industry and tobacco control advocates. Objective To examine trends in smoking cessation, pharmaceutical cessation aid use, and success in cessation in the general California population. Design, Setting, and Participants The large population-based California Tobacco Surveys of 1992, 1996, and 1999, including 5247 (71.3% response rate), 9725 (72.9% response rate), and 6412 (68.4% response rate) respondents, respectively. Main Outcome Measures Rates of cessation attempts ( greater than or equal to1 day) among smokers in the last year, use of pharmaceutical aids (mostly over-the-counter products since 1996), and cessation success. Results Between 1992 and 1999, cessation attempts among California smokers increased 61.4% (from 38.1% to 61.5%),and NRT use among quitters increased 50.5% (from 9.3% to 14.0%). A total of 17.2% of quitters used NRT, an antidepressant, or both as an aid to cessation in 1999. In 1996 and 1999, the median duration of aid use (14 days) was much less than recommended, and only about 20% of users had adjuvant one-on-one or group behavioral counseling. Use of NRT increased short-term cessation success in moderate to heavy smokers in each survey year. However, a long-term cessation advantage was only observed before NRT became widely available over-the-counter (August 1996). In 1999, no advantage for pharmaceutical aid users was observed in either the short or long term for the nearly 60% of California smokers classified as light smokers (<15 cigarettes/d). Conclusion Since becoming available over the counter, NRT appears no longer effective in increasing long-term successful cessation in California smokers.	Univ Calif San Diego, Ctr Canc, Canc Prevent & Control Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Pierce, JP (corresponding author), Univ Calif San Diego, Ctr Canc, Canc Prevent & Control Program, 0645, La Jolla, CA 92093 USA.	jppierce@ucsd.edu		Pierce, John/0000-0002-0075-7471				Burton S L, 2000, MMWR Morb Mortal Wkly Rep, V49, P665; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P504; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1217; Curry SJ, 1998, NEW ENGL J MED, V339, P673, DOI 10.1056/NEJM199809033391006; EFRON B, 1982, CMBS REGIONAL C SERI, V38; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244; FIORE MC, 1994, JAMA-J AM MED ASSOC, V71, P1940; FIORE MC, 2000, TREATING TOBACCO USE; GILPIN E, 1994, CANCER EPIDEM BIOMAR, V3, P613; Gilpin E, 2001, CALIFORNIA TOBACCO C; GIOVINO GA, 1993, TOBACCO CONTROL S, V2, pS3; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; Hays JT, 1999, AM J PUBLIC HEALTH, V89, P1701, DOI 10.2105/AJPH.89.11.1701; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903; Leischow SJ, 1999, AM J HEALTH BEHAV, V23, P61, DOI 10.5993/AJHB.23.1.7; ORLEANS CT, 1994, JAMA-J AM MED ASSOC, V271, P601, DOI 10.1001/jama.271.8.601; ORLEANS CT, 1996, TOBACCO CONTROL S, V5, pS3; Ossip-Klein D J, 1986, Health Psychol, V5 Suppl, P3, DOI 10.1037/0278-6133.5.Suppl.3; PIERCE JP, 1995, J NATL CANCER I, V87, P87, DOI 10.1093/jnci/87.2.87; Pierce JP, 1998, JAMA-J AM MED ASSOC, V280, P893, DOI 10.1001/jama.280.10.893; Pierce JP., 1998, TOBACCO CONTROL CALI; PIERCE JP, 1994, TOBACCU USE CALIFORN; RAO JNK, 1984, ANN STAT, V12, P46, DOI 10.1214/aos/1176346391; SAUL H, 1993, NEW SCI, V137, P12; Schauffler H H, 1997, Tob Control, V6 Suppl 1, pS81; SCHNEIDER NG, 1983, ADDICT BEHAV, V8, P253, DOI 10.1016/0306-4603(83)90020-5; Shaw JP, 1998, TOB CONTROL, V7, P161, DOI 10.1136/tc.7.2.161; Shiffman S, 1997, Tob Control, V6, P306; SILAGY C, 2000, COCHRANE DB SYST REV; Solberg LI, 2001, PREV MED, V33, P53, DOI 10.1006/pmed.2001.0853; Sonderskov J, 1997, AM J EPIDEMIOL, V145, P309; Stratton K., 2000, CLEARING SMOKE ASSES; *US DEP HHS, 2000, TREAT TOB US DEP; *US DEP HHS, 1989, DHHS PUBL PHS CDC; *US DEP HHS, 1990, PUBL US DEP HHS; US Department of Health and Human Services, 1980, HLTH CONS SMOK WOM R; Zhu SH, 2000, AM J PREV MED, V18, P305, DOI 10.1016/S0749-3797(00)00124-0	39	198	199	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	2002	288	10					1260	1264		10.1001/jama.288.10.1260	http://dx.doi.org/10.1001/jama.288.10.1260			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592BW	12215133	Bronze			2023-01-03	WOS:000177917700025
J	Thompson, T; Barbour, R; Schwartz, L				Thompson, T; Barbour, R; Schwartz, L			Adherence to advance directives in critical care decision making: vignette study	BRITISH MEDICAL JOURNAL			English	Article							PROFESSIONALS; ATTITUDES; VIEWS	Objective To explore health professionals' decision making in a critical care scenario when there is an advance directive. Design Qualitative study. Setting Scotland. Participants Interviewees (n = 12) comprising general practitioners, hospital specialists, and nurses, and six focus groups (n = 34 participants) comprising general practitioners, geriatricians (consultants and specialist registrars), hospital nurses, and hospice nurses. Results When presented with an advance directive that applied to the same hypothetical scenario, health professionals came to divergent conclusions as to the "right thing to do' " Arguments opposing treatment centred on the supremacy of autonomy as an ethical principle. Other arguments were that the decision to treat was consistent with the terms of the advance directive, or that, notwithstanding the advance directive, the patients quality of life was sufficient to warrant treatment. Conclusion Advance directives are open to widely varying interpretation. Some of this variability is related to the ambiguity of the directive's terminology whereas some is related to the willingness of health professionals to make subjective value judgments concerning quality of life.	Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England; Univ Dundee, Sch Nursing & Midwifery, Dundee DD1 4HJ, Scotland; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; Univ Glasgow, Dept Gen Practice, Glasgow G12 8QQ, Lanark, Scotland	University of Bristol; University of Dundee; McMaster University; University of Glasgow	Thompson, T (corresponding author), Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England.			Schwartz, Lisa/0000-0002-4959-225X				Barbour RS, 2000, FAM PRACT, V17, P83, DOI 10.1093/fampra/17.1.83; Barbour RS, 2001, BMJ-BRIT MED J, V322, P1115, DOI 10.1136/bmj.322.7294.1115; *BRIT MED ASS, 1999, WITHH WITHDR LIF PRO; Charles C, 1999, BRIT MED J, V319, P780, DOI 10.1136/bmj.319.7212.780; Collins K, 1999, BRIT J GEN PRACT, V49, P641; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; Ditto PH, 2001, ARCH INTERN MED, V161, P421, DOI 10.1001/archinte.161.3.421; Docker C, 2000, BMJ-BRIT MED J, V320, P54; DOWNIE RS, 2000, CLIN JUDGEMENT; DOWNIE RS, 1994, HLTH RESPECT, P51; DOWNIE RS, 1994, HLTH RESPECT, P141; Hojat M, 2001, ACAD MED, V76, P669, DOI 10.1097/00001888-200107000-00001; *HOUS LORDS, 1994, REP SEL COMM MED ETH, V1, P54; Ikonomidis S, 1999, J MED ETHICS, V25, P522, DOI 10.1136/jme.25.6.522; KELNER M, 1993, CAN MED ASSOC J, V148, P1331; Mallik M, 1997, J ADV NURS, V25, P130, DOI 10.1046/j.1365-2648.1997.1997025130.x; MCLEAN S, 2000, ETHICS LAW INTENSIVE, P68; MUHR T, 1997, ATLAS SHORT USERS GU; NEUBERGER J, 1999, DYING WELL GUIDE ENA; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [DOI 10.4324/9780203413081_CHAPTER_9, 10.4324/9780203413081_chapter_9]; SOMMERVILLE A, 1995, BRIT MED J, V310, P1663; Swartz R, 1998, Adv Ren Replace Ther, V5, P109; Thompson TDB, 2003, PALLIATIVE MED, V17, P403, DOI 10.1191/0269216303pm784oa	24	60	60	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1011	1014		10.1136/bmj.327.7422.1011	http://dx.doi.org/10.1136/bmj.327.7422.1011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593032	Bronze, Green Published			2023-01-03	WOS:000186294100016
J	Strayer, A; Wu, ZX; Christen, Y; Link, CD; Luo, Y				Strayer, A; Wu, ZX; Christen, Y; Link, CD; Luo, Y			Expression of the small heat-shock protein Hsp-16-2 in Caenorhabditis elegans is suppressed by Ginkgo biloba extract EGb 761	FASEB JOURNAL			English	Article						GFP reporter; ROS; oxidative stress	OXIDATIVE STRESS; GENE-EXPRESSION; DOUBLE-BLIND; RANDOMIZED-TRIAL; EGB 761(R); ALPHA; HSP27; PHOSPHORYLATION; INTERLEUKIN-1; ACCUMULATION	EGb 761, a standardized extract of Ginkgo biloba leaves, has been shown to have antioxidative properties. We have previously demonstrated that EGb 761 increases stress resistance and mean life span in the model organism Caenorhabditis elegans. In this study, the molecular mechanism of EGb 761 on alleviating effects of oxidative stress is further investigated using transgenic C. elegans expressing a jellyfish green fluorescent protein (GFP)-tagged inducible small heat-shock protein gene (hsp-16-2). The expression of hsp-16-2 induced by the pro-oxidant juglone and by heat shock was significantly suppressed by 86% and 33%, respectively, in the transgenic nematode fed with EGb 761. These effects of EGb 761 correlate with its ability to increase mean survival rate of the nematode in response to acute oxidative and thermal stresses, as well as to attenuate the basal levels of hydrogen peroxide in the organism. Thus, we interpret the suppression of hsp-16-2/GFP expression as an indication that EGb 761 decreases cellular stress resulting from exogenous treatments, therefore leading to a decreased transcriptional induction of the reporter transgene. These results support the hypothesis that EGb 761 augments the natural antistress system of C. elegans, thus increasing stress resistance and life span.	Univ So Mississippi, Dept Biol Sci, Hattiesburg, MS 39406 USA; Beaufour Ipsen, Paris, France; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA	University of Southern Mississippi; Ipsen; University of Colorado System; University of Colorado Boulder	Luo, Y (corresponding author), Univ So Mississippi, Dept Biol Sci, 2609 W 4th St, Hattiesburg, MS 39406 USA.	yuan.luo@usm.edu						Butterfield DA, 1999, LIFE SCI, V65, P1883, DOI 10.1016/S0024-3205(99)00442-7; Butterfield DA, 1997, P NATL ACAD SCI USA, V94, P674, DOI 10.1073/pnas.94.2.674; Chao SH, 2001, NUCLEIC ACIDS RES, V29, P767, DOI 10.1093/nar/29.3.767; Christen Y, 2002, CELL MOL BIOL, V48, P601; CHRISTEN Y, 2000, OXIDAT STRESS DIS, V5, P411; Curtis-Prior P, 1999, J PHARM PHARMACOL, V51, P535, DOI 10.1211/0022357991772817; DeFeudis F.V., 1998, GINKGO BILOBA EXTRAC; DeFeudis FV, 2002, DRUG DEVELOP RES, V57, P214, DOI 10.1002/ddr.10151; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Ganzera M, 2001, CHEM PHARM BULL, V49, P1170, DOI 10.1248/cpb.49.1170; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GuhaThakurta D, 2002, GENOME RES, V12, P701, DOI 10.1101/gr.228902; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Kato K, 2002, FASEB J, V16, P1432, DOI 10.1096/fj.02-0129fje; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Le Bars PL, 2000, DEMENT GERIATR COGN, V11, P230, DOI 10.1159/000017242; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Link CD, 1999, CELL STRESS CHAPERON, V4, P235, DOI 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2; Link CD, 2003, NEUROBIOL AGING, V24, P397, DOI 10.1016/S0197-4580(02)00224-5; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; Luo Y, 2001, J ALZHEIMERS DIS, V3, P401, DOI 10.3233/JAD-2001-3407; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mix JA, 2002, HUM PSYCHOPHARM CLIN, V17, P267, DOI 10.1002/hup.412; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Schutte A, 2001, TRANSPLANT P, V33, P3724, DOI 10.1016/S0041-1345(01)02520-9; Smith JV, 2002, CELL MOL BIOL, V48, P699; SMITH JV, 2003, IN PRESS J ALZHEIMER, V4; Solomon PR, 2002, JAMA-J AM MED ASSOC, V288, P835, DOI 10.1001/jama.288.7.835; Soulie C, 2002, CELL MOL BIOL, V48, P641; Taricani L, 2001, NUCLEIC ACIDS RES, V29, P3030, DOI 10.1093/nar/29.14.3030; Valdez MM, 2002, EUR J BIOCHEM, V269, P1806, DOI 10.1046/j.1432-1033.2002.02812.x; Wadsworth TL, 2001, BIOCHEM PHARMACOL, V62, P963, DOI 10.1016/S0006-2952(01)00734-1; Walker GA, 2001, J GERONTOL A-BIOL, V56, pB281, DOI 10.1093/gerona/56.7.B281; Ward CP, 2002, PHARMACOL BIOCHEM BE, V72, P913, DOI 10.1016/S0091-3057(02)00768-2; Watanabe CMH, 2001, P NATL ACAD SCI USA, V98, P6577, DOI 10.1073/pnas.111126298; Westman J, 2000, AMINO ACIDS, V19, P339, DOI 10.1007/s007260070065; Winter JC, 1998, PHYSIOL BEHAV, V63, P425, DOI 10.1016/S0031-9384(97)00464-2; Wu ZX, 2002, CELL MOL BIOL, V48, P725; Yatin SM, 1999, NEUROBIOL AGING, V20, P325	46	108	116	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2305	+		10.1096/fj.03-0376fje	http://dx.doi.org/10.1096/fj.03-0376fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525938				2023-01-03	WOS:000186343300010
J	Herrington, DM; Howard, TD				Herrington, DM; Howard, TD			From presumed benefit to potential harm - Hormone therapy and heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Winston Salem, NC 27109 USA; Wake Forest Univ, Sch Med, Dept Pediat, Winston Salem, NC 27109 USA	Wake Forest University; Wake Forest University	Herrington, DM (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Winston Salem, NC 27109 USA.							Grady D, 2003, NEW ENGL J MED, V348, P1835, DOI 10.1056/NEJMp030038; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365	2	66	66	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 7	2003	349	6					519	521		10.1056/NEJMp038108	http://dx.doi.org/10.1056/NEJMp038108			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	708JL	12904515				2023-01-03	WOS:000184563500001
J	Sepulveda, C; Habiyambere, V; Amandua, J; Borok, M; Kikule, E; Mudanga, B; Ngoma, T; Solomon, B				Sepulveda, C; Habiyambere, V; Amandua, J; Borok, M; Kikule, E; Mudanga, B; Ngoma, T; Solomon, B			Quality care at the end of life in Africa	BRITISH MEDICAL JOURNAL			English	Article									WHO, Program Canc Control, CH-1211 Geneva 27, Switzerland; WHO, HIV AIDS Care, CH-1211 Geneva, Switzerland; Minist Hlth, Kampala, Uganda; Univ Zimbabwe, Sch Med, Dept Med, Harare, Zimbabwe; Hospice Africa Uganda, Kampala, Uganda; Minist Hlth, AIDS STD Unit, Gaborone, Botswana; Ocean Rd Canc Inst, Dar Es Salaam, Tanzania; Univ Addis Ababa, Radiotherapy Ctr, Addis Ababa, Ethiopia	World Health Organization; World Health Organization; University of Zimbabwe; Addis Ababa University	Sepulveda, C (corresponding author), WHO, Program Canc Control, Ave Appia 20, CH-1211 Geneva 27, Switzerland.		Ngoma, Twalib/L-7874-2019					Ferlay J, 2001, GLOBOCAN 2000 CANC I; *JOINT UN PROGR HI, 2002, REP GLOB HIV AIDS EP; Organization WH, 2001, WORLD HLTH REPORT 20; Singer PA, 2002, BMJ-BRIT MED J, V324, P1291, DOI 10.1136/bmj.324.7349.1291; *UN DEV PROGR, 2002, HUM DEV REP 2002; *WHO, SYMPT REL TERM ILLN; WHO, 1998, CANC PAIN REL PALL C; *WHO, 2002, SEAL ANT THER RES LT; WHO, 1996, CANC PAIN REL GUID; World Health Organization, 1990, CANC PAIN REL PALL C; World Health Organization, 2002, NAT CANC CONTR PROGR	11	85	86	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 26	2003	327	7408					209	213		10.1136/bmj.327.7408.209	http://dx.doi.org/10.1136/bmj.327.7408.209			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	706DL	12881267	Green Published			2023-01-03	WOS:000184437300023
J	Wassertheil-Smoller, S; Hendrix, SL; Limacher, M; Heiss, G; Kooperberg, C; Baird, A; Kotchen, T; Curb, JD; Black, H; Rossouw, JE; Aragaki, A; Safford, M; Stein, E; Laowattana, S; Mysiw, WJ				Wassertheil-Smoller, S; Hendrix, SL; Limacher, M; Heiss, G; Kooperberg, C; Baird, A; Kotchen, T; Curb, JD; Black, H; Rossouw, JE; Aragaki, A; Safford, M; Stein, E; Laowattana, S; Mysiw, WJ		WHI Investigators	Effect of estrogen plus progestin on stroke in postmenopausal women - The Women's Health Initiative: A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; C-REACTIVE PROTEIN; ISCHEMIC-STROKE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; CIGARETTE-SMOKING; CLASSIFICATION; PLASMA; INFLAMMATION; CHOLESTEROL	Context The Women's Health Initiative (WHI) trial of estrogen plus progestin was stopped early because of adverse effects, including an increased risk of stroke in the estrogen plus progestin group. Objective To assess the effect of estrogen plus progestin on ischemic and hemorrhagic stroke and in subgroups, and to determine whether the effect of estrogen plus progestin was modified by baseline levels of blood biomarkers. Design Multicenter double-blind, placebo-controlled, randomized clinical trial involving 16608 women aged 50 through 79 years with an average follow-up of 5.6 years. Baseline levels of blood-based markers of inflammation, thrombosis, and lipid levels were measured in the first 140 centrally confirmed stroke cases and 513 controls. Interventions Participants received 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (n=8506) or placebo (n=8102). Main Outcome Measures Overall strokes and stroke subtype and severity were centrally adjudicated by stroke neurologists. Results One hundred fifty-one patients (1.8%) in the estrogen plus progestin and 107 (1.3%) in the placebo groups had strokes. Overall 79.8% of strokes were ischemic. For combined ischemic and hemorrhagic strokes, the intention-to-treat hazard ratio (HR) for estrogen plus progestin vs placebo was 1.31 (95% confidence interval [CI], 1.02-1.68); with adjustment for adherence, the HR was 1.50 (95% CI, 1.08-2.08). The HR for ischemic stroke was 1.44 (95% CI, 1.09-1.90) and for hemorrhagic stroke, 0.82 (95% CI, 0.43-1.56). Point estimates of the HRs indicate that excess risk of all stroke was apparent in all age groups, in all categories of baseline stroke risk, and in women with and without hypertension, prior history of cardiovascular disease, use of hormones, statins, or aspirin. Other risk factors for stroke, including smoking, blood pressure, diabetes, lower use of vitamin C supplements, blood-based biomarkers of inflammation, higher white blood cell count, and higher hematocrit levels did not modify the effect of estrogen plus progestin on stroke risk. Conclusions Estrogen plus progestin increases the risk of ischemic stroke in generally healthy postmenopausal women. Excess risk for all strokes attributed to estrogen plus progestin appeared to be present in all subgroups of women examined.	Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA; Wayne State Univ, WHI Clin Ctr, Detroit, MI USA; Univ Florida, WHI Clin Ctr, Gainesville, FL USA; Univ N Carolina, Sch Med & Publ Hlth, Durham, NC USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; NINDS, Stroke Neurosci Unit, Bethesda, MD 20892 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Womens Hlth Hawaii, Honolulu, HI USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; NHLBI, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Med Res Labs, Highland Hts, KY USA; Georgetown Washington Univ, Washington, DC USA; Ohio State Univ, Columbus, OH 43210 USA	Yeshiva University; Albert Einstein College of Medicine; Wayne State University; State University System of Florida; University of Florida; University of North Carolina; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Medical College of Wisconsin; Rush University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University	Wassertheil-Smoller, S (corresponding author), Albert Einstein Coll Med, Dept Epidemiol & Social Med, 1300 Morris Pk Ave,Room 1312 Belfer, Bronx, NY 10461 USA.	smoller@aecom.yu.edu	Mysiw, Walter/E-3724-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002995] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Barnett HJM, 2000, JAMA-J AM MED ASSOC, V283, P1429, DOI 10.1001/jama.283.11.1429; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; Bousser MG, 1999, CIRCULATION, V99, P463, DOI 10.1161/01.CIR.99.4.463; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; DAC NV, 1989, J LIPID RES, V30, P1437; DAGOSTINO RB, 1994, STROKE, V25, P40, DOI 10.1161/01.STR.25.1.40; DECATERINA R, 1994, ARTERIOSCLER THROMB, V14, P1829, DOI 10.1161/01.ATV.14.11.1829; Devaraj S, 2000, CIRCULATION, V102, P191, DOI 10.1161/01.CIR.102.2.191; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gillum LA, 2000, JAMA-J AM MED ASSOC, V284, P72, DOI 10.1001/jama.284.1.72; Goldstein LB, 2001, STROKE, V32, P1091, DOI 10.1161/01.STR.32.5.1091; Gorelick PB, 1999, JAMA-J AM MED ASSOC, V281, P1112, DOI 10.1001/jama.281.12.1112; Hak AE, 1999, ARTERIOSCL THROM VAS, V19, P1986, DOI 10.1161/01.ATV.19.8.1986; Hart CL, 1999, STROKE, V30, P1999, DOI 10.1161/01.STR.30.10.1999; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lemaitre RN, 2002, ARCH INTERN MED, V162, P1954, DOI 10.1001/archinte.162.17.1954; LINDLEY RI, 1993, STROKE, V24, P1801, DOI 10.1161/01.STR.24.12.1801; Lip GYH, 1996, CIRCULATION, V94, P425, DOI 10.1161/01.CIR.94.3.425; MADDEN KP, 1995, NEUROLOGY, V45, P1975, DOI 10.1212/WNL.45.11.1975; Makris TK, 2000, AM J HYPERTENS, V13, P783, DOI 10.1016/S0895-7061(00)00262-4; Murphy S L, 2000, Natl Vital Stat Rep, V48, P1; Mustonen P, 1998, ARTERIOSCL THROM VAS, V18, P244, DOI 10.1161/01.ATV.18.2.244; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; Petitti DB, 1998, STROKE, V29, P23, DOI 10.1161/01.STR.29.1.23; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Rohde LEP, 1999, AM J CARDIOL, V84, P1018, DOI 10.1016/S0002-9149(99)00491-9; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; RUSSELL WG, 1994, LAB MEASUREMENT LIPI, P207; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; STEINER PM, 1981, J CLIN CHEM CLIN BIO, V19, P850; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; WARNICK GR, 1978, J LIPID RES, V19, P65; Whisnant JP, 1997, STROKE, V28, P1840, DOI 10.1161/01.STR.28.9.1840; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025	50	852	879	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2673	2684		10.1001/jama.289.20.2673	http://dx.doi.org/10.1001/jama.289.20.2673			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682DG	12771114	Bronze			2023-01-03	WOS:000183075600026
J	Paul, M; Soares-Weiser, K; Leibovici, L				Paul, M; Soares-Weiser, K; Leibovici, L			beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis	BRITISH MEDICAL JOURNAL			English	Review							PSEUDOMONAS-AERUGINOSA; CANCER-PATIENTS; CLINICAL-TRIALS; CEFTAZIDIME; GENTAMICIN; CARBENICILLIN; INFECTIONS; TOBRAMYCIN; BACTEREMIA; RESISTANCE	Objective To compare the effectiveness of beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy in the treatment of patients with fever and neutropenia. Data sources Medline, Embase, Lilacs, the Cochrane Library, and conference proceedings to 2002. References of included studies and contact with authors. No restrictions on language, year of publication, or publication status. Study selection All randomised trials of beta lactam monotherapy compared with beta lactamaminoglycoside combination therapy as empirical treatment for patients with fever and neutropenia. Data selection Two reviewers independently applied selection criteria, performed quality assessment, and extracted data. An intention to treat approach was used. Relative risks were pooled with the random effect model. Main outcome measure All cause fatality. Results Forty seven trials with 7807 patients met inclusion criteria. Nine trials compared the same beta lactam. There was no significant difference in all cause fatality (relative risk 0.85, 95% confidence interval 0.72 to 1.02). For success of treatment there was a significant advantage with monotherapy (0.92, 0.85 to 0.99), though there was considerable heterogeneity among trials. There was no significant difference between monotherapy and combination treatment in trials that compared the same beta lactam, whereas there was major advantage with monotherapy in trials that compared different beta lactams (0.87, 0.80 to 0.93). Rates of superinfection were similar. Adverse events, including those associated with severe morbidity, were significantly more common in the combination treatment group. Detected flaws in methods, did not affect results. Conclusions For patients with fever and neutropenia there is no clinical advantage in treatment with beta lactam-aminoglycoside combination therapy. Broad spectrum beta lactams as monotherapy should be regarded as the standard of care for such patients.	Rabin Med Ctr, Infect Dis Unit, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Med E, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center; Rabin Medical Center	Paul, M (corresponding author), Rabin Med Ctr, Infect Dis Unit, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.							[Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD003038; BODEY GP, 1972, CANCER-AM CANCER SOC, V29, P1697, DOI 10.1002/1097-0142(197206)29:6<1697::AID-CNCR2820290638>3.0.CO;2-K; CALANDRA T, 1987, NEW ENGL J MED, V317, P1692; Clarke M, 2001, COCHRANE REV HDB 4 1; denHollander JG, 1997, ANTIMICROB AGENTS CH, V41, P95, DOI 10.1128/AAC.41.1.95; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ELPHICK HE, 2003, COCHRANE DATABASE SY, DOI UNSP CD002007; Elting LS, 1997, CLIN INFECT DIS, V25, P247, DOI 10.1086/514550; GIAMARELLOU H, 1986, AM J MED, V80, P126, DOI 10.1016/0002-9343(86)90490-0; GIAMARELLOU H, 1984, ANTIMICROB AGENTS CH, V25, P534, DOI 10.1128/AAC.25.4.534; Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215; KLASTERSKY J, 1977, AM J MED SCI, V273, P157, DOI 10.1097/00000441-197703000-00005; KLASTERSKY J, 1986, ANTIMICROB AGENTS CH, V29, P263, DOI 10.1128/AAC.29.2.263; KLASTERSKY J, 1982, REV INFECT DIS, V4, P294; KRAMER BS, 1986, ANTIMICROB AGENTS CH, V30, P64, DOI 10.1128/AAC.30.1.64; Leibovici L, 1997, ANTIMICROB AGENTS CH, V41, P1127, DOI 10.1128/AAC.41.5.1127; Mouton JW, 1999, INFECTION, V27, pS24, DOI 10.1007/BF02561666; Paesmans M, 2000, INT J ANTIMICROB AG, V16, P107, DOI 10.1016/S0924-8579(00)00213-2; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Wu YL, 1999, J ANTIMICROB CHEMOTH, V44, P389, DOI 10.1093/jac/44.3.389	22	169	179	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1111	1115		10.1136/bmj.326.7399.1111	http://dx.doi.org/10.1136/bmj.326.7399.1111			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763980	Green Published, Bronze			2023-01-03	WOS:000183245000016
J	Lynn, J; Goldstein, NE				Lynn, J; Goldstein, NE			Advance care planning for fatal chronic illness: Avoiding commonplace errors and unwarranted suffering	ANNALS OF INTERNAL MEDICINE			English	Article							OF-LIFE CARE; QUALITY-IMPROVEMENT; DIRECTIVES; END; MANAGEMENT; DISEASE; DYSPNEA; FORM	Patients with eventually fatal illnesses often receive routine treatments in response to health problems rather than treatments arising from planning that incorporates the patient's situation and preferences. This paper considers the case of an elderly man with advanced lung disease who had mechanical ventilation and aggressive intensive care, in part because his nursing home clinicians did not complete an advance care plan and his do-not-resuscitate order did not accompany him to the hospital. The errors that led to his hospitalization and his unwanted treatment there demonstrate how the ordinary lack of advance care planning is deleterious for patients who are nearing the end of life. We discuss serious, recurring, and generally unnoticed errors in planning for care near the end of life and possible steps toward improvement. Repairing these shortcomings will require quality improvement and system redesign efforts, methods familiar from patient safety initiatives. Reliable improvement will also require making it unacceptable for clinicians to fail to plan ahead for care during fatal chronic illness.	Washington Home Ctr Palliat Care Studies & RAND H, Washington, DC USA; Yale Univ, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA	Yale University	Lynn, J (corresponding author), Washington Home & Community Hospice, Ctr Palliat Care Studies, 4200 Wisconsin Ave NW,4th Floor, Washington, DC 20016 USA.	jlynn@thewashingtonhome.org			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011558] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM BETT CAR DYING, MAK PROM VIS BETT SY; Bates DW, 2002, ANN INTERN MED, V137, P110, DOI 10.7326/0003-4819-137-2-200207160-00009; Chassin MR, 2002, ANN INTERN MED, V136, P826, DOI 10.7326/0003-4819-136-11-200206040-00012; Claessens MT, 2000, J AM GERIATR SOC, V48, pS146, DOI 10.1111/j.1532-5415.2000.tb03124.x; Cretin S, 2000, JAMA-J AM MED ASSOC, V284, P1786, DOI 10.1001/jama.284.14.1786; CRETIN S, 2000, JAMA-J AM MED ASSOC, V284, P1787; DANIS M, 1994, HASTINGS CENT REP, V24, pS21, DOI 10.2307/3563478; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Field MJ, 1997, APPROACHING DEATH IM; Foley KM, 2001, IMPROVING PALLIATIVE; Goodman MD, 1998, CRIT CARE MED, V26, P701, DOI 10.1097/00003246-199804000-00018; GRADY D, 2000, NY TIMES        0529, P1; Kohn LT, 2000, ERR IS HUMAN BUILDIN; Luce JM, 2000, AM J RESP CRIT CARE, V162, P2029, DOI 10.1164/ajrccm.162.6.1-00; Luce JM, 2001, JAMA-J AM MED ASSOC, V285, P1331, DOI 10.1001/jama.285.10.1331; Lynn J, 2002, ANN INTERN MED, V137, P117, DOI 10.7326/0003-4819-137-2-200207160-00010; Lynn J, 1997, New Horiz, V5, P56; Lynn J, 2001, J GEN INTERN MED, V16, P315, DOI 10.1046/j.1525-1497.2001.90901.x; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Lynn J, 2001, WESTERN J MED, V175, P299, DOI 10.1136/ewjm.175.5.299; LYNN J, 2000, IMPROVING CARE END L; LYNN J, 2001, ABCD EXCHANGE    MAY; Markowitz AJ, 2002, JAMA-J AM MED ASSOC, V287, P2261, DOI 10.1001/jama.287.17.2261; MATHERLEE K, 2002, 779 NAT HLTH POL FOR; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; Meisel A, 2000, JAMA-J AM MED ASSOC, V284, P2495, DOI 10.1001/jama.284.19.2495; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; Myers S S, 2001, J Palliat Med, V4, P325, DOI 10.1089/109662101753123931; *NAT TASKF END OF, 1999, M CHALL 12 REC IMPR; Pan C X, 2001, J Palliat Med, V4, P315, DOI 10.1089/109662101753123922; STEGMAN M, 1999, HOSPICE PALLIATIVE M, P77; Teno JM, 1996, J CLIN ETHIC, V7, P205; TENO JM, 1994, J CLIN ETHIC, V5, P23; Teno JM, 1998, J AM GERIATR SOC, V46, P1170, DOI 10.1111/j.1532-5415.1998.tb06662.x; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; Tolle SW, 1998, J AM GERIATR SOC, V46, P1097, DOI 10.1111/j.1532-5415.1998.tb06647.x; Wenger NS, 2001, ANN INTERN MED, V135, P677, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00006	38	91	92	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					812	818		10.7326/0003-4819-138-10-200305200-00009	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	679KH	12755553				2023-01-03	WOS:000182920700005
J	Gaffikin, L; Blumenthal, PD; Emerson, M; Limpaphayom, K; Lumbiganon, P; Ringers, P; Srisupundit, S; Warakamin, S; Lewis, R; Chumworathayee, B; Kanavacharakul, S				Gaffikin, L; Blumenthal, PD; Emerson, M; Limpaphayom, K; Lumbiganon, P; Ringers, P; Srisupundit, S; Warakamin, S; Lewis, R; Chumworathayee, B; Kanavacharakul, S		RTCOG; JHPIEGO Corp Cervical Canc Grp	Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project	LANCET			English	Article							SQUAMOUS INTRAEPITHELIAL LESIONS; ACETIC-ACID; DEVELOPING-COUNTRIES; VISUAL INSPECTION; NEOPLASIA; MANAGEMENT; PRECURSORS; CARCINOMA; TRIAL	Background To increase screening and treatment coverage, innovative approaches to cervical-cancer prevention are being investigated in rural Thailand. We assessed the value of a single-visit approach combining visual inspection of the cervix with acetic acid wash (VIA) and cryotherapy. Methods 12 trained nurses provided services in mobile (village health centre-based) and static (hospital-based) teams in four districts of Roi-et Province, Thailand. Over 7 months, 5999 women were tested by VIA. If they tested positive, after counselling about the benefits, potential risks, and probable side-effects they were offered cryotherapy. Data measuring safety, acceptability, feasibility, and effort to implement the programme were gathered. Findings The VIA test-positive rate was 13.3% (798/5999), and 98.5% (609/618) of those eligible accepted immediate treatment. Overall, 756 women received cryotherapy, 629 (83.2%) of whom returned for their first follow-up visit. No major complications were recorded, and 33 (4.4%) of those treated returned for a perceived problem. Only 17 (2.2%) of the treated women needed clinical management other than reassurance about side-effects. Both VIA and cryotherapy were highly acceptable to the patients (over 95% expressed satisfaction with their experience). At their 1-year visit, the squamocolumnar junction was visible to the nurses, and the VIA test-negative rate was 94.3%. Interpretation A single-visit approach with VIA and cryotherapy seems to be safe, acceptable, and feasible in rural Thailand, and is a potentially efficient method of cervical-cancer prevention in such settings.	JHPIEGO Corp, Cerv Canc Prevent Programme, Baltimore, MD 21231 USA	Jhpiego	Gaffikin, L (corresponding author), JHPIEGO Corp, Cerv Canc Prevent Programme, 1615 Thames St,Suite 200, Baltimore, MD 21231 USA.		Chumworathayi, Bandit/J-9927-2019	Chumworathayi, Bandit/0000-0003-1214-1962				ABWAO S, 1998, P REG M NAIR KEN 199; ANDERSEN ES, 1992, GYNECOL ONCOL, V45, P240, DOI 10.1016/0090-8258(92)90297-V; Belinson JL, 2001, OBSTET GYNECOL, V98, P441, DOI 10.1016/S0029-7844(01)01454-5; Blumenthal P D, 2001, Medscape Womens Health, V6, P1; CECCHINI S, 1993, TUMORI, V79, P22, DOI 10.1177/030089169307900104; Cox JT, 1999, LANCET, V353, P857, DOI 10.1016/S0140-6736(98)00392-4; CULLINS VE, 1999, REPROD HEALTH MATTER, V1, P134; Gaffikin L, 1999, LANCET, V353, P869; GAFFIKIN L, 1997, WORKSH P ALT CERV CA; Goldie SJ, 2001, JAMA-J AM MED ASSOC, V285, P3107, DOI 10.1001/jama.285.24.3107; Holschneider CH, 1999, CANCER-AM CANCER SOC, V86, P2659, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2659::AID-CNCR10>3.0.CO;2-S; Kitchener HC, 1999, LANCET, V353, P856, DOI 10.1016/S0140-6736(98)00417-6; LIMPAPHAYOM K, 1997, BRIT J OBSTET GYNAEC, V23, P3107; Londhe M., 1997, Indian Journal of Cancer, V34, P88; MANDELBLATT JS, 2002, J NATL CANCER I, V94, P1; Megevand E, 1996, OBSTET GYNECOL, V88, P383, DOI 10.1016/0029-7844(96)00189-5; Mitchell MF, 1998, OBSTET GYNECOL, V92, P737, DOI 10.1097/00006250-199811000-00001; MORRIS DL, 1996, NURSE PRACTITIONER, V23, P101; Nuovo J, 2000, INT J GYNECOL OBSTET, V68, P25, DOI 10.1016/S0020-7292(99)00162-9; *REPR HLTH OUTL, 2003, CERV CANC PREV; Sankaranarayanan R, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P411; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sankaranarayanan R, 1998, CANCER-AM CANCER SOC, V83, P2150, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2150::AID-CNCR13>3.0.CO;2-0; Sankaranarayanan R, 1999, INT J CANCER, V80, P161, DOI 10.1002/(SICI)1097-0215(19990105)80:1<161::AID-IJC28>3.3.CO;2-#; Santos C, 1996, GYNECOL ONCOL, V61, P11, DOI 10.1006/gyno.1996.0088; Soler, 2000, Prim Care Update Ob Gyns, V7, P118, DOI 10.1016/S1068-607X(00)00032-9; *UNFPA, UPD 1998 1999 MATERN; [No title captured]	28	181	185	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					814	820						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642047				2023-01-03	WOS:000181466600009
J	Ketteler, M; Bongartz, P; Westenfeld, R; Wildberger, JE; Mahnken, AH; Bohm, R; Metzger, T; Wanner, C; Jahnen-Dechent, W; Floege, J				Ketteler, M; Bongartz, P; Westenfeld, R; Wildberger, JE; Mahnken, AH; Bohm, R; Metzger, T; Wanner, C; Jahnen-Dechent, W; Floege, J			Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study	LANCET			English	Article							STAGE RENAL-DISEASE; C-REACTIVE PROTEIN; MATRIX GLA PROTEIN; HEMODIALYSIS-PATIENTS; PERITONEAL-DIALYSIS; CALCIFICATION; INFLAMMATION; CALCIUM; GENE; RISK	Background Vascular calcification is the most prominent underlying pathological finding in patients with uraemia, and is a predictor. of mortality in this population. Fetuin-A (alpha(2)-Heremans Schmid glycoprotein; AHSG) is an important circulating inhibitor of calcification in vivo, and is downregulated during the acute-phase response. We aimed to investigate the hypothesis that AHSG deficiency is directly related to uraemic vascular calcification. Methods We did a cross-sectional study in 312 stable patients on haemodialysis to analyse the inter-relation of AHSG and C-reactive protein (CRP) and their predictive effect on all-cause and cardiovascular mortality, over a period of 32 months. Subsequently, we tested the capacity of serum to inhibit CaxPO(4) precipitation in patients on long-term dialysis (n=17) with apparent soft-tissue calcifications, and in those on short-term dialysis (n=8) without evidence of calcifications and cardiovascular disease. Findings AHSG concentrations in serum were significantly lower in patients on haemodialysis (mean 0.66 g/L [SD 0.28]) than in healthy controls (0.72 [0.19]). Low concentrations of the glycoprotein were associated with raised amounts of CRP and with enhanced cardiovascular (p=0.031) and all-cause mortality (p=0.0013). Sera from patients on long-term dialysis with low AHSG concentrations showed impaired ex-vivo capacity to inhibit CaxPO(4) precipitation (mean IC50: 9.0 muL serum [SD 3.1] vs 7.5 [0.8] in short-term patients and 6.4 [2.6] in controls). Reconstitution of sera with purified AHSG returned this impairment to normal. Interpretation AHSG deficiency is associated with inflammation and links vascular calcification to mortality in patients on dialysis. Activated acute-phase response and AHSG deficiency might account for accelerated atherosclerosis in uraemia.	Univ Hosp Aachen, Dept Nephrol & Immunol, Aachen, Germany; Univ Hosp Aachen, Dept Diagnost Radiol, Aachen, Germany; Univ Hosp Aachen, IZKF BioMAT, Aachen, Germany; Univ Hosp Wurzburg, Div Nephrol, Wurzburg, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; University of Wurzburg	Ketteler, M (corresponding author), Univ Hosp Aachen, Dept Nephrol, Pauwelsstr 30, D-52057 Aachen, Germany.		Mahnken, Andreas H/H-4644-2011; Jahnen-Dechent, Willi/A-7608-2011	Jahnen-Dechent, Willi/0000-0003-1315-4407; Mahnken, Andreas H./0000-0001-8077-9306				Banine F, 2000, EUR J BIOCHEM, V267, P1214, DOI 10.1046/j.1432-1327.2000.01119.x; Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; HAUCK WW, 1991, STAT MED, V10, P711, DOI 10.1002/sim.4780100505; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Kalabay L, 2002, EUR J GASTROEN HEPAT, V14, P389, DOI 10.1097/00042737-200204000-00009; Kaysen GA, 2000, KIDNEY INT, V58, P346, DOI 10.1046/j.1523-1755.2000.00172.x; Lagrand WK, 1999, CIRCULATION, V100, P96, DOI 10.1161/01.CIR.100.1.96; LEBRETON JP, 1979, J CLIN INVEST, V64, P1118, DOI 10.1172/JCI109551; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Malatino LS, 2000, AM J KIDNEY DIS, V36, P945, DOI 10.1053/ajkd.2000.19087; Mathews ST, 2002, DIABETES, V51, P2450, DOI 10.2337/diabetes.51.8.2450; Ohnesorge B, 2000, RADIOLOGY, V217, P564, DOI 10.1148/radiology.217.2.r00nv30564; Osawa M, 2001, ANN HUM GENET, V65, P27, DOI 10.1046/j.1469-1809.2001.6510027.x; Parhami F, 2001, CIRC RES, V88, P954, DOI 10.1161/hh0901.090975; Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Rumberger JA, 1999, MAYO CLIN PROC, V74, P243, DOI 10.4065/74.3.243; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; Schwedler SB, 2002, KIDNEY INT, V62, P301, DOI 10.1046/j.1523-1755.2002.00423.x; Stenvinkel P, 2000, J AM SOC NEPHROL, V11, P1303, DOI 10.1681/ASN.V1171303; Szweras M, 2002, J BIOL CHEM, V277, P19991, DOI 10.1074/jbc.M112234200; TOLLESHAUG H, 1984, BIOCHIM BIOPHYS ACTA, V803, P182, DOI 10.1016/0167-4889(84)90008-9; US Renal Data System, 1999, USRDS 1998 ANN DAT R, P63; Wang AYM, 2001, J AM SOC NEPHROL, V12, P1927, DOI 10.1681/ASN.V1291927; Wang TJ, 2002, CIRCULATION, V106, P1189, DOI 10.1161/01.CIR.0000032135.98011.C4; Zimmermann J, 1999, KIDNEY INT, V55, P648, DOI 10.1046/j.1523-1755.1999.00273.x; Zoccali C, 2001, LANCET, V358, P2113, DOI 10.1016/S0140-6736(01)07217-8	30	732	764	1	38	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					827	833		10.1016/S0140-6736(03)12710-9	http://dx.doi.org/10.1016/S0140-6736(03)12710-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642050				2023-01-03	WOS:000181466600012
J	Lin, JL; Lin-Tan, DT; Hsu, KH; Yu, CC				Lin, JL; Lin-Tan, DT; Hsu, KH; Yu, CC			Environmental lead exposure and progression of chronic renal diseases in patients without diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHELATION-THERAPY; INDUCED HYPERTENSION; SERUM CREATININE; URATE EXCRETION; NEPHROPATHY; INSUFFICIENCY; IMPAIRMENT; GOUT; PLAY	BACKGROUND Previous research suggests that environmental lead exposure correlates with age-related decreases in renal function. METHODS Two hundred two patients with chronic renal insufficiency (indicated by a serum creatinine level between 1.5 mg per deciliter and 3.9 mg per deciliter) who had a normal total-body lead burden and no history of exposure to lead were observed for 24 months. After the observation period, 64 subjects with an elevated body lead burden were randomly assigned to the chelation control groups. For three months, the patients in the chelation group received lead-chelation therapy with calcium disodium EDTA, and the control group received placebo. During the ensuing 24 months, repeated chelation therapy was administered weekly to 32 patients with high-normal body lead burdens (at least 80 microg but less than 600 microg) unless on repeated testing the body lead burden fell below 60 microg; the other 32 patients served as controls and received weekly placebo infusions for 5 weeks every 6 months. The primary end point was an increase in the serum creatinine level to 1.5 times the base-line value during the observation period. A secondary end point was the change in renal function during the intervention period. RESULTS The primary end point occurred in 24 patients during the observation period; the serum creatinine levels and body lead burden at base line were the most important risk factors. The glomerular filtration rate improved significantly by the end of the 27-month intervention period in patients receiving chelation therapy: the mean (+/-SD) change in the glomerular filtration rate in the patients in the chelation group was 2.1+/-5.7 ml per minute per 1.73 m(sup 2) of body-surface area, as compared with -6.0+/-5.8 ml per minute per 1.73 m(sup 2) of body-surface area in the controls (P<0.001). The rate of decline in the glomerular filtration rate in the chelation group was also lower than that in the controls during the 24-month period of repeated chelation therapy or placebo. CONCLUSIONS Low-level environmental lead exposure may accelerate progressive renal insufficiency in patients without diabetes who have chronic renal disease. Repeated chelation therapy may improve renal function and slow the progression of renal insufficiency.	Chang Gung Univ, Coll Med, Lin Kou Med Ctr,Chang Gung Mem Hosp, Div Nephrol, Taipei 10591, Taiwan; Chang Gung Univ, Coll Med, Lin Kou Med Ctr,Chang Gung Mem Hosp, Div Clin Toxicol, Taipei 10591, Taiwan; Chang Gung Univ, Dept Hlth Care Management, Lab Epidemiol, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University	Lin, JL (corresponding author), Chang Gung Mem Hosp, Poison Ctr, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.			Hsu, Kuang-Hung/0000-0003-2642-7689				BATUMAN V, 1993, AM J MED SCI, V305, P241, DOI 10.1097/00000441-199304000-00008; BEHRINGER D, 1986, NEPHRON, V42, P323, DOI 10.1159/000183696; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; Ding YX, 1998, ENVIRON RES, V76, P107, DOI 10.1006/enrs.1997.3796; HENDERSON DA, 1958, MED J AUSTRALIA, V1, P377; Henrich W L, 1998, J Am Soc Nephrol, V9, pS63; HOSTETTER T, 1981, AM J PHYSIOL, V241, P85; Hunsicker LG, 1997, KIDNEY INT, V51, P1908, DOI 10.1038/ki.1997.260; ISAKSSON B, 1980, AM J CLIN NUTR, V33, P4, DOI 10.1093/ajcn/33.1.4; KHALILMANESH F, 1992, ENVIRON RES, V58, P35, DOI 10.1016/S0013-9351(05)80203-8; Kim R, 1996, JAMA-J AM MED ASSOC, V275, P1177, DOI 10.1001/jama.275.15.1177; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.med.39.1.465; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lin JL, 1999, ANN INTERN MED, V130, P7, DOI 10.7326/0003-4819-130-1-199901050-00003; LIN JL, 1993, AM J NEPHROL, V13, P442, DOI 10.1159/000168661; Lin JL, 2001, ARCH INTERN MED, V161, P264, DOI 10.1001/archinte.161.2.264; LIN JL, 1992, AM J NEPHROL, V12, P457, DOI 10.1159/000168498; LIN JL, 1994, J HUM HYPERTENS, V8, P495; LIN JL, 1994, J RHEUMATOL, V21, P705; Lin JL, 2001, KIDNEY INT, V60, P266, DOI 10.1046/j.1523-1755.2001.00795.x; Liou SH, 1996, INT ARCH OCC ENV HEA, V68, P80, DOI 10.1007/s004200050032; Mitch WE, 2000, KIDNEY INT, V57, pS38, DOI 10.1046/j.1523-1755.2000.07510.x; NUYTS GD, 1991, NEPHROL DIAL TRANSPL, V6, P307, DOI 10.1093/ndt/6.5.307; Obrador G T, 1998, J Am Soc Nephrol, V9, pS44; PAYTON M, 1994, AM J EPIDEMIOL, V140, P821, DOI 10.1093/oxfordjournals.aje.a117330; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; POLLOCK CA, 1988, INT J ARTIF ORGANS, V11, P75, DOI 10.1177/039139888801100204; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; Vaziri ND, 1999, KIDNEY INT, V56, P1492, DOI 10.1046/j.1523-1755.1999.00670.x; WEDEEN RP, 1979, ARCH INTERN MED, V139, P53, DOI 10.1001/archinte.139.1.53; WEDEEN RP, 1983, ENVIRON RES, V30, P58, DOI 10.1016/0013-9351(83)90166-4; WEDEEN RP, 1975, AM J MED, V59, P630, DOI 10.1016/0002-9343(75)90224-7	32	204	207	0	15	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	2003	348	4					277	286		10.1056/NEJMoa021672	http://dx.doi.org/10.1056/NEJMoa021672			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	637JD	12540640				2023-01-03	WOS:000180507200002
J	Hendrickx, N; Volanti, C; Moens, U; Seternes, OM; de Witte, P; Vandenheede, JR; Piette, J; Agostinis, P				Hendrickx, N; Volanti, C; Moens, U; Seternes, OM; de Witte, P; Vandenheede, JR; Piette, J; Agostinis, P			Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; MESSENGER-RNA STABILITY; CYTOCHROME-C; POSTTRANSCRIPTIONAL CONTROL; SIGNALING PATHWAYS; PROSTAGLANDIN E-2; BCL-2 EXPRESSION; OXIDATIVE STRESS; HELA-CELLS	Photodynamic Therapy (PDT) is an approved anticancer therapy that kills cancer cells by the photochemical generation of reactive oxygen species following absorption of visible light by a photosensitizer, which selectively accumulates in tumors. We report that hypericin-mediated PDT of human cancer cells leads to up-regulation of the inducible cyclooxygenase-2 (COX-2) enzyme and the subsequent release of PGE(2). Dissection of the signaling pathways involved revealed that the selective activation of p38 MAPK alpha and beta mediate COX-2 up-regulation at the protein and messenger levels. The p38 MAPK inhibitor, PD169316, abrogated COX-2 expression in PDT-treated cells, whereas overexpression of the drug-resistant PD169316-insensitive p38 MAPK alpha and beta isoforms restored COX-2 levels in the presence of the kinase inhibitor. Transcriptional regulation by nuclear factor-kappaB was not involved in COX-2 up-regulation by PDT. The half-life of the COX-2 messenger was drastically shortened by p38 MAPK inhibition in transcriptionally arrested cells, suggesting that p38 MAPK mainly acts by stabilizing the COX-2 transcript. Overexpression of WT-p38 MAPK increased cellular resistance to PDT-induced apoptosis, and inhibiting this pathway exacerbated cell death and prevented PGE2 secretion. Hence, the combination of PDT with pyridinyl imidazole inhibitors of p38 MAPK may improve the therapeutic efficacy of PDT by blocking COX-2 up-regulation, which contributes to tumor growth by the release of growth- and pro-angiogenic factors, as well as by sensitizing cancer cells to apoptosis.	Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium; Catholic Univ Louvain, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Tromso, Inst Med Biol, Mol Genet Sect, Dept Biochem, N-9037 Tromso, Norway	Universite Catholique Louvain; Universite Catholique Louvain; University of Liege; UiT The Arctic University of Tromso	Agostinis, P (corresponding author), Catholic Univ Louvain, Div Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Seternes, Ole Morten/M-9520-2019; Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020	Seternes, Ole Morten/0000-0001-8537-3612; Agostinis, Patrizia/0000-0003-1314-2115; de Witte, Peter/0000-0002-9989-9567				Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chen B, 2002, INT J CANCER, V98, P284, DOI 10.1002/ijc.10175; D'Hallewin MA, 2000, J UROLOGY, V164, P349, DOI 10.1016/S0022-5347(05)67357-0; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Ferrario A, 2002, CANCER RES, V62, P3956; Granville DJ, 2000, BLOOD, V95, P256; Gugliucci A, 2002, J BIOL CHEM, V277, P31789, DOI 10.1074/jbc.M204450200; Gupta AK, 2001, CANCER RES, V61, P4278; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Kamuhabwa AAR, 2003, INT J CANCER, V107, P460, DOI 10.1002/ijc.11396; Korus M, 2002, ONCOGENE, V21, P4601, DOI 10.1038/sj.onc.1205678; Kumagai T, 2002, ARCH BIOCHEM BIOPHYS, V397, P240, DOI 10.1006/abbi.2001.2601; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu XH, 1998, CANCER RES, V58, P4245; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; Sheng HM, 1998, CANCER RES, V58, P362; Shirahama T, 2001, CANCER, V92, P188, DOI 10.1002/1097-0142(20010701)92:1<188::AID-CNCR1308>3.0.CO;2-W; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Subbaramaiah K, 2003, J BIOL CHEM, V278, P37637, DOI 10.1074/jbc.M301481200; Sun YJ, 2002, CANCER RES, V62, P6323; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Vantieghem A, 2001, PHOTOCHEM PHOTOBIOL, V74, P133, DOI 10.1562/0031-8655(2001)074&lt;0133:DPMCCR&gt;2.0.CO;2; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wong TW, 2003, CANCER RES, V63, P3812; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	42	108	117	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52231	52239		10.1074/jbc.M307591200	http://dx.doi.org/10.1074/jbc.M307591200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557269	hybrid, Green Published			2023-01-03	WOS:000187480700032
J	Gupta, R; Sheikh, A; Strachan, D; Anderson, HR				Gupta, R; Sheikh, A; Strachan, D; Anderson, HR			Increasing hospital admissions for systemic allergic disorders in England: analysis of national admissions' data	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England	St Georges University London	Gupta, R (corresponding author), St George Hosp, Sch Med, Dept Community Hlth Sci, Cranmer Terrace, London SW17 0RE, England.		Anderson, Hugh R/A-7417-2016; Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056				*DEP HLTH, PRESCR COST AN; *DEP HLTH, 1991, HOSP EP STAT, V1; Sheikh A, 2000, BRIT MED J, V320, P1441, DOI 10.1136/bmj.320.7247.1441; *UCB I ALL, 1997, EUR ALL WHIT PAP ALL; *WHO, 1977, INT CLASS DIS MAN IN	5	99	100	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1142	1143		10.1136/bmj.327.7424.1142	http://dx.doi.org/10.1136/bmj.327.7424.1142			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615340	Green Published, Bronze			2023-01-03	WOS:000186622100021
J	Clarkson, TW; Magos, L; Myers, GJ				Clarkson, TW; Magos, L; Myers, GJ			The toxicology of mercury - Current exposures and clinical manifestations	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PRENATAL METHYLMERCURY EXPOSURE; DENTAL AMALGAM FILLINGS; MYOCARDIAL-INFARCTION; RISK; POPULATION; VACCINES; DISEASE; FISH; MEN; ETHYLMERCURY		Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA; MRC Labs, Carshalton, Surrey, England	University of Rochester; University of Rochester; University of Rochester	Clarkson, TW (corresponding author), Univ Rochester, Sch Med, Dept Environm Med, Box EHSC, Rochester, NY 14642 USA.		Myers, Gary J/I-4901-2013	Myers, Gary J/0000-0003-4317-015X	NIEHS NIH HHS [P30 ES01247, R01 ES10219] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247, R01ES010219] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agency for Toxic Substances and Disease Registry, 1999, TOX PROF MERC; Ahlqwist M, 1999, ACTA ODONTOL SCAND, V57, P168; BAKIR F, 1973, SCIENCE, V181, P230, DOI 10.1126/science.181.4096.230; Ball LK, 2001, PEDIATRICS, V107, P1147, DOI 10.1542/peds.107.5.1147; Bjorkman L, 1996, COMMUNITY DENT ORAL, V24, P260, DOI 10.1111/j.1600-0528.1996.tb00856.x; BLUHM RE, 1992, HUM EXP TOXICOL, V11, P201, DOI 10.1177/096032719201100308; Bolger PM, 2002, NEW ENGL J MED, V347, P1735, DOI 10.1056/NEJMp020139; BRUNE D, 1991, SCI TOTAL ENVIRON, V100, P235, DOI 10.1016/0048-9697(91)90380-W; Centers for Disease Control and Prevention (CDC), 2003, 2 CDCP; Clarkson TW, 2002, ENVIRON HEALTH PERSP, V110, P11, DOI 10.1289/ehp.02110s111; *ENV PROT AG, 2001, REF DOS CHRON EXP ME; *ENV PROT AG, 2001, EPA823R01001; ETO K, 1992, MOL CHEM NEUROPATHOL, V16, P171, DOI 10.1007/BF03159968; Forman J, 2000, ENVIRON HEALTH PERSP, V108, P575, DOI 10.2307/3454622; Freed GL, 2002, PEDIATRICS, V109, P1153, DOI 10.1542/peds.109.6.1153; Gibson R, 2000, CHICAGO TRIBUNE 0914, P1; Goldwater L., 1972, MERCURY HIST QUICKSI; GOSSEL TA, 1990, PRINCIPLES CLIN TOXI; GRANDJEAN P, 1992, ARCH ENVIRON HEALTH, V47, P185, DOI 10.1080/00039896.1992.9938348; Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4; Guallar E, 2002, NEW ENGL J MED, V347, P1747, DOI 10.1056/NEJMoa020157; HUNTER D, 1969, DIS OCCUPATIONS, P314; IPCS, 1990, ENV HLTH CRIT 101 ME; JEMELOV A, 1969, CHEM FALLOUT CURRENT, P68; Johnels A. G., 1969, CHEM FALLOUT CURRENT, P221; *JOINT FAO WHO EXP, 1978, WHO TECH REP SER, V631, P1; Kingman A, 1998, J DENT RES, V77, P461, DOI 10.1177/00220345980770030501; Kjellstrom T., 1989, 3642 SOLN NAT SWED E; Leong CCW, 2001, NEUROREPORT, V12, P733, DOI 10.1097/00001756-200103260-00024; LIKOSKY WH, 1970, ORGANIC MERCURY POIS, V20, P401; Magos L, 2001, J APPL TOXICOL, V21, P1, DOI 10.1002/jat.721; MAGOS L, 1985, ARCH TOXICOL, V57, P260, DOI 10.1007/BF00324789; MOLIN M, 1990, ACTA ODONTOL SCAND, V48, P189, DOI 10.3109/00016359009005875; Myers GJ, 2003, LANCET, V361, P1686, DOI 10.1016/S0140-6736(03)13371-5; National Research Council, 2000, TOX EFF METH MERC; Nierenberg DW, 1998, NEW ENGL J MED, V338, P1672, DOI 10.1056/NEJM199806043382305; Pfab R, 1996, J TOXICOL-CLIN TOXIC, V34, P453, DOI 10.3109/15563659609013818; Pichichero ME, 2002, LANCET, V360, P1737, DOI 10.1016/S0140-6736(02)11682-5; Ramazzini B, 1964, DIS WORKERS; Riley DM, 2001, ENVIRON HEALTH PERSP, V109, P779, DOI 10.2307/3454819; Sallsten G, 1996, J DENT RES, V75, P594, DOI 10.1177/00220345960750011301; Salonen JT, 2000, ATHEROSCLEROSIS, V148, P265, DOI 10.1016/S0021-9150(99)00272-5; SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645; SAXE SR, 1995, J AM DENT ASSOC, V126, P1495, DOI 10.14219/jada.archive.1995.0078; Smith JC, 1996, TOXICOL APPL PHARM, V137, P245, DOI 10.1006/taap.1996.0078; Sorensen N, 1999, EPIDEMIOLOGY, V10, P370, DOI 10.1097/00001648-199907000-00006; *STRAT ADV GROUP E, 2002, WKLY EPIDEMIOL REC, V77, P305; *US PHARM CONV, 1999, USP, V24; WARKANY J, 1953, J PEDIATR-US, V42, P365, DOI 10.1016/S0022-3476(53)80195-2; World Health Organization, 1991, ENV HLTH CRIT, V118; Yoshizawa K, 2002, NEW ENGL J MED, V347, P1755, DOI 10.1056/NEJMoa021437; 2001, JAMA, V4285, P1436	52	1277	1340	11	349	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1731	1737		10.1056/NEJMra022471	http://dx.doi.org/10.1056/NEJMra022471			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585942				2023-01-03	WOS:000186219500009
J	Duke, T; Molyneux, EM				Duke, T; Molyneux, EM			Intravenous fluids for seriously ill children: time to reconsider	LANCET			English	Editorial Material							ARGININE-VASOPRESSIN; HYPONATREMIC ENCEPHALOPATHY; ANTIDIURETIC-HORMONE; MENINGITIS; RESTRICTION; MANAGEMENT; SODIUM; SECRETION; SEPSIS; PLASMA		Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Ctr Int Child Hlth, Parkville, Vic 3052, Australia; Coll Med, Dept Paediat, Blantyre, Malawi	Royal Children's Hospital Melbourne; University of Melbourne; University of Malawi	Duke, T (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Ctr Int Child Hlth, Flemington Rd, Parkville, Vic 3052, Australia.	Trevor.duke@rch.org.au						ARIEFF AI, 2002, NEW ENGL J MED, V314, P1529; BILBREY GL, 1973, ANN SURG, V177, P112, DOI 10.1097/00000658-197301000-00020; COOKE RE, 1972, CLIN PEDIATR, V11, P493; DHAWAN A, 1992, ANN TROP PAEDIATR, V12, P455, DOI 10.1080/02724936.1992.11747614; Duke T, 2002, ANN TROP PAEDIATR, V22, P145, DOI 10.1179/027249302125000878; Dunn K, 1997, J PAEDIATR CHILD H, V33, P26, DOI 10.1111/j.1440-1754.1997.tb00986.x; English MC, 1996, ARCH DIS CHILD, V74, P201, DOI 10.1136/adc.74.3.201; Halberthal M, 2001, BRIT MED J, V322, P780, DOI 10.1136/bmj.322.7289.780; HANNON RJ, 1990, J PEDIATR SURG, V25, P599, DOI 10.1016/0022-3468(90)90342-7; Hughes PD, 1998, AUST NZ J SURG, V68, P165, DOI 10.1111/j.1445-2197.1998.tb04735.x; Jackson J, 2000, AM J EMERG MED, V18, P269, DOI 10.1016/S0735-6757(00)90119-0; Jensen AG, 1999, ARCH INTERN MED, V159, P1437, DOI 10.1001/archinte.159.13.1437; KANAKRIYEH M, 1987, CLIN PEDIATR, V26, P126, DOI 10.1177/000992288702600304; Levine JP, 2001, PLAST RECONSTR SURG, V108, P1501, DOI 10.1097/00006534-200111000-00009; McJunkin JE, 2001, NEW ENGL J MED, V344, P801, DOI 10.1056/NEJM200103153441103; Moller K, 2001, SCAND J INFECT DIS, V33, P13; MOR J, 1975, AM J DIS CHILD, V129, P133, DOI 10.1001/archpedi.1975.02120380101024; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Paut O, 2000, ANN FR ANESTH, V19, P467; Poddar U, 1995, Indian Pediatr, V32, P59; POTTS FL, 1986, ANN EMERG MED, V15, P834, DOI 10.1016/S0196-0644(86)80385-7; POWELL KR, 1990, J PEDIATR-US, V117, P515, DOI 10.1016/S0022-3476(05)80682-1; Schwenk A, 2000, CLIN NUTR, V19, P35, DOI 10.1054/clnu.1999.0070; SHARPLES PM, 1992, ARCH DIS CHILD, V67, P998, DOI 10.1136/adc.67.8.998; SINGHI SC, 1995, PEDIATR INFECT DIS J, V14, P495, DOI 10.1097/00006454-199506000-00006; SOWUNMI A, 2002, AFR J MED SCI, V25, P47; STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402; THOMAS TH, 1979, BRIT J SURG, V66, P540, DOI 10.1002/bjs.1800660806; Vajda Z, 2001, NEUROSURGERY, V49, P697, DOI 10.1097/00006123-200109000-00031; von Vigier RO, 2001, AM J NEPHROL, V21, P87, DOI 10.1159/000046229; *WHO, 2000, MAN CHILD SER INF SE, P64; WINTERS RW, 1973, BODY FLUIDS PEDIATRI, P113; Zornow M H, 1995, New Horiz, V3, P488	33	88	93	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1320	1323		10.1016/S0140-6736(03)14577-1	http://dx.doi.org/10.1016/S0140-6736(03)14577-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575980				2023-01-03	WOS:000186036900028
J	Kennedy, JG				Kennedy, JG			"Doc, tell me what I need to know" - a doctor's perspective	BRITISH MEDICAL JOURNAL			English	Article									Cedar Brook Practice, Middlesex UB4 8DD, England		Kennedy, JG (corresponding author), Cedar Brook Practice, 11 Kingshill Close, Middlesex UB4 8DD, England.							*DEP HLTH, 2001, EXP PAT NEW APPR CHR, P12; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; National Audit Office, 1993, REP PRESCR GEN MED P; Say RE, 2003, BMJ-BRIT MED J, V327, P542, DOI 10.1136/bmj.327.7414.542	5	8	10	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					862	863		10.1136/bmj.327.7419.862	http://dx.doi.org/10.1136/bmj.327.7419.862			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551108	Green Published			2023-01-03	WOS:000185921200030
J	Iglehart, JK				Iglehart, JK			Prescription-drug coverage for Medicare beneficiaries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	4	4	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					923	925		10.1056/NEJMp038139	http://dx.doi.org/10.1056/NEJMp038139			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954738				2023-01-03	WOS:000185081400001
J	Murray, MD; Callahan, CM				Murray, MD; Callahan, CM			Improving medication use for older adults: An integrated research agenda	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				CONVERTING ENZYME-INHIBITOR; ADVERSE DRUG EVENTS; ELDERLY PATIENTS; PRIMARY-CARE; PRESCRIPTION COVERAGE; PROPENSITY SCORES; HEART-FAILURE; QUALITY; HEALTH; PREVENTABILITY	Effective health care is a core determinant of successful aging, and medications are one of the most important therapeutic tools of health care providers. Most older adults use at least one prescription drug. Costs for these drugs are a substantial out-of-pocket expense for Medicare beneficiaries, and low-income older adults must weigh these costs against those of other basic needs. Although medications bring welcome relief to millions of elderly persons with age-related conditions, adverse drug events are an important cause of illness and death in these patients. Thus, the appropriate, cost-effective use of medication is central to successful aging. Despite increasing attention to geriatric pharmacotherapy, there is an enormous need for additional research to improve the use of medications among older adults. The necessary research agenda encompasses much more than just the discovery of new drugs; better use of the current pharmacopeia has great potential to improve the lives of older adults. We review four domains of pharmaceutical research: drug discovery and delivery, drug efficacy and safety, pharmacoepidemiology and drug policy, and improved access to and use of drugs. These domains encompass both the pre- and postmarketing phases of drug research. Premarketing research currently has greater magnitude and a better infrastructure than postmarketing research, yet issues arising in the two phases of research are equally important to the health and safety of older adults. A national, federally supported pharmaceutical database could greatly enhance the infrastructure of postmarketing research. However, many major improvements in medication use among older adults will also depend on closing the gap between knowledge and practice and increasing the ability of older adults to manage their medications.	Purdue Univ, Sch Med, Regenstrief Inst, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Purdue University System; Purdue University; Indiana University System; Indiana University-Purdue University Indianapolis	Murray, MD (corresponding author), Purdue Univ, Sch Med, Regenstrief Inst, 1050 Wishard Blvd RG-6, Indianapolis, IN 46202 USA.	mmurray@regenstrief.org			NHLBI NIH HHS [R01 HL69399] Funding Source: Medline; NIA NIH HHS [R01 AG07631, R01 AG19105, R01 AG007631] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019105, R01AG007631] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Avorn J, 2001, JAMA-J AM MED ASSOC, V286, P2866, DOI 10.1001/jama.286.22.2866; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Bell RA, 2002, J GEN INTERN MED, V17, P817, DOI 10.1046/j.1525-1497.2002.10319.x; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; Bikowski RM, 2001, J AM GERIATR SOC, V49, P1353, DOI 10.1046/j.1532-5415.2001.49265.x; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodkin JA, 2002, AM J PSYCHIAT, V159, P1869, DOI 10.1176/appi.ajp.159.11.1869; Bull SA, 2002, JAMA-J AM MED ASSOC, V288, P1403, DOI 10.1001/jama.288.11.1403; Chertow GM, 2001, JAMA-J AM MED ASSOC, V286, P2839, DOI 10.1001/jama.286.22.2839; DARNELL JC, 1986, J AM GERIATR SOC, V34, P1; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Gattis WA, 1998, AM HEART J, V136, P43, DOI 10.1016/S0002-8703(98)70180-2; Gattis WA, 1999, ARCH INTERN MED, V159, P1939, DOI 10.1001/archinte.159.16.1939; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Gurwitz JH, 2000, AM J MED, V109, P87, DOI 10.1016/S0002-9343(00)00451-4; Gurwitz JH, 2002, ARCH INTERN MED, V162, P1670, DOI 10.1001/archinte.162.15.1670; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Hwang W, 2001, HEALTH AFFAIR, V20, P267, DOI 10.1377/hlthaff.20.6.267; Ihara E, 2002, CHALLENGES 21 CENTUR, P1; KASSBARTELMES B, 2002, RES ACTION, P1; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Knickman JR, 2002, HEALTH SERV RES, V37, P849, DOI 10.1034/j.1600-0560.2002.56.x; Knight EL, 2001, ANN INTERN MED, V135, P703, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00009; KRELING D, 2000, PRESCRIPTION DRUG TR, P1; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; Lemaitre RN, 2002, ARCH INTERN MED, V162, P1395, DOI 10.1001/archinte.162.12.1395; McCormick D, 2001, ARCH INTERN MED, V161, P2458, DOI 10.1001/archinte.161.20.2458; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; Miller LG, 1998, ARCH INTERN MED, V158, P2200, DOI 10.1001/archinte.158.20.2200; MORROW D, 1991, J GERONTOL, V46, pP378, DOI 10.1093/geronj/46.6.P378; MURRAY MD, 1986, DRUG INTEL CLIN PHAR, V20, P146, DOI 10.1177/106002808602000210; Murray MD, 2000, AM J HEALTH-SYST PH, V57, P565, DOI 10.1093/ajhp/57.6.565; *NAT ASS CHAIN DRU, IND FACTS AT A GLANC; Perkins SM, 2000, PHARMACOEPIDEM DR S, V9, P93, DOI 10.1002/(SICI)1099-1557(200003/04)9:2<93::AID-PDS474>3.0.CO;2-I; Phelan EA, 2002, J AM GERIATR SOC, V50, P1519, DOI 10.1046/j.1532-5415.2002.50407.x; *PHRMA RES DEV, DRAM GROWTH RES DEV; Rollman BL, 1999, INT J PSYCHIAT MED, V29, P267, DOI 10.2190/7CCY-D8JB-53XK-PPTK; Rothschild JM, 2000, ARCH INTERN MED, V160, P2717, DOI 10.1001/archinte.160.18.2717; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; Soumerai SB, 2001, J GEN INTERN MED, V16, P864, DOI 10.1046/j.1525-1497.2001.11015.x; Steinman MA, 2001, J GEN INTERN MED, V16, P793, DOI 10.1046/j.1525-1497.2001.10412.x; Strom BL, 2000, PHARMACOEPIDEMIOLOGY; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Tu K, 2002, AM J MED, V113, P52, DOI 10.1016/S0002-9343(02)01144-0; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269; Zhan Chunliu, 2001, JAMA (Journal of the American Medical Association), V286, P2823; ZIMMER AW, 1985, ANN INTERN MED, V103, P276, DOI 10.7326/0003-4819-103-2-276	51	58	60	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			425	429		10.7326/0003-4819-139-5_Part_2-200309021-00009	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965970				2023-01-03	WOS:000185133800009
J	van Ommeren, M; Saxena, S; Loretti, A; Saraceno, B				van Ommeren, M; Saxena, S; Loretti, A; Saraceno, B			Ensuring care for patients in custodial psychiatric hospitals in emergencies	LANCET			English	Editorial Material									WHO, Dept Mental Hlth & Subst Dependence, CH-1211 Geneva, Switzerland; WHO, Hlth Act Crises, CH-1211 Geneva, Switzerland	World Health Organization; World Health Organization	van Ommeren, M (corresponding author), WHO, Dept Mental Hlth & Subst Dependence, Ave Appia, CH-1211 Geneva, Switzerland.	vanommerenm@who.int		Saraceno, Benedetto/0000-0001-7119-5712				BISE G, 2001, MALADES MENTAUX GUER; Organization WH, 2001, WORLD HLTH REPORT 20; Silove D, 2000, LANCET, V355, P1548, DOI 10.1016/S0140-6736(00)02177-2; WEISS MG, IN PRESS J NERV MENT	4	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					574	574		10.1016/S0140-6736(03)14123-2	http://dx.doi.org/10.1016/S0140-6736(03)14123-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	712UW	12938670				2023-01-03	WOS:000184817600029
J	Selwyn, PA; Forstein, M				Selwyn, PA; Forstein, M			Overcoming the false dichotomy of curative vs palliative care for late-stage HIV/AIDS - "Let me live the way I want to live, until I can't"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; LONG-TERM-CARE; OF-LIFE CARE; ANTIRETROVIRAL THERAPY; VIRAL LOAD; SYMPTOM PREVALENCE; UNITED-STATES; DRUG-THERAPY; HEPATITIS-C	Recent advances in human immunodeficiency virus (HIV) therapy have significantly reduced HIV-related mortality in the developed world, but mortality rates have plateaued, and AIDS remains a leading cause of serious illness and death for young adults. The chronic nature of the HIV disease course and the increasing burden of cumulative HIV-related morbidity and treatment-related toxic effects pose new challenges to the care of patients overtime. Uncertainties about prognosis and the promise and limitations of rapidly evolving therapies have made decision making about advance care planning and end-of-life issues more complex and elusive than when the disease course was more uniform, rapid, and predictable. The emerging biomedical paradigm of highly active antiretroviral therapy (HAART) as the cornerstone of treatment has helped to transform HIV into a manageable chronic disease, yet at the same time has resulted in a more narrow focus and a de facto separation between disease-specific "curative" and symptom-specific "palliative" care for patients with HIV/AIDS. As patients survive longer in the latter stages of progressive HIV disease, they may in fact have increasing need for comprehensive symptom management as well as wide-ranging need for psychosocial, family, and care planning support. In the HAART era, the false dichotomy of curative vs palliative care for patients with HIV/AIDS must be supplanted by a more integrated model to provide comprehensive care for patients with advanced HIV disease and their families.	Montefiore Med Ctr, Albert Einstein Coll Med, Dept Family Med & Community Hlth, Bronx, NY 10467 USA; Harvard Univ, Sch Med, Cambridge Hosp, Dept Psychiat, Boston, MA USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard Medical School	Selwyn, PA (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Family Med & Community Hlth, 3544 Jerome Ave, Bronx, NY 10467 USA.	selwyn@aecom.yu.edu	Harding, Richard/G-9729-2012					*AM AC HOSP PALL M, 2002, 14 ANN ASS AM AC HOS; [Anonymous], 2002, FAM SYST HEALTH, DOI [DOI 10.1037/H0089471, 10.1037/h0089471]; BAXTER DJ, 1997, LEAST THESE MY BRETH; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Breitbart W, 1999, J PAIN SYMPTOM MANAG, V18, P203, DOI 10.1016/S0885-3924(99)00077-9; Breitbart W, 1998, J PAIN SYMPTOM MANAG, V15, P159, DOI 10.1016/S0885-3924(97)00260-1; Breitbart W, 1996, PAIN, V65, P243, DOI 10.1016/0304-3959(95)00217-0; Campo Rafael, 1997, DESIRE HEAL DOCTORS; *CDCP, 2000, HIV AIDS SURVEILLANC, V12, P1; Centers for Disease Control and Prevention, 2001, Morbidity and Mortality Weekly Report, V50, P430; Crawley L, 2000, JAMA-J AM MED ASSOC, V284, P2518, DOI 10.1001/jama.284.19.2518; CURRAN JW, 1985, SCIENCE, V229, P1352, DOI 10.1126/science.2994217; Curtis JR, 1997, J GEN INTERN MED, V12, P736, DOI 10.1046/j.1525-1497.1997.07158.x; Dalakas MC, 2001, J PERIPHER NERV SYST, V6, P14, DOI 10.1046/j.1529-8027.2001.006001014.x; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; DEMMER C, 2001, AM J HOSP PALLIAT CA, V1, P35; den Brinker M, 2000, AIDS, V14, P2895, DOI 10.1097/00002030-200012220-00011; Doyle D, 1998, OXFORD TXB PALLIATIV; Dube MP, 2000, CLIN INFECT DIS, V31, P1216; Dube MP, 2000, CLIN INFECT DIS, V31, P1467, DOI 10.1086/317491; Dybul Mark, 2002, MMWR Recomm Rep, V51, P1; ELLIS R, 1997, ARCH NEUROL-CHICAGO, V6, P416; Evans DL, 2002, AM J PSYCHIAT, V159, P1752, DOI 10.1176/appi.ajp.159.10.1752; Fantoni M, 1997, J PALLIATIVE CARE, V13, P9, DOI 10.1177/082585979701300203; FILBET M, 1994, J PALLIAT CARE, V10, P92; FOLEY F, 1994, J PALLIAT CARE, V10, P132; Fontaine A, 1999, J PAIN SYMPTOM MANAG, V18, P263, DOI 10.1016/S0885-3924(99)00078-0; Frenkel LM, 2001, NEW ENGL J MED, V344, P520, DOI 10.1056/NEJM200102153440710; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; Goodkin K, 1997, NEUROIMAG CLIN N AM, V7, P561; Goulet JL, 2000, J URBAN HEALTH, V77, P213, DOI 10.1007/BF02390532; *INT AIDS C, 2002, 14 INT AIDS C 2002 B; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; KARASZ A, IN PRESS SOC SCI MED; Kelleher P, 1997, PALLIATIVE MED, V11, P152, DOI 10.1177/026921639701100210; Kravcik S, 1997, ARCH INTERN MED, V157, P2069, DOI 10.1001/archinte.157.18.2069; Larue F, 1997, BRIT MED J, V314, P23, DOI 10.1136/bmj.314.7073.23; LARUE L, 1994, J PALLIAT CARE, V10, P95; Lee LM, 2001, JAMA-J AM MED ASSOC, V285, P1308, DOI 10.1001/jama.285.10.1308; Lopez OL, 1998, J NEUROPSYCH CLIN N, V10, P343, DOI 10.1176/jnp.10.3.343; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; Mathews WC, 2000, MED CARE, V38, P750, DOI 10.1097/00005650-200007000-00007; McArthur JC, 1997, ANN NEUROL, V42, P689, DOI 10.1002/ana.410420504; McComsey GA, 2001, AIDS, V15, P321, DOI 10.1097/00002030-200102160-00004; Meadows J, 1999, AIDS PATIENT CARE ST, V13, P47, DOI 10.1089/apc.1999.13.47; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Moore RD, 2001, AIDS, V15, P617, DOI 10.1097/00002030-200103300-00011; MOSS V, 1990, AIDS (London), V4, pS235; Mouton C, 1997, ARCH FAM MED, V6, P342, DOI 10.1001/archfami.6.4.342; *NAT HOSP ORG, 1996, GUID DET PROGN SEL N; Navaie-Waliser M, 2002, AM J PUBLIC HEALTH, V92, P409, DOI 10.2105/AJPH.92.3.409; OGBUOKIRI J, 2003, CLIN GUIDE SUPPORTIV; ONeill JF, 2003, CLIN GUIDE SUPPORTIV; ONEILL WM, 1993, PAIN, V54, P3, DOI 10.1016/0304-3959(93)90093-5; Percy Walker, 1971, LOVE RUINS; Piscitelli SC, 2001, NEW ENGL J MED, V344, P984, DOI 10.1056/NEJM200103293441307; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; Powderly WG, 2002, J ACQ IMMUN DEF SYND, V29, pS28, DOI 10.1097/00126334-200202011-00005; Puoti M, 2000, J ACQ IMMUN DEF SYND, V24, P211; Rabkin JG, 1997, ARCH GEN PSYCHIAT, V54, P1049; Sansone GR, 2000, J URBAN HEALTH, V77, P166, DOI 10.1007/BF02390528; Scannell K., 1999, DEATH GOOD DOCTOR LE; SELIK RM, 1984, AM J MED, V76, P493, DOI 10.1016/0002-9343(84)90669-7; SELWYN P, 1998, SURVIVING FALL PERSO; Selwyn PA, 1998, ANN INTERN MED, V129, P899, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00012; Selwyn PA, 2000, J URBAN HEALTH, V77, P187, DOI 10.1007/BF02390530; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SELWYN PA, 2002, INNOVATIONS END OF L, V4; SELWYN RA, 2002, INNOVATIONS END OF L, V4; Shaer AJ, 2000, AM J NEPHROL, V20, P332, DOI 10.1159/000013610; Simpson DM, 1999, CLIN INFECT DIS, V29, P19, DOI 10.1086/520150; SINGER EJ, 1993, PAIN, V54, P15, DOI 10.1016/0304-3959(93)90094-6; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Thiebaut R, 2000, CLIN INFECT DIS, V31, P1482, DOI 10.1086/317477; Valdez H, 2001, CLIN INFECT DIS, V32, P1487, DOI 10.1086/320164; Verghese Abraham, 1994, MY OWN COUNTRY DOCTO; Vogl D, 1999, J PAIN SYMPTOM MANAG, V18, P253, DOI 10.1016/S0885-3924(99)00066-4; Welch K, 2002, AIDS PATIENT CARE ST, V16, P75, DOI 10.1089/10872910252806126; Wenger NS, 2001, JAMA-J AM MED ASSOC, V285, P2880, DOI 10.1001/jama.285.22.2880; Wood CGA, 1997, BRIT MED J, V315, P1433, DOI 10.1136/bmj.315.7120.1433; 2001, MMWR MORB MORTAL WKL, V50, P1066; 1989, MMWR MORB MORTAL WKL, V38, P229; 1997, MMWR MORB MORTAL WKL, V46, P165; 1989, MMWR MORB MORTAL WKL, V38, P561	86	53	53	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2003	290	6					806	814		10.1001/jama.290.6.806	http://dx.doi.org/10.1001/jama.290.6.806			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	709VU	12915434				2023-01-03	WOS:000184647700032
J	Bhargava, A; Bigombe, B				Bhargava, A; Bigombe, B			Public policies and the orphans of AIDS in Africa	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEXUAL-BEHAVIOR; GENDER	International help to care for Africa's orphans is essential not only for their immediate welfare but also to protect the long term prosperity of these countries. A researcher in child health and former Ugandan government peace minister assess how to make the best use of resources.	Univ Houston, Dept Econ, Houston, TX 77204 USA; World Bank, Washington, DC 20433 USA	University of Houston System; University of Houston; The World Bank	Bhargava, A (corresponding author), Univ Houston, Dept Econ, Houston, TX 77204 USA.	bhargava@uh.edu						Bhagava A, 2001, J HEALTH ECON, V20, P423, DOI 10.1016/S0167-6296(01)00073-X; Bhargava A, 2003, J ECONOMETRICS, V112, P225, DOI 10.1016/S0304-4076(02)00162-8; Bhargava A, 2000, AM J PHYS ANTHROPOL, V111, P89, DOI 10.1002/(SICI)1096-8644(200001)111:1&lt;89::AID-AJPA6&gt;3.0.CO;2-X; Buve A, 2001, AIDS, V15, pS5, DOI 10.1097/00002030-200108004-00002; DEININGER K, 2001, DOES COST SCH AFFECT; FALKNER F, 1994, EUR J CLIN NUTR, V48, pS15; Kinsman J, 2001, HEALTH EDUC RES, V16, P85, DOI 10.1093/her/16.1.85; Machel JZ, 2001, REPROD HEALTH MATTER, V9, P82, DOI 10.1016/S0968-8080(01)90011-4; *MACR, 1999, DEM HLTH SURV DEM HL; *MACR, 2000, DEM HLTH SURV DEM HL; MARCHAT JM, 2001, RESULTS NIGERIA FIRM; Meekers D, 2000, INT J STD AIDS, V11, P21, DOI 10.1258/0956462001914850; Ndubani P, 2001, HEALTH POLICY PLANN, V16, P107, DOI 10.1093/heapol/16.1.107; NZOIKA C, 2001, REPROD HEALTH MATTER, V9, P108; Spira R, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e56; TERMINASSIAN T, 2001, DEBT RELIEF HIPCS FI; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; World Bank, 2001, WORLD DEV IND; *WORLD BANK MET, 2001, ED TRAIN MAD	19	36	36	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	2003	326	7403					1387	1389		10.1136/bmj.326.7403.1387	http://dx.doi.org/10.1136/bmj.326.7403.1387			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	694CN	12816831	Green Published			2023-01-03	WOS:000183756400029
J	Samaha, FF; Iqbal, N; Seshadri, P; Chicano, KL; Daily, DA; McGrory, J; Williams, T; Williams, M; Gracely, EJ; Stern, L				Samaha, FF; Iqbal, N; Seshadri, P; Chicano, KL; Daily, DA; McGrory, J; Williams, T; Williams, M; Gracely, EJ; Stern, L			A low-carbohydrate as compared with a low-fat diet in severe obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; HYPERTRIGLYCERIDEMIA; CHOLESTEROL	Background: The effects of a carbohydrate-restricted diet on weight loss and risk factors for atherosclerosis have been incompletely assessed. METHODS: We randomly assigned 132 severely obese subjects (including 77 blacks and 23 women) with a mean body-mass index of 43 and a high prevalence of diabetes (39 percent) or the metabolic syndrome (43 percent) to a carbohydrate-restricted (low-carbohydrate) diet or a calorie- and fat-restricted (low-fat) diet. RESULTS: Seventy-nine subjects completed the six-month study. An analysis including all subjects, with the last observation carried forward for those who dropped out, showed that subjects on the low-carbohydrate diet lost more weight than those on the low-fat diet (mean [+/-SD], -5.8+/-8.6 kg vs. -1.9+/-4.2 kg; P=0.002) and had greater decreases in triglyceride levels (mean, -20+/-43 percent vs. -4+/-31 percent; P=0.001), irrespective of the use or nonuse of hypoglycemic or lipid-lowering medications. Insulin sensitivity, measured only in subjects without diabetes, also improved more among subjects on the low-carbohydrate diet (6+/-9 percent vs. -3+/-8 percent, P=0.01). The amount of weight lost (P<0.001) and assignment to the low-carbohydrate diet (P=0.01) were independent predictors of improvement in triglyceride levels and insulin sensitivity. CONCLUSIONS: Severely obese subjects with a high prevalence of diabetes or the metabolic syndrome lost more weight during six months on a carbohydrate-restricted diet than on a calorie- and fat-restricted diet, with a relative improvement in insulin sensitivity and triglyceride levels, even after adjustment for the amount of weight lost. This finding should be interpreted with caution, given the small magnitude of overall and between-group differences in weight loss in these markedly obese subjects and the short duration of the study. Future studies evaluating long-term cardiovascular outcomes are needed before a carbohydrate-restricted diet can be endorsed.	Vet Affairs Med Ctr, Philadelphia, PA USA; Univ Penn, Med Ctr, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Med, Div Endocrinol, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Dept Family Community & Prevent Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania; Drexel University	Samaha, FF (corresponding author), Cardiol 8th Fl,MC 111C,Univ & Woodland Ave, Philadelphia, PA 19104 USA.	rick.samaha@med.va.gov	Gracely, Ed/B-7188-2014	Gracely, Ed/0000-0002-8344-3223				Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cohen J., 2013, STAT POWER ANAL BEHA; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; EADES MR, 2000, PROTEIN POWER LIFEPL, P434; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Ginsberg HN, 1997, ANN INTERN MED, V126, P912, DOI 10.7326/0003-4819-126-11-199706010-00012; Howard BV, 1998, METABOLISM, V47, P1174, DOI 10.1016/S0026-0495(98)90319-5; Jeor STS, 2001, CIRCULATION, V104, P1869, DOI 10.1161/hc4001.096152; KARVETTI RL, 1985, J AM DIET ASSOC, V85, P1437; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Kennedy ET, 2001, J AM DIET ASSOC, V101, P411, DOI 10.1016/S0002-8223(01)00108-0; NATOW AB, 1991, DIABETES CARBOHYDRAT; *NIH, 1998, OBES RES S2, V6, pS51, DOI DOI 10.1001/JAMA.2012.39; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacks FM, 2002, CIRCULATION, V105, P1424, DOI 10.1161/01.CIR.0000012918.84068.43; St-Pierre J, 2002, AM J CARDIOL, V90, P15, DOI 10.1016/S0002-9149(02)02378-0; Stuhlinger MC, 2002, JAMA-J AM MED ASSOC, V287, P1420, DOI 10.1001/jama.287.11.1420; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; Westman EC, 1999, J CLIN OUTCOMES MANA, V6, P36	21	846	871	4	131	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2074	2081		10.1056/NEJMoa022637	http://dx.doi.org/10.1056/NEJMoa022637			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761364				2023-01-03	WOS:000183008300004
J	Guttuso, T; Roscoe, J; Griggs, J				Guttuso, T; Roscoe, J; Griggs, J			Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer	LANCET			English	Article								In an anecdotal report, complete resolution of chemotherapy-induced nausea was seen in a patient with breast cancer, after she was placed on the anticonvulsant gabapentin. On this basis, we did an open-label study in which oral gabapentin 300 mg thrice daily was given for every other chemotherapy treatment in nine patients with breast cancer. Six of the nine reported at least a three-point improvement in peak delayed nausea (on an eight-point nausea scale), and three patients had complete resolution of nausea when taking gabapentin. This preliminary evidence shows that gabapentin might have a role in treatment of chemotherapy-induced nausea.	Univ Rochester, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Guttuso, T (corresponding author), Univ Rochester, Dept Neurol, Box 673, Rochester, NY 14642 USA.	thomas_guttuso@urmc.rochester.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007338] Funding Source: NIH RePORTER; NINDS NIH HHS [5 T32 NS07338-12] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Guttuso T, 2003, OBSTET GYNECOL, V101, P337, DOI 10.1016/S0029-7844(02)02712-6; KRIS MG, 1985, J CLIN ONCOL, V3, P1379, DOI 10.1200/JCO.1985.3.10.1379; Navari RM, 1999, NEW ENGL J MED, V340, P190, DOI 10.1056/NEJM199901213400304; Pater JL, 1997, ANN ONCOL, V8, P181, DOI 10.1023/A:1008247830641; Roila F, 2000, NEW ENGL J MED, V342, P1554	5	61	61	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1703	1705		10.1016/S0140-6736(03)13365-X	http://dx.doi.org/10.1016/S0140-6736(03)13365-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767738				2023-01-03	WOS:000182919700013
J	Anderson, RM; Bitterman, KJ; Wood, JG; Medvedik, O; Sinclair, DA				Anderson, RM; Bitterman, KJ; Wood, JG; Medvedik, O; Sinclair, DA			Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae	NATURE			English	Article							NAD(+) SALVAGE PATHWAY; SILENCING PROTEIN SIR2; DEACETYLASE ACTIVITY; YEAST; SPAN; EXPRESSION; LONGEVITY; GENE; METHYLTRANSFERASE; IDENTIFICATION	Calorie restriction extends lifespan in a broad range of organisms, from yeasts to mammals. Numerous hypotheses have been proposed to explain this phenomenon, including decreased oxidative damage and altered energy metabolism. In Saccharomyces cerevisiae, lifespan extension by calorie restriction requires the NAD(+)-dependent histone deacetylase, Sir2 (ref. 1). We have recently shown that Sir2 and its closest human homologue SIRT1, a p53 deacetylase, are strongly inhibited by the vitamin B3 precursor nicotinamide2. Here we show that increased expression of PNC1 (pyrazinamidase/nicotinamidase 1), which encodes an enzyme that deaminates nicotinamide, is both necessary and sufficient for lifespan extension by calorie restriction and low-intensity stress. We also identify PNC1 as a longevity gene that is responsive to all stimuli that extend lifespan. We provide evidence that nicotinamide depletion is sufficient to activate Sir2 and that this is the mechanism by which PNC1 regulates longevity. We conclude that yeast lifespan extension by calorie restriction is the consequence of an active cellular response to a low-intensity stress and speculate that nicotinamide might regulate critical cellular processes in higher organisms.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.			Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [R01 AG019719, R37 AG028730, R01 AG019972, R01 AG028730, P01 AG027916] Funding Source: Medline; NIGMS NIH HHS [R01 GM068072] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG027916, R01AG019972, R01AG019719, R37AG028730, R01AG028730] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKSOY S, 1994, J BIOL CHEM, V269, P14835; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Ghislain M, 2002, YEAST, V19, P215, DOI 10.1002/yea.810; Grant RS, 1998, J NEUROCHEM, V70, P1759; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jiang JC, 2000, FASEB J, V14, P2135; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; Kassem HS, 2002, INT J CANCER, V101, P454, DOI 10.1002/ijc.10631; Lal A, 1999, CANCER RES, V59, P5403; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Perichon R, 1998, CELL MOL LIFE SCI, V54, P641, DOI 10.1007/s000180050192; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Sandmeier JJ, 2002, GENETICS, V160, P877; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Swiecilo A, 2000, ACTA BIOCHIM POL, V47, P355; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; UNKEFER CJ, 1984, J BIOL CHEM, V259, P2311; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375	30	573	601	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					181	185		10.1038/nature01578	http://dx.doi.org/10.1038/nature01578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736687	Green Accepted			2023-01-03	WOS:000182699600049
J	Markham, R; Smith, A				Markham, R; Smith, A			Limits to patient choice: example from anaesthesia	BRITISH MEDICAL JOURNAL			English	Article									Royal Lancaster Infirm, Dept Anaesthesia, Lancaster LA1 4RP, England		Smith, A (corresponding author), Royal Lancaster Infirm, Dept Anaesthesia, Lancaster LA1 4RP, England.		Smith, Andrew F/C-5384-2012					Coulter A, 2002, BMJ-BRIT MED J, V324, P648, DOI 10.1136/bmj.324.7338.648; Department of Health, 2001, GOOD PRACT CONS IMPL; LACK JA, PATIENT INFORMATION; Smith R, 2002, BRIT MED J, V324, P497, DOI 10.1136/bmj.324.7336.497; Warner MA, 1999, ANESTHESIOLOGY, V90, P896	5	12	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					863	864		10.1136/bmj.326.7394.863	http://dx.doi.org/10.1136/bmj.326.7394.863			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702623	Bronze, Green Published			2023-01-03	WOS:000182386800023
J	Strausberg, RL; Schreiber, SL				Strausberg, RL; Schreiber, SL			From knowing to controlling: A path from Genomics to drugs using small molecule probes	SCIENCE			English	Article							STOCK SOLUTION APPROACH; CHEMICAL GENETICS; ONE-BEAD	The National Cancer Institute Initiative in Chemical Genetics is designed to encourage the development of small molecular probes. The probes are useful for activating or inactivating protein functions, thereby providing resources that help discern the functions of gene products in normal and disease cells, as well as in tissues. This initiative includes "ChemBank," a suite of informatics tools and databases aimed at promoting the development and use of chemical genetics by scientists worldwide. The information generated with such tools should provide a critical link from genomic discovery to drug development.	NCI, Canc Genom Off, Bethesda, MD 20892 USA; Harvard Univ, Dept Chem & Biol Chem, Howard Hughes Med Inst, Cambridge, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Center for Cancer Genomics (CCG); Harvard University; Howard Hughes Medical Institute	Strausberg, RL (corresponding author), NCI, Canc Genom Off, 31 Ctr Dr, Bethesda, MD 20892 USA.							Blackwell HE, 2001, CHEM BIOL, V8, P1167, DOI 10.1016/S1074-5521(01)00085-0; Clemons PA, 2001, CHEM BIOL, V8, P1183, DOI 10.1016/S1074-5521(01)00086-2; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Riggins GJ, 2001, HUM MOL GENET, V10, P663, DOI 10.1093/hmg/10.7.663; Schreiber SL, 2003, CHEM ENG NEWS, V81, P51, DOI 10.1021/cen-v081n009.p051; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Shuey DJ, 2002, DRUG DISCOV TODAY, V7, P1040, DOI 10.1016/S1359-6446(02)02474-1; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9	9	229	237	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					294	295		10.1126/science.1083395	http://dx.doi.org/10.1126/science.1083395			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690189	Green Published			2023-01-03	WOS:000182135400045
J	Kamada, H; Tsutsumi, Y; Sato-Kamada, K; Yamamoto, Y; Yoshioka, Y; Okamoto, T; Nakagawa, S; Nagata, S; Mayumi, T				Kamada, H; Tsutsumi, Y; Sato-Kamada, K; Yamamoto, Y; Yoshioka, Y; Okamoto, T; Nakagawa, S; Nagata, S; Mayumi, T			Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting	NATURE BIOTECHNOLOGY			English	Article							NECROSIS-FACTOR-ALPHA; ORGANIC ANION TRANSPORTER; POLYETHYLENE-GLYCOL; ANTITUMOR-ACTIVITY; MOLECULAR DESIGN; THROMBOPOIETIC ACTIVITY; SUPEROXIDE-DISMUTASE; SOLID TUMORS; RAT-KIDNEY; INTERLEUKIN-6	We have synthesized a polymeric drug carrier, polyvinylpyrrolidone-co-dimethyI maleic anhydride [poly(VP-co-DMMAn)], for use in renal drug delivery. About 80% of the 10-kDa poly(VP-co-DMMAn) selectively accumulated in the kidneys 24 h after intravenous administration to mice. Although this accumulated poly(VP-co-DMMAn) was gradually excreted in the urine, about 40% remained in the kidneys 96 h after treatment. Poly(VP-co-DMMAn) was taken up by the renal proximal tubular epithelial cells and no cytotoxicity was noted. Higher doses did not produce toxicity in the kidneys or other tissues. In contrast, polyvinylpyrroliclone of the same molecular weight did not show any tissue-specific distribution. Poly(VP-co-DMMAn)-modified superoxide dismutase accumulated in the kidneys after intravenous administration and accelerated recovery from acute renal failure in a mouse model. In contrast, polyvinylpyrrolidone-modified superoxide dismutase and native superoxide dismutase were not as effective. Thus, poly(VP-co-DMMAn) is a useful candidate as a targeting carrier for renal drug delivery systems.	Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Suita, Osaka 5650871, Japan; NCI, Div Basic Sci, Mol Biol Lab, Ira Pastans Lab,NIH, Bethesda, MD 20892 USA	Osaka University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tsutsumi, Y (corresponding author), Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan.		Nagata, Satoshi/B-5781-2008; Mayumi, Toshihiko/AAC-7418-2019	Kamada, Haruhiko/0000-0002-2478-3818; Nagata, Satoshi/0000-0001-9156-5215				CHANG RLS, 1975, KIDNEY INT, V8, P212, DOI 10.1038/ki.1975.104; Corvo ML, 1997, J CONTROL RELEASE, V43, P1, DOI 10.1016/S0168-3659(96)01473-3; DELAESCALERA S, 1989, BIOCHEM CELL BIOL, V67, P63, DOI 10.1139/o89-010; ELFARRA AA, 1995, J PHARMACOL EXP THER, V274, P1298; Ghielli M, 2000, KIDNEY INT, V58, P1121, DOI 10.1046/j.1523-1755.2000.00269.x; Haverdings RFG, 2001, RENAL FAILURE, V23, P397, DOI 10.1081/JDI-100104723; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; INOUE M, 1989, BIOCHEMISTRY-US, V28, P6619, DOI 10.1021/bi00442a013; Jones CA, 1998, AM J KIDNEY DIS, V32, P992, DOI 10.1016/S0272-6386(98)70074-5; Kamada H, 1999, BIOCHEM BIOPH RES CO, V257, P448, DOI 10.1006/bbrc.1999.0353; Kamada H, 2000, CANCER RES, V60, P6416; Kaneda Y, 1998, CANCER RES, V58, P290; Miyaji T, 2002, AM J PHYSIOL-RENAL, V282, pF795, DOI 10.1152/ajprenal.00203.2001; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; Mu Y, 1999, BIOCHEM BIOPH RES CO, V264, P763, DOI 10.1006/bbrc.1999.1567; Nakajima N, 2000, KIDNEY INT, V57, P1608, DOI 10.1046/j.1523-1755.2000.00005.x; *NAT I DIAB DIG KI, 1998, PROGR PRIOR REN DIS; NIETO MA, 1983, BIOCHIM BIOPHYS ACTA, V749, P204, DOI 10.1016/0167-4838(83)90254-6; NISHIKAWA M, 1993, PHARMACEUT RES, V10, P1253, DOI 10.1023/A:1018949109004; RYPACEK F, 1982, PFLUG ARCH EUR J PHY, V392, P211, DOI 10.1007/BF00584298; SCHECHTER B, 1995, KIDNEY INT, V47, P1327, DOI 10.1038/ki.1995.188; SIMIONESCU N, 1983, PHYSIOL REV, V63, P1536, DOI 10.1152/physrev.1983.63.4.1536; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tsunoda S, 2000, J CONTROL RELEASE, V68, P335, DOI 10.1016/S0168-3659(00)00249-2; Tsunoda S, 2001, BRIT J HAEMATOL, V112, P181, DOI 10.1046/j.1365-2141.2001.02508.x; Tsutsumi Y, 1997, THROMB HAEMOSTASIS, V77, P168; TSUTSUMI Y, 1995, BRIT J CANCER, V71, P963, DOI 10.1038/bjc.1995.186; Tsutsumi Y, 2000, P NATL ACAD SCI USA, V97, P8548, DOI 10.1073/pnas.140210597; Veronese FM, 2002, ADV DRUG DELIVER REV, V54, P587, DOI 10.1016/S0169-409X(02)00029-7	29	102	114	0	29	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2003	21	4					399	404		10.1038/nbt798	http://dx.doi.org/10.1038/nbt798			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	664VH	12612587				2023-01-03	WOS:000182082400021
J	Tyagi, A; Agarwal, R; Agarwal, C				Tyagi, A; Agarwal, R; Agarwal, C			Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis	ONCOGENE			English	Article						prostate cancer; MAPK; AP1; apoptosis; grape seed extract	EPIDERMAL GROWTH-FACTOR; NF-KAPPA-B; PROTEIN-KINASE PATHWAY; CANCER CELLS; C-JUN; MAP KINASES; STRESS; TRANSDUCTION; RECEPTORS; DEATH	A loss of functional androgen receptor and an enhanced expression of growth factor receptors and associated ligands are causal genetic events in prostate cancer (PCA) progression. These genetic alterations lead to an epigenetic mechanism where a feedback autocrine loop between membrane receptor and ligand (e.g. EGFR-TGFalpha) results in a constitutive activation of MAPK-Elk1-AP1-mediated mitogenic signaling in human PCA at an advanced and androgen-independent stage. We rationalized that inhibiting these epigenetic events could be useful in controlling advanced PCA growth. Recently, we found that grape seed extract (GSE), a dietary supplement rich in flavonoid procyanidins, inhibits advanced and androgen-independent human PCA DU145 cell growth in culture and nude mice. Here, we performed detailed mechanistic studies to define the effect of GSE on EGFR-Shc-MAPK-Elk1-AP1-mediated mitogenic signaling in DU145 cells. Pretreatment of serum-starved cells with GSE resulted in 70% to almost complete inhibition of EGF-induced EGFR activation and 50% to complete inhibition of She activation, which corroborated with a comparable decrease in EGF-induced Shc binding to EGFR. Conversely, EGF-induced ERK1/2 phosphorylation was inhibited only by lower doses of GSE; in fact, higher doses showed an increase. Additional studies showed that GSE alone causes a dose- and time-dependent increase in ERK1/2 phosphorylation in starved DU145 cells that is inhibited by an MEK1 inhibitor PD98059. Independent of this increase in ERK1/2 phosphorylation, GSE showed a strong inhibition of ERK1/2 kinase activity to Elk1 in both cellular and cell-free systems. GSE treatment of cells also inhibited both EGF-induced and constitutively active Elk1 phosphorylation and AP1 activation. GSE treatment also showed DNA synthesis inhibition in starved and EGF-stimulated cells as well as loss of cell viability and apoptotic death that was further increased by adding MEK1 inhibitor. Since GSE strongly induced apoptosis independent of its affect on an increase in phospho-ERK1/2, we hypothesized that apoptotic effect of GSE could be by other mechanism(s) including its effect on stress-associated MAPK, the JNK. Indeed, GSE-treated cells showed a strong and sustained increase in phospho-JNK1/JNK2 levels, JNK activity and phospho-cJun levels. An inhibition of GSE-induced JNK activation by a novel JNK inhibitor SP600125 resulted in a significant reversal of GSE-induced apoptotic death suggesting the involvement of JNK activation by GSE in its apoptosis response. Together, these results suggest that anticancer effects of GSE in PCA be mediated via impairment of EGFR-ERK1/2-Elk1-AP1-mediated mitogenic signaling and activation of JNK causing growth inhibition and apoptosis, respectively.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, C (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Chapia.Agarwal@UCHSC.edu			NATIONAL CANCER INSTITUTE [R01CA083741, R29CA064514, R01CA064514] Funding Source: NIH RePORTER; NCI NIH HHS [CA83741, CA64514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal C, 2000, MOL CARCINOGEN, V28, P129, DOI 10.1002/1098-2744(200007)28:3&lt;129::AID-MC1&gt;3.0.CO;2-0; Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006-2952(00)00385-3; Bartolome B, 1996, J CHROMATOGR A, V723, P19, DOI 10.1016/0021-9673(95)00839-X; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bhatia N, 2001, PROSTATE, V46, P98; CLARKE PR, 1994, CURR BIOL, V4, P647, DOI 10.1016/S0960-9822(00)00144-5; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CONNOLLY JM, 1989, PROSTATE, V15, P177, DOI 10.1002/pros.2990150211; DAI TN, 1995, ONCOGENE, V10, P849; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Dragsted L O, 1998, Arch Toxicol Suppl, V20, P209; ESCRIBANOBAILON T, 1992, J AGR FOOD CHEM, V40, P1794, DOI 10.1021/jf00022a013; Gioeli D, 1999, CANCER RES, V59, P279; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Harris KA, 2001, DRUGS, V61, P2177, DOI 10.2165/00003495-200161150-00003; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lin JQ, 1999, CANCER RES, V59, P2891; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Putz T, 1999, CANCER RES, V59, P227; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sato M, 2001, FREE RADICAL BIO MED, V31, P729, DOI 10.1016/S0891-5849(01)00626-8; Segawa N, 2001, CANCER RES, V61, P6060; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; TILLOTSON JK, 1991, CANCER LETT, V60, P109, DOI 10.1016/0304-3835(91)90216-5; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yu R, 2000, CANCER RES, V60, P2384; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhao J, 1999, CARCINOGENESIS, V20, P1737, DOI 10.1093/carcin/20.9.1737; Zi XL, 2000, CANCER RES, V60, P5617; Zi XL, 1998, CANCER RES, V58, P1920; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	58	114	120	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1302	1316		10.1038/sj.onc.1206265	http://dx.doi.org/10.1038/sj.onc.1206265			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618755				2023-01-03	WOS:000181360900004
J	Ou, BX; Huang, DJ; Hampschl-Woodill, M; Flanagan, JA				Ou, BX; Huang, DJ; Hampschl-Woodill, M; Flanagan, JA			When east meets west: the relationship between yin-yang and antioxidation-oxidation	FASEB JOURNAL			English	Article						traditional Chinese medicine; herbs; polyphenolics; oxygen radical absorbance capacity	CAPACITY; FLAVONOIDS; STRESS	Ancient traditional Chinese medicine (TCM) has effectively relied on the theory of yin-yang balance in diagnoses and treatments of diseases and disorders for more than 2000 years. However, in eastern society, yin-yang is regarded as an incomprehensible ideology without definite physical meaning. Consequently, the yin-yang balance in medicine has not been studied by modern scientific means. In the western world, yin-yang balance is often misunderstood as a religious belief or a principle of lifestyle. Herein, we attempted to define the physical meaning of yin-yang in TCM by correlating it with biochemical processes. We propose that yin-yang balance is antioxidation-oxidation balance with yin representing antioxidation and yang as oxidation. Our proposal is partially supported by the fact that the yin-tonic traditional Chinese herbs have, on average, about six times more antioxidant activity and polyphenolic contents than the yang-tonic herbs. Our hypothesis opens an avenue to systematically study the yin-yang balance and its health implications with the use of modern biochemical tools.	Brunswick Labs, Wareham, MA 02571 USA		Huang, DJ (corresponding author), Brunswick Labs, 6 Thatcher Lane, Wareham, MA 02571 USA.	dejian@brunswicklabs.com	Huang, Dejian/A-7439-2010	Huang, Dejian/0000-0002-2305-3960				Chau PL, 2000, NATURE, V404, P431, DOI 10.1038/35006734; *COMM ZHONGH BENC, 1998, ZHONGHUA BENCAO, V1; Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Huang DJ, 2002, J AGR FOOD CHEM, V50, P1815, DOI 10.1021/jf0113732; LEHNINGER AL, 1990, PRINCIPLES BIOCH, P359; Ni M., 1995, YELLOW EMPERORS CLAS; Ou BX, 2001, J AGR FOOD CHEM, V49, P4619, DOI 10.1021/jf010586o; Ou BX, 2002, J AGR FOOD CHEM, V50, P3122, DOI 10.1021/jf0116606; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; Prior RL, 2000, J AOAC INT, V83, P950; SIES H, 1982, OXIDATIVE STRESS, P1; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Theoharides TC, 2001, INT J IMMUNOPATH PH, V14, P119	14	88	95	3	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					127	129		10.1096/fj.02-0527hyp	http://dx.doi.org/10.1096/fj.02-0527hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554690				2023-01-03	WOS:000181456900036
J	Yanez-Mo, M; Lara-Pezzi, E; Selgas, R; Ramirez-Huesca, M; Dominguez-Jimenez, C; Jimenez-Heffernan, JA; Aguilera, A; Sanchez-Tomero, JA; Bajo, MA; Alvarez, V; Castro, MA; del Peso, G; Cirujeda, A; Gamallo, C; Sanchez-Madrid, F; Lopez-Cabrera, M				Yanez-Mo, M; Lara-Pezzi, E; Selgas, R; Ramirez-Huesca, M; Dominguez-Jimenez, C; Jimenez-Heffernan, JA; Aguilera, A; Sanchez-Tomero, JA; Bajo, MA; Alvarez, V; Castro, MA; del Peso, G; Cirujeda, A; Gamallo, C; Sanchez-Madrid, F; Lopez-Cabrera, M			Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSCRIPTION FACTOR SNAIL; EXTRACELLULAR-MATRIX; E-CADHERIN; TGF-BETA; GROWTH; ADHESION; EXPRESSION; MEMBRANE; GLUCOSE; JUNCTIONS	BACKGROUND: During continuous ambulatory peritoneal dialysis, the peritoneum is exposed to bioincompatible dialysis fluids that cause denudation of mesothelial cells and, ultimately, tissue fibrosis and failure of ultrafiltration. However, the mechanism of this process has yet to be elucidated. METHODS: Mesothelial cells isolated from effluents in dialysis fluid from patients undergoing continuous ambulatory peritoneal dialysis were phenotypically characterized by flow cytometry, confocal immunofluorescence, Western blotting, and reverse-transcriptase polymerase chain reaction. These cells were compared with mesothelial cells from omentum and treated with various stimuli in vitro to mimic the transdifferentiation observed during continuous ambulatory peritoneal dialysis. Results were confirmed in vivo by immunohistochemical analysis performed on peritoneal-biopsy specimens. RESULTS: Soon after dialysis is initiated, peritoneal mesothelial cells undergo a transition from an epithelial phenotype to a mesenchymal phenotype with a progressive loss of epithelial morphology and a decrease in the expression of cytokeratins and E-cadherin through an induction of the transcriptional repressor snail. Mesothelial cells also acquire a migratory phenotype with the up-regulation of expression of a(sub 2) integrin. In vitro analyses point to wound repair and profibrotic and inflammatory cytokines as factors that initiate mesothelial transdifferentiation. Immunohistochemical studies of peritoneal-biopsy specimens from patients undergoing continuous ambulatory peritoneal dialysis demonstrate the expression of the mesothelial markers intercellular adhesion molecule 1 and cytokeratins in fibroblast-like cells entrapped in the stroma, suggesting that these cells stemmed from local conversion of mesothelial cells. CONCLUSIONS: Our results suggest that mesothelial cells have an active role in the structural and functional alteration of the peritoneum during peritoneal dialysis. The findings suggest potential targets for the design of new dialysis solutions and markers for the monitoring of patients.	Univ Autonoma Madrid, Hosp Univ Princesa, Dept Biol Mol, Madrid 28006, Spain; Univ Autonoma Madrid, Hosp Univ Princesa, Serv Inmunol, Madrid 28006, Spain; Hosp Univ La Paz, Serv Nefrol, Madrid, Spain; Inst Reina Sofia Invest Nefrol, Madrid, Spain; Hosp Univ Guadalajara, Serv Anat Patol, Guadalajara, Spain	Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Hospital Universitario La Paz	Lopez-Cabrera, M (corresponding author), Univ Autonoma Madrid, Hosp Univ Princesa, Dept Biol Mol, C Diego de Leon 62, Madrid 28006, Spain.		SANCHEZ TOMERO, JOSE ANTONIO/Q-9346-2017; Sanchez-Madrid, Francisco/M-7889-2016; Lara-Pezzi, Enrique/E-2350-2015; YÃÃez-MÃ, Maria/AAI-4544-2020; Cabrera, Manuel López/AAA-5463-2019; Yáñez-Mó, María/K-8577-2014; Bajo, Maria A/ABF-6991-2020	Sanchez-Madrid, Francisco/0000-0001-5303-0762; Lara-Pezzi, Enrique/0000-0002-2743-1033; YÃÃez-MÃ, Maria/0000-0001-7484-2866; Yáñez-Mó, María/0000-0001-7484-2866; Bajo, Maria A/0000-0001-7364-557X; Lopez Cabrera, Manuel/0000-0002-0976-9719				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Birchmeier C, 1996, ACTA ANAT, V156, P217; BRULEZ HFH, 1995, PERITON DIALYSIS INT, V15, pS24; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; CHAIMOVITZ C, 1994, KIDNEY INT, V45, P1226, DOI 10.1038/ki.1994.163; CHAIMOVITZ C, 1994, KIDNEY INT, V46, P285; CONNELL ND, 1983, CELL, V34, P245, DOI 10.1016/0092-8674(83)90155-1; DOBBIE JW, 1992, PERITON DIALYSIS INT, V12, P14; Fang CC, 2000, KIDNEY INT, V57, P2626, DOI 10.1046/j.1523-1755.2000.00123.x; Faull RJ, 2001, KIDNEY INT, V59, P614, DOI 10.1046/j.1523-1755.2001.059002614.x; Ha H, 2001, KIDNEY INT, V59, P463, DOI 10.1046/j.1523-1755.2001.059002463.x; Hay ED, 1995, ACTA ANAT, V154, P8; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Ito T, 2000, J AM SOC NEPHROL, V11, P1969, DOI 10.1681/ASN.V11111969; Krediet RT, 1999, KIDNEY INT, V55, P341, DOI 10.1046/j.1523-1755.1999.00264.x; Lai KN, 2000, AM J KIDNEY DIS, V35, P644, DOI 10.1016/S0272-6386(00)70011-4; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Leavesley DI, 1999, NEPHROL DIAL TRANSPL, V14, P1208, DOI 10.1093/ndt/14.5.1208; Margetts PJ, 2001, J AM SOC NEPHROL, V12, P2029, DOI 10.1681/ASN.V12102029; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Medcalf JF, 2001, NEPHROL DIAL TRANSPL, V16, P1885, DOI 10.1093/ndt/16.9.1885; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Rampino T, 2001, AM J PATHOL, V159, P1275, DOI 10.1016/S0002-9440(10)62514-X; ROUSSELLE P, 1995, J BIOL CHEM, V270, P13766, DOI 10.1074/jbc.270.23.13766; SELGAS R, 1994, AM J KIDNEY DIS, V23, P64, DOI 10.1016/S0272-6386(12)80814-6; SUASSUNA JHR, 1994, KIDNEY INT, V46, P443, DOI 10.1038/ki.1994.292; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yanez-Mo M, 2001, J CELL SCI, V114, P577; Yang WS, 1999, PERITON DIALYSIS INT, V19, P211	31	583	616	0	35	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	2003	348	5					403	413		10.1056/NEJMoa020809	http://dx.doi.org/10.1056/NEJMoa020809			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639RU	12556543				2023-01-03	WOS:000180643800005
J	Cleary, PD				Cleary, PD			A hospitalization from hell: A patient's perspective on quality	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; INTENSIVE-CARE UNITS; POSTOPERATIVE PAIN; SURGICAL SERVICES; 5 COUNTRIES; OF-CARE; MANAGEMENT; OUTCOMES; COORDINATION; PHYSICIANS	Patients usually cannot assess the technical quality of their care; however, examining a hospitalization through the patients' eyes can reveal important information about the quality of care. Patients are the best source of information about a hospital system's communication, education, and pain-management processes, and they are the only source of information about whether they were treated with dignity and respect. Their experiences often reveal how well a hospital system is operating and can stimulate important insights into the kinds of changes that are needed to close the chasm between the care provided and the care that should be provided. This article examines the case of a patient admitted for ankle arthrodesis due to severe hemophilia-related arthritis. The surgery was successful, but the hospital stay was marked by inefficiency and inconveniences, as well as events that reveal fundamental problems with the hospital's organization and teamwork. These problems could seriously compromise the quality of clinical care. Unfortunately, most of these events occur regularly in U.S. hospitals. Relatively easy and inexpensive ways to avoid many of these problems are discussed, such as reducing variability in non-urgent procedures and routinely asking patients about their experiences and suggestions for improvement.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cleary, PD (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	cleary@hcp.med.harvard.edu	Cleary, Paul/AAF-7048-2019	Cleary, Paul/0000-0001-7527-4354				Aiken LH, 2001, HEALTH AFFAIR, V20, P43, DOI 10.1377/hlthaff.20.3.43; *AM NURS ASS NETW, 2000, NURSE STAFF PAT OUTC; *AM NURS ASS NETW, 1997, IMPL NURS REP CARD S; ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Chassin MR, 2002, ANN INTERN MED, V136, P826, DOI 10.7326/0003-4819-136-11-200206040-00012; Cleary P D, 1989, QRB Qual Rev Bull, V15, P172; Cleary P D, 1992, QRB Qual Rev Bull, V18, P53; Cleary P D, 1993, Qual Manag Health Care, V2, P31; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; Cleary PD, 1999, BRIT MED J, V319, P720, DOI 10.1136/bmj.319.7212.720; Cleary PD, 1997, JAMA-J AM MED ASSOC, V278, P1608, DOI 10.1001/jama.278.19.1608; COHEN FL, 1980, PAIN, V9, P265, DOI 10.1016/0304-3959(80)90013-5; Coulter A, 2001, HEALTH AFFAIR, V20, P244, DOI 10.1377/hlthaff.20.3.244; dAmours RH, 1996, J ORTHOP SPORT PHYS, V24, P227, DOI 10.2519/jospt.1996.24.4.227; DONOVAN BD, 1983, ANAESTH INTENS CARE, V11, P125, DOI 10.1177/0310057X8301100206; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; Fuss M A, 1998, Nurs Adm Q, V23, P1; GERTEIS M, 1993, THROUGH PATIENTS EYE, P45; Gittell JH, 2000, MED CARE, V38, P807, DOI 10.1097/00005650-200008000-00005; Hillier FS., 1995, INTRO OPERATIONS RES; Hruby M, 2001, AM J MED, V111, P21, DOI 10.1016/S0002-9343(01)00965-2; Johnson J E, 1973, Gastrointest Endosc, V19, P180, DOI 10.1016/S0016-5107(73)73995-X; JOHNSON JE, 1974, J PERS SOC PSYCHOL, V29, P710, DOI 10.1037/h0036555; Kaluzny A D, 1992, QRB Qual Rev Bull, V18, P380; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KEERISZA.M, 1972, SURG GYNECOL OBSTETR, V134, P647; Kehlet H, 1999, SURG CLIN N AM, V79, P431, DOI 10.1016/S0039-6109(05)70390-X; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; Kovner C, 1998, Image J Nurs Sch, V30, P315, DOI 10.1111/j.1547-5069.1998.tb01326.x; Landon BE, 2002, J GEN INTERN MED, V17, P12, DOI 10.1046/j.1525-1497.2002.10401.x; LANDRO L, 2002, WALL STREET J   0610; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEHMANN KA, 1995, ANN MED, V27, P271, DOI 10.3109/07853899509031970; Lichtig LK, 1999, J NURS ADMIN, V29, P25, DOI 10.1097/00005110-199902000-00008; Litvak E, 2000, AM J MANAG CARE, V6, P305; Litvak E, 2001, ACAD EMERG MED, V8, P1108; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; McManus ML, 2000, CRIT CARE MED, V28, pA79; MCMANUS ML, 2002, ANESTHESIOLOGY, V96, pA1144; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; Nelson JR, 2001, AM J MED, V111, P43, DOI 10.1016/S0002-9343(01)00970-6; Norrish BR, 2001, MILBANK Q, V79, P55, DOI 10.1111/1468-0009.00196; Panush R S, 1995, J Clin Rheumatol, V1, P74, DOI 10.1097/00124743-199504000-00003; Pfeffer J., 1998, HUMAN EQUATION BUILD; Rankin M A, 1984, Cancer Nurs, V7, P149; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; Seago J. A., 2001, MAKING HLTH CARE SAF, V40, P423; SHORTELL SM, 1994, MED CARE, V32, P508, DOI 10.1097/00005650-199405000-00009; Solomon DH, 1997, ANN INTERN MED, V127, P52, DOI 10.7326/0003-4819-127-1-199707010-00009; Steinbrook R, 2002, NEW ENGL J MED, V346, P1757, DOI 10.1056/NEJM200205303462225; vom Eigen KA, 1999, MED CARE, V37, P33, DOI 10.1097/00005650-199901000-00006; Wachter RM, 2001, AM J MED, V111, P40, DOI 10.1016/S0002-9343(01)00969-X; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; Willison DJ, 1998, ARCH INTERN MED, V158, P1778, DOI 10.1001/archinte.158.16.1778; Young GJ, 1997, HEALTH CARE MANAGE R, V22, P72, DOI 10.1097/00004010-199710000-00010; Young GJ, 1998, HEALTH SERV RES, V33, P1211; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1443, DOI 10.1097/00003246-199310000-00010	62	56	56	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 7	2003	138	1					33	39		10.7326/0003-4819-138-1-200301070-00009	http://dx.doi.org/10.7326/0003-4819-138-1-200301070-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645TV	12513042				2023-01-03	WOS:000180996200005
J	Richards, DA; Meakins, J; Tawfik, J; Godfrey, L; Dutton, E; Richardson, G; Russell, D				Richards, DA; Meakins, J; Tawfik, J; Godfrey, L; Dutton, E; Richardson, G; Russell, D			Nurse telephone triage for same day appointments in general practice: multiple interrupted time series trial of effect on workload and costs	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; PRIMARY-CARE; CONSULTATION	Objective To compare the workloads of general practitioners and nurses and costs of patient care for nurse telephone triage and standard management of requests for same day appointments in routine primary care. Design Multiple interrupted time series using sequential introduction of experimental triage system in different sites with repeated measures taken one week in every month for 12 months. Setting Three primary care sites in York. Participants 4685 patients: 1233 in standard management, 3452 in the triage system. All patients requesting same day appointments during study weeks were included in the trial. Main outcome measures Type of consultation (telephone, appointment, or visit), time taken for consultation, presenting complaints, use of services during the month after same day contact, and costs of drugs and same day, follow up, and emergency care. Results The triage system reduced appointments with general practitioner by 29-44%. Compared with standard management, the triage system had a relative risk (95% confidence interval) of 0.85 (0.72 to 1.00) for home visits, 2.41 (2.08 to 2.80) for telephone care, and 3.79 (3.21 to 4.48) for nurse care. Mean overall time in the triage system was 1.70 minutes longer, but mean general practitioner time was reduced by 2.45 minutes. Routine appointments and nursing time increased, as did out of hours and accident and emergency attendance. Costs did not differ significantly between standard management and triage: mean difference pound1.48 more per patient for triage (95% confidence interval -0.19 to 3.15). Conclusions Triage reduced the number of same day appointments with general practitioners but resulted in busier routine surgeries, increased nursing time, and a small but significant increase in out of hours and accident and emergency attendance. Consequently, triage does not reduce overall costs per patient for managing same day appointments.	Univ Manchester, Sch Nursing Midwifery & Hlth Visiting, Manchester M13 9PL, Lancs, England; Rawcliffe Surg, Priory Med Grp, York YO30 6ND, N Yorkshire, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England; Univ York, Dept Hlth Sci, York YO1 5DD, N Yorkshire, England	University of Manchester; University of York - UK; University of York - UK	Richards, DA (corresponding author), Univ Manchester, Sch Nursing Midwifery & Hlth Visiting, Manchester M13 9PL, Lancs, England.		Richards, David/B-4807-2009	Richards, David/0000-0002-8821-5027				*BRIT MED ASS, 1996, GEN MED SERV COMM ME; *DEP HLTH, 1989, GEN PRACT NAT HLTH S; Gallagher M, 1998, BRIT J GEN PRACT, V48, P1141; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; Jones K, 1998, BRIT J GEN PRACT, V48, P1303; Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054; Lattimer V, 1997, BRIT MED J, V314, P198; Thompson F, 1999, BMJ-BRIT MED J, V319, P1408, DOI 10.1136/bmj.319.7222.1408	8	53	54	2	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 23	2002	325	7374					1214	1217		10.1136/bmj.325.7374.1214	http://dx.doi.org/10.1136/bmj.325.7374.1214			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446539	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000179506200022
J	de Caen, A				de Caen, A			Management of profound hypothermia in children without the use of extracorporeal life support therapy	LANCET			English	Article								Profound hypothermia is managed more and more with extracorporeal life support technology, especially when a patient's circulation is compromised. Many centres do not have rapid access to this service, however, and are still dependent on active internal rewarming techniques-eg, peritoneal and pleural lavage. Such interventions are invasive, and associated with inherent risk. Here, we report our successful experience with an active external rewarming technique in children with profound hypothermia (core temperature <20&DEG;C).	Stollery Childrens Hosp, Div Pediat Intens Care, Edmonton, AB, Canada	Stollery Children's Hospital	de Caen, A (corresponding author), 3A3-06 Walter C Mackenzie Ctr, Edmonton, AB T6G 2B7, Canada.							ANDERSON S, 1970, BRIT J ANAESTH, V42, P653, DOI 10.1093/bja/42.7.653; CURRIE AE, 1994, J ROY SOC MED, V87, P293; DANZL DF, 1994, NEW ENGL J MED, V331, P1756, DOI 10.1056/NEJM199412293312607; MAIR P, 1995, LANCET, V345, P1048; THOMPSON DA, 1994, ANN EMERG MED, V23, P1390, DOI 10.1016/S0196-0644(94)70369-8	5	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1394	1395		10.1016/S0140-6736(02)11392-4	http://dx.doi.org/10.1016/S0140-6736(02)11392-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423988				2023-01-03	WOS:000179081600015
J	Seibert, C; Barbouche, E; Fagan, J; Myint, E; Wetterneck, T; Wittemyer, M				Seibert, C; Barbouche, E; Fagan, J; Myint, E; Wetterneck, T; Wittemyer, M			Prescribing oral contraceptives for women older than 35 years of age	ANNALS OF INTERNAL MEDICINE			English	Review							HORMONE REPLACEMENT THERAPY; VENOUS THROMBOEMBOLIC DISEASE; METABOLIC RISK MARKERS; BONE-MINERAL DENSITY; G ETHINYL ESTRADIOL; BREAST-CANCER RISK; FACTOR-V-LEIDEN; YOUNG-WOMEN; UNITED-STATES; MYOCARDIAL-INFARCTION	This paper addresses the use of combined oral contraceptives in women older than 35 years of age, including the potential risks and benefits, pretreatment assessment, common side effects and their management, appropriate follow-up, and diagnosis of menopause. The case-based discussion also focuses on issues that pertain to women who smoke, have hypertension, or have dyslipidemia.	Univ Wisconsin, Sch Med, UW Hlth Clin E, Dept Med, Madison, WI 53706 USA; Virginia Mason Med Ctr, Lynnwood, WA USA	University of Wisconsin System; University of Wisconsin Madison; University Wisconsin Health; Virginia Mason Medical Center	Seibert, C (corresponding author), Univ Wisconsin, Sch Med, UW Hlth Clin E, Dept Med, 5249 E Terrace Dr, Madison, WI 53706 USA.	cseibert@facstaff.wisc.edu						ABMA J, 1997, VITAL HLTH STAT, V23; Adesanya OO, 1996, J REPROD MED, V41, P431; AKERLUND M, 1993, BRIT J OBSTET GYNAEC, V100, P832, DOI 10.1111/j.1471-0528.1993.tb14309.x; *AM COLL OBST GYN, 1996, GUID WOM HLTH CAR; [Anonymous], 1983, JAMA, V249, P1596; [Anonymous], 1986, NEW ENGL J MED, V315, P405; Barrett D H, 1994, Arch Fam Med, V3, P438, DOI 10.1001/archfami.3.5.438; Berg AO, 2001, AM J PREV MED, V20, P73, DOI 10.1016/S0749-3797(01)00266-5; Bloemenkamp KWM, 1999, ARCH INTERN MED, V159, P65, DOI 10.1001/archinte.159.1.65; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Bousser MG, 2000, CEPHALALGIA, V20, P147, DOI 10.1046/j.1468-2982.2000.00050.x; Brinton LA, 1998, MENOPAUSE, V5, P145; Brinton LA, 1997, CONTRACEPTION, V55, P197, DOI 10.1016/S0010-7824(97)00012-7; Burkman RT, 1998, CONTRACEPTION, V58, p35S, DOI 10.1016/S0010-7824(98)00081-X; BURKMAN RT, 2000, INT J FERTIL S2, V45, P134; Burt VK, 1998, HARVARD REV PSYCHIAT, V6, P121, DOI 10.3109/10673229809000320; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Cardoso F, 1997, INT J GYNECOL OBSTET, V59, P237, DOI 10.1016/S0020-7292(97)00239-7; CASPER RF, 1991, FERTIL STERIL, V55, P292; Castracane VD, 1995, CONTRACEPTION, V52, P371; CAUFIELD KA, 1998, WOMENS HLTH PRIMARY, P161; Chang CL, 1999, BMJ-BRIT MED J, V318, P13; ChasanTaber L, 1996, CIRCULATION, V94, P483, DOI 10.1161/01.CIR.94.3.483; Coney P, 2001, CONTRACEPTION, V63, P297, DOI 10.1016/S0010-7824(01)00208-6; CONNELL EB, 1993, J REPROD MED, V38, P1036; Connelly PW, 1999, CAN J CARDIOL, V15, P419; COOPER C, 1993, BONE, V14, P41, DOI 10.1016/8756-3282(93)90254-8; Corson SL, 1996, INT J FERTIL MENOP S, V41, P77; Crook D, 1997, CONTRACEPTION, V55, P219, DOI 10.1016/S0010-7824(97)00010-3; Crosignani PG, 2000, HUM REPROD, V15, P1865; CULLBERG G, 1985, ACTA OBSTET GYN SCAN, V64, P195, DOI 10.3109/00016348509155112; DEWIS P, 1985, CLIN ENDOCRINOL, V22, P29, DOI 10.1111/j.1365-2265.1985.tb01061.x; DICKEY RP, 1994, MANAGING CONTRACEPTI, P60; DIEHL AK, 1991, GASTROENTEROL CLIN N, V20, P1; Dong W, 1997, J HYPERTENS, V15, P1063, DOI 10.1097/00004872-199715100-00003; Douketis JD, 1997, ARCH INTERN MED, V157, P1522, DOI 10.1001/archinte.157.14.1522; Dunn N, 1999, BRIT MED J, V318, P1579, DOI 10.1136/bmj.318.7198.1579; Eck LH, 1997, AM J CLIN NUTR, V65, P419, DOI 10.1093/ajcn/65.2.419; EDGREN RA, 1989, CONTRACEPTION, V40, P285, DOI 10.1016/0010-7824(89)90093-0; FARLEY TMM, 1995, LANCET, V346, P1582; Farley TMM, 1998, CONTRACEPTION, V57, P211, DOI 10.1016/S0010-7824(98)00019-5; Farmer RDT, 2000, BRIT J CLIN PHARMACO, V49, P580, DOI 10.1046/j.1365-2125.2000.00198.x; Farmer RDT, 1998, AM J OBSTET GYNECOL, V179, pS78, DOI 10.1053/ob.1998.v179.a92634; Franceschi S, 1998, CONTRACEPTION, V58, P335, DOI 10.1016/S0010-7824(98)00128-0; Fruzzetti F, 1999, AM J OBSTET GYNECOL, V180, pS369, DOI 10.1016/S0002-9378(99)70698-8; Gabrick DM, 2000, JAMA-J AM MED ASSOC, V284, P1791, DOI 10.1001/jama.284.14.1791; GAMBACCIANI M, 1994, MATURITAS, V19, P125, DOI 10.1016/0378-5122(94)90062-0; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; Gillum LA, 2000, JAMA-J AM MED ASSOC, V284, P72, DOI 10.1001/jama.284.1.72; GODSLAND IF, 1995, CONTRACEPTION, V52, P143, DOI 10.1016/0010-7824(95)00153-2; Godsland IF, 1996, CONTRACEPTION, V53, P9, DOI 10.1016/0010-7824(95)00260-X; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; Hankinson SE, 1997, CANCER CAUSE CONTROL, V8, P65, DOI 10.1023/A:1018435205695; HANKINSON SE, 1992, OBSTET GYNECOL, V80, P708; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; Hannaford PC, 1996, CONTRACEPTION, V54, P125, DOI 10.1016/S0010-7824(96)00167-9; HATCHER RA, 1999, MANAGING CONTRACEPTI, P97; Hatcher RA, 1998, CONTRACEPTIVE TECHNO, P405; Heinemann LAJ, 1998, CONTRACEPTION, V57, P29, DOI 10.1016/S0010-7824(97)00204-7; Helmerhorst FM, 1998, HUM REPROD, V13, P2981, DOI 10.1093/humrep/13.11.2981; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Kaunitz AM, 2001, AM J OBSTET GYNECOL, V185, pS32, DOI 10.1067/mob.2001.116525; KAUNITZ AM, 2001, DIALOGUES CONTRACEPT, V6, P4; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; Klein NA, 1998, CLIN OBSTET GYNECOL, V41, P912, DOI 10.1097/00003081-199812000-00017; KNOPP RH, 1993, AM J OBSTET GYNECOL, V168, P1994, DOI 10.1016/S0002-9378(12)90941-2; KRETTEK JE, 1993, OBSTET GYNECOL, V81, P728; Kuohung W, 2000, CONTRACEPTION, V61, P77, DOI 10.1016/S0010-7824(00)00086-X; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Lewis MA, 1998, AM J OBSTET GYNECOL, V179, pS68, DOI 10.1053/ob.1998.v179.a93122; Lewis MA, 1996, CONTRACEPTION, V54, P5, DOI 10.1016/0010-7824(96)00112-6; LIDEGAARD O, 1995, BRIT J OBSTET GYNAEC, V102, P153, DOI 10.1111/j.1471-0528.1995.tb09070.x; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; Lidegaard O, 1998, AM J OBSTET GYNECOL, V179, pS62, DOI 10.1053/ob.1998.v179.a91674; Lidegaard O, 1999, AM J OBSTET GYNECOL, V180, pS357, DOI 10.1016/S0002-9378(99)70696-4; Lidegaard O, 1998, CONTRACEPTION, V57, P303, DOI 10.1016/S0010-7824(98)00032-8; Lidegaard O, 1997, ACTA OBSTET GYN SCAN, V76, P252; Lobo RA, 1996, FERTIL STERIL, V65, P1100, DOI 10.1016/S0015-0282(16)58321-6; Lobo RA, 1998, CLIN OBSTET GYNECOL, V41, P895, DOI 10.1097/00003081-199812000-00015; Lucky AW, 1997, J AM ACAD DERMATOL, V37, P746, DOI 10.1016/S0190-9622(97)70112-9; Magnusson CM, 1999, INT J CANCER, V80, P231, DOI 10.1002/(SICI)1097-0215(19990118)80:2<231::AID-IJC11>3.3.CO;2-I; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; Marchbanks PA, 2002, NEW ENGL J MED, V346, P2025, DOI 10.1056/NEJMoa013202; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; MCKINLAY SM, 1992, MATURITAS, V14, P103, DOI 10.1016/0378-5122(92)90003-M; MEADE TW, 1977, LANCET, V2, P948; *MED EC, 2000, RED BOOK 2000 DRUG T, P313; Michaelsson K, 1999, LANCET, V353, P1481, DOI 10.1016/S0140-6736(98)09044-8; Newcomb PA, 1996, CANCER CAUSE CONTROL, V7, P525, DOI 10.1007/BF00051885; Oddens BJ, 1999, CONTRACEPTION, V59, P277, DOI 10.1016/S0010-7824(99)00034-7; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; Poulter NR, 1996, LANCET, V348, P505; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; RAMCHARAN S, 1981, NIH PUBLICATION, V3; Redmond GP, 1997, OBSTET GYNECOL, V89, P615, DOI 10.1016/S0029-7844(97)00059-8; REUBINOFF BE, 1995, FERTIL STERIL, V63, P516, DOI 10.1016/S0015-0282(16)57419-6; Rosenberg L, 1996, AM J EPIDEMIOL, V143, P25; Rosenberg M, 1998, CONTRACEPTION, V58, P345, DOI 10.1016/S0010-7824(98)00127-9; Rosenberg MJ, 1996, CONTRACEPTION, V53, P85, DOI 10.1016/0010-7824(95)00270-7; Rosenberg MJ, 1998, AM J OBSTET GYNECOL, V179, P577, DOI 10.1016/S0002-9378(98)70047-X; Rosenberg MJ, 1996, AM J OBSTET GYNECOL, V174, P628, DOI 10.1016/S0002-9378(96)70440-4; Rosing J, 1999, AM J OBSTET GYNECOL, V180, pS375, DOI 10.1016/S0002-9378(99)70699-X; Rossing MA, 1996, AM J EPIDEMIOL, V144, P161, DOI 10.1093/oxfordjournals.aje.a008903; SALEH WA, 1993, AM J OBSTET GYNECOL, V168, P1740, DOI 10.1016/0002-9378(93)90685-C; Schiff I, 1999, AM J OBSTET GYNECOL, V180, pS383, DOI 10.1016/S0002-9378(99)70700-3; Schlesselman JJ, 1997, HUM REPROD, V12, P1851, DOI 10.1093/humrep/12.9.1851; SCHLESSELMAN JJ, 1995, OBSTET GYNECOL, V85, P793, DOI 10.1016/0029-7844(95)00022-J; Schmidt PJ, 2000, AM J OBSTET GYNECOL, V183, P414, DOI 10.1067/mob.2000.106004; Schwartz SM, 1998, STROKE, V29, P2277, DOI 10.1161/01.STR.29.11.2277; Schwartz SM, 1997, ANN INTERN MED, V127, P596, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00003; Schwingl PJ, 1999, AM J OBSTET GYNECOL, V180, P241, DOI 10.1016/S0002-9378(99)70182-1; SCRAGG RKR, 1984, BRIT MED J, V288, P1795, DOI 10.1136/bmj.288.6433.1795; Seifer DB, 1998, FERTIL STERIL, V69, P387; SHARGIL AA, 1985, INT J FERTIL, V30, P15; Sherif K, 1999, AM J OBSTET GYNECOL, V180, pS343, DOI 10.1016/S0002-9378(99)70694-0; Shulman LP, 2000, OBSTET GYN CLIN N AM, V27, P695, DOI 10.1016/S0889-8545(05)70168-6; Shulman LP, 1999, INT J FERTIL WOMEN M, V44, P78; Sidney S, 1996, OBSTET GYNECOL, V88, P939, DOI 10.1016/S0029-7844(96)00351-1; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; SPEROFF L, 1994, CLIN GYNECOLOGIC END, P722; Spitzer WO, 1998, AM J OBSTET GYNECOL, V179, pS43, DOI 10.1053/ob.1998.v179.a93059; Spitzer WO, 1996, BRIT MED J, V312, P83; Stahl SM, 1998, PSYCHOPHARMACOL BULL, V34, P319; STERGACHIS A, 1992, AM J OBSTET GYNECOL, V167, P1165, DOI 10.1016/S0002-9378(12)90406-8; Stern RS, 2000, J AM ACAD DERMATOL, V43, P1042, DOI 10.1067/mjd.2000.110901; Stewart FH, 2001, JAMA-J AM MED ASSOC, V285, P2232, DOI 10.1001/jama.285.17.2232; STROM BL, 1986, CLIN PHARMACOL THER, V39, P335, DOI 10.1038/clpt.1986.49; Sulak P, 1999, CONTRACEPTION, V59, P161, DOI 10.1016/S0010-7824(99)00026-8; Tanis BC, 2001, NEW ENGL J MED, V345, P1787, DOI 10.1056/NEJMoa003216; Thorneycroft IH, 1999, AM J OBSTET GYNECOL, V180, pS280, DOI 10.1016/S0002-9378(99)70719-2; Thorneycroft IH, 1999, AM J OBSTET GYNECOL, V180, pS288, DOI 10.1016/S0002-9378(99)70720-9; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Tomasson H, 1996, ACTA OBSTET GYN SCAN, V75, P157, DOI 10.3109/00016349609033309; Tryggvadottir L, 1997, BRIT J CANCER, V75, P139, DOI 10.1038/bjc.1997.23; Tyden T, 1999, ADV CONTRACEPT, V15, P133, DOI 10.1023/A:1006749709993; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; Ursin G, 1999, AM J EPIDEMIOL, V150, P561; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P73; Van Winter JT, 1998, AM FAM PHYSICIAN, V58, P1373; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; Vessey M, 1998, CONTRACEPTION, V57, P231, DOI 10.1016/S0010-7824(98)00026-2; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; VOLPE A, 1993, CONTRACEPTION, V47, P229, DOI 10.1016/0010-7824(93)90040-E; Warren MP, 1998, CLIN OBSTET GYNECOL, V41, P976, DOI 10.1097/00003081-199812000-00024; Weiss G, 1999, AM J OBSTET GYNECOL, V180, pS295, DOI 10.1016/S0002-9378(99)70721-0; Westhoff CL, 1998, AM J OBSTET GYNECOL, V179, pS38, DOI 10.1053/ob.1998.v179.a91673; *WHO, 2000, IMPR ACC QUAL CAR FA, P1; *WHO US AG INT DEV, 1994, REC UPD SEL PRACT CO, V1; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; 1999, FERTIL STERIL S3, V71, pS1; 1998, HUM REPROD, V13, P2325; 2000, AM COLL OBSTERTRICIA, V18, P1071; 1996, CONTRACEPTION, V54, pS1	157	24	26	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 7	2003	138	1					54	64		10.7326/0003-4819-138-1-200301070-00013	http://dx.doi.org/10.7326/0003-4819-138-1-200301070-00013			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645TV	12513046				2023-01-03	WOS:000180996200008
J	Smith, C				Smith, C			Drug target validation: Hitting the target	NATURE			English	Article																			0	59	70	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					341	+		10.1038/422341a	http://dx.doi.org/10.1038/422341a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646929	Bronze			2023-01-03	WOS:000181637300045
